<SEC-DOCUMENT>0001628280-23-017390.txt : 20230511
<SEC-HEADER>0001628280-23-017390.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230511070132
ACCESSION NUMBER:		0001628280-23-017390
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPASS Pathways plc
		CENTRAL INDEX KEY:			0001816590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39522
		FILM NUMBER:		23908747

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 1 ASHLEY ROAD
		STREET 2:		ALTRINCHAM
		CITY:			CHESIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		1-716-676-6461

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 1 ASHLEY ROAD
		STREET 2:		ALTRINCHAM
		CITY:			CHESIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Compass Rx Ltd.
		DATE OF NAME CHANGE:	20200701
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cmps-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:faa56455-90dd-4209-830a-f12e1735b5b9,g:47fba99e-051e-4c82-b324-f1efc6936c36,d:132905a7c9654916bdd441350c765120--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:cmps="http://compasspathways.com/20230331" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cmps-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl8yLTItMS0xLTE0MDE2Mg_69a68532-c599-4880-b1fd-8865be75f7dd">0001816590</ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl8zLTItMS0xLTE0MDE2Mg_ed037f94-f695-41d2-bf0e-39ea043e770a">2023</ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl80LTItMS0xLTE0MDE2Mg_b91d4dba-c051-4db1-b84b-9a27d02e49bd">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl81LTItMS0xLTE0MDE2Mg_07ac0ace-e7e2-416b-8fef-cc5278b78af5">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl82LTItMS0xLTE0MDE2Mg_5b8f7f34-db2a-48f3-8c53-a84ac9b89c69">12-31</ix:nonNumeric><ix:nonNumeric contextRef="idaa046deac9b4142b090bb9346a58d27_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTAyOQ_92763bc4-2b40-44c3-9547-92efbadbe1ef">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cmps-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib00da7419466450d8612fe7a2961b23e_I20230509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i152e65e381d441028d0e315d17e7e808_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ifca3cadf83964b62a844d82c3b5e7165_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4ba3b4df2464eec920f3e4371cc1421_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i996a9a2f8d294a9f95e96689ead7e84e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied43d7e0b5ea423c95391b44528d3a53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54af68e04565485696634eacfdfb44f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i141ce2dc3cbb40bd99c09099ae6fabbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36576268599e4fd8bf18172064ed862d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i898f890161564fe59100013d33b6fbf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i791c0755a9154956b424d9d20a0f7f01_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a89f22f54c64b9e9b9aab3c0f6d7efb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if70809ae9cce49cfac3b711f0475be91_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930583009ce145dd84d88be7a117f69a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c6df05b14e473ba0b9e00b725c4e39_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03566c748b444fe94d62e9e28a827ae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67ebb5874ffc463eae558a0bca081f38_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15382a1c78b24f7781f909cac2666727_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7765db2674724718901c035cce089b95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia98b20644358427a878a9249c15fc81e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cd164da18c74147b770195a655c5b6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ecb856e1088469e91d8161b926b64b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e11cf9e5ac74fb2ac41daf1d28be1e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b92bc0ebd64ca2ac7a3bd9ea558598_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccea7b15b4b34b7881a38a9aeb5a255d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a788380d1dd41a192369ee1283627cb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib62e231bc5e04aadaa0e552da9eaa69b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie933ef689fe34ea1857fb293be2148bc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee88fb1648c24d69a547b9473b48ce0b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib62efe8423eb495089400103d98fb87b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idffcb1da5bec4469ab5d69a783ed74e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb330f455e5841ea8450b766d642b939_I20211008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cc171482c7f4d51822f9ae8848dea3e_D20211008-20211008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea51b6a765944cd995e3725b1074692b_D20230401-20230510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12a666d1e1c4e28811b0491bb87e477_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74d151acb50c43c5a8922ab30b91f0da_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7dc74026a9740bf91b61706f4057936_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269e60958eaf430baf2c5267c8716c7f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89200d84b6204258aa19770fb2ce7ef4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="region"><xbrli:measure>cmps:region</xbrli:measure></xbrli:unit><xbrli:context id="ifcb5e67ff9464397aed19cb5b9642c90_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ac0527569949da8f64c6fe440b8ed9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cmps:UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e49c2f29fa4138890d882ae5cb4ab9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cmps:UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i48ff1631256746aeb10f884e312e3153_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e6809fbe984861af6f54d5e62599f3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia690ad07e30d41c9b898dec4e27afca1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmps:VestingPeriodAxis">cmps:A2022And2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d4eb30a399e4393b48bbd2412557894_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3c9a2da33a404d81407048dc2c35ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cae53ddb92e46c3b992b638b4a42023_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaa046deac9b4142b090bb9346a58d27_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1143bd0e2ad345caa5c640706694c0b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40dc657ea5ac431794e05ae7a1ce76d8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35930be1fdbb4fa798087223a146bcb9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:OptionsGrantedBeforeJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0a16794335461d959dba6be9403f37_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i407fd6f5b5ed4bcaafd6554faeeaf095_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1adb7d0ef4fb497d9b87d9bed2778ce5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>cmps:day</xbrli:measure></xbrli:unit><xbrli:context id="i00a9c14553ea40949dd06a45c06c9b03_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie31fdecdb0224ff48a4b130a9225404d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31e66ff9fe5f4627ae22fcc1d62c3001_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395fbda845a44eac841de73744035c26_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d15bad6c8da46cf885b153b00184437_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0831ccc811b4e5d84580b833bf10c0e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aa096c9847d432ebe62c81328b458a2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3183dfe431c04796b01b1c6fdb1a0756_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i338fadaff380485fbfe31f0080cdd810_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea26013103954eadb8a7947d75c821d7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837240d0e61b4f5780239e38d5361ef5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696b4083af51453a8c2cfb18cfdb4482_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ccc93511924535a1cde0fc5143bb33_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22f0d118f1942caa4258c79bae792fb_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ab588a8f374a63b091c9535ea47d6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7cedba3e82645e49ca80bcc90a72a68_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91e30a56bc9415dbd1e86b1d6ec64dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7fb606ccca48e58144d35f683e689d_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c06e81a4384be9a4547b9d54649e6c_D20230331-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1c0a2584554db98438e2f27622af72_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478445e4a46e43758c8383eb32aaf0ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5872a113b2294faaad1b68db7ae836e2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b25b7dbd74c4562b936a90dfd191b50_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice52714f9f134f59b22998dd73137b2a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60ff16effaf4307b5d9f1c7ce5bc358_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1623488c9f64721a60c4349e61ce8bf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b773ca49914d34bba229e76da492dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ea83c879704be889d92560678ef374_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122471b5c0c34e05bdaaf376bf6de99c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbeae02a508346edb94df36fd8e95a81_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:WeWorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba372f6eca8f430eb43a67755847815d_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:WeWorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7678bc3cc61d4f73b03996330cea7a9f_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87803bd77d841e3917a974e88083e5a_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33bec60d253644c1918ad73a71213b08_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8636ff5e270740d08068434308a1c41a_I20220621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:DenmarkHillLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc7b27ad5a34f7986912f9169f8eac5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:DenmarkHillLondonUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd439c7411164a75bab3f2705e3ffb57_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4ad1b7be0048e289dcf0230cc72a31_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i132905a7c9654916bdd441350c765120_1"></div><div style="min-height:58.5pt;width:100%"><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160; </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.377%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjM4_6c3bfbad-12a4-4622-b030-f0c788460c21">10-Q</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjMx_caded53f-d0be-4e8d-8dca-fbcadc8f23e6">&#8864;</ix:nonNumeric>   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjg_e3ae8d84-d2de-4a97-a1d6-d4f90b2e4468">March&#160;31, 2023</ix:nonNumeric><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjM5_5e5c018f-ef4a-46d8-b7ec-8d5181c30477">&#9744;</ix:nonNumeric>   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjQw_e2f2db37-0237-46b9-9c79-ac666023e205">001-39522</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjI4_761aac2a-3467-4f98-82bf-b63d6b4e7956">COMPASS Pathways plc</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.035%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6OTA0ZmE3MTViOWY5NDNhM2E5ZTk0YmJlNmM3YzYzMTEvdGFibGVyYW5nZTo5MDRmYTcxNWI5Zjk0M2EzYTllOTRiYmU2YzdjNjMxMV8wLTAtMS0xLTE0MDE2Mg_ff4a8f21-6e8c-4597-b0bf-0cd5ea2ef22d">England and Wales</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjUw_9efe6725-1187-4d61-a612-62805562f91f">33 Broadwick Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjM0_4b04472c-a6db-4732-aaa7-9ba1cee6e340">London</ix:nonNumeric> <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjQ2_2b958642-43a4-4d43-b4ad-14a1c60a81fe">W1F 0DQ</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjQy_ae1ca032-1c5b-4543-a1aa-dedf49be2a92">United Kingdom</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> +1 (<ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjI5_c6a4ff9e-00bb-4da3-8b72-d358be925787">716</ix:nonNumeric>) <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8zODQ4MjkwNjk5NTI2_ae5206dc-5187-4816-9cf6-9de892b0fbf0">676-6461</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.265%"><tr><td style="width:1.0%"></td><td style="width:32.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.926%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NDhhMzk2ZWZkODEwNGFmOGE2YmIyMDM2ODYzMzFlOGYvdGFibGVyYW5nZTo0OGEzOTZlZmQ4MTA0YWY4YTZiYjIwMzY4NjMzMWU4Zl8xLTAtMS0xLTE0MDE2Mg_5ef50bd6-cd57-4bbd-b1f9-b28def7ab30d">American Depositary Shares, each representing one ordinary share, par value of &#163;0.008 per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NDhhMzk2ZWZkODEwNGFmOGE2YmIyMDM2ODYzMzFlOGYvdGFibGVyYW5nZTo0OGEzOTZlZmQ4MTA0YWY4YTZiYjIwMzY4NjMzMWU4Zl8xLTItMS0xLTE0MDE2Mg_7df6d9b3-26ef-471d-9d1c-1355355a19e6">CMPS</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NDhhMzk2ZWZkODEwNGFmOGE2YmIyMDM2ODYzMzFlOGYvdGFibGVyYW5nZTo0OGEzOTZlZmQ4MTA0YWY4YTZiYjIwMzY4NjMzMWU4Zl8xLTQtMS0xLTE0MDE2Mg_6c6c404c-ca71-4b8f-b9e9-c07795c2f493">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjM2_43e5b795-df58-460f-9dc1-30732b72936d">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjQz_7a9a0c1e-71b8-476f-8f6f-cc9bdbc31454">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.956%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NTdiNTk3ZTUzYzhiNDI2MDg4N2E0M2E1MGVmNTkwNDUvdGFibGVyYW5nZTo1N2I1OTdlNTNjOGI0MjYwODg3YTQzYTUwZWY1OTA0NV8xLTAtMS0xLTE0OTMzNg_b1dfa2d4-e2ab-43fb-a5b7-8928e6a2b433">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NTdiNTk3ZTUzYzhiNDI2MDg4N2E0M2E1MGVmNTkwNDUvdGFibGVyYW5nZTo1N2I1OTdlNTNjOGI0MjYwODg3YTQzYTUwZWY1OTA0NV8xLTMtMS0xLTE0MDE2Mg_eb661e9c-12bf-49e4-99d6-71e13415702f">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NTdiNTk3ZTUzYzhiNDI2MDg4N2E0M2E1MGVmNTkwNDUvdGFibGVyYW5nZTo1N2I1OTdlNTNjOGI0MjYwODg3YTQzYTUwZWY1OTA0NV8yLTMtMS0xLTE0MDE2Mg_6a0f3b74-ef2a-457f-8d7e-d244a29bd40e">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjMw_aea3f5b0-562e-4da0-96da-4e4e7391daa5">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The registrant had <ix:nonFraction unitRef="shares" contextRef="ib00da7419466450d8612fe7a2961b23e_I20230509" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMTY3_baa58697-5b74-46d7-ab01-64b2c2ec9d5f">45,621,678</ix:nonFraction> shares of common stock outstanding as of May 9, 2023. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i132905a7c9654916bdd441350c765120_7"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i132905a7c9654916bdd441350c765120_16">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_19">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets As of March 31, 2023 and December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss for The Three Months Ended March 31, 2023 and 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity for The Three Months Ended March 31, 2023 and 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows for The Three Months Ended March 31, 2023 and 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_100">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_100">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_124">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_127">35</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i132905a7c9654916bdd441350c765120_130">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_133">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_133">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_133">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_133">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_139">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_139">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_139">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_142">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_142">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_142">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_145">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_145">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_145">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_148">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_148">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_148">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_151">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_151">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_151">11</a>9</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_154">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i132905a7c9654916bdd441350c765120_154">1</a>20</span></div></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i132905a7c9654916bdd441350c765120_792"></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the &#8220;Securities Act,&#8221; and Section 21E of the Securities Exchange Act of 1934, as amended, or the &#8220;Exchange Act&#8221;. Forward-looking statements generally relate to future events or our future financial or operating performance. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these words or other similar terms or expressions. The forward-looking statements and opinions contained in this Form 10-Q are based upon information available to our management as of the date of this Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, progress and results of our investigational COMP360 psilocybin therapy, including statements regarding the timing of initiation and completion of trials or studies and related preparatory work,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including our expectations regarding the amendments we made to the protocols for our Phase 3 clinical program, results of discussions with the Food and Drug Administration, or FDA, regarding our trial design and the timing of the completion of our Phase 3 clinical program for treatment-resistant depression, or TRD, the period during which the results of the trials will become available and our research and development programs;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our estimates regarding our expenses, capital requirements, the sufficiency of our cash resources, our expected cash runway and needs for and ability to raise additional financing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on the success of our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope or likelihood of regulatory filings and approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the size of the eligible patient populations for COMP360 psilocybin therapy, if approved for commercial use;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify third-party clinical sites to conduct our trials and our ability to identify and train appropriately qualified therapists to administer COMP360 psilocybin therapy in our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement our business model and our strategic plans for our business and our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify new indications for COMP360 beyond our current primary focus on TRD, anorexia nervosa, and post-traumatic stress disorder, or PTSD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, develop or acquire digital technologies to enhance our administration of our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to leverage our technology and drug development candidates to advance new psychedelic compounds in other areas of unmet mental health need;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully establish and maintain Centers of Excellence and our ability to achieve our goals with respect to the Center for Mental Health Research and Innovation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing, coverage and reimbursement of our investigational COMP360 psilocybin therapy, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scalability and commercial viability of our manufacturing methods and processes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our investigational COMP360 psilocybin therapy, in particular, and psilocybin-based therapies, in general;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish or maintain collaborations or strategic relationships or obtain additional funding; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding potential benefits of our investigational COMP360 psilocybin therapy and our therapeutic approach generally;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations around feedback from and discussions with regulators, regulatory development paths and with respect to Controlled Substances Act designation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we and any current or future licensors or collaboration partners are able to establish and maintain for intellectual property rights covering COMP360;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States, under the laws and regulations of England and Wales, and other jurisdictions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our internal control over financial reporting;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain qualified employees and key personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effect of global financial and economic conditions and geopolitical events, including instability in the banking system, heightened and fluctuating interest rates and inflation, and foreign exchange fluctuations, particularly the Pound Sterling to U.S. Dollar, the risk of credit-rating downgrades and economic slowdown or recession in the United States due to debt ceiling and budget deficit concerns and efforts to curb inflation, overall market volatility in the United States or the United Kingdom, including as a result of, among other factors, the ongoing war between Russia and Ukraine or similar events, on our business;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of public health crises, pandemics or epidemics such as the COVID-19 pandemic, and any future mitigation efforts, and current or future economic effects, on any of the foregoing or other aspects of our business or operations;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are classified as a controlled foreign corporation, or CFC, or a passive foreign investment company, or PFIC, under the Internal Revenue Code of 1986, as amended, for current and future periods; and </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future trading price of the ADSs and impact of securities analysts&#8217; reports on these prices.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Form 10-Q.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events, which speak only as of the date made. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A, of this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. Except as otherwise required by the securities laws of the United States, we disclaim any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">4</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><div id="i132905a7c9654916bdd441350c765120_812"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks and uncertainties include, but are not limited to, the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">We are a clinical-stage mental health care company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">We will need substantial additional funding to complete the development and commercialization of our investigational COMP360 psilocybin therapy. Our ability to raise additional funds may be adversely impacted by macroeconomic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, including continued instability in the banking system, heightened and fluctuating interest rates and inflation and the risk of credit-rating downgrades and economic slowdown or recession in the United States due to debt ceiling and budget deficit concerns.  Failure to obtain additional funding when needed or on favorable terms may force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization efforts or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">Raising additional capital may cause dilution to holders of our ordinary shares and ADSs, restrict our operations or require us to relinquish rights to COMP360 or any future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">We are dependent on the successful development of our investigational COMP360 psilocybin therapy. We cannot give any assurance that COMP360 will successfully complete clinical trials or receive regulatory approval, which is necessary before it can be commercialized;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">COMP360 is, and any future therapeutic candidates we may develop may be, subject to controlled substance laws and regulations in the jurisdictions where our products, if approved, may be marketed, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, or changes in these laws and regulations may adversely affect the results of our business operations, both during clinical development and post approval, and our financial condition. In addition, during the review process of COMP360, and prior to any approval, the U.S. Food and Drug Administration, or FDA, and/or other regulatory bodies may require additional data, including with respect to whether COMP360 has abuse or misuse potential, which may delay approval and any potential rescheduling process;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">COMP360 contains controlled substances, the use of which may generate public controversy. Adverse publicity or public perception regarding COMP360, in particular, and psilocybin-based therapies, in general, or our current or future investigational therapies using psilocybin may negatively influence the success of these therapies;  </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of COMP360 psilocybin therapy or any future therapeutic candidates are prolonged or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals, and therefore we will be unable to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates on a timely basis or at all, which will adversely affect our business;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">COMP360 psilocybin therapy and any future therapeutic candidates we may develop may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of COMP360 psilocybin therapy or any future therapeutic candidates or following approval, if any, we may need to abandon our development of such therapeutic candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">Research and development of drugs targeting the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our therapies on our own or with suitable collaborators;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">5</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">The future commercial success of our investigational COMP360 psilocybin therapy or any future therapeutic candidates will depend on the degree of market access and acceptance of our potential therapies among healthcare professionals, patients, healthcare payors, health technology assessment bodies and the medical community at large;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">Our business and commercialization strategy depends on our ability to identify, qualify, prepare, certify and support third-party therapy sites offering any approved therapy. If we are unable to do so, our commercialization prospects would be limited and our business, financial condition and results of operations would be harmed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">We currently rely on qualified therapists working at third-party clinical trial sites to administer our investigational COMP360 psilocybin therapy in our clinical trials and we expect this to continue upon approval, if any, of COMP360 or any future therapeutic candidates. If third-party sites fail to recruit and retain a sufficient number of therapists or effectively manage their therapists, our business, financial condition and results of operations would be materially harmed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">Intellectual property rights of third parties could adversely affect our ability to develop or commercialize our investigational therapies, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our investigational therapies. Such litigation or licenses could be costly or not available on commercially reasonable terms;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and could have a material adverse effect on our business;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">We rely on third parties to supply and manufacture the psilocybin and psilocin incorporated in COMP360 and expect to continue to rely on third parties to supply and manufacture any future therapeutic candidates, and we will rely on third parties to manufacture these substances for commercial supply, if approved. If any third-party provider fails to meet its obligations to manufacture COMP360 or our future therapeutic candidates, or fails to maintain or achieve satisfactory regulatory compliance, the development of such substances and the commercialization of any therapies, if approved, could be stopped, delayed or made commercially unviable, less profitable or may result in enforcement actions against us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">There are a number of third parties who conduct investigator-initiated studies, or IISs, using COMP360 provided by us. Any failure by a third party to meet its obligations with respect to the clinical development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates may delay or impair our ability to obtain regulatory approval for COMP360. IISs of COMP360 or any future therapeutic candidates may generate clinical trial data that raises concerns regarding the safety or effectiveness of COMP360 and any data generated in IISs may not be predictive of the results in populations or indications in which we are conducting, or plan to conduct, clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.  Economic uncertainty and worsening or deteriorating global economic conditions and volatile financial market conditions in the United States or the United Kingdom, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">as a result of, among other factors, continued instability in the banking system, heightened and fluctuating inflation and interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the risk of credit-rating downgrades and economic slowdown or recession in the United States due to debt ceiling and budget deficit concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and efforts to curb inflation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">and the ongoing war between Russia and Ukraine or similar events, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">may materially and adversely affect our business, including our ability to raise capital and our financial results;</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">A pandemic, epidemic, or outbreak of an infectious disease, or new variant of COVID-19, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">We face substantial competition and our competitors may discover, develop or commercialize therapies before or more successfully than us, which may result in the reduction or elimination of our commercial opportunities; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">Our business is subject to economic, political, regulatory and other risks associated with international operations; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">We may face business interruptions resulting from failures or significant downtime of our information technology systems resulting from cyber-attacks on such systems or otherwise.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">6</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><div id="i132905a7c9654916bdd441350c765120_16"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i132905a7c9654916bdd441350c765120_19"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i132905a7c9654916bdd441350c765120_22"></div><div><span><br/></span></div><div id="i132905a7c9654916bdd441350c765120_25"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNC0xLTEtMS0xNDAxNjI_445529c6-08dd-4561-9205-319857d20692">117,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNC0zLTEtMS0xNDAxNjI_008743f6-fb8b-43bb-91c0-d75818c8e830">143,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNS0xLTEtMS0xNDAxNjI_ab246577-61b6-4838-b2af-ae6a69883b0f">271</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNS0zLTEtMS0xNDAxNjI_5ed5293b-f46f-40d4-8d4e-5bda1d8fc1a5">175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNi0xLTEtMS0xNDAxNjI_f8def8a1-ce56-4028-8851-ec9cc19b82fd">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNi0zLTEtMS0xNDAxNjI_019c1579-28b9-4ca4-9127-e44b55785718">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNy0xLTEtMS0xNDAxNjI_5968e97c-824f-4b48-9727-c76ac301b962">50,381</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNy0zLTEtMS0xNDAxNjI_40e4c1ba-9866-4805-8556-2ad455df0d47">47,695</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfOC0xLTEtMS0xNDAxNjI_4d0afed1-ca05-4f4e-996b-24571a4b5871">167,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfOC0zLTEtMS0xNDAxNjI_33e94828-9b3c-44a9-aa51-dd5e74fa0752">191,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NON-CURRENT ASSETS:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTAtMS0xLTEtMTQwMTYy_3300d9d2-9961-42b2-91e4-c41d99ff83c1">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTAtMy0xLTEtMTQwMTYy_582c46ec-3735-4750-a552-b00703149907">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTEtMS0xLTEtMTQwMTYy_0dd0d231-d33b-4bc2-81fc-d8a1494e85c7">612</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTEtMy0xLTEtMTQwMTYy_26693bfb-8f87-4742-9c87-64415849c469">617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTItMS0xLTEtMTQwMTYy_723ae5df-6bdb-43fd-a29e-6fd5437c3dd3">1,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTItMy0xLTEtMTQwMTYy_8b9f5e42-14fd-4146-bfe2-da6e2078e879">2,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTMtMS0xLTEtMTQwMTYy_235ebb51-1c07-4449-8ac9-d07f278650ba">2,598</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTMtMy0xLTEtMTQwMTYy_e7868d7e-caa3-4600-b17a-81dd81820578">2,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTQtMS0xLTEtMTQwMTYy_08c3d2b6-027f-47b9-b940-621356f8a163">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTQtMy0xLTEtMTQwMTYy_1062c5ad-52d4-4e61-9da4-758dbe2313f6">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTUtMS0xLTEtMTQwMTYy_40fe7166-0e86-4432-a7e4-eae31191b06d">173,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTUtMy0xLTEtMTQwMTYy_d6eb80fa-584c-47c4-b669-986dec8d90fd">197,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT LIABILITIES:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTgtMS0xLTEtMTQwMTYy_4516780c-3414-4a44-96fa-da4a905306e9">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTgtMy0xLTEtMTQwMTYy_bd677761-1360-4ca9-b3f1-839d5e430e44">4,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTktMS0xLTEtMTQwMTYy_4f8952f9-8613-4ae2-963d-a09ee2599e1f">6,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTktMy0xLTEtMTQwMTYy_c057f62b-a25e-4bf3-8697-7cf1d5195ac4">9,325</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjAtMS0xLTEtMTQwMTYy_f60af427-5ce8-465e-8c00-3891b5ede858">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjAtMy0xLTEtMTQwMTYy_a8e841e1-cde0-42a1-8ea2-9278a1638c91">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjEtMS0xLTEtMTQwMTYy_4e8640f8-facf-4d9d-bb4f-718a0d2017ae">11,254</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjEtMy0xLTEtMTQwMTYy_569ca36c-61ef-4dd4-9447-1ecbc3e84b16">15,596</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NON-CURRENT LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjMtMS0xLTEtMTQwMTYy_b3182dca-fad9-4df0-8efc-362eaa260f25">412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjMtMy0xLTEtMTQwMTYy_a2fa5c9b-7042-4a43-a3a2-99feb200677e">418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjQtMS0xLTEtMTQwMTYy_0dbe0e14-c8a4-40f5-8aca-9ce301f3fb4c">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjQtMy0xLTEtMTQwMTYy_79e6383d-233a-43f4-8b59-29199a71e4ad">16,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjYtMS0xLTEtMTQwMTYy_fc304270-5273-4eb8-86a8-532df4c912df"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjYtMy0xLTEtMTQwMTYy_774e33dd-848f-47e7-92da-e87afddfe584"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHAREHOLDERS' EQUITY:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMjI_1ad7058a-e391-4ecd-9b0e-6d82c5708183"><ix:nonFraction unitRef="gbpPerShare" contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMjI_95f530b0-04b4-4c77-9c29-6e97836a6bf1">0.008</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMzY_34f2783c-721e-408d-ad82-f43fa45212c3"><ix:nonFraction unitRef="shares" contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMzY_765a2d62-d31a-4205-b9f7-f2155dbfdeb4"><ix:nonFraction unitRef="shares" contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMzY_c02c65a0-af91-4b10-98b0-d7607d57dc85">42,779,485</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfNDM_33459943-9046-4258-97f4-b0b72967edb6"><ix:nonFraction unitRef="shares" contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfNDM_b37e8693-bcc1-40a1-a389-e3d6de049f8e"><ix:nonFraction unitRef="shares" contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfNDM_f17858b9-c56b-451f-813e-edae3b7fca60">42,631,794</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding at March 31, 2023 and December 31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMS0xLTEtMTQwMTYy_d478c260-8817-423d-a38c-4abb66db7b02">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMy0xLTEtMTQwMTYy_d81e7ffc-3f8e-48e2-bdb9-486ade6c5c30">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMjI_8bd09ef8-207d-4908-9052-a361f9d85713"><ix:nonFraction unitRef="gbpPerShare" contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMjI_fd12dd69-fd6b-4186-ad74-8b96c3024266">21,921.504</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_004cd51f-5225-48f2-99b6-c6a96c7d5b07"><ix:nonFraction unitRef="shares" contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_3f3b95bb-e273-4da7-9282-20a8acb8fb81"><ix:nonFraction unitRef="shares" contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_690ba02a-b06d-4a23-bab5-57aad2a0d8bb"><ix:nonFraction unitRef="shares" contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_c8bb65d8-40db-4d4b-9ced-dbcdb23a5935"><ix:nonFraction unitRef="shares" contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_df09192a-d6ae-4a7f-9309-f79d98239f4f"><ix:nonFraction unitRef="shares" contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_ff5da8ef-8b50-4b19-bf94-01d5161acd93">one</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> share authorized, issued and outstanding at March 31, 2023 and December 31, 2022</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMS0xLTEtMTQwMTYy_df19d582-cd9d-4b1d-9bca-4da71b7028ee">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMy0xLTEtMTQwMTYy_b42cd473-6438-44c4-90ce-3198cbe03788">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzAtMS0xLTEtMTQwMTYy_216549e3-274c-49ff-9ee7-1f51d9652b48">463,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzAtMy0xLTEtMTQwMTYy_dcad0306-757f-4432-9cde-d9467d998975">458,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzEtMS0xLTEtMTQwMTYy_bc3edaab-4342-464f-98b9-3142cac8bda7">17,445</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzEtMy0xLTEtMTQwMTYy_1b979236-b9f8-4875-b9db-a9d23e98732c">16,867</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzItMS0xLTEtMTQwMTYy_85c1d3c9-ea25-44fe-a36f-079763ada458">285,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzItMy0xLTEtMTQwMTYy_b97a05bd-8bf3-4536-9d26-75ae3913164b">261,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzMtMS0xLTEtMTQwMTYy_33d269eb-bca4-4237-9d29-bc0ccf03fe85">161,644</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzMtMy0xLTEtMTQwMTYy_61facf68-63e1-4123-8ebc-c3f599648f87">181,280</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzQtMS0xLTEtMTQwMTYy_0dd8582a-4db3-4b14-b4d4-a647390237ce">173,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzQtMy0xLTEtMTQwMTYy_ed3bca0c-6354-4012-a7fa-5909dfd61725">197,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">7</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><div id="i132905a7c9654916bdd441350c765120_28"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMy0xLTEtMS0xNDAxNjI_c6ad9e98-0460-4535-83e3-4d559323de1b">19,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMy0zLTEtMS0xNDAxNjI_5839b829-3f24-4bb9-94c5-5834210344de">15,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNC0xLTEtMS0xNDAxNjI_010819a8-3063-4bf8-a233-41645c6b0d3a">12,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNC0zLTEtMS0xNDAxNjI_4db96392-5894-44a0-b023-ec60dd8b38f6">10,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNS0xLTEtMS0xNDAxNjI_8c7aef83-b6ef-4664-92b0-2328c716529f">31,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNS0zLTEtMS0xNDAxNjI_f46731bc-c972-4994-8629-5fe4b9ae8183">25,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LOSS FROM OPERATIONS:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNi0xLTEtMS0xNDAxNjI_0e434ee9-b0db-44a3-a190-5628a60d18c7">31,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNi0zLTEtMS0xNDAxNjI_f3d3f1e4-117f-4c82-8832-ea92c310498c">25,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER INCOME, NET:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfOC0xLTEtMS0xNDAxNjI_63e5bb39-b4d9-4d16-b0ca-59841bc61357">709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfOC0zLTEtMS0xNDAxNjI_a07b89d1-52c5-4af5-8104-359cd632d541">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfOS0xLTEtMS0xNDAxNjI_8a49caf1-795f-4e4c-ab57-33b47e2fd5e0">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfOS0zLTEtMS0xNDAxNjI_3cae0c2b-a212-4438-a4f1-6e0bf27ff7cf">1,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTAtMS0xLTEtMTQwMTYy_ea40cad1-b858-475d-a6a8-2e0c721fa292">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTAtMy0xLTEtMTQwMTYy_f52fb8c6-1cb1-4fa0-aa1e-6e2b3aa9b7fe">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTEtMS0xLTEtMTQwMTYy_c6719d71-7cc5-4dbe-8bc3-ab4693e1d8a5">7,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTEtMy0xLTEtMTQwMTYy_a096731f-da2c-48cd-85f9-cda77f2842da">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTItMS0xLTEtMTQwMTYy_b4572873-561e-41f0-b867-0afcd0e47e02">24,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTItMy0xLTEtMTQwMTYy_a962fbd0-2dd5-442f-8d33-a7db3011babf">21,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTMtMS0xLTEtMTQwMTYy_9f8fcd99-7d42-4de0-9ff1-7334bc57e969">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTMtMy0xLTEtMTQwMTYy_dc36a0e9-f84b-4393-a75f-df76d6516dc4">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTQtMS0xLTEtMTQwMTYy_98cacd09-89e1-417a-adee-7fb358725d0d">24,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTQtMy0xLTEtMTQwMTYy_ddaf53b1-b992-44cb-bfc8-b42d3b802004">21,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTYtMS0xLTEtMTQwMTYy_1c59ced8-1fb8-4faf-a1ca-b8e092850684">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTYtMy0xLTEtMTQwMTYy_ea34f858-0d3d-4e4a-a8be-c1b8bdbb3869">7,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTctMS0xLTEtMTQwMTYy_92b0cddf-27f9-4cf8-9da4-44cd5a5baf42">24,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTctMy0xLTEtMTQwMTYy_9bf16778-14da-4d55-a85a-27f4861dcd86">28,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders&#8212;basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTgtMS0xLTEtMTQwMTYy_65ed4d81-e9a8-4f0c-9400-030f4e4232ba"><ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTgtMS0xLTEtMTQwMTYy_851f2bf9-fffc-4e95-8137-218db3411fe0">0.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTgtMy0xLTEtMTQwMTYy_e708671b-3f96-4736-9ec4-db1e696d8f83"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTgtMy0xLTEtMTQwMTYy_ece6acf3-9b79-4a35-a26d-6f603f3d465e">0.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ordinary shares outstanding&#8212;basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTktMS0xLTEtMTQwMTYy_0e4b51d0-430b-44ab-82dd-fbf6796d6e76"><ix:nonFraction unitRef="shares" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTktMS0xLTEtMTQwMTYy_2f2f64a2-a831-492c-bf73-c0e69ff3683d">42,725,863</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTktMy0xLTEtMTQwMTYy_0ea6bd18-6817-41d3-8ba4-ea56cd9312ca"><ix:nonFraction unitRef="shares" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTktMy0xLTEtMTQwMTYy_ce984243-3117-41b5-9ab7-786e44f48463">42,036,563</ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">8</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><div id="i132905a7c9654916bdd441350c765120_31"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.598%"><tr><td style="width:1.0%"></td><td style="width:18.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.399%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ORDINARY SHARES &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjUtMS0xLTEtMTQwMTYyL3RleHRyZWdpb246MDgyMGQwOWI2NWJkNDEzOGE4MzYxZGRjOTA5OTU5YThfMjE_1ad7058a-e391-4ecd-9b0e-6d82c5708183"><ix:nonFraction unitRef="gbpPerShare" contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjUtMS0xLTEtMTQwMTYyL3RleHRyZWdpb246MDgyMGQwOWI2NWJkNDEzOGE4MzYxZGRjOTA5OTU5YThfMjE_95f530b0-04b4-4c77-9c29-6e97836a6bf1">0.008</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DEFERRED SHARES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ADDITIONAL PAID-IN CAPITAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACCUMULATED DEFICIT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PAR VALUE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjYtNS0xLTEtMTQwMTYyL3RleHRyZWdpb246YzA0OTk0NTNjZWRlNDkyZmE0Y2UyNGViMmNlMTc0MWNfNQ_8bd09ef8-207d-4908-9052-a361f9d85713"><ix:nonFraction unitRef="gbpPerShare" contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjYtNS0xLTEtMTQwMTYyL3RleHRyZWdpb246YzA0OTk0NTNjZWRlNDkyZmE0Y2UyNGViMmNlMTc0MWNfNQ_fd12dd69-fd6b-4186-ad74-8b96c3024266">21,921.504</ix:nonFraction></ix:nonFraction> PAR VALUE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMOUNT</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i996a9a2f8d294a9f95e96689ead7e84e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMS0xLTEtMTQwMTYy_b457a6b1-e2a0-4a40-a62d-6116fd7790a2">42,019,874</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996a9a2f8d294a9f95e96689ead7e84e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMy0xLTEtMTQwMTYy_73845165-8442-4835-a94c-09a1c25e9e29">435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied43d7e0b5ea423c95391b44528d3a53_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtNS0xLTEtMTQwMTYy_1d8afc90-0d9c-4cee-aec4-d600c37cb481">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied43d7e0b5ea423c95391b44528d3a53_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtNy0xLTEtMTQwMTYy_a038545a-e96f-4597-84b1-ab12511b60b8">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54af68e04565485696634eacfdfb44f0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtOS0xLTEtMTQwMTYy_61faf2fe-e281-4015-9a5c-832994c16de8">444,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141ce2dc3cbb40bd99c09099ae6fabbf_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMTEtMS0xLTE0MDE2Mg_690e923d-0b9e-405b-a54f-9ab8fa064ab6">8,840</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36576268599e4fd8bf18172064ed862d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMTMtMS0xLTE0MDE2Mg_5ed18c81-d53b-4724-84f5-aef0284b3f79">169,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898f890161564fe59100013d33b6fbf8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMTUtMS0xLTE0MDE2Mg_c581b0ee-2bb8-4089-ba56-3f8ae130e072">284,412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjktMS0xLTEtMTQwMTYy_7ec75267-e69c-458f-93a8-3a3ba97c6e35">376,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjktMy0xLTEtMTQwMTYy_8da949fc-0f1b-4116-b553-45ed81e8b3c5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791c0755a9154956b424d9d20a0f7f01_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjktOS0xLTEtMTQwMTYy_45ee7713-4fee-4b9f-a289-fcdea8247300">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjktMTUtMS0xLTE0MDE2Mg_aca62236-34b7-47e9-be79-d02ecaa195ab">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzAtMS0xLTEtMTQwMTYy_d92dc5a2-4962-4c3f-ae1c-1405a4d77677">68,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzAtMy0xLTEtMTQwMTYy_06497bb7-cb74-478e-9ef7-9a5af9f10f0d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzAtMTUtMS0xLTE0MDE2Mg_ba3f1272-c202-4c47-bcbe-bc27fac9bfbc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791c0755a9154956b424d9d20a0f7f01_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzEtOS0xLTEtMTQwMTYy_1f82b9e2-5d42-4161-aa0e-f7677ff51738">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzEtMTUtMS0xLTE0MDE2Mg_80b7b20a-339e-4f94-b6bb-aef3efcaa504">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a89f22f54c64b9e9b9aab3c0f6d7efb_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzItMTEtMS0xLTE0MDE2Mg_b5004e8f-001b-4c59-95d9-5baadc9f8d2b">7,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzItMTUtMS0xLTE0MDE2Mg_3e864b6d-1707-4e15-8bb9-3e1294fa5bce">7,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if70809ae9cce49cfac3b711f0475be91_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzMtMTMtMS0xLTE0MDE2Mg_4f24c92b-abe6-42e1-b86f-24a4bf45953e">21,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzMtMTUtMS0xLTE0MDE2Mg_343ea59a-ae21-4345-a9be-0798706b9af1">21,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i930583009ce145dd84d88be7a117f69a_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMS0xLTEtMTQwMTYy_3d6090b0-a368-4bb7-b5d1-dbf935a79124">42,464,566</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930583009ce145dd84d88be7a117f69a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMy0xLTEtMTQwMTYy_525637fb-b782-42eb-be81-52d18121cba8">440</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9c6df05b14e473ba0b9e00b725c4e39_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtNS0xLTEtMTQwMTYy_dbfc3a31-5770-4e61-9dd8-599bedf5833b">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9c6df05b14e473ba0b9e00b725c4e39_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtNy0xLTEtMTQwMTYy_09e07689-e285-41db-9a16-ae7408b33aee">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03566c748b444fe94d62e9e28a827ae_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtOS0xLTEtMTQwMTYy_b7b5659e-f5a7-46bb-9feb-7b063f1c0b3f">448,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ebb5874ffc463eae558a0bca081f38_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMTEtMS0xLTE0MDE2Mg_e352eeb5-9b6d-472d-a1e6-3b6948595440">1,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15382a1c78b24f7781f909cac2666727_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMTMtMS0xLTE0MDE2Mg_c75d7f00-e047-4e56-acd9-63a681d004b2">190,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7765db2674724718901c035cce089b95_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMTUtMS0xLTE0MDE2Mg_740adf9c-3e75-4f19-a3aa-c88f3e5483eb">259,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia98b20644358427a878a9249c15fc81e_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMS0xLTEtMTQwMTYy_0fbe0853-eabd-4159-b960-7086fd1c5e14">42,631,794</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98b20644358427a878a9249c15fc81e_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMy0xLTEtMTQwMTYy_30223534-7194-46d0-a3a5-ca204e8dcd66">440</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cd164da18c74147b770195a655c5b6a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtNS0xLTEtMTQwMTYy_c6fa0e6f-1c42-4068-994d-1beace5413dd">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd164da18c74147b770195a655c5b6a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtNy0xLTEtMTQwMTYy_8cabfacd-9f0a-463b-bef1-e9f1415084c3">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ecb856e1088469e91d8161b926b64b0_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtOS0xLTEtMTQwMTYy_17f16676-342f-451b-9c79-9cc2cc43d02d">458,825</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e11cf9e5ac74fb2ac41daf1d28be1e4_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMTEtMS0xLTE0MDE2Mg_5f2390a7-5fe4-4b6e-ab8d-c7083d1cd2c5">16,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48b92bc0ebd64ca2ac7a3bd9ea558598_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMTMtMS0xLTE0MDE2Mg_be829fea-a1c2-4ac3-ab68-d8fbeb964d90">261,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMTUtMS0xLTE0MDE2Mg_17f8b6f9-0f48-4be1-8fba-a1f019ed024d">181,280</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDMtMS0xLTEtMTQwMTYy_91317d9e-9369-4f7b-b7d3-d665f9e00ba4">3,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares under ATM facility, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDQtMS0xLTEtMTQwMTYy_fabebbc7-509b-4fe9-adbd-6125778752c2">113,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDQtMy0xLTEtMTQwMTYy_bfbab56d-4f53-4829-bd66-3b7ab3404bea">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDQtOS0xLTEtMTQwMTYy_de4b52bc-0b6a-4f1e-b58f-5925e7a3a905">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDQtMTUtMS0xLTE0MDE2Mg_74925d67-79b7-44a2-8b58-fefdcdad65d9">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares to settle vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTQtMS0xLTEtMTQ1Nzg4_fe4cbd5d-d0bf-4e92-8a07-98f2dede52ab">30,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTQtMy0xLTEtMTQ1Nzg4_8f7caba2-061f-494c-948e-3d0495371f72">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTQtOS0xLTEtMTQ1Nzg4_27bdb761-3a11-4d54-8d9d-4b9320cbb35f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTQtMTUtMS0xLTE0NTc4OA_92da273b-ff6c-4bc5-a695-22dbbd567c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares tendered for withholding taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTUtOS0xLTEtMTQ1Nzg4_c3a0d432-643e-470d-9fc9-696af296db68">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTUtMTUtMS0xLTE0NTc4OA_d97a7017-ee6f-4a85-8a64-b51c1a3234f3">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDUtOS0xLTEtMTQwMTYy_f2c5e55f-a4ae-4b62-9687-63fadf38ee6b">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDUtMTUtMS0xLTE0MDE2Mg_b43b840f-f436-4434-bb9b-88bc886475df">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccea7b15b4b34b7881a38a9aeb5a255d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDYtMTEtMS0xLTE0MDE2Mg_d1f84900-9576-4a05-af1c-fce82abe2c09">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDYtMTUtMS0xLTE0MDE2Mg_132a2cb3-74e6-499b-968f-07bbfb3d9107">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a788380d1dd41a192369ee1283627cb_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDctMTMtMS0xLTE0MDE2Mg_8af6a80e-cdc2-4054-9890-29e589d65430">24,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDctMTUtMS0xLTE0MDE2Mg_b4da8da7-542d-4fd2-9f95-88b575f9d8e0">24,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib62e231bc5e04aadaa0e552da9eaa69b_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMS0xLTEtMTQwMTYy_47233eff-55ed-4bd4-88f1-8c4dc24dce5c">42,779,485</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib62e231bc5e04aadaa0e552da9eaa69b_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMy0xLTEtMTQwMTYy_aa4502cd-ad0a-4960-82aa-8dcf2c797723">442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie933ef689fe34ea1857fb293be2148bc_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtNS0xLTEtMTQwMTYy_6f48ab0a-16b6-4926-b630-6ac63f7bcbbe">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie933ef689fe34ea1857fb293be2148bc_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtNy0xLTEtMTQwMTYy_62e8c1b5-b4a8-44f1-aa67-ec21855dd8ae">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee88fb1648c24d69a547b9473b48ce0b_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtOS0xLTEtMTQwMTYy_56f65fa1-0da6-4626-b357-f20c118db992">463,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib62efe8423eb495089400103d98fb87b_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMTEtMS0xLTE0MDE2Mg_79c2177e-a4e4-43a2-a86d-3a1f9f9542dc">17,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idffcb1da5bec4469ab5d69a783ed74e6_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMTMtMS0xLTE0MDE2Mg_84b04efc-bae2-4e67-b142-7f26cad20e55">285,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMTUtMS0xLTE0MDE2Mg_9d63e1af-2e4f-4719-bf29-7a57dbbfab4a">161,644</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i132905a7c9654916bdd441350c765120_34"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMy0xLTEtMS0xNDAxNjI_c1cccf5b-630d-4c56-8111-87d127086545">24,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMy0zLTEtMS0xNDAxNjI_bd2925c8-dfbd-4ada-bec8-663ac49f374f">21,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNS0xLTEtMS0xNDAxNjI_cd00abc8-9400-49f3-a739-d0d09a2995e5">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNS0zLTEtMS0xNDAxNjI_9ecb1f5e-4d04-4cbb-a663-67dd59df66e9">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash gain on foreign currency remeasurement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNi0xLTEtMS0xNDAxNjI_3024929f-deec-4bf6-9532-b429b5c4bb7f">2,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNi0zLTEtMS0xNDAxNjI_c106ce2d-e620-4ab0-8de5-5ff802dcdee0">219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNy0xLTEtMS0xNDAxNjI_5086d244-2a7d-4207-9e61-03ff54a665d0">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNy0zLTEtMS0xNDAxNjI_475f7cae-a790-4efa-85e1-2fce56e2ab1d">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfOC0xLTEtMS0xNDAxNjI_1d1bbb09-632f-4132-8fab-a82f684be5d9">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfOC0zLTEtMS0xNDAxNjI_ce9e9474-8354-4c2e-9b65-20c49959966b">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTAtMS0xLTEtMTQwMTYy_f17c0735-5921-47da-9007-3f4f47245341">1,484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTAtMy0xLTEtMTQwMTYy_90fd87c6-1525-4ab2-ac07-d5b942d274df">1,386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and prepaid tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTEtMS0xLTEtMTQwMTYy_c326366f-17ba-4d8e-a17f-ce35d4ae2894">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTEtMy0xLTEtMTQwMTYy_5b77c736-9587-4ae1-acf4-eb7c02cd3768">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTItMS0xLTEtMTQwMTYy_59f2bbc4-9ced-4bb0-a3fe-809f77767f7c">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTItMy0xLTEtMTQwMTYy_84df1be7-e9e0-4da9-a0e7-87ba66ee5b1b">311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTMtMS0xLTEtMTQwMTYy_885c2d99-065d-4924-83fc-e5c981bacc8f">478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTMtMy0xLTEtMTQwMTYy_a0fc14be-9c91-46ef-841d-609a6f567b6f">538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTQtMS0xLTEtMTQwMTYy_9788f655-b85e-46a0-a97c-1c9babf20d6c">973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTQtMy0xLTEtMTQwMTYy_dc4b8f35-a66b-4df0-8a7a-c648bf040e3b">445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTUtMS0xLTEtMTQwMTYy_8de25093-3a88-4313-82f1-ebd6618288d1">3,216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTUtMy0xLTEtMTQwMTYy_7677723a-1daa-4492-91eb-8186bf3e1177">2,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTYtMS0xLTEtMTQwMTYy_4048359f-04ec-4ec8-82c0-65476ed8ea98">27,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTYtMy0xLTEtMTQwMTYy_5a39599d-0678-4956-8557-9a4631286d93">23,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTgtMS0xLTEtMTQwMTYy_22d0b06c-d114-4186-ab8b-509f23615738">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTgtMy0xLTEtMTQwMTYy_4eb7c98a-ab47-4669-9f6f-b2e18c540876">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTktMS0xLTEtMTQwMTYy_8d6b1e83-892d-43ce-9bdc-329a4279a30a">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTktMy0xLTEtMTQwMTYy_2589a9d6-ea67-40b7-8e57-b7798cd09896">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of ordinary shares, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjEtMS0xLTEtMTQ1NzA3_cd914c61-524d-44c4-a870-cb9cbe219b7f">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjEtMy0xLTEtMTQ1NzA3_3f695ae3-3f8c-43b3-a707-ff131ed20879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of tax withholding on stock award</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjItMS0xLTEtMTQ1NzE5_1ccf4a9a-ec80-4795-ae9a-ac7611c8b653">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjItMy0xLTEtMTQ1NzE5_563894d3-d8e6-45d2-874e-5ac4c147e896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjItMS0xLTEtMTQwMTYy_d45440dc-89df-42b6-a59a-eb1578ac301b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjItMy0xLTEtMTQwMTYy_3d0e9570-ea36-4556-b726-89cfa78add00">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjMtMS0xLTEtMTQwMTYy_69bea6ad-9003-4d0b-bcac-89be7768f5fa">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjMtMy0xLTEtMTQwMTYy_49fcd1d3-9c95-49f4-a45f-82246d5d4955">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjQtMS0xLTEtMTQwMTYy_1c785c21-1303-4444-8e34-3c3bf850b233">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjQtMy0xLTEtMTQwMTYy_858d8e8f-21f9-4367-838d-46d576dd037f">6,543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjUtMS0xLTEtMTQwMTYy_3ecb7b79-66bc-474f-8c98-6e6123be1466">26,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjUtMy0xLTEtMTQwMTYy_c682ab8b-b164-4da0-bd64-8db0a176435f">29,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjYtMS0xLTEtMTQwMTYy_89107a64-6f0e-4e37-81f4-32fc5ff5c8e9">143,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898f890161564fe59100013d33b6fbf8_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjYtMy0xLTEtMTQwMTYy_6ee24670-94ee-4d47-8b04-1ad90a70de4b">273,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjctMS0xLTEtMTQwMTYy_b11967a0-d546-433f-955c-68bfe7705157">117,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7765db2674724718901c035cce089b95_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjctMy0xLTEtMTQwMTYy_89731e85-b2cd-48d8-a122-e64fe2981d50">243,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right&#160;of&#160;use&#160;assets&#160;obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzEtMS0xLTEtMTQ1NzQw_b056cdbe-883a-4f29-a5ba-dc6fdd660507">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzEtMy0xLTEtMTQ1NzQw_85604d53-6d9f-4799-b799-a55fef27c76d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options received and recorded in other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="cmps:ProceedsFromStockOptionsExercisedNotReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzEtMS0xLTEtMTQwMTYy_e9164ac7-454d-423a-a13e-0bf674ddf90d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="cmps:ProceedsFromStockOptionsExercisedNotReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzEtMy0xLTEtMTQwMTYy_d0408c9a-26a1-444a-b380-aff46a019955">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs included in accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="cmps:DeferredOfferingCostsIncludedInAccruedExpenses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzItMS0xLTEtMTQwMTYy_6991aa42-e2be-4247-a6d6-9037e3a8f79f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="cmps:DeferredOfferingCostsIncludedInAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzItMy0xLTEtMTQwMTYy_e17ac83b-0bf2-4deb-af33-e5d302734ae8">835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the cash, cash equivalents and restricted cash balances as of each of the periods, shown above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfMi0xLTEtMS0xNDAxNjI_cfd3b41e-240b-4e85-81d8-689c9ffe6203">117,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7765db2674724718901c035cce089b95_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfMi0zLTEtMS0xNDAxNjI_73a2554f-cba2-4c3d-8ca2-bdc9e0342518">243,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfMy0xLTEtMS0xNDAxNjI_1d6be6b4-c0b2-46c0-8db6-f5d2ffe56c2d">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7765db2674724718901c035cce089b95_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfMy0zLTEtMS0xNDAxNjI_a8ebbcdb-7aa2-4a87-b453-c5daf46bb408">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfNC0xLTEtMS0xNDAxNjI_ce8d47af-7331-44c2-86fa-ed290f0e82a9">117,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7765db2674724718901c035cce089b95_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfNC0zLTEtMS0xNDAxNjI_4adbedb5-2ecb-454c-a2dc-865337741c50">243,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i132905a7c9654916bdd441350c765120_37"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i132905a7c9654916bdd441350c765120_40"></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfNDk1Mw_16b5bdd1-447c-4b79-a133-3589ef02ea8b" continuedAt="i690a73b6f23341f2ac1044c13198461d" escape="true">Nature of Business </ix:nonNumeric></span></div><ix:continuation id="i690a73b6f23341f2ac1044c13198461d"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMPASS Pathways plc, or the Company, is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has funded its operations primarily with proceeds from the sale of its convertible preferred shares, the issuance of convertible notes, and through the sale of American Depository Shares, or ADSs, in connection with the Company&#8217;s initial public offering, or the IPO, in September 2020, and its May 2021 follow-on offering. On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $<ix:nonFraction unitRef="usd" contextRef="ifb330f455e5841ea8450b766d642b939_I20211008" decimals="-5" name="cmps:SaleOfStockMaximumAmountAllowableForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTgwMg_2b977aa3-bdca-44e3-ba53-94d81059e9c7">150.0</ix:nonFraction>&#160;million of its ADSs, each representing <ix:nonFraction unitRef="number" contextRef="i8cc171482c7f4d51822f9ae8848dea3e_D20211008-20211008" decimals="INF" name="cmps:NumberOfOrdinarySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTgzNg_353960c9-119b-423c-aed2-9b0f5e6e7541">one</ix:nonFraction> ordinary share, through Cowen as the sales agent. Sales of the Company&#8217;s ADSs, if any, will be made at market prices. Through March 31, 2023 we sold <ix:nonFraction unitRef="shares" contextRef="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTA5OTUxMTY0MTcwNw_9e2e3494-e45d-4bf6-b714-be9cc6c62d07">157,836</ix:nonFraction> ADSs, resulting in $<ix:nonFraction unitRef="usd" contextRef="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTA5OTUxMTY0MTcwOQ_4e830ec4-c2c9-4521-888f-e31d8564948b">1.6</ix:nonFraction>&#160;million in net proceeds. During the second quarter of 2023, through May 10, 2023, we sold <ix:nonFraction unitRef="shares" contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTA5OTUxMTY1MjE2Nw_ed3d2f39-2943-4a86-8023-33756b0ab149">2,824,202</ix:nonFraction> ADSs, resulting in $<ix:nonFraction unitRef="usd" contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTA5OTUxMTY1MjE3OA_7a83fdfa-3dca-4542-98a8-971adacde829">26.9</ix:nonFraction>&#160;million in net proceeds.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred recurring losses since its inception, including net losses of $<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfNTQ5NzU1ODE5MDgz_c4f04603-9fa6-4759-b2a0-96dce0988214">24.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfNTQ5NzU1ODE5MDg2_79aa8249-dcc4-4f3a-8347-b9c5fd2043b5">21.2</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively. In addition, as of March&#160;31, 2023, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia12a666d1e1c4e28811b0491bb87e477_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMjI4MA_ab9bd1f1-bdf0-43ae-b2ad-245bb09c8078">285.4</ix:nonFraction> million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes the cash and cash equivalents on hand as of March&#160;31, 2023 of $<ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMjkwMg_31e2843d-719d-4bdd-b006-254e23859a89">117.1</ix:nonFraction> million, together with the net proceeds from the sale of the Company&#8217;s ADSs, through May 10, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months, including progressing our Phase 3 clinical program, our Phase 2 studies in anorexia nervosa and PTSD and costs associated with operating as a public company. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.  We will need substantial additional funding to complete the development and commercialization of our Phase 3 clinical program, and our Phase 2 studies in anorexia nervosa and PTSD.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Further, changing circumstances, some of which may be beyond our control, such as heightened or fluctuating inflation and interest rates, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. There can be no assurance that additional funding will be available on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial conditions.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Market volatility, instability in the banking system, geopolitical tensions resulting from the ongoing war between Ukraine and Russia, heightened or fluctuating inflation and interest rates and the related impact on U.S., U.K. and global economies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the risk of credit-rating downgrades and economic slowdown or recession in the United States due to debt ceiling and budget deficit concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%"> or efforts to combat inflation or other economic or other factors could adversely impact our operations, financial results and ability to raise additional funding.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i132905a7c9654916bdd441350c765120_46"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODg_fb8578ca-4b65-410f-873f-c969f1eeeb04" continuedAt="icbc85c258ee745bb8b55655a970a46bd" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="icbc85c258ee745bb8b55655a970a46bd" continuedAt="i1b2d7c2a37b84895bc8046d02034c6ae"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODQ_942beee5-cb37-483b-9748-3bda372e1f0a" continuedAt="i16758384b14547babddae577c8a7fc1e" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual condensed consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2023, the results of its operations and comprehensive loss for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023 and 2022.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i16758384b14547babddae577c8a7fc1e">The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 28, 2023. The condensed consolidated balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg2MDA_439a2655-8a56-4bc9-a45f-606a8bc5e07b" continuedAt="i99e119f65bb441478776d133620576d6" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i99e119f65bb441478776d133620576d6">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTQ_88aadfd3-a2a9-4dca-8203-f43ca77dbf7b" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg2MDE_4cc387b1-6048-421b-9b3c-456ab2811c3d" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTA_c3a8309c-77ee-4006-9927-903f85ebd51e" continuedAt="i650fbf46af7b4974b6740927c74fb819" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i650fbf46af7b4974b6740927c74fb819">Restricted cash as of March&#160;31, 2023 and December&#160;31, 2022 represents a collateral deposit for employee credit cards.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1Nzg_e6235708-6ab8-4dd9-9da6-316557e45ba9" continuedAt="i76afcea9721345ea837f8bf30b6f4775" escape="true">Investment</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i76afcea9721345ea837f8bf30b6f4775">The investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee.</ix:continuation> </span></div><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTU_931ff20b-0990-494d-82e3-0628cc7a3c0c" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i1b2d7c2a37b84895bc8046d02034c6ae" continuedAt="i52e27b9af25048979c381a0ac32f73c2"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1Nzk_c69e2ba9-30a3-4c1d-8029-f0abbe940452" continuedAt="ic86fe8ea7cde4798924581db0d9c8c15" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:18pt"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODI_4503d4b5-b599-4670-b498-ebf7f5e6e841" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"></td><td style="width:69.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74d151acb50c43c5a8922ab30b91f0da_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RhYmxlOjBjYTYyY2Y3N2U4ZDRjYjBhZDlmNzI3M2Y5OGU2ODhkL3RhYmxlcmFuZ2U6MGNhNjJjZjc3ZThkNGNiMGFkOWY3MjczZjk4ZTY4OGRfMS0xLTEtMS0xNDAxNjI_ff23c831-e6d7-440b-a689-f14044597892">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7dc74026a9740bf91b61706f4057936_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RhYmxlOjBjYTYyY2Y3N2U4ZDRjYjBhZDlmNzI3M2Y5OGU2ODhkL3RhYmxlcmFuZ2U6MGNhNjJjZjc3ZThkNGNiMGFkOWY3MjczZjk4ZTY4OGRfMi0xLTEtMS0xNDAxNjIvdGV4dHJlZ2lvbjpmODUwNzRjNmYxZGI0YTlmODQxNDViZTk2M2VmYWNkNF80_83645493-2506-4620-a7de-ccf6bac95d95">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i269e60958eaf430baf2c5267c8716c7f_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RhYmxlOjBjYTYyY2Y3N2U4ZDRjYjBhZDlmNzI3M2Y5OGU2ODhkL3RhYmxlcmFuZ2U6MGNhNjJjZjc3ZThkNGNiMGFkOWY3MjczZjk4ZTY4OGRfMi0xLTEtMS0xNDAxNjIvdGV4dHJlZ2lvbjpmODUwNzRjNmYxZGI0YTlmODQxNDViZTk2M2VmYWNkNF83_5166cbaf-932d-4696-b5f6-4ff1e264e84a">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89200d84b6204258aa19770fb2ce7ef4_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RhYmxlOjBjYTYyY2Y3N2U4ZDRjYjBhZDlmNzI3M2Y5OGU2ODhkL3RhYmxlcmFuZ2U6MGNhNjJjZjc3ZThkNGNiMGFkOWY3MjczZjk4ZTY4OGRfMy0xLTEtMS0xNDAxNjI_8be8d311-58cf-45be-a33e-fda48ac6e610">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic86fe8ea7cde4798924581db0d9c8c15">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTY_4565096f-9a4f-4d61-8309-98e02460e581" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the three months ended March 31, 2023 and 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODU_1af7653e-e397-4a2e-96c7-1b4409d243a3" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment; however, the Company operates in <ix:nonFraction unitRef="region" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="INF" name="cmps:NumberOfGeographicRegions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfNzEzOQ_db083394-c4ae-4ee8-8bb4-f2b095cc761d">two</ix:nonFraction> geographic regions: the United Kingdom, or UK, and the United States. The Company&#8217;s fixed assets are primarily located in the UK. The Company&#8217;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODY_55155859-b94e-440a-bb66-713747a43fda" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTE_3385929d-f38b-4bf8-a581-4b84bf54b0a3" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract Costs, Prepayments and Accruals</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepayments and accrual estimates have not been materially different from the actual costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODA_7429581d-9caf-45a8-98b7-2f19b2596baa" continuedAt="i52db9bd2d8634a89814357401156f6b8" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as an expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i52e27b9af25048979c381a0ac32f73c2" continuedAt="ia91f3c0f357a4fb7b3098b9d9e55bfe1"><ix:continuation id="i52db9bd2d8634a89814357401156f6b8"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimates the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 8 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMzI5ODUzNDkxMTk4NA_e858f3f6-7c3d-4abd-8a43-4bc3617cc920">zero</ix:nonFraction> is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.</span></div></ix:continuation><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTc_ea930483-7fc4-4f72-bc7a-963a0dc4dfc7" continuedAt="if26360668d59419baaff5f14c5484f13" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="ifcb5e67ff9464397aed19cb5b9642c90_I20210101" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMTQ4MDA_8b447e3b-06aa-40ed-ac08-018e8e799b86"><ix:nonFraction unitRef="usd" contextRef="ifcb5e67ff9464397aed19cb5b9642c90_I20210101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMTQ4MDA_d73cee71-fcd6-41e3-b47f-e588707c3c63">1.0</ix:nonFraction></ix:nonFraction>&#160;million, on the Company&#8217;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#8217;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 10 for right-of-use assets and liabilities recorded during the periods ended March 31, 2023 and 2022 respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#8217;s leases are classified as operating leases.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has historically not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="ia91f3c0f357a4fb7b3098b9d9e55bfe1" continuedAt="i2b4ed4d96a8d45e4add769e821e1fbeb"><ix:continuation id="if26360668d59419baaff5f14c5484f13"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.</span></div></ix:continuation><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTM_1ca62cf1-8ec9-4ad5-bb89-a63a6a1ceea5" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency is the currency of the primary economic environment in which an entity&#8217;s operations are conducted. On January 1, 2023, COMPASS Pathways plc and its wholly owned subsidiary COMPASS Pathfinder Holdings Limited changed their functional currency to the U.S. dollar. COMPASS Pathways plc and COMPASS Pathfinder Holdings Limited have no operating activities and their primary functions are to serve as a financing vehicle to fund the operations of the Company&#8217;s operating entities, to serve as the listing company needed to access U.S. capital markets, and to hold investments.  Therefore, its financing source is the primary indicator of its cash flows and its functional currency. The change in functional currency from the British Pound Sterling is due to a change in the source of the Company&#8217;s financing and cash flows going forward, which will now primarily be U.S. Dollars (&#8220;USD&#8221;).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of COMPASS Pathfinder Holdings Limited&#8217;s wholly owned non-U.S. subsidiary, COMPASS Pathfinder Limited, is British Pound Sterling and the functional currency of its U.S. subsidiary, COMPASS Pathways Inc. is USD. The functional currency of these subsidiaries is the same as the local currency.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The translated balances of monetary and non-monetary assets and liabilities recorded in the reporting entity&#8217;s condensed consolidated financial statements as of the end of the prior reporting period become the new accounting basis for those assets and liabilities in the period of the change. To the extent that the distinct and separable operation has monetary assets and liabilities denominated in the old functional currency, such balances will create transaction gains and losses subsequent to the change in functional currency. The balance recorded in the cumulative translation adjustment account for prior periods is not reversed upon the change in functional currency.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company translates the assets and liabilities of COMPASS Pathfinder Limited into USD at the exchange rate in effect on the balance sheet date. Income and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive (loss)/income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTg_249bb462-9f81-45ea-b23c-61e5538452a3" continuedAt="i91952be594034ab79448a705c02ec24e" escape="true"><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &#160;</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of March 31, 2023 and December 31, 2022, the Company has not identified any uncertain tax positions.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i2b4ed4d96a8d45e4add769e821e1fbeb" continuedAt="i95d5adcf71864bf18bd0cc050d577462"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i91952be594034ab79448a705c02ec24e">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.</ix:continuation></span></div><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="cmps:BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTk_b962916d-8e1c-4b4b-b59e-cab8e66fd731" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit from Research and Development Tax Credit </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, in effect through March 31, 2023, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to <ix:nonFraction unitRef="number" contextRef="i49ac0527569949da8f64c6fe440b8ed9_D20230101-20230331" decimals="INF" name="cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjM3NzI_59957d39-b239-4b2a-846f-26bd1fb28b35">33.3</ix:nonFraction>% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to <ix:nonFraction unitRef="number" contextRef="i72e49c2f29fa4138890d882ae5cb4ab9_D20230101-20230331" decimals="INF" name="cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjQxOTM_833d44e3-09c0-4d27-b99d-b91684295aae">21.7</ix:nonFraction>%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#8364;<ix:nonFraction unitRef="eur" contextRef="i49ac0527569949da8f64c6fe440b8ed9_D20230101-20230331" decimals="-5" name="cmps:ResearchAndDevelopmentTaxCreditTotalAidClaimable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfNTQ5NzU1ODUzMzcx_5ce6c9b5-2463-4ab4-ad2c-ffa5a95d1641">7.5</ix:nonFraction> million which may impact the Company's ability to claim R&amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on credit claims under the SME Program in excess of &#163;<ix:nonFraction unitRef="gbp" contextRef="i49ac0527569949da8f64c6fe440b8ed9_D20230101-20230331" decimals="-3" name="cmps:ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfNTQ5NzU1ODUzMzc3_68a00842-0a2d-4052-b5bf-b64bf05991cf">20,000</ix:nonFraction> with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed <ix:nonFraction unitRef="number" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="INF" name="cmps:ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfNTQ5NzU1ODUzMzg2_d57c4cba-6a31-4d0e-b5fd-a1fb6726284a">15</ix:nonFraction>% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim. As announced in His Majesty&#8217;s Treasury Autumn Statement 2022, the rates for the SME R&amp;D tax relief regime have been reduced such that for qualifying expenditure from April 1, 2023 the effective credit decreased from 33.3% to 18.6%. For subcontracted expenditure, as there is a restriction to 65% of costs, the effective credit decreased from 21.7% to 12.1%.  New rules were announced in the UK Parliament Finance Act  2023 for an enhanced rate of relief, which would be 27.0% for qualifying expenditure and 17.5% for qualifying subcontracted expenditure. The legislation is not yet final, and therefore the Company is unable to determine whether it would meet the criteria for the enhanced rate of relief until the legislation and more detailed guidance has been published.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;<ix:nonFraction unitRef="gbp" contextRef="i72e49c2f29fa4138890d882ae5cb4ab9_D20230101-20230331" decimals="-5" name="cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjY4MDc_b1025bde-f887-4344-8460-90faf40ce087">5.0</ix:nonFraction> million plus an incremental <ix:nonFraction unitRef="number" contextRef="i72e49c2f29fa4138890d882ae5cb4ab9_D20230101-20230331" decimals="2" name="cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjY4Mzg_7201e4be-f51c-42a2-aa9c-b613ad6dc042">50</ix:nonFraction>% of UK taxable profits.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODc_ee0c00a8-014f-4a25-87c5-e8c23a6e6c65" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. For the three months ended March 31, 2023 and 2022, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODM_9b0ada44-a53a-4008-b584-dcf9b45a9f98" continuedAt="i68817f539cf14ea09ba0178136e28adb" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i95d5adcf71864bf18bd0cc050d577462" continuedAt="i343bedfe3c294bf99e3702034d736c51"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i68817f539cf14ea09ba0178136e28adb">outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.</ix:continuation></span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjE5OTAyMzI4NDIwNw_7aca314a-b107-4c3d-96bb-fc93cbfdc624" continuedAt="i2537174cad4f4bdb8b4933935d064c1f" escape="true">Derivatives</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i343bedfe3c294bf99e3702034d736c51"><ix:continuation id="i2537174cad4f4bdb8b4933935d064c1f">The Company enters into foreign currency contracts to reduce the risk that its cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying condensed consolidated statements of operations and comprehensive loss as other income, net.</ix:continuation> The Company did not enter into any contracts during the three-months ended March 31, 2023 and 2022.</ix:continuation> </span></div><div id="i132905a7c9654916bdd441350c765120_55"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RleHRyZWdpb246OGJkN2IxODczMzQ1NDcyZDg0NDFlNGM0NjBhMzJlMDdfMTM1_16153cad-fa92-4f6f-a76e-5013293893b7" continuedAt="if34939bd2e9c4322b2d7de8c3c6ac381" escape="true">Prepaid Expenses and Other Current Assets</ix:nonNumeric></span></div><ix:continuation id="if34939bd2e9c4322b2d7de8c3c6ac381"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RleHRyZWdpb246OGJkN2IxODczMzQ1NDcyZDg0NDFlNGM0NjBhMzJlMDdfMTM2_019b909a-3455-4f30-afef-fef8def87829" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="cmps:ResearchAndDevelopmentTaxCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfMi0xLTEtMS0xNDAxNjI_ae5da7a3-859a-4127-b3de-746ef456a5e9">18,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="cmps:ResearchAndDevelopmentTaxCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfMi0zLTEtMS0xNDAxNjI_f5170a09-e501-4ac0-a4b9-734b96115228">13,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfMy0xLTEtMS0xNDAxNjI_ad352f5a-b2bc-48f5-8d6c-b403d0a36244">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfMy0zLTEtMS0xNDAxNjI_15838a03-3e05-4216-8575-3378f20506b7">2,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="cmps:PrepaidExpenseResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfNC0xLTEtMS0xNDAxNjI_f77e933c-02b5-4885-aef0-ea037b3c34e7">26,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="cmps:PrepaidExpenseResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfNC0zLTEtMS0xNDAxNjI_19ac2802-2640-4949-9e67-a290b3e8674c">28,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfNS0xLTEtMS0xNDAxNjI_c4274133-a8dd-461e-b4ee-5ed374451060">1,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfNS0zLTEtMS0xNDAxNjI_f85890dc-a7b1-418b-8743-a94156d83f21">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfOC0xLTEtMS0xNDAxNjI_226c9369-416b-4935-b9e2-7d08aaec8009">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfOC0zLTEtMS0xNDAxNjI_d599b5e4-4bba-4d83-8870-77c576c18876">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfOS0xLTEtMS0xNDAxNjI_45b5ba0b-e009-446a-bf79-a9b2122f3388">50,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfOS0zLTEtMS0xNDAxNjI_9563ec23-6874-461d-bd70-d90c7b9fa813">47,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i132905a7c9654916bdd441350c765120_61"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RleHRyZWdpb246MDljOGMwOWM2NDc3NDM4MGI4MTAzMWViNjhhMmY2MDdfMTI5_9af47793-f6c9-468f-9bdd-70fac00170c1" continuedAt="i449e33c2f72447c088390109bb9357dd" escape="true">Accrued Expenses and Other Liabilities</ix:nonNumeric></span></div><ix:continuation id="i449e33c2f72447c088390109bb9357dd"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RleHRyZWdpb246MDljOGMwOWM2NDc3NDM4MGI4MTAzMWViNjhhMmY2MDdfMTMw_5e0c0678-fda7-484f-9939-8258c7853fc6" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="cmps:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfMi0xLTEtMS0xNDAxNjI_8e1f9422-c0cc-4927-9f19-69c6352d3535">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="cmps:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfMi0zLTEtMS0xNDAxNjI_59fdbc21-7f6f-4585-8a71-dd04928a4390">1,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfMy0xLTEtMS0xNDAxNjI_77213987-b168-47fe-8d9f-4c934a8893fa">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfMy0zLTEtMS0xNDAxNjI_a19e66e8-b55d-4041-8571-295f7f1e7bc8">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNC0xLTEtMS0xNDAxNjI_f98a3bd3-8143-4989-aab4-c8bdb9a6743c">2,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNC0zLTEtMS0xNDAxNjI_5d7a19c5-9600-437a-a8d3-59df8657e65c">5,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNS0xLTEtMS0xNDAxNjI_7d49247a-47e4-4c39-b051-55c61b720306">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNS0zLTEtMS0xNDAxNjI_f7d41235-2bef-43ea-a686-e4924b66001d">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNi0xLTEtMS0xNDAxNjI_39e1ed0b-ab67-40d7-b9ce-03274011e3c2">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNi0zLTEtMS0xNDAxNjI_510ebec3-c818-4658-a2f7-e4e2a70034d6">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNy0xLTEtMS0xNDAxNjI_2889ef43-488e-455e-a27b-1e4eb5a0f0db">6,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNy0zLTEtMS0xNDAxNjI_7ba8cc54-287a-4303-bf79-7ef78483d2e1">9,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i132905a7c9654916bdd441350c765120_70"></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfMTY5NA_d5c948d2-554e-41a6-ba1c-620840ff7cf6" continuedAt="ia676b3238740455aba373986ba9ed46b" escape="true">Ordinary Shares</ix:nonNumeric></span></div><ix:continuation id="ia676b3238740455aba373986ba9ed46b"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $<ix:nonFraction unitRef="usd" contextRef="ifb330f455e5841ea8450b766d642b939_I20211008" decimals="-5" name="cmps:SaleOfStockAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfMzg0ODI5MDcwNDEyOA_ee1230f2-487c-4ce2-8a8b-29fc1a1e627e">150.0</ix:nonFraction>&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Sales of the Company&#8217;s ADSs, if any, will be made at market prices. Through March 31, 2023 we sold <ix:nonFraction unitRef="shares" contextRef="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4MzA4_9e2e3494-e45d-4bf6-b714-be9cc6c62d07">157,836</ix:nonFraction> ADSs, resulting in $<ix:nonFraction unitRef="usd" contextRef="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4MzMw_4e830ec4-c2c9-4521-888f-e31d8564948b">1.6</ix:nonFraction>&#160;million in net proceeds. During the second quarter of 2023, through May 10, 2023, we sold <ix:nonFraction unitRef="shares" contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfMTA5OTUxMTYzNDY1NQ_df01f27a-f5ab-49d0-990b-82106dc07286">2,824,202</ix:nonFraction> ADSs, resulting in $<ix:nonFraction unitRef="usd" contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfMTA5OTUxMTYzNDY2Ng_8788fd19-78b4-4576-8fb1-376d596c5870">26.9</ix:nonFraction>&#160;million in net proceeds.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued in total <ix:nonFraction unitRef="shares" contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE1Njg1_c2ed17f3-2507-45c1-8720-64ef31b80328">3,790</ix:nonFraction> ordinary shares to settle share options exercised by employees and non-employees compared to <ix:nonFraction unitRef="shares" contextRef="ie9e6809fbe984861af6f54d5e62599f3_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE1Njg5_dd9480d4-79c5-47ee-8ce9-451eda5a85b7">376,158</ix:nonFraction> in the three months ended March 31, 2022. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, a total of <ix:nonFraction unitRef="shares" contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331" decimals="INF" name="cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NTAw_29803105-b244-44ff-a95e-aa6f809a5c30">31,856</ix:nonFraction> restricted share units vested, of which <ix:nonFraction unitRef="shares" contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NTg4_1d13ea70-0a90-490e-9ec2-9a15b979651d">21,579</ix:nonFraction> were issued and <ix:nonFraction unitRef="shares" contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331" decimals="INF" name="cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NjIw_4a150552-8ffe-4330-be33-1895584e9c94">10,277</ix:nonFraction> were settled.  During the three months ended March 31, 2023, a total of <ix:nonFraction unitRef="shares" contextRef="ia690ad07e30d41c9b898dec4e27afca1_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODIwNzM2_93c8222e-92aa-49ad-b2eb-e9beac7ec4c1">30,481</ix:nonFraction> ordinary shares were issued in settlement of restricted share units, of which <ix:nonFraction unitRef="shares" contextRef="i2d4eb30a399e4393b48bbd2412557894_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NDM4_260e4e44-ee77-43af-ad2b-5b6394792fff">8,902</ix:nonFraction> were vested and not issued at December 31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODIwNzMx_e27ff0e8-283a-41f6-9921-94489dc982b4">21,579</ix:nonFraction> vested and were issued during the three months ended March 31, 2023.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="ie9e6809fbe984861af6f54d5e62599f3_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE2MTM2_91383a5b-6819-44bf-8d4b-5504a1173ef8">68,534</ix:nonFraction> ordinary shares were issued in settlement of restricted share units, of which <ix:nonFraction unitRef="shares" contextRef="i7b3c9a2da33a404d81407048dc2c35ee_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NzYw_db2cfdbe-7554-4b1a-a68d-80b4968a3666">57,875</ix:nonFraction> were vested and not issued at December 31, 2021 and <ix:nonFraction unitRef="shares" contextRef="ie9e6809fbe984861af6f54d5e62599f3_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE2MTQy_f31b8973-3a46-4303-bd06-fc4f711bf00d">10,659</ix:nonFraction> vested and were issued during the three months ended March 31, 2022.</span></div></ix:continuation><div id="i132905a7c9654916bdd441350c765120_73"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODMwNQ_978c865f-a9ad-4163-92e9-219db1ef18e2" continuedAt="iec98cf94da9f47ff8feb81c50b592be7" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="iec98cf94da9f47ff8feb81c50b592be7" continuedAt="i17cdaa8591de46808b9461e72e1fe388"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#8217;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company was authorized to issue a total of <ix:nonFraction unitRef="shares" contextRef="i8cae53ddb92e46c3b992b638b4a42023_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjAz_7b2b42e1-5025-435c-9b72-cc856198b133">1,600,329</ix:nonFraction> ordinary shares underlying outstanding options granted under the 2017 Plan prior to the IPO.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2017 Plan, typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTAyOQ_92763bc4-2b40-44c3-9547-92efbadbe1ef">three</span> or <ix:nonNumeric contextRef="i1143bd0e2ad345caa5c640706694c0b4_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5MQ_a5f8413f-c60b-4014-beda-895c25ecd259">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="i40dc657ea5ac431794e05ae7a1ce76d8_D20230101-20230331" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjM1_18518358-ce22-4351-bb95-c9a6fdfed435">33.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i35930be1fdbb4fa798087223a146bcb9_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTA3MA_5e6778f8-fe71-455b-bf07-37ede7de656b">25</ix:nonFraction>% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire <ix:nonNumeric contextRef="i6f0a16794335461d959dba6be9403f37_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODMwMQ_36dabdd6-f309-4b6d-88bc-0cfb68fc7f20">10</ix:nonNumeric> years from the date of grant.  Restricted share units granted under the 2017 Plan typically vest over a <ix:nonNumeric contextRef="i407fd6f5b5ed4bcaafd6554faeeaf095_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODMwMg_4f8ef2dc-3a12-4d2a-b371-94a82730b5df">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="i407fd6f5b5ed4bcaafd6554faeeaf095_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTQwNA_91dd2f45-ee30-4db9-bf39-f1271399061d">25</ix:nonFraction>% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted on June 30, 2020 were subject to <ix:nonFraction unitRef="number" contextRef="i35930be1fdbb4fa798087223a146bcb9_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTU1OA_3a557ffa-4557-4632-af83-130265947434">25</ix:nonFraction>% vesting upon the earlier occurrence of (i) the <ix:nonNumeric contextRef="i35930be1fdbb4fa798087223a146bcb9_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTYwOA_6d24cfba-3da1-4d68-b55a-2c8f5c71d229">one year</ix:nonNumeric> anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for <ix:nonNumeric contextRef="i1adb7d0ef4fb497d9b87d9bed2778ce5_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODMwMw_399dd3c0-53f1-4cce-8cd5-3accdcf48ffb">three years</ix:nonNumeric> for the remaining <ix:nonFraction unitRef="number" contextRef="i1adb7d0ef4fb497d9b87d9bed2778ce5_D20230101-20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTc5OA_adcfb4a0-160b-40b9-9e34-64f7d0abe807">75</ix:nonFraction>% of the allocation until vested in full.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted share units granted on June 30, 2020 are subject to <ix:nonFraction unitRef="number" contextRef="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTkwOA_9d9db1f7-5790-4022-94f6-a5bab5ca5036">25</ix:nonFraction>% vesting upon the earlier of (i) the <ix:nonNumeric contextRef="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTk0Nw_d44fa919-b3a2-4911-b17f-6fd74913683f">one year</ix:nonNumeric> anniversary of the date of grant, or (ii) the first day following the six-month anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is <ix:nonFraction unitRef="number" contextRef="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMjE1Ng_776716db-3587-4dab-b79c-6f8a630d55d7">20</ix:nonFraction>% higher than the listing price for at least <ix:nonFraction unitRef="day" contextRef="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331" decimals="INF" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMjIwMg_ebf3eb45-d171-458b-a11b-8040443cfb8c">five</ix:nonFraction> consecutive trading days. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Share Purchase Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of <ix:nonFraction unitRef="shares" contextRef="i00a9c14553ea40949dd06a45c06c9b03_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMjYxOA_09e586f9-5eca-4a2d-8e3e-b9cc59c6ab3e">340,053</ix:nonFraction> ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i00a9c14553ea40949dd06a45c06c9b03_I20230331" decimals="INF" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMjkwNw_cd94ac78-393d-47c1-ab47-b22b003cb207">1</ix:nonFraction>% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) <ix:nonFraction unitRef="shares" contextRef="ie31fdecdb0224ff48a4b130a9225404d_D20230101-20230331" decimals="INF" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMzAwMg_80a9c143-a8d5-4ccb-8a47-dc5901e0ee01">510,080</ix:nonFraction> ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in capitalization.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i17cdaa8591de46808b9461e72e1fe388" continuedAt="ib2f1e644a6a949ee8712032e6245669e"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 1, 2021, the Company launched the SIP and the ESPP, through which employees can purchase shares at a discounted price. At the end of <ix:nonNumeric contextRef="i31e66ff9fe5f4627ae22fcc1d62c3001_D20211001-20211001" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMzQwNQ_bc134ac3-6079-4978-abf8-ff217b664566">six months</ix:nonNumeric>, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a <ix:nonFraction unitRef="number" contextRef="i31e66ff9fe5f4627ae22fcc1d62c3001_D20211001-20211001" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMzUzOA_f194a98c-420e-4abf-abd6-6c4e99673058">15</ix:nonFraction>% discount.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Share Option Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s board of directors adopted, and the Company&#8217;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development committee to make equity-based and cash-based incentive awards to the Company&#8217;s officers, employees, directors and other key persons (including consultants).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2020 Plan generally expire <ix:nonNumeric contextRef="i395fbda845a44eac841de73744035c26_D20200901-20200930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDEzOA_c0c68cac-cfbe-4af3-ad77-2974f7aaaca7">10</ix:nonNumeric> years from the date of grant and typically vest over a <ix:nonNumeric contextRef="i395fbda845a44eac841de73744035c26_D20200901-20200930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDE5MA_ce876f6b-8914-4c19-9df6-0cbcebe7a4f9">4</ix:nonNumeric> year service period with <ix:nonFraction unitRef="number" contextRef="i395fbda845a44eac841de73744035c26_D20200901-20200930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDIxOA_6d1b2ad1-4cf6-4f28-8506-8aa3ef9a46ef">25</ix:nonFraction>% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="i2d15bad6c8da46cf885b153b00184437_I20200930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjUy_c1259cb2-eeb9-4c7b-9582-f7d69d39dcca">2,074,325</ix:nonFraction> of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to <ix:nonFraction unitRef="number" contextRef="i2d15bad6c8da46cf885b153b00184437_I20200930" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDY0MA_1c1b3163-30cc-4dde-bffd-c69a6d1fd126">4</ix:nonFraction>% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by the compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is <ix:nonFraction unitRef="shares" contextRef="ie0831ccc811b4e5d84580b833bf10c0e_I20230331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjYz_57eef420-510a-4d9a-90c1-857c1d01a8a9">5,460,391</ix:nonFraction> shares as of March 31, 2023, of which <ix:nonFraction unitRef="shares" contextRef="i9aa096c9847d432ebe62c81328b458a2_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjg5_cc145a91-7d7b-4d2c-96a9-9b31edb2c3d2">253,084</ix:nonFraction> shares remained available for future grant.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted in 2022 under the 2020 Plan to employees generally expire <ix:nonNumeric contextRef="i3183dfe431c04796b01b1c6fdb1a0756_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTIyMA_9ea9b07f-bdaf-4883-82df-a1afc08e3d3a">10</ix:nonNumeric> years from the date of grant. There are three potential vesting conditions for the 2022 grants including: (i) <ix:nonFraction unitRef="number" contextRef="i338fadaff380485fbfe31f0080cdd810_D20230101-20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTMyNw_6520e1e3-584f-46ca-b668-245496b47ac0">25</ix:nonFraction>% per year over <ix:nonNumeric contextRef="i338fadaff380485fbfe31f0080cdd810_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5NA_880522ee-cae4-4d9c-9cba-441551b7229d">four year</ix:nonNumeric> service period, (ii) <ix:nonNumeric contextRef="iea26013103954eadb8a7947d75c821d7_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5Mw_626ae6c9-a0e9-4c0f-815e-2f83bd954166">four year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="iea26013103954eadb8a7947d75c821d7_D20230101-20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQwMQ_6092ef4e-27b2-441f-85fd-edfb95d81326">25</ix:nonFraction>% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years; and (iii) monthly vesting over <ix:nonNumeric contextRef="i837240d0e61b4f5780239e38d5361ef5_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5OQ_462ccb29-6f8b-43b3-b551-757e18a4e7a6">four year</ix:nonNumeric> service period.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, the Company granted options to purchase <ix:nonFraction unitRef="shares" contextRef="ie31fdecdb0224ff48a4b130a9225404d_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMzI2_a2a4a06e-9737-4e48-9ad7-fc01327825ce">2,076,950</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i696b4083af51453a8c2cfb18cfdb4482_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMzMw_e418aa98-268a-4bdb-91e6-b6f61849bc3b">1,111,569</ix:nonFraction> ordinary shares to employees and non-employees, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Inducement Option Award</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company granted to its new chief executive officer a non-qualified share option to purchase up to <ix:nonFraction unitRef="shares" contextRef="i15ccc93511924535a1cde0fc5143bb33_I20220801" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTkwMw_6a7c1db6-dc15-41ce-8120-f1759b9a58af">600,000</ix:nonFraction> ordinary shares as an inducement grant. The non-qualified share option has a <ix:nonNumeric contextRef="ia22f0d118f1942caa4258c79bae792fb_D20220801-20220801" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5NQ_fc970074-685f-4c1f-9101-9e65de3c8bff">10</ix:nonNumeric> year term and vests one-fourth on August 1, 2023 and the remaining three-fourths in equal monthly installments over the following <ix:nonNumeric contextRef="ia22f0d118f1942caa4258c79bae792fb_D20220801-20220801" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNjEyOA_b6c81507-dc07-4741-830e-fd3003751d05">36</ix:nonNumeric> months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#8217;s 2020 Plan and the Company&#8217;s standard form of non-qualified share option agreement. <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Restricted Share Units</span></div><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5Nw_a30f9d33-994c-4e19-8d02-4e59a952c8f1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s unvested restricted share units during the three months ended March 31, 2023 are as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8ab588a8f374a63b091c9535ea47d6d_I20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMS0xLTEtMS0xNDAxNjI_4de73338-8ac6-4868-8d2d-04d4433cbc9c">271,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie8ab588a8f374a63b091c9535ea47d6d_I20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMS0zLTEtMS0xNDAxNjI_02c51038-3fcb-4884-b1ea-c6a074718a71">12.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMi0xLTEtMS0xNDAxNjI_634cf52a-506f-4f0f-9b70-3824b8271bad">175,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMi0zLTEtMS0xNDAxNjI_79383388-50fe-43d0-a5cb-ff7b4cd9bb5a">10.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331" decimals="INF" name="cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMy0xLTEtMS0xNDAxNjI_0543440d-e085-48da-9799-76ea978659b1">31,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMy0zLTEtMS0xNDAxNjI_e6636bdd-a726-45c2-a94b-061c2bb44fd5">12.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfNC0xLTEtMS0xNDAxNjI_b92c65d0-714c-4773-8da3-0356cfb60720">7,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfNC0zLTEtMS0xNDAxNjI_e16628dd-b9a5-47b2-ae33-04c6d4126768">12.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9aa096c9847d432ebe62c81328b458a2_I20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfNS0xLTEtMS0xNDAxNjI_7ae178ae-c4ec-426b-8263-7eecbe37ebca">407,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9aa096c9847d432ebe62c81328b458a2_I20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfNS0zLTEtMS0xNDAxNjI_52cf0bdf-b9d3-477c-8086-0344896201b1">11.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i9aa096c9847d432ebe62c81328b458a2_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTU4OA_b74c940f-c16f-4839-8049-23558e35ab78">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie8ab588a8f374a63b091c9535ea47d6d_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTYwNg_b4c12d20-11c3-488c-b78f-a7902acf3b0f">2.6</ix:nonFraction> million of unrecognized compensation cost related to unvested restricted share units, respectively, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTA5OTUxMTYzNjc0NQ_a6089194-3e9d-4f17-a432-5729719011ba">3.2</ix:nonNumeric> years and <ix:nonNumeric contextRef="ia7cedba3e82645e49ca80bcc90a72a68_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTYxOA_64095855-52aa-4d7b-b7eb-768da83bfbf7">3.0</ix:nonNumeric> years, respectively. The exercise price of restricted share units is at a nominal value less than $<ix:nonFraction unitRef="usdPerShare" contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMzY0_791c90fe-230c-4a8d-adb4-6abab96cca6f">0.01</ix:nonFraction> per share.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="ib2f1e644a6a949ee8712032e6245669e"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Share Options</span></div><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5Mg_331695e9-8660-452e-84cf-a20ef7114096" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share options activity for the three months ended March 31, 2023:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"></td><td style="width:43.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia91e30a56bc9415dbd1e86b1d6ec64dd_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMS0xLTEtMS0xNDAxNjI_5320dea9-cc41-4418-89ee-b832fa595487">5,092,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMS0zLTEtMS0xNDAxNjI_52546804-c9cc-44e4-b481-135475fa10a3">13.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iab7fb606ccca48e58144d35f683e689d_D20221231-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMS01LTEtMS0xNDAxNjI_1f14e88e-3e56-4d89-a7f3-8ee2cf47ceb5">8.38</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMS03LTEtMS0xNDAxNjI_7bdc3e93-488e-4d48-bc33-85e5f5724f10">13,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMi0xLTEtMS0xNDAxNjI_69fb53a1-0114-45b7-8c1a-f003965b34f1">2,076,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMi0zLTEtMS0xNDAxNjI_5a800471-caeb-434a-8d54-6b108a630b3f">10.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMy0xLTEtMS0xNDAxNjI_c682e69f-5388-457d-8893-09835c91c746">3,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMy0zLTEtMS0xNDAxNjI_5f9ff093-c590-4ccd-a396-1e2b11f0d736">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNC0xLTEtMS0xNDAxNjI_4c1b5ea2-c321-4aec-9c63-411657953837">131,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNC0zLTEtMS0xNDAxNjI_ebdd5f96-de15-4d65-835f-a4d0da2545c2">24.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNS0xLTEtMS0xNDAxNjI_88ae7c0c-a95a-4ce1-b481-7bec494a561d">7,034,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNS0zLTEtMS0xNDAxNjI_6b9ff598-9dc7-4ff4-a4a4-1bcbab33dbcb">13.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56c06e81a4384be9a4547b9d54649e6c_D20230331-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNS01LTEtMS0xNDAxNjI_530169d9-bb14-41a2-8331-9c2e7c97f41d">8.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNS03LTEtMS0xNDAxNjI_7fa6e653-9037-4f24-a907-be4e5fa7256f">17,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNi0xLTEtMS0xNDAxNjI_9f71f802-5ab0-4261-a765-d4e22157f557">2,600,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNi0zLTEtMS0xNDAxNjI_a3d328ab-d41d-4d10-becf-1e0efe43973e">10.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56c06e81a4384be9a4547b9d54649e6c_D20230331-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNi01LTEtMS0xNDAxNjI_4004a5b5-0e3b-42a0-85d7-8039c6ad62ea">7.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNi03LTEtMS0xNDAxNjI_87fd11bc-ace4-426d-a899-4f85b9e8c82f">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNy0xLTEtMS0xNDAxNjI_4c063b34-31d8-4199-bba5-8b9be4d77e46">4,434,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNy0zLTEtMS0xNDAxNjI_169012be-b00c-45f4-96a6-f711141c17cf">14.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56c06e81a4384be9a4547b9d54649e6c_D20230331-20230331" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNy01LTEtMS0xNDAxNjI_d330dbdc-954c-4509-90f7-1e5944cb5554">9.27</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNy03LTEtMS0xNDAxNjI_bf3dfdb5-564d-44ff-b406-6839d09a19db">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was less than $<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyOTEx_bc71033b-edb3-4148-8fed-811ca241ce27">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTYzMg_78d14cb0-6c9c-40e6-8da2-c052acf8d9d3">4.9</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s ordinary shares for those share options that had exercise prices lower than the fair value of the Company&#8217;s ordinary shares.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of share options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTY3MA_b6312347-804c-4ed7-a217-57cf2926d846">8.27</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTY3NA_ef58503c-256d-4048-8863-ce85b0ea663e">11.38</ix:nonFraction> per share during the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTc0MA_20aeb0d4-1f97-46b7-93fa-bda242a61eda">42.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7765db2674724718901c035cce089b95_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTc0Ng_52e87388-8976-4b1b-a278-c8547dcfc520">35.2</ix:nonFraction> million of unrecognized compensation cost related to unvested share options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i6c1c0a2584554db98438e2f27622af72_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTc1Mg_5486e295-8441-4b49-96b8-1e22a95d5d06">3.1</ix:nonNumeric> years and <ix:nonNumeric contextRef="i478445e4a46e43758c8383eb32aaf0ba_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTc1Ng_c8119729-47f2-49d8-8928-48ba1a8d5fba">3.4</ix:nonNumeric> years, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Option Valuation</span></div><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5MA_dd44ef2d-55b0-492a-9e3e-6c4810c91d7f" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the three months ended March 31, 2023, and 2022 were as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfMi0xLTEtMS0xNDAxNjI_d52b294e-13aa-448f-abac-13caada39b3e">6.05</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfMi0zLTEtMS0xNDAxNjI_5762af2e-1e7d-48cf-945f-9279de82c1bd">5.88</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfMy0xLTEtMS0xNDAxNjI_bfefc78e-540b-48bd-827c-0910840b7f43">87.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfMy0zLTEtMS0xNDAxNjI_396752d8-ea49-497f-b76b-7c42b111c2d3">80.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNC0xLTEtMS0xNDAxNjI_5695bbbf-a632-4908-aa9b-f0442d3a599d">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNC0zLTEtMS0xNDAxNjI_237dc58e-9165-4c2c-a2e6-feaa75b64b45">1.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNS0xLTEtMS0xNDAxNjI_5d3a6446-ca64-487b-97a6-84e3d5fea52d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNS0zLTEtMS0xNDAxNjI_a256fda2-c383-4e50-a273-382fee7c515f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying ordinary shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNi0xLTEtMS0xNDAxNjI_a2b820bc-7c49-431c-b2a4-776e7b4ae270">10.85</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNi0zLTEtMS0xNDAxNjI_84351bdc-1152-4b91-8eb6-ed42f0293d6a">15.98</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI4OQ_8ac9bf4c-f5f9-4ee5-9247-d371576773b5" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5872a113b2294faaad1b68db7ae836e2_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfMi0xLTEtMS0xNDAxNjI_cd26c2d4-f87b-4aa3-8514-3ec3a8cd76a7">2,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b25b7dbd74c4562b936a90dfd191b50_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfMi0zLTEtMS0xNDAxNjI_2df645ed-c736-437f-bfdf-a5ece830e159">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice52714f9f134f59b22998dd73137b2a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfMy0xLTEtMS0xNDAxNjI_50b9e90d-228a-4a54-94c6-99649afd2e18">1,827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60ff16effaf4307b5d9f1c7ce5bc358_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfMy0zLTEtMS0xNDAxNjI_daee672f-4849-4afe-a3e8-9165e8e9f069">1,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfNC0xLTEtMS0xNDAxNjI_83a2a2c7-7427-4af6-ab16-68c2225311da">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfNC0zLTEtMS0xNDAxNjI_9ff76162-d389-420f-97ad-3d50b950db9b">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i132905a7c9654916bdd441350c765120_82"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RleHRyZWdpb246ZDNhNjIzYjI0NjA5NGY3ODkyYjdlOTNiMDk4YTBjMjVfOTc4_d63717d0-5f52-4c08-9a47-fc45e29c87a3" continuedAt="if51c61cfcdac4d86a9df3877f5d0dd61" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="if51c61cfcdac4d86a9df3877f5d0dd61"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RleHRyZWdpb246ZDNhNjIzYjI0NjA5NGY3ODkyYjdlOTNiMDk4YTBjMjVfOTc5_f6e53e48-97af-4061-8112-21e1fc77f610" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfMy0xLTEtMS0xNDAxNjI_5871db2d-7472-4335-a66b-ee9cca113e3e">24,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfMy0zLTEtMS0xNDAxNjI_30bc1723-b610-4796-81b3-b8d1ee3da9a5">21,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNC0xLTEtMS0xNDAxNjI_455ff1bf-fd85-4a59-a84f-189aed91c4d0"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNC0xLTEtMS0xNDAxNjI_7acacb66-08c7-4964-998a-57858e2c0aa8">24,208</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNC0zLTEtMS0xNDAxNjI_2d321a80-27ae-4e28-aa0e-0c4adee084eb"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNC0zLTEtMS0xNDAxNjI_78feaafa-02e0-4e62-a0da-865badbda30f">21,171</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNy0xLTEtMS0xNDAxNjI_a1836849-b40d-405e-8b7d-05311dbbf130"><ix:nonFraction unitRef="shares" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNy0xLTEtMS0xNDAxNjI_ae02944a-db84-45aa-a148-88eacc7c752d">42,725,863</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNy0zLTEtMS0xNDAxNjI_600bd655-63ef-4098-ae7e-977646c100dd"><ix:nonFraction unitRef="shares" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNy0zLTEtMS0xNDAxNjI_c2ca3b39-4939-4d9f-a63c-384bae0dec7c">42,036,563</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfOC0xLTEtMS0xNDAxNjI_714253ed-6b79-4c65-8756-6348aefd7e4b"><ix:nonFraction unitRef="usdPerShare" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfOC0xLTEtMS0xNDAxNjI_889447ea-3d99-4a49-835c-64843c232c0f">0.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfOC0zLTEtMS0xNDAxNjI_724ac107-4fb8-497c-843f-14f56ceab36f"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfOC0zLTEtMS0xNDAxNjI_850947f5-9440-4004-953c-8a7ed17972de">0.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, and options granted, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share attributable to ordinary shareholders is the same. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RleHRyZWdpb246ZDNhNjIzYjI0NjA5NGY3ODkyYjdlOTNiMDk4YTBjMjVfOTgw_2bf88db9-5cf0-41a0-92f7-a98bcb9088b8" continuedAt="ie63c9584f166407cb4200b821cb049c4" escape="true">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><ix:continuation id="ie63c9584f166407cb4200b821cb049c4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1623488c9f64721a60c4349e61ce8bf_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfMi0xLTEtMS0xNDAxNjI_3033e67a-3031-43bb-acf7-b940ddc9c107">407,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2b773ca49914d34bba229e76da492dd_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfMi0zLTEtMS0xNDAxNjI_e0915a29-803c-477e-8a75-7ae4f971795c">197,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73ea83c879704be889d92560678ef374_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfNC0xLTEtMS0xNDAxNjI_5919c6df-f225-4cd3-a958-b175f224949c">7,034,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i122471b5c0c34e05bdaaf376bf6de99c_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfNC0zLTEtMS0xNDAxNjI_a367f7d7-e2e5-44ae-9f82-7e1e012edd94">4,559,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfNS0xLTEtMS0xNDAxNjI_866297de-58d0-4b5f-91d9-46568a6b081a">7,442,071</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfNS0zLTEtMS0xNDAxNjI_5dabe619-15d6-41ba-9013-d89e8950eab4">4,756,183</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:continuation></div></ix:continuation><div id="i132905a7c9654916bdd441350c765120_85"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwNA_412b888c-bc4e-4af9-8d6d-2ab6f65f27f2" continuedAt="i92311d2a416948f9969f86d2210fbf14" escape="true">Right of use of assets</ix:nonNumeric></span></div><ix:continuation id="i92311d2a416948f9969f86d2210fbf14" continuedAt="idc1a733a8f83445c8346d560f04a3604"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York, NY</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a <ix:nonNumeric contextRef="ibbeae02a508346edb94df36fd8e95a81_I20220831" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwNg_a672912b-2fcf-4638-8241-45c14a228333">twelve month</ix:nonNumeric> membership agreement with WeWork for rentable office space.  The membership is cancellable with <ix:nonNumeric contextRef="iba372f6eca8f430eb43a67755847815d_D20220801-20220831" name="cmps:LeaseCancellationNotificationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfNjIx_616ab972-8ff7-4415-b7d1-cd552d4f4c91">90</ix:nonNumeric> days&#8217; notice.  This agreement is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#8217;s condensed consolidated balance sheets. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Soho, London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a <ix:nonNumeric contextRef="i7678bc3cc61d4f73b03996330cea7a9f_I20210731" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwMQ_be01a497-8717-4279-a81a-7046444c73c1">two-year</ix:nonNumeric> operating lease with Fora Space Limited commencing on September 1, 2021. The noncancellable term is <ix:nonNumeric contextRef="id87803bd77d841e3917a974e88083e5a_D20210701-20210731" name="cmps:OperatingLeasesNoncancelableTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMTU4MA_b0b47e9c-aad3-4e21-9c65-eecbdd917aa4">24</ix:nonNumeric> months and there is no option to extend the lease. The recurring residency fee per month is &#163;<ix:nonFraction unitRef="gbp" contextRef="i33bec60d253644c1918ad73a71213b08_D20230101-20230331" decimals="0" name="cmps:OperatingLeaseMonthlyPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMTY3NQ_4f35ac9e-607c-457b-8282-7fab3461e1d2">136,200</ix:nonFraction>, and the Company paid a refundable deposit of &#163;<ix:nonFraction unitRef="gbp" contextRef="i33bec60d253644c1918ad73a71213b08_D20230101-20230331" decimals="0" name="cmps:RefundableLeaseDepositPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMTcyNA_543fd966-4c3e-4432-bf2e-9065b6f06742">136,200</ix:nonFraction> at the execution of the agreement. Additionally, at the start of each calendar year, the monthly residency fee is subject to an automatic inflation linked increase of the previous year&#8217;s amount.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denmark Hill, London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into an agreement for a lease with South London and Maudsley NHS Foundation Trust for land and buildings at 5 Windsor Walk, Maudsley Hospital, Denmark Hill, London, UK. The lease commenced on June 21, 2022 and has a contractual term of <ix:nonNumeric contextRef="i8636ff5e270740d08068434308a1c41a_I20220621" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMjczNg_2a4235c0-6a72-4b27-b3e9-77db39a1412f">five years</ix:nonNumeric>. The rent is &#163;<ix:nonFraction unitRef="gbp" contextRef="iccc7b27ad5a34f7986912f9169f8eac5_D20230101-20230331" decimals="0" name="cmps:OperatingLeaseAnnualPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMjc1Mg_29179127-b2e4-425c-b405-f70cc488bf28">180,000</ix:nonFraction> per year, with no deposit payable, and payment dates occurring once per quarter.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="idc1a733a8f83445c8346d560f04a3604"><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwMg_17288933-18fe-421d-be29-3b86dfb73988" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s costs included in its condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through March 31, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMy0xLTEtMS0xNDAxNjI_08881d8d-0e12-4ba1-ba62-73ea390bbdc2">573</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMy0zLTEtMS0xNDAxNjI_b5d43cc3-8053-432c-96fd-edf2983a675c">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfNS0xLTEtMS0xNDAxNjI_2d627c8a-3004-461d-b83d-d774609a52c2">87</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfNS0zLTEtMS0xNDAxNjI_ef8949e1-bfe7-4172-9873-c3b12d5fcbe5">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfNi0xLTEtMS0xNDAxNjI_9006e23b-cc3f-4492-a3d4-9405a8d3cecb">660</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfNi0zLTEtMS0xNDAxNjI_5dab5a34-7269-4329-bfaf-210df87c8ed1">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfOC0xLTEtMS0xNDAxNjI_fcf3cd62-3881-4b57-b664-beed9723f5f2">562</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfOC0zLTEtMS0xNDAxNjI_1c753526-621e-4ef3-88df-0e91e06e97b4">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfOS0xLTEtMS0xNDAxNjI_e1b66890-99a5-4484-b105-db20b89253d4">102</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfOS0zLTEtMS0xNDAxNjI_aca67f03-cea7-486f-afeb-30b37f4c7985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMTAtMS0xLTEtMTQwMTYy_c0cc5573-3632-489b-a717-d27b3837fbec">1.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7765db2674724718901c035cce089b95_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMTAtMy0xLTEtMTQwMTYy_fff85470-c8fb-4816-bce1-d104d6362c6a">0.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMTEtMS0xLTEtMTQwMTYy_8898dc8f-3ccd-4579-bfeb-4126b8f870ce">6.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7765db2674724718901c035cce089b95_I20220331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMTEtMy0xLTEtMTQwMTYy_44a6196f-c2f1-4e6c-a942-c0c6ec93de17">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwMw_7ad1a4cc-7f5a-4831-8891-efa377a007e5" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the future minimum lease payments due under operating leases as of March 31, 2023, (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:85.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfMC0xLTEtMS0xNDAxNjI_91fc719e-43fb-425e-b5d6-bb968783c04f">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfMS0xLTEtMS0xNDAxNjI_5b9b1c4b-9e95-445a-a13f-5a254404e92b">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfMi0xLTEtMS0xNDAxNjI_e1bbda0a-1aab-4710-8968-554c747ce719">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfMy0xLTEtMS0xNDAxNjI_a2325d24-c015-4f6f-8460-99ee43515421">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfNS0xLTEtMS0xNDAxNjI_92d2b147-628a-418d-8a3b-096d9e593982">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfNi0xLTEtMS0xNDAxNjI_5ccbc978-2535-4ead-a388-a9887875bfe6">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e65e381d441028d0e315d17e7e808_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfNy0xLTEtMS0xNDAxNjI_0bd42205-1c60-410d-99da-6f482d2ebedf">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i132905a7c9654916bdd441350c765120_88"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84OC9mcmFnOjliMzI0MGU5NTE0OTQ1ZjA4NDk0YzA3MDljNmIzM2EzL3RleHRyZWdpb246OWIzMjQwZTk1MTQ5NDVmMDg0OTRjMDcwOWM2YjMzYTNfMTMzOQ_a708bb78-4a08-442c-963f-7fe374bb3e4f" continuedAt="i57cfb2dbc33941a1babc5dabc5eb920a" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i57cfb2dbc33941a1babc5dabc5eb920a"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of March 31, 2023 or 2022.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#8217;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.</span></div></ix:continuation><div id="i132905a7c9654916bdd441350c765120_94"></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYyNzgwMg_62342abb-3c51-488f-bbe0-1fc789695e54" continuedAt="i688db2964fc142f49cc7bf25b73b1b59" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i688db2964fc142f49cc7bf25b73b1b59"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Company entered into a <ix:nonNumeric contextRef="idd439c7411164a75bab3f2705e3ffb57_I20230430" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjExMw_c971eb13-a772-41b6-91a8-4065a43eaabd">two-year</ix:nonNumeric> operating lease with Fora Space Limited commencing on September 1, 2023. The noncancellable term is <ix:nonNumeric contextRef="i4c4ad1b7be0048e289dcf0230cc72a31_D20230401-20230430" name="cmps:OperatingLeasesNoncancelableTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjA3NQ_ca637523-d9c8-4ccf-806b-0f0be678cad4">24</ix:nonNumeric> months and there is no option to extend the lease. The recurring residency fee per month is &#163;<ix:nonFraction unitRef="gbp" contextRef="i4c4ad1b7be0048e289dcf0230cc72a31_D20230401-20230430" decimals="0" name="cmps:OperatingLeaseMonthlyPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjA5NA_f2c64303-290e-4363-9d29-a33380665fd6">130,000</ix:nonFraction>, and the Company paid a refundable deposit of &#163;<ix:nonFraction unitRef="gbp" contextRef="i4c4ad1b7be0048e289dcf0230cc72a31_D20230401-20230430" decimals="0" name="cmps:RefundableLeaseDepositPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjEwNA_fb1f5b80-c636-4bfe-b3b2-1c0abd71f672">156,000</ix:nonFraction> at the execution of the agreement. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, through May 10, 2023, under our Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell its ADSs, each representing one ordinary share, we sold <ix:nonFraction unitRef="shares" contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjkwOQ_2f64d186-54c8-4104-a045-094310bbc13a">2,824,202</ix:nonFraction> ADSs, resulting in $<ix:nonFraction unitRef="usd" contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjkyMA_bc3d572d-2144-42ca-bb02-41b69894be96">26.9</ix:nonFraction>&#160;million in net proceeds.</span></div></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div id="i132905a7c9654916bdd441350c765120_100"></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND&#160;RESULTS&#160;OF&#160;OPERATIONS</span></div><div id="i132905a7c9654916bdd441350c765120_103"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the related notes to those statements included earlier in this Quarterly Report on Form 10-Q. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Important factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. &#8220;Risk Factors&#8221; and the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;  </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">References to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;the Company&#8221; refer to COMPASS Pathways plc. </span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which COMP360 psilocybin is administered in conjunction with psychological support, which we refer to as COMP360 psilocybin therapy.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our initial focus is on treatment-resistant depression, or TRD, comprising patients who are inadequately served by the current treatment paradigm. Early signals from academic studies, using formulations of psilocybin not developed by us, have shown that psilocybin therapy may have the potential to improve outcomes for patients suffering with TRD, with rapid reductions in depression symptoms and effects lasting up to six months, after administration of a single high dose. In 2018, we received Breakthrough Therapy designation from the FDA for COMP360 for the treatment of TRD. In 2019, we completed a Phase 1 clinical trial administering COMP360, along with psychological support, to 89 healthy volunteers. In this trial, we observed that COMP360 was generally well-tolerated and supported continued progression of Phase 2b studies. We also demonstrated the feasibility of administering COMP360 psilocybin to up to six healthy participants simultaneously, with 1:1 support.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, we announced positive topline results from our Phase 2b clinical trial evaluating COMP360 in conjunction with psychological support for the treatment of TRD. On November 3, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the world&#8217;s leading peer-reviewed medical journal, published the positive results from our Phase 2b trial. This is the largest, randomized, controlled, double-blind psilocybin therapy clinical trial completed to date. The objective of the phase 2b study was to evaluate the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD. The topline results from the 233-participant trial showed a rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin administered with psychological support, with 29.1% of participants in remission by week 3 (p&lt;0.002). The trial achieved its primary endpoint for the 25mg dose, with a 25mg dose of COMP360 demonstrating a statistically significant (p&lt;0.001) and clinically relevant treatment difference against the 1mg dose of COMP360 in reducing depressive symptom severity after three weeks.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are conducting our Phase 3 program evaluating our COMP360 psilocybin therapy in TRD. The Phase 3 program is composed of two pivotal trials, each with a long-term follow-up component. The pivotal program design is as follows:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Pivotal trial 1 (COMP005) (n=255): a single dose (25mg) monotherapy compared with placebo. This trial is designed to replicate the treatment response seen in the Company&#8217;s Phase 2b trial (n=233). We expect top-line data in summer of 2024.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Pivotal trial 2 (COMP006) (n= 568): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg. This trial is designed to investigate whether a second dose can increase treatment responders and/or improve responses observed in our Phase 2b trial and explore the potential for a meaningful treatment response from repeat administration of COMP360 10mg. We expect top-line data by mid-2025.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint in both pivotal trials is the change from baseline in the Montgomery&#8211;&#197;sberg Depression Rating Scale (MADRS) total score at week 6.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the first quarter of 2023, we commenced a Phase 2 (n=102) study to investigate the safety and tolerability of COMP360 psilocybin therapy in patients with major depressive disorder, or MDD.  In addition, pharmacokinetics and efficacy of COMP360 psilocybin therapy will be investigated.  We expect to submit the results of this study as part of our submission package for approval of COMP360 psilocybin therapy in TRD.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond TRD, we have ongoing Phase 2 trials in anorexia nervosa and PTSD.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Since our formation, we have devoted substantially all of our resources to conducting preclinical studies and clinical trials, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. We do not have any therapeutic candidates approved for sale and have not generated any revenue. We have funded our operations to date primarily with proceeds from the sale of convertible preferred shares, convertible loan notes, our initial public offering, or IPO, and our follow-on offering, of American Depositary Shares, or ADSs, representing our ordinary shares in September 2020 and May 2021, respectively. Through March  31, 2023, we had received net cash proceeds of $116.4 million from sales of our convertible preferred shares and convertible loan notes, $132.8 million from sales of ADSs in our IPO and $154.8 million from sales of ADSs in our Follow-On Offering. In October 2021, we entered into a Sales Agreement with Cowen and Company, LLC, under which we may issue and sell from time to time up to $150.0 million of our ADSs at market prices, which we refer to as our ATM Facility. At March 31, 2023, we had received net cash proceeds of $1.6 million from sales of ADSs under our ATM Facility. During the second quarter of 2023, through May 10, 2023, we sold 2,824,202 ADSs, resulting in $26.9 million in net proceeds. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have incurred significant operating losses since our inception. We incurred total net losses of $24.2 million and $21.2 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, we had an accumulated deficit of $285.4 million. Our historical losses resulted principally from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. In the future, we intend to continue to conduct research and development, preclinical testing, clinical trials, regulatory compliance, market access, commercialization and business development activities that, together with anticipated general and administrative expenses, will result in incurring further significant losses for at least the next several years. Our operating losses stem primarily from development of our investigational COMP360 psilocybin therapy for TRD, and we expect they will continue to increase as we  conduct our Phase 3 program in TRD for our investigational COMP360 psilocybin therapy candidate and conduct our Phase 2 studies for anorexia nervosa and PTSD and, potentially including expanding into additional indications, and initiate preclinical and clinical development of additional programs for different therapeutic candidates, as well as using digital technologies and solutions to enhance our therapeutic offering. Furthermore, since the completion of our IPO, we have incurred, and expect to continue to incur, significant costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. We will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from sales of therapeutic candidates, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to raise additional funds may also be adversely impacted by macroeconomic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as those resulting from heightened or fluctuating interest rates and rates of inflation and foreign exchange fluctuations, instability in the banking system, potential recessions in any of the regions or countries in which we operate, the ongoing war between Ukraine and Russia, and changing conditions resulting from public health crises. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurances, however, that our current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we had cash and cash equivalents of $117.1 million. We believe that our existing cash and cash equivalents, together with the net proceeds from sales of the Company&#8217;s ADSs through May 10, 2023, will be sufficient for us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and Capital Resources&#8212;Funding Requirements&#8221; below.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor current macroeconomic and geopolitical events, including heightened or fluctuating inflation and interest rates, continued instability in the banking system and the related impact on U.S. and global economies, fluctuations in foreign exchange rates, the risk of credit-rating downgrades and economic slowdown or recession in the United States due to debt ceiling and budget deficit concerns, the ongoing war between Ukraine and Russia, and continued indirect impact from the COVID-19 pandemic, for any potential impact that these or other events or conditions may have on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i132905a7c9654916bdd441350c765120_106"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue and do not expect to generate any revenue from the sale of therapeutic candidates in the foreseeable future. If our development efforts for our investigational COMP360 psilocybin therapy are successful and result in regulatory approval of COMP360, we may generate revenue in the future.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      development costs, including expenses incurred under agreements with contract research organizations (CROs) and contract management organizations (CMOs), investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services, as well as manufacturing scale-up expenses and the cost of acquiring and manufacturing materials for preclinical studies and clinical trials and laboratory and trial site supplies and equipment;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      personnel expenses, including salaries, related benefits and travel expense for employees engaged in research and development functions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      non-cash share-based compensation expenses resulting from equity awards granted to employees engaged in research and development functions; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      other expenses, including costs of outside consultants, including their fees and related travel expenses, allocated facility-related expenses such as direct depreciation costs, allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated financial statements as a prepaid expense or accrued research and development expenses.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product or therapeutic candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and related product manufacturing expenses. As a result, we expect that our research and development expenses will continue to increase over the next several years as we: (i) seek to complete the clinical development for our investigational COMP360 psilocybin therapy for TRD; (ii) fund research for our investigational COMP360 psilocybin therapy in other neuropsychiatric indications, including anorexia nervosa and PTSD; (iii) seek to develop digital technologies to complement and augment our therapies, and seek to access other novel drug candidates for development in neuropsychiatric and related indications; (iv) improve the efficiency and scalability of our third-party manufacturing processes and supply chain; and (v) build our third-party or in-house process development, analytical and related capabilities, increase personnel costs and prepare for regulatory filings related to our potential or future therapeutic candidates.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of our investigational COMP360 psilocybin therapy is highly uncertain. This is due to the numerous risks and uncertainties associated with development and commercialization, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in and completion of clinical trials and preclinical studies, including our Phase 3 clinical trials in TRD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials and our ability to raise capital on favorable terms or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving regulatory approvals or clearance for conducting our planned clinical trials or future clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving positive data from our clinical trials that support an acceptable risk-benefit profile of COMP360 psilocybin therapy and any future therapeutic candidates in the intended populations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and scaling up, through third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any therapeutic candidates are approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into collaborations to further the development of our investigational COMP360 psilocybin therapy and our future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for COMP360 and any future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching commercial sales of our investigational COMP360 psilocybin therapy and any future therapeutic candidates, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our current and future therapeutic candidates&#8217; benefits and uses, if approved, by patients, the medical community and third-party payors; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our investigational COMP360 psilocybin therapy and our future therapeutic candidates following approval.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables, amongst others, with respect to the development of our investigational COMP360 psilocybin therapy in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of our investigational COMP360 psilocybin therapy. For example, if the FDA, the European Medicines Agency, or EMA, the Medicines and Healthcare products Regulatory Agency, or MHRA, or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to commit significant additional financial resources and time on the completion of clinical development of that therapeutic candidate.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel expenses, including salaries and related benefits, travel and other expenses incurred by personnel in certain executive, finance and administrative functions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">non-cash share-based compensation expenses resulting from the equity awards granted to employees engaged in certain executive, finance and administrative functions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal and professional fees, including consulting, accounting and audit services; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities and other expenses, including depreciation costs, allocated expenses for rent and maintenance of facilities, director and officer insurance and other operating costs.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will continue to be significant in order to support our continued research activities and development of our investigational COMP360 psilocybin therapy.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also anticipate we will continue to incur significant accounting, audit, legal, regulatory and compliance costs, as well as investor and public relations expenses associated with being a public company. Additionally, if and when we believe a regulatory approval of a therapeutic candidate appears likely, we anticipate an increase in payroll and other expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our therapeutic candidate.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net relates to interest earned on cash balances.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign exchange gains</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains consist of foreign exchange impacts arising from foreign currency transactions, primarily related to the translation of intercompany balances as a result of a change in functional currency.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit from Research and Development Tax Credit</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from R&amp;D tax credit consists of the R&amp;D tax credit received in the UK, which is recorded within other income, net. As a company that carries out extensive research and development activities, we seek to benefit from the Small and Medium Enterprise, or SME, Program. Qualifying expenditures largely comprise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which we do not receive income.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on criteria established by His Majesty&#8217;s Revenue and Customs, or HMRC, a portion of expenditures being recognized in relation to our pipeline research and development, clinical trial management and third-party manufacturing development activities were eligible for the SME regime for the three months ended March 31, 2023 and 2022. We expect such elements of expenditure will also continue to be eligible for the SME regime for future accounting periods.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK R&amp;D tax credit is fully refundable to us and is not dependent on current or future taxable income. As a result, we have recorded the entire benefit from the UK research and development tax credit as a benefit which is included in our net loss before income tax and, accordingly, not reflected as part of the income tax provision. If, in the future, any UK R&amp;D tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to corporate taxation in the United States and the UK. Due to the nature of our business, we have generated losses since inception and have therefore not paid UK corporation tax. Our income tax expense represents only income taxes in the United States.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely and may be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits. After accounting for tax credits receivable, we had accumulated trading losses for carry forward in the UK of $176.9 million and $144.0 million as of December 31, 2023 and 2022, respectively, which is offset by a full valuation allowance.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, the Company recorded a tax provision of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million and $0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million, related to our income tax obligations of its operating company in the US, which generates a profit for tax purposes.</span></div><div id="i132905a7c9654916bdd441350c765120_109"></div><div style="margin-bottom:4pt;margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison For The Three Months Ended March 31, 2023 and 2022</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOSS FROM OPERATIONS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,788)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,420)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,368)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER INCOME, NET:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,078)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,031)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,047)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,208)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,171)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,037)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our research and development expenses incurred for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023 and 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $3.7 million to $19.0 million for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023, from $15.4 million for the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022. The increase in research and development expenses was primarily attributable to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.4 million in external development expenses, which primarily related to increases of $1.3 million in preclinical costs and $0.6 million in clinical trial expenses, partially offset by a decrease of $0.3 million in digital expenses and $0.2 million in drug development expenses;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.2 million in personnel expenses, as a result of hiring additional personnel in our research and development departments to support the expansion of our digital, preclinical and clinical teams;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.5 million in non-cash share-based compensation expense due to increased staffing levels year over year and equity awards granted to our chief executive officer in August 2022; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.6 million in other expenses, which was primarily related to increases in consulting fees and subscription and membership expenses.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development costs to continue to increase substantially in the near future, consistent with our plan to continue to advance our Phase 3 program for COMP360 psilocybin therapy in TRD in 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative  </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the three months ended March 31, 2023, and 2022 (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(902)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $2.7 million to $12.8 million for the three months ended March 31, 2023 from $10.1 million for the three months ended March 31, 2022. The increase in general and administrative expenses was primarily attributable to the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $2.2 million in personnel expenses, primarily due to an increase in staffing levels related to the hiring of additional personnel in general, administrative and commercial departments to support our growth initiatives; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.5 million in non-cash share-based compensation expense due to increased staffing levels year over year, and equity awards granted to our new chief executive officer in August 2022;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $0.9 million in legal and professional fees, primarily related to a decrease in expenses associated with consulting, legal advice and patent applications; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.9 million in facilities and other expenses, primarily attributable to an increase of $0.3 million in costs associated with our Centers of Excellence, an increase of $0.3 million in subscription and membership costs, and a $0.3 million increase in communications and other miscellaneous expenses.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant general and administrative expenses as a result of ongoing requirements as a public company, in addition to ongoing general and administrative support for research and development growth initiatives.</span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income, net</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $0.7 million for the three months ended March 31, 2023 and $0.1 million for the three months ended March 31, 2022. The increase in other income primarily related to increased interest income as a result of higher interest rates on cash deposits. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign exchange gains</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains increased by $1.4 million to a gain of $2.7 million for the three months ended March 31, 2023 from a gain of $1.3 million for the three months ended March 31, 2022, primarily related to the translation of intercompany balances as a result of a change in functional currency.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As our operating model and business develops we will continue to monitor and assess our legal entity structure, the predominant currency of our future cash outflows and the continuing impact of foreign exchange rates on our results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit from Research and Development Tax Credit</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we recognized an R&amp;D tax credit in the UK as a benefit within other income, net of $4.3 million and $2.9 million, respectively. The tax credit receivable increased by $1.4 million in 2023 compared to 2022 in line with increased research and development activities.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax expense</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense was $0.1 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $0.2 million for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The income tax expense was related to income tax obligations of our operating company in the United States, which generates a profit for tax purposes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i132905a7c9654916bdd441350c765120_112"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage mental health care company and we have not yet generated any revenue to date. We have incurred significant operating losses since our formation. We have not yet commercialized any therapeutic candidates and we do not expect to generate revenue from sales of any therapeutic candidates for the foreseeable future, if at all. We have funded our operations to date primarily with proceeds from the sale of convertible preferred shares, convertible loan notes and ADSs in our IPO and our Follow-On Offering. Through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023, we had received net cash proceeds of $116.4 million from sales of our convertible preferred shares and convertible loan notes, $132.8 million in net proceeds from sales of ADSs through our IPO, $154.8 million in net proceeds from our Follow-On Offering and $1.6 million in net cash proceeds through sales of ADSs under our ATM facility. We believe our existing cash and cash equivalents of $117.1 million at March 31, 2023, together with the net proceeds from sales of our ADSs through May 10, 2023, will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for each of the periods (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,723)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,007)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,559)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023, net cash used in operating activities was $27.7 million, primarily resulting from our net loss of $24.2 million in addition to a non-cash gain on foreign currency remeasurement of $2.0 million, offset by a non-cash share-based compensation expenses of $4.1 million, depreciation and amortization of less than $0.1 million, and non-cash lease expenses of $0.5 million. The net loss was also adjusted by $6.2 million related to changes in components of working capital, including a $1.5 million increase in prepaid expenses and other current assets which primarily related to the R&amp;D tax credit receivable and prepaid research and development expense and a less than $0.1 million increase in other assets related to implementation costs of our quality management system, in addition to a $1.0 million decrease in accounts payable which primarily relates to research and development invoices paid in the quarter, a $3.2 million decrease in accrued expenses and other liabilities due to decreased accrued compensation and benefit costs, a $0.5 million decrease in operating lease liabilities and a decrease in deferred and prepaid tax assets of $0.1 million.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, net cash used in operating activities was $23.1 million, primarily resulting from our net loss of $21.2 million plus a non-cash gain on foreign currency remeasurement of $0.2 million, offset by non-cash share-based compensation expense of $3.1 million, depreciation and amortization of $0.1 million, and non-cash lease expenses of $0.6 million. The net loss was also adjusted by $5.5 million related to changes in components of working capital, including a $1.4 million increase in prepaid expenses and other current assets which primarily related to the R&amp;D tax credit receivable and prepaid research and development expense, a $0.3 million increase in other assets related to a rental deposit receivable in respect of our previous London office in addition to increased implementation costs of our quality management system, a $0.1 million increase in deferred and prepaid tax assets, a $3.1 million decrease in accounts payable and accrued expenses primarily related to payment of bonuses and accrued clinical trial costs at year end and a $0.5 million decrease in operating lease liabilities.</span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During each of the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023 and 2022, net cash used in investing activities was less than $0.1 million, primarily attributable to our purchases of property and equipment, which largely consisted of lab and office equipment.</span></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, net cash provided by financing activities was $1.1 million primarily related to proceeds from the issuance of ordinary shares through our ATM facility of $1.2 million offset against $0.1 million in relation to tax withholding on stock awards in 2023, compared to $0.2 million during the three months ended March 31, 2022, primarily related to the proceeds from exercise of options.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2, on January 1, 2023, we and our wholly owned subsidiary, COMPASS Pathfinder Holdings Limited, adopted the U.S. dollar as its functional currency.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023 the effect of exchange rate changes on cash, cash equivalents and restricted cash resulted in an exchange gain of $0.7 million primarily driven by an increase in GBP:USD exchange rates from period to period, resulting in an exchange gain on balances which are held in an entity with a Pound Sterling functional currency and translated to U.S. dollars, the reporting currency.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 the effect of exchange rate changes on cash, cash equivalents and restricted cash resulted in an exchange loss of $6.5 million, primarily driven a decrease in GBP:USD exchange rates from period to period, resulting in exchange losses on cash balances which were held in multiple entities with Pound Sterling functional currencies and translated to U.S. dollars, the reporting currency.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span><br/></span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect our expenses to continue to increase substantially in connection with our ongoing activities, particularly as we advance our Phase 3 clinical program of COMP360 in TRD and continue to advance the preclinical activities, manufacturing and Phase 2 clinical trials of COMP360. In addition, we expect to continue to incur significant costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. Our expenses will also increase as we:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the clinical development of our investigational COMP360 psilocybin therapy in active clinical trial sites across Europe and North America, including costs associated with conducting our Phase 3 program in TRD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct Phase 2 studies evaluating the safety and tolerability of COMP360 psilocybin therapy in patients suffering with anorexia nervosa and PTSD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish relationships with the network of public healthcare institutions and private clinics that will administer our investigational COMP360 psilocybin therapy, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the training of qualified therapists, psychiatrists and other healthcare professionals to deliver our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any therapeutic candidates, therapy sessions, or digital support, for which we may obtain regulatory approval, including COMP360;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our commercialization strategy in Europe and North America, including using digital technologies and solutions to enhance our therapeutic offering;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the research and development program for our other preclinical stage therapeutic candidates and discovery-stage programs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discover and/or develop additional therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any therapeutic candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue necessary scheduling-related decisions to enable us to commercialize any therapeutic candidates containing controlled substances for which we may obtain regulatory approval, including COMP360;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explore external business development opportunities through acquisitions, partnerships, licensing deals to enhance our pipeline and add additional therapeutic candidates to our portfolio;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain, maintain, expand and protect our intellectual property portfolio, including litigation costs associated with defending against alleged patent or other intellectual property infringement claims;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our therapeutic development and potential future commercialization efforts;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operations in the United States, Europe and potential other geographies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses associated with operating as a public company listed in the United States; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">work to accelerate research of emerging psychedelic therapies through our partnership with Sheppard Pratt.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash of $117.1 million at March 31, 2023, together with the net proceeds from sales of our ADSs through May 10, 2023, will be sufficient for us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. As we progress with our development programs and the regulatory review process, we expect to incur significant commercialization expenses related to product manufacturing, pre-commercial activities and commercialization.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of therapeutic candidates and programs, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and completion of our Phase 3 clinical program  for COMP360 for the treatment of TRD, and for indications outside of TRD or any future therapeutic candidates outside of TRD, including anorexia nervosa and PTSD;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA, the EMA, the MHRA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more nonclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of any scheduling-related decisions by the United States Drug Enforcement Agency, or DEA, individual states, and comparable foreign authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of potential new therapeutic candidates we identify and decide to develop, either internally through our research and development efforts or externally through acquisitions, licensing or other collaboration agreements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with establishing and maintaining Centers of Excellence to serve as research facilities and innovation labs, in line with our ambition to create a new mental health care model;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost involved with hiring additional personnel in our research and development department to support the expansion of our digital activities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our investigational COMP360 psilocybin therapy and future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringements raised by third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approval for COMP360 or future therapeutic candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to COMP360 or any of our future therapeutic candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the potential commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved, and costs involved in the creation of an effective sales and marketing organization;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our investigational COMP360 psilocybin therapy and future therapeutic candidates, if approved; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of operating as a public company.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available at all or on acceptable terms. To the extent that we raise additional capital through the sale of equity, current ownership interests will be diluted. If we raise additional funds through government or third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish future revenue streams, research programs or therapeutic candidates or grant licenses on terms that may not be favorable to us. Debt financing, if available, may involve high interest rates or agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i132905a7c9654916bdd441350c765120_115"></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our significant accounting policies or&#8239;critical&#8239;accounting&#8239;estimates during the first three months of 2023. For a complete discussion, see the &#8220;Critical Accounting Policies and Significant Judgments and Estimates&#8221; section of the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation in our Form 10-K.</span></div><div id="i132905a7c9654916bdd441350c765120_118"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the market value of shares held by non-affiliates on June 30, 2022, we are a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act and have exited the &#8220;large accelerated filer&#8221; status as of December 31, 2022. We may take advantage of certain of the scaled disclosures available to smaller reporting companies. These include, but are not limited to, reduced disclosure obligations regarding executive compensation and an exemption from the requirement to provide a compensation discussion and analysis describing compensation practices and procedures. As a smaller reporting company with annual revenues of less than $100.0 million and not an accelerated filer or a large accelerated filer, we are also not required to provide an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We will be able to take advantage of these scaled disclosures and exemptions for so long as (i) our voting and non-voting shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i132905a7c9654916bdd441350c765120_124"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in market risk exposures that affect the disclosures presented in Part II, Item 7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div id="i132905a7c9654916bdd441350c765120_127"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2023. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the&#160;Exchange Act&#160;is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i132905a7c9654916bdd441350c765120_130"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i132905a7c9654916bdd441350c765120_133"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are not currently a party to any litigation or claims that we believe, if determined adversely to us, would have a material adverse effect on our business, operating results, financial condition or cash flows. From time to time, we may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.<br/></span></div><div id="i132905a7c9654916bdd441350c765120_768"></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">You should carefully consider the following risk factors as well as the other information included in this Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our condensed consolidated financial statements and related notes thereto. Any of the following risks could materially and adversely affect our business, financial condition, or results of operations. The selected risks described below, however, are not the only risks facing us. Additional risks and uncertainties not currently known to us or those we currently view to be immaterial may also materially and adversely affect our business, financial condition, or results of operations. The summary of the material risks associated with our business is included in the &#8220;Special Note Regarding Forward Looking Statements&#8221; on page 4 above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We are a clinical-stage mental health care company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are a clinical-stage mental health care company and we have not generated any revenue to date. We have incurred significant operating losses since our formation. We incurred total net losses of $91.5 million for the year ended December 31, 2022 and we incurred total net losses of $24.2 million for the three-months ended March 31, 2023. As of March 31, 2023, we had an accumulated deficit of $285.4 million. Our historical losses resulted principally from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. In the future, we intend to continue to conduct research and development, preclinical testing, clinical trials, regulatory compliance, market access, commercialization and business development activities that, together with anticipated general and administrative expenses, will result in incurring further significant losses for at least the next several years. Our expected losses, among other things, may continue to cause our working capital and shareholders&#8217; equity to decrease. We anticipate that our expenses will increase substantially if and as we, among other things: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">conduct our Phase 3 program</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> for our investigational COMP360 psilocybin therapy in TRD and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">continue the clinical development of our investigational COMP360 psilocybin therapy in other indications, including anorexia nervosa and PTSD</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">continue the training of therapists to deliver our investigational COMP360 psilocybin therapy in our Phase 3 program and clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">continue to invest in funding investigator-initiated studies, or IISs, including the IIS co-sponsored by King&#8217;s Institute of Psychiatry, Psychology &amp; Neuroscience (IoPPN) and South London and Maudsley NHS Foundation Trust that will use COMP360 psilocybin therapy to explore how psilocybin affects specific brain pathways in autistic adults;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any therapeutic candidates for which we may obtain regulatory approval, including COMP360; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">establish and expand the network of public healthcare institutions and private clinics that administer our investigational COMP360 psilocybin therapy in conjunction with psychological support as part of our clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">advance our commercialization strategy in North America and Europe, including using digital technologies to enhance our proposed therapeutic offering; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">research additional indications for our investigational COMP360 psilocybin therapy and discover and develop any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">continue to invest in the development of prodrug candidates and psychedelic compounds that could be developed into therapies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">continue to invest in our Discovery Center and Centers of Excellence; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">seek regulatory approvals for any future therapeutic candidates that successfully complete clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">experience heightened regulatory scrutiny;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">pursue necessary scheduling-related decisions by the U.S. Drug Enforcement Administration, or the DEA, to enable us to commercialize any future therapeutic candidates containing controlled substances for which we may obtain regulatory approval, including COMP360;</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">explore external business development opportunities through acquisitions, partnerships, licensing deals to add future therapeutic candidates and technologies to our portfolio;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">obtain, maintain, expand and protect our intellectual property portfolio, including litigation costs associated with defending against alleged patent or other intellectual property infringement claims; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our therapeutic development and potential future commercialization efforts; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">experience any delays or encounter any issues with respect to any of the above, including failed studies, ambiguous trial results, safety issues or other regulatory challenges, including, for example, delays and other impacts as a result of a resurgence or emergence of new COVID-19 variants;</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">expand our operations in the United States, Europe and potential other geographies in the future; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">incur additional legal, accounting and other expenses associated with operating as an English-domiciled public company listed in the United States.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">To date we have funded our operations through private placements of equity and convertible notes and, since our initial public offering, or IPO, in 2020, through public equity offerings. To become and remain profitable, we will need to continue developing and eventually commercialize therapies that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing our Phase 3 clinical program of COMP360 in TRD and other clinical trials of COMP360 or any future therapeutic candidates, training a sufficient number of qualified therapists to deliver our investigational COMP360 psilocybin therapy, using digital technologies and solutions to enhance our therapeutic offering, establishing and/or collaborating with providers to develop additional &#8220;Centers of Excellence&#8221; where we can conduct trainings for therapists, discovering and developing any future therapeutic candidates, obtaining regulatory approval for COMP360 psilocybin therapy and any future therapeutic candidates that successfully complete clinical trials, and establishing marketing capabilities. Even if COMP360 psilocybin therapy or any of the future therapeutic candidates that we may develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing COMP360 or any other approved future therapeutic candidate. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Because of the numerous risks and uncertainties associated with therapeutic development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">37</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">by the FDA, the EMA, the MHRA, or other comparable foreign authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, our expenses could increase beyond our current expectations and revenue could be further delayed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Even if we or any future collaborators do generate sales, we may never achieve, sustain or increase profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our ADSs and could impair our ability to raise capital, expand our business, diversify our therapeutic offerings or continue our operations. If we continue to suffer losses, investors may not receive any return on their investment and may lose their entire investment. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">We will need substantial additional funding to complete the development and commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We expect to require substantial additional funding in the future to sufficiently finance our operations and advance development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. We expect that our cash and cash equivalents of $117.1 million as of March 31, 2023, together with the net proceeds from sales of our ADSs through May 10, 2023, will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, such as heightened or fluctuating inflation and interest rates, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the progress, timing and completion of our Phase 3 clinical program for our current investigational COMP360 psilocybin therapy program for TRD, our Phase 2 studies in anorexia nervosa and PTSD, and our preclinical activities and clinical trials for future indications or any future therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA, the EMA, the MHRA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the outcome and timing of any scheduling-related decisions by the DEA, individual states, and comparable foreign authorities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the number of potential future therapeutic candidates we identify and decide to develop, either internally through our research and development efforts or externally through acquisitions, licensing or other collaboration agreements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our investigational COMP360 psilocybin therapy and any future therapeutic candidates, including increasing personnel costs; </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the costs of developing sales and marketing capabilities to target public and private healthcare providers and clinic networks in major markets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the costs of training and certifying therapists to administer our investigational COMP360 psilocybin therapy in our Phase 3 program and other clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the costs of establishing our Centers of Excellence and the Center for Mental Health Research, which includes conducting clinical trials, including proof of concept studies, to refine our therapeutic model; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">38</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">generating and collecting data and advancing and defending our intellectual property portfolio; and strengthening our regional presence as a scientific and clinical resource;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the costs of developing, testing and deploying digital technology solutions to improve the patient experience and therapeutic process;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringements or invalidity raised by third parties; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approval for COMP360 or any future therapeutic candidates, and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to COMP360 or any future therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the potential commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved, and costs involved in the creation of an effective sales and marketing organization;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the amount of revenue, if any, we may derive either directly or in the form of royalty, milestone or other payments from future sales of our investigational COMP360 psilocybin therapy and any future therapeutic candidates, if approved; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the costs of operating as a public company.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, strategic collaborations and alliances, licensing arrangements or monetization transactions. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Our ability to raise additional funds when needed and on acceptable terms or at all will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. For example, the continued challenging capital markets environment, recent bank failures and turmoil in the banking system, lower prices for many securities and concerns about potential recessionary factors may affect our ability to raise additional funding through sales of our securities or issuance of indebtedness, which may harm our liquidity, force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization planning efforts or cause us to grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or our investigational COMP360 psilocybin therapy or any future therapeutic candidate, or we may be unable to take advantage of future business opportunities. Market volatility, geopolitical tensions resulting from the ongoing war between Ukraine and Russia, heightened or fluctuating inflation and interest rates, instability in the banking system, and the related impact on U.S. and global economies, the risk of credit-rating downgrades and economic slowdown or recession in the United States due to debt ceiling and budget deficit concerns or other economic or other factors could also adversely impact our ability to access capital as and when needed or increase our costs in order to raise capital. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We cannot guarantee that future financing will be available in sufficient amounts, or on commercially reasonable terms, or at all. Current capital market conditions, including the impact of inflation, have increased borrowing rates and can be expected to significantly increase our cost of capital as compared to prior periods. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our ADSs, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to COMP360 or any future therapeutics candidates or otherwise agree to terms </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">39</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Further, any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, heightened regulatory scrutiny could have a negative impact on our ability to raise capital. Our business activities rely on developing laws and regulations in multiple jurisdictions. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding our investigational COMP360 psilocybin therapy or any future therapeutic candidates may adversely affect our business and operations, including without limitation, our ability to raise additional capital.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Adverse developments in the banking system and financial services industry, including the failure or concerns regarding the failure of banks and financial institutions, could have an adverse effect on our ability to raise additional capital and our operations and financial results.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, the Federal Deposit Insurance Corporation was appointed as receiver of Silicon Valley Bank and Signature Bank in March 2023 and as receiver of First Republic Bank prior to its acquisition by JPMorgan in May 2023. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis. These events exposed vulnerabilities in the banking sector, including legal uncertainties, significant volatility and contagion risk, and caused instability in the market prices of regional bank stocks. The closure of financial institutions, even if such financial institutions are unrelated to our business, may result in declines in the price of our stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">    </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Although we did not hold cash deposits at recently closed banks, we are unable to predict the extent or nature of the impacts of these evolving circumstances at this time. If, for example, other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, if any other parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to pay their obligations to us could be adversely affected. While it is not possible at this time to predict the extent of the impact that the failure of these banks or the high market volatility and instability of the banking sector could have on economic activity and our business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Although we continue to assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we have banking relationships, and in turn, us. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. The results of events or concerns that involve one or more of these factors, or other general impact on the financial markets or financial services industry generally, could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to raise additional capital on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">40</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our limited history as a clinical stage company may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We were formed in 2016 and to date, we have invested most of our resources in developing our investigational COMP360 psilocybin therapy, building our intellectual property portfolio, conducting business planning, raising capital and providing administrative support for these operations. Although we recently began our Phase 3 clinical program for our COMP360 psilocybin therapy for TRD, we have not yet demonstrated an ability to conduct such later-stage clinical trials, obtain regulatory approvals, manufacture a commercial-scale product, conduct sales and marketing activities necessary for successful product commercialization or obtain reimbursement in the countries of sale.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. If we receive regulatory approval for our COMP360 psilocybin therapy or any future product candidate, we will need to transition from a company with a clinical development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Raising additional capital may cause dilution to holders of our ordinary shares or ADSs, restrict our operations or require us to relinquish rights to COMP360 or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may seek additional capital through a combination of equity offerings, debt financings, strategic collaborations and alliances, licensing arrangements or monetization transactions. To the extent that we raise additional capital through the sale of equity, convertible debt securities or other equity-based derivative securities, your ownership interest will be diluted and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. Any indebtedness we incur would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, acquire or license intellectual property rights, declare dividends, make capital expenditures and other operating restrictions that could adversely impact our ability to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline and existing shareholders may not agree with our financing plans or the terms of such financings. If we raise additional funds through strategic collaborations and alliances, licensing arrangements or monetization transactions with third parties, we may have to relinquish valuable rights to our investigational COMP360 psilocybin therapy or any future therapeutic candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our investigational COMP360 psilocybin therapy or any future therapeutic candidates that we would otherwise prefer to develop and market ourselves. Further, any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Furthermore, certain shareholders and holders of ADSs, including those in the United States, may, even in the case where preferential subscription rights have not been cancelled or limited, not be entitled to exercise such rights, unless the offering is registered or the ordinary shares are qualified for sale under the relevant regulatory framework. As a result, there is the risk </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">41</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">that investors may suffer dilution of their holdings should they not be permitted to participate in preference right equity or other offerings that we may conduct in the future.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Development, Clinical Testing and Commercialization of Our Investigational COMP360 Psilocybin Therapy and Any Future Therapeutic Candidates</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We are dependent on the successful development of our investigational COMP360 psilocybin therapy. We cannot give any assurance that COMP360 will successfully complete clinical trials or receive regulatory approval, which is necessary before it can be commercialized. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We currently have no therapies that are approved for commercial sale and may never be able to develop marketable therapies. We expect that a substantial portion of our efforts and expenditures over the next several years will be devoted to our investigational COMP360 psilocybin therapy, which is currently our only therapeutic candidate in clinical development. Accordingly, our business currently depends on the successful regulatory approval of COMP360 and the commercialization of our investigational COMP360 psilocybin therapy. We cannot be certain that COMP360 will receive regulatory approval or that our therapy will be successfully commercialized even if we receive regulatory approval. If we were required to discontinue development of our investigational COMP360 psilocybin therapy, or if COMP360 does not receive regulatory approval or fails to achieve significant market acceptance, we would be delayed by many years in our ability to achieve profitability, if ever.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of psilocybin is, and will remain, subject to comprehensive regulation by the FDA, the DEA, the EMA, the MHRA and comparable foreign regulatory authorities. Failure to obtain regulatory approval in the United States, Europe or other jurisdictions will prevent us from commercializing and marketing our investigational COMP360 psilocybin therapy in such jurisdictions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Even if we were to successfully obtain approval from the FDA, the EMA, the MHRA and foreign regulatory authorities for COMP360, any approval might contain significant limitations related to use, as well as restrictions for specified age groups, warnings, precautions or contraindications. Furthermore, even if we obtain regulatory approval for COMP360, we will still need to develop a commercial infrastructure or develop relationships with collaborators to commercialize including securing availability of third-party therapy sites for the appropriate administration of our investigational COMP360 psilocybin therapy, secure adequate manufacturing, train and secure access to qualified therapists, establish a commercially viable pricing structure and obtain coverage and adequate reimbursement from third-party payors, including government healthcare programs. If we, or any future collaborators, are unable to successfully commercialize our investigational COMP360 psilocybin therapy, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The success of our investigational COMP360 psilocybin therapy and any future therapeutic candidates will depend on several factors, including the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">successful completion of clinical trials, including our Phase 3 program in TRD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">and Phase 2 programs in anorexia nervosa and PTSD, and preclinical studies;</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">receiving regulatory approvals or clearance for conducting our planned clinical trials or future clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">successful patient enrollment in and completion of clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">positive data from our clinical trials that support an acceptable risk-benefit profile of COMP360 and any future therapeutic candidates in the intended populations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">42</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">establishing and scaling up, either alone or with third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if COMP360 or any future therapeutic candidates are approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">recruiting, training and certifying therapists to administer our investigational COMP360 psilocybin therapy in our Phase 3 program and other clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">entry into collaborations to further the development of our investigational COMP360 psilocybin therapy and any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">obtaining and maintaining and defending patent and trade secret protection and/or regulatory exclusivity for COMP360 and any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">successfully launching commercial sales of our investigational COMP360 psilocybin therapy and any future therapeutic candidates, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">acceptance of COMP360 and any future therapeutic candidates&#8217; benefits and uses, if approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">maintaining a continued acceptable safety profile of COMP360 and any future therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">effectively competing, including with respect to cost, with companies developing and commercializing other therapies in the indications which our investigational COMP360 psilocybin therapy targets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">maintaining the strength of our reputation; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">complying with laws and regulations, including laws applicable to controlled substances, data privacy, and pre-commercial activities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates we develop, which would materially harm our business. If we do not receive marketing approvals for COMP360 and any future therapeutic candidates, we may not be able to continue our operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">COMP360 psilocybin therapy is, and any future therapeutic candidates we may develop in the future may be, subject to controlled substance laws and regulations in the territories where the product will be marketed, such as the United States, the UK and the rest of Europe, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations, both during clinical development and post approval, and our financial condition. In addition, during the review process of COMP360 psilocybin therapy, and prior to approval, the FDA and/or other regulatory bodies may require additional data, including with respect to whether COMP360 has abuse or misuse potential. This may delay approval and any potential rescheduling process.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the United States, psilocybin and its active metabolite, psilocin, are listed by the DEA as &#8220;Controlled Substances&#8221; or scheduled substances, under the Comprehensive Drug Abuse Prevention and Control Act of 1970, also known as the Controlled Substances Act, or CSA, specifically as a Schedule I substance. The DEA regulates chemical compounds as Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse, have no currently &#8220;accepted medical use&#8221; in the United States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among such substances. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II drugs is further restricted. For example, they may not be refilled without a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">43</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">new prescription and may have a black box warning. Further, most state laws in the United States classify psilocybin and psilocin as Schedule I controlled substances. For any product containing psilocybin to be available for commercial marketing in the United States, psilocybin and psilocin must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V. Commercial marketing in the United States will also require scheduling-related legislative or administrative action.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance. Therefore, while psilocybin and psilocin are Schedule I controlled substances, products approved by the FDA for medical use in the United States that contain psilocybin or psilocin should be placed in Schedules II-V, since approval by the FDA satisfies the &#8220;accepted medical use&#8221; requirement. If or when COMP360 receives FDA approval, we anticipate that the DEA will make a scheduling determination and place it in a schedule other than Schedule I in order for it to be prescribed to patients in the United States. This scheduling determination will be dependent on FDA approval and the FDA&#8217;s recommendation as to the appropriate schedule. During the review process, and prior to approval, the FDA may determine that it requires additional data, either from non-clinical or clinical studies, including with respect to whether, or to what extent, the substance has abuse or misuse potential. This may introduce a delay into the approval and any potential rescheduling process. That delay would be dependent on the quantity of additional data required by the FDA. This scheduling determination will require DEA to conduct notice and comment rule making including issuing an interim final rule. Such action will be subject to public comment and requests for hearing which could affect the scheduling of these substances. There can be no assurance that the DEA will make a favorable scheduling decision. Even assuming categorization as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), at the federal level, such substances would also require scheduling determinations under state laws and regulations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If approved by the FDA, and if the finished dosage form of COMP360 is listed by the DEA as a Schedule II, III, or IV controlled substance, its manufacture, importation, exportation, domestic distribution, storage, sale and legitimate use will continue to be subject to a significant degree of regulation by the DEA. In addition, the scheduling process may take significantly longer than the 90-day deadline set forth in the CSA, thereby delaying the launch of our investigational COMP360 psilocybin therapy in the United States. Furthermore, the FDA, DEA, or any foreign regulatory authority could require us to generate more clinical or other data than we currently anticipate to establish whether or to what extent the substance has an abuse potential, which could increase the cost and/or delay the launch of our investigational COMP360 psilocybin therapy and any future therapeutic candidates containing controlled substances. In addition, therapeutic candidates containing controlled substances are subject to DEA regulations relating to manufacturing, storage, distribution and physician prescription procedures, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">DEA registration and inspection of facilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing controlled substances must be registered (licensed) to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these facilities must renew their registrations annually, except dispensing facilities, which must renew every three years. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances. Obtaining and maintaining the necessary registrations may result in delay of the importation, manufacturing or distribution of COMP360. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">State-controlled substances laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> Individual U.S. states have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule COMP360. While some states automatically schedule a drug based on federal action, other states schedule drugs through rule making or a legislative action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness of such product. We or our partners must also obtain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">44</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">separate state registrations, permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">Clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. Because our investigational COMP360 psilocybin therapy contains psilocybin, to conduct clinical trials with COMP360 in the United States prior to approval, each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA researcher registration that will allow those sites to handle and dispense COMP360 and to obtain the product from our importer. If the DEA delays or denies the grant of a researcher registration to one or more research sites, the clinical trial could be significantly delayed, and we could lose clinical trial sites. The importer for the clinical trials must also obtain a Schedule I importer registration and an import permit for each import. We do not currently conduct any manufacturing or repackaging/relabeling of either COMP360 or its active ingredients (i.e., psilocybin) in the United States. COMP360 is imported in its fully-finished, packaged and labeled dosage form.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">Importation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> If COMP360 is approved and classified as a Schedule II, III or IV substance, an importer can import it for commercial purposes if it obtains an importer registration and files an application for an import permit for each import. The DEA provides annual assessments/estimates to the International Narcotics Control Board, which guides the DEA in the amounts of controlled substances that the DEA authorizes to be imported. The failure to identify an importer or obtain the necessary import authority, including specific quantities, could affect the availability of COMP360 and have a material adverse effect on our business, results of operations and financial condition. In addition, an application for a Schedule II importer registration must be published in the Federal Register, and there is a waiting period for third-party comments to be submitted. It is always possible that adverse comments may delay the grant of an importer registration. If COMP360 is approved and classified as a Schedule II controlled substance, federal law may prohibit the import of the substance for commercial purposes. If COMP360 is listed as a Schedule II substance, we will not be allowed to import the drug for commercial purposes unless the DEA determines that domestic supplies are inadequate or there is inadequate domestic competition among domestic manufacturers for the substance as defined by the DEA. Moreover, Schedule I controlled substances, including psilocybin and psilocin, have never been registered with the DEA for importation for commercial purposes, only for scientific and research needs. Therefore, if neither COMP360 nor its drug substance could be imported, COMP360 would have to be wholly manufactured in the United States, and we would need to secure a manufacturer that would be required to obtain and maintain a separate DEA registration for that activity.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">Manufacture in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. If, because of a Schedule II classification or voluntarily, we were to conduct manufacturing or repackaging/relabeling in the United States, our contract manufacturers would be subject to the DEA&#8217;s annual manufacturing and procurement quota requirements. Additionally, regardless of the scheduling of COMP360, the active ingredient in the final dosage form is currently a Schedule I controlled substance and would be subject to such quotas as this substance could remain listed on Schedule I. The annual quota allocated to us or our contract manufacturers for the active ingredient in COMP360 may not be sufficient to complete clinical trials or meet commercial demand. Consequently, any delay or refusal by the DEA in establishing our, or our contract manufacturers&#8217;, procurement and/or production quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and results of operations.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">Distribution in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. If COMP360 is scheduled as Schedule II, III or IV, we would also need to identify wholesale distributors with the appropriate DEA registrations and authority to distribute COMP360 and any future therapeutic candidates. These distributors would need to obtain Schedule II, III or IV distribution registrations. This limitation in the ability to distribute COMP360 more broadly may limit commercial uptake and could negatively impact our prospects. The failure to obtain, or delay in obtaining, or the loss of any of those registrations could result in increased costs to us. If COMP360 is a Schedule II drug, participants in our supply chain may have to maintain enhanced security with alarms and monitoring systems and they may be required to adhere to recordkeeping and inventory requirements. This may discourage some pharmacies from carrying the product. In addition, COMP360 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">45</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">could be determined to have a high potential for abuse and therefore required to be administered at our trial sites, which could limit commercial uptake. Furthermore, state and federal enforcement actions, regulatory requirements, and legislation intended to reduce prescription drug abuse, such as the requirement that physicians consult a state prescription drug monitoring program, may make physicians less willing to prescribe, and pharmacies to dispense, Schedule II products.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">Controlled Drug Status in the United Kingdom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. Psilocybin and psilocin are &#8220;controlled drugs&#8221; in the UK, as they are listed under Schedule 1 of the UK&#8217;s Misuse of Drugs Regulations 2001 and are classified as Class A controlled substances under the Misuse of Drugs Act 1971. Substances listed under Schedule 1 of the Misuse of Drugs Regulations 2001 are considered to have little or no therapeutic benefit and are the most strictly controlled. These substances can therefore only be imported, exported, produced and supplied under a license issued by the UK Government&#8217;s Home Office. Psilocybin and psilocin may never be rescheduled under the Misuse of Drugs Regulations 2001, or reclassified under the UK&#8217;s Misuse of Drugs Act 1971.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The potential reclassification of psilocybin and psilocin in the United States could create additional regulatory burdens on our operations and negatively affect our results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If psilocybin and/or psilocin, other than the FDA-approved formulation, is rescheduled under the CSA as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), the ability to conduct research on psilocybin and psilocin would most likely be improved. However, rescheduling psilocybin and psilocin may materially alter enforcement policies across many federal agencies, primarily the FDA and DEA. The FDA is responsible for ensuring public health and safety through regulation of food, drugs, supplements, and cosmetics, among other products, through its enforcement authority pursuant to the Federal Food, Drug, and Cosmetic Act, or the FDCA. The FDA&#8217;s responsibilities include regulating the ingredients as well as the marketing and labeling of drugs sold in interstate commerce. Because it is currently illegal under federal law to produce and sell psilocybin and psilocin, and because there are no federally recognized medical uses, the FDA has historically deferred enforcement related to psilocybin and psilocin to the DEA. If psilocybin and psilocin were to be rescheduled to a federally controlled, yet legal, substance, the FDA would likely play a more active regulatory role. The DEA would continue to be active in regulating manufacturing, distribution and dispensing of such substances. The potential for multi-agency enforcement post-rescheduling could threaten or have a materially adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">COMP360 contains controlled substances, the use of which may generate public controversy. Adverse publicity or public perception regarding psilocybin or our current or future investigational therapies using psilocybin may negatively influence the success of these therapies.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Therapies containing controlled substances may generate public controversy. Political and social pressures and adverse publicity could lead to delays in approval of, and increased expenses for, COMP360 and any future therapeutic candidates we may develop. Opponents of these therapies may seek restrictions on marketing and withdrawal of any regulatory approvals. In addition, these opponents may seek to generate negative publicity in an effort to persuade the medical community to reject these therapies. For example, we may face media-communicated criticism directed at our clinical development program. Adverse publicity from psilocybin misuse may adversely affect the commercial success or market penetration achievable by our investigational COMP360 psilocybin therapy. Anti-psychedelic protests have historically occurred and may occur in the future and generate media coverage. Political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit or restrict the introduction and marketing of, our investigational COMP360 psilocybin therapy or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If COMP360 or any future therapeutic candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of the safety and quality of our therapies. We may face limited adoption if third-party therapy sites, therapists, and patients are unwilling to try such a novel treatment. There has been a history of negative media coverage regarding psychedelic substances, including psilocybin, which may affect the public&#8217;s perception of our therapies. In addition, psilocybin elicits intense psychological experiences, and this could deter patients from choosing this course of treatment. We could be adversely affected if we were subject to negative publicity or if any of our therapies or any similar therapies </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">46</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perception, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our therapies or any similar therapies distributed by other companies could have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Future adverse events in research into depression and mental health diseases on which we focus our research efforts, or the pharmaceutical industry more generally, could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our therapies. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for COMP360 or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of COMP360 or any future therapeutic candidates are prolonged or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals, and therefore we will be unable to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates on a timely basis or at all, which will adversely affect our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We may experience delays in completing our Phase 3 clinical program of COMP360 psilocybin therapy in TRD, completing our ongoing Phase 2 clinical trials in anorexia nervosa and PTSD and initiating or completing additional clinical trials. For example, we have experienced some delays in our Phase 2 clinical trial for anorexia nervosa due to challenges in recruiting and screening participants for our Phase 2 study in anorexia nervosa and as a result, we no longer expect to have data from this trial available in 2023, as we had originally expected. To address these challenges, we amended the trial protocol and adjusted our procedures. We may also experience numerous unforeseen events, and in some cases have experienced such events, during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">delays in or failure to obtain regulatory approval to commence or modify a trial, including the imposition of a temporary or permanent clinical hold by regulatory authorities for a number of reasons, including after review of an Investigational New Drug Application, or IND, or amendment, clinical trial application, or CTA, or amendment, or equivalent application or amendment, as a result of a finding that the trial presents unreasonable risk to clinical trial participants or a negative finding from an inspection of our clinical trial operations or study sites, or the occurrence of a suspected, unexpected serious adverse reaction, or SUSAR, which we have experienced in the past, or serious adverse reaction, or SAE, during our clinical trials or investigator-initiated studies, or IISs, using COMP360; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">delays in or failure to obtain institutional review board, or IRB, or ethics committee approval at each site; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">delays in or failure to recruit and enroll a sufficient number of suitable patients to participate in a trial; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">failure to have patients complete a trial or return for post-treatment follow-up; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">challenges related to conducting adequate and well-controlled clinical trials, including designing an appropriate comparator arm in studies given the potential difficulties related to maintaining the blinding during the trial or placebo or nocebo effects; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">adding new clinical trial sites; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">47</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">availability of adequately trained therapists and appropriate third-party clinical trial sites for the administration of COMP360 psilocybin therapy in our Phase 3 program and other clinical trials, including preparation, psilocybin administration and integration of the therapeutic experience;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">sufficiency of any supporting digital services that may form part of the preparation, integration or long-term follow-up relating to any therapy we develop;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">failure to contract for the manufacture of sufficient quantities of the underlying therapeutic substance for use in clinical trials in a timely manner; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">third-party actions claiming infringement by our investigational COMP360 psilocybin therapy or any future therapeutic candidates in clinical trials and obtaining injunctions interfering with our progress; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">safety or tolerability concerns which could cause us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines, including the draft legislation in the European Union related to pharmaceutical product development and marketing published by the European Commission in April, which, once approved, will replace the current European Union regulatory framework for medicines; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">lower than anticipated retention rates of patients and patients in clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">delays in establishing the appropriate dosage levels in clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">delays in our clinical trials due to public health crises, such as the COVID-19 pandemic, due to factors such as a decrease in the willingness or availability of patients to enroll in our clinical trials and challenges in procuring sufficient supplies of the underlying therapeutic substance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the quality or stability of the underlying therapeutic substance falling below acceptable standards; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods and fires, pandemics, or failures or significant downtime of our information technology systems resulting from cyber-attacks on such systems or otherwise.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We could encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards, or IRBs of the institutions in which such trials are being conducted or ethics committees, by the Data Review Committee, or DRC, or Data Safety Monitoring Board for such trial or by the FDA, the EMA, the MHRA or other regulatory authorities or if the DEA registration of an investigator or site conducting the clinical trial is revoked. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, the EMA, the MHRA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including any SUSARs or SAEs which have in the past or may in the future occur in our trials or any IISs or other studies using COMP360 and those relating to the class to which COMP360 or any future therapeutic candidates belong, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, on June 18, 2018, the FDA placed COMP360 on clinical hold after it reviewed our initial IND submission, citing the need for additional information regarding the structure of the psilocybin sessions, study personnel, and criteria for discharge. We submitted responsive information to our IND, and the FDA removed the clinical hold on August 8, 2018. If we experience delays in the completion of, or termination of, any clinical trial of COMP360 or any future therapeutic candidates, the commercial prospects of our investigational COMP360 psilocybin therapy or any future therapeutic candidates will be harmed, and our ability to generate revenue from any such therapeutic candidates </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">48</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">will be delayed. In addition, any delays in completing our clinical trials will likely increase our costs, slow down COMP360 or any future therapeutic candidate development and approval process and jeopardize our ability to commence sales and generate revenue. Moreover, if we make changes to COMP360 or any future therapeutic candidates, we may need to conduct additional studies to bridge such modified therapeutic candidates to earlier versions, which could delay our clinical development plan or marketing approval for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Significant clinical trial delays could also allow our competitors to bring therapies to market before we do or shorten any periods during which we have the exclusive right to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and impair our ability to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and may harm our business and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of COMP360 or any future therapeutic candidates or result in the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates being stopped early. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our clinical trials may fail to demonstrate substantial evidence of the safety and effectiveness of COMP360 or any future product candidates that we may identify and pursue, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Before obtaining regulatory approvals for the commercial sale of our investigational COMP360 psilocybin therapy or future therapeutic candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that the applicable therapeutic candidate is both safe and effective for use in each target indication. A therapeutic candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process, including during phase 3 pivotal trials, and, because our investigational COMP360 psilocybin therapy is in our only product in clinical development, there is a high risk of failure and we may never succeed in developing marketable products. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We have limited experience in managing late-stage clinical trials; our phase 3 pivotal trials for COMP360 in TRD represent our first pivotal trials and we may not able to successfully execute our phase 3 pivotal trials.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">We cannot be certain that our phase 3 pivotal trials for COMP360 in TRD, our ongoing phase 2 trials or any other future clinical trials will be successful. Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our investigational COMP360 psilocybin therapy. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same therapeutic candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of COMP360, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with COMP360, we may be delayed in obtaining marketing approval, or we may never obtain marketing approval. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of COMP360 in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Even if our clinical trials are successfully completed, preclinical and clinical data are often susceptible to varying interpretations and analyses and we cannot guarantee that the FDA, the EMA or comparable foreign regulatory authorities will interpret the results as we do, or agree that our clinical trials have been appropriately designed or powered to demonstrate the safety and efficacy of COMP360. Accordingly, more trials could be required before we submit COMP360 for approval. To the extent that the results of the trials are not satisfactory to the FDA, the EMA or comparable foreign regulatory authorities for support of a marketing application, approval of COMP360 may be significantly delayed, or we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of COMP360. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">49</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">regulatory authority to support regulatory approval in that other jurisdiction. Due to the inherent risk in the development of therapeutic substances, there is a significant likelihood that COMP360 and any future therapeutic candidates will not successfully complete development and receive approval. Many other companies that believed their therapeutic candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval for the marketing of their therapy. If we do not receive regulatory approvals for COMP360 or future therapeutic candidates, we may not be able to continue our operations. Even if regulatory approval is secured for COMP360 or any future therapeutic candidate, the terms of such approval may limit the scope and use of a specific therapeutic candidate, which may also limit its commercial potential.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. These data may not be sufficient to support regulatory submissions or approvals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We have in the past published and, from time to time in the future we may publish, interim, top-line or preliminary data from our clinical trials. We may decide to conduct an interim analysis of the data after a certain number or percentage of subjects have been enrolled, but before completion of the trial. Similarly, we may report top-line or preliminary results of primary and key secondary endpoints before the final trial results are completed. Interim, top-line and preliminary data from our clinical trials may change as more patient data or analyses become available and are not necessarily predictive of final results. Further interim, top-line and preliminary data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available and we issue our final clinical trial report. Interim, top-line and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, top-line and preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects or cause the price of our stock to decline. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular therapeutic candidate and our company in general, and regulatory agencies may request further data from us. In addition, you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular therapeutic candidate. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize COMP360 or any future product candidate, our business, operating results, prospects or financial condition may be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The regulatory approval process of the FDA, the EMA, the MHRA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for COMP360 and any future therapeutic candidates, our business will be substantially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have not previously submitted a new drug application, or NDA, to the FDA, or a marketing authorization application, or MAA, to the EMA or the MHRA, and have not obtained regulatory approval for COMP360. Before obtaining regulatory approvals for the commercial sale of COMP360 or any future therapeutic candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that COMP360 and any future therapeutic candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and while COMP360 is in a late stage of development, there continues to be a high risk of failure and we may never succeed in developing marketable products. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The time required to obtain approval by the FDA, the EMA, the MHRA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a therapeutic candidate&#8217;s clinical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">50</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">development and may vary among jurisdictions. For example, we cannot be certain of the impact on our therapeutic candidates of the draft legislation in the European Union related to pharmaceutical product development and marketing published by the European Commission in April, which, once approved, will replace the current European Union regulatory framework for medicines. We recently commenced our Phase 3 clinical program for COMP360 in TRD. We requested feedback from the FDA regarding the protocol amendments for our Phase 3 clinical program and recently received and reviewed the requested feedback regarding such protocol amendments. We continue to conduct our Phase 3 clinical program in accordance with our previously announced study design. We have Breakthrough Therapy Designation and anticipate having on-going dialogue with FDA throughout the conduct of the Phase 3 trials. However, FDA may disagree with our study design or conduct, and may make recommendations or request changes in the design or conduct of our  pivotal programs that may require us to conduct additional clinical trials or otherwise delay our Phase 3 clinical program or may impact the review process for our new drug application for COMP360. It is possible that neither COMP360 nor any future therapeutic candidates we may seek to develop in the future will ever obtain regulatory approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">COMP360 or any future therapeutic candidates could fail to receive regulatory approval from the FDA, the EMA, the MHRA or comparable foreign regulatory authorities or be precluded from commercial marketing for many reasons, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may disagree with, question or request changes in the size, design or implementation of our clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may determine that COMP360 or any future therapeutic candidates are not safe and effective, only moderately effective, or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA, the MHRA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may be unable to demonstrate that our investigational COMP360 psilocybin therapy or any future therapeutic candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the data collected from clinical trials of our investigational COMP360 psilocybin therapy or any future therapeutic candidates may not be sufficient to support the submission of an NDA or other submission, or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the approval policies or regulations of the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the potential risk of our novel therapy and delivery method, including the use of third-party clinical trial sites and therapists.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market any COMP360 or any future therapeutic candidates, which would significantly harm our business, results of operations and prospects. The FDA, the EMA, the MHRA and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">51</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">COMP360 or any future therapeutic candidates. Even if we believe the data collected from clinical trials of COMP360 or any future therapeutic candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA, the MHRA or any other regulatory authority. If COMP360 or any future therapeutic candidates fails to obtain approval on the basis of any applicable condensed regulatory approval process, this will prevent such therapeutic candidate from obtaining approval on a shortened time frame, or at all, resulting in increased expenses which would materially harm our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, even if we were to obtain approval, regulatory or pricing authorities may approve COMP360 or any future therapeutic candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our therapies, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a therapeutic candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that therapeutic candidate. For example, esketamine, a drug targeting major depressive disorder, or MDD, is only available through a Risk Evaluation and Mitigation Strategy, or REMS, program, under the applicable FDA regulations and, as is required for antidepressants, has a black box warning for increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. Any of the foregoing scenarios may have a negative impact on the commercial prospects for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Even if COMP360 or any future therapeutic candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, any such therapeutic candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If the FDA, the EMA, the MHRA or a comparable foreign regulatory authority approves COMP360 or any future therapeutic candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the therapy and underlying therapeutic substance will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices, or cGMPs, and with good clinical practices, or GCPs, for any clinical trials that we conduct post-approval, as well as applicable product tracking and tracing requirements, all of which may result in significant expense and limit our ability to commercialize such therapies. Additionally, a company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the United States. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Later discovery of previously unknown problems with any approved therapeutic candidate, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">restrictions on the labeling, distribution, marketing or manufacturing of COMP360 or any future therapeutic candidates, withdrawal of the product from the market, or product recalls;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">untitled and warning letters, or holds on clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">refusal by the FDA, the EMA, the MHRA or other foreign regulatory body to approve pending applications or supplements to approved applications we filed or suspension or revocation of license approvals;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">restrictions on coverage by third-party payors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">52</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of the product; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, any regulatory approvals that we receive for COMP360 or any future therapeutic candidates may also be subject to limitations on the approved indicated uses for which the therapy may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of such therapeutic candidates. For instance, we believe that COMP360, if approved, would be subject to a REMS program, under the applicable FDA regulations. REMS programs are costly and time-consuming for providers to comply with, involving high administrative burden, which could delay or limit our ability to commercialize our investigational COMP360 psilocybin therapy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If there are changes in the application of legislation, regulations or regulatory policies, or if problems are discovered with our investigational COMP360 psilocybin therapy or our manufacture of an underlying therapeutic substance, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include imposing fines on us, imposing restrictions on the therapeutic or its manufacture and requiring us to recall or remove the therapeutic from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change our therapeutic labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such therapy may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">COMP360 and any future therapeutic candidates we may develop may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of COMP360 or any future therapeutic candidates or following approval, if any, we may need to abandon our development of such therapeutic candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Undesirable side effects that may be caused by COMP360 or any future therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials or result in clinical holds and could result in a more restrictive label, a requirement that we implement a REMS plan to ensure that the benefits of the therapy outweigh its risks, or the delay or denial of regulatory approval by the FDA, the EMA, the MHRA or other comparable foreign authorities. We or regulatory authorities may also learn of and take similar actions based on side effects related to COMP360 or compounds similar to COMP360 or any future therapeutic candidates in studies not conducted by us, including in IISs or studies conducted by other sponsors, from spontaneous reports of use of psilocybin outside of the clinical trial setting or from safety reports in literature.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The results of future clinical studies may show that COMP360 or any future therapeutic candidates cause undesirable or unacceptable side effects or even death. For example, there were a number of treatment emergent adverse events reported with the results of our Phase 2b clinical trial in TRD. There can be no assurance that deaths or serious side effects will not occur, even in a clinical setting. In the event serious side effects occur, our trials could be suspended or terminated and the FDA, the EMA, the MHRA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of COMP360 or any future therapeutic candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Further, because of the high variability in how different individuals react to psilocybin, certain patients may have negative experiences with the treatment that could subject us to liability or, if publicized, reputational harm. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Clinical trials are conducted in representative samples of the potential patient population which may have significant variability. Even if we receive regulatory approval for COMP360 or any future therapeutic candidates, we will have tested them in only a limited number of patients during our clinical trials. Clinical trials are by design based on a limited number of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">53</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">subjects and of limited duration for exposure to the therapy used to determine whether, on a potentially statistically significant basis, the target safety and efficacy profile of any such therapeutic candidate can be achieved. As with the results of any statistical sampling, we cannot be sure that all side effects of COMP360 or any future therapeutic candidates may be uncovered, and it may be the case that only with a significantly larger number of patients exposed to such therapeutic candidate for a longer duration, may a more complete safety profile be identified. Further, even larger clinical trials may not identify rare serious adverse effects or the duration of such studies may not be sufficient to identify when those events may occur. If our applications for marketing are approved and more patients begin to use our therapy, new risks and side effects associated with our therapies may be discovered. There have been other products and therapies that have been approved by the regulatory authorities but for which safety concerns have been uncovered following approval. Such safety concerns have led to labelling changes or withdrawal of therapies from the market, and our investigational COMP360 psilocybin therapy and any future therapeutic candidates may be subject to similar risks. We might have to withdraw or recall our investigational COMP360 psilocybin therapy and any future therapeutic candidates from the marketplace. We may also experience a significant drop in the potential future sales of our investigational COMP360 psilocybin therapy or any future therapeutic candidates if and when regulatory approvals for such therapy are obtained, experience harm to our reputation in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent any sales of our approved therapeutic candidates, if any, or substantially increase the costs and expenses of commercializing and marketing our investigational COMP360 psilocybin therapy and any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, if our investigational COMP360 psilocybin therapy or any future therapeutic candidates receive marketing approval and we or others later identify undesirable or unacceptable side effects caused by such therapeutic candidates, a number of potentially significant negative consequences could result, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such therapies and require us to take our approved therapeutic candidates, if any, off the market;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS plan to ensure that the benefits of the therapeutic candidate outweigh its risks;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may be required to change the way the therapy is administered, conduct additional clinical trials or change the labeling of the therapeutic candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may be subject to limitations on how we may promote the therapeutic candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">sales of the therapy may decrease significantly;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Any of these events could prevent us or our potential future collaborators from achieving or maintaining market acceptance of the affected therapeutic candidate or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Even if we obtain FDA, EMA or MHRA approval for COMP360 or any future therapeutic candidates that we may identify and pursue in the United States, Europe or the UK, we may never obtain approval to commercialize any such therapeutic candidates outside of those jurisdictions, which would limit our ability to realize their full market potential.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials conducted in one country may not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">54</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a therapeutic candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Seeking foreign regulatory approval could result in difficulties and costs and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our investigational COMP360 psilocybin therapy and any future therapeutic candidates in those countries. The foreign regulatory approval process may include all of the risks associated with obtaining FDA, EMA or MHRA approval. We do not have any therapeutic candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets for COMP360 or any future therapeutic candidates. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our investigational COMP360 psilocybin therapy and any future therapeutic candidates will be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The results of preclinical studies and early-stage clinical trials of our investigational COMP360 psilocybin therapy or any future therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Therapeutic candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Furthermore, there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of COMP360 or any future therapeutic candidates. There is a high failure rate for drugs proceeding through clinical trials, including in phase 3 pivotal trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Research and development of drugs targeting the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Discovery and development of new drugs targeting central nervous system, or CNS, disorders are particularly difficult and time-consuming, evidenced by the higher failure rate for new drugs for CNS disorders compared with most other areas of drug discovery. Any such setbacks in our clinical development could have a material adverse effect on our business and operating results. In addition, our later stage clinical trials may present challenges related to conducting adequate and well-controlled clinical trials, including designing an appropriate comparator arm in trials given the potential difficulties related to maintaining the blinding during the trial or placebo or nocebo effects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">55</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Due to the complexity of the human brain and the central nervous system, it can be difficult to predict and understand why a drug, including COMP360, may have a positive effect on some patients but not others and why some individuals may react to the drug differently from others. For example, the population of those suffering with TRD is large and heterogenous and individuals may have different levels of severity of TRD. These differences may further result in different reactions to impact the effectiveness of our investigational COMP360 psilocybin therapy which may cause the percentage of patients, if any, that go into remission to fluctuate. All of these factors may make it difficult to assess the prior use or the overall efficacy of our investigational COMP360 psilocybin therapy. In addition, certain diseases or conditions that we decide to target may present increased or unique challenges in clinical development. For example, drug development for anorexia nervosa is not well understood, and we have experienced challenges in recruiting and screening participants for our Phase 2 study in anorexia nervosa.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We have learned from our experience and we are making amendments to our trial protocol to reduce the trial burden for this highly vulnerable patient population. These amendments may delay our clinical development, increase our costs and may not be acceptable to regulatory authorities or IRBs. Moreover, these increased or unique challenges could ultimately impact our ability to seek and obtain regulatory approval in these conditions.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We depend on enrollment of patients in our clinical trials for COMP360 and any future therapeutic candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Identifying and qualifying patients to participate in our clinical trials is critical to our success. Patient enrollment depends on many factors, including:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">identifying and enrolling eligible patients, including those willing to discontinue use of their existing medications; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the design of the clinical protocol and the patient eligibility and exclusion criteria for the trial;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">safety profile, to date, of the therapeutic candidate under study;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the willingness or availability of patients to participate in our trials, including due to the perceived risks and benefits, stigma or other side effects of use of a controlled substance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the willingness or availability of patients to participate in our trials, including due to any public health crisis such as the COVID-19 pandemic and the emergence of new COVID-19 variants;</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">perceived risks and benefits of our approach to treatment of indication;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the proximity of patients to clinical sites;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the availability of competing clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the availability of new drugs approved for the indication the clinical trial is investigating;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions of the potential advantages of the drug being studied in relation to other available therapies, including any new therapies that may be approved for the indications we are investigating; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to obtain and maintain patient informed consents.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">56</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In addition, any negative results we may report in clinical trials of COMP360 or any future therapeutic candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same therapeutic candidate. Delays in the enrollment for any clinical trial of COMP360 or any future therapeutic candidates will likely increase our costs, slow down COMP360 approval process and delay or potentially jeopardize our ability to commence sales of our investigational COMP 360 psilocybin therapy and generate revenue. We have experienced some delays in our Phase 2 clinical trial for anorexia nervosa due to challenges in recruiting and screening participants for our Phase 2 study in anorexia nervosa. To address these challenges, we are making amendments to our trial protocol to reduce the trial burden for this highly vulnerable patient population. Even with these proposed protocol amendments, we may experience challenges recruiting participants for our anorexia nervosa study. As a result of these challenges, we no longer expect to have data from this trial available in 2023, as we had originally expected. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of COMP360 or any future therapeutic candidates.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Further, timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters, including, among other things, pandemics. For example, our clinical trial sites may be located in regions which may in the future be impacted by the emergence of new COVID-19 variants, other pandemics or public health crises. For example, in the past, enrollment in our trials was adversely affected as a result of the pandemic due to limited availability of participants, the inability of patients, therapists or physicians to participate in our trials, interruptions in supply chains and delays with regulators and other similar bodies. The conduct of our trials may continue to be adversely affected by future public health crises, including COVID-19, despite efforts to mitigate this impact.<br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our therapies on our own or with suitable collaborators. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">While we are currently assembling a sales and marketing infrastructure, we have limited organizational experience in the sale or marketing of therapeutic candidates. To achieve commercial success for any approved therapy, we must develop or acquire a sales and marketing organization, outsource these functions to third parties or enter into partnerships. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If our investigational COMP360 psilocybin therapy is approved for commercial sale, we plan on establishing our own market access and commercialization capabilities in primary markets in North America and in the EU. In select geographies, we might also consider relying on the support of a Contract Sales Organization, or CSO, or enter into commercialization arrangements with companies with relevant commercialization capabilities. There are risks involved in establishing our own sales and marketing capabilities, as well as with entering into arrangements with third parties to perform these services. Even if we establish sales and marketing capabilities, we may fail to launch our therapies effectively or to market our therapies effectively since we have limited organizational experience in the sales and marketing of therapeutic substances. In addition, recruiting and training a sales force is expensive and time-consuming, and could delay any therapeutic launch. In the event that any such launch is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Factors that may inhibit our efforts to commercialize our therapies on our own include: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our inability to train an adequate number of therapists to meet the demand for COMP360 psilocybin therapy;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the ability of our therapists to perform their roles consistently with our training and our guidelines for the administration of our investigational COMP360 psilocybin therapy;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our inability to recruit, train and retain effective market access and commercial personnel;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the inability of commercial personnel to obtain access to or educate adequate numbers of physicians on the benefits of prescribing any future therapies; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our inability to identify a sufficient number of treatment centers in third-party therapy sites to meet the demands of our therapies;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">57</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the lack of complementary therapies to be offered by our commercial personnel, which may put us at a competitive disadvantage relative to companies with more extensive therapeutic lines; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent market access and commercial organization; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">costs of market access and commercialization above those anticipated by us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we enter into arrangements with third parties to perform market access and commercial services for any approved therapies, the revenue or the profitability of these revenues to us could be lower than if we were to commercialize any therapies that we develop ourselves. Such collaborative arrangements may place the commercialization of any approved therapies outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our therapies or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy. We may not be successful in entering into arrangements with third parties to commercialize our therapies or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources and attention to commercialize our therapies effectively, to set up a sufficient number of treatment centers in third-party therapy sites, or to recruit, train and retain adequate number of therapists to administer our therapies. In addition, we are exploring ways in which we can use digital technology to improve the patient experience and therapeutic outcomes of our therapies. Commercialization partners may lack incentives to promote our digital technology and we may face difficulties in implementing our digital technologies in third-party therapy sites through such third parties. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we do not establish commercial capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our therapies, which in turn would have a material adverse effect on our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The future commercial success of our investigational COMP360 psilocybin therapy or any future therapeutic candidates will depend on the degree of market access and acceptance of our potential therapies among healthcare professionals, patients, healthcare payors, health technology assessment bodies and the medical community at large. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We may never have a therapy that is commercially successful. To date, we have no therapy authorized for marketing. Our investigational COMP360 psilocybin therapy requires further clinical investigation, regulatory review, significant market access and marketing efforts and substantial investment before it can produce any revenue. Furthermore, if approved, our therapy may not achieve an adequate level of acceptance by payors, health technology assessment bodies, healthcare professionals, patients and the medical community at large, and we may not become profitable. The level of acceptance we ultimately achieve may be affected by negative public perceptions and historical media coverage of psychedelic substances, including psilocybin. Because of this history, efforts to educate the medical community and third-party payors and health technologies assessment bodies on the benefits of our investigational COMP360 psilocybin therapy may require significant resources and may never be successful, which would prevent us from generating significant revenue or becoming profitable.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Market acceptance of our future therapies by healthcare professionals, patients, healthcare payors and health technology assessment bodies will depend on a number of factors, many of which are beyond our control, including, but not limited to, the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">acceptance by healthcare professionals, patients and healthcare payors of each therapy as safe, effective and cost-effective; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes in the standard of care for the targeted indications for any therapeutic candidate; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the strength of sales, marketing and distribution support; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">potential product liability claims; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">58</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the therapeutic candidate&#8217;s relative convenience, ease of use, ease of administration and other perceived advantages over alternative therapies; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the prevalence and severity of adverse events or publicity; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">limitations, precautions or warnings listed in the summary of therapeutic characteristics, patient information leaflet, package labeling or instructions for use; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the cost of treatment with our therapy in relation to alternative treatments; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the steps that prescribers and dispensers must take, given that COMP360 includes a controlled substance, as well as the perceived risks based upon its controlled substance status;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the ability to manufacture our product in sufficient quantities and yields;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the availability and amount of coverage and reimbursement from healthcare payors, and the willingness of patients to pay out of pocket in the absence of healthcare payor coverage or adequate reimbursement;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the willingness of the target patient population to try, and of healthcare professionals to prescribe, the therapy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">any potential unfavorable publicity, including negative publicity associated with recreational or professional use or abuse of psilocybin or with adverse outcomes or side effects from the use of psilocybin such as unfavorable publicity related to use of psilocybin at Oregon state-licensed psilocybin service centers under the supervision of a state-licensed facilitator;</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any restrictions on the use, sale or distribution of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, including through REMS;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the extent to which therapies are approved for inclusion and reimbursed on formularies of hospitals and managed care organizations; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">whether our therapies are designated under physician treatment guidelines or under reimbursement guidelines as a first-line, second-line, third-line or last-line therapy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If our investigational COMP360 psilocybin therapy or any future therapeutic candidates fail to gain market access and acceptance, this will have a material adverse impact on our ability to generate revenue to provide a satisfactory, or any, return on our investments. Even if some therapies achieve market access and acceptance, the market may prove not to be large enough to allow us to generate significant revenue. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our business and commercialization strategy depends on our ability to identify, qualify, prepare, certify and support third-party therapy sites to administer COMP360 psilocybin therapy. If we are unable to do so, our commercialization prospects would be limited and our business, financial condition and results of operations would be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we are able to commercialize our investigational COMP360 psilocybin therapy or future therapies, our success will be dependent upon our ability to identify, qualify, prepare, certify and support third-party therapy sites that offer and administer our therapies. Our commercial model of delivering our investigational COMP360 psilocybin therapy will also involve third-party therapists before, during and after the COMP360 psilocybin administration session, which will be hosted in one of the third-party therapy sites. We intend to commercialize our investigational COMP360 psilocybin therapy and any future therapeutic candidates by building close relationships with qualified third-party therapy sites where these therapists will administer our investigational COMP360 psilocybin therapy. Because we expect our COMP360 psilocybin therapy to be subject to a REMS program and because we intend to work only with third-party sites and providers who agree to adhere strictly to our treatment protocols, we may face limitations on the number of sites available to administer our investigational COMP360 psilocybin therapy. Any such limitations could make it impracticable or impossible for some potential patients to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">59</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">access our investigational COMP360 psilocybin therapy, if approved, which could limit the overall size of our potential patient population and harm our future results of operations. Although we plan to develop Centers of Excellence to train and certify such third-party therapy sites, conduct further research on and continuously improve our treatment protocol, we expect this to involve significant costs, time and resources, and our efforts may not be successful.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we are unable to establish a sufficient network of third-party therapy sites certified under applicable standards, including regional, national, state or other applicable standards as needed to render psilocybin therapeutic services, including the certifications that such third-party therapy sites may require, it would have a material adverse effect on our business and ability to grow and would adversely affect our results of operations and commercialization efforts. We expect the therapists to be employed by the third-party therapy sites where the therapists administer our therapies. Third-party therapy sites could, for a number of reasons, demand higher payments for our therapies or take other actions to increase their income from selling our therapies, which could result in higher costs for payors and for our patients to get access to our therapies. For example, legal regimes may have higher levels of licensure which force us to contract with third-party therapy sites that demand higher payment rates to provide psilocybin therapeutic services. In addition, third-party therapy sites may have difficulty meeting regulatory or accreditation requirements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Given the novel nature of our treatment, third-party therapy sites may face additional financial and administrative burdens in order to deliver any approved therapy, including adhering to a REMS plan in the United States or a Risk Management Program, or RMP, in Europe. The process for a third-party therapy site to obtain a certificate under a REMS plan can be very costly and time-consuming, which could delay a third-party therapy site&#8217;s ability to provide our therapies and materially adversely affect our commercialization trajectory. Furthermore, third-party therapy sites will need to ensure that they have the necessary infrastructure and equipment in order to deliver our investigational COMP360 psilocybin therapy, such as adequate audio-visual equipment, ancillary equipment and sufficient treatment rooms. This may deter third-party therapy sites from providing our therapeutic candidate and reduce our ability to expand our network and generate revenue. Our ability to develop and maintain satisfactory relationships with third-party therapy sites may otherwise be negatively impacted by other factors not associated with our operations and, in some instances, outside of our direct or indirect control, such as negative perceptions regarding the therapeutic use of psilocybin, changes in Medicare and/or Medicaid or commercial payors reimbursement levels and other pressures on healthcare providers and consolidation activity among hospitals, physician groups and the providers. Reimbursement levels may be inadequate to cover third-party therapy sites&#8217; costs of delivering our investigational COMP360 psilocybin therapy. The failure to maintain or to secure new cost-effective contracts with third-party therapy sites may result in a loss of or inability to grow our network of third-party therapy sites, patient base, higher costs to our patients and us, healthcare provider network disruptions and/or difficulty in meeting regulatory or accreditation requirements, any of which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We currently rely on qualified therapists working at third-party clinical trial sites to administer our investigational COMP360 psilocybin therapy in our clinical trials and we expect this to continue upon approval, if any, of COMP360 or any future therapeutic candidates. If third-party sites fail to recruit and retain a sufficient number of therapists or effectively manage their therapists, our business, financial condition and results of operations would be materially harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We currently administer our investigational COMP360 psilocybin therapy in our clinical trials through qualified third-party therapists working at third-party clinical trial sites. However, there are currently not enough trained therapists to carry out our investigational COMP360 psilocybin therapy at a commercial scale, and our efforts to facilitate training and certification programs for therapists, including through our planned Centers of Excellence, may be unsuccessful.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">While we currently provide training to the therapists and expect to continue providing trainings in the future (either directly or indirectly through third-party providers), we do not currently employ the therapists who deliver our therapies to patients and do not intend to do so in the future. Such therapists are typically employed by the third-party therapy sites. If our investigational COMP360 psilocybin therapy or any future therapeutic candidates are approved for commercialization, third-party therapy sites may demand substantial financial resources from us to recruit and retain a team of qualified therapists to administer our investigational COMP360 psilocybin therapy or any future therapeutic candidates. If the third-party therapy sites fail to recruit, train and retain a sufficient number of therapists or if a competitor develops a similar product that is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">60</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">effective without the use of therapists, our ability to offer and administer our therapies will be greatly harmed, which may in turn reduce the market acceptance rate of our therapies or limit our ability to grow our business. If this occurs, our commercialization prospects would be negatively affected and our business, financial condition and results of operations would be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Although we currently provide training and expect to continue providing training to the therapists (directly or through third-party providers), we generally rely on qualified and certified third-party therapy sites to manage the therapists and monitor the administration of our therapies and ensure that the administration process of our therapies comply with our established protocols. However, if not properly managed and supervised, there is a risk that therapists may deviate from our training protocols, fail to follow the guidelines we have established, or abuse patients during psilocybin administration sessions. The therapists might also administer unauthorized therapies to patients using illegal psilocybin compounds in &#8220;underground&#8221; clinics. Such illegal activities would put the patients at risk and subject us to potential liabilities, litigations, regulatory proceedings and reputational harm. If this were to occur, we may face serious setbacks for our commercialization process and our financial condition and results of operations would be materially harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Commercialization of our COMP360 psilocybin therapy or other therapeutic candidates is dependent on our relationships with affiliated professional entities, which we do not own, to provide physician services, and our business would be adversely affected if those relationships were disrupted.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There is a risk that U.S. state authorities in some jurisdictions may find that our contractual relationships with our affiliated providers and our Centers of Excellence violate laws prohibiting the corporate practice of medicine and certain other health professions. These laws generally prohibit the practice of medicine and certain other health professions by lay persons or entities and are intended to prevent unlicensed persons or entities from interfering with or inappropriately influencing the professional judgment of clinicians and other health care practitioners. The professions subject to corporate practice restrictions and the extent to which each jurisdiction considers particular actions or contractual relationships to constitute improper influence of professional judgment vary across jurisdictions and are subject to change and evolving interpretations by state boards of medicine and other health professions and enforcement agencies, among others. As such, we must monitor our compliance with laws in every jurisdiction in which we operate on an ongoing basis and we cannot guarantee that subsequent interpretation of the corporate practice laws will not further circumscribe our business operations. State corporate practice restrictions also often impose penalties on health professionals for aiding a corporate practice violation, which could discourage clinicians or other licensed professionals from participating in our network of providers or Centers of Excellence. Any difficulty securing clinicians to participate in our network could impair our ability to provide therapies and could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Corporate practice restrictions exist in some form, whether by statute, regulation, professional board or attorney general guidance, or case law, in at least 42 U.S. states, though the broad variation between jurisdictions with respect to the application and enforcement of the doctrine makes establishing an exact count difficult. Because of the prevalence of corporate practice restrictions on medicine, we contract for provider services and other services provided by the Centers for Excellence through various agreements, such as service agreements, rather than employ providers. We expect that these relationships will continue, but we cannot guarantee that they will. The arrangement in which we have entered to comply with state corporate practice of medicine doctrines could subject us to additional scrutiny by federal and state regulatory bodies regarding federal and state fraud and abuse laws. In addition, a material change in our relationship with providers, whether resulting from a dispute among the entities, a change in government regulation, or the loss of these affiliations, could impair our ability to provide therapies and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Changes in methods of therapeutic candidate manufacturing or formulation may result in additional costs or delay.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As therapeutic candidates are developed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, may be altered along the way in an effort to optimize processes and results. Any of these changes could cause our investigational COMP360 psilocybin therapy or any future therapeutic candidates to perform differently and affect the results </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">61</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of COMP360 or any future therapeutic candidates and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Breakthrough Therapy designation by the FDA for COMP360 or any future therapeutic candidates may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our investigational COMP360 psilocybin therapy or any future therapeutic candidates will receive marketing approval.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have received Breakthrough Therapy designation for COMP360 for the treatment of TRD and may seek it for any future therapeutic candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe any future therapeutic candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for COMP360 and any future therapeutic candidates may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even though COMP360 has been designated as a breakthrough therapy, the FDA may later decide that it, or any future therapeutic candidates that are designated by the FDA as breakthrough therapies, no longer meet the conditions for qualification. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Fast Track designation, if granted by the FDA, may not actually lead to a faster development or regulatory review or approval process. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may seek Fast Track designation for any of our therapeutic candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular therapeutic candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we receive Fast Track designation for any future therapeutic candidates, we may not experience a faster development process, review or approval compared to non-expedited FDA review procedures. In addition, the FDA may withdraw Fast Track designation for any therapeutic candidate that is granted Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may in the future enter into collaborations for the discovery, development and/or commercialization of additional therapeutic candidates or research programs. Such collaborations may not result in the development of commercially viable therapeutic candidates or the generation of significant future revenue, or we may fail to enter into profitable relationships.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">We may enter into collaborations with pharmaceutical companies or others for the discovery, development and/or commercialization of future therapeutic candidates or research programs. For example, we established a Discovery Center under a sponsored research agreement with University of the Sciences Philadelphia (which merged into Saint Joseph&#8217;s University in 2022), or USciences, through collaborations with academic laboratories at the University of California San Diego, School of Medicine (California), the Medical College of Wisconsin (Wisconsin), and Dr. Matthias Grill, CEO of MiHKAL GmbH (Switzerland). If we fail to enter into or maintain collaborations on reasonable terms, our ability to discover </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">62</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">and develop future therapeutic candidates and research programs could be delayed or become more costly. Any future collaborations may subject us to a number of risks, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the inability to control the amount and timing of resources that our collaboration partner devotes to our future research programs and therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">for collaboration agreements where we may be solely or partially responsible for funding development expenses through a defined milestone event, we may never recoup the costs of these investments if the therapeutic candidate fails to achieve regulatory approval or commercial success; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may rely on the information and data received from third parties regarding their research programs and therapeutic candidates without independent verification; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may not have control of the process conducted by the third party in gathering and composing data regarding their research programs and therapeutic candidates and we may not have formal or appropriate guarantees with respect to the quality and the completeness of such data; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may not have sufficient funds to satisfy any milestone, royalty or other payments we may owe to any third party collaborator;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our collaboration agreements may contain non-competition provisions which place restrictions on our business operations and the therapeutic candidates and/or indications we may pursue; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">a collaborative partner may develop or commercialize a competing therapeutic candidate either by itself or in collaboration with others, including one or more of our competitors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our collaborative partners&#8217; willingness or ability to complete their obligations under our collaboration arrangements may be adversely affected by business combinations or significant changes in a collaborative partner&#8217;s strategy; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our collaborative partners may experience delays in, or increases in the costs of, the discovery and development of our future therapeutic candidates and research programs and we may be required to pay for any cost increases; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may have disagreements with collaborative partners, including disagreements over proprietary rights, selection of lead therapeutic candidates, contract interpretation or the preferred course of development that might cause delays or termination of the research, development or commercialization of therapeutic candidates, might lead to additional responsibilities for us with respect to therapeutic candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our collaborative partners may not properly obtain, maintain, defend or enforce intellectual property rights; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our collaborative partners may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may face significant competition in seeking appropriate collaborative partners. Our ability to reach a definitive agreement for a collaborative partnership depends, among other things, upon our assessment of a potential collaborator&#8217;s resources and expertise, the terms and conditions of the proposed partnership and the potential collaborator&#8217;s evaluation of a number of factors. Proposing, negotiating, and implementing collaborations, licensing arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. We have limited institutional knowledge and experience with respect to such activities and we may also not realize the anticipated benefits of any such transaction or arrangement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Should any of the foregoing risks materialize, any collaborations we enter into could fail to result in the development of commercially viable therapeutic candidates or the generation of future revenue, which could have a material adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">63</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our business strategy includes developing Centers of Excellence, which has in the past and we expect in the future will involve significant costs, time and resources. If our efforts are unsuccessful, our business, prospects and financial condition would be adversely affected.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A key element of our business strategy involves setting up research facilities and innovation labs, which we refer to as Centers of Excellence, in key markets. We announced the establishment of our first Center of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, in January 2021. In March 2022, we announced a strategic collaboration with King&#8217;s College London and South London and Maudsley NHS Foundation Trust, or SLaM, to establish The Center for Mental Health Research and Innovation with an overarching goal of accelerating patient access to evidence-based innovation in mental health care by driving forward research in psychedelic therapies through, among other things, the development of working model psychedelic treatment clinics, therapist training programs, conducting clinical trials, and data analysis.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We intend to use these Centers of Excellence to gather evidence to optimize our therapy model, train and certify therapists, conduct clinical trials, including proof of concept studies, develop and test digital technology solutions to improve patient experience and outcomes and pursue other activities to refine our approach to delivering our investigational COMP360 psilocybin therapy safely and cost-effectively. Our efforts to design, build and staff these Centers of Excellence, or identify suitable third parties with whom we may collaborate to open these centers, will involve significant time, costs, including potential capital expenditures to acquire and develop facilities, and other resources, and may divert our management team&#8217;s focus from executing on other key elements of our business strategy. If we fail to enter into or maintain agreements with third parties to develop and operate these Centers of Excellence on reasonable terms, or at all, our ability to develop our future research programs and therapeutic candidates could be delayed, the commercial potential of our therapies could change and our costs of development and commercialization could increase. If our efforts to develop these Centers of Excellence are unsuccessful, it will have a materially adverse impact on our business, future prospects and financial position.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may become exposed to costly and damaging liability claims, either when testing our investigational COMP360 psilocybin therapy or any future therapeutic candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of therapeutic substances. Currently, we have no therapies that have been approved for commercial sale; however, the current and future use of our investigational COMP360 psilocybin therapy or any future therapeutic candidates by us and our corporate collaborators in clinical trials, and the potential sale of any approved therapies in the future, may expose us to liability claims. These claims might be made by patients who receive our investigational COMP360 psilocybin therapy in clinical trials and if regulatory approval is obtained, by patients who receive it under prescription and by healthcare providers, pharmaceutical companies, our corporate collaborators or other third parties that sell COMP360 psilocybin therapy or any future therapeutic candidates. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our investigational COMP360 psilocybin therapy or any future therapeutic candidates or any prospects for commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If COMP360 or any future therapeutic candidates causes adverse side effects during clinical trials or after regulatory approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with warnings that identify known potential adverse effects and describe which patients should not use COMP360 or any future therapeutic candidates. Regardless of the merits or eventual outcome, liability claims may cause, among other things, the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">decreased demand for our therapies due to negative public perception; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">injury to our reputation; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">withdrawal of clinical trial participants or difficulties in recruiting new trial participants; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">initiation of investigations by regulators; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">64</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">costs to defend or settle the related litigation; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">substantial monetary awards to trial participants or patients; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">loss of revenue from therapeutic sales; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the inability to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">It is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial therapies if we obtain marketing approval for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business, financial condition and results of operations could be materially adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Liability claims resulting from any of the events described above could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Regulatory Compliance</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Psilocybin and psilocin are listed as Schedule I controlled substances under the CSA in the United States, and similar controlled substance legislation in other countries and any significant breaches in our compliance with these laws and regulations, or changes in the laws and regulations, may result in interruptions to our development activity or business continuity. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Psilocybin and psilocin are categorized as Schedule I controlled substances under the CSA, Schedule 1 drugs under the UK&#8217;s Misuse of Drugs Regulations 2001 and are similarly categorized by most states and foreign governments. Even assuming that COMP360 or any future therapeutic candidates containing psilocybin or psilocin are approved and scheduled by regulatory authorities to allow their commercial marketing, the ingredients in such therapeutic candidates would likely continue to be Schedule I, or the state or foreign equivalent. Violations of any federal, state or foreign laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges and penalties, including, but not limited to, disgorgement of profits, cessation of business activities, divestiture, or prison time. This could have a material adverse effect on us, including on our reputation and ability to conduct business, our financial position, operating results, profitability or liquidity or the market price of our publicly traded ADSs. In addition, it is difficult for us to estimate the time or resources that would be needed for the investigation or defense of any such matters or our final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. It is also illegal to aid or abet such activities or to conspire or attempt to engage in such activities. An investor&#8217;s contribution to and involvement in such activities may result in federal civil and/or criminal prosecution, including, but not limited to, forfeiture of his, her or its entire investment, fines and/or imprisonment.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Various federal, state, provincial and local laws govern our business in the jurisdictions in which we operate or currently plan to operate, and to which we export or currently plan to export our products, including laws relating to health and safety, the conduct of our operations, and the production, storage, sale and distribution of our products. Complying with these laws requires that we comply concurrently with complex federal, state, provincial and/or local laws. These laws change frequently and may be difficult to interpret and apply. To ensure our compliance with these laws, we will need to invest significant </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">65</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">financial and managerial resources. It is impossible for us to predict the cost of such laws or the effect they may have on our future operations. A failure to comply with these laws could negatively affect our business and harm our reputation. Changes to these laws could negatively affect our competitive position and the markets in which we operate, and there is no assurance that various levels of government in the jurisdictions in which we operate will not pass legislation or regulation that adversely impacts our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, even if we or third parties were to conduct activities in compliance with U.S. state or local laws or the laws of other countries and regions in which we conduct activities, potential enforcement proceedings could involve significant restrictions being imposed upon us or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on our business, revenue, operating results and financial condition as well as on our reputation and prospects, even if such proceedings conclude successfully in our favor. In the extreme case, such proceedings could ultimately involve the criminal prosecution of our key executives, the seizure of corporate assets, and consequently, our inability to continue business operations. Strict compliance with state and local laws with respect to psilocybin and psilocin does not absolve us of potential liability under U.S. federal law, EU law or English law, nor provide a defense to any proceeding which may be brought against us. Any such proceedings brought against us may adversely affect our operations and financial performance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Despite the current status of psilocybin and psilocin as Schedule I controlled substances in the United States, there may be changes in the status of psilocybin or psilocin under the laws of certain U.S. cities or states. For instance, the city of Denver voted to decriminalize the possession of psilocybin in 2019, and in Oregon, Measure 109 was passed in November 2020 to pave the way for the legal medical use of &#8220;psilocybin products,&#8221; including magic mushrooms, to treat mental health conditions in licensed facilities with supervision by licensed facilitators. Oregon psilocybin service centers opened and licensed facilitators began offering psilocybin services to adults over the age of 21 in January 2023.  In November 2022, voters in Colorado approved a ballot measure legalizing the use of psilocybin and psilocin in state-regulated centers under the supervision of state-licensed facilitators. Some cities have also been passed measures that decriminalizes or minimizes enforcement actions for psilocybin, including, for example, Washington, D.C. (November 2020), Somerville, Massachusetts (January 2021), Cambridge, Massachusetts (February 2021), Northampton, Massachusetts (April 2021), Seattle, Washington (February 2022) and San Francisco, California (September 2022). The legalization of psilocybin without regulatory oversight or with minimal regulatory oversight may lead to the setup of clinics without proper therapeutic infrastructure or adequate clinical research, which could put patients at risk and bring reputational and regulatory risk to the entire industry, making it harder for us to achieve regulatory approval. Furthermore, the legalization of psilocybin could also impact our commercial sales if we receive regulatory approval as it would reduce the barrier to entry and could increase competition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from manufacturing COMP360 and developing and selling our investigational COMP360 psilocybin therapy or any future therapeutic candidates outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our operations are subject to anti-corruption laws, including the UK Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, a financial or other advantage to government officials or other persons to induce them to improperly perform a relevant function or activity (or reward them for such behavior).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">66</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We, along with those acting on our behalf and our commercial partners, operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we expand our operations, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the UK and the U.S., and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from manufacturing COMP360 and developing and selling our investigational COMP360 psilocybin therapy or any future therapeutic candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by UK, U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may become subject to U.S. federal and state forfeiture laws which could negatively impact our business operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Violations of any U.S. federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, seizure of assets, disgorgement of profits, cessation of business activities or divestiture. As an entity that conducts business involving psilocybin and psilocin, we are potentially subject to federal and state forfeiture laws (criminal and civil) that permit the government to seize the proceeds of criminal activity. Civil forfeiture laws could provide an alternative for the federal government or any state (or local police force) that wants to discourage residents from conducting transactions with psilocybin- and psilocin-related businesses but believes criminal liability is too </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">67</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">difficult to prove beyond a reasonable doubt. Also, an individual can be required to forfeit property considered to be the proceeds of a crime even if the individual is not convicted of the crime, and the standard of proof in a civil forfeiture matter is lower than the standard in a criminal matter. Depending on the applicable law, whether federal or state, rather than having to establish liability beyond a reasonable doubt, the federal government or the state, as applicable, may be required to prove that the money or property at issue is proceeds of a crime only by either clear and convincing evidence or a mere preponderance of the evidence.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Investors located in jurisdictions where psilocybin and psilocin remains illegal may be at risk of prosecution under conspiracy, aiding and abetting, and money laundering statutes, and be at further risk of losing their investments or proceeds under forfeiture statutes. Many jurisdictions remain fully able to take action to prevent the proceeds of psilocybin and psilocin businesses from entering their state. Our investors and prospective investors should be aware of these potentially relevant laws in considering whether to invest in us.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We are subject to certain tax risks and treatments that could negatively impact our results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Section 280E of the Internal Revenue Code of 1986, as amended, or the Code, prohibits businesses from deducting certain expenses associated with trafficking controlled substances (within the meaning of Schedule I and II of the CSA). The U.S. Internal Revenue Service, or IRS, has invoked Section 280E in tax audits against various businesses in the United States that are permitted under applicable state laws. Although the IRS issued a clarification allowing the deduction of certain expenses, the scope of such items is interpreted very narrowly and the bulk of operating costs and general administrative costs are not permitted to be deducted. While there are currently several pending cases before various administrative and federal courts challenging these restrictions, there is no guarantee that these courts will issue an interpretation of Section 280E favorable to psilocybin and psilocin businesses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable UK tax legislation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a UK incorporated and tax resident entity, we are subject to UK corporate taxation on tax-adjusted trading profits. Due to the nature of our business, we have generated losses since inception and therefore have not paid any UK corporation tax. We had accumulated trading losses for carry forward in the UK of $176.9 million and $144.0 million as of December 31, 2022 and December 31, 2021, respectively. Subject to any relevant utilization criteria and restrictions (including, but not limited to, those that limit the percentage of profits that can be reduced by carried forward losses and those that can restrict the use of carried forward losses where there is a change of ownership of more than half of our ordinary shares and a major change in the nature, conduct or scale of the trade), we expect these to be eligible for carry forward and utilization against future operating profits. The use of loss carryforwards in relation to UK profits incurred on or after April 1, 2017 is limited each year to &#163;5.0 million per group plus, broadly, an incremental 50% of UK taxable profits. In addition, if we were to have a major change in the nature of the conduct of our trade, loss carryforwards may be restricted or extinguished.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a company that carries out extensive research and development activities, we seek to benefit from the UK research and development tax relief programs, being the Small and Medium-sized Enterprises R&amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. Under the SME Program, we may be able to surrender the trading losses that arise from our qualifying research and development activities for a cash rebate of up to 33.3% (reduced to 18.6% effective April 1, 2023) of such qualifying research and development expenditures or carried forward for potential offset against future profits (subject to relevant restrictions). The majority of our research, clinical trials management and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. We may not be able to continue to claim payable research and development tax credits in the future if we cease to qualify as a SME, based on size criteria concerning employee staffing levels, turnover and gross assets. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The SME Program incorporates a cap on claims to a multiple of payroll taxes (broadly, to a maximum payable credit equal to &#163;20,000 plus three times the total PAYE and NICs liability of the company) subject to an exception which prevents </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">68</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The SME R&amp;D tax relief regime have been reduced such that for qualifying expenditure from April 1, 2023 the effective credit decreased from 33.3% to 18.6%. For subcontracted expenditure, as there is a restriction to 65% of costs, the effective credit decreased from 21.7% to 12.1%.  This will impact the level of repayable credit that can be claimed.  However, new rules were announced in the Finance Bill 2023 for an enhanced rate of relief for R&amp;D intensive companies, which would be 27.0% for qualifying expenditure and 17.5% for qualifying subcontracted expenditure. The legislation is not yet final, and therefore the Company is unable to determine whether they would meet the criteria for the enhanced rate of relief until the final legislation and more detailed guidance has been published.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There are also proposals to introduce restrictions on relief that may be claimed for expenditure on contracted out research and development activity where the work is undertaken outside the UK.  These changes may impact the quantum of R&amp;D relief that the Company is able to claim in the future and, for the Company, will take effect from January 1, 2025.  In addition, the UK government is currently consulting on the potential merging of the SME and RDEC regimes, which may, inter alia, change the present treatment of sub-contracted research and development work and introduce different thresholds and caps on expenditure and relief.  The outcome and timing of this consultation is still to be confirmed but could have a material impact on the quantum of research and development relief that the Company is able to claim. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may benefit in the future from the UK&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenue from patented products (and other qualifying income) to be taxed at an effective rate of 10% by giving an additional tax deduction. We own two UK patents which cover our investigational COMP360 psilocybin therapy, and accordingly, future upfront fees, milestone fees, product revenue and royalties could be eligible for this deduction. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term rate of corporation tax lower than the statutory to apply to us. If, however, there are unexpected adverse changes to the UK research and development tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected. This may impact our ongoing requirement for investment and the timeframes within which additional investment is required.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and could have a material adverse effect on our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the United States, the EU and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. For more information regarding the risks related to these laws and regulations, please see the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Business&#8213;Healthcare Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We expect that changes and challenges to the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies, and additional downward pressure on the price that we receive for any future approved product. For example, the Inflation Reduction Act of 2022, or IRA includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">69</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the U.S. Department of Health and Human Services, or HHS, rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one rare disease designation and for which the only approved indication is for that disease or condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In February 2023, HHS also issued a proposal in response to an October 2022 executive order from President Biden that includes a proposed prescription drug pricing model that will test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#8217;s accelerated approval pathway. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">New laws and additional health reform measures may result in additional reductions in Medicare and other healthcare funding, which may adversely affect customer demand and affordability for our investigational COMP360 psilocybin therapy and any future therapeutic candidates and, accordingly, the results of our financial operations. These continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.8pt">the demand for our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if we obtain regulatory approval;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.8pt">our ability to set a price that we believe is fair for our products;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.8pt">our ability to obtain coverage and reimbursement approval for a product;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.8pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.8pt">the level of taxes that we are required to pay; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.8pt">the availability of capital.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:16.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from one or more of our approved products or other therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">70</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers may be subject, directly or indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, other healthcare laws and regulations and other foreign privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Although we do not currently have any therapies on the market, our current and future operations may be directly, or indirectly through our relationships with investigators, health care professionals, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute or the federal Anti-Kickback Statute. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any therapies for which we obtain marketing approval. These laws impact, among other things, our research activities and proposed sales, marketing and education programs and constrain our business and financial arrangements and relationships with third-party payors, healthcare professionals who participate in our clinical research program, healthcare professionals and others who recommend, purchase, or provide our approved therapies, and other parties through which we market, sell and distribute our therapies for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business, along with foreign regulators (including European data protection authorities). Finally, our current and future operations are subject to additional healthcare-related statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business.  For more information regarding the risks related to these laws and regulations, please see the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Business&#8213;Other Healthcare Laws and Compliance Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The distribution of pharmaceutical products is subject to additional requirements and regulations, including licensing, extensive record-keeping, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Further, if any of our Centers for Excellence conduct clinical studies, we may face risks relating to operating a clinical trial site. Such risks may include, but are not limited to, research misconduct and patient injury. In addition, we may end up possessing a large amount of individually identifiable health information. Such activities are subject to a wide variety of laws, such as the Health Insurance Portability and Accountability Act (HIPAA).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Even if precautions are taken, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">71</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Failure to comply with health and data protection laws and regulations could lead to U.S. federal and state government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We and any potential collaborators may be subject to U.S. federal and state data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, which are subject to privacy and security requirements under HIPAA, as amended by the Health Information Technology for Economics and Clinical Health (HITECH). To the extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent requirements on entities like ours. Depending on the facts and circumstances, we could be subject to significant civil, criminal, and administrative penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, in June 2018, the State of California enacted the California Consumer Privacy Act of 2018, or CCPA, which came into effect on January 1, 2020 and became enforceable by the California Attorney General on July 1, 2020. The CCPA provides new data privacy rights for consumers (as that term is broadly defined) and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. In particular, the CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has resulted in an increase in data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. There continues to be uncertainty surrounding the enforcement and implementation of the CCPA, exemplifying the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, a new California ballot initiative, the California Privacy Rights Act, or CPRA, was passed in November 2020. Effective starting on January 1, 2023, the CPRA imposes additional obligations on companies covered by the legislation and will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The effects of the CCPA and the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the United States, which could increase our potential liability and adversely affect our business. Certain other state laws impose similar privacy obligations, and we anticipate that more states may enact legislation similar to the CCPA, which provides consumers with new privacy rights and increases the privacy and security obligations of entities handling certain personal information of such consumers. The CCPA has prompted a number of proposals for new federal and state-level privacy legislation. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">72</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">At the federal level, a comprehensive federal data privacy bill, the American Data Privacy and Protection Act, has been proposed and, if passed, will further change the privacy and data security compliance landscape.  This proposed legislation, if passed, would help to streamline certain of our privacy obligations, but would also introduce new stringent privacy and data security obligations that would apply to personal data collected from throughout the United States.  In addition, the SEC proposed cybersecurity rules that may go into effect during 2023 that will likely require, among other things, increased monitoring and reporting of data security incidents.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Compliance with U.S. and foreign privacy and data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">European data collection is governed by restrictive privacy and security regulations governing the use, processing and cross-border transfer of personal information.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our clinical trial activity conducted within the Member States of the European Environment Agency (EEA) is regulated by the General Data Protection Regulation (GDPR). The collection, use, storage, disclosure, transfer, or other processing of personal data (including health data processed in the context of clinical trials) (i) regarding individuals in the EU, and/or (ii) carried out in the context of the activities of our establishment in any EU Member State, is subject to the GDPR, as well as other national data protection legislation in force in relevant Member States. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The GDPR is wide-ranging in scope and imposes numerous additional requirements on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring that consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, limiting retention periods for personal data, increasing requirements pertaining to health data and pseudonymized (i.e., key-coded) data, creating mandatory data breach notification requirements in certain circumstances, and requiring that certain measures (including contractual requirements) are put in place when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenue, whichever is greater. The GDPR provides individuals with various rights in respect of their personal data, including rights of access, erasure, portability, rectification, restriction and objection. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The GDPR provides that EEA Member States may make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result in differences between Member States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In addition, we are subject to evolving and strict rules on the transfer of personal data out of the EEA to third countries such as the United States. In 2020, the Court of Justice of the EU invalidated the EU-U.S. Privacy Shield, which was one of the primary mechanisms used by U.S. companies to import personal information from Europe in compliance with the GDPR&#8217;s cross-border data transfer restrictions, and raised questions about whether the European Commission&#8217;s standard contractual clauses one of the primary alternatives to the Privacy Shield, can lawfully be used for personal information transfers from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">73</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Europe to the United States or most other countries. Similarly, the Swiss Federal Data Protection and Information Commissioner has opined that the Swiss-U.S. Privacy Shield is inadequate for transfers of data from Switzerland to the United States, and the UK Information Commissioner&#8217;s Office has stated that the Privacy Shield framework is inadequate for transfers from the UK to the U.S. Furthermore, on June 4, 2021, the European Commission issued new forms of standard contractual clauses for data transfers from controllers or processors in the EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EEA. We will be required to transition to the new forms of standard contractual clauses and doing so may require significant effort and cost. The new standard contractual clauses may also impact our business as companies based in Europe may be reluctant to utilize the new clauses to legitimize transfers of personal information to third countries given the burdensome requirements of transfer impact assessments and the substantial obligations that the new standard contractual clauses impose upon exporters. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or pharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national clients or pharmaceutical partners to continue to use our products due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the GDPR. Such clients or pharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the foregoing could materially harm our business, prospects, financial condition, and results of operations. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR. While we have taken steps to comply with the GDPR, and implementing legislation in applicable EU Member States, including by seeking to establish appropriate lawful bases for the various processing activities we carry out as a controller or joint controller, reviewing our security procedures and those of our vendors and collaborators, and entering into data processing agreements with relevant vendors and collaborators, we cannot be certain that our efforts to achieve and remain in compliance have been, and/or will continue to be, fully successful. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Further, the United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, and ongoing developments in the United Kingdom have created uncertainty regarding data protection regulation in the United Kingdom. Following December 31, 2020, the data protection obligations of the GDPR continue to apply to United Kingdom-related processing of personal data in substantially unvaried form under the so-called &#8220;UK GDPR&#8221; (i.e., the GDPR as it continues to form part of law in the United Kingdom by virtue of section 3 of the European Union (Withdrawal) Act 2018, as amended (including by the various Data Protection, Privacy and Electronic Communications (Amendments, etc.) (EU Exit) Regulations 2019)). However, going forward, there will be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the United Kingdom and EEA. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but currently still aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU&#8217;s GDPR, the European Commission has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. It is not subject to the new forms of standard contractual clauses but has issued its own transfer mechanism, the international data transfer agreement, which, like the standard contractual clauses, requires exporters to carry out a transfer impact assessment. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">74</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved, could limit our ability to market those therapies and decrease our ability to generate revenue. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford therapies such as our investigational COMP360 psilocybin therapy or any future therapeutic candidates, if approved. As Schedule I substances under the CSA, psilocybin and psilocin are deemed to have no accepted medical use and therapies that use psilocybin or psilocin are precluded from reimbursement in the United States. Our products must be scheduled as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V) before they can be commercially marketed. Our ability to achieve acceptable levels of coverage and reimbursement for therapies by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize, and attract additional collaboration partners to invest in the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. There is limited clinical data on the long-term efficacy of psilocybin on treating TRD. Certain patients may need repeated treatments over their lifetime to avoid relapse. This may increase treatment costs, making it more difficult for us to secure reimbursement. Even if we obtain coverage for a given therapy by third-party payors, the resulting reimbursement payment rates may not be adequate or may require patient out-of-pocket costs that patients may find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, Europe or elsewhere will be available for any therapy that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. For more information regarding the risks related to these laws and regulations, please see the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Business&#8213;Coverage, Pricing and Reimbursement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We intend to seek approval to market our investigational COMP360 psilocybin therapy or future therapeutic candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for COMP360 or our future therapeutic candidates, we will be subject to rules and regulations in those jurisdictions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In some foreign countries, particularly certain countries in Europe, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our investigational COMP360 psilocybin therapy or our future therapeutic candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a therapeutic candidate. In addition, market acceptance and sales of our investigational COMP360 psilocybin therapy or future therapeutic candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our investigational COMP360 psilocybin therapy or future therapeutic candidates and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Third-party payors are increasingly challenging prices charged for therapeutic substances and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our investigational COMP360 psilocybin therapy or any future therapeutic candidates as substitutable and only offer to reimburse patients for the less expensive therapy. Even if we show improved efficacy or improved convenience of administration with our investigational COMP360 psilocybin therapy or any future therapeutic candidates, pricing of existing drugs may limit the amount we will be able to charge. These payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed therapies at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates, and may not be able to obtain a satisfactory financial return on therapeutic candidates that we may develop. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved therapies. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">75</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">reimbursement policies for drugs. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug therapies exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug therapies can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our therapies to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.  </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On the state level, local governments have been very aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our therapies or put pressure on our therapeutic pricing, which could negatively affect our business, results of operations, financial condition and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, and other countries has and will continue to put pressure on the pricing and usage of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. In many countries, the prices of medical therapies are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical therapies, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Accordingly, in markets outside the United States, the reimbursement for our therapies may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU-wide, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of therapies in that context. In general, however, the healthcare budgetary constraints in many EU Member States have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with increasing EU and national regulatory burdens on those wishing to develop and market therapies, this could prevent or delay marketing approval of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, restrict or regulate post-approval activities and affect our ability to commercialize any therapies for which we obtain marketing approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">EU drug marketing regulation may materially affect our ability to market and receive coverage for our therapies in the EU Member States. Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">76</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal therapies is also prohibited in most countries within the EU. The provision of benefits or advantages to induce or reward improper performance generally is typically governed by the national anti-bribery laws of EU Member States, and in respect of the UK, the Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Payments made to physicians and other healthcare professionals in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in individual EU Member States and the particular requirements can therefore vary widely amongst the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, in most foreign countries, including many EU Member States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, individual Member States in the EU have the ability to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced Member States, can further reduce prices. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our investigational COMP360 psilocybin therapy or any of our future therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapies. Historically, therapies launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our therapies is unavailable or limited in scope or amount, our revenue from sales and the potential profitability of our investigational COMP360 psilocybin therapy or any of our future therapeutic candidates in those countries would be negatively affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Moreover, increasing efforts by governmental and third-party payors in the EU, the United States and elsewhere to cap or reduce healthcare costs may cause such organizations to limit coverage and the level of reimbursement for newly approved therapies and, as a result, they may not cover or provide adequate payment for our investigational COMP360 psilocybin therapy or any future therapeutic candidates. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific therapies. We expect to experience pricing pressures in connection with the sale of our investigational COMP360 psilocybin therapy or any future therapeutic candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">77</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could experience difficulty enforcing our contracts.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Due to the nature of our business and the fact that some of our contracts involve psychedelics including psilocybin and psilocin, the use of which is not legal under U.S. federal law and in certain other jurisdictions, we may face difficulties in enforcing our contracts in U.S. federal and state courts. The inability to enforce any of our contracts could have a material adverse effect on our business, operating results, financial condition or prospects.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In order to manage our contracts with contractors, we ensure that such contractors are appropriately licensed at the state and federal level in the United States, and at the appropriate level in other territories. Were such contractors to operate outside the terms of these licenses, we may experience an adverse effect on our business, including the pace of development of our investigational COMP360 psilocybin therapy, any future therapeutic candidate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We rely on patents and other intellectual property rights to protect our investigational COMP360 psilocybin therapy, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for COMP360, any future therapeutic candidates and associated therapies, digital therapies, methods used to manufacture the underlying therapeutic substances, and the methods for treating patients using those substances and therapies, or on licensing in such rights. Failure to obtain, maintain protect, enforce or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our investigational COMP360 psilocybin therapy and any future therapeutic candidates. We also rely on trade secrets and know-how to develop and maintain our proprietary and intellectual property position. Any failure to protect our trade secrets and know-how could adversely affect our operations and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We cannot be certain that patents will be issued or granted with respect to patent applications that are currently pending, or that issued or granted patents will not later be found to be invalid or unenforceable. The patent position of companies like ours is generally uncertain because it involves complex legal and factual considerations. The standards applied by the European Patent Office, the United States Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in pharmaceutical patents. Consequently, patents may not issue from our pending patent applications, and even if they do issue, such patents may not issue in a form that effectively prevents others from developing or commercializing competing therapies. As such, we do not know the degree of future protection that we will have on our proprietary therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The patent prosecution process is expensive, complex and time-consuming, and we and our current or future third party partners, licensors, licensees, or collaboration partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaboration partners will fail to identify patentable aspects of inventions made in the course of research, development or commercialization activities before it is too late to pursue patent protection on them. In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published until and unless granted. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly we cannot be certain that for any licensed patents or pending patent applications, the named applicant(s) were the first to make the inventions claimed in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">78</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">such patents or pending patent applications or that the named applicant(s) were the first to file for patent protection for such inventions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued that protect our therapies, in whole or in part, or that effectively prevent others from commercializing competitive technologies and therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors, licensees or collaboration partners. If our current or future licensors, licensees or collaboration partners fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or collaboration partners are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The patent examination process may require us or our licensors, licensees or collaboration partners to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaboration partners&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Even if patents do successfully issue and even if such patents cover COMP360 and any future therapeutic candidates, third parties may initiate an opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation proceedings in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We cannot provide any assurances that we will successfully defend ourselves against this challenge or any future patent challenges. For example, in December 2021, a third party filed two petitions requesting post grant review of two of our patents (U.S. Patent 10,947,257 and U.S. Patent 10,954,259) before the Patent Trial &amp; Appeal Board of the U.S. Patent and Trademark Office, or the USPTO Board. On June 22, 2022, the USPTO Board issued decisions in both cases denying institution of post grant review on the merits of the arguments presented in each of the challenges. On July 22, 2022, the third-party challenger filed a request with the USPTO Board for rehearing of the USPTO Board&#8217;s decision, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">well as a request for Precedential Opinion Panel on August 16, 2022 in each of the challenges. On February 10, 2023, the USPTO Board denied the request for Precedential Opinion Panel in each of the challenges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The USPTO Board has not yet issued a final decision on the requests for rehearing in each of the challenges.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our and our licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. In addition, patents and other intellectual property rights also will not protect our technology, COMP360 and any future therapeutic candidates if third parties, including our competitors, design around our protected technology and our investigational COMP360 psilocybin therapy and any future therapeutic candidates without infringing, misappropriating or otherwise violating our patents or other intellectual property rights. Moreover, some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing therapies and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">79</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our current or future licensors, licensees or collaborators were or will be the first to file any patent application related to a therapeutic candidate. Furthermore, if patent applications of third parties have an effective filing date before March 16, 2013, an interference proceeding can be initiated by such third parties at the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If patent applications of third parties have an effective filing date on or after March 16, 2013, a derivation proceeding can be initiated by such third parties at the USPTO to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, we may be subject to third-party challenges regarding our exclusive ownership of our intellectual property. If a third party were successful in challenging our exclusive ownership of any of our intellectual property, we may lose our right to use such intellectual property, such third party may be able to license such intellectual property to other third parties, including our competitors, and our competitors could market competing therapies and technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Issued patents covering one or more of our investigational therapeutics could be found invalid or unenforceable if challenged in court. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">To protect our competitive position, we may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable and expensive, and many of our or our licensors&#8217; or collaboration partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaboration partners can. Accordingly, despite our or our licensors&#8217; or collaboration partners&#8217; efforts, we or our licensors or collaboration partners may not prevent third parties from infringing upon, misappropriating or otherwise violating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the UK, EU and the United States. We may fail in enforcing our rights, in which case our competitors and other third parties may be permitted to use our therapies without payment to us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, litigation involving our patents carries the risk that one or more of our patents will be narrowed, held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize our therapies, and then compete directly with us, without payment to us. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our investigational therapies, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States or in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. A claim for unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement, during prosecution. Third parties may also raise challenges to the validity of our patent claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (i.e., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover COMP360 or any future therapeutic candidates. On July 22, 2022, a third-party challenger filed with the USPTO Board requests for rehearing of the USPTO Board&#8217;s decisions to deny institution of post-grant reviews of U.S. Patent 10,947,257 and U.S. Patent 10,954,259, and on August 16, 2022, the third-party challenger also filed requests for a Precedential Opinion Panel in each of the patents.  On February 10, 2023, the USPTO Board denied the request for Precedential Opinion Panel in each of the challenges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The USPTO Board has not yet issued a final decision on the requests for rehearing in each of the challenges. The outcome following legal assertions of invalidity and unenforceability during patent litigation or other proceedings is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant or third party were to prevail on a legal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">80</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on COMP360 or one or more of any future therapeutic candidates. Such a loss of patent protection could have a material adverse impact on our business financial condition, results of operations, and prospects. Further, litigation could result in substantial costs and diversion of management resources, regardless of the outcome, and this could harm our business and financial results. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the European Patent Office, the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The European Patent Office, the USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our collaboration partners to pay these fees due to United States and comparable foreign patent agencies and take the necessary action to comply with such requirements with respect to our intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our investigational therapies, third parties, including our competitors might be able to enter the market with similar or identical therapies or technologies, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our investigational therapies, our business may be materially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the United States, if all maintenance fees are paid on time, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our investigational therapies, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive therapies. Given the amount of time required for the development, testing and regulatory review of new investigational therapies, patents protecting such candidates and concomitant therapies might expire before or shortly after such candidates and concomitant therapies are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing therapies similar or identical to ours. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Depending upon the timing, duration and conditions of FDA marketing approval of COMP360 and any future therapeutic candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar legislation in the EU. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term loss during product development, the FDA regulatory review process and the issuance of a final decision controlling the product under the Controlled Substance Act. The patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method of manufacturing it may be extended. However, we may not receive an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will not be lengthened and third parties, including our competitors, may obtain approval to market competing therapies sooner than we expect. As a result, our revenue from applicable therapies could be materially reduced and our business, financial condition, results of operations, and prospects could be materially harmed. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">81</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">others may be able to make compounds or develop digital assets that are the same as or similar to our investigational COMP360 psilocybin therapy, any future therapeutic candidates and digital assets but that are not covered by the claims of the patents that we own or control; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the patents of third parties may have an adverse effect on our business; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we or our licensors or any current or future collaboration partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or control; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we or our licensors or any current or future collaboration partners might not have been the first to file patent applications covering certain of our inventions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">it is possible that our current and future pending patent applications will not lead to issued patents; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by third parties; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive therapies for sale in our major commercial markets; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">third parties performing manufacturing or testing for us using our therapies or technologies could unknowingly use the intellectual property of others without obtaining a proper license; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may not develop additional technologies that are patentable; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property, or otherwise develop similar know-how.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Many of our consultants, advisors and employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Some of these individuals executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we intend that our consultants, advisors and employees do not use proprietary information or know-how of their former employers while working for us, we may be subject to claims that we or these individuals have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s former employer. Litigation may be necessary to defend against these claims. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">82</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">and we could be required to obtain a license from such third party to commercialize our therapies. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract our management from its day-to-day activities. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Intellectual property rights of third parties could adversely affect our ability to compete or commercialize our investigational therapies, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our investigational therapies. Such litigation or licenses could be costly or not available on commercially reasonable terms. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our commercial success depends upon our ability and the ability of our future collaborators to develop, manufacture, market, and sell any investigational therapies that we may develop and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In the past, we have been subject to, and in the future we may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to COMP360 or any future therapeutic candidates. If the outcome of any such proceeding or litigation is adverse to us, it may affect our ability to compete effectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our therapies or elements thereof, our manufacture or uses relevant to our development plans, the targets of COMP360 or any future therapeutic candidates, or other attributes of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. In such cases, we may not be in a position to develop or commercialize such therapeutic candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, which may not be available on commercially reasonable terms or at all. In the event that a patent has not expired at the time of approval of such investigational therapies or therapeutic candidate and the patent owner were to bring an infringement action against us, we may have to argue that our investigational therapies or the manufacture or use of the underlying therapeutic substances do not infringe a valid claim of the patent in question. Alternatively, if we were to challenge the validity of any issued U.S. patent in court, we would need to overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we would need to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. The same applies to other jurisdictions. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. In the event that a third party successfully asserts its patent against us such that such third party&#8217;s patent is found to be valid and enforceable and infringed by our investigational therapies, unless we obtain a license to such patent, which may not be available on commercially reasonable terms or at all, we could be prevented from continuing to develop or commercialize our investigational therapies. Similarly, the targets for our investigational COMP360 psilocybin therapy have also been the subject of research by other companies, which have filed patent applications or have patents on aspects of the targets or their uses. There can be no assurance any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such licenses on acceptable terms, or at all, and any such litigation would be costly and time-consuming. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">It is possible that we have failed, and in the future may fail, to identify relevant patents or applications that may be asserted against us. For example, certain U.S. applications filed after November 29, 2000 can remain confidential until and unless issued as patents, provided that inventions disclosed in the applications have not and will not be the subject of a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">83</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">corresponding application filed outside the United States. In general, patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapies could have been filed by others without our knowledge. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications in the areas in which we are active. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our therapies or the use of our therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Third-party intellectual property right holders, including our competitors, may actively bring infringement, misappropriation or violation claims against us based on existing or future intellectual property rights, regardless of their merit. We may not be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we are unsuccessful defending in any such claim, in addition to being forced to pay damages, we or our licensees may be temporarily or permanently prohibited from commercializing any of our investigational therapies that were held to be infringing. If possible, we might be forced to redesign our investigational COMP360 psilocybin therapy or any future therapeutic candidates so that we no longer infringe the intellectual property rights of third parties, or we may be required to seek a license to any such technology that we are found to infringe, which license may not be available on commercially reasonable terms or at all. Even if we or our licensors or collaboration partners obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or collaboration partners and it could require us to make significant licensing and royalty payments. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217; or collaboration partners&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future investigational therapies. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Intellectual property litigation could cause us to spend substantial resources, distract our personnel from their normal responsibilities, harming our reputation and our business operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development and commercialization activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">84</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may not be successful in obtaining or maintaining necessary rights to COMP360 or any future therapeutic candidates through acquisitions and in-licenses. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the future, our programs may require the use of proprietary rights held by third parties, and the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, with respect to any patents we co-own with third parties, we may require licenses to such co-owners&#8217; interest in such patents. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for COMP360 or any future therapeutic candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of an investigational therapy or program, we may have to abandon development of that investigational therapy or program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our applicable investigational therapy or program. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights to or from third parties, or otherwise experience disruptions to our business relationships with our licensors, licensees or collaborators, we could lose the rights to intellectual property that are important to our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are or may become a party to third-party agreements under which we grant or are granted rights to intellectual property that are potentially important to our business and we expect that we may need to enter into additional license or collaboration agreements in the future. Our existing third-party agreements impose, and we expect that future license agreements will impose, various obligations related to, among other things, therapeutic development and payment of royalties and fees based on achieving certain milestones. In addition, under several of our collaboration agreements, we are prohibited from developing and commercializing therapies that would compete with the therapies licensed under such agreements. If we fail to comply with our obligations under these agreements, our licensor or collaboration partner may have the right to terminate the agreement, including any licenses included in such agreement. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The termination of any license or collaboration agreements or failure to adequately protect such license agreements or collaboration could prevent us from commercializing our investigational COMP360 psilocybin therapy or any future therapeutic candidates covered by the agreement or licensed intellectual property. For example, we may rely on license agreements which grant us rights to certain intellectual property and proprietary materials that we use in connection with the development of our therapies. If this agreement were to terminate, we would be unable to timely license similar intellectual property and proprietary materials from an alternate source, on commercially reasonable terms or at all, and may be required to conduct additional bridging studies on our investigational COMP360 psilocybin therapy or any future therapeutic candidates, which could delay or otherwise have a material adverse effect on the development and commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Several of our existing license agreements are sublicenses from third parties which are not the original licensor of the intellectual property at issue. Under these agreements, we must rely on our licensor to comply with its obligations under the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">85</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">primary license agreements under which such third party obtained rights in the applicable intellectual property, where we may have no relationship with the original licensor of such rights. If the licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate the sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property and, in the case of a sublicense, if we were not able to secure our own direct license with the owner of the relevant rights, which it may not be able to do at a reasonable cost or on reasonable terms, it may adversely affect our ability to continue to develop and commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates incorporating the relevant intellectual property. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Disputes may arise regarding intellectual property subject to a license or collaboration agreement, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the scope of rights granted under the agreement and other interpretation-related issues; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor or collaboration partner that is not subject to the agreement; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the sublicensing of patent and other rights under any current or future collaboration relationships; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our diligence obligations under the agreement and what activities satisfy those diligence obligations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaboration partners; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, our third-party agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidate, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We consider proprietary trade secrets, confidential know-how and unpatented know-how to be important to our business. We rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and confidential know-how are difficult to maintain as confidential. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">To protect this type of information against disclosure or appropriation by third parties and our competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or confidential know-how. Also, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our trade secrets and confidential know-how to our competitors and other third parties or breach such agreements, and we may not be able to obtain an adequate remedy for such breaches. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is difficult, expensive, time-consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore, if a competitor or other third party lawfully obtained or independently developed any of our trade secrets or confidential know-how, we would have no right to prevent such competitor or other third party from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">86</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Failure to obtain or maintain trade secrets or confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets or confidential know-how. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may not be able to protect our intellectual property rights throughout the world and may face difficulties in certain jurisdictions, which may diminish the value of intellectual property rights in those jurisdictions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Filing, prosecuting and defending patents on therapeutic candidates in all countries and jurisdictions throughout the world would be prohibitively expensive and our intellectual property rights in some countries outside of the UK and the United States, could be less extensive than those in the UK and the United States, assuming that rights are obtained in the UK and the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the UK and the United States, or from selling therapies or importing therapeutic substances made using our inventions in and into the UK and the United States, or other jurisdictions. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. It is also quite common that depending on the country, the scope of patent protection may vary for the same therapeutic candidate or technology. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Competitors may use our and our licensors&#8217; or collaboration partners&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own therapies and, further, may export otherwise infringing therapies to territories where we and our licensors or collaboration partners have patent protection, but enforcement is not as strong as that in the UK and the United States. These therapies may compete with COMP360 or any future therapeutic candidates, and our and our licensors&#8217; or collaboration partners&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the UK and the United States, and companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors or collaboration partners is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">87</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Proceedings to enforce our and our licensors&#8217; or collaboration partners&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensors&#8217; or collaboration partners&#8217; efforts and attention from other aspects of our business, regardless of whether we or our licensors or collaboration partners are successful, and could put our and our licensors&#8217; or collaboration partners&#8217; patents at risk of being invalidated or interpreted narrowly. In addition, such proceedings could put our and our licensors&#8217; or collaboration partners&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaboration partners. We or our licensors or collaboration partners may not prevail in any lawsuits that we or our licensors or collaboration partners initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our future product candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We rely on the protection of our intellectual property in various jurisdictions. Changes in patent laws in the U.S. and other jurisdictions could cause us to lose protection over certain of our patents and therefore impair our ability to protect our future product candidates. For example, in Europe, a new unitary patent system takes effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.  </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We rely on third parties to supply and manufacture the psilocybin and psilocin incorporated in COMP360 and expect to continue to rely on third parties to supply and manufacture any future therapeutic candidates, and we will rely on third parties to manufacture these substances for commercial supply, if approved. If any third-party provider fails to meet its obligations manufacturing COMP360 or our future therapeutic candidates, or fails to maintain or achieve satisfactory regulatory compliance, the development of such substances and the commercialization of any therapies, if approved, could be stopped, delayed or made commercially unviable, less profitable or may result in enforcement actions against us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We do not currently have, nor do we plan to acquire, the infrastructure or capability necessary to manufacture COMP360 or any future therapeutic candidates, including the psilocybin and psilocin incorporated into such therapeutic candidates. We rely on, and expect to continue to rely on, CMOs for the development, manufacture and production of the psilocybin and psilocin used in our investigational therapies administered in our clinical trials and will continue to rely on such CMOs for the development, manufacture and production of any commercial supply, if our investigational therapies are approved. Currently, we engage with multiple different CMOs in the UK for all activities relating to the development, manufacture and production of all components incorporated in COMP360. Reliance on third-party providers, such as CMOs, exposes us to more risk than if we were to manufacture COMP360, or any future therapeutic candidates. We do not control the manufacturing processes of the CMOs we contract with and are dependent on those third parties for the production of COMP360 or any future therapeutic candidates in accordance with relevant regulations (such as the FDA&#8217;s good laboratory practices, or GLP, cGMPs or similar regulatory requirements outside the US) for the manufacture of drug substances, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. Some of the suppliers currently engaged in the production process of COMP360, including our current supplier of API, have not in the past been subject to inspection by the FDA and/or EMA and there can be no assurance that they are in compliance with all applicable regulations. Our failure, or the failure of third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of COMP360 or any future therapeutic candidates, operating restrictions and criminal prosecutions, any of which could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">88</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">significantly and adversely affect supplies of COMP360 or any future therapeutic candidates and harm our business and results of operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for COMP360 or any future therapeutic candidates, we could experience delays in our research or planned clinical studies or commercialization. In addition, quality issues may arise during scale-up activities. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. For example, the COVID-19 pandemic created supply constraints generally globally. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, may significantly delay our clinical studies and the commercialization of our therapies, if approved, which would materially adversely affect our business, prospects, financial condition and results of operations. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In complying with the manufacturing regulations of the FDA, the DEA, the EMA, the MHRA and other comparable foreign authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the therapies meet applicable specifications and other regulatory requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of therapies and shutting down of production, any of which could materially adversely affect our business, prospects, financial condition and results of operations. We and any of these third-party suppliers may also be subject to audits by the FDA, the DEA, the EMA, the MHRA or other comparable foreign authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize the therapies could suffer significant interruptions. We face risks inherent in relying on a limited number of CMOs, as any disruption, such as a fire, natural hazards or vandalism at the CMO could significantly interrupt our manufacturing capability. We currently do not have disaster recovery facilities available. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all, and we would likely experience months of manufacturing delays as we build or locate replacement facilities and seek and obtain necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis or at all. In addition, operating any new facilities may be more expensive than operating our current facility, and business interruption insurance may not adequately compensate us for any losses that may occur, in which case we would have to bear the additional cost of any disruption. In such a scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">For these reasons, a significant disruptive event of the manufacturing facility could have a material adverse effect on our business, including placing our financial stability at risk. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">89</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, academic collaborators and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates and our business could be substantially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, academic collaborators and third-party CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the EMA, the MHRA and comparable foreign regulatory authorities for all of our therapies in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we, our investigators, academic collaborators or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure, or the failure of our third-party contractors and CROs, to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action up to and including civil and criminal penalties. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Further, these investigators, academic collaborators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our investigational COMP360 psilocybin therapy or any future therapeutic candidates and clinical trials. If independent investigators, academic collaborators or CROs fail to devote sufficient resources to the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. In addition, investigators, academic collaborators and CROs may have difficulty staffing, undergo changes in priorities or become financially distressed or form relationships with other entities, some of which may be our competitors, any of which materially adversely affect our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There is a limited number of third-party service providers that specialize in or have the expertise required to achieve our business objectives. If any of our relationships with these third-party CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative CROs, academic collaborators or investigators on commercially reasonable terms or at all. If CROs, academic collaborators or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates. As a result, our results of operations and the commercial prospects for our investigational COMP360 psilocybin therapy or any future therapeutic candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">90</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Switching or adding additional CROs (or investigators) involves additional cost and requires management time and focus. In addition, delays occur during the natural transition period when a new CRO commences work, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future, or that these delays or challenges will not have a material adverse impact on our business or financial condition and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">There are a number of third parties that conduct IISs using COMP360 provided by us. Generally, we do not sponsor these IISs, and encourage the open publication of all IIS findings. Any failure by a third party to meet its obligations with respect to the clinical development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates may delay or impair our ability to obtain regulatory approval for COMP360. IISs of COMP360 or any future therapeutic candidates may generate clinical trial data that raises concerns regarding the safety or effectiveness of COMP360 and any data generated in IISs may not be predictive of the results in populations or indications in which we are conducting, or plan to conduct, clinical trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There are a number of academic and private non-academic institutions that conduct and sponsor clinical trials relating to COMP360. We do not control the design or conduct of the IISs sponsored by third-parties, and the FDA or comparable foreign regulatory authorities could determine that these IISs do not provide adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the studies, safety concerns or other study results. Third-party investigators may design IISs that are underpowered, use clinical endpoints that are not widely accepted, questionable, or more difficult to achieve, or in other ways increase the risk of negative clinical trial results compared to clinical trials that we may design on our own. In addition, these IISs may be conducted using different populations or indications than are used in our clinical trials or IISs which we sponsor, including milder or more severe patient populations. We also do not have control over academic or private non-academic institutions&#8217; disclosure of information, and these parties may disclose sensitive information or results of studies without our approval or consent.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a result of these IISs sponsored by third-parties, we will receive certain information rights with respect to the IISs, including access to and the ability to use and reference the resulting data, including for our own regulatory filings. However, we do not have control over the timing and reporting of the data from IISs, nor do we necessarily own or control the data from the IISs. If we are unable to confirm or replicate the results from the IISs or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of COMP360 or any future therapeutic candidates. Any data generated in IISs may not be predictive of the results in populations or indications in which we are conducting, or plan to conduct, clinical trials. Any data perceived to be negative, however, could harm our ability to advance the clinical development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, and we may not be able to investigate whether such negatively perceived data reflects issues with the design and/or conduct of the IIS or if it actually reflects characteristics of our therapeutic approach. Moreover, we rely on our investigators and institutions to provide us timely information. We have in the past, and may in the future, experience delays in receiving notice of reportable adverse events or SUSARs from IISs. For example, we were informed in September 2020 of a SUSAR in an IIS at the University of Zurich that had occurred a few weeks earlier, despite an obligation by the site investigator to report such an event to us immediately. Such delays, or any failures to provide contractually required information, could negatively impact us or cause delays in our reporting requirements to applicable regulatory authorities. Further, if investigators or institutions breach their obligations with respect to the clinical development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the IISs been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, the FDA or comparable foreign regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these IISs, or our interpretation of preclinical, manufacturing or clinical data from these IISs. If so, the FDA or other comparable foreign regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned trials and/or may not accept such additional data as adequate to initiate our planned trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">91</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Our Business Operations, Managing Growth and Employee Matters</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">A pandemic, epidemic, or outbreak of an infectious disease, such as the COVID-19 pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We are subject to risks related to public health crises such as the COVID-19 pandemic. The COVID-19 pandemic and policies and regulations implemented by governments in response to the COVID-19 pandemic have had a significant impact, both directly and indirectly, on global businesses and commerce. For example, indirect effects of the COVID-19 pandemic such as worker shortages and supply chain constraints continue to impact segments of the economy. Other global health concerns could also result in social, economic and labor instability in the countries in which we or the third parties with whom we engage operate.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The future extent of the impact of any public health crisis on our preclinical studies or clinical trial operations, our supply chain and manufacturing and our office-based business operations, will depend on future developments, which remain highly uncertain and cannot be predicted with confidence. For example, at the onset of the COVID-19 pandemic, we paused the enrollment of new patients into our clinical trials. In the future, we could also experience significant and material disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of COMP360 and any future therapeutic candidates due to a public health crisis. Future developments are inherently hard to predict and there can be no guarantee we will not face difficulties or additional costs in enrolling patients in our Phase 3 trials for TRD or future clinical trials, that we will be able to achieve full enrollment of our studies within the timeframes we anticipate, or at all, or that supply disruptions would not adversely impact our ability to initiate and complete preclinical studies or clinical trials.  Any public health crisis may in the future affect employees of third-party CROs that we rely upon to carry out our clinical trials and may cause disruptions that could severely impact our business and clinical trials, including the diversion of healthcare resources away from our clinical trials, the interruption of key clinical trial activities, delays in receiving authorizations from regulatory authorities, changes in local regulations, supply chain disruptions and continued volatility in the public equity markets and global economic disruptions, among other things.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Any public health crisis in the future may cause significant volatility in public equity markets and disruptions to the United States and global economies. Increased volatility and economic dislocation may make it more difficult for us to raise capital on favorable terms, or at all. To the extent that any future public health crisis adversely affects our business and financial results, it may also heighten many of the other risks described in this &#8216;&#8216;Risk Factors&#8217;&#8217; section, such as those relating to the timing and completion of our clinical trials and our ability to obtain future financing.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our future growth and ability to compete effectively depends on our ability to manage senior management changes and our ability to retain our key personnel and recruit additional qualified personnel, and on the key personnel employed by our collaborative partners. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our success depends upon the continued contributions of our key executives, managers, scientific and medical personnel, many of whom have been instrumental for us and have substantial experience with our therapies and related technologies. These key management individuals include the members of our board of directors and certain executive officers. We do not currently maintain any key person insurance. The loss of key executives, managers and senior scientists or medical personnel could delay our research and development activities. In addition, our ability to compete in the highly competitive pharmaceutical and biotechnology industry depends upon our ability to attract and retain highly qualified management, scientific and medical personnel. Many other companies and academic institutions that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Therefore, we might not be able to attract or retain these key persons on conditions that are economically acceptable. Moreover, some qualified prospective employees may choose not to work for us due to negative perceptions regarding the therapeutic use of psilocybin or other objections to the therapeutic use of a controlled substance. Furthermore, we will need to recruit new managers and qualified scientific and medical personnel to develop our business if we expand into fields that will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">92</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">require additional skills. Our inability to attract and retain these key persons could prevent us from achieving our objectives and implementing our business strategy, which could have a material adverse effect on our business and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the area of sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth or raise funds to support our growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, certain key academic and scientific personnel play a pivotal role in our collaborative partners&#8217; research and development activities. If any of those key academic and scientific personnel who work on development of our research programs, our investigational COMP360 psilocybin therapy and any future therapeutic candidates leave our collaborative partners, the development of our research programs, our investigational COMP360 psilocybin therapy and any future therapeutic candidates may be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our employees, independent contractors, principal investigators, institutions and researchers of IISs, CROs, consultants, vendors, third-party therapy sites, therapists and collaboration partners and third parties may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are exposed to the risk that our employees, independent contractors, principal investigators, institutions and researchers of IISs, CROs, consultants, vendors, third-party therapy sites, therapists and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and negligent conduct or unauthorized activities that violate, among other things: (i) the regulations of the FDA, the EMA, the MHRA and other comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our commercialization model also entails the risk of malpractice and professional liability claims against both our third-party therapy sites and us as a result of actual or alleged therapist misconduct. Although we, and the third-party therapy sites with which we engage, carry insurance covering malpractice and professional liability claims in amounts that we believe are appropriate in light of the risks attendant to our business, successful malpractice or professional liability claims could result in substantial damage awards that exceed the limits of our insurance coverage and our third-party therapy sites&#8217; insurance coverage. In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as we expand our services. As a result, adequate professional liability insurance may not be available to our providers or to us in the future at acceptable costs or at all. Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us and divert the attention of our management and our third-party therapy sites from our operations, which could have a material adverse effect on our business, financial condition and results of operations. In addition, any such claims may materially and adversely affect our business or reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">93</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">It is not always possible to identify and deter misconduct by employees and other third parties, including our therapists, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We face substantial competition and our competitors may discover, develop or commercialize therapies before or more successfully than us, which may result in the reduction or elimination of our commercial opportunities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The pharmaceutical and psychedelic industry is intensely competitive and subject to rapid and significant technological change. Our competitors include multinational pharmaceutical companies, universities and other research institutions. We also face competition from 501(c)(3) non-profit medical research organizations, including the Usona Institute. Such non-profits may be willing to provide psilocybin-based products at cost or for free, undermining our potential market for COMP360. In addition, a number of for-profit biotechnology companies or institutions are specifically pursuing the development of psilocybin to treat mental health illnesses, including TRD. In addition, an increasing number of companies are stepping up their efforts in discovery of new psychedelic compounds. It is also probable that the number of companies seeking to develop psychedelic products and therapies for the treatment of mental health illnesses, such as depression, will increase. If any of our competitors is granted an NDA for their psychedelic-assisted therapies before us and manages to obtain approval for a broader indication, and thus access a wider patient population, we may face more intensified competition from such potential psychedelic-assisted therapies and increased difficulties in winning market acceptance of our investigational COMP360 psilocybin therapy or any future therapeutic candidates. All of these risks are heightened because psilocybin, which is a naturally occurring substance and therefore not subject to patent protection, may be deemed an appropriate substitute for COMP360.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We also face competition from major pharmaceutical, biopharmaceutical and biotechnology companies who have developed or are developing non-psilocybin or psychedelic based therapies for the treatment of MDD and TRD, and will face future competition for any other indications we may seek to treat with our investigational COMP360 psilocybin therapy. There are a number of companies that currently market and sell products or therapies, or are pursuing the development of products or therapies, for the treatment of depression, including antidepressants such as SSRIs and serotonergic norepinephrine reuptake inhibitors, or SNRIs, antipsychotics, cognitive behavioral therapy, or CBT, esketamine and ketamine, repeat transcranial magnetic stimulation, or rTMS, electroconvulsive therapy, or ECT, vagus nerve stimulation, or VNS, and deep brain stimulation, or DBS, among others. Many of these pharmaceutical, biopharmaceutical and biotechnology competitors have established markets for their therapies and have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market superior products or therapies. In addition, many of these competitors have significantly greater experience than we have in undertaking preclinical studies and human clinical trials of new therapeutic substances and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA, EMA or MHRA approval for alternative or superior products. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Smaller and earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The field in which we operate is characterized by a growing and shifting understanding of disease biology, changing technologies, and strong intellectual property barriers to entry, and many companies are involved in the creation, development and commercialization of novel therapeutics and technology platforms. Our competitors may develop therapies that are more effective, more convenient, more widely used and less costly or have a better safety profile than our therapies and these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">94</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">competitors may also be more successful than we are in manufacturing and marketing their therapies. Additionally, there can be no assurance that our competitors are not currently developing, or will not in the future develop, technologies and therapies that are equally or more economically attractive as our investigational COMP360 psilocybin therapy or any future therapeutic candidates. Competing alternative therapies or technology platforms may gain faster or greater market acceptance than our therapies or technology platforms and medical advances or rapid technological development by competitors may result in our investigational COMP360 psilocybin therapy or any future therapeutic candidates or technology platforms becoming non-competitive or obsolete before we are able to recover our research and development and commercialization expenses. If we are unable to compete effectively against these companies, then we may not be able to commercialize our investigational COMP360 psilocybin therapy or any future therapeutic candidates or achieve a competitive position in the market. This would materially and adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We anticipate that we will face intense and increasing competition as new treatments enter the market. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Acquisitions and investments could result in operating difficulties, dilution and other harmful consequences that may adversely impact our business, financial condition and results of operations. Additionally, if we are not able to identify and successfully acquire suitable businesses, our operating results and prospects could be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may in the future make additional acquisitions or investments to add employees, complementary companies, therapies, products, solutions, technologies, or revenue. These transactions could be material to our business, financial condition and results of operations. We also expect to continue to evaluate and enter into discussions regarding a wide array of potential strategic transactions. The identification of suitable acquisition or investment candidates can be difficult, time-consuming and costly, and we may not be able to complete acquisitions or investment on favorable terms, if at all. The process of integrating an acquired company, business or technology and managing our future investments may create unforeseen operating difficulties and expenditures. The areas where we face risks include:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">loss of key employees of the acquired company and other challenges associated with integrating new employees into our culture, as well as reputational harm if integration is not successful;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">diversion of management time and focus from operating our business to addressing acquisition integration and investment management challenges;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">high uncertainty with respect to any investment in companies engaging in early stage drug discovery and development with limited proof of concept, which might result in significant investment loss;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">challenges in identifying suitable investment opportunities in the digital health market and diversion of management time and resources to integrate such investments into our business due to our lack of experience in such market; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">implementation or remediation of controls, procedures, and policies at any acquired company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">difficulties in integrating and managing the combined operations, technologies, technology platforms and products of any acquired companies and realizing the anticipated economic, operational and other benefits in a timely manner, which could result in substantial costs and delays or other operational, technical or financial problems;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">integration of the acquired company&#8217;s accounting, human resource and other administrative systems, and coordination of product, engineering and sales and marketing function;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">assumption of contractual obligations that contain terms that are not beneficial to us, require us to license or waive intellectual property rights, or increase our risk for liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">failure to successfully further develop the acquired technology or realize our intended business strategy;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">95</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our dependence on unfamiliar affiliates and partners of acquired businesses;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">uncertainty of entry into markets in which we have limited or no prior experience or in which competitors have stronger market positions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">unanticipated costs associated with pursuing investments or acquisitions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">failure to find commercial success with the products or services of the acquired company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">difficulty of transitioning the acquired technology onto our existing platforms and maintaining the security standards for such technology consistent with our other solutions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">responsibility for the liabilities of acquired businesses, including those that were not disclosed to us or exceed our estimates, as well as, without limitation, liabilities arising out of their failure to maintain effective data protection and privacy controls and comply with applicable regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">inability to maintain our internal standards, controls, procedures, and policies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">failure to generate the expected financial results related to an acquisition in a timely manner or at all;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">difficulties in complying with antitrust and other government regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">challenges in integrating and auditing the financial statements of acquired companies that have not historically prepared financial statements in accordance with U.S. GAAP;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">potential accounting charges to the extent intangibles recorded in connection with an acquisition, such as goodwill;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">trademarks, client relationships or intellectual property, are later determined to be impaired and written down in value; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">failure to accurately forecast the impact of an acquisition transaction.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Moreover, we may rely heavily on the representations and warranties provided to us by the sellers of acquired companies or strategic partners, including as they relate to creation of, and ownership and rights in, intellectual property, existence of open source and compliance with laws and contractual requirements. If any of these representations and warranties are inaccurate or breached, such inaccuracy or breach could result in costly litigation and assessment of liability for which there may not be adequate recourse against such sellers, in part due to contractual time limitations and limitations of liability.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Future acquisitions and investments could also result in expenditures of significant cash, dilutive issuances of our equity securities, the incurrence of debt, restrictions on our business, contingent liabilities, amortization expenses or write-offs of goodwill, any of which could harm our financial condition. In addition, any acquisitions or investments we announce could be viewed negatively by collaborative partners, employees, vendors, patients, shareholders, or investors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, competition within our industry for acquisitions of business, technologies and assets may become heightened. Even if we are able to identify an acquisition or investment that we would like to consummate, we may not be able to complete the acquisition or investment on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions or investments that are not ultimately consummated. Those negotiations could result in diversion of management time and significant out-of-pocket costs. If we fail to evaluate and execute acquisitions or investments successfully, we may not be able to realize the benefits of these acquisitions or investments, and our operating results could be harmed. If we are unable to successfully address any of these risks, our business, financial condition and results of operations could be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we are not able to maintain and enhance our reputation and brand recognition, our business, financial condition and results of operations will be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">96</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing and future third-party therapy sites, therapists, patients and collaborators, and to our ability to attract clinics to become our third-party therapy sites offering our therapies. The promotion of our brand has required and may continue to require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing and other initiatives may become increasingly difficult and expensive. Brand promotion and marketing activities may not be successful or yield increased revenue, to the extent we generate any future revenue, and to the extent that these activities yield increased future revenue, the increased revenue may not offset the expenses we incur and our business, financial condition and results of operations could be harmed. In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our network of third-party therapy sites, therapists and patients, could harm our reputation and brand and make it substantially more difficult for us to attract new third-party therapy sites, therapists and patients. If we do not successfully maintain, protect or enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with third-party therapy sites, therapists and patients, which would harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our current and potential future digital technologies may not be successful, which may adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We currently employ or are developing digital technologies to collect data, educate patients and therapists, collect digital phenotyping information, and harness artificial intelligence. We are expanding our research into digital technology to complement and augment our current or future investigational therapies, and may work with technology companies or other third parties to acquire or develop new technologies. Our efforts to develop or acquire these technologies will involve significant time, costs, and other resources, and may divert our management team&#8217;s attention and focus from executing on other key elements of our strategy. If our efforts to develop or acquire these digital technologies are unsuccessful, it may have a materially adverse impact on our business, future prospects and financial position.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our current or future digital technology solutions could compromise sensitive information related to our business, patients, healthcare professionals, therapists, third-party therapy sites and collaborators, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Our current and future digital technology solutions may involve the collection, storage, usage or disclosure of sensitive data, including protected health information, or PHI, and other types of personal data or personally identifiable information, or PII. For example, as part of our clinical trials, we may use digital technology solutions to record and analyze therapeutic sessions. We may also process and store, and use additional third parties to process and store, sensitive information including intellectual property and other proprietary business information of ours and our third-party collaborators.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may also be highly dependent on information technology networks and systems, including the internet and external cloud providers, to securely process, transmit and store this critical information. Security incidents or breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, and employee or contractor error, negligence or malfeasance, could create system disruptions, shutdowns or unauthorized disclosure or modifications of confidential information, causing patient health information to be accessed, acquired or altered without authorization or to become publicly available. In addition, we use certain systems rely on machine learning systems, which are complex and may have errors or inadequacies that are not easily detectable. These machine learning systems may inadvertently reduce the efficiency of our systems, or may cause unintentional or unexpected outputs that are incorrect, do not match our business goals, do not comply with our policies, or otherwise are inconsistent with our guiding principles, and mission. Any errors or vulnerabilities discovered in our systems or data could also result in damage to our reputation or liability for damages, any of which could adversely affect our growth prospects and our business.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We utilize third-party service providers for important aspects of the collection, storage and transmission of patient information, and other confidential and sensitive information as well as encryption of data at rest and in transit, along with appropriate system logging and access controls, and therefore rely on third parties to manage functions that have material cybersecurity risks. We take certain administrative and technological safeguards to address these risks, such as by requiring </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">97</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">outsourcing contractors who handle or subcontract the handling of patient information for us to enter into agreements that contractually obligate those contractors and any subcontractors to use reasonable efforts to safeguard PHI, other PII, and other sensitive information. Measures taken to protect our systems, those of our subcontractors, or the PHI, other PII, or other sensitive data we or our subcontractors process or maintain, may not adequately protect us from the risks associated with the collection, storage and transmission of such information. Although we take steps to help protect confidential and other sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses, failures or breaches due to third-party action, employee negligence or error, malfeasance or other disruptions.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A security breach or privacy violation that leads to disclosure or unauthorized use or modification of, or that prevents access to or otherwise impacts the confidentiality, security, or integrity of, patient information, including PHI or other PII, or other sensitive information we or our subcontractors maintain or otherwise process, could harm our reputation, compel us to comply with breach notification laws, cause us to incur significant costs for remediation, fines, penalties, notification to individuals and for measures intended to repair or replace systems or technology and to prevent future occurrences, potential increases in insurance premiums, and require us to verify the accuracy of database contents, resulting in increased costs or loss of revenue. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, or if it is perceived that we have been unable to do so, our operations could be disrupted, we may be unable to provide access to our digital technology solutions and tools, and our ability to conduct our clinical trials may be negatively impacted, including patient enrollment in clinical trials and therapist recruitment for our clinical trials, and we may suffer loss of reputation, adverse impacts on patients, physicians, clinical trial sites and investor confidence, financial loss, governmental investigations or other actions, regulatory or contractual penalties, and other claims and liability. In addition, security breaches and other inappropriate access to, or acquisition or processing of, information can be difficult to detect, and any delay in identifying such incidents or in providing any notification of such incidents may lead to increased harm.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Any such breach or interruption of our systems or any of our third-party information technology partners, could compromise our networks or data security processes and sensitive information could be inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such interruption of access, improper or unauthorized access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws and regulations that protect the privacy of patient information or other personal information, such as HIPAA, and the GDPR, the CCPA, and regulatory penalties.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct clinical trials for COMP360 psilocybin therapy or any future therapeutic candidates, obtain regulatory approval of and commercialize COMP360 psilocybin therapy or any future therapeutic candidates, conduct research and development activities, collect, process, and prepare company financial information, provide information about our current and future therapeutic candidates. Any such breach could also result in the compromise of our trade secrets and other proprietary information or that of third parties whose information we maintain, which could adversely affect our business and competitive position. While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our current operations are headquartered in one location, and we or the third parties upon whom we depend may be adversely affected by natural disasters, as well as occurrences of civil unrest, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes, outbreak of disease or other natural disasters.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our current business operations are headquartered in our offices in London, UK, with additional offices in New York and San Francisco in the United States. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents, including events of civil unrest that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">98</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our investigational COMP360 psilocybin therapy or any future therapeutic candidates or interruption of our business operations. Such natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot ensure that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Social media is increasingly being used to communicate about our clinical development programs and the diseases our investigational COMP360 psilocybin therapy or any future therapeutic candidates are being developed to treat, and we may use appropriate social media in connection with our commercialization efforts of our investigational COMP360 psilocybin therapy following approval of COMP360 or future therapeutic candidates, if any. Social media practices in the biopharmaceutical industry continue to evolve, and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to certain prohibited activities. For example, patients may use social media channels to comment on their experience in an ongoing clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment may be adversely impacted, we fail to monitor and comply with applicable adverse event reporting obligations, or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational COMP360 psilocybin therapy or any future therapeutic candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to the Ownership of Our ADSs</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The market price of our ADSs has been and will likely continue to be volatile and you could lose all or part of your investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The market price of our ADSs has been and may continue to be highly volatile and could be subject to large fluctuations in response to the risk factors discussed in this section, and others beyond our control, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">positive or negative results of testing and clinical trials by us, strategic partners or competitors; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">timing of completion of our Phase 3 clinical program;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">delays in entering into strategic relationships with respect to development or commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">99</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">entry into strategic relationships on terms that are not deemed to be favorable to us; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">technological innovations or commercial therapeutic introductions by competitors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes in government regulations and healthcare payment systems; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">developments concerning proprietary rights, including patent and litigation matters; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">public concern relating to the commercial value or safety of any of our investigational COMP360 psilocybin therapy or any future therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">negative publicity or public perception of the use of psilocybin therapy as a treatment therapy;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">financing or other corporate transactions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">publication of research reports or comments by securities or industry analysts; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the trading volume of our ADSs on Nasdaq;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">sales of our ADSs by us, members of our senior management and directors or our shareholders or the anticipation that such sales may occur in the future;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">general market conditions in the pharmaceutical industry or in the economy as a whole; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">general economic, political, geopolitical and market conditions, including the recent significant increases in inflation in the United States, U.K. and Europe, and overall market volatility in the United States or the UK as a result of, among other factors, macroeconomic conditions and the ongoing war between Russia and Ukraine or similar events; and </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">other events and factors, many of which are beyond our control.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In recent years, the stock markets, and particularly the stock of pharmaceutical and biotechnology companies, at times have experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of affected companies. In addition, if the market for pharmaceutical and biotechnology stocks or the broader stock market continues to experience a loss of investor confidence, the trading price of our ADSs could decline for reasons unrelated to our business, financial condition or results of operations. Since our ADSs were sold in our IPO at a price of $17.00 per ADS, our ADS price has fluctuated significantly, ranging from an intraday low of $6.54 to an intraday high of $61.69 for the period beginning September 18, 2020, our first day of trading on The Nasdaq Global Market, through March 31, 2023. If the market price of our ADSs does not exceed the price at which you acquired them, you may not realize any return on your investment in us and may lose some or all of your investment. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our executive officers, directors and certain significant shareholders own a substantial number of our ordinary shares (including ordinary shares represented by ADSs) and, as a result, may be able to exercise control over us, including the outcome of shareholder votes. Certain of our directors and officers hold interests in one of these shareholders and these shareholders may have different interests from us or your interests. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Based upon our ordinary shares outstanding as of April 4, 2023, our executive officers, directors, greater than five percent shareholders and their affiliates beneficially own approximately 45% of our ordinary shares and ADSs. Depending on the level of attendance at our general meetings of shareholders, these shareholders either alone or voting together as a group may be in a position to determine or significantly influence the outcome of decisions taken at any such general meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any shareholder resolution requiring a simple majority, including the appointment of board members, certain decisions relating to our capital structure, the approval of certain significant corporate transactions and amendments to our Articles of Association. Among other consequences, this concentration of ownership may prevent or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">100</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">discourage unsolicited acquisition proposals that our shareholders may believe are in their best interest as shareholders. Some of these persons or entities may have interests that are different than those of our other shareholders. For example, because many of these shareholders purchased their ordinary shares at prices substantially below the price at which ADSs were sold in our initial public offering have held their ordinary shares for a longer period, they may be more interested in selling our company to an acquirer than other investors or they may want us to pursue strategies that deviate from the interests of other shareholders.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Because we have no present intention to pay dividends on our ordinary shares for the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be declared and paid. Therefore, we must have distributable profits before declaring and paying a dividend. We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs will be your sole source of gains for the foreseeable future, and you will suffer a loss on your investment if you are unable to sell your ADSs at or above the price at which you purchased them. Any recommendation by our board of directors to pay dividends will depend on many factors, including our financial condition (including losses carried forward), results of operations, legal requirements and other factors. We are unlikely to pay dividends or other distributions in the foreseeable future. If the price of our ADSs declines before we pay dividends, you will incur a loss on your investment, without the likelihood that this loss will be offset in part or at all by potential future cash dividends.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If securities or industry analysts do not continue to publish research or publish inaccurate research or unfavorable research about our business, the price of our ADSs and trading volume could decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The trading market of our ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have control over these analysts. If one or more of the analysts who covers us downgrades our ADSs or publishes incorrect or unfavorable research about our business, the price of our ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our ADSs could decrease, which could cause the price of our ADSs or trading volume to decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Holders of our ADSs will not have the same voting rights as the holders of our ordinary shares, and may not receive voting materials or any other documents that would need to be provided to our shareholders pursuant to English corporate law, including the UK Companies Act 2006, or Companies Act 2006, in time to be able to exercise their right to vote.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Except as described in the deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon our request, the depositary shall distribute to the holders as of the record date (i) the notice of the meeting or solicitation of consent or proxy sent by us and (ii) a statement as to the manner in which instructions may be given by the holders. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Otherwise, ADS holders will not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders may not know about the meeting far enough in advance to withdraw those ordinary shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. As a result, ADS holders may not be able to exercise their right to vote, and there may be nothing they can do if the ordinary shares underlying their ADSs are not voted as they requested or if their shares cannot be voted. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">101</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims of U.S. civil liabilities may not be enforceable against us.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Many members of our senior management and certain members of our board of directors are non-residents of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtain in U.S. courts against them or us based on civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The United States and the UK do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the UK. In addition, uncertainty exists as to whether the courts of England and Wales would entertain original actions brought in the UK against us or our directors or senior management predicated upon securities laws of the U.S. or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If the courts of England and Wales give a judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the courts of England and Wales discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a result, U.S. investors may not be able to enforce against us or certain of our directors any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may increase the risk of holding our ADSs. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our ADSs trade on the Nasdaq Global Select Market in U.S. dollars. Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may result in temporary differences between the value of our ADSs and the value of our ordinary shares, which may result in heavy trading by investors seeking to exploit such differences. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, as a result of fluctuations in the exchange rate between the U.S. dollar and the pound sterling, the U.S. dollar equivalent of the proceeds that a holder of ADSs would receive upon the sale in the UK of any ordinary shares withdrawn from the depositary and the U.S. dollar equivalent of any cash dividends paid in Euros on our ordinary shares represented by ADSs could also decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">102</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The deposit agreement governing our ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ADSs or the deposit agreement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and our ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or our ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our articles of association, or Articles, provide that the courts of England and Wales are the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act or the Exchange Act, and that the United States District Court for the Southern District of New York is the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act or the Exchange Act.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our Articles provide that, unless we consent by ordinary resolution to the selection of an alternative forum, the courts of England and Wales shall, to the fullest extent permitted by law, be the exclusive forum for: (a) any derivative action or proceeding brought on our behalf; (b) any action or proceeding asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us; (c) any action or proceeding asserting a claim arising out of any provision of the Companies Act 2006 or our Articles (as may be amended from time to time); or (d) any action or proceeding asserting a claim or otherwise related to our affairs, or the England and Wales Forum Provision. The England and Wales Forum Provision does not apply to any causes of action arising under the Securities Act or the Exchange Act. Our Articles further provide that unless we consent by ordinary resolution to the selection of an alternative forum, the United States District Court for the Southern District of New York is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act or the Exchange Act, or the U.S. Federal Forum Provision. In addition, our Articles provide that any person or entity purchasing or otherwise acquiring any interest in our shares is deemed to have notice of and consented to the England and Wales Forum Provision and the U.S. Federal Forum Provision; provided, however, that our shareholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">103</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The England and Wales Forum Provision and the U.S. Federal Forum Provision in our Articles may impose additional litigation costs on our shareholders in pursuing any such claims. Additionally, the forum selection clauses in our Articles may limit the ability of our shareholders to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts, including the courts of England and Wales and other courts within the United States, will enforce our U.S. Federal Forum Provision. If the U.S. Federal Forum Provision is found to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition. The U.S. Federal Forum Provision may also impose additional litigation costs on our shareholders who assert that the provision is not enforceable or invalid. The courts of England and Wales and the United States District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we were classified as a passive foreign investment company, it would result in adverse U.S. federal income tax consequences to U.S. holders. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Under the Code, we will be a passive foreign investment company, or PFIC, for any taxable year in which (i) 75% or more of our gross income consists of passive income or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable year during which a U.S. Holder (as defined below under &#8220;Taxation&#8212;Material U.S. Federal Income Tax Considerations for U.S. Holders&#8221;) holds our ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements. Based on the current and expected composition of our income and assets and the value of our assets, we believe that we were a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2022. However, no assurances regarding our PFIC status can be provided for the current taxable year or any future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by the spending of the cash we raise in any offering. Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences to it if we are or were to become a PFIC.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we are a controlled foreign corporation, there could be adverse U.S. federal income tax consequences to certain U.S. Holders</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation,&#8221; or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. In addition, if a non-U.S. corporation owns at least one U.S. subsidiary, under current law, any current non-U.S. subsidiaries and any future newly formed or acquired non-U.S. subsidiaries of the non-U.S. corporation will be treated as CFCs, regardless of whether the non-U.S. corporation is treated as a CFC. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for U.S. federal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">104</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of the value or total combined voting power of all classes of stock entitled to vote of such corporation. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Based on our review of beneficial ownership reports filed with the SEC, we do not believe that we were classified as a CFC for the 2022 taxable year. However, the determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. Failure to comply with CFC reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any Ten Percent Shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the CFC rules of the Code. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We have incurred and will continue to incur increased costs as a result of operating as an English-domiciled public company listed in the United States, and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As an English domiciled public company listed in the United States, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">requirements on foreign reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our board of directors, management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">regulations have increased and will continue to increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, each year in our annual reports on Form 10-K, we are required to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. However, we will not require an attestation report on internal control over financial reporting issued by our independent registered public accounting firm for so long as we do not qualify as an accelerated filer or large accelerated filer. In order to achieve and maintain compliance with Section 404, we have documented and evaluated our internal control over financial reporting, which is both costly and challenging. In this regard, we continue to dedicate internal resources, have engaged outside consultants and adopted a detailed work plan to continually assess and document the adequacy of internal control over financial reporting, taken steps to improve control processes as appropriate, validated through testing that controls are functioning as documented and have implemented a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk in any given year that we will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. Moreover, if in future years an attestation report on internal control over financial reporting issued by our independent registered public accounting firm may be required and if our independent registered public accounting firm were to be unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">105</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">the accuracy and completeness of our financial reports and the market price of our ADSs could be negatively affected, and we could become subject to investigations by the SEC or other regulatory authorities or to stockholder litigation, which could have an adverse impact on the market price or our ADSs and cause us to incur additional expenses.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our securities less attractive to investors.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We qualify as a &#8220;smaller reporting company,&#8221; because the market value of our stock held by non-affiliates was less than $560.0 million as of June 30, 2022, and our annual revenue was less than $100.0 million during the most recently completed fiscal year. We will reassess our status each year on the last business day of the second quarter and will continue to be a smaller reporting company until the fiscal year following the determination that (i) our voting and non-voting shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. As a smaller reporting company, we may take advantage of many of the same exemptions from disclosure requirements as an emerging growth company, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">You may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. federal courts may be limited, because we are incorporated under the laws of England and Wales, conduct most of our operations outside the United States and many members of our senior management and certain members of our board of directors reside outside the United States.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are incorporated and have our registered office in, and are currently existing under the laws of, England and Wales. In addition, most of our tangible assets are located, and many members of our senior management and certain of our directors reside, outside of the United States. As a result, it may not be possible to serve process within the United States on certain directors or us or to enforce judgments obtained in U.S. courts against such directors or us based on civil liability provisions of the securities laws of the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The United States and the UK do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the UK. In addition, uncertainty exists as to whether courts of England and Wales would entertain original actions brought in England and Wales against us or our directors or senior management predicated upon the securities laws of the U.S. or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is subject to determination by the court making such decision. If the courts of England and Wales give a judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the courts of England and Wales discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a result, U.S. investors may not be able to enforce against us or certain of our directors any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">106</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">As an English domiciled public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">English law provides that a board of directors may only allot shares (or grant rights to subscribe for or to convert any security into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and being valid for a maximum period of five years, each as specified in the articles of association or relevant ordinary resolution passed by shareholders at a general meeting. Such authority from our shareholders to allot additional shares for a period of five years from September 11, 2020 was included in the ordinary resolution passed by our shareholders on September 11, 2020, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, but not longer than the duration of the authority to allot shares to which this disapplication relates or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). Such authority from our shareholders to disapply preemptive rights for a period of five years was included in the special resolution passed by our shareholders on September 11, 2020, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">English law also generally prohibits a public company from repurchasing its own shares without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five years.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Shareholder protections found in provisions under the UK City Code on Takeovers and Mergers, or the Takeover Code, will not apply if our place of central management and control remains outside of the UK (or the Channel Islands or the Isle of Man). </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We believe that our place of central management and control is not currently in the UK (or the Channel Islands or the Isle of Man) for the purposes of the jurisdictional criteria of the Takeover Code. Accordingly, we believe that we are not currently subject to the Takeover Code and, as a result, our shareholders are not currently entitled to the benefit of certain takeover offer protections provided under the Takeover Code, including the rules regarding mandatory takeover bids.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> In the event that this changes, or if the interpretation and application of the Takeover Code by the Panel on Takeovers and Mergers, or Takeover Panel, changes (including changes to the way in which the Takeover Panel assesses the application of the Takeover Code to English companies whose shares are listed outside of the UK), the Takeover Code may apply to us in the future. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Takeover Code provides a framework within which takeovers of companies which are subject to the Takeover Code are regulated and conducted. The following is a brief summary of some of the most important rules of the Takeover Code:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">When any person acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares already held by that person and an interest in shares held or acquired by persons acting in concert with him or her) carry 30% or more of the voting rights of a company that is subject to the Takeover Code, that person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights in that company to acquire the balance of their interests in the company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">107</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">When any person who, together with persons acting in concert with him or her, is interested in shares representing not less than 30% but does not hold more than 50% of the voting rights of a company that is subject to the Takeover Code, and such person, or any person acting in concert with him or her, acquires an additional interest in shares which increases the percentage of shares carrying voting rights in which he or she is interested, then such person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights of that company to acquire the balance of their interests in the company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">A mandatory offer triggered in the circumstances described in the two paragraphs above must be in cash (or be accompanied by a cash alternative) and at not less than the highest price paid within the preceding 12 months to acquire any interest in shares in the company by the person required to make the offer or any person acting in concert with him or her.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">In relation to a voluntary offer (i.e., any offer which is not a mandatory offer), when interests in shares representing 10% or more of the shares of a class have been acquired for cash by an offeror (i.e., a bidder) and any person acting in concert with it in the offer period and the previous 12 months, the offer must be in cash or include a cash alternative for all shareholders of that class at not less than the highest price paid for any interest in shares of that class by the offeror and by any person acting in concert with it in that period. Further, if an offeror acquires for cash any interest in shares during the offer period, a cash alternative must be made available at not less than the highest price paid for any interest in the shares of that class.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">If, after making an offer for a company, the offeror or any person acting in concert with them acquires an interest in shares in an offeree company (i.e., a target) at a price higher than the value of the offer, the offer must be increased to not less than the highest price paid for the interest in shares so acquired.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">An offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of the offeree company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Special or favorable deals for selected shareholders are not permitted, except in certain circumstances where independent shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the offeree.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">All shareholders must be given the same information.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Each document published in connection with an offer by or on behalf of the offeror or offeree must state that the directors of the offeror or the offeree, as the case may be, accept responsibility for the information contained therein.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Profit forecasts, quantified financial benefits statements and asset valuations must be made to specified standards and must be reported on by professional advisers.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Misleading, inaccurate or unsubstantiated statements made in documents or to the media must be publicly corrected immediately.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Actions during the course of an offer by the offeree company, which might frustrate the offer are generally prohibited unless shareholders approve these plans. Frustrating actions would include, for example, lengthening the notice period for directors under their service contract or agreeing to sell off material parts of the target group. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Stringent requirements are laid down for the disclosure of dealings in relevant securities during an offer, including the prompt disclosure of positions and dealing in relevant securities by the parties to an offer and any person who is interested (directly or indirectly) in 1% or more of any class of relevant securities.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Employees of both the offeror and the offeree company and the trustees of the offeree company&#8217;s pension scheme must be informed about an offer. In addition, the offeree company&#8217;s employee representatives and pension scheme </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">108</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">trustees have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors&#8217; circular or published on a website. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are incorporated under the laws of England and Wales. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by the laws of England and Wales, including the provisions of the Companies Act 2006, and by our Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. See the information under the heading &#8220;Description of Share Capital and Articles of Association&#8212;Differences in Corporate Law&#8221; in our prospectus dated September 17, 2020, filed with the SEC pursuant to Rule 424(b), which information is incorporated herein by reference, for a description of the principal differences between the provisions of the Companies Act 2006 applicable to us and, for example, the Delaware General Corporation Law relating to shareholders&#8217; rights and protections.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The principal differences include the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Under English law and our Articles, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned. Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Under English law, it is only on a poll that the number of shares determines the number of votes a holder may cast. You should be aware, however, that the voting rights of ADSs are also governed by the provisions of a deposit agreement with our depositary bank. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Under English law and our Articles, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll of shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the Articles. This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors. Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve other significant transactions.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">In the UK, takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#8220;squeeze out&#8221; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares (including those represented by ADSs) will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware law. By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares (including those represented by ADSs) voting at the meeting for approval.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Under English law and our Articles, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">109</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The quorum requirement for a shareholders&#8217; meeting is one or more qualifying persons present at a meeting and between them holding (or being the proxy or corporate representative of the holders of) at least thirty-three and one-third percent (33 &#8531;%) in number of the issued shares (excluding any shares held as treasury shares) entitled to attend and vote on the business to be transacted. Under U.S. law, a majority of the shares eligible to vote must generally be present (in person or by proxy) at a shareholders&#8217; meeting in order to constitute a quorum. The minimum number of shares required for a quorum can be reduced pursuant to a provision in a company&#8217;s certificate of incorporation or bylaws, but typically not below one-third of the shares entitled to vote at the meeting.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Our Controls Over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, testing required to be conducted by us in connection with Section 404, and subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we fail to maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which could adversely impact our investors&#8217; confidence and our ADS price.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures and that we furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. We cannot assure you that we will not identify other material weaknesses or deficiencies, which could negatively impact our results of operations in future periods. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">More generally, if we are unable to meet the demands that have been placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results in future periods, or report them within the timeframes required by law or stock exchange regulations. Failure to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose confidence in our reported financial information. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Risks Related to the Ownership of Our ADSs&#8212;We have incurred and will continue to incur increased costs as a result of operating as an English public company listed in the United States, and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;  </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Even effective internal controls </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">110</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information, and the trading price of our stock may decline. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">General Risk Factors</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Exchange rate fluctuations may materially affect our results of operations and financial condition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Due to the international scope of our operations, our assets, earnings, expenses and cash flows are influenced by movements in exchange rates of several currencies, particularly the U.S. dollar, the Pound Sterling and the Euro. Our reporting currency is denominated in U.S. dollars and our functional currency is the U.S. dollar (except that the functional currency of our U.K. subsidiary is the Pound Sterling) and the majority of our operating expenses are paid in both Pound Sterling and U.S. dollars. We also regularly acquire services, consumables and materials in U.S. dollars, Pound Sterling and the Euro. Further potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and the price of our ADSs has been affected and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">may in the future be affected by fluctuations in foreign exchange rates between the Pound Sterling and these other currencies, which may also have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. See Note 2 in the notes to our condensed consolidated financial statements for a description of foreign exchange risks. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, the possible abandonment of the Euro by one or more members of the European Union, or the EU, could materially affect our business in the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the Euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the EU. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the abandonment of the Euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Unfavorable global economic conditions have in the past and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:133%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">could in the future adversely affect our business, financial condition or results of operations.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Our results of operations have in the past and could in the future be adversely affected by general conditions in the global economy and in the global financial markets. Key national economies, including the United States and UK, have been affected from time to time by economic downturns or recessions, supply chain constraints, heightened and fluctuating inflation and interest rates, restricted credit, poor liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies and overall uncertainty with respect to the economy. For example, while we do not have activities in Russia and Ukraine, the ongoing conflict and any further escalation of geopolitical tensions related to this conflict, including the imposition of sanctions by the United States and other countries, has and could result in, among other things, supply disruptions, fluctuations in foreign exchange rates and increased volatility in financial markets. In addition, U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the United States. Although U.S. lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, ratings agencies have lowered or threatened to lower the long-term sovereign credit rating on the United States. The impact of this or any further downgrades to the U.S. government&#8217;s sovereign credit rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions. Any of these disruptions could adversely affect our businesses, results of operations and financial condition. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A deterioration in the global economy and financial markets could result in a variety of risks to our business. In addition, due to the international scope of our operations, our financial condition is and will continue to be influenced by movements in exchange rates of several currencies because our functional currency for our wholly-owned U.K. operating subsidiary is the Pound Sterling, and we report our financial results in U.S. dollars. For example, inflation rates, particularly in the United States, have increased recently to levels not seen in many years. Increased inflation may result in further currency fluctuations, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">111</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks. In addition, increased interest rates or a general economic downturn or recession could reduce our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy, supply disruptions or international trade disputes could also strain our third-party suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current and future economic climate and financial market conditions could adversely impact our business. Moreover, there has been recent turmoil in the banking system with the appointment of the FDIC as a receiver for several U.S. banks. It is likely that, if the banking sector situation continues to deteriorate, the U.S. and/or other global economies would be adversely affected, including the possibility of a recession, the duration and severity of which is difficult to predict.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Even if market concerns about the financial health and stability of U.S. and global banking sectors are successfully addressed, many observers believe that the risk of a recession occurring in the United States, and perhaps in other major global economies, has increased because of the recent events in the banking sector.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Relatedly, these events may prompt the Federal Reserve Board and other central banking authorities to slow down the pace of future increases in benchmark interest rates, which could make it more difficult for the United States and other governments to mitigate inflationary pressures in the economy and contribute to a period of higher inflation. These developments may adversely affect our business, financial condition and results of operations. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Changes and uncertainties in the tax system in the countries in which we have operations could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We conduct business globally and file income tax returns in multiple jurisdictions. Our consolidated effective income tax rate could be materially adversely affected by several factors, including: changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms being implemented or under consideration (such as those related to the Organization for Economic Co-Operation and Development&#8217;s, or OECD, Base Erosion and Profit Shifting, or BEPS, Project, the European Commission&#8217;s state aid investigations and other initiatives); the practices of tax authorities in jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could increase the estimated tax liability that we have expensed to date and paid or accrued on our balance sheets, and otherwise affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders and increase the complexity, burden and cost of tax compliance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, His Majesty&#8217;s Revenue &amp; Customs, or HMRC, the IRS or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8216;&#8216;permanent establishment&#8217;&#8217; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. If we are assessed with additional taxes, this may result in a material adverse effect on our results of operations and/or financial condition. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">112</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher taxes than applicable law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable, or result in other liabilities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new therapies from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The ability of the FDA to review and approve new therapies can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Additionally, the COVID-19 pandemic and policies and regulations implemented by governments in response to the pandemic had significant impact on FDA operations, including postponement of FDA inspections and a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Because we are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, manufacture, handling, release and disposal of and the maintenance of a registry for, hazardous materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. Furthermore, if we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous materials and, as a result, may incur material liability as a result of such release or exposure. Environmental, health and safety laws and regulations are becoming more stringent. We may incur substantial expenses in connection with any current or future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">113</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">our financial condition and results of operations may be materially adversely affected. In the event of an accident involving such hazardous materials, an injured party may seek to hold us liable for damages that result.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general or prevent us from obtaining patents and thereby impair our ability to protect our investigational therapies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As is the case with other companies in our industry, our success is heavily dependent on our intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve technological and legal complexity. Therefore, obtaining and enforcing patents for therapeutics is costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, the America Invents Act, or the AIA, enacted in the United States in 2012 and 2013, has resulted in significant changes to the U.S. patent system. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Prior to the enactment of the AIA, assuming that other requirements for patentability are met, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 16, 2013, under the AIA, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention regardless of whether a third party was the first to invent the claimed invention. On or after that date, a third party that files a patent application in the USPTO before us could be awarded a patent covering an invention of ours even if we made the invention before the third party. The AIA will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide additional opportunities for third parties to challenge any pending patent application or issued patent in the USPTO. Such opportunities include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> review and derivation proceeding. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim in our patents invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, the United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our business is subject to economic, political, regulatory and other risks associated with international operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed by a variety of factors, including the following: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">economic weakness, including heightened and fluctuating inflation and interest rates, political instability, and the  emergence of any COVID-19 variants, any future public health crisis or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">any future mitigation efforts and current or future economic effects;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">114</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">differing regulatory requirements for drug approvals; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">differing jurisdictions potentially presenting different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">potentially reduced protection for intellectual property rights; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes in regulations and customs, tariffs and trade barriers; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes in currency exchange rates of the Euro, U.S. dollar, Pound Sterling and currency controls; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain international markets; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">negative consequences from changes in tax laws or practice; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States, United Kingdom and European Union; </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war, terrorism, pandemics, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber security or cyber security of our collaborators, vendors and other partners.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Given our reliance on technological infrastructure, we continue to evaluate internal security measures and policies. Our internal computer systems, which are managed partially by a third party, and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, pandemics and telecommunications and electrical failure. Any system failure, accident or security breach that causes interruptions in our own or in third-party service vendors&#8217; operations could result in a material disruption of our therapeutic development programs. In addition, our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. Cyber incidents have been increasing in sophistication and frequency and can include third parties gaining access to employee or clinical trial data using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks, ransomware, card skimming code, and other deliberate attacks and attempts to gain unauthorized access. Whilst we conduct periodic penetration testing and perform continuous security monitoring, as the techniques used by computer programmers who may attempt to penetrate and sabotage our network security or our website change frequently and may not be recognized until launched against a target, we may be unable to anticipate these techniques, and the costs to protect our network and systems may increase.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">115</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, it is also possible that unauthorized access to employee or clinical trial  data may be obtained through inadequate use of security controls by customers, suppliers or other vendors. While we continue to devote time and resources on the remediation of such risks, there is the possibility of a material impact from such an attack in the future.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">While we have not, to our knowledge, experienced any such material system failure or security breach that caused interruptions to our operations to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of COMP360 or any future therapeutic candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our investigational COMP360 psilocybin therapy or any future therapeutic candidates could be hindered or delayed. Furthermore, we may incur additional costs to remedy the damage caused by these disruptions or security breaches, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. Although we maintain cyber liability insurance, we cannot be certain that our coverage will be adequate for liabilities actually incurred or that insurance will continue to be available to us on economically reasonable terms, or at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">116</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="text-indent:18pt"><span><br/></span></div><div id="i132905a7c9654916bdd441350c765120_139"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the surrenders of our equity securities during the three months ended December 31, 2022:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.870%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Programs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 to January 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1 to February 28, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,277.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.61</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1 to March 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,277.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.61</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Represents ordinary shares surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of equity awards under our equity incentive plans.</span></div><div id="i132905a7c9654916bdd441350c765120_142"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div id="i132905a7c9654916bdd441350c765120_145"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div id="i132905a7c9654916bdd441350c765120_148"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i132905a7c9654916bdd441350c765120_151"></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">117</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="-sec-extract:summary;padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="-sec-extract:summary;margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The documents listed in the Exhibit Index of this Quarterly Report on Form 10-Q are incorporated by reference or are filed with this Quarterly Report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporation by reference</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule/Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1816590/000162828020013522/exhibit32f-1a1xformofa.htm">Articles of Association of COMPASS Pathways plc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form F-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-248484</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9/14/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1472033/000119380520001149/e619934_ex99-a.htm">Deposit Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form F-6/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-248514</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.(A)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9/17/2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form of American Depositary Receipt (included in exhibit 4.1).</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span id="i990cb17ae4c34d469e48f01f3746ea5b_5-2-1-1-150132"></span><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="foraresidentagreement.htm">License Agreement between Fora Space Limited and COMPASS Pathfinder Limited dated April 4, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q1x23xex311ceo302cert.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a), by Principal Executive Officer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q1x23xex311ceo302cert.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q1x23xex312cfo302cert.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a), by Principal Finance Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q1x23xex321ceoxcfosec.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer and Principal Financial Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">_________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">** &#160;&#160;&#160;&#160;The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">118</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="-sec-extract:summary;padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="i132905a7c9654916bdd441350c765120_154"></div><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934 the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMPASS PATHWAYS PLC</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2023</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kabir Nath</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kabir Nath</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2023</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Falvey</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Falvey</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="12" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">119</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:139%"> </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>foraresidentagreement.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>foraresidentagreement</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:964;"><!-- foraresidentagreement001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement001.jpg" title="slide1" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  Fora Space Limited (&#8220;Fora&#8221;)    Licence Agreement       Contract number:  007211                     Licensee details    Licensee Name Compass Pathfinder Limited Telephone +16469053974  Principal contact  name  Kabir Nath Email kabir.nath@compasspathways.com  Street   Mobile +16469053974  City  Company reg no. 10229259  Postal Code   Alternative Company  Identifier    Country       Licensee Invoicing address           Licensor  details     Name accounts payable  Company  Name  Fora Space Limited  Street   Registered  office address  (Street)  89 Wardour Street  City  City London  Postcode  Postcode W1F 0UB  Country   Country of  Incorporation  UK  Email accountspayable@compasspathways.com Email luke@foraspace.com    Product description                 First month&#8217;s fees    Deposit &pound;156,000.00     First month fee (pro rata) &pound;130,000.00    Additional charges &pound;0.00  Total ex. VAT &pound;286,000.00      Product Type  Number of Desks Total Fee PCM  Open Desks 0 &pound;0.00  Owned Desks 0 &pound;0.00  Owned Office  Desks  99 &pound;130,000.00  Total 99 &pound;130,000  Access Limit 99    Number of  Passes  124    Commencement  Date   01/09/2023  Earliest End  Date  01/09/2025     Initial term    24  Home Building Soho  Home Building  Address  33 Broadwick Street, W1F 0DQ  Initial Office  Space  2nd Floor  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F 3rd Floor 1 Ashley Road UK 3rd Floor 1 Ashley Road Altrincham Altrincham WA14 2DT WA14 2DT UK </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement002.jpg" title="slide2" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  Execution                                                                                      \i2\        For and on behalf of the Licensor: For and on behalf of the Licensee:  Name: \n3\    Title: \t3\    Date: \d3\    Signature:                                        \s3\    Name: \n1\     Title: \t1\    Date: \d1\    Signature:                                                                    \s1\        Services and Payment Schedule    Monthly Licence Fee (excl VAT) &pound;130,000.00  Period Licence Fee excl VAT   01/09/2023 - 31/08/2025 &pound;130,000.00                    Monthly Service Fee (excl VAT)   Service         DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F Kabir Nath March 31, 2023 | 11:54 EDT CEO Luke Parkinson Portfolio Manager April 4, 2023 | 15:16 BST </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement003.jpg" title="slide3" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  General Terms and Conditions   1.  Definitions &amp; Interpretation  1.1. In this Agreement, the following words and phrases shall have the following meanings:  &#8220;Access Limit&#8221; means the number of persons per day stated on page 1 of this Agreement;  &#8220;Additional Charges&#8221; means any fees (together with any VAT payable thereon) payable by you to us in respect of additional goods,  services or amenities delivered to you other than the Services, including without limitation (i) Bookings; (ii) use of photocopying  facilities; car parking facilities (where the same is not provided by way of separate licence); (iii) postage charges; (iv) catering  services; (v) excess usage charges; and (vi) any other services provided to you in any FORA Building;  &#8220;Agreement&#8221; means this agreement, incorporating the scheduled information on pages 1 and 2, these terms and conditions, any  addendum to this Agreement and the House Rules;  &#8220;Bookings&#8221; means ad hoc meeting room bookings in any FORA Building made by you in accordance with the House Rules;  &#8220;Building&#8221; means a building within the Portfolio where you may access Services pursuant to this Agreement;  &#8220;Business Day&#8221; means a day (other than a Saturday, Sunday or a public holiday) in England and Wales;  &#8220;Commencement Date&#8221; means the start date on which the services shall commence as stated on page 1 of this Agreement;  &#8220;Common Areas&#8221; means, in any Building, the Co-working Areas, Lounge Areas, Meeting Rooms, reception areas, kitchens, cafes  and restaurants, gyms, gardens, terraces, toilets, corridors, staircases, landings and any other designated communal areas or  facilities;  &quot;Co-working Areas&quot; means space at any of our Buildings designated by us as a shared co-working area from time to time;  &#8220;Deposit&#8221; means the deposit amount specified on page 1 of this Agreement and any additional deposit required under this  Agreement under clause 6;  &#8220;Earliest End Date&#8221; means the earliest end date stated on page 1 of this Agreement;  &#8220;Eligible User&#8221; means you or your employees as notified in accordance with clause 4.1.3;  &#8220;Eligible Users List&#8221; has the meaning given in clause 4.1.3;  &#8220;Equipment&#8221; means any computer, server, desktop, laptop, television, mobile internet device or other IT or telephony equipment,  such as handsets or headsets, owned, used or provided by you and brought into a Building;  &#8220;Force Majeure Event&#8221; means the occurrence of circumstances beyond our reasonable control, including, but not limited to, acts  of God, fire, lightning, flood, severe weather, terrorism, explosion, civil unrest, war, disorder, epidemic, pandemic, industrial  disputes (whether or not involving our employees) network failures, any computer virus, hacking or malfunction, change of law,  acts of local or central government or other authorities, breakdown of any equipment, or default of any suppliers, subcontractors,  utility service or transport network;  &#8220;Group Company&#8221; means in relation to any company, any other company within the same group of companies as that company  within the meaning of section 42 of the Landlord and Tenant Act 1954, as well as any parent company or subsidiary of a group  company and &#8220;Group&#8221; shall be construed accordingly;  &#8220;Home Building&#8221; means the Building identified on page 1 of this Agreement;  &#8220;House Rules&#8221; means the guidelines and policies relating to the fair and reasonable usage of the Services, as stated on the FORA  website https://www.foraspace.com/houserules and as may be amended by FORA (acting reasonably) from time to time,  &quot;Insolvent&quot; means in respect of any party, any corporate action, application, order, proceeding or appointment or other step is  taken or made by or in respect of a party for any composition, compromise or arrangement with its creditors generally, any  restructuring plan, any moratorium, its winding-up (other than for the purpose of a bona fide scheme of solvent reconstruction  or amalgamation), dissolution, administration, receivership (administrative or otherwise) or bankruptcy, or if it is unable to pay  its debts as they fall due, or if it ceases to trade or if a distress, execution or other legal process is levied against any of its assets  which is not discharged or paid out in full within three Business Days or if any event analogous to any of the foregoing shall occur  in any jurisdiction in which that party is incorporated, resident or carries on business;  &#8220;IT &amp; Telephony Services&#8221; means the IT and telephony services as described on page 2 of this Agreement and to be provided to  you in accordance with the House Rules;  &#8220;Licence&#8221; means the licence to occupy granted to you pursuant to clause 2.1;  &#8220;Licence Fee&#8221; means the licence fee (together with any VAT thereon) payable by you to us in consideration of the Services, as  specified in the payment schedule on page 2 of this Agreement;  &#8220;Licensor&#8221; means we, us, or &#8220;FORA&#8221; as more specifically referred to on page 1 of this Agreement;  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement004.jpg" title="slide4" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  &#8220;Licensee&#8221; or &#8220;you&#8221; means you, as more specifically referred to on page 1 of this Agreement;  &quot;Lounge Areas&quot; means space at any of our Buildings, as designated by us as a lounge from time to time;  &#8220;Meeting Rooms&#8221; means any meeting rooms in any of our Buildings as designated by us as a meeting room from time to time;  &#8220;Member&#8221; means any FORA client or their employee who has the right to access and use services or facilities at any Building;   &#8220;Office Space&#8221; means that part of your Home Building licensed to you and identified on page 1 of this Agreement or any alternative  office space that may be licensed to you pursuant to clause 10;  &#8220;Portfolio&#8221; means, collectively properties within the FORA offering, from time to time;  &#8220;Product&#8221; means the product as stated on page 1;  &quot;Sanctioned Country&quot; means a country or territory that is, or whose government is the target of Sanctions broadly prohibiting  dealings with each government, country or territory.  &quot;Sanctioning Authority&quot; means each and any of: (a) the United Nations; (b) the United States of America; (c) the European Union;  (d) the French Republic; (e) the United Kingdom; (f) the governments or institutions or agencies of any of the entities listed in (a)  to (e) above, including the United Nations Security Council, OFAC, the US Department of State, the Council of the European Union  and Her Majesty's Treasury through OFSI or any other relevant sanctioning authority.  &quot;Sanctions&quot; means:  (a) any law or regulation of any applicable jurisdiction relating to terrorism or money laundering administered, enacted, or  enforced by a Sanctioning Authority;  (b) any regulation or measure of a Sanctioning Authority which:  i. restricts the export of goods (whether directly or indirectly) to or the rendering of services in a country; or  ii. imposes other economic or financial sanctions, trade embargoes or restrictive measures on a country or;  (c) any other economic or financial sanctions, trade embargoes or restrictive measures administered, enacted or enforced from  time to time by any Sanctioning Authority or any other law or regulations promulgated under or based under the authorities or  any of the foregoing.  &quot;Sanctions List&quot; means any of the lists of specifically designated nationals or designated persons or entities (or equivalent) held  by any Sanctioning Authority, each as amended, supplemented or substituted from time to time.  &quot;Sanctions Restricted Person&quot; means any person or entity:  (a) that is listed on (or owned, controlled by or acting for or on behalf of any person listed on), any Sanctions List;  (b) that is located in or incorporated under the laws of any Sanctioned Country (including, without limitation, the government or  any state organ of any Sanctioned Country); or  (c) that is otherwise the subject of any Sanctions; or  (d) that is, to the best of our knowledge and belief, acting or purporting to act on behalf of any of the persons listed in paragraphs  (a), (b) and (c) above.  &#8220;Schedule of Condition&#8221; means a schedule of condition evidencing state and condition of the Office Space at the commencement  of this Agreement, including an inventory detailing our fixtures (including walls and carpets), fittings, equipment and effects in the  Office Space at the Commencement Date, their general condition and the general condition of the Office Space as a whole, in a  form agreed by the parties;  &#8220;Services&#8221; means each of:   (a) the grant of the Licence; and   (b) access to WiFi;  (c) access to lounge and common areas of the Portfolio;  (d) access to meeting rooms;  (e) access to utilities within the Buildings;  (f) reception services;  (g) cleaning services;   (h) security services;  (i) access to Member events and promotions;  (j) maintenance of the Buildings, the Office Space (if applicable) and any common areas and lounge areas;   (k) coffee and tea making facilities offered in lounge areas;  (l) the IT &amp; Telephony Services,  &#8220;Term&#8221; means the period from the Commencement Date until the Termination Date;  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement005.jpg" title="slide5" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  &#8220;Termination Date&#8221; means the date on which this Agreement shall end, in accordance with clause 11;  and  &#8220;VAT&#8221; means value added tax charged in accordance with the Value Added Tax Act 1994.  1.2. In this Agreement:  1.2.1 references to &#8220;the Licensor&#8221;, &quot;we&quot;, &#8220;our&#8221; and &quot;us&quot; shall be deemed to include references to us as agents for any owners  or  managers of the FORA Buildings providing the Services, and any of our Group Companies or any associated company;  1.2.2 references to &#8220;the Licensee&#8221;, &quot;you&#8221; or &#8220;your&#8221; shall be deemed to include, where the context requires, your employees and  any permitted lawful guests but shall not include any of your Group Companies or any associated company;  1.2.3 the headings in this Agreement are included for convenience only and shall not affect its interpretation;  1.2.4 references to the singular shall include the plural and vice versa and the masculine shall include the feminine and vice versa;  1.2.5 references to clause numbers, paragraphs and schedules shall be to those of this Agreement unless the contrary is stated;  1.2.6 references to 'include' or 'including' in this Agreement shall be treated as being by way of example and shall not limit the  general applicability of any preceding words;  1.2.7 references to persons includes any individual, firm or company or group of persons or unincorporated body;  1.2.8 references to &quot;writing&quot; shall include, without limitation, email; and  1.2.9 an obligation on you not to do something includes an obligation not knowingly to cause or allow that thing to be done.  2.   Licence to Occupy  2.1 Subject to payment of the Licence Fee when due and complying with your obligations under this Agreement, we hereby grant  you a licence to occupy:  2.1.1 the Office Space; and   2.1.2 the Common Areas and Lounge Areas.  3. Our Obligations  3.1 We will use our reasonable endeavours to:  3.1.1  deliver the Services to you;   3.1.2 keep the Common Areas clean, tidy, in reasonable order and well lit;  3.1.3 provide an adequate supply of hot and cold water and heating;  3.1.4 keep the service media, the lifts and other infrastructure at our Buildings in reasonable working order.  4.  Your Obligations  4.1 You acknowledge that: 4.1 You acknowledge that:  4.1.1  the Licence and any other rights granted to you pursuant to this Agreement are personal to you and cannot be assigned,  or transferred (temporarily or otherwise) to any other person;  4.1.2 You will be allocated up to the Number of Access Passes specified on page 1 of this Agreement.   4.1.3 only Eligible Users shall be entitled to access the Buildings and use the Services under this Agreement. A list of all Eligible  Users must be submitted to FORA prior to the Commencement Date (the &#8220;Eligible Users List&#8221;). You are responsible for maintaining  the accuracy of the Eligible Users List and any changes shall be subject to prior written notice to FORA.   Should you activate more  passes per day across the portfolio than your Access Limit, you will incur an additional charge of &pound;40 plus VAT per access (or &pound;25  per day plus VAT per access for any Building outside of London), which will be recovered from you as an Additional Charge.  If you  require more/replacement Access Passes, subject to FORA&#8217;s discretion as to whether these are issued, any additional/replacement  Access Passes will incur a one-off administration fee of &pound;20 plus VAT per pass.    4.1.4  you shall at all times be wholly responsible for the actions or omissions of any of your Eligible Users, any of your guests or  any other party to whom you permit entry into a Building.  4.1.5 no interest in land or tenancy is created between you and us as a result of the grant of the Licence;  4.1.6  we retain control, possession and management of the Building and you shall have no right to exclude us from any part of  any Building at any time whatsoever and you shall have no right to market or deal with any part of any Building;  4.1.7  when accessing the Office space, we will always endeavour to: (a) except in case of emergency, consult with you regarding  an appropriate time, and arrange for access to take place outside of working hours where reasonably practicable (b) ensure that  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement006.jpg" title="slide6" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  we cause no unreasonable disruption and (c) respect any of your reasonable security procedures to protect the confidentiality of  your business;   4.1.8  our standard operating hours for mechanical services (heating, cooling and fresh air supply) are 7 am to 7 pm Monday to  Friday (excluding public holidays);   4.1.9 your guests shall only be permitted to access meeting rooms, Common Areas and Lounge Areas and solely for the purpose  of conducting meetings;  4.1.10 all Eligible Users shall be issued with an access card for your Home Building.  We may refuse entry to any person (including  Eligible Users) who fail to produce a valid access card. Eligible Users may not share, duplicate or distribute access cards and a  replacement fee will be charged for any that are lost or damaged;  4.1.11 we shall be entitled to suspend the delivery of any of the Services to you (including denying you access to any Building),  without prejudice to any of our other rights under this Agreement, if you are in breach of any terms of this Agreement and for the  duration that such breach subsists. You acknowledge that in the event you are suspended from the FORA Building under this  clause 4.1.11, your payment obligations under this Agreement will continue for the period of such suspension;  4.1.12 we are not responsible for any property that you leave unattended in any of our Buildings. Items left unattended , may be  removed and either stored or destroyed at our discretion and you waive all claims or demands regarding left property; and  4.1.13 it is your sole responsibility to determine whether your Office Space (if applicable) meets the needs of your business and  is suitable for the purposes for which it is used.    5  Fees, Charges and VAT  5.1 In consideration of the grant of the Licence and the delivery of the Services to you, you shall pay the Licence Fee to us in  accordance with the terms of this Agreement.  5.2 The first payment of the Licence Fee shall be the amount specified on page 1 of this Agreement. This amount shall be payable  by you to us on or before the Commencement Date.  5.3 The Licence Fee and any Additional Charges shall be payable by BACS direct debit to an account held by FORA or a FORA Group  Company, unless agreed otherwise by the parties in writing. We may at any time, with reasonable prior written notice, request  that your direct debit mandate be cancelled and set up with a different FORA Group company.  5.4 The Licence Fee (other than the first payment referred to in clause 5.2 above) shall be payable by you in advance within four  days of receipt of an invoice from us each month. We issue invoices for the Licence Fee on or around the first day of the month.   5.5 We shall notify you of any Additional Charges incurred by you on or around the first Business Day of the month following the  month in which the Additional Charges were incurred, and you shall pay any such Additional Charges in arrears on or before the  5th day of that month.  5.6 You will pay us interest at the statutory rate of interest on all sums payable under this Agreement which remain unpaid for 7  days from the due date of such payment, such interest being calculated from the due date for payment to the date of payment  both after as well as before any judgment.  5.7 All amounts referred to in this agreement are:  5.7.1 exclusive of VAT, save where expressly stated otherwise; and  5.7.2 subject to VAT where applicable.  5.8 All payments to be made by you under this Agreement shall be made free and clear of and without any deduction or set-off.  5.9 You agree that the Services are provided to you in the United Kingdom and that we are not providing any Services to you  outside of the United Kingdom.  To the extent that you are incorporated outside the United Kingdom or conduct any business  operations outside the United Kingdom, you accept that Licence Fees are payable without deduction or withholding on account  of any taxation which might be applicable to Services provided outside of the United Kingdom.  6.  Deposit  6.1 You shall pay the Deposit to us immediately upon signing this Agreement as security for your obligations under this Agreement.  You shall ensure that all title in any cash paid by way of the Deposit shall vest absolutely in us (free of third party interests). No  charge is intended to be created over any such Deposit unless agreed by you and us in writing.  6.2 If at any time you cancel a pre-agreed direct debit mandate you have set up with us, you shall immediately pay us a deposit  top up, in an amount equal to 1 month&#8217;s Licence Fee including VAT (where applicable), and the value of the Deposit will be deemed  to have been amended accordingly.  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement007.jpg" title="slide7" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  6.3 We shall be entitled at any time to deduct from the Deposit an amount equal to any loss or damage we incur as a result of  your failure to perform or observe your obligations under this Agreement, including a failure to pay the Licence Fee. If you become  Insolvent, this right will remain unaffected and we shall be entitled to draw down from the Deposit any pre-existing losses and  any such losses that may arise as a result of you becoming Insolvent and this action will not constitute a breach of our statutory  obligations nor require the consent of any administrator, liquidator or insolvency practitioner.  6.4 If any deductions are made by us from the Deposit, you shall replace any such sum deducted within 10 Business Days of  demand from us.  6.5 Subject to there being no subsisting breach by you of this Agreement, we shall return the balance of the Deposit to you within  30 Business Days of the Termination Date.  6.6 The payment of the Deposit under this clause 6 shall not affect our rights to demand payment at any time of any amounts due  under this Agreement.  6.7  You will have no right to offset the Deposit held by us against outstanding amounts due from you.  6.8 We reserve the right at any time to require a reasonable increase to the Deposit amount if:  6.8.1  you fail to pay and amounts owing under this Agreement by way of agreed Direct Debit;  6.8.2  you cancel or you fail to notify us of a change in your Direct Debt instruction;  6.8.3  there has been a proper deduction from the Deposit already held by us; or  6.8.4 the circumstances relating to the services delivered to you otherwise reasonably require us to take such action, including  but not limited to, you taking or transferring to a new space that is larger or of higher quality.    7  Your obligations  7.1 You will access and use the Buildings and the Services at all times in compliance with:  7.1.1 the terms of this Agreement (including, for the avoidance of doubt, the House Rules) and any other rules we may reasonably  require you to observe from time to time; and  7.1.2 all rights, regulations, restrictions and covenants affecting your Home Building and any other Building that you access  pursuant to this Agreement.  7.2 You agree:  7.2.1 to only access the Buildings and use the Services for the purpose of office use and other reasonably ancillary purposes;  7.2.2 not to make any alteration or addition to the Office Space or any FORA Building whatsoever other than with our prior written  consent (which may be withheld in our absolute discretion), and with contractors appointed by us;  7.2.3 not to apply for any planning permission in respect of any Building nor to object to any planning application made by us;  7.2.4 not do anything that will or might constitute a breach of any applicable consents affecting any Building or which will or might  invalidate in whole or in part any insurance effected by us in respect of any  Building from time to time;  7.2.5 to comply with the reasonable requirements and recommendations of the insurers of any Building from time to time, which  have been notified to you;  7.2.6 to comply with all laws and regulations that in any way relate to your use of any Building, including in respect of health and  safety, that might be enacted from time to time, and to comply with our reasonable requests in respect of any Building&#8217;s  compliance with applicable laws and regulations from time to time;  7.2.7 to comply with any reasonable requirements or recommendations of our suppliers and providers relating to the supply of  electricity, gas, water, sewage, telecommunications and data and other services and utilities to or from any Building and/or Office  Space;  7.2.8 not to block any fire exit, corridor or other route of entry or access either in any Building, nor to block accesses to any  mechanical services requiring maintenance, service risers or landlord cupboards housed within your office demise;  7.2.9 not to damage or indirectly cause damage to any Building;  7.2.10 not to do anything which may be or become illegal, be disreputable or cause a nuisance, annoyance, disturbance,  inconvenience, injury or damage to us, our employees or the other occupiers of the Buildings or adjacent or neighbouring  premises;  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement008.jpg" title="slide8" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  7.2.11 not to take, copy or use any information or intellectual property belonging us or to other Members or their guests, agents  or invitees without their prior consent. This includes, without limitation, personal names, likenesses, business names, trademarks,  logos or any other intellectual property whatsoever;  7.2.12 not to employ or solicit employment to, in any capacity, directly or indirectly, any of our employees during the Term and  for six months thereafter provided that if this clause is breached, you agree to pay to us the sum equivalent to one year&#8217;s salary  of the employee in question (such amount being agreed by the parties as being a reasonable estimate of damages);  7.2.13 not to do anything or carry on any business or activity that may damage the goodwill or reputation of FORA any  Building  or the business; and  7.2.14 not to invite into any Building any 3rd party service provider for the purposes of delivering services to you or in respect of  the building without our prior written consent (including, for the avoidance of doubt, any cleaning contractor, IT services provider,  security provider, or tradesperson);  7.2.15 to comply with the health and safety at work act 1974 at all times, including the undertaking of an annual fire risk  assessment for your Office Space only and to provide a copy of such annual fire risk assessment to us within 2 Business Days&#8217;  of  written demand;  7.2.16 not to interfere with or restrict the supply of mechanical and engineering services, (such as the covering of air vents);  7.2.17 not to instruct or undertake (a) intrusive 3rd party risk assessments or surveys of the Office Space or (b) non intrusive or  intrusive 3rd party risk assessments or surveys relating to the condition of the Building outside of the Office without our consent  (such consent not to be unreasonably withheld);  7.2.18 to comply with the reasonable recommendations of our 3rd party risk assessors which may be notified to you from time to  time in writing;   7.2.19 only to use your Home Building or any other Building&#8217;s address for postal services in respect of the Licensee entity specified  on page 1 of this Agreement, unless otherwise agreed with us. You acknowledge that you will be liable for a reasonable charge  per company receiving post) in the event of a breach of this clause 7.2.20;  7.2.20 that as an occupier of non-domestic space in the UK you are considered liable for business rates and applicable taxes on  the Office Space occupied by you in a Building, however, you further acknowledge that the Licence Fee is inclusive of business  rates, calculated after any reliefs or rebates for which your occupation may be entitled. You hereby appoint us in perpetuity to  manage and pay the business rates and/or recover any rebates or reliefs due, in respect of the Office Space (if applicable). We  agree to pay the cost of any unexpected increases to this liability from external factors and is conversely entitled to any rates  reductions secured on the Office Space. To ensure we pay no more than the correct liability associated with your occupation, if  requested by us, you will provide any reasonable information we request and you agree to sign any relevant documentation in  regards to business rates within 5 days of a request from us. You agree to forward all correspondence you receive, in respect of  business rates, to FORA, within 2 working days of receipt.  8.  Our rights  We reserve the right to:  8.1 re-develop, refurbish, redecorate, repair, maintain and/or otherwise alter or make additions to any part of the Buildings,  including the Common areas but excluding the Office Space from time to time without requiring your consent;  8.2 when accessing the Office space, we will always endeavour to: (a) except in case of emergency, consult with you regarding an  appropriate time, and arrange for access to take place outside of working hours where reasonably practicable (b) ensure that we  cause no unreasonable disruption and (c) respect any of your reasonable security procedures to protect the confidentiality of your  business;  8.3 disconnect any Equipment and/or withhold Services if, in our opinion, we believe that:  8.3.1  your Equipment, hardware or software, or use thereof, is damaging or potentially damaging to our property, any Building  or our IT infrastructure; or  8.3.2  the Services are being used by you for an unauthorised, immoral or illegal purpose or in an inappropriate or excessive  manner; and  8.4  assign, transfer, subcontract or deal in any other way with any of our rights under this Agreement and our proprietary  rights to any Building, and you acknowledge that we may novate any of our obligations under this Agreement to any third party  or agent without your consent.  9 IT &amp; Telephony Services  You shall comply with the provisions of the House Rules in respect of the IT &amp; Telephony Services.  10.  Alternative Office Space  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement009.jpg" title="slide9" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  10.1 Without prejudice to our rights under this Agreement, you acknowledge that we may require you to transfer to alternative  Office Space:  10.1.2  elsewhere within your Home Building provided that we will give at least four weeks&#8217; prior notice to you and alternative  office space is vacant and available in that building; or  10.1.3  in another Building within the Portfolio provided that we will give you at least four weeks&#8217; prior notice of such move.  10.2 In either of the circumstances referred to in clause 10.1 above, we will ensure that (a) we consult with you regarding the  alternative office space and (b) the alternative office space is of a reasonably equivalent size and quality to the Office Space or  greater.  10.3 If pursuant to clause 10.1.3, alternative office space in the Portfolio is not available within your Home Building&#8217;s  neighbourhood (or in any event, within a 2 mile radius), then we may serve written notice to Terminate this Agreement on no less  than 2 months&#8217; prior written notice.  11 Termination  11.1 This Agreement shall (subject to clause 11.5) continue until the Earliest End Date, and shall continue thereafter unless and  until terminated on the Earliest End Date or at the end of any calendar month thereafter by not less than 3 months&#8217; prior written  notice if you have an Owned Office or 1 months&#8217; prior notice if you hold any other product given by you or us. Any termination  notice served pursuant to this clause 11.1 must be drafted in the following format:  We hereby give notice of our intention to terminate this agreement on [DATE], in accordance with clause 11 of the Licence  Agreement dated [DATE] between FORA and [YOU].  11.2 YOU ACKNOWLEDGE THAT THIS IS NOT A FIXED-TERM AGREEMENT. IF THIS AGREEMENT IS NOT TERMINATED IN  ACCORDANCE WITH THIS CLAUSE 11 AND NO RENEWAL AGREEMENT IS ENTERED INTO, THIS AGREEMENT SHALL CONTINUE IN  FULL FORCE AND EFFECT.  11.3 Before the Earliest End Date we may elect (in our absolute discretion) to send you a draft renewal agreement setting out  proposed terms (including any adjustment to the Licence Fee or the Deposit) from the Earliest End Date.  11.4 If this Agreement continues after the Earliest End Date and no renewal agreement is entered into on or before the anniversary  of the Earliest End Date, the Licence Fee shall automatically increase by 15% on the Earliest End Date, and again on each  anniversary of the Earliest End Date until such date that a renewal agreement is entered into or this Agreement is terminated in  accordance with this clause 11.  11.5 We may immediately terminate this Agreement (and your consequent right to use the Office Space and the Ancillary Services)  at any time by notice in writing to you if:  11.5.1  your Office Space (if applicable) or your Home Building are no longer available due to circumstances beyond our reasonable  control;  11.5.2  you fail to pay an invoice pursuant to this Agreement within 14 days of the due date for payment stated on such invoice;   11.5.3 you are in material or persistent breach of any of your obligations under this Agreement or any other agreement which  you hold with us;  11.5.4 you become Insolvent; or  11.5.5  you are in breach of clause 19 of this Agreement,  and, in respect of clauses 11.5.3 and 11.5.5 you fail to remedy such breach within 5 business day of being notified of such breach.  11.6 On termination of this Agreement for any reason:  11.6.1 other than in the case of termination pursuant to clause 11.5.1, we shall be entitled to charge you for any Licence Fees that  would have been payable by you until the Earliest End Date;  11.6.2  you shall immediately pay to us any outstanding amounts payable to us under this Agreement together with any applicable  interest;  11.6.3  you shall immediately leave the Office Space and any Building, and you shall remove all your personal goods and items,  and you agree that any items left on our premises following the Termination Date shall be deemed abandoned and shall be  disposed of (in our absolute discretion) at your cost;  11.6.4  you shall immediately return any materials or equipment in your possession or under your control which belong to or were  supplied by us;  11.6.5  you shall comply with the provisions of clause 11.9 (dilapidations).   11.6.6 your rights to access to the Services and any Building shall immediately cease; and  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement010.jpg" title="slide10" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  11.6.7 you shall comply with the provisions relating to termination contained in the House Rules.  11.7  The accrued rights, remedies, obligations and liabilities of you or us at expiry or termination shall be unaffected, including  the right to claim damages in respect of any prior breach of this Agreement.  11.8. You waive any claims or demands regarding any property abandoned at our Buildings or our handling of them. You indemnify  us for the costs of disposing of such items and we will be entitled to deduct such sums from the Deposit.  11.9       Dilapidations  11.9.1   On expiry or termination of this Agreement, we shall charge you a reasonable dilapidations fee, which shall be used to  return the Office Space to the same condition as it was on the Commencement Date or to a condition consistent with the Schedule  of Condition (if applicable) but subject to fair wear and tear. For the avoidance of doubt, the dilapidations fee shall at a minimum  include a deep clean and repaint of the Office Space. If this agreement is terminated pursuant to clause 11.1, the dilapidations fee  shall be invoiced to you no later than 30 days before the date of termination and will be due and payable on or before the date of  termination. Where this agreement is terminated for any other reason, the dilapidations fee will be invoiced to you as soon as  reasonably practicable following the termination date and shall fall due immediately.     11.9.2    The dilapidations fee shall include a charge for removing any alterations that have been installed in your Office Space at  your request, and reinstating the Office Space to its original condition, provided that this clause 11.8.2 is subject to any other  express agreement between the parties in respect of alterations.  11.9.2    The dilapidations charge shall also include costs for any lost or damaged property owned by FORA (including, but not  limited to office furniture, keys, and access passes).   11.9.3    You acknowledge and agree that the dilapidations charge shall be calculated on the basis of FORA completing the works  itself and using its own contractors.   11.9.4    In the event of a dispute between the parties regarding the dilapidations fee, FORA shall be entitled (in its own discretion)  to appoint an independent surveyor to verify the dilapidations fee, and in this respect the parties shall share the cost of such  appointment equally.   11.9.5    You acknowledge that FORA is entitled to retain title to any alterations made to the Office Space at your request on expiry  or termination of this agreement, and that FORA may choose to retain or repurposes any such alterations in its absolute discretion.  12  Damage  12.1. You are responsible for the Office Space and its state and condition for the duration of the Term. Any damage to the Office  Space or any Building or their contents or equipment incurred as a result of your action or omission (or those of your employees  or visitors) will result in a charge to you based on the cost of replacement of such item and/or any subsequent loss of business or  trade or other commercial activity suffered by us.  12.2. You agree to indemnify us against all losses, claims, demands, actions, proceedings, damages, costs, expenses or other  liability in any way arising from any breach of your obligations and/or the exercise of any rights given in this Agreement.  13  Limitation of liability  13.1 To the extent permitted by law, the liability of FORA, its employees, affiliates, sub-contractors, suppliers or other  representatives (together, the &#8220;FORA Parties&#8221;) under or in connection with this Agreement, shall be limited in aggregate to an  amount equal to the Licence Fees paid by you in the twelve (12) months prior to any liability arising.  13.2 The restrictions on our liability under this clause 13 apply to every liability arising under or in connection with this Agreement,  including without limitation, contract, tort (including negligence), misrepresentation, repudiation, statutory duty, renunciation or  other breach of contract, restitution or otherwise and whether arising under any indemnity, whether caused by any total or partial  failure or delay in supply of the Services, and whether deliberate (but not in bad faith) or otherwise, however fundamental the  result.  13.3 Notwithstanding any other provision of this Agreement, we shall have no liability however caused whether suffered by you  or any third party for:  13.3.1 damage, loss, or theft of personal or business belongings;  13.3.2 direct or indirect loss of or damage to use, profits, revenue, business, contracts, opportunities, goodwill, anticipated  savings, data, information  or corruption of software;  13.3.3 indirect, special or consequential loss; or  13.3.4 any third party claims.  13.4 Nothing in this Agreement shall limit or exclude our or your liability for:  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement011.jpg" title="slide11" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  13.4.1  death or personal injury caused by negligence, or the negligence of any of our or your employees, agents or subcontractors;  or  13.4.2  fraud or fraudulent misrepresentation.  13.5 You acknowledge that we are not liable for the actions of any Member and if a dispute arises between Members, we have  no responsibility or obligation to participate in the dispute or indemnify any party to it.  13.6 This clause 13 shall survive termination of this Agreement.  14 Force Majeure  14.1 We shall not be liable for any breach of this Agreement, any failure in performing our obligations under this Agreement or  any losses resulting therefrom caused by a Force Majeure Event.  14.2 We will be entitled in our sole discretion to reasonably interrupt or withdraw or cease to provide the Services at any time in  order to respond to, carry out maintenance, repairs and/or support services in respect of any Force Majeure Event.  15  Insurance  15.1 We, or where applicable, our landlord or superior landlord, shall insure the Buildings against loss or damage by all risks that  we consider prudent to insure against, provided that such insurance is available in the market on reasonable terms. You  acknowledge that such insurance will not cover your business or contents kept at any of our Buildings.  15.2 You agree to carry insurance for (i) your business and business interruption (ii) all your contents kept at any of our Buildings  and (iii) public liability, all to appropriate levels. You agree to indemnify FORA in respect of any loss or claim that arises if at any  time and for any reason you do not hold any such insurance.  15.3 We may at any time request a copy of a valid certificate of your business and contents insurance policy and your public  liability policy.  16 Confidentiality  The terms of this Agreement are confidential and neither party shall disclose them to any third party without the other party&#8217;s  prior written consent save in respect of disclosure to Group Companies, professional advisers, purchasers, lenders or as may be  required under applicable law. This clause 16 shall survive termination of this Agreement until the date being 3 years from the  date of termination.   17 Data Protection  17.1 You agree that we may process, disclose or transfer any personal data which we hold on or in relation to you, provided that  we take such reasonable steps to ensure that it is used only to fulfil our obligations under this agreement, for fraud prevention,  to process your payments for our Services or to make available information which we reasonably consider may be of interest to  you.  17.2 We will both ensure that all personal data provided or disclosed by the other party (i) is kept confidential and reasonably  secure; and (ii) is not disclosed to any unauthorised third parties. The party to whom such personal data is provided or disclosed  will comply with all reasonable instructions from the providing or disclosing party relating to the security and confidentiality of  the personal data.  17.3 A party to whom personal data is provided or disclosed by the other party (i) will only process that personal data in accordance  with the instructions of that other party; and (ii) will not do anything with any of the personal data (including processing it) other  than in accordance with instructions given by the other party.  17.4 Each of us (i) will obtain and maintain all appropriate registration and consents under the General Data Protection Regulation  (&quot;GDPR&quot;) or any such other applicable legislation as may be in force from time to time in order to allow that party to perform its  obligations under this Agreement; (ii) will process personal data in accordance with the GDPR; (iii) will use its reasonable  endeavours to make sure that no act or omission by it, its employees, contractors or agents results in the breach of the obligations  of either party under the GDPR; and (iv) you shall ensure that such personal data shall have been obtained and supplied to us in  compliance with the GDPR, all codes of practice issued thereunder and all data, protection legislation, including you obtaining any  necessary consents to the processing of such data as contemplated by this Agreement, and that all your instructions to us to  process such data shall comply with the GDPR and data protection legislation.  17.7 Nothing in this clause 17 will operate to prevent or restrict any disclosure by either party which is required pursuant to an  order of a court of competent jurisdiction or pursuant to a proper demand made by any competent authority or body where the  party concerned is under a legal or regulatory obligation to make such a disclosure.  18 Miscellaneous  18.1 We reserve the right to make reasonable changes to the House Rules from time to time if we consider them appropriate to  the operation of our business, and you acknowledge that such amended terms will continue to apply to you from time to time.  DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement012.jpg" title="slide12" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  18.2 If any provision of this Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum  extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision shall be deemed  deleted. Any modification to or deletion of a provision shall not affect the validity and enforceability of the rest of the Agreement.  18.3 If either of us fail to enforce (or delays enforcing) the provisions of this Agreement then such failure or delay shall have no  effect on the rights of that party. Waiver by either of us of any of its rights shall not operate as a waiver of any other rights in  relation to any subsequent breach of this Agreement. No right, power or remedy available to either of us under this Agreement is  exclusive of any other right, power or remedy available to that party and each such right, power or remedy shall be cumulative.  18.4 Variations to this Agreement shall not be effective unless they are in writing and signed by or on behalf of all parties.  18.5 A person who is not a party to this agreement shall not have any rights under the Contracts (Rights of Third Parties) Act 1999  (the &#8220;1999 Act&#8221;) to enforce any terms of this Agreement, except that Fora Space Limited (together with any of its successors in  title or permitted assigns) shall have such a right to enforce any of the rights granted to us under the terms of this Agreement in  accordance with the provisions of the 1999 Act.  18.6 Nothing in this Agreement is intended to or shall operate to create a partnership between the parties, or to authorise any  party to act as agent for the other, and no party shall have authority to act in the name or on behalf of or otherwise to bind the  other in any way (including without limitation the making of any representation or warranty, the assumption of any obligation or  liability and the exercise of any right or power).  18.7 This Agreement contains all the terms and conditions agreed between the parties. We both acknowledge that, in entering  into this Agreement, neither of us have relied upon any statement, warranty or representation made by or on behalf of the other  that has not been set out in this Agreement, whether in any service description document or otherwise.  18.8 Notices issued to FORA shall be delivered to the following addresses (or such address as may be notified to you from time to  time):  Email: notices@theofficegroup.com   Post:  Notices    c/o the Building Manager  The Office Group  Smith Building  179 Great Portland Street  London  W1W 5PL  United Kingdom  18.9 Notices issued to you shall be delivered to the address and/or electronic mail address stated on page 1 of this Agreement (or  such address as may be notified by you to FORA from time to time).  YOU ACKNOWLEDGE THAT ALL NOTICES SERVED BY YOU MUST BE DELIVERED IN ACCORDANCE WITH THIS CLAUSE 18.8 AND THAT  NOTICES PHYSICALLY LEFT AT FORA BUILDINGS WILL NOT BE DEEMED TO HAVE BEEN VALIDLY SERVED.  18.10 Provisions of this Agreement which expressly or by implication are intended to survive termination shall continue in full  force and effect.  19  Anti-Money Laundering, Anti-Bribery and Sanctions  19.1. You warrant that you shall at all times comply with and will continue to comply with all applicable laws and regulations,  including (but not limited) the UK Bribery Act 2010, The Money Laundering, Terrorist Financing and Transfer of Funds (Information  on the Payer) Regulations 2017 and the London Local Authorities Act 2007.  19.2 You agree to take all reasonable steps and promptly do all things required in response to our reasonable requests in respect  of compliance with applicable law, which may include (but is not limited to) the provision of &#8220;know your customer&#8221; (&quot;KYC&quot;)  information relating to you and/or any person that may use our Buildings or services pursuant to this Agreement.  19.3. FORA reserves the right at any time to carry out further periodic KYC checks (including but not limited to background checks)  relating to your compliance with applicable laws. In respect of such KYC checks, you agree to provide us any reasonable  information that we may request from time to time. If, in our reasonable opinion, there is a reason for us to suspect that you or  any of your occupants in a Building are in breach or has been in breach of applicable laws (and in particular, with respect to anti- money laundering, anti-bribery and corruption, and anti-modern slavery laws), we reserve the right to immediately terminate this  agreement on written notice to you.  19.4 Neither you nor any member of your group nor any of your respective directors or officers shall at any time:   DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- foraresidentagreement013.jpg -->
<DIV style="padding-top:2em;">
<IMG src="foraresidentagreement013.jpg" title="slide13" width="964" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  19.4.1  be a Sanctions Restricted Person; or   19.4.2  engage in any transaction, activity or conduct that could reasonably be expected to result in its being designated as a  Sanctions Restricted Person; or  19.4.3 engage in any transaction, activity or conduct that would violate Sanctions applicable to it.   20  Modern Slavery  20.1 You and we shall each comply and use all reasonable endeavours to ensure where applicable that any persons engaged by  us shall comply, with all applicable laws, statutes, regulations and codes from time to time in force relevant to the Modern Slavery  Act 2015.  20.2 The parties represent and warrant to one another that neither it nor its officers, employees or other persons associated with  it:  20.2.1. has been convicted of any offence involving slavery and human trafficking; and  20.2.2. having made reasonable enquiries, has been or is the subject of any investigation, inquiry or enforcement proceedings by  any governmental, administrative or regulatory body regarding any offence or alleged offence of or in connection with slavery  and human trafficking.  21 Class Action Waiver  Any proceeding to resolve or litigate any dispute in any forum will be conducted solely on an individual basis. Neither we nor you  will seek to have any dispute heard as a class action or in any other proceeding in which either party acts or proposes to act in a  representative capacity. No proceeding will be combined with another without the prior written consent of all parties to all  affected proceedings. We and you also agree not to participate in claims brought in a representative capacity, or any consolidated  claims involving another person's account, if we are a party to the proceeding.  22 Governing Law and Jurisdiction  This Agreement shall be interpreted in accordance with English law and any disputes (including non-contractual disputes or claims)  shall be subject to the exclusive jurisdiction of the English courts.                DocuSign Envelope ID: 453114D9-976B-4B2F-8C4B-D9660B22DB4F </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>cmps-q1x23xex311ceo302cert.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i428689292b9c4b6ca77e428635eb3333_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">I, Kabir Nath, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of COMPASS Pathways plc (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%"> </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>cmps-q1x23xex312cfo302cert.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id5383b6bc0d1472ea8cc9068102efa86_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">I, Michael Falvey, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of COMPASS Pathways plc (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Falvey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Falvey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>cmps-q1x23xex321ceoxcfosec.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4c598988ca8c4248b7e5672068ca7cfe_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Kabir Nath, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on&#160;Form 10-Q&#160;of COMPASS Pathways plc for the period ended March 31, 2023 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on&#160;Form 10-Q&#160;fairly presents, in all material respects, the financial condition and results of operations of COMPASS Pathways plc.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:4.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The foregoing certification is not deemed filed with the Securities and Exchange Commission for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and is not to be incorporated by reference into any filing of COMPASS Pathways plc under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Michael Falvey, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on&#160;Form 10-Q&#160;of COMPASS Pathways plc for the period ended March 31, 2023 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on&#160;Form 10-Q&#160;fairly presents, in all material respects, the financial condition and results of operations of COMPASS Pathways plc.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:4.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Michael Falvey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Michael Falvey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The foregoing certification is not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and it is not to be incorporated by reference into any filing of COMPASS Pathways plc under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cmps-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:faa56455-90dd-4209-830a-f12e1735b5b9,g:47fba99e-051e-4c82-b324-f1efc6936c36-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cmps="http://compasspathways.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://compasspathways.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://compasspathways.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://compasspathways.com/role/NatureofBusiness">
        <link:definition>0000007 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>0000009 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilities" roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilities">
        <link:definition>0000010 - Disclosure - Accrued Expenses and Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinaryShares" roleURI="http://compasspathways.com/role/OrdinaryShares">
        <link:definition>0000011 - Disclosure - Ordinary Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://compasspathways.com/role/ShareBasedCompensation">
        <link:definition>0000012 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://compasspathways.com/role/NetLossPerShare">
        <link:definition>0000013 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Rightofuseofassets" roleURI="http://compasspathways.com/role/Rightofuseofassets">
        <link:definition>0000014 - Disclosure - Right of use of assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://compasspathways.com/role/CommitmentsandContingencies">
        <link:definition>0000015 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://compasspathways.com/role/SubsequentEvents">
        <link:definition>0000016 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>0000019 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilitiesTables" roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables">
        <link:definition>0000020 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://compasspathways.com/role/ShareBasedCompensationTables">
        <link:definition>0000021 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://compasspathways.com/role/NetLossPerShareTables">
        <link:definition>0000022 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsTables" roleURI="http://compasspathways.com/role/RightofuseofassetsTables">
        <link:definition>0000023 - Disclosure - Right of use of assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://compasspathways.com/role/NatureofBusinessDetails">
        <link:definition>0000024 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>0000027 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilitiesDetails" roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails">
        <link:definition>0000028 - Disclosure - Accrued Expenses and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesDetails" roleURI="http://compasspathways.com/role/OrdinarySharesDetails">
        <link:definition>0000029 - Disclosure - Ordinary Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2017EquityIncentivePlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails">
        <link:definition>0000030 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails">
        <link:definition>0000031 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2020ShareOptionPlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails">
        <link:definition>0000032 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2022InducementGrantOptionAwardDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails">
        <link:definition>0000033 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedShareUnitsDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails">
        <link:definition>0000034 - Disclosure - Share-Based Compensation - Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationShareOptionsDetails" roleURI="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails">
        <link:definition>0000035 - Disclosure - Share-based Compensation - Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofValuationAssumptionsDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails">
        <link:definition>0000036 - Disclosure - Share-Based Compensation - Schedule of Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>0000037 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>0000038 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>0000039 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsNarrativeDetails" roleURI="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails">
        <link:definition>0000040 - Disclosure - Right of use of assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails">
        <link:definition>0000041 - Disclosure - Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails">
        <link:definition>0000042 - Disclosure - Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1">
        <link:definition>0000042 - Disclosure - Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://compasspathways.com/role/SubsequentEventsDetails">
        <link:definition>0000043 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cmps_RefundableLeaseDepositPayments" abstract="false" name="RefundableLeaseDepositPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_OrdinarySharesMember" abstract="true" name="OrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" abstract="false" name="BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" abstract="false" name="ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_DenmarkHillLondonUKMember" abstract="true" name="DenmarkHillLondonUKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditCurrent" abstract="false" name="ResearchAndDevelopmentTaxCreditCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_SaleOfStockMaximumAmountAllowableForSale" abstract="false" name="SaleOfStockMaximumAmountAllowableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" abstract="false" name="ResearchAndDevelopmentTaxCreditCashRebatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_NumberOfOrdinarySharesConversionRatio" abstract="false" name="NumberOfOrdinarySharesConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cmps_AmericanDepositarySharesMember" abstract="true" name="AmericanDepositarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" abstract="false" name="ResearchAndDevelopmentTaxCreditTotalAidClaimable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_OptionsGrantedBeforeJune302020Member" abstract="true" name="OptionsGrantedBeforeJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" abstract="false" name="RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_GrantDateJune302020Member" abstract="true" name="GrantDateJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_SohoLondonUKMember" abstract="true" name="SohoLondonUKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cmps_DeferredOfferingCostsIncludedInAccruedExpenses" abstract="false" name="DeferredOfferingCostsIncludedInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" abstract="true" name="UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_A2017EquityIncentivePlanMember" abstract="true" name="A2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_VestingPeriodAxis" abstract="true" name="VestingPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cmps_UnvestedRestrictedShareUnitsMember" abstract="true" name="UnvestedRestrictedShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_PrepaidExpenseResearchAndDevelopmentCurrent" abstract="false" name="PrepaidExpenseResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmps_ShareOptionsMember" abstract="true" name="ShareOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" abstract="false" name="ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_LeaseCancellationNotificationPeriod" abstract="false" name="LeaseCancellationNotificationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_VestingPeriodDomain" abstract="true" name="VestingPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" abstract="true" name="UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_A2022And2023Member" abstract="true" name="A2022And2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionOneMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_DeferredSharesMember" abstract="true" name="DeferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_OperatingLeasesNoncancelableTerm" abstract="false" name="OperatingLeasesNoncancelableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_A2020ShareOptionPlanMember" abstract="true" name="A2020ShareOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" abstract="false" name="ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_SaleOfStockAmountAuthorized" abstract="false" name="SaleOfStockAmountAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_OperatingLeaseMonthlyPayment" abstract="false" name="OperatingLeaseMonthlyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_OperatingLeaseAnnualPayment" abstract="false" name="OperatingLeaseAnnualPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cmps_WeWorkMember" abstract="true" name="WeWorkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_NumberOfGeographicRegions" abstract="false" name="NumberOfGeographicRegions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmps_ProceedsFromStockOptionsExercisedNotReceived" abstract="false" name="ProceedsFromStockOptionsExercisedNotReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_A2022InducementGrantOptionAwardMember" abstract="true" name="A2022InducementGrantOptionAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cmps-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:faa56455-90dd-4209-830a-f12e1735b5b9,g:47fba99e-051e-4c82-b324-f1efc6936c36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3523a4a9-518a-453b-bbcf-90563b7773da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_440ce54d-77dc-45c1-96bf-38a27e894299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3523a4a9-518a-453b-bbcf-90563b7773da" xlink:to="loc_us-gaap_CommonStockValue_440ce54d-77dc-45c1-96bf-38a27e894299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fc25e56-d2f6-4402-b168-3a4bb10f39d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3523a4a9-518a-453b-bbcf-90563b7773da" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fc25e56-d2f6-4402-b168-3a4bb10f39d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2f3d6421-9242-4c97-b3dd-728bfe0c6084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3523a4a9-518a-453b-bbcf-90563b7773da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2f3d6421-9242-4c97-b3dd-728bfe0c6084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c7e76240-0a99-4629-afbc-a949594fa63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3523a4a9-518a-453b-bbcf-90563b7773da" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c7e76240-0a99-4629-afbc-a949594fa63d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2270c62e-c4b6-412b-83c4-7454db80aa61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35cc47fa-e11f-4ea0-b321-a22f6c4bb783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2270c62e-c4b6-412b-83c4-7454db80aa61" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35cc47fa-e11f-4ea0-b321-a22f6c4bb783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a4e078ef-6f80-44ed-90cf-2896812644fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2270c62e-c4b6-412b-83c4-7454db80aa61" xlink:to="loc_us-gaap_LiabilitiesCurrent_a4e078ef-6f80-44ed-90cf-2896812644fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1a62064b-c80d-4f4b-b424-dbd51af7ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a20d8ad7-cc86-4956-8b94-81229ec9da8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1a62064b-c80d-4f4b-b424-dbd51af7ca61" xlink:to="loc_us-gaap_AccountsPayableCurrent_a20d8ad7-cc86-4956-8b94-81229ec9da8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0bd31dcf-001c-4e1c-864d-de55df36961b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1a62064b-c80d-4f4b-b424-dbd51af7ca61" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0bd31dcf-001c-4e1c-864d-de55df36961b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eea6609c-1c67-4529-a361-42e1a1d31317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1a62064b-c80d-4f4b-b424-dbd51af7ca61" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eea6609c-1c67-4529-a361-42e1a1d31317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8768f64b-89ce-4ffa-aa86-bd4f912d9d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_b7b9ebdc-b124-4ee1-a405-0c212387208e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8768f64b-89ce-4ffa-aa86-bd4f912d9d5b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_b7b9ebdc-b124-4ee1-a405-0c212387208e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_87667457-954b-47a3-82f0-397b202b3aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8768f64b-89ce-4ffa-aa86-bd4f912d9d5b" xlink:to="loc_us-gaap_PrepaidTaxes_87667457-954b-47a3-82f0-397b202b3aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_377478c2-27f1-4fa9-8b9f-9b201f5956dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8768f64b-89ce-4ffa-aa86-bd4f912d9d5b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_377478c2-27f1-4fa9-8b9f-9b201f5956dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_a5f01265-5a1f-4a15-b460-33cd1b2ed547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8768f64b-89ce-4ffa-aa86-bd4f912d9d5b" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_a5f01265-5a1f-4a15-b460-33cd1b2ed547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66f255fa-7e8f-40fd-b02b-5af82bd161a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1fa14a29-a4c1-4485-ad33-5ad5b4c15c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66f255fa-7e8f-40fd-b02b-5af82bd161a1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1fa14a29-a4c1-4485-ad33-5ad5b4c15c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_90b10fb2-c36f-4088-895d-a69859370629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66f255fa-7e8f-40fd-b02b-5af82bd161a1" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_90b10fb2-c36f-4088-895d-a69859370629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cb72f90a-a128-4bb3-98a3-5e2556ce26fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66f255fa-7e8f-40fd-b02b-5af82bd161a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cb72f90a-a128-4bb3-98a3-5e2556ce26fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9cd23857-47d9-4dda-9a3b-62f470e1c23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66f255fa-7e8f-40fd-b02b-5af82bd161a1" xlink:to="loc_us-gaap_AssetsCurrent_9cd23857-47d9-4dda-9a3b-62f470e1c23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cfc033b8-ae27-4f35-88b1-bda219be93b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66f255fa-7e8f-40fd-b02b-5af82bd161a1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cfc033b8-ae27-4f35-88b1-bda219be93b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d5cc8331-a312-4a1f-88fc-92c84b35c1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66f255fa-7e8f-40fd-b02b-5af82bd161a1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d5cc8331-a312-4a1f-88fc-92c84b35c1d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3daab06-061f-4b67-b13b-02a7213c452f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bdc2803a-fa2c-4526-a559-b3000a7e9aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3daab06-061f-4b67-b13b-02a7213c452f" xlink:to="loc_us-gaap_Liabilities_bdc2803a-fa2c-4526-a559-b3000a7e9aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8f434237-c9b7-469f-b34f-fec22cb5e176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3daab06-061f-4b67-b13b-02a7213c452f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8f434237-c9b7-469f-b34f-fec22cb5e176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3904f87f-2ce6-4a6a-894b-9b96c2ba9af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3daab06-061f-4b67-b13b-02a7213c452f" xlink:to="loc_us-gaap_StockholdersEquity_3904f87f-2ce6-4a6a-894b-9b96c2ba9af5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_27511156-7ed4-4d9f-bfff-2d5729311c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_47546614-5e9a-495b-9baa-a882feac46c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_27511156-7ed4-4d9f-bfff-2d5729311c9a" xlink:to="loc_us-gaap_OperatingExpenses_47546614-5e9a-495b-9baa-a882feac46c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc6f8644-e284-4b8c-9488-af284fc9324e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a09dd5dc-eddb-4084-a8bb-0c9cecf7798b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc6f8644-e284-4b8c-9488-af284fc9324e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a09dd5dc-eddb-4084-a8bb-0c9cecf7798b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_17fd3c4b-7504-4e28-9ac5-f0370f70f167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc6f8644-e284-4b8c-9488-af284fc9324e" xlink:to="loc_us-gaap_OperatingIncomeLoss_17fd3c4b-7504-4e28-9ac5-f0370f70f167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c9f6e823-667b-410b-acf0-d53a411de3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_277818d4-bbd7-4ee8-8c08-58abfbd2f47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c9f6e823-667b-410b-acf0-d53a411de3cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_277818d4-bbd7-4ee8-8c08-58abfbd2f47a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c60b4626-f162-41ff-8be7-6d3a9a6b76d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c9f6e823-667b-410b-acf0-d53a411de3cd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c60b4626-f162-41ff-8be7-6d3a9a6b76d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_091b20e9-62c8-4167-8b79-324570d449b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_f91343a3-87e5-49e3-93f9-da6d3209fb25" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_091b20e9-62c8-4167-8b79-324570d449b8" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_f91343a3-87e5-49e3-93f9-da6d3209fb25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_42224b65-ced8-44f2-bf7a-c8c8509180e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_091b20e9-62c8-4167-8b79-324570d449b8" xlink:to="loc_us-gaap_OtherNonoperatingIncome_42224b65-ced8-44f2-bf7a-c8c8509180e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9bb0edcc-ac3d-44a8-9142-656c520ff4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_091b20e9-62c8-4167-8b79-324570d449b8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9bb0edcc-ac3d-44a8-9142-656c520ff4f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9aa2502d-8182-42dd-8580-10502add7e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f56b599f-8633-4126-b392-7e4d81031d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9aa2502d-8182-42dd-8580-10502add7e4c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f56b599f-8633-4126-b392-7e4d81031d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4ec3dd2e-f7eb-4958-8c5d-ef4f932ff2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9aa2502d-8182-42dd-8580-10502add7e4c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4ec3dd2e-f7eb-4958-8c5d-ef4f932ff2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_92f5f16f-ace8-440b-8a5c-68acd8d324ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_782d7f13-7f23-466c-a3d9-9b9a6af8e590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_92f5f16f-ace8-440b-8a5c-68acd8d324ad" xlink:to="loc_us-gaap_NetIncomeLoss_782d7f13-7f23-466c-a3d9-9b9a6af8e590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d742e6f3-41cd-424d-9863-c246f34b465e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_92f5f16f-ace8-440b-8a5c-68acd8d324ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d742e6f3-41cd-424d-9863-c246f34b465e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_2976d19c-729e-4ceb-9504-734f92279ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_2976d19c-729e-4ceb-9504-734f92279ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_001d68c1-0026-4d10-9d7d-2481b194ecec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_001d68c1-0026-4d10-9d7d-2481b194ecec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d9077847-0116-4fcc-83ba-25f07b560609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d9077847-0116-4fcc-83ba-25f07b560609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_118d6b28-5717-422f-8f46-3b67076f8a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_ShareBasedCompensation_118d6b28-5717-422f-8f46-3b67076f8a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93eea74a-9bc1-4e36-988b-b79d9d45c6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_NetIncomeLoss_93eea74a-9bc1-4e36-988b-b79d9d45c6f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_edd7ff5b-2354-46ba-8939-2a221607ba73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_edd7ff5b-2354-46ba-8939-2a221607ba73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_079d1a23-4adc-413b-ae62-ad197186c9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_079d1a23-4adc-413b-ae62-ad197186c9cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_19329d11-6c1d-4c05-9491-de18070128cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_19329d11-6c1d-4c05-9491-de18070128cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8c5f3dd4-d420-4281-8a27-e1a3bf72909f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8c5f3dd4-d420-4281-8a27-e1a3bf72909f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7cd71654-7d2a-42cd-a2cf-a79fcf8b8e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7cd71654-7d2a-42cd-a2cf-a79fcf8b8e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_59e2e739-3a04-45db-8f4b-81f818ca28ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc46d6c8-9c4e-4512-a2dc-f30297e2479d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_59e2e739-3a04-45db-8f4b-81f818ca28ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7033d5bd-a8d2-4e57-83d8-e95a46c375eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_99126123-9ae8-41ec-b4f8-f447f4434e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7033d5bd-a8d2-4e57-83d8-e95a46c375eb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_99126123-9ae8-41ec-b4f8-f447f4434e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c8d42ee8-9770-4370-9769-3cd08caff94e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7033d5bd-a8d2-4e57-83d8-e95a46c375eb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c8d42ee8-9770-4370-9769-3cd08caff94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_832c212c-41ba-4ca4-bfa1-64e406c10c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7033d5bd-a8d2-4e57-83d8-e95a46c375eb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_832c212c-41ba-4ca4-bfa1-64e406c10c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e38eb88-4ff4-4b50-bad7-7703d1232cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7d7e5a8-b798-4062-8250-1149dfd5483a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e38eb88-4ff4-4b50-bad7-7703d1232cbe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7d7e5a8-b798-4062-8250-1149dfd5483a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_48b459b0-9eee-4276-be5a-7656346ca7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e38eb88-4ff4-4b50-bad7-7703d1232cbe" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_48b459b0-9eee-4276-be5a-7656346ca7ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a5636f77-795a-4249-b402-c547b788f4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49ebb2f2-458d-46bf-8d0e-10650e5591f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a5636f77-795a-4249-b402-c547b788f4dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49ebb2f2-458d-46bf-8d0e-10650e5591f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47952e2a-39e6-48f7-928a-3fb11f7f6f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a5636f77-795a-4249-b402-c547b788f4dd" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47952e2a-39e6-48f7-928a-3fb11f7f6f02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc96778f-37b6-414e-8d82-7a098e00d6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a5636f77-795a-4249-b402-c547b788f4dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc96778f-37b6-414e-8d82-7a098e00d6ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_83ca9c2c-9012-431f-99c3-6b0d274674ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a5636f77-795a-4249-b402-c547b788f4dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_83ca9c2c-9012-431f-99c3-6b0d274674ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ba0871e-2876-43b1-a4b1-a90caee93543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e30d7d44-17f3-44fe-a58f-d20a0531feab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ba0871e-2876-43b1-a4b1-a90caee93543" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e30d7d44-17f3-44fe-a58f-d20a0531feab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09367e9c-9086-4481-9031-5ca1bae66718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b5eb212f-670b-42b9-a48c-e932d86f89d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09367e9c-9086-4481-9031-5ca1bae66718" xlink:to="loc_us-gaap_OtherAssetsCurrent_b5eb212f-670b-42b9-a48c-e932d86f89d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_75b76f50-0ccf-442d-9205-ff46f653fcc2" xlink:href="cmps-20230331.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09367e9c-9086-4481-9031-5ca1bae66718" xlink:to="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_75b76f50-0ccf-442d-9205-ff46f653fcc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_71ac5e01-0b62-4d26-b614-8aa6fc3da993" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09367e9c-9086-4481-9031-5ca1bae66718" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_71ac5e01-0b62-4d26-b614-8aa6fc3da993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_99f0d224-fa2a-4dac-9cdf-4dbf4f8318ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09367e9c-9086-4481-9031-5ca1bae66718" xlink:to="loc_us-gaap_PrepaidInsurance_99f0d224-fa2a-4dac-9cdf-4dbf4f8318ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_88aeeeb6-6f02-4993-b59c-818e3ac91fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09367e9c-9086-4481-9031-5ca1bae66718" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_88aeeeb6-6f02-4993-b59c-818e3ac91fbf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#AccruedExpensesandOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6bd9e19b-06c7-427c-858a-9e527be34a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_52f77fe6-7591-4a43-99cc-addda0d87ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6bd9e19b-06c7-427c-858a-9e527be34a52" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_52f77fe6-7591-4a43-99cc-addda0d87ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_06f23792-ff7a-4f6b-8a15-93830994727e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6bd9e19b-06c7-427c-858a-9e527be34a52" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_06f23792-ff7a-4f6b-8a15-93830994727e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c2a51064-3de1-438e-8ae1-a2f1a6822b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6bd9e19b-06c7-427c-858a-9e527be34a52" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c2a51064-3de1-438e-8ae1-a2f1a6822b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_93cc022b-9c1d-4253-ab06-2dd3086be139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6bd9e19b-06c7-427c-858a-9e527be34a52" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_93cc022b-9c1d-4253-ab06-2dd3086be139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent_edfe6af6-d064-490e-b894-0d915af234d3" xlink:href="cmps-20230331.xsd#cmps_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6bd9e19b-06c7-427c-858a-9e527be34a52" xlink:to="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent_edfe6af6-d064-490e-b894-0d915af234d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0aa3ebc6-12c3-4d7b-b3a4-7b8b9b4bc363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_59dd9313-bab4-4a92-87a1-9ed798966146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0aa3ebc6-12c3-4d7b-b3a4-7b8b9b4bc363" xlink:to="loc_us-gaap_OperatingLeaseCost_59dd9313-bab4-4a92-87a1-9ed798966146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_e9570f17-ffa3-41fe-8046-78aa2a00663a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0aa3ebc6-12c3-4d7b-b3a4-7b8b9b4bc363" xlink:to="loc_us-gaap_ShortTermLeaseCost_e9570f17-ffa3-41fe-8046-78aa2a00663a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27c95634-f6a4-42c4-9e9a-f88b4395ee78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9480b485-0253-4ab6-bd0b-39aad3082b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27c95634-f6a4-42c4-9e9a-f88b4395ee78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9480b485-0253-4ab6-bd0b-39aad3082b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d0b77e6c-2bfb-48a0-9a5a-cc58b41ed3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27c95634-f6a4-42c4-9e9a-f88b4395ee78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d0b77e6c-2bfb-48a0-9a5a-cc58b41ed3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_81cb6fb5-9d8c-4aa9-9e59-f62b9d72e1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27c95634-f6a4-42c4-9e9a-f88b4395ee78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_81cb6fb5-9d8c-4aa9-9e59-f62b9d72e1fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_28f6e33a-24a6-44ab-b5d4-5aae9d12c521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27c95634-f6a4-42c4-9e9a-f88b4395ee78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_28f6e33a-24a6-44ab-b5d4-5aae9d12c521" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b86dc9-6a2b-4548-ac95-d61bd1ca27bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1d74a7ba-270f-4839-b03f-e6a18727f662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b86dc9-6a2b-4548-ac95-d61bd1ca27bf" xlink:to="loc_us-gaap_OperatingLeaseLiability_1d74a7ba-270f-4839-b03f-e6a18727f662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d3ff6428-97d3-40bc-957e-da54f3f34f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97b86dc9-6a2b-4548-ac95-d61bd1ca27bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d3ff6428-97d3-40bc-957e-da54f3f34f12" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cmps-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:faa56455-90dd-4209-830a-f12e1735b5b9,g:47fba99e-051e-4c82-b324-f1efc6936c36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i317b75ad60a6413c8089fb586f320b28_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_22a3cd24-2745-41c6-a75f-e357c26c032d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22a3cd24-2745-41c6-a75f-e357c26c032d" xlink:to="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9af81917-6ab6-416c-8751-9f58dd621076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9af81917-6ab6-416c-8751-9f58dd621076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f8e5a2f4-9d2b-4199-a363-016a1e3ed52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f8e5a2f4-9d2b-4199-a363-016a1e3ed52a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_e36abed7-3c7e-421c-b627-31c7c301ab63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_PrepaidTaxes_e36abed7-3c7e-421c-b627-31c7c301ab63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_2358a63d-175f-41a1-a0d7-e8bd534cddf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_2358a63d-175f-41a1-a0d7-e8bd534cddf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4878504b-69b4-46a6-b1a8-06477216cf98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_AssetsCurrent_4878504b-69b4-46a6-b1a8-06477216cf98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_64ab2059-c066-4079-b986-11ac778c00eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_64ab2059-c066-4079-b986-11ac778c00eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ab24cd53-a323-4f03-a3be-1aadd2b14b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ab24cd53-a323-4f03-a3be-1aadd2b14b9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_38864c44-84e3-4bcd-abea-ea8ac1c39f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_38864c44-84e3-4bcd-abea-ea8ac1c39f18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5f74b14d-84ce-4d14-af36-e4b3bc81402b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5f74b14d-84ce-4d14-af36-e4b3bc81402b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a0b16141-0835-4eda-b3ab-d8542a400205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a0b16141-0835-4eda-b3ab-d8542a400205" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8d05ab7a-3eae-41e4-96a5-e112b726f7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:to="loc_us-gaap_Assets_8d05ab7a-3eae-41e4-96a5-e112b726f7e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22a3cd24-2745-41c6-a75f-e357c26c032d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_580d71ba-6c77-4986-887a-a6a5ae274854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:to="loc_us-gaap_AccountsPayableCurrent_580d71ba-6c77-4986-887a-a6a5ae274854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_4390c2f9-93d3-4b00-a9e4-bae00557605f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_4390c2f9-93d3-4b00-a9e4-bae00557605f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_241799b7-754a-47ad-9ff0-45a21fc22453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_241799b7-754a-47ad-9ff0-45a21fc22453" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a5e22f0-061d-42a1-8e8f-5541c1100d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:to="loc_us-gaap_LiabilitiesCurrent_0a5e22f0-061d-42a1-8e8f-5541c1100d83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_184ea8ea-be3f-4735-a6dd-bbb1d8d63801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_184ea8ea-be3f-4735-a6dd-bbb1d8d63801" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1de8b3c1-278b-4877-8d00-b1c223e643b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_184ea8ea-be3f-4735-a6dd-bbb1d8d63801" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1de8b3c1-278b-4877-8d00-b1c223e643b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_625c972a-a67b-4624-98f4-dec3bf19886a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_Liabilities_625c972a-a67b-4624-98f4-dec3bf19886a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8394f959-9eb8-4c5c-8192-49564c0174ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8394f959-9eb8-4c5c-8192-49564c0174ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fde45b23-7a55-4551-90af-1e8e5f4aba04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_CommonStockValue_fde45b23-7a55-4551-90af-1e8e5f4aba04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7d953752-e68f-4e6a-bfa9-d0db12b786b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7d953752-e68f-4e6a-bfa9-d0db12b786b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e76404dc-8e46-419b-ac99-df0c337cf35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e76404dc-8e46-419b-ac99-df0c337cf35b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3aef655-4c6c-4220-94e6-c72e4f57772a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3aef655-4c6c-4220-94e6-c72e4f57772a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_efc7ca95-8f37-4921-9eb7-1c6ceaf2a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_StockholdersEquity_efc7ca95-8f37-4921-9eb7-1c6ceaf2a7bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad56a97b-8d5b-4c6c-83cb-d8ce605e9538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad56a97b-8d5b-4c6c-83cb-d8ce605e9538" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b8bdf700-56ad-4f70-afaf-6ae2dd1b9bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_22a3cd24-2745-41c6-a75f-e357c26c032d" xlink:to="loc_us-gaap_StatementTable_b8bdf700-56ad-4f70-afaf-6ae2dd1b9bbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7c1e1c64-9e3f-47dc-97b1-f30b8731b584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b8bdf700-56ad-4f70-afaf-6ae2dd1b9bbb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7c1e1c64-9e3f-47dc-97b1-f30b8731b584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c1e1c64-9e3f-47dc-97b1-f30b8731b584_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c1e1c64-9e3f-47dc-97b1-f30b8731b584" xlink:to="loc_us-gaap_ClassOfStockDomain_7c1e1c64-9e3f-47dc-97b1-f30b8731b584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_106affa6-3a9f-4d40-8d2e-a7102d649dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c1e1c64-9e3f-47dc-97b1-f30b8731b584" xlink:to="loc_us-gaap_ClassOfStockDomain_106affa6-3a9f-4d40-8d2e-a7102d649dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_41c312af-f318-4f4b-80ef-04025b8fc987" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_106affa6-3a9f-4d40-8d2e-a7102d649dfd" xlink:to="loc_cmps_OrdinarySharesMember_41c312af-f318-4f4b-80ef-04025b8fc987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_b504a7f5-5b65-48b5-9cbb-0ba96634bbd2" xlink:href="cmps-20230331.xsd#cmps_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_106affa6-3a9f-4d40-8d2e-a7102d649dfd" xlink:to="loc_cmps_DeferredSharesMember_b504a7f5-5b65-48b5-9cbb-0ba96634bbd2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ia08d2b354ac3456b98d61f1406b3b3b0_CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_477172f8-2b1d-4d56-8865-724da555408b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_477172f8-2b1d-4d56-8865-724da555408b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_749325a9-3602-4023-9c58-870c3ec23f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_749325a9-3602-4023-9c58-870c3ec23f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_654de97d-f0ba-4707-8325-13236815f9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_CommonStockSharesIssued_654de97d-f0ba-4707-8325-13236815f9dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b3636ef3-c8df-40f0-b209-3ad2bf478fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b3636ef3-c8df-40f0-b209-3ad2bf478fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d637df75-7b58-4596-b6ac-a9f3c37fb9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_StatementTable_d637df75-7b58-4596-b6ac-a9f3c37fb9be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f53d947f-0332-4a75-b5d1-f4aa67558aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d637df75-7b58-4596-b6ac-a9f3c37fb9be" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f53d947f-0332-4a75-b5d1-f4aa67558aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f53d947f-0332-4a75-b5d1-f4aa67558aa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f53d947f-0332-4a75-b5d1-f4aa67558aa1" xlink:to="loc_us-gaap_ClassOfStockDomain_f53d947f-0332-4a75-b5d1-f4aa67558aa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_60e43832-2d03-4c2a-b216-18b98487b185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f53d947f-0332-4a75-b5d1-f4aa67558aa1" xlink:to="loc_us-gaap_ClassOfStockDomain_60e43832-2d03-4c2a-b216-18b98487b185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_2b041633-fb8b-4762-87de-138b70325ad3" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_60e43832-2d03-4c2a-b216-18b98487b185" xlink:to="loc_cmps_OrdinarySharesMember_2b041633-fb8b-4762-87de-138b70325ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_3afd1a67-deae-4339-956b-85a6edd997c6" xlink:href="cmps-20230331.xsd#cmps_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_60e43832-2d03-4c2a-b216-18b98487b185" xlink:to="loc_cmps_DeferredSharesMember_3afd1a67-deae-4339-956b-85a6edd997c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i9c07fb6be5ec4dbf96da2b4f10561d16_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a199f857-1bee-4e56-8acd-092a67c401f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a199f857-1bee-4e56-8acd-092a67c401f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ae77a2a-6b10-4805-bc20-2c22573da7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockholdersEquity_5ae77a2a-6b10-4805-bc20-2c22573da7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b05140d-004d-4dd0-8456-198f64064ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b05140d-004d-4dd0-8456-198f64064ef7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dcef1b21-7dc3-4c51-8b44-57afb44fb5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dcef1b21-7dc3-4c51-8b44-57afb44fb5c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fecd0f4f-5686-49a0-a94a-74abf6a3367b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fecd0f4f-5686-49a0-a94a-74abf6a3367b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_86d20f8b-0bbf-4ceb-9b5e-2ff23c7d45f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_86d20f8b-0bbf-4ceb-9b5e-2ff23c7d45f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c0803199-dfc4-4b21-ac3c-1d8ffd56ba29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c0803199-dfc4-4b21-ac3c-1d8ffd56ba29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_deba1338-6978-4a5f-939c-5aaefb5e011b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_deba1338-6978-4a5f-939c-5aaefb5e011b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b199e63d-962e-4bdf-8251-b7ad7d5d6ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b199e63d-962e-4bdf-8251-b7ad7d5d6ef5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_00fc3bc0-8bcf-4b81-91d8-4babd5069cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_00fc3bc0-8bcf-4b81-91d8-4babd5069cbb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_58a9b800-2c60-495f-9040-643a602097f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_58a9b800-2c60-495f-9040-643a602097f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a330dab-0598-408a-8e47-ebc78e85aa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_NetIncomeLoss_0a330dab-0598-408a-8e47-ebc78e85aa03" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fd5da9b9-a983-4c90-8b09-1477eea91c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d61b960-3809-491e-a915-b34b1eb2fb86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cf62670-ef12-4d24-99db-47a18c74913f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cf62670-ef12-4d24-99db-47a18c74913f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4923b4bf-0ef3-4991-b208-fc05c2545bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4923b4bf-0ef3-4991-b208-fc05c2545bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4923b4bf-0ef3-4991-b208-fc05c2545bd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4923b4bf-0ef3-4991-b208-fc05c2545bd7" xlink:to="loc_us-gaap_ClassOfStockDomain_4923b4bf-0ef3-4991-b208-fc05c2545bd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_027dc2d8-067b-4706-bf1f-9456855304aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4923b4bf-0ef3-4991-b208-fc05c2545bd7" xlink:to="loc_us-gaap_ClassOfStockDomain_027dc2d8-067b-4706-bf1f-9456855304aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_b923411f-de40-44b1-9827-56916e494d9d" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_027dc2d8-067b-4706-bf1f-9456855304aa" xlink:to="loc_cmps_OrdinarySharesMember_b923411f-de40-44b1-9827-56916e494d9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_07528f39-90be-4682-a7a7-4335fa8652e3" xlink:href="cmps-20230331.xsd#cmps_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_027dc2d8-067b-4706-bf1f-9456855304aa" xlink:to="loc_cmps_DeferredSharesMember_07528f39-90be-4682-a7a7-4335fa8652e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bd1a50df-fb25-46d7-beaf-5b6658e114e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bd1a50df-fb25-46d7-beaf-5b6658e114e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd1a50df-fb25-46d7-beaf-5b6658e114e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd1a50df-fb25-46d7-beaf-5b6658e114e2" xlink:to="loc_us-gaap_EquityComponentDomain_bd1a50df-fb25-46d7-beaf-5b6658e114e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd1a50df-fb25-46d7-beaf-5b6658e114e2" xlink:to="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8bb6323e-ca22-4395-b302-aa1941fa954c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:to="loc_us-gaap_CommonStockMember_8bb6323e-ca22-4395-b302-aa1941fa954c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9f6dbb3b-b044-4e77-82c8-80727e3369f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9f6dbb3b-b044-4e77-82c8-80727e3369f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8329afe-01cb-4821-985f-5fc02de150a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8329afe-01cb-4821-985f-5fc02de150a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_544904ef-113a-4f40-aea0-b7232c8b29be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:to="loc_us-gaap_RetainedEarningsMember_544904ef-113a-4f40-aea0-b7232c8b29be" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#NatureofBusinessDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="extended" id="icdb520e178f149dca2288d1f228c7584_NatureofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_7cd8e9a6-bc2d-404f-b772-1c0cbcfa2678" xlink:href="cmps-20230331.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_7cd8e9a6-bc2d-404f-b772-1c0cbcfa2678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio_db765446-b8c9-4efa-9cb4-267a75ff69ac" xlink:href="cmps-20230331.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_cmps_NumberOfOrdinarySharesConversionRatio_db765446-b8c9-4efa-9cb4-267a75ff69ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7098b3cb-9ea3-4113-a56e-85182172f6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7098b3cb-9ea3-4113-a56e-85182172f6a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_269afc00-d474-4c9d-9fde-0eae8d503398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_269afc00-d474-4c9d-9fde-0eae8d503398" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f2d2c342-703d-4ab3-97ad-0f57832b5e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_NetIncomeLoss_f2d2c342-703d-4ab3-97ad-0f57832b5e2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7eb4dee0-86fb-4abe-a4ce-45a3b4801f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7eb4dee0-86fb-4abe-a4ce-45a3b4801f80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07fdda2d-5472-44de-810a-caa11b2f0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07fdda2d-5472-44de-810a-caa11b2f0d9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a871ad98-e713-410f-bb94-3a0fca6e29e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a871ad98-e713-410f-bb94-3a0fca6e29e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a871ad98-e713-410f-bb94-3a0fca6e29e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a871ad98-e713-410f-bb94-3a0fca6e29e5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a871ad98-e713-410f-bb94-3a0fca6e29e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac23ddaa-a0e3-41d3-98d5-4bd33288dceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a871ad98-e713-410f-bb94-3a0fca6e29e5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac23ddaa-a0e3-41d3-98d5-4bd33288dceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b74bcc34-c821-43ba-abc4-e9749bf0cb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac23ddaa-a0e3-41d3-98d5-4bd33288dceb" xlink:to="loc_us-gaap_IPOMember_b74bcc34-c821-43ba-abc4-e9749bf0cb9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_1310f19d-204b-4d69-bc17-8ac5ef531b72" xlink:href="cmps-20230331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac23ddaa-a0e3-41d3-98d5-4bd33288dceb" xlink:to="loc_cmps_AtTheMarketOfferingMember_1310f19d-204b-4d69-bc17-8ac5ef531b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8fc80f99-a91e-4830-bae9-3e16959df057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8fc80f99-a91e-4830-bae9-3e16959df057" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8fc80f99-a91e-4830-bae9-3e16959df057_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8fc80f99-a91e-4830-bae9-3e16959df057" xlink:to="loc_us-gaap_ClassOfStockDomain_8fc80f99-a91e-4830-bae9-3e16959df057_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_52dcaa60-1b4d-43f9-8f5d-c2def34a8a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8fc80f99-a91e-4830-bae9-3e16959df057" xlink:to="loc_us-gaap_ClassOfStockDomain_52dcaa60-1b4d-43f9-8f5d-c2def34a8a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_52d8b894-ec69-4f1c-bb52-f47f15e3e739" xlink:href="cmps-20230331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_52dcaa60-1b4d-43f9-8f5d-c2def34a8a45" xlink:to="loc_cmps_AmericanDepositarySharesMember_52d8b894-ec69-4f1c-bb52-f47f15e3e739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b9b672c2-6175-4c82-bcb1-335ccdd5e19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b9b672c2-6175-4c82-bcb1-335ccdd5e19d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b9b672c2-6175-4c82-bcb1-335ccdd5e19d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b9b672c2-6175-4c82-bcb1-335ccdd5e19d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b9b672c2-6175-4c82-bcb1-335ccdd5e19d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7eb62ba2-01fc-4477-8943-138787819177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b9b672c2-6175-4c82-bcb1-335ccdd5e19d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7eb62ba2-01fc-4477-8943-138787819177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32247b6e-1b77-4ee2-9110-758c68f33a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7eb62ba2-01fc-4477-8943-138787819177" xlink:to="loc_us-gaap_SubsequentEventMember_32247b6e-1b77-4ee2-9110-758c68f33a53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended" id="i126e174616b34e238d2a0c559e6d6d8c_SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e4e4484-eb26-4ffa-ab66-09475923ef45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5bdd004a-ee81-400e-8e6a-7d0ae69e4182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e4e4484-eb26-4ffa-ab66-09475923ef45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5bdd004a-ee81-400e-8e6a-7d0ae69e4182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e4e4484-eb26-4ffa-ab66-09475923ef45" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f8180360-9236-4a32-9bdc-a974a9094245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f8180360-9236-4a32-9bdc-a974a9094245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f8180360-9236-4a32-9bdc-a974a9094245_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f8180360-9236-4a32-9bdc-a974a9094245" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f8180360-9236-4a32-9bdc-a974a9094245_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f8180360-9236-4a32-9bdc-a974a9094245" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aef9c55a-51a8-4563-af13-614d7b76e6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:to="loc_us-gaap_EquipmentMember_aef9c55a-51a8-4563-af13-614d7b76e6d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ce188be8-f160-4b78-b835-c9ae089c85de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:to="loc_us-gaap_OfficeEquipmentMember_ce188be8-f160-4b78-b835-c9ae089c85de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b6e21688-c65f-4d3b-8068-a2ad98d32d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b6e21688-c65f-4d3b-8068-a2ad98d32d5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c07637e7-b18e-47c2-8754-299e288ad8c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:to="loc_srt_RangeAxis_c07637e7-b18e-47c2-8754-299e288ad8c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c07637e7-b18e-47c2-8754-299e288ad8c4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c07637e7-b18e-47c2-8754-299e288ad8c4" xlink:to="loc_srt_RangeMember_c07637e7-b18e-47c2-8754-299e288ad8c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b4665110-5dca-470c-b5dc-dcc8764bfdb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c07637e7-b18e-47c2-8754-299e288ad8c4" xlink:to="loc_srt_RangeMember_b4665110-5dca-470c-b5dc-dcc8764bfdb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_317d4cfd-452a-4f8d-8932-4a699d0569e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b4665110-5dca-470c-b5dc-dcc8764bfdb3" xlink:to="loc_srt_MinimumMember_317d4cfd-452a-4f8d-8932-4a699d0569e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ea8deb7-ac90-414e-84de-105d13f491a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b4665110-5dca-470c-b5dc-dcc8764bfdb3" xlink:to="loc_srt_MaximumMember_4ea8deb7-ac90-414e-84de-105d13f491a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i75c9e304903a4d5f97bb6ae4a9ff7c7f_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfGeographicRegions_d3e5daf1-30a7-4f6a-90b3-f37b20752153" xlink:href="cmps-20230331.xsd#cmps_NumberOfGeographicRegions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_NumberOfGeographicRegions_d3e5daf1-30a7-4f6a-90b3-f37b20752153" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b614e490-5975-4acc-82b5-7a572b2c8a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b614e490-5975-4acc-82b5-7a572b2c8a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca1233fb-f159-4821-a6ca-fcfcecda8ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca1233fb-f159-4821-a6ca-fcfcecda8ad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_124c1953-d3da-4e61-a011-e37982343a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_124c1953-d3da-4e61-a011-e37982343a28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6b9b446f-4017-438d-a756-e3aa087a632f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6b9b446f-4017-438d-a756-e3aa087a632f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_afa4abd7-cb2b-4a5e-a946-665824aaaea3" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_afa4abd7-cb2b-4a5e-a946-665824aaaea3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_0749dd21-e7d5-4a3f-a9e2-643c44ebedce" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_0749dd21-e7d5-4a3f-a9e2-643c44ebedce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims_139fde64-266b-4d45-993c-2ef2f971606c" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims_139fde64-266b-4d45-993c-2ef2f971606c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim_ad491add-b07f-46ec-a4e6-f7b866d842e8" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim_ad491add-b07f-46ec-a4e6-f7b866d842e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_bcffd2c7-5a27-4fc7-9e4d-0c2778ac7ad6" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_bcffd2c7-5a27-4fc7-9e4d-0c2778ac7ad6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_6ee77853-2083-4191-be5b-48650eddbdcf" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_6ee77853-2083-4191-be5b-48650eddbdcf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e6d86019-91a8-4a06-8eb5-2aaa545124a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e6d86019-91a8-4a06-8eb5-2aaa545124a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e6d86019-91a8-4a06-8eb5-2aaa545124a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e6d86019-91a8-4a06-8eb5-2aaa545124a8" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e6d86019-91a8-4a06-8eb5-2aaa545124a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_b7e15f23-547a-4214-806d-dfc32ed9295b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e6d86019-91a8-4a06-8eb5-2aaa545124a8" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_b7e15f23-547a-4214-806d-dfc32ed9295b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_3652adc1-a60a-4213-9e74-2f50a00ccaee" xlink:href="cmps-20230331.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_b7e15f23-547a-4214-806d-dfc32ed9295b" xlink:to="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_3652adc1-a60a-4213-9e74-2f50a00ccaee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_f2358100-bcab-4df5-862e-0d4aeab7dfea" xlink:href="cmps-20230331.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_b7e15f23-547a-4214-806d-dfc32ed9295b" xlink:to="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_f2358100-bcab-4df5-862e-0d4aeab7dfea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637ea4fc-a977-4152-aa51-2d7890c0819d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637ea4fc-a977-4152-aa51-2d7890c0819d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_637ea4fc-a977-4152-aa51-2d7890c0819d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637ea4fc-a977-4152-aa51-2d7890c0819d" xlink:to="loc_us-gaap_TypeOfAdoptionMember_637ea4fc-a977-4152-aa51-2d7890c0819d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e8d3bf3a-7ed4-4bff-8878-6d24877e53a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637ea4fc-a977-4152-aa51-2d7890c0819d" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e8d3bf3a-7ed4-4bff-8878-6d24877e53a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_c14d8a1a-5aa7-43ef-a746-357ee4975604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e8d3bf3a-7ed4-4bff-8878-6d24877e53a5" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_c14d8a1a-5aa7-43ef-a746-357ee4975604" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/OrdinarySharesDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#OrdinarySharesDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/OrdinarySharesDetails" xlink:type="extended" id="i6cc7c6d2c0c4477ba2638818e0cc1457_OrdinarySharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockAmountAuthorized_29d55985-7113-4c07-a32e-e507d94d859f" xlink:href="cmps-20230331.xsd#cmps_SaleOfStockAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_cmps_SaleOfStockAmountAuthorized_29d55985-7113-4c07-a32e-e507d94d859f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85546a86-61dd-480f-9bd5-d178d21dfaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85546a86-61dd-480f-9bd5-d178d21dfaa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65ed56e3-2a6a-45fe-81e8-691097c4b443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65ed56e3-2a6a-45fe-81e8-691097c4b443" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1742ce9a-b163-4077-950a-25cbe7fa0409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1742ce9a-b163-4077-950a-25cbe7fa0409" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_a478ac63-28bb-44ed-b52d-f4a07d9dcdb4" xlink:href="cmps-20230331.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_a478ac63-28bb-44ed-b52d-f4a07d9dcdb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ed246941-3563-4ac8-9cae-46a896a716c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ed246941-3563-4ac8-9cae-46a896a716c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod_dc67b0b4-e701-488a-8506-f51a4c16f38c" xlink:href="cmps-20230331.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod_dc67b0b4-e701-488a-8506-f51a4c16f38c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_32c23e85-4be4-4c7f-bae7-8f8ebc7f7330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_32c23e85-4be4-4c7f-bae7-8f8ebc7f7330" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98ef47c0-d757-4a47-92da-8789ab504adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98ef47c0-d757-4a47-92da-8789ab504adf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_01960e9e-9e09-4547-ac6d-e87ec662762c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_01960e9e-9e09-4547-ac6d-e87ec662762c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_01960e9e-9e09-4547-ac6d-e87ec662762c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01960e9e-9e09-4547-ac6d-e87ec662762c" xlink:to="loc_us-gaap_ClassOfStockDomain_01960e9e-9e09-4547-ac6d-e87ec662762c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d7754e65-5442-4fef-a480-77038631ed68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01960e9e-9e09-4547-ac6d-e87ec662762c" xlink:to="loc_us-gaap_ClassOfStockDomain_d7754e65-5442-4fef-a480-77038631ed68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_a971f9fe-170c-42f1-87ed-6725aa1c5d59" xlink:href="cmps-20230331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d7754e65-5442-4fef-a480-77038631ed68" xlink:to="loc_cmps_AmericanDepositarySharesMember_a971f9fe-170c-42f1-87ed-6725aa1c5d59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_6986e9da-8348-4a63-8846-1d59271c9364" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d7754e65-5442-4fef-a480-77038631ed68" xlink:to="loc_cmps_OrdinarySharesMember_6986e9da-8348-4a63-8846-1d59271c9364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc9de7e5-6731-4257-9e16-eee399824f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc9de7e5-6731-4257-9e16-eee399824f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_26acf952-d15b-4f25-be07-2fb1518df660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cc9de7e5-6731-4257-9e16-eee399824f3c" xlink:to="loc_us-gaap_SubsequentEventMember_26acf952-d15b-4f25-be07-2fb1518df660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VestingPeriodAxis_1af32ffe-cb7d-468f-8ef3-339143ddf96a" xlink:href="cmps-20230331.xsd#cmps_VestingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_cmps_VestingPeriodAxis_1af32ffe-cb7d-468f-8ef3-339143ddf96a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VestingPeriodDomain_1af32ffe-cb7d-468f-8ef3-339143ddf96a_default" xlink:href="cmps-20230331.xsd#cmps_VestingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cmps_VestingPeriodAxis_1af32ffe-cb7d-468f-8ef3-339143ddf96a" xlink:to="loc_cmps_VestingPeriodDomain_1af32ffe-cb7d-468f-8ef3-339143ddf96a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VestingPeriodDomain_9abe4cdd-c3bd-4c3c-b368-1cac55f05a4a" xlink:href="cmps-20230331.xsd#cmps_VestingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cmps_VestingPeriodAxis_1af32ffe-cb7d-468f-8ef3-339143ddf96a" xlink:to="loc_cmps_VestingPeriodDomain_9abe4cdd-c3bd-4c3c-b368-1cac55f05a4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022And2023Member_f4de813f-0341-4eb7-88e1-fb5ebec6f59c" xlink:href="cmps-20230331.xsd#cmps_A2022And2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmps_VestingPeriodDomain_9abe4cdd-c3bd-4c3c-b368-1cac55f05a4a" xlink:to="loc_cmps_A2022And2023Member_f4de813f-0341-4eb7-88e1-fb5ebec6f59c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ab05d0b3-7902-4026-8fac-2540ca9d8e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ab05d0b3-7902-4026-8fac-2540ca9d8e76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ab05d0b3-7902-4026-8fac-2540ca9d8e76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ab05d0b3-7902-4026-8fac-2540ca9d8e76" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ab05d0b3-7902-4026-8fac-2540ca9d8e76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96cdc44c-2b43-465b-8b90-3fef00469a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ab05d0b3-7902-4026-8fac-2540ca9d8e76" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96cdc44c-2b43-465b-8b90-3fef00469a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_a225b69f-b20b-4603-8eda-11659bfb09ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96cdc44c-2b43-465b-8b90-3fef00469a07" xlink:to="loc_us-gaap_IPOMember_a225b69f-b20b-4603-8eda-11659bfb09ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_f5c3f085-3952-49c3-b977-d7a708487b35" xlink:href="cmps-20230331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96cdc44c-2b43-465b-8b90-3fef00469a07" xlink:to="loc_cmps_AtTheMarketOfferingMember_f5c3f085-3952-49c3-b977-d7a708487b35" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation2017EquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="extended" id="i7f38fb62b1ac4b9494e99df9777c3794_ShareBasedCompensation2017EquityIncentivePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cc0d3af0-e183-44a9-8d27-f304f21c7830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cc0d3af0-e183-44a9-8d27-f304f21c7830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7f108525-34a2-4aed-973f-14518c8f80a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7f108525-34a2-4aed-973f-14518c8f80a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2115382f-d635-43fa-ab39-1e8e27222d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2115382f-d635-43fa-ab39-1e8e27222d63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6d36b9b0-05a2-4575-bfe6-e9378873f54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6d36b9b0-05a2-4575-bfe6-e9378873f54f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_51e0e2b2-02a9-4764-8183-d41a389059dc" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_51e0e2b2-02a9-4764-8183-d41a389059dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_e05865c1-dacc-4574-98a4-e5a0a4f4af26" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_e05865c1-dacc-4574-98a4-e5a0a4f4af26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7f6b6f38-7b20-40e2-b09e-46a63f9cf479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_AwardTypeAxis_7f6b6f38-7b20-40e2-b09e-46a63f9cf479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f6b6f38-7b20-40e2-b09e-46a63f9cf479_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7f6b6f38-7b20-40e2-b09e-46a63f9cf479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f6b6f38-7b20-40e2-b09e-46a63f9cf479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7f6b6f38-7b20-40e2-b09e-46a63f9cf479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_bae5bbaf-47b6-4d2a-8355-93590550aa2b" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:to="loc_cmps_OrdinarySharesMember_bae5bbaf-47b6-4d2a-8355-93590550aa2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bc3c599c-86c6-43c6-b718-10d4a0f7ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bc3c599c-86c6-43c6-b718-10d4a0f7ef29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b51e0f42-3a20-44d9-a42a-1e263fb198cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b51e0f42-3a20-44d9-a42a-1e263fb198cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_55e2029d-af9f-4695-b977-6f4ec65f7c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_PlanNameAxis_55e2029d-af9f-4695-b977-6f4ec65f7c82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_55e2029d-af9f-4695-b977-6f4ec65f7c82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_55e2029d-af9f-4695-b977-6f4ec65f7c82" xlink:to="loc_us-gaap_PlanNameDomain_55e2029d-af9f-4695-b977-6f4ec65f7c82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aac04f71-b751-4b15-b1f1-6615b4ce9d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_55e2029d-af9f-4695-b977-6f4ec65f7c82" xlink:to="loc_us-gaap_PlanNameDomain_aac04f71-b751-4b15-b1f1-6615b4ce9d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember_31afdaac-956a-4768-945f-98cb3b9b9a27" xlink:href="cmps-20230331.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_aac04f71-b751-4b15-b1f1-6615b4ce9d82" xlink:to="loc_cmps_A2017EquityIncentivePlanMember_31afdaac-956a-4768-945f-98cb3b9b9a27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_srt_RangeAxis_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab" xlink:to="loc_srt_RangeMember_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37b729df-8e1f-43a6-8236-1a015d67c16b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab" xlink:to="loc_srt_RangeMember_37b729df-8e1f-43a6-8236-1a015d67c16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b629f66-ae4a-4b4c-ae00-402087d51ab4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37b729df-8e1f-43a6-8236-1a015d67c16b" xlink:to="loc_srt_MinimumMember_5b629f66-ae4a-4b4c-ae00-402087d51ab4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8780610b-8bb6-4e1d-87f3-6e2550660a1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37b729df-8e1f-43a6-8236-1a015d67c16b" xlink:to="loc_srt_MaximumMember_8780610b-8bb6-4e1d-87f3-6e2550660a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c65556bd-e904-471a-b989-1a43c3480223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_VestingAxis_c65556bd-e904-471a-b989-1a43c3480223" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c65556bd-e904-471a-b989-1a43c3480223_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_c65556bd-e904-471a-b989-1a43c3480223" xlink:to="loc_us-gaap_VestingDomain_c65556bd-e904-471a-b989-1a43c3480223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cc0c4568-e381-44d1-8fd4-a6e5c4e18f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_c65556bd-e904-471a-b989-1a43c3480223" xlink:to="loc_us-gaap_VestingDomain_cc0c4568-e381-44d1-8fd4-a6e5c4e18f09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a9e99dbc-0a97-4a66-99c7-48a3e6ae2b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_cc0c4568-e381-44d1-8fd4-a6e5c4e18f09" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a9e99dbc-0a97-4a66-99c7-48a3e6ae2b76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3f3fe237-fa87-4ba3-9a82-0923f0e51a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_cc0c4568-e381-44d1-8fd4-a6e5c4e18f09" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3f3fe237-fa87-4ba3-9a82-0923f0e51a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_7bc88a37-d64c-47e0-904b-0b5611046476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_AwardDateAxis_7bc88a37-d64c-47e0-904b-0b5611046476" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_7bc88a37-d64c-47e0-904b-0b5611046476_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_7bc88a37-d64c-47e0-904b-0b5611046476" xlink:to="loc_us-gaap_AwardDateDomain_7bc88a37-d64c-47e0-904b-0b5611046476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_5fde4176-162a-4c05-80e4-86b2cd48fc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_7bc88a37-d64c-47e0-904b-0b5611046476" xlink:to="loc_us-gaap_AwardDateDomain_5fde4176-162a-4c05-80e4-86b2cd48fc2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member_0ae69dfa-8733-40aa-aea5-99de6d623099" xlink:href="cmps-20230331.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_5fde4176-162a-4c05-80e4-86b2cd48fc2e" xlink:to="loc_cmps_OptionsGrantedBeforeJune302020Member_0ae69dfa-8733-40aa-aea5-99de6d623099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member_8e91ff17-ac33-492d-92e2-cdf3491f3442" xlink:href="cmps-20230331.xsd#cmps_GrantDateJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_5fde4176-162a-4c05-80e4-86b2cd48fc2e" xlink:to="loc_cmps_GrantDateJune302020Member_8e91ff17-ac33-492d-92e2-cdf3491f3442" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="extended" id="ice8a7427b1234410bc0c700359157106_ShareBasedCompensation2020EmployeeSharePurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55e73b9f-0d86-4ce1-add5-9b6167753b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55e73b9f-0d86-4ce1-add5-9b6167753b9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_faba8521-7596-4dff-9bf6-b50bdb8e7802" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_faba8521-7596-4dff-9bf6-b50bdb8e7802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_7f40ceba-9f4c-4125-9d8a-6755fa2d34e5" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_7f40ceba-9f4c-4125-9d8a-6755fa2d34e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_0dd90315-8525-4d1d-8d04-d0b69302362f" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_0dd90315-8525-4d1d-8d04-d0b69302362f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_aaf72011-1a65-4015-871f-371d4467e73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_aaf72011-1a65-4015-871f-371d4467e73d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75bef30f-6d50-4b41-8bf1-39a83ca041d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75bef30f-6d50-4b41-8bf1-39a83ca041d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b06296b0-3bbc-4a65-b86e-f7bf73627fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75bef30f-6d50-4b41-8bf1-39a83ca041d7" xlink:to="loc_us-gaap_AwardTypeAxis_b06296b0-3bbc-4a65-b86e-f7bf73627fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b06296b0-3bbc-4a65-b86e-f7bf73627fc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b06296b0-3bbc-4a65-b86e-f7bf73627fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b06296b0-3bbc-4a65-b86e-f7bf73627fc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_916bc00f-8424-441e-a1c6-332aa5b15f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b06296b0-3bbc-4a65-b86e-f7bf73627fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_916bc00f-8424-441e-a1c6-332aa5b15f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_dd559122-b7d6-451e-80d8-fec8b22a979a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_916bc00f-8424-441e-a1c6-332aa5b15f48" xlink:to="loc_us-gaap_EmployeeStockMember_dd559122-b7d6-451e-80d8-fec8b22a979a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation2020ShareOptionPlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="extended" id="i4db51fd5f35b4a02bf3e38eaa1b56b95_ShareBasedCompensation2020ShareOptionPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e4f49870-507c-46da-b1c4-c185e5653995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e4f49870-507c-46da-b1c4-c185e5653995" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df3b004c-8e91-4dae-9ccb-381bdc7c0176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df3b004c-8e91-4dae-9ccb-381bdc7c0176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2bad4ea2-1eb8-4e9f-abd2-b0e9891e136b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2bad4ea2-1eb8-4e9f-abd2-b0e9891e136b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_aac5acbe-7d97-401d-bad8-d09932d36fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_aac5acbe-7d97-401d-bad8-d09932d36fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_99c0e7c8-6f5f-4627-a466-69305c6c4f93" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_99c0e7c8-6f5f-4627-a466-69305c6c4f93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_42f3932e-2434-4b20-b513-5e877666dac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_SharesIssued_42f3932e-2434-4b20-b513-5e877666dac6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_147ec6eb-dbe5-4230-8ce6-2b44fd4407b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_147ec6eb-dbe5-4230-8ce6-2b44fd4407b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8bef7a9-2de2-423f-b67a-4c6f8806caa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8bef7a9-2de2-423f-b67a-4c6f8806caa3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_068f81de-725a-481d-a678-a719df647fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_AwardTypeAxis_068f81de-725a-481d-a678-a719df647fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_068f81de-725a-481d-a678-a719df647fcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_068f81de-725a-481d-a678-a719df647fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_068f81de-725a-481d-a678-a719df647fcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_068f81de-725a-481d-a678-a719df647fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_3e559228-295e-4097-b25c-0732feb49cce" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:to="loc_cmps_OrdinarySharesMember_3e559228-295e-4097-b25c-0732feb49cce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4e90ba24-0eda-42ca-86c5-126f357b0f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:to="loc_us-gaap_EmployeeStockMember_4e90ba24-0eda-42ca-86c5-126f357b0f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa8d3e21-21cf-4a28-912c-cea40802ee39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa8d3e21-21cf-4a28-912c-cea40802ee39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3f824660-267a-4f7a-9d62-677dd8edc1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_PlanNameAxis_3f824660-267a-4f7a-9d62-677dd8edc1e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3f824660-267a-4f7a-9d62-677dd8edc1e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3f824660-267a-4f7a-9d62-677dd8edc1e5" xlink:to="loc_us-gaap_PlanNameDomain_3f824660-267a-4f7a-9d62-677dd8edc1e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_56ed6b1f-7b27-4bae-b5a9-7d7606e4d1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3f824660-267a-4f7a-9d62-677dd8edc1e5" xlink:to="loc_us-gaap_PlanNameDomain_56ed6b1f-7b27-4bae-b5a9-7d7606e4d1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember_aa7a9bac-1811-4cb4-a906-9f43661caa43" xlink:href="cmps-20230331.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_56ed6b1f-7b27-4bae-b5a9-7d7606e4d1cd" xlink:to="loc_cmps_A2020ShareOptionPlanMember_aa7a9bac-1811-4cb4-a906-9f43661caa43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ee2042a9-d2be-43da-a07d-83388115ea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ee2042a9-d2be-43da-a07d-83388115ea1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ee2042a9-d2be-43da-a07d-83388115ea1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee2042a9-d2be-43da-a07d-83388115ea1e" xlink:to="loc_us-gaap_ClassOfStockDomain_ee2042a9-d2be-43da-a07d-83388115ea1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_55ee1606-68ad-4115-92d5-6d017d9ae2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee2042a9-d2be-43da-a07d-83388115ea1e" xlink:to="loc_us-gaap_ClassOfStockDomain_55ee1606-68ad-4115-92d5-6d017d9ae2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_8534bbd5-ce1f-471a-8709-aa7fc8f8aabb" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_55ee1606-68ad-4115-92d5-6d017d9ae2fa" xlink:to="loc_cmps_OrdinarySharesMember_8534bbd5-ce1f-471a-8709-aa7fc8f8aabb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0c785f8a-2657-4bc0-9508-26811dad8080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_VestingAxis_0c785f8a-2657-4bc0-9508-26811dad8080" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0c785f8a-2657-4bc0-9508-26811dad8080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_0c785f8a-2657-4bc0-9508-26811dad8080" xlink:to="loc_us-gaap_VestingDomain_0c785f8a-2657-4bc0-9508-26811dad8080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_0c785f8a-2657-4bc0-9508-26811dad8080" xlink:to="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_67f185a9-23fa-477b-be3e-755ceb38aa29" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_67f185a9-23fa-477b-be3e-755ceb38aa29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_a09794d9-2110-4c6f-8bfe-b88308f3afcf" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_a09794d9-2110-4c6f-8bfe-b88308f3afcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_b7d4af21-477d-410d-a19f-ca922bb56f5d" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_b7d4af21-477d-410d-a19f-ca922bb56f5d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation2022InducementGrantOptionAwardDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="extended" id="i786ebc6c3c1d4ffdac5efa49d061dd42_ShareBasedCompensation2022InducementGrantOptionAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c870e9da-8fa0-490f-9379-b0c96e3395f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c870e9da-8fa0-490f-9379-b0c96e3395f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8db73f84-2220-48fd-a426-f1fc7bb7edc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8db73f84-2220-48fd-a426-f1fc7bb7edc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4b8e11d1-6a3b-4d67-8a4f-fc355e4fe2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4b8e11d1-6a3b-4d67-8a4f-fc355e4fe2c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_40ab17c5-fbf2-4c60-9068-e739a1f5d8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_40ab17c5-fbf2-4c60-9068-e739a1f5d8fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_62b5101f-ccca-4ff2-a1ad-5975572890c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:to="loc_us-gaap_PlanNameAxis_62b5101f-ccca-4ff2-a1ad-5975572890c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_62b5101f-ccca-4ff2-a1ad-5975572890c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_62b5101f-ccca-4ff2-a1ad-5975572890c9" xlink:to="loc_us-gaap_PlanNameDomain_62b5101f-ccca-4ff2-a1ad-5975572890c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0465ee5b-abc6-425b-a8fb-14ab76d2fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_62b5101f-ccca-4ff2-a1ad-5975572890c9" xlink:to="loc_us-gaap_PlanNameDomain_0465ee5b-abc6-425b-a8fb-14ab76d2fa4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember_48d09b2e-48cd-4723-a8ab-ca29b0cb70d5" xlink:href="cmps-20230331.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0465ee5b-abc6-425b-a8fb-14ab76d2fa4b" xlink:to="loc_cmps_A2022InducementGrantOptionAwardMember_48d09b2e-48cd-4723-a8ab-ca29b0cb70d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1791ec8a-c0be-4f51-af0b-ef9d8198f430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:to="loc_us-gaap_VestingAxis_1791ec8a-c0be-4f51-af0b-ef9d8198f430" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1791ec8a-c0be-4f51-af0b-ef9d8198f430_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1791ec8a-c0be-4f51-af0b-ef9d8198f430" xlink:to="loc_us-gaap_VestingDomain_1791ec8a-c0be-4f51-af0b-ef9d8198f430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b7279df1-b521-4d8f-841f-f554b50113be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1791ec8a-c0be-4f51-af0b-ef9d8198f430" xlink:to="loc_us-gaap_VestingDomain_b7279df1-b521-4d8f-841f-f554b50113be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_c49c8c22-c3b7-455f-8f20-52d755e36b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b7279df1-b521-4d8f-841f-f554b50113be" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_c49c8c22-c3b7-455f-8f20-52d755e36b58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_706d335a-8701-448f-bc40-3acd457e872f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b7279df1-b521-4d8f-841f-f554b50113be" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_706d335a-8701-448f-bc40-3acd457e872f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_872c8f83-e188-4910-8d6c-1e1d2162c648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:to="loc_us-gaap_StatementClassOfStockAxis_872c8f83-e188-4910-8d6c-1e1d2162c648" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_872c8f83-e188-4910-8d6c-1e1d2162c648_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_872c8f83-e188-4910-8d6c-1e1d2162c648" xlink:to="loc_us-gaap_ClassOfStockDomain_872c8f83-e188-4910-8d6c-1e1d2162c648_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_98453581-2ae2-453d-81f6-b92a8c660ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_872c8f83-e188-4910-8d6c-1e1d2162c648" xlink:to="loc_us-gaap_ClassOfStockDomain_98453581-2ae2-453d-81f6-b92a8c660ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_1b88117a-8910-4b0b-babf-ebb6166cc4d5" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_98453581-2ae2-453d-81f6-b92a8c660ee4" xlink:to="loc_cmps_OrdinarySharesMember_1b88117a-8910-4b0b-babf-ebb6166cc4d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensationRestrictedShareUnitsDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="extended" id="i66d58aabd74f445c9c4e532609acb7c4_ShareBasedCompensationRestrictedShareUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_8f47e20d-ebcf-4b9f-8f22-9374e216d315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_8f47e20d-ebcf-4b9f-8f22-9374e216d315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac93d099-ddb0-4c70-b14c-a248c5a6138d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac93d099-ddb0-4c70-b14c-a248c5a6138d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_9443d9e9-5bc4-4ba6-8138-8fbbca58cf71" xlink:href="cmps-20230331.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_9443d9e9-5bc4-4ba6-8138-8fbbca58cf71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_51c731df-4484-42cb-91a5-6c166de32dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_51c731df-4484-42cb-91a5-6c166de32dba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1b96f389-f515-4e8c-b75c-e9dc7916c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2abacaa6-ed47-4efe-9aa1-6ccaf68fdd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2abacaa6-ed47-4efe-9aa1-6ccaf68fdd4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2c011a4-f0b4-40ab-b760-ed64bb53f3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2c011a4-f0b4-40ab-b760-ed64bb53f3d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6cbc00aa-9a10-415c-978a-6745b2f03b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6cbc00aa-9a10-415c-978a-6745b2f03b1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_cc7a9336-c7da-441f-85a7-4a8aacb5fbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_cc7a9336-c7da-441f-85a7-4a8aacb5fbb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_aa1681f8-f40f-446c-b2e7-9fdc1cb4132f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_872e2ca8-1f63-421d-9866-b539617d4a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_872e2ca8-1f63-421d-9866-b539617d4a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf9218c-757e-4c20-808a-1de4327b3960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf9218c-757e-4c20-808a-1de4327b3960" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_e10b4492-08a5-421d-9858-8ffb830ef7ed" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_e10b4492-08a5-421d-9858-8ffb830ef7ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41e7f8ab-e0c3-492f-b7b1-cd17032386cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41e7f8ab-e0c3-492f-b7b1-cd17032386cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_052c81bf-eda7-47a9-803a-e8f4607d6319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41e7f8ab-e0c3-492f-b7b1-cd17032386cb" xlink:to="loc_us-gaap_AwardTypeAxis_052c81bf-eda7-47a9-803a-e8f4607d6319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_052c81bf-eda7-47a9-803a-e8f4607d6319_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_052c81bf-eda7-47a9-803a-e8f4607d6319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_052c81bf-eda7-47a9-803a-e8f4607d6319_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244bd729-1086-48cb-9552-383ec588fecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_052c81bf-eda7-47a9-803a-e8f4607d6319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244bd729-1086-48cb-9552-383ec588fecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62549777-d607-4520-a337-83988829fbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244bd729-1086-48cb-9552-383ec588fecf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62549777-d607-4520-a337-83988829fbc0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#SharebasedCompensationShareOptionsDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails" xlink:type="extended" id="i81ba017884694abda2bfb3e5075dfa42_SharebasedCompensationShareOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb817f18-1c12-4047-81d6-762c065c248a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb817f18-1c12-4047-81d6-762c065c248a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3085113b-72d7-436c-a995-dc3bb3391795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3085113b-72d7-436c-a995-dc3bb3391795" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68df1aec-3c80-4686-83d8-17544d489f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68df1aec-3c80-4686-83d8-17544d489f90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_36602ac5-0832-441f-8f32-9309c21c21e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_36602ac5-0832-441f-8f32-9309c21c21e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8eb13792-534d-431a-af64-87d805819775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_606a7995-d4ba-4898-b2f2-94e199536ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_606a7995-d4ba-4898-b2f2-94e199536ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_09a35ac2-3873-4383-84e1-3b3a5c6210c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_09a35ac2-3873-4383-84e1-3b3a5c6210c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0555e8ab-9e19-4af2-bffb-9767957b5a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0555e8ab-9e19-4af2-bffb-9767957b5a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a292b88c-0750-43e8-8dd1-e30d835c3905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a292b88c-0750-43e8-8dd1-e30d835c3905" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_346502f8-4b8b-4ab4-99a3-3de936d997ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_346502f8-4b8b-4ab4-99a3-3de936d997ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ca7b27b4-4438-4a89-9fc0-c58434078996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ca7b27b4-4438-4a89-9fc0-c58434078996" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92ef0838-9049-471b-b55d-4c9a29b65770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_807a5e37-4d06-4930-92c0-7c323d861305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_807a5e37-4d06-4930-92c0-7c323d861305" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_480bd15c-389d-403c-8fb1-dabdeced6432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_480bd15c-389d-403c-8fb1-dabdeced6432" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_44d3bccf-e895-4c21-89eb-dd770366406f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_44d3bccf-e895-4c21-89eb-dd770366406f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74ccef2b-2bb4-4411-a0d1-9dc734a6c894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74ccef2b-2bb4-4411-a0d1-9dc734a6c894" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_7427e893-ccfc-431a-90fc-d81a0216d039" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_7427e893-ccfc-431a-90fc-d81a0216d039" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_09363ad1-59dd-4b32-b7fb-1b28e0d676c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_09363ad1-59dd-4b32-b7fb-1b28e0d676c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_19d18cf4-c295-4f34-b7aa-0a5aa1ec1c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_19d18cf4-c295-4f34-b7aa-0a5aa1ec1c21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_2b8e4f1d-79a2-4ac8-b167-2e37d41d122e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_2b8e4f1d-79a2-4ac8-b167-2e37d41d122e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_39259439-a0bc-4956-9e72-60cad514beba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_39259439-a0bc-4956-9e72-60cad514beba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6dec3f2-f4b2-4d47-b2de-f5dcd7a3f49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6dec3f2-f4b2-4d47-b2de-f5dcd7a3f49a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5969aaba-b093-4643-9118-7aec5c5d239d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5969aaba-b093-4643-9118-7aec5c5d239d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_522fed6f-41a7-447b-a6bf-3221a83314dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_522fed6f-41a7-447b-a6bf-3221a83314dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ff3b9d81-b859-4de2-8a9f-52866c004a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:to="loc_us-gaap_AwardTypeAxis_ff3b9d81-b859-4de2-8a9f-52866c004a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff3b9d81-b859-4de2-8a9f-52866c004a03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ff3b9d81-b859-4de2-8a9f-52866c004a03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff3b9d81-b859-4de2-8a9f-52866c004a03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3def7867-6ae7-479d-9ce0-4e716b2158c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ff3b9d81-b859-4de2-8a9f-52866c004a03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3def7867-6ae7-479d-9ce0-4e716b2158c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c893d823-59fc-4a45-b9b7-ca850345c607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3def7867-6ae7-479d-9ce0-4e716b2158c8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c893d823-59fc-4a45-b9b7-ca850345c607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8" xlink:to="loc_us-gaap_ClassOfStockDomain_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dea358e0-0e84-44ef-ba0a-2d8c6c326253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8" xlink:to="loc_us-gaap_ClassOfStockDomain_dea358e0-0e84-44ef-ba0a-2d8c6c326253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_43e7c1e4-2f81-40e3-b2dd-9a82148d7eab" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dea358e0-0e84-44ef-ba0a-2d8c6c326253" xlink:to="loc_cmps_OrdinarySharesMember_43e7c1e4-2f81-40e3-b2dd-9a82148d7eab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="idae086bdfcc6477394a937c5e443c2bf_ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e24d54f8-9068-465c-bcf5-3310b3b002db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_30c2d679-1ec8-4d5d-b5ca-d045079aa0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e24d54f8-9068-465c-bcf5-3310b3b002db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_30c2d679-1ec8-4d5d-b5ca-d045079aa0bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6027091c-07cc-4ebb-9e48-ed842bae28f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e24d54f8-9068-465c-bcf5-3310b3b002db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6027091c-07cc-4ebb-9e48-ed842bae28f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4ee1ee20-a012-4111-9d98-505ec9c6506c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6027091c-07cc-4ebb-9e48-ed842bae28f8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4ee1ee20-a012-4111-9d98-505ec9c6506c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4ee1ee20-a012-4111-9d98-505ec9c6506c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4ee1ee20-a012-4111-9d98-505ec9c6506c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4ee1ee20-a012-4111-9d98-505ec9c6506c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ba86ab5b-4665-4a68-8d98-b0667c254c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4ee1ee20-a012-4111-9d98-505ec9c6506c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ba86ab5b-4665-4a68-8d98-b0667c254c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7c6ba0d1-9717-4dd9-b4e4-1bbbb62c012d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ba86ab5b-4665-4a68-8d98-b0667c254c65" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7c6ba0d1-9717-4dd9-b4e4-1bbbb62c012d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_accb63e2-75a3-4503-8c49-f9791d2b8834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ba86ab5b-4665-4a68-8d98-b0667c254c65" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_accb63e2-75a3-4503-8c49-f9791d2b8834" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i9148dadf0c904191980a4ecfd82e69fa_NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3d2f1add-45ab-4928-94a5-f8857ded1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e7e5545a-6d99-4ea2-b300-f5a8e976e17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3d2f1add-45ab-4928-94a5-f8857ded1e58" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e7e5545a-6d99-4ea2-b300-f5a8e976e17a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9dad6894-3a0b-4f81-b564-2e3cc26b86f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3d2f1add-45ab-4928-94a5-f8857ded1e58" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9dad6894-3a0b-4f81-b564-2e3cc26b86f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1bebc62-c79c-4201-8665-e70113c7e386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9dad6894-3a0b-4f81-b564-2e3cc26b86f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1bebc62-c79c-4201-8665-e70113c7e386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1bebc62-c79c-4201-8665-e70113c7e386_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1bebc62-c79c-4201-8665-e70113c7e386" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b1bebc62-c79c-4201-8665-e70113c7e386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bead0ac6-ead9-42f9-80db-4ec8f6f9248d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1bebc62-c79c-4201-8665-e70113c7e386" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bead0ac6-ead9-42f9-80db-4ec8f6f9248d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember_00dd7e5a-c5e5-4272-87aa-914707711bc2" xlink:href="cmps-20230331.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bead0ac6-ead9-42f9-80db-4ec8f6f9248d" xlink:to="loc_cmps_UnvestedRestrictedShareUnitsMember_00dd7e5a-c5e5-4272-87aa-914707711bc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember_12666d63-1ae8-425e-a494-d87801569337" xlink:href="cmps-20230331.xsd#cmps_ShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bead0ac6-ead9-42f9-80db-4ec8f6f9248d" xlink:to="loc_cmps_ShareOptionsMember_12666d63-1ae8-425e-a494-d87801569337" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails" xlink:type="extended" id="i9a778923fb46481c8644868b0cb1f4bc_RightofuseofassetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_34daa9fc-21f5-49b9-bfc1-d9f74c2365f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_34daa9fc-21f5-49b9-bfc1-d9f74c2365f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseCancellationNotificationPeriod_33a1c649-44b8-4b42-9870-fba5bbafea29" xlink:href="cmps-20230331.xsd#cmps_LeaseCancellationNotificationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_LeaseCancellationNotificationPeriod_33a1c649-44b8-4b42-9870-fba5bbafea29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeasesNoncancelableTerm_51969fb4-f6a3-40f5-9ddc-90fea812da59" xlink:href="cmps-20230331.xsd#cmps_OperatingLeasesNoncancelableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_OperatingLeasesNoncancelableTerm_51969fb4-f6a3-40f5-9ddc-90fea812da59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseMonthlyPayment_5a59de8b-070e-4952-975b-d4de1171de6c" xlink:href="cmps-20230331.xsd#cmps_OperatingLeaseMonthlyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_OperatingLeaseMonthlyPayment_5a59de8b-070e-4952-975b-d4de1171de6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RefundableLeaseDepositPayments_e60ffd62-4e80-4ed2-932e-56a6ded91371" xlink:href="cmps-20230331.xsd#cmps_RefundableLeaseDepositPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_RefundableLeaseDepositPayments_e60ffd62-4e80-4ed2-932e-56a6ded91371" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseAnnualPayment_121ea607-d183-484a-b64d-85e08ce3a053" xlink:href="cmps-20230331.xsd#cmps_OperatingLeaseAnnualPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_OperatingLeaseAnnualPayment_121ea607-d183-484a-b64d-85e08ce3a053" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9caad056-d37c-49f0-bcba-4eece6bc4a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9caad056-d37c-49f0-bcba-4eece6bc4a47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_28243423-226b-47a3-b60d-2193adc8e782" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9caad056-d37c-49f0-bcba-4eece6bc4a47" xlink:to="loc_srt_CounterpartyNameAxis_28243423-226b-47a3-b60d-2193adc8e782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28243423-226b-47a3-b60d-2193adc8e782_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_28243423-226b-47a3-b60d-2193adc8e782" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28243423-226b-47a3-b60d-2193adc8e782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_28243423-226b-47a3-b60d-2193adc8e782" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WeWorkMember_caeab20d-030a-4489-9952-a2545525bc6b" xlink:href="cmps-20230331.xsd#cmps_WeWorkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:to="loc_cmps_WeWorkMember_caeab20d-030a-4489-9952-a2545525bc6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SohoLondonUKMember_30ab2d04-588d-4a65-94ee-022d95589e00" xlink:href="cmps-20230331.xsd#cmps_SohoLondonUKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:to="loc_cmps_SohoLondonUKMember_30ab2d04-588d-4a65-94ee-022d95589e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DenmarkHillLondonUKMember_fa36717e-40d1-4473-af66-3e221aeeb404" xlink:href="cmps-20230331.xsd#cmps_DenmarkHillLondonUKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:to="loc_cmps_DenmarkHillLondonUKMember_fa36717e-40d1-4473-af66-3e221aeeb404" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/SubsequentEventsDetails" xlink:type="extended" id="if8c638ff64b24c76a949b60281caa748_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6ccb1b20-2e7b-4181-a3e8-d09f55b68911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6ccb1b20-2e7b-4181-a3e8-d09f55b68911" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeasesNoncancelableTerm_6bab532a-f783-468a-99d1-0ed9698dadf5" xlink:href="cmps-20230331.xsd#cmps_OperatingLeasesNoncancelableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_cmps_OperatingLeasesNoncancelableTerm_6bab532a-f783-468a-99d1-0ed9698dadf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseMonthlyPayment_e041da12-1b4c-4a10-95a6-4c3fca460d4a" xlink:href="cmps-20230331.xsd#cmps_OperatingLeaseMonthlyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_cmps_OperatingLeaseMonthlyPayment_e041da12-1b4c-4a10-95a6-4c3fca460d4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RefundableLeaseDepositPayments_e5865d6b-6b8f-425b-8e49-93783f9950ef" xlink:href="cmps-20230331.xsd#cmps_RefundableLeaseDepositPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_cmps_RefundableLeaseDepositPayments_e5865d6b-6b8f-425b-8e49-93783f9950ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f57917a7-3f02-4f5e-be16-f6b821c2db92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f57917a7-3f02-4f5e-be16-f6b821c2db92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_387c6709-8508-4428-99a6-bbc83916778c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_387c6709-8508-4428-99a6-bbc83916778c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e5fdcce2-7cdb-4555-ae10-22044cee4769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e5fdcce2-7cdb-4555-ae10-22044cee4769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b60589ea-ad80-4288-aa5c-34e733e27495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e5fdcce2-7cdb-4555-ae10-22044cee4769" xlink:to="loc_us-gaap_SubsequentEventMember_b60589ea-ad80-4288-aa5c-34e733e27495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f3cba185-ea0e-470b-af15-5c64085d4526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f3cba185-ea0e-470b-af15-5c64085d4526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f3cba185-ea0e-470b-af15-5c64085d4526_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f3cba185-ea0e-470b-af15-5c64085d4526" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f3cba185-ea0e-470b-af15-5c64085d4526_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3fcca7e1-3855-493c-91d8-9fda0a0a1907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f3cba185-ea0e-470b-af15-5c64085d4526" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3fcca7e1-3855-493c-91d8-9fda0a0a1907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_438dc906-746e-48a4-af90-54fa7361d17a" xlink:href="cmps-20230331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3fcca7e1-3855-493c-91d8-9fda0a0a1907" xlink:to="loc_cmps_AtTheMarketOfferingMember_438dc906-746e-48a4-af90-54fa7361d17a" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cmps-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:faa56455-90dd-4209-830a-f12e1735b5b9,g:47fba99e-051e-4c82-b324-f1efc6936c36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_294ca118-073d-4ef1-bc74-353f78c39923_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_7723fa25-a6d4-4045-ba89-a8ca9bb3960a_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in pound sterling per share)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_2edd9028-7f14-4daa-8d82-02faa68dc119_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_071bf207-f985-4921-a1f8-76c5d6270716_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f56c286-b21d-4bc5-a957-9518b1eb6554_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1374c9a3-bbbc-4024-be1b-e61fdc8c399b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_c73b86ed-d75d-4df6-8b53-20ccf841dd26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e30f31b8-9bc6-49fc-9851-1da08291ca13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NumberOfGeographicRegions_6757fb2b-ee34-48ac-bdab-0ada26573567_terseLabel_en-US" xlink:label="lab_cmps_NumberOfGeographicRegions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of geographic regions</link:label>
    <link:label id="lab_cmps_NumberOfGeographicRegions_label_en-US" xlink:label="lab_cmps_NumberOfGeographicRegions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Geographic Regions</link:label>
    <link:label id="lab_cmps_NumberOfGeographicRegions_documentation_en-US" xlink:label="lab_cmps_NumberOfGeographicRegions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Geographic Regions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfGeographicRegions" xlink:href="cmps-20230331.xsd#cmps_NumberOfGeographicRegions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NumberOfGeographicRegions" xlink:to="lab_cmps_NumberOfGeographicRegions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d71bb7f3-1ebd-4f23-b8a0-32516f0cf843_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_5cac4f93-1c59-467c-9176-d6303bca21f1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_a7d8ee01-18b5-4ae7-a669-134e77ea4e35_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b11aa0ce-264c-45c0-a7c1-24f09c36e842_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9bf01b43-1de7-496f-883e-3d6765842a18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_788ae3d8-d205-470d-b6b9-74ee6c5bdee2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0f1d8d44-7ab7-4d6d-8d10-8bb7a88ca495_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5e99208d-ab34-4bc9-8ae0-2c1eed59370a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_25f1e0ea-977f-4276-a382-97e78191cd61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised during the period (less than in 2023)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_d879e400-9bd6-4edf-976e-d1385a134870_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fba6aa48-b9ba-4682-932d-c797fbd1f75c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average ordinary shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_919bf35f-f4e4-4ad5-979b-b5d778be60a9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived_69c30f20-2ed8-4db6-8f1f-aa198ec1f677_terseLabel_en-US" xlink:label="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options received and recorded in other current assets</link:label>
    <link:label id="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived_label_en-US" xlink:label="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised, Not Received</link:label>
    <link:label id="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived_documentation_en-US" xlink:label="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised, Not Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:href="cmps-20230331.xsd#cmps_ProceedsFromStockOptionsExercisedNotReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:to="lab_cmps_ProceedsFromStockOptionsExercisedNotReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f1e8b205-8713-4826-830d-ba6e6071ee6f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_0d5ce5bb-d154-456f-baae-6f85295b720a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INCOME, NET:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_aa6c824e-d2df-4e0e-b57a-e88a2834af53_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary and deferred shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2f96243c-6089-4f67-b721-0d2d6c334b14_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f9cc5aab-0995-4847-9ba7-97fcd0a5d08f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c25a2440-09c7-44a4-9133-beb239469cdc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units issued in settlement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2478cf63-fa55-42a9-9be9-3660f197b215_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e8f8c84-958d-4810-91a9-fc780b30b1bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of share options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2a4823a4-5ab7-456c-8d8e-2a2e0cf8c674_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_448fc40f-a0ea-4a78-a6cb-ef36c9847589_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_fffa1ad7-d969-4132-bc4c-b6fab656cd90_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued related to vesting of restricted share units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_04d784b6-6a5b-4c37-aec1-bb2e5e33be79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7f807057-baf8-4ccb-884f-acffe0e4fa5a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_82c7682e-8e65-4108-aeec-fa35e82b08de_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_7e3fe0ed-9613-4a8a-9f17-735d983d8910_terseLabel_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary share conversion ratio</link:label>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_label_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ordinary Shares Conversion Ratio</link:label>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_documentation_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ordinary Shares Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio" xlink:href="cmps-20230331.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NumberOfOrdinarySharesConversionRatio" xlink:to="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_813e5937-c305-4528-aabf-21a58af170cd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8ce2d44-b676-421f-a9fa-cc107f356b34_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eed789a8-96a1-4b59-8f58-2047ce05b83c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a6adddf7-fb56-4fd8-bcd6-24b070e2da8a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_ca8780fc-1acb-411c-bb05-a963a5a83635_terseLabel_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Research And Development, Current</link:label>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:href="cmps-20230331.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:to="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_db92b04d-3eda-4b79-8aac-f0caabc5c081_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c521f446-8ec3-4f9b-9431-02c33e2e9594_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0f6e73ae-a904-426f-9d3e-6c150c2c9c2a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to ordinary shareholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod_60ba6d9a-9651-4b9d-aa69-2bf6330cf0e3_terseLabel_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled (in shares)</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod_label_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Settled In Period</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod_documentation_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Settled In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" xlink:href="cmps-20230331.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" xlink:to="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3139d634-b9a3-4ec5-9302-c6f7e26b7079_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_cd7acf69-8328-49fd-869a-2302a7678d97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_e6eed434-3de0-44a1-a9f8-cf5dec4ab10b_terseLabel_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember" xlink:href="cmps-20230331.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2017EquityIncentivePlanMember" xlink:to="lab_cmps_A2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims_bbccdd50-2301-42d5-8b80-034807328b34_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap on payable claims (in GBP)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Cap on Payable Credit Claims</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Cap on Payable Credit Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_31e4f5df-edd6-4d2e-b6a4-81fcfdd18763_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7b931255-e29a-4675-8d17-8a04c7417c8a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_dc9e7b69-b7fc-4292-b60b-451d86a6baa6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9753246e-a798-46a0-be1c-e318c338ce36_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9fa46888-6b4a-4e8c-bd4d-774449117b1e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6e6248b8-182c-493b-833e-a2fd05b98fbb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_f592f7d4-5ea1-4bfa-9f08-51b52302e3c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_0a8abebf-e975-4914-998c-e245aa4f741f_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting condition three</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Three [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b6cc2e34-2982-48f6-806a-3a4f74be6ae7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1e4c4b4e-d34b-4319-8c8e-b371d457a75a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cb217b05-b041-440e-b4aa-b50c2d23a68b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_11d82ccd-aad1-477e-a82a-33901a061801_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aid claimable (in euros)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Total Aid Claimable</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Total Aid Claimable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_6da0c5ae-3287-4f53-ad2c-1b07b235f832_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance premium</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b7f170a5-f758-475c-89a4-54eecf9dd4fa_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bc5c6f0e-2232-4529-bbd4-e7a1647a7e3d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2126ccf9-5a74-4d02-8233-b23250c0f50e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ed359f25-7e68-4a74-9811-9382fc560304_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_de7dd66e-1215-4b93-bdce-163f37de07dd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_f10c533d-e1b9-4ed0-a835-f735685fba16_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_dfaac23e-12c2-4f8b-bc98-55c52386409f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9f075d5d-6c78-4f1c-b976-055ab2db65e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting percentage (in percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_59d063d4-3445-4d91-9d34-45aa1c2acf2e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_6fbf9603-f4f5-4070-b41e-7a34ea1a35fa_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UK R&amp;D tax credit</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Current</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_5537498b-bf58-4c9d-9180-93d6776b0865_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim_f3ab5466-1037-4af6-8caa-8e2f11610f04_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum qualifying research and development expenditures with connected parties (in percent)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expenditures Tax Credit, Connected Parties Maximum Percentage of Total Claim</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expenditures Tax Credit, Connected Parties Maximum Percentage of Total Claim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" xlink:to="lab_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c93f6e33-ccb6-4737-b71e-b729ce296f5b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2b1c7dc5-e5f6-49f0-96b4-f654530f4810_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_f031943b-cc7e-4de5-bb7c-9bbcf5552be5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_55e54274-d254-42ef-848e-a67dff718048_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0eb27dd0-e346-4a40-a929-10f97ed19dc8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_29705a5e-86c7-45ed-86ad-836e6641e7cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_292b359f-4a2b-4657-b73e-faf9715d3c0d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fc7a68db-d437-4868-a873-9d24cd1dd435_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e8c3d884-1e64-4113-ba99-b9413f2029aa_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e20ec714-e88c-410a-81d5-2d7baafd8889_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_22a20e75-e762-4dc4-97f8-c4397d529da7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9d162db9-4a64-4458-ac41-ab43794e8a38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1b498f03-a949-4048-a61a-7ae8f3281c33_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_e0f8e106-d836-4e5f-a70d-a6c603421fd6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_83f4b188-1bcb-45f4-aaef-707db5b4ba55_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d1789582-b650-4cd9-adae-f6f8845d853b_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e31cacf-8d8f-42d3-b47d-5af7b20b30e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ab6cd87-0d41-48fa-8651-394a82c17789_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_5a0f65ba-fce4-49e3-bc5e-59414e773e5e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Contract Costs, Prepayments and Accruals</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f3a578a9-4f2a-478c-b637-5bf5afb777b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_0b356411-8428-4216-ba36-316817a28789_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage amount closing price is higher than listing price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_38280c48-2b80-40bd-8bf8-9ca27f515613_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_db52b7b6-4db6-4b9c-9d0c-acf1eeec45cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_118346cf-1b77-4c60-8573-f5e532c3298f_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0249e3e-e6ce-4684-aa5b-f72215f24b14_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b010f6b-9356-40ab-ab66-52821ad78ee7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_48872262-93db-452b-bdb5-3ce904690a19_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_394fc754-3356-4690-90be-c1afaab217f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a9645d1c-ee09-49d9-a8aa-c932039f4cbc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b31018ab-5f71-4744-8686-e40cd8d79134_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e6cb13dc-7dbb-4c43-bb4c-114963fcb0f1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_cb9398f0-4c63-45b7-88f5-41259b3cfeca_terseLabel_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted share units</link:label>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_label_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Share Units [Member]</link:label>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_documentation_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Share Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember" xlink:href="cmps-20230331.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_UnvestedRestrictedShareUnitsMember" xlink:to="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_da696c1b-e53e-4ba2-88a3-004d0c2d2938_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c86b3084-967e-4457-a053-11fc5f753ae2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_a60b6c9f-a6b5-43d2-994a-acc16b140388_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_820bb66c-40e5-4a06-aa4b-4f51d65f7665_terseLabel_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research and Development Tax Credit Regime, Small or Medium-Sized Enterprises (SME)</link:label>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_label_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research And Development Tax Credit Regime, Small Or Medium-Sized Enterprises (SME) [Member]</link:label>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_documentation_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research And Development Tax Credit Regime, Small Or Medium-Sized Enterprises (SME)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:href="cmps-20230331.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:to="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_0c556d96-68dc-4b39-b7ea-ebecac04e18f_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_797919a8-8530-4908-9e14-d5aee9a4186e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b3ba2f34-a965-4ce4-bfda-e337bd114192_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3ecab169-2033-4823-bea0-2c1d34fdac8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_53a6a4c5-6829-400a-baea-cdf93fec6c67_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_13da2bbc-dc1c-4d6c-9da4-9ce53c9b6192_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_dbd529e3-33c5-4b2d-87a8-a3764de89eef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1bdfd258-9511-4289-90df-e9127a98d4ad_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_50c65e53-e5ba-479c-bd00-499953201f72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_b2ade068-c8a5-4960-a6e7-7a6f9d831aac_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5eb72862-5f6e-4c6e-a013-338258c41c50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9cec9253-2a33-455a-bc62-207046f25ce5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c16b503b-1ae2-42a2-a35c-d9a5486d7434_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_73218a2d-cc1d-44d8-ade0-a7b139c98127_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_2e76ebc0-5973-4d16-8309-7e101cdbfe9c_terseLabel_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of stock that may be sold</link:label>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_label_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Allowable For Sale</link:label>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_documentation_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Allowable For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:href="cmps-20230331.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:to="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_385b7db0-ec6c-44c7-836d-980592b5ab4d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1f95a3d1-9e76-4116-8d50-ec66b0a7b27d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares under ATM facility, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_5e404066-08fb-4465-a03b-a967d7a52376_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ddf09e22-11db-4ba9-8164-412db969bb01_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_addafb59-0f4c-4eba-b76a-5b8c261b2fc9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7a1ad625-0a03-4e68-b968-01b2d237cbd2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f5c3e0cd-3991-4f25-9ab9-f8196d115b0d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_024b4cf5-fc65-4482-9d70-f52c840e30c8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e6e819d2-ab83-4367-818a-297d37a96848_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_eef2ca33-d786-47d3-8e80-d033c259e83e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OperatingLeasesNoncancelableTerm_61b943e8-4f75-4c86-9134-27f449d127cf_terseLabel_en-US" xlink:label="lab_cmps_OperatingLeasesNoncancelableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, noncancelable term</link:label>
    <link:label id="lab_cmps_OperatingLeasesNoncancelableTerm_label_en-US" xlink:label="lab_cmps_OperatingLeasesNoncancelableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Noncancelable Term</link:label>
    <link:label id="lab_cmps_OperatingLeasesNoncancelableTerm_documentation_en-US" xlink:label="lab_cmps_OperatingLeasesNoncancelableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Noncancelable Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeasesNoncancelableTerm" xlink:href="cmps-20230331.xsd#cmps_OperatingLeasesNoncancelableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OperatingLeasesNoncancelableTerm" xlink:to="lab_cmps_OperatingLeasesNoncancelableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_05779e39-bd67-4d12-9303-9276ac67566b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d4f060c5-04ca-4aaa-b8fe-443aac9280c4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_88e7f5e0-8e61-40cd-8acd-c8a8c87c8852_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97c0ae5a-510e-431a-9e5a-b8022ff5a92e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6ca8f218-e4a2-42de-943f-51228dd7b2d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_88f0b113-358c-40b7-aa8c-d6036692649f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_CashFlowLesseeAbstract_bfe55de1-a066-45b9-b65e-311037662b9b_terseLabel_en-US" xlink:label="lab_cmps_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_cmps_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_cmps_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_cmps_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_cmps_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashFlowLesseeAbstract" xlink:href="cmps-20230331.xsd#cmps_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_CashFlowLesseeAbstract" xlink:to="lab_cmps_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_16b86901-4f65-4b7f-82be-71277ef41e0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OrdinarySharesMember_81f1a75b-8cae-426d-9236-bbba4a38f932_terseLabel_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_cmps_OrdinarySharesMember_label_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares [Member]</link:label>
    <link:label id="lab_cmps_OrdinarySharesMember_documentation_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OrdinarySharesMember" xlink:to="lab_cmps_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8b34dc2e-0bf6-44d4-8249-fa55656747ee_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_5248a4c1-762b-4b77-88fc-2a9cbab84cfe_terseLabel_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Option Plan</link:label>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_label_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Option Plan [Member]</link:label>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_documentation_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember" xlink:href="cmps-20230331.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2020ShareOptionPlanMember" xlink:to="lab_cmps_A2020ShareOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2bb87c24-91cf-4ff6-9e13-be4713087de4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_95809517-7d91-4005-89af-dfa7cfb6304f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8ab6fbac-53d9-47e1-9832-24754fec8f61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_24b5fa49-1c71-4da8-8526-871559e0fe09_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting condition two</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Two [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bb92bed0-722a-4c54-a320-7fd586508d8b_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_d78fabf2-1f13-467d-a2d2-c2733639801d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption_3de101b3-f9da-415b-bd45-a187daed785c_terseLabel_en-US" xlink:label="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right&#160;of&#160;use&#160;assets&#160;obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption_label_en-US" xlink:label="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use&#160;Assets&#160;Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adoption</link:label>
    <link:label id="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption_documentation_en-US" xlink:label="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use&#160;Assets&#160;Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" xlink:href="cmps-20230331.xsd#cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" xlink:to="lab_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent_791e95e9-8fce-4e80-be99-1a1f5f2f7a59_terseLabel_en-US" xlink:label="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense</link:label>
    <link:label id="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="cmps-20230331.xsd#cmps_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_cmps_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4c21d233-aa1a-4344-ae07-f29eecfcdc0a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7f92ce51-2b77-4000-b1c5-d22c77b443e1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a1a4a2e1-b911-4a9b-a11a-fdaed5c945ff_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_0544ea1b-8b71-40e1-8d3e-d8243e9eb536_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan, offering period</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b898a6e4-5474-4a42-b8d4-d29ad3fefee6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4fcb0983-a6e5-4492-b791-6fc25d541a62_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5a0ed0f9-62f5-4d94-83c1-a9203e27a043_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche one</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2fb23b2f-fdbe-4642-b5d3-cd000d7f2500_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_ab523b3b-ff9e-44e7-b18c-7254a762c17d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_b2bf4404-5f40-493e-8132-66d2c27c4ed0_terseLabel_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted Before June 30, 2020</link:label>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_label_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted Before June 30, 2020 [Member]</link:label>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_documentation_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted Before June 30, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member" xlink:href="cmps-20230331.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OptionsGrantedBeforeJune302020Member" xlink:to="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4642159b-060f-4376-b0f6-27a129e372c9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_304a36d8-4d3a-4c8f-ab22-2f58e2102198_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e95d302b-cad1-4ded-af9a-00acc3d7fc7c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_9b6d1daa-4f0a-4ef0-8989-6ef1f70b0e49_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockLineItems" xlink:to="lab_us-gaap_ConversionOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_94ebf1af-4555-4321-99f9-28409bc1508d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_8020ff59-8d80-4368-bee9-7b879300342f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_78f54778-6343-4ad6-9cc3-1ffe853fa4a7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cd25ee80-8e66-4101-805d-d4439af57170_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OperatingLeaseAnnualPayment_dc144832-3915-4451-8186-24adc978a7fc_terseLabel_en-US" xlink:label="lab_cmps_OperatingLeaseAnnualPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, annual payment</link:label>
    <link:label id="lab_cmps_OperatingLeaseAnnualPayment_label_en-US" xlink:label="lab_cmps_OperatingLeaseAnnualPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Payment</link:label>
    <link:label id="lab_cmps_OperatingLeaseAnnualPayment_documentation_en-US" xlink:label="lab_cmps_OperatingLeaseAnnualPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseAnnualPayment" xlink:href="cmps-20230331.xsd#cmps_OperatingLeaseAnnualPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OperatingLeaseAnnualPayment" xlink:to="lab_cmps_OperatingLeaseAnnualPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DenmarkHillLondonUKMember_e3c77a67-5a38-417b-904f-eb4ed5bf8ae6_terseLabel_en-US" xlink:label="lab_cmps_DenmarkHillLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Hill, London, UK</link:label>
    <link:label id="lab_cmps_DenmarkHillLondonUKMember_label_en-US" xlink:label="lab_cmps_DenmarkHillLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Hill, London, UK [Member]</link:label>
    <link:label id="lab_cmps_DenmarkHillLondonUKMember_documentation_en-US" xlink:label="lab_cmps_DenmarkHillLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Hill, London, UK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DenmarkHillLondonUKMember" xlink:href="cmps-20230331.xsd#cmps_DenmarkHillLondonUKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DenmarkHillLondonUKMember" xlink:to="lab_cmps_DenmarkHillLondonUKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd2e6d06-95d6-4c76-924f-bf7174a53eab_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5a56dab6-2409-4e65-b335-2e3fa65f2ffb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_e1812c93-e5f5-4fee-9b99-510b9a093e69_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f910fe98-45bf-4bd9-8676-8c08e5185969_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c611b783-e00a-499b-9b0e-d22fcad7c095_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee375282-565b-4c85-86d1-7e861eb5feae_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_76e2ac3a-a39c-41b1-89ff-2618655b019a_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_5c57b41e-23cc-4e0e-9612-c3937b492ba6_terseLabel_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research and Development Tax Credit Regime</link:label>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_label_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research And Development Tax Credit Regime [Member]</link:label>
    <link:label id="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_documentation_en-US" xlink:label="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Research And Development Tax Credit Regime</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:href="cmps-20230331.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:to="lab_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e5d8be43-c19b-45eb-a40a-ba66e3ecbebc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_467efee1-2c8a-4c74-ac58-004481c519a8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_46726827-3190-444c-94cc-cafda9e8a3f1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6815ba5f-02b8-42ef-834d-aac4b073f290_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dd7da2d3-62f6-4d96-a358-bf001adb0e5a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_abe1f0c1-3542-4318-8735-5ea044b88123_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7a5dec76-c199-4e03-900d-5508093b956b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5e1a31dc-e05a-48db-9e45-2a417cd69972_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_126d441f-90aa-486d-b688-4bcf2a9d408c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_8435fa6f-c7e9-4618-8ae2-50c40a6b67af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_14b975f0-f195-4b6d-ad47-0c01189833ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_28586de6-2f34-4feb-98dc-56d65d9f55fc_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ecc54a75-83ac-4281-9a99-40049f5b99c5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2c6f5bad-c4d7-4a7d-9d12-94dad38caadc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average ordinary shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bb927dc-7dc3-4d74-8fa4-a05298e980bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OperatingLeaseMonthlyPayment_0ef30cfe-b6cb-4d2a-9d74-835c9b9544d6_terseLabel_en-US" xlink:label="lab_cmps_OperatingLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, monthly payment</link:label>
    <link:label id="lab_cmps_OperatingLeaseMonthlyPayment_label_en-US" xlink:label="lab_cmps_OperatingLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Payment</link:label>
    <link:label id="lab_cmps_OperatingLeaseMonthlyPayment_documentation_en-US" xlink:label="lab_cmps_OperatingLeaseMonthlyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseMonthlyPayment" xlink:href="cmps-20230331.xsd#cmps_OperatingLeaseMonthlyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OperatingLeaseMonthlyPayment" xlink:to="lab_cmps_OperatingLeaseMonthlyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e6eaa6b7-0315-4cb7-a517-d68af6f15979_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_20ce1fc7-ed5e-4b28-a31a-1a8e17d0a683_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_AtTheMarketOfferingMember_43c0dd50-7667-4503-8e1e-81aea902f41f_terseLabel_en-US" xlink:label="lab_cmps_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_cmps_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_cmps_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_cmps_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_cmps_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember" xlink:href="cmps-20230331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_AtTheMarketOfferingMember" xlink:to="lab_cmps_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b2101399-8c47-4ab4-b964-9372fc46d4a1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bd47e4c1-7a04-4c68-a727-dd51f3ca00ec_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5f0423f9-e663-4430-b86c-fd2ba99aaa32_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_91dffdf8-6b48-4311-ac67-0a59ac6e94d4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ac48f7a1-3738-4337-9c21-17f4d97713fa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_680334c3-ac1b-45ac-8bb7-19dab5034b97_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_595ace2b-bfd3-41a2-903f-b4f658266c10_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9c3c0505-f67a-4b37-abbd-f3323e2721a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares under ATM offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f2288401-cbc7-4982-abdd-2abb67adc3af_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_002dbddd-2a80-402f-91a7-8211139ff848_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2022And2023Member_6739a607-aaec-4285-b285-683ab9f58548_terseLabel_en-US" xlink:label="lab_cmps_A2022And2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 And 2023</link:label>
    <link:label id="lab_cmps_A2022And2023Member_label_en-US" xlink:label="lab_cmps_A2022And2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 And 2023 [Member]</link:label>
    <link:label id="lab_cmps_A2022And2023Member_documentation_en-US" xlink:label="lab_cmps_A2022And2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 And 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022And2023Member" xlink:href="cmps-20230331.xsd#cmps_A2022And2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2022And2023Member" xlink:to="lab_cmps_A2022And2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_884e066b-4005-42f6-a3b6-2ee711f32881_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0c41027e-c0ad-4e9c-ae68-457e9e27ef44_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b99c532c-62eb-402d-bd84-72c0e72e32fe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_VestingPeriodDomain_53a15b71-f19e-4b30-9020-0a5f8739cd41_terseLabel_en-US" xlink:label="lab_cmps_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period [Domain]</link:label>
    <link:label id="lab_cmps_VestingPeriodDomain_label_en-US" xlink:label="lab_cmps_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period [Domain]</link:label>
    <link:label id="lab_cmps_VestingPeriodDomain_documentation_en-US" xlink:label="lab_cmps_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VestingPeriodDomain" xlink:href="cmps-20230331.xsd#cmps_VestingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_VestingPeriodDomain" xlink:to="lab_cmps_VestingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_79379f4f-025d-4c23-9b13-0508dd678c78_terseLabel_en-US" xlink:label="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred issuance costs included in accrued expenses</link:label>
    <link:label id="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_label_en-US" xlink:label="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included In Accrued Expenses</link:label>
    <link:label id="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_documentation_en-US" xlink:label="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included In Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:href="cmps-20230331.xsd#cmps_DeferredOfferingCostsIncludedInAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:to="lab_cmps_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_46cbc781-f2aa-406e-ba24-30b21671847b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_VestingPeriodAxis_5f0b85d6-49f9-4af0-9082-5a7a3feac244_terseLabel_en-US" xlink:label="lab_cmps_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period [Axis]</link:label>
    <link:label id="lab_cmps_VestingPeriodAxis_label_en-US" xlink:label="lab_cmps_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period [Axis]</link:label>
    <link:label id="lab_cmps_VestingPeriodAxis_documentation_en-US" xlink:label="lab_cmps_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VestingPeriodAxis" xlink:href="cmps-20230331.xsd#cmps_VestingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_VestingPeriodAxis" xlink:to="lab_cmps_VestingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_59974f5d-8680-488b-96a4-b353f0a4fc32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_567fae44-56ed-4cd2-8dd6-eae1a82921df_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NON-CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SaleOfStockAmountAuthorized_e7565c01-28d9-40a3-9110-b2e6c78aeda5_terseLabel_en-US" xlink:label="lab_cmps_SaleOfStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount authorized</link:label>
    <link:label id="lab_cmps_SaleOfStockAmountAuthorized_label_en-US" xlink:label="lab_cmps_SaleOfStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Authorized</link:label>
    <link:label id="lab_cmps_SaleOfStockAmountAuthorized_documentation_en-US" xlink:label="lab_cmps_SaleOfStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockAmountAuthorized" xlink:href="cmps-20230331.xsd#cmps_SaleOfStockAmountAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SaleOfStockAmountAuthorized" xlink:to="lab_cmps_SaleOfStockAmountAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_ef491a0c-1b93-4b49-a125-49844ccbaf67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_35eae6cb-cd64-48f9-b8e1-63c4bd571343_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_96e496c3-1af8-4459-95c5-18478340cf24_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c6baa032-6765-406b-ad96-71771ea8ae2f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8d30cfb5-9b18-4a42-b002-5c60354ae6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ed619495-ec6c-4ebd-b15c-eed20969c7dd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e06c04c7-20aa-4218-be52-2798f1ca7958_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred and prepaid tax assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7ed3edd2-6afd-40fa-8659-131fae77f1fa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6dcef28f-c876-49ff-9fe2-151279d55b72_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dc039b6c-495c-4c04-9b44-df4c63fe17c4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_228d5072-77c7-4184-b4ef-1205004d70bf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in GBP per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6b18f52d-6392-4dcc-a01d-9d7097dd5b01_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_c5e9673f-b148-4d85-afe4-7b9f5ee427c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0f019a1f-b8d9-49ba-9b50-3b499d052e84_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1650b8f1-0b01-4fcf-a093-41a23d14cc1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a8924830-bbcd-40ca-8c49-fd7b7218507d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_9fe76729-61ad-4a34-92b8-99dcb3f298a5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_bcdab934-e275-4369-b3c4-1ebcd6cdbdd0_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash rebate percent (in percent)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Cash Rebate Percent</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Cash Rebate Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_df2547e2-294b-446f-81ea-2a8193013747_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of tax withholding on stock award</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_65cff640-57eb-46ac-8b6d-27d9919da39b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e5cb636b-ae6f-4389-8fac-a3675d7da31f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_36e42609-d01f-4a90-ad09-d678c7420185_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LeaseCancellationNotificationPeriod_64d12cc6-55b9-4f4e-a494-1d7bf8673d47_terseLabel_en-US" xlink:label="lab_cmps_LeaseCancellationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cancellation notification period (in days)</link:label>
    <link:label id="lab_cmps_LeaseCancellationNotificationPeriod_label_en-US" xlink:label="lab_cmps_LeaseCancellationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cancellation Notification Period</link:label>
    <link:label id="lab_cmps_LeaseCancellationNotificationPeriod_documentation_en-US" xlink:label="lab_cmps_LeaseCancellationNotificationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cancellation Notification Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseCancellationNotificationPeriod" xlink:href="cmps-20230331.xsd#cmps_LeaseCancellationNotificationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LeaseCancellationNotificationPeriod" xlink:to="lab_cmps_LeaseCancellationNotificationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7206a167-faeb-4ca5-b54b-036c52ce7459_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash gain on foreign currency remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_5a66fa19-7aed-451f-ab86-78a1978dc62b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:to="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4a852d68-3934-4854-b96c-264a19f5487c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_7f008aaa-350a-4174-92e0-1eebafdefd12_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_3c72fc30-183f-4cda-ad91-d3b68f03a67c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e62454e6-7a86-4204-9de1-62c5fd0486d7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3303bf5f-3083-40ee-891a-e77e509bfdd4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bcfa9f0d-56bf-4387-b05a-fdbbb7366958_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5d577469-ff53-48b6-92a1-d2b1c893e185_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to ordinary shareholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_7e235abd-3b76-43f4-b923-c555828f3030_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9d8e54e2-10f7-439c-b9f8-8c714e135e2c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_22e42d91-41e7-4ada-812e-a8ffb711fbda_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_40d5c605-7e69-48d4-8b60-61ab74bcccea_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e6b496b8-5f67-4059-899f-0f4f7f0c4245_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7ff7cc29-c3fb-405a-be7f-d72ecad61544_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_53d2bcaf-57a0-4576-8d38-13ac390526b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a6c8f81-4030-4f3c-9e28-268de5484b7f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_48892fac-9c6f-428e-ac0b-c1285c813919_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (in years)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_98cf5bb3-b734-4093-9284-bdad3759dfa7_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum increase in shares available for issuance (in shares)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_dd00464b-4c89-4503-9e4d-5e7d29f42e0b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_31ba0277-2885-4fd4-a7df-5d3859f744c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_8d2c6269-0903-40a1-8902-dab54eb4d1ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SohoLondonUKMember_a164b2ab-5b31-442e-a336-7b4aed627483_terseLabel_en-US" xlink:label="lab_cmps_SohoLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soho, London, UK</link:label>
    <link:label id="lab_cmps_SohoLondonUKMember_label_en-US" xlink:label="lab_cmps_SohoLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soho, London, UK [Member]</link:label>
    <link:label id="lab_cmps_SohoLondonUKMember_documentation_en-US" xlink:label="lab_cmps_SohoLondonUKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soho, London, UK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SohoLondonUKMember" xlink:href="cmps-20230331.xsd#cmps_SohoLondonUKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SohoLondonUKMember" xlink:to="lab_cmps_SohoLondonUKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_17adabf8-2069-437f-be92-07368a75187a_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT recoverable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e2fdea86-a128-42d0-a256-5f1086466c13_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_003b4f1d-84fc-4878-9279-49428899eebf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_GrantDateJune302020Member_f80425ed-e95b-4f92-b91d-e76d0be21902_terseLabel_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Date June 30, 2020</link:label>
    <link:label id="lab_cmps_GrantDateJune302020Member_label_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Date June 30, 2020 [Member]</link:label>
    <link:label id="lab_cmps_GrantDateJune302020Member_documentation_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Date June 30, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member" xlink:href="cmps-20230331.xsd#cmps_GrantDateJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_GrantDateJune302020Member" xlink:to="lab_cmps_GrantDateJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ccbdfa54-18a0-475d-ab37-a16b3da47430_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9d06d896-b893-4eac-9910-2c5bf21a8f39_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_de6b1f6b-6383-4c83-8049-3f2a9210bdd8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2b805d43-ea9b-49e2-85f5-767c8687fa78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Due Under Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5989a5bf-5dfc-468a-9b41-8cdc2d2edac6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_32f47a0d-7892-471e-9095-92e2bfb6c270_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual offset amount (in euros)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:to="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_58c70086-ef3f-4ed4-8734-d6eb4615fbc8_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bcda7dfa-89fa-4b67-8fba-d6f06fe3b1a7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_764a7260-e4c6-41b1-be34-0afd884725ec_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4c1b47b9-23a0-4f48-87d3-9834f3e61f48_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_9e453f35-29b8-4806-bdb0-154cf5d34065_verboseLabel_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_83257853-fef6-4bf1-9467-2f9a7726ce14_negatedTerseLabel_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_label_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_documentation_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:href="cmps-20230331.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:to="lab_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_4b0c5b3b-06c3-4f0f-a4ab-5e1881024b17_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_fa62ebc7-f450-409d-af06-34a39f654343_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of taxable profits (in percent)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:to="lab_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_68d3d4e4-0984-48ab-9aff-d009c79ff946_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_18756e96-527d-4977-8731-e777f081eeee_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_ee25ec8c-73ba-4d2c-a3d5-748095dea826_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting condition one</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition One [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0f0f50b8-b149-46b9-b2e5-cc41100ba3fe_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_ad1b9fac-df94-4189-b4bb-8d98e8f95706_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7024e48c-dcf6-4702-872e-6beaf5bece88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e3870fa9-b4c6-4565-9c35-1df83ed07107_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DeferredSharesMember_12242e88-990a-4aaa-94f4-cd5e9160245d_terseLabel_en-US" xlink:label="lab_cmps_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred shares</link:label>
    <link:label id="lab_cmps_DeferredSharesMember_label_en-US" xlink:label="lab_cmps_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares [Member]</link:label>
    <link:label id="lab_cmps_DeferredSharesMember_documentation_en-US" xlink:label="lab_cmps_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember" xlink:href="cmps-20230331.xsd#cmps_DeferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DeferredSharesMember" xlink:to="lab_cmps_DeferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ccd884dd-492c-4f36-a1b9-245870105f2e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_e4c40f5f-c522-4141-af2d-f9a963f5fa98_terseLabel_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Grant Option Award</link:label>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_label_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Grant Option Award [Member]</link:label>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_documentation_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Grant Option Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember" xlink:href="cmps-20230331.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2022InducementGrantOptionAwardMember" xlink:to="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_77041128-a930-4880-981e-f7ab0deefbe7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_WeWorkMember_fe4b620f-af63-4e3d-8e53-64e8c6426984_terseLabel_en-US" xlink:label="lab_cmps_WeWorkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WeWork</link:label>
    <link:label id="lab_cmps_WeWorkMember_label_en-US" xlink:label="lab_cmps_WeWorkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WeWork [Member]</link:label>
    <link:label id="lab_cmps_WeWorkMember_documentation_en-US" xlink:label="lab_cmps_WeWorkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WeWork</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WeWorkMember" xlink:href="cmps-20230331.xsd#cmps_WeWorkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_WeWorkMember" xlink:to="lab_cmps_WeWorkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_25398826-f088-4b1a-8e21-51666e15ca8d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED DEFICIT</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_f460899f-ccaa-4888-9c45-531bf7291e7f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d1e926a6-2f95-490e-87e5-c68370cebdd4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost of options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3a47891e-0aea-40e7-aad0-2b2cb91d3699_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested not issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_207da91e-9e68-496d-b584-ddab9e64ae86_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ec40db47-f45d-4377-b591-ec384d344051_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f5a26d60-e3ce-47e8-ac4e-d9f6acd98060_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saving period (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f42ad449-8704-4c32-856f-6bb44aa84086_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMON STOCK</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_677d1dd4-7694-42a1-9984-26dc413eee56_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Costs Included in Operating Expenses Related To Right of Use Assets</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f2abde4-b294-4d04-b6b1-93f32e1e6d10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_2c24d999-4b68-4a14-9938-3177bbd546c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_543a01f1-6ed9-419c-9738-7fd4673801b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_735286f9-7941-4147-880e-811ff4c9c11a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Share Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_bdac10b1-b824-4f82-9861-b57f522a980b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ecb989fc-ef53-42e3-afcc-c7b8bc1fb9f8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f4b7336f-ee83-414e-bd84-3b986fc74d07_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockTable_4807e65a-4400-4424-bb44-b26802733d73_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockTable_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockTable" xlink:to="lab_us-gaap_ConversionOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_e242da30-5c64-4870-b0f6-a83183fe461d_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_679d7d0e-7f57-4acc-a3a7-5ad298dba3ea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_16b95d6f-410f-4f84-a614-20da0948306a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9831e916-ee30-4ebd-af53-9182b4a09290_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9497aacd-3af0-442b-ab58-a5a2676df43f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2439eb36-f21d-438d-8d01-a8bff43a7850_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ad35af61-563b-4874-bb3b-6cac47661958_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4fb28c6e-364e-4a08-aebf-52ed4192a18b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_489e8d1c-9733-4d61-a726-f2a4a49cd8ba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_303f97a3-d15b-44be-a6c2-27a3942ead93_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_fc324e8d-957a-4438-8292-1cf43ceb505f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a82705c6-9dce-4d76-af41-50c04836984e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a6ccc3b2-01d3-4de6-b273-3257d8285dd4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares tendered for withholding taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9f3c8d90-7933-4c6c-845a-986e244e1160_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e304adb5-ae29-47f9-8169-4776d9eab473_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_48212728-b85e-4ecc-91bb-c093f7f3eb9f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_e7c6de6c-2108-4eac-ac25-94f6e9d74309_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_4011c53d-ac49-4d3a-ac4a-7fa0c0f8c784_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bfbc68da-1ad4-4a90-86ad-3e7aa9779eb5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_05c93705-5037-48f6-9ac9-73945a61aaf7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_566fa0db-243c-448b-a8b2-50bc810998bd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8d13e1fb-0f01-49c1-adf9-ca953343ea70_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_778a5bbe-dd06-4fd2-b076-5f485bbd142c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a1ff91b6-120e-424b-a41a-e9cd6f94eeaa_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_19965e4e-b021-4bda-a59d-4121e0af5a14_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_699ba3aa-5c6e-4f2e-ae56-67b502a23e0d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareOptionsMember_33f7ec65-05e0-4f13-9cb8-617d9c9708bb_terseLabel_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options</link:label>
    <link:label id="lab_cmps_ShareOptionsMember_label_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options [Member]</link:label>
    <link:label id="lab_cmps_ShareOptionsMember_documentation_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember" xlink:href="cmps-20230331.xsd#cmps_ShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareOptionsMember" xlink:to="lab_cmps_ShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3dcd571c-6f13-4f71-a0de-5c1a8047dab6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_e10f5f9a-13b3-4c51-ad29-f66e8ff8f9fd_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_bc6833c3-8045-4c7e-ae96-51f9c52224ae_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_ceb407fb-0d9b-4f70-be0d-bc8b8ab45063_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_57c62f0a-67aa-4847-9300-1c96e4eec822_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_490997a0-3e30-4404-ae89-719c2ffcb847_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7ac024bc-dc9e-4b54-a489-28b8381e08c8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_32df6daf-dc2e-40e1-979c-a6b34dfde0d4_terseLabel_en-US" xlink:label="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from Research and Development Tax Credit</link:label>
    <link:label id="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit From Research And Development Tax Credit, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit From Research And Development Tax Credit, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:href="cmps-20230331.xsd#cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:to="lab_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_50c81497-436a-4600-870b-03066899bbd7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_accada0a-cf88-4425-9990-746670f096b0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8d9fb69b-169c-458c-adfb-37263a905bfe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0347b90f-ca29-4bb5-be34-5dd8f1dd9d83_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_b716a016-6cde-4e8b-b1d1-bdcfc6246502_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_12361664-828a-43b7-a4bf-8eae4ee7416e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3ed00907-5bdd-42ae-81d3-c06366ed0bd5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8b45bc09-ae2e-412e-8f26-2d2edb0cb33f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5803acd1-9819-4bd3-8d6b-adefe0c2aae0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_e36ed0d9-6a7f-4afd-8f25-e398b4fcd850_terseLabel_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depositary Shares</link:label>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_label_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depositary Shares [Member]</link:label>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_documentation_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depositary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember" xlink:href="cmps-20230331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_AmericanDepositarySharesMember" xlink:to="lab_cmps_AmericanDepositarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8d73e3a9-5bb0-4221-941b-aa0294ae1a4f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1deeef19-2703-45da-a752-ba914c5aeaf5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8b44b66c-3aa9-4f19-b5b2-8c33270deec1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_223d2fe6-dd32-4d8b-b549-f55429a5a247_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1d79c528-fe8a-4a21-8fcb-616ee1ad921c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS FROM OPERATIONS:</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_41aee260-1310-4570-8a76-7c55def30693_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5a918966-7b77-42c5-8dbc-82f8f097dbd1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_f43c8040-5058-4339-b085-be70d020bdb6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_687f857d-15d8-45ac-b276-71936c99b417_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e184d6d8-6de3-4f4f-9d4f-485005523047_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_acde51de-0e26-4bbd-a2ac-bfb5f1c90839_negatedTerseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from R&amp;D tax credit</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f3f875a7-beb7-429c-84c7-c2a33e997011_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_01c4b1a0-a8b5-4db8-8ae4-4edfb3b5f550_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c0f13426-3f39-43a9-b593-7de4909cd018_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_RefundableLeaseDepositPayments_8071b005-1606-4c52-a6e1-9197b9218058_terseLabel_en-US" xlink:label="lab_cmps_RefundableLeaseDepositPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable lease deposit</link:label>
    <link:label id="lab_cmps_RefundableLeaseDepositPayments_label_en-US" xlink:label="lab_cmps_RefundableLeaseDepositPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable Lease Deposit, Payments</link:label>
    <link:label id="lab_cmps_RefundableLeaseDepositPayments_documentation_en-US" xlink:label="lab_cmps_RefundableLeaseDepositPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable Lease Deposit, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RefundableLeaseDepositPayments" xlink:href="cmps-20230331.xsd#cmps_RefundableLeaseDepositPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_RefundableLeaseDepositPayments" xlink:to="lab_cmps_RefundableLeaseDepositPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_29cb44d4-8601-4a07-ac98-5a5bd39e3131_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid income tax</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cmps-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:faa56455-90dd-4209-830a-f12e1735b5b9,g:47fba99e-051e-4c82-b324-f1efc6936c36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://compasspathways.com/role/Cover" xlink:type="simple" xlink:href="cmps-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b062311b-0feb-4505-8377-557aee1ebe44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_DocumentType_b062311b-0feb-4505-8377-557aee1ebe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a24b4046-fb63-4e18-832f-28a115d4ca77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_DocumentQuarterlyReport_a24b4046-fb63-4e18-832f-28a115d4ca77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c20ae508-68d5-4906-9168-27a9a98321db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_DocumentPeriodEndDate_c20ae508-68d5-4906-9168-27a9a98321db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_57be266f-320d-4b0f-82b7-44b59cf7718b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_DocumentTransitionReport_57be266f-320d-4b0f-82b7-44b59cf7718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7d522bfa-be5e-4180-8a70-40bc126e3c2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityFileNumber_7d522bfa-be5e-4180-8a70-40bc126e3c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f6a377dd-f456-43a9-8e44-93ce113a6eea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityRegistrantName_f6a377dd-f456-43a9-8e44-93ce113a6eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7bbeef4b-36d1-4acf-94cb-a1c59e8e3071" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7bbeef4b-36d1-4acf-94cb-a1c59e8e3071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_14524ffb-4d7c-48ca-9220-2b5ab10d7319" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityAddressAddressLine1_14524ffb-4d7c-48ca-9220-2b5ab10d7319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2482ce25-8caa-4310-a373-3b1c28ae3ec8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityAddressCityOrTown_2482ce25-8caa-4310-a373-3b1c28ae3ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3d5c77fa-fb29-4213-8e1e-39fabebe9536" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityAddressPostalZipCode_3d5c77fa-fb29-4213-8e1e-39fabebe9536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_830c8bea-2c25-4574-9da9-5ffa1e22a6e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityAddressCountry_830c8bea-2c25-4574-9da9-5ffa1e22a6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fe456384-942a-45a9-88d5-c79ba6ef0159" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_CityAreaCode_fe456384-942a-45a9-88d5-c79ba6ef0159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_49abfa90-20ac-4e98-91de-8f06860e7d03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_LocalPhoneNumber_49abfa90-20ac-4e98-91de-8f06860e7d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b974b5fb-8ff6-4907-9adf-b1655dee24c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_Security12bTitle_b974b5fb-8ff6-4907-9adf-b1655dee24c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0861660f-6587-4901-aad5-d2703dc88601" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_TradingSymbol_0861660f-6587-4901-aad5-d2703dc88601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fecac926-248a-407f-be03-d1f56e7fa065" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_SecurityExchangeName_fecac926-248a-407f-be03-d1f56e7fa065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7814cc5c-ff88-417f-8afd-271c67b4525d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityCurrentReportingStatus_7814cc5c-ff88-417f-8afd-271c67b4525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_de390d96-c0b1-40f3-b624-8cf284e17e9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityInteractiveDataCurrent_de390d96-c0b1-40f3-b624-8cf284e17e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_74da724e-c9f0-48fc-bca8-5919e599f7c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityFilerCategory_74da724e-c9f0-48fc-bca8-5919e599f7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6b7998ff-386d-43fe-8458-359ee88c3a0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntitySmallBusiness_6b7998ff-386d-43fe-8458-359ee88c3a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1fa0065a-345a-46b3-aeec-82be87841998" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityEmergingGrowthCompany_1fa0065a-345a-46b3-aeec-82be87841998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f6d6caed-0c5d-47ee-8941-4b2946ac502d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityShellCompany_f6d6caed-0c5d-47ee-8941-4b2946ac502d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_105c0055-1ec8-4f41-b7bb-f47293155cd9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_105c0055-1ec8-4f41-b7bb-f47293155cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_376daf7f-acee-4045-a83a-d16deaf81184" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_EntityCentralIndexKey_376daf7f-acee-4045-a83a-d16deaf81184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a2449e02-bdf9-4f80-a9e1-5da5bfa30053" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_DocumentFiscalYearFocus_a2449e02-bdf9-4f80-a9e1-5da5bfa30053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0ab45670-1fab-468e-9dd6-22f1ef7a1754" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0ab45670-1fab-468e-9dd6-22f1ef7a1754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b6fe4a02-eb6f-4b70-bf2a-c595776319e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_AmendmentFlag_b6fe4a02-eb6f-4b70-bf2a-c595776319e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bf00a27a-2d67-47d2-8079-7d462659358f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_151ae5e5-9629-4999-89ac-d232fcd48fb8" xlink:to="loc_dei_CurrentFiscalYearEndDate_bf00a27a-2d67-47d2-8079-7d462659358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_955b6078-0b25-4628-93c5-00ad704ff15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b8bdf700-56ad-4f70-afaf-6ae2dd1b9bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_955b6078-0b25-4628-93c5-00ad704ff15a" xlink:to="loc_us-gaap_StatementTable_b8bdf700-56ad-4f70-afaf-6ae2dd1b9bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7c1e1c64-9e3f-47dc-97b1-f30b8731b584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b8bdf700-56ad-4f70-afaf-6ae2dd1b9bbb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7c1e1c64-9e3f-47dc-97b1-f30b8731b584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_106affa6-3a9f-4d40-8d2e-a7102d649dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c1e1c64-9e3f-47dc-97b1-f30b8731b584" xlink:to="loc_us-gaap_ClassOfStockDomain_106affa6-3a9f-4d40-8d2e-a7102d649dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_41c312af-f318-4f4b-80ef-04025b8fc987" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_106affa6-3a9f-4d40-8d2e-a7102d649dfd" xlink:to="loc_cmps_OrdinarySharesMember_41c312af-f318-4f4b-80ef-04025b8fc987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_b504a7f5-5b65-48b5-9cbb-0ba96634bbd2" xlink:href="cmps-20230331.xsd#cmps_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_106affa6-3a9f-4d40-8d2e-a7102d649dfd" xlink:to="loc_cmps_DeferredSharesMember_b504a7f5-5b65-48b5-9cbb-0ba96634bbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_22a3cd24-2745-41c6-a75f-e357c26c032d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b8bdf700-56ad-4f70-afaf-6ae2dd1b9bbb" xlink:to="loc_us-gaap_StatementLineItems_22a3cd24-2745-41c6-a75f-e357c26c032d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22a3cd24-2745-41c6-a75f-e357c26c032d" xlink:to="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9af81917-6ab6-416c-8751-9f58dd621076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9af81917-6ab6-416c-8751-9f58dd621076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f8e5a2f4-9d2b-4199-a363-016a1e3ed52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f8e5a2f4-9d2b-4199-a363-016a1e3ed52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_e36abed7-3c7e-421c-b627-31c7c301ab63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_PrepaidTaxes_e36abed7-3c7e-421c-b627-31c7c301ab63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_2358a63d-175f-41a1-a0d7-e8bd534cddf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_2358a63d-175f-41a1-a0d7-e8bd534cddf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4878504b-69b4-46a6-b1a8-06477216cf98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3dcc2769-4e9c-4b9a-8232-7c104aa1f8ed" xlink:to="loc_us-gaap_AssetsCurrent_4878504b-69b4-46a6-b1a8-06477216cf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_64ab2059-c066-4079-b986-11ac778c00eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_64ab2059-c066-4079-b986-11ac778c00eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ab24cd53-a323-4f03-a3be-1aadd2b14b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ab24cd53-a323-4f03-a3be-1aadd2b14b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_38864c44-84e3-4bcd-abea-ea8ac1c39f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_38864c44-84e3-4bcd-abea-ea8ac1c39f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5f74b14d-84ce-4d14-af36-e4b3bc81402b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5f74b14d-84ce-4d14-af36-e4b3bc81402b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a0b16141-0835-4eda-b3ab-d8542a400205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d5c758ce-35b0-47d5-8891-069c6cd77a52" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a0b16141-0835-4eda-b3ab-d8542a400205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8d05ab7a-3eae-41e4-96a5-e112b726f7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c940f87-f1b1-4593-b033-ba95660b4c59" xlink:to="loc_us-gaap_Assets_8d05ab7a-3eae-41e4-96a5-e112b726f7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22a3cd24-2745-41c6-a75f-e357c26c032d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_580d71ba-6c77-4986-887a-a6a5ae274854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:to="loc_us-gaap_AccountsPayableCurrent_580d71ba-6c77-4986-887a-a6a5ae274854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_4390c2f9-93d3-4b00-a9e4-bae00557605f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_4390c2f9-93d3-4b00-a9e4-bae00557605f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_241799b7-754a-47ad-9ff0-45a21fc22453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_241799b7-754a-47ad-9ff0-45a21fc22453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a5e22f0-061d-42a1-8e8f-5541c1100d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35efcd1e-fea5-4272-ab37-05ed48a9c884" xlink:to="loc_us-gaap_LiabilitiesCurrent_0a5e22f0-061d-42a1-8e8f-5541c1100d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_184ea8ea-be3f-4735-a6dd-bbb1d8d63801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_184ea8ea-be3f-4735-a6dd-bbb1d8d63801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1de8b3c1-278b-4877-8d00-b1c223e643b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_184ea8ea-be3f-4735-a6dd-bbb1d8d63801" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1de8b3c1-278b-4877-8d00-b1c223e643b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_625c972a-a67b-4624-98f4-dec3bf19886a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_Liabilities_625c972a-a67b-4624-98f4-dec3bf19886a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8394f959-9eb8-4c5c-8192-49564c0174ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8394f959-9eb8-4c5c-8192-49564c0174ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fde45b23-7a55-4551-90af-1e8e5f4aba04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_CommonStockValue_fde45b23-7a55-4551-90af-1e8e5f4aba04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7d953752-e68f-4e6a-bfa9-d0db12b786b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7d953752-e68f-4e6a-bfa9-d0db12b786b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e76404dc-8e46-419b-ac99-df0c337cf35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e76404dc-8e46-419b-ac99-df0c337cf35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3aef655-4c6c-4220-94e6-c72e4f57772a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3aef655-4c6c-4220-94e6-c72e4f57772a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_efc7ca95-8f37-4921-9eb7-1c6ceaf2a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b90cd940-93d7-44d9-81d4-4901a34fb751" xlink:to="loc_us-gaap_StockholdersEquity_efc7ca95-8f37-4921-9eb7-1c6ceaf2a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad56a97b-8d5b-4c6c-83cb-d8ce605e9538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3b2c8cc-a103-40cb-9163-e83a18e6ac88" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad56a97b-8d5b-4c6c-83cb-d8ce605e9538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7ef9fb0c-90d3-481c-95af-a3fbe81ffafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d637df75-7b58-4596-b6ac-a9f3c37fb9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7ef9fb0c-90d3-481c-95af-a3fbe81ffafc" xlink:to="loc_us-gaap_StatementTable_d637df75-7b58-4596-b6ac-a9f3c37fb9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f53d947f-0332-4a75-b5d1-f4aa67558aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d637df75-7b58-4596-b6ac-a9f3c37fb9be" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f53d947f-0332-4a75-b5d1-f4aa67558aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_60e43832-2d03-4c2a-b216-18b98487b185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f53d947f-0332-4a75-b5d1-f4aa67558aa1" xlink:to="loc_us-gaap_ClassOfStockDomain_60e43832-2d03-4c2a-b216-18b98487b185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_2b041633-fb8b-4762-87de-138b70325ad3" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_60e43832-2d03-4c2a-b216-18b98487b185" xlink:to="loc_cmps_OrdinarySharesMember_2b041633-fb8b-4762-87de-138b70325ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_3afd1a67-deae-4339-956b-85a6edd997c6" xlink:href="cmps-20230331.xsd#cmps_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_60e43832-2d03-4c2a-b216-18b98487b185" xlink:to="loc_cmps_DeferredSharesMember_3afd1a67-deae-4339-956b-85a6edd997c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d637df75-7b58-4596-b6ac-a9f3c37fb9be" xlink:to="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_477172f8-2b1d-4d56-8865-724da555408b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_477172f8-2b1d-4d56-8865-724da555408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_749325a9-3602-4023-9c58-870c3ec23f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_749325a9-3602-4023-9c58-870c3ec23f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_654de97d-f0ba-4707-8325-13236815f9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_CommonStockSharesIssued_654de97d-f0ba-4707-8325-13236815f9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b3636ef3-c8df-40f0-b209-3ad2bf478fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f1cbc9be-74c1-47d4-86ad-add257466bf3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b3636ef3-c8df-40f0-b209-3ad2bf478fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a37a7f30-4128-4748-a67e-0186e730fbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a37a7f30-4128-4748-a67e-0186e730fbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6a4621d6-a3cb-41ff-9a7b-853f500f6f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a37a7f30-4128-4748-a67e-0186e730fbf1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6a4621d6-a3cb-41ff-9a7b-853f500f6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ffded3e4-a729-4881-920a-c84afe3d891e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a37a7f30-4128-4748-a67e-0186e730fbf1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ffded3e4-a729-4881-920a-c84afe3d891e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f6fb7653-7d81-4749-830b-ad06b430dbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a37a7f30-4128-4748-a67e-0186e730fbf1" xlink:to="loc_us-gaap_OperatingExpenses_f6fb7653-7d81-4749-830b-ad06b430dbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_11e080d2-8623-48d6-b3ee-284943e3826e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_OperatingIncomeLoss_11e080d2-8623-48d6-b3ee-284943e3826e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_5f2ac544-9361-4a86-ba4b-f518e3c735e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_5f2ac544-9361-4a86-ba4b-f518e3c735e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_8003df66-f76e-45be-afb9-ffe3d8b516e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5f2ac544-9361-4a86-ba4b-f518e3c735e1" xlink:to="loc_us-gaap_OtherNonoperatingIncome_8003df66-f76e-45be-afb9-ffe3d8b516e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_71e9b91c-7a25-40b4-88dc-e57bd343290e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5f2ac544-9361-4a86-ba4b-f518e3c735e1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_71e9b91c-7a25-40b4-88dc-e57bd343290e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_c0cebf85-0ca1-405b-b1db-c629b2650b4d" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5f2ac544-9361-4a86-ba4b-f518e3c735e1" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_c0cebf85-0ca1-405b-b1db-c629b2650b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b99dbbd0-0101-4853-96bf-888b1306c869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5f2ac544-9361-4a86-ba4b-f518e3c735e1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b99dbbd0-0101-4853-96bf-888b1306c869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4cc515f-f83e-481b-8768-289062bc7f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4cc515f-f83e-481b-8768-289062bc7f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8962109e-5593-4bf9-bc3c-d385f2297e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8962109e-5593-4bf9-bc3c-d385f2297e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6237350-a8ee-4883-bd73-107e0e4d3397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_NetIncomeLoss_e6237350-a8ee-4883-bd73-107e0e4d3397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7bdb92b6-bd29-4350-a37e-5ad68abca4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7bdb92b6-bd29-4350-a37e-5ad68abca4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_601d51d3-1328-4d5f-8819-90255c4cdc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7bdb92b6-bd29-4350-a37e-5ad68abca4a6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_601d51d3-1328-4d5f-8819-90255c4cdc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0edc7130-52cd-4b88-b1f8-3d5da42935f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0edc7130-52cd-4b88-b1f8-3d5da42935f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3526bf1b-effc-4dab-ac86-5c7397ff7e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_EarningsPerShareBasic_3526bf1b-effc-4dab-ac86-5c7397ff7e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3f115279-00c4-4421-8e5d-b239214fbeef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3f115279-00c4-4421-8e5d-b239214fbeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_71fe17c1-5384-449b-96f3-67ce75bb7f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_71fe17c1-5384-449b-96f3-67ce75bb7f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e981f4e-0633-4a4c-8102-85e42fd6e357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23ac62da-ec20-4191-97bd-3bf407039f6e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e981f4e-0633-4a4c-8102-85e42fd6e357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6fdd218c-500f-40e8-a339-0e1dccbcf476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6fdd218c-500f-40e8-a339-0e1dccbcf476" xlink:to="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4923b4bf-0ef3-4991-b208-fc05c2545bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4923b4bf-0ef3-4991-b208-fc05c2545bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_027dc2d8-067b-4706-bf1f-9456855304aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4923b4bf-0ef3-4991-b208-fc05c2545bd7" xlink:to="loc_us-gaap_ClassOfStockDomain_027dc2d8-067b-4706-bf1f-9456855304aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_b923411f-de40-44b1-9827-56916e494d9d" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_027dc2d8-067b-4706-bf1f-9456855304aa" xlink:to="loc_cmps_OrdinarySharesMember_b923411f-de40-44b1-9827-56916e494d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredSharesMember_07528f39-90be-4682-a7a7-4335fa8652e3" xlink:href="cmps-20230331.xsd#cmps_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_027dc2d8-067b-4706-bf1f-9456855304aa" xlink:to="loc_cmps_DeferredSharesMember_07528f39-90be-4682-a7a7-4335fa8652e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bd1a50df-fb25-46d7-beaf-5b6658e114e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bd1a50df-fb25-46d7-beaf-5b6658e114e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bd1a50df-fb25-46d7-beaf-5b6658e114e2" xlink:to="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8bb6323e-ca22-4395-b302-aa1941fa954c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:to="loc_us-gaap_CommonStockMember_8bb6323e-ca22-4395-b302-aa1941fa954c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9f6dbb3b-b044-4e77-82c8-80727e3369f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9f6dbb3b-b044-4e77-82c8-80727e3369f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8329afe-01cb-4821-985f-5fc02de150a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8329afe-01cb-4821-985f-5fc02de150a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_544904ef-113a-4f40-aea0-b7232c8b29be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6d13a149-843e-4d52-add1-14fee3d59774" xlink:to="loc_us-gaap_RetainedEarningsMember_544904ef-113a-4f40-aea0-b7232c8b29be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_481348f8-55e2-47cd-bf8a-d548bd420704" xlink:to="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a199f857-1bee-4e56-8acd-092a67c401f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a199f857-1bee-4e56-8acd-092a67c401f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ae77a2a-6b10-4805-bc20-2c22573da7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockholdersEquity_5ae77a2a-6b10-4805-bc20-2c22573da7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b05140d-004d-4dd0-8456-198f64064ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b05140d-004d-4dd0-8456-198f64064ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dcef1b21-7dc3-4c51-8b44-57afb44fb5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dcef1b21-7dc3-4c51-8b44-57afb44fb5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fecd0f4f-5686-49a0-a94a-74abf6a3367b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fecd0f4f-5686-49a0-a94a-74abf6a3367b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_86d20f8b-0bbf-4ceb-9b5e-2ff23c7d45f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_86d20f8b-0bbf-4ceb-9b5e-2ff23c7d45f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c0803199-dfc4-4b21-ac3c-1d8ffd56ba29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c0803199-dfc4-4b21-ac3c-1d8ffd56ba29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_deba1338-6978-4a5f-939c-5aaefb5e011b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_deba1338-6978-4a5f-939c-5aaefb5e011b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b199e63d-962e-4bdf-8251-b7ad7d5d6ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b199e63d-962e-4bdf-8251-b7ad7d5d6ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_00fc3bc0-8bcf-4b81-91d8-4babd5069cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_00fc3bc0-8bcf-4b81-91d8-4babd5069cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_58a9b800-2c60-495f-9040-643a602097f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_58a9b800-2c60-495f-9040-643a602097f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a330dab-0598-408a-8e47-ebc78e85aa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_NetIncomeLoss_0a330dab-0598-408a-8e47-ebc78e85aa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fd5da9b9-a983-4c90-8b09-1477eea91c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fd5da9b9-a983-4c90-8b09-1477eea91c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d61b960-3809-491e-a915-b34b1eb2fb86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_StockholdersEquity_3d61b960-3809-491e-a915-b34b1eb2fb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cf62670-ef12-4d24-99db-47a18c74913f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f2b93315-d32e-48de-ab88-e5156a165d20" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cf62670-ef12-4d24-99db-47a18c74913f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cmps-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b2433a9-2542-4bcb-93a4-ba09e9ab34e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b2433a9-2542-4bcb-93a4-ba09e9ab34e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5ad9fc60-7ece-4299-9a4a-4bdaf0bad35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b2433a9-2542-4bcb-93a4-ba09e9ab34e7" xlink:to="loc_us-gaap_NetIncomeLoss_5ad9fc60-7ece-4299-9a4a-4bdaf0bad35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fb00beb-6062-4944-abb9-e8eeff96e2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b2433a9-2542-4bcb-93a4-ba09e9ab34e7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fb00beb-6062-4944-abb9-e8eeff96e2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7ad2e9e8-7017-4c9f-a69d-f1fcd4b475e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fb00beb-6062-4944-abb9-e8eeff96e2f9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7ad2e9e8-7017-4c9f-a69d-f1fcd4b475e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_be7343a1-99ff-48b2-8ee0-e79458049a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fb00beb-6062-4944-abb9-e8eeff96e2f9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_be7343a1-99ff-48b2-8ee0-e79458049a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3ba09a81-d42e-4462-b837-d8cae5fdb025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fb00beb-6062-4944-abb9-e8eeff96e2f9" xlink:to="loc_us-gaap_ShareBasedCompensation_3ba09a81-d42e-4462-b837-d8cae5fdb025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_903e30c1-39ab-4b3f-82a7-81de8b9438ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fb00beb-6062-4944-abb9-e8eeff96e2f9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_903e30c1-39ab-4b3f-82a7-81de8b9438ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2f772003-f1ba-43c1-875d-6456387151f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b2433a9-2542-4bcb-93a4-ba09e9ab34e7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2f772003-f1ba-43c1-875d-6456387151f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5234d086-3539-41bc-996c-7b2d5fb62e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2f772003-f1ba-43c1-875d-6456387151f9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5234d086-3539-41bc-996c-7b2d5fb62e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_cb767b20-ff33-454f-83c2-04ea442a4ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2f772003-f1ba-43c1-875d-6456387151f9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_cb767b20-ff33-454f-83c2-04ea442a4ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1a7f12b7-2abe-4c95-8668-11a5f36eaffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2f772003-f1ba-43c1-875d-6456387151f9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1a7f12b7-2abe-4c95-8668-11a5f36eaffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8ad134a2-76d4-4da2-b83f-141a1e12d46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2f772003-f1ba-43c1-875d-6456387151f9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8ad134a2-76d4-4da2-b83f-141a1e12d46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b6d2fb63-ea7d-4f01-9bb7-225e4f691b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2f772003-f1ba-43c1-875d-6456387151f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b6d2fb63-ea7d-4f01-9bb7-225e4f691b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1beec9cd-d06b-463f-a6a8-c0b09490cfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2f772003-f1ba-43c1-875d-6456387151f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1beec9cd-d06b-463f-a6a8-c0b09490cfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cecf3c5e-13ec-41ff-baea-6fcf7884670c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b2433a9-2542-4bcb-93a4-ba09e9ab34e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cecf3c5e-13ec-41ff-baea-6fcf7884670c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3f14b561-6f8a-40db-b769-c5c0e1ffc4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3f14b561-6f8a-40db-b769-c5c0e1ffc4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7d39bba-e230-47f5-943e-363599a74170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3f14b561-6f8a-40db-b769-c5c0e1ffc4fa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7d39bba-e230-47f5-943e-363599a74170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aed8081a-ae87-49a6-b415-c949515dfadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3f14b561-6f8a-40db-b769-c5c0e1ffc4fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aed8081a-ae87-49a6-b415-c949515dfadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5dd3454-7754-4e0b-8baf-5fe6a1c61e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5dd3454-7754-4e0b-8baf-5fe6a1c61e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_16d3fdbb-5b9b-44f6-a8cc-718ce6a94cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5dd3454-7754-4e0b-8baf-5fe6a1c61e2f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_16d3fdbb-5b9b-44f6-a8cc-718ce6a94cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b6333c8d-9c56-48c5-aea9-ad74a4868597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5dd3454-7754-4e0b-8baf-5fe6a1c61e2f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b6333c8d-9c56-48c5-aea9-ad74a4868597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7f9cbfab-1834-46b6-905a-cf96eb9ab4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5dd3454-7754-4e0b-8baf-5fe6a1c61e2f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7f9cbfab-1834-46b6-905a-cf96eb9ab4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4eb141fb-21a9-4f01-b835-af94ccd48e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5dd3454-7754-4e0b-8baf-5fe6a1c61e2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4eb141fb-21a9-4f01-b835-af94ccd48e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0316d42-4adc-4607-aee5-09a5de885882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0316d42-4adc-4607-aee5-09a5de885882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3436f13c-bd0c-479f-8aa0-a9b077882ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3436f13c-bd0c-479f-8aa0-a9b077882ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9995592-abe4-44f5-97b3-d534a0174a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9995592-abe4-44f5-97b3-d534a0174a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6e17383-8c24-4b85-93af-a0f22ce14edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6e17383-8c24-4b85-93af-a0f22ce14edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5fe91a0d-5537-4b11-afeb-598b8ef5cc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5fe91a0d-5537-4b11-afeb-598b8ef5cc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption_daff2ceb-8405-49f0-8b54-4571dd1aae39" xlink:href="cmps-20230331.xsd#cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5fe91a0d-5537-4b11-afeb-598b8ef5cc2d" xlink:to="loc_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption_daff2ceb-8405-49f0-8b54-4571dd1aae39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ProceedsFromStockOptionsExercisedNotReceived_5e239558-7957-4cc6-b291-79751b1c3359" xlink:href="cmps-20230331.xsd#cmps_ProceedsFromStockOptionsExercisedNotReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5fe91a0d-5537-4b11-afeb-598b8ef5cc2d" xlink:to="loc_cmps_ProceedsFromStockOptionsExercisedNotReceived_5e239558-7957-4cc6-b291-79751b1c3359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_12e20c9e-2e21-4fa6-a0c4-7ec4a740f5d2" xlink:href="cmps-20230331.xsd#cmps_DeferredOfferingCostsIncludedInAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5fe91a0d-5537-4b11-afeb-598b8ef5cc2d" xlink:to="loc_cmps_DeferredOfferingCostsIncludedInAccruedExpenses_12e20c9e-2e21-4fa6-a0c4-7ec4a740f5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_94c5ed16-b4d0-4e05-9eba-6ff8af60fe03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d136306c-1dad-4408-951a-e62dfc98db15" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_94c5ed16-b4d0-4e05-9eba-6ff8af60fe03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d314c41d-2fd4-4d28-b9f0-5d673480ae57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_94c5ed16-b4d0-4e05-9eba-6ff8af60fe03" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d314c41d-2fd4-4d28-b9f0-5d673480ae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e69bde7c-d01c-4e46-9fc6-0cccf924d474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_94c5ed16-b4d0-4e05-9eba-6ff8af60fe03" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e69bde7c-d01c-4e46-9fc6-0cccf924d474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83e126f2-d5af-4d00-8210-48cfca74602e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_94c5ed16-b4d0-4e05-9eba-6ff8af60fe03" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83e126f2-d5af-4d00-8210-48cfca74602e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusiness" xlink:type="simple" xlink:href="cmps-20230331.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21c23465-4a20-4f60-a3f3-af85b3ee21ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_62e5521e-9c28-4b99-b77a-4263d4a0f08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21c23465-4a20-4f60-a3f3-af85b3ee21ca" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_62e5521e-9c28-4b99-b77a-4263d4a0f08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cmps-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05a17fc3-a5b3-4a19-a8c6-450afc968710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4b878c83-7837-4e00-85e7-75d34aefce17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05a17fc3-a5b3-4a19-a8c6-450afc968710" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4b878c83-7837-4e00-85e7-75d34aefce17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="cmps-20230331.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8c4f3784-6222-469b-a0f3-2282c8928188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_475c3353-bced-480e-b670-96bfe8838782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8c4f3784-6222-469b-a0f3-2282c8928188" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_475c3353-bced-480e-b670-96bfe8838782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilities" xlink:type="simple" xlink:href="cmps-20230331.xsd#AccruedExpensesandOtherLiabilities"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/AccruedExpensesandOtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_bc35853e-a678-4d5b-bf01-1ce676c66a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0558fc59-dee9-4f20-a231-7542b85d8a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_bc35853e-a678-4d5b-bf01-1ce676c66a7b" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0558fc59-dee9-4f20-a231-7542b85d8a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/OrdinaryShares" xlink:type="simple" xlink:href="cmps-20230331.xsd#OrdinaryShares"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/OrdinaryShares" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8de20e6f-e342-4563-8bf0-1cca3c6b7420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c21fb683-ce9c-46e2-a6c9-d027e055170a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8de20e6f-e342-4563-8bf0-1cca3c6b7420" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c21fb683-ce9c-46e2-a6c9-d027e055170a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb51dd08-4bd2-4a53-a31c-de266493fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9a5a7542-bb71-4bb1-8103-522220bd90a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb51dd08-4bd2-4a53-a31c-de266493fdf8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9a5a7542-bb71-4bb1-8103-522220bd90a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShare" xlink:type="simple" xlink:href="cmps-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_64a7a2c6-4489-420b-aeef-6156aa95bc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_885bbdd3-80d1-4d8b-8132-664271a97850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64a7a2c6-4489-420b-aeef-6156aa95bc71" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_885bbdd3-80d1-4d8b-8132-664271a97850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/Rightofuseofassets" xlink:type="simple" xlink:href="cmps-20230331.xsd#Rightofuseofassets"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/Rightofuseofassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_23d94357-7fd2-48de-82db-e8a4df9db802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1cfffd31-8c65-48f4-a2bc-a719d43b16c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_23d94357-7fd2-48de-82db-e8a4df9db802" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1cfffd31-8c65-48f4-a2bc-a719d43b16c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cmps-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7e60c3b-8971-4858-8912-ad1eeacc1661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_27aa1c75-c4fd-482d-b55e-58e90d5f8e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7e60c3b-8971-4858-8912-ad1eeacc1661" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_27aa1c75-c4fd-482d-b55e-58e90d5f8e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cmps-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e4bd2e53-6cae-4076-926f-c99f72a021e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_55430203-5700-4ac5-be81-25d7e8ca96a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e4bd2e53-6cae-4076-926f-c99f72a021e6" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_55430203-5700-4ac5-be81-25d7e8ca96a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cmps-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ebc902aa-d7da-45e9-b798-c371adb8668c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ebc902aa-d7da-45e9-b798-c371adb8668c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8eff52f9-9dee-4e4b-ae9a-d771ae25bdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8eff52f9-9dee-4e4b-ae9a-d771ae25bdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e3bcb5f0-fbd4-4321-bf00-3cca20a7f266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_UseOfEstimates_e3bcb5f0-fbd4-4321-bf00-3cca20a7f266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ffb1809c-19f7-49fc-8f21-56d642069fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ffb1809c-19f7-49fc-8f21-56d642069fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_eb228ad6-7542-4d16-a752-60e8058ea386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_eb228ad6-7542-4d16-a752-60e8058ea386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_862de52d-71cd-4247-aeb0-0131f91a637f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_862de52d-71cd-4247-aeb0-0131f91a637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_05ea34d7-b391-4855-afdc-b3c3df6e3399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_05ea34d7-b391-4855-afdc-b3c3df6e3399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c030ae31-7efe-4767-890f-ca6ec17f9803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c030ae31-7efe-4767-890f-ca6ec17f9803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_02146e3c-f3bc-4104-8cf4-b4d0a1ea0f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_02146e3c-f3bc-4104-8cf4-b4d0a1ea0f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_552f2e91-5e93-488f-875c-9b331c9c66ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_552f2e91-5e93-488f-875c-9b331c9c66ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f8fb2bc8-e9ca-4f93-913e-a94e5f24f15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f8fb2bc8-e9ca-4f93-913e-a94e5f24f15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_20c51744-6dbb-4c5c-aeb3-254fe8d636b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_20c51744-6dbb-4c5c-aeb3-254fe8d636b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8373292f-b9b6-45c1-be2a-7aeeba60fd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8373292f-b9b6-45c1-be2a-7aeeba60fd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f9d15475-9ee0-4d69-9326-4b8973941232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f9d15475-9ee0-4d69-9326-4b8973941232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_27a2f41d-4fe4-4194-be21-edab8a94eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_27a2f41d-4fe4-4194-be21-edab8a94eb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_fcc7eec2-612a-4718-8e43-4d03bf9ce392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_fcc7eec2-612a-4718-8e43-4d03bf9ce392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_9f41887d-aa9c-4da4-bda5-52e935ca430b" xlink:href="cmps-20230331.xsd#cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock_9f41887d-aa9c-4da4-bda5-52e935ca430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_db4eb59d-b607-4435-8146-a43002b34166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_db4eb59d-b607-4435-8146-a43002b34166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_353b17d9-3333-4cce-9d35-ca33bf54ec62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_353b17d9-3333-4cce-9d35-ca33bf54ec62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_2894175f-d155-4ed9-b7f4-7a3d01a1b6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_300f5a0c-9891-485a-a7a1-04d8d4e53875" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_2894175f-d155-4ed9-b7f4-7a3d01a1b6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cmps-20230331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_29069d19-51f6-4221-8ddb-e60c15b1f5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_93409d4b-8e13-40d7-afac-d78e73b412b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_29069d19-51f6-4221-8ddb-e60c15b1f5d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_93409d4b-8e13-40d7-afac-d78e73b412b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="cmps-20230331.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_92c36bd3-dd86-4b11-8636-037fea33b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_90b3c9c9-306d-4266-bc62-b8417c4f9577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_92c36bd3-dd86-4b11-8636-037fea33b9bf" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_90b3c9c9-306d-4266-bc62-b8417c4f9577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="simple" xlink:href="cmps-20230331.xsd#AccruedExpensesandOtherLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_627c8588-acc4-45d9-ab41-e8b8bf1524aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a6b81e4f-842b-49d6-89b0-65d0e0b394d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_627c8588-acc4-45d9-ab41-e8b8bf1524aa" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a6b81e4f-842b-49d6-89b0-65d0e0b394d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27fefae8-7b8f-4a50-855d-7db1421c16a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_305800ab-a645-4893-a8ca-50452d149818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27fefae8-7b8f-4a50-855d-7db1421c16a3" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_305800ab-a645-4893-a8ca-50452d149818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_13fea513-2dff-4ec6-aff5-a669a9e8d6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27fefae8-7b8f-4a50-855d-7db1421c16a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_13fea513-2dff-4ec6-aff5-a669a9e8d6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2cb80f2a-8d96-4b16-a3dc-4aace8cb3dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27fefae8-7b8f-4a50-855d-7db1421c16a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2cb80f2a-8d96-4b16-a3dc-4aace8cb3dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_4cc9e6ab-12d7-4715-ac85-038491bea4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27fefae8-7b8f-4a50-855d-7db1421c16a3" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_4cc9e6ab-12d7-4715-ac85-038491bea4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="cmps-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_588c41cf-21a0-422f-8543-eac6d250098f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2b109e8d-b141-4d45-a317-7ea8678a4d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_588c41cf-21a0-422f-8543-eac6d250098f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2b109e8d-b141-4d45-a317-7ea8678a4d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_93cdba1a-24e1-44a4-9d21-2ad6d495bc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_588c41cf-21a0-422f-8543-eac6d250098f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_93cdba1a-24e1-44a4-9d21-2ad6d495bc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsTables" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4e46a316-1e3b-42e7-b671-41b141efaaac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a644580e-1995-4a3b-b28d-0bcd0c074f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4e46a316-1e3b-42e7-b671-41b141efaaac" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a644580e-1995-4a3b-b28d-0bcd0c074f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_641c2fac-b063-44b0-afb7-40b6a27b5bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4e46a316-1e3b-42e7-b671-41b141efaaac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_641c2fac-b063-44b0-afb7-40b6a27b5bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6916f6f7-8c8d-4919-ae2e-ebc351c0533b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6916f6f7-8c8d-4919-ae2e-ebc351c0533b" xlink:to="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a871ad98-e713-410f-bb94-3a0fca6e29e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a871ad98-e713-410f-bb94-3a0fca6e29e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac23ddaa-a0e3-41d3-98d5-4bd33288dceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a871ad98-e713-410f-bb94-3a0fca6e29e5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac23ddaa-a0e3-41d3-98d5-4bd33288dceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b74bcc34-c821-43ba-abc4-e9749bf0cb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac23ddaa-a0e3-41d3-98d5-4bd33288dceb" xlink:to="loc_us-gaap_IPOMember_b74bcc34-c821-43ba-abc4-e9749bf0cb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_1310f19d-204b-4d69-bc17-8ac5ef531b72" xlink:href="cmps-20230331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac23ddaa-a0e3-41d3-98d5-4bd33288dceb" xlink:to="loc_cmps_AtTheMarketOfferingMember_1310f19d-204b-4d69-bc17-8ac5ef531b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8fc80f99-a91e-4830-bae9-3e16959df057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8fc80f99-a91e-4830-bae9-3e16959df057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_52dcaa60-1b4d-43f9-8f5d-c2def34a8a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8fc80f99-a91e-4830-bae9-3e16959df057" xlink:to="loc_us-gaap_ClassOfStockDomain_52dcaa60-1b4d-43f9-8f5d-c2def34a8a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_52d8b894-ec69-4f1c-bb52-f47f15e3e739" xlink:href="cmps-20230331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_52dcaa60-1b4d-43f9-8f5d-c2def34a8a45" xlink:to="loc_cmps_AmericanDepositarySharesMember_52d8b894-ec69-4f1c-bb52-f47f15e3e739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b9b672c2-6175-4c82-bcb1-335ccdd5e19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b9b672c2-6175-4c82-bcb1-335ccdd5e19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7eb62ba2-01fc-4477-8943-138787819177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b9b672c2-6175-4c82-bcb1-335ccdd5e19d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7eb62ba2-01fc-4477-8943-138787819177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32247b6e-1b77-4ee2-9110-758c68f33a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7eb62ba2-01fc-4477-8943-138787819177" xlink:to="loc_us-gaap_SubsequentEventMember_32247b6e-1b77-4ee2-9110-758c68f33a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6a3fc649-0861-495e-90a0-1ac87e50ea76" xlink:to="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_7cd8e9a6-bc2d-404f-b772-1c0cbcfa2678" xlink:href="cmps-20230331.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_7cd8e9a6-bc2d-404f-b772-1c0cbcfa2678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio_db765446-b8c9-4efa-9cb4-267a75ff69ac" xlink:href="cmps-20230331.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_cmps_NumberOfOrdinarySharesConversionRatio_db765446-b8c9-4efa-9cb4-267a75ff69ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7098b3cb-9ea3-4113-a56e-85182172f6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7098b3cb-9ea3-4113-a56e-85182172f6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_269afc00-d474-4c9d-9fde-0eae8d503398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_269afc00-d474-4c9d-9fde-0eae8d503398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f2d2c342-703d-4ab3-97ad-0f57832b5e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_NetIncomeLoss_f2d2c342-703d-4ab3-97ad-0f57832b5e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7eb4dee0-86fb-4abe-a4ce-45a3b4801f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7eb4dee0-86fb-4abe-a4ce-45a3b4801f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07fdda2d-5472-44de-810a-caa11b2f0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_16ef2e61-1ae5-4a0d-a4b3-361424fde4b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07fdda2d-5472-44de-810a-caa11b2f0d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_96f5a4a4-5d89-4d3b-afd9-01cc57ec704f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96f5a4a4-5d89-4d3b-afd9-01cc57ec704f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f8180360-9236-4a32-9bdc-a974a9094245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f8180360-9236-4a32-9bdc-a974a9094245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f8180360-9236-4a32-9bdc-a974a9094245" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aef9c55a-51a8-4563-af13-614d7b76e6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:to="loc_us-gaap_EquipmentMember_aef9c55a-51a8-4563-af13-614d7b76e6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ce188be8-f160-4b78-b835-c9ae089c85de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:to="loc_us-gaap_OfficeEquipmentMember_ce188be8-f160-4b78-b835-c9ae089c85de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b6e21688-c65f-4d3b-8068-a2ad98d32d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b470e023-9a02-461f-95c7-5fcd812fb28f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b6e21688-c65f-4d3b-8068-a2ad98d32d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c07637e7-b18e-47c2-8754-299e288ad8c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:to="loc_srt_RangeAxis_c07637e7-b18e-47c2-8754-299e288ad8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b4665110-5dca-470c-b5dc-dcc8764bfdb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c07637e7-b18e-47c2-8754-299e288ad8c4" xlink:to="loc_srt_RangeMember_b4665110-5dca-470c-b5dc-dcc8764bfdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_317d4cfd-452a-4f8d-8932-4a699d0569e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b4665110-5dca-470c-b5dc-dcc8764bfdb3" xlink:to="loc_srt_MinimumMember_317d4cfd-452a-4f8d-8932-4a699d0569e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ea8deb7-ac90-414e-84de-105d13f491a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b4665110-5dca-470c-b5dc-dcc8764bfdb3" xlink:to="loc_srt_MaximumMember_4ea8deb7-ac90-414e-84de-105d13f491a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e4e4484-eb26-4ffa-ab66-09475923ef45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e03a9771-404c-4336-b610-7e6f7e11db10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e4e4484-eb26-4ffa-ab66-09475923ef45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5bdd004a-ee81-400e-8e6a-7d0ae69e4182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e4e4484-eb26-4ffa-ab66-09475923ef45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5bdd004a-ee81-400e-8e6a-7d0ae69e4182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6bb0d7e4-06c3-4fb4-b8a0-726e86ea884d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6bb0d7e4-06c3-4fb4-b8a0-726e86ea884d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e6d86019-91a8-4a06-8eb5-2aaa545124a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e6d86019-91a8-4a06-8eb5-2aaa545124a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_b7e15f23-547a-4214-806d-dfc32ed9295b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e6d86019-91a8-4a06-8eb5-2aaa545124a8" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_b7e15f23-547a-4214-806d-dfc32ed9295b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_3652adc1-a60a-4213-9e74-2f50a00ccaee" xlink:href="cmps-20230331.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_b7e15f23-547a-4214-806d-dfc32ed9295b" xlink:to="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember_3652adc1-a60a-4213-9e74-2f50a00ccaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_f2358100-bcab-4df5-862e-0d4aeab7dfea" xlink:href="cmps-20230331.xsd#cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_b7e15f23-547a-4214-806d-dfc32ed9295b" xlink:to="loc_cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember_f2358100-bcab-4df5-862e-0d4aeab7dfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637ea4fc-a977-4152-aa51-2d7890c0819d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637ea4fc-a977-4152-aa51-2d7890c0819d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e8d3bf3a-7ed4-4bff-8878-6d24877e53a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637ea4fc-a977-4152-aa51-2d7890c0819d" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e8d3bf3a-7ed4-4bff-8878-6d24877e53a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_c14d8a1a-5aa7-43ef-a746-357ee4975604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e8d3bf3a-7ed4-4bff-8878-6d24877e53a5" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_c14d8a1a-5aa7-43ef-a746-357ee4975604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7cd668b-24b4-4a18-8edf-98c561aac934" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfGeographicRegions_d3e5daf1-30a7-4f6a-90b3-f37b20752153" xlink:href="cmps-20230331.xsd#cmps_NumberOfGeographicRegions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_NumberOfGeographicRegions_d3e5daf1-30a7-4f6a-90b3-f37b20752153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b614e490-5975-4acc-82b5-7a572b2c8a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b614e490-5975-4acc-82b5-7a572b2c8a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca1233fb-f159-4821-a6ca-fcfcecda8ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca1233fb-f159-4821-a6ca-fcfcecda8ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_124c1953-d3da-4e61-a011-e37982343a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_124c1953-d3da-4e61-a011-e37982343a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6b9b446f-4017-438d-a756-e3aa087a632f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6b9b446f-4017-438d-a756-e3aa087a632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_afa4abd7-cb2b-4a5e-a946-665824aaaea3" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent_afa4abd7-cb2b-4a5e-a946-665824aaaea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_0749dd21-e7d5-4a3f-a9e2-643c44ebedce" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable_0749dd21-e7d5-4a3f-a9e2-643c44ebedce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims_139fde64-266b-4d45-993c-2ef2f971606c" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims_139fde64-266b-4d45-993c-2ef2f971606c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim_ad491add-b07f-46ec-a4e6-f7b866d842e8" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim_ad491add-b07f-46ec-a4e6-f7b866d842e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_bcffd2c7-5a27-4fc7-9e4d-0c2778ac7ad6" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount_bcffd2c7-5a27-4fc7-9e4d-0c2778ac7ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_6ee77853-2083-4191-be5b-48650eddbdcf" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1d9c9f6a-d2e1-4c5d-a1cc-9c804b4a4f43" xlink:to="loc_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent_6ee77853-2083-4191-be5b-48650eddbdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf73b6b8-645f-4f37-baf6-c36f4216fd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_fcdf9940-6428-4938-9a34-3cc9a8e8e07e" xlink:href="cmps-20230331.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf73b6b8-645f-4f37-baf6-c36f4216fd0f" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_fcdf9940-6428-4938-9a34-3cc9a8e8e07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_93eb93ad-2a57-4c02-9c4f-da3429b5ad9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf73b6b8-645f-4f37-baf6-c36f4216fd0f" xlink:to="loc_us-gaap_PrepaidInsurance_93eb93ad-2a57-4c02-9c4f-da3429b5ad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_f374f23b-f24f-4f7d-bdea-764667ada7eb" xlink:href="cmps-20230331.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf73b6b8-645f-4f37-baf6-c36f4216fd0f" xlink:to="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_f374f23b-f24f-4f7d-bdea-764667ada7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_d8dd5f32-ebc2-4de0-b92a-032edfb0876d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf73b6b8-645f-4f37-baf6-c36f4216fd0f" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_d8dd5f32-ebc2-4de0-b92a-032edfb0876d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9d644572-f264-4d8b-921c-f2288699a8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf73b6b8-645f-4f37-baf6-c36f4216fd0f" xlink:to="loc_us-gaap_OtherAssetsCurrent_9d644572-f264-4d8b-921c-f2288699a8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_603b8b57-0c23-46f2-b920-e966d4327247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf73b6b8-645f-4f37-baf6-c36f4216fd0f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_603b8b57-0c23-46f2-b920-e966d4327247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#AccruedExpensesandOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4326b23c-52d9-4ca8-9894-bd5b4905fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent_2ba16c48-e99f-45da-a6fc-1f7533c0469b" xlink:href="cmps-20230331.xsd#cmps_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4326b23c-52d9-4ca8-9894-bd5b4905fec0" xlink:to="loc_cmps_AccruedResearchAndDevelopmentExpenseCurrent_2ba16c48-e99f-45da-a6fc-1f7533c0469b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a96bdf6a-a89c-48be-a386-2296bbfcc99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4326b23c-52d9-4ca8-9894-bd5b4905fec0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a96bdf6a-a89c-48be-a386-2296bbfcc99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_324ed1c2-1200-4fab-b89a-c6dd8fb49471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4326b23c-52d9-4ca8-9894-bd5b4905fec0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_324ed1c2-1200-4fab-b89a-c6dd8fb49471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_51220be5-a41c-4095-9512-a1ad1d3394b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4326b23c-52d9-4ca8-9894-bd5b4905fec0" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_51220be5-a41c-4095-9512-a1ad1d3394b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5704be0d-99b0-46d2-8c8f-972d5839e0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4326b23c-52d9-4ca8-9894-bd5b4905fec0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5704be0d-99b0-46d2-8c8f-972d5839e0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_72077cf7-f6cf-495e-89dd-d441a2e3fac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4326b23c-52d9-4ca8-9894-bd5b4905fec0" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_72077cf7-f6cf-495e-89dd-d441a2e3fac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/OrdinarySharesDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#OrdinarySharesDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/OrdinarySharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_983947dd-9b2e-4716-878f-d607d8ca8179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_983947dd-9b2e-4716-878f-d607d8ca8179" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_01960e9e-9e09-4547-ac6d-e87ec662762c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_01960e9e-9e09-4547-ac6d-e87ec662762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d7754e65-5442-4fef-a480-77038631ed68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01960e9e-9e09-4547-ac6d-e87ec662762c" xlink:to="loc_us-gaap_ClassOfStockDomain_d7754e65-5442-4fef-a480-77038631ed68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_a971f9fe-170c-42f1-87ed-6725aa1c5d59" xlink:href="cmps-20230331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d7754e65-5442-4fef-a480-77038631ed68" xlink:to="loc_cmps_AmericanDepositarySharesMember_a971f9fe-170c-42f1-87ed-6725aa1c5d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_6986e9da-8348-4a63-8846-1d59271c9364" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d7754e65-5442-4fef-a480-77038631ed68" xlink:to="loc_cmps_OrdinarySharesMember_6986e9da-8348-4a63-8846-1d59271c9364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc9de7e5-6731-4257-9e16-eee399824f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d4d83c0-803a-41a9-9795-2f5e6f4f09f7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc9de7e5-6731-4257-9e16-eee399824f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_26acf952-d15b-4f25-be07-2fb1518df660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cc9de7e5-6731-4257-9e16-eee399824f3c" xlink:to="loc_us-gaap_SubsequentEventMember_26acf952-d15b-4f25-be07-2fb1518df660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VestingPeriodAxis_1af32ffe-cb7d-468f-8ef3-339143ddf96a" xlink:href="cmps-20230331.xsd#cmps_VestingPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_cmps_VestingPeriodAxis_1af32ffe-cb7d-468f-8ef3-339143ddf96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_VestingPeriodDomain_9abe4cdd-c3bd-4c3c-b368-1cac55f05a4a" xlink:href="cmps-20230331.xsd#cmps_VestingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_VestingPeriodAxis_1af32ffe-cb7d-468f-8ef3-339143ddf96a" xlink:to="loc_cmps_VestingPeriodDomain_9abe4cdd-c3bd-4c3c-b368-1cac55f05a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022And2023Member_f4de813f-0341-4eb7-88e1-fb5ebec6f59c" xlink:href="cmps-20230331.xsd#cmps_A2022And2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_VestingPeriodDomain_9abe4cdd-c3bd-4c3c-b368-1cac55f05a4a" xlink:to="loc_cmps_A2022And2023Member_f4de813f-0341-4eb7-88e1-fb5ebec6f59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ab05d0b3-7902-4026-8fac-2540ca9d8e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ab05d0b3-7902-4026-8fac-2540ca9d8e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96cdc44c-2b43-465b-8b90-3fef00469a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ab05d0b3-7902-4026-8fac-2540ca9d8e76" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96cdc44c-2b43-465b-8b90-3fef00469a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_a225b69f-b20b-4603-8eda-11659bfb09ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96cdc44c-2b43-465b-8b90-3fef00469a07" xlink:to="loc_us-gaap_IPOMember_a225b69f-b20b-4603-8eda-11659bfb09ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_f5c3f085-3952-49c3-b977-d7a708487b35" xlink:href="cmps-20230331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96cdc44c-2b43-465b-8b90-3fef00469a07" xlink:to="loc_cmps_AtTheMarketOfferingMember_f5c3f085-3952-49c3-b977-d7a708487b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e77cc97e-9d0c-4e37-b052-f6b9f85a75d9" xlink:to="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockAmountAuthorized_29d55985-7113-4c07-a32e-e507d94d859f" xlink:href="cmps-20230331.xsd#cmps_SaleOfStockAmountAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_cmps_SaleOfStockAmountAuthorized_29d55985-7113-4c07-a32e-e507d94d859f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85546a86-61dd-480f-9bd5-d178d21dfaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85546a86-61dd-480f-9bd5-d178d21dfaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65ed56e3-2a6a-45fe-81e8-691097c4b443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65ed56e3-2a6a-45fe-81e8-691097c4b443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1742ce9a-b163-4077-950a-25cbe7fa0409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1742ce9a-b163-4077-950a-25cbe7fa0409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_a478ac63-28bb-44ed-b52d-f4a07d9dcdb4" xlink:href="cmps-20230331.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_a478ac63-28bb-44ed-b52d-f4a07d9dcdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ed246941-3563-4ac8-9cae-46a896a716c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ed246941-3563-4ac8-9cae-46a896a716c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod_dc67b0b4-e701-488a-8506-f51a4c16f38c" xlink:href="cmps-20230331.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod_dc67b0b4-e701-488a-8506-f51a4c16f38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_32c23e85-4be4-4c7f-bae7-8f8ebc7f7330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_32c23e85-4be4-4c7f-bae7-8f8ebc7f7330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98ef47c0-d757-4a47-92da-8789ab504adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b418e61-8b60-445f-8057-9469d17bee92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98ef47c0-d757-4a47-92da-8789ab504adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation2017EquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8aab2554-e5ec-4558-99f6-a5bf1289f2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8aab2554-e5ec-4558-99f6-a5bf1289f2f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7f6b6f38-7b20-40e2-b09e-46a63f9cf479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_AwardTypeAxis_7f6b6f38-7b20-40e2-b09e-46a63f9cf479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7f6b6f38-7b20-40e2-b09e-46a63f9cf479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_bae5bbaf-47b6-4d2a-8355-93590550aa2b" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:to="loc_cmps_OrdinarySharesMember_bae5bbaf-47b6-4d2a-8355-93590550aa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bc3c599c-86c6-43c6-b718-10d4a0f7ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bc3c599c-86c6-43c6-b718-10d4a0f7ef29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b51e0f42-3a20-44d9-a42a-1e263fb198cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e0d9319-0947-458b-88e4-cbe482477ef5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b51e0f42-3a20-44d9-a42a-1e263fb198cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_55e2029d-af9f-4695-b977-6f4ec65f7c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_PlanNameAxis_55e2029d-af9f-4695-b977-6f4ec65f7c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aac04f71-b751-4b15-b1f1-6615b4ce9d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_55e2029d-af9f-4695-b977-6f4ec65f7c82" xlink:to="loc_us-gaap_PlanNameDomain_aac04f71-b751-4b15-b1f1-6615b4ce9d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember_31afdaac-956a-4768-945f-98cb3b9b9a27" xlink:href="cmps-20230331.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_aac04f71-b751-4b15-b1f1-6615b4ce9d82" xlink:to="loc_cmps_A2017EquityIncentivePlanMember_31afdaac-956a-4768-945f-98cb3b9b9a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_srt_RangeAxis_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37b729df-8e1f-43a6-8236-1a015d67c16b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0ebeb381-7a98-4cf9-abfc-c3637f6c38ab" xlink:to="loc_srt_RangeMember_37b729df-8e1f-43a6-8236-1a015d67c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b629f66-ae4a-4b4c-ae00-402087d51ab4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37b729df-8e1f-43a6-8236-1a015d67c16b" xlink:to="loc_srt_MinimumMember_5b629f66-ae4a-4b4c-ae00-402087d51ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8780610b-8bb6-4e1d-87f3-6e2550660a1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37b729df-8e1f-43a6-8236-1a015d67c16b" xlink:to="loc_srt_MaximumMember_8780610b-8bb6-4e1d-87f3-6e2550660a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c65556bd-e904-471a-b989-1a43c3480223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_VestingAxis_c65556bd-e904-471a-b989-1a43c3480223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cc0c4568-e381-44d1-8fd4-a6e5c4e18f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_c65556bd-e904-471a-b989-1a43c3480223" xlink:to="loc_us-gaap_VestingDomain_cc0c4568-e381-44d1-8fd4-a6e5c4e18f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a9e99dbc-0a97-4a66-99c7-48a3e6ae2b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_cc0c4568-e381-44d1-8fd4-a6e5c4e18f09" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a9e99dbc-0a97-4a66-99c7-48a3e6ae2b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3f3fe237-fa87-4ba3-9a82-0923f0e51a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_cc0c4568-e381-44d1-8fd4-a6e5c4e18f09" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3f3fe237-fa87-4ba3-9a82-0923f0e51a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_7bc88a37-d64c-47e0-904b-0b5611046476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_AwardDateAxis_7bc88a37-d64c-47e0-904b-0b5611046476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_5fde4176-162a-4c05-80e4-86b2cd48fc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_7bc88a37-d64c-47e0-904b-0b5611046476" xlink:to="loc_us-gaap_AwardDateDomain_5fde4176-162a-4c05-80e4-86b2cd48fc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member_0ae69dfa-8733-40aa-aea5-99de6d623099" xlink:href="cmps-20230331.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_5fde4176-162a-4c05-80e4-86b2cd48fc2e" xlink:to="loc_cmps_OptionsGrantedBeforeJune302020Member_0ae69dfa-8733-40aa-aea5-99de6d623099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member_8e91ff17-ac33-492d-92e2-cdf3491f3442" xlink:href="cmps-20230331.xsd#cmps_GrantDateJune302020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_5fde4176-162a-4c05-80e4-86b2cd48fc2e" xlink:to="loc_cmps_GrantDateJune302020Member_8e91ff17-ac33-492d-92e2-cdf3491f3442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7020a901-4516-42e7-9e83-9090f7584222" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cc0d3af0-e183-44a9-8d27-f304f21c7830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cc0d3af0-e183-44a9-8d27-f304f21c7830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7f108525-34a2-4aed-973f-14518c8f80a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7f108525-34a2-4aed-973f-14518c8f80a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2115382f-d635-43fa-ab39-1e8e27222d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2115382f-d635-43fa-ab39-1e8e27222d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6d36b9b0-05a2-4575-bfe6-e9378873f54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6d36b9b0-05a2-4575-bfe6-e9378873f54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_51e0e2b2-02a9-4764-8183-d41a389059dc" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_51e0e2b2-02a9-4764-8183-d41a389059dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_e05865c1-dacc-4574-98a4-e5a0a4f4af26" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9858cf7e-0adf-4b5c-b02a-df9a4034ba89" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_e05865c1-dacc-4574-98a4-e5a0a4f4af26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_067d1fc1-022a-4b32-bc30-3259080b0a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75bef30f-6d50-4b41-8bf1-39a83ca041d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_067d1fc1-022a-4b32-bc30-3259080b0a7a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75bef30f-6d50-4b41-8bf1-39a83ca041d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b06296b0-3bbc-4a65-b86e-f7bf73627fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75bef30f-6d50-4b41-8bf1-39a83ca041d7" xlink:to="loc_us-gaap_AwardTypeAxis_b06296b0-3bbc-4a65-b86e-f7bf73627fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_916bc00f-8424-441e-a1c6-332aa5b15f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b06296b0-3bbc-4a65-b86e-f7bf73627fc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_916bc00f-8424-441e-a1c6-332aa5b15f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_dd559122-b7d6-451e-80d8-fec8b22a979a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_916bc00f-8424-441e-a1c6-332aa5b15f48" xlink:to="loc_us-gaap_EmployeeStockMember_dd559122-b7d6-451e-80d8-fec8b22a979a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75bef30f-6d50-4b41-8bf1-39a83ca041d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55e73b9f-0d86-4ce1-add5-9b6167753b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55e73b9f-0d86-4ce1-add5-9b6167753b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_faba8521-7596-4dff-9bf6-b50bdb8e7802" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_faba8521-7596-4dff-9bf6-b50bdb8e7802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_7f40ceba-9f4c-4125-9d8a-6755fa2d34e5" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_7f40ceba-9f4c-4125-9d8a-6755fa2d34e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_0dd90315-8525-4d1d-8d04-d0b69302362f" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_0dd90315-8525-4d1d-8d04-d0b69302362f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_aaf72011-1a65-4015-871f-371d4467e73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6ae117a-976a-4e74-b783-10fd976b3eb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_aaf72011-1a65-4015-871f-371d4467e73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation2020ShareOptionPlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_001a67b6-8ad8-471b-8f82-a78412d07ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_001a67b6-8ad8-471b-8f82-a78412d07ce8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_068f81de-725a-481d-a678-a719df647fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_AwardTypeAxis_068f81de-725a-481d-a678-a719df647fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_068f81de-725a-481d-a678-a719df647fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_3e559228-295e-4097-b25c-0732feb49cce" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:to="loc_cmps_OrdinarySharesMember_3e559228-295e-4097-b25c-0732feb49cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4e90ba24-0eda-42ca-86c5-126f357b0f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:to="loc_us-gaap_EmployeeStockMember_4e90ba24-0eda-42ca-86c5-126f357b0f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa8d3e21-21cf-4a28-912c-cea40802ee39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a1dade-1d64-4b39-a166-42fb896f6d48" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa8d3e21-21cf-4a28-912c-cea40802ee39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3f824660-267a-4f7a-9d62-677dd8edc1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_PlanNameAxis_3f824660-267a-4f7a-9d62-677dd8edc1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_56ed6b1f-7b27-4bae-b5a9-7d7606e4d1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3f824660-267a-4f7a-9d62-677dd8edc1e5" xlink:to="loc_us-gaap_PlanNameDomain_56ed6b1f-7b27-4bae-b5a9-7d7606e4d1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember_aa7a9bac-1811-4cb4-a906-9f43661caa43" xlink:href="cmps-20230331.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_56ed6b1f-7b27-4bae-b5a9-7d7606e4d1cd" xlink:to="loc_cmps_A2020ShareOptionPlanMember_aa7a9bac-1811-4cb4-a906-9f43661caa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ee2042a9-d2be-43da-a07d-83388115ea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ee2042a9-d2be-43da-a07d-83388115ea1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_55ee1606-68ad-4115-92d5-6d017d9ae2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee2042a9-d2be-43da-a07d-83388115ea1e" xlink:to="loc_us-gaap_ClassOfStockDomain_55ee1606-68ad-4115-92d5-6d017d9ae2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_8534bbd5-ce1f-471a-8709-aa7fc8f8aabb" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_55ee1606-68ad-4115-92d5-6d017d9ae2fa" xlink:to="loc_cmps_OrdinarySharesMember_8534bbd5-ce1f-471a-8709-aa7fc8f8aabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0c785f8a-2657-4bc0-9508-26811dad8080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_VestingAxis_0c785f8a-2657-4bc0-9508-26811dad8080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_0c785f8a-2657-4bc0-9508-26811dad8080" xlink:to="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_67f185a9-23fa-477b-be3e-755ceb38aa29" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_67f185a9-23fa-477b-be3e-755ceb38aa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_a09794d9-2110-4c6f-8bfe-b88308f3afcf" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_a09794d9-2110-4c6f-8bfe-b88308f3afcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_b7d4af21-477d-410d-a19f-ca922bb56f5d" xlink:href="cmps-20230331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_275a5ff5-d6ca-4a9d-954e-54c9a7024a78" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_b7d4af21-477d-410d-a19f-ca922bb56f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_735180c3-8361-459e-b4c3-bf8be9607539" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e4f49870-507c-46da-b1c4-c185e5653995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e4f49870-507c-46da-b1c4-c185e5653995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df3b004c-8e91-4dae-9ccb-381bdc7c0176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df3b004c-8e91-4dae-9ccb-381bdc7c0176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2bad4ea2-1eb8-4e9f-abd2-b0e9891e136b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2bad4ea2-1eb8-4e9f-abd2-b0e9891e136b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_aac5acbe-7d97-401d-bad8-d09932d36fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_aac5acbe-7d97-401d-bad8-d09932d36fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_99c0e7c8-6f5f-4627-a466-69305c6c4f93" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_99c0e7c8-6f5f-4627-a466-69305c6c4f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_42f3932e-2434-4b20-b513-5e877666dac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_SharesIssued_42f3932e-2434-4b20-b513-5e877666dac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_147ec6eb-dbe5-4230-8ce6-2b44fd4407b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_147ec6eb-dbe5-4230-8ce6-2b44fd4407b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8bef7a9-2de2-423f-b67a-4c6f8806caa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25a1281e-a391-4798-b731-8ad62ea3d271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8bef7a9-2de2-423f-b67a-4c6f8806caa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensation2022InducementGrantOptionAwardDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34203ec6-448a-4583-8940-4be5bfa02e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34203ec6-448a-4583-8940-4be5bfa02e96" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_62b5101f-ccca-4ff2-a1ad-5975572890c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:to="loc_us-gaap_PlanNameAxis_62b5101f-ccca-4ff2-a1ad-5975572890c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0465ee5b-abc6-425b-a8fb-14ab76d2fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_62b5101f-ccca-4ff2-a1ad-5975572890c9" xlink:to="loc_us-gaap_PlanNameDomain_0465ee5b-abc6-425b-a8fb-14ab76d2fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember_48d09b2e-48cd-4723-a8ab-ca29b0cb70d5" xlink:href="cmps-20230331.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0465ee5b-abc6-425b-a8fb-14ab76d2fa4b" xlink:to="loc_cmps_A2022InducementGrantOptionAwardMember_48d09b2e-48cd-4723-a8ab-ca29b0cb70d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1791ec8a-c0be-4f51-af0b-ef9d8198f430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:to="loc_us-gaap_VestingAxis_1791ec8a-c0be-4f51-af0b-ef9d8198f430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b7279df1-b521-4d8f-841f-f554b50113be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1791ec8a-c0be-4f51-af0b-ef9d8198f430" xlink:to="loc_us-gaap_VestingDomain_b7279df1-b521-4d8f-841f-f554b50113be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_c49c8c22-c3b7-455f-8f20-52d755e36b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b7279df1-b521-4d8f-841f-f554b50113be" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_c49c8c22-c3b7-455f-8f20-52d755e36b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_706d335a-8701-448f-bc40-3acd457e872f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b7279df1-b521-4d8f-841f-f554b50113be" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_706d335a-8701-448f-bc40-3acd457e872f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_872c8f83-e188-4910-8d6c-1e1d2162c648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:to="loc_us-gaap_StatementClassOfStockAxis_872c8f83-e188-4910-8d6c-1e1d2162c648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_98453581-2ae2-453d-81f6-b92a8c660ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_872c8f83-e188-4910-8d6c-1e1d2162c648" xlink:to="loc_us-gaap_ClassOfStockDomain_98453581-2ae2-453d-81f6-b92a8c660ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_1b88117a-8910-4b0b-babf-ebb6166cc4d5" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_98453581-2ae2-453d-81f6-b92a8c660ee4" xlink:to="loc_cmps_OrdinarySharesMember_1b88117a-8910-4b0b-babf-ebb6166cc4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8b6b4b8-b5a5-4b98-aa42-28cd6a5c8a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c870e9da-8fa0-490f-9379-b0c96e3395f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c870e9da-8fa0-490f-9379-b0c96e3395f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8db73f84-2220-48fd-a426-f1fc7bb7edc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8db73f84-2220-48fd-a426-f1fc7bb7edc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4b8e11d1-6a3b-4d67-8a4f-fc355e4fe2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4b8e11d1-6a3b-4d67-8a4f-fc355e4fe2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_40ab17c5-fbf2-4c60-9068-e739a1f5d8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d44c116-aafa-4ef2-9601-322353f5f988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_40ab17c5-fbf2-4c60-9068-e739a1f5d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensationRestrictedShareUnitsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe544895-7418-42d8-804a-82b0d968c6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41e7f8ab-e0c3-492f-b7b1-cd17032386cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe544895-7418-42d8-804a-82b0d968c6e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41e7f8ab-e0c3-492f-b7b1-cd17032386cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_052c81bf-eda7-47a9-803a-e8f4607d6319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41e7f8ab-e0c3-492f-b7b1-cd17032386cb" xlink:to="loc_us-gaap_AwardTypeAxis_052c81bf-eda7-47a9-803a-e8f4607d6319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244bd729-1086-48cb-9552-383ec588fecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_052c81bf-eda7-47a9-803a-e8f4607d6319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244bd729-1086-48cb-9552-383ec588fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62549777-d607-4520-a337-83988829fbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244bd729-1086-48cb-9552-383ec588fecf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62549777-d607-4520-a337-83988829fbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41e7f8ab-e0c3-492f-b7b1-cd17032386cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_8f47e20d-ebcf-4b9f-8f22-9374e216d315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_8f47e20d-ebcf-4b9f-8f22-9374e216d315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac93d099-ddb0-4c70-b14c-a248c5a6138d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac93d099-ddb0-4c70-b14c-a248c5a6138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_9443d9e9-5bc4-4ba6-8138-8fbbca58cf71" xlink:href="cmps-20230331.xsd#cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod_9443d9e9-5bc4-4ba6-8138-8fbbca58cf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_51c731df-4484-42cb-91a5-6c166de32dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_51c731df-4484-42cb-91a5-6c166de32dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1b96f389-f515-4e8c-b75c-e9dc7916c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0fe4a5db-e0e8-44aa-8c22-6a74d465ab5b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1b96f389-f515-4e8c-b75c-e9dc7916c2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2abacaa6-ed47-4efe-9aa1-6ccaf68fdd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2abacaa6-ed47-4efe-9aa1-6ccaf68fdd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2c011a4-f0b4-40ab-b760-ed64bb53f3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2c011a4-f0b4-40ab-b760-ed64bb53f3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6cbc00aa-9a10-415c-978a-6745b2f03b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6cbc00aa-9a10-415c-978a-6745b2f03b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_cc7a9336-c7da-441f-85a7-4a8aacb5fbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_cc7a9336-c7da-441f-85a7-4a8aacb5fbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_aa1681f8-f40f-446c-b2e7-9fdc1cb4132f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6788d2fb-529d-482e-ad92-c68eb995d853" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_aa1681f8-f40f-446c-b2e7-9fdc1cb4132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_872e2ca8-1f63-421d-9866-b539617d4a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_872e2ca8-1f63-421d-9866-b539617d4a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf9218c-757e-4c20-808a-1de4327b3960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf9218c-757e-4c20-808a-1de4327b3960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_e10b4492-08a5-421d-9858-8ffb830ef7ed" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9651d8b-8a38-4846-8bca-4f5b6c7df984" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_e10b4492-08a5-421d-9858-8ffb830ef7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#SharebasedCompensationShareOptionsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73a37cdd-64bf-4cce-b8c3-19bf5ca04b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73a37cdd-64bf-4cce-b8c3-19bf5ca04b95" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ff3b9d81-b859-4de2-8a9f-52866c004a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:to="loc_us-gaap_AwardTypeAxis_ff3b9d81-b859-4de2-8a9f-52866c004a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3def7867-6ae7-479d-9ce0-4e716b2158c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ff3b9d81-b859-4de2-8a9f-52866c004a03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3def7867-6ae7-479d-9ce0-4e716b2158c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c893d823-59fc-4a45-b9b7-ca850345c607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3def7867-6ae7-479d-9ce0-4e716b2158c8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c893d823-59fc-4a45-b9b7-ca850345c607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dea358e0-0e84-44ef-ba0a-2d8c6c326253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7adc687f-7d7a-4c3a-9a0d-4462ff8bf8a8" xlink:to="loc_us-gaap_ClassOfStockDomain_dea358e0-0e84-44ef-ba0a-2d8c6c326253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_43e7c1e4-2f81-40e3-b2dd-9a82148d7eab" xlink:href="cmps-20230331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dea358e0-0e84-44ef-ba0a-2d8c6c326253" xlink:to="loc_cmps_OrdinarySharesMember_43e7c1e4-2f81-40e3-b2dd-9a82148d7eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea04a522-743d-4048-a121-e810aae609b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb817f18-1c12-4047-81d6-762c065c248a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb817f18-1c12-4047-81d6-762c065c248a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3085113b-72d7-436c-a995-dc3bb3391795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3085113b-72d7-436c-a995-dc3bb3391795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68df1aec-3c80-4686-83d8-17544d489f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_68df1aec-3c80-4686-83d8-17544d489f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_36602ac5-0832-441f-8f32-9309c21c21e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_36602ac5-0832-441f-8f32-9309c21c21e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8eb13792-534d-431a-af64-87d805819775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d19f5d4-c76d-46bd-9682-da6c0c1dcc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8eb13792-534d-431a-af64-87d805819775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_606a7995-d4ba-4898-b2f2-94e199536ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_606a7995-d4ba-4898-b2f2-94e199536ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_09a35ac2-3873-4383-84e1-3b3a5c6210c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_09a35ac2-3873-4383-84e1-3b3a5c6210c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0555e8ab-9e19-4af2-bffb-9767957b5a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0555e8ab-9e19-4af2-bffb-9767957b5a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a292b88c-0750-43e8-8dd1-e30d835c3905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a292b88c-0750-43e8-8dd1-e30d835c3905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_346502f8-4b8b-4ab4-99a3-3de936d997ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_346502f8-4b8b-4ab4-99a3-3de936d997ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ca7b27b4-4438-4a89-9fc0-c58434078996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ca7b27b4-4438-4a89-9fc0-c58434078996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92ef0838-9049-471b-b55d-4c9a29b65770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92ef0838-9049-471b-b55d-4c9a29b65770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_807a5e37-4d06-4930-92c0-7c323d861305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_807a5e37-4d06-4930-92c0-7c323d861305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_480bd15c-389d-403c-8fb1-dabdeced6432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_942a60d3-95e9-4117-a71a-cda8e0f317fa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_480bd15c-389d-403c-8fb1-dabdeced6432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_44d3bccf-e895-4c21-89eb-dd770366406f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_44d3bccf-e895-4c21-89eb-dd770366406f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74ccef2b-2bb4-4411-a0d1-9dc734a6c894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74ccef2b-2bb4-4411-a0d1-9dc734a6c894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_7427e893-ccfc-431a-90fc-d81a0216d039" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm_7427e893-ccfc-431a-90fc-d81a0216d039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_09363ad1-59dd-4b32-b7fb-1b28e0d676c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_09363ad1-59dd-4b32-b7fb-1b28e0d676c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_19d18cf4-c295-4f34-b7aa-0a5aa1ec1c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_19d18cf4-c295-4f34-b7aa-0a5aa1ec1c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_2b8e4f1d-79a2-4ac8-b167-2e37d41d122e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e0adac0-4700-416b-8085-3985c8f8f483" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_2b8e4f1d-79a2-4ac8-b167-2e37d41d122e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_39259439-a0bc-4956-9e72-60cad514beba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_39259439-a0bc-4956-9e72-60cad514beba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6dec3f2-f4b2-4d47-b2de-f5dcd7a3f49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6dec3f2-f4b2-4d47-b2de-f5dcd7a3f49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5969aaba-b093-4643-9118-7aec5c5d239d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5969aaba-b093-4643-9118-7aec5c5d239d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_522fed6f-41a7-447b-a6bf-3221a83314dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e7c2423-1f63-442f-85cc-ec6341a51deb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_522fed6f-41a7-447b-a6bf-3221a83314dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensationScheduleofValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923ccf5b-6a86-402f-9974-be9c8ac66198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_500368d6-da4f-48f8-b7a8-241e6b49996b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923ccf5b-6a86-402f-9974-be9c8ac66198" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_500368d6-da4f-48f8-b7a8-241e6b49996b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87df5348-08f1-4ca2-9ed8-09e745aa3c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923ccf5b-6a86-402f-9974-be9c8ac66198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87df5348-08f1-4ca2-9ed8-09e745aa3c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35e0fa3f-5258-4856-81a7-6e7f5b551e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923ccf5b-6a86-402f-9974-be9c8ac66198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35e0fa3f-5258-4856-81a7-6e7f5b551e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_643583ea-da58-47b2-9946-027dd0695b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923ccf5b-6a86-402f-9974-be9c8ac66198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_643583ea-da58-47b2-9946-027dd0695b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_fc64e523-cabf-4aec-b501-847a3382e8f0" xlink:href="cmps-20230331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923ccf5b-6a86-402f-9974-be9c8ac66198" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice_fc64e523-cabf-4aec-b501-847a3382e8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5796efa4-c552-4f73-a43c-eaf47492e6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923ccf5b-6a86-402f-9974-be9c8ac66198" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5796efa4-c552-4f73-a43c-eaf47492e6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13b02339-deb3-4611-831a-b185816eb980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6027091c-07cc-4ebb-9e48-ed842bae28f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13b02339-deb3-4611-831a-b185816eb980" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6027091c-07cc-4ebb-9e48-ed842bae28f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4ee1ee20-a012-4111-9d98-505ec9c6506c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6027091c-07cc-4ebb-9e48-ed842bae28f8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4ee1ee20-a012-4111-9d98-505ec9c6506c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ba86ab5b-4665-4a68-8d98-b0667c254c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4ee1ee20-a012-4111-9d98-505ec9c6506c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ba86ab5b-4665-4a68-8d98-b0667c254c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7c6ba0d1-9717-4dd9-b4e4-1bbbb62c012d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ba86ab5b-4665-4a68-8d98-b0667c254c65" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7c6ba0d1-9717-4dd9-b4e4-1bbbb62c012d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_accb63e2-75a3-4503-8c49-f9791d2b8834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ba86ab5b-4665-4a68-8d98-b0667c254c65" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_accb63e2-75a3-4503-8c49-f9791d2b8834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e24d54f8-9068-465c-bcf5-3310b3b002db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6027091c-07cc-4ebb-9e48-ed842bae28f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e24d54f8-9068-465c-bcf5-3310b3b002db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_30c2d679-1ec8-4d5d-b5ca-d045079aa0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e24d54f8-9068-465c-bcf5-3310b3b002db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_30c2d679-1ec8-4d5d-b5ca-d045079aa0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5a3b21cc-2b26-4ef3-a9af-c6defea93afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_678e3c6f-bf48-42a0-a148-d48af4a83b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a3b21cc-2b26-4ef3-a9af-c6defea93afa" xlink:to="loc_us-gaap_NetIncomeLoss_678e3c6f-bf48-42a0-a148-d48af4a83b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1b28ce74-49a6-4555-a24a-5cf0dc8700f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a3b21cc-2b26-4ef3-a9af-c6defea93afa" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1b28ce74-49a6-4555-a24a-5cf0dc8700f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_55705d5a-6493-42cc-9803-77a732a565a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a3b21cc-2b26-4ef3-a9af-c6defea93afa" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_55705d5a-6493-42cc-9803-77a732a565a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6478215-80cc-4438-8455-86c7b9366f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a3b21cc-2b26-4ef3-a9af-c6defea93afa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6478215-80cc-4438-8455-86c7b9366f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4c8be4a4-257c-4c55-8059-bb0a5d1aabc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a3b21cc-2b26-4ef3-a9af-c6defea93afa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4c8be4a4-257c-4c55-8059-bb0a5d1aabc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_463894a6-2dbc-40a3-ba35-898c5b595d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a3b21cc-2b26-4ef3-a9af-c6defea93afa" xlink:to="loc_us-gaap_EarningsPerShareBasic_463894a6-2dbc-40a3-ba35-898c5b595d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_af94e97c-8433-409d-be09-579a2e65f962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a3b21cc-2b26-4ef3-a9af-c6defea93afa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_af94e97c-8433-409d-be09-579a2e65f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1a13c2ba-f169-42df-97b9-3ccf2327334a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9dad6894-3a0b-4f81-b564-2e3cc26b86f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1a13c2ba-f169-42df-97b9-3ccf2327334a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9dad6894-3a0b-4f81-b564-2e3cc26b86f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1bebc62-c79c-4201-8665-e70113c7e386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9dad6894-3a0b-4f81-b564-2e3cc26b86f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1bebc62-c79c-4201-8665-e70113c7e386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bead0ac6-ead9-42f9-80db-4ec8f6f9248d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b1bebc62-c79c-4201-8665-e70113c7e386" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bead0ac6-ead9-42f9-80db-4ec8f6f9248d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember_00dd7e5a-c5e5-4272-87aa-914707711bc2" xlink:href="cmps-20230331.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bead0ac6-ead9-42f9-80db-4ec8f6f9248d" xlink:to="loc_cmps_UnvestedRestrictedShareUnitsMember_00dd7e5a-c5e5-4272-87aa-914707711bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember_12666d63-1ae8-425e-a494-d87801569337" xlink:href="cmps-20230331.xsd#cmps_ShareOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bead0ac6-ead9-42f9-80db-4ec8f6f9248d" xlink:to="loc_cmps_ShareOptionsMember_12666d63-1ae8-425e-a494-d87801569337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3d2f1add-45ab-4928-94a5-f8857ded1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9dad6894-3a0b-4f81-b564-2e3cc26b86f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3d2f1add-45ab-4928-94a5-f8857ded1e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e7e5545a-6d99-4ea2-b300-f5a8e976e17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3d2f1add-45ab-4928-94a5-f8857ded1e58" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e7e5545a-6d99-4ea2-b300-f5a8e976e17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4119d5fb-cb53-4305-9bb0-0e760907b992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9caad056-d37c-49f0-bcba-4eece6bc4a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4119d5fb-cb53-4305-9bb0-0e760907b992" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9caad056-d37c-49f0-bcba-4eece6bc4a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_28243423-226b-47a3-b60d-2193adc8e782" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9caad056-d37c-49f0-bcba-4eece6bc4a47" xlink:to="loc_srt_CounterpartyNameAxis_28243423-226b-47a3-b60d-2193adc8e782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_28243423-226b-47a3-b60d-2193adc8e782" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WeWorkMember_caeab20d-030a-4489-9952-a2545525bc6b" xlink:href="cmps-20230331.xsd#cmps_WeWorkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:to="loc_cmps_WeWorkMember_caeab20d-030a-4489-9952-a2545525bc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SohoLondonUKMember_30ab2d04-588d-4a65-94ee-022d95589e00" xlink:href="cmps-20230331.xsd#cmps_SohoLondonUKMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:to="loc_cmps_SohoLondonUKMember_30ab2d04-588d-4a65-94ee-022d95589e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DenmarkHillLondonUKMember_fa36717e-40d1-4473-af66-3e221aeeb404" xlink:href="cmps-20230331.xsd#cmps_DenmarkHillLondonUKMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fdd4dde6-669e-4c28-87f5-03aa95ba25b7" xlink:to="loc_cmps_DenmarkHillLondonUKMember_fa36717e-40d1-4473-af66-3e221aeeb404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9caad056-d37c-49f0-bcba-4eece6bc4a47" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_34daa9fc-21f5-49b9-bfc1-d9f74c2365f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_34daa9fc-21f5-49b9-bfc1-d9f74c2365f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LeaseCancellationNotificationPeriod_33a1c649-44b8-4b42-9870-fba5bbafea29" xlink:href="cmps-20230331.xsd#cmps_LeaseCancellationNotificationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_LeaseCancellationNotificationPeriod_33a1c649-44b8-4b42-9870-fba5bbafea29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeasesNoncancelableTerm_51969fb4-f6a3-40f5-9ddc-90fea812da59" xlink:href="cmps-20230331.xsd#cmps_OperatingLeasesNoncancelableTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_OperatingLeasesNoncancelableTerm_51969fb4-f6a3-40f5-9ddc-90fea812da59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseMonthlyPayment_5a59de8b-070e-4952-975b-d4de1171de6c" xlink:href="cmps-20230331.xsd#cmps_OperatingLeaseMonthlyPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_OperatingLeaseMonthlyPayment_5a59de8b-070e-4952-975b-d4de1171de6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RefundableLeaseDepositPayments_e60ffd62-4e80-4ed2-932e-56a6ded91371" xlink:href="cmps-20230331.xsd#cmps_RefundableLeaseDepositPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_RefundableLeaseDepositPayments_e60ffd62-4e80-4ed2-932e-56a6ded91371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseAnnualPayment_121ea607-d183-484a-b64d-85e08ce3a053" xlink:href="cmps-20230331.xsd#cmps_OperatingLeaseAnnualPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61857202-c023-49a2-8582-f8021dd1a9a3" xlink:to="loc_cmps_OperatingLeaseAnnualPayment_121ea607-d183-484a-b64d-85e08ce3a053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0b9ceccb-7508-4084-b4d1-a2e3da413e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_681d67bf-fbc7-4c13-848a-5aaff3b660b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b9ceccb-7508-4084-b4d1-a2e3da413e4e" xlink:to="loc_us-gaap_LeaseCostAbstract_681d67bf-fbc7-4c13-848a-5aaff3b660b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_213710e8-ad94-4174-ae03-ef17fdc32d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_681d67bf-fbc7-4c13-848a-5aaff3b660b3" xlink:to="loc_us-gaap_OperatingLeaseCost_213710e8-ad94-4174-ae03-ef17fdc32d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_1ae80437-07aa-434e-9258-03375d8e46f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_681d67bf-fbc7-4c13-848a-5aaff3b660b3" xlink:to="loc_us-gaap_ShortTermLeaseCost_1ae80437-07aa-434e-9258-03375d8e46f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_31fc81a0-cc0b-49d2-9a60-fb46c79f440c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_681d67bf-fbc7-4c13-848a-5aaff3b660b3" xlink:to="loc_us-gaap_LeaseCost_31fc81a0-cc0b-49d2-9a60-fb46c79f440c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CashFlowLesseeAbstract_cdfce47b-9b87-48df-bedc-694219554429" xlink:href="cmps-20230331.xsd#cmps_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b9ceccb-7508-4084-b4d1-a2e3da413e4e" xlink:to="loc_cmps_CashFlowLesseeAbstract_cdfce47b-9b87-48df-bedc-694219554429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_82926d82-f2db-4e37-9753-a540971f007d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_CashFlowLesseeAbstract_cdfce47b-9b87-48df-bedc-694219554429" xlink:to="loc_us-gaap_OperatingLeasePayments_82926d82-f2db-4e37-9753-a540971f007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_24fe624d-ed03-4be0-aacf-7f5238aa6353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_CashFlowLesseeAbstract_cdfce47b-9b87-48df-bedc-694219554429" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_24fe624d-ed03-4be0-aacf-7f5238aa6353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a02db14f-33c7-42a2-802b-544a4dbc55dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_CashFlowLesseeAbstract_cdfce47b-9b87-48df-bedc-694219554429" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a02db14f-33c7-42a2-802b-544a4dbc55dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5dbe9673-c4f9-4899-887c-8017ce76de1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmps_CashFlowLesseeAbstract_cdfce47b-9b87-48df-bedc-694219554429" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5dbe9673-c4f9-4899-887c-8017ce76de1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0d354ce9-9d4e-456e-a5e4-716bdf202a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_640cb45e-67bd-404b-a819-ef41f773a3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d354ce9-9d4e-456e-a5e4-716bdf202a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_640cb45e-67bd-404b-a819-ef41f773a3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_328f596e-2926-4409-9679-0fa4818df203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d354ce9-9d4e-456e-a5e4-716bdf202a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_328f596e-2926-4409-9679-0fa4818df203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3ecb8e7f-3606-472c-8d70-ebf13a9700c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d354ce9-9d4e-456e-a5e4-716bdf202a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3ecb8e7f-3606-472c-8d70-ebf13a9700c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_13971b51-e18c-4bc9-90c2-efde5f49ae3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d354ce9-9d4e-456e-a5e4-716bdf202a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_13971b51-e18c-4bc9-90c2-efde5f49ae3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e6ecb1e3-0714-49c9-8e2d-a0713a542e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d354ce9-9d4e-456e-a5e4-716bdf202a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e6ecb1e3-0714-49c9-8e2d-a0713a542e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6082d1bd-ec0d-4ab3-a9d0-feb5ea64787e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d354ce9-9d4e-456e-a5e4-716bdf202a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6082d1bd-ec0d-4ab3-a9d0-feb5ea64787e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ea1a0dd6-dc80-426b-8bb2-622c833291ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d354ce9-9d4e-456e-a5e4-716bdf202a08" xlink:to="loc_us-gaap_OperatingLeaseLiability_ea1a0dd6-dc80-426b-8bb2-622c833291ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" xlink:type="simple" xlink:href="cmps-20230331.xsd#RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://compasspathways.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="cmps-20230331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_82e8102a-ae82-47dc-9f59-ba926194ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_82e8102a-ae82-47dc-9f59-ba926194ff14" xlink:to="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e5fdcce2-7cdb-4555-ae10-22044cee4769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ec2ef37-06c0-4d0d-8861-a80a1c5e9deb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e5fdcce2-7cdb-4555-ae10-22044cee4769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b60589ea-ad80-4288-aa5c-34e733e27495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e5fdcce2-7cdb-4555-ae10-22044cee4769" xlink:to="loc_us-gaap_SubsequentEventMember_b60589ea-ad80-4288-aa5c-34e733e27495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f3cba185-ea0e-470b-af15-5c64085d4526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f3cba185-ea0e-470b-af15-5c64085d4526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3fcca7e1-3855-493c-91d8-9fda0a0a1907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f3cba185-ea0e-470b-af15-5c64085d4526" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3fcca7e1-3855-493c-91d8-9fda0a0a1907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_438dc906-746e-48a4-af90-54fa7361d17a" xlink:href="cmps-20230331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3fcca7e1-3855-493c-91d8-9fda0a0a1907" xlink:to="loc_cmps_AtTheMarketOfferingMember_438dc906-746e-48a4-af90-54fa7361d17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e0d91003-27e8-4a1f-86b5-f2a2b43766a8" xlink:to="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6ccb1b20-2e7b-4181-a3e8-d09f55b68911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6ccb1b20-2e7b-4181-a3e8-d09f55b68911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeasesNoncancelableTerm_6bab532a-f783-468a-99d1-0ed9698dadf5" xlink:href="cmps-20230331.xsd#cmps_OperatingLeasesNoncancelableTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_cmps_OperatingLeasesNoncancelableTerm_6bab532a-f783-468a-99d1-0ed9698dadf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OperatingLeaseMonthlyPayment_e041da12-1b4c-4a10-95a6-4c3fca460d4a" xlink:href="cmps-20230331.xsd#cmps_OperatingLeaseMonthlyPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_cmps_OperatingLeaseMonthlyPayment_e041da12-1b4c-4a10-95a6-4c3fca460d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_RefundableLeaseDepositPayments_e5865d6b-6b8f-425b-8e49-93783f9950ef" xlink:href="cmps-20230331.xsd#cmps_RefundableLeaseDepositPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_cmps_RefundableLeaseDepositPayments_e5865d6b-6b8f-425b-8e49-93783f9950ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f57917a7-3f02-4f5e-be16-f6b821c2db92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f57917a7-3f02-4f5e-be16-f6b821c2db92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_387c6709-8508-4428-99a6-bbc83916778c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_58346c46-189d-4fbc-bbba-d3bc6895d429" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_387c6709-8508-4428-99a6-bbc83916778c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>foraresidentagreement001.jpg
<TEXT>
begin 644 foraresidentagreement001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1;V<<?[]Y<X*;<\$$<\X_,4_3?&#3:S!I.KZ/=Z1>7*LUL)V1TFVC) 921N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT>SGV"YZ+\/;>6U^'VAQ3 A_LB-@]@WS#]"*Z6O,4^.W@2-%1+B[55& !:L
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M9S[!<],HKS/_ (7SX&_Y^KW_ ,!6H_X7SX&_Y^KW_P !6H]G/L%STRBO,_\
MA?/@;_GZO?\ P%:C_A?/@;_GZO?_  %:CV<^P7/3**\S_P"%\^!O^?J]_P#
M5J/^%\^!O^?J]_\  5J/9S[!<],HKS/_ (7SX&_Y^KW_ ,!6H_X7SX&_Y^KW
M_P !6H]G/L%STRBO,_\ A?/@;_GZO?\ P%:C_A?/@;_GZO?_  %:CV<^P7/3
M**\S_P"%\^!O^?J]_P# 5J/^%\^!O^?J]_\  5J/9S[!<],HJ."9+B".:/.R
M10ZY]",BI*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD_XZ_P#)4[[_
M *X0_P#H KZPKY/^.O\ R5.^_P"N$/\ Z *Z,-\8F>;4445VDA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%, HHHI %%%% !1110 44447
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ME?\ ('L?^O>/_P!!%6Z\IEA1110 4444 %%%% !1110 4444 %%%% !1110
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M.3U>PQAZUN^#O#\GB?Q7I^DH"5GD_>$?PH.6/Y U@UZIX%3_ (0_X?ZUXUE
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MA!=7.%MG# (WEE#P>X!_KS7*$YJX0MJ(2BBBM "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[NTK_D#V/_7O
M'_Z"*MU4TK_D#V/_ %[Q_P#H(JW7E,L**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN[&XEW.-KG><L/0^M0'K5)-;@&3ZTE%%4 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'W=I7_('L?\
MKWC_ /015NJFE?\ ('L?^O>/_P!!%6Z\IEA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#0M7__ 'P/\:/^%7^-_P#H6K__ +X'^-'/'N!R5%=;_P *O\;_ /0M7_\
MWP/\:/\ A5_C?_H6K_\ [X'^-'/'N!R5%=;_ ,*O\;_]"U?_ /? _P :/^%7
M^-_^A:O_ /O@?XT<\>X')45UO_"K_&__ $+5_P#]\#_&C_A5_C?_ *%J_P#^
M^!_C1SQ[@<E176_\*O\ &_\ T+5__P!\#_&C_A5_C?\ Z%J__P"^!_C1SQ[@
M<E176_\ "K_&_P#T+5__ -\#_&C_ (5?XW_Z%J__ .^!_C1SQ[@<E176_P#"
MK_&__0M7_P#WP/\ &C_A5_C?_H6K_P#[X'^-'/'N!R5%=;_PJ_QO_P!"U?\
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M /0M7_\ WP/\:/\ A5_C?_H6K_\ [X'^-'/'N!R5%=;_ ,*O\;_]"U?_ /?
M_P :/^%7^-_^A:O_ /O@?XT<\>X'V#I7_('L?^O>/_T$5;JMIT;Q:7:1R*5=
M(45@>Q"BK->8R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$Q\16MKJ45P[M#($-UYK$[3OQDDX!P,#@<#B@#L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FNB2+M=0PZX(S3J* $9%8@LH)4Y&1THP/0=<TM% #0B
M $!5 /& *3RHRNWRUVXQC'&/2GT4 )M7=NP-V,9QVHP/0>M+10 U8T485% ]
MA2[5_NC\J6B@!OEIM9=B[6^\,<'ZTH50   ,#'3M2T4  &!@=*0*H8L% 8]3
MCDTM% #0B*I4*H!Y( H9$?[RJWU&:=10 WRTR#L7([XH$:*<A%!]0*=52^OO
ML,:-]EN;C<<8MX]Y'UII7)E)07-+8MT5C?\ "0?]0C5O_ ;_ .O1_P )!_U"
M-6_\!O\ Z]/DD8?6Z/\ -^9LT5C?\)!_U"-6_P# ;_Z]'_"0?]0C5O\ P&_^
MO1R2#ZW1_F_,V:*QO^$@_P"H1JW_ (#?_7H_X2#_ *A&K?\ @-_]>CDD'UNC
M_-^9LT5C?\)!_P!0C5O_  &_^O1_PD'_ %"-6_\  ;_Z]')(/K='^;\S9HK&
M_P"$@_ZA&K?^ W_UZ/\ A(/^H1JW_@-_]>CDD'UNC_-^9LT5C?\ "0?]0C5O
M_ ;_ .O1_P )!_U"-6_\!O\ Z]')(/K='^;\S9HK&_X2#_J$:M_X#?\ UZ/^
M$@_ZA&K?^ W_ ->CDD'UNC_-^9LT5C?\)!_U"-6_\!O_ *]'_"0?]0C5O_ ;
M_P"O1R2#ZW1_F_,V:*QO^$@_ZA&K?^ W_P!>C_A(/^H1JW_@-_\ 7HY)!];H
M_P WYFS16-_PD'_4(U;_ ,!O_KT?\)!_U"-6_P# ;_Z]')(/K='^;\S9HK&_
MX2#_ *A&K?\ @-_]>C_A(/\ J$:M_P" W_UZ.20?6Z/\WYFS16-_PD'_ %"-
M6_\  ;_Z]'_"0?\ 4(U;_P !O_KT<D@^MT?YOS-FBL;_ (2#_J$:M_X#?_7H
M_P"$@_ZA&K?^ W_UZ.20?6Z/\WYFS16-_P )!_U"-6_\!O\ Z]'_  D'_4(U
M;_P&_P#KT<D@^MT?YOS-FBL;_A(/^H1JW_@-_P#7H_X2#_J$:M_X#?\ UZ.2
M0?6Z/\WYFS16-_PD'_4(U;_P&_\ KT?\)!_U"-6_\!O_ *]')(/K='^;\S9H
MK&_X2#_J$:M_X#?_ %Z/^$@_ZA&K?^ W_P!>CDD'UNC_ #?F;-%8W_"0?]0C
M5O\ P&_^O1_PD'_4(U;_ ,!O_KT<D@^MT?YOS-FBL;_A(/\ J$:M_P" W_UZ
M/^$@_P"H1JW_ (#?_7HY)!];H_S?F;-%8W_"0?\ 4(U;_P !O_KT?\)!_P!0
MC5O_  &_^O1R2#ZW1_F_,V:*QO\ A(/^H1JW_@-_]>C_ (2#_J$:M_X#?_7H
MY)!];H_S?F;-%8W_  D'_4(U;_P&_P#KT?\ "0?]0C5O_ ;_ .O1R2#ZW1_F
M_,V:*QO^$@_ZA&K?^ W_ ->C_A(/^H1JW_@-_P#7HY)!];H_S?F;-%8W_"0?
M]0C5O_ ;_P"O1_PD'_4(U;_P&_\ KT<D@^MT?YOS-FBL;_A(/^H1JW_@-_\
M7H_X2#_J$:M_X#?_ %Z.20?6Z/\ -^9LT5C?\)!_U"-6_P# ;_Z]'_"0?]0C
M5O\ P&_^O1R2#ZW1_F_,V:*QO^$@_P"H1JW_ (#?_7H_X2#_ *A&K?\ @-_]
M>CDD'UNC_-^9LT5C?\)!_P!0C5O_  &_^O1_PD'_ %"-6_\  ;_Z]')(/K='
M^;\S9HK&_P"$@_ZA&K?^ W_UZ/\ A(/^H1JW_@-_]>CDD'UNC_-^9LT5C?\
M"0?]0C5O_ ;_ .O1_P )!_U"-6_\!O\ Z]')(/K='^;\S9HK&_X2#_J$:M_X
M#?\ UZ/^$@_ZA&K?^ W_ ->CDD'UNC_-^9LT5C?\)!_U"-6_\!O_ *]'_"0?
M]0C5O_ ;_P"O1R2#ZW1_F_,V:*QO^$@_ZA&K?^ W_P!>C_A(/^H1JW_@-_\
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MJE#^4QO^$=B_Z"6J_P#@8]'_  CL7_02U7_P,>MFBCGEW#ZI0_E,;_A'8O\
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MX[@#UXK=U"[6PT^XNV7<(8R^WUP.E)P:-*>*ISBY+IN3231PJ&ED2-20H+,
M"3T%/KDM5?5'TNQFO'MG2:Y@8I'&5,1+ CDD[O3M5N;7))M0NX(;_3[)+9O+
M'VGEI&QD\;A@=N]5[-VT,?KT5)J2MM;OK=][=._XG145R=QJMYJ5IHT]M+%
M9;ORY%VEQO ;N",KQT^G-:&H7]W;W9B;4-.LHU0%6N.6E;OQN&T?G1[-[%+&
MP:<DG;373JK_ "^9LR31Q%!)(B%VVKN8#<?0>IHCFCEW^7(C[&V-M8':WH?0
MU@)K3WFF:-=F" M<W8B<$;@I&X$KZ?=X/O56+4)=-M-6FB5,MJS(TD@)6($+
MEF ["CV;(>.@K27P[_*USK**S-,N+N>1C)=6=W;%<K-;_*0WH1D_GFM.H:L[
M'93FIQYD%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'U6ROI=5T^^LD@<VRR
MAEE<KG< .P/H:V**:=G<SJTE5CROR?W.YB7MOJVIZ3>VEQ!:1-+'MC*3,W.>
M^5&*62QOK/4VOK%(9O.A6.:*20IRO1@<'UZ5M457.S)X6+?,V[Z:^E_*W5F#
M<:5J-Q%9W4TMO/?VTKOL=<1E6X* XSP,8)':IXK6^FCN_.M[.V62$QQQQ'<<
MD'DM@<>V*UZ*.=@L+!.]WY^>EK]]C#N-(N9?"UMIJM'Y\:PAB2=OR%2><>QJ
M6_@U":66-K&QOK5_]6)FV%..0?E.?K6O11SL'A86T;6B7R5^_J<W'H%U:6^F
MR1&"XN+1'C>.4D*ZL<X!P<8[<59?2[G4=/O;>\BM;99T"QI -Q3'.2V!GG'&
M.U;=%'M&3'!4HKE6W;Y6]=O/\3%MK;4S) DUGI\2QD&69#N,@']U=HVY^O%:
M.H6BW^G7%HS;1-&4W>F1UJS12<G>YK&A&,7%NZ?<YN?3]:O;*TM9DM(Q;2QN
MSK*6\W:1VV\>O>IFTV[LM0O)K6UM+J&Z?S-LS[&C?&#SM.0<9K>HI^T9E]3A
M>]W?OZ77:W7^F8=YIM_)9Z>R"V>ZM;@3.BYC1N""!P<=:9'I^I6VIWEQ%!:2
M&[*MYLCG,.% (QM^8#MR*WZ*.=C>$@WS7?\ 2M^1S5IH=]#9:?:.82+.^\[S
M YRZ98],<'YNE6H;#4;..^:W-NTDUZTX20G#QD ;2<<'CWK;HH=1L4,%3@DH
MMZ?Y6_(Q-.TR>/67U"2UMK)3#Y9A@?=YASG<W '']:VZ**F3N;4J4:4;1]0H
MHHI&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6?=Z[H]A.8+S5;&WF !,<UPB,,].
M"<UH4A52<E03]* ,K_A*?#W_ $'M+_\  R/_ !H_X2GP]_T'M+_\#(_\:NO<
MVD=]#9,R"YFC>6./;RRH5#'\"Z_G3XVBD>5!&P,;;26C(!. >"1R.>H[Y'4&
M@#/_ .$I\/?]![2__ R/_&C_ (2GP]_T'M+_ / R/_&M38G]U?RHV)_=7\J
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M^@]I?_@9'_C4>H(O_"3Z-\H^Y<=O9:TKN:WLK66YG:**&)2[R.0%51R23V%
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M (2GP]_T'M+_ / R/_&M38G]Q?RHV)_<7\J ,O\ X2GP]_T'M+_\#(_\:/\
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M:6\$T\TL,<4()E=B $P,G)[<51;7M(72[;41.'MKH@0&.%G:4X)PJ %B< G
M'0$]J #_ (2GP]_T'M+_ / R/_&C_A*?#W_0>TO_ ,#(_P#&I)-9TF&TLKJ2
MZA6"^DCBMG(_UKO]T#W-,.O:.NH2637*+-'N#EHV" JNYEWXV[@O)&<@<XH
M3_A*?#W_ $'M+_\  R/_ !H_X2GP]_T'M+_\#(_\:CB\3:'-:3W2W($<.PN'
M@=6PYPA"E0S!CPI .X],TC>)]$6.!Q-(YG,@2..UE>3*$!PR!2RX+ '('44
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M3X>_Z#VE_P#@9'_C1_PE/A[_ *#VE_\ @9'_ (UJ;$_N+^5&Q/[B_E0!E_\
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M)_\ XS0!:T6UDL=#L+29Y7DAMTC9IF#.2% ^8C@GU/>KU8_VKQ'_ - C3?\
MP9/_ /&:/M7B/_H$:;_X,G_^,T )J'_(T:-_USN/Y+2>+-.GU;PS=V=ML,[!
M619#A7*L&"D]@=N#]:R[ZYU\^(](+:5IX<)/M4:@Y!X7.3Y/'Y&M7[5XB/\
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MQS51O!M]':^1;Z;'%&[76]8F1 0]_'(G0_\ /)/P  ]!7??:?$/_ $!M,_\
M!B__ ,9H^T^(?^@-IG_@Q?\ ^,T <?-X:EM=7E9=$2YT9=2:9+&(1;"&M8U#
MA&(7B0/QP<MNQWK(@\':OY%M%=V=R,6<44)@,#M:2"1RQ#N<J?F1MRY)QST
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M;:YN8Y+> E!A1"BD[4)"_,K<5H_:?$/_ $!M,_\ !B__ ,9H%UXB'31]-_\
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M .,T ;%%8_VKQ'_T"--_\&3_ /QFC[5XC_Z!&F_^#)__ (S0!L45C_:O$?\
MT"--_P#!D_\ \9H^U>(_^@1IO_@R?_XS0!L45C_:O$?_ $"--_\ !D__ ,9H
M^U>(_P#H$:;_ .#)_P#XS0!L45C_ &KQ'_T"--_\&3__ !FC[5XC_P"@1IO_
M (,G_P#C- &Q16/]J\1_] C3?_!D_P#\9H^U>(_^@1IO_@R?_P",T ;%%8_V
MKQ'_ - C3?\ P9/_ /&:/M7B/_H$:;_X,G_^,T ;%%8_VKQ'_P! C3?_  9/
M_P#&:/M7B/\ Z!&F_P#@R?\ ^,T ;%%8_P!J\1_] C3?_!D__P 9H^U>(_\
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M HHHH **** "BBB@ HHHH *QKG_D=-,_[!UY_P"C+:MFL:Y_Y'33/^P=>?\
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M,.,[LX/% 'IUQ<P6MO-<3RI'#"A>1V. B@9)/H,5';:A;7=Q=P0R;I+240S
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M"(.(V.Y00QZ#C!QFO1PZ$@!ER>1SUJ.XNK>UMYKB>9(X8$+RNQP$4#))].*
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M(M2U:UMI8@I>.1\, V=O'7G:WY&F:QXJT;1X!]HU*UBGE@,T"2/C>,<'V4G
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MN>* &?\ "6^&_P#H8-*_\#(_\:/^$M\-_P#0P:5_X&1_XU)J7B+1](B@EO\
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M3P*1O%FCA(&$MS(TQD"Q16<SR QD!]R*A9<%ESN ZB@!_P#PEOAO_H8-*_\
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M#(_\:/\ A+?#?_0P:5_X&1_XUL44 8__  EOAO\ Z&#2O_ R/_&C_A+?#?\
MT,&E?^!D?^-;%% &/_PEOAO_ *&#2O\ P,C_ ,:/^$M\-_\ 0P:5_P"!D?\
MC6Q10!C_ /"6^&_^A@TK_P #(_\ &C_A+?#?_0P:5_X&1_XUL44 8_\ PEOA
MO_H8-*_\#(_\:/\ A+?#?_0P:5_X&1_XUL44 8__  EOAO\ Z&#2O_ R/_&C
M_A+?#?\ T,&E?^!D?^-;%% &/_PEOAO_ *&#2O\ P,C_ ,:/^$M\-_\ 0P:5
M_P"!D?\ C6Q10!C_ /"6^&_^A@TK_P #(_\ &C_A+?#?_0P:5_X&1_XUL44
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M,4?:?$G_ $"=*_\ !G)_\8H V**Q_M/B3_H$Z5_X,Y/_ (Q1]I\2?] G2O\
MP9R?_&* -BBL?[3XD_Z!.E?^#.3_ .,4?:?$G_0)TK_P9R?_ !B@#8K&N?\
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MW/JESHFI/-=3W$D<=EJ2P36RLD* -MD53N\D,<,<''!ZCI_M/B3_ *!.E?\
M@SD_^,4?:?$G_0)TK_P9R?\ QB@#G;[3_$=W8Z38W5I-/=VWV61[R*XC^S2N
MI0R&9"0QP58@*#V/!Z/TCP_J$/B2S9H[R#3M.:Y:))Y860^8<*(]GSD8)/SX
M(P!SR:W_ +3XD_Z!.E?^#.3_ .,4?:?$G_0)TK_P9R?_ !B@#)7P]JEYH0CE
ME@M[NZO6N[])HS*LJY.V([6'RA1&O7D)@]36GX2L;_3?#-G9ZEY0N8PP81C
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M_0)TK_P9R?\ QB@#8HK'^T^)/^@3I7_@SD_^,4?:?$G_ $"=*_\ !G)_\8H
MV**Q_M/B3_H$Z5_X,Y/_ (Q1]I\2?] G2O\ P9R?_&* -BBL?[3XD_Z!.E?^
M#.3_ .,4?:?$G_0)TK_P9R?_ !B@#8HK'^T^)/\ H$Z5_P"#.3_XQ6A9O=O;
MAKV""&;)RD,QE7';YBJG]* +%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!B:KJ5_P#VU::/I?V9+B:"2YDGN49TCC0JN BLI8DN.XP ?85F:KXF
MU+0+?_B86T5Q>+:7$XBM!A)0DD2!LNV4_P!:,K\W?YN!G:U31(]2N;:\CN[F
MRO;8,L=S;%=VQL;D(=64J=JGD=0",5GW'@RSNX&2YOK^:5K>>W:=Y5+GS6C9
MF^[@$&)<  *.>* +4/B:UEG2V-O<QW37ILF@8+N1Q'YF3AB-NS#9![CO6U7.
MV.@2KXNN-;N@,K:I:P_/DRD'+2L   Q&U>.P/KBNBH **** "BBB@ HHHH *
M*** ,;4/^1HT;_KG<?R6L ^*M17QU&K-'_PCLERVDJ=HS]K"!]^[K@G='C^\
MM;VHY/B;1PIP?+N,'&?X5K%D^&.@OHJVJPHFIJ5E&K")?M'GA@_FY]2PS^.*
M (O$>DZ?:>/O"6H6]G!%>7-_,LTZ( \@^RR\,>_0?E4OB+6?$]EXVT73M,M]
M.>SNTN"%GN60RE$4_,1$VS!)Q@G/?%;^I:(FI:GH]]),R/ID[SJJKQ(6C:/!
M]/OD_A4&O>'Y=5OM-U"SU!K&^T]I#%)Y0E4JZ[65E./0=".E %/7/$6K:7=:
M#I]OI=M<ZAJAD1D^TE8XF2/<3O*Y*CGG;G Z9XJMKEWX@_X0B_FU#2M-9D@N
M1>VYNI%22%0V"C*I/S*,\X(SVK8FT%KO4M$U"ZO&DN=+\PY6,*)F>,H21VZY
MJ]JM@NJZ/>Z<[F-+NWD@9U&2H92N1^= '-WWB*70?"/AZ?3=+6=KQ[6TAM?.
MVA Z<#><], 9/UJN/'-YINF^(I-<TZ%;S17B4QV4Q=)_-"F,*64$$E@IR/>M
MJZ\,PW6FZ)9-<.JZ5<03HP49D,0P ?3-07O@RQU)O$(NYI6BUH0B14.TQ&-0
M%93ZY ;ZB@"AKTOB%O _B)M7M].A0Z3<,HM)W=D;RV^4[E /U'Y5#X8\1ZPM
M[H>DZIIEO;V]_IS36CQW!DD'E",$2#: "0X/!..G-:I\.ZI=:1J&F:IX@>\@
MN[.2U!^R)&R[UV[R1U8#/H/:IV\,0-?Z-=&XDSIEG+:*H&-ZR*@))[$>6.GK
M0!C67C>X?QA8Z)<-H\XO&F0?8+PRO;O&I?#Y4#D CM@UB+\3M:-B;PZ!:K#]
MC%\";LY$2RF-\C;]XG&T>F22.E;6F_#^?37T/9X@N)(]%<_8XFMHPHC92C*V
M "S%3C=D>N,T[_A7-K_91L/M\VW^S3I^[8,[3+YF[ZYXH [6BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L:Y_Y'33
M/^P=>?\ HRVK9K&N?^1TTS_L'7G_ *,MJ )?$&JOH^DFYAA6:X>:*W@C9MJF
M2618UR>PRP)]@:IR:EJVB0RW&LFTN[?]VD1L8FCD:5W"+'L=F!R6&&W#W ZU
MJ:IIEMK&G2V-T&\J3!RC;65E(964CH0P!!]167)X56ZAD6_UC4[R0A/*ED>-
M3"4=9%951%7<&53EE/3'3(H B;QE")_L@TK4&OQ+)$]HOE;E9(UDY;?MP4=2
M#GVZ\5"GCVQ>T6Y_L[4 LD=K+;J43=.EQ((XRHW\?,1D-@@&KUKX6M;:_%^]
MU=7%X9))))I2N9&=%CY"J  %10  .G?-9VI>"HVTNRMM/N)DDMDL+979P"(;
M>=)-WW?OX![8)QQ0!/<>-[2UM)9IK"[CD@G>WGAD>%#$RHK\LT@0Y5U(PQ)S
M['"MXWL<AXK.]FM@EM))<(J!(UGQY9(+!CUY !(H_P"$)M?M7VLZC?\ VMFF
M,T^8]TPD$:L#\F%^6*, J%( Z\T^V\&6%MIDEC]INY(WCMHB[LN[; 1LZ*!V
M /% %NR\26E_<6EO%%.)K@W *,HS%Y+;'W\\?,0!C.<CM5*[\:V-F;KS;2Z"
M078LED8QHLLV,E5+., +R2V!]3Q4VB:&]GKFL:Q<1I%+?2*$B20N$15 )Z#!
M8C) ]!U-/N/"UG<02IYT\<C7QOTE4J6CEQMX!4C&,C!!X)H H#Q]ITMHUQ;6
M5[="*&6>Y2'RV,"1L5;)WX;D'&TMD#(K5OM>ALK33IQ:W-PVH2+%!%$%W;C&
MSC.Y@ ,*><US^O\ A/49H/+TRXEDEFLYK2>>6X2(N'.1N B(V@EON;2!P.O'
M2-HT,L.E)+(Y;39%EC*X&YA&T?/MAS^E &1_PG-HUL\T6G7\I@ADGNHT6/=;
M(DCQMNR^"=T<F N[.T^V>GCD2:))8V#(ZAE([@]*YN3P39%)TAOKZW%RDT=S
MY3)^^CEE>4J<J< -*X!7! ;KWK?MK46ID"RR-&Q&R-L;8@%"[5P,XXSSGDGM
M@  GHHHH **** ,;Q)_QZ67_ &$;7_T:M:[_ '&^E9'B3_CTLO\ L(VO_HU:
MUW!9&4'!(QF@#CE\0:D+*\$L%JEZFI1V,2J6:-=XC.6/!; <],9QVS0^M:JM
MM?!YM-MVTZ=HKJYEC<HWR(Z;4#9R1(!]XX(X!S5N/P?MCNTEU6^F-S,MR6?R
M@4F7;M==L8Y&Q>#D>HYI)/!JNT,JZI?)/'.]P\O[IC+*P"AF#1E<JJ@# &!0
M!6N=9UJ&WTZZ:WM(?M(MU^PN&:=Y'QYB@@@+L!)Z-]TDX%5[/Q7=W.HQ6^;%
MY+I[F*&T#%987BW8$AR>"%.?E&,CK6NWAB8ZHNHC6+X3B)82=L!!4<GK&=NX
M\G;C/'H,*_A8274UP^H7C2,LJPG<@-N7&"R$+DD#@%BV!P* ,6?Q%K-N;B B
MUN'BGAA-S;6DLB(S;BZ>6K%F9-J]#_&.!BBY\57"0VXAOM.#-!/,\]Q \2.\
M;!?*",^Y&YYR21C[OIL6OA>6ST]+.'6;]8XBIA*B%3'C/98P&!SSN!]>O--?
MPBALQ;IJ-['N>1YI%9-TS2'+%LH0#Z%0I';% &WI5XNHZ19WR*52Y@295/4!
ME!Q^M6ZBMH([6UBMXD"1Q($11T  P!4M !1110 4444 %%%% !1110 4444
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M_P"$8L?^?G5O_!M=?_'*V:* ,;_A&+'_ )^=6_\ !M=?_'*/^$8L?^?G5O\
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M_GYU;_P;77_QRMFB@#&_X1BQ_P"?G5O_  ;77_QRC_A&+'_GYU;_ ,&UU_\
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M_P &UU_\<H_X1BQ_Y^=6_P#!M=?_ !RMFB@#&_X1BQ_Y^=6_\&UU_P#'*/\
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M_P"$8L?^?G5O_!M=?_'*V:* ,;_A&+'_ )^=6_\ !M=?_'*/^$8L?^?G5O\
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M-7?M/B7_ *!6D_\ @RD_^,4?:?$O_0*TG_P92?\ QB@#9HK&^T^)?^@5I/\
MX,I/_C%'VGQ+_P! K2?_  92?_&* -FBL;[3XE_Z!6D_^#*3_P",4?:?$O\
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MQ+_T"M)_\&4G_P 8H^T^)?\ H%:3_P"#*3_XQ0!LT5C?:?$O_0*TG_P92?\
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MB7_H%:3_ .#*3_XQ0!LT5C?:?$O_ $"M)_\ !E)_\8H^T^)?^@5I/_@RD_\
MC% &S16-]I\2_P#0*TG_ ,&4G_QBC[3XE_Z!6D_^#*3_ .,4 ;-%8WVGQ+_T
M"M)_\&4G_P 8H^T^)?\ H%:3_P"#*3_XQ0 >)/\ CTLO^PC:_P#HU:V:Y#Q!
M<>(3:V?F:9I:C[?;8VZA(<GS5P/]2.,]_P"=:WVGQ+_T"M)_\&4G_P 8H V:
M*QOM/B7_ *!6D_\ @RD_^,4?:?$O_0*TG_P92?\ QB@#9HK&^T^)?^@5I/\
MX,I/_C%'VGQ+_P! K2?_  92?_&* -FBL;[3XE_Z!6D_^#*3_P",4?:?$O\
MT"M)_P#!E)_\8H V:*QOM/B7_H%:3_X,I/\ XQ1]I\2_] K2?_!E)_\ &* -
MFBL;[3XE_P"@5I/_ (,I/_C%'VGQ+_T"M)_\&4G_ ,8H V:*QOM/B7_H%:3_
M .#*3_XQ1]I\2_\ 0*TG_P &4G_QB@#9HK&^T^)?^@5I/_@RD_\ C%'VGQ+_
M - K2?\ P92?_&* -FBL;[3XE_Z!6D_^#*3_ .,4?:?$O_0*TG_P92?_ !B@
M#9HK&^T^)?\ H%:3_P"#*3_XQ1]I\2_] K2?_!E)_P#&* -FBL;[3XE_Z!6D
M_P#@RD_^,4?:?$O_ $"M)_\ !E)_\8H V:*QOM/B7_H%:3_X,I/_ (Q1]I\2
M_P#0*TG_ ,&4G_QB@#9HK&^T^)?^@5I/_@RD_P#C%'VGQ+_T"M)_\&4G_P 8
MH V:*QOM/B7_ *!6D_\ @RD_^,4?:?$O_0*TG_P92?\ QB@#9HK&^T^)?^@5
MI/\ X,I/_C%'VGQ+_P! K2?_  92?_&* -FBL;[3XE_Z!6D_^#*3_P",4?:?
M$O\ T"M)_P#!E)_\8H V:*QOM/B7_H%:3_X,I/\ XQ1]I\2_] K2?_!E)_\
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MZI_WT*//A_YZI_WT* )*QKG_ )'33/\ L'7G_HRVK5\^'_GJG_?0K'N9HO\
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M !-&_P "?\^>D_\ @$O_ ,37744[Q[?C_P  RY<1_/'_ ,!?_P D<CO\"?\
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M_@3_ )\])_\  )?_ (FNNHHO'M^/_ #EQ'\\?_ 7_P#)'([_  )_SYZ3_P"
M2_\ Q-&_P)_SYZ3_ . 2_P#Q-==11>/;\?\ @!RXC^>/_@+_ /DCD=_@3_GS
MTG_P"7_XFC?X$_Y\])_\ E_^)KKJ*+Q[?C_P Y<1_/'_ ,!?_P D<CO\"?\
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M #YZ3_X!+_\ $UUU%%X]OQ_X <N(_GC_ . O_P"2.1W^!/\ GSTG_P  E_\
MB:-_@3_GSTG_ , E_P#B:ZZBB\>WX_\  #EQ'\\?_ 7_ /)'([_ G_/GI/\
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M?_R1R._P)_SYZ3_X!+_\31O\"?\ /GI/_@$O_P 377447CV_'_@!RXC^>/\
MX"__ )(Y'?X$_P"?/2?_  "7_P")HW^!/^?/2?\ P"7_ .)KKJ*+Q[?C_P
M.7$?SQ_\!?\ \D<CO\"?\^>D_P#@$O\ \31O\"?\^>D_^ 2__$UUU%%X]OQ_
MX <N(_GC_P" O_Y(Y'?X$_Y\])_\ E_^)HW^!/\ GSTG_P  E_\ B:ZZBB\>
MWX_\ .7$?SQ_\!?_ ,D<CO\  G_/GI/_ (!+_P#$T;_ G_/GI/\ X!+_ /$U
MUU%%X]OQ_P" '+B/YX_^ O\ ^2.1W^!/^?/2?_ )?_B:-_@3_GSTG_P"7_XF
MNNHHO'M^/_ #EQ'\\?\ P%__ "1R._P)_P ^>D_^ 2__ !-&_P "?\^>D_\
M@$O_ ,377447CV_'_@!RXC^>/_@+_P#DCD=_@3_GSTG_ , E_P#B:-_@3_GS
MTG_P"7_XFNNHHO'M^/\ P Y<1_/'_P !?_R1R._P)_SYZ3_X!+_\31O\"?\
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M[>5[;FU5"ZU>"UNQ:^7/-.4WE((RY5>F3Z5?KG?M<&E>*-0DOG\J.ZBB,,C
MX.T$%<^O/2HBKW.G$U734;.UW9M]-'_PWS)-+UJ,V&HWMW<$P1WCI&Q7G;QM
M4#&<\].M78-9MYIC"T-S#-L,BQRQ%6<#KM]3[=:Y<Q2W.CW=Q''/&D>LFX<(
MOSJG'(!'49SC':M2R6QO-8M9(M4OKZ6 ,ZD[2B9&#N(4=<]/:M906K/.H8JK
M[L+]M^MV[];Z?\.6K#Q%#<:7-?74<D$<;LN3&<,-Q"@>IX&<=ZMVNKP75U]E
M,5Q!.5WJD\90LO<BN;MM1>T\-&"&3RYHKPI<MLW&!&D;+8(]*E2>!?$NF3I>
MW-S;E9(_/F(*;R!A5( H=-:A3QLTH7E?X;_-V?7IZ?\  NOJ+^5IC6UW+(DN
MH&*1G4 D?-E?H"/TJ[+X@LXFE_=W+Q0L4EG2$LB$=<GV[XK!M4;[#I'RGC5W
M)X]WI]S=6UD;N73M1N+.[WNQL98]PD?/9<9^8]P>]-P3=B8XJI&'->VW_I*V
MNU^=SKU8.H92"I&01W%+4=N\DEM$\J;)&0%T_NG'(J2N<]I.ZN%%%% PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,BYTB[F-Q&FJS)
M;7!.^,H&90>H5CT'\JT[>".VMXH(AMCB0(H] !@5)13<F]#*%&$).2W]7_2"
MBBBD:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_C-;-% &-_8E_P#]#/JW_?NU_P#C-']B7_\ T,^K?]^[7_XS6S10!C?V)?\
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M_P#]#/JW_?NU_P#C-']B7_\ T,^K?]^[7_XS6S10!C?V)?\ _0SZM_W[M?\
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M^HMYH6&1XRWE^5CG83C=T/6@"[_8E_\ ]#/JW_?NU_\ C-']B7__ $,^K?\
M?NU_^,U!_P )GHPMGN))+F-56)PLEK(K.LKA(V52N6!8@<<C/.*M+XCL#?PV
M;+=123.(T:6V=4,A3?LW$8W;<_B,=>* &?V)?_\ 0SZM_P!^[7_XS1_8E_\
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M_8E__P!#/JW_ '[M?_C-;-% &-_8E_\ ]#/JW_?NU_\ C-']B7__ $,^K?\
M?NU_^,ULT4 8W]B7_P#T,^K?]^[7_P",T?V)?_\ 0SZM_P!^[7_XS6S10!C?
MV)?_ /0SZM_W[M?_ (S1_8E__P!#/JW_ '[M?_C-;-% &-_8E_\ ]#/JW_?N
MU_\ C-']B7__ $,^K?\ ?NU_^,ULT4 8W]B7_P#T,^K?]^[7_P",T?V)?_\
M0SZM_P!^[7_XS6S10!C?V)?_ /0SZM_W[M?_ (S1_8E__P!#/JW_ '[M?_C-
M;-% &-_8E_\ ]#/JW_?NU_\ C-']B7__ $,^K?\ ?NU_^,ULT4 8W]B7_P#T
M,^K?]^[7_P",T?V)?_\ 0SZM_P!^[7_XS6S10!C?V)?_ /0SZM_W[M?_ (S1
M_8E__P!#/JW_ '[M?_C-;-% &-_8E_\ ]#/JW_?NU_\ C-']B7__ $,^K?\
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M^;+\ +QMXSWY#T\*WD5XM_'J"+?M++)-(;?*,)%12%7=\N!&F"2>ASG-:?\
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M_P!;?_':/[8U+_H6=1_[_6W_ ,=H V:*QO[8U+_H6=1_[_6W_P =H_MC4O\
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M[ T<*9SM5?-QV &<D#@8'% '6T5C?VQJ7_0LZC_W^MO_ ([1_;&I?]"SJ/\
MW^MO_CM &S16-_;.I?\ 0LZC_P!_K;_X[1_;&I?]"SJ/_?ZV_P#CM &S6-XM
M_P"10U?_ *])/_031_;&I?\ 0LZC_P!_K;_X[63XHU;4)/"NJH_AV_C5K60%
MVFMR%^4\G$A/Y4 =?7.VG@S28+"[MYK6WFENI;J1[GR%67$TCN0&Y/ ?;GVJ
MS_;&I?\ 0LZC_P!_K;_X[1_;&I?]"SJ/_?ZV_P#CM &;_P (=-<&)[[5!-+
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M!/FRR0LOTPCD_I6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45FZEK4.G7-O:^1<7-W<*[QP6Z L43;N;)(  +J.3W%10>)M(FEB@>
M[6WN9(3.(+D>5(J!MI)5L8YR/P]* ->BJ2:QI<LT$,>I6;RW"[X46=2TB^JC
M/(X/(J*Y\0Z/:07TTVIV@2Q0O=!90S1 ?W@.0>V.N: -*BF12QSPI-#(LD3J
M&1T.0P/0@CJ*?0 4444 %8NF[O[<U_9C?YL6W=TSY*]:VJQ-/9DUOQ R(782
M1$("!N/DKQS0!FZ)K>KR>+)=&O;K3=1A6S-P]S80M&+>3>%$;@NX.021R#\I
MXJRGCSP]+J(L(KR66?[4;-_+MI66.8.4VNP7:I+# R>>HXK,T?2[V7QNFLPZ
M"V@V2V<D5U&[Q;KR5F4J2L3,/EPWS$Y^;'2M3PAH]SI5AJ45[ J//JMW=( 0
MV4>4LC<=\8]Q0!E^*_'EKI]E<0Z5.[7T-[!:M)]E=H0S3(KQ^9MV;PK-QG(_
M"NWKRV;P]XGC\-77AB'1TEC&K"[6_-T@66(W8GX7.[>!P00!QP3P*]2H YW4
M_$MS:>(UT2PT>6_N/L@NV99TC"H7*8^;J<BL[QGJ6OZ?X,N]>M+C^S+BSMGE
M>S>..<,P/&6^GIZU)J7A/^U_'_\ :5Y'<"P72U@62"\D@;S?-+8/ELK$8/?B
MK7C'1+C4/A]J>BZ9&TD\EF8($DER6. !EW/)XZDT :>K:[8:)# ]]*X>X?RX
M8H8FEDE;&<*B L> 3P.*JCQAH9T5M6^VD6JS?9V!B<2B;./+\O&_?D_=QFJ/
MB33=1_M_0->L+,WQTWSXYK19%1V255&Y"Q"Y!4<$C()YKGG\*Z[+YFO?8D6^
M.O1ZJNF&9<F)8O)VEON^81ENN,X&>] '96?BG2;VQO[N.>1%T]2UW'/ \4L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ$'(_P!G.>^:VZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?*R+'&0@+$#.2<9('/6@#8_M75/^A<N__ B#_P"+H_M75/\ H7+O_P "(/\
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M$0?_ !=;%% &/_:NJ?\ 0N7?_@1!_P#%T?VKJG_0N7?_ ($0?_%UL44 8_\
M:NJ?]"Y=_P#@1!_\71_:NJ?]"Y=_^!$'_P 76Q10!C_VKJG_ $+EW_X$0?\
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MZI_T+EW_ .!$'_Q=;%% &/\ VKJG_0N7?_@1!_\ %T?VKJG_ $+EW_X$0?\
MQ=;%% &/_:NJ?]"Y=_\ @1!_\71_:NJ?]"Y=_P#@1!_\76Q10!C_ -JZI_T+
MEW_X$0?_ !=']JZI_P!"Y=_^!$'_ ,76Q10!C_VKJG_0N7?_ ($0?_%T?VKJ
MG_0N7?\ X$0?_%UL44 8_P#:NJ?]"Y=_^!$'_P 71_:NJ?\ 0N7?_@1!_P#%
MUL44 9UG?WUQ<".XT>XM4P3YCS1,/IA6)K1HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHK-O+S5(;@I:Z4EQ$ ,2&Y"9_ B@"IJNGZ@NN
MV>LZ9';SRPP26TUO/(8PZ.R,&5@IPP*=",$$\C%8^M>'M>UQ#/<?8$N#I]U;
MK%'(VU6>2!T4L1\W$39; Y(XK<_M#7/^@#'_ .!J_P#Q-']H:Y_T 8__  -7
M_P")H Q=/T^6Z\=7$P&-/M]MY)& =JWS(8F"L0 P$8R<=WSU-=G6-_:&N?\
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MLT5C?VAKG_0!C_\  U?_ (FC^T-<_P"@#'_X&K_\30!LT5C?VAKG_0!C_P#
MU?\ XFC^T-<_Z ,?_@:O_P 30!LT5C?VAKG_ $ 8_P#P-7_XFC^T-<_Z ,?_
M (&K_P#$T ;-%8W]H:Y_T 8__ U?_B:/[0US_H Q_P#@:O\ \30!LT5C?VAK
MG_0!C_\  U?_ (FC^T-<_P"@#'_X&K_\30!LT5C?VAKG_0!C_P# U?\ XFC^
MT-<_Z ,?_@:O_P 30!LT5C?VAKG_ $ 8_P#P-7_XFC^T-<_Z ,?_ (&K_P#$
MT ;-%8W]H:Y_T 8__ U?_B:/[0US_H Q_P#@:O\ \30!LT5C?VAKG_0!C_\
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MY %AIMQ:S>63R\CPL"..1^[;/N16E_:&N?\ 0!C_ / U?_B:/[0US_H Q_\
M@:O_ ,30!LT5C?VAKG_0!C_\#5_^)H_M#7/^@#'_ .!J_P#Q- &S16-_:&N?
M] &/_P #5_\ B:/[0US_ * ,?_@:O_Q- &S16-_:&N?] &/_ ,#5_P#B:/[0
MUS_H Q_^!J__ !- &S16-_:&N?\ 0!C_ / U?_B:/[0US_H Q_\ @:O_ ,30
M!LT5C?VAKG_0!C_\#5_^)H_M#7/^@#'_ .!J_P#Q- &S16-_:&N?] &/_P #
M5_\ B:/[0US_ * ,?_@:O_Q- &S16-_:&N?] &/_ ,#5_P#B:/[0US_H Q_^
M!J__ !- &S16-_:&N?\ 0!C_ / U?_B:/[0US_H Q_\ @:O_ ,30!LT5C?VA
MKG_0!C_\#5_^)H_M#7/^@#'_ .!J_P#Q- &S16-_:&N?] &/_P #5_\ B:/[
M0US_ * ,?_@:O_Q- &S16-_:&N?] &/_ ,#5_P#B:/[0US_H Q_^!J__ !-
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MA!:7ELLT202.T@)P0&R .F>E=-6-X3TB?0/"6E:1<O')/9VR0N\9.TD#&1D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'PT+NU%O<Q#3_-B=HW9DV2-N8)N*JP)4G;G@G)K=_P"$N\-?]##I/_@;'_\
M%4?\)=X:_P"AATG_ ,#8_P#XJ@#DK;0?$%I9C3I[.2[EDNM*GDO!,FS]QY E
M)W,&)_=,>G.1WXJM=>!KQO#HMX-+A%Y-I.H6]P<IF25RIA#'/S<C@]%QVKMO
M^$N\-?\ 0PZ3_P"!L?\ \51_PEWAK_H8=)_\#8__ (J@#E+[1H=-T_Q!KLEC
M#IUS'<P7>G&38&"Q6\ $(VD@!F1TVCKGC/%==X;L9;'18OM2[;RX9KJY'I+(
M2S+]%SM'LHJ)O%?A=\;]?T=L'(S>1'!]>M._X2[PU_T,.D_^!L?_ ,50!LT5
MC?\ "7>&O^AATG_P-C_^*H_X2[PU_P!##I/_ (&Q_P#Q5 &S6-I?_(P:]_UV
MA_\ 12T?\)=X:_Z&'2?_  -C_P#BJR=-\4^'DUS6G?7M+5))8BC&\C ;$2@X
MYYYH H6_A/7(K"'PZPL?[&BU,7HNQ,WG-&+CSQ'Y>S&[=\N[=C'.,\4Y? ]_
M:ZCJFMV%S;P:U)J,ES:R9;9+ R1@P3<?=)0GC.TX([BNC_X2[PU_T,.D_P#@
M;'_\51_PEWAK_H8=)_\  V/_ .*H UXRYC4R*JN0-RJV0#W .!G\J=6-_P )
M=X:_Z&'2?_ V/_XJC_A+O#7_ $,.D_\ @;'_ /%4 ;-%8W_"7>&O^AATG_P-
MC_\ BJ/^$N\-?]##I/\ X&Q__%4 ;-%8W_"7>&O^AATG_P #8_\ XJC_ (2[
MPU_T,.D_^!L?_P 50!LT5C?\)=X:_P"AATG_ ,#8_P#XJC_A+O#7_0PZ3_X&
MQ_\ Q5 &S16-_P )=X:_Z&'2?_ V/_XJC_A+O#7_ $,.D_\ @;'_ /%4 ;-%
M8W_"7>&O^AATG_P-C_\ BJ/^$N\-?]##I/\ X&Q__%4 ;-%8W_"7>&O^AATG
M_P #8_\ XJC_ (2[PU_T,.D_^!L?_P 50!LT5C?\)=X:_P"AATG_ ,#8_P#X
MJC_A+O#7_0PZ3_X&Q_\ Q5 &S16-_P )=X:_Z&'2?_ V/_XJC_A+O#7_ $,.
MD_\ @;'_ /%4 ;-%8W_"7>&O^AATG_P-C_\ BJ/^$N\-?]##I/\ X&Q__%4
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M,<AL]/EQWH [-?%.AM:R70U.W$,90.Q;&-_W.#V;!P>A[4^#Q'H]S>K9PZC
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M_P#@;'_\50!LT5C?\)=X:_Z&'2?_  -C_P#BJ/\ A+O#7_0PZ3_X&Q__ !5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#9HK&_X1'PU_T+VE?^ <?^%'_"(^&O\ H7M*_P# ./\ PH V:*QO^$1\-?\
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M1\-?]"]I7_@''_A0!LT5C?\ "(^&O^A>TK_P#C_PH_X1'PU_T+VE?^ <?^%
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MDV%M, 1YD-NB-@]1D#-:- !1110 4444 %%%% !1110 4444 %%%% !1110
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M*LA6!X2OF;<<DD9&/US48\3:6T2S"64PDX,HA?8A]&;&!3][M^!/[A;U&O\
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MIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\
MXJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\ XJMFBCG\
M@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\ XJMFBCG\@^K1_FE]
M[,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_
M #^:=_WX?_XJCR?$?_/YIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX
M?_XJCR?$?_/YIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$
M?_/YIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?
MA_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\ XJMF
MBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\ XJMFBCG\@^K1
M_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\ XJMFBCG\@^K1_FE][,;R
M?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:
M=_WX?_XJCR?$?_/YIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJ
MCR?$?_/YIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/Y
MIW_?A_\ XJMFBCG\@^K1_FE][,;R?$?_ #^:=_WX?_XJCR?$?_/YIW_?A_\
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MC>!=[J6VVGG%ZZ_W3F+B:*_UJ]NK-UEMX=->*25#E2Q.0N>_'-1W:@> +'
M^2V/_CRUU:JJKM50!Z 48&,8&*7M-O(;P3:E>6LDUMW^8M%%%9G>%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-M[:6L<44NY8_-498-M!;DYP0* -;_A+?#W_ $&;+_O\*/\ A+?#W_09LO\
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MV KY+&-B%) '3=6S;>*VN/$2Z8UFD$;D"-KB8QRR@QA]R1E<,O8X8D$'(XH
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M]6%7O!>KZAK6GWUQJ0"2+>,(XPNTQQLB.J'U8!\$^HH N?\ "6^'O^@S9?\
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M.><UJ6MS>6;W+P>%[Y6N93-+_I,!R^T+G_6<<**Z&B@#&_M?5/\ H6K[_O\
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MUZ  8P.@-3W7A?4[FTU?31:6F^\>ZDBU1Y/GC\V)E4 8W;AN"^FT=<\5W=%
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M"VHP:MIU[:7GF7ANIKF\O)8E*Y,/EJ/+!!V@!0 #D8R2><[']AW7_0Q:M_Y
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MU_T,6K?^0/\ XU1_8=U_T,6K?^0/_C5 &AIUG_9^F6MEY\L_V>%(O-F;+OM
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MR23^-4_[#NO^ABU;_P @?_&J/[#NO^ABU;_R!_\ &J -FBL;^P[K_H8M6_\
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MX2S0_P#H(1_]\M_A0!LT5C?\)9H?_00C_P"^6_PH_P"$LT/_ *"$?_?+?X4
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M5Z!E! HCMX(@!'#&@&?NJ!UZ_P A^5244 1&V@+JY@C+*-JG8,@>@]JEHHH
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ML5JLTWFLL8"Y4ODYPY<=3C&,\4 =-1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 8VI_\C%H?^_-_Z+-;-8VI_P#(Q:'_ +\W
M_HLTGB^]GT[P=K%Y:N$N(K.1HF+[<-M."#@\YZ#N<#O0!M45Y[JXM[3X>:RD
M.HRVE[!;-<.D&J/,ROY;;/G8[ADKNP,9(/7)S/XXN+<6UU>VNH/]IM;=)6$=
M^T9MH]S'S8XQ@2N2",,<':!Z@@'=T5Y_!<N=6M[O[9.=3DUZ:TD@,[;?LX$F
M%\O. !&$?..O/>F^([WS+G7;R._E%Q9V=M+I2Q7+*KLQ;:0H.'WN G.<@ 4
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M4_\ H6M0_P"_]O\ _'* -FBL;^V-3_Z%K4/^_P#;_P#QRC^V-3_Z%K4/^_\
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M^_J?_$4?V!)_T'-6_P"_J?\ Q% &S16-_8$G_0<U;_OZG_Q%']@2?]!S5O\
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M@.X'8GJ:+6SM;&,QVEM#;QEBQ6*,("3U.!WK-_L"3_H.:M_W]3_XBC^P)/\
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M@GN!2>%=<N]<URWN+DA6-C<1O&APA:.Z:/=@,PR0N>">O!- ';T444 %%%%
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MC,S1[(DN#&HB)VC'E1'(&3GK\U='X?)M?$,EE;WUS>6CZ;!<LT]PTQ$C,XW
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M1?P__P! +3/_  $C_P * -/S8_\ GHOYT>;'_P ]%_.LS_A%_#__ $ M,_\
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M^@)IO_@*G^%:E% &7_PC6@_] 33?_ 5/\*/^$:T'_H":;_X"I_A6I10!E_\
M"-:#_P! 33?_  %3_"C_ (1K0?\ H":;_P" J?X5J44 9?\ PC6@_P#0$TW_
M ,!4_P */^$:T'_H":;_ . J?X5J44 9?_"-:#_T!--_\!4_PH_X1K0?^@)I
MO_@*G^%:E% '*ZCX>T5=?T5%T?3PKO-N46R8;$9QGBM;_A&M!_Z FF_^ J?X
M5%J?_(Q:'_OS?^BS6S0!E_\ "-:#_P! 33?_  %3_"C_ (1K0?\ H":;_P"
MJ?X5J44 9?\ PC6@_P#0$TW_ ,!4_P */^$:T'_H":;_ . J?X5J44 9?_"-
M:#_T!--_\!4_PH_X1K0?^@)IO_@*G^%:E% &7_PC6@_] 33?_ 5/\*/^$:T'
M_H":;_X"I_A6I10!E_\ "-:#_P! 33?_  %3_"C_ (1K0?\ H":;_P" J?X5
MJ44 9?\ PC6@_P#0$TW_ ,!4_P */^$:T'_H":;_ . J?X5J44 9?_"-:#_T
M!--_\!4_PH_X1K0?^@)IO_@*G^%:E% &7_PC6@_] 33?_ 5/\*/^$:T'_H":
M;_X"I_A6I10!E_\ "-:#_P! 33?_  %3_"C_ (1K0?\ H":;_P" J?X5J44
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MZBL?_A)+7_GRU;_P6S__ !-'_"26O_/EJW_@MG_^)H V**Q_^$DM?^?+5O\
MP6S_ /Q-'_"26O\ SY:M_P""V?\ ^)H V**Q_P#A)+7_ )\M6_\ !;/_ /$T
M?\)):_\ /EJW_@MG_P#B: -BBL?_ (22U_Y\M6_\%L__ ,31_P )):_\^6K?
M^"V?_P")H V**Q_^$DM?^?+5O_!;/_\ $T?\)):_\^6K?^"V?_XF@#8HK'_X
M22U_Y\M6_P#!;/\ _$T?\)):_P#/EJW_ (+9_P#XF@#8HK'_ .$DM?\ GRU;
M_P %L_\ \31_PDEK_P ^6K?^"V?_ .)H V**Q_\ A)+7_GRU;_P6S_\ Q-'_
M  DEK_SY:M_X+9__ (F@#8HK'_X22U_Y\M6_\%L__P 31_PDEK_SY:M_X+9_
M_B: -BBL?_A)+7_GRU;_ ,%L_P#\31_PDEK_ ,^6K?\ @MG_ /B: -BBL?\
MX22U_P"?+5O_  6S_P#Q-'_"26O_ #Y:M_X+9_\ XF@#8HK'_P"$DM?^?+5O
M_!;/_P#$U9L=6AOYFCCM[V,JN[-Q:21#\"P S[4 7Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH Y'QC97NO7=GHD%C%<V>Q[B\%Q,T,;C!
M1$WA'YW,7QC_ )9C\<B*^U27[-'KK:Q;R068A4Z<LG[V\21D=N!A@P$;*'&T
MACQP<>BT4 ><W%SJPL-5:WEUK^WP;L&)5D,"Q"4^65!!7/E[2NSYB<YR<U&6
MU+[ [C5+O[(+M2D9%[AOW1W(9L>:JDE2#R P*]\#TJB@#SJWO=2.JZ5<2#5F
M,JVJFSD:='A!P'8D+Y<HY);>%88/(.!6WJE[%IGCJUN[F.X^SMIDL7F16TDH
MW>:AP=BG' -=510!Y],-6U+6+F,SZI'9%KUXS$\D60(K<Q<C!'S%R!Z[AZBH
M[<:Y"]JIFU1Q<0Z5-.9'<XD>5Q/C^X-H7<HP!Z#->BT4 <YX%A-OX0LH'%PL
ML8995N"Y8.&.1\_/]*Z.BB@#&\3?\@VV_P"PC9_^E$=:5[#]IL;B#<Z>9$R;
MH_O#(QD>]9OB;_D&VW_81L__ $HCK9H \EATZZN8O/$2QVEA9V<9V:;,B2O%
M,&4/&1N. #N !V;LY/2NT\%172V.I3W$8CCNM0DG@18FC 0JH)"MR 6#G) S
MG.!FNFHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#&U/_ )&+0_\ ?F_]%FMFL;4_^1BT/_?F_P#19K9H **** "BBB@
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M.+K[(9O(^V_9V^S[]VW&_&,;N-WW<]Z -ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K.N]9BL[@PM:7\A !W0VCR+^8&*T:* ,?
M_A(X/^@?JW_@!+_A1_PD<'_0/U;_ , )?\*TI+RVBNX;22XB2YG#-%$S@/(%
MQN*CJ<9&<=,TZ&>&X#F&5) CE&*,#A@<$'W![4 9?_"1P?\ 0/U;_P  )?\
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M =CE@O/S+UYS0B\'ZY'H/]GR6-K/-+86-N9GG'[EK<X;MD@XW+CNQSBO3:*
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M_P (ZAJ&@/! R64R0W*B&=OM'G2RI@S,_P N'.6&<' 8X'0  [E'$D:NOW6
M(IU06,4T%A;Q3R+),D:J[JNT$@=AVJ>@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH QM3_Y&+0_]^;_T6:V:QM3_ .1BT/\ WYO_
M $6:V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH S;N;7$N66RL-/E@XVO->O&QXYRHB8#GWJ#[1XF
M_P"@7I/_ (,I/_C%;-9]WK5E8:C'9W4GE,]M+=>:Y"QHD;(K;F)X_P!8OZT
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MPPVTED;,1/:K)Y(Y^>+) 1N<$X/"C&,9K7\[7_\ GPTW_P #I/\ XU1YVO\
M_/AIO_@=)_\ &J ,I_"-Q+JO]H/J-M'/M<-+;V(CDD+1E-LAW$.@)R%92?E7
M)..:?_"O(616>:P+QW FBMQ8?Z&GR,A'D%SU#9)##E5]#GH?.U__ )\--_\
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M_P :H U:*RO.U_\ Y\--_P# Z3_XU1YVO_\ /AIO_@=)_P#&J -6BLKSM?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-[_T,.I?]^[;_P"-4?V3>_\ 0PZE_P!^[;_XU0!JT5E?V3>_]##J7_?NV_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8W]JZK_T+\__ ($1_P"-']JZK_T+\_\ X$1_XULT4<R[?F'L:G_/Q_\ DO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/TX'3I5RBBDW?4UA",(\L=@HHHI%!1110 4444 %%%% !1110 4444 %%%%
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MC_VEK/\ T &_\"XZ/[2UG_H -_X%QUL44 8_]I:S_P! !O\ P+CH_M+6?^@
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M_P#:6L_] !O_  +CH_M+6?\ H -_X%QUL44 8_\ :6L_] !O_ N.C^TM9_Z
M#?\ @7'6Q10!C_VEK/\ T &_\"XZ/[2UG_H -_X%QUL44 8_]I:S_P! !O\
MP+CH_M+6?^@ W_@7'6Q10!C_ -I:S_T &_\  N.C^TM9_P"@ W_@7'6Q10!C
M_P!I:S_T &_\"XZ/[2UG_H -_P"!<=;%% &/_:6L_P#0 ;_P+CH_M+6?^@ W
M_@7'6Q10!C_VEK/_ $ &_P# N.C^TM9_Z #?^!<=;%% &/\ VEK/_0 ;_P "
MXZ/[2UG_ * #?^!<=;%% &/_ &EK/_0 ;_P+CH_M+6?^@ W_ (%QUL44 8_]
MI:S_ - !O_ N.C^TM9_Z #?^!<=;%% &/_:6L_\ 0 ;_ ,"XZ/[2UG_H -_X
M%QUL44 8_P#:6L_] !O_  +CH_M+6?\ H -_X%QUL44 8_\ :6L_] !O_ N.
MC^TM9_Z #?\ @7'6Q10!C_VEK/\ T &_\"XZ/[2UG_H -_X%QUL44 8_]I:S
M_P! !O\ P+CH_M+6?^@ W_@7'6Q10!C_ -I:S_T &_\  N.C^TM9_P"@ W_@
M7'6Q10!C_P!I:S_T &_\"XZ/[2UG_H -_P"!<=;%% &/_:6L_P#0 ;_P+CH_
MM+6?^@ W_@7'6Q10!C_VEK/_ $ &_P# N.C^TM9_Z #?^!<=;%% &/\ VEK/
M_0 ;_P "XZ/[2UG_ * #?^!<=;%% &/_ &EK/_0 ;_P+CK0LYKB>W#W-J;:3
M)'EEP_'KD58HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLZ[TDW
M=P9AJ5_!D ;(90JC\,4 0:KH<FH:I9ZC;ZE/97%K#+"&B1'#+(8R<AP>\:_K
M6=)X%L2+>2*YF6[C$V^YFCCF:8RL&=F#*5W94$$ 8Z 8XK1_L!O^@SJW_?\
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M,X8,V<;B,NS8)ZMGTQ-_8#?]!G5O^_X_^)H_L!O^@SJW_?\ '_Q- &Q16/\
MV W_ $&=6_[_ (_^)H_L!O\ H,ZM_P!_Q_\ $T ;%%8_]@-_T&=6_P"_X_\
MB:/[ ;_H,ZM_W_'_ ,30!L45C_V W_09U;_O^/\ XFC^P&_Z#.K?]_Q_\30!
ML45C_P!@-_T&=6_[_C_XFC^P&_Z#.K?]_P ?_$T ;%%8_P#8#?\ 09U;_O\
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M%%8_]@-_T&=6_P"_X_\ B:/[ ;_H,ZM_W_'_ ,30!L45C_V W_09U;_O^/\
MXFC^P&_Z#.K?]_Q_\30!L45C_P!@-_T&=6_[_C_XFC^P&_Z#.K?]_P ?_$T
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MS^M35C_\)5HG_003_OEO\*/^$JT3_H()_P!\M_A0!L45C_\ "5:)_P!!!/\
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M-.O]>TS3;:*>YO(469#)#EQ^\4#)(]N1ST&1535M DUC6K.YFNY8;6SB<QI
M^US*_P I8G'0)D#_ 'VK'@\)ZKI\5I':7%K.MM:7.G1_:6;Y;=W4QG@'+*J!
M2. V.HH T;KQKI=IHEO?RR*)I[6*Z6U+C?MDQMSZ<Y ]<'%79O$=A;7L=K<2
MJDDU[]BB"MNS)Y?F8./N\=C[>M<U+X,U5-,EL+>>R:.YL;.VFDE+9C: 8)4
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M@=#4M9CL!9I%;RWEQ>.4@A@*@MA2Q;+$   =<]QZU@7/AO6YH[LQRZ;&^H6
MT^=5WA;>-6DV,G!WD+*P(.T$@'CI6E>Z3J!FL+FS^R>;ITK"WCE=@LD+1["&
M8 E6SSD C  [\ %=O'-C]G:XBLKV6&"W%Q>NH0?9$W.IW@MR08Y,A=W"GVSU
M%<*/!.I0:??V4%W:LFKVI@OY'#*8V9Y7=XQ@YSYS  D8V@Y/(KN5 50HZ 8%
M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-XH_Y ;?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*RIM.U22=WBUR6*-F)6,6\9VCTR1DUJT4 8_]F:O_P!#!-_X"Q?X4?V9J_\
MT,$W_@+%_A6Q10!C_P!F:O\ ]#!-_P" L7^%']F:O_T,$W_@+%_A6Q10!C_V
M9J__ $,$W_@+%_A1_9FK_P#0P3?^ L7^%;%% &/_ &9J_P#T,$W_ ("Q?X4?
MV9J__0P3?^ L7^%;%% &/_9FK_\ 0P3?^ L7^%']F:O_ -#!-_X"Q?X5L44
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M ("Q?X5L44 8_P#9FK_]#!-_X"Q?X4?V9J__ $,$W_@+%_A6Q10!C_V9J_\
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M* ,?^S-7_P"A@F_\!8O\*/[,U?\ Z&";_P !8O\ "MBB@#'_ +,U?_H8)O\
MP%B_PK0LX9X+<)<737,F2?,9%4_3 XJQ10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>foraresidentagreement002.jpg
<TEXT>
begin 644 foraresidentagreement002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB"WU=YK<PSV=_  9[.Z7;(@/0\$AE/9E)'O6M0 4444 %%%% !1110 4444
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M6W0YFXTCR]7NKN71DU"*Z"N =F^)@,$'<<8/L:DETJY6QLI[:QMH+FVN//\
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M&Y?FV%%%%0=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBMRHE:^A2OU"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***YS5[OQA%J#IH^DZ3<68 VR7-Z\;DXYRH0CK[T ='17'?;_B)_P!
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MWV_XB?\ 0 T#_P &4G_QJC[?\1/^@!H'_@RD_P#C5 '8T5QWV_XB?] #0/\
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M;M"\/C)QSJ<G_P :H [*BN.^W_$3_H :!_X,I/\ XU1]O^(G_0 T#_P92?\
MQJ@#L:*X[[?\1/\ H :!_P"#*3_XU1]O^(G_ $ - _\ !E)_\:H [&BN.^W_
M !$_Z &@?^#*3_XU1]O^(G_0 T#_ ,&4G_QJ@#L:*X[[?\1/^@!H'_@RD_\
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M3_H :!_X,I/_ (U1]O\ B)_T - _\&4G_P :H [&BN.^W_$3_H :!_X,I/\
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M5A5S_HT$J1EBFSEI)#TR0@'KF73KZZT_X3Z'/!,;<F.TCFN-@S!$SJLDF&!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6_HFAV>@6+6EDURT32&0FXN'F;) 'WG)..!Q0!I4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3J7B*STK6M,TRY642:@)/+E"CRT*E!ACGC<9%
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MW5?$-_:^(X=%TW28KV=[-KMFEN_) 57"8'R-DY8>E;T">7;QQ[57:H&U3D#
MZ US.K>$(];\90:E?*)+"/3GMC&LSHQD,BL,A2,K@'J?PH DL?&<%]X?L=6B
MTO4I1="3]S;P>:T91BK D<=0<<\]JGN?&>B6N@Z=K;W$C6.H.B6[I$S,S."5
M&T#.>",8SGBLW7?#FHO?:;'I5M:2:-;6[PG3FNI+6-')7;)^[4[P "-I]<U4
MTWPCJUOX5\+Z5/\ 9!+HVH1S2,DK%9(D#C(^7ACN''ZT 6M0\727"Z-+8)<V
M:RZVEC=1W<&Q]OE.Y&&Z?PG-;,7B2TN=);4[."\N[;S3&C6\!<RX.-Z#NF<_
M-T/;BJ7C3PP?%=GIMDQ7[-%?+-<@R%"T7ER(P4CO\X]*M^&+'5=+TO\ LW4Y
MH+A;4^5:W,?#2P@?+O7 "L!P<9!QGCI0!0TWQ1:6/@"V\0:IJDEY;;5,EXUL
M(F?=)L!,8^[@D#\,U8LO&ND7D.IRO]KM!ID(N+D7EL\3"(AB) I&2I"M[\=*
MR5\(:B/A?:>&S);?;87A9FWGR_DN%D.#C/W0>W6M*?0[S_A)-<U-8;.YAO=-
M@M8[>=R%D9&E+*_RG"D2 9P>_% %VQ\2VMW:7%W-:WUC;00^>TU[ 8E,>,E@
M?H,XZU!IOC'3-3NH[=8[RVDF@:XMQ=6[1?:(QC+)GKC(.#@X(.*YNR\#ZA-8
M:YISA=)TF_L&M8K"*]>Z2.4YS*NX#8,$#:O!]JT+?0]?U+6-)N]8AL+5=)MI
MHT^S3M)]HED0)NY1=B@9..3D^W(!<T;Q_HFNWEC;V8O0+^-GM9Y;5TBF*KN9
M58C!8#.?H?2NHKBM*\):A96G@>*62W+:'&RW6UCAB;=H_DXY^8CKCBNUH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH X[P;_R-'C;_L*I_P"D\5;>J>(K/2-6TW3[I90VH%UC
ME5040J5 WG/&6=5'!Y(K$\&_\C1XV_["J?\ I/%6OJ^@1ZQJ=O+<A'M%L[BV
MEC.0S>:8B"#VQY9YZYQB@!S>*-*A2=KJY6U$5P]O^^(&YD +$8[ 'KV[T^X\
M2Z':S"&?5;2-R%.&E'1AE3^(Z>O:N8A\':]' L4VIQ7&Z6Y,K":6 OYFP)*3
M'@LP"-E,A26ZC J73_!E];Z7';SS6OFK)IK$H6((M6C+=0/O!#CTS^- '1/X
MET2.SBNWU2V6"4N$<N.=AP__ 'R>OIWJ_#=V]Q))'#,DCQA2X5LX##(_,<UQ
MESX*O?[0:^AECE=I+O,7VR:V&R:17!W1\DC;@J>#GJ,5U>EVDFGVD5D$A6UM
MX8XH!&6)PJ@'.XD]N.2<=30!>)P":Y;P]XT3Q(FF_8K%B]Q;BYN_WN5M$;.T
M,<?,[$<+QQDG'&>H/((K@_"/@S4_"%MI?V.6V.^)8M6M=[>7(P&!-&<<.  "
M, ,,=",T ="WBJSBUF#39[6_MVN)VMX)YK9EBED4$[0Q]0K$'H<<$U@:7X^A
M@GU6+6&NF2#5Y;07*6I\FW3>%C5W P.2!DY/(SC(K/\ ^$0\3-J=A>7,=E=7
M-CJANVNY+^4M<1G> HC*%8MJN.!D?+[YJ>Y\)>(+FPUC0VCL!IVJZH]V]V+A
MO,BB:0,5\O9@L0N =V!GVY -^_UPKXOTG2EGO+3S)) 5:RW17F(BVT2'[NW&
M>.N,58U?Q;IVC:HFF31W<]])!]HCM[6W:5G0'!(QTQ[X%+J^CW-_XC\/:A$T
M8ATZ>:28,2&(>%D&WCGEAZ<4?V/<?\)V-;W1_9?[,^R;<G?O\W?TQC&/>@#4
ML+V+4=.MKZ .(;F)9DWKM;:P!&1V.#6'J/C"UTKQGIWAVZ@=/M\)>*ZS\@DR
M0L9XX+;3@YZC%=)7+:_X17Q#JEVUTRK:3Z<+9'0D213+(761?0J<$'/44 6;
M?Q2D^D)?C3;Z4O<3P"&UB,K?NI7C))X !V9Y]<<U3U;Q[86'@^/Q':VEW>V\
MO"(D+@@A]C!S@["#D<]QBL2V\)>*+30=#M)Y;2_:WENY-0MA>26T=P\LC.C[
ME4DA=QRI&/F]A5BU\&ZLOPNO/"TILX[L22FWD21FC<&8RKG*Y7KM/7IGF@"Y
MXD\8&QTG3M1MUO+.%M5@MK@7-FR.T9^\ C+DYX (&<\"MW0O$5GX@2Z^S1W4
M$UI+Y4\%U"T4D;%0PRI[$$$5EZEIVM>(+72S=65I936>JP73(MT90T:<G!V#
MGG@8_&KVD:/<V/B3Q#J$K1F'49H7A"DE@$A5#NXXY!]: -RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$NDL[$ *+R,DD_C0!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M75T4 %<YXNT[5M4ALK:PM[2YLQ-YE[!<7+0^<J\JFX(_REL%ACD#'0FNCHH
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MRY)"DGD$YJFNBZW);^<]A<K<S1:>UZ\D1<S*B%958!@6.\*Q7/S =\X/J]%
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M[LUWB"UU2]@@1B3LB6=PJ@GG '2NMHH H:S=VEEI<TM[J2Z; 0$-T75/+).
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MJ-O!&9);:.0)Y("CEM@B12!GEB<5W&@7^HZG92W>H:>U@KS-]F@D_P!:(A@
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M!6_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%<K>^.[6QOI[5M#\12M"Y0R0:5*Z-@XRK 8(]Z .JHKCO^%BV?_0O>*/\
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M$9_ @_0BI*X[_A8MG_T+WBC_ ,$\W^%'_"Q;/_H7O%'_ ()YO\* .QHKCO\
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M]M)2@CNH7+D!0L@.[*[ACU^7GZ<U/7'?\+%L_P#H7O%'_@GF_P */^%BV?\
MT+WBC_P3S?X4 =C17'?\+%L_^A>\4?\ @GF_PH_X6+9_]"]XH_\ !/-_A0!V
M-%<=_P +%L_^A>\4?^">;_"M_1-9CURQ:ZBL[ZU59"GEWMLT#G !SM;G'/7Z
MT :5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW-ZMI:J+-G2=6=OG*'YMGH,>M'LV1]>I>?7H^F_W'2T5BW6LR->06EGY"R/
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M (EMV8(3Z,K8Z^QK0HIIV(G#G5KM>AA&UOM2U>RN[BS2SCM"S9,@>1R1C''
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF+;
M1M,U37M=DO["VNG2ZC16FC#%5\B(X&>V2?SKIZQM'_Y#7B#_ *_(_P#TGBH
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M=(L0NV@LPT-N\G"JS8]3U],$X!K6G\-*W@Z[T.%X(WFBD"R16ZQ(KL200B\
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MWCQ:6SV\LMIY88NT"HJ8?L"(HPPP<[>HR: -'_A$_#O_ $!-/_\  =?\*/\
MA$_#O_0$T_\ \!U_PK8HH Q_^$3\._\ 0$T__P !U_PH_P"$3\._] 33_P#P
M'7_"MBB@#'_X1/P[_P! 33__  '7_"C_ (1/P[_T!-/_ / =?\*V** ,?_A$
M_#O_ $!-/_\  =?\*/\ A$_#O_0$T_\ \!U_PK8HH Q_^$3\._\ 0$T__P !
MU_PH_P"$3\._] 33_P#P'7_"MBB@#'_X1/P[_P! 33__  '7_"C_ (1/P[_T
M!-/_ / =?\*V** ,?_A$_#O_ $!-/_\  =?\*/\ A$_#O_0$T_\ \!U_PK8H
MH Q_^$3\._\ 0$T__P !U_PH_P"$3\._] 33_P#P'7_"MBB@#'_X1/P[_P!
M33__  '7_"C_ (1/P[_T!-/_ / =?\*V** ,?_A$_#O_ $!-/_\  =?\*/\
MA$_#O_0$T_\ \!U_PK8HH Q_^$3\._\ 0$T__P !U_PH_P"$3\._] 33_P#P
M'7_"MBB@#'_X1/P[_P! 33__  '7_"C_ (1/P[_T!-/_ / =?\*V** ,?_A$
M_#O_ $!-/_\  =?\*/\ A$_#O_0$T_\ \!U_PK8HH Q_^$3\._\ 0$T__P !
MU_PH_P"$3\._] 33_P#P'7_"MBB@#'_X1/P[_P! 33__  '7_"C_ (1/P[_T
M!-/_ / =?\*V** ,?_A$_#O_ $!-/_\  =?\*/\ A$_#O_0$T_\ \!U_PK8H
MH Q_^$3\._\ 0$T__P !U_PH_P"$3\._] 33_P#P'7_"MBB@#'_X1/P[_P!
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MW5XFEVSR)(XD8G:@)89SU/?O0!TO]MW?_0NZM^<'_P =H_MN[_Z%W5OS@_\
MCM9EIK5U<:_=)+J<$(BOGM$TUHP7E58MX(.=P8_>S]W;QC/-<Y9^,/$,^C1W
MWF0*]S:Q3%9?)/DR--$F%1&+E,.P._D%1R"<  [;^V[O_H7=6_.#_P".T?VW
M=_\ 0NZM^<'_ ,=K EUS5+:XN--EU!1MUB.Q-^\2 QQM;+-DC[NXL=@)&/F'
M!/6KJGB?5H7@M[*_MYE6PDN1>H(8XYW60K\WF.!L7 W;3GYL@@8H ZG^V[O_
M *%W5OS@_P#CM']MW?\ T+NK?G!_\=K(\8-<W%AX?00;Y+C4(Q+;K<F-7S#(
M2I=>V1G\!5"_U#4]$FL-,M;3^S5GBN+AV2YCF.Y#& -\Q48PQ)'7"\8Y- '3
M?VW=_P#0NZM^<'_QVC^V[O\ Z%W5OS@_^.UR<'BO7[G4U1EMH6BDLHVB6:'R
M91*D;.0S-O;EW5"O!*=\G&IXLUW4[#5[>QLG\A&LY;GSLQ %E*@ F5@-HSEL
M<\CD4 ;']MW?_0NZM^<'_P =H_MN[_Z%W5OS@_\ CM8EEXCU*?Q1:Z9/+;I!
M*B2R2H-P64Q;C:ANA;_EH&Z[>,=#65=:U=:GX+O;FXU:!YKFQ:9K!(P'MF$@
M! (.<+G:=V22.".10!V']MW?_0NZM^<'_P =H_MN[_Z%W5OS@_\ CM0>*));
M"&SUJ.1U33YP]RH;AK=OED)'^R"'_P" 5S=S?7=UH:O&MY-<>)+WS(XK=\21
MV2XY7+ +F)1SD8:6@#J_[;N_^A=U;\X/_CM']MW?_0NZM^<'_P =KD=0D?4?
MA5J[7PN8]5T:SN869I2DJ2)&2CML;&63RWZD?-7>6%A;:=:B"U1DCSNPSLW)
M]R2: */]MW?_ $+NK?G!_P#':/[;N_\ H7=6_.#_ ..UL44 8_\ ;=W_ -"[
MJWYP?_':/[;N_P#H7=6_.#_X[6Q10!C_ -MW?_0NZM^<'_QVC^V[O_H7=6_.
M#_X[6Q10!C_VW=_]"[JWYP?_ !VC^V[O_H7=6_.#_P".UL44 8_]MW?_ $+N
MK?G!_P#':/[;N_\ H7=6_.#_ ..UL44 8_\ ;=W_ -"[JWYP?_':/[;N_P#H
M7=6_.#_X[6Q10!C_ -MW?_0NZM^<'_QVC^V[O_H7=6_.#_X[6Q10!RNL:I<7
M26$4FC7]LIU"V_>S>5M'[U?[KD_I755C>)/^/2R_["-K_P"C5K9H *Y/0+G6
MDTV1;;2[.:$7EUM=[TH3^_DZKY9Q^==96-X7_P"0*?\ K[NO_2B2@!KZAKT>
M-^DZ<N3@;M2(R?\ OU3OMGB+_H#6'_@Q;_XU7/>+X=/_ +?^T7-UIR3?8Q'Y
M&KV9E@E7<QQ&V1M?LP&XD;?EZ5F1ZQKDE[:1(5T@>19&SL[F=P2K ;UV>4S2
MG.4))!7 )V]: .T^V>(O^@-8?^#%O_C5-_M#7O,\O^R-.\S&[;_:1SCUQY58
M4-]JEEX=77;B]NYO)U*5KF%D!'V8321850,X52K^IV>^*J37_B&VLYIW>87;
MZ4MR^V(,T!><E@O')CC. .?N#@T =5]L\1?] :P_\&+?_&J/MGB+_H#6'_@Q
M;_XU7,ZEJUQ%IUK_ &7K$MUISZB8Y[VXE\I43R2P43B-OEWX&_!Y.W(KJ?#4
MMY/X>M9+ZX2XG8-^]3.'7<=IR57)V[<G: 3R.#0 S[9XB_Z UA_X,6_^-4?;
M/$7_ $!K#_P8M_\ &JV:* ,;[9XB_P"@-8?^#%O_ (U1]L\1?] :P_\ !BW_
M ,:K9HH QOMGB+_H#6'_ (,6_P#C5'VSQ%_T!K#_ ,&+?_&JV:* ,;[9XB_Z
M UA_X,6_^-4?;/$7_0&L/_!BW_QJMFB@#&^V>(O^@-8?^#%O_C5'VSQ%_P!
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M  R6QQ1;Z3JD<MGJKZ;<2ZC;WGVBZ\Z:(/<AH7C^3#%5"[AA21QGDDDGH/\
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M8S(T"Y/E)L$IV@+U08. 1T-[9ZIJGB!TO].F.G0MMLVBFCV*2F#,X+;BPW,
M,8'7D]-/_A)M/_YXZI_X*KK_ .-T?\)-I_\ SQU3_P %5U_\;H YZUT[Q':0
M64\6FPB\TG26L(%:92MQ([19<<C" 0YPQ!.<<=:7^PY7M();GP_>7=R+AY9W
M>_6.>1V0+Y@V,%(P NTD8 &!Q70?\)-I_P#SQU3_ ,%5U_\ &Z/^$FT__GCJ
MG_@JNO\ XW0!+X?M;VRT"RMM1E,MW''B1BY<]> 6/+$# R>N,UIUC_\ "3:?
M_P \=4_\%5U_\;H_X2;3_P#GCJG_ (*KK_XW0!L45C_\)-I__/'5/_!5=?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6,_\
MR.D'_8.D_P#1B5LUC/\ \CI!_P!@Z3_T8E &S1110 4444 %%%% !1110 44
M44 %8WAC_D%3_P#80OO_ $JEK9K&\,?\@J?_ +"%]_Z52T ;-%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<GH%MK+Z;(UMJEI%";RZVH]D7(_
M?R=6\P9_*NLK&\+_ /(%/_7W=?\ I1)0 OV/Q!_T&;'_ ,%[?_':/L?B#_H,
MV/\ X+V_^.UL44 8_P!C\0?]!FQ_\%[?_':/L?B#_H,V/_@O;_X[6Q10!C_8
M_$'_ $&;'_P7M_\ ':/L?B#_ *#-C_X+V_\ CM;%% &/]C\0?]!FQ_\ !>W_
M ,=H^Q^(/^@S8_\ @O;_ ..UL44 8_V/Q!_T&;'_ ,%[?_':/L?B#_H,V/\
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M'_P7M_\ ':V** ,?['X@_P"@S8_^"]O_ ([1]C\0?]!FQ_\ !>W_ ,=K8HH
MQ_L?B#_H,V/_ (+V_P#CM'V/Q!_T&;'_ ,%[?_':V** ,?['X@_Z#-C_ ."]
MO_CM'V/Q!_T&;'_P7M_\=K8HH Q_L?B#_H,V/_@O;_X[4?A)9%T-UF=9)1?W
MH=U7:&/VF7) R<?3)K<K&\,?\@J?_L(7W_I5+0!LT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5S.BZI%IUA):W5MJ*RK=7)(73IW&&F=@050@
M@@@\'O7344 97_"167_/#4__  5W/_QNC_A(K+_GAJ?_ (*[G_XW6K10!E?\
M)%9?\\-3_P#!7<__ !NC_A(K+_GAJ?\ X*[G_P"-UJT4 97_  D5E_SPU/\
M\%=S_P#&Z/\ A(K+_GAJ?_@KN?\ XW6K10!E?\)%9?\ /#4__!7<_P#QNC_A
M(K+_ )X:G_X*[G_XW6K10!E?\)%9?\\-3_\ !7<__&Z/^$BLO^>&I_\ @KN?
M_C=:M% &5_PD5E_SPU/_ ,%=S_\ &Z/^$BLO^>&I_P#@KN?_ (W6K10!E?\
M"167_/#4_P#P5W/_ ,;H_P"$BLO^>&I_^"NY_P#C=:M% &5_PD5E_P \-3_\
M%=S_ /&Z/^$BLO\ GAJ?_@KN?_C=:M% &5_PD5E_SPU/_P %=S_\;H_X2*R_
MYX:G_P""NY_^-UJT4 97_"167_/#4_\ P5W/_P ;H_X2*R_YX:G_ ."NY_\
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>foraresidentagreement003.jpg
<TEXT>
begin 644 foraresidentagreement003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9V !'&,$5P_A>VU#5_#?AG3X-$E@BM-5-])J!:/RBB2R$D8.[>V=N-O<\XH
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M3UX- '<4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %4]1TC3=8@6#4]/M;V)6W*EQ
M"L@!]0".M7** (;2SMK"UCM;.WBM[>,82*% BJ/8#@5-110 4444 %%%% !3
M2B,ZN54LN=K$<C/7%.HH **** "BBB@ HHHH **** "BBB@#/U+0=(UDQG5-
M*LKTQ_<-S;K)M^FX'%7HXHX8DBB18XT 5448"@= !V%.HH **** "BBB@ HH
MHH **** "HK:UM[*W6WM8(X(4SMCC4*HR<G 'N34M% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;>^'=$U*\2\O
MM'L+JY0 +-/;([C'3DC-:5%% !1110 4444 %-=$DC:.159&!#*PR"#V(IU%
M &=IN@:-H[R/IFDV-D\@P[6UND98>AV@9K1HHH **** "BBB@ HHHH ****
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M8AY.K#YCCH0,9S@4 4=.\;:K8Z'X@U;Q!:6RVUA?2V\7DW0)W>8$6/E% 7+
M;R?<BIH/B5;"UU9KB&SFGL((YU73+];J.;S&**@?:NUM^ 01W!YJ_+X(2>VU
MJREU*8V&I7!NTB6-0]O.65]ZOWPR@@$?G4\_A>ZU/1+_ $S6-8:Y2Y151X+9
M(#$RG<'&,Y;<%//''2@#-TG4-9N?B3)!JMDMD5T<.(8;OSXFS-]X':O/8Y7Z
M$BM'4?$NHC6+W3M$T>/4)-/A26Z::[\@ N"51/D;<Q SSM'(YYJ32?#5U9Z^
M^M:AK$NH7;VGV7!@6)%4-N& O3G.<D]?H*9J/A:ZFU>\U'2]:FTV2_A2*[58
M5D#[ 0KKN^ZX!(SR.G'% %)/'%UJ<]A#X?T9;UKW35U)&N+H0*B%L;6^5CNS
M@< \^@YK9T[Q#%J?A"+Q!# ZQR6AN?)<\C"Y*D_4$9J+2O"EGHVHVES9NZQ6
MNFKIT4)Y^16W!B>YI+70?['\#MH=L[W!ALY(8V( +D@XX_&@#.TCQG>WUYHJ
MW^B"RM-;B+V4HNA(^X1^9M==H"Y4$@@GIS@TVS\<L=>_LN_M+*-VMYIU%EJ
MN9(_+P621 J[6P>,$C@C-0>&?!EY'8:!-K.J7,YTZQ"6]HT:H;=WB"-N9>6*
M@LHZ8![GFHHO %SI=A$;;43>2:=IUQ:6%MY*0!MZ #>Z\EB57+<>N <F@"2Q
M^(%S+-'+?Z5:V^GOI+ZOYT5\972!0.&3RP-WS#C=CK@G%3>'/'\.N:Q;:=)'
MIZO=V[7$'V/45N60+MRDH"C8V&!XW#@\\5@^$_#%Y;[=*;3[F+2[NP>#5OM=
ME:VY9B@4!&A 9CRW+;ACOFNUT+1-1TDQQW.M&]MH8O*B1K5$; Q@NP^\0!V
MZ]* ,WQT^IVJ:7>6FJRVT"ZE9Q/;Q(!YN^=%;<QYV[21M&/<GI70:WJUOH.B
M7FJW0<P6L32LJ#+-CL/<GC\:S?%'AR\\1);11:N;*"&:*XV"W60M)&X=3DGI
MD#BKVH:-'K'AR?1]3F:=;B PS2H C,2/O = <\B@#%7Q/K45\FG:AH=O:WMW
M:RW%B$OC(CF/;NC=O+&Q@&!X##KSQ5;X;+??\*_M;^6W#W]Y MQNDO7E^T,4
M!#L67]V22<@ @>]:5AX8N4U2+4=7UB34KBVMWM[;,"Q+&'QO8@?><[5&>!Z
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M"T.1D;Q_#D<\T 6J*P8?&_A2XGCAA\2Z1)+(P1$2]C)9B<  9Y-;U !1110
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M110 4456O-0M=/$!NIA']HF6"+()W2-]U>/6@"S1110 4444 %%%% !1110
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MI-'L6T^-_,2V,"[%;GY@,=>3S[FK+Z1ITL-Y"]C;M%>?\?*&,8F^4+\P[_*
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MQ%/J.EVEW-$,1O/"KE1UQR.F><58@TVRM94D@M(8G2!;=61 "(E^Z@_V1Z4
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MFY%K=2-]NW#"%XBH5&'!+ DD\9P: -?5_$=II%W!9F"[N[V=&D2VM(3(^Q<
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M'/S!E.<?*QJI>>!ISK>K2C2],U.RU.X^T,;N\EA:$E55E**K*X^7(Y'7!]:
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M!S[&@#3O/&-AISBW:*]OIXK9+BY-G:LXA1@<,^.F<$A1DX'2EN_&NE6\MI#
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MV[+!<. 3M1O?:<9P#CC-5-&\>VU]I.JZCJ-E=:?;Z?<RQ,\L)PP60HH'<N<
M%1W.*I:;X5UY;+P_HM^VG#3-$GCE2YAE<RW(B!$8,94!.Q8[FZ<=:=)X1UB;
M1M;TGS+*..;4FU*QN?,9B7,XG"2)M& ",9#'(/2@#9@\::4RWWVQ;K37LK?[
M5-'?0&-O)Y^<#G<,@CCG/&*GM?%%E/I]Y?7-O>Z?;VD7G2O?6[1?N\$[AZ\
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M 0O3B@#T&_O[;3+*6\O)/+MX@"[!2V.<= ">])J6H6^DZ9=:C=N4MK6)II6
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M0 ;<,W?=YR ^OE-71^-KNXTO2;36()Y(HM/O89KI48@26Y.R0,.X"N6Y[J*
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MXT[PP98+E[19+JWAGND.&@A>55D<'MA2>>W7M0!M7NIVNGSV,-PY5[V?[/
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MM [DR.H'MSDUBMX[LI+?1WLM.U&\EU:*62V@AC0,#&5#JY9@%(+=2<<'GID
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M,BHH)SA&8=!G&<UG+XPB71%U2YTJ_MTE>)+6)O*=[HR?<";'(R<_Q$8[\<T
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MT:$/%O5'@)8;U/#*3@$>F:@_X0B670=0L18Z!IDURT!#:;:E,B.0.=YXSG'
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M=ANIX&!UI?\ A !#KU[=QZ?X?O(+R\-V9;^R\R>$M@LJG^(9!(R1C/>N\HH
MX+4_!6M7%KK.EV6I646EZG=F\)EA9ID9BK,@(.-I9<YZ@$C'>NE\4Z-+K_AV
MYTZ"9(9W:.2-W4LH9)%<9 [$J ?K6Q10!R<VB>(8M:_MNPN=,6^N;-+6\AFC
MD,649F1T(.>-[ @]>.E:WA[0X]!\.VVD^;]H$2MYDC+CS&9BSG'8%F/%:U%
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M>ZW+;Z#;?V3%I]DEO,;I?(:-516V0!%8Y4L!O*G) X/-=A110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %1375O;%!//%$7SM#N%W8!8XSUP 3
M]!4M8&O>$K+Q#.\MW<W:;K1[3;$ZA0CNK.1D'EM@4^JDB@#;6>%XHY5E0QR
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MW@[OF8A&X/&2/3D ]/HKS:3QEK45C:Z<S"349-7N=.>[M[0R$I"K/O6+/WB
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M= L\MDFG-*@[XEE!PNX#C&".O-5_$7BG7/[=U+3M)NQ#<6TEM%;6R6)G-P9
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MEM\^6ALVR"N[YF SR3R3S5J;QCK5MIT5@[+-J+:U+I9NX+4N2B(9-XB!^^5
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MX:]CGU2#3]-N3IY0LK*"\GEY!?!+*.@)4>M 'IE%< NM^+O[(U$1V5U*T%Q
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M=J+R^FFCM[6V+[?-D<XQGL -S'V4TVU\5Z9-X7L->N)Q;VUY&A12"S;V'W
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M!.BJ[HV255NC' X7WZ#O0!%JW@K0M;N;J>^MYF-W&([E([J6-)@!A=ZJP#$
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M#%L8SCJ3SUK(E\"^'Y8;6'[+/'';VBV*K%=RQAX%Z1OM8;U'/WL]3ZFNCHH
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MRL<CCCZ54TWPW?2V96[TC5HKZVTN:UADNM0BEAWN@4K&%8G!P.6"XP*](HH
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M]Q<:C]IN8I+>0X)$L0#%T8GYFR%'7C-=-X?O&U#P_8WC:>=/,\0D%J<9B!Y
MZ#MCM6B0""",@]0:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU&-+2Y,BR1DLNTL57:04Y.",'/:JW_"<:M FN&;3=/N1I=M#-NL+MY5<RD@
MG9P% +,>3C! YH [RBLS0-2DU;28[R26PE#D[9+"<S1.OJ&('/J/:N2TGQ3?
M_P!F^'K+2=-6>;4X[MPU[?.PB\J0#+.59F!W'MZ#IR #T"BLCPSK3Z]HB7DU
ML+:X6:6WFA5]X62.1HVPV!D94D<=#6'IGC:2Y\66^B7/]DNURLI46%_Y[P-'
M@E9!M&,@GD=",>] '9T5PNB>-]6U%=!NKS1[:VL-:9HH&2Z+R)((V<%EV@;3
ML;&"2.,]<"[IGC-]370H4L0E]?RSQW<!D_X]?(RLISCG#[%'3.\&@#K:*X#Q
MI=8\::+9SS:W]BDL;J1X=)>8.SJ\(5F$1R0 S=>.:DCB?Q!XH.BM?:K;:5IV
MF6\_E+<RPSSO*7 ,C@B3Y5CY&1R3F@#NZ*\HUK4=1TK1_$VC?VEJ,T6GZCIX
M@N%F8W(AGDCW1[Q\S'[P!SDA@,UK>%-:^R+XIOY;K43H6G!2D>IR%KB)T0M+
MG>2X4@I@-[XX- 'H-%>=_#W6+W^UKG3-4U3[=<7]K'JT0\X2>07.)81SPJ'9
M@?[52>,KE_\ A-=,LY#KDEJVFW,I@TB:1',BR1!6(1AD %ASQS0!Z!17"^$?
M%%U-I?A:SNY/MES?QW*3SN2KQ/#_  NN!\X^ZW3D&IO^$D_M'4M)#VTD9_MZ
MZT]?+N64?NHYOF8#A@=GW3P"<]J .THKSCPUK^H6^@Z-I6FVL-WJ-[+?R[KJ
M=DCCBCN&!)(5B3EU  '?VJ+PSJ<^_2EO89DN+KQ'J4;(MVVV(@3L5..) -N
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MV/:)7+,V6V[F&7;&3QGOQA@\ 1!XHEUF_738-074(+$"/9'()?-(W;=Q7=G
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M!H@"S=?XB3CKTZ$T >H45YZM[?6'B:]@OKN[GFOC=G39K:[#P;44D1M%_ Z
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MF:?_ &@VH?8;;[:T?E-<^4OF%/[I;&<>U6Z* *.GZ+I6DF4Z;IEG9F4YD-M
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MSCM+."."WB&$CC&%4=>!2FUMS>"[\F/[2(S$)=HW;"02N?3(!Q4U% !1110
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MT;698Y=2TRUNI(U*J\L8+!3U&?3VZ5IT4 1P016T$<$$210QJ%2.-0JJ!T
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M=0!HT444 %%%% !1110 445#:W=M?6L=U:7$5Q;R#*2Q.'5AZ@C@T 34444
M%%%% !152^U33]+C234+ZVM$<[5:XF6,,?0$D5/!/#=0)/;RQS0N,K)&P96'
MJ".M $E%0W-W;6:(]U<10*\BQ(9'"AG8X51GJ2> .]-M;ZVO?/\ LTRR^1*T
M,NW^%QC*GWY% %BBJ)UG31+-$U] CPW"6KAW"XE8 JG/5B&7 [YJ]0 4444
M%%0W=W;V%E/>74JQ6]O&TLLC=$51DD_0"I$=9(UD0AE8 @CN#0 ZBBH+R]M-
M/MFN;VZAMH%^]+-($4?4GB@">BH+2\M;^V6YL[F&Y@?[LL+AU;Z$<5/0 444
M4 %%%5VOK9=0CL&F47<D33)%W**5#-] 64?C0!8HJ$7=L;QK,7$1NEC$IAWC
M>$)(#;>N,@C/M4U !114-S=VUE&LEU<10(S! TKA06/ &3W/I0!-1110 444
M4 %%%1P7$-U"LUO-'-$V</&P93@X/(]P: )**** "BBB@ HHIDTT5O!)//(D
M44:EGD=@JJHY))/04 /HID4L<\*30R))%(H9'0Y5@>001U%/H **** "BBH(
M[VUFNIK6*YA>X@QYL2R O'D9&X=1D>M $]%0"\M3>FR%S";L)YA@WC>$SC=M
MZXSQFIZ "BBH9[NVMFA6>XBB:>3RHA(X4R/@G:N>IP"<#T- $U%%% !15>]O
M[/3;?[1?7<%K#D+YD\@1<GMDG%.M;RUOK=;BSN8;B%ONR0N'4_0CB@":BBB@
M HHHH **** "BBB@ HHHH **AFN[:WD@CGN(HGG?RX5=P#(V"<*#U. 3@>E3
M4 %%%% !1110 4444 %%%5[2^MKX3&UF640RM#)M_A=?O*?<4 6**AM;NVO8
M!/:7$4\)+*)(G#*2"01D>A!!]Q4U !15>ROK;4(#/:3+-$)'C++TW(Q5A^#
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MVTRVBB\]+G8B8'FH %?ZC:.?:IFT737M9[9K*(P3S_:)4(X>3<&W'WW*#^%
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MFU&V2ZMHH+621FB;HQ"@X [YZ5.OBK33K$6F.EY#+-*T$,LUI(D4LB@DJKD
M$X5B.QP<9K+\.>&K[2M1T>XN#"4M- BTZ38V3YJLI../N\=:R8O"GB*?Q!IM
MW?LLWV/5)+I[I]1E821$2!%2WQL0@.H/?CJ<F@#H;?QWH5U?Q6D4MR3)<M9B
M8VL@B$ZDCRS)C;N)4X&?3U%5=.\?6-T=<:\M;RS@TJ=HVFDMI-KJ G?;]\E\
M!.21@]ZK1>%-13PY8V!,'G0:\=1;YSCROM;2\<==I''K4BZ'JD$GB>TDTJPU
M#3]3N#=1B:Z*;]R1(T;+L./N,0V3VZ=0 =/INHQZG;&>."Z@PQ4I<P-$X/T8
M#(YZCBG:EJ5KI&G37][+Y=O",NVTL>3@  <DDD  <DFN4T;^WM CM-/FA-P;
M[46\J"2Z>X-E:",%MTK#+$,. ?[X&3BK'Q+8CP+=J&";YK=?,8X6,><GS,W\
M"CJ7_AZ]J +$'CG1YKAX'6^MY8[B*V=;FSDCV22_<!)&!GCGW%6-1\8:+I<M
MU'=W+JUK-%!+MA=\22#<BC .21C@>H]:X:P%IJOA_P 76-Q<6\S_ &9+J76K
M>^-U&9%4E,OL4*T?EJVU1T(/4UIZ+X?U/4O">BW]P(EU*[U6'6KX,2N 3G:/
M=4V*!_LT ;'_  L7P^!)YCWL;02".Z62RE4VI)&#+\OR Y&">O7L:U3XBL?[
M;?242ZEN(RJS-%;.\<+,-RAW PI(P?Q&<9KGM9\)ZC?Z?XW@A,&_6MGV7<Y
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M+T:K-,"Q39E(G&%##KZ=!F@#9TCQQH>N75G!92W)^VQ&2UDEM9(XY@!E@C,
M"0.H]CZ&KNC>(K'7@SV*730[=\<\ELZ1RKG&Y&(PP_\ U]*P=,\+:C9Z?X'A
M<P&31(RMUAS@G[,T?R\<_,1^%4+2TUOPK%J>HV^F16UL;<1VVCP7CW$<EVSX
M5D!4>4A)P0,#G) Q0!Z!-*(())F5V$:EBJ*68X&< #DGV%<KHGCZQU+PR-9N
M[:[LP9?*$36\A,CERJK'\H,A..B@X/7I75QES&ID #X&X Y ->='P;K4WA2S
MTF6"V\S2=2^UVQ2\=!=IND)!95#1';)P1GD>E '2R>-]#@TR6_N9I[>.&X6U
MFCEMW66.5@"JE,;N001QSD8H/C72EO;2Q:+4!>W42S):_89?-5"Y3<R[<J 5
M.2>G'J*QE\)W,MG T6F0V%Q_:UK>3!]0DNFDCB8')=Q][ ( &1P.:WTTFX'C
MJ;63Y?V9]-2U'/S;Q*['CTPPH 6'Q5ILNL1:84O(9IG>.!Y[22..9D!+!'8
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M@H; W-@*2<#DGTJK<^!]2-M:3A(IY[35KZ[^S+=R0>;#.[D8D3E6 93CIU%
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M7EU=7$EP-MG9O*=L<K+DA 0, +UZ^]=5:M.]I"US&L=P8U,J(<A6QR >XS7
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MT\7:7=WXLR+NVD:)YHC=VDD*RHF-Q4N!G&0?H<]*YGPOX+N]'.F6=WID,O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ;CR..#Q7(7&AW#6@U:WM-;OG&LV][>07T,,<DZ1H4RD:!02,J>0"2GTK?\
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MUO2K2^CL;G4[.&[E942"295=F;.T!2<DG!QZXKAM3L+ZT?QCI[>'[G4'UO\
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M8L(K*?\ U5P]P@23_=;.#^%6UO[-]/\ [06[@:R\OS?M D!CV8SNW=,8YS7
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MJ@=  . *DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M8\,<CQN\:,\9+(Q4$J<$9'IP2/QI]%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5S?B33?$5_<9T>_AM8DM)$3,C*?/=E7<V
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M9Y6?+^:,[<9Y_P!7UXZT 0ZM\0+32[S4$^R/-:::ZI>W GC4H2 QV(3N?:K
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MGW8V@G=]T'IS6E'X&O%M4T9M7B;P]'>"[6V^RD3D"7S1$9-^-@?'\.<#&>]
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MGB\PJH!)V@G&[I@G('H>E9GASPY>:-,INIM)E2.'RE>UTWR)7Z?,[;R.@Y
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MWG>%'08'(!XI;/PC=Z;/X<GLM2A#Z5IPTV?S;8L)XOW>2N'&QLQ<'YAST.*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU9X[B8NK+(A'( 7Y20#D^E 'H&F:G9ZO8)>V,WFP.2 2I4@@D,"I *D$$$$
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MSI<UE)<@/P!$!OP>_P#6@#3B\4VEO9W-Q?WD<NW4);*%+2VE9V96($83!9W
M!R5&.">E2GQAHO\ 9\-XL\\BS3M;I#':RM.95!+)Y07>" "2". ,URMYX+U1
MA'=K&99+?6KR]%O#>O;-+#-N VR(0589!QG!Y!/-6I?#+KH2QQ>&Y1</>-='
M;K3FYBD*!1*)FR<D#!&<8]>10!K'QM9?\)59Z(MI?'[5:"Y2?['-@$LH4$;.
M!ALEB0%(P<&M;5M<L=%6'[6\IDG8I##!"\TDA R=J("QP.2<8%<Y8Z1XCLM;
MT#4KQ8=0G336L-0E$H0HS/&WF#CYA\I'&,GTS4OC#P]>:GJ^CZK:12W'V%9H
MI;:&^DM'99 GS+(A'(*#@D @^U %^;QKH$-G97)O'9+XNMLD=O(\DCH<,@0+
MNW \%2,\'T-.;QCH8T:WU474CV]Q,8(D2WD:5Y02#&(@N_<"K9&.,&LG3O#$
MUMJ7AZZAL%LXK66\FN8GO&N'#2C 8NW+$GD^F>]4QX8UJPN;?4[6W@N;BTUN
M]O!:F;9YL,X=<AL8##<#@^XS0!N>$/$3>)/[:F5P]O;:BUO;GRRC!!%&V&!P
M0P9F!R 1TK.\1>/;*S9+33+AGO/[3M[)W:VD,)+3(LB"3&PN%+< Y&/8UH^$
M=,U.P_MJ?588(9K_ %%KM(X)"ZJABC4#) Y!4@\5S;^&O$D>F+H$5E:/9PZT
MM^+UKG#21?:Q.1LQ]\9(.3CY>.M '73>*M)MM533IGN8Y7F%NLC6DHA,IZ)Y
MNW9N/IGKQUJCI/CG3M2NM;BEBN;./2I762>>WE2,HJ(Q8LR!5/S?=)S@;NAK
M!U7PUXEU+7 \X>>*+68+N*8ZBR1);)(C;! /E+@ \L/<'H*LW_A75KZV\8Z/
MY<,=KK$ANK:\\[H_EQ*(V0#(YC.2#T- '3Z3XDTW6KB2WM'G6=$$IBN+:2!S
M&> ZAU!*G'44LGB/3DUEM*#7$ETA42>5:R2)$6&5#NJE5)'.">X]16/X8T66
MVU1[^[T>XM+D6_D">XUB6])!8$JH<G"Y4'/!XZ5%J.C:M)XSAO\ 2[/[$#/$
M;J]2]^2Z@4?,LD.,%^J@]A@[NU %C1/'FGZO8ZC=-:WUNEE<20L&LIR7"R;%
M('E@EB<?(,LN<&F:K\0=+L/#]UJL$-W<-;7$=M+;-:S1RQNY'WU*;E&TY!(P
M> #DBL_^QO$]II.NZ?81QQ/-J;WD%S'<A6FBDF#O&.,QMM++N]<8]12'@[6I
M=&\4(+<13:C+;36L5Q?O<,?*VDJ\C9.3M]P,^@H ZVZ\7:39QV[2F\+W$1F2
M!+&9IEC!P7:,)N0 ]V I+SQEH5DMHSWCRB[@^TQ&V@DF_<\?O&V*=J<CYC@5
MS^K^']6O?$4&OG3KAS-8+:S6=MJ\EJ\+*[,#O0J'!#D$'I@8S4EMH&K>']6M
M;W1-(M'@?2HK!K5[UL6KH[.#O9273]X0>,\#B@#;\'ZS-K/@K3=7OI(Q+/;^
M;*ZC:HZ\^PP*=IGC'1=7O8K2TN)O,G0R6YFMI8DN%'4QLZ@.!U^4GCGI5'1O
M#-U#\,D\-7DB17+:?):221G(4LK#(_.J>G:1KU[J'AS^U+"ULH=##,TD5QYG
MVA_*,0V# VIABQSST&.] &KI?CGP_K%W:VUC>22-=AOL\C6TJ1RE1EE5V4*6
M !RN<C!]#5[6/$.F:#]F&H3M&]RQ2!$B>1I& SM55!)..W>N:TSPKJ5KH/@N
MSD6(3:1=^;=8?@+Y4J\>O+K4OC.2]A\4^$9-/MHKFX6YN"(9)/+#C[.^0&P<
M'&<9XSZ=: -B/Q;I$VDKJ,,ES-$9C;^7%9RO,LHSE#$%W@C!SD"D_P"$PT4Z
M9;7Z7$TD=S*T$44=M(TS2+G<GE!=X*[6R".,<US(\/\ B:*RFND79)?ZN]]?
M6-I>&)_),0C5%F '(*(S8QGD ^O.WVF:GX?&A6LMU!I][+J=_=QS2ZAM5%8<
M*;B1'W-A\89"6Y/&* /1(O&VA3Z9;ZA#-=217,K0P(ME-YLKK]X+'LWD#!R<
M8&#S6MIFIV>L6$=[8S>; Y(!*E2""005(!!!!!!&017FEAH[ZWI6AZCI5E,T
M6E37EK+!#JLD9N=[ M-'<)MW@NN>=H.3Z"N^\-:8NE:.(18FR>262:2)KMKE
MMS,26:1N23U/N>] %+0M>U34/%&L:7J-A!:):06\T*I*9'*R&0?.>F?W8.!G
M&>IK1U?Q!I^B-!'=O,T]QN\F"W@>>5POWB$0$X&1DXP,CUK"TFVU^/QWJ.IW
M6CQ0V5[;P0;Q>*[1^493NQCG/F 8[59UG3]5M_%=GX@TRTBO@EG)936SS")@
M&=7#J2".JX(..H]* ,WQ)XYB6ST(Z)=R[-5NC']JBT^6X,:*CE@$"_?W(%VG
MD?,<<'&SXE\4P^%H]+^TV]S<M>7*VY,$$C[<CEL(K<^B]3SCH:QK#PGJ=O\
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M,HU8)\$ZK!;Z/<^2]Q+8SZCYMM;Z@]J[1W$YD5ED0CD +E20#D^E '63>-=
MAM+&Y-X[K?%Q;)';R/)(R'#($"EMP/!4C/!XX-4M1^(.E6=GH]Y;175Y;ZE=
MFV#0VLQ:(J&W94(3N!7&P@,>2/NFH=.\,36NI^'KJ&P6SBM7O);F)KQKAP\W
M1B[<L2<D^A/?K52;PSK-OI\<EO;PSW%OXCFU18#,$\R)VDP V,!L29Y]* .R
MMM5LKN^FLH9LW4$<<LL11E9%?.TD$=]IXZ\<U<K(TW5;F^UG4;5[(16]FL2^
M?OSOE92SH..0H*<^K>U:] !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9[.XC\J168Y(]<]<Y .?6N>T3X<Z9H^K6FI2:EJ^ISV4;1V8U&Z\U;92,'8
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M#%N&\(20&QUP2",^QH EHJEI&JVVMZ5;ZE9EC;W"[D+K@XSCD?A5V@ HHHH
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MXY=Z?=6GPU\/ZB?%,IN-0$-_=PZGJK6XNQY63$DH(*8R.,\X&>E=C'J4.K_
MZ\O[>*ZBBFT6X*I=RF20 1N.7/+=.">HQ7:36%G<6ZV\]I!+ F-L;QAE7'3
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MHIF"B/.T8**00,]<DYI?#EUJ^I:C97TVJ65OJ']IR)=I-K,OF,@D93!]E*;
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M;W5Q:VKW CY&5 )#8."5)'4<>] '0T5S?AOQCI?B"SM(XK^U?4I+1)Y((V(
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M(+>&UMX[>WACAAC4*D<:A54#H !P!1<7$-I;2W-S*D,$2%Y))&"JB@9))/0
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M"8:?)"DOFY79N:7HF-V=O.<=JR?"7AG5--NO"CWUF$&GZ-<6T[;U;RY6DB(
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MBC:21U1$!9F8X  ZDF@#SW4M*UNWC\7:5!HCWZZ]([V]Z)HUCC#PK&1*&8,
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M*UQ$(T.UG+C /H3ZTLMS!!$)99HXXSC#NP /XT 2T5'+<0PJK2RQQJQ !=@
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M$'&!C(X[BL:#2-(UG4_!@AT96TR&VNS+%)9-'&LNV+[R,H&<@]1R1GM7I5%
M'C\VEWMMI.DQ/;M%H]CK>HAXY;![F.)/,D$#&$$$H.QZ#*FNX\&V"V/ANXCL
MKII4EN)I8=UD]JD1;G:D;<A-V2.W/%=110!Y%H=A T'A.UL](N;?Q+9W:2:K
M<O9NC !6\\R3$8<.3Q\QSD8Z<6M#M85T&\L5TJ>/QJ$O=UXUDX83-YFUS.5V
ME6RN/F/8=N/4Z* /*)+32;KX>7EKH/A^YAU.&PA^TJ-.>&1BCHS(6*CS'RK'
M@DGGUY=XBN7\0R^++O3K&_>WD\,-;Q226DD?G2;I#M0, 2?F':O5:* . U/P
MCI?]J^$;"/1HCIRS3RW,8ARC/Y'#2_WB2%Y;.2!G-8/B+10_B3Q!;:B1:V]S
M'#'ITJZ+)=LD0B Q Z']VRON.T#.2#7KM% 'E^L^&(;^7QY<7FFF\N5TZ-;.
M>6$LQ<6YYC]&W!?N\Y ]*?)'8IXDN9O%>D7%^MSIMHM@QL7N>0&\U%PIV/O(
M)SCL<\<>FT4 >0W>CR7'B+68-4N&M;V?5%FM)UT:6XF,8*&(Q3J<*!C!';YL
M]:Z_QY!Y@T.6ZM9;O1X-0$FH01Q&7*>6X1F0 EE60H2,'H#CBNOHH \CU#18
MM0\.>*9+#1V&D3W]G+I]L]H4^<&-9I$C(RH.2,X&<,>AKL?'&GL/!,EGI]DS
M6L<L'G6EK'@O;+*AE157U0,,#J,CO75T4 >?3QZ5=S>'Y?#NE26]JFNI),4L
M'MU.+>4;]I4<#*C=C&>*RX_#31_#?7+BUTI_[6N;VZ\XK$1<36_VPED4_>PT
M:\*.#GU->JT4 >;ZF=%.F66H>']&F@L[/5K6XNS!ILD.47(+!-H+;0PS@' ^
MG&?J<$FO0^*)H]/OC:WNL:68Q);O&TL2M K, 0&"X!.>,#GBO6** /*]6\&Z
M=YWCP0Z#$$73$:P1+?Y5E,+Y,2@8#Y2/)7G(%3ZBGV;Q-INH1VK:CJ<T=E%-
M9W>FO)@!L^;%/C;&5W,S9)&5[&O3:* /*X;:TT2Q\9P0>&HI[_[:\B0MI[%)
M;9C%@Y5<.@Y;8#D[3Q68VGW%QHWC6*VM2]M<I8-#]DTV2SCE;>0Y2,DG( &6
M![#ZU[/10!YAXA\/3V%YXEM/#>FM;17&@1 1V<?EK+(LL@(&.-Y3CUY%,UR#
M2K[PU_Q2VCR6MK'=VC:BHTF1!)"I;*F+"F7:<%E&>..>E>I44 >4G1]-?0[^
M?^TI5MYK^"=!#H,J6R2HIY: @[T; W$8&0.0:ZBP>YO?AA<E]+2QG>SN56U@
MA,:G[X5EC(RN\8;:>1NKKJ* /(]!T^)KOPXGAW2;C3M1M--G34I9+-X,,T("
MK([ "0F7##EN 31X.\/VUV^DV]ZS17<-I+!?6HT:6%Y=\9619IR2K_-\V?XB
M 1UKURB@#R'3+37=7TW6+9!+_:'AS2Y]&LY,X,MRV?WBGU,:P8/JYJ_I=IIT
M^N:))X:T>>Q2UL9TU)C8O;_*8P$B<LHWOOY[]">_/H>GZ7::7'.EG%Y8GG>X
ME)8L6D<Y8DD__J&!5R@#RWPSX=32X/AW<VNEFVNVMG2^E$)#_-:DXE/7[X7
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M#YS?: AF\D2XQMQNP=N<X[YXJ];>"!%<Z>;G7]6O+33IA/:VMPT15' (7+A
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MA;5)K!D6ZCM9&1G) &%))R.<XSCWQ7GF@"/PW+X9O+BVMK>-- O;V<6F3Y@
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MS?VRNRXBE8%%4[MRH ,@,68GGJ: ,70?'EUJE_;V\L%@XN[22XC^S3.?L[*
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M2,+M0(-O'H.^>:SY/!]D_AC2]$2YNHAI8B-G=(R^;&\:[5?D;2<9!!&"">*
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MQ"I2\M;B=I">5,9B  'OYA_*N>3QIJEY#I"6&G6KW6HWM[: 33,J1B!Y!O)
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MN, =SW.:M:MX934M6BU.WU*]TZ\2 VSR6A3][$3NVD.K 8/((P1DT </X?\
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M3QSQAA"SN2F[MSGC\Q72^/\ 3+S4?"RP6$<DGE75O-+#"JLTD22*S*JM\K'
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M$<\)5YD1QO.WJ,#/!P0.H%:7B?2)[/Q5I=_:PW<.EQ6,MN/[.L4N##(S*?\
M5E6P&48W*/X<'@T =I=:QI=BD#W>I6=NEQQ"TTZH)?\ =R>>HZ5=KRN]TB31
M-)TR31+76)M2M[.2*WCN=.$L5PCR%_)E  $7(&#E<+CKC%>A:?K,6H:CJ-BD
M4JRZ>T<<SD#RR[('VJ<\D C.0.HH EFUG2[?4(]/FU*SCO9,;+9YU$C9Z84G
M)I)M:TJVN5MI]3LXKAY/*6)YU5B^ =H!.<X93CW'K7G7C&#6M1OM5LX],N5Q
M>6LEL+73PRW"*8V,KSGHRD,,#! 4=0:GUWPU/=:;\19ETEI;V\=#9OY.7E"V
MT6W8>IPX;&.X- 'HAOK-8KB4W4 CMB1.YD&(B!D[C_#@$'GL:DEN(8;=KB66
M..%5W-(S *%]2>F*\X\4:;<GQM%HT$>;'Q0(GO,'[GV8@RG_ (''Y:?A72>.
M[&YO= @%O:/>1P7UM<7%I& 6GA20,Z@'AN!G'?&* -A=<TAM-.I+JMB; '!N
MA<)Y0/\ OYQ^M/75M->RCO5U"T:UE.(YQ,I1^IX;.#T/Y&N+U39=WVB:U!X<
MOO[,M+Z5[JW-EME=FAVI/Y/WFVGY>1N[@8 -9O\ PCUS?MYYT:6/3;SQ-#>)
M930X*0K#M:1T_A#.I.#ZC/6@#T"/Q!HLJVS1ZQI[BZ8I;E;E#YS#@A.?F/TJ
M2YUK2K*80W6IV4$K.(PDLZJQ8@$+@GK@@X]Q7GNK>%7.F>/'MM&_TFYO8I+,
MI!\SA8X3E..S[SQWS5;65BF\0>/[,>'KG4;N]BAM[>6&W$@#&V4!6;_EF 2&
MR<#WR* /4S=VP>9#<1!X%#RJ7&8U.<%O0<'D^AK+;Q9HBZ_!HIU"W^V3P">,
M>:N&!("@'/+'<"!W'-<?<V^JZ+=ZS!+IE_J$NI:);6T,UK%O5IHTE5P[=%Y<
M')ZC/?BK&EV$VF^(?"]U=:3<.C:$ED\B6Y?R9PT1_>8^Y@ \GT- ';1ZMILN
MHOIT>H6CWR#+VRS*9%'NN<BEM]4T^[N6MK:_M9KA5WM%',K,%SMR0#G&01]:
M\U\+Z!<PSZ58ZJ=96^L+^2X)2P00,Y+Y?[0$Y5PQR-V><$5U?@'1AI7A]FFL
M!;7LUY=R2LT>UW!G?:2>N"H3'MB@#HFO[-8;B9KN 16Y*SN9!MB(&2&.?EP"
M.M5(=9A)O3=O;VL5O<>0LC7*$/\ (K9//RGD_*><#/0UQNOZ#J,OC"73;:TD
M?1=>EM[F^F4?)"8/]8I]/,5(5]_FJ&_\/W=[-J$,^FR36\WBRWN2CQY5X!#$
M"Y'=<@@]N#0!Z#;:E87JAK6]MIP8Q*#%*K90D@-P>A(//3@U%-K>DVZ6KSZI
M91+=X^SL]PBB;/39D_-U'3UKE]36XT;QI<W<&CWES:WFD1VL'V*'<HE221MK
M= @(D!R<#KS7.II^I:5X>\-S66G:@=>@T6WM6MI+'S;:8<9BD;_EDP()W9&,
M_P 70 'K-<_<>*[*Q\37>E:A/:V<$%I!.MQ/.$#M(\B[.<#_ )9^O>M"WUB"
MYUV]TF..4S6<44LLF!Y?[S=A0<YW87)&.A'K7.7N@K?>.-;O+G35GB?1(;>&
M62(,"Q><NBD]\%,CW% '2WVLZ7IAB%_J5G:&7_5^?.L>_P"F3S3KW5M-TWRO
MM^H6EKYQVQ>?,J;SZ#)Y_"O,[JWUQ?#6E:7+IETH;P[%"TD.GB>:2?;M:&1F
MXC4<'YL<D\C%6]/M9](O[2YUG0;W4H;C0+2TC$=KYYBD0-YL3J?N[MR\G ^7
MD\4 =E9^(H9M3UJUNO*MHM-N8K<322@"0O$CCKC!R^ .]6(-9A*73WKVUHD-
MR]NC/<HP?:-V>#\IQD[3R *X.71=3M?']]K[Z;/=:9'J$.++R\[<VT*"XC ^
M\T;!E(YP"Q&".9)?#]W=3QQW.F22P'Q>]VRR194P^2P#D'^'=CF@#ODUC2Y-
M-.I)J5FU@.3=+.IB'./OYQU]Z=8:KIVJQM)IU_:WB(<,UO,L@!]RI->8^(+*
M\TZYU!+6Q93<^)[:>RA$(=9B+5&9EC+*'&Y&S\RXP3G(KJ_ )@2TU6 B5-1%
M\\U]%);"#RY) & 50S#;M((^8]SWH Z%]8TN+45TZ34K-+Y^5MFG42M]%SG]
M*=_:FG_;EL?M]K]K9BJP><OF$A0Q 7.<@$'Z$&O,[S2KU]&UG0#H=V^M7>K/
M<0Z@+?,6UI@Z3>=T78F!C.?EP!76^&]&%OXG\4ZC<6 2>XU!#!</'\SQBWB'
MRGTW;QQ[T ;U[JVFZ8";_4+2U 7<3/,L?&<9Y/3/%+%JNG7%Z;*&_M9+H()#
M DREPAZ-M!SCD<U@7NC+??$BUO+JP6>TBTF6,221AD60RIQSQDKN_#-<WX<\
M-W&FZ9X ,>DM!<6LDQO"(MK(&@E'SGJ,ML'/?% 'H%KK.EWMW+:6FI6=Q<P_
MZV&*=7=/JH.1^-<C%\1/M-MX:2&+3XK_ %J(SF*ZO?+6%!CC.TDEB<+P,X/I
M63H$&LWGBOP[>7FFW-LULEREU$NGBW@M2R<(C=7&0.<D' Z$XJSX9T&\A/@)
MKK39%:STZYCN3)%S$Q\O:&ST/#8_&@#T$7]FT22B[@,<DGE(XD&&?)7:#W.0
M1CKD8J$ZUI0O4LSJ=F+J1F5(//7>Q!P0%SDD$'->=06^IQV&E: =%U$SV7B,
MW4UQY/[D0FZ>0.'_ (@5<<#D8.<8J:X\-3_\(]K<L>DM_:,OB5+J)Q#^\9!=
MQD.#UP$W'/IF@#T";5],M[Y;&?4;2*[==RP/.JR,/4*3G%9-MXTTS4],FO-(
MFM[QH;H6[Q&YCC(_>^5NR3C!Y*_WN,=:Q])B_L[Q%J]IJ6@7=W<7NJ_:8+Q;
M421&(A-C&0\+Y>,8//' .:R5TN[7PGJVD1Z/=1WD>O)<9%L0LL)U 2JR-T8!
M.3CICG% 'HD^L:7:W\5A<:E9Q7DN/+MY)U61\^BDY-)<ZUI5G.L%UJ=G!,SB
M,1RSJK%B 0N">I!!Q[UYSJ^F71T_Q=HLF@W=UJFK7<DEE>)!NC*LJB)C+T3R
M\="01MXSFKFJ^&9KJ/X@22Z9]IN;JP2*TE:'+3,MMC"'_? Z=\4 >D53O-6T
M[3I(8[[4+6U>8[8EGF5#(?103S^%4]+U=);_ /L9HIS=VME#//(0-BE]P"DY
MSO\ D)QCH17.ZA%_9_C;5KO4=!N]5M;^S@AM6@M1.%V%]\39X3)8-DX4YY/%
M &UI_BRQN-5U+3[N>UM)K:_^QP)).H:X/E1OE0<$G]YC STK3FUG2[:_CL)]
M2LXKV7'EV[SJLCYZ84G)KS_5_#4\^B^/9DTEGO[J_5[1Q#F215BAVE#U(#!\
M8[@U#XU@UK4;S5[*+3+D#[1;/:_9=/#K<*OEL9'G/1E(8!1@X48SF@#T6?6M
M*M;E;:XU.SBG:3REBDG56+X!V@$YSA@<>X]:2^US2-+F2'4-5L;25QN5+BX2
M-F'J 2,UP>N^&IKNR^(TPTDRW=X$%F_DY>7;;1[=AZG#@].XK)\1>;/XA\4?
M:(9CHZM:'4+F&S6=HA%&DAVN9%*$ Y("/@'(Y.* /5)M9TNWN;>VGU*SBGN0
M#!$\ZJTH/3:"<M^%6Y)$BC:21U1$!9F8X  ZDFO*M5T6:[UCQ'%>?VN;+6#$
M]M)I^GI.LD7E(H7>4)C96#$9*@9!')-=CXYTZZO_  D]O:P/>&.>WEFM@1NN
M(DE1I$YX)*@\=^G>@"W>^+-&M?#NH:W!J-G=VME$SNT%PC L!D)D'&XG@#U-
M)HVMSZAX7_M>=;(L8FE5;.Y,T> ,XW;1R#D'CM7':GITVN-XHU#3M%NK:UF\
M/R6:Q3VIA>YN/G*XC(R=H. 2.K<=*[>*T:+PH+6.#8XL]OEJN/FV=,>N: (+
M#Q5ILN@Z1J.I7MGI\FHVL4Z13W"KRZAMJ[L;L9Q6J]]9QBX+W<"BV4//ND \
MI<9RW]T8!.37EMY:ZTGAC3=(;2KE$/AR&#=!IPGEDGV%6A=FXC4<'G'+'GBI
MM1\.ZK-_8=HEE</;:SIEK8:N0"/)$+(Y+^FY&F3ZD4 >GBZMVF2$3Q&5T,B(
M'&YD& 6 [CD<^XJ6O-/#!O?#VGZMKOB.UN5&C6::7;C:-]Q%"6)= 2,F0L@'
M/)45Z3&_F1J^UEW ':PY'L: '4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%<GXP\0WFC,$L;^PBF%N\_V>:SFN9),?[,3 HO;<<\_2@#K*KWMC:ZC;
M?9[N%9H=Z2;&Z;D8,I_!@#^%<E:^)]:\0W=K;Z(MA:L=*M]2G:\C>4$S;MD:
MA67'W&RW/;BHK"]\3+XP\5 W%K=P6D,3Q6*QN"6,3%%1B^%R0-QV\^@H [JB
MN;\':Y<ZW93/>7EI+=1%1+;Q6DEM);,1DI(DC,?HW .*Q)?&&N#29_$T<>G_
M -B0WS6WV4QO]H>)9O),GF;MH;()"[>G&<T =V9X1.(#*GG%=PCW#=CUQUQ3
MED1RP5U8H<, <X/7!_,5POA6RO'^(7BZ]O6T^8Q74<2NMJ1*H^SQ%0KESA=K
M'(QRQ)XSBJL6LW6DZIXBBL(X7O=0\216<#3Y,:%K2)BS $$@*C< C)P,B@#T
M8@$8/(J"SL[>PLXK2TA6&WA4)'&@P%4= /:N)N?&&LZ7+J.D7<5C<ZM%/9PV
ML\2/'#)]I<HI="S%=I5B0&.>,8S6GJ6IZUH^F1+?ZKH\5Y+<%(I5L9I/,7;G
M"P*Y8OD'HQ&!GVH ZAI$5E5G4,YPH)Y/?BG5YO8Z[/XBU#P3?W,:).-1OX)/
M+1D5C'%,FX*WS+G;G!Y&<5T>JZMJ\OB>/0-&:R@E6S^V3W%Y$TJA2^Q55%9>
M20V3G@#H<T =+17G\/C'7]5_L*TT^WTZWO;YKV&Z>X5Y(XGMG"%D (+ G. 2
M.HYX.>@\1:O?V$FD:=IXMO[1U.X,"2SHS11!8VD=BH(+<)@#(Y/6@#H**X?5
M_$^M:7J&GZ+)):+J$MO+<SW4.G7%S'L5PJA88SN!.[DEL#'4Y%1V_BGQ)J<V
M@V=K9V=A=:A:74UP;V"7]T89$0,L>58AMQ(!P<,#GC! .\HKS1]?\2:RW@ZX
MM+NRL9KF]N[:YB,4CQO)$DZDD!U)3]V2%/(.TY.,'=M-<UR\U[7D+Z5;Z5I$
MQB9Y5??)^X23);=A I;DX.1V&,D ZUF5%+,0J@9))P *%8,H92"",@CO7FDG
MBR\U.S\0:5<W%I>1-H4]Y%<VUE-;#@%2O[QCO'S AE.*W[S6Y/#WPULM2B6(
MR);6L8:;.Q-Y1-[8Y(7=D@<G% '6T5YU;>-=9-G?2+-I.HAM1M]-TVZMH'C@
ME>0*6=CYC;E7<00IZJ1GGB?4?%NO:#)J=KJ$=A=RZ?!;W[S6\+QJ]HTA27Y"
M[%74*S Y(([4 =]17!ZQXZN[.;4/L<,$ELE_;Z;:S>5)+F9D,DK%4Y=54J J
MC)((SZ0OXS\01Z7-LLH9;L:E;6=O<3V<]I#<+,0-VR3YE*DD'DCC/?% 'H5%
M<9<:IXL.OKH-M+HWVE-.%Y+=26\NPN9'4*J"3." O);CGKG K6GBW7-=/AV+
M28M/MGU72I+^5[I'D$+*8QA0K+N&9".2/7/&" =Y17G^B^+_ !!=KX=O]0@T
MU+'5[E[,P0!S)'(J2'?O)P5)B;Y=N0"/F-1Z'X\U76+S3KF*T\W3[ZY:+R(]
M-N0]O'\P65IS^[;H,@ 8W<$XY /0+BWAN[:6VN8DF@E0I)'(H974C!!!ZBL[
M3/#>CZ-.T]A81Q3%/+\S)9@F<[0220O3@<<5RFG>+O$,T6DZG=Q:8--OM3?3
M_(B23S5^>1%DWEL=4Y7;TYSV%_P//KMQ=Z\=4U"WN8(=2FA14A=64C;T)=@$
MP>%QU[T =C17"ZCXIU_[/XAU734TX:=H4LD<D%Q&YEN?*0/(0X8"/J0,JV<<
MXS5ZPUW6=8\6W=G9BQBTJSCMY7>6-VFD$J;MHPP"D8ZG/ICO0!UE%<QJ6K:S
M<^*)-"T1[&W>WLTNYY[R%Y0=[,J(JJR_W&);)QQQ7.V_B'Q!KVM^$KFSN;6R
MBNX+Q;BV>-Y%,D3A'Y#KN&1\O'').<X !Z.DB29V.K;25.#G!]*=7EVGZOK>
MAQZYJ,(L&TJ/Q&\,T+HYFD$DR(65@0JXW#@ALX/(J[J'CS55U35!IUIY\&G7
M8MOLBZ;<S27. I<B9/DC(W' (/3G&: .\CL;6*_FODA5;J=$CDD'5E0L5!^F
MYOSJQ7+Z3J^N:IXKU>VQ81:3IEV+<_(YFES"C\'=M7!<<X.0<8&,G.\:^,+W
MPXUW+9W>GO\ 8[<7$EDUI--*XYSN=#MA! ."P(_"@#N:K6-A:Z9:BVLX%AA#
M,^U?[S,68_4DD_C7/7'B>[CG\5HD4.W2+*.YM\@Y9FB=R&YY&5'3%9MCJ/B"
M_P#'NG[;ZUCL9]%CNY+8PN1RZ[L?/C=DG#8X'&#UH [I)$E0/&ZNIZ%3D4ZO
M+O"&KZWI.B:"T@L'TF]U.:R$2H_GKNEE(DWYV_>7&W;T[UI2>,-<&DR>)DCT
M_P#L..^-M]E,;_:&B$_DF3S-VT-N!.W;TXSF@#N+FSMKSR?M,*2B&59HPPSM
M=>C?45/7!W6N:UJ%KXN>6'3#I&EBYMC"Z2&2X(@#\D, H^8 ]SD_=QDLTBZU
MR;QS900WEI%I9T2WN/LGDN0JEB" ?,QNR#\V#Q@8.,D [^BO,-.\83VVC:!I
MVG6]O927<%Q<NR6-Q=I$B2[<+'&=Q+%LY+8&/<"KT_C36TTS2;NYMX-'AG68
M75Y>V,SQ1R(X5 5RK1*XRP9^ ,#K0!Z#35D1RP1U8J=K8.<'T/YTJL&16!!!
M&01T->7C5M=T$>-M8L1I[Z?8:J\\\,R.99@(8=X5@P"87H2&R>P[@'J-%<=_
MPD>L2>(M<55L8]&T94DE)C=IYE: 287Y@%(/<@YX&.]9^@^-=8U&>QDN;>(V
ME[:O.S#3[F!+$A-Z[YI/DD4C(+ +STR#0!Z S*BEF("@9))X H5@RAE(*D9!
M'0UYJWBV]U.#6M*N+BSO(9="N+R*XMK*:W4;0%*CS&(D!W@AE/;I3M%\:W4?
M@6[U:"V@-EI=K%:0PR9$TMP%527Y^1,LN 1DCYN!@$ ]'WIYGE[EWXW;<\X]
M<4ZO-+K4]6\/^,KS5->-E=-9>&Y[A?L,;Q!PLJ$J59FP<C&<\YZ"M7^W/%-C
M>Z?9WPTJ>;5K:=K46\4B""=(]X5\N=ZGD9&T\=.> #MJ*\\L_B6)]2TGS8(H
M],N=-%Q=S\Y@N"CN(^O989<CUV\^LUGXB\6:K=:?8V\6DVEU<:0FHRM<12.(
MV9R!'M#C/&T$YX()YZ4 =[4<-O#;AQ#%'&'<R/L4#<QZDXZD^M<U#XP'_"M!
MXNGM<$:>;M[=&X+!<E0?3/&:K+J_B>RU>QTS4I-)>75+:9K:2WMY +>:-0VU
MP9#YBX)Y!4\=.: .NCGAF+B*5)#&VUPK [3Z'T-25P_PMMGL_AUI]U-]A#SP
M"8R10^46&,YE8D[FSDEN.O2J^F^-[^75GM)+BPOXI--GO89[:RF@16C*?*&=
MB)5._P"\N.GN* .W:PM6U)-1:!3=I$85E/54)!('U('Y"K-<'I/B;Q+<R:$;
MU-*VZ[8R3VR0QR V\@C5UWDM\ZD'D *1TR>M6]!\876NW6A6T5O"DL]I+<:H
MI!S;LC>5L7G@F7<.<\(?K0!V-%<%X@\::G:Z[JFG:5"A.FPQN4;3KBY-S(ZE
M@@:+B,8P,MGD],#E]WXJU^ZEU632;:QMX=)LHKB>"_C<R2N\9D* JPV;5P,D
M-SV% '=57@L;6VNKJZAA5)[IE:=QU<JH49^@ %<]HOB:\U+5;>UFB@5)-#M]
M1)0'/F2,P(Z_=^48[^]85CXIGOCI&L2V5I]MG\,W%^9%#_*P:([ -WW23SGG
M@<T >C45P^E>)M?^V^'SJL>G&VURW>2*.U1P]NZQ>: S,Q#@J#T"X..M9VF>
M+/%^H6WAJ8QZ(G_"00L8P(Y?]&98_,WGYOG!4-\HVX.!N/)H ])HKSN3QYJ<
M=C96DD5NFJ3:C=6,L\5I-/$H@)W2+$A+G/RX7/&3D\5+'XN\0W%OI-O%96T5
M[>:E-8F6[MIH8W1(GD$RQL0X!"CY2>H(R.H ._HKS35-?\2W>DP)%=V5K?VG
MB.'3KB6*&3RY@70J0N_(4AQN4DYY&17H\ F6WB%P\;SA!YC1J54MCD@$D@9[
M9/UH DHKB-1\2:_(WB&[TA=.6RT)C&\5U&[273K$LC@,& C&& !(;)]JGT_Q
M%K.M^*&M=/2QATN&TM+R5YT=IF68,=@PP .%ZG./0YX .LCMX87E>**-&F;?
M(RJ 7; &3ZG  SZ 4Y'21%=&5D89#*<@BN7U/5];N?$USHVB"P065E'=3O>(
M[>:9&<+&NUAMXC8ECNQD<&N1\/>*KS3_  MX3T6P*0ROHJ74D[Z?/> #A54)
M#@\G.6)P,=\T >J2SPP!3-*D89@JEV R3T'/>I*\PFEU7Q-XJ\%W%[:6=NDE
MI=2R65[9NQ1T:-7(#,N"0?D)&5R<YSQJZ?XRO)O%VGZ<UWI]]9W\D\:M:6DR
M"%HU9AB9F*2_=(.T#!H [JFI(DBED=6 )&5.>0<$?G7'6/B^^NM!\*W[PVPE
MU>^^S3J%;"KLE;*\\',8ZYZFN8L[C7(8-#CTB_M[9;CQ-J44BRQ.X<[[EANV
MNN5^7IZ[3GC! /3=3TFPUFV6WU&UCN(T<2(&ZHPZ,I'(/)Y'K2:?I>G:):/%
M96\5M"6,DA'\38Y9F/). .2>U9_B76+W2X],M;!(&U#4KM;6)YP?+C.QG9R
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MDZ5>PS-;RO')&LBLP"L5#X4GY6QE3W%6+CQ+H5K?+8W&L6$5VTODB%[A0Y?
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M2E LC1@^OS#GH"<8J+PAX!BTC3-';4IKJ6ZL 9$MFN2]O%,00753WPQ]ADX
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MGZR(P@TR*V=9$$0C:-S(I9"""0<@?-D$'-;]G8SV?CK5(Y["YGL-2L;:)+G
M9!Y8E#K(<Y!.Y>W.:ZZB@#QF/PYXLTZU&J6]A++J>A$:7I\>\?Z1; 2IYG7H
M?,B8YY_=5TMOI$_@_7;*:/2;O4["/18M/C:U17>.1'8ME21P^X'/JO->@T4
M>=>&_"M]8:CX3-_8+ML;._+CAUM7EEC9(P?4*67(XX/:HK'0-6TSQS=Z^]C)
M=6LFJ2QB!L$PI(D0%S&/JI5N^WIT(/I5% &1X?O;*_CU"6QL1;1K?31NX15%
MQ(I"M(,=<D$9//RFM>F111PQK'%&L<:\!4& /PI] !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-G:5S&?FST.?:@#L**XA/B#*(Y)KCP]>0V]I>K8W\IFC(@D9U4;<'+K\Z$D
M8##KR!+J/Q#L["^O$^R^996-PMM=7'VA%97.W)6,G<RKN&3QWQG% '945E:]
MK0T2T@D%L]S/<W"6T$*L%WR-TRQX P"2?;O6!_PGTL>FRW,V@W G34QI:VT4
MZ.SRGT/ QG')]>V#0!VE%<M+XJU#[6;"T\/37.HP6RW%Y MS&JP!BP50YX9C
MM8@#C Y(JSI'BZRUN]L(+.*7R[W3C?I(^!M4.J%"/[V6_2@#H**X]/'1NH-%
M-CHUQ<W&K1W#PQ"55">4R@[V/ 'S9SSTQ@YK;\/ZY'K^FM="WDMIHII+>XMY
M""T4J,59<C@\C((Z@B@#5HKD+;QV+C[%>-I%Q'HM]="UMK\RH=S,Q5&,?549
MA@'KR,@9JMX'N=2U/7/$-]J,-W&T=[);1AKTO$BKMPBQ [01UW8R=QYH [BB
MN>@\2W%]K-Q:6&CSW-E:W(M+B\$R*%DP"VU"<L%W#)^N <51@\=B;[)>G2+A
M-$O+H6D&H&5/F9GV*QCZA&;@'KR"0 : .OHKBKOX@M:M=R_V!?2V%I?_ -GS
M7$<B9,I8(NQ"06!9E';&X=><2R^._L6GZO-J&CW,%WIDENLMJDB2%UF8*C*P
MX/4\>H_&@#L**YJS\4W4][?:=<Z'<6^I6]LMU%;>?&WGQL2HPV=H(88()XXY
M-4CX_CM[#6IKS37CN-)2*26&&=)@Z2$A2K#OE6R".WO0!V5%<9?>+I?[-\06
M]_IU[I5U9:6]^OES1M(T6U^58957!0C!R <=11J/CR#3));:&T:\:RM([B[9
M[F.)E5E+ *&QO? )P,#D<\XH [.BN9M?%Z:CKZZ;IUD;B,0PSR3-.L9$<HRK
M*AY8 =3QZ<FM;5[^ZT^T66UL?M;EL$&=(E08/S,S=NW )YH T**XU?'\4^GZ
M;+;Z>S7=]<S6JP2W"1HDD1(<&3D')7Y<9W?G6MXFU6^TOP9J6JVEIF]M[-YE
MA=U^1@N3D]#MZX'7'% &Y17GUWXAUS^U?",PTVX-Q>071>QBN5"2$)&5=CG:
M ,D]R,\<UNVWBF>_\/KJ5GI,C3BXDMI[>6XCC%N\;,K[G)P0"N 1G.1QUP =
M)17 WGCO4;BTT&YTC2M_VO4Y+&ZB>9,J\8D!16Z')3(8<8'O75:WK<>AZ1]N
MG@DED9XX8K>(@O)+(P54!/'+$<].] &I17,W'BF]LX;6&YT&=-5O+@P6UFMQ
M&PDPF]GWYP% !SD9R,8.1563QXL%G)YVCW0U&'4(]/EL4=&822*&0JV=I4@C
MGCKSC% '845PTOQ"N+6+47NO#=Y$-*E5-283QE858*P9#G]Y\K!B !@5=U3Q
MI/8ZAJ]M:Z#=7JZ2B2W4J2H@",F_Y0QRS8SQ[=1D9 .LHKE-;\:?V1IJ:LFF
M-<:3]G6Y:Y^TQH2A&3L0G+$#G''MFFZMXUEL+_4[:TT.YOETVW2ZN94E1%$;
M*S<;CDMA3@=\=1QD ZVBN9D\;:? -3>:.2.*RTZ/4D<D?OX75CE1Z@KMQZD>
MM=!:327%E!/+"T$DD:NT3')0D9*D^W2@":BBB@ HHHH **** "BBB@ HHHH
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M2*S"6<UY<WMP+:W@B95+N59CDL0  J,?PJW>:E;:=I_VV_?[-"-@<MSM+$*
M<9[D#B@#G;SP6][/XB@EU!?[+UQ=TL(@_>Q2B-(PRR;L8P@."O7O5G3O#NI?
MVW:ZKKFK0WT]E \%JMO:&!1OV[W;+MEB% XP!SQS6G_;$/\ PDAT7RW\X6@N
M_,XV[2Y3'KG(K1Z4 <AXE\%RZ]J[WT=[:QB6R-DZ75D+@QKN)WQ$L CG=@D@
MYPOI5W2/"_\ 9>HP7?VSS?*TF#3-OEXSY98[\Y[[NGMUKHJHZ1JUKK>F1ZA9
MES!(SJN]<'*L5/'U4T <)K_@>4^&_"/A^WDGFDM)5LY[J*/:#:F,B</UVAE
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M"@>;[],8KKZ* .5N?!OVC2M9L?MVW^TM22_W^5GR]K1'9C//^JZ\=>G%0_\
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M41V*ACN "LH(YX%=O\-[2PLO"[QV+VQ+7<TDZ6\;(L,C-N\O#A6^52J_, <
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M7IU% 'F_@<WVJ:['#J(D+>%[9M.9V&!-<,V/,]_W21G/_34U<\7#3?\ A,K
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MVJ2&-Q,%WGS_ #6Q_JRN=N3CE<59?44BTY="87']IQ^+!*\(B<E8FOMZN3C
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MN]LDN]'6UM=2L9+ZP<7(=V5 A*R*%PA(=2,%OSJ+1O&VH7S:!<7^B1V=AKJ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJCJ&LZ=I3(+ZZ2 O')*-V>
M$1=SL<= !CD^H'4B@"]15.UU:PO;J2UM[N)[F*-))(-V)(U<94LIY7(]13]/
MU&RU6S6[T^[ANK9B0LL+AU)!P>1Z$$4 6:*** "BBJ]_?V>EV4E[?W4-K:Q
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M **** "BBFJZ/NV,K;3M.#G!]* '4444 %%%% !1110 4444 %%%% !1110
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MAUH7#76D3RZC$D@8M((007 Z'<&_$&O2]-T#1M'21-,TFQLEEXD%M;I&'^N
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MU>0ZD4NX_$BV<.6 81FZC'E@?]<R?PIFIWMS=WUU'/*SI;>,+**$'^!/+A;
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M=>..:?3418XU1%"HH 50,  =J=0 4444 %%%% !1110 4444 %%%% !1110
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M$T<,>Y5WR,%&20 ,GN20![FHY+ZSA:=9;J!#!&)9@T@'EH<X9O0?*>3Z'TH
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M0M+MH&VRBWF60QGT;!X/!ZTV;6M*M[_[!-J=G'>;"_V=YU$FT#).TG., G-
M%ZBL+2O&6@:QI<^HVVJ6JVT#LLS23HOE8=D!;G@,5)!/48-&H^,= TS2(=5E
MU.UDLIIT@CEAF1E9F8+P<X(&<GT )[4 ;M%9UQX@T:TAMIKC5["&*ZYMWDN4
M59?]TD_-^%.U'6M.TH(+R_M8)90?)CFF5#*1V4$\_A0!?HK,\.ZJVN>&M,U9
MHA"U[:QW!C#9"%U#8SWZU)9:WI.HSS06.IV5U-#_ *V."=79/]X \?C0!?HJ
MA:ZWI-]=?9;35+*XN/+$OE17".^P\AL YP<CGWJKK'BG1M!O["SU*^AMI;UF
M6,R2*H4*I;<Q)&!QC/J0* -FBN>L/%MA/JVI:=>W-I9S6]]]CMTDN%#7'[J-
M\J#@DYDQ@9Z5J7>L:787<-I>:E9V]S/_ *J&:=4>3M\H)R?PH NT5E^(]:3P
M[H%UJKP/.MN%/E(P!8E@H&3[FJ%QXGN=+TF:^UC1IK1Q*D-O;Q3)-)<R.<*J
MXP,DD=?KVH Z.BN;L_%%T-:M-+UG19=,FO5<VDGGI-'(RC<R$K]UL9.,8(!P
M>*HZ9X]-Z^G2W.BW-K8:E=/:6MWYR.#("X 90=RYV-@X- '945SMYXOM;/QE
M:>'7MY6>X0;KD$>7'(P=DC/^TPB<CZ#UKHJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \NF\!Q^(/BMXCO=6MK^.Q:VMA;3PSO"LC!,,,J1G&
M/PKEM&\,ZQH^@^"+O4?#M[?66EW5\;S3EA$DH,C'RY/+/WL=?:O>J:[I%&TD
MC*B*"69C@ #N30!X;_PC6N6F@IK$&@7<=NGBU-8BTF)!YT=L 1P@. QX^4=*
MLR:)>:O!XOO-6T'7;.*_U*UNK1;>!))TVH=KE,D,!QN7G&<=J]K!! (.0>]%
M 'A=YI7B^[LO"FK:CIMTBV,]V)DL=/B:<!\".9K8Y7<<'(QQUZUZ3\.])31O
M"BV\::C&DEQ+,(]0A2*1=S9/R)PJYR0/?H*ZNB@#P+1O!&M:/IF@:Z^GZC=3
M6FM2/<Z3,6=%B9R!-''T#KP01USFI?$^D^(ETOQWX=M_#6I73ZMJBW]O=PH#
M#Y6^-NN<EODQM SS[5[L'4N4##< "5SR ?\ ]5.H \7\7^%/$&IZA\06L;&=
MDNY-,DA 4?Z4D2_O%7/#$>A],4V/PQ;ZCHWB*YO+'Q8QO5M5D7^S8;>0M&Q*
MLD2X#[<#=QR#QGM[510!Q_PZ&L/X:E_MVR6"?[5(L+-:K;R3P\;9)(UX5CSD
M>PKJ+Y&DT^Y1 2S1, !W.#5BHY)XHGC225$>5ML:LP!<X)P/4X!/X4 ><Z+X
M3$"?#LRZ*B&RL'^U[H!^ZE,*??X^]OR>>]4&T'5K*+2+A8+^WL['5M38I:6R
M2R1+)*WE2+&RG*XR. 2 ^1WKU43Q&=H!*AF50YCW#<%)(!QZ<'\JDH \U6UO
M=(T[3$TZVU1K.XNKJ>XN9=-22Y@9R" D07"*[;CG;QQD#-1>&O#EX%\%+J.E
MR8L6U%I5GB7]R6D/ED@?*"1TQQZ5Z?10!YA_8\UAI 8VNJ6MU::Q?SV#V=D+
MA8U>1\!H^Z,K<8Q]1763VVHZK\.9;6\L8H=3N=+9'M8\;$E,>-H[ !O?CUKH
MZ;)+'#&9)75$'5F. /QH \_LM..J7?@F6319XX;".83I=6VSRI!"H#$'_:!P
M>^.*R[C0-5MK>TFBMKV&TLO$-[<&*UMTDD2)S((Y$C8$, 6[ D!LCI7JH((!
M!!!Z$4M '.>#=/CL-,NWC;4#]JNWN&-_ L+[F"@D(H&U3C/(!R2>]<#X-E87
MGAVZU.*>*R%U<C395LU"2R3%R-THD+,",D$QIG@GI7L-8UGX3T'3[U+RTTJV
MBG0EHV5>(R>I0=%)R>@'6@#A=,MM56R\+:&^B:@DNE:NTMU<-%B$(/. 96S\
MP.\'(Z=\<9DBTN_L%T>^N])NKFTL];U*:>WCA\QP)9)?*E"=6 W=N<-FO3Z*
M /(CH.J-I$MQ;Z5>Z?;IXG;4#:Q01M+Y!A #K&<JQ#D-MYZ'N*U(=$E9+&[M
M$U:<S>(H;RX-[:K 0%B*EPBJNU>!DD DY->DT4 >:V?AZ[EU#11>::[P1>)-
M3NI!+'E51O/,;G/8DH0?4BJM_P"']5BCEE@M;N*UMO$\MX8[:!'<PM#@2)&P
M(;#MG&#W(Y%>J44 >:-HT$6D&]0^)!<MJIOHKC^SD+QS>5L+& */D89!^4')
M)R.M=/#-K3_#QIIM*MSK)L7/V J!&\FTX0KG !XRN>^,]ZZ2B@#R-]-UC45\
M23BTU&7[3X9EM4,]@MMOF^;$:H!GC=QG/7@D5N7OANZ34K2/2;(6F[PW=V7F
MQIL5)28O+4D=#G<1^-=W%<V\Y(BGCD(+*0K X*G##\#P:EH:L%SS/0[-YM?\
M'O!X9N]/&F6<MO=336PC",8@ @/5AN!^;ISP<DUH>+YH;;X@^%KB?3)K](K6
M^;9!")7C.8!O"]3C..,GFN\JO)8VTM]!>O"K7,"/'%(>JJ^W<!]=J_E0!YGI
M^D:AIAT/5;K1;I].BU#4+C^SXHO,DM%G;,+>6.X&[(&2OF?6K-EHNHF:RO$T
MV>VMI_%!OX[9DPT$!MW0LRC[NY\MCMO&>:]+HH \OM-,O]+;0M0O=(N[FTM-
M0U0S010^9)&99F,4H3J1MR,CH'S4NNZ)J6L/JITG3)K!;OPXUO!&Z+'B0RLW
MEG!PK$'\-W->ETU75BP5@2IPV#T/H: /-+?1+74H+^:]A\22J=+:QD@?3XK<
MK&64[4"HN]EQQC(QGKG!Z?P9-JDMG>C48Y/*2XVVMQ/:BVFN(]B_-)&.A!RN
M<#(4<"NFHH \UE\*WLW@3Q;;VMAY6IW^HWDJDJ%>>,SE@,GLR# SQS5/4-%F
MU+0/$5S:QZ[<7\VE?9%BN[".V# -E5551=S#GGD8/!KU:B@#RWQO!KFHSZS8
M0Z==!&>W:T%I8JZW(78S/),>C*00 ,'"C&<ULRV<]OXL\4J=,N&&I649M;B.
M'=&2L3JREA]ULXX/7(KMVD1&16=5+G"@G&XXS@?@#3J //O#OAV0ZSH\NHZ7
MN2#PQ;VI:>($)+GYTYZ''45RL%IK5O'H.FPV,S7D7AO[/=1&T6X:%'?;RKRQ
M[3\AQRV<$%>*]KK+U/PYH^LSI/J%A%-,B>6)#D-MSG:2,$C/8\4 4-*CLM2^
M'EO!I)>:TDT_R;<S+AFPFT;@>^1S[URMM;W*Z#X+NI-"OVM]'81W]D;7]X)!
M;[!*L?\ &%8]1D\Y&<5Z1;V\%I;1VUM#'#!$H2..-0JHHZ  =!4M '*^#;.>
M*ZU_4&LI;"TU"^$UM:RIL8 1(C.5_A+,I.#SW/6N9U/2[S^PO'^D1:/=&ZO9
M)KBUD2#*3(T<0"JPZMD-\O7BO4*:\B1*&D=4!(4%CCDG 'YT <#XA\,W<NJZ
ME!H=FMJD_AJ:SBDB41H)=XV)D< X)QZ FG>#]-#:S:7LHUN.XM+!K;R[NQBM
MXHU)0[,HB[\%>,$@<^O/?44 <I=Z=<_\+!;48K$2HNC/&CLN%:7S00I;L<?I
M7*Z/::U>ZYI]Y<V%[&R:/=07"-8+;10RMY1$4>.6 *G!)(XX/6O5:* ///"_
MAZ9-6\-SZCIA_P!#\,06Y:://E3 KN7GHV,_K6YXQFU&'^S#9VLCP&X;[1<0
MV@N9K==C8*)SR3@$X. >E=/10!Y;H7AV]=/#$=_I<YAM];U"YD2YA4>6C"9H
MV95^4?,RD8XR1BGSZ+>V8-PVDSSV%KXIDO7M(HMQ>%HB!(B?Q 2,&P/0GM7I
M]-,B"18RZAV!(7/) ZG'XC\Z .1\$VDD6J>)KS^R9M-MKV^CFMXI8PA9?)C!
M; Z98,3WR>><UF-X7O+CP]X[2VLQ!JFHW5R+:9E"M(IB4+ANP/S#TY->ATUI
M$5U1G4,^=JD\G'I0!YG:6-T+>]U*RLM6NM3M]'DM8;+4=/B@@;)4B([57S,%
M>,$C&>1FH(-*GU*_UV;4K/6I]/N])AMV<6*V\K.LCDA(P 3M# _,">OWAC/J
M9D02+&742,"P7/) ZG'XC\Z=0!YBT>N75OIM]J.FW-_8Z=K!E*_8Q%<7,/D%
M5F>'NR2-T !(4$**CNM!NM6;4+M=&FBT[4-=T^9;.:':S1QE!+*\?\(;!R#R
M0N2.:]2HH \]U*RU33;_ ,5W&FZ2)([B2P:,?9Q(I XED1. [J "!ZJ*PKG1
M=4O-&\3%M+O[Y+S4].FCBN+9(7N41XO,.P8 &%.=V.!S7K]% 'E>KZ9>ZS#X
MKOM-T6\M+>YTZVM8[>2#RI+B5)&8L$ZX"LJY[XXX%+K>@W4NO>)K?4/[:-IJ
M[1F)M/LHIUDC$2KM+LA,;*P8C)4<@CG->IT4 <UXXL;J[\'30V<,MU/#-;3B
M-<%Y!%/'(P'JVU#]37.7-LVO:EXGN[[1]9@TVZL+**(K!B=RDLI+*AR<J64[
M2,X'0Y /HL4T<Z;XI$D7)7<C C(."/J""/PI] 'FPO?$ITZS>YL)O*^WRJ;]
M-+#77DB,;)#!SM9FRI..@!P,\8-M;ZUID?AFV@L)_P"THIM5G%O+:I*RQM-P
MS1^9&H&''*MQD  @U[/6=JFA:7K1A;4+*.=X<^4YR&3/7##! .!D=\4 >:6U
M@R6_AF\TN353IVFPW=E.T%C')/!<[U#$PE6 &5=<J#C@9P37=>'-*^P>#18V
M4EY&SB=HFO(UCD1G=FY50 H!;@ <#%;5C8VFFV<=G96\5O;1C"11*%4<Y/'U
MYJQ0!Y?H^FW,]KX-TN+P_=V%[HTR/?7,L 2-0L3)(%D_Y:>8Q'3.<Y.,5U?@
M?3I=-T:[CGM3;R/J5Y( 4VDHUQ(4/T*D$>QKI:* /,-2TN\_L/Q_I,6CW1NK
MV2:XM9$@RDR-%$H57'5LAOEZ\5?U_P ,W<FJZC!HEFMJD_AJ:SBDB41H)=XV
M)D< X)QZ FO0** .!\'Z:#K-I>2C6X[BTT]K;R[NQBMXHU)3Y-R(N_!7C!(Z
M\\\KXZMX[JX=K71M:&O0P$:=J6G)@;CR$9P<;-W59!C!.*[VB@#RC4]$U1]7
MUI=:_M5HM5L[>,MIMC'<(^(MLD>61C'A]S#H/FSG-=+HWAV-?%^NW-[8F6-[
M2S@AN+E S.JHP<9]<XSCOBNP:1%=49U#OG:I/+8ZXH:1$*!W52YVJ"<;CC.!
MZ\ _E0!Y9IOA[6GLM4L[ZSG,>AZ5<Z9I;,,_:?,+8=?^V:PI]2U7K>UGT?6(
MKK4] O-2M[C0[6TB$-L)C$Z;_,B8'[N[<IR<#CD\5Z.2 ,DX%,BECGB26*19
M(W4,CH<A@>A![B@#RS4?#]U+JWB*SU$:W';ZI<I+";"RBF5XQ&@4>85)C9"I
M') & 1UK;,-Y8^/"^E6E\T5Y>!]12ZM!Y"@1;?.BF['"H-N3GG@=:[=+B"2:
M2%)HVECQO16!9<],CM3W19$9'4,K#!!&010!GZ+K$6O:-'J=I#*D4I?RUF !
M8*Q4-P3\K8R#Z$&O.]'M]9O?$.A7>H:7>Q_9[:Z2[MX[%+>&W+)Q%&PY<$C@
MY(Z<@FO4HHHX(DBB18XT4*B(,!0.  .PI] '$^!([ZSFGTY;>[_L6UMHH[2:
M_M!;SJ06!B/3>JC;AL#J>3UJ)X;NT\>,VEV=\\5[=JVHQW5H#;A1%M\Z.;L<
M*HVY.>>!UKNZ* /,[)=4TKPC<:?;Z'.MW;:M(9Y&L?-'DO<R.)8EZ2%5(( S
MC/3C%4UT;4Y/#'B&1].OIV;7K6^B2:V5)9HD-NSLL:X&2$?C )Q@C.17K%%
M'F6LV%U-XFN]0DAUB+3-1TR&"$6FG).R %]\3HR,T>=P/0 ]^E..DMI&I3Q7
M.AZAJ]K=:':V-FSPK*RF,.'CE/1"VY"2<+P>>*]+HH X_3=)U)O@];:/&KVV
MJ'0Q;*K_ "M'+Y.T ^A!K*TRTDU#6/##66@7>EKI%M*EVT]OY0 :+8(5/\?S
M8;(R/ESG)KT6B@#S7P]X;N-.TOX=;-+-O/9E_MI6+:T>ZVD#;_J^W.>^*W?&
M%O(NK^&]3&G3WL%E>2&X6WA\UU5X)%!V]2-Q'TKK:* /,]7\-7%QHOCZ5-*+
MWUY>*]H_E9DD58H=I4]<!@V/?-0Z_H=W+XB\317XUDV.KK$L1T^QBN \8B"%
M"S(3&P8,1D@?-D'.:]2HH Y;QUIMS?> +[3[2.>XG9(D4+S(V'7)X[X!-4_$
M/AF>TTBSGTK[?J$UAJ4%^8+F\>9Y53(94,C'!VL2!D D5VM% '%2S77BOQ-H
M4L.E:A9V.ES27<\]]#Y)9S&T:QHIY/WR2<8XZ\US^@^%;[1[?PUK!M;Z:>*^
MFCN[*>1Y%A261P)HT8D(5RI)4#*LU>JT4 >57?AKQ7J>BZMK44UM!>7%]_:=
MO936+&X4P$"!/,\P 92-1C8?OMZUZA:S&YM(9VB>(R1JYCD&&3(S@CU%2T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7(^)?%EWX?U.\MVAA>-M+>
MYL,@@R7".$,9.>03)%C&#R:ZZLG6?#FFZ]<:=/?QLTFGW"W,!5L?,,$ ^HR
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M=V(X?,AU/[&HP<%//6/)YZX/YUGMJTFD-K3PINFN-86!"8VD"DPQDDJOS-@
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MNS836:W"LN>(Y>05((/)'2NDKG+KPU=-8PV=OK%^RO=Q37,\]RQE\M#NV)C
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M2*@;,P^7!P9.!M_BZX[UZQ5&'2;:#6KO54W_ &FZABAD!/R[8RY7 ]?G;]*
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M#:@0_N<>7&8MW*=<@MDDYS0 Q?B&#HUS=#2Q/=V^I1:<UO:72RI(\FPJ4DP
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M[54@0N489 .XC&1CKGMBL^V^)5G<ZI;Q)#;?8KF]-C%(+U#.7W% Q@QD(6&
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M9KK5-8CBTJVAO[=[=K6?^S))[JX V-YD<RD"-5.5[_=.<9H ]<,B*0&=02<
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M+VTT^X_X2*;PIIS0:6WANYAN%@M&@CEN"/W0"E1N<+OR0,C< :W$T&VTF_\
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M$@C+KO(R%SSCZ4>8GF>7O7?C.W/./7%>/W5E!)9:A:OIL[>-WUAI(+K[*YD
M\_,;K+C B$6!UQ@$8S6LL0M/'EXNE00W]W>RW#/-/8.EQ8.(B ?.(PT1*A0.
M/O#!(H ]*61&=E5U++]X \CZT.Z1H7=E51U+' %>4> M+1=1T.5[N*WU.U@=
M;VWCT::&>5BF'$\Q<AOG^;<1R0,=:Z+QC':#Q3HD^NVAN= 2"X#JT!FB2Y)3
M8TB@'^$2 $C )]Z -[Q#KZZ';V9CMC=W-[<K;6\(D"!F(+9+'H %)S6LCDP+
M)*OEL5!920=IQR,UY-#X<@O;'01<:*)-//B29K.&YM<F*R:.4A2K#*H6 (4X
M_AXZ5V_CB9;?PV =-@O87N(8Y%G@:6*%"PS(\:\LJ]<?RH Z-'61 Z,&4]"#
MD&LW3M;AU#4=4LPGE/872VQ+,/WA,229'X/C\*YKX:Q/ GB!%C1+4ZEOMQ%9
MO:Q%3#$28XV)*J6R>N"<GO7*>(K+37OO'276D7,VM74ZC2)EM'<F3[-$$,3@
M84A\$D$< 9R!P >Q-(B,H=U4L<*"<9/M0TB)]]U7IU..O2O*]9MK$:KXC3Q3
MILM]?3VT*Z6XM'FW#R0"L+!3L?S=Q."#R#TJQ;^&/[4UJ5/$FGB]N(O#%G$[
M3IO4SYF#D=B^>_49XZT >F/(D>-[JN3@;CC)H=UC1G<@*HR2>PKQW4FDO/#6
MB66I:5;/</X=C87=]IDMY+),5P88PI&QQ@$DG/(XXKT;1[?[=X!TZ#48?/:7
M38A/'<)NWL8QD,#U.?6@"+P_XIEUZUL;L:/<PVM^&>";S$<"/;N5I #E2<\
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M)MA@(:(]OFSDKUQ@YQ7K- !1110 4444 %%%% !1110 4444 %%%% !1110
M445SNJZYJ2^($T/1;.UFNQ:_;)I+N9HXT0L54#:I)8D-Z  ?A0!T5%<,GCC4
M]171(=*TB WNI+=K(ES<E4MI+=U1P6"DL,E@,#)XZ9..JU:]ET_2)KM/LBR1
MJ"3=7'DPKR 2SX. .3TYQ0!?HK@(_B).VBZI<QVEE>W5A?6MJ/L5UNAG$S(
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M)8E6]@!WS63%XXU+5?[$AT?2(&N=3M[F61;NY*);-!(B."54EAN) ('IVS@
M[FBL#QC=K8^'O/=)7'VNU3;%.T1^:>-?O+SCG.._3O6%X;@OKOXE>)[R_M[1
MOLDL<$,JS.SQ*848*H*@8(8LW^T>_6@#O**X/Q=K-[I]UXG.E@I?6GA];M)I
M+AMBC=-R(\%=PV9!QSP#Q75Z'-J%QHUM+J:6ZW3H&;R'+*01P<D#G\* -&BO
M.[;QC+I^AZ1]G@@@CO;B\0W.IWLABC:.9E"&0@G<_.T'  ! S@"NPU[5GT7P
MMJ.K^2DLEG:27'E;_E8JI;&['3CKB@#4HKG+_P 3/9ZI%9BU5@^DSZCN+XP8
MS&-G3OOZ^U4=$\6ZK>WVC1ZEI5M;6^LVC7%H8;DR.A55;;("H RK9&"<8Q0!
MV-%<+9^-I;[67T:X.DR-/9SRJVFWQN#"T>T%)/E'/S<$=U(Q5/P5XBU:ST'P
M;:ZEI]NECJ5I%;V]PER7E#K!O4NNT##!&/!)'&?8 ]&HKRO0O&G]C>&M"TQ)
M+);JX@GN&FU"X,<:HLS*!D EF)/3L 3[5WF@:TWB'PS;ZK!;B*6>-L1.^5#J
M2I&X#E<C@XY'.* -BBO/-"\6Z]%X/M[W4K>UN[Z\U!K*R"3%=\AFD7]X=@"J
MH3J 20O3-='H>N7UUK&H:+JUI!!?VD<4X:VE+QRQ2;@",@$$%&!!]O6@#H**
MY/4O$>MKK^I:7H^E6EP;"TBNGDN+DQAM^_" !3R=AP>GK5#5OB UKX?L=:M/
M[)2WN; 7J07]\8II<KN,:*%.3CC.<9.,=Z .[HKC;CQXMK;ZO+)9$-;6,%[9
M1[^;I9AA5Z<'S/D[]0>]=?"9#!&9E592HWJIR <<@&@!]%%% !1110 4444
M%%%% !1110 4444 %%%% !6%JWAMK_5HM6LM4NM-OU@-L\L"HXDBSN"LKJ1D
M')!'3)ZYK=K.O-7CL+MTN(BEK':M<O<F10J[2!MVYW9YSG&.V<T 4-/\(6&F
M3Z1);23_ /$LBN(TWL&,IF96=W..6++GC'4U=U_1(?$&E-8S32P8ECFCEBP2
MCQN'4X8$'E1P1@TZTUW2[W28-4BOH!9S*K+([A0-P! .>AP1QUK0!!4$$$'D
M$4 <L/ \,D5]]KU2\NI[ZZMKJ:9PBG= RLH 50 OR 8]/?FKUWX7M;N37G>>
M93K5JMK-C'R*J.N5XZX<]<]*>GB.VF\2VVCVWESK-:37)GCE#!3&\:E<#O\
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M[G/46]W;7:,]M<13*IVL8G# 'T..]8]UXMTR&'7!;S)/=:1$TDT ?:6(C\S
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M6I?ZA]DTM[VWA-V %*)'(B[P2!D,Q"]#GK69!XF^V>,+G0K6"!X[-$-S.UR
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M;BRU1+K5+N:]U&2"62\"1HR-"P:(JJKMX(YR#G\L=*]_9QV@NWNX%MCC$S2
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MZ#)]!5C[;:>>L'VJ'SG)"Q^8-S$=<#VH R]0\,6>I7NIW-Q)-C4=-&FS(I
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MMQYYSGWK.\(^';6\.EVMZ+J*>"PEM;NU.C/;A@\>V1))B-K\\@Y.XC->LT4
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MNBD"0B>8O&IX!8H<8S_$/6J=IX8MM=M=86SN+B.>;3E@1/[&>PCCE1M\3'<
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M@::%/NA]R$9'/S* 1DX-6I_"=A<6NO6[RW.W6XQ'<G>"R@1"+Y21UVC/.>:
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MS8'+9QC.<GUJO+H$3^)H]=BO+N"X$ MY8HRGESHI9E#@J3P78Y4CKSF@#A_
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MM.HV[6 P4/.,'.[H,8J_7$>*=-O;K7]0F@M9I8W\-7=NK(A(,K,I5![G!XH
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M3^%<_P"!-&73-+O)9K 6][/J-[([M'M=U:X<J2>N"H7'MBL^UB&G>+M<34]
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M44 1SV\-U%Y5Q$DL>0VQU##(((.#Z$ _A4E%% !1110 4444 %%%% !1110
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M)GV1L) =H7=D$G&,'VS=NO%%Q:QZ? =&G?5+]I/)LTGC/RH,LYDSM"X*^^6
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MQ7&/1J\^?6M1U2YN+BWGN1:>-3]EL1DC[.L4BQ,P_N[HFD?_ (#0!ZW)K-G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6?J&CVVIW>G7%RTA^P3_:(HP0$9]I4%ACG&XD>]:%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(X/4XV]:Z;QAIM]J.EVAT^%)[BTO[>\$+.$\P1R!BH8\ XSC- &7+X]L]/\
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M!=PS?V@4A6V21&""$<%P <EA[@]!0!TTOCCP]#J+V+WS>='<"UE(MY"D4I(
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M:AXNT72V1;FXFW-"+AA%:RR&*(]'DVJ=B\'EL=#Z&M*ZFN)--:;2Q;S3N@:
MRR$1MGH25!.,<\=:X"X\)ZTNJ2WM];SZL]]86\-T;/5)+(":-2KY52H9&W9'
M<<\<UV-U#?Z7X2^SZ#90->V]LD5K;2S'RU( 4 N>2 /7DX[9H I>&]<U.]UO
M6=&U:&T^TZ;Y+>?9[A&ZRJ2!ALD,-O/)ZBCQ%K^IZ/JND06^GPO97=Y%;2W,
MLO(+EN$0=QMR2<#D8SSBCX;M=;T;1;]3H8;4G!N'GGOD+7MP>NXJ/D'  [
M =*?XPMM=U";1UT_2$N$M+R&]D<W2IRF[* $>XYH Z;^T;/^U?[,\]?MOD?:
M/)YSY>[;N^F>*M5CVFK7%SXADTXV&R.&SCFGGWY\N5R<1=,'@$D@^G'(K8H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BDR#T-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&1G&>: "F
MI&D:[415&2<*,<DY)_.G44 -6-%=G5%#/C<P')QTS3)[>"Y0)/#'*@.=LBAA
MG\:D+ ,%)&3T'K2T ( %    '  I:** "BBB@ HHHH **** &R1I*FR1%=>#
MAAD<<BG444 %%%% #4C2/.Q%7)+' QDGJ:=110 4444 %%%% !1110 4444
M%%%% !103@9-("& (((/((H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHR,XSS0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7-^)/"\_B"X\Q=5>U1;22WC18\[&=EW2 Y'S; R#T#D@U
MTE% ' >')YE^+WBJP$T@L[>RLQ#;[SY<?R?PKT'X5@:9XQGTN/4K+1=,A;4]
M0\575C"+FXD:+*A2TK$DD#&/E7 ]*Z[4OA[:7_B:ZU^#6];TZ[NEC29;&Y6-
M'"# !&TG]:CN?ACHUQ9W$*W>H03RZK)J\=U#*JRP3OC.P[<;>.A!H R?$'Q
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MV*[" H39M*\%=N#G/7FK7_".)+_9CWFHWMY/I]T;N.:8QAG<HZ88*H&W#G@
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M;FW1UBF5P3P'&005((R>Q[U+-X5%[I<MEJ6L:C?,TL<T=Q(8DD@=#N5D\M%
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MC^U DY2$N [CW4'=] :S;_PRU_\ $C2];:#;;6%FX\S>,2RDD("O^PK2G/\
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MF+;26$UQJ4XC@-Q=B*(+M9C(6 ;Y<+C@=6%4_$<36OC73-7O-,N=0TR.RF@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<66Q7E#2E0A7:Q5@=PQ@]B.M:'B/1+G5?[.NK"YCM]0TZY^TP-,A>-LHR,K
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M"0,)Y!&28E<EMH"G&2!SM'3FNAT'1WT==2#S+)]KOYKL8&-H<@[?PH Y*_\
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MJ73\W@4L6"[\XW G ?T XJY%X.FCT'3].-W&6M=8.I%]APR_:'FV_7#8S[4
M-T+Q=J-^_B%KW0;R.+3+B5(S#Y;LX1$81[5D):0[B1@;>@SFNLAE\Z".78Z;
MU#;)!AER,X([&N4?3=<\/CQ)=::UO=K?R-<VD/E'S%N75$ 8YP8P5R>,X)]*
MZJW$RVT0N&5I@@$C(, MCD@>F: )**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>foraresidentagreement004.jpg
<TEXT>
begin 644 foraresidentagreement004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)#)MB905WDX^;).<<5QL'A+7O"5F^O&\M]6O=.TZYE6!U8>==R2&227.>IC
M0?3TH ]/HKS.;XMQ>4]]:V23Z?;:&FIW3!SN25V"I#Z YSDU)%X]\0Z;?Q6?
MB#2]/C>]TR:_LFLYG8 QIO,<FX=<=QQ_0 ](HK@K'QY>WLO@:+[' C>)+>>6
M4Y)\DQQ!QM'<9/>M?PYX.AT"\6Z^U-<2I:_9U)3;RTC2RN>>KNV<=@ !WR =
M-17'ZYXEUNUUS4M.TJPL95L=.COWEN9F7=EI1L  /)\O@]!SG-067C:_6:RN
M-6T^WM]/U'39M1MO(E+RQK&J,5?( )*N#QT((YZT =O17!^'_'MUJVH64,MO
M9-'?V[S1BW>3-L54,%E8KCD9&X=",8/6DT_Q[<3:C>6<CZ3>&/39K^*33IV=
M 8RH*,2.<[AAAZ'B@#O:*XO2/%FLSWFDKJ6FVD<.KV,EU:K;3,\B%%5MKY '
M(;MT(QSUJ[X-\27/B.UFGNFL(Y%"%[2%G\ZU8YS'*K $$<<X&>>/4 Z>BN/N
M/&5Q ;^R-G%_:L.JQ:?!#N.V1)=K)(?;RRY/O&U5;OQKJL-CJ&NPZ?:-H6GW
M;VTH:5A<2*DGER2*,;1ALX4]0O49H [JBN0U#QA/9:1XMO5M(V;0YO+C4L<2
MCR8Y,GTYD(_"NOH **XGQ)XUGT#5O*\W2)8$F@C>U%PQNBLC*N[ &%QN) /4
M#J,U=M/$UU<^-+K1I196L<+E4AG=UN+A-@;S8^-K+DXP,XP22.E '4T5S>MZ
MWJUOXCL-$TBTLY9;JTFN#+=2,JQB-HQT4$G._&.*R-'\:ZQ??V#>7NEVEOI^
MK7#6:B.=GECE5'.X_*!M)B<8ZXP?8 '=T5PL7C757L;37FT^T&@75ZMJ@$K?
M:%1Y?*24C&WEB#MZ@'J3Q2MXVU*WL?$&L7.GVJZ3I,UQ;J%E;SIY$?:N!C"J
M<@'/.<GIU .YHKDO#/BRYU?69=-NDM)2+87"W%EYGECYMIC;>!\PR"#W&>!B
MI)?$UTOC<Z&PLK6$;/+^U.ZR789<L83C:=O3;R>#T% '4T5P4/C;6OLD6K3Z
M;9+I!U0Z<Y69C-_Q\& 2 8QC=C*]>I]JCN/B-*NJW2V\%K):6NH?87@S(;F3
M#A'D7"[0 2?E/4*3D=* /0:*YG2]<UC6=3NI+2TLETBVO9+-FEE83.8SM=P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZTS[.ULEG,8MJ1E=N-RH'.!P"6/XU7L_ MM;2*\^K:E=E-/DTV(3&,".!]O
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MA00"$Z CI5"QAU&XTGPOJ#>(-9%QJ>J2V=R1=MM,/[X[57HI'EK\P&[D\],
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M9_WUC-6Z* *.DZ5;:-8"TM=Y4N\KR2'+R2.Q9G8]R22:O444 %%%% !1110
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M) !$,9RV>@QDY/%9U[X[\/6OA_4-8BU&&Z@L8]\B0N"Q)!*@ ]VQQV-<O?\
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M_M.S;\P?RS@@'@$\GOZUB6WAO4OM^FO-8YBA\3WE^^XJ0L3)-L?KZLF.XR*
M.WTW5+'6+);S3KN*ZMV)421-D9!P1[$>E58?$VB7&K'2H=4M7O@S)Y"R L67
M[RCU(P<CJ,53\,:=<Z?>>(VN(3$EUJSW$'(^=#%$-W'^TK5RK6'BC4?$6DR7
M]M?XL]8>>3'V=;2.'$JHT>/WC$JRYSW+9[4 =G'XKT"74DTZ/6+-KQW:-81*
M-Q=205QZY5N.O!JT-:TQK)+P7T!MWF^SK)O&#)OV;/KN^7'K7%1^&M13PW#
M+#;=#Q/]O8 KGROMI?S,Y_YYX]\<>U16^E7!^*,VCJ%;2+>;^WR ?NS2*8PA
M'^^))?K0!W>IZOIVBVPN-2O(;6)F"*TK8W,>P'<^PKG/$WCS3]+T33[W3M0T
M^4ZC<K!!/*^Z)1G#N=IR0O<9'/I4WB6UOHO$F@ZY;:?-J%O8K<1300%?,7S
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M.#STX-<;XDT/5=97Q1/#ILH&I:/9Q0Q2,FXR*\K.A^8C(#KGG'/!--\?Z=+
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M **** "BBB@ HHHH **** &NB2+M=59>#AAD<<TZBB@ HHHH **** "BBB@
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MC*)/FB8,N]3PX^49!ZUFQ^!@8;T7.J233WE_:WTD@A5 &@*$*JCHI\L#U^M
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M7TXV4KZI:PI]AU LKAVQ\S;%) _B4C!]:R=.U26&Y1))+J5YO%5W;1A;DHH
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M57(8'&20"0*GT&R\3Q:?!8VZ&RL8]20Q/+!!%*+-5#.K1QC8"SY48 (!R<4
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M<#)/ Y(% %BBD!! (.0>A%+0 4444 %%%% !1110 44BLKJ&1@RD9!!R#2T
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M7D8Y'N?SH YW1]/<?%?Q'<'4;S"6UF_D%UV.&$XP1MSA<9'/4\YJ+59[V_\
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MO<7D7DW,C0J6F3CY6..1P.OH/2@#B;RVGM?&?C34(=2O%D@T:&9(]RE,E;C
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M/)\@W;0[2-N20.0V>P'UMQ:[JQU]?"37DAU"/5C*\V!N.G@><#T[DK#GZUW
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M(Y.XM] 3@9('.*J'P]J$UYXCNI6MD?5M.@MT179@DBI(&R=H^7,@P<9X/ K
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHIKR)&5#NJECA<G&>,_R!/X4 .HI%970.C!E89!!R"*6@ HHHH **CAN(;A
M2T$T<JJQ4E&# $=N.]*\L<9022(A<[5#'&X^@]30 ^BD!!Z$'Z4V2:.%0TLB
M("P4%F R3T'UH ?13(IHYEW12)(H)&58$9'!%/H **** "BBB@ HHHH ***C
M>>&,N'EC78 S98#:#T)].AH DHHHH **** "BBFK(CE@CJQ4[6P<X/H?SH =
M1110 4444 %%%% !1110 4444 %%%% !136D1"H=U4L=JY.,GT%.H **** "
MBF^8AD,8==X 8KGD ]\?@:=0 4444 %%%% !1110 445 ;VT596:ZA"PG$I,
M@PA_VO3\: )Z*16#*&4@@C(([TM !1110 445')/#"T:RRQHTAVH&8 L?0>I
MH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF5D!.,  J.  .3ZT <_=>(?&-M<:]9[M#>72+1+YIO(E"RHRN1$$W_*<QO\
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MC:-V[ STS1@9S@9Z9H \.\6Z^FC:W\3=/NY[F.ZU"SMFTZ-4=O, @(=EP,
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M<QCOY+B,*H>25+262.)2< NZJ50?4BM::>*WMY)YI%CAC4N[L<!5 R23Z8H
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M.X^1ORKN** //=)\,ZK!;[AILEIJ]KI\L%K?7&L2W<23,H4%(W)PI(!.0,
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M33;+[/JMI8VUL=3BO=JJ$QO26/&)$')'!Y)QMZUU'C#2;G7/"&J:;9E/M-Q
M5BWG"ENH!/;.*VZ* .:M;#4KKQ?8ZY=V:6J+IDUM)%YPD*2-+&RC(Z_*A.:Y
M=/!.JVEGH%P;>2XEL([N">VM=1>U<K+*'5ED0C.-HRI(!SZBO3:* ,GPWIJ:
M5HD5LED;(EY)7A:Z:X(9W+$F1N6))R?<GKUKFCI'B>TL/$MEIT4<4EU?->6M
MVMP 75W0O& 02C;0X#'@'!^G=T4 >9?\(=K-Q8>)%:U:(ZD]BT$=S?M<OB*3
M+[W;/;L"1Z4GCJ6<^.;>*WU""R(TF02O-?I9AT:094.T<F[[O0 %>N[FO3JB
MFMX+@*)X8Y0IR-ZAL'\: /-+71IM4_L;Q%I>E7GV"32(K);&#5)+22 1LQ0A
ME91(I#'J>P('-;EMH%[H^M>';K3=+B6SMK"2QGMA=EC;!WB?<&89D V,/4\5
MVE% '/>+=*OM1M]-N-.2*6YTV_CO%@E?8LP564KNP<'#D@^H%<_J'AG6M:LO
M$M[-:PVMYJD=K!!:><'VI"Q;<[ 8W'<W S@ <UZ#10!#=-<):3-:1QR7 0F)
M)'*JS8X!(!P,]\&O/_\ A'/$4NIZOJ^E:=:>'KNXTYX!''<!Q<7!8%96VKM!
M4!@&()^;D<5Z-10!Y=<>#=<OK3Q.?LLD+ZCI"6=NEWJ37,AD5I"=S-D*/G'
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M1^/F/O\ *OY4 <1!;W=GXN\=7\6K7FZ"WCE6(B+8286*Y^3.%[<]N<TZWO\
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MH:=5:TT^TL#<?9+>.'[1,T\VP8WR-C+'W.!5F@ HHHH **** "BBB@ HHHH
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MBW_LV:&%Y97 5VD167'_ 'V![F@#7HK)N/$%F=&N=1TRXL]06 [2([N-4W9
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MV[FXBSY<V4!4YZ-C</IFL:XMM7\+^"_#.K6=HZ:K!%)I36[_ "L5G)$0(/\
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MEMXQ\3 Z7.W]I6,9M;F.WW)N6.0."X^ZV2.#UR*[."SMK66XD@A2-[B3S9F
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MO+/08IWF@1T,KF9U" %FPF<'N>3R>E=#=^$M,O;;58)?/QJ<L4\[K+AEDC5
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M:.0L1L&[+9/'SGO5'4?"6NV=II.G6B/.-2TJ#1]7GC;B(1E<R^_[MIU]<E:
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MC)+\W//S,>F.*;92:U+\3M3C;5(O[/33K64VI@8\,TPPIWX#97);'(P,#&:
M.SAFBN(4FAD26)QN5T8,K#U!'6GUY=X"U/6]-T+P/!<S64NFZG!]G2&.%EDA
MVPM(K%RV&R$((VC&1C..;]IXLUZ32M(\2RR6)TO4KV*W%BL#"6*.63RT;S-W
MS,"5)&T#J!TS0!Z"2 "2< =S2UYIJFMZW>^$/&&I7HTN;3;%KVUALGMF;S?*
MD(5I&W=,#&T#GKD=!H1GQ&_C[Q'!9:K;>3#I]N]O;2VS% S"<)C]Y@?,H+''
MS# XQF@#NZ*X_P />+KCQ'J.EQ6T<:1'33=ZB"I+12EMBQCG@[DFSG^Y784
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M"S7UK/<!1<?9+N2$3;1@%@I'('&1@XXS6A:Z9:V=_?7L*$3WSH\Y+$@E4"#
M[< 5<HH I2:3:2ZNFJ/&6NDMGM02>/+9E8C'3JHK.L?!NB:;I%CI=I:F*TL;
MH7<"!SD2!BP)/4\D]?:MZB@#FCX)TF*[%Y"ERSQ737L%LUW(($G)+%@N2!DD
MYX.,G YJKI?@[SM&>/6@([Z34I]11[*X<&V>1F("2 *3A6P> #D\5U]% &))
MX8MI+&.V_M'5U*.S><NH2B1MW4$YY' X[=L4D?A'2;>YTR>TCGM6TV$6\ @G
M= 8@0=CC/SC*@\_UK<HH YO0?#7]F>)_$6MRQPK+J<\?EB,DXB1 ,G(X9FW$
M@>U6]7\,6&MSA[V2\:(JJR6R73K#*%.0&0'!YZ^O0Y%;-% $<\"7-O+!*,QR
MH48 XR",&L[_ (1[3O[.TNQ\I_(TMXGM1O.5,:[5R>_'K6K10!BZEX8L=2U'
M^T#+>6MV8Q"\MG<O"9$!)"MM/."3@]1DX-5=2\#Z-JKSM<?;56YMUMKE([R1
M1.B@A=^#\Q )Y/7OFNDHH Q+OPKIU]>13W$EZ\<;1N+4W3^0S1D%"4SC@@'T
M) )S56?P)H=Q?274B77SW:WOD"Z<0B=6#>8$SC<2HS]3ZFNEHH IV.F6NG2W
MLELA5KRX-S-EB<N55<CTX4<5C^"?#7_",Z-/!)'"ES=W<UW,L))12[?*JD\X
M5 J_A7244 9,OAVQEUQ]7S<)<R0B"98YV6.90&"[T!PQ&]L'WHM_#FFVL>C1
MQ1.%T=-EGER=@\OR^?7Y3WK6HH QCX5TEO#B:"T#FP3!1?,8.C!MX96!R&#<
M@@U#%X.T=+'4;6=)[S^T8Q%=2W4[R22( 0%W$Y &3C&,$YZUOT4 <7JOP_MI
M-&U2/3IIGU.]M!:M<W]R\Q9 P.TDY([@$#C.>M1:;X.N[A]0@U5&M](N[06[
M:>FJ3WFY]V3)OD *<<87KU-=S10!3_LNU_MD:ML/VL6YMMVXX\O=NQCZCK5'
M5O"^GZO?1W[O=VM]''Y0N;.Y>&0QYSL8J?F&><'.#TK:HH Q(O"6CPZ7!IT=
MLRP0W27H)E8N\RN'#NQ)+$L 223FK.KZ);ZPL/FW%[;R0DE)+2Y>%AGJ#M(R
M.!P<UI44 8MGX4TBP.G&V@=6T^266%C*S,7D!#LY))8G<>3FI-8\.V.M36UQ
M.US!=6VX0W-K.T4B!L;ERIY!P,@^@K6HH QK3POI-D--%O;LG]G222P$R,QW
MR*RNS$G+$[V))SR:M:QH]IKEB+6\$FU9$EC>*0H\;J<JRL.00:OT4 <_!X-T
MB"*1 MQ(9+V*_DDFN'=WFCV[6))S_ O'2K=SHMN/[7N;>W26[U" 1R),Y\N3
M:K*H/H/F(.*U:* ,3PAH"^&/">FZ.&#/;P@2N.CR'YG;GU8DU!)X(T66_DN6
M2Y\N6X%U+:"Y<6\DP(.\QYVDY /H2,D9KHJ* ,6X\+:;<ZC?WK_:5?4(/(NH
MTG98Y1MV9*YQN"G&:L?V#I_VBPF,)9K"W>V@!8D"-PH8$=^$7K6E10!A:9X3
MT_22%M9]0^SHACBM7O)&AB4C&%0G& .!G..V*T],T^WTG2[33K12MM:PK#$I
M.2%4 #GOP*M44 92^'=+&EW^FO;"2TOY99;B-V)#M(2S_3D]NG:JG_"'Z>^F
M7NG7-SJ5W;7D)@D6YO9),)Z+D\'WZ^]=!10!AWWA33[[4I;\37UK<3(J3M9W
M<D/G!?N[MI&2 <9X..]37?AO2[[7M/UJXMRU]8*RP2;S@!@1R.AQDXSTR:UJ
M* .<G\$:-<7[W3B[ >[2^,"W3B+SU96$FS.,Y49[?C5N7PQI<UAJ%D\3F"_N
M?M5P/,.6DRIR#V^XO%;%% &8N@V:>()-;C:XCNY8UCE5)F$<H4$*63."0"<&
MH=4\,6&L7:S7DMX\>4+VRW3K#(4.Y=R X/./K@9S6S10!SG_  A&C?V@+O%W
M\MY]N2#[4_DI/NW%PF<9)R3]3ZU;?PQI;Z?/8M$_D3WOV^0>8<F;S1+G/IN4
M'%;%% &'_P (GIHUJ35(VO(9)95GEABNI$AEE4 !VC!P3P/K@9S3!X-TE8[R
M+%R8+NZ6\> W#F-95D$NY5SA<N,G'6M^B@#G;SP3HM]?7%Q*ER([J19;FU2Y
M=8)W&,,\8.">!GUP,YJ[/X=TZY36%DB<C5X_*O,.1N7R_+X]/E]*U:* ,2Z\
M)Z3>)?+-"Y%[;PVTV)",QQ%B@'I@L>:J^*_"JZYI^HM:F--1NK(68>4G9Y>_
M?M.,X)Y^8#(SD=*Z6B@#DO#&@ZKINKSW=Q_HEDUN(EL1J4UZ#)NSYFZ4#;QQ
M@=>IJUJ'@C1M2O+JXG%V!=R)+<0QW3I%)(@ 5R@."0%7\AW%='10!S>L>!=$
MURYO9KQ+K%]&$NHHKIXXYL#:K,H."0.A]AZ"K\GA^R?78M9!N([M(1 WES,J
M2H-Q4.H.&P68C/K6K10!CVWAG3+2UT:WAB<1Z.<V8+D[?W;1\^ORL>M5;;P1
MHMI?17$:7)CAG-Q!:-<NUO#*2276,G:#DDCL">,5T5% &/)X8TN71=1TAXG-
MGJ,DTEPOF'+-*Q9\'MR34CZ#9MXA76U:XCO!$(7\N9E251NVAT!PV-[8SZUJ
M44 <MX<\))I</B W*)'+K%[/,XMY&&R-LA0&X(."6..C.<5T=I;)9V<%K$7,
M<,:QJ78LQ &!DGDGCJ:FHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N?USQ7;Z'=O;RVL\K+;+<9C
MQ@@RK%CD]<N#]!705#-9VMPVZ:VAD;;MRZ G&0<<]L@'ZB@#G+GQ_H\'B&71
MHX=1NIH)$BN9K6S>2&W=_NAW P.OX5U.1G&>:\1\47T6C>-[B]\%ZAJ4?B.Y
MO4CO=%>U=H+O!P9,E< 8YW ]/2L?Q'=+<^.&N;33(K'4[7Q%%&S!;A[N2+>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#!K]BQNX7GW365K%=7)6-@ CAB"/KL;CDBL[XAW=O:?#[7OM$\<1GL)X(@[
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M TK6P3Y<*QSEL ,2.37K&NV#ZKX>U+3HW5'N[66!6;HI="H)_.@#+3QII_\
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M7N;)K*:VFG,) WAU=6VL.N01CT]* 'S^.M!ALM/NEGGG740_V1+>VDDDE9"
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M$)A*A4?.TEASP1ELT 2:+X^L=2\*VFMW=K=VAN"D:0?9Y&:21LX6+Y09.AY
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MSNV<YSG//2IY]3UJUTOQIXA75+J5]*GNH;.SPODH%12&88RV"V>O0?6@#TK
M)!QR**\^UZXO_#?AQ7L?$%[J,U[/:0F6:2$M$LC[6D0[0%W9P,Y4'&.]5;R\
M\3Z3IUQ;W-S<V=K=:A9VUO<W$\4T]NDK[93N QV&TMG!8^@H ]"BU"UGU"YL
M(Y@UU;(CS1X/R*^[:<].=K?E26^H6MW=WEK!,'GLW6.=,$;&90X'O\K \>M<
MAX1MS9^/_%EL=2FO_*M[%?,G96D3B8[&*@9(SWYP16%JIG@U?XB:E;>()]/G
MT[R;F.&(IM+BTC*F0$$LI*[<<#KWZ 'JU%>::KXDUJRNKO2S.\=]KEO:R:3D
M?\>\DF(YE'_7/B3G/4UU?BF]73]'MXC<:@LMS<1VT/V(QB:5ST7<_P JYP<G
MCIP<T =!68GB+19-8.D)JUDVHC(-J)U,F0,D;<YSCG'I6)X!U&^O;36;>_EG
MD:PU22UC^T2(\BH(XWVLR<,07(S],UF6S3^#]7LX(Y++4M#U?5)/(8<7%M-*
M7<G/(D3.[GA@#W H ]!HKS31_$%Y/XLT"6UN]6ETS5VN1NOY(2DRHC,&CC3Y
MDP5[@<'D9J/0[_6DL?"FM7&N7ER^I:@UI<6T@3RO+*RXP N=P,:G=GGGMP #
MTX*H)( !/4XZU7GU&SMOLWG742?:I!%!EA^\<@D*OJ< G\*X[PS]K\0:=_:U
MYXBOH+B[GN8#9Q/&J1[6=0BJ5)#*%#9SG(.>*Q?"KW.E^!O /D:A<2+>WD"2
MK(RL%0P2DHO'"Y4>_'6@#U2BO+HM8U9O#]GXI&M7+7T^K+:G3/D\G:USY1A"
M8R&"9.[.<@GI3KJ_UJ.SUG71KEX#I^NBUAM $\DPF:-&5AMRV0YYSQ@8[Y /
M1[>^M;N:YAM[B.66V<1SJK9,;$!L'T."#^-6*\WU75]7-QK5O:ZE);,/$EE9
M12HBDQQR10;@ 1@\LQYSUJ#5-9U30+?Q%IXU>[G2VO+!(9Y2AN%CG91(JL0%
MSC=M+=,^PH ]/JM+J%E!?6]C+=P1W=R&,,#2 /(%&6*KU.!UQ7.>!A?RQZI=
MW-Y?3V<MR!8K>R(TBQ!%R3MZ9<OUYP%S7$>)-1GO-:U?Q+;:7J%S)HMW"EC<
M0Q Q".W)^T@G.?FWRJ< _=6@#V.F[UW[-PWXSMSSCUKB9?$;_P!I^*9%U!5L
MX-&MKRS+, J[UFRXSZ[4_(5EZ/;SZCXW\-W]QJEZ)IO#B7#A74*[!X=RD;?N
ML3DCU]* /0M/U"UU2T%U93"6 N\8< CYD8HPY]&4C\*M5Y/H']H:5HVC:G!J
M]T8[CQ!-:-9$)Y/E/<RJ1C&=V?FW9]NE3W>L:L= U/Q.FM7,=[::J]K%IHV>
M3M2?RA"R8R69><YSEACB@#TV::&UMY9YG6*&)2[NQP% Y)--M[JWNHHI8)DD
MCEC$L;*V=R'HP]N:X99=4N;SQEJ#ZS=K%I<LL5K:)M$8_P!%1LMQEN6R!G@C
MWJGI%I-J/CC1KR;5;Y)9O#<4[B-U 8[D!&-O0DY/N: /2R >HH(!ZC->>>&]
M>U75-8TS09[MS=Z0;C^V'  ,NP^7#G_?#>9V^[7:Z.LB:7"LNI#4I!NS=!57
MS/F/9>..G'I0!>HHHH **** "BBB@!" >H![TM%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 FU0Q; R>IQ2T44 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 & "2!UZT444 %%%% !1110 4444 %! (P1D&BB
M@!  H    ["EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]4T/2=
M;2-=4TZUO!$28_/B#[">N,],UH44 5;?3+"UDB>WLK>%H8?(B,<879'D'8,=
M%R!QTXIL.E:?;_9O)L;>/[+N^S[8P/*W?>V^F>^*N44 9B^'-$75SJRZ19#4
M2=QNA OF9QC.[&<XXS5R*RM85G6*VB1;AS),%0 2,1@EO4D 5/10!DVOA?0+
M&SN;2UT73X;:Z&)XDMT"RCT88P1[&EM_#&@VNG7&GP:/8QV=S_KX5@7;+_O#
M'/XUJT4 4=-T72]'5ETW3K6S#*%;R(E3< 20#CK@LQ_$^M07?AG0;^]%[>:-
M83W0<2>=+;JS[@  <D9SA5'_  $>E:M% &/?:!'?^)]*UB:52--CF$,/E\^9
M(%!?=GLH(QC^+.>*O:AIUEJMHUIJ%I#=6[$$Q3(&4D<@X/<5:HH J:?I=AI,
M#0Z=96]I$S;V2",("V N2!WPH'X"JMKX9T*QU-]3M='L(+YR2UQ';JKDGJ<@
M9Y[^M:M% &7:>&M"L;TWMIH]C!=;R_G1VZJ^X@@G(&>=S?F?6K":5I\<%M E
ME;K%:R>; @C $3\_,H['YFY'J:N44 9L/A_1K?5GU:'2K*/49,[KI8%$ASU.
M[&<GOZT6OAW1;+'V72K*#$_VD>7 JXEP1OX'WL$C/N:TJ* ,Q/#FB1ZNVK)I
M%BNHL2QNA HD)/!.[&<X[U.VE:>\$T#65N89I?.EC,8VO)D-N([G(!SZ@5<H
MH IMI6GN[NUE;LTDZW#DQC+2J %<_P"T JX/48%9OB+PO;ZY9ND30VUP\\,\
MDC0"19C$<JLJY&]?;([5O44 <]X:\+C0+G4+MYK=[B^,9D2TM1;PJ$! VIN;
MDY.222>/2MF"QM+6T-I!;0Q6QW9B1 %.XDMQTY))/KFK%% &3-X6T"Y-H9]%
MT^0V<8BM]]NI\I!T5>. /2IIM"TFX:Q:;3+21K#'V0M"I,&,8V<?+T'3T'I6
MA10!372M/6WB@6QMQ#%-Y\<8C&U)-Q;>!V;<2<^IJ!O#FB/JXU9M(L6U$$$7
M1@7S,C@'=C.<=ZTZ* *XL+-5NE%K"%NV+7 "#]Z2H4EO7Y0!SV%5Y="TF>6R
MEETVT>2PQ]D9H5)@QC&PX^7H.GH*T** ,33O#PL-3UW4A< WFJRJQD6(+Y2I
M&$1>IW8Y.3USTJ[HVDVVAZ/:Z99AA!;IL4L<ECU+$^I))/N:O44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-!)9R"*:%$>58IU=D0!N=JJ<= <\9YH Z>VUNWO-0,=O-9RV1LUNDN8[M6+
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MEAO3K U:VD>#<D;>4L11EW LI4-T(^][57F\ W%];:JVHZM'/?7UW;WJRBT
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M$<T;318,D:L"R9Z9'49P<4 2T5!=WEM8PB:ZF2&,ND89S@;F8*H^I) _&IZ
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ME!VH'!7)+=2#PIXKCM5NM8U*V@LI]9F$NF^*(;$7<,,8,ZD(RLP*E=R[R,
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M(J+'.Z*Q8#<6PA'7&".,\G3L?".@Z;J(O[338HKA2S(025C+?>**3M0G)SM
MZUI6-A:Z;;?9K.%88=[R;%Z;G8NQ_%F)_&@#SC4H[VS\0?$*_34I'%OI$<@@
MD@B:-OW4Y52"F2%(Z=\G.:N3W_B"^U'4+6QUK^SX++1;6\18K6-BTKB7^\"
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M)D^Y)Y@VMP3P>AX!/X4 3T5435-/D$!2^MF%P2(2LRGS2.NWGG\*MT %%%%
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MMLQY#_:.8!_P"-I5_*MGQ;"L?BC0=1U"PGOM'MX[A)$BMFN/*F;9LD,:@DC
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MLQ8&0NXR'Y>,[O>K&M:7?/-XAF?3;FXL?^$AL[F>!(2QN;9((0^U?^6@##)
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M.,XKF=!@U.\\2Z'=)I;:?,EK=1W$4.D/:Q6CL@VQF0_ZSYAU'!(SQD"O6Z*
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M70K>YAGU,RKJ$]Y;%]!E>)79 K(UN%W*C98@_+R3@^O;6\U\W@1)I-&B2_\
M[.W'3  $\SR_]5CL,_+CM6[0"#T/2@#QRUT_6-1N-4DT^TE@FN/#4]NK1Z4]
MA&EP67;$-W)(R<'ZX/7&II-I9W'BO1+G1_#=YI\-OI-S;W,LE@UN Y$6V,Y
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M>&1S7JU% 'E-_P"%$CTCQG+:Z'B[_M:*2Q:.V._8! V8L#IO,ARO?=7JU%%
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M4<RN&X"R<AE*G/)ZCUJQ?>$=-U"34Y)FN!)J#P2NZ2;6B>''EO&0."" >_\
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MY=/B65L1E7()SQD'Y>#V]*J^%=*UJQUEY)1>VVE_9BK6][>K<O).6!#J1G:
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M9Q\HW,YQS]]O6@#3T379+[PA#KU]"(%E@:Z\M >(N63KWV;2?<UBV'BK7/\
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M[D$98;\*?<YIVG^([I$ATS2+.VCOK[5M0B5KB21XT6&5M\A&=Q)^7Y00,MV
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MVX4$DKQEB< X&!1IW@6STZ6TD75-5F-E:O9V@EF3$$3 #"[4'("KACD\#)-
M&/%\0+F+PK<:I<M837@E@@6SB26-[:65@NR96RWRYSD ;L' Z4J^/-22TO8F
MM(+F\6>UM[.=(I8()GG<H P<;AL()."<@CIFM@^!K">*^^WWVH7US>"%6NYI
M$66/RF+1["BJ 58DYQDGKFIYO"<=[I-Q8:CJ^IWWFO'(D\KQK) Z-N1H]B*
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MVI26=O8SFSGTYT6>UL5N))922/*9FR(TQ@Y. <GD8H ZV]UK2M-&;_4[.U&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M6N;"UO9;:2Y@65[67SH2W\#X*[A[X8C\:LT4 %%%% !1110 4444 %%%% !6
M?JFAZ9K7D_VA9QSM"28G.0R9ZX88(SQGGG%:%% %:PL+33+-+2QMH[>WCSMC
MC7 &3DGZDY.:LT44 %8UOX3T&TOUO8-*MX[A7,B,%X1SG+*O12<GD#/)K9HH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5-Y7 8L. V"1@[3CMG7\/:.VA^%M.T9IA*UI:I;F4+@-M7&<5E:?X/ELM/\
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MP(Y(U(5E W%G9069@V .N#TJ];^-[74;RQM]*L;F^-U9QWQ*M''Y<+L5!P[
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MCD4*=BH$SG/?]X,=1P:S]$\8V4FF1"ZDNLQ:-#JC7-RJ S0LIW-A>-P*_,
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M9./>O0:X34? ^K7-OJVF6FKVL.E:A>&]97MBTR.65V0-NQM+#.<9Y(]Z[N@
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M%P1M&&Z\=:&BC<J716*G*DC.#[4ZB@!,#=NP,XQFFM%&R;&12N<[2./6GT4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4449 ZGK0 4444 %%%%
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MVD?*@+<8Y))X^N0#-T3QKK-^GA^\O=,LH+#6G:"'RYV:2.01NX9AM VGRV&
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M W+N W+DCD9'(K9H **** "BHK>Y@NX1-;31S1$LH>-@RY!((R/0@@^XJ6@
MHJ.>:.VMY)YG"11*7=VZ*H&235'3]<L]2%F(A.DEW:"\CCDB8$1G'4_=!^8?
M+G/M0!I4452U?5+;1-)N=2O"PMK=-\A5<G'L* +M%%1W$Z6UM+/(2(XD+M@9
MX R: )**SM/URQU/[*+9Y"UU9I>QAHF ,38P2<8SSTSFM&@ HHHH ***I-J]
MA'->1RW"P_8]AG>4%$7?]WYF 4_@3B@"[15(ZI;#6UT@EOM;6QN0-O&P,%//
MKDBKM !1144]S!;",SS1Q>8XC3>P7<YZ*,]2?2@"6BJ6K:I;:+I<^HWA86\
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MWELQ!YR << 8& ,5I6@_X1C5]/Q?ZG/:W.@7-U=I)</*6>+R2'12<*V'884
M=..*]!>RM9)FFDMH6E9#&SM&"Q0_PD^GM4GDQ;U?RTWHI56VC*@XR![<#\J
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MZ';:SHDVE.3!!*RL3" ""'#_ $Y(Y^M78+2VM5=;>WBA5V+.(T"AB>I..IH
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M;NT8)9/[I/<>U 'GCK?^&]3:+2KR_NY9_#=S=B*YN'F#W,1CV,JL2%)WD;5
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M:CI-]92Z?Y$D\,IC8B&5BHERK$8&&W#.1M-;EMK$-UKM]I44<A>RBBDFEXV
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M]9#( <#W#HA_.@#(\(7&K^(=(M=<O]1A>SU&%G.GBV7;&K?=4/G)('!SG//
MI? 9N+KX;Z=$ERT4R0R6T4^T,5$;M&C8/!X4=:NQ>$M.TQKF[T>W%O?,DA@W
MS2-#%(^<E8R2JY/7:!WJ_H.DQ:#H%AI4+%TM(%BWGJY Y8^Y.3^- 'E]A%JT
MOP\\"/\ VKYMS/J5LT,L\(;R08I?0@OW/)KI$\0:C:6FM:?J.L$75EJ45I;W
M<5D'EG$D:2*@B7@O\Q&<8P,D=:Z*S\(Z)80PPV]HRQ07(NX8S/(RQ2 $ J"Q
M"CYF^4<<]*DO/"^CWXN_M%H2UU.ES*Z2NC^:BA5=64@J0% RI% 'GM]JVN:O
MX>DBDU*XMY[#Q+:68E>V6.21&>!E+J. 09.W! &1S79>-)IM-^'FIRR&&\GA
MM?F:XA5DD88R60C;SUQTJTO@[05TJ[TT6)^RW<RW$X,\A=Y1MP^_=N#?(IR#
MG(SUS5ZXT>QN]%;2+F)IK%HA"T<DK,64>K$[B>.N<T <]/J^IV?CC[-J5S-9
MZ;-*D5AMM5>"YRG*O)]Y)-V[ . 0!U)JUKNH:E+XFTS0-.O%L/M-M/=377E+
M(VV,HH1 W&29,DD'@>]7Y/#.E2ZPNJ202O<K()5#W$AB60# <1%M@;'?;FI-
M7T#3=<$!OX7:2W8M#+%,\,D9(P=KH0PR.HSS0!Y]?:AKFKKH<3ZM]GN;3Q)+
MITD\$"[9]L4A60J<XX&"O3.?04[49M<TW5O'FJZ=J<4(TZ."Y:-[8/\ :&2U
M5B&)/RJ0,?+SD]>,5W$OA/1)=&@TDV6RS@E$T2Q2O&Z29)WAU(;=DG)SDY.>
MM3OX>TN2#4H7M=T>I1B*[!D;]ZH3R\$YR/EXXQ^= '':MXGU^\US4;/1DNH_
ML-K#)&L%HDPFED4N!(6(PG 'RX/WCGM5^TU#Q'K'BR:R%Y'IEM:V-G<S6_D+
M))YDOF;DW'@ ;#SUR!COG;OO"FCZC<I<S03).L0A\RVNI8&>,=%8QL-P&3P<
M]35ZWTNRM+Z:]@@"7$\4<,C[B=R1[M@P3CC>WYT >>6?Q!U+[;H$=X85AA#6
M^O/MQY<Q=X8R/[H,D3<>C"KFDZSJ^H:CHES)!:O>WVC7U[ )(55D!EB,*;NH
M&UU#>I&3TKIKCP9X>NK?5H)M,C:/5I%DOAO8><RG(/!XP1GC'-79M#TVXFCE
MDM5+QVLEHA#$;87V[E ![[%]QCB@#@SXQU:P\/RQS7%U)KS7-I;2VUS8JCVK
M3-M+*%(613AMO)R1@FNG\*7FMSSZC!JL5T;>(QM:W-U D,D@8'<I5#CY2!S@
M<-[58C\&Z%'97EHUF\\=YL$[7-Q),[A#E/G=BPVGD8/!Y&*O:7HUGHZ2+:?:
M3YA!=KBZEG8XZ?-(S''M0!YS=0ZB-(^*#W&JR7$$:7""!HE R;.-@01R, XP
M.#UZUK6>LZUH%Y#!J-Y'J%O+H<VH+'' (C$\/E_(I!)*D/WR<CWQ733^%=&N
M;O4;F6U8R:E 8+L">14F0J%.4#;=VT ;L9QWJX=)L3>V]X;<&>W@>VB8D_+&
MQ4LN,X.=B]?2@#CO"FM^)M1O=+GNXKJ:QOK8RW#26B11V[%0R>4P8LRGE?FR
M>AR.E7O$^KZGI6O6TDMS-8Z#Y2;KN&U69?.+D%9L\HF-N& ').2,5KZ7X5TC
M1;A9K"&>+8I6.(W4KQ1@]0D;,54?0"G:EX9TK5[Q;F^@EE90H*?:)%C<*<KO
MC#!7P>?F!H YO4/%.IVWAWQ?>)+&)M,U'[/;$H,*FR$X([\NWYUFWKZS:Z_X
M]U+2]4@M%L1#<&)[<2><RVJMM8D\+@8XP><YXQ76ZAX(\.ZK>W%W>Z?YLMQM
M,P\Z14D91A6*!@I8  !L9&.M&H>"?#VJ7]Q>WFGEY[DK]H99Y$$P4 !756 9
M0%'RD$>W)H Y;5/%]SI\NM:K;V4'G+HNGSQ Q N'FED7#,,%E7(.,]CTS4D_
MB7Q+HFE:U=7,%S<006B26US?VR0%9V?85(0\H,JW8X!&3UKH(/#+W.N:Y>:N
MEI-:7]M%91VJ*2/)0R'+Y_B/F=!P,=:N6WA72+6TNK4033P74?DRI=W4MP"G
M/RCS&; YZ#% '+>,;'Q!:>&$\[Q(\K'4;$"1;1(V&ZX12.."N2"!CL020:Z+
MQ)JMWX:\%W5^)$NKRWB55DE7:K.S!0S!>@RV2!V%+'X,T&/2[K3OLDLEM<[/
M-$MU+(YV'*8=F++M/(P1CM6FVE64FD'2YH?/LFB\EHYV,F],8PQ8DM]2<T <
M9J5SKVGWUQH5UK0NQ>Z3<7,=R+5$>!XB@(P."K!^,\@CJ:U?!*R:=\-M)ENK
MY65=-BE$KQA5B3RE(! QD*._4UH:=X3T;2_/-M;2%YXO(DDGN))G\O\ N!G8
ME5YZ @5H0:=:6^EQZ9' OV*.$6ZPM\P\L+M"G/48XYH X+3/%6J_VM);M>7-
MW:SZ//?P375@+;YXRF"@ZE"'SAN1@<\U+I&K^)9)/#IN]5@F_M_3I) JVJH+
M641*ZLO.6ZG(/4],=*Z.P\%Z#ILOFV]G)YGV=K0-+<RRE86QF,;F.%^48 Z=
ML9-7XM#TZ$Z:8[8*=,C,5I\S?NE*A2.O/R@#G- '+^&O%>H>(-0TBT&R.2"R
MDEUA-H^697,(0?W<NDK?1!ZU!XRT:2UUBY\33Z/9:[IBV ANK.Y"^; B%F9X
M=P*G(;E3@G:,&M_PYX<&BZAKM_((?M&JWS7#&($ ( %13GOU8^[&I-4\(:)K
M-VUS?VLDCR*$E5;B5$E4= Z*P5Q_O T <EXG\97-K;W&HZ'J,\L=I!!.UHFG
MAHE5P& ED/(+*<@*00",BK&NZSXC6]\6R6&IP6UOH=LES%$UJ)#,?),A5B3P
MIVGISSUXYZ'4?!/A[5;B::[L"QG14F1)Y(XY HPI9%8*2!T)&1@8Z5H2Z'IL
M_P#:?F6P;^TXQ%>?,W[U0I3'7CY21QB@#G(=4UKQ%K]W:Z?J,>F0V-I;3%3;
MB8S/,K-\V2,(  .,$G/-8KG4K5OB3=2ZE]JAM4D*VL]NC1D_8T=<@CH!QCH>
MIZUV-]X/T+49XI[FR8R1PB#,<\D>^,=$<*PWJ/1LCDU)<>%M'NKV_NY;5C+J
M$!M[H+/(J3(5V_,H;;G;QNQD#O0!SL&H:WK6H7EAINI0Z5%IEC;/Q;*_FR2(
M6YSPL8  P,'KSQ573/$/B#Q7=:3%97T6E)>:&FH2D6PE82%]N%W'&WZYX'OF
MNGU#P=H6J2I+=6;[UA%N6BN)(M\0Z(^QAO7KPV1R:T(=(L+>^CO(+9(YX[86
MJ%,@+$#D(%Z  ^U '!MXKURX\.Z#K<\LECILUB9;Z\M+03B*8$<NAR5BP&)*
M@D=R.M=[;"\:^N99+B"2PD2,VR(A#*<'<6;."#\N, 8K+F\$Z!/96]FUI*+6
MWB\E8$NI41H\YVNH8!QDGAL]:MZ=HJV.L:IJ;3>9+?&-0H7:L44:X50,^I8D
M_P"U[4 <MJ6M:]=+XIU#3]2@LH-!=HX[9[=7$Y2%96,C'D [L#;C&,\U:TO5
MM;U[Q9+'#>I9Z;;6=G=O;^0'D<RAR4+'H,+]<XZ<YU]0\':#JM_)>WED7EF"
MB<+/(B3[?N^8BL%DQ_M UIPZ=:6^H7-_%"%N;E(TF<$_,J;MHQT&-S=/6@"U
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !116;>ZPEIK6F:6L1EGOO-;AL"..-<LY]
M?F9%Q_M>U &E169JVM0Z5+I\;H9&O;Q+0!2/D+*S GV^6ET?6$U9;U?*,,UG
M=R6LT9;."N"#GT965O\ @5 &E16'J?BJPL-#UG4XB;D:1O6XB0%2'50Q4$CT
M9>>G-;2NKYVD''7!Z4 .HJ"XO;>ULY[N:55@MT9Y7'.T*,GI[4MO=17=G%=6
M[>9#*@D0@8W*1D=?:@":BJME>B[L+>ZD@EM3,H(AN,!U)[$ D9^A-6J "BJE
MGJ=G?SWD-M,))+.;R)UP1L?:K8YZ\.IR..:LJZOG:P;!P<'.#0 ZBJG]I69U
M8Z7YP^VB 7!BP?\ 5EBH.>G4'CK5?P_K4/B#1+/4XHS$+F/S!$S LHR1S^5
M&G12;UWE-PW 9QGG%9M[K,5EKFFZ6\;%KZ.9UDR $$84G/UW?I0!IT4TNH3>
M6 7&=V>,4%T5-[,H7U)XH =150:G9G5CI?G#[:(!<&+!_P!66*@YZ=0>.M6F
M=44L[!5'4DX% "T5C^(->_L2*R6*T>\NKZY%M;PJZIN;:SDECP %1C6JKGR@
M\@\L[<L"1\OXT /HI RE0P8$'H0>M&1ZB@!:*I:IJ4>EZ+?:FRF6.TMY)V5#
MRP122 ?PJ:TNEN[."Y VB:-9 I/(!&?ZT 3T4BLK9VL#@X.#T-()$8$AU(4X
M.#TH =11D9QGFLV'68Y_$=WHRQ-YEO:PW)ER-K"1I% 'T\L_G0!I44BNKC*L
M&&<9!S6:NM0OXD_L54+/]C^U^:""N-^S'US0!IT4U71_NLK?0YI5=7!*L& .
M.#F@!:*:74.$+ ,>@SR:"Z@@%@"3@#/4T .HJGJFH1Z5I=W?2#>+:"28H#@L
M$4L0/RJCJ7B*'3O"3^('@=XEMTG\H$!L-CC/XT ;5%(&5L[6!P<'!Z&J.KZK
M%I&AZCJC+YR6-O).Z(1D[%+$>QXH OT52L]1-Y.T8M+B-!#',)G V/OS\JG.
M<C'/ ZBF:QK%KHNA7VKSDO;V<+S.(\$D*,X'OVH T**J:9<W-Y81SW=D;.9L
MYA,JR;?3YAP:LLZJ5#, 6X )ZT .HI"RJ0"P!;H">M9K:Y:O;:E+:++>2:<[
M1300)\YD"JVQ=V 3AE[XYZT :=%,$B[5+'83CACR">U*SJI 9@,],GK0 ZBB
MFJZ.NY74KZ@\4 .HI RMG:0<'!P>]('4MM# G&<9[4 .HI,CU%)O3.-PSC.,
MT .HI RL2%8$@X.#TI%=6)"L"5.#@]* '453OM4LM-BCEN[A8TDFC@4X+9>1
M@J#CU)'/2G)>%]0FM3;3JL4:2"X8#RWW$C:ISG(QSQW% %JBD#*V=K X.#@]
M#2*Z/]UE;Z'- #J*J0ZG9W&HW6GQ3!KJU5&FCP1M#@E>>ASM/2K(=69E5@2O
M4 ]* '44UG5,;F"Y.!DXR:5F5<;F R<#)ZF@!:*J0:E9W.H7=C#,&N;39YZ8
M(V;AE>>AR/2K+.J8W,%R<#)QDT .HI&=4!+,% ZDG%07]VMAIUU>,I=;>%Y2
MHZD*"<?I0!8HJIIE_'J>F6M[&-HN($FV$Y*AE# '\ZL&10'PP)09(!Y% #Z*
MS= UF+7]"L-4B0Q+>6Z3B)F!9 PR :T ZEBH8%EZ@'D4 .HKDXO&ZW=AH4UE
MIDT]SK =HH#*J;$098LQX],#OFNK9E12S,%4=23@4 +161X@UT:':6KI;-=W
M%W<I;6\*.%WNV3RQX  !.?:M..0FW229?*8J&=68'8<<C/3B@"2BDW*0#N&#
MT.>M =6 *L"#T(/6@!:*,C\J:'4N4##<!DC/(H =16+I&OMK&IZC!#8NEI93
M-;_:FD7]Y(N-P"]0.>O?!IFI^*["PT75M2B+7(TMS%<1H"I#@*2N2/1UY'%
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M@*H& ![8J2@"AINCZ?H>GFTTVTBMH<EF6,8WM@ LQZEC@9)Y->1^"8=-GLO
MQT:PFCUN)P^H7!MW5OL_DN&WR$89"?+VC)'3&,5[61D8-5-+TRUT;2K73;)"
MEK;1B*)2Q8A1TY/6@#R^PNL:9X;T$VUY_:%CX@9[I/LSA8E\V4ABV-N"&4CG
MG/L:2^T.TMOA_P".]6>R"ZC)<:DHN'7]X(_-8A5)Y"GK@<$\UZY535-,M=9T
MJZTV]0O:W,9BE4,5)4]>1TH \O>U2:^U*3P+8W%HX\/W$5PPMWA+W1*^4&W
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M7UD@39+\JKM!*[E!" '!Y% $UG-]F^)5];1-F#4=,BO2.PDC<QEOQ5HQ_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC#!<,H?8<G:I. S8'R@G/)P.* ->BBB@ HHHH ***CDGABDBCDE1'E8K&K,
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M9\B(S^?Y2>=MV>9M&[;G.,^F>U 'EBWFOZ7HVIZII^H131#1)IU1M6:_DDF
M4I,JL@V@ MD#Y>5XI]O%:0>-=.&EZ]=ZI(V@7DN9;LSLK$PX<$Y*[L=.GR\
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M?-!(\<?F&.-IP"P)P!D<G;C/-=IX1CU2/1KR*]NX9W6YD%J4NS=&*/ *H\A
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M-FOUEU9I3,3&3M2W*!8F5P.%(P 0<]:]+2TMH_(V6\2_9UV0X0#RUQC"^@P
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M0=1LAI^@:9/=&#:^G6Y7(20.=YP">G QQSR<UJ:MX6DU35-9N#<K'%J.C#3
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MZTT]BSM8)9WZ;6'*L7W1_4L>#[5D:?X,UNU.B64NH6+:9H]\US#LB;S95(D
M#$G ($F.,YZ\=" :5OX^T^>ROK\Z?J4=A:,\1N7B7;+*LGE^6@#;F8M@#C'.
M,Y! ?)XYL[2VOFU#3K^RNK,0LUI,(S(XF?9&5*N4(+?+RPP1SBJLO@AKGP#/
MX<GN83(]U)<I(8]Z;C<M.@93U'(!'?FBS\*W-MIE_$FB>%8);E4C,,-JWE3(
M"=PD. 2#G@8.#ZT =-9WSW%@;JYLKBQ9=V^&X*%E [Y1F4COP:Y/0-;NY],\
M*W5Y?7 FUN>6?RQ&KJR-')*D9)Y154+@KR2O/4UL>&?#\VCZ!+IUW.L@EED9
M8HBQC@1ND:%CG:/?UZ <5B^&=#O9M%\(K<?N)O#TTL$Z2(09 D4D *^Q!5@>
MF#0!>T_Q]8ZC<6(73=3AM+V=K:"\FB58FF7=\GWBW\#8.-I(QFIX?%B:D;E;
M'3=0:U7SHDU+8GD-)&&#8^;=C*D;BN"1C-5;7P?<V^@Z!IYNHB^F:E]L=@#A
MUW2' ]_W@_*G:-X>US1X)-(2[L'T8/.T3&-_/VR%F"'G:-K/][G('09S0 _P
M?XB^WZ3H-E=M-+J5SHL%_+,P&ULA023ZECGI2KXZLI[/3);'3M0O9]1B>>&U
M@1/,6-" SMN<* "0.N22,51M/"6M:0NA3:7>V/VFRTA-+N/M,;LA"[2)$P0<
M@J>#C(/45'IW@S6-"AT.?3+VRDOK"REL9_M*-Y<L;N'##;R""HX[Y/2@!OA;
MQ+<ZA:: ]U>W0DO[_44$;0+\Z1O+M5\X*;54=!G(P:T=*\?6.JSZ<$TW4X+7
M47:*UNYXE6-Y%5F*<,6!PK8.,'!P34&C>#;W3?[!-Q?0SR:;>7MS*ZH5\WSS
M(1@=L>8,_2I++P?<VNA^%[!KJ)GT>\^TR, <2#9*N![_ +P=?2@"6U\<VUYJ
M=C:P:3J307\TD-K>8B$4ACSO/,F\ ;2>5R0. :T=0\3V&EWU[:W8E1K33VU%
MWVC:T2DAMO/)&!D?[0KS;P5%=V.K:2_V0W-W)/*L]M-:W226"N69W+NYA!S@
M'8B[L\9KN/%_A*7Q)=:7-!=);_9Y#'=!E)\ZV8JTD?U)1>OO0!9M?&.GWT6G
M/:07<[7]A)?QQQQ@ND:;<AAGALN% &>0?2LC7_&$Q\,^)8H[._TG5K'2WNXE
MN?++;2K!74HS+PRG@G(]*;:> KRT3Q((M5\EK^*2#3I(E(:SC=Y)"/\ ON4]
M.RKZ523X=WC6VNKC2K)]2TDZ>L=G&^U6^;]X['EB=WUX[]: -/\ X2AM*UGQ
M'/J,LTEE96M@T<2 $[Y=ZD#.!EFVCDX^E=3I]Y+>VGG3V%S92 D&"X*%ACOE
M&92#[&L&7PW>+>:Y=1?8+C^T;>U@$%Y&6C(CW!PX'8AN.N/0]*G\,>'[K1-!
MN;"6Z56FEDDB2 L8[16  2/=S@8SVY)X H 6U\6QRZD+&\TG4=/EDMY+F W2
MQXF1-N[&UV((W+PV#S5?1O'5EK-SIT:Z=J5K%J<)FLKBYB54FVJ&8##%@0#G
MD $ D$BL70_ %_I^IV=Y<R::)+:QFM))H$<RW3.%'FR.QR3\N<<XR>3GC8L?
M"4]M;>$(7N(F_L. Q38!_>Y@,7R^G)SS0!F7?C>34M0\.#3+34;>QO=4$:WD
MD:"&[B$<N0N&+ $A2-P7(&173:SXABTFZM+*.RN[^^N@[16MJ$W%$QN8EV50
M!N4<GJ0!7-:=X,URUB\/Z?-J%@VF:'="6#9$PEF14=%#'.%(#8XSGKQTK;US
M1=2FUZPUS1YK5;RV@EM9(KL-Y<D4A1NJ\@AD!Z<\T )JGBW^RK$7TNA:N]HE
MN+FYE6.,?9TY)W!G!) !)"AL4]_%EN?$:Z):V%_=S^7%-)+"B^5''(2 [,6'
M'R]!SZ X..=\2>!=8\0O=&YN=+NFN]/6VW7,+E;20!MSPID@;MPY)R-HY/2N
MDTG09=.U^]U%YD=+BRM;8( <@Q>9D_0[Q^5 %"P\?V%_)8,--U.&ROIS;07L
MT2K$9N1L^\6Y*D XVD\9J>/QK927D2"QOOL,MV;*/4=J>0\X8KM'S;\;@5#;
M=I/>N8\)>'=<U'P_H,.H3VT.F65Z;T1^2ZW#,DCE$;)P!N(.>I  QWK1T?P#
M_8^IIMT[P_<VT=VUS'>36F;M 7+@9Z%E)P'ST XH ETSQ_))I6K7^JZ->6L5
ME>O:I@1GS#YHC2/_ %A^?+ $G"^^*MZUK-[;P:)JIM[JP4:G':W5I.4)9)28
M@3L9E.&9&!![>],A\.:M:6^N6:#2;NROKN2ZCBO(W8-YC ND@Z8ZX(SVXK+D
M\-WUEH^C:"[>=]HUI+MUA#M#:01MYVQ6;)V@HJC..7X % 'H9X'3->9:1XDU
M*YEO]1OIM8LE;7$L(HGCMWB"F<1B,*&)![,V?XB1GBNXT6YU*[_M"74(%AA%
MVZ6:;"KF%<*&8$]2P8CI\I6L4^#[DZ<]M]JBW-KXU;.#C9YXEV?7 Q0!0?Q[
MJBZ;XMN/^$>NMVC/*(6/E;#MC1@'_>Y)^<L<<;1Q\W%:MIXBFO+WP_\ :(KS
M3WOH9W:TDBB82;54Y+!F*@9R,'G/.*C;PM?LWBJR-U;#3=<61U;:WG12/"D1
M!'0J N?7FI+/P_JCWGA^[U">S\W2X9X76W#;7#HJJ1G_ '<GZT -T7Q[8ZW/
MI:QZ;J5M;ZHA:SN;F)525E7>R<,6! !.2 #M.":+/QY:7M]8PQZ5J2VU^)7M
M;UA$(I$C^\^-^\#N,KD@YQ45AX2NM/TGPA;FXCD?0,F78#^^_P!'DBPN>G+@
M\UQO@2"]T^\T9(K=;F\DBDBN%GM+M7TX%2S%C(_EC+A0P14W$\<4 >E>'O$"
M^(K-;R'3KRVM)8UEMYKCR]LZ-G!7:[$?1@#R.*L:SK%OHEDMS.DLK22I###"
MH+RR,<*J@D#)]R ,$D@5R$.AZ]X=34]0TVWT^.\O1%!!8V4<AMA*7.Z=U)&W
MAN<8X7J3BM_Q?X;'B;28;8&W\VVN8[J);F+S(G9<_*Z]U()'MG/:@"!_'%E#
M9W+W-C?PWUO<QVK:>RHT[2R &,+M8H0P.<[L<'.,&F+X[L1;ZC)<Z?J-K+IT
MEO%<P31H'5IF"KC#%6'()(.,=,U1;P7<G2D^R6FAZ7J%O?17L"V-N1$[1@C$
MAX+9#,,@#&>]9T?A[6-:O?&5G?SP0WES]ADAFCA;R5:/YU R<L 5 )]SP.E
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MXTZ.B_<5G('F,GW<D9R/6@#T6BN-^&=FP\&:;JEQ>WUY>WUK&\TEU<O)T!P
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MB 7(Q&%+9_[Z%<'>B_\ #FJWT>E7M_<SS>&[F]"7-P\^^YC9 C@,2%)WD84
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ML21LQ)B++':@%70HQR3C/S'G%.UY;HVGCK65U34DN=)O5-BD=VZQP[8(7/R
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MC&F695*! ?,DRO0C XYYKL_#=U-?>%M(N[A]\\]E#+(Q_B9D!)_,T :=%%%
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MY]:=10!%);P2RQRR0QO)$28W902A]CVI1;PA$40QA8SN0!1A3ZCTZG\ZDHH
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M6T)FC&U)"@W*/0'J*GHH CG@AN86AGB26)OO)(H93]0:6*&*%2L4:1J><*H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU[_A'8KYQI=S'#;VD5M 89!@%C,SL'&X9QMZ4 >RTR::*W@DGGD2**-2[N[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"1_P)6H ZOI7.WGC+38M#NM4LF%XEM=K:2(K;2',PA/4= 23GH<<5T) 8$$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*<EI">& RQ^K=L<@'14444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\G)XR,G/O/K-OJ7B+P>+.S\/7^G3V9M':-Q"K2+'(K-%'DLIP%R-PVDXZ\T
M=A#XET.XTR;4HM7LGLH#MEG$Z[(SQPQSP>1^8ILOBC08-.AU"76+%+.=BL4S
M3J%<C.0#GDC!SZ8-<?\ V)%=V>J7UU:>*IY[A[7,LJ6T<ZM"S,CQJ@4$H3SN
M!SQC(%,NX=?GT73[Z[M-6&NVSW(LKJTAA+;&("B>,MM&\!2<=-O530!V6O\
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M8U*88E@21S@8R/P .DL_'NDZQI5Q>:/<V<[V]TMO)'-=I'@&;R@^1NX;JO\
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M)\Q", ;L\D $T >D*P90RD%2,@@\$4M,AY@CQ'Y0VC]WQ\O'3CTI] !1110
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MXX( &.30!ZCYB&4Q!U\P#<5SR!ZX_ TZO/=<UZ[\-ZMK$QBM+J\M-#MI!<-
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M7:VT2$9"%\;0QR,*3DY'% #+KPGI-WJ<NH,EU%<3%3/]FO)H5F*C +JC ,0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *Y+4F&G_$K3KZ;B"ZTJXME;&<2(Z2X_
M%0Y_X":ZVJUU/9Q7%I%<M$)I92MLKC)+A6)V^^T-SZ9H \G^']R]O/X3.I&6
M=9K:2'31%=0ND&Y-[$HJAP-J8&XMMX!Y.:[?P IDT.]U ?ZK4=3NKN'WC:4A
M#^*@'\:V-,M=%D5M0TNVL<3[@T]O$H\S!(.6 YY!_*K-C<6=S:@V+QM!$S0X
MC& A0E2N.V"",>U %FN$T&PUW3?#DOAB;125BCN474!<Q^7*&+E"%SNW$L,@
M@ <G)KNZ* /,4\+:QI]SIEVUGJ5RG]B6MA-%IU]'#)#+%NR#N9593OZ@G!'3
MFG:SX?\ $(TG^Q--LKX:5_8ZVUK;P7L2"&8JP83LQW.N"@&W(X/'.:],HH X
MW3?#]_!JUW<3VRA)- M;%6+J<RH9=Z]>GS+ST/X5D0>%-:31[6!K4>;'X0;2
MV'FKQ<E4 3K['GI[UZ34;7$*W"6[31B9U++&6&Y@,9('4@9'YT <'KNDW5E8
MZ;?R0(MKIGAZ]@NB2"$8QQ87 .2/D;IZ?2J'@2>2VUS2H-4,T][-I/E6DBW4
M,R10)L+*1&JD$DK\QSG;C/KZ>0""",@]0:J6>EZ?IS.UE86MLTGWS!"J%OK@
M<T <MK^G:L?%$5[H=C=P7;- DUZMS']FFA5LLLT;'<2%+[2JYY'(K)A\)7L6
MIWUE?:?JMY9W.JM>I-;Z@B6X5I1("Z%@VY3V"G.T<UZ510!RFF>&#+I?BC3]
M3MU2'5KZY?@@EXI%"AN._'?D8KG(/"OB2\\):H^K01MKMT]G JK*I!AMW3YM
MV<#<?-?'^T!UKTZH_M$/VD6WG1^>4\P1;ANVYQNQUQGC- ')Z?;ZSH?B36$C
MT<WMIJE\ETEXMQ&@B4QQHRN&.[Y=A(V@YSVK%T7PE>V5S;Z?J.GZK<Q6VI-=
MQ72:@@M3^]:1',>[>&&>5VD$YYP:]*HH X*QBU#0-6OKT65UIOAZ*&YN+R"Z
MN8Y86D)W!H I+*#\Y(.!SPN:[#2)Y+G1K*>:R-C)+ CM:DY\DE0=G0=.G3M5
MT@$8(R** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<3%\,FV(D%<8(R,CGD\5U]KX2T*TM[N!-/62.[C$4XGD>8O&,X3+DG:,G '
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "L._P!5N!XOTG1K5E59(9KRZ)7)\M-J
M*H],O(#G_8-;E<K?*;/XFZ3=R?ZF^TZ>R5O25624#\5$A_X#0!%%XENS_P (
MU>/<VL]GJ-S-9SM;Q,J[\.8V7?\ ,,&,J<]2V?2NOKSA-)NK+3O!?AZX51>)
MJDEY(%;(6*,R.6S]7C'U:O1Z "L6V\5:1=:LFF1S3K<R%Q%YMK+&DI3[P1V4
M*^,$\$UM5YQI_ASQ--XET2^U5)9'L;RXDN;EM0+1R*T4J(8H1\J@;E'0$>_)
MH ZNU\7Z)>7,T,-VQ$0D+3M!(L)"??VRE0C;<'.">AIEOXST*YL;F]%W+';6
MZ+(\D]M+$&1CA63<HW@G@;<Y./45SMAX>U\^!;CP5<65O# MA-9IJ2W.1)D$
M(PC R"<@MG'?&:FU;3/$7B7PL;"ZTN"PGM7MIHU2_.)WB<,RAD&44A>&SD$C
M@8H WD\8Z(UE<W37$T0MG2.6&6UECF5G.$'E,H<EB>,#GM3I_%FDV]K:SR->
M W1<0P"QF,[;/O\ [H)O '<D8Y'J*YU/#7F:=J,DWABZDGN3 K)<ZV\LSB-F
M9660L=A1CE<,,Y/3',%SH/B&;P]9I=6EQ=ZK!)<-:7<>I".XLU8_NU9\ 2?+
M@-USM'#=: .I\3>)8/#?A>YUQH);B.*/>D:(V7R.,X4[1[D8'>FW'B_1[:UM
M)Y7N]UWO,$"V,QG<*<,?*";P!ZD8Y'J*AU_1M3UCX>WFD230RZK/8>4\GW4>
M;;R>G +?SJA/;:^FOV'B6'1DDF-C)97%@;M0\69 ZNKXVMG'(XZCKB@#J--U
M*SU?3X;^PG6>UF&4D7/.#@C!Y!!!!!Y!%<MX%\;R>)=(O+G5((;*XM0LSA&)
M0P,NY9.?HX/NAK6\(Z1=:-HKQ7IC%U<W4]Y*D1)2-I9&?8I(&0-V,XYQ7%#X
M?ZS_ &+X?M(GBA8VO]FZTH?.^U,@D.T]SPR_24T ;OACQY_:>E:MJ6LPQZ?;
MVERBQ ;F9HY(T>/(ZER)%&T#J< 5K_\ "9:$NF76H37C6]O:2I%<?:8)(GA9
MR N]&4,H.X<D8P<]*YO6/!FHWHUQX%0&35[74+6);AH?-2**)2N]>8S\K8(Z
M$ TLOA2YNM$OA!I,]I>W-Y92.;S4VNGD2&97.69F"X7=@ \T ;#?$7PQ&DK/
M?3HT)_?1M93AXEP#O==F53!!WD!?>J]WXWM=*\7:A8:A.?L45A;W4/D6[S/\
MS2AW.P$[ %3G&!GKS3M1\.WUS>>,98XXRNJZ9%;6V6'S.J2J0?09=:H+I7B3
M1]8GO+'2K:^2?2+6R*O=",K+'YF3R#E/G&>_3 - '27OBS1K!+9WNGF%S#]H
MB%K!)<$Q<?O"(U8A.1\QXIEQXQT&VN;.W-Z99KV))[=((7E,D;' <;%/R^I[
M=ZXZ+P+J.BS:5)'%<ZBD&D0Z?,MGJ<EFZO&S'<"K*&0[R,$Y&!QS70Z'X:DT
MOQ#974-G':V,&BI9+$)C*8G\S<5#'E@!W[T ;VJZQ8Z+;QS7LK*)9!%$D<;2
M22.03M5%!9C@$\#H#5:R\4:/J$UI#;79,MWYHBC:)T;=%CS%8,!M89'RM@^U
M9?C/0+O5KC1[^SCDG;3YY&>WBO'M7D1T*G;(I!# X."0",C-9EUX6OXO#D=U
MHFF_9-;M=1_M"&*ZOVN#*Q'EN'E8G&Z,D8R1P* .CF\7:+#$)/M,LI:XEMDC
M@MY)9))(SB0*BJ68*1R0,>],G\::!!:V-PU\72_5S:K%!)(\VP@,JHJEMP)Y
M7&>O'!QS-UX'O+"+PY+:1SWO]G6<MM=16]^]I)(\A1VE5U*YRZDE20#NSVK2
MTSPQ-9ZKX=N8+ 6=O:)?-<1/=M.ZO,RL#O;EB2&)]">] $^H_$'2+.WT6Z@6
MYO+;5+EH%D@MI6,857+$J$)W!DV[.&ZG'RFM:+Q)ID^KG3(GN'N5(5RMK*8T
M8KOVM)MVJVT@X)!Y'K7*MX;UFTTVQD@M(KBXLO$5SJ7V?S@GF0R-.!ACP#B4
M'!]#5QM)U@>,XK^PL6TZ*2</J$JWH>&ZC$>WF+'$F=HW #A>IZ4 =#JVO6.B
MB/[9]I8R!F5;>TEG;"XR2(U8@#(Y-5+KQGH-I'8N]ZTGV^ W%HMO!),TZ#;D
MJJ*2?O XZXR>QQ3\46.NW6J636*SSZ:(9%EM[>^-HWG$KL=G'S% -PP#GG.#
M5#PMX6U+2)_"[7218TW1IK.<J^<2,\)&/481N: -R;QAH<.F6.H"\:6"_P B
MU$$$DLDN!DXC52W&#GCC'.*C\':^_B/3+R],D<D2ZA<0P.BX#1(Y"'GOC%<[
M8^&]=T4:%?P64-Y/82:A'+:^>$)2XFWJZL>,@*N1Z,?2NA\&Z7J&EZ7>+J<<
M,=S<ZA<712%]Z@2.6 !P,]?04 %KXY\.WM[#:6]\SO-*8(W^SR",RC.8_,*[
M=_!^7.:DB\9:!-=7T"7W-@)/M<AA<1PF,X<,Y7:",=,Y(Y'%</X:T_6M;\.:
M/8"PMXM.M]8>]-]]HR2L=R[[0F,ABPQZ8YSVK>E\(W]UX,\1Z3F&*YO]0N;J
M L<J0TN]-V.Q  /L: -JS\9:'?"Y\NYFC:VMS=2)<6LL+&$=9%5U!9?<9JJG
MQ#\,R,%COII'=!)"B6<Q:X7UB 3,@'<KG'>LR^T?7?$=[/?WFG1:<T.DW5E!
M#]I$C32S!<DD# 0;!C///08K0LM O8-;\,W3I&(M/TF:TG(89$C>1@#U'[MN
M: +\OB_0XM.L;Y;MYH;\$VJV\$DLDV!D[8T4MQWXX[XK/U'X@Z191:-/ +B\
MM]2N6@$D%O*QCVJQ;*JA.X%<;#ANIQ\IK'TOPWKN@-HNHP645[-:17MM/:"<
M(0DT_FJZ,>,C: 0<<'VIW_",ZW:Z?8WZ6L$^H)KTFKS623A559$D38KD $@.
MI)P 2#0!T?\ PDUI:RZS+?WULEI8R1)A8I!(F^-6"L"/F8EA@*.X'6EC\9Z"
M^GWMZ]X\$5B5%TMS;R0R0[ONED=0P!['&.OH:Y_4_"VL7%]JNHV\4!F.JV6H
MVT$DN%F$,2*R%L':<AL''4 U%JOAK6_$$>O:A/916=S>VUK:6]H9PYVQ2F1G
M=AQD[B !G@>] '2VWC/0;JWOIUO6CCL8Q+<>?!)$5C.=K@.H+*<'!&0>U6(O
M$NER6D5R\LUO'+<I:(+JVD@8RMC:NUU!YR,'&*R-9T&XN_$.IWK:=#?V5QI$
M=F;=YO+\UA*[,N<<?*V0?7N.M5=)GUS0+:&UN[>:Y-]J:165K<77G2VUOM!=
MGE .[;M=ADGJHW9- ';T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML=U:7$5Q;R#<DL3AU8>H(X-8/BG1;G4[G2[S3;RUAU33I7GMHKM-\4P*[&#
M'(X8?,.GXUS$'B&[U^\\-6=M=-H4=X^H0W<5J8VW20LH(C<K@Y;<=P&<$]^0
M >ET5YK::]>W.F1Z9-J.JW-Z-4N[.VDT\0)+=QPD_,SN @VC@D8)(^M1:/KV
ML:Y:>&=,N-4N+1KV34%N+J,1B:3[/*41,@% Q')*CG8<<&@#T^@G R>E><ZG
M?:[+XF70+*]U.YCM=-2X%Q9O;1RS2-(Z;G+X4A=@&% &2<]JV-;N]7A^$NHW
M5^J1ZNFCRM/Y1!"RB(Y(QQUYXH WK/7-,OTLVMKV)_ML;2VRD[6E1<990<$C
MD<^X]:-*UO3M;29].N//2)]C.$8*3R/E) ##@\C(KFY3)#K/A;1K*Y>WLYM(
MNEW0A=PV+ $920<$!C[>N:7X7P&S^&^DR2W<\RO;B7]\5Q$,?=7 ''&><GGK
M0!V=%>;:!K]_-XIT7RKO5I],U:UGE5]1^SA90H5DDC6/YD')X8#@CC-5O#VL
M:S_9G@O6)O$$]_+J\XMKFT98_+VF-R2H5<AE* DY]<XX  /4JSXM<TN=T1+Z
M'>]S):(K-M+3)G>@!ZD;3T]*\\L-9UD:3I&NMX@GN9KC7/[/>Q*Q^48C<-&5
MP%W;PHWYSVZ8JQH][<6NH6$,,FV.Y\6:E'*-H.Y0MPV.>G*@\>E 'I=07EW!
MI]C<7MU((K>WC:660C(5%&2>/0"N&T'5+F7PB?%VJ^([N(36T\TULJ1&. +N
MX1=N[<@7N3D@YSVQ+[5-3-AXJTRZDU0VDGAF:\C34V@:4-AUW#RN@((X/0CC
M% 'JQN(A:_:2X\G9YF__ &<9S^5)9W<%_907EK()+>XC66)P.&5AD'GU!KSN
M&XO].N-,L_[;FU2VU31;B:5)%CVQ%$0J\>T#"G>5P2>W)/-9^F:EK5U;>'M$
MT_\ M%((?#5G=#[!) CN[#;DF7JJ[1P.[<]J /43J%J-3733+B[:$SK&0>4!
M"D@]#@D9^H]:LUPDLFI#5_ $VJ(B:M(9X;L1D%3FV9GQCC&Z-#QQTJ_XLOI#
MJ%IIEI=:NMV\$MP8=-,"?(I4;W>;@ $@  \YY!Q0!UE%>::1JNM^)CX3@DUF
MXLEO]%EN[Q[5(PTCJT(!!*D+]XG@=R/H:;K.L:W%X7TN?5Y[5KM;\W-Y J++
M.;>3RU494@$@[C@?P^F: /0K._M=025[282K%,\#D _*Z':R_@1BK-<;\-MP
MT'4=UT+MAJ][FX  \W]\WS?+QSUXXK'T?Q#>S^+-!DMKS5KC2]7-P-]]]G$<
MRHC,K1(GSH 5Q\P&0>>: /2J*\QT34M=6Q\*ZS<ZY<W)U/4&LY[5XXQ%Y967
M!&%W;@8P<YYY[<5;T77M6O=9T_PS+>.VH:=>7!U.;:-TEO&!Y1(QQYGFQ'C^
MZU 'H=%<GK4][?\ C2RT"+4[C3;9K"6\:2VV"29U=5"@LIP &)( YR.U9KSZ
MCJNL:Q9_\)-<64.D65N\4T"Q#SV>,L9Y,J05R,8&%X/X '?45YI8:GKOBFYT
MQ'U:YTM9_#L5_*EK&@)F9B,Y93A>^/ISUR_PUJNMR3^#M0O=8FNAKUK(US;M
M&BQ1D0^8I0 9!&"#DG.>W& #TBBO*-(NO$=Y8>#[F3Q1>[]=+PW($,6$58GD
M!C&WA_W>-QS]XG'0"Y;:SK$S6.@2:O/'YFN7=@^H[4\YHHD9T7.W;O;A<XZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQTS49TB2.]A,L#7-N9[5T%Q$N,M'QENH..N".* +=_X9T/5;Y+V_TFSN;E
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M?.FV+1VL9M(/+M'#VZ! !$P!4%1VP"1QZTR72-.GCNXY;*!TO&#W*L@(E8
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M%X6T"&]N+V/1K%;FY#+-((%RX;[V>/XN_KWI+7PIX?L89XK71[*))XF@F"Q
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M%=^%?#]\T!NM&L9?L\0AB#0*0D8Z(!C[H[#H.U:]% &2_AC0I+Z"^?2;-KJ
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MQ#9QR,\9Q70^+-,U34X+$:<X:.&XWW5J;I[;[1'M8!?,0%AABK8Z'&#70T4
M<%H_@O4[&'2%F:T4VFMW&HRK'*[@1R1RJ%5F&6(,@Z^A-)K'@RZF\3:IJ,6G
M66IV^II'OCN;^:V,3*FP@A%8.I 'H>OK7?44 >;^*/!.NZP=2M+?[*]G/!%'
M9>9?S1I9A% 91$JE7R1G<3GGV .QJ7A_5+GQC;:E96]I9*D\;37T5W()+B%1
M\T4D(7:Q/(!+' P1SQ7844 9>@7][J=A)=WEJ+=7N)1;K@AFA#$(S ]"P&<>
MXK4HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[I2IRI8X^8@@$9Z&@#@M:U35_"H\5VMGJ5W>?9]-MKN"2\82/ \DDD;L#C&
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M]\/^)-8MM:U"34+6_O$L[;S (@D-P6$>W')8(5R>S8KNF\/Z*VJC5&TBP.H
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M6)QN21&#*P]01U% $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\Z% PBD\T-\_/ QGGVKJJ* /-[#PW>6WAGP]&--,=W#X@:[GP@#*AFERY/\
MN%?PQ573/#M['>_V;JO]OL4UIK]#;P6YMG_?F1)#*4WC@@,"V[@@<8%>I44
M<KXMLK]-4T'7K"SDOCI<\OG6L1 D>*2,HQ3) +*<'&>1FL_7;C4-=ATK4(O#
MVHBUTW4X[B6UG5%EG0(ZEE3=SL9E;!P3CCH*[JB@#S#4-"O]:77+Y='FBM=2
MU+3"MI.BAY$BE3S973)P"O&#SA.15[5_#4L]QX_ECTM7>_TN.&U81C,K"%P5
M7\=GY#TKT&B@#@6\/W-QJVM7%QI_F&;PY!:12.H):3]]O0'\4S^%5T\,7ZVW
MA>"SM/LDL6@75I-*JA?)E>.':&QWWAC]0:]&HH \Q\.Z'<F#3H[N'7UO=-T^
M6W2*>"V2WC+1A657C4%P2!CD] 35O2O#EY:6?@!(K$VTEE8R1W;*@!A=K8 [
ML=S)U]37H=% 'FFG:=J5Q\.9/"B:%=66JP:5+:&[D5!$92NTE9,Y/F'G('UP
M:BCT6XO]+U"0P>(3?Q:%<V445Y;V\42[U'[I?*1=YRHQU YZ9Y]0HH XBP\.
M"#Q5X:N#I<:06>B2P,_EKB*0M#A?8X\S\V]:YVUT#6M-LO"MTT6IP1V$%Y;R
MI80Q230%Y 48)(K J54CY1D9'8FO6:* //M+\,_9]7\*2165Z]I:C4)G:_CC
M$D,DK*P)" *N26P !@<<=*JC2-1T[2-+E_LJXE2P\375VUO @+BW=K@*RKGD
M?O%.!V->ET4 <QX[MKJ_\(,MG:37$RW5I-Y$8!<JEQ&[8&>H53^59URFK^(?
M$%IJL.C36D&E6MR8$O\ :K74\B!57:&.$ !R3C.1QQFNXHH \S\/V.N7WBBU
MOK^WU$+_ &)/;2M=6T4$<<S/$?+0(,E1AL%L].#UJM'IFL/X2\'8L-5M)-"9
M(KR*&&)IMP@,?FQJX97 8]<9P21R*]5HH Y[P?IZ6.G7<B_VGNN[M[F0ZC''
M'(S$*"0L8 4';G& <Y/>N/L[+6([+0M";0[T/IVNFXGNB%\GRO-D964YRV0X
M[<8.<<9]1HH \WNO#=XWAOQ&L>FG[;<^(%NHB$&]T6>(AP?90WX9JW>V5\FJ
M^-K9=,N7&JV@>UG1 8V(M_+*DYX;<.GO7>T4 <?X<TN]M/$ZW$]L\<(T"RMM
MYZ>:CREE^HW#\Z#;W=KX]UF0Z?<26^IZ?;I#<QH#&CQ^?N#G/RGYUQZYKL**
M //-$\.W=C8_#Q5T\V\EA;NMX50 PLUL0V[ZR8SZFJ/A#P]>6QT'3]6&O_:M
M)E>0?N;<6H?:ZEQ*J!V5@QXW$DL,CC->HT4 <YXZL;K4O"LEM9PM-,;NT<(O
M7:MS&S'\%!/X5D^*]/U)?&&G:Q VIBS2REMB^FPPS21.SJV2DBM\K 8)49^4
M9X-=S10!P&B>%UM/$'AQUL;I[&RTR\57OD0R1222QD A?E!VEP .@XJGJGA:
MXN_#_B^(Z4);B^UJ*:,&,%I8E,'/N!B3]:]+HH \Y\3^'[^>Y\6?8;!S'=Z=
M81PB-0!(Z2R;@/<*5_#%/UKPY<W<'Q&==-\R?4;94M&V M,5M5 "GV<?G7H=
M% 'EGC:U\2:C9ZSID5E?F.6RB%JMG;Q,MRVWY_.D?)!5A@ 8/3&2:Z1+>[M/
M'^K2-I]Q);ZE86Z0W,: QH\?G;@YSE3\RX]<UU]% 'F.@V&I>'&\.W]]HM[=
MQ1^'HK!H[>,226TRG+ J2,!A@9']SFI_#WA>^L]0\)/>Z<%2TCU*5D.UA:&:
M5&C3/3(4E>/0XXKT>B@#G/!.GW&F:#-:W$#0$:A>/'&1C$;7$C)@>A4@CZUQ
M]K:ZW=?#R7P='H-]#=W/GV\MW<!%@BCDE<E\[LM\K< #K7J=% 'EWBRR\0WT
MFI:9#9W_ )"W%JUHMK;Q&*:-/+)DEE;YMX*L,#!^5>HR:U;_ $S4I=:\964%
MI<1MK-BJV=ZJCRE<0,A#-G*G=CMWKO** /._#5@(+FTOM3378GTS3I(66^M[
M:*WB0A-Z;HU7>/D!')& 3Q79>'I[:Z\.Z=<6=@UA;2VZ/%:M&$,2D9"[1P..
MU7Y8HYX7AFC22)U*NCJ"&!Z@@]13Z "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>foraresidentagreement005.jpg
<TEXT>
begin 644 foraresidentagreement005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=3<71$K8RX^TR_,<>O6NPH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JUSI]E>21275G;SR0G,;2Q!BA]0
M2./PJS10!%':V\+*T4$2,L8B4J@!"#HH]O:H9=+T^>WBMYK"UD@A(,<;PJ50
MCH0",#\*MT4 ,BBCA39%&D:9)VHH R3DG\22:?110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC Y$>%7MU[8K0\0V&MPWGB^"RT6XOEURQ2.VFBDC5(V$31L'W,".H(P#G.*
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M!(6CB60@LY4?PC&XDX-&H^#/$D%_ITMGJ]O<JVMF_G=K##QY20;F/F_,%!5
M !QCTH ])HJI9W5Q<37:3V4ELL,WEQ.[J1,NT'>,'@9)&#SQ5N@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *0@,I5@"",$'O2T4 9NG^'M%TB=Y]-TBPLYI!AY+>W2-F'7!(%:
M5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7(?$234[7P_]OL-5ELTMYH=\<*#=*6FC7!8\A<$\#!/KC@]?7/^*_#M
MUXET\6,>JFRMRRM*JP+(7*NKKR3Q@K^- &^X+(P5BI(P&';WKB-*CO+#XB?V
M9::SJ&HVB:>TNHB\E$@BE++Y6" -K,-YVC P <=*Z1-/U/?;/)K+L8X)(Y56
MW0+*[8VR8[%<'@<'/-9/AGPIJ'AQMAUYKN!W>6=7M$62>1NKM)G).<?D!TH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQKA&=G<]%55!+'V JW%(LT22H24=0RD@C@^QH ?1110 4444 %%%% !1110
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MZ59IJ+9+72PJ)"2,$[L9R1QFHK7PMH%E=RW5MHUA#/*&5W2W4$AOO#IW[^M
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M"'92BH/G#+@<]20<\&NA\4$#Q?X+).!]OG_]))JUU\-:&FK'54TBR6_+%_M
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MGR>3L-SY/D[=N[<%^;.<Y&>G%6K_ ,27]OX8\1SG4/+NK?7EM+<DJ"J&6+"
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MR"!PH&<9_'FEM]8U:9=/T*75[B-9-=N]/DU#""9HHD=T7.-H=L!<XR<'N:]
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M.D65U<* HDF@5FP.0"2.1[&@#A;A[W1O$?CO7(+JZDNK/2X+A;9F5HBWES$
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M8H9)I=RJ3E^,#.2%[L.PK1@/B74-9T#2-2U>XL)FTRXGO3:>66E:.6-4.[!
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MPS[58#<>3B@!ECXXTN_N+>*.WU"-;N-I+*2:U9$NPJ[CY9/4E1D X)'(JGX
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M)D6\G>^>6*"WAMF:4R1G#H4ZA@<YSZ'M7-I\.KVTT_171+&\GL'NB]DT\D$
M2=P^R-U!90A50,CD9Z5N6'A:>VU#0+M+2QL4L6NWN+>WF>0;I1@%6906/<D@
M4 :'_"7:6-,N[YO/5;2[%G+$T1$@F+*JJ%[YWKCV-5H_%=M9V]W)=7,MY)_:
M<EE;P6]J1(S@9\M5R=Q !);@8':JEYX/N[CQ[%JJ3PC2'>*[NK<YWO=1*Z1L
M.,8PR$\]8UJO)X1U>VN%U*R>RDO;?6KC4(89I&6.2*5"A1F"DJV#G(!&1[T
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M7UA[R[:=;:_2TB@BMB'#M&C+&N"?,)WYSQU/89I3XUTP6CR-#>K<I=+9FQ:
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M^4\[<8/X5SR>"M4MO"-KI)L=+N[F.YNIUF^VS0-;-)(S(T4BH7R V".,^IH
MZO\ X2:T;5DTV*UOII]L33&.W)6W$F=GF9Y'0YX..^*JOXXTB.\:(I>&V6Y^
MQM?"W;[.LV[;L+_[WRYZ9XS63<^%M<FO])F5K,7EJMLL^LI<R1SS*F#(CQ!=
MKAOFQN; W9QD<PGPAKITB7PQNT_^Q)+YKG[9YK^>(C/YQC\O;MW9)7=NZ<XS
M0!TB>*;&;69-.@M[Z<Q3"WEN8K9FACEP#L9QWY&3T&>2*J6'B@#P_97C17VJ
MR7!E^>RL2,A'(.5R0N.!RV3C('HS2=*U[1-6OH+=-.FTJ[OY+TSR2N)HQ(=S
MIY87#'.<-N'!Z<5C)X.UZUTS1[19+6[@M4N5GM#>S6\;/))N23<BY?:,C:0!
M\W!H TY_'L!U?0(+&QN[RSU:W>X2XBA)P!MQQ[9.[/3BK[^,]+34#;%;HPK=
M"S:\$!\A9R=HC+^NXA<XQGC.:Q-.\):UHUGX2-N;"XN-'BFM[A'F>-&63'S(
MVUCD;1P1SZBHK/P-/9:M.CZ7IE]92ZBUZMS->2I)&&D\P@Q!2K,I)P=PS@9H
M G\4^.X[6SN8=*%YY\-]!:&\%J6@$AF021[B",[2PSTSQG-=5K&LVFAV2W-V
M9"'D6&*.)"\DLC'"JJCJ3_B:XV[\(^(S87VB6K:9_9D^J_V@MS)*_F[3<"=H
MR@7&0V?FW'C''<=)XJT>]U2WTZ?3F@^VZ=>I>1)<,5CEPK*58@$KE7.#@X..
M* &S>+[*"WM6>SU(7=T[QQ6/V5O/8H,L=O3: 0=V<<CGFHG\=:,FG6EY_I;?
M:;IK)(%MF,RSJK$QLG4-\I'Y=N:JW>E^)9]3TO7T@TO^T;1)X'LC<R")H9-A
MXEV$[P8P<[,')'O4%EX/U&*XTV]N)K4W0UJ;5;Q8RVQ=\#Q!(R1EL93DXS@G
MCI0!:A^(>BS,@\G48U^TBTG>2T95M9BVT)(W0$DCIGJ"< BI+WQ[H]A=7L,L
M=\R6$PAO)TMF:*W)"D%VZ8^8=,XZG JG=>$;^?1-<LEFMA)?ZS'?Q$LV!&LD
M+$'C[V(V]1R.:PSI.O:W)XWT>R6P33]0U(PS3SNXEA!@A#E5"D/E>!RN"._8
M [/4_%5GI%WY5W:WZP*\<;W@MF,",Y 7+=QE@,C(&>2*JZCX\T?3+Z^M9X[Y
MO[/D1+R6.V9H[<,JL&9AQC#CID\'C K \1^"=<U>\U"-)+6:VFD@>UFN+V93
M:HFS,8A52AR58[LY^;D<"M35/"5_>Z;XVMXY;</KN/LQ9FPG^CQQ?/QQ\R'I
MGC% &Q<^*M+M(-9EGDD0:/C[4I3YN4#*5'\60<#U.15ZUU*WN[VZLXQ*)[4(
M90\;*!O&1@D8;CK@G%<3XCT1[WXC:);P2#[/=VXEU2(+PZ6T@>$GZR/MYZCZ
M5UVFW]]>:KJL<MJ(K&VD2*VE((:8[<R'G^$$@ CK@T :E%%% !1110 4444
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M0L9XQN91]XXR!G(&?6NVK&\0>&;+Q+ D%]/>K"I!,=O<M&KD$,"P'7!4$>E
M&PZAT93G##!P<'\ZX#0='T^#XBS3>'+<6^G6-H]MJ$L;$I<7#,I53D_,Z ,6
M;DC< 3UKK$T&W5[9S<WSO;P20*SW3DLKXR6YY;@8)Y%4="\&:?X=,(L+O4Q#
M"&"6\E[(\0SG/R$X[D_7F@"/QK:^'GTG[9X@LA>I""EO;DLQED? "(@/+D@
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M]U69G_WCZ#%.\3:O>V$NE:?IOD+>ZI=&WCFN$+)$HC>1F*@C<<(0!D<FM\#
MQ6=K.B66NVL<%X) 891-#+#(8Y(I!G#*PY!P2/H2* ..O?%OB#3HM1TXC3[C
M5;34;*UCG\IHXI4N64 LNXE2,D'!/8^U=B+*^GT&2ROK\&\EA>-KNUB\K:6R
M RJ2V" 1W/(JE#X/TF&T\@K/*S7D5])/-,SRRS1LK(S,>2!M48Z8&,5O4 <3
M>V/_  @.ES:M8/YT"R6D=TLRY\JSC41D)C&-N6DY]6]:CNO%VJ2W4\.GI:*E
MSK"Z3832HS*I2,M-(P##< 5=0 1RO6NLUJU>^T+4+2*&*:2>VDB6.8D(Y92
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MPB\L+V6RF> %8Y"F,.H))&0PXR<'/-1-X*TUK*QM_M.HB6P+?9KH7;^?&K
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M6YOF>/RW4;QO3#%CNW!CD#'.:['7=/N[KQ+X8NK>$O#9W,[SOD (&MY$!/\
MP)@./6@"S:^*M O;F:WM=7LYI84:1U24'"K]XCU [D=*MQZOITLMG%'>P,][
M$9K90XS,@ )9?488?G7 Z+I_B:]\3Z!>ZS:W^ZT6X6\\X6ZV\;.A 6$)\Q3@
M<MGMWSC(7PIXHTV-K^TL#+>^'I5M=&C\U?\ 2+8M*&/)P/W<L8P>\5 '7ZMX
MZMD\1:/H^E7^FE[XRF26=BP 1PFQ0I'S,Q8 YP-IX-=,FL:=);V]PE[ T-S+
MY,+AQB23)&T>IRI_(US.F^&KC2-9\)QQ1F2UTW2[FWGGR/\ 6,8#D]R6*N:Q
M+'2]>CM- T1]#N%72]9-S/>&6/RFBWRE63#;CD.,@@8P: .V\.:Q-K5G>S31
MHC0:A<VJA,\K%*R G/<@<TD'BWP_<ZD-.@UBTDO&9E6)) 2Q7[V/7&#FJOA:
MSN-(TG5#?1^3NU*]N5W'.8VF=E;CU!!]:X3P&\\#>$SK$5V(YK22WTID\DQ#
M>GF,3M;S"-J<%@,?Q<G- 'J,6KZ=/%8RQ7L+QW__ !ZL'&)OE+?+Z_*"?H*@
M@\1Z+<ZJVEP:I:R7REE,"R ME?O >I'<=1WKAM TW7HQX)TVYT.XMTT*1TN[
MIY8RC8MY8U9 &)922.2!C(XZX3POX9OK)M)TW5K?79)--NFF259+?['N&_$@
M(Q(0P8Y'7+'/K0!UU[XV\/V=CJ5S_:=O-_9\;231Q2 M\IQ@=B=V%^I -.A\
M9^'Y='M=4;5+>.VN>$+N,EL9*X'4@=<=*Y:RTC6FMM9TBQL;^TT:?3;E([;4
M6B/DW+_=6)D8DH<L3N) XP>HJ6^@U"Y\.Z)<1:+KMIK%C T4$EL;<M$^Q5(=
M6<JT;D?^._P\&@#I_$^NG1?"=UK-H(9_*1'CW'*,&8#.1VP<U):^*=!O;>\N
M+75[.:&R0O<NDH(B7!.X^V >>G%97BG3M7UCX:SV+VL4VKSVL0E@C8!&ERI<
M G^'(/X5BZAHVK>)[K6KA-'ETM9/#\VEQ1W+QYEF<Y&-C$;%Q@$X^\<"@#M[
MS6]-T]2;F\AC(MVN0&89,:X!8>P++^8JOX:\2:?XJT6#4].EW1R(I9"1NB8J
M#M;'<9%<WID.L:IXJTZ]N=#N=.MK?1I[1GN9(R3,SPG "L?E^4X/?!X'&=;P
M%%>VG@W3-.O]/N+*YL+>.UD64H0Y10"RE6.5/;./I0 FL>,].MM!URZTJ]M+
MR]TRTFG,(?(R@/7'49&#CI5_3/$^BZJLPM-4LYGMHP]P(Y0?+'<GVX//3BN$
MET?77T+Q#H^FZ;J,&DSZ5<I#9W[0DQW+_=2%E8DH<M]XX'&#U%;^H:1JL&O1
M7NDV4.Z#P]<VL._:(_/W1&)"/3Y6]L9H T+KQCI<N@:Q?:/?VE[/I]G)<F-7
MST1F4D#G:2.HIVC^(+C4M?GT^2&)8X]-M;P,N<[I3("/H-@Q]37&+HWB+4IM
M7N;FUU21[CPY/9*U_P#9U9IV(.Q5BP N2<$^_P"/4^']*OK/Q1<W5Q;E(&T>
MQMU<D',B--O7KVW+^= &G?\ BO0-+NS:W^L6=M<!@ICEE"L"0",CL.1STY%2
M:KXET31)8XM3U2UM))%W*LL@!V]-WL/?I7,ZIX>O;G_A8#)8AWU.Q6&T/RYF
M(MRN!Z?,>^*C2VU70]:U&Z?0;G5DU'3[:&/R7C_=O&C*T4F]AA26SD9')H W
MI_&>BVWB>UT"2[C%U<P>=&V\;3EE55Z]6W9'L#6C>7[VVJZ=:+]GVW32!O,F
MVO\ *N[Y%P=WOR,#GFN.T70M5\-:CX4$MI-?1V^CMIMQ+;LI$,A>)@QW$'8
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MF3#LN0Y!R0<YQ5.QT36=#&@ZHVDS3^3>W\\]A:NA>W2Y9F15RP4[> <'N<9
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M;07EM+;7,,<T$JE)(I%#*ZD8((/4&I  H    X %+10 4444 %%%% !1110
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M$"AX^8;&RG7GKTH SM,\62#2],M=/L[G4=0OIKSRX[NZ VI#,RNSR;>%!*@
M*3R!V)J4^/'-K:"+19Y-1FU*32Y+/SE'E3+&SYW]"N%!SZ-G&1BG1>!YK&#3
M9--U;[/J&GO=%)Y+<2))'/(9'1DW#.#MP0P^[[XJ>T\%I;-ITSW\DUU;ZE)J
M=Q,T8'VB5XGC(P#\H 88Z\*![T 3:;XGN;_3[F3^QIA?6=\+&YM8I5?8<J2X
M8X#*%<-T!]JZ.N7ET75-->[_ +'N?WNJ:O'=SRLBXMX0J!Q@YW9$6T8&<OVQ
MFNHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***ANKRUL81+=W,-O$6"!Y7"#<3@#)[DT 3
M4451L=:TK5)IH=/U.SNY8?\ 6I;SK(4^H!XH O45'//%;023SRI%#&I9Y)&"
MJJCJ23T%$$\-S!'/;RI+#(H=)(V#*ZGD$$<$4 24455U'4K/2+&2]O[A(+:/
M 9V]20 /4DD@ #KF@"U145M<Q7EK%<P-NBE4.C8(R#TX/(J6@ HHHH ****
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M0]7NQ=:AI=M<3A=A=TY9?[K?WA['(J_#96UO=3W,4")/<;?-=1R^T87/T'%
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M3:RW3LKM*T8)++C:W^\, 9ZXXH X2[_Y">I?]CI9?^B8*['7[R>W\2^%H(G
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MBM+$ZEJ.EP7-VH,:QW:E)<]/++8+ \=JMRZII\%VEI-?VL=R[!$A>90[,1D
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M9SC</3K0!I44@(8 @@@\@BJ5UK6E64PAN]3LK>4N(PDLZH2Q (7!/7!!Q[T
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MO[6*\F&8K=YE61Q[*3D_A6=I7B_0M8CO7M-2MBMG(Z3$S)\H4X+]?N'LW0T
M;E%8>H>,-!T_09-:;4[6>Q1Q'YMO,CAF)^Z"#@GOCTJY-KVCV]E#>S:M816L
MQQ%.]RBI(?16)P?PH T**JW>I6.GVGVN]O;:VMN/WTTJHG/3YB<5GZ%XAAUF
M&]E(BBCM[^2SC<2AA+MQA@??/3F@#:HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "N/^(\LTGAA]/M=/OKNXGDA=1;6[2 !)HV;<1TX!QZXKL**
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M3QGDK]WG-48XK_2=)\46MIH#R7IU-[B,R67F120/*AW)T$C*N6" YRM>E44
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M\\5WU% ')ZGX5O=2\26%^T^GQ164T<L<\5LRW>Q1\T1DW8*,<YXZ'&,\U?\
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M!"*,9QQTSUH \KAU*X\/Z%9Z]-=W4MAHNL7MA<J\C.3:-,T:ELG+%&$6"><
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M$!N.O!.:U_#M_IDNB7MK/=-8)9ZA;H]W8:E)-!/(2A4)(V3AB55D]SDG.:]
M2"&-=J1(JX(PJ@#%5;K2+*\%HDL(\NUG%Q'&O";QG:2!UP3D>X![4 7J***
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M7HE_J0T^VOE>X9G5/W;!)"GW@CD;7(P<A2<8-16'C3P[JE]#966IQRSS[A$
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M5!8X'7CCOBL;1/&,FJVUK<_:+'R+C5;NUC8!R988_,*&/&<MM0$YP",XYP*
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MY<9! '4Y/2J_A[PW=P)9KJ6A7SW-A9/"CW&J"6W<E A6-=Q(5@/XE&!7H=%
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M(QDD@\#@FU/I&NZ1?:_'8Z4NJ0ZO#$L4[7"((F6$1$2ACDK\N[Y0W4\5WM%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7I$<,W"G!_"KGAI]0M9_ ]W+K&HW;ZU8LUXES.71CY D4JO12#QD<D'G)YH
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MDN+62[RF_P LEPL1X38?E^4#WS6FFO'3;[6XKO4OLT,7A^TGMDDEVA6Q,&9
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MM7\_=;0M]H&V;* ^:,8PWJ,<<]J=)&?LS10L(CL*HP7(3C@X]O2I** ,K1=
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M9DD01NY0991G"D]QR>/<U6L]&TO3XY8[+3;.VCF_UJPP*@?_ '@!SU[U>HH
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MH5$0850.  !T%/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPB;.1!K%U9MX>ND#9+"8$J >^P[N1[5[AI&FP:-HUEIEL,0VD"0I[A0!G]*
M+M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5633[./4);]+6%;R5!').$ =U'0%NI JS10!6N=.LKVX
MMI[JT@GFM7WP/)&&,3=,J3T/N*LT44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ<7;7E_?S":YN&0(&(4*JJH^ZH50 ,GOS7*:3X,U*]AOH-2U&>#3)=;N+QK
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M05UZUME%PUM<VEPMU;3A ^R0 CE3PP*LP(]^U '/#XE6:Z/<W$L5K]KAOH[
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M"Y$$MM<QW43-$)4+)G ="1N7GID<X/:LNT\#BWBQ-J3S2G6$U9W$"H"ZHJ;
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M]<49 (&1D]!7C\>FO<^)KQ=2OK2RUC^VS+!*VE2R79B$H,0CF#X\LQX4C;M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5S_BB;7;6QGO=+OM-M(+6W>>0W=NTI<J"<9#J%7
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MC,J*69@J@9))P * %HH!!&0<@T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 44BNKC*L&&2,@YI: "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX1DGMRC56UW0?$/E>,=/T[38+N'7T+Q7,ER$\DF!8F1@1D_<RN..>2*]$HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH,?ER1VZQ,K#)Y&]&VMSU%9T?@BWT]K1]#U&[TI[>S2R)B6.02Q(25W!U(W
MLQW#^\>M=310!E6^AQP:TFJM<SS7*V*V3&3;\X5BV\X ^8D\XP/:JMIX2L+/
MQ?>>(XY)C<W,>PPDCRT8A SJ,<,PCC!/^S6_10!R<?@6&SM],&F:M>V-UI\,
MENES&(V:2)V#,KJRE3R 1QQBK$OA21;X7UAKFH65V]M';7,JK%(;A4SM9@Z$
M;QN;D =>G2NDHH YW4_"K:O/;K=ZQ>R644D,QM2D6'DB(96W;-PR5!.".^,
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MSUJ>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH+.:4&3RT55R.A8#CG'<=,UG>%?[.M?'7B>UL?LL4"Q62Q10;0H C?(4#TH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGTY-(L%L7.YK86R")CZE<8K1HH SY-!T>:R-E+I-B]H6#F!K9"A8  ';C&<
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MQQJ)XT8$':Y!(ZU:LK.WTZQM[*TB6*VMXUBBC7HJJ, ?E4]% !1110 4444
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M!MZKXDT;0Y$CU/4K>U=UWA9&P=O3<?1?<\4FI>)=%TAH%O\ 5+6W:X&Z(22
M;E_O?[O(YZ<USGC.#Q%=WT]I8PWSZ;/I[1I]A,"EIR6!$S2\A-I7&WU;VJG8
M:;K.AWUG<OH4VI"?0+73V1)(QY$L>[<K[F'R-OY(W?=Z'B@#<TCQG8R>$-'U
MG6KJVLI=0@601@G!.,G:.20/TK2O?$^A:=:VMU=ZM:1078W6\AE!$JXSN7'4
M8(.>@KS^P\,:YI%MX8NI+?4_]%T?[!<1:;+#YL,FY6S^\."IQ@X.>!VK3LM&
MO/#>J:3?V.A:A>6:Z;+9_9FFA,]N[2B3+$L$PW(.TG&!VH [2VUO3+S[+]FO
MH)?M?F?9RC@^;L.'V^N#UJ&Y\2:+9VIN;C4K=(A.]MDMG,JDAD ZDC!R!Z&O
M/O#%MJ$&@>$=8M=*DNTL9M0CGM;5TWH))7 *[BH(!7'4<'-7;6S\56&DQ[;&
M[MA<ZO>7-Y'8O!)<)'(S-'L,GR8R1D]<=* .CU+Q[X?TT:1))?Q26^J2,L,\
M;@H%"L2Q/IE=OU-:-UXFT2QOX[&ZU2VBN9-N(V< C=PN?3/;/7M7#V&B:YIF
M@:!/)I5U<7%AKEU>36RRQ-,8I/M #9W!"?WJDX(ZFDU#PS?2:MXAMKVSURYL
M=8N%F7^SYK=4*F-$*2;R&4J5Z@D8QCF@#T34-2LM)M#=7]S';P A=\AQDDX
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MT^#+(J -)@8&X]\#@9J6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *S]1T+2-8>-]3TJRO6C^XUS;I(5^
MFX'%:%% #(X8H1B.-$& ORJ!P.@^@I]%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLOD*H#0,A"JH/"G8!ZCW- %*S\27&ERZXHAEO[NX\1&RLK=IMHR8(VQN.=J
M!V. ?IS5"'7;\7WB"34H[VUD76M.MQ;PW8/E[Q"ORM@@H2VXC )!.<$UT%UX
M*\T7,UOJ3P7C:M_:MO-Y0812>6(RI7/S*5# \C[WM4:>!I'2]:\UB2YN;S4+
M6_EE,"J T!0A0H/"D1@>H'J>2 1W7CNYMI=1F&A.VF:;?K975U]I4$$E!N1,
M9;&\9!(]L]EU?QQ=V-Y>1V6C1W5O:7T&GRR2WGE,9I=FW:FQB5'F+DYSUP"!
MFKESX.CN-'UK3S>NHU2^^V,_E_ZLYC.T#//^KZ^]<;?:'K$'BS5M5L],F?5G
MOQ)8F2Q@E@:/:BAFG;YT& V0&!7H >X!VVF>)Y=5\1W^FPV<"PV4S0RN]T!.
M"%!#>3M^X<X#;N?2HM8UQ=*\1W!*W,AMM%GO3$)L1,$=>-N/O=MV>!GBI'\+
MSW/BJTUJ\U&.5;)Y'MHTM%CD =2NQY <L@#' P.0"<XJ75_#":MJ%S=M=-&9
M]+FTTJ$S@2$'?UZC'2@"KHWBVZU#5;*SOM&:P34;1KNSD-PLA=5V;E=0/E;#
MJ>I^H/%3ZIXCO+3Q+;:'I^D&]GFMC=-(UP(DC0.%.<@\\C '7VZU/'X<2/4M
M$O/M+$Z5:2VJKL_U@<1C<>>,>7^M6#HZGQ0NM^<=RV1M/*V\8+A]V?PQB@#F
M1\2K-M56%8;4V37_ /9XD^W)]H\S?Y>[R,9V;^,YSCG&*O3^,);/Q-::5>6-
MM''=W)MHF2^5Y@=K,K/$!\JD+UW$C(R!3M/\)7.DW[FQU.)-.>Z>Z^S262O(
MI=R[*LN>%+$]5)&>#5.U^'YMM2MIO[4#6UMJ4FHQQ_9%$KNY<D22YRP&\XX'
M&,YP* )K'QW'<:=JVJW%I%#ING+,9"MT'N%,;$%7BVC8QP2!D]NF:DA\77T%
M]#:ZSHGV![JVEN+4I="7?Y:AF1_E&Q\'/&X<'GBH9_ 8U2^O;G6M06Z^TV,M
MAF"U6!S'(0278$[V&T8X '/'-3P>$KR6[BNM9UMM0DMK:6VM=ML(@GF *SM@
MG<^ !G@=>.: (M#\:76J7>CK=Z(]E;:Q;-/9RFY61CA Y#J -N5.0<G..0#Q
M3K/QC+/XA31;VQMK>:>&62+R+]9W0IC*RJ -AP>,%AP>:M6_A*."'PW']L<C
M1+8VZD+@R@PB+/7Y3QGO6;H7@!M&O-+E;5$FBTR"2WMXTLUB+*X +2,"2S\#
MGC/IDYH SO!'BO48_#OA.#5=-E6VU&!+>&_>Z$CR3",L"ZXR P5L'<3TR!FF
M:-XT_LGPSH]M,\-QJ%[)>,KWUZ((U2.=@2TC!CW4  '\ *UM%\"3Z:NB6UWK
MDM]8:+A[2!K=4/F!"@9F!Y #-@8&,C).*5? ?V6VTPV.I".^T\W"I--;"5)(
MYI-[*R9'0[<$$'CWH U]#\1)K_AK^UK*WW2#S4\CS 09(V92H<9!!9>&'4$&
MLJQ^(5A?:EH%HL#J-7LC=>8S<0':6$;<=3LE]/\ 5FNFTZVFL["*"XG2>9<[
MI$B$0.23PHZ#G'X5Q4_PNMI-,U:TBU6>&2]NQ<6\RQC-HH9V\M>>1^]E'_ _
M:@"]:^-KK5(M-CTK1?/O+VU:^$4USY21V^_:C,^TG+\$ +ZY/&:9_P )[-<Q
M:0FG:)+<7VHO<Q&WDN%C\B2!@LBNV", YY&>@XYK0O?"THU"SO\ 1-0&FW-M
M:?8<- )HWA!!52N1@J1P0>YZTW3?!MOIEQH\T=W+(^G_ &EW:11NN))R&=V(
MZ?-DX [X[4 8VD>)IXO&6O:.D4EYJ$NI1LMMYWRVL MH-[DG.%#,< #YF/'<
MB=/%DEA$ZVUC=W\]UKUQIT<<MTORL%=L@D#:@V=.2 3UQ@W9O!$3:S<ZS;WS
MP:B]^MY%,L8.Q?*CC>(C/S(PCYZ<X/45)%X.CCN;>;[:Y,.L2ZKCR^ID1UV=
M>@WYS[4 5E\;S?8'$FD[-575!I9M3<CR_.*APWF[?N%"#G;G/&,UJ>&-=N=>
MMKR2ZL([-[6[DM2J7'G!F0X8@[5XS_D=*Y;Q?X2F:-FA2XN[:]UH7]V(;>.5
MH4%OY0 C?*R#*KU!QG(&1FM[P/!J%KI-Q;7=K]GLXIRM@K6\<$AAV@DO''\J
MG>7QP"1@D4 5(_'4SQ6^IG1V70+B\%I'??:!YF6D\M9#%MX0O@9W9P0<4I\=
M21QZY>S:/)'I6CR3137/G@M+)'T5$QSG(Y)&"<<]:2#P))%';Z<VL.^@VUV+
MN*Q^SJ'R)/,5&DSR@?!QC/ &:OMX0M9M"US2;BXD>'5KB:=V4;6C,GIUY! (
M- &"/$>IV_C=)]=L7TRUMM"NKN2)+KSHV"R1'/ 'SJ-P/'?@G-6-.^(\-Y+Y
M<UK:JTME+>VZV]^D[8C 8I*%'[M\$?WAP>>*MQ^"[BZOY+O7=:?43+ILVFO&
MMNL*F.0H21@D[OE.3GG/ &.9M/\ "U_:V$MA<ZO%<6IM&M8RMBL<F"-H9V#'
M<0/0*#0!>\,ZS>Z]I<>HW.EFPAG1);=6G$CNC#.6  VGVR>O;I6U63!I-S9Z
M3I%A9ZBT*V/E)*WE*WVB-%VE#G[N>#D<C%:U !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M5>]OK33;1[J^NH+6V3&Z:>0(BY.!DG@<T 6**9#-%<P1SP2I+#(H=)$8,KJ1
MD$$=01WI] !151-5TYVNU2_M6-E_Q] 3*?(XS\_/R\ GGTJ:VNK>]MH[FUGB
MG@E7='+$X96'J"."* ):*** "BFR2)%&TDCJB*"S,QP !U)-9VF^(]$UB9X=
M,UBPO98QETMKE)&4>I )H TZ*I:7JUAK5JUUIUREQ"LC1%US@,IPPY]#50^*
M]!#2*VJ6Z&.]&GMO;;BX/2/GJ: -BBBB@ HJIJ&J6&DZ?-?W]W#;VD./,FD;
M"ID@#)^I _&K2LKH'4AE89!'0B@!:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[;26UU!'/!*I62*50RL#V(/!%96C>$/#OA^X>?2-&LK.9QAI(H@&(],]<>U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)XSGD5H3^(M$MK_[!/K&GQ7N0OV>2Y19,GH-I.>: -*BJ0UG2SJ9TP:E9G4
M,FU\]?-QC.=F<]/:JFM>*-'\/75A;ZG>PV[WLICC,DBJ%PK,6;)&%^7&?4@=
MZ -BBN=MO%^GG7=3TR]NK.T-M<106YEN%4W!>))/E!QD_/C S6G=:WI-E>Q6
M5WJ=E;W<V/+@EN%5WSTPI.30!?HK&MO%6C77B.ZT&.^A_M&V52T1D7+%@Q(4
M9R2H4DC'&16M%-'/$LL,B21M]UT8$'\10 ^BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M')&@08ZLSL,#Z9-8!\>P26&DS6FDWUU<ZG)-!%:IL#I)$2'5B6V@ JW.<8%
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M\JJI,>?)Q"L?///W<]JKZGX(>?Q%>ZK:)HTQOUC\Y-3T_P"T&-T78&0AAP5
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MC.>G>@#S*\M&LYO$&COKIL(;;1M,A6[N)F"*WF3*2QR"-^ K$$'GK69<ZO\
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MQSEFY.#D?A6I5>QL;;3;""QLXEAMH(Q''&O15 P!5B@ HHHH **** "BBB@
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M2XCB>0(A. [E00BGGYFP.#1)XJT:+5DTR2Z=;EY1 I,$@C,AZ)YFW9N]LYH
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M18YS'Y\$FR0I&K;B2H Y;&W.>,]#6]I'BS1M8:2*UOD:6&$3R!D9 4/\:E@
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M1C! 7<6V$Y7Z$\5C^$O%4VM:/>7&L6T6FWEB_P#I4)?Y8T*+(K$GML89]P:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&YV\8ZXP3TYQG%==10!Q]W9ZWI/BK5]2T_24U2'5+>%!_I"1&%XPPPV[JAW
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M6WTJX>)B2,AFVNI.,<=<9Z5)X%NIKSP-H\]Q?B_G:W42W SEV'!SD Y!&#D
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M+C5+R-8FU"3RQ)&BDE510@10"2<;3DGG-:\VI6%O,L,][;12LX14>55)8C(
M!/7':HI]6MUL[^:TDANYK-&,D,<Z A@"=K$G"$XZM@"@#$_X06T>WN#/J-])
MJ$]W'>_V@/+65)D4(A550)@+Q@J<@G.:NMX:-S;6T>HZM?7LEO>QWJ2R")3N
M3HN$0#;^&>>M21^*=).K?V5-=PPWRVR7+Q/*N%5L\9S@D8)^F#T-2:1XDTG6
M],?4+*]B:W0L)&9P-FUBI+<\#Y3C/;F@"MK7AD:Y<+]JU2]%AOCD>Q01^6[1
ML&4[BA<<@9PPZ=N:T]2LYKZU\JWU"XL90P830!"W'8AU8$'Z4Z/4;&:R-[%>
MV[V@!)G653& .OS9Q6?I/B&'5]9U.QMQ&\-DL++<1RAUE$BD\8],>IH K:9X
M-L=+N-/N([BYDFLVN7WR%?WKSL&D9@% '(X"X ]*A?P1;*8);34;VTNH+RYO
M([B/RV93<,6D7#(5(^;CC(P.>M:>E>(]*UJ2\CL;R*5[25HI5#C(*XR1S]WD
M<]*N6>H66H([V5Y;W*H=K&&57"GT.#0!BZ;X-L=+.EF.YNY3ILUS-&TKJ2[3
MEB^XXY^\<8Q^-:>AZ1!H&B6FE6SR/#;)L1I""Q'O@ 5ES^*;D^(;S2+#0;R^
M:S\KSYHYH45?,&1P[@GCT%%WXKE&J7=AI&B7FJR66!=/"\<:1L0&" NPW/@@
MX'3(R: *MEX M+.6T0ZKJ4]A:W1O8K&5T,8FW%@V0H; 9B0N<9YQ5ZR\+'3+
MUWL=9U"WL7N&N6L%$1BWLQ9@"4+A2Q)(#=SC%5'\=6TMAH]QIFG7=]+JDLD,
M5NI2)T>-6+J^]@ 5V,",]15VR\66-WX>O]8EBGM$TXRI>0S@;X7B&64X)!XY
M!!(.10!;US1(-=LXH99IK>6"9;BWN(" \,B]&&00>"1@@@@FJC>&C<VUM%J.
MK7U]);WL=ZDL@B0[DY"X1 -OX9YZU8\-Z_#XDT9-1A@FMR7>*6WG $D,B,59
M6 [Y'ZBKC:G8)<);O?6RSR,42,RJ&9AU &<D^U &3J'A"PU)-<6::Y7^UQ%Y
MQ1@#&8U 4IQUX!YSS4B>&(7NS=WM[=7EPU@UA*\NQ?,1FW$D(H /;C Q6A<:
MG:0.T/VB!KG#;8#,JN[!=VT GK@@_0YJ)-9M(]+M+W4)[>P^T1JP6:X3 8@'
M:&!VM]02#0!FZ?X0ALDT99M2O;PZ0S_9C/Y8^1HC$$;:HR IZ]<]2:=HWA8Z
M(T,%KK.H-ID&X0Z?((C&BG.%W;-Y49X!;L.M;%QJ-E9H'N;RW@4KN#2RJH*Y
M SR>F2!^(]:J:IXBTO1KRQM;^[C@EO79(M[ #A68DDG@84C/K@=Z ,6Q\ VM
MC/IF-6U.6TTJ<S6-G(Z>7#\K+MX4,P 8@;B2!P#USM:]HD6O:>EK)<36SQ3Q
MW$,\&W?'(C!E(W @\CH0:M3:E8V]U%:S7MM'<2_ZN)Y5#O\ 0$Y-5]9U[3M
MAMY=1N%A2>=+="Q RSL%'X#/)["@#*O/!HN;J:Y@US4[2:[@2"^:#RA]J"C
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M7;NDD=MS,0H ')Z  5CZ?X$M=.O-.E35-0DMM-N))[.T<Q^7&9%<,"0@9O\
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MH *[>V>O-=!IUI-96HBN+^XOI=Q8S3A QSVPBJ /PIFJ:K;:3HEWJTY+6UM
MT[&,;BR@9X]<US%[\0H]*\.:QK5_ILJPZ4T,$Z0R!F:=PA=5R!E5\Q!N[_-Q
MQR 7KKP3;72:[ VHWJ66LAC/;+Y>U)&55+H2NX'"#@DCD\5>U#PSI^J:A/=7
M@DD$^GOI\D.0$:)V!/OGCKFN?U3X@7ND^&+[6;SPM?VGV:6"-(KN:-?-\Q]I
M(*%ONYSR.XKH++7_ #K_ %F&[MX[.WTV15^T/<QLL@*Y+$ Y3'^U0 NCZ)=:
M4P$VNZA?PI'Y4<5R(L*.,$E$5F;C&23W[\TW6=!N=5GWP:]J>G(T7E2Q6IB*
MNN3S\Z,5;G&5P>GI4&H^++2&SAGTIK75B]S% ZP7L2^6')&XDG!Z=.I[57T+
MQO8ZKJ.K65TUO8S66I/I\*RW*[KDJ =R@XYYZ#- #_\ A"K:UDM)=&U"\TB2
MWM$L<VWEN)(4R4#"16!().&Z\GK6E;:'#;ZR-5-Q<377V)+)FD*_,JL6W' '
MS$L<]O:J6G^*5O?%WB#0WMA"FD1V\C7+2\2"1"QR,?+C'J?PK7L=2L=3B,MA
M>V]W&IVEX)5D /ID'K0!F6GA/3[+Q;>^(XFF-U=Q[&C9AY:$A S*,<,PCCR<
M_P (JC'X$MK2VTQ=-U34+&YT^![:.ZB\MG>)B&*N&0J>0".."*M:7XNM-4_M
M_P JWG3^Q;B2WFW8_>%%W$KST^M+I'C'2=4\-Z=K<US%I\%^NZ)+R9$8G.,<
MG!/':@".7PD5O?MEAKFI6-S)!'!<R1^5(;@("%9O,1AOP3\PQFI-3\+#5KF$
MW>K7[V4<L,QL\1;&>,AE.[9O'*@D!AG\36K<ZKIUG<0V]U?VL$\W^JBEF56D
M_P!T$Y/X42:GI\5T+62^MDN"ZH(FF4.68948SG) .!WQ0!7U[1(=?TX6DLTU
MNR2QSPSP$!XI$8,K#((ZCH0160O@2T:VU*.YU+4+J749K>>XGE=-Q:%E9< *
M H^4# &,=,5OVNJ:??330V=_:W$L)Q*D,RNT9_V@#Q^-9^C^)K;6=<UO2H8)
M4ETB6.*5WQM<NNX%<'^= #=2\)Z=JUSJLMV9F&I64=E,@8 *B,[*R\9#9D//
ML*J0>"+8WD]UJ>IZAJLL]A)I\GVMD"F%RI(VHJ@'Y>O4Y.>V+6E^*+>YT7^T
MM5%OI*>>\($]Y&RG:Q ^<'&3CIU%*_C'0D\2PZ U_%]NFMQ<1C>-K*2 !NS]
MXY! [CF@"*U\+2Q:?<:?<Z_J=Y9RVKVB13"$>6C#&=RQ@LP' +$_C6W8VB6&
MGVUG$S-';Q+$I;J0H &??BN<T?Q9>:U??9[?2@L;033I,TQV[!)L@)&W_EJ
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MOQ/HEOJ&K3Z;9>>?E\N]$D1]@Y"Y/J,=10!-KNAP:]:P123SVTUM.MQ;W$!
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M.=G>N@\%VR+XG\37UKI%QIUC=FV:#SK8P>:0K!F"D CGJ" >Y'-=J2%4LQ
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MN5V.HVL5SP0#@^]<M:Z3JEG8^$;B^@OHK2UTN6V8+IINWMY2ZXW1;2PRBXW
M<8QP#7L-% &)X0T^/2_"UE9PO<O$@<H;F'RG +LP!3 V@9P!V %87Q?T^]U7
MX7ZO9Z?:37=U(8=D,"%W;$R$X Y/ )_"NXHH \9URS;4OAKJ^GZ-I'BQIOM5
MK)Y>KQ2O(_[U<^7N)) "Y..E9OC&ROK27Q<\MC.%U#7].%H'AW"YP,D*AP)A
MQC:"/J,5[Q6?K.AZ9X@L?L6JV<=U;AQ(%?(VL.C CD'D\CUH \1M],2[T:[M
MK"PN7UQ?$MG=ZG:IIIMS;H>5P@+8C !.2>Y/&>:^O>';J<^,K(>#=1N-8U36
M2VF:DMI\B('4Y\SJBXR<]#GKP<>YZ+X=TGP[!+#I5C';+*V^4@EFD;U9B23^
M)K3H \3\6>&?$5]=_$);.SNI&NH-,\MUC(%T(Q^]5">&/!R!].]='\-]*CAU
MW5-4C35(3/;Q121W.D#3XB5)QM4?>8#() []:])HH \A%SJGA'5?&UC-X<UB
M_P#[8N7N;">QMC+$^],;68?<(/7/O^.-JWA?4=#\,^&!'IM[<Z_8:<81;#3!
M>VDN]\M$YZ(P_O<<=Z]WHH \$\1>'-3NO$^OC6]/U)8=4@MO(>PTD7P4+& 8
MU?\ Y9%6SZ9ZUUFD>$TD^)OB'4M5TJ>Z2"QLULKN>'EG$>'*$\;\J.0<@]^:
M]/HH \I^%EC>:3K5WIT&F7(T2&U_<7NH:6+2Y5R^?)+<>:,9.[UJ71+^\\._
M$OQ6MSX?UR:#5;VW^SW5M9,\( 3:69^  ">O/0UZC10!X$?#][;>"-+EGTW6
M(M6LK^_FM8UTHW<;;FX66,C@.,;6QQR?2MV#29H/B%X4UG5/"&!<:/%;RK9V
M(DCM+L.NTMC[@10 "?N@8'2O8** "N*\!WOV?PYIZ_9;J2/4[Z]FADBBW1Q1
MM-+(I<_P@C&#W) KLI8DFA>*091U*L,XR#P:;;6T-G:PVMM$L4$*"..-1@*H
M& ![ 4 <E\0M!&N6^BJ+6:<QZG"DOD@Y^SN=LH;'\!7KVX%5M9BAL?'-Q?ZO
MHUUJ.GS:;';VA@L6NA$X=S(A50=NX,G) !VXSQ7=T4 >7Z)::CX6E\+W>I:=
M?RQQZ3<V;I:P-</ SRQR1QL$R0 J[<] 1UK8\/Q:E8_"B=#H[2Z@(KQETZZ3
M_6%I9"$8=P01]0?>NXHH \=?3]2O8?%4L%C>2+=>&GMTVZ2]F))AOQ&L9&YB
M-V!GGG S6[XE\/M8V?AAM.LG@TZRF+W<=I8BX9&,)5)#$ 2Y!X)P2,Y[5Z+1
M0!R?AK34L_"FI);->2+<RSS*MQ9FV8,PY"Q$ JI.3TZDURTWAF:R^''A%+33
M9+=K>2UN-4BBL_,F.(FR6C(S(5D8,5P3P3CBO5:* /,6T6R_L&XNO/UH&754
MO(W71' CF6(+N^S;,F,@<G;]XYR.M5!=K_PDGAFZ\0>'G9UTB[9K6UL&D\EO
M.C"R>2,LN0>F"5+\]S7K-538V;ZHFH&-3>Q0M LF3E48JQ7'3DJI_"@#S'2]
M+N=)B\-7FKZ-=RZ3!]O*V:6K3O9&64- 6B4$\1[EX!VYQQ4MAX<FN)-#%QH\
MJZ8_B&ZO8[2:#BW@,,NS>G1 7^8 ]"P'7BO4Z* /,9M%2WL=42:WU"R2#Q$]
MW8-;:<URBYA7YC$JG=&2T@X'4]0:1K36=0A-S<Z,]K-+X5NX&A@@*H)6==J!
M>=K,!G9U'3M7IVX!@N1N/(&:"0" 2,GH/6@#R[1=.$NH^'UTWP_>::^FZ9/%
MJ#RV9@#%HU CW8Q*2XW9!(XSG)JG#I.HV<'A.XOH+V*TA\/QVC!-+-XT$_R[
MU:+:64L !G'\.#7KU% '"ZEH6SX,WVD6L-U>,NERI;QSP8F)VML&S&01P ,9
M&!4%[9VVD^++>[U#0Y[O2CI*V]LMM8-<+!-O9I%,:*2I<%.<8.W!->@T4 >8
M:#X5G-YX/BU?23)!:66H-Y<T?F);[Y8S%&W4;@AP!_LG'2NE\5:2-4\0^%%E
ML?M5I#>RR3@Q[T0""3:6[ ;MN,]\5U5% 'E?_"*_9M&U"6VT0QWB^*(YX&2W
MPZPBZC.Y>,A I<\<8+>]-UN+4[_Q&B#2)8)+?7[:15M]);#P+*F9VN>AR,Y
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M))M8'"8#8&0V2.U4].CGUGXKS:A+'836L6E6L]OYL!,L*2-,1L).%<D?,>X
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MF@KCG)!!)QSD'.36(? VGFR6(7NH+=K>F_\ [0651/YY786^[MP4^7&W&.U
M'.^(]9O]42!8(+?[18^*HK2W#L55@(]P+GD]7.<>E3ZIXBOO[/U?3M9M+.>[
MTZ_T]=UN9(XI4FFCVMC=N#*<\9(.!V.*V/\ A -*_LUK+[3J.&OQJ)F^TGS?
M/VA=V_&>V?K[<51U7P=.FG_8M/\ .O9]0U"VN;_4+V==ZK#)&PX  /RIM"J
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MHJ95 B. Q7Y<CIQQ7-V&G:CKR:"MEH\^D+I^CSP-<2A%0M+$JHL>TG<,C?G
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M4K2>[@SYL,4RLZ8.#D ]CP?0U6DUB0^+H-%@C0H+-KNY=LY4%@D8'U(<_P#
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MK&TBT:./(N;<RFXD:/S,$AEV)@J,C)SGTQ0!V5,BBC@B6*&-8XT&%1!@ >@
MK@[?Q+X@\17MI%I$UE817&AV^J$W$#3,KR,XV##*,<#GVZ<\.T_Q3K?B9M%@
MTR2ST^6YT=-4N))H&F!+$*(U&Y<#.XDYSC% '9V<-B'GO+)("UTX>6:+!\UE
M&W)(ZX"@?A5JO+O!VIZO+HN@>'].GM;2XEMKN\N+F2$RA52X*;47*Y)9^IZ
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M]T^QQ6=J?C*S_P"$>;5-$N;:]V7MO:N,DA#),B,"."#M?(S[=10!8'@S11I
MTX13[1<_:Q/]H?S_ #_^>OF9W;NV<]..G%6(_#5@L-K'+)>7)M;H7D<ES=/*
MPE"E0<L>F"?EZ>U.?Q/HB:L-*;4[<7I?RA%N_CQG9GINQVZTX^)-%76?[(.I
M6_\ :&[;Y&_G=C.WTW8YQUQ0!/JVDVFMZ=)8WR,T+LK91RC*RL&5E8<@@@$$
M>E92^"-$^QW]M+'<SB_,;W$LUS(\C.GW&#DY5AQ@C&,#'2KMMXET6[U1M-M]
M3MY+P%E\I7Y)7[P!Z$CN!R.]5!XX\+F4Q?V]8APK,090.!U&?4>G7VH 23P9
MI<UC';RR:A))'/\ :8[M[V4SI)MVY63=D?+Q@<8[4Z;P=I<L=IMDOH9[572.
MZBO9%F*N=S!GW98$\X.>>F*M1^)=%ET8ZNFIVQT]6V&??@!LXV^N[/&.N::/
M%6@G3!J1U6U6S\WR3,[[55^NUL_=/L<4 07_ (1T[4K:.VN9M1:W6'R)(OM\
MVV=.XD^;Y\Y.2>2#C.*DD\+Z=+JT6H2M=R-%*)HH'NI# D@&T,L>=H('MC/.
M,\U3U+Q[H%AX=DUM+U+FU2=;<^4?F\PD#:0>A .[![5O6]_:W=@M]!.CVK*7
M$N<#;ZT 1W&F6MUJ5EJ$J$W%F)!"P8@+O #<=^ *R8_!.BQ7ZW2QW&Q;@W:6
MIN9#;I,3G>(L[0<DGI@'G&:B\'>+QXJM[QY;)K&2!T9(W?<7@D0/%+T&-P)X
M[$&KUIXM\/WR73VVL6<B6J&69Q* JH.KY/!7W'% %VQTRUTU[Q[9"IN[@W,V
M6)S(0 3[<*.*R=7\$Z-K5Q>37:W0^VQK'=1PW4D:3A1A2RJ0"0/Y#TJS%XMT
M";39=0CU:V-K"X21RV-K'[HP><G(P._:G'Q3H0TM=2_M.W^R-)Y*N&R3)_<Q
MUW<'C&>* ))/#^G2MJC/$Q.J0B&Z^<_,@4H /3ACTK*U;PG'J.N>&)A'"++1
M6>3YF)DR% C4>HR Q)/5%K1N/%.AVJVC3:G;J+M/,A^;.Y./FXZ#D<GBH/$V
MN7FCG2X+"R@N[K4;S[*BSSF%%_=N^2P1C_!CIWH OZSH]GKVERZ=?+(UO(R,
M?+D*,"C!U(8$$$,H/X5GP>#=%B@OHI89[LW\/V>YEO+F2>1XN?DW.Q(')X&.
M>>M5].\:6CV-Y)K*QZ7<65X;&:,R^8K2[0X\M@ 7RK ] >O'%:#^*=#CTN#4
MCJ=N;.X8I#(K;O,89RH Y)&#D=L'/2@"E;^!M%M_M3$7<\MU9M8S2W-W)*[0
MM_#EB<>V/?U-6IO"FC7*7:3VOF)=V<=E,K.<-%&6*CKP07/(YZ>E23^)M$MY
M;2*74K=7NT62 ;L[T8X5N.BD]">*6;Q+HL&K+I<NIVZ7I94\HOR&;E5)Z!CV
M!Y- %"'P-HL8O2XO+B6]LVLKB:YNY)7>%NJ[F)Q[8]_4UHQZ!I\4]W,D3![J
MUCM)3O/,:;MH]OOMS[TL>OZ3-J[Z5'?0O?(2&A4Y((&2,],XYQUQ5VZNH+*U
MENKJ:.&WB4O))(P544=22>@H X/5/ ]XNJ^;IMM;S6J:=!8VV[4Y[-[81[L$
MF)29!\PZD$8]ZZJ/0TNO"L.BZW)_:6;9(;F5\@S, ,OQR#D9SG(-/M?$6D7D
M,,L%_$Z33_9H^H+2[2VS!YSM&?I6?XC\5V^CV@F@GMF\G4K:SO#*V! LC)N)
M.1@A'#<\4 3V?A'2;5+P2+<7CWD'V:>2]N'G=H>?W>6)PO)X'7.33=*\&Z1H
M]^E] +J6Z2W:U62YNI)B(25.SYB>!M&/Q]323>*]/N="N]1TB^L+C[,ZHYFF
M*(A) PQ )'!XXYXJW>>)=%T_4%L+O4[>&Z;;^[=^1N.%W=ER>F<9[4 48/!6
MFVFF1:?:W>JV]O"Q,0BU&93&I &P'=]T # [=JG7P?H20-;BP7[.U@NFF(L2
MOV<$D+U_VCSU]ZGNO$NBV.J1Z9<ZG;17KE0(6?G+'"@^A)Z9Z]JJ^&_&&E>*
M&O%T^;<]K,\3*>I"M@./8]J &V'@O1K"Z>ZV7-U.]J]F\EY<O.6A8J2AWD\?
M*./<^IJSI'AJST20-:W&H,B1^5%#/>RRQQIQPJLQ'&  3R!Q531O&^B:U-J<
M<%VD9TZ1UE,C!1L4*3)GH%^;'/I5_2?$>CZZ\J:9J$%R\0#.B'Y@#T.#S@]C
MTH KZKX3TS5[YKR8W<-Q)$()GM;J2'SHP20K["-PY/N,GFK<&A:=:WMG=V]N
M(I+.U:S@5"0J1$H2H'3^!?RK(;Q!K=UXGU+2M+TJPE@T\PB::YOGB8^8N[Y5
M6)N@]2*:_B36=0U#4(?#VCVMW;Z?,;>:>[O#!YLH +)& C9QD DX&>.V: -'
M6?#-AKEW:W=S)>0W-JKI%+:7<D#!7V[AE",@[5_*JEWX'T>\??(]^&>!;>X:
M.^E4W4:C $I#?/P2,GG!(S6?_P )Q<W]OH)T72XI;C5C.IBO;DPB!H0=ZL51
M\D$$=.U6[?QG')X.U'7;BR:&6P>>&:U$@?=-&Q38C@?,&8  X[]* -F'1;"V
MU#[;# (YOLB68"G"B)22JA>@P6-9C^!]%:UTZ"-+JW&GV_V6&2WNI(G\GC,;
M,I!93@=>XJM%XIU+4?!;:CI^F!=:\\V9LG)D6*X$GEL'(Q\HY8GCCFMI]?TJ
M+5UTI[^$7[8_<YY!(R >P)'(!Y- &<? ^B+8V%K;1W%H+#S!:RVMR\4D:N<L
MH8')4GL>.!Z5;M/"^DV(TT6]N4_LYY)+<^8Q.^0$.S$G+$[B23DY.:FU;Q!I
M.A"'^U-0@M?.)$8D;!;'4X]!W/0=ZQO#WBN?6++1KB7[ @O_ +46 E(;$3E5
M,8P0PP,DDC';- $VJ^%([JT6RL]D5M<ZHE_?AW),@5@Y"_5D08X&,_2M#2]*
MFL]1U6^N+EI9+Z=65 3LBC50JJ >_!)/J?:F6WBK0;NSNKN#5;9K:U4/-,7P
MB*<X;)X(.#@C@XJ/_A,?#G]G_;SK%JMKYIA\QGVXD"E]I!Y!V@G'<4 .N/"F
MC76KWNJ36F^ZO;,V,[%CAXCU&.F3@#/7@4MKX6TFST_2;&"!E@TJ7SK4>825
M?:RY)_BR';KW-)<>+O#]HMLUQJUM$+F)9HRS8S&W1S_=4^IP*A3QCI,GBNX\
M.+,!?0PI(,GY7+;OE'N N3]10!9D\,Z7++-*T+%YKZ/4'/F'F:,*%;Z81>.E
M10>$],M=8?4H#=QO),UPT"74@@,I&"YCSMR?IUYZ\U'%XMTVVT+3M0U:_L8'
MO8@Z"&4R(_&24X#,!ZXJS<^*="L[.VNY]6M$M[I"]O)Y@(E Q]W'WNHX'K0
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MVUFQLRUJL=Q',[^9*5D^0+]Q<8(^;G)&..M5H?%N@3V-Q>Q:K;-;6^WS)=V
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MVN6YOX[R2)([J6TNY+?[3M& 7"$<^XYQQFM6WTZ"VU"[OHS+YUT$$@:5F7Y
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MSQK$$*1!E;+;MP,9P,8.1R*N:[X:U*_N/$@6Q$L-[J.F2QAF7$D<31>8<$]
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M%'@DCR-[*#@N._2L75?#6I7.A^/8HK$-<ZI<![0;DS*H@B4<YXPRMUQ7H-%
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MM!:$1M)C$DYY9N>,EBQYXR>>*Z*>UM[I46X@BF5'61!(@8*ZG*L,]"#R#4M
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M9TF^SSP2+"L!-K=RP;XUX57\MAN [9S4MQX7TJZU2/4)XIY)D=)51KJ7RMZ
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M+?>\N-F*IG)^Z!UH Y;3O$7B-K;1]8NK^VDM+W5WT]K-;8+B/S9(P^_.=P*
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MC,O,NQ7VA.N,..?7- &Y13#-$LJQ-(@D895"PR?H*#-$K!6D0,3M +#)/7%
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MZ*P]8\0MINL:;I5M9_:KN^$CA3,L8CC3;N8D]3\XP._/2MO<N[;D;L9QGG%
M"T5&\\,<?F/*BIG&YF &?3-/W+D#(R>0,]: %HIAFB52S2(%&>2PQQUIP(8
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MQ@?-GJ:V]&CALOB+-'96J7RW=Q<2W%Q-I[QW%BV.GG$8>-B JCT(P2!7HE%
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M7:F6/SR+N(!XQG\O:** /*-6T[PSJ?P^U.+0O#A$T-O \B'3'C;*-T^91ND
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M4J(L:*B*%51@*!@ 4 >-:;;R37.K2V5C;Q0W'ABX1X[#29;2,397;&=Q/F.
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MM#%B#Q\O8UN^.X5>30I;ZUDNM$AOB^HPI$905\MQ&SH 2R"0J2,'L3TKL**
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M);K<E-IQY98J#GIU4\4 6Z*J0:G:W&IW>G12$W-HD;S+M(VA]VWGH<[35N@
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M>H:M?>:9;G4KD32.5 VJJ*B(/8!?S)JS:Z1IMC=2W5IIUI;W$W^MEBA5'?\
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M/B:5KVZ\[%LZ0O=-M<-&^?DS@@8./3M79-8V;Q31-:P&.9]\JF,8D;CEAW/
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M][(X.>O%34V.-(HTCC4(B *JJ,  = *=0 4444 %%%% !1110 4444 %%%%
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M^S;@JH&"OS<G(QD5';>,M+AT'1KS6+^TL[G4;..X$;/@?,JEB,]%!;&3Q[T
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M;IBJ^6S="WW03T4GMG&:9?>+?#^F7K6=[J]I!<JZHT<DF"I(!&?089>3QR*
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MZC@GZ5G:3H.M>'GT'59=)DO/(2^$]C;21E[4W$PE79N95;:!L.#WXR*]&-M
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M#0='TJ>2;3M*L;.608=[>W2-F^I &:MW-S!9VTES=31P01*6DEE8*J =22>
M* .*\*^'M0L-3T&>]LP@M/#<5C(S,K%)@R[DX/H#R.*SM$T;6_#B>&;Z319[
MTVFF3V,UK!)%YD#O(C*PW,%((3:<'CBO2Z* .:\!Z;>Z3X5CM+^T6TN/M5U(
M8$<,J*\\CJ 1QC:P_P !7*^']#NIO%>L:3O":?H0GCT^13G8]V!)CV,:DJ/9
MQ7I]10VMO;-*T$$41F<R2E$"[W( W''4X &3Z"@#S[2]*UFYM?".D3Z%)I_]
M@RQR7%VTD9C?RXFCQ%M8L=Y;)R!@9SS4&F:3K\=MX8T:70YHX]'U1IKB\::/
MRW3$H5D 8L<AP3D#'3FO3:BGN8+6,27$T<*,ZH&D<*"S$!1D]R2 !W)H Y[Q
MC9/=0V4L%EJDMU;R,\%QIDD2RV[E2N2)&"LI!((.1[=ZI:+I.M/XDAU36[6$
MW#Z##:SRIM*^?YCLZ@?B,]J[.B@#S"WTOQ78^&M!TG[+?K;QZ.()H[&2W#BY
M&!ME:0G$>WNF>_M6EIGA_58(?!BRVI4Z?HDUK=?.O[N5HX0%Z\\HW(R.*[B"
MY@N?,\B>.7RW,;^6X;:XZJ<="/2I: .9T/2[VT^&=AI,\!2^BTE+=XMP.)!%
MM*YSCK[UF66@:E:IX(,5FB/IFGR0W&64+$Y@50#@\@N.<9Z5V[21K(L;.H=\
ME5)Y;'7 IDUS!;>7Y\\<7FN(X][A=[GHHSU)P>* /.M$TCQ#J'B/1[O7;/4&
M6&RN8+XW;V_E"20("L2Q\[/E/)[8]ZJVG@G7[S0-<T^^ BFM],?1M)D:0$2P
M[F/F'&<;E$2G//R&O5** .,\+Z9,=:34;RPUR"ZALVMP^H3P-&H9E)1!$<GE
M0<D 8'O5YM(N'\?7NIO;*UK)H\=JDIVG+^;(S+CKT*^U=+10!YKH.DZWX:_X
M1Z_FT6YOC#H,>G3P6\D1EMY58-_$X4J>A(/\([5U7@O2;K1O#,5M>HD4[SSW
M#0HVY8?,E:01@C@[0P'''%=!10!Y];>&=2@^&.CZ0MB$O8+VUFFA5E& MTLC
MMG.#\H)ZUS]K<R1:K<7]\ES)H4?B61X_LSQ8^T&7RE)#$2$!CR!W!(^7BO8:
MSAH&C#4_[3&DV O\Y^U?9T\W/KOQG]: ./F\-:D?#.K6R6(^U7'B,7T8#*"T
M0NXWWYS_ '%)]>,5M:#;7^G^*O$44^GS"UOKI;R"\#(8R/)BC*$;MP;*'^'&
M.]=/56_U*QTJU-UJ-Y;VEN" 9;B58U!/09)Q0!@W=M?V_P 0[;4H[">XLKC3
MOL;S0LG[AQ+NRP9@=N">F3QTKF],T/6SHGASPS-HTL#:1?PW$^HM)&876)RV
MY,,7+2=""HQN;/OZ6K*Z!T8,K#((.012T <EXXTB_P!0;1;VP6ZE_L^\,TL-
MI(B2LK1NFY"_R[@6!P>HSCFL.\\*W>J>'VTVSL]3LY=1U,7<]_?S1&:U**O[
MU?+;ACL"@#U)/OZ310!YUI]AK6CW'A[4G\.R2BQTZ;3)K.SDCS$V]-LL>]P"
MKB/UW#(SWIVN>'=8UD>)'BT\6[W^B6D,$32J1YR/,S1Y![;E&>G->@)-%(Q6
M.5'*]0K XI] 'FVKZ1KWBRZUJ8:1-IB76@O8P?:IHRS2E]V&",V <XSGIGI4
ML^F:SXCUI9SH4NC1?V%=Z?YLTL1999#'M ",?E&&P?8\#C/>O?6D14274*%I
M1"H:0#,A&=@_VL=NM.GN8+5%>XFCA5G6-6D<*"S'"J,]R2 !W)H X7PCHEU%
M>Z4^I:?K<5SIMJT*O<W%NUNA*JK*FP[F!P,9'0#.#6IK<.I6/C.PUNSTJ?4H
M/L$UD\=O)&K1NSQNK'>RC:=A!(Z>E=2DD<F[8ZMM;:VTYP?0^].H \NCT+6]
M/\*:1Y.EZE%XAM8KE89[&:!DC9Y2WERB1@&C;"'.#C'8UU_BNPU'5?A[JM@D
M22ZE<Z<\7EQD!6E*8P">V?6NBHH YJ/2;@?$"+57MA]G32!;"8D963S=Q4=^
MGX5RXT+6V\/'PFVC2A_[4^TG5O,C\GR_M/G^9][?YF/EQMZ]\5Z;10!YYJ'A
M:_N?#OBBU_L]7FO]<BNHE)3][$'@)8\^B/P>>/>NCT_3;JW\=:YJ#0[;2YL[
M2.*3(^=T,VX8Z\!EZ^M=!10!YKXVT[Q3K$FLZ?!;7\MI*(?L*VSVZ0,H"ES*
M6_>;MP. .,;?<U>U;PY?W5M\0Q'9!Y-6MA'9G*YF(M0@&<\8?(YQZUWE% 'F
M7B?2+I_%>E:;"%\CQ#;QP:FF[D+;,LA;WW(S1D^ZUO\ Q-!/@"_"Q+*?-M@(
MV. _[^/@^QKJ3:V[7:7301&Y1#&LQ0;U4D$J#UP2!Q["BXMH+N$PW,,<T1()
M210RD@@C@^A /X4 <%=6_B:^U+6->T[2)-.NUTN.RM8;EXF>602%V8 ,5^4'
M"[CR3SQ67<>&M=U*S\7,]CJ,G]HV5G%;C498/-E*22%P1&=J@!AP?7\!ZM10
M!R_B2TO8M=\.ZG8Z=+>06,DR2PV[(KJKQ[5(#LHP#C//>G>+["^GDT34+*T:
M^_LR_%S+:*RJTB&-TRNX@%E+A@"1TZUTU% 'G%]H.L:K9>([]=,DM9=3O+!H
M;.21/,"021[G?#%02 >,DX4=^*]'HHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N/\8ZW>6$YM].U.2&[CM&N?LT&G&Y8@$@,[9PJ9&.Q/.#Q785C
MZKX6TG6KQ;J]@E:81&!FBN)(O,BSG8X1@'7.3ALCD^IH YFWUSQ!XAU'3;:P
MOK;3DNM"AU*1C;>:RR.<;5R0,=.N>GOD0VGCZZM]/T;6=7$2:?J&C27!6-<;
M;J)=[*#Z,F[ _P!BNSLM!TW3IX)K6V\N2"S2QC.]CMA4Y5>3SCUZ^]8NM>"K
M34-(T/1;6""/3-.O8IVCD9F(CC#$*I.<DD@')^Z6H BUMM1?X0:K)JQ7^T'T
M2=[@(NT*YA8E0/;./PKE]$230/$UI<-HMIHPO-$E2W2Q=7CNI4"R%I0%7#!>
MG!SN;GM7J-]96^I:?<V-W'YEM<Q-#*F2-R,"",CD<$]*R],\(Z+I%T+FUMI6
MG$9B62YNI;AD0XRJF1FV@X' QTH R=/\1W]RO@?S'C/]L6C37>$ZL+</QZ?,
M:YC2M7^SIX8U@VL">1H&IS^1;QB-/E>$X51P,XKM]-\$>'](O;:\L[.19[4,
M+<O<RR"%6!!5 S$*N"?E Q^56[7PSH]D+,06046<$EM &=F"QR%2ZD$G.2HZ
MYZ4 <7:G6I_%7@F]U;4;:[6\AN)Q'%;^7Y+-!DJIR=RX..>>.O/#?#^KZUJ%
MEX3TW3)[+3([W29[J8Q6:D(4>,#RTR%'WS[<GBNLTWP3H&DWMM>6EI*)[4,M
MNTES+)Y*D$%$#,0JX/W1Q^56[#PYI.F/8O9VOEM8V[VMN?,8[(F*EEY/.2B\
MG)XH XH>--3FTK0%N+U+*6[^V"ZNX+,SG-O)Y8*QC. QY)P<<#J175>'KW4_
M^$*M]0UZ58;XV[3SO+#Y8BX)^90>,#J.M9&M>!5EN]-DTVSLIK2S2X L[J>6
M,!YG#M()%#-G(;Y3QSVP*W- T.33_#"Z3J<XOMPE$@8LR['9CY8+$L556VC)
MS@4 <GI_B+6+_4[G2QJ4\L-SI$M[;W<VFFW*LK(N44GYE(DSSR,#GFN@^'BW
MO_"!:++?7S7;S64,BLR!2JF-?E)_B/7D\G-6]+\(:+H]XMW:6\QN%MS:J\]U
M+,5A)4^6-['"Y5<#M^)S;T70[#P_8?8M.26.V#96.2=Y0@P!M7>3M4 #"C '
MI0!R&F>*[^?Q9I,$>H/J&FZG)/'YATXP1 HC.#$Y.6'RD<Y!Z@U#HOB/Q');
M>&M5OKZUFMM7O&LY+2.VV;!MD*N'SDMF/D8Q@^V3T]AX*T'3;ZVO+6UE66U9
MVM@UU*Z0;P0P1"Q500QX QT]!BU%X<TF"ST^TCM=L&G3>?:KYC'RWPPSG.3P
M[=<CF@#F=)\4ZK?7NEZ([Q?VK%>W,>J,$X$,'\0';?YD!'^\:GUZ/5'^)7AY
M+756MK=[.Z9H1$&!VM#G//.00,]L<=:T]+\-BR\8ZYX@E6#S;]88HO+SD1HF
M"6S_ !%O3LJU?U+0M/U:ZL[J[CE\^S8M!+%.\3+G&X90C*G R#P<4 <5'K6J
M)Y-KI9L;*6]\37=E)(+8$;%65MY (R_R Y/4]:C_ .$@\4VEA?W\^I6<T6DZ
MNFGR1"TVF[1I(U+,=WRL%E&-HQE3G.<#MD\.:3'+%*MKAXKV2_0^8W$[AE9^
MO<.W'3GI1)X<TF:TO+5[7,-Y<B[G7S&^>4%2&SGCE%X'''UH XVX\5^)+K5=
M4?2[6YECL-0^R1VD=D'CF52H<O+NRK'+$8X&!G.:ZGQ-JMUHITF[C9!9-?QV
M]Z&7I')E%;/;$A3\,T^;PII,VJ2:CY=S%/*ZR3""\FBCE9< %T1@K'  Y'..
M:OZKI=EK>EW&FZC )[2X7;)&6*Y'7J"".1U% ' :-XZU;5GBLML4=Y>:K&UK
MA,_\2YU,H<CUV1NN?4BJVAWVMZ/81WT5[;G3Y?$L]FUF;?DI+>.A8OG.X,V1
M@8P*[Z#PSHUMJUKJD-BB7EK:"RAD#-\D(Z+C./QQGD\TH\.:2+)+,6O[A+S[
M<J>8W$_F^;NSG/WSG'3MC'% ')WOBN_M_$MJ+34'O+*355T^:(:<4ACR2I F
M)^9U.,XXR","H-%;Q/;Z7XNN+.__ +1NX=1FC@MWA4?,/+RRY8?PDX3(&?K7
M4_\ "%:#_:(OOLLOFBZ^V*GVJ7RDGSDR+'NVAB>I YR?4U(_A/2'N-0G$=S&
M]^0UP(;R:-2XVG> K *WR+\RX/'7K0!S<7B:_O5TG2M.U4M>7MY-!/=75CY<
MMJ(H_,:,Q' \SE<'I@YP>]6\\8ZWIR7.CNZW.H1ZQ'IRWL%KN+1O!Y^[R\X+
MA<KC.,X..U=4?!>A-IPLC;3%1<&Z$WVJ7S_.QCS/-W;]V.,YZ<=*?_PB&A_V
M.=+^QL;=IOM!8S2>:9LY\SS=V_?_ +6<T <VGB/Q%I]DEYJ,4BV5MJL4$L]Q
M;"%YK650N\J"=I21QDC@@=*KW/C+6)Y+9;3>L.J:C<QVDMO:B:1+:!=I*J3@
ML[@D$\!3T-=DOAK3!HUWI,J7%Q:7883BYNI9F?(P?G=BPX Z$8[4R?PKHT^D
MV.F&U:.VL OV0PS/')!M&T%9%(8'&03GG/.: .5_MWQ9-'HE@2EC>7NHSVIN
M+FTP7@2)Y%D\O/#$+TSC(].*ZG7;Z32?#HDEU-8+G,4(N?LIE:21B%PD2GEF
M/ '.">X%2P>'=-MS8L(YI)+&5YH))KF25U=U*,2S,2V58CG/7BK&JZ39:U8F
MSOXC)%O60;79&1U.5964@J00""#0!P*^+M?72]1@293?6VLV=C#/>6GE%DG\
MK_61@]1YAZ8R,=*LWGB;7=%@\0V,]U;WMY9RV4=K=/!Y:C[2X0;U!P0IR>,9
M'%=+;^#]#MH9(TM)&$EU%>2-)<2.SS1E2CEF8DD%5[\XYS5B[\.:3?\ ]H_:
MK-9?[1C2.Z#,W[Q4SL[\$9/(P?RH YO0[?4;;XGZC%J5_'?2#1K<I,L(B.WS
MI>& )&<YY&.,?4IK?BK5-+O]:TA6B.H2M;?V,2G#"8^7R.^QU=C[8KHM)\+Z
M3HEY->64$OVN:-8Y9YKB2:21020&9V).,_TJMJ/AL:EXUT;6YA!Y6EP3B/KY
MC2R;0/;:%#?B: ,#4=>\02VGB?5K&_MK>VT"22-;62W#?:3%&LCEVSE=V2!M
MQC@\U<;Q3?21>+)DV1KI^FQ75JK+RC/"[G=Z\@5K7_@S0M2OYKRZM)&DG*FX
MC6XD2*<K]TR1JP5\8'W@>E&K>#="UN\DNK^S>226(0S!+B2-)D&<!U5@'QDX
MR#B@ O+[5W\$"^TN%)]5>T26-"!@L0"< D G!) R,G KC]2U"ZUB#PP+/53+
M?1Z\86EN[(Q26[?9I25>+(^8 Y'0'(ZCD^@SZ5:7&E#3&61;4(J*(IGC90N-
MN'4A@1@<@YJG:^%='LUMQ%;.S071O%DEGDD<S%"A=F9B6.TD?,3QCT% '-Q>
M(]1ATS4K._U98[VTU?\ L^*YAL#+)<@Q+*H6)3C?ASS@C"DX],U=9O=9L]&_
MM LT]GXJ6UWO#Y3.JQN063^%L-@X]*[6[\*:->I.);9U:>[%ZTD4\D;B<($#
MJRL"IVJ!P0.OJ:+7PEHEG!%#!9L$CO/MR[II&/G[=N\DL23CKGKUZT 4/ /_
M "!M1_[#.H?^E,E<IX.OM;TC0O"DKWMO+IVH7CV1M!;X,:GS65]^<ELISQC!
M]LGTJPTVTTN&2&SB\J.2:2=QN)R\C%W/)[L2<=*J1>'-)@L]/M([7;!I\WGV
MJ^8Q\M\,,YSD_?;@Y'- ')1>*M0;Q1ID5OJ3WNG:A>S6A;^SC%"FU)&!CD)^
M<@QX/4'G&*2R\:ZG/#IUM(L;7]FEY)K*HG:VRF%';>Y1A[9KH[7P5H-GJ$%[
M#:RB6WF>>!3=2M'"[A@Q1"VU<[FR ,<_2KMIX?TJQU?4-5M[-$O=1"BZDR3Y
MFT8'!.!QUP!GOF@#D_"GB'Q+J=[I,]U!<366H6YEN"UEY,=L2F]/+?<2ZG[O
M.2<@\=*T]8O-<N?&<.AZ9J$%C VG-=/*UN)7#"0* H) [\YST]\C2TOPKI6C
M7"RV"74:H"L<)O)GAB!ZA(V8HOX#CM6@=-M#JPU3RO\ 3! ;<2;C_JRP;&,X
MZ@<XS0!Q&E^)];\21^'[&WN8-/N;S3Y;V[N5A\S_ %;K'MC5C@99LG.< 8[Y
MKHO".K7FJZ7<C4#$]W97L]E)+$NU93&Y4.!DXR,9&>#FEE\&Z'+8V-H+:6%+
M'<+62"YEBEB#?> D5@V#W&<'\*T]-TRST>PBL;"!8+:/.U 2>2<DDGDDDDDG
MDDT >>0ZMK=]X#LM=U:XL;L7E[9+':FS4I$#=(F[))RV#GH,'&.E3-XEU[4/
M$C6EA>LA35S:-:QV!=%MD^]*93QG(.>>#\N,UV:^'-)71;?2!:XL+>2.2*+S
M&^5D<2*<YR<, >37(#P%J::K/-%+9PM+J1O3J4,\J3[#)O\ +\H (?E^0DG!
M')!- &?8WVMZ-;ZOJUO>V_V"/Q-)"]F;?)D62Y6-B7SD$;\C QQSG/'0>%8]
M4_X33Q8;C56GMHKV-5@,0 &;>)A@YXP#C Z]>];[>'-)>QGLVM<V]Q=_;94\
MQOFF\P2;LYR/F4''3CIBGQ:%I\&N7&LQ1RI>W"A9BL[A),  $IG:6  &<9Q0
M!S9&IK\5[PC5'%E'I,,YM1"""OF2#:.>N03NZ\X[52T_Q)X@.G>'/$-S>VTM
MGK5S#$VGI !Y"39V%7SDLO&[/!YZ5V-QH6GW6M6^L21RB^@3RUDCG= R9SM9
M5(#C)SA@>:I67@S0=.OXKRVM)%>%VD@B:XD:&!FSN:.,L40G)Z =30!7\3:A
MJT6MZ#I>EW4-K_:#S+++)#YA54CW949'/'?CZ]*YVS\1>)XX+6^O-0LY88M=
M_L>6!+7;YR^>8?-+;OE;.#@<<>_'?W&FVEU?6=[-%NN+,N8'W$;"R[6X!P<C
MUJI_PCFD_9OL_P!E_=?;O[0V^8W_ !\>9YF_K_?YQT[8Q0!R=WXKOX/$UH+7
M4'O+*751I\L8TXI#'DE2!,3\SJ0,XR"01@5FZ[>ZWJW@3QM>7M]!]AMS?V<%
MK'!@D1R%5=GSUP,8 QWZUV8\%:"-1%]]EE\U;K[8B?:I?*2;.3(L>[:&)ZD#
MG)]35Q_#FE2:3?:6]KFROWEDN8_,;YVD8LYSG(R2>A&.U ''S>--4_X1C4-:
MB6-9'U"/3K6Q,.Z2T8RB,F49!9SG=M! ^Z,G.:S_ !!J/B:;PAK\<T]Y;Q6_
MV>2WO9K,022AGP\94''!"G<,<'%=[=>%]&O9-0>XL5<Z@B)=#>P$FS[A(!P&
M'9A\W YX%,3PII(TR\TZ5+JYMKQ DXN[R:=F4= &=B5QGL1ZT -UC4KGPUX,
MO]2N)!?W-C:R3%M@C$K*"1D#H.@K$&J:_HVKZ9:ZCJ-MJ":G:SO^[MA'Y$L:
M!\K@G<AR1SSTYYKJX=,M8=*_LTJ\]J8VC9;F5IBZG.0S.26SD]36=IO@_1=)
ME,MM;S,_DFW0SW4LWE1'JB;V.Q>!PN.@]* *_@>YUG4O#5EJVL7T,\E_:PSI
M%#!Y:PAESC.26)R,^ASCBN/U>_UK7-$MM7EOK=-.?Q#! EB+?YD2.]6-3OSG
M>2F3D8P<>]>FV%C;:9IUM86<?EVMM$L,*;B=J*, 9/)X'>L63P-X>FOFO)+%
MS(URMYL^TRB-9PP;S%CW;0Q(&2!SSGJ<@'-/XK\1WFJZA+IMK<RQ66I&S2T2
MR#1RHC!9&:7=E6Y8C' P,@YJ;4_%=_:^([?['J#W=H=5BT^>%=.*PQ[V"$><
M3RZDCIQGC KII/">DR:I)J(CN8IY9%EE6"\FBCE<8PSQJP5CP.HYQSFHW\%:
M#)J)OFM)3+]J6\"?:I1$)P0WF"/=M#9 R<<\YZG(!5\$?ZOQ!_V'+O\ ]"%<
MW#X]U6.ZT6UN!"SP74MMKC[,!/WP@B8>@9F5_H#7H=CIMIIHN!:1>6+B=[B7
MYB=TC?>/)XSZ#BLRX\':!=/K#3:>K-K"HM\?,<>:$&%Z'Y<?[..>>M ',V&L
MW^M:EX>N7^S(^I)J4EG.;96>"$%1"5)]5VL?7CTK"LTUB7X>^#Y&U19[J?5K
M<P23PY$7^L'.#E_7DCTKU"/1-.BETZ6.V"MIT+06F&.(D8*I&,X/"J.<]*IV
MGA#1+**.*"VE$45T+N*-KF1EBD&<% 6PH^9OE''/2@"OX8U#49=0US2M3N8[
MN73;E$2Y6(1F1'B20;E'&1N(XZ\5A:CXKO[7Q);"SU![NT;58]/FA73BL,>Y
MMA'G$\NI(SCC((P*[>VTVTM+V\O((MD]ZZO</N)WE5" X)P/E '%9+>"M!?4
M?MS6LIE^U"]"?:I?*6<$-Y@CW;0Q(Y..><]30!S-QXC\1Q0ZIK OK7[%I^M"
MQ%G]FYEB,R1DE\\, _&!VYSGBW<^*=5AU"\T /%_:[:M%!:MY?'V60>;O([[
M429<^J#UKIG\.:3)975F]KFWNKG[7,GF-\TN]7W9SD?,JG XXJF_AL3>/T\2
M3"#;!I_V2 #._<SEF8]L 8 _WFH C\6:EJEG<Z%::7/!!)J%^;:22:+S J>3
M(^0,CG*#'/Z5C)XDU&WM]6TV_P!61+RRU*.SANX;$RR7(>)9558E./,PQ!/(
M 7.*W/%/AE?$LVC+*5^S65Z;F9=[(Q'E2(-C+R&#.I!R,8ZT\>#-"&EC3Q:R
MB,7/VL2BYE$WG]/,\W=OW8XSGIQTH Y2+Q7XAN=&@AAGBCOSX@.E&XN;7:3&
M8R^YH\\,,C@$ X[9J_9V^MQ_% P3ZZTT4>D0R2)]F55D_>.IXSP203D>N.U=
M#:^$M$LH8XH+-@L=Y]O4M-(Q\_;MWDEB2<=<]>O6K%SH6GW>LVVKR1RB^MT\
MM)(YW3<F<[6"D!QGG# \T 96M:AJ=QXJLO#^F7<=CYEG+>S7+0B5MJNB!$!X
MZODDYX'O7(7MYK'B"X\,)-?PPW-KK]U8R21VP9)'BBG E"D\9 QMSP2?2O0M
M7\/:;KCV\EY'*)[?=Y,]O<202)N^\ Z$'!P,C.#BD@\-Z1;0:=#!9K''ITK3
M6JJS?(Y5E+'GYB0[9W9R3GKS0!6\4:BVGVEI%!J#V=Q<3>7&L-F;F67"DE40
M=#QDD@@ 'US7+6GBKQ!J&F:)##<0P7MUK%SILT\UKC*1+,0WEY^5\1@XSC/M
MQ7;:MH=AK:0"]27?;R>9#+#.\,D;8()5T(89!(//.:KV?A71;".SCMK/8MG<
MO=P?O7.V5U96;)/.0[=<]: .8A\3ZU90-)?7$-Q#INN_V;?3"$)YD+HNR3 ^
MZ5:5,XXP#71^%=4NM:L+K49BOV::\E%D%7'[A3L4GUW%6;Z,*BUWPQ'>^&=>
MT[38X(KC5P[2O.S%?,950OWP0JC '&0/K6SIUA!I>F6NGVJ[;>UA6&,>BJ !
M_*@#QGPW;&P@\(ZL^B6ME;_VG)%)JEJZFXG,CR1HDB[5.PLRY.6^Z..X[7_A
M*=2_X1TWN^+S_P#A(O[.^X,>3]L\K&/79W_&MBQ\"^'M/N8)X+.8M;R&6%)K
MN:6.)R2=RQNY53DGD#C-$O@?P]-J+7TED[2M<K>;?M$GEK.&#>8$W;0Q(&2!
MSSGJ<@'*W5S]HOHQY$$7E>,TCS#$$+XA!W-C[S<]3SP*K:I?ZUKNCZ=K,U];
MKI\OB*WA2Q%O\R)'>!%._.2Y*9.1CGC&*] _X1S23(9/LOS&^_M#/F-_Q\;=
MN_KZ#&.GM5)_ WAZ2_-XUBYD^U"\5/M,OEI.&#>8L>[:K$CD@<\YZG(!S;ZW
MJ<'GPZ4+&TGN?%+V#2?9@04,18NP!&Y\@<D\X I;KQ5K.F6.IV5S>1275IK$
M%A]N6URWDR1I(7\I?O,H8CCCC..#78#PYI(D$GV7YA?'4 ?,;_CX*[=_7T.,
M=/:L?Q/X.CU6 O8PVWG2ZA%?745R[A+DI'L +#)3@(<J/X>0<F@!GANY\2ZC
MI=U.U]')C4 EM+=61B\VU4C<VT8.6&X GCC.,&NPKB=.\%WJVYAO+Q8+5]1B
MO?L5O+)*D2Q@$1H[X/S.JLW '4 <YKMJ "BBB@ HHHH **** "BBB@ HHHH
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M!ZT +112 @]"#0 M%("",@@B@$$9!!'K0 M%)N&W=D8]:6@ HHHH **0$$D
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MEI 7"$[B)7SCUQ7JM% '+>/;F&WT.W6XL+>[MYKN..1KM&>" $$^9(J_>4$
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M=-N)Y8&2UT*#37",23(AR2,@?+^OM5KP_H=]H_@2TT0W,<=]!9F 3Q994?!
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M>+:^:&WDENG=6AW6J*74!2'X)X)7D=:TKSP=JL::PNE7T<)N;.PMK=C*Z.1
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ME<S_ ,(/JT'@[3]'2UTN>\MC<M'>"\F@>U>21F5XF5"QP&&5)&<8R:T6\/\
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M@$5MYVGO9H$!V19C*#'? _E0!S][XTN(=7\-N+/4$M]0M[HR62VNZ61T$>W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>foraresidentagreement006.jpg
<TEXT>
begin 644 foraresidentagreement006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\CDYQ@C.0>E6H_&=U)HUE):OI6H7VH7PLK;[-*XB1MA=C*"-RE0K97J>.F>
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MSEMH[2%'.VY\_"QGGG&_>#[)6QXCUJXT>"PBM+>.>_U"Z6TMUD<K&&*LQ9B
M3@*C' Y/ [T ;=%>8^+]>UJY\*>)-(GALX=0LC;":2&1_+EMYFP"O&0<@J0>
MV>>:] T:Q73=(MK-;:UM1$N/)M%VQ(2<G:/3)H O4444 %%%% !1110 4444
M %%%% !1110 4444 %8FO>%K#Q%=:7<7C3*^G7 N(_*8 /@@[&R#E254D?[(
MK;HH YFV\"Z-;IK\96::+6V8W,<C\*K%B53 &T;G=OJQK0TC1[K3')GUW4=1
M0)L1+H184>N412QXZDFM:B@#G[SPJEQK4VIVFJZAI\ETJ)=QVK(%G"?=)W*2
MIP<94@XJH? EI]N\X:GJ(MAJ/]IK9AH_+$^_>3G9N()SP6P,\=L=710!R5WX
M!L[NXN2=4U*.SN+Q;][*.1!%YX96W?=W8)4$J3C))QG&+\GA=+G7+?4KS4[V
MZCM9GGMK241^7$[*RG!"!R,,P +$<_2MZB@#G]%\+G0F@BM=9U%M.MP1!82>
M48XU(("[MF\@9X!;C ZXK0ETB";7[766>07%M;2VR*"-I61D8D\9SF,8Y[FM
M"B@#ESX'LXK2PCLM0OK.ZL)IY;>[B*&1?.<O(I#*5923T(_A'<5K:)HEOH5E
M)!!)-,\TS3SSSL#)-(W5FP ,\ 8     %:5% ')1> ;.*ZMW&J:D;2UOC?VU
MEYB"**4L7/1=Q&6;@DXR<8J])X1L)-*N]/,UQY5SJ U%V#+N$GG++@<?=W*!
MZX[]ZWZ* ,B+PY8)#K4$@>:'6)6ENHY#Q\T:QE1@# VH/?DU2B\(_P#$KN=+
MOM;U._T^>T>S\B<Q#9&PQG<B!BP' ))KI** .8M/!OV6ZDO&UW5)KUK,6:7#
M&(&*,,&&T+&%R".I!SDYS49\"6<D$[3:E?R:C+=I>_VCF-94F1-BE0J!,!<C
M!4Y!.<UU=% ',KX)LVMKA;J^O;JZN;NWNY[N4H))&A=6C7"J%"C;C  ZGN<U
M+JO@^PU:75))I[E'U&.W1VC91Y9@<O&RY!YW-DYR#@<5T-% '*2^ [.ZM-5A
MOM3U*ZDU0VYN9V=$?]RVY=NQ0%].!^O-#^!+2ZM-6BU#4]1OI]2M1927,[1B
M2.$9PJ;4"CEB<D$D]:ZNB@#G[OPMYFK7.HV&L:AIDMVJ+=+;>4RS;1A6Q(C;
M6QQD8X ]*O:WHMMKVDMI]S),BEDD2:)MLD<B,&5U..H(!Z5I44 <FW@*TG@U
MA;W5-2NYM7M8[:YGE= VU"Y!4*@5?OG@#''3.2;U[X874=7M[R[U2^EM[>X2
MZBL3Y?E)*HPI!V;\=\;L9_*MZB@#!_X1+3CX6N_#[O<-:7+S2,^\!U:21I"0
M0.,,W''8=:QM7\$3'1/$,L.H7^J:QJ&DR6*M=R1J&X;8 %557EO8=SZUV]%
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M9E9D<,IX)1>1@]>:UZ* .5B\"6<4R1_VCJ#:7'=?;(]+9D\A9=^\<[=Y4/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXO- \S/D?N3+CI\W3':H['PG<C4+2[UG6'U,V,+PVJ>0L07> K.^"=SE1C/
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M0R,LA !4AAU QSGI5A?!/V?1](MK/4Y(+[2II)K:[\H,/WF[<K(3RI#D=0>
M<TL?@I2HFNM1DGOY-3AU*XN#$%$C1@*J!0?E4*H'4GKUS0!K7>JW.G>%[K5K
MZR2.XM;62XDMHYMXRBEMH?:,YQUQWZ5ST7C36I[^VL8_"^+F]M#>6@>_4*8@
M0&\TA3L(W)PH?.X<CG'4ZOIZZMHM_IK2&-;NWD@+@9*AU*YQ[9JG!X>2#6=-
MU$7#%K'3WL0FWAPQC.[/;_5]/>@# D^)%LUCH[V]O;1W6HV[W'EZA>K;1PJC
M!6!DPV3N.  #G!/ %36GCM]8@TQ=#TM;N]O899WBENA''"D3^6^9 K;OGX7
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M%(RD+( "4..#@\''O7'/X -W!K#7NJ;KW4A!F>VM5A5&A?S(WV9.YMW4D\@
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M2 <YZ9 KMJ\\\(^#-2&BZ&NL:C.+>PF-TFG-"JLDH+;=SCDJ-VX#'7&2<8H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 52U32K36+:.VO49X4FCGV!B S(P9<^HR <>U7:* "
MJFG:;:Z3:?9+.,QP"1Y FXD*78L<9Z#)/'05;HH **** "BBB@ HHHH P]1\
M*:=J5_+>O)>V\\\:Q3FUNY(1,BYP&"D9QN//7GK5JZT'3KOP^=">W":<85@$
M,9*[4&  #VQ@5I44 %%%% !1110 4444 %%%% !1110!2GTJTN=6L]2F1FN;
M-)%@.X[5WX#''K@8SZ$^M7:** ,RV\/Z9:VUK!'; QVL[7,6]BQ$K%BSG)Y)
M+L<GN:TZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KF/&OB.ZT+2BNEQQ3:K+')+$DH)1(XUW22, 0< 8'7E
MF4=ZZ>N4\3^#!KCW][;:G?6M]<6#6:K'*HB9?F(# J2 2W..OX4 ;^DW4E]H
MMC>2A1)/;QRL%X&64$X_.L3PWK6L7^OZYI^KP6<!LA;M%';,S;1(K'#,<;B,
M#D "K6AZ?JNCV6DZ:TL5S:06A2YGFD)E\P;=H7"@%?O#G!P!6;H6G^)+?Q=J
MFIZAI^F16VHK"&\B_>1XO+1@, PJ&R2.XQ[T 6-;U;4SXGL?#^E3VEG+/:2W
M;W-U"91A&50B*&7)RV2<\ =.:N>$M;E\0>'(+ZX2)+D22P3"(DIYD<C1L5S_
M  DKD>QK.U?3=6U;2[!-1\-^'M4NU5C*MU.WE02=BF8F+#'7H?K6IX6T)?#?
MAVUTP.CO&7>1HTV*7=B[;5[#+' [#% &Q6*?%6EBPEN_,DVQWW]GLGEG?Y_F
M",+M^I!^AS6U7GO]CM/\7Y4BD#:;%%%JUQ"!PMV5>!#Z<H-WU0&@#??QOHZ7
MQ@/VOR%N?LC7HMF^SK-NV[#)C&=WRYZ9XSFK4WBC3(+#4KUY)!#IUS]FN"$.
M0_R\ =Q\ZURY\):Z='D\+D6']C/?FY^W><WG>49_/*>7LQOS\N[=C'.,\4FK
M^%/$<\.OZ78C338ZK>K>BYFF<21\1[H]@4@\Q\-NZ'I0!TZ>*=/E\23:##'=
MRWL#*LYCMV:.'<@=2[] "#Q[@TS7/%^FZ!++%<QW<SP6_P!JG%M TGDPY(WO
MCH/E;W^4^E2:3I%Q8^(?$%_*T9BU">&2$*3N 2%4.[CCE3ZUY]XX9#XVU(7-
M[;6UNVEPQ-!=W4EJ+U=TI:-2@)D'.".HS@=3D ]%MO$=A=23Q+YR26]G%>R(
M\9!6.3?M_'Y&XJI+XSTQ+>RDACO+MKRT6]CBM;=I'6 @$.P'0<XQU)S@'!K$
M;3=?O+AM8TNQL[=-9T>"VFM[V5D>R==[#A5._ E(*_+RO453_P"$$U"U?1[E
M;6TU"2WT:WTVX@>^EM@KQ9PZ.BG<"68$$#L?:@#J?^$PTN6XM(;,75\;FWCN
ME:T@:0)"Y(1VQT!(/OP>.*H6?CRVDO/$*7UE=V=KH\A#7#P-M*B-&.>.&)8X
M4=1@]ZH:GX2U%X],BTC3M/TZ>U@BCCO[>^E1[4!LN@79^^3K@,0#DY J]_8>
MK0:GXF5;'3;[3]699U6YG9<MY4<31.NPC:0A.[)Z]#0!T6F:BNIV[3"TN[8J
M^TQW4)C;H#D ]1SU'N.HK"O?%T5UH&MW.E1W8:TL[F2&[>V(A=XP0=K$8.&'
M0]<'&0*G\'Z1J.CVEY'>L(X))]]K9K=/<BUCVJ-HD< D%@3C&!G K"/A+699
M]9$,%EIEM>V%S ]O;WDDL5Q/)]V4H4 BQ\V2N2=W.<9H V?#WC*QU:.VMY!=
MI=O9"Z#36KQK<* H=H^/F +#IZC'!I7\76]S;ZA;P0WMG?PV,EW"EY:M$711
MC>H8<X)7(/(R,BH;KPWJ<EWHD]M<PP26&DW-F9>25ED6$(RC'(!C)YQVK$TK
MP7K<>H/=WBVT;MHT^GNQU&:Z>69S&?,)=1M4[3P.GOV -?PWKNHZCK-A;W,X
M>*;P_;7SC8HS,[$,W [XZ=*T-5\8Z7I-Y<6TJ7D[6D8ENVM;9Y5MD(R"Y XX
M!.!DXYQBJOA_PW>Z7JUE=3O 8X-#M].8(Q)\R-B21Q]WG@]?:JM_H7B"VU+Q
M =(CT^>VUL*S274[HUJXB$1.T(WF+A00,KSD>] &AJ/C?2-/NFML7=U*MJEZ
M19VS3#R&W8?*C&/E/YC&<U2O?&,5EKRW+7)?0O[$.HDQQ[B09% ?IG&UL_2I
M-+\)SZ5?7'E31O:_V):Z9"6)WEHO-R6&. 0Z]_6H-$\'7-HVEQZA]GEMH/#J
MZ3<HK$[WRN[&0,J0#SU]J .F75K1]9&E(Y:Z^S?:B%&5$9;:"3[G./H:Y4^.
MHM+\1^);75/M<EII\\.UX+1G2VB:"-BSLHZ;F8\Y.,]A4?PLL+A-$N-3O)_M
M,MPXMK>;&-]K;YCB/_ L._OOI-6\.>)9;OQ5#8+IC67B#;&)9IG62V7[.D3,
M5"D/T;"Y'0<\\ &]J?C'2M+N)8I!=3BWB6>YDMH&E2WC;)#.1T& 3QDX&<8J
M]JVN:?HNCMJM[-MLE,8,B*7^^P53QU&6%<9>^ YX-9O)[?3[35+2\@AB*7.H
M2VQB,<8CY"*P=2H!['.?6M/X@P/!\/S;V:11O'<6*1*02BD7$0 ]<"@#0@\:
M:/)#J$EPUS9'3XUFGCO+=XG$;9VN%(R02"!CG(QC--/C?28K._N+M+RR-C"M
MQ/%=6[1R")B0' /49!''3'.*P=4\':SXG76;G53965U=64-I:Q6\SRH/*E,N
MYVVJ?F; P!P/>DG\&7M]H&LVPTC3]/OKNU%O'*NHS7.[YMQ!+H-J^F,T ;LG
MC?3(H+.1[;4E>]=TM839/YDVT Y5,9P0003COG&#4=E\0-#OYK2.'[:%N9OL
MPEDM'6..?G]T[$8#Y!&/7ZU?U/2+B\\3Z%J4;1B"P^T>:&)W'>@48X]16(OA
M+4!I$-KYEOYB>(CJA.XX\HW+2XZ?>VGITSWH ;>>.&TL09AFU/S]9EL";:U9
M?)52?EQD[F&,#INY.!BK]AXR6\\5ZCHTFG7D$=I%%)]IDA95&Y7)WD\*/DX/
M?GTK-G\*:O%8[[7[)+=0^(9-6BBDE9$DC9F^4MM.UL/Z$9%79= U2;Q%JTKQ
MVO\ 9^LZ?';7+K.PDMW191\J[,.#Y@Y)7H>* +NG>,M)U&XBB3[3 L\33VTU
MS T4=Q&N"S(QZ@ @\X.#GI61'XX35?%'AVSTT7<=G?&=V:XM&C6XC6(LK(S#
MD9 /&#@CL:IZ+X&N(;2.QU#2[&,PV<EJ-1AU":5R6C\O<L3+A,@G/S<=!FK.
ME:!XE_M'PPVI1Z9%;:'&\3-;S.[SYA,8< H O;Y>>IYXY -;7/%G]B^)=)TG
M^SKNX6^61FEAB9]NT< 8Z^_H,&ENO&^CVEY-#)]K,%O.+>XO$MV:WAE) VL^
M,#D@$] 3R12^(-+U*?7-$U73([:9[!YEDAN)C$&21 N0P5N00#C'/K6!>>$M
M>ETW6/#D0L#I.J7LMPUZTS":*.63?(GE[,,V2P!W#J,].0#MM2U!--M?/>"Y
MGRP58[:%I78GV'0>YP*R1XTTG^R?M_\ I0)NC9"U^SMYYG'_ "SV==V.?3'.
M<4_Q9INJ:GIMO%I<H#1W*23PFY>W^T1 ',?F("RY)4\==N.AKE[+P5K6GVL=
MW MC]OMM:?4H;9KF1HVC>'RFC,C*6W8+8;!Z#CG@ Z:;QAI\$%H3:ZBUS=%_
M+LELW\_"'#DIC@#(YZ'(QG(I+SQGI=GMS%?3$6RW<RPVCLUO$V<-(,97HWR_
M>X/'%4+G3?$QUG3_ !%%::8]_';36D]DUTZQB-W5E*R^626!09^4 Y]JS]2\
M(:E/KT^K2:?8:B]]:PQW,+7\ULL4J @E2JMO0ANA (Q[T =*?%.GMJ4-C;)=
M7DDD<4K/:P-(D:2$A&9AT!P3]!DX%26/B*TU+4Y[*UANW$,CPM<^0WD^8APR
M[_4'(],@C-<]J?A;49+_ $UM*L;'3WM$MXEU""\D1XXD(+1&,)B5< @!CCYL
M\'K8LM U2'QJ=3CM[73K-FE:Z%M>2.+[<,(S1%0J.."6!))XY!H T=8\7Z;H
MFH-83QWL]VML+HQ6MLTI$66!;@< %3G\/6FZ7XTT?6+^"UM&N<7,32VL\ENZ
M17"KC=L8@;L9'],TZ;1+F3Q;>:J'B^SS:4MFH).[>)';)&.F&%9=AX1O8+3P
M=!/)!C1[%[:Z*.?F+0+'\G'(R#UQ0!IZ?XRTG4KVWMX?M*I=;Q:7$D#+%<[0
M2=C'KP"1Z@$C(IEKXVTF]FCCA2]*3K(UI*;9@EWL!+"(_P 1P"1Z@9&17/\
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M'@Y_>+N'*\?RKDG\":Q=6OB+,5I:/J6D"QAC;4)KHB0%SN>1US@[NPKH-?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9/92'<]NUNIC8\<E<8)X'Y5?HH H#0](6QFL5TNR%I-CS8!;IY<F %&Y<8.
MJCGL!Z5&WAO0WTM-,;1M/;3T;>EJ;9#$K>H7&,^]:=% %4Z;8,S,;*V+-,L[
M$Q+S(H 5SQ]X!0 >HP/2LWQ!X9M];M"D;1VMP9XKAI1"KB5HS\HD4_?7V)],
M=*W** ,#P[X970KG4+QYXY;J^,9E\BW$$2A 0NU 3@\G)))/'H*U3IMBT3Q&
MRMS')*)W0Q+AI 0P<C'+9 .>N0*M44 5WL+.1KAGM(&:Y0).6C!\U1D -_>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)')521P2%QG'&<URNM6?B?4]:2&6UU#R;?7+>>)(4MUM?LR2H?,+']X7QDD
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M 6R5&#TX[&M6]T;[-X-\.VXL-2CN]/CB:)]+6,R6LHB*DE7.U@=S*1@]?QH
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MAKZ-[?[-]E?]^94D+$>8.HW#.>"!D8KK->L+JY\3>&[N&W:6"TEN&G((&T-
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M=O(MN;.WM%M_(8 (7\UV^;<K @!<<!<9ZUT-OH-T^L^-9A"()-2$4=M<G&6
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M FD19-P^OW1S[5J16MQJOCG2-<ETN>WMXM+N8\72J'AE:6+ (!."55^G;\J
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M1#YCP+'$"["/"=5/ ';UK3UGP[=7)\:S!!;^:;:\L;AB OG0QA@WMAD )]*
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M@['C)Z\YST((Z]3S7B'Q+XCLY_%=U8W-C'9Z L4RPR6Y=K@&)9&4MN&T=<$
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M4UMY)F2UTB2=I0#A7958^6G0'/4YP1TJ"Q\1:_X@U+0H+&>SL8;W18M3N&>
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MD%MAV.W>/G)R?F)ZDG)R<U6U#P7HFIWT]W<0SYN=INHH[F1(KG:,#S(U8*_
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M0'AF7[RJW1B,'(!)&#4-SXST*WMM0E2]28V$;R2K&"<[3M(!Q@X8A3C.">:
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MZCE%D66-HY&C>-U.5964@@@^E7Z* .>'@G0QIUU9&WG9+FX6ZDD:YD,OG*%
MD$A;<&&T<@TLO@S2)K2WA?[;YMO*TL5T+V7[0KL,,?-W;N1@$9Q@#C@5T%%
M&!/X.TB8VSI]LMYK>'R%GM[V6.5H\YVNX;+C.3\Q)R2>]/N_"6EWTD!N#>R1
M1+&OD->RF*3RSE-Z;L.00.3G..<UN44 8\7AC3HM9753]JEN$=Y(EFNI)(X6
M?(8HC,54D$C@< D#%3:QH5CKL$,=ZDH:"3S89896BDB?!&5=2"."1[@UI44
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M?_5_,Q*X(+8P <Y)%8>A>-AHWA/PWIYFL!>75G)<--J=[Y$2HK[?O88LQ)X
M'0$]N0#U&BN)L_'-WK<>EQZ'I<$UY>6TMU*MQ=%(XDCD\L@.J-NR^0I P0,U
M;^',\]SX)MYK@.)FN;O<KON*G[1)\N>^.GX4 =717GND^+]=M-$UG4-:M+6<
MP:G)96L=M<$L\IF$:1<QJ H+ ;SDXY(KH-)U[4)/$$NAZS86]M>"U%W$]K<&
M6.2/=M8995(8'';G- '145S.J^*)[+Q9:Z'#!9*9H5E$M[=&'SLN5*180AG
M&2,CJOKD17/C)K?1-<U'["&.EZA]B">;CS/FC&[../\ 6=.>E '5T5S-KXHG
MN_&5WHBP64*6KA66>Z*W$JE WF1Q[,,F3MSN['TP<S3/'6I7<&CZC=Z+#;Z5
MJ=R+1)%N]\J2$L%8IL V%EQ][/(..U '<T5P%E\3;>]U6UCC73VL[J^-E&B7
MP:[4[BHD:';PI8?WL@$'V$\?CC4FD%S)HL*:4-7;2GF^UYEW><85D";,;=VW
M.6!Y/&!D@'<45YIXP\2ZMJ.@:R;#3XUTNUODLFNOM168NDR!V";<;=V5^]GJ
M<5U/CO4=2TCP/K&H:28EN[>V>17D;&S )+ ;2"1V!&#ZB@#HJ*\_U&^\1+XP
M\-[+&S?4)=.O?,A%XPMU&^##E_+W'CL$ZMZ<U+-\1XTTC1Y6@LK2]U&2XC*W
MUX(H(3 Q23,FTY^8   <Y[<T =W16+X6\0)XET47RQQHRS202"*7S(RR,5)1
M\#<IQD' X-<=K7B75M9M-,N[?3XX=&DU^V@BN5NCYS!+D(6:/: %8J1C<3TR
M.> #TNBN N/B;;PZM<0HNGM:V]^+"2-KX"[9MX1G6';RH8^N2 3]8+'4&@O)
M%D-Q(9O%TMNFRY:,*/))&X#[R\?=/'0]J /1J*X^U\<B>STEGLA'=W5S<07<
M!ES]E$ ?SF)QS@JH' SO%4M ^),6M:GIL'EZ?Y6IH[0);7XFGAVH7 F0*-N5
M!Z$X/'O0!WM%<+I?CG5+K1M)UR_T2"TTO4IX(E9;LO)$),J'8;  N_8!ST?)
MP1BNDT363K,NILD 2VM+Q[6*7=GSB@ =L8X ?<O?[M &M17$WOCB^M[?4M6A
MTF&70M,NGMKB9KDK.VQMLCHFP@A3G@L"=IZ<5#HL>H7WQ2U^XO;:V:*Q$,=O
M(+N0M$C(2-J;0OS DMSP<8W8S0!WE%<KXP\5S^&(S,JZ1Y2PM+MO=1^SR3$9
MRD:[#N.!U)') J"Z\7ZI/J7V/1='@N?^)7#J?F7-T8@%<N-F K'=\@QVY.2,
M#(!V-%<C;>/+618;FYMC;V5QHHUB&9GR64#,B$8ZJ&0]>=WM6O'K9M_"(U[5
M+8VOEV7VNX@5MYC 3>5S@9(Z?6@#7HKC[;Q3K8O-.M]0T:TMVU:&1K#9>L^V
M18S((YOW8VY4'E=V,'@\9K_"V*Z?PL-1O881<WLCR/,EP\K3?.W+;E&TC)
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M!)")DFC:)C@.K J><=?K0!S[^%;F'49;[3==O+.>YBCCNV,4<OG&-=JR?,N
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M$1.<*YD&UCZ ]Z .4G\ 1R^'[?P^FKW2:0D0CFMS#$QD^<L6#;<H23CC@ #
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MNOM/0_,,GWKTFB@#ROPMH#:?#\/KN'37@OGMY5OYS$1(=UN3B4GG[P7 ;I@
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M?I8TL17%W)_9UU<741ED#%VFW[MQQD_ZPX[],DT 97B'QK>>';I5N'T5_+,
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M_I<JV-LMJ[JMM-(ZW,J!01*@(VLA)QQT'4YXK:T/2FT728=/-_<WJPJ$CDN
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MVD1DQ^:2%W8XSCG%>7QZEXBOO"?@"_N1:76H7%_"\1,K() UK+\TAV\'DD@
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M$8@S,68 E"X4L2<!N_X4 6?$^KW&AZ!/J%M:_:)(V0;<,0BLX4NVT$[5!+'
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MWHTQN"I4N<KL(*G;MVXQVIUKX'L;:$HU]?3NVIQZH\LTBEGF557GY0-IV@X
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MVV$+KYN5VG(&#CH2!SUK9\%ZWJ_B/18-7U"SM+2WNH4DMXX96=^^2V0  >"
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M;;>)(!!%O9(SQ(!)\Q SDJ>]=5X*L88&U2\AFOG%Y,CN+G3S9C<$"Y6,JIY
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M>2-7)WK/C$3(&8\GD@?+GFLC48[^+3=;T)='U.6ZG\0)>))':LT)@-Q')O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!4^GZ=9Z59)9V-ND%NA)"(.Y.23ZDDDDGDU:HH **** "BBB@ HHHH ****
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M\2P0[$B\Q6)4$Y9N@Y)_ =*T-&T:[T2VTNPM[M6T^UMC',DN^2223C#!V8D
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MA# 8*X!R.,9% &K_ ,)8LOB)-&M-*OKF;R8;B65-@CABD+ ,Q9AR-IX&2><
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M[GWE0^><$G:QZ<<'% $MQ\1+:WDF8Z+JKV<%^VG274<:%?/#E%55W;FW-@9
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M% #2B$,"JD-][CK]:1HHW<.T:,R@@$C) /6GT4    P.E1I;PQHR)#&JL<L
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MRPCD2"($"-2^ 6QC.[ P.>A/K6C10!4M--M;.[O+J)#Y]Y())I&.2V%"J/8
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M*** "BBB@ ID<,41<QQHAD;>^U0-S>I]3P*?10 4444 %%%% !1110 4444
M%,DBCF"B6-'VL'7<H.&'0CWI]% !1110 4444 -6-%=G5%#/C<P')QZTZBB@
M IBQ1I(\B1HKR8+L% +8&!D]^*?10 P11K,TPC02N K.%&2!G )]LG\S3Z**
M "BBB@ HHHH :\:/MWHK;3N7(S@^HIU%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ,:&)Y4E:-&DCSL<J"5SUP>V:?110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDMJS?>$>" 1QQN_Q);J?PWO+_P -^,=+2_@5]>U!;R)RIQ$H9&PWJ?D/3UH
MVO$?CV#PQ/,U[HFKMIUNT:SZC'"OD)OQ@C+!F + $@'!XZTDWQ!L(_%UWX<3
M3M2FGLBANKB.$&&!&C#AV;.0,''3/!]*Y3QA\*-4\3:IK,PO].>*_$1AFNXI
M'FM-@'R1X.U5)')QGD\=ZZ8>&[S2-6\;:]&_VEM6M8?L]O /W@:&!DQSP2Q(
MQ0!!IWQ2TW4-0MH&TC5K6WNK62]BO+B.,1&W0$F0X<L!QTQGD<5)IWQ.TJ]F
MB%Q8:E807-I+>6<]U$H6YBC7<Q7:Q(.WYL$#BO-?A[HMPT]MHO\ 98EAU'2I
MK34[IK&YAET\%/N;Y6*$ECR$ !(S7:^%/ASJ'AUHU:W\,%[:VDA@OHK!_M$C
M%2JL^6QW^8#KSSS0!U?A7Q4GBNR-Y#I=_9VK(LD$MR(]LZ-G!78S<C'(.",B
MJ6M>/8-!U'R;[1-72Q%PENVH^2H@#O@ C+;BN3C('YU4\#>";SPQJNJW]S)8
M0)?! +#3$=+=&7.7 8G#'/08 KGO$/PHU36];U*[:_TZ1+F]CNH;BYBD>XA5
M2/W*G.U4X/09_H ;FK_%?2='OM3MI-*UB=-+F6*]N(+=6BA# 88MNZ'.,=>#
MQ4?C/XC0:;!K.F:7::E=7UMIS3R7=G"'CM"Z$QLY)SZ'@' Y]:34OAY>7VG^
M-K=+Z!6\0RQR0DJ<1;0!\WKT[57U3X>:ZVIZQ)H^L65O:ZY816E^MQ;L[J8X
M_+!CP0.5)'/3.>>* -3^TM=F^#5OJVGW.=:_LB*Z$KH'WN$5VX(P2P!'XU3;
MQM>:RW@:#1I$276O]*O#L#;((TS*O/0ECM!]177^'=+?1O#&EZ3,ZRO9VD5N
M[J.&*H%)&>W%<=X)^&]QX1US4;]K^*YB6%[;2H2I MH6E:0JWXD=/0T 9UW\
M0-8@^)*HK1?\(G'J2:-*VP;C<M&6SNZ@!B >W%3>*+SQII_CO1-(LO$]O%;:
MY+<^4&TU&-LL:!P"2WSYSC/%57^"=M-X/EM)M1G;Q!*[7#7HN)1"9R^[?Y><
M>V<9[]:ZW4?"]]J?B7PCK,]W )-&6?[2H4_O6DB5,KZ#()YH Z:SCGBLH([J
M<7%PD:K+,$V"1@.6V]LGG':IJ** "BBB@ HHHH **** "BBB@ HHHH ****
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M;R9V30R!T;!P<$<'D$4^:X@MPAGFCB$CB--[!=S'HHSU)]* )**** "BBB@
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MR+IUV[230EF(9FQDY)R.@QCI@8QBD7PCI?\ 9]U8S-?74%R%6075]-,<*<@
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MKH]U:Q_:)XG_ '[&(H"$)^3*'!Z]<@<9S;+0?$MYJ,]Y?6FH^8^@7-D[WUS
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M %>]L+/4K?[/?6D%U#G/ESQAUSZX(Q3[:VM[.W2WM8(H(4&%CB0*J_0#@5+1
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYU1))VEAOI&$I^SAO,E4@!F//'(4X()K1@\>:L_A)?$<^BVMO9SM&D)>[8[
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MW1CED94#N(UV$':K#[Q&3D>]:VA^'#H^HZAJ$VI7-_=WZQ":28*H'E[@-H4
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MMVBARJ2@!>6#C;NSG/UK1\,1V.G7U[K=N]PR0:=LEM+70I;,$*=P^4_?D'S
M <\F@#T6BF12":%)0K*'4, PP1GU'8T^@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"I?:99ZD;4WD/F_99UN81N("R+G:V ><9Z'(S@]A5NBB@"IIFF6>CZ=%86$
M/E6T6=B;BW4DDDDDDDDG)/>K=%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1VEI)/82VRK I$,;.A' ZXR: %U+5I+;1M(NGNFMWNKJTB9DA$F\R,HVX)&
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M_P"F2T =+XJU:;1O#UQ<6BJU](5M[1&&0T\C!$!'<;F!/L#65I7B\0^$6O\
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MK.58KR]BC!AMW;!PQ)!. RD[0<9YQ6%>>#=?>RO]'M;O3AI5QJ?]H+)('\X
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M 09\SS5BXYZ;F'/I7/V_@W64TVT\.RW-@="M;U;E9EW_ &AXTE\U8RN-H.X
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MII=K=0SB=<M.\Q0EL8QR58D>] $,/BO5'^'*ZK)#$-6N)#:V>(RJ3R-*8XI
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M!)+=*^Z,-;*I=,</P2,''(Z]J[^QM([#3[:SB),=O$L2D]<* !_*@"Q1110
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M#@[AR3C!X&,5Y]X4DALO!7@9=.OYS)-J,,=X@O'DP?)ES&5+':,J/D&!D=*
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MV4@G*;3D$$YZX)R1:LO_  CVFZ7?S7-S*VHW]M#+<:K)9H8X)74>;,N68A0
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MF%GO%9H"B,RL%&2=P&!P1C)&>U>::E#:2R>(M)T;4[N^TEO#\MQ.%U&6<1W
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M >N45Y5KOB:ZD/C*?1]3,MO ^G1>='<$1P(S%9F5@#LP,Y90<8)ZBI8[>_\
M[+UF&W\1Z79VT@M3#$NNRW/EOO)=3,RJ\:RJ HQD@@D4 >ERW-O!+#%+/'')
M.Q2)'< R, 6(4=S@$\=@:EKR&X?2-5_X1*ZN9+VQM8-5NK.9VUB9D5A#-]R<
M.,@L,!L@XRO3(KUT8P,=* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3,@O1&R*%8G.T;3G ))QQ0!U]AX86WU234]0U"XU.[:V-H&GCC55B+!BNU%
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MB^85VEL<D>F?3DTZB@"O#8V=M%)%!:P11R9+HD84-GKD#K4ZJ%4*H 4#  '
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MD=2H#'US@\4 =[<75O:",W$\<0ED6*/>P&YST49ZD^E/EFB@CWS2I&F0NYV
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MQ3P6<45S<FYF10'F*!"Y]<#@?A0!/1110 4444 %%%% !1110 4444 %%%%
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M$FV<MY;E=LF,'[I/2L_P3XEN?%#:G=O.OV>.YDAAM_L4D1C59&527;AR0N2
M/E/!Q0!J3^%-&N;"VLY;>4I:NTD$@N91-&S9W$2AM^3DY^;FM&PL+?3;-+2U
M5UB3)&^1I&R3DDLQ))R>YK/B\5:/-JZZ6MTXNGD>)-]O(J2.N2RK(5V,1@\
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M$3F-)&QM1I -BL<C"D@\CUH CD\&Z!)IMGI_V#R[:R=GMA#-)&T18DMM96#
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M!_L<P:/8K'E-F[.5QC&1UZ5NZKJUCHMB;S4)Q#"&5 =I8LQ. JJ 2Q)[ $T
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M2/&\<G/SAU(8,=S9.<G)SUKG;_XC0S>'/$UUID4D=YI'F!/M%O($<+M^8DJ
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M)$Y9=B#Y@S< Y  RW)KJ?"6E7.D:9>0W4:I)-J-W<#:0<I),[*3COM(K>HH
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MC91\I(.50G(KIJ* /,(_!NL6=KX?N3;7$TEC'>03VUG?_9Y LLP=61PP!X4
MJ2.H]*[CPUIJ:5H<5NEG)9DO)*\,MP9V#.Y8DN2<DDY/UK7HH X31O#&J6>F
M^!X9H4#Z3+(UV!(#L!@E08]>77I4EGX=N+7X=P:1>:2;R=)GD:""Y$3J?.:1
M71\@!AE2.1]:[>B@#S^/2O%$4/A[4+FW;4+K3KVX<P/<1B802(Z1[GX5F4%<
MD=??ON^+M-O[V+2;O3H%N9]-U!+LVS.$\Y0CH0"> P#Y&>,BNCHH \];2O%A
M'B#4(+1;*XU"]M91!!<H93 B*DBAR-JR$+UZ#L>AJA<>'KZP\)^+=0OE:SE%
MRFJV3W-UY[HT$494N_KF,@CG@X&17J-,EBCGB:*:-)(V&&1QD'Z@T 8/@JQG
ML_#,$UXFV_OW>^NQZ22G>5_X""%^BBN9MO#>O_V%8>%)=/B2UM-02X;5!<*0
M\23^<"J?>$AP%.1CDG)KT>B@#!\.:7=:=>>()+E JWNJ-<PX8',9BB7/MRC<
M5D7>C:O_ &GXPABL1);:S;9@N!,H"N+<1;&4\Y)&<],&NUHH XNX\+WUU)X>
MCPL4=KI%S97$BL,QO)'$JX'?E&Z>E5/"/AFZL+C25U+2;U9],@,:74FJF: -
MLV$QQEB0".Q48_"N_HH Y^32;I_',NJ>6IM6TG[*&+#._P TMC'IC%8.F>$]
M2@TKP1:S1K$VEVLD-X4<9C+6Y3CU^8]J[ZB@#SS3- U^33_"^AWNF0VMOH4\
M4LE\MPK+.(D95\M1\P+9!.[&!GK4]MX7U.+PSH]DT*"XM==-]* XXB^TR/G/
M<[6'%=Y10!Y[J/A[6Y]&\9Z/'8*ZZG-)<VESYZA7+K&-A!Y!&UN3Q6_=:=?Q
M>,I-9M;9)HDT=[>-#($WR^9N5/8'UQQ71T4 16KS2VD,ES"(9VC5I(@^X(Q'
M*[N^#QFI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKB?&&GWU
MQK]G='3M9O\ 2XK.421:9?\ V=A+O0AB!+&6^4-QSUH [:BLS1+VSU/PY97>
MER226DMNI@:1F+XQ@;BQR6]23G-<;X( T:\TO3M:LM<M==N;+:9;W4&N8+ET
M53+M E=5.>>0O&<>E 'HM%<GKE^^B>-M(OI[F1=.O+6XM9D9SY:2(/.1L=,[
M4E&?I7%:;K.MIX4UG2[R]G_M;57M9[%V<[X4OL+M4]O+(DZ=,4 >PT5Y[K'Q
M!?2=0U.TLX;:6+1]D<D4TCF>Y;8KL(\*1D*P +=3D<=:ZCQ+K4^C>'I-2M;4
MSL&C&&#8C5F ,C!06VJ"6.!G H VJ*\ZU'4]3U#6_!UWI[Z7>74PO0LL-PQM
MBNU?FR 2<#^'UXSWK23QA>2>'!>2G2;"\BOIK&X-Y<L(M\;,I\O R^=N0.#@
MGTH [.BO.[/Q WB34_!6H-&D;F^OX9%B<LA:.*5"5) )4[<C([UL_#QROP[T
MR0\D12'GO\[4 =717"Z!XSUB_;PY<:EIME;V6NQ,8?)G9I(G$1DRV0!@A6Z<
MCC.:6S\::K-:Z3K4VG6B:)JMU';P!96-Q&)&VQ.PQM()QD#INZG% '<T5YBN
MM:XWA/Q/<ZVMM<P6NHR0(L$\D;@B9!M#+@A1GCG)[TV[GU6T\;>+-<.G:??2
M:/;0O;AF<RI%M=BL?& 67=GU..M 'J%%86F^(5U?Q!<6EDB26,%G#.UR#U>7
M+*H'^X Q_P!X5F7_ (RN+(ZS:&SC;4[2\@MK.'><7"S[1$Q].2^?^N9H ["B
MN'U#QGJT%KK&L6FG6DFC:1</!.))F$\HC($K( -HP<X!Z[>V:N7WB^6ULO%]
MQ';1O_840DBRQ_?9MUEY].3B@#K**Q]=UX:'X9EU=K<S.JH$A#;=\CLJJN>P
M+,!GM7.ZGXA\0VL>I:3>6^GQ:@VE37MI/;2N8\(0KJ<C(8;E((X/M0!W5%<M
MX L3IO@73_\ 1;."26W2=A;DA9"47YW)&=QP,GG\:RK/Q_.^H7=I*VDW9339
M[Z-].N&D13$5!1B0,YW###T/% '?45Q%CXKU^>73TN=+L4;5M.EN[!8IV8K(
MBJP23( P0XY'3!'/6KVC>,/[=O-%AL[==MYI[7UV6)S;\A GU+[Q_P  - '4
MT5Y]\2-2DEN+/0K/6DTJY,$VH&8W AR8UVQ)DD9#2,"1W"&KR>,[G5K/PX-"
MM[:2[UFV>ZS<NPC@2,+O!V@DG<X7'U]* .SHKS/P[KVJ6EA]A@L[<ZQJ>O7\
M8268F&#8[NY+ 98#&!P,Y'2HM*O[F$WS:E:J+F3Q?'"R0W+A$8Q1#<",%E[[
M6&.>10!ZC17F+:UKA\+>,+C65MKFUL[N6)$@GDC<$%,*&7!"C/7.:W=1\4:R
M;G7&T?3[.:TT3Y;@W$S*\[B,2,L> 0,*R\GJ3^- '8T5P]QXRU>\N;I="T^S
MEM[?2X-2\R[F9"RR"0A,*#R0G7H/>C6_',UEHMGJMH^D11W&GK?+;WMRRS2@
MKNV*JCCC W<C)Z4 =Q17':/>C4/B%->(&6.X\/V<RJ3TW2S'^M126Q\4^.=9
MT^^N[R/3])AMUBMK6YD@$DDJLYD8H0QP  !G P: .VHKSV>'6-.^("6>B^7>
M2QZ&H,NI7#'@3/C) )9CP,GZDGO9N?',[^&M)U>U?2+3[=:?:/)U"Y8.6P"4
M15'(]6[<<<T =S17%0>,-5U>[T.#1].M?^)EI:ZF[W4S 0H2N5^4'<?F [>O
MM5:#QSJ-YX@M+.VATSR;C5)K!K<S,;J)8M^Z1E P ?+./3<O)S0!WU%>?:;\
M1Y-1U*S,4%J]C=WAM4BC9S<1KN95E;Y=N"0,C/ 8')Y%;'A;Q-=:]?7D5RMC
M;M 7#60=A=08?:/,5@,@@9W#CTSUH ZFBN(USQ&="U;Q-=PV9FFL-,M9_FG;
M;)N>4;=N=JXV]0,G//2G7'C/4-#DU9->T^V5K33?[1B%G,S[EW%3&2P'S;@.
M>AST&* .UHKD[O7?$&CZ6MUJUCIVZ6[M($%M,[8\V58V!RHY4,"".OH*CUWQ
ME<:0_B-8[))CI-M:S(-^#*96=2#Z8V\?6@#L**XV]U[Q3:ZAI&DC3M*;4=1C
MN92?M#^5 L?EXR=N6^^1P.N#TS6?>?$>6#4[U(8+22VL;P6<D&]S<2D%5=T
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MW&[S,E(UV \X4Y8\#(X/:<^-[F?4-&BCM[6P@U&SAN5?4G>/S'<G,*$# D4
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MI6$%NEQ+>VT<#KO61Y5"LOJ#G!'O0^IV$5Q!;R7ULDTXS#&TJAI!ZJ,Y/X4
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M+'"]R,]<<4 5-)\$0:;-ICW&K:EJ":6FRQANC$$A^38#A$7<0I(RQ/4U'8^
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MRM95BN+NWBD8J%220*26)"@ GN00/7!I%U&Q>^:Q2\MVNT&YH!*ID ]2N<T
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MP!@\<]:UAXSO%\5V6F_:=+NK:\NY;0+:Q2EH&5'8%I"=CGY,,H ()[XK0M/
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M=R>YH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*JZE?1:7I=WJ$X<PVL+SR!!EBJJ6./? H M45EV.O6FH:E)80K*)DM(;PEE
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M;R%4K#'N"[W)(XR>V3P>* -:BBB@ HK%U;Q3IVBW)@O(M1+!-Y:WTZ>9 /\
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MODQ)(C_<93D$]?F(JQXTO+;3O%=M?W%W;W@CC@C&E?;7AN(V,IQ+"JG]X3D
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MIO\ Z%/5+4[RVL/B3%)+=V^HO<W,%O':1WKI<V#%.HB!P\9^\V<=3U KT0*
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MO;'6;1I6%S;SZ;Y8)*^>Z[X&QZ[T*Y_VZ[LHA96*J67[I(Y'TI2H;J ><\T
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MD5F7."1G%*%4'( SC'2@#SCPLNA+\2YQX>O3=68T<99;EIXU?S1D*S$\XP2
M>I]36C)I-G+\8ENGC<S#2!*")7 W"7:.,XZ=NG?K7:I''& $15 Z!1BEP,YP
M,],T >/27L+V$US_ &E./'(UDQ):BZ?S /M.%019QY7DX.<8QDYS77>%-/CN
MO$OB/5+B:YEN+;59+>W5IW\N)/*C) 3.WG<>H[#TKLO+3S/,V+OQC=CG'IFE
M  S@ 9Y- '*^.9Y+FRL_#=J[+=:Y-]F9E/,=N!NG?_OC*_5Q740PQVT$<$**
MD4:A$11@*H& !3L D' R.AI: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K U?Q'-9:S%I.GZ5-J5X;<W4J)*D8CBW;0<MU8G( ]CDBM^N=U;P]?W'B
M"/6=)U2.QNC:_8YQ+;><KQ[MRE1N7# EL$Y'/(- &+X:\0ZI'X T>]^QR:A-
M,DC2RW5XD6W#G 9G))8] ,8X.2.*U-,\<6&HM:,8I+>WN]+.I132D ;5.)$/
M^TN5)]C68GP[EM[31HH-3MIGTV":#-]8B='$CAMX3> L@QC/(P3Q5'7_  -(
M/"_A;P_:RW$TEM<BUENHH]O^BNCB??U"AEX_WMM &W9>-Y-1O=.L[;2'$]W9
M17SQS7"1LD4C$#:#]]@%)(&,9'.33OB/?ZCI_@Z9]-67S99X(&DBF\IXU>5%
M)!Z@G.W(Y&[/:I/$GA2X\02V\7VRS@L(7C=5^Q;KB%D8',4N\;,X ^Z<5I^(
MM&_M_1GT_P _R-TT,OF;-W^KE23&,CKLQ[9H QM.\03V^JKX>@T:[8V<$,MW
M//>B06Z2;NKN2SD;3ZY //3*6/CDW3:9<RZ/<6^DZI,(;*]:5279@2A9!RH?
M'!YZC.,ULVVAK!K^K:F\WF+J,,$30[,;!&''7/.=_H,8K"T[P3>6R:387>LI
M<Z/I$JRV=N+79*2@(C$DF\A@N>RKG S0!$?B'+MBN%\.7SV<U])IT4J2QY>=
M7=  I(^4E,;CC!]AFM_P_KK:S]OAN+)[*]L+C[/<0-(' )174AAP058'\ZSX
M?!OE:586/V_/V35GU/?Y/W]TKR;,;N/OXS[9Q6IIFC?V=JVLWWG^9_:5PD^S
M9CR]L21XSGG[F>W6@#E;OQ)KEQ+XWLGLO(M].MW^SW,<X#QG[/O4\<DDG<#V
MZ5<\/^+Y3#IMIK&G7%D)]--W#=32J_G+&J>86 )*GYPW.<@]CQ5NZ\*74VI:
M_+%J4<=GK5MY4T+6Q9TD$7EAE?>!C&"5([=14LOA.*>;1VFN=\6GZ?-8O'Y>
M/.618U)SGY>(^G/7VH IZ)X]M]8U*PMFL_L\>I1M)9O]HCD9@J[L2(IRA*\@
M<]"#@\5IZUXAET[4K/2['3I-0U"ZCDF$2RK&J1)M#,S-TY90!W)[51\-^%+O
M0'MHGO-.GM;6+RHF331'<, ,#?('()QUPHS5O6M O+S6;+6-*U&.RO[:&2W8
MS6_G1R1.5)!4,I!!12#GUR#0!A^#O$\TFGZ7!?1W3W&IZGJ$2F=\M (Y)6"M
MR>BKMP#@8]*OW?CJUMK>8BU9K@:F^F0Q-*J"215W%BQX50H)S[=R15>'P-=V
M6FZ:EGK0_M'3[^XO([J>U#K)YQDWJZ*R]I#R".1G Z5&?A](=/"R:JD^HIJC
MZG'<3V:M'O=-K(T>X J03T((XYXY -_PYXAB\0VUTRQ>3/:7!MYXQ(LBAPH8
M%67A@592#^G%<GXK\7WUQI%__9>GWD=I;ZC#9G4HYU4B19T5\+G=LSE,]SVQ
MS79Z)I]QIUDT5S)9/*TA<FSM/L\8& ,;=S'MU)KFKSP)?3Q7NGP:ZL&D75_]
MO-O]C#2+(9!*R[]^-A<$XV@\]<<$ T=9\62Z)J445UI;"QDN(K<7/VF/>3(R
MJ&$><E0S $\'J<8K/L_&-_!J/BN36+%8-+T:0GSDD5F51"CXVCEB=Q(],@5'
MJ'P\DOM5O+D:E:K#=7\-\S26 >X4QLA$8EW\)^[X&W(SUQP;]WX-:]N_$4<U
M^ITO78\3VX@_>I)Y2Q[EDW8QA0<%3SWH DT+QBFK:N-,N+,6MS);&ZA"7*3!
MD!4,&V_=8%EXY'/!.*L:IXCN+;61I&F:5)J-\MN+J51,L21QEBJY9NK,5; Q
MV.2*3P_H-]I4Y>\N=,G B\M6M=-^SNW(^9VWMGIT  INI^'M0DU\ZUHVJ0V5
MU+:K:SK<6IG1T5F96 #J0P+-W(.>E ',:GXANO$NK^$DT^VOETR^6>:58[TV
MTF^/"LC%3GY#DD9PQ]<5UWB/Q$N@"P06XGGOKC[/"'F6*,-M9OF<\#A2 .22
M0*IZ;X-ATN;0&AO'9=)CN%.] 6G>;!9B0>/FR<8[UH>(-+N]7L1:VTU@L;9$
MT5]9?:8Y%/\ L[UY'7K^% "6VNF;7!I,UF\%R+!+U\N&";F*[..I!4\CBLBV
M\<MJ=KI)TK1YKN\U"R^W?9S,L8ABR!EG/&23@ #G!Z8J.#P1>Z:VG/I.NF"6
MVTY=-GDN+;SC)&IW!E^8;6!+8SN&#T.*;9^![W1X-';1]9BAO+"P_L^26XL_
M-2>+(8'8'4JP(R/F/4YH I2^*-5T[Q5X@E32;V\MX-/M+J2W-PBBU&V4N "2
M"YQT7@[>O3/9R:M OA]]9C5I+<6INE'0LNS</IQ68OA>0S:U--J!EEU6QAM'
M8P@;2B.I?@X.?,SCC&*FN],DM/ D^E0EKB6'3&MD*K@R$1;1@<]?2@"AI?C.
M2^OM-@NM%N;*+58&FL99)48R[5#%64'Y"5.1GJ!S@\5%_P )O<17ES976B/'
M>)937D$$=U'*T@BV[HVV_<?YEP.0>>>*JZ#X0U.:TT6?6=69Q86!BM8([;R9
M87DB",7;<=S*N5&%7U/-2>&_ 4FA:IIU[+?64@L+.2S1+;3Q 90VSYY&WL6?
MY.3T.>@YR 7;OQS90VPN+:"2ZB_L>36&9& VQ* 5!]VYQ_NFJL?CC4)K^*PB
M\+7AN[JU^V6B-<1 /$" Q<Y^0@LO'/WA[XSO"_@N3_A'/%%I,9[4:H]S8VAG
MC^:WM 76,;>. 7=@,C((KJH/#_DZ_8:I]IS]DTU[#R_+^]N:-M^<\?ZO&,=^
MO% &.WQ!M9K/27L;3S+G4;9KI8;BX2 1(I"MN9N,[C@ 9S@]AFEC\>B^72%T
MG2+B\GU.WGFCC\U$$1A=4<.Q.."Q&1GI[U7C^'KV=MI+6=_:->6%O);%[RQ\
MZ*:-WW\IO!4@]"&]?6MJU\./#J^EZE+=0F2QLY[9HX+;RD<RO&VX#<=H'E].
M<YZ^H!@W/CC4[IO#$^D:29(M3N)X9X9I55U>-)-T>>@(:,G=T(&.]=Z.E<?_
M ,(5<VVF:5%8:K'%>Z;?W%[%/-:ET;SFE+*R!P>!,1G=_#GOBMO2#JTEYJDN
MHX2V-SMLH<#<L:J 6)']Y@S 'H"/H "I;>)FO?%-YHUM8[TLG6.XF:X564L@
M<,(SR4^8#=ZYQG%16WC&"YTC1=0%I(JZK>_9$0L,QGY^3ZC]V?SIM]X6NM2\
M3V6J7%]:"&RG\Z 1V6VY VD>69M_*$DDC;SQ5"T\"WUM)IENVNJVEZ9?M>6M
ML+,!SDN=KOOYQO(! 'N#0!>M/$]UK"W$EGI$XTO,\4>H><@RT>X%MF=VW<I
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MW4+*\TT?;RDEREYIHG(D5 A:,[UVY"C@[AGFMSQ#HD?B#0KC3'F>#S-C1RH
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M6BV8?[.K$*&,6>QYSCC.:ZIM'T'1_BK;9M+>V:72T%B7R \ZR,,+ZL%V\>E
M'HM%>/\ @>)KC4]%EN-6L(->221M1M]LGVR<[7WI*"V-H."#C VC;75_#32;
M:V\,6^IE)&O[KS!--*[,S*)&"KR>  !@#^M ':T5X_K.H03^,H9;:WM;348-
M?M[=_P!Y*]Y)$9$5G/9865B .5(([G%;.AS6=I\2+BWADM-4GNY[EWN8RPN;
M+'/ES Y!CR-JGCM@'K0!Z/17G'CE;RT\1+;6IF$?B6T73&://[J191\_M^ZE
ME.?^F8K#MY=?O_#NN2VYNO[0T'2CHZ%0V^28.?.D7U8QI$01SEN* /5-;U:'
M0M#OM6N$D>&S@>=UCQN(49(&<#--M-9@O-;OM+2.036<,,SLP&TB7?M YZC8
M<_45Y1<6]FWA3Q5-I.JZ7-;MH<J266FK)C?U61]S'#XW YPQSSTKO=$5A\0O
M$1((!L-/P<=?]?0!U=%>/^+]0@E\17CV]O;6NJV>I6B1N\DK7DJ[HLNBCA8M
MI*GJIPV<$ULVLUG9_$]ECDM-5N;RZD#,"PN]/ B.0PZ&'Y<#[O+C&[K0!V\F
MKP1^(8-%,<GGS6LETK@#:%1D4@\YSEQV[&M"O._&2Z(/B!I+^(CMTW^S+E6:
M0L(MWF18$A'&.N-W&<=\5S1:[_L7PPNIRQ1Z 7OMK:LLAA*^9_HHFY'_ "RS
MMW''3OB@#U+7->71FLH4LKF^N[Z8Q6]O;E S$(SL<NRJ %4]3Z5K@Y .,>U>
M46^@65U=^"!<S0:M";R\$<Z!]@B\N5D0%B254X )/852N'M9+6[W/+_PGPU=
MA"NY_."_:/DVC_GAY.,_PXSGF@#V2BO.;72I99?'.KVD<LFMV]S<1:<S.Q\M
MOLL>T(O099N?7CTJKX AM7UFQN+'5].\U;)EO;2V67SI6.WYI]['#JV>2 ?F
M(H ]0HKRGXFWEI)>:E:26UK%>P:7YMK<W,DOFR.=^!;(O\:D EASR,C K0DT
MBW\1^+BFK1RW$/\ PCMM)L,C*AD,DN6(! +#L>V: /1JKWUT+&QGNC#/.(D+
M^5!&7D?'95'4^U>3G5=6T7PUX:UZ(SSW>L:-'I;;B2?M97=;NWODR GW%==X
MKL!HGP@U6P@D<_9-(>)9"3N)6/&XGU/6@#L5.Y0V",C.".:1V"(SGHHR:\VU
MO6(-'U?Q;!>SR12WVD0?8(PK,9F"2JPC ZD$KG'3()XK/D;3'O[1/%#S"'^P
M+0Z6-T@+3$-YOE[>3-GR^GS8QB@#TS1=5AUW0['5K=)$AO($G19  P##(!P2
M,\U?KP>20-H?AK3[JUCN(V\,1A([EI52"1N/-'EH_P PP,Y"GI@]:ZBWT#2M
M5UJTL7D^WZ9%X:B,312,(I7\QAYF <$]2/3- 'J%%>3^'K*:TC\#ZG:F=M4U
M+3YOMDTTK.9V^S[U#Y/0,!CTZ"HO 42S:GH<[:O81:ND;_VE;*LOVN=C&=ZS
MAFZA\-DC'&%X- 'KM5[*^M=0A::TF66-9'B9E[.C%6'X,"/PKROPMI,5EIGP
M]U&-)_ME^6@O97D=C+&;:5MC9/W047 [8XK5\"W'AWPSI>ME_*M+FVU.>.Z5
M48NB-<NL.5 )P0RX/H<T >CT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %#4-(MM3N;">YWM]AG^T1(&PIDVE06'?&XD>_-,
MUW1+;Q#ICZ=>23K:R$>:D,FSS5[HQ_NGN!6E10   # Z"BBB@#$U'PS;:AJA
MU)+R_LKMX5MY)+2;9YD:DE0001P6;!&#R>:T=-TZUTG3;?3[*(16MO&(XTR3
M@#W/)^IJU10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7U+9]LO[C;&$;<([:,;8ESZ_>8^[F@!OC'7+_1=+A71[:*ZU:[F$-I!+G:Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@$'.#TH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** &O&DJ%)$5U/9AD4X    8 ["BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KB?%^F7MUK]G=G2]4U+3(K.59(=/O_ +.PE+H0V/,3=\H8=^M=M61J^B7&
MJ3!X==U33U,?EO':-$%<9//SHQ4\]5(- #]%NM/UGPS9SV#2M87%LHC+NPDV
M8Q@L3NW#H3G.>]<IINBVD?Q)$.E37Z6ND6I>[\S4)YEDFE&$0AW(^5 S'_>6
MNIL/#]KI?]G1V,US!:6%NUO':))^Z<''S.",EAMX.>Y]:DTC1;;1EO/(>622
M\NGNIY92"S.WT X  4#L * .?^)\%PW@35+JWU&\M#:VTDH6VD\OS&QQN8?-
M@<\ C/?-=7<W4=G837<Q/EPQ&1\<G &3_*L+4_!ZZMX:30KC7-7^S>6T4TOF
M1-+<*?[[-&?TQ6Q:6!@TT65S=3WX*LKRW(3<X.>#L55Z''3I0!QF@>/-0UJ]
ML(1;V974H'DA$2RDVC!-ZB5B &!'!*XYX&<YIMK\2)I]*U;4'TL(FC6YCOHM
M_P QO0VWR4/3:,9W?[:^AKH-,\*OI, M;?7]6-G%"8;>W=HBL"D8&UO+W':.
MFXMT&<U6C^'NA16TMM&DZV\]A]@N8A(,7"YR)'.,F0$L=V0?F/7C !F^*&UP
M^'(AK,=@K?VKIIC-F[GK=1[E(8=N.0><]!CF[=^,+FWT+Q#J"VL1?2]0^QQJ
M2<.O[OD^_P"\/Y5<'A%);$VM_K6JWX\^WF5[B2/*&&0.H 5 .2!N)&3Z]*K:
MEX!L=2GOR^I:G!:7\RW%Q9P2HL32J% ?E2W\"Y&<''2@!T'B:[E\;3Z+-]BM
M(HWVQ17!=9KI/+#&2(_=8!B5*C)&TDXZ5F>&O%26UEH44]LEKIM]:7,B2&9Y
M#'+$Y8J6<DD%-S<G^$UT%QX82\UJWU"[U._GBMI_M,%FYC\J.3:5!!";^ QX
M+$<]*I7W@#2-0\*6OAV:6[%I;2&2.1) LO.[<,XQ@AV4\=#0!AM\0[^1=/@$
M%E97=Q8#47^U"5E6-W81( @)W%5RQ/ ]#VZ-_%B0> #XIN+*:(+9_:6M&X<-
MC[F2/7C./>I]1\,17FI1:C9ZA>:7>1P?9C+9^7\\0.0K+(C+P22#C(R:NW6D
M6U_H4ND7QDNK:: P2M*WSR C!)(QSWR,<T <\-=\1VFJ6^E:E;:8MSJ%K-+:
M20.Y2.2,*2D@/)&&^\,=#Q5;X7:=M^'=C)<06T<NH6ZRR2VP*O-N4?/(W4R9
M)R?I6SIGA2*QU".^NM4U'4[F&!K>W>]=#Y*-C<%"(N2=JY8Y)QUK1T728-"T
M2RTFU:1[>SA6&-I2"Q51@9( &?PH X&WU&^O/"FG>%9+N;^UO[4_LFYG5R)/
M*A/F/)NZ_-"J\^L@JMXO\51VGC*34%UJ.WA\/26\<EE]I"FZ$I_?_)GYML;(
M1QU!KNH?"FG0>+Y_$R&;[;-#Y+(6'EC[H+A<<,0B G/111;>$]*@TV]LI(?M
M*WLDTEQ).%9W,I);D >N!Z "@#G?%^B64OB/P[,LU\O]HZD8KD1:A.BR(+>5
M@ JN O**> .E=Q:6L5E:16T._P J)0J[Y&=L#U9B2?J366OAFT%MH4+W%U)_
M8KJ]N[LI:0B)HAO..?E8],<XJ6SL]07Q!J5]=71-I(D45K;*Y*J%!+.1V9F8
MCCLJ_@ 94WB:[3QN=$?[%:0#R_*^U%U>\#+EC$WW25Z;>3P>@JC'XTN_^$LM
M-(,VD7*7DTUN@M)7=H'1'<;VQM;[A! P03WK;O\ PPFIZK#=W6IW[VT-Q'=)
M8YC\D2IC:V=F_J,XW8SVJEI_@2ST^]T^9-2U&2#39Y)[.T=X_*B+JZL.$#,/
MWC8W$D<<]<@%2Q\=/=VNC,UHB3S17,VI1@D_95MP5DQ[^9M49[$U7\->/;O6
MM3TR*6VMC!J<32*MNLI>UPF]1(S+M;(R,C&#@<YS6_I_A#2]-UO5]5B$KRZH
M )HY&!C0<[@@QQN)RW)R:-%\,G0S#%!K.IS6-NGEP64[1F.-<8 W! Y ' W,
M: *?B#Q;+H.I7UM+;(Z+I;7MF<D&:57V-'^;Q8_WC6+?>+IM>\+W,$=JD9E\
M.W-W?<G,$F#&(Q_P)91S_<KJM=\+Z?XBNM+N+TS!].N!<1>4P <@@[7R#E25
M4D<<J*JVG@G2K./7TA>Y UPO]HRX/EA]V1'QP,R.V#GEC0!C:+XGU/2H=,MM
M;M+1+2;1WO(6MI&=T$*IN5\@ DJX.1W!'/6F:'X_O-2NK02VUJ\5[:R3HMN)
M=UJ53>%D9E"MD9&1CD8P<YKIW\,V$EQITLAE<6%I+9HC$;7CD"!MW')Q&.F.
MIJ#2_"QTJ%;5=;U2>QCA,$-I.T12-,8 W! [8' W,: .=7QUJ\'A/2]9U"ST
M^!]9>!+*-7D81AT9V>7 R1M7("\\XSWKH?"?B"?7H+Y;F*,26D_E":%76*=2
MH8,H< CK@CG!!YITOA*QD\.:9HR3W42Z6(OL=U&ZB:)HUVJV<;2<9!R,')XK
M2TRQFL+=HY]2N]0D9]QENO+##@# "*H X].YH XJT^(L][JD!AM[>2QFU V0
M@193<*OF&/SB<;,;ADKV7G.>*T=*\7WVH>*9O#CV,4=]8O(]^X8[!#@&%D]2
M^Y>/X=K9[9T;'PJNFWK26.KZE!9-.UP=/4QF'>S%FP2A<*6).T-CFF6?@O3K
M&^MM0@FNOM\4LTLER77?<^;]Y9?EP5X7  &-BXZ4 8NB^--;NK7PYJ6HZ?8Q
M:=K;K BP2LTL4C(S*QR,%3L(QU&1R>:8GCK5HO"]SXAO+"Q2T,YM;2)97+O)
MY_E!G."%7.3@9.![X$O@WP))IFD: VK7M]+/IL0>.QDF1X()BI5F7"Y. 6QE
MB!DX K=_X1'3?^$7/A]GN#:^8TJR;P)4<RF4,K <%7.1QV&<T <_%XYU+^S=
M9=;&*]N+!()(YK6*81.LC%6)4C=F, L0,Y&,8J:]\9W=MH>F7L=QI,T-U,Z2
MZG'YC6D"@$C>!RI)&WDX!ZGM6['H-XEE/ _B35I9I"A6Y;R \6TY^4+&%Y[Y
M4YJI'X.6WT][6UUS5+=YII9[F=#"7N'DQN+!HRHZ#&U1B@#G]1UJZTKQ-K.L
MP0P73V^@V-Q*D3ED:,33&0H>^%W$>N!75Z9KK:KK^I6ELD;6%E'"/M .2\KJ
M7*CM@(8S_P "IEAX4TW2&:2UBE=1IL6G"W=@5,46\J.>YWD$DXZ56^'_ (<D
M\+^#K/3[A=MV<RW +[R';^'=WVJ%7/HHH @M?$VHWGB?4-(']G6DL!D6WMKH
MR+-, N5E7LR$GD+T'?/%9GAWQ#KD?P]M=4U2^TE997VI<7<CJ,;F'S #YFR
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN>UU.!XK-=UPS'9Y2XR&.[&%(!(/0XJ72O$&E:V95TZ\69X@I=-I5E!^Z<,
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M2RU*"1+10\[$[1&I!(8YQ\I )#=#@\U'8>+M!U);@VFI12?9X?/D!#*1'_?
M(!*^XR* -JBL^77-,ACMWDNT"W,#W$. 3OC50S, !V# _C5/PMXIL?%FD)J%
MCO4'[\;@@H<GC.,'IVH W**R(?%.B3ZL-+BU"-KPN\:QX(#.N=RAL8+#!R <
MC!]*BA\8^'KG48]/AU:W>Z>5H50$_P"L4D%,XP&^4\'DXH W**SEU[2WL8KU
M;V,V\MQ]F1^?FEW^7LQUSN!%+JVN:;H<,<NI7:0+*^R,$%F=L9PJ@$G@$\"@
M#0HKE=%\:V5YHEYJU]=VL=HFHS6EO+%DB95<A-HY+,1SQU]*TG\5:%'I"ZJV
MI0BS:3R5?G)DSC9MQNW9!^7&>.E &Q17+>'_ !E::O\ VE-)<VPM(]5%A9RQ
MY_>[HHV /7YMSL.W3%;-QKNEVBWS7%]#$M@%-T7; BW#*Y^H(Q]: -"BN3O_
M (B>'[&*PE6Y,T=W=_924C8&(A=Q+*1D8!7C&?F!K13Q#;13:M+>7EE%8V0B
M;S/,8,BN@;]X"  3G@ G/UXH VZ*Q;?Q;H-U8W=[%J47D6>/M!<%#%GH64@$
M ]CCFIM)\1Z1KDD\>F7\5R\&#(J9R <X89ZJ<'!'!QUH U**Q]5\5:'HER+?
M4=1B@FV>8RG)V)G&YL [5Z\G XIUSXGT6SU*#3I]1A6\G$9BA&69PY(4C'8E
M3ST]>HH UJ*SM5U[3-%\D:A=K"TV[RTVLS,!C<0%!.!D9/09%0:AXJT/2[A(
M+W4H89&19,')"(3@,Q PJD]"V!0!L45S]MXPTRY\77?AQ6<7=ND; E3M<MO)
M XXP$SD\'/%:]_J%II=C+>W]Q';VT0R\DC8 YP/S.!B@"S17*ZOX\TFT\):M
MK5A<QW+6$39A*LI$FW**RD;ESQR1TK'MO&]Y<:YH>C+J>FO-=1/<7%P+"95<
M!T58T4OE2=S?,21\O3F@#T*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]H7:ZA<QR2X%N\?F':Q'78, D]Z[^B@#S_4_#FKM9>)&M[+S7FURTU&VB$B
MS1Q"W+8). 28W'S8Y'O74ZM#_:WA>XBNM(GG^T0XDL/-1).<97<&VAAZAL9'
M7O6O10!Y[;Z-XCO8])^WPW,EO9ZZES M])$UQ';"!QF0H=K$2-Q@EL$9J:\T
MOQ'93:_/ID,JK>:Q#.?L[Q":2V$$:2&/>=H;<I'S8X!QV-=Y10!YKIOAG6Q
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M3P5&,\]*V?%<'B&XU.&*QBO9=,>U=66QFAB;SR1M,C2<^7MS]W)SG@\5U]%
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M_)D2:-%B98O+*2AV!V\;LJ&^\>*G\+>&+S0]=C>X598H-!LM/6YR,O)&TF\
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MC.>BMSTXKHJ* *FFW%W=:?%-?6)L;AL[[<RK(4P2!\R\'(P?QJW110 4444
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M/SJ_I=\-3TFROQ&8Q=0),$)SMW*#C/XU,EU;R3O!'/$TT?WXU<%E^H[4 4M
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M:/>:586GV&:\U%V\O[3>"&-4"EMQ8*QYP ,#DFMZ\O[/3H//OKN"UBSCS)Y
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MD;JZ,,JRG((]C0 ZBBB@ HJ&:[M[>2".:>.-[A_+A5V ,C8+8'J<*3] :FH
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M* "BBB@ HHJ/SXO/\CS4\[;O\O<-VW.,XZXSWH DHHILDB0Q/+*ZI&@+,['
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M1BC X8<$''<>E24 %%%1QSQ3&012HYC;8X5@=K=<'T/(X]Z )**** "BBB@
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M,O&N8L2..#CYN>>:P="U'6=&\ B==4-S<7NL/8P/<0KMMB][)&TAQ@MUS@G
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M#;W6)G59D*[?F4';G;QNQG'>K,FC:?+/!.]L#)!;O:QMN/RQ/MW+U[[%]^*
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MQA71E#+G(Z@=:Y74?!FLZE:7FJW B&JW&IV]\;.VNFC"Q0KL6(2@ [\%FW8
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MM+F.UOC:RN[E':56!4'+*V02/O ]J .JE\8:'%;6=P+QIH[Q&DA%M!),S(I
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M@" '0[6'/7!!&1QQ7G.J6^K:+\+M)N9[)+76?#CVR6JF8.MR5582 5Z"0.P
M/.<9KO/#>D#0O#EAIA??)!$!+)_?D/+M^+%C^- &9;^,]-MM*L;C5-0@,]XT
MPA%I#*PF\M]I"+M+$CC(QR<XXJ/4?B#HUE;:-=0F:[MM4N#"DD,$C; JL6)
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M^PO+Q9S'*K$L%<9VQD!  2<8/0<4 =?-XNT:!;4O-<[KE#)'&ME,T@0':69
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MHFEV;0M;6,$1AMS:QA%P%B)!*8Z8R :OT4 4=)T;3]#L_LFF6J6UON+>6A.
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M%HWGN+J:[N'C38K22.6X'8 87\*+KP\MYXRT_7IFC*V%K+% FSYA)(5W,6]
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MQZ#<6&1WSZ5CZ7H4]W82C3VU.UU6'1)[.&*32C9QQLZJ IDV@.0P!!!/<YH
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M6]JK16\4<0+M(RH ,LQ)+'W)).>]1&PLX]2?53$HNS (&F)/$8);'H!DD_\
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M!N(H")> GR[B2=F N%]JP+Z\\077P^\3R:G<VMUY.JM#"J*ZD,MV@VY).$[
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M ,6\\+Z;?>)['Q!,LAO;)"D8#X1N& ++W*[WQZ;C5+_A!=.^W"X%YJ A6_\
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M95^4?,RGC@$\5ZE10!YG<^%YTT+Q)]GTG;=S^(8;J I$ [1K-"V\'T \P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>foraresidentagreement007.jpg
<TEXT>
begin 644 foraresidentagreement007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(HHEBC5!'",(F!C"CT':@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK3WUI&'+W4"B-Q&Y,@&UB 0I]#@@X]Z6&[MKBU6Z@N(I;=EW"9'#(1ZY'&*
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M1ZG9/<J2IA6=2X(Y(VYSQ@T 0^'M%'A[1X=,2_NKR" !(#<[-T<84*J JJY
M ZG)]ZR(O EI%>PRC4]1-K!?MJ,-GNC\M)F9F8YV;B,LW!8XS6^FK:;)%-*F
MH6C1P*KRL)E(C5AD%CG@$<C-/CU&QEL?MT=Y;O: %OM"RJ8\#J=V<4 9/_"(
MV']F?8/.N/*_M/\ M/.Y<^;Y_GXZ?=W<>N._>KFNZ)#KVGK:S330-'-'<130
MD;HY$8,K#<"#R.A!%68M3L)K5+J*^MI+9SM2995*,?0'.#42:WI,D<#IJEDR
M3N8X6%PA$C?W5YY/L* ,>+P19A+@W&H7]S-<7]OJ$LTK)N:2$IM&%4 +\BC
M'3IBK5YX5LKY-?226X UR 07&UA\BB,QY3C@X/?/-:=SJ5C9S0PW5[;02S'$
M22RJK.?103S^%)<ZIIUFX2ZO[6!RP4++,JG)Z#D]30!B7W@R&YO)[BTU;4=/
M-W D%VMJT>)U4%03N1BK8.-RX./H*6Y\%63W%K+8WM]I@@LUL"EFZ@26ZG*H
M2RDC'.&4AN3S6@_B328_$0T)[R)=0,(F$;.!D$X Z_>[X].:TII#%!)(%W%%
M+!<@9P.F3P* ,32/"=CHTNER6\UPQTW3CIT7F,#NC)0Y; 'S?NQTP.3Q58^"
M;2/3],MK34+ZUETVXEGM[F,QEP9-^]2&0J00Y'3TK5BURR73;>[O[FUL3+"D
MK)+<IA-P_O X(SQD<'M5FZU&QL;=;B[O;>WA<@+)+*J*Q/3!)Q0!!K6CVVNZ
M7)871D5&9762)MKQNK!E=3V(8 CZ5G3^%#?Z1<V&J:UJ-]YK1O'._E1O \;;
MD9-B* 0P!R0>GIQ5B#Q##)K^IZ=*(XH;&WMY_M+2C:_FF08]!C8.<\YK5,\(
MF,)E3S0F\IN&X+TSCTXZT <7;^"99=;\0QZK=7=_8:IIL%L]U/(@D9@TVX*$
M "8#(1A0,G/)S5O_ (0&TN#>MJ>JZGJ,MY8-I\LEQ(@(B)S\H15 (]<<YYS5
ML^+;677!IUAY%ZG]GSWGG0W*D;HW1?+]!G?U)XQ6BNMV,5A!<W]U:V321)(R
M2W"?)N' W9P><C(X..* ,5O EO<1:B+_ %?4KV6_T\Z=)+*8E*Q'/W0J  \G
MG!]ZZ.:SAGT][*4%H9(C"PSR5(P?TIMWJ>GZ?'')>WUM;1R'"--*J!C[$GFG
MK>6KVGVM+F%K;;N\X."F/7=TQ0!SB^"$33]-@36]3%UI9(L[W]UYL494*8R/
M+VLN%'WE)R,YK7T31+?0K26&&6:>2>9KBXN)V!DFD;&6;  Z #     Q5NSO
M[/48//L;N"ZASM\R"0.N?3(K TKQA#JNN:O;1M8)IVFN8I+AKT>8SA48MLVX
M$?SXW%NHZ4 1MX$M&OC,-3U%;;^T1J8LU:/RQ.'#DYV;B"1T+8Y..V+C^$;!
M]+N-/,UQY4^I?VDS;EW"3SA-@<?=W #UQW[U<GUJW.FI?:>\%_$TT<6Z*YC"
M_,X4G<3C(SG'4]!R:BTK7X]1GU.*5$M_L>H&Q0M)_K2$1P1TY._ISTH RU\,
MM+\3Y/$3P%+>+3TAC;>")9BS OM'0JAVY/7?[5N:II$&K&Q,[R+]CNDNX]A
MRZ@X!R.G)JR]Y:QF0/<PJ8V5'S(!M9L;0?0G(P.^14#ZWI,=G%=R:G9+;2MM
MCF:X0(YSC ;.">#0!ACP)9B8Q_VCJ']E&[^V'2]R>1YN_P SKMW[=_S;=V,]
ML<59E\*"XUA-1NM8U&=H#,UI&QB MFD4JQ4A QP"0-Q./>M+6-8LM"T:YU6^
MF"6EO&9'8$9( S@>I/8=Z/[;TH:<FH-J5HEFYPL[3J$)]-V<9H J:/X=72M0
MN]0FU"[U"^NDCBDGN1&IV)NVJ!&JC^)N<9YJKJ?@Z&_U"]NX-5U'3_[0C6.^
MBM63;<!1M!.Y&*G;\N5(. /2NA2:*2!9XY4:)EW"16!4CUSZ5!;ZGI]U<-;V
M]];33J@<QQRJS!3T. <X.1S0!4L?#UCIVJ_;[4/&18PV"0@C8D43.5P,9S\Y
M'7L*37=!AUR*UW7-Q:7-I.+BVN;<KOB?!7C<"""&(((((-68]8TR9[A(M2LW
M:V!:=5G4F(#J6Y^4?6K/VB /$IFCW3 F,;AE\#)QZ\<T <N/ -F+6=1J>I&Z
MEOTU+[8[HTBSJ@0, 5VXP/ND8YXP ,36W@FR@CQ)?7UQ(=335'EE9-SS*BK@
MX4#:=HX 'M@<5?7Q-I+Z[=:*EW$=0MHED:(N 3NW8 YY(V$D=@1ZU'X9\36G
MB+1["Z62WBN[FTCN7LUG#O$& /(X..>N!0!'>^$;"_M=>MY9K@)K;*UP59<H
M1&B#9QQP@ZYYS5/4_ EIJ=UJ+G4]1@MM1ECGNK6%HPDDB!0K9*%APBY .#BN
MACU*QEO9+*.]MGNXQEX%E4R*/=<Y%5Y-9BC\2V^B&)S-/:278DXVA4=%(]<_
MO!^5 '"7'AKQ'#KVJ7>G074-[<W_ )UM>1W,)M4C.P'>C9DSM4Y ')Z$=NM3
MPM]FU.XNK#6=1LH+JX^TSVD/E&-Y.-QRR%EW8Y (_"M*+4=U[?PS1I##:!#Y
MS3(0P*Y)(!RF/]K&>HIRZOICV#7ZZC:-9+UN!.IC'_ LXH =J5A!JNEW>G72
MEK>ZA>&0#J58$']#7.6WP\TBVET&437COHWF&-GD!^T,[;R9>/F(?YAC'-='
M_:5@+:.Y^VVWV>4$QR^:NUP 2<'.#P"?H#0NI6+V'V];VV-GC=]H$J^7CUW9
MQ0!DCPMY&J7-W8:QJ-C#=3BXN+6'RC'))@ G+H67=@9VD9]C6AK6D0:[I;Z?
M<O(D3R1R$QD!LHZN.H/=1^%2/J^F1V"W[ZC:+9M]VX:=1&?HV<4ZZOX;72I]
M0!\V"*%I\QD'<H7/!Z<B@#*N_"-A>6&OV<DUP(];D\RX*LN4/EI'\G''"#KG
MG-)/X41M;GU.TU74;$W1C:[@MV0).4 "D[E+*<  E2,@"G^']>O-;MX[J;1+
MBPM)8%GBFFGB8.& (X5B1P<\UIVFI6-_$\MG>VUS'&<.\,JN%/H2#Q0!SEUX
M!L[JYN"=4U*.SGO5U!K*.1!$)PZN6^[N()7)4G&23C."-W3=(@TNXU*:%Y&:
M_NOM4H<@A6V(F%P.F$'KWJ>SU&RU&-I+&\M[I%;:S02JX!]"0>M5M=UF+0=,
M^W31/(GGPP;4QG,DBQ@\^A8'\* *FK>&8]3U:+4HM1O;&Y6W:UD:V*?O(F8,
M5.Y6QR.JX/O5&?P);S:%::'_ &MJ*:3!:QVDEJ#$5G1.FXE"P)Z$J1^%3V7B
MH:EXROM$M%LFAL HGE-W^]+E<X2,*<A> 26&">G%;IO;40/.;F'RD8H\GF#:
MK X()['/&/6@"IKNBV^OZ2^GW$DL2EXY$DA(#HZ.'5AD$<,HX((J#1?#R:-=
MW]XU_=WMU?%&GEN2G)0;1@*J@#'8#M5]M3T]+];![ZV6\896W,JB0CV7.:D>
M\M8TG=[F%5M_]<2X CX!^;TX(//8T 5;?1[>VUR_U97D,][###(K$;0(]^W'
M&<_O#GGL*SM(\*G16BAM-:U(:;#N$-@WE&.,'/RAMF\@9X!;C ]*N>)-9_X1
M_P /W6J"#S_("GR]^W=E@O7!]:N6NH65[YOV2[M[CRFV2>5('V-Z'!X- '//
MX%M+M;_^U=2O]1DO+/["99S&C1Q9W87RT49SSDY/ I%\"V\G]H27VKZG?7%_
MI[:=+-.\8(B;/W0J!01D\XY[YKH;34K#4%D:RO;:Y6,[7,,JN$/H<'BFP:KI
MUU;RW%O?VLT$.1))',K*F.N2#@?C0!0'AJ*/7;35K>^NX)8+5;22--A2>)22
MH?*DC!).5(ZU)K>@1:S)9W"W=S97MD[/;W5L5WIN&UAA@RD$=01V%7(-4T^Z
MM/M=O?6LMMNV^=',K)G.,;@<9R1^=1_V[I'DF;^U;'RA)Y)?[0FW?_=SG[WM
MUH RXO!EA'91P/<W<THU%-2EN9&7S)YU((+84#&%48 & !C%='56\U*QT_R_
MMM[;VWF':GG2JFX^@R>35J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\\^(4=_IVJ6=_I*G[3K$+:'(0?N-)\T4O_   ^9_WU7H=5;G3K2[NK2YN(
M5DFM',D#$GY&*E20.F<$C\: .#ETVS\/>(KU+[0+O4=-?2[:TT[R+)KD(L8<
M/"0 =A.5.3@'N>*@T2VU3PG=>'I]3T^_NBN@_8G^R1&<I,'5A&VWIQQN/R_+
MUKTVB@#R_P />&YIW\#+JNCNR66GWWG)<0Y6&1GBVAL\9(W8SZ''2NG\8:7_
M &C>>&2MB+E8-65I3Y6\)'Y4H)/'"YV^V<5T[ND<;/(RJBC+,QP /4TX'(R.
ME 'E.KPZI?>(X4&DRP-;>(()%2VTLA6@$B_OVN.A)4G('('!& 35^'2M0%_:
ML;*X"KXNGNB?+/$)AD D_P!W) STYKT>B@#RJ&/4(]/TW0/[&U(W-IXD^TS3
M"V;R1";MY!('Z,"KCIDCG.,5;D\+W<WA;QO]CT_RM7OKR[\B5DVR2QG& K'L
MPR!VY->E44 <+X/L(#KQU&-M321+'[,T5QI/V*-5W*0/N@.RX(&,@ GGFJU[
MI=ROB+QE;VFGS17VJ6*G3[Q+<^6'\EE/[T#"-NQU()R#S7H+R)&NZ1U09 RQ
MQR3@#\Z=0!YQHMI'=Z[X6;2] N],&EP2K?/-9M;@*8MHB#$#S/GPV5R/ESGF
MEUZ;3[;XHS2ZAHMQJ4?]AQJH@LS<E"9I>-H!(W=,XQZD9KT:JPL+5=2?41"/
MM;PK TN3DH"6"^G5B?QH \HMM"U?24\-R:HEXEO#HYM3Y%A]N-O(7W;&0*Q&
M4VKN Q\F,UN:-X5@C\0^'DFLKB[L++19DBEOK?!C<RQ[5*D85MI8 =0!7HE-
M>1(EW2.J+D#+' R3@#\Z /,KWP[=?V+XG\G2'<2:_'</ D05KJT7R&=5Z;@0
MK\="015?7=.FUFW\57NBZ->6UI/H@M!$UF\#W4X9B"L9 8[5.,XYS@9Q7J]%
M '&:GX9L_P#A)_"D5OH\)TZT%RSJD \N-O+4(6XQGCC/I[5@67A9K+1[![?1
MC#=1^*FFW)!AU@^TN W3(3RR/;::]2H) !). .] ''>*H3%XJT+5+O3[B_TJ
MVBN(Y$@MVG,,S[-DAC4$GA77(!QN]ZYVR\-37+Z(+G1Y%TR3Q%<WJ6<L/%O
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M$I:?0[A;S (!>+!29,^\;-^(%=;574-.M-5LGL[Z$36[E2T;$X;:0PSCW H
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M:09[BYLU2RD:#<TA%MP(SCD[P.G<#TJ#5;%UU+7/[5T"\U234M*MX;%TM#,
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M &D^;:_+L"HV/N[<C!R"#SFM;1M$M-#MI8K8RN\\IFGFGD+R32$ %F8^P ]
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MIA%,+B.U><F%) ,!@O7CKC.,\XJNG@O3$AN;<2WAMI[Q+WR#-E(I5E\[*#'
M+\D?RH P;_Q;XBMUUS48H],_LW1]16U>)HW,LZ'R]Q#;@$($G'#9]!WBUOQM
MJT?B&]TS3+K28KBWOK>SBL9X'FGG601EI1MD7"J')QCHAR1D5U<_A;3;C3]4
MLG$ODZG<?:;C#\[\(.#V'R+7)7_A+Q$=7U>:P=X)[V\$\%]#JDL4<*[47Y[<
M#:[ *<YSN[D=@#=^(O\ R)%U_P!=[7_THCK/U'Q1KY@\1:IIBZ<NG:%))&]O
M<1NTMT8T#R8<,!'P<#Y6R1DXKK=6TJVUK37L+P.879'.PX.4<..?JHK(O_!&
ME:A>7<TDM['#?,&O+2&X*0W)  RZ^X !P1D#G- %%O%-ZWBNVM))+;3].N%A
M:U-S:R,;PNN6590P1''0*02?QJI!XWO;2#7;K5S;13:=;W%Q_9/V:2*<)&QV
ML)&8K*K#'S*H +"NBO/"]I?ZG%=W%U?/%%+'.MGYY\@21XV-M[8(!P#C(SC-
M11^#M.^TS3WDUYJ!DMY+54O9S(L<4F-ZK]<#).3QUH Y_3_%WB.7[0O]G'4)
M#ITMU"(M,N;14G7&V$M+P^[=PPQ]T\<BN@\):S+K.GS23W]K=3QR!9$AM)+9
MX3@'9)'(S,&_+([4ZR\+165O) FK:Q)$T)@C62\8^2O&-I&#D8&"<G\S5K1]
M!MM&>ZECFN;FYNW5I[BYDWN^T;5'0  #L!0!S&O^,;S2=;"07EA<6R7MO:S6
MD=G,\B"1D4EIPWEHPWY"D<C'.346H>+?$-LNO:C#'IG]FZ-J"VSQ/&YEG3$9
M;#;@$($G!PV?0=]NZ\#Z7=WD\[S7RQSW27LELEP5B:="I#[?^ +D9QWQGFK<
M_A;3;C3]5LI%E\G5+C[1<X?DOA!QZ#$:T <AXTU?6]4T/QM;Z?\ 8(]-TRTE
MMIEG1S+,6M][E6# )M5Q@%3D@\BO0-._Y!EI_P!<4_\ 016%JW@;2M9N;^6>
M6^B34(PEY!;W+1QSX7:&8#N!@>AP,@UT<42PPI$F=J*%&?04 /HHHH ****
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M;=H)(&2/<<UQC6GB.?1MSV=_>6NFZI9W-FMU'''>30QD&0$*0I*]B<$X/L2
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MW"JVX@$#!.>C+^8]:X?QM:>)-4FUG3X;2_-N[P-9I:10>3,HV,S2NX+[@P(
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M*.ZT:XA_LB3R[M+E%^1DM&0.,$Y&_&#Z\THT#4EN/ELG"#Q;]N&,8\@Q\O\
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MQ;KIDMY(X'0ML/R)GC)'/8\51L_$FN>([G2[?2Y;*P>;18-5G:>!I@S2\+&
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M&21G.?J >@45Y_KWBW4=(U$FWU*"[2VN[:VN+:+2Y2@\QD5MTX8HC_/N [<
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MLL;*R,SDY."B\=,#&*L#P[I8\3'Q"+?_ (F9M_LQEW'&S.?N],]L]<<5JT4
M8=GX4TW3[_[3:27T*>:TPM4O)! '8DL?+W;>22<=,G.*E3PSI<=A:V2P,(+6
M[^VQ+YAXE\QI,YSS\S$XK7HH P[?PGI=IJ[ZE;_:HW>9KAH%NI! 96&&?R\[
M<G)[=>>O-5_"_AK^P[_7K^5(%N-4OWN,0DD",<(#D#D_,Q]W-=)10!R6I^"T
MUGQC/JUW--';/IT5HAM;J2&7(DD9P=N,J0Z]^H[8!K;M- TVQN[2YM;80O:6
MALH A.U(<J=N/JB\]:TJ* .=3P1HL=^EVJ768[LWD4/VJ3R8YB26=8\[0223
MT[GU-36?A/2[#5FU"V^U1LTKS^0+J3R!(^=SB/.W)R>W4D]:W** ,"S\':18
MV]O;PI<&"VNA=V\3W+LL+C=@*">%^8\=.:)/!VD2_P!I*R7'DZDXEN(/M+^6
M7R&+!<X4DJ,D5OT4 <]J/@O1M4OKBZN([E?M>T7<,5U)'%<[1@>8BD!N ![C
M@Y%:/]BV'VV\NQ"1-=VZ6LQ#$ QIOV@#M]]NGK6A10!S\O@W27CL1#]KM9+&
MV6TAFM;IXG\E0,(S*?F'&>>_-:%MHME:W\=]&LAN([46:R22LY,8.0"6)).>
MYY-:%% %2PTZ#34G2W,N)IWG?S)&?YG.3C)X'H!P*MT44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %96K^(+/1I;>"9;B>ZN=WD
MVUK"99'"XW' Z 9&2<#D>M:M>=^*S!9_$&WO=3UJZT>PETIH8[J%E4-*)=Q0
MLRM@D%2 ,9V]\8H [ZTN!=VD5PL<L8D4-LF0HZ^Q4\@UG6_B73+KQ-<^'X9F
M?4+:'SI5"':H^7C=TW?.IQ_M"L;0-?U&7PI8079\SQ)=64T]M%<1F/S@APC/
M@83(,9(X^\>*Y[PQ:ZQI?Q TZUN]("2'29S=7!NU<R.TR,\IPHY+?P]@?04
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M[3F2[9I&/F_Z,'4/D] P&!V' H ]5K.UK6K30-.-]>^:8O,2(+#&7=G=@J@
M<DDD"O,/ T1GU/1)IM7L(-=1G.I6X63[9.VQMZ3 MC ;# D8&T;>M=E\1Y4@
M\,V\\K;8HM4L9)&/156XC))]@!0!K:3XFT[6+R:RA^TP7L*"1[6[MWAE"$X#
M!6 RN>,C(K8KSG5[^7Q+XACU'PMOG;3-*O1]L1"(WFD51%$K$88[EW'&0,#U
MK#\-Q6[6YN;+6-/%PFD3B]M;<2^?*Q0?-/N8X=6'4@'DCI0![%17COA>6REN
MO"DGAJ6675CI\AU8LSDD?9_E\[=_TUV;<]NG%/\ #S:?))X2;29)F\4&=3K6
M6<S!?+;S_M /0;\;<]]NV@#UF\N19V4]R8IIA#&S^7"F]WP,X51U)["HX=1M
M9KTV2R8NQ EPT+ AE1B0"1]58?A7DGGVUKIWBVRL9+;4YI-'OYSJELSB=#R1
M%<*?X_F^4Y!PA^45O65EI%M\4K:XO8HH[NZT>V:U>3(,DRM('V^K!=F1Z4 >
MCT54TS4[/6-/COK";SK:4L$?:5SABIX(!Z@UY[%'=CQF/!9\[[)%J)UL29./
MLOWUCS_U\'&/1: /3:*\;@>UDM;8K)+_ ,)]_:X\U=S^<%^T?-N'_/#R<_[.
M,=ZLZKK$5KI'B/199Y5U637TEBMPK%_):>)@_'1-N>>G;KQ0!ZW6?JNKP:1]
MA\^.1_MEW':)L X9\X)R>G%1^)8XYO#.IQ2WSV"26SH;N,$M#D8WC'/&<_X5
MYDBVFJZ+8Z;#9VJVL7B&UC>ZTJ5Q;W0*9+(>JGLV">>YH ]AK/U?5X-&AM9)
MXY'%Q=PVBA .&D<*"<GH">:\\NVM?#T'BK3A8B324U*T2."69TM[<21QEG8C
M)$8;YB.G/N:SM,8MIUQ!;M"]E%XKT\VPM0_DJA\DGR]W.S<6/'')(X- 'JFE
M:O!JXO?(CD3[)=R6C[P.63&2,'IS6A7+^"E*CQ#D$9UNZ(S]5K*BTD7OCGQ5
M?^6\M[9K ; .YV1R&#J%SC). 30!WM%>0^!XHY;W2;A=7L(]22UD_M*UC67[
M7.YC.X7&YCAE?!R1VP.#57P5+IDT7@9]&FGDUTJ/[4+/(7^S^0V[S-W\.[R]
MF>.FV@#UC0]7@U[2(=2MXY$BE+@+(!N&UBIZ$]U-:%>.0W-BGA;P[I^IV=EY
M<HO9%N-2>00JPF/R!%^](<Y'0@ XZTNFW-I+8>$SXQF?^QSI$@5KMF$;70=0
M-Y_O[ =N[G[V.: /8J*\A\0K;3^()8;Z^L[32VTNW&DRZIYPP"&W-&=P(E!V
MYS\_W?>O3].\ZW\/VGGSM>SQVJ;Y57#3L$&6 /0D\X]Z +]%>.>%KZ"Y\4Z9
M<:;%:6J76G71N[>TDED=&PA5;AVX,H.>OS#GM5OPQI$%E!\/;N-)OM&I6CQ7
M\CR.QF0VK/M?)Z!E&!VQ@4 >L45YIX1%[=^)+;0;MIBGA-94DD<G]\SDK;D^
MN(-Q/N16S\0X[1]/L&N]1L;9(K@R"#4=PMKKY&&QR.GWLCKR!P: .RHKS73O
M$5II^OZ7J6H0S:79WGA^)+>VD#/^\60DQKQEGVLN!C)':L729+ :;X03Q<Y7
M1CH>8_M+,(C=;ESN_P!O9]W/^UCF@#U2VU>"ZUS4-*2.0364<,DC$#:PDW8Q
MSGC8<_A6A7E=[H6F:MJOBJ=H;B2*WT2T:S+R2*5/ES%7P3G>,#D_,.?4UZ%X
M>GEN?#.E3W#,TTEG"\C-U+% 23^- &E17B\?E_V!XITK23!JUR^DSS#5+,OY
MSMNXCG4Y_>\\<Y(4\#I6_+K]GKOBBXGTJZ:YMD\-7(,D8;9OWH< ]"P'4=1G
MF@#TFBO)]+\,:>][X+22*X>/4=)DDU%6GD(NF5(67S>?FP6; /';H,5V'P]\
MQ?!\,4C2,(+FZ@C\PDD1I<2*@R>>% 'X4 ;&N:O!H.CSZE<I(\,.W<L8!8[F
M"C&2.YK0KQ/Q,-+FMO$RZF9F\3#5/]&3+^8+8.GE[0./*V<G^'.<\XJWXAC>
MZ\4^((=3U:PTV]\Z,:7/=K)YL<?EH5:WPP!^??D $DY!XQ0!ZGK6JPZ'H=]J
MMPDCPV<#SNL8!8JHR0,D#/%7$<21JXZ, 1FO&/&HTR6'QQ'KC2MK@0C3$4ON
M-OY"X,07^#?YF_MUW<5O:MJ\&C:OXIAOIY(I+[1K?[!'M8F9@DRL(P.K E<@
M>H/2@#TNJ\-]:W%Y<VD4RO/:E1,@ZIN&5S]1S7ER2:0;^P7QA(RV/]@V9T[S
M6<*9<-YNW;UE_P!7T^;&,5-)9VEAXJ\:G3(5B\03V0GTL'(DD8P-N9 >OSCG
MWH ]3K/NM7@M-:T_2W20S7R2O&R@;5$84G/.?XABO+M#B<V5U=>'=6L#J*:+
M<![.R67SI9MHV-,'8XD5NY&X[C4_AI?#S>,O"LF@-)(XL;C[:P9V D*)_K,\
M"7.[/\73/:@#UJBN5\=N]AIEEKT>_.D7L=S*$R2T)S'*,#K\CLW_  &N(T :
MM-K-AH-\;@C5+J'Q'*S9Q'&5+M%GVF2(8]&H ]0BUJT<6XF$UK)<W#VT$=Q&
M4:1TW$X'H0C,#W%+8:O!J.H:I911R+)ITZP2E@,,6C20%>>F' Y[@UY7<V>F
M2:;X?U#78D-I#XCU".>:?.U(V>YVACV&[9^E3>(-(MI8/B)K"QR_;K*2.6QE
M61AY3):0L&0 X!SU/<#% 'JL-X)KZYM1!<(8 A,KQD1ON!^XW\6,<^F15FO+
MO%7VB27QHJR3IE=*"-&Q4KF3DJ1T/TK?T'38-#^(&JZ?I\;PV,FF6UP8M[,O
MFF292W)/S$*N3WP": -KQ%XGTKPM9"ZU2X,:MDHB(7=@,9(4<X&1D]!GFGZQ
MX@L]%>VBF2XGN;DMY-M:PF61PHRQ '89&2>.1ZUS_P 5-0L[3P#JMO<7$<=Q
M=6[I;HQ^:0C&0OKVJO?Z[I=KXVT?Q%->P_V+<:9<6D=[G]TLOFQM@MT&0C 9
MZE<4 =AI.K6>MZ;%J%A(7MY,@;E*LI!(96!Y!!!!![BL>\\=:-8:A=VMR+U4
MLY4AN;D6KM!"[!2 S@8'#KR>!FHO ,<G]B7MVT;QPWVIW=W;JZE3Y3RDJ<'D
M9'S?C7G_ (D:)K_QQ:OKEQ#<O>1RP:0L*R+?,MO"54@+YA#,NT[6 _6@#VJB
MO+]8UM=,N_%\6IM):WFH:1"UG;@,QD?R9%98\=2&QG'3J>*@NY[2QUK0KV62
MUU*[:VL85TR9G6YA.1^]@QP?O9<8Z)RW:@#TZSO!>+,1!<0^5,\6)HRF[:<;
MESU4]CWJS7E+VK:C-8VER9S!+XPO%D59&7='Y4YVD@YVG&,=".*AU"&YT[0-
M:T^R+0Z5:^)(XY4;>T<5HT43L#M.X1[VY /0GMF@#URBO)UL[ ^%M2V>)M(C
MTR2^@DB2%7-BC* 6B8[ON/@9 ( /UP:FIW^G2^'=(U22#3XEMH;E8M#N))/*
MNP),![9\ [SL^3Y3P_0=: /87<1HSL<*H)/TKFM-\>Z+J36.!?6T=_M%I-=6
MDD44Y(RH5R-N2.@SSVK>D<S:6S^6Z%X2=C?>7*]#[UY39:G::[\*_#WAC3'-
MUJ[16*,D2,?LIC9&=W;&$VA3U.2< 4 >OT5X_J^HP3^,X9;6WM;348-?@MW_
M 'DKWDD1D56<]EA8-@#E<$=^*T[2.[_X3-/!;>=]DM-0?61)DX-J?GCCS[3L
M1CTCH ]-HKSCP--9V_BF[L+62TU1I(99WU2 L)E_> ^5<J>-_P W!SG"'Y15
M[QH]BOB715\0N$\.F"X\PRL1 ;G*>6)3TQM\S&>,^^* .EUW6X]"LX9FMI[J
M6XG2V@@@V[I)&Z#+$ ="22>@K1A=I8(Y'B:)F4,8W(+(2.AP2,CV)%>1G2;?
M4]%T07-M)<:</$S)IWG[B?L;;L 9YVDKQG^$+7KJ(L:*B#"J, >@H =1110
M4444 %%%% !1110 4444 %%%% !1110 445SVK>(KRUUR/1]*TH:A=_9C=S!
M[D0K''NVC!VG+$@X' X.2* .AHKS+0?&YTSPCX=MYC!+J-]#-,6U*^%NB(DA
M!W2$,2<L   >AZ 5L0>/I=2BT8:1I N[C5$N2%:[5$B:!U1\N <KDG#*#G X
MYX .UHKB=,\>W=]_9=Q/H#VMA?W;6/G-=*SI<#>"-@'*;D9=V0>,[<5:/C&6
M#Q5::->65G&MW.\$1BU!99E*JS@R1!1M4A#R&.,C- '645Q5CX[N[I["XET(
MP:7>7[Z>ES]J#.) [H#Y>W[A*8SD$'MCDYGB;Q5J>H:3+)8::\6F)K%O9B_2
M[VR%DND1SY>/N$ADSN)/I@YH [G4-(MM4N+"6YWM]AN/M,2!L*9 I4%AWQN)
M'O@U?KCOB1<ZC#X?M(;"/<+O4;6WF(NF@8H\R#:&4$@-G:2,8!)YZ4ZQ\175
MOJL^BQZ-Y=II,,37EU)?%Q$K1[L+E2TA&".<<#.><4 =?17(:?XTO+B31Y[W
M1/LFF:RX2RN/M0>0%D+H)(]HV;E4XPS8. <51A^(.HSP:?=)X8<VNHW+V=JP
MO5W-,N_&Y=ORH?+;YLYX^[TR =[16-X<UR76[>\%S9BSN[*[>TN(5E\Q0ZA6
MRK8&05=3T'7I5#_A,E_L<:A]A./[8_LK9YO?[3Y&_./^!8_#/>@#J**YS2?$
M\NK^(=0TZ*SMTALIGAD9KO\ T@%<88P[>$;/#;N>N*Z.@ HHHH **** "BBB
M@ HHHH **** "BBB@ JAJVD6VLV\-O=[S#%<1W&Q6P'9&#*&]1D X]JOT4 %
M%%% !1110 4444 %%%% !1110 4444 %175NEW:36TN?+F1HVP<'!&#4M% %
M;3[*'3=-M;"WW>3;0I#'N.3M4 #)^@JS110 4R6-9H7B8L%=2IVL5.#Z$<BG
MT4 06=G;Z?906=I"L-M @CBC7HJ@8 JO#I%M#K=UJXWM=W,4<#%FR%1"Q"J.
MPRQ)]35^B@ HHHH **** "BBB@ HHHH 1E#J5/0C!JGI&F6^BZ/9Z7:;_L]I
M"L,>\Y;:HP,GUJ[10 4444 %%%% !1110!0T_2+;3;F_N(=[37\_VB=W;)+;
M0H ]  H %7Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H0:1;6^LWFK+O:
MZNXXXG+-D*B9VJH[#+,3[FK]% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7/ZMX<N;O7(]8TW5GTZ[^S&TF(A6421;MPP&Z,"3@\CDY
M!KH** .-@\!?V?9Z0-.U1HKW38I8%GGMUE6:.1@Q5TR.X4@@CI[UK1>'W_M3
M2=1N;XS7&GP3Q$K"J+)YI0DX'W<;  .:W** .9@\'10Z7IEB+QRMAJ;ZBK;!
MERTDC[3SP/WA&?:J.G^ #8ZA82_VJ7MK"^EO88OLJ!V:02 ^9)G+$>8<'CWS
MP1VE% ',P^#HH=&TW3A>.5L=2.H!]@RY\UY-N,\#Y\9]JHS^ II5FLX]=GBT
ME]0&H+9B!25D\T2E=_4H6!(& 03U(&*[2B@#,US1DUNUMH'F:(07EO=@A<Y,
M4BN%_';BHX- @BU/6;R20RKJJQK)$1@*%39C/?(K7HH Y+3?!<]I)I,5[K4M
M[I^D,&L;9H%0J0A1#(X^_M5B!P/4YJ>U\'16VFZ)9"\=AI5\UZK;!^\)\WY3
MSQ_K3S[5TU% &9I&C)I-QJLJS-(=0O3=L"N-A,:)M'K]S/XUS\O@.9YVC77)
MDTW^U%U5+00+D2B42LI?J5+ X'!&>IQBNSHH YIO"UQ<>*+?6KS4UE-H93:H
MEJJ.@D!7:[@_.H!X&!R 3DBMO3K>YM=.MX+R\:]N(T"R7+1JAD/KM7@?A5JB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6IZQINBVZSZG?6
M]I$S;5::0+N;T&>I]A5VN"UM-1G^*-HEI>V5HT6C22027=N9@"90)-@#K@X"
M9.>GUH [>UN[:]M([NUGCFMY5#I+&P*LOJ#6;I?BOP]K=T;72M;L+VX5"YBM
M[A78*" 3@'IR/SJKX7\0C7?"]C>7KVUO=74,C%$?"L$8J70$YV'AO8,.:QM!
MEU3PKJGA_P )W%]8ZG92V3QPR0V[0RPK"BX9AO8,I'&>.2* .IU7Q#HVAF(:
MKJEI9&7/EB>4(6QU(SV'K6BCK(BNC!E89# Y!'K7&^*;2ZLM8E\2Z1?6'VVT
MT\Q7=C>GY)8 Q<88',9SNYP0>XXJI8^*6N;[4[IYS963>';34+>"9@ODE_.W
M'\,(#]!0!VG]HVG]J_V9YO\ IGD?:/*VG_5[MN<XQUXZYITM_:PWT%E).BW5
MPKO#$3\SA<;B![;A^=>8Z:)=<\0>'&N]<NK.>Y\*Q32R02*DLS%E)^8@]SN.
M/3TS5C2_%&LS67AF[>9KF673=3E<!0!=-"R")R!_>'/']Z@#TZFNZQHSNP5%
M&69C@ >IKS+P_J'BG[!8ZYOGNK>?3Y+BX%Q=Q2)-)Y>]#$B#*?,,;1V//(S4
M>IVTE]\)=1U&;Q-?7=Q>Z%)=21>:FQFV!F*J%RJ@G:0.,'GGF@#U/(QG/%-1
MTD17C961AE64Y!'M6/:Z?M\)_8UU"\EWVYQ<-*#*,C/#8_+BN"\//<VO@OP'
MID.L7<%OJZHL]SYBEH@MN6$,;$?)N9<>O! YH ]7JG?ZK8Z983WUW<+';0'$
MK@%MIR!C R>I%87A"[NFU#Q!IDM[+?VVG7BQ6]S,0SD-$CLC, -Q5F(SUYP>
ME<+<:<;;P'XY9=1O)7&I31;9I P!$D9WXP/FY% 'L=%>;:SJFL>$IO$<-MJ5
MUJ)AT,:A$;S:YCFWNK,, #;@!MO08XQ44\_B;2]!UZ]^U72V:Z%<7$4MS>13
MR?:%7*R1[!PI!)(Z9"XH ].HKSC5I-:TW_A'=+BU+4;U]6DEFN9O/CAD9EC4
MB.-B,(I)+8'/RD ]:ZOPF-731VCUEM\\<\BQLTBR/Y6?D#LO!8#@_2@#2TW4
M;35].M]0L9?.M;A \4FTC<I[X(!%6J\@\&W%UIOASP+=6FN7%T;^<6<UB60Q
M"/8Y(50,@H5!)SGKGKBM#PMJ'BG67TS6=\X2>\=;Q);N+R!%N=3&L0&Y67"X
M[D@YSF@#T>QO[74K1;JRG2>!F91)&<@E6*L/P((_"K%>8Z??ZMK">%[1M8N[
M=;V?4Q<R0%0[K'*P0 D'&  ,CG'YU6F\27]MIVG6-[J=\\*:Q?6<TT#(ES-%
M"7"?,<#KLSC!./K0!ZO17.>#H]1A\(0OJ=U//>2>9*7FE61E4L=@)7C(7;G'
M&<URGAB]UB./P+J%UK=[>OK<3)=PS;?+_P"/9I5*@ 8(* 9SSDYH ].HKRW3
M=7U1]%\->(SK=S-?:IJ,4%Q8,RF$([E7C5,94QCG.<_(<YS71^-Y-3M_LMW;
M377]FVT<TM]#8SI%<8 7;(N[AE7#Y7(SD=<8H Z^JHU&T.JG3!+_ *8L N#%
MM/\ JRQ4'.,=01US7$S>)I%7Q?.NILMO;Z1;W5DTI"E=\4A#@'')8+^/%44C
M?5_&>G"XURYL))?#,,KO;R*DDIWL2=Q!X&<G'X\<$ ].JO!?VMU<W5O!.DDU
MJX2=%.3&Q4, ?P(/XUYDNN:W/X5T;Q#J%Y>/IL-B\E\VGRI%,"'PMP588="J
MD[1ZG /0:MY=Z[J-WXFMM,O&S!J=JL<0E$3O";>)WCC<CY6.2<GWY'4 '?&1
M%=4+J';.U2>3CKBH;6_M;YKA;6=)3;RF"8(<[)  2I]\$?G7FR^1KOB3P;>0
M:GJ\2&.^A(GF42*\3 ,K$ @G(*D@G(4<]ZGO-5U>=I[:'5)[9G\5_81+&%+)
M 802HR".O/(/- 'I5%>6ZEK>I:):ZSIC:K>2PVNM6MLD[,GVCR)8HY'17( S
MRV"><<9SBNH\"K?/IU]=7=W>3PSW;FS%W,LCI   N=N0#G=WSC&><T =!8:C
M::I;M<6<OFQ++)"6VD8=&*,.1V92/PJU7D&FW%UIFB2:K9:Y<&X3Q-+:C3E9
M/*99+UE:,KC)8JQ?).1QCBM2;4M9M=(\9^(DU2[FETRXNH;.T.WR8U500S#&
M6(SGD]!]<@'I=%><6][K&BVM_J&IWM_'HHTMY7F>ZAN9O-!7;)$ , $,>#\N
M=O3FLVX\1ZWH:>)X$FO8S;Z;;W,0OYH[B2W:21T9\ID8"@-M)(^7T- 'I]]J
M-IIJ0-=R^6L\Z6\9VD[I'.%' [G\*M5YUXITQK?2M/M+?Q#>W,DNL6!62>2.
M62 F3 =?E[]0#D<<#J*V_"TEW;Z_XAT>>_N;V"RD@>"2Y8-(HDCR5+ #(R"1
M]: .@L]1M+^2[2UE\QK2<V\XVD;) JL1R.>&4\<<U:KR&]GN=/MO'>L66O7%
MM=Z=JAEALXV38[>5#@.N,MO^Z!GMQSFMC5-;U:UUR^\++=RK>ZG>6\NG2\%H
MK=P3/C_<\J7'^^M 'HU%<UXNU&XT-])U@7#1Z=!=B+4$)^7RI?D#G_=<H?IF
MN9L]2U;5I?#MO=ZG=65OKS7E_NB8)((QM,$"L1\OR,&..3M/O0!Z717FNEZ]
MJ2:KI=G-J<D]G'XANM/%S(5S<1+;.R!B  2'^7(ZE/6NE\(:I+JLGB!WNA<Q
M0:O+!"P8$*BI'\H(]"6H Z6LZ#7-/N=9N-)@F>2\M@#,%A<HAP#M+XV;L,#M
MSG!Z5Y]%J^J-X?M/% UJZ;49M76U;3=R^3M-SY1@"8R&"9.<[LC/2MOP+IYM
MM;\6S&]NYL:N\?ERR J?W$#;L8^]SC/H!0!UUW?VMC9W5W<3*D%I&TD[#YO+
M55W$D#GISBI!<PM:"Z\P" Q^9O/ VXSG\J\ONM/\D_%*8W]Y(5@D_<R2@J=U
MDC9(QVZ#V&*T=/;4M$U+3;4ZQ>7D5]H<]PZ3[<1RQ>5M9  -HQ(1CV'?F@#O
MK2[@OK.&[M95FMYT$D4B'(=2,@C\*?--';PR332+'%&I=W8X"J!DDGTKS*#5
M=5ATSP[KFI7U])I+:;8F9[*9%>*X?&YY4(RZMN0<9Q@_+SFN@^(EXPT6VT:&
M">XFU>Y6V:&W ,C0#YYL D#_ %:L.O\ $* .IL[RVU"SBN[.>.XMIE#1RQ,&
M5QZ@CK4]>1Q:_<Z#X:\1:5!%=:6]KJ$,EI'*J)*EK<S+D)DE00QF4$G ^7.*
MG:ZUJ+PYJ=]9ZQJ,4-SJUE;Z?)=2I-)%$TD2.2!D<LS\$Y(QF@#U6BO.=6;6
M(?%%KX:M+O5;FWBTXW0E6\CBGFD:5@2SL/F" #@#^(9SQ4$^H>*+K4]'T2\:
M<W']D_:;@Z?=1PF:;?L+;R,$  $JO&7YX H ]-HKSNV'B'4]:T;1]4UFYLY&
MT>6>[-BZ RR+*B*V[! .&R=O?CI57PWJ.M%/!FJ7FMW5W)J\LEM=0N$$140R
M,I50.&S&"3GG)[8  /3J*\P\+:AXIUE],UG?<!)[QUO$ENXO($6YU,:Q ;E9
M<+CN2#G.:32[[64L-"UR77+V>2[UI[*2V?;Y/DF65 , 9R-H.[.>W3B@#TY9
M$?=L=6VG:<'.#Z4ZN#\"VL6F3^*+J?5+EHXM5G1Q<S#8H 0[SP,''?TK;\:7
M=YI_AB;5+"5U>P>.[D5.?-A1@9%/L4W?I0!T-%>2_P#"7:Q=W]_9Q7S!=>N8
MUT21,?NXEG,,S+_P!!*/]ZK8U#Q3JNK:O<6#W"R6&JFVB0W<26Z1(RY5XR-Q
M+J2=W7YAC&* /3ZJ_P!HVG]JG3/-_P!,$'VCRMI_U>[;G.,=>.N:QO&$>K2V
MEF-*DE(6??=6]O.L,\T05N(W;@$,5/;(&,BN5M$7Q3XML+BQUG4[:VE\.HXF
M0JD\G[X@;S@X(/)QU(].H!Z;5"[UO3K"YDM[FY$<L=J]XR[&.(4(#-P.Q(XZ
M^U>?0^(+S6?#6A*]YJK:I+I37DWV&:*W3"D*979\=_X1QR<CI50:C<ZO8VNH
MWCA[FY\#W$LK 8W,3&2<#WH ]7M[B*ZMHKB!M\4J!T;&,J1D'GVJ2N*UJ^N]
M-^$/VRQG,%U%IL+1R@9*G:O-4-;_ +8T[6M&\/6]_J=XEU#<7,LWVF.&:9T,
M8"*Y "J-S-M7G\ : /0C(BNJ,ZAFSM!/)^E.KRZ73]5NM;\%C6]2NH;T27L1
M>"=.556*$D#&\K@-CT-6=3\27EKX:\5RG4C%=6VM+;6Q+ ,B$PX0#W#-^9H
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M >CG)& >PZG!P#BD_P"$QTZ:>SBL8KO4#=6R7BFUBW!(7.%=LD<$@\#)X/%
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MP2"".A!/0^E<W=S^*T\9V^BQ:]8K#<VDUVKG3<E CHH7_6<\2=>.G3F@#?\
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MGN+<I',57<R@^H&>V#@X)JQ'XMMFU)+&33M3@EF21K8SV^P7&P98)SD''(#
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MKZX^ZW+%L(/(CC^?CCE">,\8K6\7Z/<Z]X6N]-LWA2XE\LH9B0F5=6Y(!/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4$@#).!17GWBJ.ZU?Q]:Z5_9-IJUI;Z8;L6E[<>5 TC2
M;=S#8V\@+@ C W$\4 >@TF1G&1GTKG-%UBWG\ IJFF6(LXHK60QVF!B)H]RE
M!CC 92!CM7)^"GBT^3PU<:CX>M%O=:@)CUA;@37,LIB,K>;E 0& 8@!F P!Q
M0!Z?D#O3!/"9S )4,P4.8PPW!22 <=<9!Y]C7"?$#PYHMW>Z'>7&E6DMS<ZQ
M;0S2O$"TD>&&UCW& ./:H+C3;[3_ !_=V?AE[#3(8-!@8*]L74?OYR%50R@
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MUH+=O,EB%QY6[?NX8 C P0<>^  >BT5Y]J/BG7UTW7_$%G-8II^BW,L/V*2
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M312H3C<K#!''L:S;;POIUO\ 9"3=3O:02V\4EQ</(P23;N!)//W%QZ8K:HH
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MTI(9=HVIA^25XP>* .SHKB-2\2>(X]8\-0VFG6#)J!F\Z-;[<C[48C:_E],
M,#@9SC ZUO\ B#7#HL-HL-J;N]O;@6UK '"!W*EB6;!VJ%5B3@].AH V**Y
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MNQ)0(YC<_<W*H!X/J,5UM% &1K.@0:KX=.C)(;:#]T%*KG:(W5@,?\! K/\
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M^7' ^4]Z .^HK@]$\3W][?-+?S+;1OX:M-1,+858Y7,N]N><<+UZ8%4M+O\
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MD:=!%91164"1V/-JJH (?E*_+Z?*2/H:NT4 9,7AC0H-5.J1:39I?%S)YZQ
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M_LD/DWA9KE-@Q*6&&+#OD#!JQ##';P1P0QK'%&H1$48"J!@ #TI]% !1110
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MJVEN;?4;2:WASYLL<ZLJ8Z[B#@?C7/P1ZA8_":UBATL7=_#H\2?8;B/(=Q$
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M ZA:B:X4/!&9EW2J>A49R1]*\ZO="FM])OR='FDM[;Q4EXD$=L7)M]T9=HT
MRP^\<*.>:O7B/!XQMKW1M/O7>\DM%N;:ZTMO)$( _>)*0!$R*3\I/5<;<\T
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M+7D2Z@L*R^67 R&)  Y^]QG'H0:R/">BI:ZQXDU"XT\1W4^JR-%/)%AWB\M
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ME^5XXZGCGC8U;PY-9^$/"BV%A)!#9S0S7\-M:"63_4L-YC(S(5=@2,$]^HH
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MY(F;>,1X&3N]."#SVKRSQMIMZMAJNA6.D2BWCTF."P:VTLW#W15&&UI>D>S
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MX( SD#)SZ\OFTRZOEUN^T[2+NVL;O5M+>"W>V:)V\J6/S9?+(!48 Y('"$T
M=]I_B72-3U&_L+6]A>YL9/+F3>,YVJQ(YY W $]CD5JJRNH92"I&00>"*X.S
MCLM'U[QHVIZ5(EK,3=B?[*?*DMQ;QK(OF8VYW*V5)![^]=CI#6[Z+8M:6S6U
ML;>,PP.NUHDVC:I'8@8&/:@"Y1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;B;S/-W]?[YSCI^%5#X-T!M2^WFPS/\ :1=C]])L6;.?,";MH8GJ0,GG.<T
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M:S;?9]0-O*LR8 Z;@&P"0-P ;&3C.*DE\'Z%-8V5I]B:..Q!6V:&>2*2('J
MZL&P>XSS6G;V%M:Z>MC%&1;*A3:SEB0>N222>O4F@#RT:5IVF?#+PAK6G6=O
M:ZXJZ:+>:",)).TAC5T8CEPRE\@Y]>U::>)O$^H:I>SZ=;7DD5KJK6:VJ6T7
MD/$D@1V:0MO#XW,,<#@8/6NITSP5X>T>X@GL]."RVZ[8&EE>7R1C'R;V.WCC
MC'%2R>%-&DU1M2^S2)<O(LLGE7$B)(XQAFC5@K'@<D'I0!Q^I^(?$<&G^)M;
MBU6%;?1-0:*.R^S*1.B["5=^N2&P,8YZY[6M2UO7KF#Q5JMCJD5E!H,CQQ6C
MVZNLYCB61C(Q^8!MV!M(P!GFM&R\ :8-4U+4-2MX[F:YU W<>)'"XPNP.F0K
ME2I(R#C/%:=_X/T'4]0DOKRP$DTNWS@)75)MOW?,0$*^/]H&@##GU_5(_$-A
M/?37.GZ-=I;?9C';)+$\DGWHYFP61B2JJ>!SU)XK GDU'4#H;6NH#3_^*IOK
M;%M;Q@':;D!B,8)PO.>I.3S7H%SX9TF\U5-2N+9Y+A'20 SR>7O3&UC'NV%A
M@8)&1@4VY\*Z+=V!LI;/]Q]J:\ 25T99F9F9U92&4DLW0]R.E ">)+\Z9HRM
M_:$EK-++'#')%;>=)([' 5$Z;CSU! Z]JX9M8U#4[&&WU%Y7EL/%5I;I)/"L
M4K(1&XWJORY^<CCJ .*]$U+1K#5[!;*^@,D",KIAV5D9>5964A@1Z@YJI;>$
M]#LX?*AL0JF[2].9'8M.H $A).2?E'7KU.<T <G+XDU^ST7Q3XAEO8IH-,N;
MFUM;$6Z@':^U7=NIQGH,<#UY%BTUO7M/34I-6GO(=-CL3,-0OK*-6AF! VJD
M3?."#D#KD8R<UV$>C:='9WEH+2,V][)))<1/\RR-)]_(/KZ=*H0>#]#@L[FT
M%I)+;W,7DR1W%S+,-G]T;V.T?3% '&OXQUO2K?Q%%+)<3R6MI:SVDFHVJ0NK
M32/%EE3 * @-V/4&I9;/Q#:^-M0ABUA;W4QX>=[2=[9$(?S>%91\I!8>@X/?
M&:ZVW\':#;17L:V'F"^A$%T;B9YFF09P&9V).-Q_R!4NE>%=&T2[:[L+0I<M
M'Y3323/*[)D':6=B2!@8].U &3X9\4S>*=86:S8)ID.FPR3IM&?M,OS;,]04
M5>1_MCTK!U1M9M?$?CG4=*U-+/[#:6]QY9MUD\YEA9@K$]%P"..>>O'/6^$?
M#@\-Z9<Q-Y/VB\O9KR<PC";I') &>P7:/PK0DT73IFU%I+8,=2C$5W\Q_>J%
M*@=>."1QB@#B-1\4:]J.KS6>DI>0BWTZWN0+6VCF\R64,0'\PC"#:!\O)YY&
M*JZCKVI:5J6LZS):QP:I_P ([IY:&3E(9GFF4YP>0K-SST%=M>^$]%OY()9K
M61)8(1 DD%Q)"_ECHA9&!9?8Y%3R^'=)G^T"6QCD%Q:+93!R2'A7=M0@GMO;
MGKS0!R^E6NHV?Q2,6HZH-1;^Q"R2&!8F \Y<@A>",]./SZU%>VVJ7/Q'UT:9
MJZ::4TBT=G,"R%B'N-OWN O7/&>F"*Z?2O"NC:)=F[L+0I<M'Y+323/*[)D'
M:6=B2!@8].U,U7P?H6M7KWE_8F2Y>(0O*DTD;-&,_(2K#*_,<CH>^<"@#D(_
MB!J%KI=KJM_&GE:GH2WEG"J8_P!+7 :('J0_F1D9]#71^(=1U70?A])>O<(^
MJ6\$7FS;!M,FY0YV],<FIM;\+0ZO=>'D$=O'8Z3=BZ\O9S\B%8U3L "03_NB
MMJ^LK;4K&>RO84GMIT,<L;C(93U% '-:QJ^MKXCU32](\F2>/11=6L,@&#.9
M'49/I@#@G%+H-_J&J:;)%;ZK,;^VO(UNTU*R6.6),*S1E4PN2I)5AD<]\5=M
M?!>@6:W AL6#7,0AFD:XD:1T!R 7+%N.QSD8&*BE\&:=Y-K;VV^&W2^COKG<
M[RR7+QCY TCL6X8(><\+CC- #O%6IWUI)H^GZ?,EM/JE[]F-TZ!_)41O(2 >
M"Q"8&>.>]<S?^(O$6G)JNE1ZA#/>VFI6%O!?2VZC<ERZ@AT7 R,GIC((Z&NZ
MU72+#6[/[)J-N)H@XD7YBK(XZ,K*05(]00:JP>%=%MK$6<=D/*^TI=DO([.\
MR,&5V<DLQ!5>I/0#I0!?T^"YMK&*&\O&O)USOG:-4+\G'RKP.,#CTJS110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !116/J_B"/2[NVL8;*ZU#4+E6>.UM=F[8N-SL795502
M!DGDG S0!L457AN]VGK=W$$EI^[WR13;=T?&2#M)''L36#I'C6WU6]T^ Z9J
M%I%J4+36$]P(]EPB@,<!7+*=I! 8#CWXH Z:BL_6]9MM!TF;4+L2,D> L<0R
M\CDX5%'=B2 *?H^IPZWHMCJMLDB07D"3QK( &"LH8 X)&>?6@"[116#>^+-.
MMK'7IK>1;B?1HG>> -M)*QB3 /T(Y&<&@#>HJM97T-];I)$Z%RBL\8<$IN&<
M&I([F":22.*:-WC.'56!*GT([4 2T5'-<0VR!YYHXE)V@NP4$^G-5X[_ '7]
MW;R0/%';B,B=W7;)NSP #D8QCD#KQF@"Y14#7MHL/G-=0B+=MWF0;<],9]:D
M\V/+#S%R@RPST'J: 'T5#)=VT2[I+B)%P#EG &#T_.G+/"\SPK*AE0 L@8;E
M!Z9':@"2BLW4=>TS2M-NM0NKR,6UK_KF0[BI],#G/M5M[ZTCB25[J!8W.$=I
M  Q] >] $]%137,%NI::>.( 9)=PN!TSS2S7$%O%YLTT<<? WNP Y]S0!)14
M4MS!!L\Z>./>=J;W W'T&>M+)<012QQ231I))]Q&8 M]!WH DHIKR)$ 9'5
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M$C/8FIVN8$G2!IHUF<96,L S#V'>@"6BFLZH 78*"0,DXY/05$U]:+ D[74
MB<X60R#:Q] >] $]%137-O;[//GBBWG:N]PNX^@SUI9;B"%XTEFCC:0X168
ML?0>M $E%1-<VZ3I \\:S.,K&7 9A[#J:'NK>-PCSQ*[,$"LX!+'G'U]J ):
M*BDN;>&6.*6>))).$1G +?0=ZS;?Q!;S:[J>F2A8#9&%1(\@ E,BE@ /48H
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M64+!<PW*LA )>)PZYXZ$J,_TJCJ/A#3M3DU9[A[C=J20+(4<*8FA),;H<9#
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M9&C\N(.K*1P@9N'."Q)&!SUR <]\/_$$M[X?.F6L"O;Z=#,;Z:1RK;V=V1$
MYZ<ENG89.<7=)\1ZO<VGA_3-$T^S#7.AQ7^^\N)&$0^4;<\L_4#).>I)['9L
M? VFZ:]H]K/=1R6\$MN[AES/$[,VV3Y>=K,2I&"/Q.;6D^%K+1[BPFMY9V:Q
MTU--C$C @QJ003@#YOE'M[4 <Y+\0IYM-T::"/3[&6_L)KQWU&<K$IC*JT:D
M?>;+9SV S@UO6?B.1/ ">)M5MQ"PL#?2P19^5=F_:,]\8'UKE]3\$SV-]I4=
MC::A>:=96+VZ&UN88Y@[2!\OYF%*\<8Y!SP>*Z[2M-O;GPA'IOB5DNKF:!X;
MO!&'5LC:2  3M(!( R<F@#+L_$FMP:II5MK5A91QZM'(UN;65F:%U3S-C[@
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MB3(.02=WUH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^J*2#;*^6! R1Z9 !..M &Q1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+!!<)&>8\GCOW]*XS6?"WB+Q)#XSU>/0I-/?4K""TM;&26/S9F1P2[8.T<#
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MS/;QR9CDW"0,BG?T&W))^7G'K5&T\82OXHM]$O;"WMY+H2F+R;Y9I$*#)$J
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M"MO8'YR!E1P.ISD\T^#X?P1:;:V+:C,4@T271RZ(%8J^S,@.>"-G3GK7944
M<1!\/G$5\+G5(F:YTF32@+>Q6%(T;H^T,<MZ\X/;%:]WX4MKZZLI+B9FAM]-
MGTYXMN/,241@G.>.(_U]JZ"B@#D!X,O+GP]+H>J:_)=V8@2&WV6J1O&4961V
M/.]@57T!YR*V=%TS4+ RM?W]M=%@ HM[(6X&,\GYF))^H''2M:B@#FM2\&6F
MI^+K;79IVV1P&*6TVC9,=LBJS'U59I!_P+VJEIOP_BT[PQ;Z.=2EG>._@O7N
MGC&Z0Q.A52,_W8T3/MFNRHH Y2]\&RW7_"2P)JGEV.NQ.)(3;AFBE:)8MX;=
MR-J#Y<=>]:;:$/\ A(+75EN65[?3Y+)4V YWM&V[/MY?3WK8HH K:?!<VVGV
M\%Y=F\N8T"R7!C"&5N[;1P,^@JS110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !65J?B;0M$N$@U76;"QF==ZQW-P
MD;%<D9 )Z9!_*M6N<\:ZC+IWA]DLE4ZG?2+96.1G$TAP&^BC+GV4T ;EE?6F
MI6<=W8W,-S;2C*30N'1AG'!'!Y%-M]1LKNYN;:VNX)I[8A9XXY S1$] P'0\
M=ZKZ18V.A:98:);2(JP0!(D+#>ZJ "V._)R3ZFN=\*6%IIGC?Q5:6-M%;V\<
M=EMCC4*!\CY_'WH ZJ_U"RTNT>[U"[@M;9/O2SR!%'XFK.1C/:N)^)=MI^I?
M#G5[\QV]T8;*5K>;APA(P2I]>,9%=5J,!N=(N85FEA+PL!)$0&7CMD&@!;C4
M[.UDLTFG56O9?)M\ D2/M9\ C_95CGVJW7D&G:;,W@KX;PPZK>(]Q=0N)LHS
M0 V<N53*X P"!D'&:O7>NZWI^FW>EQ7MU<NGB--,6Z9HQ.(&A67&]@%W9;8&
M([COB@#U&D5U<$JP8 D'!S@CM7.^%(];B34(-6\X0K,#9FXFCDF5"@R&9.#A
MLX)YP>:X:TFOO#?@O7[VQU&\EG;79;3=,Z$0AKO8T@R  V&SD\9(.,4 >N45
MYGJ5SXJT?P[KDAN+JVC'V0V4MW-%/-&[3!9,[.J$;<9]6_#3U&RU*#Q'X>T"
M/Q%J8@N+:]EN9R8_.E*&':-VW"X+GH.A(H [FBO+]&U#7([+PWJUSKMW=/=:
ML^FS0.B")XE:9 2 N=^8PV[/4D=.*V_#5YJ%MXEET_7+F]>^N8YI[=A)&]I/
M"L@PT8 W(RJR#!ZY/+=0 =K6==ZYIUCJ=KIL\["\NAF*)(G<XR!N;:"%7) R
MV!7'ZI>7^H:GXM<Z]<Z6NAQI]FCA*!>81)YL@93N!8E<=,*>_-0Z%'=:I\0K
M#5KJZNX)Y_#MO=2VRL BLS$%,$9VYYQG.>] 'HV]=^S<-^,[<\X]:KZ?J%KJ
MMDEY93"6W<LJN 1DJQ4]?<$5R$^GM)\8HYO[0O(\:3YOE(ZA"!,!MQC.T]3[
MGK7/^&O[1TG1?#>H1:O=-%=ZQ+:26;!/)$3R3=!C.X$!MV?4=.* /4+2^M;]
M)'M+B.98Y7A<HV=KJ<,I]P>*L5YL;S7[[2YIK:XN98;;6;];J&TECBN'@21U
M01EA@[3C(R">.>QZ#4_$T=G\.?[=T^26Z:6SC-DTJ@232R +%D #DLRY 'K0
M!T%EJ%EJ,<DEE=P7*12-%(T,@<*Z]5..A'I5FO*/#-U_PB.I7VG1V5Y8V]SI
M(N8GOXMH>ZMTVRMA2<[E\MCW^4T:!J.M7MG<ZLFJ:JT$&AO+/]JDBVF\*Y!1
M5_A W'T^[CO0!ZO17F-Q>:[8Z#X80:IJ%Y<:[*AN90\4;+^X:3RXB0%3<0!S
MDX!QR<TZ]U+Q5IVFV&G7)NE>]U@VT<HN(3<?9_*,BH7^X'+ KGKCW.: /3**
M\WN)O%%M9:=8W5_<V37.O+;13%XI9_LS0,Q5R 5W!@<'&<!2<]Z5S<Z[8:;X
M@O5\1W\O]A:I';VT<@C(EC/E,PE.W+\2E1TQ@'K0!ZK17F>IZCXIU/7?$<>D
MM=I-I<R16B)<0QPK^Z1]TJO\S!BQ&>@ XY!I-?O-;+^-[^'7+NU&AI'-:6T0
M3R]PMDD(?*DLI.>..I]L 'IF]2Y3<-P&2N>0/\BJUQJ-K:WMI9S2[;B[9EA0
M*26VJ68\=  .IXY ZD5QNGV33?%J^NSJ%XN=(M)O)#KL;+SC;C&=HQD<]2>:
MT9"9/BQ DG*PZ([0@]B\ZAR/P5* .CLKZUU*SCO+*XCN+:0$I+&V5;G'!^HJ
MQ7F&CWVKZVGA"T;6;NU2]L;Z6Z>W"!Y#')$%P2#MQN/('3/KFGZ;J^K:JOAW
M1KG5[B 7$^HQ3WD6U)I_LTI2-<XP"1\QP,G:?>@#T/\ M"U.J'3?.'VP0BX,
M6#_J]VW=GIU&*LUYEKL]SIFIZU<6>HRW-U:^$Y7BNSM+EUD?#': ,@CT[5HZ
MMXGN[35X?L=RL^SPU=:@;<$$22*8C&Q YYRP'KDT =E/J-I;7UK933!+BZ#F
M%"#\^P9;GIP".M/LKVUU*RBO+*>.XMIEW1RQME6'J#7G&G13)XO\%7,_B"XU
M.6\LKBX9)BA +1*2Z!0"%.<8Y' QWRW0;W5]?3PC9R:U>6L=WHL]S=/;A%>5
MU>(#DJ=OWCR![=Z /4**\F/BG4)-,\-P7^I7^)DOA<26(C2>5H)1%&Q)XQSD
M@=R.V:[SPI]MM?#6E6^M7GFZK+!OE\R569FZL!C@XR.G% %R_P!<T[3;ZTLK
MJ=EN;LD0Q)$\C-@@$G:#M4%ERQP!GK6C7":I9R?\+8M;M+R\S'HL\P@C<!6V
MRQ?)C'1N_N!6;I>J:HNG>$-=_MVXO+C6[F..ZLVV&';(C,P10,KY>.N?X3G.
M: /3:K7E_:V%C=7MS,J6]I&TL[]=BJNXD@<].:YGP&-0OK&;6-0U>[NFEN+J
M!+=MHBC1)W5< #);"]2>AQVKE[O3V@LOBK,=0O)-L,Z^3(ZE3NL48$C&<CH/
M8?C0!ZK'(DL22(<HZAE/J#3J\X2]U;PS=Q(NI76IK-X?N+[R+@+@30^7MV!0
M-H.\C'/0=^:L>#Y?$EQ=Z5?3RW<VGWEH9+I[JXA=7<JK(\2IRH^\,=,$=Q0!
MW]%><>/M<N[7^V9-*O-66ZTFQ6X?R9($MH6(9DWA_FD+;>0,C'3!-&M^(M6T
M_4=1T:.Z87>L1VSZ.V ?*:0B*4#_ ',>9SG[U 'H]5XKZUGO+BTBN(WN+;;Y
MT2MEH]PRN1VR*\ZU/4M3DTSQ=K"Z_=6<^A3/%:VJE/+(CC5E\Q2N7,A/KW&,
M4[5_$>K0RZ\J7+6>9M+@$A53]C6<A9&Y'49/7H<4 >A)J%K)J4VG),#=PQ)-
M)'@Y5'+!3GIR4;\JLUY?Y\7AWQ/XM>XUS4+A(-,L5\]?+>XB+23 ("1M+988
M+#C<,\#-5Y]=UW3]-\7VJW=]!+8QV4ML;V2*:6%I7(8%DR""%!P3W/M0!ZQ1
M7FVLZMK'A.7Q'!#JESJ'DZ,E_#)>*C&&4R.C,-J@;< -MQ@8]*L^()[_ ,-Z
M%&MAKU]J$M]=VD#22R0EX4D8@NA*@+OQM&[*@]* /0**YKPG'KD,NHPZJ)_L
MH=&LQ=3QRS*"OSAF3J,C(SSR?2N3?6-6;P])XI76KD7RZN;5=,&SR=HN?)\D
MIMR6*\YSG)STH ] CUS3I=:ET>.=GOH5#2HL3E4R,@,^-H)!!P3G'.*L:AJ%
MKI5A-?7TPAMH1NDD()VC..W-<CX.T]H/&'C&<W]W*!J")Y<CJ4.;>%LX ZC.
MT>WYUS'B^XN]5\->,+ZYUR>V6ROOL45BI01%!Y> P(R6?<6!SGICC@@'KU%>
M>:K>ZA?7?B^X_M^YTS^PE46L,)0(/W"R>9(&4[PS$C'3"\<\U+9>);Z2YUB6
M_N!:A/#UI?+$Y"B&1Q-O(S[A1SZ"@#M?[0M?[4_LWSA]L\G[1Y6#_J]VW=GI
MUXJP74,%+ ,V< GDUY;IZW&N>)- :XUNYLI[GPK#-+);LBRS,6!)RP.!DY.!
M^F<PZ8][XBU7P)J-[JMVEQ+:WJF2 JBR>6R@.!M/WU )QVQC% 'K-5+[4[+3
MK-KRZN%CMUD6-GP6PS.$ XS_ !$"IUEBG$JQ3*Q1BC[&!*-CH?0\BO(&TZ6W
M^''B+9J=W)(VOM$OG,KA&&HJ-^,#YCP3V/M0!['17FFL:QK/A1?%5M!J=S?F
MUTZUN[>6[",\+RR21N> !M 0-@\#![5O>%XM?@U>=+TW9TQ[96C^VW,4THEW
M<E3'_"5(X/0CCK0!T\5W;SSSP13QO-;D+-&K M&2 0&';((-%K=V]]:QW5I/
M'/;RC<DL3!E8>H(ZUPEBGB!O'GB_^QI],CC^T6V\7D,CDG[.G3:PXK)\(W%W
M>Z/X,T!=1GT^UGTF:Z>2V(62=T=%$:L0< !RQQR<#MF@#U>BO.-%\0ZI)J&@
MVL^H-/;G5[^Q-P0H^UQQ))Y9;  )RN,C&2M*-0UW6=.OY--O);F.WUV>.2.U
MG2.:2V1<!(G;Y<ABI[9 (R* /1JBN;F"RM9;FZFC@@B4O)+(P544=22>@KS5
MM?U'7]4L+'2+C5I+$Z/'>1R130PSRNSLA9RXP=NP9"C&6YR,5K^*&U%_@OJC
M:OY?]HG1Y/M)B(*E]AR1CCGKQ0!U&EZ[I&MK(VE:I9WPCP'^S3K)MSTS@\5?
M)"@D]!R:\QC;4K;Q-K-UJ7V:WU6+PZQL/L*G9+'G+,2W)=7"C&, -WSQJVVO
M7%QJ/@VW%^)!?:3-<7*!@3(1'$58_B6_6@#L=/O[75-.M[^RE$MK<1B6*0 C
M<I&0<'FK->/Z#J&KW&E>$]#LOMRV_P#PC\=V193Q0R2/D+]Z3J%'.!W89XK7
MU"]\2:=I^F:GKUU=+96MGG4#IDT0DBEWX\UU(PZ%1R%Z'=P>P!W]KJ-K>7%W
M;P2[IK.413H5(*,5##KU!# Y'%6JY2R)C^*6KQQ?ZN72;264?[8DF4'ZE1^@
MKG_%OB"\MKZ_O-*N]6)TZ]MK>7,D"VB,QCW1[#\[Y5\D\X+<'C@ ]+J*ZN8;
M*TFNKAQ'!!&TDCD9VJHR3Q["O-=>O]:1/&VJ0:Y>0#0YT:TMHPGE\6\4C!\J
M2P))XSQDGZ.\4W-WJA\:I+KD^GV^DV*K#!&4"2!X"[-)N!+!B2@Y&-IQS0!Z
M3!/'=6\5Q"V^*5 Z-ZJ1D&I*Y6XU"+3/AQ97$MQ=P VMM$KV@0REGV*JKO\
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M :.9"-QW/G##/!'W>M2>-O$-[X7U*WO$E9K2[LKBWBA(&/M:C?#CW8!U_ 4
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M(((%LK=8;>7SH4$8VQODG<H['))S[FH'\1Z)%I2:H^KV"Z?(VU+HW""-CDC
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M(VEZ7:632 !S!"J%@.@.!T'I6E10!#%:6\%Q//%!&DUP0TTBJ TA "@L>^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK"\0
MWFMV$4EY8-I*6,$#2SO>M("NW))^48Q@4 ;M%97AK4+W5?#6GZAJ-JEM=7,*
MRO"A)";N0.>^,9]ZH>'?$&HZMK6LV&H:;'8FQ\AHXQ+YC[9%8_.1\N>.@R.>
MIZT =)165K4FNHD8T2+3F.UFEDO9'4+C&  HYSSSD8QT.:;X6UO_ (23POIV
MLFW-N;N$2&(MG:>AP>XXX/I0!KT5C7OBK1M.U$6-W=21S;TC+?9Y#&C/C:K2
M!=BDY& 2.HK!OO%>HV]_J4""#9;:[8Z>F4.?*F6$OGGK^\;!^E ';T5'<7$5
MI;2W,[[(8D,CMC.% R3^5<]'XPT_4FT]])OH)()[Q;=GEAE DS&[8B.W!/R]
M?N\$9S0!TM%8,?C/09M5BTV*[E>YFE:&+;:RE)'4X8+)MV':0<X/'>LOPEX\
ML-9L[*WO;M%U2X>6/8D+B,LK-\@?&W=M .W.?:@#LJ*Y32OB!H^I6FI74AGM
M8K"X>%VE@D 8!PJD94?,Q(&P9;)QBNAT_4+?4[07-MYOEDE<2PO$P(Z@JX##
M\10!:HJMJ&H6NE:?/?WLPAM8$+RR$$A5'?CFLK_A,]!-C%>+=R/%-*8H1':R
ML\S 9.Q NYQCG<H(QSF@#>HK$E\6Z'%I]I??;3+#=EA ((9)7D*YW81%+?+@
MYXX[XJ33?$^CZL+(V5V9/MT<DMMF)T\Q$*AB-P' W+]<\9H UZ*YJ?Q,LVM:
M!!ILL<MI?7=U;3L4.0T*/D#.,8="/PJQ;^,-#NKA[>*ZE,JQ/,H:UE7S43[Q
MC)4"3&1]S/6@#=HKD-,\<V^N:)I^HV>RU-Q>QV\D=W%*!\S$;4;: S''!Z#O
M6E+XQT&'4SI\E_B<3"W9O)<Q+*>D9EV[ W(^4MGF@#=HK N?&WAVTU"2QGU$
M+<13+!*/*<K$[8VAV"[4!W#!) /X&K9\0Z9_;)TD32/>*0KJD$C(C%=P5I N
MQ21S@D'D>M &I1161/XGT>WUQ=%DNS_:+;?W"1.Q ;H20" /<\4 :]%8MEXM
MT/4+\65M>[Y6W^6QB=8Y=GWO+D("OCG.TGI6=J7Q!T:S\-W^LVOVB[BM(Q(
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MAFM]1U-;Z.\:Y50J;HV9=G7<"A]L'.>Q]$G$I@D$#*LI4["PR V.,^V:DHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!!>VMS;)<V]S#+ YPDL<@96YQP1P>:GH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%W.9.>-IPIQGYB!2ZMXH33=8CTF#2[_4+Z2W-RL=JJ8V!MI)9V4#G'4\YXH
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MB&0.DD9+&3C800?NCG(KG/"F@>(=%NII-1NM+NVNW,MY=)'()YFP=O).T*O
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M1-.5SU4R, #T^6I=8M=<;XD6]SHYMT*Z0Z,UW$[1-F5?EW*1AN_?@'ZCMJ*
M.(@\%ZEI-OH,FE:A:O?::ERDS743>7-]H8/(P"G*X< @>G'O4NC^#+O3CH;7
M%_%/)IU]>W<KK&5\WS_,Q@9XQYGZ5V5% 'G=SHWB#4?$WC&VT^XMK6SOQ! \
MES;NQ , 4O&00&(!(P>,XYZ@Z?\ PBNK:1?7$OAR^LXH;NTAMI%O8F<Q&)"B
MR*5(S\N,J>X'-=C10!P=[X"N&T[2-+L9;&.WTV*&.&_>)A>0E"-Q1@<?,!TX
M')SGI2Q^ 1:Z[>74=AX>N[>[O6O#-?6/F7$19@SJ&_BYR5)(QGOBN[HH Y >
M'+Z+QA_PD,IL84@$I?[!"ZS7B%2$249PQ7@@\DD#&.E;N@2:G-H5I+K,<<>H
M2)OFCC& A))"]3R!@'GJ#6E10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4QYHXSAY$4^C,!3ZY#Q_9Z,FB3:A>:'IVI:H56TL!=6J2L
MTKMMC4%@3C<V2/3- '7*RLH92"#T(--26.1F5)%8H<,%.<'WK-\/:%;^'_#-
MCHL/S16T B)'&XX^9O;))/XURF@:/IA^(+WOARQ@L]+T^SDLKJ:V0(EU.74[
M>/O^6%.6]6QV- '>R2QPKNED5%SC+' I]<SXTB\/KIBW>MZ7!J4B;H;.VDC$
MC2RO@!$4_P 1P.>PR<@9J+2;74/"OPOC@N)A)J&GZ:S%B=P#JA('N!P/H* .
MKHK@++Q'KNG7&ESZM<VUY;ZEI4]\88+?RS \2H^U3D[@0Y'/<9&.E%GK?B.*
M+PU?WFH6D\&OLL1MXK;;]E:2%I4*-NRP7;@YZ]>* ._HKC?ALNI-X;DFU#4S
M>!KRZ5 T>TIMN)5/.3D' P.PXK!TW5=<T+P]XCU"34DOI5UE[.!)X=J)(\Z1
MAR0<[1OSM&.G6@#U"BN6TJ_U>R\8-H&IWL6H)+8&]BN%@$3(5<(R$ D$'<"#
MUX/6L+Q!XD\26<OBV\LKRSCM- >)H[=[?<TX,,<C*S9X'S'! SS[4 >C5%<7
M,%G;O<7,T<$$8W/)*P55'J2>!7&-KNKZ-JFJV.LZM9;(]+6_2[^R$+;L79"N
MP-EUR 1SD]*YS7=>U&]\,>,M*OI9IX[?3(KF&6XLC:R?.SJ04/4?("#@=2#T
MH ];HKSR;QKJA\,7FM1+&KSZC'IUK9^27DM&,@C)E&06DYW;!@?=&3G-;GA3
M4=:N[K4+?4X;AK>'RVMKJXM?L[R;@VY2N<?*0.1CAAZ4 =/17G[^*[^/Q18)
M;Z@;[3[K4WL74:<T<*8#_<F)^9U*8/4'YL8Q4-MXD\1^5:ZM->VC64FO-I9M
M%ML$Q&Y:$.7S]X<'@8P/4T >C45PD7BK5&OTT!FB_M@:RUM(VSC[(!YWF8]X
MBJ9_O&M/Q5JMS:W5M9V&IR6]U)$\H@M].:ZD< @;C@X5 3@YZDC!% '1FY@%
MTMJ9HQ<,AD6+<-Y4$ L!UP"0,^XJ6O+[?5+WQ!>:1JJR):7MWX3GF+HFX(YD
MA)P">G7O2V.O:WI?@SP;:"\ENKK5X(V^T):>;)#$MNKE0N?G;/\ $>Q)QQ0!
MZ?17GAU_Q7);Z/9?)97EYJLMG]HNK0J9(%A>02^7GAOEZ9QE?0TWQ1XIU30O
MM#6NJ_:YM-6 7-O'I;&,D[=WF2YPA8$D = 1D'N >B$A022 !R2:$=9$5T8,
MK#(8'((]:X&$:HOC/QBTNI":R@M8G^R20 H0T<F%Z\8QSQ\W>F:)JNL:RFE:
M3I=U:Z4D.A6E[*Z6@<,TH(5$3("H-ASCU &,4 >A45YWI_B?Q!XAD\/6UK<V
MEA)?65W+=2"#S0'AE2/,8)Z$DD9SP>^*V=)\3W3?#JX\07\:2W5G#=-*L0VK
M*T#2*2!SC=Y>?;- '5T5Q%AJVOV6J^'%U._M;V#7%<-%%;^7]G<1&4%#DEEP
MI4YYY!SVJYX!OM;UCPW::SK%[;RF^@22.""#8(NO.[)+$\$] .U '5U%-<06
M_E^?-'%YKB./>P7>QZ*,]3P>*X2V\67S>+-+ABU W^FZA=S6Q(TYH8DVI(P\
MN4GYR#'M/4'DC&*RI-0UO7+3PEKMW>VQLK[6HG2R6#:T _>!,/GYC@?-D=3Q
MC'(!ZA/<06L8DN)HX4+*@:1@H+,0%&3W)( '<FGI(CE@CJQ0[6P<X/H?SKRS
M6M0UO7=!CU:2]MDTT^((+=;'R/F5(KU8PV_.=Y9,D8Q@_C3M9N-0GCOQ87,.
MG-'XNMK=G@MP#*&^SX9\$;CEN<]0 #0!ZB)$,C1AU+J 2H/(!Z<?@:=7GNK:
M_>:!J?B%TBLYKVWL-.1;EH ADEEEDCW2$<E <-MSQSCK3M5U[7_#<FKV5S?P
M7\B:'<:G;3_9A&8Y(L JR@D%264COP1S0!Z!17'Z/JFN1>*++3]5O+:ZBU'3
M9+U1#;^7Y#HT8*@Y.Y2)>IYROOBJDT^IV?Q*UFY.ILUC:Z1#<FT$((9=T_R@
MYX.5SNQDY [4 =W17!:?KWB"%/"^IW][:7-KKTB1O:16^S[/YD32(4?)+ ;<
M'/7.>*LZNFJ/\4=$CMM5,%LVGW+M!Y(8,%D@W \]3NX/;!]: .O@N8+I&>WF
MCE57:-C&P8!E.&4X[@@@CL14M>6:/?ZWH]I-J$5Y;'3G\43VC69@RS++>-&6
M+YX8%L@ 8P.<YJXWBWQ%>:K?RZ=:W$L-GJ9LEM$L2R2QHX21FFS\K?>88&!@
M @YH ]&)"@DD #J338Y8YD#Q2*Z'^)3D5R'C&*/4?$OA;1;T;],O)YWN(6^Y
M.T<6Y$;U&<MM/!VUDZGID.B>,I;/PZL.FK>Z'<S745O$!&K1N@CDV# W'<ZY
M[_A0!VA\2Z"MF]X=;TT6L<ODO,;I-BR?W"V<!O;K6DDB2@F-U< E25.<$=17
MD.E:7J1M/AF@U2$));F1%^Q+A/\ 1,\\_,=N1GWS6U8ZWJ$DT&D:;]CT^:^U
MK4HVN$M@0J0NY)"Y :1OER3[GF@#T:BN"U?7=>L];M?#Z7,C7"6)NY[RST[S
M6D)D*(-A;"C"DMR<G&,5IW-GJWBWX</:7:C3-5O;7;*K A5?/((SD*V,$9SA
MJ .GCECF7=%(KKG&5.13Z\Q_MQO#^C:O;:?X>L-"U^UELO.BB56MIDEF$:R*
M5 R"-XY 88K6;7M4T74]8TS6-7M&6#3H[^*_-F0(=SLA5HU;YN5!4 Y.<<T
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M:R+%.\@*>4S$!=P8 C.X<D8YI]CXJT/48+R>VU*$QV:[[AGRGEJ02&.X#Y2
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M5YV=?NM:UCPO*;9;>^@U&_M+BW$I:/S8X)1PV!E20"#CO6SI'C(ZR_A^*"S
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M0Z?#,+>4O'(KNCJRD@'!#8((Z@UI7GC:73_%-KI<_P#9#QW%X+00P7^^ZCW
M[7:/: !P,C/&1R: .SHKAAXWU7S'NWT>V728M8;2I)?M1,I/G^2LBIMQC)7(
M)SU]!DOO&^JVKZQ=1Z/;/I>D7RVMS*UT1*X(C)*+M(R!(#R1GH* .YHKA]0\
M3OHU[XDFM[&2ZG@OK&V$3W;;9#,(U&T'B/&_MP2,FGS^-;_3+774U33+9;[3
M!;.%@N289%G8JA+LH*A2&W''09H [6BN:\,:_J&L:CJUI>06"KI\B1":SN&E
M61F0.>JC& P!'K5'5O&TND>)+;3YO[(>*>\AM!!'?YNQYA"JYCVX R1QGISG
MM0!V=%<+<^.-5MX=2U$Z/;?V1IFH-9W$ANCYS*) A=$VXXW D$C/./4NU+QI
MJ]H?$-S;:-;3:?H,VVYD>Z*R2H(DD;8NTC(#D\D X&.^ #N**\VU'4U@U+Q7
M='SY8?M.DA%CG:$X=D&0R\@?-DCOT/6NDLM?U75=9NTT_3K5M+LKPV<TTMRR
MRLP WLBA2,*3CD@G!Z<9 .EHKB8/&UR_BF#1&&C2RW7G)$EIJ!EDA>-2P$HV
M# (!SCH>.:R],U_6;KP797VN)'*TNL16\3VMV\;G-X8_FPJC"\#'.X#G% 'I
M5%<1?>-]1M[74]8@TNWDT/3+I[>XD:X(G<1MMD=$VE<*<\%LG:>G%-U;QMJM
MA-X@FM]'MIM/T*1/M,KW15Y4,22'8H4_, YZD#@>IP =S16-XHUQ_#_AR?58
M;;[4\;1*L._9OWR*G7M]ZN=N/%_B:WN-6LVT'3C<Z9;+?3,+]O+:%@Q"J?+S
MORCCD <9SSB@#NZ*XGQ'X[DT?2X-3@&DBWDL1>K#>W_DSS#&XI&@4Y.,<YY)
MQ[TFL^)]3OAJEGHFG03Q6FGK/<R3W!B;]ZC%5C 4@L%&<D@<@>] ';T5YK9^
M.#I.B>'M*A?3Q=?V';7<LNHW9A4AE"JJD*26)5LGH,=\UMZ[K UGX0ZMJ\,<
MEO\ :=%GF5&.&C)A8XSZ@]Z .OHKAHO%.O6"06=WHMM]HN=,ENM/2*Z+F1XE
M4F*3Y1AB&'(R.H]ZU]+\5Q:UJMC;6$(DMI],74)9BW^K#D"-<>IQ)]-E '14
M5ST_B5X;[Q';?95(TBSCN5;?_K2RR-@\<?<]^M9^I^,[BTMM!>.WLH/[5M_.
M,]_<-%!&VU"(MX4_,V\XSC[IZGB@#L:*IPW%Z^HRPRV2I:K$CI<B8-O<D[DV
MXR,8'/?/M5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LS5M
M$AUFXTU[F6016-T+H0KC;(Z@A-WLI.X>X%:=% %*YL9I[Z.XCU"Y@1(9(S#'
MMV,S8PYR#RN..W-8GAKPA<^&RL<?B&^N;7<\DD,T,/[UVSEW<('+9YR3V]*Z
MBB@# DT#4_L-I!;^*-1BF@0I).T<,AGR<[F#(0&'8C'OFKFBZ'::%H4.D6AD
M,$2L-\C;G=F)9F)]223^-:=% '/V?A*TLK7PY EQ,RZ$NV MC]Y^Y:+YN/1B
M>.]4K+P)!9O96YU6]FTFPN/M%II[A-D;@DJ"P7<RJ3E03Q@9SBNMHH Q])T#
M^Q]2U&XAOYWMKV=K@VKJFV.1L;F# ;N<="<<FH+CPK!<:UJ%ZUW/]FU*V%O>
MV6U3', K*#G&Y>&/0\X%;]% ',Z7X/\ L-]87-YK%[J*Z:C1V,=P(P(05VEB
M54%VV_+D]B>YS4VK^%QJ>L)J<&IW5C<?96LY3"J-OB+;L#<IVG/<?X5T%% '
M!?\ "&7]KKVC1Z;J-Y96FFZ)]A2\C\MBS!D 5D8$'*J3TX('/:EN?!-S:ZIX
M9@T:\N[2VTVWO ]ZK([^9(T;9=6&&WG>3QU].*[RB@#F]/\ !MGI[:7(MS<R
MS6%S/=M+(5+7$LRL'9\ ?WR>,8P*J^%?#3Z9XF\2ZO- \(O;K;:QLX;;$!N9
MACH'D9VQUZ9KKJ* ,V71H)?$,.LL[F6.TDM/+XVE7=&)/O\ (/SK%T_P+#8O
MI\+ZK?7&F:;+YUE82A-D3 $+E@H9@N3M!/'&<X%=910!G:)H\.AZ:;*"1Y$\
M^:?<^,YDD:0CCL"Y%8>H>!(KZZU!AJU[!::A<Q7=Q;1K&0TJ;,'<5+;?W:\9
MZC\*ZVB@#G;SPA:7NG^(;-[B=4UR3S)F&,QGRTC^7CT0'GU-4]7\-/JGQ%T/
M53 ZVMA;2/-+O&V63(\I"O4E2TCYZ"NNHH YGQKHU[K=KI$%D\T;0ZG#/)-"
MRJ\2*&RXW<'!(XP<^AIB>"('M[G[9J-U=7EU>V]Y/=.$5F,#*T:!5 4*-F,
M=R<UU-% ')-X$B:^:1=6O5M#J:ZK]D"Q[?/#ASEMNXJ2.F>,^PQ;E\(6DVDW
M^G&XG$=[J OW88RK^:LFT<=,H!^-=%10!SMSX0M+K2]=L&N)Q'K%S]IF88RC
M;8UPO'3]V.OJ:+[PA:7TVI2O<3J;^ZM;J0+CY6MRA4#CH=@S]:Z*B@#B_&/A
M2:_M-5NK!);BZO\ [$DL*NJD1P3%R8RV%WX8X#';D#-3>"[#5=/FO8IH;JWT
MC;']E@O5MQ,LGS>8?W'RA3\F,Y.0:ZZB@#@8_!%YJ=_XE2_U"]M=-U'4=[VD
M1C*7,(BB'7!9,E64X() _&MR?PM*NK7=_I>LWFF_;2C744,<3J[*H4,N]3M;
M: #VX'%=%10!F6NBPVNIZK?++(TFI&,R*<878FP8_ 52L?"5I80^'8X[B9AH
M41B@+8_> Q^7EN/3GBN@HH YVW\'VEO=VMPMS.6M]1N=14''+SAPR].@\PX^
M@J*#PC/%?7&HRZ_?2ZD]L+6*Z,4*M%&'#] FUB2!DD=.F,UT]% '+VG@FV@E
MBN)KZXGNEU,:I+*51!)*(C$!M4 !=I[<DC)-10^!((6BMCJEZ^CP77VR+36"
M>6L@?S -VW<4#_,%)[#J!BNMHH YV7PA:2Z1?Z<;B<1WNH#4'88RKB59=HXZ
M90#Z&M'5]'AUA+-9I'3[+=Q7:[,<LAR <]JT:* .=D\(6DFDWFG&XG$=UJ0U
M%F&,A_.67:..F5 ^E:.K:/#K LA-(Z?9+N.[39CYF0Y .>W-:-% &#J'AN2X
MUE]6T[5;G3;N6%8)S%'&ZRHI)7*NIPPW-@CUYS46L>%9-;2*VN]9O&L0(C-;
MF.+]ZT;!@V[9E22!G;CVQ71T4 <!:^![O4+C78]2U"]M]-OM5>=[%#&4N(QL
M*G."R@E<$ C(';OO/X7FAU6\O--UJ\T^.]E$US!%'$ZM(%"EE+J2I(4 _3UK
MH:* .>7PLUOKEQ?V.L7MI;W=PMS<V<:QE)9%"C.2I90P50P!YQVJSHV@?V+>
M:A)#?SR6UY</<BVD5-L4CG<Y# ;B">Q/%;%% '*7_@>*\GU)(M6OK73]5???
MV4039*2H5L,5+)N  ;!Y[8K8M-$M[+7+S5(F8/<VT%L8N-J+$7*X_P"_A_(5
MIT4 <QK?@U-7U"]NH]4N[+[?9BRNTA6-O,C&[&"RDJ?G8''7/KS5RU\,VUK>
M7%RL\Q:;3X=/(.,!(]^&Z=3YA_(5MT4 <)KO@@7=GX/TBWCEEM=+FC2>X9U'
M^CQQX*,/XM[+&" *ZK7M'A\0:#?:1<221Q7<1B9X\;E![C/%:-% ',Q>#HY;
MN2ZUC5+S59FM)+-#.L<:Q128WA5C5>3@9)R>*BTSP2+&^LKNYUO4+YK&UDL[
M=9A&%2)@HZ*HRWR#YCR:ZNB@#EH/ >F165O9RRSS00Z.VCE&(&^([<L<#[WR
M]O6DLO!9@U"VO;W7-0OY;:UELX1,(U"QN%!X51EOE&6/6NJHH P='\*VNC7&
MG30SS.UCIB:8@?&&12I#' ^]\OTKC]6\$36=YI$$%GJ5]IUE8R0))9FV,WF-
M('^=9_DVX'!49SUXKTZB@#!T[3M2O_!0TWQ!+_IUS:R0W#Q[<@,"!T&W<%(S
M@8SG'%.?PO9RSZ7)*\CKI]G+9+&V,2)(J*V[WQ&.GJ:W** .6TSP4EA<::;C
M5[Z^M=*S]@MIQ&%A.TH"2J@N0I(!)XSW/-;&A:/#H.C0:9!(\D4.[#28R=S%
MNWUK1HH YNY\'6UW?:U)->7#66LQ;+NRPNQF\L1[PV-P.U1WZC-/TSPL]IJE
MOJ.H:Q>:I<6L+06IN%C41*V-Q^11N8A0"Q_3)KH:* ,#5/#3WFL#5K#5KK3+
MUK<6TKP)&XEC#%E!5U(R"S8(]3UJC_P@D%LVF2:3JM]ITVG6LEM%)'LDWJ[*
MSEPZD,25S]3FNMHH XBW\+R6.O\ A^RM;2XDTW38[J6XO;B1#Y\DP((P#N+%
MBS'Y0.>/2M71O"\VBQPV<>M7DVE6Z&.&QECB*A,8"E]NXA1TYSP,DUT5% '+
MZ=X-%AILNE/K-_<Z2;5[2&SD\L"*-AC&X+N8@<#)X'K6QHFFRZ1I,-C+?S7O
MDJ$265$5MH  'R@#@#K6A10!R4?@2*+2$TY=6O1':W8N]/D"Q[[-\L< [?F'
MSL"&SP<5JZ)H"Z3/>WDU[/?7]ZR&>YF"J2$&%4*H 51D\>I)K8HH Y*7P)%)
M>R2+JUZEH^IIJAM%6/:9U=7Y;;N*DKTSQGZ5;G\(6EQI6K:>UQ.(]2O?MDC#
M&5;*' XZ?(/S-=%10!R-UX:>\^*%IKC0,MK:6/+[QMEGRZI\O7*(\O)_OC'2
MIO&>BWVMMH*6,DT)MM36>6XA90T*B*4;ANX/S,HQ@YSTQ7444 <O%X)MQ QN
M;^ZN;R748=1GNG"AI)(BNQ<  !0$ P!42>!(DO4D75KW[''J1U..TVQ[1,6+
M-EMNXC). 3QGO@8ZVB@#G6\(6C:5-IYN)_+EU3^TRW&0_GB?;T^[N&/7%%SX
M0M+G2];L&N)Q'J]U]JE88RC8087CI^['7U-=%10!SM[X0M+VXU&9[B=3?7EK
M=N%Q\K0%"H''0^6,_4UF>,?"DU]::I=6"37%S?M9+-"CHK"."4N3&6PN_#'
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M/0[A+?5-3M[69TWJDK8)7)&?S!K7KG?&NJ7&GZ ;?3VQJ>HRK8V7^S))QO\
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M$^3[==-*+=R(9+@E2&LU;)7OCD ]@,=J /48)H[FWCGB.Z.10ZG&,@C(IY(
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MI6A?>);BW\-ZV&U5H[Y/$:VL"F7$@0W$?R*.N/++<>F: /25EC>22-)$9XR
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MRQP1[WE1@V4 ]R!1#XXT]V\NXM+ZSN%OHK&:"XC4-"\@S&S;6(VMP 03R0*
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MNI9XG6WT6#36"YR7C8DL/;FKWAG1&T7PAIVB7;1SM;6JP2E0=KX&#U[5M44
M>6#X6:E_82VG]K0_;!<&'[1AO^/#R?(\K_>V<YZ;J[5?#[Q^)+_48WB6WGTR
M&QCB .4*-*<^F,2#\C6]10!PVG^$];T :1<Z7<:?-=6^CPZ7=1W)=8V\OE71
ME!/5FX(Y!'(IUKX!>&+3()KQ98X;._ANW52K2273*S,HYP 0W!/I7;T4 <3X
M4\&RZ#<VGVC3-!!M(?*6^MHF$\O&W<01A"1UP3G-:&I:-K$/B=]<T22Q:2XL
MTM)X+TNJ_(S,CJ5!.?G8$8YXY%=-10!R.B>#9=&O=!E%VDRZ?:7<4S%2IDEG
MDCD+ =AE6XSW%:VOZ/+J\FD-%(B?8M0CNWW9^955@0/?YJV** .._P"$/N_[
M"^P?:8?,_MW^U-W.-GVOS]O3[VWCTS3O'L-_-_PCG]F[!<IK,;JTB%D&(I?O
M8Y [9[9KKZ* .#N/!VMWEKJ-W->6@U*_OH+B>WB>1;=X8E"B$N/FP0,DXY/&
M,4W3O EY:6S(TEA#NUV'5?*ME81HB(BE!GG.5//?KQT'?44 <_>:1J'_  F=
MGK=E):F'[(;.YCF+!@F\/N3 ()X(P<?6J_BKP]?ZSJ&GSV[6D]M DJ2V5ZSB
M)V;;MDPOWBN",'CYCR#S7444 <;X=\&W6BR>'#+<P2#2K*YMI-BD;S*\; J.
MP 0_G6/XC\.7^E> X(+*<?VU#J[SV,L*$X:XN'X/H/+F;)Z<9[5Z510!EQ:-
M%9^%UT2SPD45G]EB)[ )M!-9>@>&+G2=1T^YEGB=;71(--8+G)=#DL/:NHHH
M \[G\":HWA+2-$B.EF>RM1$FHEI$GM9.\D17D]OE)7)'.1Q4^N^#M>O!XDM=
M.OK!;778%662Y1S)&XB$1P%X(8*O/;)X-=[10!AZ?H<]GXAU;4C.FR]MK:%
MH^9#$) 2<\?QC'TKFO#W@74]-US2M0O9=/>2QBFCFN8S(\]X77'F.6Z'C.WG
MJ<'M7H-% ''Z;X0NK+2O!UH]S"S:$^Z8C.)/W$D?R\>K@\]A4&G^$M8A\-3^
M$[JZL3HAMIK6.>-7^T-&X8+D'Y05#<G)SCH*[>B@#C_"OA6;1KN.6YTK0(7A
M@,0NK&-A+(>.3D#8#CD GMS4.N^"GO?$]QK,%CI&H"ZMXX98=25OW;(6PR,
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M,,2)8QNT87=\SRMA3A5WD<#' Y)Q79T4 %%%% !1110 4444 %%%% !1110
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M3 6 4$#G=Q_=P<=:=IE_K>C6^H:G!>6QT_\ X2B:V>S,&6=9;ORV;?GA@7R
M!CCG.> #U.HDN8)+B6W2:-IH@IDC5@60-G!(ZC.#CZ5R?Q &H^3H7]GZB;,O
MJUO&Y$>[=N;C/(X'IWK$O#KUIXG\776G:G;0R66FVDTK26N_SW1)2!C< JG!
MSC)Y&.G(!Z917G5[XPUG4-12TTM9K?9ID%ZQAL3<EY)MQ53R-J#;]3GJ,5N:
MWKVJ6'PUGUTVJVNJ1V*SM;R#(CE(&5/T)(H ZFBN"U?6?$.DWVEZ+)>F>\O$
MGN9KFST_>8T38 B1[O[S_>.>!TR<T-XAUF32--BN[F73M6F,^8(=+:>:=(WV
MK($R?+4@J3N[L ".X!WM%><'Q;KMSX7T#678V5E<6TDFH7EO9&X\F12 N8\Y
M6,_.21G& ,CK6A<ZQK>K:GK46CZG9VEOI,,3*SV_FBY=XO-R3N&U,%1QSUYX
MH [>BO/K;Q%X@\27EJFF7=MIL4^@V^IGS+?SF$DA<;1D@;>!S[<=<AEQXOO[
M_P .:1>VNH&UO[K2UOGM+;3FNCD@?,QSA(\Y'/)['B@#O_M,'VK[+YT?VC9Y
MGE;AOVYQNQUQGC-#7,"7,=LTT:SR*SI$6 9E7&X@=2!N&?3(]:\YM+K5_$7B
MO1[^QO(-.GO?#,5S*Y@\[;O<-M4$@=3U.>![Y$-OXFGN[SPYXAO(4-Q#HNJR
M3)#PKM%)"#MST!*9'UH ]1HKA/"NO^(]0U#37O(9YK*^MFEG9K P);/M#*$?
M)WJ<D<\]#[5H7M]K=SX_&C6-[;VMC#817DQ:#S'<F5U*#D  A>O;''6@#JZ*
M\XT/Q;XBUBZL;^&UN)+*ZO6ADMA8E8X8-S*'$V>6& 3QCJ !C-%OXE\1SV.D
M:Z+VS%CJ>K):?8OLWS11&8H,/NY;"\Y&.>,8Y /1Z:LB.6"NK%#A@#G!ZX/Y
MUQ%QXJU*/PUJU\K1>?:ZZ+"/Y./*^TQQ\CUVL>:IWFN:E9S:VFE1V-O=/XCM
M[%9&@X820PY9\8+$;NN<X % 'HM%>>ZGKWB&WUN30K:ZFDGLK&.>6Z@TSS3/
M)(SA05#810$YQR2>",4Z76_%6HWZVD$MOI,J:%#J,\4MOYK).S2 Q]1\N5&>
M_'O0!Z!17G^C^)]=,_A^]U*>UFM-;T^6[^S00%3;E8UD4*Q8ELAB#GOTIGA7
MQ/XCUBYT:\EMYY;'4HS).GV$QQVJE"Z%),_.,@*<]=V1CI0!Z'17G&@>(_$M
MQ;>%-1U"^M)8-<9H'MXK;;Y)\EW5PV[DYCY'3YN.F3'H4_BFU\'ZK=6UZVI7
M"ZM<1!!;AGC1;IUD= 6^8[<E4R , <]* /2Z*Q-"U:*]\-_;CJ:7(C\P27$M
MN8"A4G(DC."I7&"..G:N4T[Q=JAU22 WCWMM/I$]_!/+IK6HWQE,% QRR$/G
MGG@<\T >C5'+<00/$DLT<;S-LB5V +M@G"^IP"<#L#7":1XAU^&X\/W&JW=M
M=6^LZ?)<M##;^68&2-9!M;)W9!(.>_3'2LV&[US5;OP#K.HWUK);ZC>&Y2VB
M@VFW+6LS*H;)W *<'(SD?A0!ZC17+>);_65\1Z)H^D7=O:"^CN7FFE@\TH(Q
M&05&0,_,1SQSGM6!<>+/$D^I:FVF6\\ZZ=>BT2UCL"Z7 7;YA:7=\K'<V,<#
M SG- 'I%%<GI-_K>N:SJ-Q!?V]MI]AJ#6?V0VV]I50+O8ON!!))Q@8  SG-8
MUIXHU]](TCQ/)=6S6&HWT5N=.%O@QQ2R^6I$F<EQD$\8ZC H ]%HKS6]\2>*
M4M]1U.VO; 06NMC38[62V)WJTJQAF<-G(+@\#L?7B;4/$OB'1[+Q%:O=VMW>
MZ=-8_9[AK?RU99Y%4JR@GI\W(/0CTH ]$HKSJ[U/Q?;7?B"R76;!CI-DE^LQ
ML<&7<KD1%=^ N8FYY/(].5OO%^LZAJ26FEK-;[-,@O6,-B;DO)-N*J>1M0;/
MJ<]1B@#T2BN"_MCQ3JVK16$$UOI$O]B07\\<MMYKQSLS@IR0,949ZGCWR&Z=
MXEUSQ/)HEO87-MILEQHR:I<2-!YP9F(4(H+#"YW$G.>@XZT =W;W$%W"LUM-
M'-$V=KQL&4X.#@CW!J2O+O#NJ75IX%T"TM]3:VO9Q<N8K73VNY)-LQRP&<*@
M)Y)'.0,CNZSU77/$6J>!M074ELC>V5R\T*0;D+KMW'!;OV!^[[YH ]-21)-V
MQU;:=K8.<'TIU>=PZ[?+=2Z7IJ6=G<ZAXAN;7[2+<814B,C.5!&Z0A<9/KST
MI+OQ/XAL?MVE"YM)M0M=5L[..\> A'CN-I&] ?O+DYP1D8Z9H ]%HK@VUGQ1
M;P^(M.A>/4=0TZ6V,4\5N%<PRX+XCW89U <@9&>/QW='UN.;PK-J1O&U VRR
MF1C;F"0,F<HT9Y5AC!X'TH WZJV^IV%W=W%I;7MM-<VQ GACE5GBSTW '(_&
MN*L]<\110^&M1O+^TG@U]UB-M%;;?LQDA:1"C;LL%VX.>O7BK'PRM;N+P[=S
M7-VD[2ZA>8(@"$,+F4,2<_-D\^W2@#LKBY@M(3-<S1PQ @%Y&"J"3@<GU) _
M&I:\@N$U@_#OQ,]UJHO&76FBB62':%=;U1G().T_W>PZ5O:CXIUOPP/$4-_-
M;ZE+9:?!>VSI;F(!I'>/8R@G*AE!ZYP2,]Z /0::LB,[(KJ63&X \C/K7*>&
M=2UZ?6)[348[F:R^SB5+J>Q^S%9=V"F,G(((([C!R365K&NWVEWGBJ738;*.
M[BOM-@25X?\ 6>:8D/F$<M@,0/0=* /0J*X1]7\4VC^(]+BD@U/4;*WMKFUD
M2W$9*RLX<;-V"5$;%1D9R :DL/$]Q-=^'K>+4/MBW=_<6UV9K0P2QE('DV,A
M^ZP('89'YT =O17G][XHUQXYH;&:UCN&\2'2HY)8MRI%Y><D C)!YZC.,5'J
M?B'Q'%K-YH]E--+/IMI$[30Z;YOVF9PQ&X!L(F% XY))Y&* /1**XNRU7Q%J
MWBU+(2P:=;0:=9WMU;O!YDN^1I \6<@ ?)C/)! QU-2^%M:U.[U>YL=;N&@U
M$*\G]GM:;%5 ^ \4N2)%P0#U.2,[>E '7U5NM3L+&:WAN[VVMY;E_+@2654:
M5O103\QY' ]:Y6_U37M0UG7[?2K^UL(M%CCPLMOYOVB1H_,^8Y&U,$#CG.3G
MM65I-Q>^(/'^AZS]H2&*Z\/)=_9F@#;%9XRR!B?7!W>U 'I-%<=XRUV\TZ9X
M=.U-HKJ*T:Y^S0Z:URQ )PSL#A$)&.Q.#@\54BUSQ#K^J6-KIU[:Z='<:'!J
M3LUOYS"1V8;1DCCIUST]\@ [RD)"@DD #J37GMKX_N;?3])UC55B33]1T1[L
M*BXVW,2[W0'T92<#_8-7O%#:@_P:U9]5*?V@^CR-<!%VJKF,D@#V/'X4 =FC
MK(NY&##U!S3J\IL/-\->);F<:):Z&;G0I6M8+-E>&XDBP[.X4+A@&4#Y>03S
MVKJ(/$%[-<^$H7,135=/EGN1LZLL4;#'H,L: .G2\M9)DA2YA:62,RH@<%F0
M$ L!W&2!GW%.>Y@CGC@DFC6:4,8XV8!G"XR0.^,C/IFO*=*UPV,&BZ]]D@4P
M>#+F[^SP((X\J\+;54=!Q6DJZR/&/AB?6-0M;WS].O956*V\L(Q2(LO4[EY&
M,\]<YSP >CHZ2(KQLKHPRK*<@CVIU>;:#JVMZE;>&-,TRXL=,BN= 6]E9+,,
M$8%% C3( 'S?E^C#XXU.YTS0#+>1:=)>6=Q-<7$-FUP3)$ZH%5!DJK$DY/H
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MRI)WH<CKSUS4VGZEK>LW[:=I5Y::;%I^GVDK VOF"5Y58@8W#:@"XXYYZ\4
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M2:;;:<(KJ&SMXVA6""]FC5HR<E&"L-P]CFG:AX,T/4K@S36TL;-"L$JVUS)
MLT:]$=48!P,D8.>#CI6_10!1BT>P@OS>Q6ZI.;9+3*D@")22JA>@P6/:LM_
M^@/#9PBUFCCM+46<8BNI8]T _P"6;[6&]?9L]_4UT5% '.W'@;0;A+,?9[B%
M[*U6SMY;>[EB>.%> @96!QCKGKWJ[!X;TBV:Q,-E&@L;9[6W0$[4B?;N7&<'
M.Q>3D\>YK5HH QM)\+:9HDRR6/VQ%12D4+WLTD42GLD;,54?0<=JO#3;1=6?
M5!%_ICP+;M)N/,:L6 QTZL>>O-6Z* ,2V\*:59ZB;RV6[A)E:;R([R58/,8Y
M+>4&V9))/3KSUK(U/X?V$EY8W>F(898-3BOF22XD,2X?=(8X\E59O8#J?6NR
MHH YVZ\#>'[R_EO)[25GEG6Y>,7,HB,RD$2>6&VA_E'.,G\35U_#>E22RRM:
MDO+>QW[GS&YG0*JMU[!%XZ<=*U:* ,C5/#6FZM>QWLXN8KM(_*\^TNI;=V3.
M=K&-@2,\X/3M4T>AZ?%<M<K"WG-:+9%VD9B85)(7D^K'GKSUK1HH S+?P_IE
ML-*$-MM&E0F"S^=CY:%0A')Y^4 <YJOIOA32M(NEFL5NXE0L8[?[9,8(]V<[
M8BVP=3T'';%;=% &5!X;TJVM=*MH;8K#I3[[-?,8^6VQDSG//RNPYSUJO_PB
M&DK]M\H7L'VR;[1((+Z:,+(2260*P"$DDG;C/?-;M% &?8Z)I^G:6^FV]O\
MZ+)O,BR.TAD+DER[,26)).236=8^"="T^420P7#.+5[-3-=RR[(&QF-=S'"_
M*,8Z5T-% &;%H.FPMIC);X.F1&&T^=CY:%0I'7G@ <YK.LO OA_3[VUN[>TE
M$EI(TEJK7,K);E@P(C0L552&/ &.GH,='10!4FTVTN-2M=0EBW75HLB0ON(V
MA\;N.ASM'7TK/G\)Z5/J<NH;;N&>9U>86]Y+"DS*  71&"L< #D<@8.:VZ*
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MW$C/)""QVEBV<Y9OFSGGK5X:79C5!J0B_P!+6W^S"3<?]7NW8QG'4=>M7**
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M8RSN?]7M+9VG.<<'I523P?XDM/!_AU-,A2/6(+.33+P><HV0RCE]V<,4948
M=>:]3HH \ZU#PI=Z;X@DFL;'4[K3)=.M[)(M.O(X7B\K>-K!V4,I#CD'((/'
M-;6N^'YI_A?=>'],M2LITT6L$$DH)4A0 I<\'&,9KJZ* /.]3T#7/%=W?//I
MHT8#0[G3(R\Z2>;)*5Y&PG]VNSO@G=T%0)X3O=8TJ]MKG3M5L;\Z3/917-[?
MQS1*T@4%4",3M)4') X'3->ET4 >;P^'+Z\TV^\[1]6AU%='N+.%[S4(I8RT
MB@%(PKG@E1RP7&!6Y;Z'>PZ[X5N1;JL%AI<]M<$,OR.P@VKC//W&Z<<5UE%
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MQ+B8?,2%8Y[#"]^H%17'Q*M?L&BR0QV5O<:I;-<[=3OA;10JI 8%]K;FW'
M'.">,4 =W17%_P#"=/=>&;#6K*#2XXKGS YU#4UMXU=&*E4<(V_)#8/ P,]Z
MBN]=;6E\!ZK9J\2:A=-+Y+/C.;29MK$=0#CMVS0!W-%>57/B#Q'??#V\OM0M
MXO.AUJ**$VMS\\FW4 ACQL0   *#GYAR<<UVVA:]>ZAJNI:5J>GQ6=[9+%*1
M#<><CQR;MI#%5.048$8[=30!OT5R'B/QI)X<U)(Y[?3C:F6*/#:B%NG#LJ[D
MAV?, 6_O G!J#5O'-_IT^O/#H:3V&AR(+N=KO8S(8TD)C3:<L YR"0.!@Y.
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MMIXFMVNI%&O#$A"C]U^Y6+CUX7/XUMF]MTC1IY8X&8+E9)%!!;H.O7K^56*
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MI*"ZJ$#IN^Z=H4'J.!Q71*P90RD$$9!'>H_M5O\ :?LWGQ>?C=Y6\;L>N.M
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MX.#BKU]X0@OK'Q-:M=2*->_UC!1^Z_<K%QZ\)G\:W5N[9YA"MQ$96!8('&2
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M<$6IG9(3'(IRH!)7<4R /3TK!UW29KY_$L2Z?</:W6JZ2440LH>(>0'P,9P
M#GTP>F*]1HH \LU;P=8>9X]\G08]O]F(;!4MOE$ODODQ # ;*QY*\Y"U#K>G
M3SZ_</K>\6MWI5O#;RR:1)?8.&\U!MYC?)!Z9/']VO6:* *>D0-:Z+8V[32S
MM%;QH99E*NY"@;F!Z$]2*\SN-'\C3_'6G:=I$D6JSW+31&"T*&:T*P[D24 *
M=V'&T-G.>*]8HH X'0(+"X\<P7WAW2Y;#38M->&\8V3VJ22%T,2;65=S*!)D
MXXW8SS6C\1]/2_\ "#EK'[8;>[M9]@A\U@BSQF0JN"3\@;('49%=;10!Y;XG
MLGNXO$LFE:?.+2;PI'%:I':O'EO,G(15P"#@CY<9Y'%:(\%Z./':I_8-N=/_
M +&P5,&8FE$A )XP7VLW)^;!->@T4 >,V]A?QV?A.?5XI$LH]"%O_I.E/>B*
M?(W!HQRC% H#$?PD=Z[_ ,,7-II%CHWAQ9[NXG-D\T3S6[1$1(P'S*W*??4
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MB'*GCT].E6J /)+C2!/HNL76G&XO()I;$WME;Z1)9K+#'+F0(C??8QY# =0
M*OZ_:>'[[2M.O].\.M]AM=8AEN?^)2Z%DV[781E-S+]P$A>=O?%>F44 16QB
M-K"8$V1%!L384VKC@;2 1QV[5Y+#IP?3+;3AH]ROC!-9$\MZ;)Q@"YW-,9]N
MTH8LC&[H0N*]?HH Y'P;HT&GZQXIN!IL=L\FJMY4@@"%XC!"?E..5W;NG&<]
MZ;XYF9)=)C;3K>:W>23S+N?3GO1;$+\H$:<Y;D;N@QCO7844 >3^'] DO+3P
M5;:II4DEO;W&I&2&>V*I&-[>7N0Y"C[NT'C@8Z4Z:UE\-^&Y-=CLY(D\/Z[=
MS1P!-N;)Y&614!XV[6W#M\HKU:JFI:99ZQ8M97\/G6[LK-'N(#%6##.#R,@<
M=#WH R_!NFSZ;X8MA>+B_NBUY=_]=I6+L/P+;?HHKC_%=E;3>.=4_M%_$$%K
M=:1!#&VE03/YK;YMRDQJP) 8<-_>KT^B@#S32KC4=#U'P]J.NZ==*[Z";-UL
M[1I-DPD1E0K&"%)4>PR".U&D6%\OA3P#')97$<L&JEYXVC.Z)?+N.6]!D@9Z
M<CUKTNB@#R:WL?LMOX=GUO2[F?28+_5C<0FT>8)(]PYA=HPI)&W?@X/WQZU)
MH&F30IH@M]*NK2V3Q3=3I#) R&*%H9MI(_A7D#\0*]5HH \JTWPV+70]!OX]
M):/51XB>2:<0$3",W$JDL<9";"/;&*S=%2TN?$5I<ZG;1PV\>OW4T%\;!Y&N
M)6DDCCC,^-FW+#!]54<$9KV>L&#P;H5O>1W$=K+^[F,\<+74K01R9)WK$6V*
M<DG(7@\T 9GCVUMI+?39Y'>.:TE>2W4Z<][ [;"NV2- 2,@\'(([>E=!X?DF
MF\.Z;)<6"Z?,UM&7LU&! =H^0#L!TQVK1HH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N;U76M5/B-=#T6WLVN$M/MDTMX[! I<HJ@*"<DJW/8#OFN
MDK"U;PRFI:I%J=OJ5]IM\D)MWFM"F9(B=VU@ZL.#D@@ C)YH RKSQ-KTESJZ
MZ7I]@R:-&GVI;B=LRRF,2-'&0O "L/F/4GH*K7'C75KR29M#T^SDMXM'@U;?
M=RLI*R"0^7A0>2$Z]!SUK3O?!%O=7%U)!J^J6:7T217T<$B$7(5=@+%E+*Q7
M +*02!5U/"VGQ7%Y+#YL2W6GQZ<8T(VQQ1[]NWCK^\/7/04 8VF>+]4GOM/%
M_I]K#:ZKI\M]9B*9G>,($.V3( R5D!XZ$$<]:BT;QCK-T/#=WJ>G64-AKRA8
M?(F9I(G,1E7=D8(8*W Z<=:VF\+VL4>EM#).TFE6,EG;!F&'5U1<MQU_=KTQ
MU-8_A#P.^F:9X>EU6^OI[G3;1!'932HT5M,8]KE2JY;&6 RQ !..U &5X-O1
M!:>$(/)WRR:=?R+(T[(J[)(^"!\ISNZD$C''>K]AX]N)M0O;.1]*O#'IDU_%
M+I\SN@,94%&)'S9W###T/%:\'@;2X;6QMC)<R16=G<V:JSCYXYRI?=@#GY1C
M&.IJ*S\"VUM('GU;4KPII\FFQ^<T8$<#[> %0<C8.3DGOGC !4TWQCJOVC3)
M-9L;."SU.PDO(3;2L[Q>6JN5?( .5;/'0C'/6A/%^KVOA.7Q3J>GV2Z:]D+N
M"&&9C,"VWRT<E=IR&&2.A[&MQ?"]B&T<LTSC2K9[6)6((=&14._CDX4=,=ZH
M6O@6TATJ;2+C5-2O-*:V-K%9SR)L@C.,;2JAB5P I8D@4 1^&?%=UJVLS:;=
M):RE;87"W%F)/+'S;3&V\#YAD$$=1G@8JMXA\;W6AMKUNFGI/>V?V9K&$,0;
ME9CM_1EDSCL!71:3I-UIS,;C6]0U$%0B+="(! ._R(I)]SFH-0\+:?J7B;3=
M>F:876GJZHBL DF00-XQSMRQ'(P2: .;UOQ='J.G7S6]J)].@CTZ7S!,\;-)
M/,I"Y4@X5"C=>=P!XJM>W^OW+?$*UNY;5M/M+9UC52V^,-:AE"\8YSDY[YQQ
M6[8_#_2-/\-W&A02W7V:>Z2Z9V<%P49&10<8V@1HH&.@JW<^$K>YU#5[D7]Y
M%'JUOY%W;(4\MCY?EAQE2P8+QP<<#(H R?"^N:O%<Z'I.JV=I'#?:89[5[>5
MG=/+$8*OD $D2 Y'0@CGK5OQAXGN?#PW6]QI"$0-,(KR9Q+,5_A55' Z?-SR
M>E:J>'[2._TF\$DWF:9;26L()&&5P@);CD_NQTQU-5-8\)0:OJ<E\-1OK*2>
MT^Q7 MF3$T.6(4[E)4Y9N5(/- &<?%.LZGJ=G9:)8V0-SI,6I>9>2L @<D;,
M*,D]/3N?0&O9^-=5UIM$ATG3K1)]2L9[F4W4K;;=HI$1A\HRXW,1V[&ED\%W
M?_"36KV>I7]A96FC1V$=U;R1[V*N<JRLI!^7!SMX/0BB?P1+#KNA)I-U=Z=8
M:;IL]NMS;R(9 [/$0&#A@^X*Y.01GG@XH JVNMR:]XA\)75Q +>Y234K:XB1
MRRK)$-C8/&1E<CZT[P_XDU"]TK0-,T*RM4GFTL7TIO;B1TBCW!54'EF).>2>
M .]=#8>#].TTZ28)+@MIOGE&=PQE:;_6.YQR2<GC')JI'X$M;2VTM-.U34;"
M?3[4V:7,#1EY(20=KAD*GD9! !!H H>*/&U[X;S),VC9ABCDFLOM+M<-G&[;
MA0% YP2/FQVJE/J.N:9XK\:WFEVEE/#:K;SS"YF96<+ "40 '!(!Y/'3CTV=
M1^']GJ/V]&U;5(H-0CC2\B21#YYC0(K%F0MG &<$ XY'7,NI^!K?4M0U*Z75
M]4M!JBK'>PV\B!)45 FWYE)7C/*D'D\], '/S^*H-,UK7_$BQ-)"=#TV6*)C
MMW&228("><<L,GG%;WACQ3<ZQJMUIUTEM*8H$G2YLQ((CDD%#O (88!]P>U6
MKKP9I-X;]9%E$5Y9P6;1H^T1I"S-&4XR&!?.<_PBKVE:7=:<9#<ZU?ZD6 5?
MM2Q (!Z>6BY)[DYH Y>/49-,U[QM=1S64)2ZM!YE],8XES!&,D@'GT'<X&12
M6'CZXFLFGE@M)4MM8BTZZGMV;R_+E5=LB[N1\TB*0??FMG4/!MCJ$U]<&ZNX
M;BZNH+P2QLN8985"H5!4CHO(8'.33%\$V1TC6;"XO;ZY.KOYMS<2NGF!PBJ&
M7:H"D;%(XP"/3B@#(MOB'+>"_AAL4%TFK16-DK,<3Q/(5$OTQ',WT2M3P_XF
MNM7U^_L;D65L;9Y4^Q,SBZ55?:LA!&&1A\V5X&0,FG6G@32++5=&U&)KDS:5
M:"UA5G!5P%8!W&.7 >3GC[YJU;>&%BUV+5KK5+Z^EMUD2UCN/+"P"0C=@J@+
M= /F)X_.@#+\:>+[GPSYLD,VD%8+8W)MKB=Q/,!G(55'RC P&.02<8&*;J'B
MG6WU6^M-&L+%X[338=0:2[E920_F?( H/)V=>@YZU=UKP5;:S>7\_P#:6H6B
MZC:K:WL5LT869%W!<ED)4X=A\I&>]7H?#=G#>7ERLDY>[LHK%P6& D>_!''7
M]X<_0<4 8L?BW5-8NK&#0;"T9I=+AU2;[9*R@++G9&I4'YCM;+'@8'!S1X%N
MGM?A/I=WMW/%IYDVD]2 3C]*LGP/:Q#3S9:IJ5C):6":<TENZ!IX$^ZKY4X(
MY.Y=I&XX-:FG>'[32_#,>@0/,;2. VZL[ OM((ZXZ\^E '*MXXU:U\-Z5J6H
M6>GV\NLR1+9()798E:,R%I2!SA5SA>Y SWH7Q_='3H]T-E%<OJ?]GB\E=TM"
M/*,HDRP!P0-NW^]QFNAN?"EG/H>EZ8ES=0-I?EFSNHF7S8V1-@;D%3E2001@
MY/%8?B?POJ=S;Z2HN-0UA;:[>>X82PPW&#$R )PD>WGD'GGK0 _1?&6HWR:,
M;JVLR-2U*YLUDMG8H8XDD(D4GJ&,?';!JKK&LR:M<V2/$L8L?%<5HI4GYU$>
M[)]_F_2KFG>%]2U#1HDU>^O+.YL[]KG394DB>>VCV; KD*4;AGR,$88#)QFK
M]IX(L+2%(_ME],RZF-4:2:169Y@H7D[?NG&<#'M@<4 9TGC6X@\5VNEO+I%Q
M%=7CV8CM9W>:!@KLK.<;?X,%>"I/>LB'6=:?P9KEUK@MKJ*'5FMXUAFDC8$7
M83&X8(4<8YR0,&NDM? EI:W=I(NIZBUK97KWMM9LT?E1R/O+<A-S#]XV,L<9
MI[^";1[;5+1M0OOL6H70NVM\Q[8I/,$K%#LW<L.02>IQB@"CJ/BW6$37=0TW
M3[.73-#D>.X$TK++.40/)LP,+@' SG)':HM1\9:SYVM/I.GV,MGI5G%>N]S*
MRO*C1F38H .#@'D\#C@]M*_\#VE]<Z@5U+4;:RU)M]_8P.@BN#M"G)*EEW*
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MU7Q/I&B7"6^H71AE=-ZJ(7?(R1U4'T- &O15/3]5L=5TR+4K*Y2:SE4LDPR
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MYT?G[/,\K<-VW.-V.N,\9JOI6J6NLZ='?V;,T$A8*67!^5BIX^H- %RBBB@
MHHHH ***IW^J6NFRV4=RS*U[<"VAPN<N59L'TX4T 7**** "BL_6-9M-#LUN
M;OS2'E6&..&,N\CL<*JJ.235V&43P1S!70.H8+(I5AD9P0>0?:@!]%%% !11
M10 4444 %%%% !1110 4444 %%%% !7-^-M2N+/0A9:>^W4]4E6QM".J.^<O
M_P  4,__  &NDICPQ22QR/$C21DE&902N1@X/;B@#.LAI6@VEEHD<\$ AML0
MPNX#&*, %L=P,C)]ZY?0M2L?%?C1=?AN[9;2TMI+33HO-7S;C<P,DQ7.0OR
M*#U&3QD5V[VT$LHDDAC>0*4#,H)"GJ,^AP./:J]OHVEVDPFMM-LX95SAXX%5
MA^(% &1XC\2QVWA%M0T>>&[N+TK;:<T3AEEFD.U,$<$ \GV4UHZ)HL&B^';3
M1X6<QP0B,R D,[?Q/D<Y)).?4U<6RM4CAC6VA5(#NB41@",\C*CL>3T]:GH
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MA;2=HFE"HI ++R.>XYZ^M<K?7&N7NM:_'!J4-I=Z?=I#9O=ZU);K#&$1E9H
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MBU\4^9K,&FWND7^GM=)(]M)<^65E"8+#".Q4X(.& X]^*S=*\!II/BL:E!=
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MD<J #VW.^#W 4U<U#P[KG_"0ZK?Z7>Z;'#J=M#!(MW;O(4V!QD , ?OG@^E
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M*0V:WLC6BH1#"V=K'<P))P<*N3P>*Q4UO49OA%HLJW3MK.KVMO:PSD_-YTP
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M9 S%LD]3E3T% 'K]%9EF;7^WM3$>H3377EPF>T:7<EN,-M*K_#NYSZ[16G0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6-R95">82 !G[O.#SVZUSL>EZWKNLZ5<ZEID6EQ:;;3QG;.LIEDD0)A O1
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MP:LXM_\ 6,Z/Y.[AAGE=N,YYYJ:+P[K>G:;H<T-BES<Z=K-[>/;+.JEXIFN
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MS1'.' 13E?E.3V[XR*Q?&.E>(M3OIX;-)Y]-FL#%%'!>BV$<Y+9:4_>9=I7
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M70[.;5B+JR\3W%C'J/E)N=5MY<-MQLWX8KTQN&<'I0!ZQ17FK>(-;@FG\/\
M]JM)(->CTU-5>*/S%B>#SB,!=AD!^3.W'(XS5E]<OM+GU[1KW6KV;[++9I:7
MD5O$URS3Y_<XVB,M\O!*C <$],T >@T5Y</$?B-=*U&R2]N8+V#7;.PAGOH8
M'F2.;RB0XC^1B/,/3MC.#6S*=9E\3'P^GB6YMTL=-6\:Z:&$R7+O(ZC>"FW8
MH3D*%)W=10!V-E>VVHV45Y9S)-;3+NCD0Y##U%)=WMM81I)=3+$DDJ0J6[N[
M!57ZDD"O+=(OM6TWX?\ AB]6ZO;?0X=-+W=QIT<4DD3@@AW616)B"[L[!G\*
MZKXA^9<>&[#[),L<DFK6'E2E=P4FXCPV._8XH ["BO.+_7];T"+Q)8'5&O)+
M62Q6VO+J*,-"+E]C%@BJI"G+#CV.:C\0ZSKOA?\ MRQBUJ>^,>BMJ$-Q<11>
M9;R*X3'R(JE3G(R/X30!Z717(ZMJNKMXIN=*TFXA\XZ%+<V\<@&W[1Y@5&8]
M<<_2N?N/%.J6FCPV$-QK$FKRZG#972745L+BV#QL_P"[("Q-NV84DD?-[ 4
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MH52>Y*F9QU?:,+GZ#BJ47AO1H=7.JQZ?$+TLS^;R<,PPS = 2,Y(&3DUJT4
M8]EX6T/3;_[;9Z;#!."S*4R I;.XJN<*3DYP!UJY%I-A!I TF.UC73Q"8/L^
M/E\LC!7'IBKE% &?%H>F06EA:16420:>P>UC4<1,%*@C\&(_&H+?POH=IJSZ
MI;Z9;QWKLSM*J_Q-PS = 3W(&3GFM>B@#$M?!_A^R>5K?2K=!(CQLF"4"M]Y
M0I.%![@ 5:TK0=,T02C3K-(#,09&!+,^.F6))('.!VK1HH K06%I:_:?)MT3
M[5(99\#_ %CD!23^"@?A5#3O"NAZ3,\MCIL,+,ACP,E0AZJJDX4' X  K8HH
M Y:V\#:7IGB/3-4TJV@LTM(YTDC1"3('"A0#G@+@X'3GC%7K+PAX>TZ_2^M-
M)MH;F.1I(Y%7E&8,#M_N@AFX''-;=% %"WT33+1K5H+.*,VGF>00/]7YAR^/
MJ>M#Z)ICR22-9Q%Y+E+MSCK,@4*_U 5?RJ_10!S?B;PE!KEG,L MHIYKB&>?
MSX3+'<B(_*DBY&5_'L.O2CPIX7/AV34)BUI']L=&^RV,!AMX=H(^5<GYCG)/
M&<#CBNDHH H-HFF-;RP-9Q&*6Y%W(N.&F#!PY]]R@_A3;S0-*OQ>"[L89OM@
M1;C</]9LY3/N"<@CI6C10!CV_A70[6VEMX=-@2*66.:08)WNC!D9CU)! .35
MF31-,FMKVWDLXFAO9/-N4(XE?"C)]\*OY5?HH SWT/3)-875WLXS?K'Y7G\Y
M*\\'L?O'KZFJUCX3T'3)7DL],AA+HT>%SM56ZJHSA0?08K9HH HIH^G1K8*E
MI&!8(8[48_U2[=N!_P !XJGI_A'0-+N5N;'2X(9D5D1U!RBMU5?1?8<5M44
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M(J=<@^9(IZ#/3'-;%<SXV2]O])@T2QCFW:K.MK//&IQ!;G)E8GH,H"HSW84
M:>A:U'KOAZTUF*VN(8KJ+SDBE4;]O;@$CD<C![BL_3?%OVS78](O='U#3+F>
M!KBV^U>61,BD!ON.VUAN'!P>:TGO8--GM].CL[GRQ;NZ-# 6C18\#:2.C'/
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M7I6EW.A7'B*4:= #>?V=;NUQ&F$-NQ?RESVZ,<8Z$4 ;]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4$9&#THHH PK'P?H6FW4%Q:V3*UN28$>XD>.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR^FZ+I-]J>O6>KI9V<C2VL&K/#).OF?)+"ZD&5PJ[>>IS@@GD ]<HIJMNC#
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MJ9SM=0P_(U)10!%);030B*6&.2(8PC("./:AK:!S&7@C8Q?ZLE =GT]*EHH
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MQX8V?;MW%03M],^E.,4;%LQH=Q!.5ZD=*?10!F:WH=MKNG/:3O+#N>.19H2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>foraresidentagreement008.jpg
<TEXT>
begin 644 foraresidentagreement008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPL223&I)/?BN*T'QIK.H#PY=ZAIME!8:X6CB\F9FDC<1M("V1C:0C<#D<<T
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M^MVMI6?:NUE*/D#+#*\C@\U8LO%>I:*EC%KUE:QVD^F2W<#VLK.Z>2BLR/D
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MA9I(U9C"^Y"2,_*>X]#Z4 34444 %%%% !1110 4444 %%%% !1110 4444
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M"2=&R"K?NL  ''R@'WK635-.DNDM4O[5KAP2L2S*78 D' SDX((/T-2"]M3
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MF$GEB7S+A&#!"?FR#@<*20>1SGI4L>KZ9*]ND>HVCM<@M %G4F4#J5Y^;\*
M,C4_!\5_J-Y>6^JZCIYOXUBO8[5H]LX4;03N1BK;3C*D'&/2LRX\&7+^+1/8
M7MYI.GPZ/#8PR64B9^623*%7#=%*X;&1V/6MB[\6V&EJ[:JT=FIOQ90DSHWF
M$[<.<'Y1\W(/( R>HK2DUC3(I;>*34;1)+@ P(TZ@R@]"HSSGVH QO\ A";.
MU73SI%]>:5-8VOV..6W*.7AR#M<2*P;D9SC.2?6M&WT&*#5[;5'NKF>[@LVL
M]\I7YU9E8LV%'S94=,#VIJ>)M*EUR[T6.[B;4+:-)&A+J"V[=@#GDC8<CMD>
MM20ZY:+H]IJ&HS6VGK<(K8FN4*@D9VAP=K?4'F@"M;>'(;"^U:ZBN+F:WU$M
M)-I[[#$9"JJS E=P)"@8+8Y/%5/A_P"'9?#'@VRL+D$7A!EN,OO(=OX2W?:H
M5<_[-;T^HV-K$LMQ>6\,;(7#R2JH*C&3DGIR.?<5-#-%<0I-!(DL3C<CHP96
M'J".M '*WO@&SOKG4F;5=3CM-3G$U]9I(GE3X55V\J64$* =I!(X)Z8N7/A4
M-JMU?Z?K&H:8UYL^U1VOE%92J[0WSHVUMH RN. *V;J_L[%=UW=P6Z[2^99
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M0ZKIUQ<BV@O[66<IY@B2968KZX!SCWHBU33Y[V2RAOK:2[CY>!)E+K]5!R*
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MXZF0=^XJEX*T.6&?P_!J']J0:EI>\RH=+V1[RC*Y:X"X=6)S]XDG!/->JT4
M>7^&O#4LL_@I=5TAWCLM)NQ(MQ 2L4K/%M# C )&[ /H?2M?XA&W74?"375A
M)?0+JC,]O'%YC,!;RG(3^+&-V!SQP">*[<2(<8=3G.,'KCK4%S86MW<6EQ/"
M'EM)#+ Q)^1BI0D?\!9A^- 'F7]@2ZE"\@T:>/2;WQ/!=1V<MN4Q"(@KR/&1
ME59U8X('7D<U>\5Z#J%S?^)(M+L'\J71+6&)8EV++MGF:2)3P,E#C'^T/6O2
M** /,-0LO[8NM2O-#T.\LK9/#UW9RK)8M;M/*X7RHU0@%BNU^0"/FP#S77:?
MHPL?! L-,MX[&Z>PV+M781*8\ MWSGJ3S70TA90P!(!/09ZT >6?81??#J32
M--\,WMKJMOIL<-QYEGY)<*R&6%9#C>7"MRI(/4GFI-3LCK$^KWFAZ)>6=J/#
MEU9R+)9-;M<2L 8XUC(!8KAN0,?-@'FO4** //?^$=BL=5T8P:3+%:?V!=6]
MY]DAVL2?)(0D?QGY\9YSGWK#ET[5[KPQ=Z=9V=S-IME<6+1S2:7]GN;F%'S)
M&T3 "78 I^Z V2,&O7J* /*KO0%U#0]4DMX]2O?M^H:=Y\-QIAM594G3>PC*
MJ3\GWFQT4>E6O$7AJ:5/'EK8:5B*[TFW^S)'" DLRK,#LXP6 V#CGI7I=% &
M-IFJVTBZ?;VFEW\$-S'(ZE[-H4AV$9#A@"I8G(XYP35/QA:7%VWA_P"SP22^
M3K-O+)L4G8@#98^@&1S72T4 <9?:!%J/Q U*[O-,6X@.B1012RP[EW&2;<H)
M&,X*Y[X(]:P--T:ZDT_28M5L-1^SGP>UG=^5$WFJY,0*#_;P#QUXZ5ZE2%E4
M@$@$G R>M ')^!GO?(OH9[=OLD,B):W<M@;.6X78,[XR <J>-V #V'%<]IGA
MZXGG\,QW^ER/#!JVJSRK-"2J!I)FC9@1C!RI!/MBO3J* /+#I%SIYMII](N9
MM(LO$EW/)9Q6Q?$3HXCD6,#+*';/ /7('%:LVGMJ.MV,VF:1/96<FCZC"%DM
MO)"22218W+_"6(9L'!/)(ZUWU% 'F&E'4M0G\'VT.DZG:2:9ITUO<3W-LT:1
M3>0J  G[W*GYAD=.:JZ!IP%UX$AB\,WMK>Z4[QZC=26914;[/(K?O"/G#/SN
M&1R,D$@'UFB@#R?PMH5Q'=:5::JVJ1ZE8WTEPY32\1NY+Y<W(7#*X8Y^;)SC
M'%:&@W8\-7FH.EI>'0;2SN+N2:\T\P3V[[PYB61@!,&RQXSC:,L<BO2*BN+:
M"[A,-S"DT1()210P)!!'!]P#0!A>*+*7Q%X(NEM(Y([J2!;FU5UPZ3)B2,$=
MCN50:\]&CZ]J-[]IETR\BB\72 :E&Z'_ $.**8% _P#=W0;E^N!7LE% 'F6M
MZ-=26GB>9M+FG4>(+*\C18"[20HMMO*#'S<*XXZX(K1;0[75O%^H7\NC%[.3
M0((;8W%H5VDO.60*P^5L%,CJ,BN\HH \MTNUFTN3P[?:]HU]>6R^'(+0*MD]
MPUO<#F16C +*6&T9(_AP32Z38ZAX;7PG?7FF7S6]O%J$3PVT+3R6RS2*\*%4
MR<!5V\< @"O4:* /*(=-N(M"\/7^H:%=L+;7[RXN;?[*9IHXI&N=I**"6&70
M\9'0].:[+Q9:SW8\/FVMY9!%J]O*X1"=B -DGT R*Z6B@#S*W\/W%S?:1'>Z
M7));)XGU&YD66$E1&1.8W.1]TDI@]#D5"_A4V^B:Q);:*4O?^$FBGMV2WPXB
M%S$=R<9"!3(>.,%O>O4Z* /,-3T>Y^PZI<SZ5/.D7BJ*]V+;F1WMQY.YD7&6
M& >F<X-5/'2ZAJ=MK%I9Z+/''+8Q-8B#1V>2Y^7.'DQ^Z*' "G##'&20*]:H
MH XE;,6?Q'U.:72YF_M#3K=;>ZCM2Z"1//\ ,#.!A#AEZD9R!6!HEE+HZ^&;
MO7-$O;FTC\.Q6BQI9/<-;7 (+AHP"REEVC./X<'%>JT4 >8Z%X8N1=>#TU+2
MF-O:IJ4HAEC#K:K)(K0HW4 A3@#MCCI6SX5NE\.Z=:Z3=6EQ%)>:Q?0VD*QX
MV1^;+(K8.,)M P1ZCUKM:B:V@>YCN6A0SQJR)(5&Y5;!(![ [1GZ"@#A_&<M
MI!X]\*S7NFS7\,=M?,4AMS.R']QA]@R3CV!(SFN=71-4MK/1;XV=Y::9'J=_
M<BUCLOM$EK'*Q,),&">!NX )7?\ 6O5I;"UFU"WOY(0UU;H\<4F3E%?;N'X[
M5_*K- 'F=GX8AENO"Z?9+N\T]=1O+N47EEY*Q%HV(S&0-B[^0"!R:N-;2Z?X
M]SI%E<R+=W2&\BN=./E0JL6T30W& HP%4;,G.3@"O0** /)M(TN=M,\,Z0NA
MWD&NZ?J,<]]>O:LJ85B9I//QA_,&1@$D[N1Q5F/PU)%HGVA-(9=1/BS[49!!
M^]\K[<?GSC.WRR>>FTUZA10!Y5J46JW_ (FMA_94T#VWB".39;Z60GD!\>>U
MQT8LIR0#D9((X)KL?!UI<6D&LBX@DB,FL7<J!U(W(SY##U!]:Z2B@#R_1/#4
MEAH/@B6/2&@OX=3:2[<0;9$1HY@Q<XR <H.?]GVJ&PBU6]\7>'[F72I;22VU
M&Y-S##I9ABMT,<P!\[_EIN^4D@X)/.#@5ZM10!Y39^$$;0/# GT(&Y&O2S7F
M^W^?RRT_S/QG:1Y?7C&WVHU70-1CMM36ULKB*RB\4)>-%#:B3?!]G0%TC(PX
M$IW8 /*GN*]6HH \P;1K/^R)[T3ZX'DU1+N.0:*V(YEBV;C;;,E"."=OWN<C
MK74>&]=E:#2=+U'3S::I<6<ER\,,6R.)%<+EAG*%MP(7GN,\5T]1+;0+=/<K
M"@GD14>4*-S*I) )] 6/'N: //O&NE:A>7?BYK:RN)A<>'H8(3'&6\R023$H
MN.K88<>XJKK&CZDGCR^UMM/N+W2K::T>6R$9/GXC*^:@'WVB/.WGJ?X@*]0H
MH \GN]"GFUK7+34VU2,WVI+<6\MKI?GAT&PQD3;3Y93;C#$8QD=:L:QX:DN-
M'\>7*Z0TFH3WZO9R>1F1U6*$J4.,D!@W3N#7J%% 'E/B#1)Y_$?B:'4_[2%M
MJGE"VEM-+^U;HQ$J[0X4^6RN&(R0,G=6LUO/I_CQ7TVUO+IKNYC^WK=Z>3&@
M6(+Y\=Q@ $!5&W)R<X S7H%% 'D9TO5)=%UW0]!L[QK.33IC%+>6!MIXI6D!
M, D8 2A@7Y'3 RQS5ZTT6PU"#5)IUUPQ2Z4;*:!-'-H0A88"C8-[KSC&X8)Z
MYKTZB@#AO#NNSZ99LFI6DK17&I16=C<+IYM);K<@^=X6P1MPP+8&0N0,"IO'
M-J)=6\,7<VDW&I65I>22W$<-OYQ0>2X5BO?#$''7C@$\5UTEM!+-#-)"CRPD
MF)V4$H2,'![9'%2T >5QZ?>6]D-7ATB]BT]?$XU&.S2V;SDM_)\MG$0&X9<E
MMN,X.<5+):'4H_$5]?6.LV,4^L6]U9NM@TL@V6\861H<,63*D$8R,\X(X]/H
MH \WM+?6+^ZT2[N]*:W==+U.*00VYC7+21>62G.QG"[MI.<Y]*31O#<NGP^
MFM-,-I<16$J7DBP;3&[6X)\SCJ9!W[UZ310!Y/X/T22$Z%!J*ZM%J.EI(98E
MTORT+F-E?-P%PX8G(PQ).TGFGZ=IRG0-4T.2SU1] BM($ANO[*:&\1A)Q&5*
M_O@N Q(7GD'=FO5:* .<\%SW\^D7!O[41%;IUAE^R&U:YC 7$C1'E&)R.<9V
MYP,UR7AWPU)IVB_#^2+2&M[V"Y8WK"#;(BM;S!O,.,@%M@Y[X]J]0HH \ITB
M+5;SQ?X<NI]*ELWM[JZ%U##I9@AME:*0*/-/^L#':<C*DXZ' HTWP?'_ &'X
M-$^A#STU:26]WVWS!"L_,G&<9$?7C[OM7JU% 'E&HZ#J,5M=>197,5C;^*&N
MVAAM?,)@,( =(B/G42'=@ \@D<BIVT:S31WO5FUP2-JOVV&7^Q&(CF$.PDVP
M3.Q@3DX'S'.1UKU"B@#FO#FN221:7I6H:>;/5); W<L,,86*%0P7!&<J3G(7
MGHPSQ5.:U2U^*BWTNF2R17>FQPQ7,=J9%699')W, =AVLO)QG&*ZQ;:!+F2Y
M6%%GE55>0*-S!<X!/<#)Q]34M 'F6F:5/H/POTX6^@1F^>:/[8)+$S21J926
ME,?WG91@@=N/3%9\>DZB^AZU(^FWMQ9GQ!:WKV[67DO=6ZK#O*P]^5)VXR=I
MR,\5Z[10!Y'?Z/=ZI%XUFT71+NR@OHM/:-'M?)-TL<CF;:C8Y*@C:P!.1D?,
M,Z4.E"YT;Q7=V9U2:YNM(:V\J;2C9AV"2;0J;5+M\V,@'C KTJB@#SZQ\)6<
M?BKPZ[:'"+:#1)4E)MQL6;=#M#<8W8,O7GEO>LFR@U.PT#P_I]QI$L<"6MRC
M3?V4;N9&\W"0A?\ EFK+SEN#M R*]7HH \Q\+>&YI;KP:-8TIW6Q\/RQN+F'
M*PS;X0%.> VW?@>F:32M(U+3O'$^KWFGW%WI\NJW$<49B)-H[[=MRJ_Q*PRA
M;^$<@X+5Z?10!YOX?NAX;O-09+2[.@VEG<74DU[IYMY[=]X<Q"1@!,#ECD9Q
MM&6.:]"M+@7=G!<K')&)HUD"2+AER,X([&EN+:"[@:"YA2:)B"4D4,#@Y'!]
MP*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "N&\0ZM'H7CB?5ID:2
M.S\-W,[(IP6VRQG ^N,5W-95]X=T_4M0DN[N-I3+8R6$D9/R-$Y!8$=<\=<T
M 8 \2Z]I5_8Q:W;6$R:A;32PK8AU:*2./S#&Q8D,"N1N&.1TYK)TOXB7\Z3W
M\TVDWFG6^COJEP-/5R\# 9$#,7(#=>H&=IX%;<W@:./3[GR;^[OKU;":TL3J
M4HDCMPZ[<851G.%!)RV!UK-\/>%]6BFBM+V*ZAT@V3VU];7FH_:A=%E"C:,?
M*  V3D=<8] "_;^(?$-GJ6E0:O:Z?,NK0RM EGO5HI4C\SRV+$A@0"-P"\CI
MS5KP9XAN]?MIGOI[(7480RV<4,D4UHQ!RDBN23CLP !P<"I-/\%V=C/%,^H:
MG=O;P-!:&YN WV9&&#L( .[  W')]ZMZ1X=ATJ^N+][V\OKV>-(6GNW4L(T+
M%5&U5&,LQZ9.>30!S^H^+-<6WU_5M.MK Z7H<LD<L4^_SKCRE#2E6!VIC) R
M&SCMFKUEKVL:KXNO+"SBL4TNS2"2264.99!*F[:H!P"/4_3'>I;[P-IM]=7K
MM=7\5K?R"2]L89@L%PV "6&,C( !VD9QSFM>TTBVLM4O]0AWB:]$8E!/RCRU
M*K@=N#0!C>+?$%WHQC2SO=,AE,3RB*ZBEFDEV]E2,@A?5CG&>E9\'BO7-;N=
M)M]&MM/@-_HR:FSWF]Q$6(&S"D;OO =1W//2MS5O"]KJVI+J!O+ZTG^SFUE-
MK*$\V(G.QL@D<YY7!YZT[2_#%AI$]C-;-,6LM/73HM[ _NE((SQ][@<T 86G
M>/'EBT>]U*WBM;#4-,FN2X))CGA^:1,]UV;F'?Y#6B?$US8?#P^)=4LU6X2R
M^U/:QDC!(RJ9.<'E03ZYK.\0>!(+WPQHOAVTB9[.UOHWDDEDPR0C=YG(QDL&
M*8]']JZ[4-/M=4TVXT^\A$MK<1M%+&> RD8(]J .6.L^);+5;;2M272OM&HV
MLTEK+;I)MAEC"DHX+988;A@5Z=.:Y>&[\0WO@WP!>7$]I=ZA/J$#PO)O4$&U
MFYD.26;J3C&>G'6N[TOPI:Z=?I?37VH:C<10F"![Z4/Y,9QN"X Y.U<L<DXZ
MU%I_@NPT^STVT2[OI8--NA<VB32*?*PC($'R@E '/7GIS0!B7'CK4=-TJ\CO
MH+0ZI!JZ:6LD*2&%B\:RB38,O@(QRH))(QGGAC>.-:72YO+L;>>\74K>RAF>
M":W@N%FP P5_F4J20?O=/?%='=>$--NTOP[7*27EXE]YL<FUX9D1$5D..,!!
MUSU/8XI__",136L,-[J6H7K0WD5XLMQ(F[?&05&%4 +D<@"@"MXFGNK+X=:Q
M<:G':W5S#83/*D6^.*0A2<#YMP!&.^?>LO4?$GB".]UBVTFVTT0:380W;-<^
M86DW*YV#!X^X?F/3T.>.MU?3(-:T>]TNZ+BWO(7@D*'#;6!!P?7FJA\.6)FU
M27,V[4K:.UG^8<(BLHV\<'#G]* .<M-7US4?'U@;:YMH]*N='2\-M(C$A6=<
M\A@-_. <8QVJMH7Q O\ 6;[39DM8Y+#4)VC$,5I.);=,-MD:4CRV!VC(&,;N
MIQ73+X4LXK[2[RWNKR"73[86B^7(,30@J0D@(.1E0>,'K3=,\*0:/<H;+4M2
MCLHW9X[#S5,"%LD@?+NQDDA=V!Z4 <+H%REF/"-U+GRX?[9D;'7 D8G^5:NB
M_$*^O)+.YN[6-[&[M9+EEM[2=6LPL9D >1QLDR 1D;><8R#736GA#2[/^S]G
MG.MC]I\I78$-Y[$N&XYZ\4FE>%(-)5((M2U&:PCC,45C/*K0QH1C;]W<0!P
MS'% '.ZCJ_BVX^'6J:YOTRT672)+RW$(D\VW^3<!NSAFVY^88PP'!%:]AK.J
MP:CX=TS4#:32:A:7$TLL*,N/+$6W&2>N\Y^G:I;+P58V>G7&FM?ZE<Z=+:/9
MK:7%QNCBA88*K@ ]. 6)(' -$G@RWEM=.C.K:J+G3MX@O1,@F"L &0G;M*D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>\][Y6]7P57RP0I7C@_,: /--0O-:@BU2[)GCU<>%-/:X:-?WB,99?-8 ?Q
M%S]15I++3M5UFXTGPAJ\DEC=:/,;J6"]>9(9]R>0^XL<2??)&<D#FO4<#.<#
M/3-(D:1 B-%0$Y(48YH X?P+JUWXKU*YUVX$L,=K;1:?Y!R%%P!ON#COABJ
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MD"213*&$8_B?YDX'/(KTAHT9@S(I8 @$CD9H,:,5+(I*_=)'3Z4 >7^'K/\
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MBD$;1@\GCK0!XYXWGTV=/'::WJ,T.IPPE-+MQ<NA:$VX(V1@X<,YD#<'@'.
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MC/ME==C*^",'D$$=C[&I;?P5=1:8FF2:K&]G;ZK'J%J!:D.@6X,[(S;\-DG
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MH+7$QVR>8D;2[\% V#]T$@ 9H W/$6OCP_:VDOV*:\DNKI+6.&$J&+L#C[Q
M[=S5&S\575U%J<!T66/5-.DC66T-Q'M*N,JXD) VXSGN-I&#4?CK3[_4K71H
M].:2.>/5H)3,D7F>4 &^<KW4<9^O452N? =U?VE_)?:M#-J=[=V]S))]C_T<
MK#]R(PER63KG+9).: +%GX\AG6/[18M"PU1=,N"DRR)%(Z!D8,.&5MR+V(+=
M*W-)UF/5YM26&%EBLKMK42D\2LH&XCV#$K]5-<G?>#Y-,\%>*8R_VRZU F[B
MCL+3RO+F6-!&(T!/1XU(Y^N>M=1X8TEM#\-V-A*V^X2/=<2?WYF):1OQ=F/X
MT <WI?C?4(]/U^_UO3#%;:?>O!$89%=G;<JI$!W8E@-W3FMS2O$=Q=:TVCZG
MI4FG7QMOM42F994DC#!6PR]""5R/<8)K.G\$S7-OKMB^J!;#4[G[9$JV_P"]
MMY]R,&W[L,H:,'&T=>M7]*T"_BUTZUK&I0WMZML;2$6]L8(XXRP9C@NQ+,57
MG...!0!=_MN/_A([C1O);S(+)+PR9X(9W7;CU^3]:PK;QX+_ /L5+'3&DGU.
MQ6_6*2Y2+;&2!M4G[[C/08XZD9J[JWAN_NM?_M;3-62QDEL_L5P'MO-W1ABP
M9#N&UP6;DAASTXK*O/ %U<^%=-\.?VI:&RM+2.W:22PW3*R?\M8GWCRVQCLV
M,9H U?'&MZEH'AT7NF6RSS?:H(CO8 *KRJIZ]<YV^V<]JQKK7M<MO'+QPZ1<
MW3MHL4[V*W2B.)O-DR=Q."Q  &!S[ 5T_B313K^@3::ES]FD9HY(YBF_:\;J
MZDKD9&5&1D5#9Z%<1Z\VL7E['-<R:>EG(L4!C4E79]XRQ('S8QSTZT 9<WC^
MTD@THZ=;"XFU&R%\B3W"6XCB.,;F;^(DX &>AZ 9K:TSQ!::KX9CUV!)?LSP
MM,8]N7&W.Y<#J001Q7.1?#U[*UT4V5]9O=Z=8#3W>]L/.BGC!!!V;P58$$@A
MNY'-=9;6<]MI"VBSPK<+$5$L4 1 W]X1Y.!GMG\: .?MO&QE\-1Z[+INRUFE
MMD@,5TDN\32*@R1T*[AD?J:L:QXQM]'?7%DM)9/[)M(+I]A'[P2LX 'N-A_.
MLL_#^:>UU@W&I6T5YJ+6\@>QLO)BCDA?>DAC+MN8MC<<C( 'O3Y_ U]J$.OM
MJ6MI-<ZQ:P6[-%9[$@\IG(VKO)(._H3G(//.  /D\;ZE'>W6G_\ "*7GVZ&V
M%YY1N8MI@)89+9P'RI&WGGOCFN@BUZQD\,)XA+LE@UF+TLPY6/9OR1ZXJ&70
M?-\17>K?:<?:-.6Q\K9]W#NV[.>?OXQCMUIMIX;@B\$P^&+F5I[==/%A)(J[
M"Z^7L) YQD?7% &/9?$2SD<_VA:_8XFLI;^)EN$F)CC +API^1P&!QR.O/%3
MZ?XRN;G4]/LK[0;FQ.H6\ES;N\R."B!20VTY#?,,CMGJ><1V/@N=--N=,U*Z
MTZ>SFLGLRUMIH@G967;N9][ G&>B@9Y]JI6^@:[:>,/#CZC?C4K:VL[J#S(;
M/R5C&V, N=S9=L>H'R\#K0!M6/BZ"^M/#%PMK(HU\$Q@L/W7[EI>?7A<?C5/
MPWXIAF32;.7[6XOX[IX;JZD5F9HI2&1MH SM.1QT7VJ#2/ U_IUSH GUU9['
M0F<6D"V81F1HGC D?<<L XY  X.1DY!??#XW7@VTT.'5GM[JTGDFAODA^9?,
M+[QMW=TD9>OH?:@"=_&UPWAZ#6[717DLYHWF#2W<<68PQV[<\EF4;@, 8(YJ
MI)XLMX/$$NLRW%P-''AQ-0$63WD)!VYQN(P/TJQK/@,:A>V\MG<VL$$6G_V>
M(;FR%P(HP>&BRP"/CC)!!P..*&^'UO/8"RNKYY(3H4>CMLCVGY#GS0<G!SVY
M^IH :GQ!B2'4OM>G^5/9Z;)J2Q174<WF1QCYE)7[K@E1CISP34T/C&\GGDM6
MT&>VN9;![ZQ66=/WR*5!#8/R,-ZG!SP>M(OA"^FT75--O+[3,7MC)9K-9Z7Y
M#KO7;O;]X=WK@;16FWAU7UK3]0:Y.VTT^6Q,>S[XD,9W9SQCR^F#U]J (O!.
ML:CKWA'3M2U.U6"XN+>.3*N")0R [P!]W))X[5BZ7XWU"/3=>U#6]+,5O87L
MEO%Y,BNSMO5$B [L2P&[IS70^%=&N_#^@6VDW5]%>):(L-O(D!B(B50%#?,V
M6XY(Q]*R9_!,UQ;:Y8OJH6QU&Z^VPA;?][;S[D<-OW890R XVCKC- &CI7B.
M>ZUI]'U/2Y-.OOL_VJ)3,LJ21[@I(9>A!(!&.XP33=2\27,&L2Z5I6D2ZE=6
M\"W%P%F6)8U8L$&6ZLVUL#VY(HTK0+Z'76UK6-2AO;T6WV2$6]L8(XXRP9N"
M[$LQ5<G..!@4S4?#NI?V]<:OHFK0V,]W;I;W23VGGJP0L4=<.NUAO8<Y!XXX
MH J+X[%^^F1Z+I%S?RZC8M>QJ9%B$:JP5@Y;H06QQGG\Z:WQ M9-/TB6TM"]
MUJ<4DJ07$Z0B)8R%?>YX&&(48SD^V35S1?!]OH=_IL]M<NT5CIKV 1URTA:1
M',A;/7*GC'\59@^'S6]II)M+ZU:]TY9XP]W9>=%+'*^\JR;P000,$-V/K0!T
M.C:_'KOAT:K96[EB)%^SLPW>8C%63(R/O*1GIWK-B\=:=-::3=+')Y-]937\
MI)YMHHE!<N/4,0N/7/I6[I=I)8Z=%;S/ \BYW-;P>3&223PF3@<^IKC?#?@]
M&U#Q:U[%.EC>RRV5K%(NTI;MN>4I_LM)(Y!]%% &AHWCJ+5=0MK22P,#7MN]
MQ:!;F.5G"@$JX4_(^&!P21UYXIT'C5AJ%W8W^EFUN(;&2^1$NDFW)&0&5MOW
M6!9>.1SUXIND^$+RQM'LI]0L&@^RM:QS6NG""YY7:':3>06 ]%&3S[51TKX=
MRV$HDEU"R^72IM,5;33A "K[/WC?.2S?)SV.>,<Y +]E=ZMXOM])OTMI]'T]
M9TO#NG'FW,>PE5VKT4D@D,>@''/%W0_$KZ[J%[%!8;+2UFEMVF-PI<21MM(:
M/JH."1GJ.<#-:FDV/]EZ/8Z?YGF?9;>.'?MQNVJ%SCMG%8EKX6NE\7)KUY?6
MDCQ1R1(+:R\F217(P)GWG?M XX'/- $^I>)6L_$EOH=K8_:;F2 7+;KA(ODW
M%?DW??88)(XP,<\BF>)_$\_AN&2Z.E&XLH(3---]JCC.!DLJ*3EF &<<=1@D
MU'XK\+77B?9;F^M(;(;2=]EYD\3AL[XI=XV,1@9VG&*H^)O <GB#4=0N4O[6
M)+^R%G)]IL1.\(&[F%BPV9W\\'H#Q0!-;:M='QAK[6ZSWD,>FV,UO:B4*,NT
MV2-Q"KD 9/H.^*C/Q B@TO6;FZTUUN-):$306\ZS!UE("E&'4]>"!TI^I>!?
M[0AU1/[1,9OK*TM?]3D+Y#,V6&[YE;=@KQQD9YJLGP^D:SUJ*;4+5)-4^REA
M:6(ABA\E]V%3><YZ<GW]@ :UKXID&I)8ZQICZ7+)9R7B&2974JC .,KQD!E8
M_7VK4T34SK.AV6I_9WMQ=Q+,L4ARRJW(S[XP?QKFOB+H$WB"UTBVM5G$S7PA
MDFA7_5VSHRS[CV4ID?[VVNR1%CC5$4*B@!5 P /2@!U%%% !1110 4444 %%
M%% !1110 4444 %%%% !117 >*WTD>-K=/%3JNA_V<3;?:&*P&Y\P[\]M^S9
MMSSR<4 =1K>OKH\UC;)8W-]>7TC)!;VY0$[5+,2795  'KW%7[F^M;2:UAN)
MECDNI?)@4_QOM+8'_ 58_A7EFEZ,FH77@675K269_,OA&UUN\S[.N]H-V><A
M=IYY]:W_ (CV6DO>>&+_ %B&(V<.I%+B:7(5(VAEQN/8%]G/KB@#K+'5X+_4
M]4L(XY%DTZ5(I68##%XUD&WGT8#GO6A7DGB#1K2X'Q%U81RF[LTBEL94D8>4
MZ6<;*R ' ;('/7 Q3/% -WXIU:+6=1T^Q5[2#^S)KX2 IE#N> JP'F"3.<?-
MPO:@#UZBN/\ &W]I1?#QQ;3O).!;BYFC1@S1;T\YL+\P&W<2!SC-<=/;PCPG
MXBDTG6+"6TE^Q*+?2-ZQP/YPRZG<<,PQD#^Z": /8:*\LO\ PGI::[XGLDMY
MA9P:/%=00B>38MPWG R@9^_B-/FZ]^]4Y;S0[C7;%O%]PYMY?#%G*1,[B-I2
MTF2<<;^NW//7'- 'I[:O OB*+13')]HDM'NP^!M"JZH1USG+CM6A7D-G_P )
M"EA8R*MR=;'@ZZ\HR ^;YGF1[,_[>-O7G-3Z7::!J>L:19^&I)'AN;&XBULQ
MNY.QHL+YQ/27>1C/S?>[4 >KT5Y'877B#6-+U5XO/_M3PWI$^FQE0<RWQR&=
M?4[(XR/^NM-T6)OL>HW/AG5M.>^719U^QV"R>9)/A3&\N]CB0-D<_,=QSTH
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MM/T[5AJ2FPEN5D^T+"-AC\C# %#R" #DEMU=G\07V:?I7VII%T@ZC&-39"P
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M44 %%%% !5/3=+MM*CGBM%98YIY+@H3D*[G<V/0%B3CU)JY10 4444 %%%%
M!1110 4444 %%%% !1110 4444 8&H>$;+4+^ZNQ=ZA:O>1K'=);7&Q9U48&
M>#@X.,K@UM6MM#96D-I;1B.""-8XT7HJJ, #Z 5+10!GZSHUKKEFEO<M,GE2
MK/%+"Y1XY%/# ^OUXJ/2-!MM(FNKA)KFYN[HKY]S<R;W<*"%'8 #)P !U-:E
M% !1110 4444 %4-,TBVTG[8;?>7O+E[J9W;)9VQ^@   [ "K]% !1110 51
MO-*MK[4-.O9M_G:?*\L.TX&YD9#GUX8U>HH **** "BBB@ HHHH **** "BB
MB@ K)U?P_;:O=6EVUQ=6MW:!UAN+638RJ^-RG(((.U>H["M:B@"AI&D6NBV1
MM;02$-(TLDDKEWDD8Y9F)ZDFK]%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &)J/ABVO]3?48[V_LKJ2%8)7M)]
MGFHI8J""#T+-@C!YZUI:=I]KI.G6^GV40BM;:,1Q("3M4# Y/)JS10 5DMX;
MTR2*_CFA,JW]PMQ<AW/[QEVA0?\ 9 11MZ8&#G)K6HH **** "BBB@ HHHH
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M)*1AG9@B9YVJ"%&>P[=*QK3PGJ,'AWP[8.T'G:=JGVR8AS@INE/R\<G#C]:
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MMGC$T*]7CW ;@,CIZCUJT_B33T6P(,SF_MGN;9(XF9I$10QP!WPPP.IKG(M
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MBB@ HHHH ****  C/6BBB@ HHHH **** "BBB@!" >H!I:** "BBB@ HHHH
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M.EOJ"V%C;:=<7T3137-I B28;J<XZ\Y^O-;5% %6#3K.VTN+3(K>,64<(@6
MC*^6!M"D'J,<54MO#&@V5O-;VNBZ?##/&8I4CMD42(>JL .1[&M6B@"$V=L;
ME+DV\7GI&8EDV#<J$@E0?0D#CV%4K#PYH>ES>=I^CV%I+N+;X+=$.3P>0*TZ
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!=)&X_W16C!!<:1XCU"6_T"\U*+4+*TBMVA@64+L4AXGW$!!N.[G@YZ\4
M=G+K>E0:G'IDNIV<=_)REJTZB5OHN<FK%U>6ME&)+NYA@C)VAI7"@GKC)^A_
M*O,F\/W;:KJ^GZF==\N\U?[9$UE:PO$Z[U:-C*4+(5V@'+# 7C@UO_$G;_9>
MBE[(WJ#6;8FV4*3* 6X ;@GV- '2V^N:3=V!O[;5+*:S#B,W$=PK1AB0 NX'
M&<D#'N*AD\3:##I\>H2:WIR64CE$N&ND$;,#@@-G!(P:X+4M%O=;T_Q7=0Z-
M<PVNIW.GK%:31;'E$4B>;(4[ CCGDA,UO:O:MI'C6QU;^QY[S3$TZ2U1;. 2
M&WE+AB=@Y 91C(_N\\&@#K(=0LKB2..&[@D>2+SD5) Q:/.-X /*Y(YZ<U4A
MUB*YU9;6W>UFMS \IGCNE9@ROL9=@YP#G+= 1CK7GIT37]!\-Z9K.EZ7(VJ6
MUS>;-.0@F.WN6=DC.#CY&\IB.@PU6+WP;J-M;R:5IJ.2OA6>Q2YS@/<,ZDY/
M8L=Q_&@#JH?%^GWWB:PTK3+JSOHKB&XDEFM[A9/*:(QC:=N>OF'\JU+77=(O
MKBXM[35+*XFM\F:.*X5FCQUW 'C\:X%+"ZU?7=/FTWP_=Z0(=$NK(W$\(BV2
M,(PB<')"D'!Z<G&>:9X:T.;R=,2ZBUZ.]TS3Y;=89K2".",M'M90Z("X) (P
M3G )H ]$L=6TW4VE6PU"UNS%M,@@F5]FX97.#QD<CUKG]$\:6^M:WK$45UI:
MZ=IK-&9!>!I6*A29"O01_,1G/5?RN>!]*&C^"-$M&LUM;A+"$7$>P*PDV ON
M]]Q;/N37*WWA[4'T;Q"(]->4-XBCO3;!0#=VR&%F5<\'.UN#U(Q0!W-KK^C7
MUE+>VFK6,]I"<23Q7",B?5@<#\:E@U73KJTFN[>_M9;: LLLT<RLD97[P9@<
M#'?/2O.?$&EW_B"'Q1J&GZ->6T-SHZ620S0^5)=2AV;.SKA5.T$]<G' KTRW
MM+:TMEMK:"*&!5"K&B@* !C&![4 <J?B%I-WH]EJ>ESP7$4U_#:3*TRAH [E
M=S $XZ$C/45T5KK.EWU@]_::E9SV<>=]Q%.K1KCKE@<#%>=VFBW5QX/TK1+C
M1+@266MQ-=)+ /+DC^T.Q8'HZ[2"3[U-XB\-ZG<R>*A8VDJPS7FGW*I"J9N%
MCVF4(&^5FPO0\$@ T >@Z=JNGZO;FXTV^MKR$-M,EO*LB@^F03S4-SK^C6=T
MMM<ZM8PW#2>4L4EPBL7P#MP3G.&4X]QZUB>$;%5U+5-3+ZR\]TL*2-J-K';A
MMF[&U45<D;L$D>F#Q7(:K&;O4/B'ID'A^XOKS49([:"XCB5D#FUB"AV)R@4D
M/D\>G- 'JC7UHC7 :Z@4VRAYP9 /*4@D%O[HP"<GTJO-K>DVTL,4^J644DVS
MRD>=09-Y(3:">=V#C'7!Q7":M:ZMIMQXGM5TJ^U&35M*AAMY[= R-(L3QL'8
MD;>2#SU!XR>*U-"T*1/%\-_>:?Q#H%G;QS2(#LD#R%U![$?+G\* .ECU_1IK
MY+&+5K%[N0$I MPA=L$@X7.3C!_(TKZ[I$>J+I;ZI9+J#?=M6N%$I_X!G->7
M:%;2ZGH6FZ=9:%<)<IXA>\?4?*41;([MRS[\_>VJ8]IY_#FKMQI.HOH6I>&S
MHEVVK7.KO<QZCY0\G:UQYBSF7/!5,#'WOEP!0!Z.-8TMM4.EKJ-H=0"[C:B9
M?- QG.S.>G/2DM=;TJ^O9K*TU.SN+J#_ %L$4ZN\?./F4'(YKC1::G!XLNK;
M18+^*UO9IY+S[9;*(H)#$0LT,HY.Y@GR_-P3PN*S_"6ARPC0X=1AU\7>D6SQ
MFW:U@2W5C$4<"55!<,>1\Q).">] 'H=AK&EZI)/'I^HVEV\!VS+;S+(8SZ-@
M\=#U]*9>Z[I&FW<-K?:I96MQ-_JHI[A4=^W )R>:YGP-%?V5Q-IR6]Z-#MK:
M-+234+80SQD$CRLC&]5&/FQWZMUK-U:RNK:Z\8VD_A^[U*76@/L4\40=&4P+
M&(W8G]V%<,><#YLCF@#?N?%R?\)W#X9M)=.,BP":X\ZZVR<DX1$ .7"C<0<<
M$>N:W+_5],TKR?[1U"TL_.;9%]HF6/>WH,GDUS>AZ+>6/C!)KJ(RB+0;6V:Z
MQD/,CR;N?7!!_&H]<@EL_'0U.XT6YU2QGTK['&L$2R[)/,+,K G"AU*C)X^7
MDT :>D^+K&Y\)V.NZK<VFF1W0/\ KYPJ Y(P&;&>E3W?B 0ZYH]C;I%/!J,%
MQ,LRR<8C"$8/0@[^M>>Z?H.LZ78^$[F:#4[:*SL+BVE2QMXYY;:1Y%(.QU;@
MJI&5&1QV)K=TW0);&\\+BSM[]K2WM]1+M=HJR1F5E90P4 +DYP .  * .OTC
M5X=4LH)/,MEN7@2>2"&Y6;RU<'!W+U4X.&Z'!Q39_$>AVR6KSZSI\278S;L]
MR@$P]4R?F_"O.'T'Q#IWA7PS)I=C,-1N-'71;Y<8:W#J"DK#_IFV_P#[ZJSJ
M?AJ;3M<U&VV:N-(N].M[*W_LZTAN!Y<:LC1-O1BG7(/ .X\Y% 'HEQK&F6MW
M':7&HVD-S(RHD,DRJ[,V=H"DY).#CUP:J6_B.Q72H[W4[JPL YDX:\1DPCE2
M0_ /;/H3@UBZ!X?%IXRO;N:SD>.+2K&VMKFY4,Y*&3>-PXW?<)QWQ61H7AV\
M%QX0-]IK%;*74I)?-CR(B\A,9.>A(.10!W,VNZ1;Z9'J<VJ64=A)C9=/<*(F
MSTPV<&IK#4K'5;;[3IU[;7D&XKYMO*LBY'494D9KRNXM=6TF]TBWL;%Q>)K.
MJW%M;^0LG[DLV&"-)&-N)!SO!&1@')KMO QLX_""6MH+ES:RS0SI-&L<@F#L
M77:"5'). "0!CF@#9M=<TB^-R+35+*X-K_Q\"*=6\KK][!^7H>OH:;:Z_HU]
M9RWEIJUC/:Q-MDFBN$9$/H6!P*\UDT;6[KPKJN@:5::@=+AM8/L@OK9(;A=L
MH9[=2>)%V*0"PQDX);)JQJ6A3:MH'B&>"+7KJ]NK."V*7UG% '59-P"JB+N(
M!;GI@\&@#T6RUG2]2D,=CJ5G=. 3M@G5S@'!. >QX^M10ZQ%<ZJ+6W>UFMS;
MM+Y\=TK'<K["NP<X!SEN@(QUKG/&6FW^EKINL^&--$U[8K+:BV@4*&BE3 X]
M%D6)OH#6/J/@S4;>VFTG2T<[?"TMC'<9P))RX)!;L6Y/XT =[::_H]_#<36>
MK6-Q%;?Z]XKA'6+_ 'B#QT/6B#7]&N=-EU&#5K&6QBXDN4N$,:?5@<#J*XO6
MX)_$/A"6WTOP[?Z?+;M:-)');1QO+''*&:) V0VT XR-IR!SDU&=&MKRRU:^
MN5\432W#VFZ5K**.1'A<LCI&J#=M.,Y4Y&!SC@ [^WU.PN]/_M"VO;::RVE_
MM$<JM'M'4[@<8&#GZ5F:-XPT+7=(EU.TU*V%M"3YY>9 80&*Y?!.T':2,]11
MX3EU2XT$-K$'ESF:0*6A$32Q[CM=T!.UF')'\NE<3!I>H)X0L;%M$NW?2-9%
MS>6_E#%U%YTK QY.),;D?'MCK0!Z1I^J:?J]M]ITV^MKR#.WS+>59%SZ9!ZT
MK:E8+;SW#7ML((',<TIE7;&P."K'. 0>,&N<\,V\\_BG7=;&GSV%E>16\4<=
MQ'Y;RO&'W2%.HX95YY.WZ5A:KIEPWQ%&@1(#I6KRQ:Q= 'A#!PZD>CNMM_X]
M0!W4NNZ1;ZFFF3:I91W\F-EJ]PHE;/3"DYJ>34;&*.ZDDO+=$M.+AFE4"'@-
M\YS\O!!Y[$&O--0TG4'T;Q%X=_L.[EU/4=3DGM[\1 P[7D#1RF3/RF-<#'7Y
M, '-/\3VNK16WCK3+?1+^\DU@++:2P(#&P^SI&V6SP04/'4Y&,T >GR21Q1-
M+(ZI&H+,['  '4D^E4+3Q!HM_9W%W9ZO87%M;@F>:*Y1DB &26(.!P.]9GCC
M3;O5/!US:V<!N)=\,C6X(!F1)49X^>/F56'/7.*Y37-/O?$'_"1:AIVBWEI"
M_AV:P6.>#RI+F9B2H"=3M (R?[^!0!Z-9ZC9:BLK6-Y;W*Q2&*0PR!PCCJIQ
MT(R.*S[?Q)8KI,-]J=W86'F!VPUZC)M5MI(?@'JN?0G%7M,LH-/TVWMK>WC@
MCCC51&BA0, #H/I7 ^'_  [=K<^#3?::VVQCU$R^;'GR7>12A.>A(SB@#T2V
MN8+RVCN;6>.>"1=R2Q.&5AZ@C@BJ::_HTKSI'JUB[01^;,%N$/EIG&YN>!D=
M369X)L)],T2YM9[=K<#4KUHHR, 1M<.R8'H001]:Y(^%;Y/AE#;6^GR17RZG
M]KNHHHT\Z:-;HN<!QM8[0I ;(.T"@#T"+Q!HT^F2:G#JUC)81G#W2W"&)#[M
MG ZBD;Q#HB6,=Z^L6"VDJ,\<YN4".JD!B&S@@$@'TR*X@Z-;W-CJE_./%$L]
MQ/:R><UE$DL<D)8I(D00;L' ;*G(QZ<4YKS4$UKP==ZYHTMU<1G46$<-LHEV
M90),8LG#D8)4$D;C]* /1Y-;TJ'2UU.74[--/8 K=-.HB(/3#9Q1)K6E1:6N
MJ2:G9II[ $733J(B#TP^<5YF- UF"WTO5%M=0L[1-7O;S[+:PQR3VT<V1&WE
ML&7(Y) !(\PXZ&KRZ-)IJZ)JD-CJ]_90:G<W=U!<6Z"<-+&5$JQ* ,!B3@#(
MWDXH ZR;QMX=AU;3].;5K,RW\32P.MPA0@%0.=W5BWRXZ[6]*V;V^M-.M7NK
MZZAM;=/ORSR!$7ZD\5QMTC?\)-X9UF+P_=Q6@AO()(EMUWPM(\91G53\H.QF
MSVSS@YJ]XQM;EK_P_J2V,U_9Z?>-+<VT*AWP8G19 O\ %M9@<#GG(Z4 2>(O
M&VF:/X935[2]T^Z6>:."V8W:K$[LX4G>,\+DL<= IK>TZ>2ZTVVN)7MW>6-7
M+VS[XFR,Y5NX/4&O.KC0[^_M-7OH=)F@@O\ 7;"Y@M)(P'"1O"))63^'=M8D
M'G R>M>F@!0   !P * %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
MXS5CK)^)^C06FJ)!9OI]Q(\#0%PP62'=GYP"3NX./EYZYH Z^*>*=2T,J2*K
M%"48$!@<$<=P0014E>6Z+J6MZ-:RWT<]FVF2>)[BT:U,+&1EEO&0OYF[ (9N
M!MQ@=>>+C^,]=N=5O7T^UEF@L]2-D+--,E<2HCA)',X.U6^\P&,   ]: /0G
MGBCDCC>5%DE)$:LP!<@9( [\ FI*XSQFE[)XG\()ITL$-RUW<!9)T+J@^SR9
M.T$9.,X&1SBJUKXLU=)K>PNS:RW,7B#^RKB>.(JLL9@,H8+D[6Y4'D\@^M '
M=E@O4@<XYID4\4V_RI4DV,4?8P.UAU!]#[5PNL:]/<75_;7%M:3Q67B/3[2$
M21[MJN(&+=?O R,0>W%4['5;^SN;S3=,>&*[U3Q-<P">>,NL2K%YC-M!&3A,
M 9ZF@#T9;B%WD1)HV:-@C@,"58@$ ^AP0<>XJ2O*;:6[L[S5QJ4=C>71\66,
M3/Y)"<QP .JDG:P&#U.#ZUI3^*/$<46HZMYVG_V?I^LBP-K]G8R2QF9(RV_=
MA6&\$<'ISUP #T2BO.;[Q;K=QXDGT[3;RTCEBU2.R6R^Q-,[0D*7G+A@.-S'
M'0;<'DUTGB+Q!)X?U72I+@QKI-P)X[AR.4D6,R(<^A"2#ZD4 =%2*P90RD$'
MH17GWAKQGJ^M_P!C:?=V]O#JDMQ/_:,04D1P)&'&!G@GSH!D^IK,T"ZUB\N?
M 36-[:Z=:7.DSRO9PVI\H;3$6&-X'(;C^[SUSP >HQ3Q3AC#*D@1BC%&!PPX
M(..X]*DKRW3=2UO18-4U.">S.FKXFEMY+5H&,DBRW0C+;]P"D%P0,'IR>>-+
M4O$^O_8/$6NV,UC'8:)/+%]CE@9GN!$ 9"9-PVD\[< ]!G.: /0**XR\\5WT
M=GXTGB6(?V1:+/:!D/4V_F_/SS\WTJ&PFUNY^)C9U2-;)M'MKAK7R"1AGD!
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MY"_+@\9/6@#T>D+!<9(&3@9KS^^\4Z]H<FK6UY):7ATDVEW-<1P&/?:2NRR
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MM'Q7H*Z6NIMJUJMD9#%YS/@!P"2IST. >#S6C9WEOJ%G%=VLHE@F4,CCHPH
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M\.-XEBTF#<!#;:@ES-^\:-MBHX^1EY#98$<CIUJ[IOB71=8>9+#4H)VA022
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MDPV[<,S$G !P!T%-M/">CV6DZ=ID%NRVNGSBXMU,C$B0$G<3G)Y8DY]:VZ*
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M>5WLH."X[]*AL=+U.SN_&=[;VD27E],LEBTI4B3;;1JN[!^Z'##!]_6NMHH
M\LB\.^)-9N=0>[CU**2Z\/7%@9]0D@XN'*<*L/1.O/L?;-^+3=:UG5]&=]!F
MTB*STNYLI)I)8B5D=$4;0C$E 5.#Q]!7HE% 'FGAOPY=0P:7;ZII.MR3Z7:/
M"JRW5N;4DQ&,JFTAB&'3(&.,XQ6;K-IK%GX(U:T>SO5T>*33TL+75)(FE#"Y
M0-'N0MF/&P L2>O45Z[45Q;07<)AN88YHB0Q21 RY!!!P?0@$>XH \XUOP_K
M?BQM?O4TR72VFTV"S@@N)8]\[QS&5LE"RA?X 2>Y.,4M]X>O=5T#Q%)'INN?
MVG<Z4UG%_:=Q;GS,Y(1?+;'!/4X'/%>ET4 <=XNTVY\C3Y=)T[4O[0M(9$L[
MC3GA40$A1L=9&"F-MHSP<;>W%4!;>(-+U+6+BXT)M5FUBSMU+6LD8CCE2(H\
M;[V!";B6!&>&/&:] HH XCPUX6O='UFQ%W&LT5KX=M].-QD$-(KMN49YQC';
MTK-T_3KRTL?AMH5W$8KZSS<W";@QC6*W=#R,C&Z5!^->DU'Y$)N!<>4GG!-@
MDVC=MSG&>N,]J ,SP[J,&JZ=+=VUD+6!KJ98R ,3@.1YHQV?&<]\YK7I%540
M(BA548  P *6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJW#!V5=R0[3N +<_,#P<"@#K**\U;6KC3O&7BO6M8MG^PZ-%&(C'?N=BF/(
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MOJ*X#_A)9M/\?ZSIR127E_=)9BTL?.PJC:YD<GD*JC!)QSP,$D5W] !1110
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M/:C< 0,C)Z4 <O<>%=2U'3Q%J7B&2>[@GBN+2XCM4C$$D><-MYW;LD-DX(Z
M5%-X(:^LM6&HZJ]Q?ZFL,<ERL 18XXFW*B)DX&2Q.222U=)!J-I<W]U8PS!K
MFTV>>F"-FX97GH<@=JH:MKYT_5].TNWL9;R[O1)(%1U01QQE0S$L?]M< =:
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M(!!(Z^U ()(!!(Z^U ')-X)=]/U73CJK&QOK[[=''Y W0N9Q,XW9^8%A@<#
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M:Q%X@\/V&KPQ/%%>0K,J.1E01G!Q5C3M2M-6TZ'4+&82VLR[XY,$9'K@X(H
MXKQ7X3U'4/!VF:,;N6[O4O(HEO8(A$882"DC$9/'E%QUY)%=Y##';P1PQ($C
MC4(BCHH P!3@0P!!!![B@L 0"1SP* .,N_ !N=1NIEU4QVUSJ,6HO']E5I#(
MC(VWS"<[/D&!C(]<<'9T_0IM.\1ZGJ45^3:Z@ZS26C1#Y90B)N#YSC:@XQU[
MUM$@$ D<T;@20",CJ/2@#*\2Z&OB+0YM.-R]K(S))#<1C+0R(X=6'N"HK(T[
MP%8Z9XBT_58+B01V5BEJEMM&TNBE%E)_O;&*_C75N^R-GP6P,X7J?85#9W7V
MNQ@N6@EMC,BMY,X"NA(^ZP!(S^- '+6_@1X4M]/;6)7T*VNQ=Q6!@4,&#^8J
M&3.2@?! QG@ FKTGA**3PYK^C_:W"ZQ)<R-)L&8O.!S@9YQFM#0M:AUW0K;5
M8HVABG!(60C(PQ'/Y5IT 8NC^'8]#U"]EL[AEL[O;(UH5^5)NC2*>V[@D>HS
MW-1>(/#;ZSJ&FW\%ZMM<V'F!/-MQ.C"0 'Y21\PVC!SQSUS6\&!) ()'7VH)
M"C)( ]Z ./@\"/8:?I":=K$D-_I;7'E74D"N)$F8LZNF0#SMZ$<K^%7V\-WG
M]LZ9JRZRYN[6W:VN6DMU(N8V=7(P,!#E>",\'\:Z$L%QD@9X&:"P49) 'O0
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MA64/$S*V,-T8%00>?<&J^C^#(M(;0BE[++_9,-S"N]!F7SF4DGT(V_CFNF#
MYP0<=>>E&X<\CCK[4 <D?!#0QVLMAJKVU_:7UU=PSM '7%P[,\;)D9'S#G(/
MR@U&O@'98;1J\SZ@FI/J<5Y)"C8E9-C!DX!4@L,#'48Z5U&G:C::MIT%_8S"
M:UG7?'( 1N'K@\T6>HVE_)=):S"1K28V\P (V2!0Q'/7AEZ<<T 9#>&[BYBT
MW[?J2S366H"]#16RQ*V$9 FT$X'S$Y))J6Z\/RS>*$UJWU!H ]H+2Y@\H-YB
M!F9=K9!0@N>>:VPP;."#CCBEH XS0? 1T6]TJ9M4$\6EPR06\2VB195P 2[
MY9^!SQGTR:33?AY!I.GK:6>HR1I+IG]G7@\L8N,)M24C/#J"1GN.#T&.S+ 8
MR0,\#FEH P=/\,1Z??BZ6Z9R-+ATW:4QQ&7._P"IW]/:N$U;P7+9ZAI=K):W
MMY9:=I$-I;SP6-O=>9*C-G<DH/E\;>1C.>6^45ZSFLR;7+6T6X>]CGM(HKF.
MV665/EE>0J%*8R2"SA<G'.>W- #]";4FT&Q;6$BCU(P+]I2+[H?'(&./RXKG
MKGP(\XOK%=8E30[^Z:ZN+'R%+%F;>ZK)G(1FR2,$\G!%;T>LPOXCN=&\MA)!
M:Q71D)&TB1W4#Z_NS^=6C=D:D+/[-/M,)E^T;1Y0P0-N<YW<YQCH#S0!5L=&
M2QUO5=2$Q=M1:(LA7 38FW@]\]:J^(_#K:Z^G317:V]Q83F>(RP":-B49#N0
MD9X8X.00:W 020""1UK)UO7UT4)G3-2OBRLY%E;^9L4=222!^&<GL* ,O3/!
M*:<=,9M0DF>RU"XORS1*OF-,LBD8'  \PG@=JV-(T=-(EU-UF:3[?>M=D%<;
M"RJNWW^[^M6-,U*UUC2[74K&7S;6YC66)\8RI&1P>E86D^/-,U:XL8UM=0MD
MU LMG/<0;8YV4$D!@3@X5CSC.#0 :]X0;6-9_M*'4?LSO9FRE#6RS?NRQ;*%
MON-R><$'CCBK&C^%H](O;*Y6Z>4VNE1:8%*8W!#G?UZGTKH,TQY B.0"[*N[
M8O4_2@#G-%\'1:-+HCI>/+_95A+8J"@'F!VC;<>>,>7T]ZKCP0]M9:8MAJSV
M][IUU<SQ7#0!U83N[.C)D9'S\'/\(-=-:77VJQ@NGAEMO-C5S%. KQY&<, 2
M 1WYJ<L%&6( ]30!Q8^'[16EJ(]7>2[MM0FOUFNK995=Y00VY 0"?F)!&,&K
M6E>"8],ETN0ZA).]C=W5UN:)5\QI]V00.!C>>@_*NJ+ 8R0,\<T9&0,C)[4
M9WB'2%U_P]J&D/,85O(&A,BKDKN&,X[UG:SX2BUB?4I6NWB-]I#Z60$!V*Q8
M[^O)^;I[5<UWQ#;Z"+)9;:ZN9;R8P00VL8=V8(SGJ1V4TNB^(K'7&N8H%G@N
MK5@MQ:W,1CEBR,J2I[$=",@^M %76/#/]H_V7/;7GV6^TW<()FA$JLK*%960
MD9!P#P000.:U-,M;BSLEBNKI;F;)+2)"(EY/0*,X'XFK896&001Z@T$@ DD
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MC..@)-9UR]GXU\6VUQ:6S76DV.G745Q-+ PBF>7R]L0W ;\!"QQD#CO7H%%
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MRZ*D]I)(5CV'<D8()67=C/1ON^E4$CT^#6M&A\=6[W+KX:A$RSPO,@F#M]\
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MZ2+<7!\DRA=^_?MSLV?-]W/;%7=/\%V]BVGN;^YGDL]0GU#S)0N99)5=6W8
M&/WA/ %%UX*MYX[EHKZXM[J35!JD-P@4F&;8$P 1@KM!!!_O&@#*T#4=;&K>
M,)9=,6;4(KJV5;*.[&P_N4!*NP& 1\W(![=:[RN0;PMJ>GV>I'3=7N9=3U6Y
MA>>]FV PJNU695 Q]Q2 N.X]S77T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4DTZT6_<8:Y6!1*1[MC/ZT)H^EQ2RRQZ;9I)-*LTK+ H+R*<JY..6!Y!/(H
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MNYK5" TT:YR%W$ D$A@"1DK735%'<P3330Q31O+ 0LJ*P+1D@$!AVR"#SV-
M'FVL:%J7B"'Q+?KH\\$.HG3X8[2X"B280S!I)&4$@#:V.3DA/I7I;*J0,JQY
M 7 1<#/L*?2$A5+,0 .23VH \L_L77;CPOK.AZ=8WZZ4EB@L+?4A$LJ2J^?)
M1E/S)M  +=\<D=+6KVNL>(KCQ)>1Z'>VL=SX;DLK9+DH'EE)<XVACC[P')KT
MA)$E7=&ZN/53FG4 <3XCTF_L=#T/4=!TX2ZEHQ7R[2/"^9&R>6\8Z#N&_P"
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M62?<8'-))#>Z_KUS>WWAK48M-?09K*2&1HUEF9G0LB@/QQD DC.#TX)]"HH
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MS>5Y#[)Y(Q+'DG9(JL ZY).&R.:CG\&:)<16L,D%P;>VAC@2W%W*(F2/[@=
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MU+.?))!V?.Q^7@8';GU-.T_PII&F1V$=M!-ML)&DM1+<R2>22AC(7<Q^7:2
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M9K96N962!CG/EH6VH#N.0 !^0H YK1/%?B/6+JQU"&VN)+*YO6ADMOL6V**
M.R!Q-G)88!/&.H '6ND\2ZG?PZGHNCZ;-';3ZG+(&NI(_,\I(T+G:N0"QX S
MP.3@U8M_"FDVFHF]MDNH6,IG,,=Y,L'F'DMY0;9DDD].O/6K6KZ)8:Y!%%?1
M.WDR"6&2*5HI(G (W*Z$,IP2.#WH \Z\0WFLZE82Z3=:A$9]-\16-LUREL-L
MZN\+H67. RE^0.#CMFNF^(BWUO\ #74S;7S0W$-N"\T:8+XQG !^7/MTK7A\
M*Z-;Z?'8I:$PI=)>9>5V=YU8,)&<G<QRHZDYQCI6AJ%A:ZKIUQ87L(FM;B,Q
MRQDD!E(P1QR* .(O[+6F^(.D6T&L1)>#1KKS;QK0$E?/A^ZF< _='.> >YJH
MGC76;ZP\.VT8>.\OHKF2ZGM+3SF_<.(_D0G W$Y.<X''?([BR\/Z?87%M<0I
M,]Q;P/;1RSW$DK^6[!V!9V)/*CD\C&!Q567P?HLMC:6@MI84M'>2WD@N9(I8
MF<DOMD5@P!).1G'Y4 2>&KW5+WP^DVK6K0WRO(A4IY?F!6(1]N3MW* <9XS7
M":1H.B:M\)9-=U.V@DU2YLY;VXU)U'GQSC<<B3[R[",  C&W%>F6-E#IUG':
MV_FF),X,LK2L<G))9B6)R3U-8<O@+PY-<RRO92>7++YTMJ+J46\CYR6:$-L)
MSR<KS0!RFBQ:UJ?C+2[N?4A#<R^&8)75[57*,Q&X<GKO^;\,57\(_:;+0O!G
MGO;7?VO59E4R6JAHAY=PQ*MUW%EZ]<$BO3!IMH-5_M,1?Z9Y'V?S-Q_U>[=C
M'3K56#PYI5M;Z=!%:[8].F:>U'F,?+=@X)Z\\2-USUH YC3?$&MR^$;CQG<7
M<$ED+2XNETQ;?!54#% ),YW?*-V1CDX Q4OA;6?$=YJEHM]%<3V5U:M+-+)8
M_9U@E^4J$.X[E(+#GG@'/-;5IX/T2RNY;B"UD D,A,#7$C0*7SO*Q%MB[LG.
M .I]:ETGPQINB2A['[8 J>7''+>S2QQIQPB.Q51P.@]J ,3Q7XHOO#NJ3QCR
MVAN=+D>P4KR;M'"A">^[S$X_V36))XNU+5/#UY')':O)8Z!=S:K')$'1KE2T
M2H5/\):*8D'J,5WNJ:%INM26,FH6JSO8W"W-N2Q&R1>AX//T/'2J\?A718DU
MA4LE4:SN^WX=OWVY2I[\<$],=2>M ',Z2-4F^(R%=3$=G_8EK-]D6 ; "[C:
M.>.03G'0@=JRO!=]K>DZ#X/>2]MY=.U&=K/[(+?:8QLE=7#YR6S'SQC!]LGO
MW\.:8VJ6>I"*5+JTB$$;QSR(#&.0K@, X!YPV>:(?#FE6]GIMI%:[8--E\ZT
M7S&/EOAESG//#MUSUH X^+Q/K[:)9^*S>6YL+C4$M_[,%ORL3S^2,29R9!D,
M>W48[U;N?%6I1>&M9OE>+S[37!8Q$IP(OM$<>".YVL>:VXO!FA0ZD+Y+20.L
MYN5A-Q(8%F)R9!%NV!LDG(7KSUIEUX'\/7M_->7%E(TDTRW#H+B01F5<8D\L
M-MW_ "CYL9_,T 9OAN/5#X]\5^?JK36L5Q"!;F( #="K+@YXP#CCKUJUJ5]J
M^H>+I=!TR_BTY+:Q2[DG:W$KR,[NJJ 2 %&PD]SD=*V$T+3XM=EUF..5+V9
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MVB#^XNW:I'TX_*O./^$)\4WUO;WE[;QIJ.KNUIKBB93LMLQ#(.?F^2%A@?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !37BCD*%T5BC;D+#.TX(R/0X)_.G44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5')!
M#+)'))$CO$=T;,H)0XQD'L<$C\:DHH **** "BBB@ HHHH **** &1Q1Q($C
MC1$!)"J, 4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-)+(Q9FP  .3T XK$A\""#1K?3DUBZ'V"Z%SILPC3?:D;OEZ8<$.P.>H/XT
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MD# DA6);D#@?B*T8OA^EI#IR66KW-NUIIHTQY!%&YDA!SD;@=K=>1^7 J1/
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MKK3M<LVNI575[Q;N1@!F-@L0P/;]T/S-++X8N8M7O;[2]:N-/2_=9;F%88Y
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M)Y&W[F[_ &L[?FQVK4N/!*W$.FV+:K<'2K V[16K11E@8=NW$F-PR5&>YYY
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M/O0!T0N(3((Q-&7;)"[ADXX/'M3RZA@I8!FZ GDUY3;>'4@TBSU*/2F75?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=8Y"K,06"*J_*,EN<CN:NW?B^&WDCAATK5+NY-J+N:WAB426\1) +AV7G*L
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M?RA$=H'!!55ZXP<GGI77V-NUII]M;,P9HHEC)'0D "@"Q1110 4444 %%%%
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M>+&B6-;EA#Y;WHC=#&#M;(8G)!.<8(Q0!ZG:WUO>R7*0,S-;2F&7=&RX< '
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MU33O#7B.XL]8MX[<6$;Q16NM2W\L4N__ %H>105# XQD@D?6M&YT%E\5ZGI
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M":P35;B*-?%4=BLMIJ#SLD#1J619F 9AEFY(R/P%-\8W(LM<O= 35+NV*:;
MFFS3:V;402LTF9'+R!IAPO/SGC&.<T >PT5Y1K<FHS^(]6TQ-2AMH[*RM_[.
MEN=<FM-@*',V K>=\PP2Y/W<'J<^GV)F.GVQN9(Y)S$OF/%]QFP,E?8GI0!8
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *@NK*TOD5+NVAN$4[@LL8<
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MM?+ADSL)WLN6.#A1SP:;J'CJTL+F]_T"[FLK"58;V\0QA(6(4D;2P9MH92V
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M 'H$D<<T31RHKQN,,K#((]"*Q]6\,V6I:=%:0_Z 89HYX9+6-!L>,Y7Y2"I
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M'%?:I>WM[>0P(_DQ,1#*RL,DJN!@ =R,9[X .P2*.,N415+MN<J,;CC&3ZG
M'Y5%-86=Q,)I[2"64(4#O&&8*>HR>Q]*K:IK-OHVAS:M?)+'%%&':,*&DR<
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M@R:*"P::_22[363JUW((BJR.4=2J+D[0 R@9)^[[U?\ %F@3^(+.SBAEM_\
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M=9\1K>^+9+#4[>VMM"MDN8HFM1(9CY/F%6)/"G!Z<\]>.>EUO7WTKP3>:^D
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M^HZ79!1*]]=&URKC]T1$\F2/HF/QI^LZRFCMIP>$R?;;U+08;&PL&.X_]\T
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M)'(A*LC#U!!J>\OOLHB*6\MP7G2%A$5S'N/WFR1P.IQD^@- %"Z\*:+>:O\
MVK-:O]K)1G9)Y$64I]PNBL%<CC&X'I5S5-)M-8@2&[\\*C[T:"XD@=3@CAHV
M4]">]0:3KD.J0W\I3[.EG>2VC%W&"8SC=GL#5>U\2K=W%[%#8SR?9=26P9HV
M4CF-'\PY(^4;QTR>.AH S+GX?Z;<:WITHA$6FV-A+;110SR12H[R(VX.I#=
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M5#U58W8JHXZ "MC>@+#<N5&2,]!5#7-7BT30;_563SEM+:2Y\M6 ,@12V :
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M4(!IT(5+(Z>$YVFW_P">97.&'USC)]34=MX0T>UMIK>-+PQ3((R)+^=RJ@Y
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MCL1WI-<TN.XUW4X[]!9Z?=6%O%IIN-%ENWBB$>"D95LQ2*V3C&[.T]J]?HH
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M:UT/6M*UV_DTZ[L?[,U"\6\F6>)S+&VU5=5P0"&"#!/0D\&H$\'W":%::?\
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M;[1IT\<VFQV<;WD3N;-D0J6B ./FR#G@C'?&*LZ]X>DOOB!X>2(R?9S;[]3
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MK(TDN6!4L"" O()Z8Z@U4/@>:;1KN".RT'2;QI;>>WDTZU('F0R"1?,Z%E)
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MZ:#0FO;'1;QKN#4X=/NK2<1AX69T!S^\ .5<;2"1EAG SCJWU 0:.^HW%M/
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M$?08/.,C%,U_Q5J&GZLTMCJ,ES#;W]M:7%NFG?N$WO&K*TQ.=_SY&#@9 (H
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MS7>Q\HE60]3S\KL.<]:J:=X+T'2KVWN[2TD66UW"WWW,KK &!#*BLQ"J<]
M/R%;DDT4./-D1-QP-S 9-!FB&W,J#=C'S#G/2@#.@\.Z5;6NF6T5H%ATM_,L
MUWL?*;:R9Z\_*[#G/6J5OX)T.SNHKNTMI(KBW>22V)N)'2W9U8,41F*J#O.0
M !^0K>$L9E:(2*9%&2H/('TH$L9E,0D4R*,E0>0/I0!P'AKP%?Z+>:2Q:RMH
M[ $32V<LI:^RA7#HV%4$G<1\W(&,5U&F^%-(TBZ6>QBN(MF[RX?M<IACSUVQ
M%MB]3T%7M1U6RTF.&2]G$2S3I;QD@G+NP51Q[D<]!5AIXD"%Y44.<+E@-WT]
M: *.K:#I^MFW:]CE\RV8M#+#.\,B9&&PZ$'!'!&<&HK'PQH^FK8K:60B6P>5
M[8!V(C,I)?J><[CUZ=L5KTQ9HF?8LB%L;MH89QZ_2@#(NO">BW=H]M+:,$>[
M:]W1S.CK.Q)+JZL&4\GH1U(JSH^@Z9H$,\6F6WD)<2^=+\[,7?:%+$L2<D*,
MGN>3R2:O":(R-&)$+H,LNX9 ]Q2[UPIW##?=YZ_2@#D9? .GZCXCUK4M5B$\
M=\\.R..>1-R)&JE) I =<C.#D5HZIX*T#69[B6]LW<W,0BG2.XDC295&%WHK
M!6(SP2,CMT%:5]JUCIDMG%>3B)[R;R( 03N?:S8XZ<*W)XJO8Z[!>ZOJFGE/
M*:PFCAW,X_>EXED&!]&Q^% %._\ #8U#QKH^MRB'RM+MYEB&#YADDVC)[;0H
M;\6K9O[&VU/3[BQO85FM;B-HY8VZ,I&"*E>6.-E5Y%4N<*&.,GVI] &99>']
M.T^:UG@BE::U@>WBEFN))7$;L&8$NQ)R57KG&,#BJTWA'1)K"VL_LKQQVLCR
MV[PW$D<D3.27*R*P89+'(SBME)8Y"P1U8J<-@YP?0T1RQS+NBD1USC*L"* (
M;"Q@TVSCM+82>4F<>9*TC')))+,22<D]36/;^!_#MK?I>PV#+*D[7*J9Y#'Y
MQ))D,9;:7R3AL9'&.@K2O=:T[3X;>6YND6.XG2WB8?,&D8X X]^_05>!! (.
M0>A% '/W7@?P]>7\M[<6#/++,MPZ^?((S*N,2; VT/\ */FQD_B:M)X9TI-8
M&J^5,]TKM(GF7,KQQNP(9DC+%%)!(R .I]:U%FB9G594)3[X##Y?KZ5C^&O$
M#>([6:\CLC!9B1DMY&E#-*%9E)*C[O*YP<\$4 3V'AW2M+>R>SM!$UE;-:6Y
MWL=D3%25Y//*+R>>*KS>$-$FL;:T^RR1):R22V[PW$D<D3.27*R*P89+'(SB
MMDRQB41&1!(PR$+#)'TH,T0<(9$#$X +#)/I0!BW/A#1[NSAM)DO##$KI@7\
MX+JQRP<A\N"?[Q-/;PIH[:E%?-;RF2%D>.+[1)Y*L@"JPBW;,@ 8.WM6QO3:
MS;UPO4YZ4K,%7+$ #N: *U]IUIJ2P+=Q>8()TN(_F(VR(<J>#V/;I6=JWA+1
M=;NWN;^UD>22$02^7<21K-&"2%=58!P,G&X'&:V2ZKG+ 8&3D]!ZT+(CLRHZ
MLRG# ')'UH S'\-Z6VH6-\()$N;*(0PO'/(G[L=%8!@'7(!PV>:ALO"6CZ=>
M?:;2&XBPS.L*W<OD*6SN*Q;M@SD]%[UKB>([\2H?+^_AA\OU]*<71>KJ.,\G
MM0!EZ5X:TO1KF2YM(IS.\8B\R>YDG94!R$4R,=JY[# J+5?"6BZW=M<WUM(\
MDD/D2^7<21K+&"2%=58!P"3@,#UK921)"P1U8J<-@YP?0TB2QR[O+D5]IPVT
MYP?2@"E!H>G6T[SPVP61[6.S9M[',*;MJ]>V]N>O-4+CP7H-Q;V$#6;HEA;B
MU@\JXDC80X \MF5@77@<,2#6CJ&LZ?I=@][=W2);HZQLX^;#,P4# R>I%6FG
MB1%9I456.%)8 $^U &'I_A2TTS6;2ZM=L5E8V;6MG:*IQ"7?=(V23UP@ [ '
MUI^I^#]#U>^DN[RT=I9E5)Q'<21I.HZ"158+(!_M \<5MO(D>W>ZKN.%R<9/
MH*SO#VL)X@\/V.K1PM"EW$)1&QR5SVS0!8ATRSM]1FOX8 ES-%'!(X)Y1"Q0
M8Z#&]N@[TMYIUIJ#VKW47F-:3BXA.XC9(%*@\'GACP>.:2ROQ=68N)8)+3YG
M'ESE0P"L1G@D8.,]>AYQ5@RQB+S3(HCQG?GC'KF@#*U+POI6JWPO;B*X2Z\L
M1-+;74MNSH"2%8QLNX<G@YZFH[[PCHFHWB7=Q:R><L:PL8KB2,2HO(60*P#@
M9/#9ZULM-$JAFE0*1D$L,8_R1098Q*(C(HD(R$SR1]* ,2Y\&:#=ZE)?363&
M2619I8Q/((99%QAGB#;&88')!Z"KLV@Z9<:];:Y+:*VI6T30Q3DG*H<Y&,X[
MGMW/K5[S8_-\KS$\S&=FX9QZXH$L;2-&'4R*,E0>1^% &1_PBFD#5'U%(KB*
M=YA/(D5W+'$\@Q\[1JP1CP.2.>]:%CIUIIPG%I%Y8N)WN)?F)W2,<L>3W].E
M3K+&[,J2*S(<, <E?K1'+'*"8W5P#@[3G!]* ,K5?"^D:U=K=7UO(TPB,#-'
M<21>9&3G8X1@'7/.&R.3ZU/9:%ING3P36MMY<D%HEE&=[';"IRJ\GMZ]?>I%
MU:Q;6)-)%POVZ.%9VBP>$8L <].JGCK5I98VD:-9$,B\LH89'U% ',:UX*L]
M0TC0]&M88(M,T^]BG:.0LQ$<88A5SGDD@')Z$UU+*&4J1D$8-5-2U6RTBV2X
MOIQ#$\T<*L03EW8(HX]R.>U54UZ!O$=SI#*$,%I#=><7&UA(\BA1[_N_UH )
M/#6D2:!!H;68_L^W5%AC$C Q[,;2KYW C P0<^]02>#]$N-,;3KJWGNK9IEG
M(NKN69BXZ'<S%N/3.*TS>,-46R^S3;3"9?M'R^6"& V=<[N<],8'6IXY8Y5+
M1NK@'!*G/- &&O@K05T^:R^R2LDTRW$DKW,K3&1<;7\TMO!&!@[N*5?!NA+I
M=[IWV-S;WLJS7&ZXD9Y)%VX?>6W;AL4Y!SD9ZTZ;Q((M3U:QCL+BXDTZ&WE*
MPE=TOFEP  Q &-A)R:V3+&LJQ&1!(PR$+#)_"@#&NO".CW;6\DB7:S00B!9X
MKZ:.5HQSM=U<,XSS\Q/)/K2W'A/1[NYAGGAG?R?+VQ&ZE\IO+QL+1[MK$8'+
M GBIM-UV'4;[5+39Y3V%Y]DRSC]Z?*23('T?&/:H-8\2#1[>\FEL+ADMIK:(
M.2H67SG5,KR3\I;G('M0!HZGIEEK.GRV.H0+/;28W(21R#D$$<@@@$$<@BLV
M+P?H<5A>61M9)8[W;]I>>XDEDEV_=#2,Q; [#/%3S^(+2R$S7Z2VD:7<=G')
M* 1,[[0I7:2<9<#)QC![<UJ"1&!*NI ZD'IWH =68/#^E#1I](-FC6$[2-)
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M$00QR 80JXR3D< 9)QQJ:[8WSR>*=UO+)))<Z.0R1DARLD>\CU P<^E>H44
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MQR<GD=*FT[PQI4?PU:6]@:QO+FY9I[HV33N=MR619%P2T7RJ"IPN/3K7JE%
M'.^")Y+CPVC/IMO8!9I51+:!H(Y5#G$JQMRH;K@^O>N$NS)=^,;.:'2;:SNX
M/$ $BPZ7+]H,6XJ99+G.THZD'&,8(&>*]=HH \G;P[''I5[JJ:8W]KKXK\R*
MX\HF58S? ':>H0HS9 X()/>J'B:QLY;3Q5!?Z/<W/B*74?-M)ELW=_L_R;"L
MH& @4$$9ZY&,GGV>B@##\:123>!?$$42-)(^FW*HB#)8F-L #N:XV[BBLO%F
MFW<-HFH7THLH);.ZT]V>%1C][!-C:@4,68=,J>0:].HH Y[QU!?7/@C5H=.2
M9[EH<!(?ONN1O5<=RNX#ZUR6JQ:!<Z) V@:-(FD)J%JVK10:=)$LT #<%-H,
MFT["P /'!STKTZB@#R'4=-BO=-\3MHFGS0Z%=3Z8L,45N\*R2K<+YSQI@$#;
ML!8 9*D]LUJWWA&-]5\4Z3I%DEC!-IEG/:^3%LB%VCS%6&.-P*1YQS@#->DT
M4 >17D6K^)/"VJ>)6L;BWEOKFSA>UDMV=ULH67S5,8(9@7:4E01N7CO27.BP
M7/AG6OL-P+J"\O-.#V]CI<ME$A6X3<R@DY8KC<5Z;1FO7J* /,O&&EZ7HE]9
MRZ9I=K--;VQC@T=]+:2"<-)N/E,J[8Y<CD\]B1CFLW7-*DN_$GB&'5;E+.XN
M;F-K"Y.C2W4RQ!$V&"5&PI5PWR@<').<UZ_10!YGK&G78G\8:K#!)]JTW4[7
M4K4E2/-\JUBWJ#WW+YB<=S72>!8VN-'N-=F1EGUNX:^PPY6(X6%?PC5/Q)K?
MU&PM]5TVYT^[5FMKF-HI55RI*L,$9'(XJ:*)((4BB0)&BA54= !P!0!Y'J^D
MR77B37X=4NDL[JXO4>QN3HTMS.(@J>68)5;"[6#?*!P<D]:G\1>'8[JR^(>I
M-IC2ZE'.CV$QB+2*5MH2&B/8[AU7KC!Z5ZQ10!P(T[3;/XHZM//I<:W-YI\+
M6=P+/=F0"82D2!<*V"H.2"1CK6'HNE6-I<_#Z\U71U;_ (DGV9I)+(R%+@>0
M8PWRDJPP^"<8YZ5ZU10!Y#?6%\--M6FAV::GB349;L3V+W,8!DE\IWB4@LF2
M.>@)4]JD_LRTL['1I+HOJ7AO^UIY[F)-,DB@A+1$1@0G<3$),G/*Y;VKUJB@
M#BOAQ;0VUKKXM+&:RLY-7DDMHI86B_=F*+!"MR%ZX';I@8Q6;<:9!:^.O%#6
MFFQPZQ>Z>CZ7="TZR^7*'(D"X4YVYR1G(ZUZ/10!Y9X>M-.?5O"7]@Z5/9WU
MHC_VO(UF\+!#"0R3,RC>QEVD<DY!/O73>/)ECM=,BFTZTN;>2[Q)<7EFUU%:
MX1B',:X))/R@Y !;K76T4 >0Z/HK7]AX:LK[3WDL4\07S&%K5X8Q#Y<Y3]VV
M2B$D84G'.#FK<NFOHVB:QJ5I:- GA_7WOK6%$VK]F\M/.5!_=*O*<#C->IU4
MU33+76=,N-.OD,EK<+LE0,5W+W&1S@T 8O@:VE3PZ-1N4*7>K3/J$RGJOF'*
M+_P&,(O_  &N?M=(AM4\<:V^@B_U);NX%NDD9+RQ^0GR(2,@,2P.WKGO7H@
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M($_MC2XK*'?GY'7S<EN.G[P=/0UUJ+LC53V % #J*** "BBB@ HHHH ****
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MM':S\/75QJD4D6]#<J6C$>#_  [HIL@]0!5'Q&P:W\8,%5 =$TL[5& /WDW
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MYL)A7QD9R?U /3**\ZU?Q=X@;6-;AT>WFD&E2+%%;)I[S"Z?RUD8-(#\F=X
MQTZG(.*FUG7_ !(+OQ.^GW5G;6^B6L=TL4UL9'F)B,A1CN&T?*1D9//MR =_
M17"6=QJMY\2UF74Q%82:-!=&U,60%+L",[L9SD[L=..U0:9XJU.\\16%E#J:
MWEKJ<%P8KG^RY((XW105:-F/[Q>O?G@@\T >@,ZIC<P7)P,G&3Z4ZO+-#N=1
MC\$>';C4KF#4C<:S#'']HM\M%^_=2P8L<MZ'M5^Y\4Z^-%OO%,5Q:#3K2_>W
M&G&W)>2))_)8F3=D.2"P&,=!SUH ]$I'=8T+NP50,DDX KSO5?$OB.W3Q-J=
MO=626.AWJQ+;-;EGG3RXG8%]WR\.<$#KUKI/'=S]C\!ZY<^1!/Y5G(_E3IOC
M; Z,O<4 =#17 ZQK?B,:AXD33+NQMK;1;.*Z1)+8R-*QC9]A.X;5^7J.>1Z<
M]KI]U]NTRUO-NSSX4EVYSC< <?K0!9HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *J'3;4ZNFJF,_;$@:V#[C_JRP8C'3JHYJW3'ECC^^ZK_O''M0!CIX
M3TN'5'OX#>0/)/\ :)(8;R5(7ESDN8PVTDGD\8/?-8^O?#^QO@9].#0W3:A!
M>LDES)Y =9D>1Q'DJ'9589QU/;)-=AYL?F^5YB^9C.S/./7%(9X1+Y1E02?W
M2PS^5 &!J7@70-6O+JYO+:=C=E6GB6ZD2*1U "N4#!2P '..P]*L7OA32[[4
MI;]C>07$P59S:7DL F"C WA& ; XSUQQTK8$L;2-&LB&11EE!Y'U% EC+%1(
MA(&2 PX'K0!E2>&--FUA-3F^U2RQR^<D4EU(T*28QO$9;:#C/;WZ\U"/!VBB
MTU"T-O,UK?R^=+ US(45]Q<M&-W[L[CNRN.<'L*LVVN077B&[TF-,FWM(;KS
M@P*L)&D7 ^GEG\ZTXY$E0/&ZNAZ,IR#0!B'PEI<FEW.G7)O;N"Y*F0W5[+*X
M*G*E69B4(/(*XYYJ;1_#.F:'=7-W9I.;JZ1$N)Y[AY7E"%MI8N221N(^F!T
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MJ<^FW&N6_B=K=4MTLDGV3R*"8@1CRW7+8)/ YSBMWQA#JES\.]1B@C=M1>T
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M_+0@$GR2%.!R>.33M3L[*ZA\3S^%=->#2W\-SP3+#9M DUP<^6%0J-SA=X)
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MD18^7N!)(?9MR.QSTH P-$\?+=^&'UC4]-N[0BX:WC18PQN',K1HD8#$EOE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445&+B!KEK
M831F=%#M$&&Y5)(!(ZX.#S[&@"2BJPU"R-I)=B\MS;1;O,F\U=B;3ALMG P0
M<^F*L@@@$'(/>@ HHHH **** "BBB@ HHIKR+'&TCL%5068GL!0 ZBH;2Z@O
MK."\M95EMYXUEBD7HRL,@CZ@U-0 445#!=VUT9A;W$4QAD,4HC<-L<8)4XZ'
MD<>] $U%5[B^MK6>VAGF6.2ZD,4"GJ[!2Q _X"K'\*L4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*Y4#IP3^=:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&UO]4T]+U(&E&%W!/DR<98EQ@8YP?2MP:II[:@=/%];&] W&V$R^8!Z[<YH
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MS7)5C$0#P1PW'->CT4 >9Z5'K&@S>%=0U;3+V?R=*N;&5+.W\UX29(FB#*G
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M.V#AX7$1E!+,2&!"MQ@8R.6ZUMZ;X-L=.NH;AKO4+Q[:%H+47<_F"W1@ 0G
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M!=/4M"5!D*[@PW8RG^T,\U9TG5[?6;:>>V614AN9K5A( #OB<HQ&">,J<>U
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MA&ZXVN"K?,0!P23U-9-SJ%Q?MX;;6[ZRCL;CP[;SI)J5W);Q27+?ZQMRD R
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M XQU&>M>L[%#E]HW$8)QS1@>@H \4O9=,N((Y+Z]F/BH>)8EGMS<.66,7JA
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M6HRM#-;QO,P:16B^=E4GYAN![<>U4_&IO;?Q,^D6]Q<1IXIMHK6-T8_N9(Y
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M"OMZ9XX!JQ;W&E6'A33[>:2QN8[_ %.X9GFU25+6T.&98I9.K%4VJ%8#)Y[
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MW[,]]FS=COC/-/\ $,#W?BGQ!#J>JV&FWIFC_LN>ZBE,T<7EIM:W*L!]_?D
M$DYSQB@#V&L9/$<$EYJ%M':7DCV-Y%9R>5'O^:1$<-P?N@.,D],&L;X@&-;?
M1!J3-_8AU!1J9&0GE^6^W?C^#S-F<\=,UR%FEK'!JQT=9EL&\4Z:8"=_,?\
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MU 'K-9^BZQ!KFGF\MXY$C$\T&) ,YCD:,G@]"5)'M7FODZ?;-X;M_$VHK?\
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MVWSL^0;K<F/,[9V;MN[CKCF@#I==UU=$2S5;.>\NKVX^SV]O 5#.VUG/+$
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M4\AQLV;?*SQG ).[)/4XXKK** .7T70;_0I])TRSN6&C6-M*9V94S<2N^54
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MQXZYS\ISG- 'IM06M[:WOG?9;B.;R96AE\M@=CKU4^A'I7F5OK&L+I,&O?\
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M)XGF@%LENLS1LFS_ %F\*,YZEO8XJQ8:_J\VKVOA=KN1]2LM1G>]EP-TEG&
M\9(QQO\ -A7/LU 'HM(64,%+ ,>@SUKS7P?J/BK6/[$UES=O;WK,UZLTT'V<
M(5; B1?G5E8*.>2 V>:T_$^GO=?$;PJRZE>6P:&[ 6%D &T(>,J>N<'V QB@
M#K[/4+6_^T?99A)]GF:"7 (VR+C*\_459KR?.I:9:>)-=L]7N8OLWB+:MFJI
MY,BM)$CA\C<<ACW&,#'?-[Q'X@O;?5I;W2[S5GCM-5MK*;<T"VBEGC5XMA_>
M,=KYW8.">#@< 'I(96) 8$J<$ ]*6N$\+Z=+%XQ\:2_VK>$K>(NR0H4&ZVB8
M,1M'*]!SC YSUKL-,61-+M5FOA?2")=UT%51,<??PO SUXXH MT444 %%%%
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MM8V\)M8VB@\N,+Y:,065<= 2H)^E0W/AW1;S3ET^YTNTELUE,RPO$"H<DL6
M[$EF.?<^M:=% %34-+L-5LS::A:0W-OD-Y<J!@".A'H1ZU#;:!H]G D-MIEI
M#%',+A$CA50LH&T. /XL #-:-% %&XT;3+J*\BN+"VE2]P;I7C!$V  -V>N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!K%Z][K%A)=KJ=M%%O2.1=S"-%7C;U)'.*L>(?#U_<Q^.TL]/9A>VMJ;95
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M&5?E'S,O3C)H ] NO$6B65M;7-UK%A!!= -;R2W**LP(R"I)^88(Z>M:0(8
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M^:VA6]@6(3S!T*1LN>G;G /...: .UM/$6B:A;W-Q9ZQ87$-J"UQ)#<HZQ
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M:GT+PH]O9_#I9M'5&T^"0W8:(?N9#!U;W+_K0!W$WB'1;;3(M3GU>PCL)?\
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MY("R;2^<_>)*@Y/.<^M3ZSHMGKMFMM>+)B.19HI(I"DD4B]'5AR".?S-:%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN+^5(II,X;R57[\I;)_O#(^@W_"%Q/>>(M"NKF1I)YO"<#R2,<EF+J23[DT
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M0+AY&V>4>9P2=K^;MQG!Y(Z5O?"_3(+?P5INHEIY;V]M4:XFFF9V;&=HY.
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M9)X?/'G<JQZMPF<<' SSFM#5+C3?*\,1V5[IP\,R6TY:2YNG^RM<_)A7<'J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZB1KB>$O*U76H)(=<DM9EN&B\Z*189B02%*DKC (R,,>IY !ZC&ZRQK(ARK
M,#C'!IU>90ZGXLU;5-1NM/%X39ZNUJD?G0+;"&-PK!U/SEF7+9ZY88XK=\-/
MJ%]K6NZA?:S<&ULM1FMH;3"+$J!5.6.,DC/J,8^M '844S>'@\R-T*LNY7SE
M>G!^E>73:YK6C>&M8@U*_P!0C\0V]K#<2-*T3P,IE"M+"57A3R-K8(&..Y /
M3;Z]M]-L+B^NY1%;6\;2RR$$A449)XYZ"I4=9$5T.58 @^HKSSQQJDTK^+],
M6Y#6T7A:28P@@[9&\T9/?)4"J\VKZIX9DMWMM7FUE+G0;J_,,H0JCPJA1DV
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MA001C!R3G.:@AUC6AX4T?6[N]OO[)BM)9+Z33S$LT3B0XD967YD"@\+SUX-
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M1NVUBH*%ATR.X!YYR >IT5YQK>LZMX;OK_04U&>YN=2MH%T::X"EUF+"&3.
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MR3#?6R?9&OA-<VYCC, _Y:9/0?7FK6D^*K#5[U;2.*\MYI(3<0+=6[1>=$"
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MS:TU"UANK=B"8Y4##(.0>>X/>J]MX>T:S@6"VTNTAB69;@)'$ !*H 5\?W@
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MD$?+]WY#D]>G%6[SP_?6EEH-SF.3^QM*N(9DB!=Y',**/+4C#<H>#CM7:44
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M$C' (R(\L1T+DC->D44 <WX7T1]-GN[F?1[*PFE5$S;WLERSJNX_,SJN ">
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M9PZIYH (<JWW3P<'J5%>OT4 >9Z=IFJZSHFBS:?8PQ:9;13VW]GOJ$\$;L'
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M#Q'.!D>8^WD#('3BO1*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*D8M$>%RR;#NCX!(7H<@BGZ3X/TZPTBZT^]B@U".[N6NITFMT$1D( ^6/&%
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M# ^Z,GCIR: //-(U>]\32>'+34]6N;**XT!+]VM9?(:YG) ;YASA1SM&/O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYHC^Z'QSCVSFIZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLA.<89B,C/(Z<Y !V-%<<WCU'TK1[F#3\7.IS2VZPW-PL*121%@ZM)@C.Y2
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M'[^U6!/(]!FJ%K>WVL?%.13%.VFVNGP3V[1WS)&!(9?WC1C <MM"X;.,9[T
M=Y17*2Z[K*_$<:+'81OIOV%9S)YP##+X+XQGCIM]LUB^$/%NH0Z5I,6I:?<R
M6MY?36::C)<!F:3S)"N4Z[?EV@YZCIC!H ]%HKBH_B-9R:G'&MO&;&6__L])
M_M:>:9-_EAO)Z["_&<Y[XQS6CXEOKNVUOPQ;6]P\4=Y?R0SA<?,OV>5@.?\
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MTTDMPL3&*7)#(A&7  R>F.G)KJ* "BBB@ HHHH **** "BBB@ HHHH ****
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M'UI+:[M-+ATR9Y[3S4GCC'RMM#J58$L>I'S8(-6])\&P:/=Z/-#=R.-.M;F
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M%I^OW.IPRXCELK>S6#;PBQ&0@YSSGS,?A[UL44 8=WH5S)XKM=<M+](2EO\
M9;B%X-XECW[QM.X;6SGG!Z]*IV_@U8-%T?3OMQ8:;J'VX/Y7^L^=VVXSQ]_&
M>>E=110!R>F>#[C1[\_8[ZS_ +-^U/<B&73P\Z;W+LBR[Q\NXG&5) XS6OJN
MBC4]2T:\,YC_ +-NFN NW/F9B>/&<\??SGGI6K10!E6^BB#Q1?:WYY8W=K#;
M^5M^[Y;2'.<\Y\SICM577?#UQJ6IZ?JNGZ@EG?V22Q*9K?SXGCDV[E9-RG^!
M2""/QK?HH X_PGX&;PGJ-S<P:GY\5VF)X&MPJHP9F418/[M!O;Y/FZYR*V]8
MT4:M=:1,9S%_9UZ+L#;GS,1NFWKQ]_.>>E:M% '+ZIX3GN-?FUC3KRT@FN84
MAN([RQ%RC;"VUE^=2K88CJ0>..*;J7@B#5FU$W5XVV]TZWLB(X@NQHG=UD';
M[SCY<8^7WKJJ* ."\1>'-8_X0;7K9I;2]N9[0Q0QV&G?9V8Y[_.VXGVP/:KL
MG@N\OVU";5M;^UW%QIDNF6\B6HC$,<GWF8!CN<D+DC:/EX S7844 <[=>$X+
MVYT][BX+0VNFSZ>\03'FK*(P3G/'$?3GK[55TSPA?076DMJ>M"_MM'!^Q1+:
MB)MVPQAI&W'>0I(X"CG.*ZRB@#E[/P:MII'AVP^W%AHUU]H#^5CSODD7&,_+
M_K,]^E4O#WAQ[;X@^(M8>.:.T+A+-)!A=\BHT[I[,RISZAJ[6B@#%UG3M;O9
M<Z9K<-E"\7ER1360G&>?F4[EP<''.X<#CKG#B^'RZ8]F^B7MO"T%C%8R+?V8
MNED2,DJV R%7^9N0<<].*[:B@#&L]!-MKZ:L]R'<:='8M&L00':Y;>,'C.>G
M:J6F^#H=.\87^OK=O(ER&,-J4PMN[[/-8'/)<QH?;GUKIJ* .+M/ UWI4&DO
MI.LK;WUA:/9O--:>:DT3,'P4W@@@C((;USFIKCP=>?VK)J5IJ=K]IN8(HKQK
MW3UG$K1@@2* R;&(/(Y' XKKJ* .6UCPI=:S?6+3ZA;"SM)H9T46(\]&C(.$
MEW?(&*\C:3@D9K>L;>[MQ<?;+W[47G=XCY0C\J,GY8^.N/[QY-6Z* "BBB@
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M%2-P)&?E)'( /'K0!LT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;6DMJ=,MS!+=_;7CV\-/G/F'WR!6O10!BR>$/#TNOKKKZ/:-JBD,+DQ_-D#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>foraresidentagreement009.jpg
<TEXT>
begin 644 foraresidentagreement009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9>C<J0R'USD54U#Q%K4FJZO::)8V4J:0B&X-U*RF9V3S-B;0<?*1\Q[MTXH
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MKJMJ^DI'-IRWZVMW<,)Y05W;551QQ@;CD9.,#%6KSQR-/.IM<VH$<6EQZE9
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M("%)W(VU@"1N7!Q^%.N_!.D74N@N%E@31,"UCB;"E1M(5\@D@&-&^JBNCHH
MY2'X?Z3!I&O:;'+="'6GD:=MZ[H@V3LCXP%!+$ YZFK=UX6\S5;G4;#6-0TR
M6[5!=+;>4RS%1M5OWB-M;&!D8X ]*Z"B@#EM6\#VNJW6HRC5-2M(M3B$5]!;
M2(%N,+L!)*EE.W .TC( !KG-7\*:Q#KU]<Z=:WSL;:"+3[BUNH46-HT*[IED
MYSD]5!R .,UZ910!S/\ PBMP]R=036[VPU"Y@B2_:R$12X=%QO D1MI[9&.,
M>E;.J:9;ZOHUWI5WO:WNH&@D(.&VL,$@^O-7:* ,2S\-I;7NFWMQJ-Y>W5A!
M-;I+/Y8+K(4)W!5 R/+4#&.^<U1_X0>UB2Q-EJ5_9W%E-=2Q7$1C9L7#EY%(
M9"N,GCC(P.>N>IHH Y9? UI!IFEV=IJ6H6TNF3RSV]TK(TN9"^\-N4J01(1T
MSTKI+JVBO+2:UG0/#,C1R*>ZD8(_(U+10!QUM\-M&MK70X//O9/[(G>>-Y)%
M+3LSB0B0[?F&Y4/&/N"M&;PM_P 36[OK#6-1T[[:ZR74-MY125PH7=\Z,5)5
M0"5(S@=^:Z"B@#/UO2(-=TB;3;EY$AF*EFC(##:P88R#W J*;0+6?5+_ %!I
M)A+?6264B@C:$4N01QU_>-^0XK5HH Y"?X?63P>1!JFI6L,FG1:;<K"T?[^&
M,,%W%D)4X9LE<9S3->\(_P!IZQX31(6:STN0M/,9 "415*1D?Q;I$C;I@;/<
M5V5% &?K>D0:]HMUI5T\B07*;':,@,!GMD$57UCP^FJW=I?17UU87]H'6*YM
MMA;8^-R,KJRLIVJ>1U Q6Q10!SMYX4^UG3[C^VM2BU&R61%OT\KS9$D(+JP*
M;".%Q\HQM&*R-&\$2KH$-K=75Y97MEJMW=V=W%*DDH5Y),%BP8-N1^01W]:[
MFB@#F;/P186D,4?VN^F:/4_[4,DTBLSS;=IR=OW3UP,>V!Q5G_A$].;P_?Z+
M(9I+6]GFN)"7PZO)(9"5( QACD>F!UK=HH S-*TNZT\R&ZUJ^U(L J_:5B4(
M!Z>6BY)[DYK&UOPRVK^/= U0P$6VG13/-+O $CY7RD*]3@[GST!'O7644 <O
MJ'@>UOKG4"FIZC:V>IL&O[*!T$=P=H4DDJ67<H ;:PR!1JO@BTU.[NI8]1O[
M&*]M5M;N"T=%2:-00N<J2N Q'RD9'%=110!3CTRW31ETH[GMA;BV.X\E-NWD
MCOBL%/!$<>G:; FMZF+K2R197O[KS8HRH0QD>7M9< ?>4G(SFNJHH S-$T2W
MT*TEAAEFGEGF:XN+B=@9)I&QEFP .@ P    ,5EW/@FTN8];MVU"^6SU@EYK
M93'M20A070E-P)V#@DCD\5T]% &+J_AQ-4U*TU&+4+RPO+:*2%9;;82T;E2R
MD.K#JBG(P1BH=+\(6&DOH[6\URW]E6\UO!YC@[EE92Q;CD_(,=._6N@HH YI
M_!ZII9TZSUG4;.!Y;B241>4WFB9R[ [T(X+$ C! ]:L6WA+2[6;<BR-#_9D>
ME>0[93R$W8'KG#$$YK=HH Y_3O"[Z?:FS;7=3N;%8#;Q6T_E8C0C ^8(&8@<
M L3[YK5TO3XM)TBRTV!G:&T@2!&<@L510H)QWP*MT4 <W-X+L;B36DFN[MK+
M5\O<6>Y0BRD(OF(=N\-A%_BQGG%3Z5X96PU/^T[O4[[4[U8#;Q2W9C'E1D@D
M*$51DD+DD$G YK=HH YW6?"$&KZE/>C4KZS>YM!97*VQ3$T0+$ [E)4_.W*D
M'FI(?"6GQ,Y+SNKZ7'I3*S#!A3=@\#[QWG)Z>U;U% '+KX+5+'38EUO4A>:9
MN6TOOW7FI&RA3&1Y>QEPJ]5)R <U?3P\ANM*N[J_O+NYTYI6268H#(9%*G<%
M4#@'C %;-% &%=^%+&\M_$,,DUP%UU=MR5890>4(ODXX^50><\UGZMX!L]5?
M4@=4U&VM]3B2.\@@:,++L7:IRR%AP!P" <<CKGK:* ,63PY$WB*;6(KZZA:X
MMU@N;=-ACF"A]A.5+ C>WW2.V<UGW?@#2+W1]!TR:2Z,.C>6(6#@-*B@ I)Q
M@JVU<@8S@=*ZJB@# O?#'GZO-J=CJ]_IEQ<QI'<_9?*99@N=I(D1L, 2,C'%
M;J+LC5=S-M &YNI]S3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MCM8-QHGCR#7VL+N[T^?3C92M9PM,\#K)O4E%RQ4@D9 ."!FNQHH \MUW2K[Q
M%IGC'6%TBZ1;RS@M;&VF@(FE\HN3)Y?5<F0@ \X'09KI&T6-/B/'=Q::BVR:
M.R+*L("K)YHP <8#8S^%==10!Y/H=C-H\7ABYUS0[VZM(] 6T$2633M;S[@6
M#1@$KN7 SC^'!(I=9T>1]>U;[9;:C;Z;J-A;PVJ6VDB[V1A"&A^56\HAB3V'
M.<\5ZO10!@ZM;V<7A$6>I6%WJMGY,<,T2P^;*XX&XJ.201D[>0>17G6IQW:>
M'+F&>VU6\T :SIZV%OJ2'[1(GF+YD>),,5S@+OYZCI7L=5KVPM=1CBCNX1*L
M4R3H"3PZ,&5N/0@&@#SB2.[#^)M7TCP](MC<+8Q1VUUI[#>R.?-F%N0&;8K+
M@8!8IQTK/_LG4I[37IQI][=6,FIV%T\+6'V=KR"/;YNV$XS]W[I )V].:]@H
MH \U\00#43H^I:7I5]9:;;:A))=*NE9D9C#M2;R"NY@#\N2NX=0, &M31-.T
MZQT6#S;'4=0CGU<7$0FT_P HV\K'B3R\*8T!R<X_B)[UVU% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[A(!I;ZF'=0,HC%9$QG[ZD $=.1S5/5/&T%[X5:73EN8[F]T6ZOXF& UL(T
M^?GA@[ <=P?2@#MJ*Y#0?&0FCL[75+"]L6DTXWD=S=;-LZ(%\QOE8E2-P.&
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M_P N3A<D;3G'&0#MJ*Y?5?&UMIUU>106%U?1V$*SWLL+1@0HP+# 9@7;:-V
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M^&_[0M[8D*&8N"&() X4\\YP"!0!WU%<A:>-)_["T::[TB<:IJ: PVB21#S
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M1$8G/83/^GI5+3/ $]EX6BTN?4Q<7@U&VO9KMHL>8(7CVKC/]R)5SZ\UW-%
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M!(UK;1P%P,;MJA<X_"KM% '%ZM\/XM7\2ZAJ$UV!97MD\+VNSI.R&+S@<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+>_^QHR*_P K&-6"/D??YSQQR.] '0T5GZ1KFG:[!+-ITYE6&0Q2J\;1O&X
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M[)'+Y#EHW5UDR!Y9C(W[\D?+C/(XJYI6L6&M0236$QD$3F.17C:-XW !VLC
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M"[O)Y<TBJ%1068[4R<#L30!U5%8K^+-%73H+];J26"=F2,06\DKEE.&&Q5+
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M456T_4+35;&*]L9UGMI1E)%Z'G!^A!!!!Z$59H **** "BBB@ HHHH ****
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M^96Z_6J/C/0/%&M-J]E%%<7%K/%$+'R[U888P -XD7[SL6!QG(P1TP:])HH
MYJTL=1L?'VIWGV/S=/U&W@'VE95'DM$) 0RGDYW+@C-4/'?AK4M:N-/FTH)N
MD633[XE]I^R3;?,(]2-@P/<UVE% 'FEMX!U.2+Q)I\[106;65QI^CNK9V1SN
M\C9 Z $QICT2M?PMHEQ!JEO=ZAI%_;W-M:M"L]SJIN4&XIN6-=Q^4[0<D#H.
M*[2B@#B/%GA:^U?Q-I]Q:1QOI]U&EMJP=@,Q1RK,F!_%G$B$>CUB6_@?7!X1
M\16-RD<EX]LFF::/-!W6L1)C)/8G><@^@KU*B@#A->\,:I?W'B9[>%&%^^G&
M#,@&X0R!GSZ8 _&I/B5+*EIH*6TRP7+:JABE:58@I$4ASO965?Q5L],<Y';U
M'/;PW4+0W$,<T3=4D4,I_ T >;Z':R:O!916<+//IGB+[3J%PUTDRS,87+.K
MJJJ>9%&T*,8QCBM#2O"&HV_BVZ^T;%T.U>YGTTHXW"2YVE_E[;#YN/:3VKN(
M8(K:%88(DBB7A410H'T J2@#SKPCX3N],?1K34]+O7?201'>'5"]OD(R!TBW
M9&02,%0!D^E3?$NSNR^D7.E2K%J%W*^D$]"8KA3N(]T*!_\ @)KOZ8\4<CH[
MQHS1G*,R@E3C&1Z<$B@#CWTG4O#GB1K_ $;2%U"RETV"Q2%;A(FMS"7V_>P-
MA#\XY!7H:SM-\-:YX8;P]<VME%J4MK87-I<PQSB((TLB2@J6ZH"I7UQ@X/2O
M1** .;\):7J>D>"HK"Y6&+4E-PW#;XU9Y793GN/F%8'AS0O$7_"4:3J>KP70
M:VL)X+J:YOEE\R9S$<QHO"(=AZ8/J!@9]#HH YKP+9:CI/A6TTG4K+[/+8H(
M XE5UF _C7'0'T.#7,2^#M8BBTV[$$TLEGJ6HRO;6M[Y$CQ7$K,K*X(&0-O!
M(X8UZ910!Y^^B:S9V-@FEV%_!:2W$\^H6D>I*;F1VQL8S,>F02P5L\CKS5&/
MPMK=EX1TNUCTRX_MNU^UF"\M-056MVDE9@&+8$B,-I.0>GW<UZ=10!REG8:S
M9>-1?SVJ74-YIEO;7%S%(JB*6)I68[3R5;S!C'XU=OM,NI_&^C:G&@-K:V=W
M%*VX9#2&$KQW^XWY5O44 >;V/AO7QHNC>%Y].CCMM-OXKA]3%PI66.*7S%*I
M]X.V #D #)Y-%QH'B,0W&CQ:9$]JWB!=3%Z;E0#";I9B G7>.0<X&!P2<"O2
M** ,'PWI5SIM[X@EN(U47NIM<1$$$M'Y4:@GTY5N*Q?%/A2]U?Q78S6\4;Z7
M>1QPZLKL!E(91+'Q_%D[U/LU=Q10!Y;;> M<F\(ZS9WKQ_V@?LUK8GSL;[:U
M8-'EARI<[\]QD5;N_!]UK.AZRBZ=?6.HW$$,<<NH:H;@R".3S F0S;5R,9Z_
M,>*]'HH \VO?"M[J>@ZX$T>_M]2N;);:-[_5/M!<;]VT?,0H!YR<'GI5N/PW
M>Z?H5YH,NE/J>GPW2W%C-!=+!<89B^2Q(/FH_P#%D;@<DYR#WU% &-X6@U>W
MT&&/6Y6DO \F"[*SB/>?+#LH 9@NT$@8)_.L'Q5/>VWC_P +S6-@+Z5;6^S#
MYHC8K^XR5+<9Z<$CC/-=O3#%&TJ2M&ID0$*Y'*@XS@^^!^5 '!Z3X5U6&]T.
M]NX(5==7O=2NHED#"W$R2!5!_B(++DCODT[6O"VK7>HZU?6L43LU_87UK%)(
M%6?R I9">=N<'!(ZXKO:* /.=;\.:YXEBU^_ETU;*:[TZ*PM[22='9]LA=F<
MJ=H^]@#)Z'IFO0ID+6\B*!DH0!^%244 <-I7AG4K73O 4,L*(^D1%;S:X^0F
MU>/CU^8CI]:HZ;X<U\:1X>\-W.G10V^CWD,[ZB+A669(6++L0?,&;C.0 ,MR
M:]'HH \\NO#VMRZ%XFT9;!2+O4&O+:X\]-LBO*C[<9R" #G/''&:U=/M=;T/
MQ%JZ0:4EY9:G?K=K>?:53R5*(CJZGYB1L)& <Y XKKJ* /-]#\'W=A<VUA?Z
M;?W4-KJ#745VNJD6_P#K6D1S#NR&&>1MP3GGFNB\1Z?J7]OZ)KFG68OC8">*
M6U\U8V990OS*6^7(*#@D<,:Z:B@#@(O"^KR6Z74UO%%<7/B./59K=90P@B 5
M<;NC-A 3CN3C-=%XKL#J&E1Q#3)[YDG611;70@FA8 XD1R0-P/&,C@GKT.[1
M0!P,&F^*K*X\/ZO<VJZI?6UK=6MU%]H1'"R.C1L6P%8@1@,1W.0#572_#OB'
M1(= U$Z=%=W=D^H)<V<5PH^6XG\Q7C9L XVCK@X;U&*](HH YFQT[4I?&)UJ
M]M(X$ETF.V9%E$FR02NQ7.!G@CG&*BT70[^S^%MOH4\:B_32S;,@<$>9Y97&
M>G7O75T4 <C8^'[V#5O"5P\*"/3=*FM;@AA\DC+  !Z_<?D?UK(TWPYKFA?V
M'J$>GK>2V)U"&:T6=%8)//YB.A8[<@* 02.&]J]%HH \]D\+:TGA^?4(+>!=
M>&LG6+>U\T;$)(5HB_3YH]P)Z9:H)O!6HZ?#X<N(8[F\ELK6>*^CM+W[-*\L
MS)(\BME0?G5L@D<$>E>DT4 <[H-I<Z/9Z?8VVCO!;323RW1FO?->!F8N"2<[
MRS$YP>,]ZZ*BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHKCOB.+^'P[]OL]5NK,6\T&8[<A/-+31K\S=<8)X!&<\YZ4 =C17'ZM'
M)KGCQ=#FO+VWL+?3/M92TN7@:21Y"@)9"&PH0\9QEN<U;\"WUWJ'A&!KVX>>
MXAFN+5IV^]((IGC#'W(49]Z .EHKA-.M9K#XCPV.F:KJ=Y;Q64CZL+N[:=%=
MBODXW'".?G.%P-N..E:WBJZN+;5O"J03R1)/JWERJC$"1?L\QVMZC(!QZ@4
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MC]RC!2"_.>?; /:;1]7\0S^+_$UK<QV3V%E(@A7SR&3,091]SOG))/!)QD4
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M_.,W3H(MS8]5(S4NJ>)1<W;Q"VD-K:ZW9V*317+1^9(VUF)V]57> 5/#8(-
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MI)%-9ZM(RF<S!?LX$#3?,.><* 02,9K>74+)K'[<MW;FTV[O/$@\O'KNSC%
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M!,D2S*70#J2,Y%9=OXNT_4M+DO=)>.]\NY%N\8G1"O[WRRQW'&,@D?WATZT
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M#JNG7,'GP7]K+#O\OS$F5EW?W<@]?:EBU.PFLVO(KZVDM4SNG252@QURV<4
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M$$,P((Y!JX=3L!=);&^MOM#DJD7FKO8CJ ,Y..]9OB?Q/:>&](O;IG@FNK>
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M7&.!C;U]JDU/2;T+J\KZ9<SV*>)X;N:W2$L;BV6"($JG\8#@' SG8?2O3J*
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M]"P'7BO48XTBC6.-%1$ 5548  Z "G44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7$>,O&5SH.I/96UQI=JT>GO>J^H%C]H8,0(HP&7YN/<\C -=O
M7"^)?#VJ7?BQM4M[:YGA:RCMXOL>HFU='5W;+_WA\PQUQ\W'- $]OK_B6[U^
MPTF.VTZ)FTV"_O))E<%-SLK1JN>N!P2>"#G-9^E_$"_U/4+.6&UCDL+N]:V$
M$=I/YL2;F42M+CRR,@$J!P#U.*Z;0M"GLVM=1U2Z-SK(T^*SN95.$?:2Q(&!
MSN8\_H*;8>%8=+O/,LM2U&&S\YIA8+*OD!F)9L?+N )).W=CGI0!B1>,[UO%
M=GI8N=*NH;V>>W3[+'*3 Z([C=(3M?[A! P0?I6;I7BO7-)\$S:EJDUM>S2Z
MI)96N$DRKFY>,E\%B44#@*,X7')YKI+#P+I^GWMA/'>Z@\6GS236=M),#%"7
M5U8 !<D?.<;B2.QQD%X\$:;]BOK(W-\;6ZN?M<<7F@?99?,,F^(@94[SNY)_
M+B@#"?QSK$&D:E*+*"ZN;6YLXH)OL\UM#<">4(1B3)5EYSR1RI]J[C3A?BPC
M&IM;-><^8;966/J<8#$GICOUK+;PM%<:>UG?ZIJ-\K7$-QYEQ(FY6B=74 *H
M &5&>,GUK3>Q#ZK%?_:;D&.%HO($N(FR0=Q7NPQ@'T)H MT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVL 1D>N#0!;HJM87T&I64=W;^9Y4F=OF1M&W!(Y5@".G<59H **** "BBB@
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M\L83"CY1[>E/H \7L+'3_P#A7]C9VM[.MVWB&"*Z5;QWD@/VUE7 9CY;8YR
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M6*WU.2_2.1C(&(=P""0JY49' />M&^N+)7URWT'5Y]1T^;PS=3WI>\:X59L
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MHY;:">2.26".1XSE&= 2I]CVJ6@ HHHH **** "BBB@ HHHH **** "BBB@
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M'/;C\'2>!;]I?LZ:XB:4NKKJR6_V3,F_SA,R&3=RN[=C"@C(R2!@ZG_"*_\
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M$NM-$LR,Q!<))O& 3DC*G&: -/Q%XB?0GTV&'3IK^YU"X-O#%$ZK\P1GR2>
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MT4LUMOC=+B1G>-D#@\97D,.5SWQ0_@FX.E%4U5/[6;5%U5[M[;,;3+@!?+#
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MS6MX>T*]O],L8KF);&UTK5A<V7^A>0]Q$(R/FCS\A+R/R>3C)'- %K4O'O\
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M4%CA%R68GIU-3-\1+:.QN&DL@+V"\BLVB%TABW2#<C>=T"$9Y(SD8QTJ74_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %$:5;#77U@;_ +4ULMJ>?EV!BPX]<L:O444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Q/Q'\7:UX0TN.]TS2H+B .@GN+B3"IN<*%"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW&G7$Z2Z=*[K&8]H*EF&&!W\,,=#Q72-X5T^0:6)&G9=.M)+2)2PPZ.BHV[
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M?,*28W*1Y>S'RKSMR,=: ,6W\;ZOJUEX<_LK3[+[5JZW.\SRMY<)A8 L,#+
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MBNPA0$V;2N05VX.3GFEA\&6$<,8ENKRXN1J":C+=2NOF3S( %W84 *  ,*
M!Q0!S>O^)_$:>&]>@3[%;:KI5W;QO-"S%'CDV,"H/(/S8(/;-7]3UNZTC5KZ
MXN;6"34+/P]->,T4LGEL4<D(%)QC@?-C/OBMF_\ ".GZC'K:32W*_P!K^49B
MC@&,QJ I3C@C:#SGFFW'A"VO5N#>W][<S7&F2:9+,YC#-&Y)+850 W/88]J
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M1WT%S*TA/*F+R\ ?7>?RK ;QGJD]IIWV*PM7NK[6+K35661E15B,V') )Z1
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MP.W ." 0!D&NE@A6WMXX4)*QH$&>N ,4 24444 %%%% !1110 4444 %%%%
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M,T^:VN[5;%;H75O.)%+&1D*\<<;<]>]:5_K6E:7+%%J&IV=I)-Q&MQ.L9?Z
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MC@\CTI7UO28]373'U.R6_;[MJTZB4_1,Y_2N MO"\UKHT @TCRKA?%ANODB
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M\0A\\XW*?I567Q?KHTB;Q/&NG_V+%?-;?8S$_GM$L_DF3S-V V02%V].,YH
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MEU)K%OIZ-87/FI.-R2/Y4N%R-@=2> "#D\5M0^-Y4G>UO])^S74.J0:=.J7
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M6P-RG&0<#((-8^L>-+BQ;5Y=/T<WUGHRDW\YN1%M(0.RQC!WLJD$Y*CG&<T
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M_3I_M*QX?:&V1@@[R RD\CK@9/% '8T5QI\2:U_PG$EB;*WCTFTTZ.YO'>X
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M&)&0-\[?+P,A3@=A@<'I0!UE%<[X#FOKGP-I%UJ5Q+<7=S +AY)<;B')=0<
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M8FZU:#4I!Y?40J@2+KT!C4Y^O%/OO&MA:7-U#!9:EJ'V/B[>RMO,2 XR58Y
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M=S@$\GCV'.>VHH XJY\ -J8U2;5=4$M[?6J6OGVUHL(4(^]69<MO;<!U.,#
M S71Z/9:A90NE_?P73$C9Y%J(%4?3<V2?K6E10!B>*-%OM?T>?3;35%L(KF*
M2&=OL_FLR,,<'<-IP3SSUJK?^'=5O?"JZ(FN10%H'MYITLA\T; J J[_ )2
M>N3TKI:* *&BV$^F:1;6-Q<I<O @C$B1>6-HX4;<G&!@=:QM1\*7D^L:A?:=
MK;V"ZE#'#=H+=9&P@8!HV)^1L,1R&]<5U%% ''^&]),7B6:ZBT^>RTS3].BT
MNQ2<89PK,SL!G.WB, GK@FMOQ)HO_"0^'[K2_M)MC-L(E";]I5PPRO&1\N"/
M0FM6B@##AT&<:PVK3W_F7ATY;(,L.U5.XLS@9/4E>.VT<FLJ/P*]C'HC:5J2
M07.F6'V#?<6HF25#M)8KN&UMR9R#W/6NQHH C@22.WC267S9%0!Y-H7><<G
MZ9]*YVR\-:GI_B'4-1@UM?LU_=BYGMVLP6.$5 H?=P,(.WK7344 <;#X&N+"
M+1GTS63;WNG13PM/);"19Q,P=R4W#!W*"#G\ZM3^%;Y=;;5;'65BN)[:*WN6
MN+-9BYCW8=<%0C'><\$>U=110!@7?AG[3<:_<"]9)]6LTLU?R\_9U57 (YYY
MD9NU1:CX5>9-$?3-0^PW.CJ4MW> 2HR&/859<CL!@@\8KI** .5N/"FH-K$6
MKVNM(M]]C2TN)+BR642!69@R@%=C9=O48QQQ74J"J*&;<0,%CWI:* "BBB@
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M]&LM2O+.YNUE=[.3S85$SJ@<=&* [6([9!Q6A0 4444 %%%% !1110 4444
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M$&H_:'B:33I&:)8PI .)P&)#8S@=.E6;'QC;0Z_K>EZWJ>F6K6$D*1%Y!"9
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M*_OUQEG( P>W6I_[5\5ZAKGB"#29=($.EW"0QV]S;R;YLPI(<RB3"\N1]PT
M=I169X=UJ+Q%X>LM6AB:);F,.8V.2C=&4_0@C\*K7VL7%MXQTC2$6,V]Y:W4
MTC$'<&C,07!SC'SG/'I0!N45YCI'Q(U.\\!W^HWMK:0ZU:P1721JK>5+!*1L
M< G/]Y3SU7WKTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?QSIN
MLZUHATS2;6SD$KQO)+<W31;-DB.  $;.=I'48]ZZBJNH:E9:3927NHW4-K:Q
MXWS3.%5<G R3[D"@#F_%UAXBU[PF=-M;#3DN;I1]H\R^<+"5=6&TB+Y\X/4+
MCWK:CFUQWLS)9V,2-'(;I!<LY1QCRPC;!N!YR2!CMFKMY?6FGV<EY>7,-O;1
MC<\TKA44>I)XJE9>)-$U&PGOK/5K*:UM_P#73+,NV+O\QS\O'K0!SWA;3/$U
MEK$]]KFGZ;+=7A(N+Z*_=F2,9*1QQF( (#VW<DEB2:[6LO3?$NAZQ!/-IVK6
M=S';C,S13*1&.N6]!P>3Z4S2_%.@ZU<O;:9K%E=SJNXQPS*S;?4#N/<<4 5M
M.T%[7QAK^KR)!Y.HPVT:;?OGRU<-NX_VEQSVK MM \6Z=X8;PG:+IC60B:V@
MU22X<21P'(&8=F"X4X'S@' /M740^*O#]QJK:7#K5@]^KM&;87"^9O7@KMSG
M(P>*;<>+O#EIJ3:=<ZYI\-ZK!&@EN%5@Q (&">N"/SH QY?#VIZ%K%EJ'A^"
MUNXH=,CTR2UNIS"=D;$QNKA6Y^9@01Z5J^%M'NM(L+HW\D+WM]=RWDXAR8T9
MS]U2<$@  9(&>N!6EJ&I66DV,E[J%W#:VL>-\TSA57) &2?<@4E[J=AIJ0O?
M7D%LD\JPQ-+(%#NW11GJ3@\4 97BW0[GQ'8V>FQS"&S>[CDO65RKF),L%3CJ
M7"?AFL*\^'DDU[JT*:C<2Z?K&FFVNWNIC)*DRG]TZY'( 9LC(Z"NW^UV_P!M
M%GY\?VDQ^:(MWS;,XW8],G&:SK;Q3H%[JC:9:ZS8S7RD@P).I?(Z@#/)'<=J
M *&G_P#"731K9ZM:Z2D2Q,DMU!<R.T[;2 50H-G."<D^@]:S?"GA#4O"O]D&
MUDM_*>RBM]7MPYVM+'&%6:/C[W&TYQD8/45OZ=XM\/:O>"ST[6K&ZN6!(BAG
M5F('7@5I->VR7T=DT\8NI(VE2$M\S(I + >@+#\Z /.-6^'&IWG@#2M.M+BU
MAUJR@:V>0LWE2PN?G0D#./NL..JCUKHKC2]=TCQ/J6K:+;V5];ZFL1GM[FX:
M!HY8UV!E8(P(*@ @@'CBNAAU.QG6[:*\@<6;F.X*N#Y3  D-Z$ @U6F\2Z)!
M;/<S:K:1P)#'.TC2@ 1R'",3Z,00#WH YUO!M]-X-UNTN+FW.M:I<-?&1,B*
M*X&TQ!21G:OEQC.,G!..U9FI^ -6O/#6C6L-S;1ZBKSKJ<FYMKQ763<!#C).
MX@C..G:NJMO&_A:\,HMO$&G2^3&TLFRX4[4499CST ZUKRWUK ULLMQ&ANG\
MN ,P'F-M+87U.%)_"@#G-8TK6H?%>GZSHMG87,<%A+9M#<7308W/&P((C?.-
MF,<=:I-I'B&W\47^L1Z+H]Y]N@M@4GOF0P/&K;@I\EMPRW!XZ=*Z?5M?TC04
MB?5M2M;)921&;B0)NQUQGZBH+'Q9X?U)0;'6;&X!E6$&*96R[ E5X[G:<#V-
M &/+IOB:P\5:QJ.E6FESQ:C%;JK75V\9B:-6!RJQG</F]1TJK%X*U'1H-'O=
M(NK>XU>P-P;C[3F..\$[[Y1E02GS@%3@XQ@YKL)M2LK>>2":ZA26* W#HS@%
M8@2-Y]N#S5._\4:%I<-M+?:O9V\=RN^%I)@/,7 .X>W(YZ<T <7-X(U:]TSQ
M5C3])TR;5K:WA@M+:8M&IB+DL["->3N[*>E=GH8U)1.M_I&G:<O!06=T9=YY
MSG,:8QQZ]>U:J.LB*Z,&1AE64Y!'J*RK7Q3H%[JC:9:ZS8S7RD@P1SJ7R.H
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MS"5IA(L2AO,8;6?./O$<$]2* /)7U:YU6'QP-001ZI9^%C:7R <><AN<L/\
M98%7'LPKH];DM9I/ Z6CQ-K"WD#1^609%M_+/G9QSLV\'MG%=N^EZ?)+=2O8
MVS27<8BN6:)29D ("N<?,,$C!]:BTW0='T=G;2])L;)G&&-M;I&6^NT#- '/
M?$6QM]3TS2+&[C$EM<ZO;Q2H?XE8L"/R-<K87FIKXM30IG>36M'T34((Y3UG
M0M 8)?JPP#_M*U>K3VT%SY?GPQR^6XD3>H;:XZ,,]"/6FFRM#?B^-M#]L$?E
M"X\L>8$SG;NZXSSB@#S2>71&_9_6*)H2'TM4B12-YO"O  Z^9YOXYKM/$ F'
MP_U07!S.-+E\P_[7E'/ZU:3PUH,>J'5$T73UU MN-T+9!)GUW8SGWK1EBCN(
M7AFC62*12CHXR&4\$$=Q0!YKX66^_P"$M\/-KAM48:$1IC6JE1*#Y?F+(6.2
MR@(0!QRQJ]\+3JG_  @NC_:;S3WLOL \J&*!EF4]MS%R#QGHH[5V_P!@LRUJ
MWV6#=:9^SGRQF'Y=OR?W>...U4;'POX?TRZ%U8:%IEK< $"6"T1' /7D#- '
MBZJWAKX:6*@'^R_$%A;,/2&]783]!(BY_P!Y/>O0;8ZH/B9XD-A>:?;Q>78^
M<MU SLPVO]TAUQQGJ#VKL7TG39-/CT]]/M6LH]NRW:%3&NWE<+C Q@8]*K7_
M (8T#5;HW6HZ'IMY<$!3+<6J2,0.@R1F@#A/%VZP\3:KHT9*CQ9!;1QXX^<2
M"&?'_;%U/_ :9X;3SO$6F^$S_J_#5Y=W#J?[@P+7_P <N,C_ *YUZ7-86=Q<
M6UQ-:023VQ)@D>,%HB1@[2?NY''%(FGV4=W<7:6D"W-PJK/,(P'E & &/4@#
MIF@#R&;5Y/[4/C@:7?F./5LB^")Y/]G >01G=NQUDZ=?SKN?#TT2>.?&(:1%
M+7-K@%@,_P"C)72C3[(:=_9PM(/L/E>3]F\L>7LQC;MZ8QQBJ4_A?P_<WJWL
M^AZ;+=+MVSO:(SC: %^8C/&!CTQ0!D_$2^DA\,_V;;1S2W6K3+8I'!@R%&R9
M2N2.1&KGJ.<5Q4US=6?A?QOX?L]/O=/"Q_VA9VTBJL@MI3^^"!21@,LN,'^,
M5ZY):V\UQ#<2P1O-!DQ2,@+1Y&#M/;(XXI#:6QO%O#!$;E8S$LVP;PA()7/7
M&0#CVH XZYUN.QD\-II,>CW&@7ES#;6RQY+QY5B&7'RX&WZ\UR,:WS*OVXVJ
M^'QXOG:26-3Y\4@N6,9))VA#)M4D<X;W->H6WAC0+/4#J%KHFG07I)/VB.U1
M9,GJ=P&:M-I>GO:36C6-LUM,YDEB,2E'<MN+$8P26YSZ\T <;X=.J#QEXI^S
M7FGQ67]KIYT4T#-*W^CPYVL' '&.JGFCPT=4'BWQ3]FO-/BLO[9'FQ30,TK?
MZ/#G:P< <8ZJ>:Z>X\+^'[O4#?W.AZ;->E@QN)+1&D+#&#N(SD8'Y43^%_#]
MUJ!U"XT/39KTL'-Q):(TA88P=Q&<C _*@#SE;J+PUXLUKQ9*VRSBUR2PU%@.
MD,EO;E'/^[(%'T<TFFVDZ:SJ&I7J%+_5?#MU?7"GJF^1=B?\!C"+_P !KU*7
M2M.F@N8);"VDANGWW$;1*5F; &6&/F.%7D^@]*DDLK66<SR6T+RM$82[("QC
M)R5S_=SVZ4 </H)U3_A6 %[>:?-;_P!A+Y,=O R2(/)_C)=@>,= .:Y!U;PW
MH>AZ40?[,UF?2[RS/:*X$T)FC]@P_>#WWUZQ9>%O#VFR226.A:9:O)&8G:"T
M1"R'JI('(.!Q5R73+":"W@ELK>2&V9'@C>)2L3+]TJ,<$=B.E '/:A_R530_
M^P5>_P#HRWH^)'_(C7G_ %WM?_2B.NF:UMWNH[IH(S<1HR)*4&]58@D ]0#M
M&1["BYM;>\@,%U!'/"Q!,<B!E)!!'!]" ?PH X/6)9O".IZCKUA<V5_IE[>P
MB_L)"/.CF^2(&)AU/"G8P['!%:?Q-W_\('=^6RK)]HM-K.,J#]IBQD<<5N-X
M=T1]6&JMI%@VH@Y%T;=/-SZ[L9S5N]LK34;22TOK:&ZMI,;X9HPZ-@Y&0>#R
M : .+\8QWL_@*YAU>XL+QGO[-3]EA9$*&YB&"&=LGKW_  K&TUYM*\?>'?"E
MTSLVF27+V4K\F6T>%O+Y[E""A_W0>]>@6OAO0K&WDM[31M/MX965Y(XK9$5V
M4Y4D <D'D>E79+*TEO(;R2VA>Z@#+%,T8+QAOO!6ZC/?% '-Z'_R43Q;_P!<
MK'_T!ZS?A>=4_P"$7T_SKS3VL-LOEP) PG!\QNK%R#W_ (17<):V\5Q-<1P1
MI/,%$LBH S[>F3U.,G%9UIX7\/V%\M]9Z'IMO=J21/#:(D@)!!^8#/()_.@#
MS#PLM\8/ AU4VJ:2+J=K.6!2)1<8E"I(Q. K O\ =ZD &NH\"'5!<ZKB\T\:
M=_;5_N@:!O/)\Y^C[\=<?P]/SKLAI>GK:PVHL;86\#B2*(1+MC<'(91C (/.
M1WJHOA?P^NI?VBNAZ:+[S/-^TBT3S-^<[MV,YSWH X,RZ4/AGXMBU-H2C:EJ
M8C1R-QD\^39L'7=NQC'.<5U]X+M?AK<+?DF\&D,)RW7S/)^;/XYJ_%X:T*'4
M6U&+1=.2^9S(URMJ@D+$Y+;L9R3WK1EBCGB>*5%DC=2KHPR&!X(([B@#R671
M[C5K_07T]@FJV7AF"[L9#T$JNN%/^RP+(?9C6]X"U:+7;?Q9J<*-&MQ?AC&X
MPT;"TA#(?=6!!]Q7;Q6-I!+'+%:PQR1Q"!&6, K&.B ]EX''2BWL+.T\_P"S
M6L$/VB0RS>7&%\QSP6;'4G Y- 'F,A0?!GP8;K']FA]-^W[ON>1E<[O]G.W/
MM71>)GMI_&/@Y;%HVU!;N20^602MKY+A\X_A+&/VSBNL2QM([!;%+6%;-8_*
M%N(P(PF,;=O3&.,54T[P]H^C"4Z3I=EI[RC#-;6Z1D_7 YH OP7$-S'YEO-'
M+'N*[HV##(.",CN""/PKF+?_ )*UJ/\ V [7_P!'SUN:+I%MH6D6^G6NXQ0@
MY=SEG8DLS-[EB2?<U:%K;B[:[$$8N601M,$&\H"2%)ZX!)./<T >/W$7B$_#
M/Q@]M=Z6NF>?JNZ*2UD:8KYLN[#B0+GKCY>/>MZ_TZSU?Q-K.FW]S]FM;KPU
M:0O-N"[-TTP!R>.N.._2N]_LVQ^QS6?V*W^RSES+#Y0V2;R2^Y<8.223GKFD
MFTO3[@RF>QMI?.B$$F^)6WQ@DA#D<J"3QTY- '/>&=7U+^W[[P_J_P!BN;NT
MMHIEOK-=JRQL650Z<['^4G )!!R,5SWCH'Q'XCFT9=-O[V"PT]V+6:H?)NIA
MB-CN9>516(Q_?%=_IFC:7HL#0:7IUK91,=S);0K&&/J0!S5F*UMX)IYH8(XY
M)V#S.B &1@  6/<X '/84 >:PZY%K6I>!-3UD+';-%<QR++@)'J*A5PV> PV
MS!<]^E0^*]7O[OP]XWTS4(=.^T6FGV\@GLPWSAV?"MGGC;_X\:](DT?3)K.>
MSETZT>VN':2:%H5*2.3DLRXP23SDU!:^&]#LK&:QM=&T^"TG_P!;!';(J2?[
MP P?QH X.Z6]_MOQ<VNFV35/^$?9;86:E8I;?#Y8[B27#\'L 5QUK1M3JG_"
MJ[T7]YI\\7]A'R4MH&1T'D'[Q+MGC'0"NWGL+.YF$UQ:02R"-H0\D88[&QN7
M)[' R.^*HV?A;P_IS2M9:%IEL9HS%*8;1$WH>JG Y!QTH Y:(ZI_PJO41?WF
MGSQ?V$WDI:P,C(/(/WB7;/;H!7/6<T^EV#^![8O&^N+!-8,O_+.&9<W1'ILV
M2,/>1:]*L_"WA[3_ #OL6A:9;>?&89?)M$3S$/56P.0?0U>%A9B>"<6D'FVZ
M&.&3RQNC4XRJGL#@<#T% 'DT4$EKH^B6^F-;6SQ>,;U(#,A:- #=  J""1CW
M%=#XTTMM<L_"VF:S+;W!N=5>.:2T0QKS;7&"H+,01P<Y/(S77W6@:->VAM+O
M2;&>V,S3F&6W1D\PDDO@C&XECD]>33K70])L888;32[*WB@E,T210*BQR$%2
MR@#AL$C/7!- '">$-3N[SX@R6.J'.JZ9I)M+ML8\PB8%9![.A5OQ([5O^!^O
MB3_L.W/_ ++72+96BWSWRVT(NW01M.(QO9 <A2W7&>U.@M;>U\W[/!'%YLAE
MD\M0N]SU8XZD^M ')>*+2YL]9?Q'I&H6"ZA:6!CN;*]/R36^XN.0<QG(;#8(
M/<<5C6=[JVM>-[?4="-E8_:O#=I.T5];O+M5I9"% 1UP1FNYU'P]HNKSQ3ZE
MI%C>31<1R7%NDC*.N 2*N+:6RW1NEMXA<&,1&4(-Q0$D+GK@$DX]Z /)EN[I
M/!5]HTD;75_JWB*[M)H[),%X_.9IRBLW V*XY;C<.:CO+PVW@;QMH#V5Q8I;
M,+RSM[A55EMYGW8 4D8$@D'!Z8KUB/2]/AG6>.QMDF1Y'618E#!I#ER#CJQ'
M)[]Z2ZTK3KYI&N["UN&DB\AS+"K;H\YV'(Y7/..F: .<\;3PM_PC;+*A5==M
MLD,,#AZZU)$D7<CJR^JG(K(7PCX:2TDM$\/Z4MM(P=X19QA&89P2,8)&3@^]
M7[#3;#2K46NG65O9VX)816\2QKD]3@ "@#C?A]<:8G@AEU&6U6[%W/\ VF+A
ME!^T><V=^>_3&>V,4[P;/IT6G>)O[3DMTN1JMV=1\\@?)O.S=G^#RMF,\8KI
MYO#NB7&IKJ<^CV$E^I!6Y>V0R CH=Q&>*2^\-:%J=ZEY?Z-I]U=)C;-/;([C
M'3DC- 'E5GH3ZYH?@;3I9)+>4V5_+93-G?!M>-[=QWX 3\.*ZCX?ZQ)K?BGQ
M'<W,/D7T=O907D/_ #SG3SE<#VR,CV(KO&M;=[B*X>"-IH0RQ2% 60-C(![9
MP,_2FPV5I;W5Q<PVT,=Q<%3/*D8#2[1@;B.3@<#- 'F#_P#)!=1_ZZW7_I8]
M2ZS97,?CO7_$.FQM)J.CQV<PB7K/ 4D$T7XJ,C_:5:]&_LO3S8-8?8;;[&Q)
M:W\I?+)+;CE<8Y))^M3);01W$MPD,:SS!1)(J@,X7.,GOC)Q]: /)]-O[6XT
M+P[JL<R_87\7W4HG/"A)'N0A)[ EE'XBMKQ%(EQXL\0&%UD%OX6E24J<[&9V
M*@^A(4G%=L-'TQ=-?35TZT%@^=UL(5\ILG)RN,<GFFV.AZ3IEE)96&F6=K:R
MY\R&&!41\C!R ,'CUH QO QU3_A'=.%]>:?-#]A@\E+:!D=!L'WB78'C'0"J
MVK_\E*L/^P%>_P#HR"M[3O#>AZ/<-<:9HVGV4S+L:2VMDC8KD'!*@<9 X]JN
MO:6TERMR]O$TZQM$LI0%@C$$J#UP2!D>PH \+56\-?#S2K< _P!EZ_9V$L?I
M#>*8BX]A(B[O]Y&]:]ZJF^E:=)8PV,EA:O9P[/*@:%3&FW[NU<8&,#'I5R@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *XSQ1K]Y9>*]/TJ+6[#1[::
MRFN'N+N)7#.CQJ%&YU'1R?PKLZP+SP]]M\96>L3+;RVL%A-;&*1=S;WDC8$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%!('6@ HH) &310 44@922 02.H!Z4$@=3B
M@!:**CFGBMH'GGE2**,%GDD8*JCU)/04 245%;W$%W;I<6TT<T,@W))&P96'
MJ".#4M !1110 45&)X6N&MQ*AF10[1AAN"G(!(ZX.#S[&I* "BBD#*3@$9^M
M "T45'+/#!L\Z5(][A$WL!N8] ,]2?2@"2BD5E;.U@<'!P>]+0 444$@#).*
M "BD!!Z$&EH **C6>%YI(5E1I8P"Z!@64'.,CMG!_*GY ."1F@!:*** "BBB
M@ HHHH **** "BBB@ HHI"0 22 !U)H 6BF0S17$$<T$B2Q2*&1T8,K ]"".
MHI] !114<]Q!:QB2XFCA0LJ!I&"@LQ 49/<D@ =R: )**0,K9VL#@X.#T-+0
M 4444 %%%% !14<L\,&SSI4CWN$3>P&YCT SU)]*DH ***CDGABDBCDE1'E8
MK&K, 7(!) '<X!/T!H DHHHH ***"0 23@#J: "BHX;B&XCCDAFCD210Z,C
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M)A=OL5V#2*<1YWX'IU.0<5UOBC4+[3/"M_J6G1JUS:Q?:!&ZYW*I#.N/4J&
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M(TEC:.15='!5E89!!Z@UBZ9X4T[2#BUDO_)6,Q1V\M[*\42'LJ,Q ]!Z=L4
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M*Q%9=S!@%*DC:&R#QS5I?#%]#=Z^# )UFT"WL()F*YED19@PY.1G<G7CGVH
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M&@N88YH7^]'(H93WY!J6B@ HHHH *9-#%<0O#/$DL4BE71U#*P/4$'J*?10
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M4 V#EI5D!3Z#S#S[4_2O#$UGXB?6[[4A>79MC:JR6RPY0L&R^W[[?*,'@#G
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MOFLI[*[6[BE$0D^959<%3V^8T 4(M0ETCPU'=68N+D/*=SZ]=&U,8Y&69T+
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ML@,)R,/&2 H'HPP2!0!Z.DT4DCQI*C.GWE# E?J.U9_B#6%T#1)]2>$S+$R
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M2RD G.2"V<<5M21Z?'XMU"3Q/I,]ZUQ;6@TUVL7N. OSHA"G8WF98].H/;@
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MI+39<L[(XB\P;_EQM8 ],D<5=^'VHZWJGAYKK66MG)N)TCDB8ECMFD4AAM
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MKEHDA,5O<O-/&ML9@SD12O'N X.#LSTXSBK4.KP_9[F>^\NQB@N'A#S3IM8
MX#9!P,^AP1W% &'%X$BVW/VS6+^\>?3'TO=((E$<+8^Z%0#<,=3G^5:\V@6T
MSZ*S2R@Z1)YD."/G/E-%\W'HY/&.:U%='C$BLK(PR&!R"/7-8VI^)K2RM+6X
MM&AODGOX+(F*8$(9'"9)&>F<X_E0!17P1;6UKIZV&I7EG=V#3F&Z38S%9G+N
MC*RE64G';(VCFI]2\,7.IZ4-/F\1:CY3Q/#<GRX";A7/.<QX4@' *@<>IYK:
M%_9F]-D+N W0&3 )!OQZ[<YI_P!JM]A?SXM@?RRV\8#9QM^N>,>M &/;>&(;
M'7H]4LKVY@46L=K-:C8T<R1AO+R64L"-YZ$9XS2ZYX;.L:EI^HPZI>:==V*R
MI');+$V5DV[@1(C#^ 5J_;;3[9]C^U0_:MN[R/,&_'KMZXI(KZTGN9;:&Z@D
MGB_UD22 LGU Y% &?!H 35-/U*YO[FZN[*VFMA)*$7S!(R,2P50,CRP!@"LT
M^![:*VL%L=2O;.ZL)[B6"ZC\MG G<O(A#*5*DD=OX15WQ/XIMO"]FEQ<6EY<
M[B.+>+<$&Y5W,QPJC+#J<GL#S2^*?%%MX4TF2_N+2\N@B,_EVT6XA5&6+$X5
M0/<CVR: )O#^@P>';&:U@N+BX$UQ)</)<.&=G<Y8D@#O6._@&&4W\#ZYJO\
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M"7?VRR(\L-92;V?*'9\PRYX?=QQ5V3PT]W9PP:EJ][>O#>PWBR.D28:)@RJ
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MA-QR@8,<$ ]Z] HH XK0O#FH7-M&FKM=06MCJ*7>FP3&$S(JIC;(8ALP69B
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(HTASCY0Y<*<$ E:;;^,;&YL].F2WN1+?7SV"VY"^9'*A</N&> HC8GVQZT
M=%17.ZCKJ:;XAN4EFNFBM](DO6MT1-A"ORP8_-O[8SMQ[UGQ>/\ [1<6UO%X
M;UAI[VW^TV*%8E^T1C&YLE\)C<OW\'D=SB@#LJ*Y/_A/+6:VT=['2]0O)]6C
MF>WMXU164Q%0ZN68*N"3SG'!]LLT[X@6NH2:>PTC4X+2]N#9K=3(BHEP-V8R
M-V[@JR[@"N1C- '7T5R__"<6GVP 6%V=.-[]@_M#Y/*\[?LQC=OV[_DW;<9]
MN:QO$7C6>:U5=*L=0CMAK%O9?VDH3RG87*)*N-V[;]Y=VW!.1GID ]!HKFK3
M7)_^)R;>WU#5);;4C:K JPIY?[M&PI)4;!NSECG)(YXK+U+Q[=II^GW&FZ)<
MRRR:J-.N[>1H@T3@X* ^8%+'^%@2OKB@#N:*Y?4?&L6GRW2#2;ZX^P0)/J!B
M,7^BAEW;3EQO8*,D)GCZC- >+%L/$FM3W,LT^EC^SDB*8*PB?</,.<84DKDT
M =O16;:ZU#>:GJEC;PRN^G;%D88VN[+OV*<]0"N<X'S"N;T3QU<3^&KS5M9T
MFXM1#=R6T0C,;>>WGM$D: .3OR%4DX!))!QS0!VU%<G/X\M+&PU*?4--OK:X
MT\P>=:X21RLS[$9-C$,,YXSGY3QTS)<>,9K>;3[1_#NJ'4;Z*:6*S!A+*L;*
M#N;?M7(<'K[=< @'445R.F>/[35)=,9=*U*"SU&4V\-W.B*GGA6)C(W;N-C#
M=C:2IP>]16GC)+?3M/40:GJMU?W=Y! JQQ*Y:*1P0<%5"@+P3V&3S0!V=%<]
M:^*6U#1Q>V.C7\]P+A[6:S!B5X9$)#;V9PN 1U!.<C%8]_X]NC!H4^EZ)=3B
M]U&2QN87:)7B>-9-T8S(!NW1Y!R5PIYR10!W-%<MJ7CBVTZ:^!TV]GMM."_V
MA<Q>7MMB5#$$%@6*J0QV@X![]*?XN\1W^@II#:?IKWPO+Z.W?8R#"MV&YU^8
M]CTX.<<4 =-17 2^,+W2O$WB(SZ7J=W:6EK;7+Q0F,BT38QD)RP!/'12<[36
MG?>+K/3=2O[J6YNI;.WTF"^$*1IL*O(ZAE)PVX[0,$A0,'UH ZRBJ6F7L]_:
M>=<:?-8ONQY<KHY(P"&!1F!!SZ]JY'3O%.IS^.BLTB'P_>SSV%D @!$\ !9B
MW<,1, /^F8]: .[HKDY?',::C';PZ/?SVTFH'35NT:((9USN&&<-@;6&<<D'
M&>,NA\=VDD>K74FG7\.G:6\\4][(J;&DB?840;MS$]00,=LYXH ZJBN6'CBT
MMUO?[6L+S3)+6U^V>7-L<R19VY7RV8;MV!MZY(]:1O'$%M;ZD^HZ7>V4]C8M
MJ!@D,;M+"N<E2CD9!&""1C(H ZJBN/'CQWO?L,?AG66O)(!=6\.V(&:'."^2
M^$P<?*Q#?,./2P/&]I=6^FOI=C=ZA/J%K]LC@C*(R1# )<NP .3C&3DY[ F@
M#J**Y/\ X3RUN/[-33-+U#4)]0M9+F&*)44J$95<.78!2"V.N,C'/%4[CQY<
MS7'AJ32-%NKNTU8S"128TD4HC$H-TB@,K*<YR, X)- '<45SGB>]N%U'P_I5
MM,\+ZA?CS71L'RHD:5AGW**I]F-/O/%!T_5;>UN]'OHK2>Z6TCO28C&TC<+\
MH??M)XSMZ^W- '045R+>/K9+J8'2=1^Q6^H?V=/?%4$4<I<(.-VXJ6*\@'&1
MGOC,\;>-9[?0M?CTBQU FQ_<2:E"$\N&;"G&"VXX# $A2 3]< 'H-%9NI:S!
MI=]IEM<1R8U"<V\<H V))L+ -SGG:0/>LJ7QM: %+6QN[NX>_EL+:"((#</&
M,R,I+ !%PP))'*GVR =/17,P>-;.6.-9K*[M[K^T4TV:UD"[X967<"2&(*E<
M$$$Y!I=4\:V&E)JS36UW)_9ES;VTJQ(&9VFV;=@SDX\P9[\'&: .EHK&N/$*
M:?X:?6M4L;JR$8^:U?8\N2VU5&QBI+$KCG^(9Q52;Q:]G9))?:%J-O>37"VU
MM9DQ,]P[ L-K*Y7  8DDC&#[9 .DHKDY/'EI;6-Y+>:;J$%W9W4%K/9;4>4-
M,0(RNUB&4[NQSP1C-*WCJVM[#5)K_3+VSN=->%9;64QEV\X@1$,KE,$G&2PQ
M@YZ4 =717/77BAK."R2;1[P:E>R.D-B'B+D*,LY??L"@8YSW QGBJW_"<VLE
MK:?9=-O;C4;FXEMET]?+$B/%_K-S%@@"\<[L'<,9S0!U5%<Q9>-[*]BM7^Q7
ML#7&IMIGES(JM'*J,YW#/3Y2.,_ES4MUXQL;7^T5-O<R36=]'8+"@7=/,Z(Z
MA,D#&'Y+$8P>U '145R<OCRTMK.XDNM-OX[NWNX;.6S54DDWRX\LKM8JP.1T
M/KZ52UGQ[=VGAO6+JUT2YBU33)(TFM+DQG8'P5<E9,,I!QP<Y[<4 =S16-J/
MB!=(\,3ZYJ-C<VR0)OEMB4>11G'\+%3Z\$UG?\)*YU72C>0:AI:307<IMITB
M(=(Q&=[E2S*0&X .>N1P* .JHKB'\<27]M-;PZ/J-F]QI4VH6MS*T6/*"\-A
M7+ Y9>,9&1GO3O#7C*:ZT_2K6[TG4A=W6F_:+:67RQ]M9$7>%^?Y22P(W[<@
MYXH [6BN9\&>(]1\1>%8M4O=*D@G9"RJK1[9\$_<^<XZ8^8CGVK.T3QY<3^%
MO[5U?1[F"5[MK6WCA\MC=2&9XU1 )#@C: 2Q ZD'% ';T5C:+XA75;R\L)["
MYT_4+,(\MM<%"=CYVNK(Q5@=K#KP0<U7D\7V4>E76H&"X\JVU'^SG4!=QD\Y
M8=PY^[N8'UQVH Z&BL*T\2I?:Y>:?;Z?<O!92F"XO"\8CC<('P5+;\8(&=N,
MGTYJIIGC:UU*[L$&GWD%IJ186%W+LV7&%+= Q9<JI8;@,@=NE '445R\OB34
MH_B"N@)I$LMD;-9S<*T8P2^TORX.P=,;=V1P"*Q_"'C2=],TJ'5++4&%Y=S6
MJ:E($\MY0\A5<;M^-JX#;<9&* /0**Y=_'%HMXP%A=G3EO18-J V>4)B^S&-
MV_;O.W=MQGVYI?$.HZE)X@TOP]I5TMG+=Q37,]WY8D:**/:,(K?+N9G R00
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M.33+G3;^U&H6$]ZP\^)C%+%<RF0J<$$$?)@^QXYI-5\$W6HZM;:Q.NB:A?\
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MMN3S2I)P29 6(P $R<]:[O3[-=/TRULD.4MX4B4^H4 ?TJS10 4444 %%%%
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M@?\ UC6Y_8UN?$?]ML\K7*VOV1$)&Q%+;F(&,Y)"YY_A%:!56()4$@Y&1T-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%<WXP\0W_ (<T]+NSTQ;J,21K-+),$2,-
M(J=.69CNX&,<')Z @'245SGC+Q#?^&])^VV6F+=JI!EDDF")$I95Z<LS'=P
M,<')'&>CH **Y/P;XAUCQ)96VHW,>DQV=Q )?+MKAWFC+8(# J .^>:M^,]>
MO_#?AVZU*PTT7K6\+S.9)1&D:J,DGJ23V 'U(ZT =#13(G\R%'(QN4'%9_\
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MPC%6P0-R$K]Y>#ZU<N/%VD:;#;C4KQ8IY+=9Y%2-W$:'^-]H.Q<YY; X//%
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MQWH V:*SK'7]*U*>*&RO8IY)K<7483/S1;MNX'IUX(ZCO5*?QIX?@M;:X;4
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M!N;F&SM9KJYE6*"%&DDD<X"*!DD^P HB2W9C=0I'NF5<RJ!EU'W<GN.3CZT
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MV#\QR!45]X5U*'6KVX:QU&^M-0LK>%TL=16W\MD0HRN&90RD'((R>3Q7I%%
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M7.2 ,94^W)KTBB@#CSX?OSJ/B>8P*4O]*M[6 EA\SJDH8>W+KU]:H:=I>O\
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MRFV6$S/(-J?>SA^0<=.,YKJO"FE7.E0:L+F)8VN=5N;I,$'<COE2<>V*WZ*
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MXU W$NP QTSS]12B>%IO)66,R[=^P,-VWUQZ4 245&+B!KAH!-&9E&XQAAN
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M5H2S;EM5(,1QUW@?=YR!Z5TOC2"YN_AY<Q1PRS7#QP$HJ%F)\Q">!SZUU=%
M'EOB+PW'?1_$:^DTDSWIC0V$IA+/N6UC(,1QUWCJO.0!VJ;Q'I>I?\)!-I5K
M:W#V7BF*!;N9$.V!HB!.6(^[OAPHSU*UZ910!Y'K>GV_D^+K"]T2YN=?O)V_
MLF9+)W^3RU$!CE"[8PC#GD8P3WJUKNFZD\OB,RVEQ=0&?2FNTBB8FY@3'GA
M/O< Y ZC([UZE10!Y?K\%C>6VE76AZ:UKHL6I-)>@Z/(49O)PDI@PK.H.!G'
M! /\-=3X&L8;'1KD6]Q)-!/=R3(#9/:)'N RJ1MR%R"?3+'%=/10!XKX=M[*
M[T_08M-TBX778];,\UY]D<8@69_,8S8P4*?)MW=>,5I7,D\6GW>A?V=J+7Q\
M4K=G9:2&,0->K*)-^-NW:>QSG/'!(].TW3;32;%+*QB\JW0LRIN+8+,6/).>
MI-6J //+7PWI\Z^-[S4K"=)KB\GA6ZC@9IU@,"*3%P3_ !/]T<G/6LE!<_\
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M)K<UXD8M6MM]H^%E"1-]U2KLP'JHKV"JFIZ99ZQI\EC?Q>;;2%2\>XKNVL&
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M,Q^2JPK'(%(CV.&)Y&#S4NLZ7J[)XD66UN;HM;Z3]I$2$FZC1V-PJ?WB5W9
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M\+)D#'4'#<CCKC7N/%/D&SMQHVI2ZE<QO,-/3R?-CC0@%G)DV 9(Q\V3GZX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+ ,>"0.!SDX !VM%<C:ZWKD_Q&O=+%M:MI,=E;SJWGD.H=I1O \ODDJ!M+8
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MEIXIC:(8_F0H5,?L"<'.0>_:JT7@,VEI9FTUB>/4;2[N+J.\:%&W&<DR*R<
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M1I,8;H5W$ ]/4&KU_P"%K:^\+VGAXSRBQ@$".&PS311%3L8_[6T GT)K>HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT7Q99V=WX:OC>00RB&"66+S5!V.(V 89[\F@#0?4K*/3?[2DNX4L?+$OVAG
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MC)9E8MG.1QC % 'L%%<6IU&]\=ZZ?[3O1:Z7#;RP6,+!4D=D8D-QD@[>GO\
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M>/LWF6ZMY.,8V9'R]!T]!4<OAG09VM&FT73Y&M%"6Q>V0^2HZ!>. /05JT4
M9MYX=T34;Z.^O=(L+F[CQLGFMT=UQTPQ&>*<FA:1'JS:JFEV2ZBW6Z$"B4\8
M^]C/3BM"B@#/U/0M(UKRO[5TNROO*SY?VF!9-F<9QN!QG _*HIO#&@7%C;V,
M^AZ;+:6Y)A@>U0I'GD[5(P,^U:M% %"VT32;)+5+73+.!;0LUN(H%40EOO%<
M#Y<Y.<=<U'I_AS0])NI+K3M'L+.XD&'EM[9$9AZ$@5IT4 9ESX;T.]L_LEUH
M]A-;>8TWE26R,N]CEFP1U))R?>KMK:6UC:QVMI;Q6]O&,)%$@15'H .!4U%
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M$AEA01*!&YSEE&.#\S<CU/K5<^'=$.J_VJ=(L#J.=WVK[.GFY]=V,Y]ZTJ*
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MG,=G;H7B6%RL8&Z-<[4/^R-QP.@R:LT4 1P016UO'!!$D4,2A(XT4!54#
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M//)"Z_9HMZJ$F1SN.>. <4 :/BOQ/_PB^G"[_LVZO1D;O*PJ1KN5<LQX'+#
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M,:#,L:?9FD*#N?D?ZD&NI\312ZO\/M7BM;2;SKK39EBMW3#[FC.U=O8Y(XH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU;4-.B%H(K74RRV4PN4=V(4N-\8Y3<JDCKZ'!-:/A/Q+<>*-/74?[(FLK*5
MT$DLJLTO)#?*.0 1P3UZU4\.>$+GP\]K;I>V$VGVBE(1_9P6Y*X(4-+OP<#'
M(4$XK8\-Z-_PCWAVQTD3^?\ 98_+\W9MW<]<9./SH X/4O%/B"[\%^+YKBT:
MR:PN)(H)[><;UVLGR#;SG!/S=ZZRP\3W5QJ%[IUUH=Q:WT-H+R"#SHW,\9)
M&0=JMD8()QR.<53NO!5S<V?B'3QJT:V&KRM<*AM<R0R-LW?-OPR_+P, \]35
MO7?"(UN\U"<W\EO]LTIM.Q&G*98MOSGGKC'ZT 43X^6VMM;-]IHBN-*LOMS1
M0W23+)'\PP&'1@4((([CK6EI/B::^UQM*O=)GT^9[7[9;^9*K^9%N"G=M^ZP
M)7(YZ]:Q/^%=2RVNLQSZC9QOJ6F?V=BRTX011*"V&";SD_-W/Y5TW]B#_A*+
M?6OM'^IL7L_)V==SHV[.?]C&,=Z ,;5/%$6AZEXCN)%O;A=/M+25H Z[,2-(
MO[L8R&^7G).>,8K0T?Q%/?ZS<Z5?Z5+IUW% ETBO*L@>)BR@Y7@,"I!'TP35
M76/!HU:;79/MQB_M6WMH,>5N\KR7=L]1G._';&.]:JZ-M\5R:YY_+V*VGD[.
MF'9]V<_[6,8[4 <U+XBUN?5_%NG/9"*TL+;,-PDP#1YB9@V!R22 ?:E\*^+K
MEK/0[/5].N+87>FB>&\FF5S-Y:(7+@$E20VX9SD=<'BM2X\,7+ZWJ]Y!J4<=
MKJML(;B![?<P949%97W# PPR"#G'44J>$H_^*?$EUYD>DV<EHR^7CSP\:H3U
M^7[N<<]: *.B_$"VUC4=.@^R"&#4PQLI!<H[MA2X\R,<QDJ"1UZ8.#Q6CJGB
M.XMM:_LC3-)DU&\CMQ=3@3+$L<98JO+=6)5L#VY(JIX;\)77A]K6#[;83V-H
MGEPXTX)<E0,*'E#X) [A1FK&I^'=0D\0-K.CZM'87$ULMK<+-:^>KHK,RLHW
M+M8;VY.1STXH BUOQ=-H5S&;K2F6Q:2*-IFNHQ)^\*KE8\DL%+8/(/!P".3-
M9^*3?>(-0TZ*R46^GR&*YG>X4.A"!]WE]=AR &[GMCFL;5/AW+J-_?S'5;?R
M[V>&XD>6P$EPK1A/E67<,(=F<!>,G!YK2N_"4^I>)[;5+Z]M7AM7D:)(K+RY
MV5D9?+>7>=R?,3C:,D#TH K:-\0;75]0TZ$6@BMM4W?8I1<H[MA2X\R,<IE5
M)'7T.#6GJOB*XMM972-+TM]1OA;_ &J5?.6)(XRQ5<L<_,Q#8&.QR15+PWX1
MNO#SVL"WMA-86B&.$?V<$N2N,*&EWX.!W"@G%6M4\/7\NO\ ]M:/JD5C=O:B
MTG6>U\])$5BRD .I# LW.2.>E '+ZIXANO$VJ^$TT^UO5TV^\^29([TVTGF1
M_*R,4.?D.20#AC]*Z#Q%KVL:;XJT+3]/T]+FWO?.\W,JH6*KG STQU]^E/T[
MP;#IDN@M#>.PTI;C=O0%IWFY=B0>/FR<8[U;UW0[G4]0TK4+&_CM+O3Y'93+
M!YR.KIM8%0RG..0<]NAH Q[KXB6=MJ%Q']F5K&VO!93W'VE XD+!"5B^\RJS
M $]>#@$"IV\:3>;KK1Z+.UEHWG"XNC,JAFCCW[57J<@CGMD=><)!X-GL=8NK
MBRO-/%G=7AO)(KG3A+,KL<N$EWC )R>5.,U='A8#2?$EA]L_Y#4L\F_R_P#4
M^9$L>,9^;&W/;- &9%XYU&>]M[*/PM=_:;VU-W9JUS& \0(W&0Y^0C<O'/WA
MTYQ+8^*8-7U'0+J'[;"M]8W4_P!G+J$!C:,,'&"2P)(!! Z]<UIV_AT0:UI>
MH_:MWV#3I+'R_+^_N,9W9SQCRNG/7KQ5#2O!0TQ](;[>9/[.MKN#_4X\SSW5
M\_>XV[<8YSGM0!%H?CJ35YM%,VB7%E:ZS$SV<\DR,694WD,HY *AB#WQT&:F
MC\7W UZ+2;G2/)N+F.5K91>1NS,B[ML@7[A(Z')%/L?!XLK/PI;_ &XO_8"%
M=WE8\_\ <-%Z_+][/?ICWK-T'X>R:+J>E7+ZE;2QZ9YHC$=@(Y9A(I!,LF\E
MFYSG SSQSP 5M*\5:GJ/A32]0U:">TDGU2&W22TF3][F<IA@0<+P 1U(Z$5I
M77CLVZW=\ND3R:)9W1M;B_$J@JROL=ECZLBMP3G/!P#BBU\%7,&E6^ER:M')
M:6FI1WUKBUVNJK,92CG>0Q).-P QCH:CG\"W4L5[I:ZPJZ!>W;74UH;7,OS/
MYCQK+OP$9L_P$@$C- #M1\>/87&KE=$N9K'2+A8KVZ$R *&1&W*IY8@/R..!
MU.<5M^(]=7P]IL=XUI-=F2XBMUAA(#,TCA1C.!U/<BLV^\&B]TOQ/9?;BG]N
MS>;O\K/D_NHX\8S\W^KSVZ^U+X\T^]U+0[.WL/-6<:G9OYD2!S$%F4E\'C"C
MGGCB@""3QRUG!JBZEI,MK>Z>;<O;B97#QS/L1U8>^[(Q_#5O6_%\&BS:Q'):
M22_V9IBZBY5@-ZEI!M'H?W9Y]ZHS>![C4;36FU35Q-J.IQPQBX@MO+2!86+1
MA4+-GYB6.6YSVIESX&O]3CUQ]3UU)KG5=-73RT5GY:0@%R"J[R3]\\$]<\XP
M  3W'C*\MCIT$VA-!>:B\GV:"XNTC!1%4_,W(#G=@)R>#S@9K1/B5$NM:MWM
M)%?2K.*ZD!8?-O5VVC'<>61GWIGB?P_=Z_IHT^*[L8[9XVCF2[L?M .1@,OS
MKM8<X//7I69=>![S?<+IVO-;0WFG16%YYUL)I)%C5E5U8L K$.0<AL^QH GU
M7QE/IVB6^L)I!ELI+);R1WNXXR 5W%$!Y=@.<< Y&#27_C2:/4)K33-$GU!H
MK"+4&<3)&OE.7X^;^+Y.!WSU&*S]1^',EX@CCU.V"MI4>F2-<6 F9%0,-\1+
MCRR=W/#=!Z5N67A<6E]<W/VPOYVEP:=M\O&/*\SY\Y[^9T[8Z\T 9:^+M2O?
M%>A0:;IXFTG4M,:]#O*J/M+1?-CMM$GW>^?:K?B'7M8TWQ;H6G6&GI<VUZLQ
ME)E5"Q5<X&>F.OOG%-M?!]SI[^&I++5(TET>Q_L^4RVV\7$1\O=@!QL;]T,'
M+8ST-:&N:%<ZEJ6E:C8W\=I=:?)(5,L'FHZ.NU@0&4@]"#GMT- &7>^.S:B_
MO4TB>;1M/N3;75\)5!5E8*[+'U95)P3D=#@'%;6O:X-%@M=EJ]W=WEPMM:VZ
M,%\QR"W+'@ *K$GVK!NO UU/'J.FQZRL>A:C=-<W%H;7,N7;=(BR[\!6.>JD
MC)P:VO$6A2:U#9/:W@L[ZPN5NK:8Q>8H8*RD,N1E2K," 1UZT 9,VIZE+XO\
M-I<VT]B98+[SK03AU<J(MIR#ANIQG!&>U26_C1_[4FT^_P!+^RSK9RWD:I=)
M,2L94,K[?N-\R\<CKSQ4\GAB]O;NPO-2U?S;FVANH6>"W\H'S@H^3YB5V[>,
MEB<]:R]#^'ATR\M);F^M)8K;3Y=/$=K8"W,B/L^=VWL2_P G)Z'/0<Y -F#Q
M5#,/#Q^RR#^VK9KA,')B C$F#ZG!QQ6=:>/H9?"L_B2XL/*T\(C0&.Y21Y&=
M@JHP& CY*@@G SR>#3-*\%:E8W6C277B!;B+1H'M[2-+(1_(R; 7.X[F  Y&
M <=.<U%+\/&U :M)J6H6YN+^*)-]C9"! \4GF+*ZEVWONQDG' Q0!K^'_%2:
MUJ-WITMO'!>6T23%8KE9T>-RP!#KW!4@@CCCKFJ>H7.L6OQ%T2!M2!TV\2Y
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M<;BEJ94=V&,CD':">F,\'OWKGKOP1=:M:ZL^K:O'-J&H6T=H)H+3RXX(D8N
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M)V:3B!DQ@JT?F9;/KN_"K/A_PZFA^&QHYG\Y"92S(GEJOF,S%43)VJ-V ,G
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MZ;X0C\4971?[&?R1+N$?VK>O7'\>S.WOUQS0!ZKHNLP:YI*ZC;QR)$SRH%D
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MR*)+&5I4W-+YC.H7<H 5,[@,?4UMWOBO2;);;]Y/<M<P?:8DL[=YV,/'[PA
M2%Y')Z]JI1:/J,VO:KJ<\,4(OM)M[81B7?LE4S%AG R!YB\]^:YU/!.J61T.
MZ^S&]>WT2WTVY@@U26T*/%SN5DQO4EF!!] 10!U4_C70X9[&%+F6YEOX5N+9
M+6WDF,D1.-XV@\#N3TK4EU6S@U6'3)9=EU/"\\:E3AD0J&YZ9&Y>.O-8&B^&
MI-,\06-W%:06MG!H_P!C\B.9I?+<R!RH9@"PZ\GKZ4WQYX>U+7+"TDT66*+4
M;=Y$621L 12QM')^(#!A[H* -"V\7:-J&G:=>6-Z)(]3,BV;^6QWE%8MD8R
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M:;SFV#,N -YQ][CCGKQ4E !1110 4444 %%%% !1110 4444 %%%% !1110
M@4 D@ $\D@=:-HW;L#=C&>]+10 4A4$@D D<@D=*6B@ HHHH **** "BBB@
MI H#%@!D]3CK2T4 %%%% !1110 4444 %%%% !36C1RI=%8J<C(SBG44 %%%
M% !1110 4444 %%%% ";1NW8&X#&>]+110 A4$@D D'(R.E+110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !37C21=KHK+Z,,BG44 '2BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>*?$_\
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M,2?+O7<P4D!F5<L!W(%>?S:%JNI:=XJ$MEJ%RFH7&FM']LMXXWG5)5\PE$
M  [@' YH ](M_$.BWEN]Q;:O830)*L+R1W*,JR$@!20<9)( '?-71<P&Z:U$
M\9N%02&'>-X0D@-CKC((S[5Q>I^%6U37O$MJMO\ 9[._T>VABF1=JB='F*D8
M[KF,_E3_ (<2W>LV%WXIU&(1WFIE(P@((6*%=@ ]B_FM]&% %W6?%UUIVLWM
MA::*]\+&R2]N)%N5C(1BXPH;J?W9[BMO3]7LM3MK2:WG7-W;+=Q1,0)#$P!#
M%>N.0/K7!^*=$AO/&NI3:EHFLZA97.EP01'3W=07#S;E;:ZCHR_>R.:DTZ'7
M]!U#0=0U73;J_G_L4V4_V)5<I,'5E#<@ $#&[ID>E '7W&NQB:W^R&UN;>>V
MFG69;I<GR]O"KU<<\D=.,]:K:?XMTZ3P[HVHZG>6=A-J=K'-'#-.J;F90VU=
MQ!/7%<EH.A:M;VWA<7%A+&]MI6H13J1_JW=XRJGW.#CZ5%H^F7VC?V>VH^'K
MK44N/#=I8+&D2OY,J!O,B<,<*&W+R>/EYZ4 =;H'BIM7T[2+N>"VMX[[33?2
M$W0!CQMR AY*_-RW0<9ZUK66N:3J-U):V.J65U<1*&DB@G5V4'H2 <@<BO/=
M(\/ZM!I6B12V$RO!X4N;.12/NS,8L(?<[3^56CHTFDV?A2Y6P6VBT_1;E+QP
MNP1$PH<.1R,LI/U!- '9VOB70;Z_^P6FM:=/>9(^SQ72-)D=?E!SQ@_E6I7D
MW@JY;2IM$N-?BNK5XM%:WL"UI%%&T2JDCEF65R6 0$%@@QGC)->F:7J']JZ-
M::C';RP?:8%F6&<;77<,@-C.#S0 RRU[1]1O);2QU6QN;F$9DAAN$=T&<'(!
MR.:2T\0:-?W@M+/5K&YN3&)1##<([E#R&P#G&".?>N T&VU^]\4>'KW4+&]A
M:U@N4NHS:1PV]LS(,)&5^9ER.I)' [\5/H'ANZT_1OAZJZ88)[*5VO-L85HM
MUM*&+?5RN??% '2ZMXQTZRU"ST^TN[*ZO9;^*TGMTN%,D(?.6*CD8QW]:WY;
MJW@EABFGBCDG8I$CN 9& )(4'J< GCL#7EECI6H)8>&M(D\.77V[2]8$]U?-
M$OEE?,<M(KYRV[<"<=.<XP*[+Q[;._A6;4(-HN])==2@+' W1?,1G_:7<O\
MP*@#9N=8TRSBN9;G4;2&.U8+<-),JB(D @,2?E)!!Y]11!K.EW5I#=V^HVDM
MM.XCBF2=621R<!5(."<]NM>?6^EWRZ9X>\13Z=/>&74I=5U"TB4-(OG1LL1"
MG[QC!C7'7C(Z4D^DZG(FHZY;Z1=16\FNVFH1V&P"9HXE19)-F>&8@G;U./4T
M >E1W,$L\T$<\;S0X$L:L"R9&1N';(YYJM/K.EVNHPZ=<:E:17L_^JMY)E61
M_HI.36#X56\G\2>)-3N-.NK*"\DMS;BY4*SJL>TG )QR.AY]<=*I:K#?VGC9
M;G1K2_::ZGMDO4EMU:TFB7K().J.BDXYY('RGK0!JZ#XPT_59'M;B[L[?4/M
MES;QVAN%\R18I70,%/)R$ST]:U!KVCG5?[*&JV)U'_GU%POF],_=SGIS7"Q^
M&[J/P\NS3"MZ?%?VUB(P',?VTGS"?3R^_P#=J'4;?Q!J/B"U26QO46UU^.=8
MX+2-;<6X?B8R_>9BIR<'N<C H Z.#QC--=VD)LXP)]<N-*)WGA8TD8/]3Y8X
M]ZZ6\OK/3X1->W4%M$3@/-($&<$XR?8$_@:X.TT74DU'3G:RE"Q^*KR[<D=(
M6CG"O]"67\ZWO&>E/JZ:%"+3[5#%J\$TZ%=P"*'R2/0'% &E-XFT&W@M9Y]:
MTZ**[&;=WN459AZJ2>?PI]]K^CZ6^S4-6L;1_E^6>X1#\V=O!/?:V/7!]*XC
MQ!HUY'XNU2>4:O\ V;J%A%;1G3+6&<87?OB<.C%0=P((P#DY/%3)X79=0U8'
M3YIH1X:M["VENE5I&8><&0D<;N4W8XSB@#M;;6-,O;V>RM=1M)[NW_UT$4RL
M\?\ O*#D?C4-OXCT2[N+BWM]8T^::V4M/''<HS1 =2P!X [YKBD\,7\=MX7A
ML;/['-'X?NK6:55V^5*\<6T,1WWAC]032:5I]Q?R^$+-/#UUIIT53]MEGB54
M"^0T;1H0?W@9F!R.,+D\T >@B_LR+8B[@/VKFW_>#]]\N[Y/[WR@GCMS4%AK
M>DZK--#I^IV=W+ <2I;SK(4^H!XKSK3_  KKL\.IZ5+%)!%H^FW6G:-<.V!*
M9BVR0'_8C$:9]VK3\'Z4W]IZ9/=)K\=SI]BUN([NU@B@B!V H&C12_*@C!(X
MS0!V>I:UI>C1I)JFI6EBDAPC7,ZQAC[;B,UGWGB+R->M;"&..:"?3;B^697S
MGRVC  QP01)G/M6?XLEU9-6L4M;:Z^PO!*)+BRM(YYA)E=L?SY"HPW9)&,@9
M(K!\-Z%JMI!X;6YLID:V\.W5K+N'W)&>':A]R%/Y4 =OHFL+J7A33M;N?+ME
MN;*.[ER_RQ!D#'D]AGJ:O?;K3=;K]JAW7()@'F#,H W';_>XYX[5D^$K&2W\
M":)I]] 4DCTV"&>&0<@B-0RD?F*X+1-$U74X->TH/AM!L+C1-,G+_>>3+!\]
MB(_LZ^QW4 >DV.OZ/J=S-;V&JV-U/#_K8X+A'9.W(!XJQ'J5C+':R1WMNZ7?
M_'LRRJ1-\I;Y.?FX!/'89KA=,M+C4M8\+_9]!N]*31[>5+IYXEC4!HO+$2$'
MYQNPV1Q\@YR:I>'K75PO@73)M#OX#HDCQWMQ*H$8(MY8P5.?F!)'(XY'<T >
MA6FLZ7?W3VMGJ-I<7$:[WBAF5V5<XR0#D#/%,O\ 7]&TIRFHZM8VC#;E;BX1
M"-V=O4]]K8^A]*R/ .D'2/"T44UD+:[>>XDE!0!FW3.02>^5V_ABL#5;F.U^
M)&O,^@W.JF31K:)?L\*R%=SS_(<G(#8Y/3Y>>U '<:AK>DZ3'%)J.IV=FDQQ
M&UQ.L8?Z9/-%WK>E6#QI>:G9V[R[?+66=5+[CA<9/.3P*\UM_#FM:)/H[7SZ
MJ8DT&#3Y'TVWAN2DBEBZ,KHQVD,HR!@[>>U;V@^&$L?%&E2?8KA[.ST!+:"6
M]56DC;S,[21P&V]<4 =;;ZUI5W?SV%MJ5G->6X)FMXYU:2/'!W*#D<^M,L?$
M&C:H\Z:?JUC=O ,RK!<(YC'JV#Q7GTNDZU/::WH>AVU_#I]U8WFT:A"L9M[B
M1LA(I0<NKEG)SG''S=JOQVMQK&LZ3<66@7>EQ:;I]Q#/]HA$6=Z*JPI@_, 1
MG(^7Y1SS0!V=GKVCZC=M:6.JV-S<*@D,4-PCL$.,-@'..1S[BDL]?T?4KJ:T
ML-5L;JYA!,D,%PKNG;D Y'-<;HOAZZT^U^'QBTSR9;&TD6[ 0+Y;-;<A\>LF
M,^]4] MM>O/%/AZ]U"QO86M;>YCNHVM(X;>V9E&$C*_,RY'4DC@=Z .Y\+ZP
M_B#PMIFKR0K"]Y;),T:G(4L,X!IT7B709]1_LZ'6M.DOMQ3[,MTADW#J-N<Y
M&#^59_@FVGTGX>:+;W\1MY[:P19DDX*$+R#Z8KS_ ,&K=&W\-KJ*W5HTFGS6
MNCRBU1$9Y8_,)9UE9FX3()1,]2,T >J6VO:/>ZA+I]KJMC/>Q9\RWBN%:1,=
M<J#D8HCU[1YM4;2XM5L7U!,[K5;A3*,=<KG-<%H^FWMQ:^#=*30+K3[K1)5>
M\NI8U6-0L3(X1P?G\QF!X[<FH-,TG43HOAWP\VB74.I:;J4=S=7[Q@1820L\
MBR9^8R#(P.?G.<8H [#7_&.G:0Z6L%W97&HF[MH)+/[0OF(LLJ(6*CG@/GIZ
M5K)K.ER:HVEIJ5HVH(-S6HF4R@=<E<YKS632;]=,AT9_#EW-J$'B);Z2_P#*
M4QM&;L2>:'SDGRR%('( .>!6_IL-_9>.'BTVTOUTVYNIY[Y+VW41Q.5.)890
M<G>P'R\\$_=QB@#K-2U?3='@6?4]0M;*)CM5[F98P3Z DBF7&NZ1:6L=U<ZI
M90V\L9DCEDN$5708RP).".1R/4>M8OBZ;58;W2_L,%Q]E;S1<7-G:I//$<+L
M50V0 WS9.#T'3.:YWPSX<OHO^$*&H:9(/L"ZB91,BGR69QY><< D=,<>E '>
MRZYI,&EKJDVIV<>GN 5NFG41-GIALX-5/#FOIX@&IR1"(PVEZUM%)$^]95"(
MP?/3G?V]*XJ#1[_2SI5Y+I%Q/96&N:C*UI#&&98Y7D\J14[@;NW(#9%=%X"L
MI[.WUQYM+DTU+K5I;F&W=5!V,D>#A21R0<^^: +6J>,M/T)+Z75I+>W@M[N*
MUC*W2,[F0(<E21LQOR0>=HW=*T+CQ)H=I;VUQ<ZSI\,-T,V\DERBK*/523AO
MPKB]<T749;?Q?)'I\TWFZO87<"*H+31Q+;%RF>I^1Q[D8IFL6-[-XHN-4:'6
MX=.U#3(K>-;.RAE=,,Y>*1)$8IG>IXP.N>@H [F^U_1M,;;?ZM8VK?*<3W"(
M?FSMZGOM;'K@^E26^LZ7=WEQ9VVHVDUU;C,T,<RL\8_VE!R/QKA[?PJ8KO4T
M_L^>:!?#%M86LEVJM(Q F#(2.-W*9QQG%%OX=DMD\)@Z1+Y,&@W-M?1P(%;<
MT</[L\CYF8/C)ZYYH [C3M8TS5UE;3-1M+U8FVR&WF638?0X)Q5VO/M"U:\\
M.:=>?;+74)]*MS:VNG&YMDBNY&9MGE;1C>%RF&P,Y;KC->@T %%%% !1110
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MB=3\87MCXDMX(+VUN[5]2BL);>+3YCY6]@O-SDQ[P2"5P/3K61;_ /(1L?\
ML=KG_P!$34 >H2RQP1F2618T'5G. /QI]<I\2BX^'VJF, OB+:&. 3YJ8S67
MJ?B_6?"TVJPZP+*^>'2SJ-N;6%X@&#B,QL"S$C++AA@XSQ0!W]%<CX9UW6;W
M6I+&_ADFMS;><MW_ &5<62I(& ,>)<[L@Y!'H<BK?B+5=2AUG2-%TE[:"YU
M32-<W,1E6..(+G"!ERQ+J.O S0!T$<L<N[RY%?:Q5MIS@CJ#[U%:6-K8K*MK
M D0EE::3:,;G8Y9C[DUYCIGB+4M#TV:UVQ?VEJ'B*\A>6&UEN$CV@N[+$GSM
M]W &>,Y)P*T9/'&LPV%I;36DD5]<ZC):1W3:5<8>%(O,\U;;_6$X^7&<9!.<
M"@#T6BO/QXK\2/8Z="EK!#>76LMIPGO+*:!)8O(>03+$Q##[H&"<$J1D9R(#
MXJ\56UE?WMR^E/!I&J)87"I;N&N@SQ@NOSXC(65>/FR0>@H ]'JJUO96MS/J
M+)%%-)&J2SL<9122H)] 6;\ZX2]\;ZRVJ:G_ &;:230Z?>BU%G'I5Q,USMV^
M8?/7Y$/S' (/3GKQ1\::KKFL^%_%<EM)8Q:58SM9-!)$QEEV[-[[PV%Y;@;3
MD#KSP >ITA(52S$ #DD]J21Q'$[EE4*I)9C@#W/M7G=GXNOK[4)--FN[:_M;
MS2[FYCG@TZ>V52FP81I"1*I#]5]/<4 >B1R)+&LD;J\;@,K*<A@>A!IU>;^$
M-6US2M+\$V]_)82Z=JEE'!''#$RR0%;?S$8N6(?*H<_*,$C&>]O1_&-]<^)[
M&Q>]M=0L[^&=TEM].G@1&C (V2N2LJD$C*^@/?% '>TQY8XMOF2*F]@J[CC)
M/8>]<#X=\5>(KQ?"E[JATUK77T*^3;0NKPL(6D#;RQW [#D8&,CDXR<VXU77
M-?MO"FM7,EBNF7FM1/#;1Q,)85!<(2Y8AB0.1M&">* /4B 000"#U!K)T_PM
MH6E78NK#2;2WG4$(\<8&P'J%_N@^V*Y67Q;KPT>;Q1&;#^QXKYK?[$86\YHE
MG\DOYF_ ?(+!=N,<9SS2:AXK\1VZ:_J4)TT:=HVHK;&!H7,LZ8C+?-N 0@2<
M'!R>P[@'H5-DD2&-I)75(T!9F8X  [DUY]K'C;64U;68M)M7F72I%B6V32[B
MX:[?8KL/-C^6+A@!D'GD\$54\9ZMKFL>'/&JV+V4&FZ;;R6LL,\+&68F .[!
M@P"8#@ ;3D@YQG@ ].!!&1R**@M.+&#_ *YK_*N)TCQC>W/BBPL6O;74+._C
MG99;?3IH$C:, C9*Y*RJ1D$K['OB@#O:8\L<9022*A=MJ[CC<?0>IK@?#WBK
MQ%=)X5OM3.FFTUT-'Y%O"ZO"PA>16WEB&SL.1@8R.3C)S9-5US7H?!VMW<E@
M--OM7CEAMHXF$L*[)=F7+$/E>O"X/2@#U.F/+'&Z(\BJTAVH&."QQG ]> 3^
M%9WB*\U"P\/WEUI5K]JOHTS%%M+9Y&3M!!; R< @G&.]</J&IWNL/X2FL-3L
M;N]&L31"9K22%8B+6;(DB+;@R@D[<C/'3.: /3*8\L<1022*A=MJ!CC<<9P/
M4\'\JXJ+Q1J2Z-?)?7]A;7]GJC:=]H%G)*L_R!QY<*MN+D,/E!/0GI66NO76
MOQ>'9+P*9[7Q.UJ76!X/,"PS8;RW^9"01D'O0!Z3'+',F^*177)7*G(R#@C\
M""*!+&TK1"13(@#,@/(!S@D>^#^5<S\/O^17D_["5_\ ^E4M9%TNN'XB^(3H
MEQ80.FEV;NUW"TFXAKC:H"LN ><MDX]#G@ [V2&*9HVDB1S&V]"R@[6P1D>A
MP2,^YI]>;?\ "P-0U7^SH]-C^R-/I,.HRM_9D]]\TA8+'B+&T91LL>O&!UKN
M=#OKG4]"L;V\LY+.ZG@5Y;:0$-$Y'*D'G@^M &A1110 4444 %%%% !1110
M4444 %%%% !1110 5B:MX5T[6+_[;.]W%,T'V:4V]PT7G19)V-@\C)/H>3S6
MW6=JFOZ1HGDC5-2M;,S$B/SY N['7&>P[GM0!'I_AW3],N+:>V1Q);V*:?&6
M<G$*'*CZ^]4&\#Z0+338(&O+4Z="UO!-;7+1R>4V-R%AR0< _49&*B\/>*IM
M8L=%N)DLHA?PW$KCSRK#RV &Q2#N'/)R,<=<UI6_BK0+JUFNH-8LWMX61))1
M*-JESM3)]"> >AH L:-HUEH&E1:;I\;1VL3.R(S%B-SESR>>K&LFX\-?:OB+
M:>(I8XA%9V#01,&.]I68\D=,*I8 _P#31JTK#Q'HNJ6MS<V.JV<\%M_KY$F!
M6,8SECV&.<],4RP\3Z%J<%S/9:O9S16R[YV688C7&=S>@P#STXH I3^!]'N+
MZ:X?[6(9YQ<SV:W+"WEE!!WM'G!.0"1T)&2#3-4\!Z+J]U>S7/VP)?%6N8(K
MITBE=0 KE <%@ OY#C(K0B\3Z'-I<NI)JMH;*%MDDWF *K'& ?<Y&!WR/6G?
M\)+HG]D-JW]JVG]GJVQKCS1M#9QM)_O9XQUH T9H8[B"2"9 \4BE'4]"",$5
MR-Q\/[.+3+B/3[BY-X-.FL+1[V=IHX8W4 +M/&T;5[9P.<UH^'/$T7B+4-92
MUDMYK.RGCC@GA;<) T2.23TR"Q'X5;N/$^A6NJKI<^K6<=\S*H@:4!MS?=!'
M8GL.IH Y;1?"&I)-]GO!)9Z4UA):7-M_:\]Y]H+ *& D $> &Y7D[N@Q73W_
M (;T_4+"RM)//B^PE6M9H92DL)"[<AA_LD@YX(/-95EXO&I^/KW0;6YT\06*
M*)49B9Y7(8MMP< *0H.0>IZ5?EUR<^)[O3+=(3#9:>+JX>0D?O'8B-<]AB.0
MG@]J "?PI8W6GP6L]Q?R2V\WGPW;73^?')@C*OG@8)&.F#TK2TZP73;7R%N+
MJXRQ8R7,QD<D^YZ#V&!68?%VCV>F6=SJVIZ?9RW%M'<;1<!E(89RAX++UP<=
M!FMJ&>&XMX[B&5)(9%#I(C JRD9!![C% &=-X>LY=?&LA[B.Z,(@D$<Q5)D&
M[:'7H<;VQ]:9;>&=,M;?18(HWV:,NVT!<G:/+,?/K\K&GZ=XFT/5[N2TT[5K
M.ZN$!8QQ2AC@'!(]1GC(JQ%J^G30V4T5[ \5\=MJZN")CM+87UX4G\#0!D:9
MX(TC2KRRN;=KQOL&\6D4MR[QP*P*E54G&,'OSP.:T-%T&TT%+B.R>X\B:1I!
M#),72(EBQ" _=!+$XIUCX@T?4[Z2RL=2M;FYB4M)%%(&90#M.0.G/%,E\2Z)
M!JRZ5+JMHE^S!! THW;B,A<=B1T'4T 5-7\':7K5W<W%P]Y&;N 6]TEO<M&L
M\8W;0X!YQN;\\'(XJY#X?T^"XN9T1P]S:1V<F7/,<>_:/K\[<UDV7CC33J^I
MZ=JE]96<]OJ!M+>-Y0K2+Y<; D$]2SD>G'K6R^O:3'JZZ2^HVRZ@V,6YD&_D
M9 QZD#./2@#"UGP9#?\ _"*6,,4?]GZ-<)*6D<E]D<>$0?W@6"$Y_NUUU947
MB?0I]6.E1:M9O?ABGD+*"VX=5QW([CJ*JZ%XC34HY1>-!!.=2N[&WC#8,ODN
MXXSU.U"3]#0 G_"&Z4MGI5O";J#^RRWV62&=E=0WWE)'4'O]*>GA2QAU22^M
MKF_MA+/]IEMX+ITADDR"6*@]R.0.#W!R:CUOQKH>@Q127=[$0]XMDVUU_=N2
M-V[)X"A@3Z U:N_%.@V/V;[5J]G#]IC$L.^4#<AZ-_NG/7I0 V3POIDEE=6C
M1R>5=7JW\@WG)E#JX/L-R+Q3KKPY9W-U?72S7=O<W@B$DUO.T;#R]VW&/]XY
M'0]ZTKBY@M+62YN9HX;>)2\DLC!551U))Z"N2_X3RVN]0U1-*N-/N[2RTL7H
MG:XV('WN"KMSM "@YQGF@#H](T>TT2R-K:"0J\C3222N7>1V.69F/4DU3N_"
MFE7PU#SHI=U_<1W,CI*RLDL:JJ.A'*D!%Z?UJP_B#2H;^#3KC4+6._F52MOY
MH+'=T_/G'K35\2Z&^IRZ:NK6;7L08R0"4;EVC+#'J!R1VH A/A>SETR2PNKF
M_O(Y)HIV:YN6=MT;JZX[ 94< #-3R:#:/XA37%>XBNQ$(7$<Q5)4!8J'7HV"
M[$?6HHO%OAZ:TN;J+6K%[>VV":59E*H6^Z"?4]A^%4]3\>>'=,T^ROWU&"6V
MN[E;9)(Y%(#9PQ.3P%SSW'I0!K:QHUGKMC]DO5<HLBRQO&Y1XW4Y5U8<@@]Z
MSD\&:2+"[M9?M-PUY+%+<7$\[/+(T;!DRQ[ J, 8'7U-6H-<@EO[E3/9"QAM
M(KL3BX&[8^_YF7&%3"Y#9YY]*2R\4Z#J-K=7-GJ]G-#:)YEPZ2@B),$[F]!@
M$YZ<4 6H]+M8]9GU95;[7/!';N=W&Q&9EX^KM5?6?#]GK<EK-,]Q!=6I8P7-
MM,8Y(]PPP!'4$ 9!R.!Z46?B'2M8EN;72=5LKF[A7+)'('V=@2 >1GCCZ4GA
MG6&U[PY9ZC)&L4\BE9XUZ)*I*.H]@RL* *DG@O2&TFWT]!<PBWN#=QW$=PPG
M$QSND,F<ECN8'.<@TMIX,T>RMUAB2<JM^NHYDG9V:<*%W%B23G'.>]3VWBSP
M]>O<);:S93&WB::79,#MC7[S>ZCN1Q2>&/%.F>+-*6_TR8,O\<98%XSSPP!.
M#QF@#:KB?#?@"WT^"VEU)YY;B"]FNU@6Z=K<2-*[))L/&X*P]L\]>:ZA-9TV
M2TMKM+Z!K>YD$4$@<;9')("@]SD$8]J@A\3Z%<:L=*AU:SDOPQ7R%E!;<.JX
M[D=QU%  OAS2_P"R]0TU[?S;34)99;B-V)W-(26^G)XQTJI_PB%D^EWNG75[
MJ=W;7<!MW6YO'?:A[+GH??K[UI_VOIWV?[1]M@\G[1]EW[QCS=^S9_O;OEQZ
MU%'X@T>75O[*CU*U?4!N!MED!<;>N1VH D_LFT_MC^U-K?:OLWV7.[CR]V[&
M/7/>L^U\'Z59P6T5N+F(6U@=.B=)V5EB)4\,.0V5'/6K>I>(M&T>YAM]2U2T
MM9IAE$FE"DC.,\]L\9Z4VZ\3Z%8ZFNFW6K6<-ZQ4"!Y0&RWW0?0GL#UH H_\
M(1I+6MQ%.UY/-/-'.UW)<L9Q)&,(RN,;=O;'J>N35C_A&8OL'V;^U=8W^;YO
MG_;G\S.-N,]-N/X<8SSUYJQ-XBT:WU,Z;-J=JEZ%W&%I!N V[N1V^4$X].:H
M:'XWT'7],GO[:_@CA@D,<WFRJOE_O&123G #%<KZ@B@#6TK2[31M-AT^R1DM
MX@=H9BQ)))))/)))))]35*?PMI-S9:G9S0.\.I7'VFX'F$'S,( RD<J1Y:D8
MZ$9K9HH YP>"=):RU&WN7O+M]1@%O<7%S<-)*8QG"!C]T#)/'<YJU>^%M)U!
MM2-U T@U&.*.X&\C(C)*%<<J06SD<Y K9HH R-(\.6>D74UVDMW=7DR+&]S>
M3M+)L7)" GH,DG ZDY.:S!\.O#:Z5'IHM'^S1W_]H*OFG/FXQU_N[?EV],<5
MU5% &-J?AC3-7DU![N.1FO[);&?:Y&8@68 >AR[<U5\4^%UUO3]0:U*)J,^G
M26$;RDF,(Y!((P>X'.#BNCHH X_PQH.KZ=K374^^TL/LIB-FVJS7WF2[@1)F
M4?)@ C Z[N<8K<UK0;378[87+W$4EK-YT$UM*8Y(VVE20P]59@?K6I10!C7'
MA;3+JRUBTE20Q:NVZ[_>'+'8J<'M\J+3+[PK8WNIRZ@EQ?V=Q.JI<&SNFB$P
M7A=P'<#C(P<=ZW** $ P !V]35&WT>RMKS4KI(R9-196N0YRK%4"#CTV@5?H
MH PM,\)V6D@1VUUJ)M4C,45K)=NT42$8PJD] .!G..U3+X;TY-*TK30DGV;2
MVA>V&\Y!B&$R>_%:]% &-=^%],O;?689HY"FL%3=X<C=A%08]/E0477A?3+R
M6^DFCD+7L]O/-AR,O"5,>/3E!GUK9HH Q=1\*Z7JLFH274<A>_BABE99"I B
M9GC*D="&8G/L*KIX*T@6FJV\YN[K^U8EBO)+BX9WD"@A2#_"1N[8Z"NBHH Q
MH_#&GB2.2X-Q>2)9RV3/=2F0R12,&<-GKDJ/PXJ#2_!VF:5=17"27MP]O$T-
ML+JY>46\9P"J GC@ 9Y.!C-=!10!CVWAG3;2WT6"*.0)HPQ9Y<G;^[,?/K\K
M&K.LZ1:Z]I,^FWH<V\VW=Y;E6&&# @CIR!5^B@##L/"6EV-S+=-]IO+J2(P-
M/>W+SN(SU1=Q.T'OC&>]1:5X,TO1[VTNH)+V62SA:WMA<7+2+#$<?(H)P!\H
M]^.IP*Z&B@#FXO ^D0Z0FF(]Z+>&<3VO^E/NM6&<>4V<J!DC'H2#D5L:9IRZ
M9;-"MS=W)9R[274QD8G '4]!QT&!^=7** ,6_P##%EJ>HI=W<][(BR1S?9?M
M+>0SH048ITX(!QT)&2#2GPOIAL'LC')Y+W_]H$;SGSO.\[.?3>.GI6S10!S;
M^!](>_-T6O /MJWXMQ<L(1<!@V_9G&21R.G)XJVOA?3$ECD$<FZ/4'U)?G/^
MO964GZ88\5LT4 4=8TFSUW2I],OT,EK. )%#%20"#U'N*S+;P7H\*7RSK<WW
MVV#[+,U[</,WDC.(P2<A>2?7/).:Z&B@#*TG0HM(=F2^U&YR@11=W32A%]@>
M_N<GWHUGP_9ZXUK).]Q#<6CEX+BVF,<D>1A@".Q'!%:M% '.)X'T6+2UL(4N
M8E2Z:\BF2X?SHYB,%P^<Y()SG.<G.<U-/X4L;G3HK6XN=0EDAG^T0W3W3F>.
M3&,J^>."1@<8)XYK=HH QX_#=F$L1-/>7+V5T;N*2XN&=O,*,G)/;:YX&!23
M>%],GLM0M'CD,5_=K>3@.<F0%""/0?NUXK9HH PI?"EBVJ37\-S?VKW$@EN(
MK6Z>..9P -S*#UP "1C..<U5U+P%HNJSWKW'VQ8KYA)<VT5TZ0R2  !R@.-V
M /;@'&1FNGHH 9-#'<020RH'BD4HZGH01@BN>L/ ^DZ?-#*DE],T%J]G")[I
MY!%"VW**#P!\HYZ^I/%=)10!S>E>!M&TBXM98/M<JV<316L-Q<O)' K##;%)
MP"1Q]"0,"ETOP3I.DW=G<0/>N;&-HK1)KIW2"-A@HJDX QCWX'/%='10!C6O
MAC3+.UT6WACD$>C<V@+D[?W;1\^ORL:HP^ M%@N[>=/MFRVN?M5M;FZ<PP2$
MDDHF<#))^F3C&:Z>B@#G#X(T<WS7'^E^0US]K:R^TM]G,V[=O\O.,[OFQTSS
MC-6I_"^F7%AJEE)'(8=3G^T7(#G)?"#@]ON+6S10!A7?A2QN=3GU".YO[2:Y
MV_:1:73Q+,5& 6 /7  R,' '/%5]6\"Z-K-Q?2W)O$2_0+=PPW3QQSD+M#,H
M."0,?D,YQ72T4 ,6)%A$6,H%VX//%<_IG@C2=)N[.XMWO7-BCQVD<UT[I C#
M!55)QC'X\#GBNCHH QK;PQIEI::-;11R"/1VW6@+DE3Y;1\^ORN:HVW@+1;6
M[MIX_MFRTN#<6MNUTYAMW.2=B9P!\Q^G08%=/10!6O[)=0LI+5YIX0^/WEO*
M8W4@@@AASU'X]#Q679^$=+LWMI5%Q)/!=O>^=+,6>29HS&68GK\AQCH,#TK=
MHH P+KP?I=TLI_TB&62^_M 30S%7CGV"/<I[#:,8Z<FEM/!^DV<<"1K<-Y-^
M=05I)V=C.4*%B2<G(8_C6]10!2TO2[71[,VMHK+$9I9B&;)W2.SM_P"/,:R]
M5\&:9J^I3ZA++?07,\"V\KVMT\6^(;OD(!Z'<??TQ70T4 8-SX0TR:2TDMFN
MM/EM;<6L<EE.T1\D=(SC@@=L].<=:VK>!;:VB@1I&6- @:1R[$ 8R6/)/N:D
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N/UB"_L/'":S%H]QJEK
M/IAL@MN8]T4@D+?,'8 *P(!/^R,UV%% 'FFB>&M3M++PM'>:4S)9Z=J,-U;H
MZ\&1DVH#D#Y@" >GKBLS6(-7MO!6HV<ME>R:/#/IR6%OJGE"8D7*!HB4)!3&
MP MSR>HYKUZH;FUM[R'R;J".:+<K[)%##<I#*<'N" 1[B@#SC6=#UGQ/)K^H
M0:1-8B:QM;:*UNG17NFBF,K@[6( *G8"3SD]JNWFGW'B36+S4KOP[?PZ>-'D
ML)+61HTGNB[JV%P^ %"G!)'+<5Z!10!Y?=Z7XIU'3+:65=4E@TW5H[BV$GD+
M?20")E)(YC+*[Y&<$@>N#4\FA7<4-IK%KINL74D6M)?W=M?- )IP(#%O14(7
M*Y4X."=A]J])HH Y/PA:7L>K^)-0N]+?3H]0O(YH8I&0L5$**6.TD DJ21GJ
M:YW4-%UE]$\1>&%T6>6;5=1EGAU$-'Y"I)(&#L2VX-&.,;<_(,>WIU% '/:1
MI]U;>,/$=Y-$5M[H6ODR$CY]L9#?D:S%ADC\<>*[7;F74-+MYK<?W@HEC8?@
M2O\ WT*[2HVMX&N4N6AC,\:LB2E1N56P2 >H!VC(]AZ4 <3X7\/WMGJVASWM
MCM6V\-063NVT[)01N3\A]*LZ)H6HK\)8]!D!M-0;3)+4;C_JG965>1Z9'2NQ
MHH X'3+/4M1U3PJ'T&XTJ/0XW^T23-'M),)B$<>UB64D[LX PH[UGZ%IFNQ0
M^#-)GT.YA30[IA=73R1^6P$,J*R88E@=PYP,9 ]<>G44 <YX'TJ;2/#0M[FV
M%O<-=W4LB\9;=.Y5B1URI7\,5R_B6Q\4:KJ%U:&UU!H$U2UFMEMQ;BU,"21,
M7=C^\+Y5N 1T'&*]+HH \NU;2-8DMO&6CQ>'9I7UV\S;7P:/RU4QQKND);<
MA4L.#D].:V7L]5L_&JRZ1::C%'<W"'4FG\IK2>-8POFJ=V]9,*JX&,XY&.:[
MBB@#S'3=%UDZ'X>\,RZ+/#/I>HQ7$^HLT?DLL<A<NA#;BT@XQM!^<Y]YTT?5
M],:PU(:7/<_8_$6H7;V\+)YC03><JNH) /\ K%.,YQ7H]% 'FATG6VT6]O)-
M&G2?_A)HM4%F)$:1H%,1.#NVEL \9Z@C)I=6T?49O$.KWDUIKS6&LVD"^5IY
MMBR@(5>&429P>2<@[?F/->E44 <KXIT2YN_ 7]F:? \TL MF6WE<;IEBD1C&
M6Z98(1Z9-<[J^FZOK\WBN]AT"YLQ?>'C96ZSF,232@R=0K''W@!D]!7IE% '
M"7-GJMIXKMY]&L=1BEGDMDOW?RFLYX54!FY;>KJN0,8R0.".:3P];:IIVAR^
M'+G0;DS1-=$W^Z/R9-YD97!W;BS;@",9&3GBN\HH \YN_#6IQ> _!L%K;7$<
M^D-;S75M:&,2Y$+(Y3?E"P9]W/7!QSBDGT.Z716O[/3]8FN3K=MJ%Q#>M")Y
MEC*!F14(4?*O0X)VGU%>CT4 >=^(_#^K:W/XAGMK%U%[IE@(HIG5?,>.:21X
M6P2 2I"GM\W6F:SIVJ^)9M7U"#1;JQ7_ (1ZZT^.*Y,:R7$LF"J@*Q&U=N,D
MCE^.]>CT4 <E;Z/<6OBGP_=):B*UM-&GMIF7 ",6@*K_ ..O[<&E^'ZR'P8+
MN-1F]N;J\A5N!LEF=T_ J5/XUU4D:2QM'(BNC JRL,@@]012111P1)%$BQQH
MH5$08"@<  =A0!YSX?L?$MUXIT'4-7MM15K2VN([LSK;I!%(ZK\L(C^8IE>K
M$\8[YKH? ,%[I_A>#2K^PGM9[$M$S2%2DOS,0R$$Y&,=<=:ZBB@#S;2-*N/^
M%CW>D84Z1I,TFJP8.=LMRN%0CMM)N&'^\M1:;HVL'1/#GAJ719X)M*U"*XN-
M09H_)98W+%T(;<6DZ8P#\QS[^D16EM!///%!%'-<,&FD50&D( 4%CWP !4U
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MQ\A&Y.!N^\.G. #M:*XI_B);26.D26MK&+O489)Q#>7:6Z0K&P5]SG/.XX
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MA[*27^R+>WG;8XS*)68 #T(V?CFH&\;FP_M4:YI4NGR6%D+\(LRS&6(EACC
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M: -JBN)M_'4>LZ)I[VUG-#<:E;W;O&SX:U\@$.6XZA]J]OO9J+P7XIOI=/\
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MS%$&?4-4NG>"+FU&DV=WK1NM)TB19+*V^S!),J"L8DDW'<%!XPJY(&<UV-%
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MQ.[Y#GG!R, 8YET[PI?6EC+8W.J6D]N;1K6-H].6*7!7:&=PQW$#T"YKJJ*
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M1W0DEWY(,;9V< <]#G!/%>MT4 <_:6%]K?@3^SM=C6UN[RQ:WN5A 'E[E*\
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M5@+CYU4(&0[EVG:%!!W#C.*ZD#  ]*6B@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1)'$6EGD(X"JHZG!/H #T H TZ*Y0^))KCQ/H<4*W$%E=6E[)/!/;E)-\31
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MS*#UP2,C@C(XIFF>--*U>[@M;87<37<+36DMQ;/''<*H!8H3C=C(/N.1D<T
M='17)V?C6RCT;1Y)I;G4;N^M/M(^Q63EFC&-TAC!)1>0,9)R<#-0^'?%\EQX
M.TW4KR"^O[B[,Q'V.T+G:LC $X "\;>N"??F@#LJ*Y"?Q[:_VIH,%C97=Y::
MM \Z7$,#':!C QCKR=P/W>*LIXJM;.WOIKVZ:Y*:F]E!#;VK"0N "(E4$ER!
MD[N!C/3% '345S;>.=%CTR:]G:Z@$%REI/!);N)HI7QM!3&3G<"",YSQFG1^
M-=):PO;J1;R![.:."6VFMF68/(0(U"=3NW#&/7V- '145R^J:_<0'0=0B2YM
M[2XU 65U;7,.Q\2 JAYY&'"=#@AC[5U% !1110 4444 %%%% !1110 4444
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M9XYJ*'P?XAL]'T6R,MM=QVJW(NK9+V:UCDDDDW))N0%F"C(V'^]WQ7HM% '
MZ=X3UK1K'PF;<6-S<Z0D\-Q&\[QJRR_Q*VUCD8'!'/K4DGA+5[>Y_M*S:SDO
M+?6YM1@AED94EBDB,91F"DJV"2#@C(]Z[JB@#A'\):O?33ZE=FSAOKK5K*\D
M@BD9TBAMRORABH+.0"<X R0.V:NZAX;NYK_Q%<&QL-0@U(6H2UN9FC#",$-E
M@IVG)!4@'D=JZZB@#SN;2=4@TWP]H=],9KB;6UNU3SGG^SV\+&8*96 9]NU%
MR>[ 5W-BVH%KK[>ELH$["W\AF.8L#:7R.&SG(''2K=% !1110 4444 %%%%
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M3DJ-QVX(SBK<GCC6;31==N)+2*ZEL(H9;>X^PSVD4V]RI0K*<AEQU!(PP^E
M'H5%<BWB/5=#U6UM_$K:>+:XL[B<3VB.H22+#LAW,<_NR3GC.P].@PSXNN;
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MC0/#NH-!;B74]2^QRJ V%7,HRO/7]V.N>IH [$NJLJLP!8X4$]>_%*SJN-S
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MJ+F,Q[]BKN.Q@ WS$L.GR]:LZOXKU]+O7/[*ATT6NDZ?%?,;I7+RAD=B@VL
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>foraresidentagreement010.jpg
<TEXT>
begin 644 foraresidentagreement010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEE );. P[@\=* /0**P/">N2Z_IKW4MQITQ# $6;/F,XR4=6&58>_P"0K?H
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MG?PV.D6Z3?:MUW=QVT8M[HVV7;) :4<HO!R1ST ZUPMGK=ZVB&SN-5F@L/\
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MOK74;I[(V<,4%O/K OFC;=F1SMDD49.W&3G@] <4 >S22)#$\LKJD:*69V.
MH'4D]A0CI+&LD;JZ, RLIR"#T(->:ZUI\MG=>(M$74M4N+6?P^UV1/=N[B96
M894YRH;C*C"GIC'%,EC$'@OP])IVKM/:Q0>?<VC:R\$MP/*7.R7=D;"0=F0O
M(SCB@#T^BLK1-8L-1L+#[-<,9)[**Z2&=_W_ )3#Y689S[$^H-8$<%SJ/Q&U
MGS-0OQ!IUO:2V]G%<M'$TC>9DL!U!V@8/'/(/& #M**\J\$W6N:G-H6J2:E
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M$G7=EN#V!([X!!)9^,[6:94OK"]TM9+1[V"2\"!984P68;68J0&4E6P<'ZX
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MRYY"5V[F/\.1R0,Y]JU+'PO-:7'A>1KF-AHU@]I( I_>%DC7(]!^[/YUTU%
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M](\MS&V665G&&R#Z@=.E4]*\)Z+HLYGLK1A*8O)#33R3%(^NQ=[':O ^48'
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MB"&210H4D'"J<Y(QCJ.IJ'4?'-OHJ3/>;+A?[673U%I%*QC!"9W_ "G+#?G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9_=49;]V.>]&G>"HK#3M(L'U.ZN+?2;M;BS$BH"BK&R+&2%&0 YY// KJ:*
M.2A\"01-%;'5;U]&AN_MD>F$)Y:R!_, W;=Q0/\ ,%SV';BK<OA"TFTG4-.-
MQ.([W4!?NPQE7\U9-HXZ90#\:Z*B@#GYO##7?B"TU.\U2YN([.9Y[6V:.-1$
M[*5^\%#%0&. 3Z9SBN@HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:KK
M>F:)%%+J=]#:K+((X_,;!=B<  =2?I5^N*^)WV"/PG-+/]F6[\RW6)WVA]OV
MB(L%)YQP"<>E '3:MK>F:%;I<:I?0VD3N$0RMC<QZ #J3]*O]!DUP_Q,ETR3
MP/=7326C3%46WE+*6*F6/<$/7' SCT%=->76G7UL;!M0@5KZ"41;95W.@&&9
M>>=N1D]J (=-\5:'J]Z;.PU*&>?:755SAU!P2A(PX![KFK6K:SIN@V#WVJWL
M-I;+P9)6P,^@]3["O/-.@U"/Q/X*T@WNDW::5'*?,L-Q?R%@,8=QG" DH,<Y
M/0\5M_$&[TB_^&VL7Z7%E<!M/N%M9PZMDE2&"-Z\8./2@#M58,H93D$9!I:K
M6$\-Q80202I+&4 #(P8=/459H Q]6\5:'HERMMJ&H1Q3E/,\H!G8)_>(4$@>
MYXK2M+NVO[2*[M)XY[>50\<L;!E8'N".M<;X=U"PTSQ5XPCU2ZM[:_>^2<-<
M2!"]MY*",@GJH(<>QS7.:,EQ<IH=K:7MY8Z3JFN:C)"+60Q%[7;*Z 8Y"DC(
MQ@X.1C@T >MT5R_@B6X-GJUG/=3W*V.J3VT,EQ(7D\L;2H9CRV-V,GG %<B]
MYK^I:YK,L-]#;7=EJOD0>?J[PI'$I7"M;A"KAU).2<G=P1@4 >K45YI#JU[_
M ,+(.D-JET=!^WN\=P6/S78C#&SWY^X,E\>HV=L5EZ9JLK6&D:E%XCO;G69-
M>^QR6;7A93";AE9#%TXC^?<1D8'.,"@#U:SO[:_69K:3>(9G@?Y2,.IPPY'.
M#WZ59KRY[K4M2DL+(ZM?P)<>*;ZUD>&<JYA5)R(P>P^4 8Z<$8(!J76KS4M%
MU>Z\*6^H7K2:T+8:7/),SR0CB.XPY.<JB>9GU?- 'IE%<UXZO[G2O!]Q/:7#
MVQ\V"*2Y7EH(FE19).>X4L<]NO:N/UN^FT9/%%KHFM7MS:1>'I+LR/>M<-;7
M&2$*R$EE++DXS_#D8H ]5J.*>&<.894D".4;8P.UAU!QT(]*HZ'IO]F:<(VO
M;R\DD/FR2W4QD8L0,XSPHXSM& ,\"O,8G?P]X2\77.EZA=?;H]7D@?SKUV\F
M)IT5I"&W;3M8G?@GOS0![!17E5_+K>E>%_$\\&IK% EE%);I'JSWTT$NX@N'
M90P5ACC)&5..M;.J:3-:ZWX:T2/6M8^S73W3W4GVQ_,FQ&IQNZJ,C.%QC)QB
M@#O*K6=_;7ZS-;2%Q#,\$GRD8=3AAR.>>_2O,;!M1M;'3]2;7-4GGA\2'2PL
MUR61K<7#0[67HQQSN;+9[U8>\U'4);*S.JWT*3^*[RU=X9BK&%8YB(P>R_*,
M>G!&" : /3ZCFGAMU5II8XU9PBEV RQ. !GN3P!7FPU(V&FZEI-U=ZG<JGB#
M^S[(_;VBD(:%)0CSD[@HR_.=W '-8\TCZKX-'V_4+DPV'BF&W25-1>39%YT7
M6;@OMW'#'D<>E 'KD=_;2ZA-8I)FY@1))$VGA6SM.<8/W3T]*LUYGX@UB_TI
M_$J:?J-Q]GM=,TWRIFE,ODH\LJ23 G.6V#<6.<[03TJ+5+R32)?$%KHFMWMW
M:+X:N;QWDO6N&MYU&(W60DE2P+G ./DR!0!ZC17"Z*EUIGC#2;<ZI?W<6I:1
M-<7"W<YD!E1X<.H/"<2,,* .G%6/$MQ]H\8Z3H]]J-QI^ES6<\^Z"Y:W,\RL
M@">8I!&%9FP",_A0!T.LZW9Z';PRW?G,9Y1!#%!$TDDCD$[551D\*3] :MO=
M016PN)I%AB(7YI3LQG  .>AR0,>M>3B&37$\,&ZU*_GAC\175I:W:7;HTT"Q
MS['W*1N;Y=N_J0#SR<]9\4;:.X\"7)EEFB6&>WD+1S-'QYR [B",@ D\]" >
MU '3?VG:G63I.\_:Q;BYV[3C9NVYSTZCI3WO[:/4(;!I,7,T;2HFT\JI )SC
M ^\/SKA)M$M]2^($5I%JNHK;1Z$,2V]ZXDD_?L 3*#N.#[\]\]*JZ/K>JZA:
M^&7FU9H)+GPY>2RW$C802J80LSCH2N2<GU/K0!Z=5&_UC3M+GLX;Z[B@DO9A
M!;JYP9'/117-^ [LYU#2[EKEM0LUA-S(^H->12%P</&['*YVDE<#'''-<[XN
MCO\ Q1K^M0V&D7E\-,M%M+2>"2%5@O"5F+'>ZG(VP#@'^(4 >J45X]K_ (Q_
MM@Z?(+NZMDO-%\Z".#4DL?*NV8KEF:1-X4J00-V,<J<BNALK"[N?&-AIMQK>
MH-;6FB6]RRV]X^V>;S7&]FSE@<=,\C&<X% 'H%%>4Z)>:_JFHQ:@;Z&"Z76'
MAN$FU=PHA69D,(M=FT-L VG.XG!SS1H=YK^J:A#J!OH8;I=7DBN4FU=P!$LK
M(81:[-H;8!@YW$X.>: /5J*\FG&IRV<^IIK^K17)\4/I\82X/EQP/=&(J$.5
M. V02"1@8P!BGZOJ.J:#!XBTRRU"[>VAU&PC$]U=L7MXI@OF?OF#%1G^(YV[
MB1TH ]6J.>>&V@>>XE2*&,%GDD8*JCU)/05YA>-KEAH.HHFK?9X9-0TY+86^
MJ->36^^=%DS(Z@[6!& V1][MQ4'BBTE@T3Q]HQU#49[2UTR"\A$]V\CHS++O
M&XG)0^6#M)QUH ]:HK*TN;3;.TLK&#4A.9E=H#-=F:24*<L0S$EL;A].*P_'
M.M3>%IM+U]II?[/A::"[A#':P>,F-B.F0Z*H/^V?6@#L:*\I\.ZIXB:_LO#5
M]>7$^J:2T][?-O(,Z&)6A1CW4O/C'_3'VJ7P/<:WJ$^@:I)J4+"[C9K]9=7>
M8SDQD[5MR@6)E?'"D8 (.>M 'J-4X]3M9=8GTI7)NX(([AUVG 1RRJ<_5&KG
M?'7VH16,D%V!!"9);BR34#92W*!>J2*0?E)!QD Y&2*YQ+>+Q)XCO;ZVU'5;
M6!O#5E<0F*X:&5BS3E&<KR2/3."2<@\4 >HUEZAXAT[3)[J&ZE97M;%[^4!"
M<0J2"?<\=*\^U#7WU+P]HPFN;Q=1DT%-1EE34S8Q+E1ER5Y=MV?EP5'?K5:\
MO9]2T>>^NGWW%SX ::5\8W,RY)_,T >MPRI<01S1G*2*'4X[$9%5M4U.UT>Q
M:\O'*0*\<9(4GEW"+P/=A61JM[>:;\.+J^T]=UY;Z6TL(VY^<19!QW^E<CK\
M&G?\(%<+I_B2[OYK@V#NTE]]H*YN8\2JK9V9/887CIQ0!ZC17G%W>CPM?>)[
M.?4=6N-.AT^TN5W71>9))9)(VV2.?E!*KWPO)&*Q9=6U2TTOQI:6^H3P&S2Q
M>W*ZDUX]N\CL'Q(W/(4':<@9/8T >PT5Y=XMN$\.:EIFDS:GJTMG)9W$N3JX
MMI7GW($8RR2)N RWR X&<[2,5#+)K"7>@:'<:@US'_8PN'F&M26WVFX+8=A,
MH9I O!"YQANF , 'J]%8>AP7]UX-MK;4K]);V2V,<EW:2YR2" ZN .<8.0!S
M7"V7B77K^PNC#+,U_P"&M(N5O$7.)[X;D3</XN(F?'_31: /5J*\VTNY%MKG
MAI=)U^\U/^TK69[Y);PS@J(MRRA22(_GVK\N!\V,<5'H'B5[RU^'%O\ VNTU
MY<J_VV/S]SR;;63/F#.3AP.O<>U 'IM%<MXSOH85TRP8W9FO;ADB6"]-HK;4
M9COE'S 8'0<DX]Z9\.M0N=1\)B2YN3<-%>7,"2F;SBR),ZI^\_C^4 ;N^,T
M=917ELMQJMIX8\8>(H=3U":^M;R]M[:-YR8K>)9<9"="5&2"0< 8Z<5)#>W>
MB66JW]WJ#G2/[/#F*WUIKVX,A< 2([J-@(;!.=HX(Q0!Z=17E>G76IR2>+=(
MMM7%B8[2U>W>XU5KH6\LAD!!F;YE+;5&.<$Y'6E36EN(]+TEKK4-,LVU:2SU
M&5M2:8AU@\Q(TN2=VUB5YR#G*\4 >IT5Y3-?7_EW>F6&MWSZ?'XBM+.WOEN#
M)+Y;HIEC$ASNVLQ&3G'0]*N3:A_80\2Z7<7NJ7%I%>V<5K_II$RM.J_+Y['*
MINZDG(!..U '?:EJ=KI4$4UVY5)9XK="%)R\CA%''N11JFIVNC:=+?WKE+>+
M;N8*6(RP4<#W(KR.]OYG\.ZU:7>HO#:V/B'3UCG-\;HVJEH6;$SC)VDL?FS@
MY':KFMS^58>+M,L]3N-0TN"&PE1Y[DW!BF>4[T#L22"JHV,\9[9H ]<HKRG5
M;S7M1\0>(TMK^*SNM/N$CLC/J[VT<*>6C!FA"%958ELEL^@QBNR\>7]WIG@J
M_NK6=K>5?*1ITZPHTBJ[C_=4L<]L9H T[G7-/L[VXM)YF26WM#>RC82%B!(W
M<#G[IX'-.M=9LKS47L8)&:=+:*Z(*$#RY"P4\_[C<5YM-]FTWQ!XH.DZU=7A
M@\,,ZRO>&=X'RY $A);T;!/&>,#%69M5CT^_UC4;V6ZP/#NFEWMY LI9I9AP
MQ^[DMRW;DT >GU!>WD&GV,]Y=/Y=O ADD?:6PH&2<#D_A7DD^M:CI^D>-8(M
M1GMUL([&6%AJ37C6S2.P?]XW/(4':<@9/8U;U;49=,7Q/!HFOWE[:KX;DO3,
MUX9S!<?,$97S\A9<G P/E! % 'J%Q>0VUA+>RL1!%$9F8 _= R3CZ4MI=17U
ME!=P,6AGC66,D8RK#(X^AKS#Q%=I?3^*8]4UVZL!8:;$;*&.Z,2OOB8LY7I+
MN?*8(/3 Y-5=;U?R_#,45I<7L%[IWAZ"Y\P:H;2*,LC;"J#_ %K$K@@@CH.I
MH ];\^$W!MQ+'YX0.8]PW!2< XZXR",^U16%_;:G91WEI)YD$F=C%2N<$@\$
M ]0:X/3X(+CXGV]]=7MREQ<:';3JGVMT1WWL"H3."O0[<8R<XR:SM'U*XU6/
MPQ8:QK%W;65S9W<[S+=M"]S,DP54,H(;A2QP",X]!0!ZM17E6GW>HZL^@:>V
MM7YL9=5O[9+J&<K)=6T2N4RXZ_=QN')QD'/-3*VJ3:'-91ZM)*NGZW<0^3<:
MBUO-=VZ XC$X^;*E@<YY"X)H ]/K,T77K+7X))[ 3M C%5FDA9$EY(RA(^89
M!Y%0:%<VVO>$+.>W>\2VNK4!6DE(G (QDN#G=_M ^^:\QTEKS3_!G@FRM;BX
M%KJ9D:Y,NIR6X+*F4C64 F,'D[5QDK[F@#VBBO*KV\U^TT_1--N;^&6WNM2N
M(VDCU9E/EA"T<+W03=NSD9P&.T#/)KK?"ES<6&E>1K.IVCO)?/#9_P"F_:&V
MD;EB,C %W&&[9P!UH ZBBN8\:WT^C6FFZVEQ)%:V-]&;U0Q"M ^8V+#N%+J_
MMMKB] UW7+[4K+0[R]N5NM2O8M95MY#1V#H9#%GT#H(\>CXH ]/TS4[75[,W
M5FY>(2R0Y*D?-&[(W7_:4T^TO[:_$YMI-_D3-!)\I&'7J.1S]1Q7EVD07&FZ
M3INKV^IWZR2^)I;9H///D>5)>2(R^7]T]2VX@G/?'%6I=6O)[F.QO=5N;;3[
MGQ+=VL]PLYC98UC9HXA)G* L ."#V'6@#T234[6+5[?2W<B[N(9)XUVG!1"H
M8Y^KK5RO.+C2[34O&?AZSM=:OY[1-.O\W$-Z3(X$T(*&5?FP#QP<_+@D\YZ/
MP'=W-YX0M7O+B2XFCFN(#-*<NXCF>-2Q[G"C)[T ;M[=PZ?87%[<,5@MXFED
M(&2%4$GCZ"G6UQ'=VL-S"28ID61"1C((R*\ON+R2U3Q#8W]Y-?7-[INH3V]U
M!J#36[Q#D*8<XB90RJ"!@X/.:MZ69?#=[H!.J:E/:WNAW$]TDTQD :)865HT
M/"$!V&% !XXH ]%N)X[6VEN)21'$A=R!G  R:HV&OZ?J5S!;VTK-)/9)?("A
M&87.%/U]J\UTW5II=4EAAN+G[%?^'KF[,-SJIO')'E['8'(B.'884X/X5M>#
M/^1AT?\ [%*S_P#0S0!V_P#:=K_;(TG>?M9M_M.W:<;-VW.>G7M5RO/?$45C
M<?$^V@U#5I].B?1G(,-V;<R$2YQO!!X&3@$=.<@&L.#6]:U+3_"5K<W+R07=
MM=2-*^H/8M=F.0+$3*BELF,[\#&[KVQ0!Z]16'X1&H+X:MUU.[AN[E6D7SH9
M_.!0.P0%\#<P7 )QR0:XNS\2RMH/AJW?5V.I2Z^]O/&9\RLBS2@JPSG:!M&#
MQT]J /4**\NDUB_T2YUO_29M1U2:SOKK3[B"_,\#JAW*C09Q&R951@$-@\Y.
M*AL[S7['2+K5K"_BG7^Q)[CRWU=[YYY@JLDJ(R#9@Y!"_+\P&.* /2Y]3M;?
M5;339'(NKM))(5VD@K'MW<]OOK5AYX8I8HI)8TDE)$:,P!<@9( [\ FO--&2
MP3Q[X7-GKUSJC2Z7<RR^?=F?:6$7SC))7=SP,#Y> .:U/'%C:S^+?"4MW>W-
MK$;B>-GBNW@"_N)".5(P21C/4CB@#NZ*\HUG4Y7L/%NJ2Z]>6FLZ9>21:?9Q
MW11 %53"OD@XD\PGJP.=V!TKU2)G:%&D7:Y4%E]#W% #Z*** "BBB@ HHHH
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MM%)%!IUI%'*P>14@50[ Y!( Y(/.:QS-?^%;&ZU+7==;4;*.,97[$J2"0L
MFSKN)P%()R1S4;>.+:VAU(ZEI6HZ?<6%BVH-;SB-GEA7.60H[*2#P02""10!
MT<EI;2F4R6\3F5!'(60'>@S\I]1R>/<U##I&FV\#00Z=:1PL IC2%0I )(&
M,<$D_B:YP>/5>\^Q1^'-;>\> 7-O!Y48,T.<%P2^%P<<.5;YAQDU,_CJR>+1
MVL-/U#4)-7M7NK6*W1 =J;-P8LP"GYQU..",YP" 6M7\-/J&LQ:K:ZB]I=);
MFV8&%)D*%MW 8<'/<=>,@X%2Z?X5TFQT"TT:2TBO;6VR4^UQK)EB22V,8!))
MZ  =JS-,\?V.J3:=Y>FZG#::A*;>&[GB58_/"L3&1NW9&UAG&W((!-3V_C:S
MN+RW46-ZMA<W1LX-18)Y,DH)& -V\ E2 Q4 GOR,@'21QI#&L<2*D:#"JHP
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MW-Q<7<AC@@MH][OA2S'&0, #)YJQJNKV&B61O-1N5@@W! 2"2S'HJJ,EB?0
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MC.6W!\9_0XY[NB@#GO"OA^?0=&N+.::(^=.\L<,&[RK96  CCW'.T8)[<L<
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MFV_7#8^HJ;2- UC1[JXLH;RQ?1)KN:YVO$_GJ)69VC!SMQN8_-UQQCO74T4
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M8$LC.!]1G%:]4=1U6VTMK,7._-W<K:Q;1GYV!(SZ#@T <]?^$+J_OO$L,EU
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M[L@HIW?48J*T\&744UA=W%[#)>+K$FJW92,JC,T+Q!$&20 "G)/.TGO78T4
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MC2K6]^(7A.28W 8BY'[NYDC'RH&'"L!U//J.#D<5V4=K;PRR2Q01))(<NZH
M6^I[T\HC.KE5++G:2.1]* /)[77$N/&FB76GR-!]KU6XMYXY=7EFGD15E!#V
MY&V-0RJ1@Y'R\<U)8"XUM/"ME=ZC?B"YO=5%P(KIXVE5)9-JE@<X& .#T&*]
M06TMEF:9;>(2L=S.$&2>F2?Q-/6&)2I6)!M)*X4<9ZX^M '->-6FTOPY!J=K
M-,BZ3<PW4JK(W[R!3ME#'/S#RV8\YY -<-INL:O>ZE#I,MY=?\5)>0ZK:N'8
M&&TWN[HI_A'EPQ#_ +:^]>P,JNA1U#*PP01D$4T0Q!D81(&1=J$*,J/0>@H
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M40G;"JF=O;KC/;..*ZY;6W6X:X6"(3L,-($&XCT)ZT]$2,$(JJ"23@8R3U-
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M:7)=7&JRC3AXP55NTF*^7#Y0Y5_X5Y)R. #D'O7KTEO!+!Y$D,;PX \ME!7
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M<J.>O49P37,-<:I?>(-5+ZK8V.HVVK^5;M=:Q+"\<(==B"WV['5T]3\Q8\Y
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MPW47^I"^;YSJV>#A<;>G?/:@!J>.!<Z;IKV>E3S:E?SS6Z6+2*AC>$L)=S]
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MLP<@HO "@\\<\7+/0=7M;"^1-0TJVO)HPD%Q9:4(A&1GYF4R-O\ ID 4 /\
M&VHW>E^&C=64QAF^V6D>\ 'Y7N(T8<^JL1^-9.B7.I:C\2]>^UPW26U@8XH
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MH]G<1W"BZA\^*8J"-LB97<.<]1R >U %"'QU'<:3'/%ITC7SZB=,6U$R%3,
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M:[BC,3Q3/;S1%P^R1#@@,O##H01U!%<S'\.?(L[1H;RS%]:W<]T@>QW6BB4
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MMTE/90G&#QN49IL-TMAI]M?Q2S1^&[;Q.'M9G+;([4P%2P)_Y9>:S8/3\,4
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MF[NHK*SGNYVVPP1M)(<9PJC)_054T/57UK2HK]K"YLDF >..X*%F0@%6^1F
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M7GCCA"<MCIDT =Y17$3?$>V_LW1IHK>WBN]3CDD$5_>K;QPB,A7W28;)W$
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MU8U#0IKKQ)I^M6M^;::VB>WE0Q"19H79&*]1M.4'//7I6T64#)( ]2:"0.I
M^M ',Z1X4N=$N%BL]50:6DSRI;/:*9%#,6*"7/W<DXXSCC-*_@Z)_"%]X?\
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M-HFJ1ZWH.GZK%&T<=[;QW"HQR5#J&P?SJ.?688/$-CI!C9I+R">99 1M41%
M0?<^8/RH Q+[P5/--JD=CK<UG8:MC[;;B%9&)V"-C&Y/R%E4 Y#>HQ5Z/PI;
M0S:NT,S1QZA8PV0C"\0K&KJ".>>'_2N@S2;@20",CJ* ,'1]/U33]2AM#/\
M\2:QTZ*UB4A<SS#K)QRH"@#&>2QXX!,FLZ%-J6J:7J5K?FTNK!I "8A(KI(
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M,9YZXKI:* .7T/PG<Z+%!8_VJEQI5O&88K=[11)Y>"H5I0>0!W !..3573O
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MQCP/EYS7KM% 'CQTZ2Y\3ZBFI7UI9:L=9\VUF?2I9;LPB0&(13!\>64PI 7
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M<^]6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%,DBRQA3C)VX4MR6 /UQ0!W-%<\?&>F26&FW5G'=WKZDC/;6]O%F5E7[Y()
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M<1VV8K:-DBV!V&/XF;U(SS@8H [NBL+4_%5KI-[Y-W9:@MN)8XGO1;_N$9R
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MF>)<;BG)Y&1E3@\CB@#HZ*YK2O'&E:M<VL4<-] EW;M<6LUS;F-)T4 MM)]
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M662)PV7RJ[5;;C R1G.>*U/"^AOI4EW/-I&F6$TP1?\ 0KAYBX7=]YG1>.>
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MA;R64T-V(O-5HRQN&*X$F6&/[O'3FN]O]+T_58DCU&PM;R-&W*MQ"L@4^H#
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MRL8&S<<MCTSW]:BBT?2X'=XM-LXVDF$[LD"@M(.CGCEO?K0!YK-JMZVAW7B
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MC'7'0D5#>ZM>MHNK:^-<NX];M=6>VM]/6XQ%A9Q&D)AZ-O3!SC/S9!KU(6T
MG2<01B5$,:R!!N5"02H/IP./857;1]+?4AJ3:;9M?@8%T8%,H[??QG]: .%N
M=5U./Q)<^#Q>W N[K5(KJ"?>=Z6# RR 'T#1O'[;EJLFJWU]<:?IUYJUU;6=
MWKVI02W$<QC<K$\GE0A^J@X[8.%Q7I1M+8WBWAMXC=*AC$Q0;PI.2N[KC/:H
M9](TRZM'M+C3K2:VDD,KPR0JR,Y.2Q4C!)))SZT >36VHW=CI-S;:;J,ES;W
MGBN2UEO3="-GC\D$#S@/E+,JKN R?J<UK33ZW9VMEINH:H]M8WFMK;^?%?\
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M X_5[RXTWQO%=7MW<3:;-<6]K;I:7NW[-*W&V6'@.&+ [N2 >@ S68GB6==
ML(I-58:@_BDV;(9OWAC%ZP\LCKCR\#'IBO0&TC3'U)=2?3K1K]1A;HP*90.G
MW\9_6D_L72C>O>G3++[7(59Y_(7>Q4@J2V,G! (],"@#RJXN386?BW5++7;F
M'5+/7&^SV,<X".S,@"M'_'OR1SGIQC!K5\1Z]J]I<^)(;>ZD6(:Q86@<S>6+
M>*2&(OM<@A,L<;L<%L]:] ;1=*>]2];3+(W<;%TG,"[U8]2&QD$U2TOPY'9M
MJTE].-0EU2<2W'FQ*$*A%14V],!5'7KS0!Q5U=:[I.EW$%SJ)M;"YU.S@$HU
M#[3-:12'$F96 (!( !.<;CSP*E\1Z58?;O#$<>OZA- FLO$\IU$LT)-M(=N_
M.0>!C))PY&<'%=Y;Z'I-I8RV-MI=E#:2_P"L@CMT6-_JH&#2'0='.FC33I-C
M]@#;A;?9T\H'UVXQG\* *OBFV%SX.U: 23*#9R$-%(0QPI/4<\XY]:XJQ=8]
M-\%:.FM7D.G:A;/+/.MX0[2+#&4A63.4!W,< @_+]:]."J%V@#;C&,<8K/\
M^$?T7^SVT_\ LBP^Q,_F&V^S)Y9;^]MQC/O0!C^![RXN;35H)+R2^MK/4I;:
MTNI6WM)$%4X+?Q;6++G_ &:Y;Q)KTT>M2WFFW6H(UKK%K8R-+?A(B6>,/&MO
M_&-KGD@'.2#@5Z;;VT%I;I;VT,<,,8PD<:A54>@ X%5I=$TF:^-]+IEE)=L
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MP2I 8J 2.#TI=$\+'1-8BGBG#VL&D6VFQJ1\Y\IG.X]N0P_6L;0/ /\ 85]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !112,RHNYV"CU)Q0 M%(S*BEG8*HZDG I: "BF)-%([HDB
M,Z<,H8$K]?2B6:.!-\LB1ITW.P H ?11UHH **1G5%+.P51U). *@>_LXXGE
M>[@6.-2[LT@ 50,DD]@!SF@"Q134=9$5T8,C#*LIR"/44Z@ HHJ".]M)<^7<
MPOB4PG;(#B0=5_WA@\=: )Z*BM[F"[B\VVFCFCW,N^-@PRI(89'<$$'W%2T
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M;WUT)(F%X! Q9B48LXWJK9< @D=S7;>,$T"/35O-=TV#43%F.UMI(A*TLCX
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MKM)<2.SSQ[=KEF8DGY1U/..:TK'3;33OM/V6+R_M,[7$OS$[I&QD\].@X'%
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MJ?WK2(YCW;@PSRNT@G/.#0!M:[X\TZRN[:PTZ\MYKY]3M[*2-D8KAY520*W
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M[B>WNW8':8@"6C+$Y;(4<G@GF@#H[?Q7HESIMQJ"7RK:6ZAI)98WC 4_=(W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q
M_P 13J-OX>^WV6JW%FMO-!NC@ 4REIHU^9NNW!/ QG/)QQ785@>*O#D_B:P6
MQ75IK*W)5I$CA1]Y5U=3EAQ@J.G6@#.^)!U&#PM-?6.JW%D+8HS);@*TI,B
M MU  )X&,Y'..#U-ZUPEA<-:('N5B8Q*W0O@X!_'%8.O>%[W7]"CTJ?7IXT(
MQ<2);QYG(8,IZ87!':M&+3;]9+-Y=9N)#!'(DH$4:B=FQM8@#@KCC''/- 'G
MWAW6I8=<\*QC4M9GOM162'5K>_24(DHA:0D!P%C(=",)C()Z]:[+Q@D0T^.>
M9M>:.,L/)T8N)')&03L^;C!QR!D\YXI]CX;G35X-3U75Y]2N+9&2V#Q)$D6[
MAFVJ.6(&,GH,X R:=)HFL"QM(8/$]W'/"'62=[>)_.R<@LI7@CH,8]P: (_
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MGXGC\2V]Z0+;S;.X\B1[2X$\,GRJP9'P,C#>F0017*>(_$VJZKI/GV>G)%I
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M6T8P,.'5 2??]V/SH S-;U;7[7Q[H>FZ?#9O875M<22K-.4+E#'D\1MC:&X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!4U+3;35]/EL+^$36TN-Z;B.A!!!&""" 01
MR"*K:7X>T_2+B6YMUN)+F5!&\]U<R3R%020H:1B0,DG XK4HH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y7QUJFM:/HZWVE26D444L
M0G:5"[L&E1-JCH.&)+'/3&.<CJJYGQKH^L:_H_\ 9NF/8QQR.CRO<E\@I(KC
M;M!Z[<'- $?CW5-;T;0'O])DM(DA*F9YD+N0750JKTYR<DGC'0YR.CO;AK2P
MN+E(FE:*)I!&O5R 3@?6N:\5:/XA\0>&!I<3:7%-.!]I=VDVJ5=6&SC)Z<YK
M8B&NF2S:9M.5/+D^U*@=B7X\O83CCKG(],4 <;H'BW4)M0\,-=:W8:A'KT3F
M2UAC53:N(C*-N"6*C:4.[G..G2NJ\3:M<Z?:0VFG;&U6^?R;4.,JG&7D8?W4
M7)]S@=ZS-.\+WDGB.UU?4X-)M39^8\46G1$&65U*F21B >%+ #'\1.:LR^%6
MU@6M[K5U+'J\,+P--IES+;IM9LX #9[+G/I]* +7@[4[G6?!FC:G>,K7-U:1
MRRE5P"Q7)X[5N5A>#O#[^&/"FGZ1)</<2V\2J[F1F&X  [=W1>.!VK=H XY/
M&7]G/X@FU199;>SU>*PMTMH=SX>.$J,#ECND/O6UHGB&'6I;VW^QW=E=V3JL
M]M=JH=0PW*WRLP((]#V-8L_@ZZEFOW%S"!<Z]:ZJN0>$B$.5/N?*..W(K9L-
M'EM/$VLZHTJ-'?I;JB#.5\L,#GZ[J .7O_&>IW&E^.(H]-NK*32()_LUWA,*
MRVZN-WSGYLMN&!C;C/.16QI'C.TNV%O>6M]8R+8_;1+>1!%FA7 =UP21@D9#
M!3R.*JW_ (5U2X/B^UAN+/[%KT#[&?=YD4I@6'! &"ORYSU]JM:EX3;5+^!I
MIU%L-&N=,E"YW'S?+^8?0(?S% %C2O%MMJE];6K6%_9&\A:>S>ZC55N$&,E=
MK$@X8'#!3@].M+JWBRVTN]N+5+"_OI+6 7%V;1$86\9S@MN9<D[6.U<M@=*S
M/"OA&70[JW:XTO0$:VA\I;RS@99Y3@#<<C"9 Y )J+6_!+WGB:ZUB"QT;4!>
M0QQRQ:G&3Y3)D!D(!R"",J0/NCF@#5/C32!::M=;Y?)TRWCNI&VC][$\>]&C
MYY!Y SCD$5%=^.+&SDN"]AJ#VUF46^NDC3R[1F4-M?+;B0&4MM#8SS5+6? [
MZCJ^CW%O-;VUG##';ZA;)&0LT43K)$J#L ZD8/\ "Q%5KSP$3KVIW<>FZ#J%
MOJ,XG9M2A+20-M56 P"'4[<@$K@DT :6I>/M/TR\U*%]/U.6/2W1;ZYBA4Q0
M*R*X<DL"1A^0H)&"<8P3):^*+N?QY?>'SI-S]F@MX95N@$P"YDRS?/G:=@ P
M,YSD8Q5?4O"-S>Z=XRMDN(5;7?\ 4D@XC_T=(OF_%2>.U7H]&U"U\:/J]O+:
MM9W5G#;7*2;A(IB,A4IC@Y\SG..E $NJ^)HM-U)=-@TZ_P!2O?)^T/#9(A,<
M>2 S%V4<D$  DG!XKFM5\53ZQK?A:VT<ZHNFZE'+<//9K$K-MV@*?,.0%))<
M8ST SR*VM1T768/$TNMZ'-8E[JT2UN(;W>%&QF9'4KD_QL"O?CD5#I/@V32;
MCPXR7:RII<%TDS,NTRR3%6+ =AN#<>XH VM7U>72Q'Y.D:AJ+,&8BS5/D QU
M+LH[\ $D^E)'XATV3PPOB+S]NFFU^U^:RD$1[=W(ZYQVK(\4>&[[6M4L[F%K
M*XM8H9(GL[[?Y0=BI$H5?O, ",''7@BE@\'D_#)?"-S<KN_L_P"R-/&O .W
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MU2CU2VEUFXTI6;[5;P1SR#;QL<N%Y^J-7-^/3*D5A*M]$D,)EEGL6U%K)[I
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MP6/+$  *K$DG@"LG_A.K8V8*:=>/J1OO[/&G*8_,\[9OQNW;-NSYMV<8]^*
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MLT4 1/:V\EK]E>")K?:%\ID!3 [8Z8H2V@BSY<$:90(=J 94=!]!D\>]2T4
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MW^U8QY_EC?C_ 'L9J:2..:)HI45XW&&5AD$>A%.HH AAM;>WV^3!%'M0(NQ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ IKR)$NZ1U1>F6.!3JXGXH:9:W7A5KV9&>:UGM_)R
M[;5+3Q@MMS@G&1DC(!..IH [1Y$B0O(ZHHZLQP!3JXGXIZ9:W?@VYNYT9Y;4
MQM""[;58RH-VW."<="1QDXZUU][%-/87$-O+Y4TD3+')_<8@@'\#0 Z.Y@EE
MDBCFC>2,X=%8$K]1VHFN(+< SS1Q ]"[!<_G7EFC:?<Z+XC\$V9\.KIEY&LU
MO=W*2Q,+M1 Q9OD)9@7"-EP""1ZUUOB[PY=:W?Z5=V]EI5\MEYV^VU+/EOO"
M@$81N1CTH ZE)$E0/&ZNAY#*<@TZL+P?J=OJOAFWN+;3X]/1'D@:TBQLB>-V
M1@I  *Y4X( K=H C\^'RC+YJ>6N<ON&!C@\U)7FM[HLY\=MX70I_86I2?VW/
M'GD&-@)(L?W7E,3GZN.]/O\ Q+KZZ-K7B>"^ACM-,OI;==--N")8XI/+;<_W
M@[8)&.!E>#0!Z/17"ZMXHU.ST;QW<Q2QB71Y-MH2@^4?9XGY]?F=NM;_ (FU
M$Z?I,;K?O9RSS)#&T=MY\CL?X$3^\<'D@@ $F@#;J)[JWCN8K:2>-9Y@S11L
MP#.%QN('?&1GZUYW9^+-<N;&/3O/\J^EUYM*6\N+8*Z1B'SMS1@[=^/E';H<
M=JB\9:GJ/A;5O#U[<2KJ5S#!? 3F+RU16,(#R!<_*H.6*CH#P* /3J*XJ>Y\
M0S>(M.T*UUV% ^E-=SWHM$<R.'5047.T [N^>/?FJ6E>)=;\1IX?T^*[AL+F
M[L9[N[NDA#EC%(L>V-6R!DMN.<X Q0!Z%17G5OXTU*Q%G<:O-"UE;W][IE].
MD>T2/&I:*4#^'(1E(SC<U)X8\7ZYJ\NCZ5>B*'5OM,SZDJH/EMUC610!VSY\
M"Y]C0!Z#:W5O>VT=S:SQSP2KN26)@RL/4$=:EKR+P]KVJ0^'O"NAZ=]JB#:0
M;N6:TMDGD.'"*H#G '))/)Z 8ZUOVFL>*-8OM+TB25-&OCITEY=N;=9&=EE\
MM0%)(53]X\D\@9'6@#N;:ZM[R 3VL\<\)) >-@RD@D'D>A!'X5+7D>AZ]?:=
MX8\.:>M^UFMS_:$UQ<VMF;EPR7!"A4PV%)<\D'H!D$UHKXC\4"/0=*NC>1:C
M<Z<]]>26]E&\JG<JJ@1B%4#=SG)Z#U- 'I=1275O#/#!+/&DLY*Q(S -(0,D
M*.^ ":YEKC6;_P"&US-?AM.U4VDWF$1C(*[@&VY.-R@'&>-WM7+QVVKR6OP[
M1=7#7DP=UN98 QC0VAR-N0&.,X)[G)STH ]3HK@8?$>H'19;6[U5H]1BU:73
MTFMK$2RW00%AMC^ZK;<$D@J IX&>,:?5-=US3/#[MJ<MI<P^(Y+&1Q;*K2;1
M(%9TZ @#E>A)]A0!ZI)+'#&9)9%1!U9C@#\:;'<P31F2*:-T7JRL"!^-<A\2
MHF;P;!$\27CG4;%3%)@+,?M$?!X( /3ICFLO5[%!'X=TB[T*ST;3=0UC9=VM
MJRF.<+"[(K[54$,ZJ"".=H% 'H<%S!=(7MYXYD!P6C<,,_A1#<P7&?)GCEQU
MV.&Q^5<1>Z;8Z)\0]%71K6"S-[97:WL-L@17C0(4=E'&0QP#U^8BN2^']H$O
M_ SOI-KI).FR21WD# OJ7[L QOA1@C/F8;/W>.AH ]G\Q/-\K>OF;=VS/./7
M'I2231Q%!)(B%VV(&8#<W7 ]3P:\=_X2*S'C6/Q:'NM[:H=-8_991%]@(\H-
MYFW9CS@).O>O0O%5R;:[\-J(H)/.U>.,F6(.5'E2G*Y^ZW'4<\GUH Z.BN/\
M-ZOJ<NOW.GZ[<RP7S"5XK%K55B:-9 %>&4?? 4KD$YRW05E:UXF\1RZ]KMKH
ML-T3I1CCAABM%E2XD,:R$2,6!4'<%&W&.3D]* /1:*\\UC7/$K3^*9[._@LH
M=$M([J.W>V$AD8P^8R,V>%X(XYYZ\<SV3:E>_$_[0NJ21VLFC6]P;7RU*X9W
M&W/U!.[KSCH* .YBFCGB66&1)(VZ.C @_B*;!=6]UYOV>>.7RI#%)L8'8XZJ
M<=",CBO+=)DU/4;GP)+;:@FGQSV]WN@MK9%C!4Y/R].1@>V,CK4HUV^TDW]I
MIZR"?4?$]Q 9(H1*\:B(.2JD@%CLP,\<DX.,4 >I5%%=6]Q)-'#/'(\#[)51
M@3&V V&'8X(./0BN"77O$[16&E3[[*ZOM4>UAO[FV57-NL)E+^6"5WY4IZ<9
MQVJ_X%CNXM4\71WMRES<+JJAIDCV!_\ 1H<';DX.,9[9STZ4 =G17EVG:EK6
M@^'/$5^=4^V3?VT]G"+B$!(W>=(_,..<#=G;TXKI]*O=6L?&+Z!J.H+J,4EA
M]MCG,"Q/&1($92%X(.X$<9X/6@#JJ*XLZMK3^*?$3?;8TTK15CD%JD ,D^Z
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M+R6QP.Q(#8YK5O?&&@Z?J+V-UJ"QS1LJ2'RW*1,V-H=P-J$Y'#$=10 T>"]
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M8@!B,C(!R.^*R[_Q[I[ZOI&GZ3=Q3RW.I?99MT3[2@1]QC8@*Q#*H)!.,\T
M;6G>&=*TN_:^M8)?M!0QJ\US++Y:$@E4#L0@) X7 X'I3-0\*:/J=^]]<03K
M<R($E>WNI8/-4= XC8!\9_BS4&K>+[#1_$NG:)<1SF6]C>02)"[!-I4 <*<Y
M)/TQSU%9^C>/-/GO[W3]3O(HKM-4FLH56)]N ^V,,V"JLW8$C/84 =!+H6FS
M#4_,M@W]IQB*\^=OWJA"F.O'RDCC%,?P[I;ZE9ZA]G=;JSB$,,D<[I^['16
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M;W<\=\1':6YNIO-ADC(A )\P!E!9>#RN12+XST&2R^V17DDT!E,2&&VED,C
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MXDN(+.WBFD^_)'$JLWU(&35F@#S:]\(7FHZ3=SV^FZA:Z@;JTG*WNJ>9)<+
MY;:'5F$?#-@YZXSC%2W'A:ZO=!U00Z3>V]]>3V1?^T-06X>1(9E<\[F  &[O
MD_E7HE% '(7_ (?OKC5/%UPD"%-2TF*UMB6'SNJS @^GWUZ_TK%F\*ZK::G#
M>&SO[R*?2K:SEBL=1%N\4D08$-EE#(=_J2"#QS7I-% '(:3X;ET[7O-BLQ!8
M)H-OI\2&7S"C(\A*9/) #+SWK.TC0=;T9?!,W]G_ &AM/TM]/O8TG0&%G$/S
M9)PP'EG..>F,UZ!10!CZ/J]QKFEW=U#;"W GFBM'=MRS*I*K+T&%8C./3G)S
M7&Z1H'B:;7--O]6M[KS8-/N8+J:YO4D62:0)S&B\(A*GT/3(XY]*HH X?3/#
M6HVUGX#BDA5&TBW,=YM<?NR;8Q\>OS'M]:S=+T#Q'#8^%-&GTF*.#0KU7EO?
MM*$3(J2(&11SSN!.<$'L>H]*HH YK7K+4?\ A*= U:QLOM<5JMQ!.BRJC*)0
MF'^8@$#9R.O/&:R)_"^IOX9U>S2W3[1<Z^+Z,;UYB^U1R;L^NQ3QU[5WE% '
MF^MZ'XHU76'6:&YFACU>VN;>1;Q$MTMDDC;'E_>:088G</H>@KH]#LM1TWQ3
MX@$UEFQO[E;N&[65<?ZF*,H5SN!RA.<8QWKI:* ./LO!MI+XSUW6M4TRVF>:
MY@ELIW 9E"0HI(],,IJ"QM_$?A>;5+*QT1=3M;F]FO+6=;M(A'YK;V20-R,,
M3RN[((XKMZ* /.H_AT)%\+V.JVMMJ-I90WK7Q<#;YTQ5\J#SC=OP>HP*(?"F
MOW&GZ+H$\\EI8:7>RRK?0O$TCQQ_\>WRL&&?FYRIYCSW!KT6B@#E?#&@ZEX?
MU[68Y;J:^T^^,=VES-Y:N)R"LBE451R%0Y"COWK,'A;4O[%CMC;1F4>)CJ+#
M>O\ J?M1DW?79CCKVKO:* .%U/1_$4.H>(;S2E91>WEHX\F5%EE@2-5E"%N%
M;C )Q]1P:Q[C0;_3?!WBK4;Y&M)XKU=7L6N;H3.IABB*[W&>28V4CG@X&1@G
MU*F30Q7$3131I)&W#(Z@@_4&@#FO#>C7 \#M;W9,.H:G'+<W3#JDL^6(_P"
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M"W^UJ&BQ),%&Y_O+Q@G.> <&IM*\.:[X4?0);2QCU1K;2&T^X1)UB$<A=7#
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MX=2Q"D<8/.>G6O2** .071=3GU3Q'>W%I%&VHZ3;V\:K*''FJLV]<\< NO)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9UCA\GH<JJMG&XYSG% 'H-%>8>"+C7-0FT#57U!'CO(6>_$NJF;SB8R<) 5
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M",'"A<^G'2@#UVBN$M;R:Q\?B/4+R>[34+J6.QDMK\M%&%C),,EOG"E=K?.
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MY)<R!.D>UPH^4 ?-B@#TJBO+/#LVI0V'@K6)=:U*ZGU.[:VNHYYRT31F*5@
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MH WYH(;B/RYXDE3(;:ZAAD'(.#Z$ _A5>[TG3=0GBGO=/M+F:'F*2:%79/\
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MZ=]BTZ\N;R^>=$M 8XWC:$[958LX7(/& 3GJ..:ZB-B\:N49"P!*MC*^QQ0
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MHEB:",QKRJ%!@?04 >=VGBFRMM96[N[J;3[*\\-VTMG!>3,6+AY,@9)+R89
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MH0?VG+-<7#&,DAX6 ",C\\?=&0.*J^#[^TEB\#3Z9K-S>ZW<_)J<3WCRGR1
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M>=8Q3/OD9_F,:YQN)P..@P/:NKCABA#"*)$#'+;5 R?4TY55%"J % P !P*
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MAV[K;:C:P&XU 7=Q#;V>R 1[ K11H6.S) 8MD\YXYH ZJBBB@ HHHH ****
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M()F61V=C(,8?>26W# P<Y&* *WA.;7)+:]CUJ&Y41W&+66Z6)9I8BJG+B(E
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MSSVX!/[N1]VYASWWO^=4[;PZL?C:_P#$<IB,DUG%9P!5PR(K,S%CW))'X**
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MB@#S Z[JDXUC3[FZU&YL;GP]<WL3ZA;0PMD87*", [2'Z.,C%:_A/_D;8O\
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M1 B+"S6DK 1E0&*@':=VXYP<CI7J=85EX,\.Z=?17MII4,5Q#(TD+@L?*)#
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MULGTY%MK562*.)VC"JV-RG:1D' R#G/>IIO#>CSWMM>/81>?;0^1$RY4"/\
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M<VMI#"V[+$Q>;NR/^!K7.>./#GB377UBUMU>XL[NR$5F%U%K:.!]K!_,1?\
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M0 4444 %%%% !1110 4444 -**S*S*"RG*DCD?2G444 %%%% !1110 U$6-
MB*%51@*HP!3J** "FNBR*5=0RGLPR*5F5<;F R<#)ZFC(! R,GH* %HHI,@$
M#(R>@H 6BBD!!&001[4 +4<L$,ZA9HDD .0'4'!_&I** "BBB@ HHHH ****
M "FE%+JY4%ER Q'(SUIU% !1110 4444 %%%% !1110 4U45,[%"Y))P,9)[
MTZB@ HHHH **** "BBB@"-H(7E65XD:1/NN5!(^AJ2BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II12ZN5!9<
MX)'(S3J* "BBB@".*"&'=Y421[CEMB@9/O4E%% !1UHHH CB@B@4K#$D:DY(
M10!G\*DHHH **** "BBB@ HHHH **** "HW@ADD21XD9T^ZS*"5^A[5)10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5YI\:(+V+PFNIVVKWMJMO-"OV>W?8LC-(HRY')P.@
MSCO7I=<QXN\$67C.&*#4-2U2"W3K!:3A$<@@@L"IR01Q0!@_%BQ\W1GNTT_7
MKZ9+:40C3KDQQ6[@9$CJ&!)Y]&X4\5T/@"\:_P# .B7+ZB-1=K50]US^\8<-
MG=@D@@C)YXJKJ/@&/4K."V?Q+XCC6. P2/'?8:X0DG]YE2"?F(R #CBM_1-&
ML?#VC6NDZ;#Y5G;)LC3.3UR23W)))/UH Y'1KJX?XT^);9IY6@CTZV9(BY*J
M3U('05S=OXPNM!CU8Z-I-J]U=^,Y-+*33R;9&9<AR23M)('08 Z"NRU;X>V6
MJ>(Y]=CUC6].O;B-(I?L%V(E=5Z _*3^M._X5WHQDW^;>9_MP:]_K%_X^,=/
MN_<]NOO0!Q=W\2_&>G6&N7-SI&B,OA^Z2+4&CFE_?*Y4#R@>A .26/?I5?Q?
MKE_97WQ"N=#CBM+VUMK!Y+PS2;V1D/W1DJ&' & .,YYKOK[X?:/J%EXAM)I;
ML1Z]*DUV5D4%67&-GR\#Y1US3[OP%HU]+KTDYN6_MRWBM[I?, "K&NU2G'![
M\YY% '/:MXP\1:%X?TEKJ\\-PZC/;M*ZSO.YEQRH1%&[I]YCP#6,_C/Q7KNO
M^ +K2396L&KVUR[VLTC['=%^??@=  "F.<DYKK7^&>GO]@<ZSK@N;.W>T^U"
MZ'FS0,<F-SMZ#H,8(]:<_P --(_L[0;2WO=3M6T/?]CN;><+* _WU8[<$$<<
M 4 <K!XP?0[GQ#%I6EP'4[[Q/_9L'FS2&-Y&4'S'R3@#'1<=JLZC\2]=T'3/
M$\.J:?I\FKZ&UHV;9G\B>.=U'&?F4@$]^M=+>?#?0[VWU&.22]22]U$:F)XY
M@LD%P!@-&0.,>^>M0M\,-%FT35=.NKO4KJ359(I+R]GG#7$AC8%!NVX &,8Q
MT- "^&/$^O7?B_4O#GB&RL(;FWM8[N)[&1V78QQM8MU8'N,"J&N>-/$1UWQ!
M8^';'37A\/6\<UX]\S[IBZ&0)&%Z?*#R>]=;#X=LH?%5SXB5IOMMQ:K:NI8;
M-BMD$#&<Y]ZQ=<^'6EZYJUWJ/V_5+"6^B6&^2QN!&ETBC #@@YXXXQQ0!PEU
M>7OC?XE>"[QK2P?3IM.^WPV]R[DQ<KYC<<&0$?*>G S74>*\?\+>\%Y&1]EU
M#(SC_ED*Z6#P?I5IK.F:G;)+"^FV1L;:%&'EB(XZC&2>.N:FO_#=EJ/B'3-;
MF:876G1S1PJK (1*H5MPQD\#CD4 >9Z%XRN-)^&GAR72VT+3A<Q7#B"^EGE8
ME96X11ER#R2Q.!5>;Q'K'BCQ-\/=;TBSLTU*\L;TB*ZD80H0 K$E1N(X) Z]
M*[.'X5Z-:VNE0V6H:M:-IL$MO'-!<*LDD4C%V1CMZ9)Y !]Z&^%>BBRT>WM[
M_5K5](BEBLY[>Y"2)YC;F)(7D]1Z8)R#0!S<'C!_$=WX0EU/2X%U&+7+BQF\
MN:0)%+&O+)@C(.1PV>]8GA6Z6#2_!T8M(IIY==OUA>25U$398@X4@'\0:]*L
M/ASH>G6^BPP-=_\ $INGNXW:4,TTK@AFD./FSGMBEL?AWHU@NDK#+>$:7>2W
ML&Z13EY,[@WR\CGCI0!PFA>-?&>F>"]9U_4%L=0MK'57CE&Z1I5C$@60+T&U
M01M]LY%>@>&O%,OB/Q#KT-O'"VDZ<\4$%RF2TTI3<_MA<J/QJO'X%LM)T[Q&
ME@U[=1ZM'.[:=/<#R/,<'(08&W<>,DG%/^&OA63P?X'L=+N%47GS3714Y!D8
MY//? P/PH ZVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S=7U_2=!CA?5+Z*V$SB
M.(.<L[$@8 ')ZCZ4 :5%9.L>)-*T'8-1N'C+*7"QP22D*.K$(I(4>IXK1MKF
M"]M8;JVE26"9!)'(ARKJ1D$'T(H EHK-T[7])U>]O;/3[Z*YGLBHN%B.1&6S
M@9Z$_*W0\8YK2H ***YJ;Q]X<M[UK.6\N!<C=^[^PSDD*<$C"<@$CD<<T =+
M12 AE!'0\TM !16;J.NZ?INE:CJ,LZR0:<K&Y\DAVC*J&*D#O@@X]Q6B#D C
MO0 M%%% !1145Q<P6D7FW,\<,>Y4WR,%&YB%49/<D@#W- $M%%% !143W,$=
MS%;//&L\H9HXBP#.%QN('4XR,^F14M !1110 4444 %%5I-0MHK]+)W83O$T
MP_=MMV*0"2V-H^\."<T+J-BT%K.MY;F&[*BWD$@VS%AE0AS\V0"1B@"S115;
M4;^#2]+N]0N2PM[6%YY2HR=JJ6.!WX% %FBHX)DN+>.>/.R10ZY]",BJUKJM
MM>:E?V$1;S[%D68%< %U##![\&@"[1110 452T_5;;4WO5MBQ-G<M;2[EQ\Z
M@$X]1AA5V@ HHHH **B>Y@CN(K>2>-9Y@QCC9@&<+C.!U.,C/UJOIVJVVJ"[
M-L6/V6Y>UDW+CYTZX]N: +M%%% !163;^(].N7V(TN[[;)8#]RQ_>H"6&0#@
M<'DX%:U !15+2=5MM:TR+4+,L8)2P4NN#\K%3Q]0:K#Q'IS75E;JTI>\N9;6
M+,++^\B5F?.X#C"-@]#VH UJ*HVFL6%[%;20W 'VK?Y"2J8WDV_>PC -QCT]
MZO4 %%%% !167INO6NJZA>VMK%<L+.1H9)VB(B,BG#*K=R#P?QJ75]:T_0K1
M+K4IS#$\BQ*1&SEG/0 *"2>/2@"_16,WBO14T<ZK+>&&S\SR@\T+QLS]E5&4
M,Q/8 '-&G^*M%U2*[>UO.;--]Q'+$\4D2X)W%' 8# /..U &S16+I'BW0]<N
M1;Z??"2=HO.6-XGC9TX^90X&X<CD9ZU:AUS3)]<N-%BNT;4K:)99;<9W(AZ'
MT[C\QZT :%%%5KF^@M+BU@F+B2ZD,<06-F!8*6Y(&%X!Y.!0!9HJ*"Y@ND=[
M>>.94=HV,;!@KJ<,IQW!!!'8BI: "BBB@ HHHH **I:;JMMJJW36Q8BVN9+:
M3<N/G0X;'M5V@ HHHH **** "BBJVHZA;:3IMUJ%Y)Y=K;1-+*^,X51D\#K0
M!9HK 7Q;:--I]N;'45NKX,Z6[6Q\R.-652[C^%<LO/O4\?B;39IK&*-YB;V&
M::'= ZDK$5#Y! (/S# QS0!L45!9W<-_907EN6,,Z"1"Z%"5(R,JP!'T(S3O
MM,'VL6GGQ_:2GF"+<-^S.-V.N,\9H EHHHH **** "BBJ6FZK;:JERUL6(MK
MF2UDW+CYT.&Q[9H NT444 %%%(S*BEF("@9))X H 6BHX)X;JWBN+>5)H)4#
MQR1L&5U(R""."".]24 %%%107,%SYGD3QR^4YCDV,&V..JG'0C(XH EHHHH
M**** "BBB@ HHJEJVJVVBZ=)?WA80(R*Q1<G+,%''U84 7:*K6]]!=7%U!"7
M,EK((Y0T;* Q4-P2,-P1R,BK- !1110 4444 %%%-EECAB>65U2-%+.[' 4#
MJ2>PH =16?+K-E%>Z;:^9O?4=YMFC^96"IO)SZ8Z5H4 %%%% !1110 4444
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ML;B<DDYJG8:DC6=E>V_B"\G\0_\ "0M:_9&OG8>2;IE:,PYQM\K+;B,C'7@
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MZ=ONH]S[V19-PZ$G:Q&1QP<5F:=X7UO5H-8L+F[CMM'N=<GN)(9+5A.R+/O
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M<,\YVDCY<]\5)?\ @V_NK7Q5I\>H6RV&NAY%W0,9(9FC2,\[L%<)G&,\]>*
M+MEXQB>[N;;4M.O-+:&R-^K76PAX <,WRL=I'&5//(J&S\=6]PZ"XTV[M!/:
M27EJ9'C;SD0 L,*Q*-@@X;^A%6]3\+QZKK$MU<3_ .C3:3-IDD2CYB)&4E@?
MHI'XUEZ/X*N-.M9+65-! ^QO;)<VNF^5.Y*[0S-NP..H Y/I0!N>'->?Q%IR
MZ@-+NK*UE19+=KDIF9&&=P522!]<=0:K>-M=OO#GAM]0T^S^U3">&,J2H"JT
MBJ2<L,]<#'<@] :%M=5TC3/#FCZ<5D\DPPW=PR?(((TPQZ\%B !UZ^U6_$^C
M/X@\/7.FQ7"V\LA1XY63<%9'5UR,C(RHSS0!SEUXDU>V\;)#'H^HW'F:.LYT
M^.6/]T_FL"S,6VYP ."2?SQHMXYM)[;2WTRSN+Z;4K7[9%"'2(I$,9+EV !R
MP&,G)SV!-7++1;Q?$:ZW>W,#SG3UM)(X8RJ[A(7W#))QSC%<VGPX:VLM#\J3
M3+RZTVQ-C(NH6?FPRH2&# 9RK @\\\$B@#LM%U>VU[1[;4[0.(9U)"R##*02
M&4^X((/TKF1;^*;"VO=2U&^CVP65U<!(I"RB<L2@P1C8D:J /4L3GK74Z59G
M3]+@M62U1HUP5M(/)B!)S\J9.!SZT[4[0ZAI-Y9!PAN('B#$9V[E(S^M 'G>
MF^,FM?!=UKB^)VUR_CL(Y&LI(X42*9]H&?+16QN;')Z5JZF_B+PI!8:K=>()
M-3A:[@M[ZVEMHDC"RN(]T150RE68'#%LBMN;PQ!>^!U\,WDK-']B2U::/Y2"
MJ@!QZ$$ BLX^&]?U22PA\0:Q97%C93QW&RUM&B>Y>,Y0R$NP # ,0HY([#B@
M#E[OQ?JR:YJ<%KK[2:G#K(M+/13;1LL\/[O=E@N\85G.[=@;:W?''B/5M,U"
M)-'<"/3;?^T]33RPQDMQ(%\L9Z$J)6R.?W?O5JZ\$O<:3K-NEZL=U=ZG_:=I
M<>7_ ,>THV;.,\\ISTR&(J0^ ].O]4U74=;47L]](H4*SQK'"J!5CP&YYW'/
M^T: .IBE2:))8F#QNH96'0@\@UY=X>\6:K<SZ!)_PD2:G=:A>RP7>E>5#F"(
M&3]X-BAEV[5^]D'=]*[[PUI,^A>'++2I[K[4UHGDI+MP3&"0@/N%V@_2HO"W
MAZ/PWH<-AF*69"Y>9(]I?<[,,_3=C\* (8O%#C7[72[W1[RR^VF1;6:5XF$A
M12Q!"L2N5!(SZ=CQ7/ZC\0[^3PE<ZWI'AZ[,*.B1SW+1A'/F;&^7>&(!XSW)
M]!3M$^'EQI>N:5J$UUI\AT^::0SI9E;F[\Q'7,LA8Y(W#VX^F-,^#I#\/&\,
M"^42[3LN/+R WF^8N5STS@'F@!T_B:.PU:275#>6,<&D/>SVLGEND:K)@ME<
MDOCC .,'UIL7CNV077]HZ;=V+0V$FHJCM'(9(4QOQL8X897*GU'OA-1\'SZ]
M)<R:O=P[KO2'TZ86T94 L^[>NXGIQP>_Y4:-X7O]+2<B/PY#<&W,,<]II1C9
MFX^9\/RO'*C\^* )FN=7\1Z;92VEO+IB?:HIW<W*,985&_"F,L/F(53GL6Z\
M9HW/]J^';/PM+>ZC+<SG4!;7WSDI)]HW8'/4(Y0*3S@>YK2\*>&I?#[:C)+)
M:)]ME606ME"8H(<+@E5)/+=2>.W'<IXIL[C4[_P]8PPR-$NHI>3RA3MC2$%@
M">Q+[ !WY]* -/6]8AT/3A>SQO(AGA@VIC.9)%C!Y[ L#6=J_C"ST=]96>WG
M?^RK2&ZE* '>LC. %YZC8?SJWXFT5]?T&;3XK@6\Q>.6*4IN"R1R+(I(R,C*
MC(STKG;KP3JNJ1>('U+5;5KG5[."V'D6Q6.#RV<\ L2P._N>N>V  #1C\;V\
M+:B-6TZ\TLV5G]O(N-C&2#D;AL8X8$8*GGD5EQ>*[V7QI8B_L;[2+%=(NKN6
M.Y9"KJK0X?Y&/*@MD'D9]ZU=>\'IK]_J$L]R8X+S26TXJJ_,I+[MX/MZ54'A
M'5M2U);KQ!JMK<)_9MQIS16ML8LK+LR^2S?,=AXZ#C'?(!-8^.K>ZEB6?3;N
MT6YM9+NT:1XV\Y$ 8@A6)1MI!PW;/<$5I>&M??Q'IRZ@NEW=E:RHDEN]R4S,
MK#.0JDD#ZXR"#6)HG@JXTRW:VD300JVK6R75KIOE7#Y7:&9MV!QU ')]*Z;0
M]..D:!INF-()6L[6*W,@& Q10N<=LXH Q-2\;Q6,NI/%I-]=V&EMLO[R$IMA
M(4,V%+!GVJ06P./<U9C\5+=>)9-&LM,N[KR5BDGND*"*-)%RK9+ GZ $\&LR
M_P#!VJ2_VW8V.JV\&DZW(TETLEL7FB+H$D$;;@/F XR#@D]:VM)T :5K6IWL
M<H,-W';QQQ!>8Q$A7KWSF@!=7O\ [+K>@VWGW$?VNYDCV1*A23$+OAR1D#Y<
MC;SG':LG3O'L.H3:>QT?4+>QO[AK2"\EV;#,-WR[0V[!V, V,9'XULZIH[:C
MK&B7PF"#3;B29D*Y\S=$\>,]OOY_"LFU\'26^AZ%IYO58Z9J'VUG\O\ U@W2
M':!GC_6=?:@#:US6H-"T];F6*6=Y)4@@@A +RR.<*HR0.O<D  $UFS^*YK:*
MTAFT*^75+N9XH+#?$6?:NYGW[MH0 CG.<\8S5OQ+HDFN:?!';7*VUY:W,=W;
M2NF]1(AR RY&5(R#R.M9MWX?UZ\ET[5'U.P&L6$LICVVK?9S%(H5HR-^[^$-
MNSU[8H :_CVVCL8Y3I=^;PZC_9DEBH0RQS["X&=VTJ0 0V<88'CG"MX[MX-*
MN;JYTN^BN;6_CT^:R4(\@EDV;=N&PP(=2,'O4<'@N</;75SJ$<M\=8&JW4B0
ME4<B(Q"-!DD +MY)/0^M27?@Z2YN]0F%ZJBZUBTU(#R_NB$1 IUZGRCSVS0
MX>.+:"RU274=.O+*ZTYXDDM'*.[F7 BV%6*G<3CJ,'.?6F_\)W:6]OJ'V^PN
MK:\LQ"3:!HY6F\YBD?EE6*DE@5Y(P1SQS3-;\#KK4NNM+=(HU$6C1!H=XB>
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MTNYTJ\T^Y%N+J);G8?-B+;<_*QVD'&5.",BL;4/!>I:Y:ZS+JVI6OV^_T_\
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M[_9\L\HC"PW.XIY9 ;+#<,;@",D>^)=*\'2:<^@L;U7_ ++FO)&Q'CS//+$
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MMSGD +V)J'4;FU74;U/%&MR+<6^C6SZ;+%<O")I2K^9+$JD;W+A>,$XP,8-
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M_>QVDZQ6MI"Y("A%S(<>OF.ZY_Z9BL*6:6'4M3\J1TW^-+5&VL1E3!!D'VH
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M##*"/<4M% &?K.CV^MZ)<Z3.\L5M<)Y<GD$*VSNHX/!'!]B:OJJHBHBA548
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MHH 3:N",#!Z\=:1HT?;N16VG*Y&<'VIU% "8&<X&>F:&174JZAE/4$9%+10
MTQHS*S(I9?NDCD?2E(!!! (/4&EHH :(T5=JHH7@8 XH9-RM@E6(QN&,BG44
M 4-%TBVT'1K72[0N8+=-H:0Y=SG)9CW)))/N:O;5_NCKGIWI:* &^6@<OL7<
M>IQR:/+3>'V+N&<''/-.HH 3:O\ ='7/3O2-&C*59%*DY((XIU% &?\ V/;G
MQ#_;;/*UR+7[*BDC8B%MS$#&<DA<G/\ "*O.BR*5=0RGLPR*=10 FU>/E'!S
MT[TC(C!@RJ0PP01UIU% "!%4* H 7@8'2D*(5VE1@=!Z4ZB@#F-.\#V6GMIR
M?VAJ-S9Z:^^RLYW0QP,%*@@J@9L!B!N8UTP 48  'H*6B@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *YKQEK^I^'M-2\L-/AGB62,3RS2[0@:1
M4P%'+,=WL!CKV/2UROCVSU?5=!;3-*TY+DS/&[R/<+&(]DJ/C!ZY"D4 7/$^
MH:MIMHUS83:3!#%$\DDFH._) R% 7&._.3]#5W0]1EU?P]I^I26K6TMU;),T
M#GF,LH.T_G6+KT%[JME;I=^#;'5%:,DQ7%S&3!(>.K+C&,?,IS[5/X=L]<T/
M1=%TJY6._:*U=;N[:X.5<8V*H(RPY(R<<*#WH K6>NZ_:^+K'1M:M]-9=0MI
MIXFL6<F QE<A]WW@=XPP Y'2D\4ZOXDT>^LOL TE[2]O(K.(3I)O5G!^8X.,
M9!Z56\+6GB*/79]2U[18_MUYE)+M;Q66WB&2D4:8SMSC)SDDY/8#9\3Z5=:H
MVBFU53]DU2&ZEW-C"*&SCU/(H QI?&<NA^)I=-\031;4TR*Z(L;667YC)*'8
M!0S! JKDG@>O-;U[XKT>QBM)'N9)OM<7GP+:V\EPSQ8!W[8U)"\CD\<U7;1[
MH^,]1U/:GV:?2HK1#NYWK)*Q&/3#K7)6_@O5]/CT"Y:VN+I[;18=-N;>SU1[
M1XW0YW!E8!UY(()[ C- '>S:[ID&@G7'O$_LP0B?[0H++Y9&=W'-4O\ A,M$
M-A%>+/</'/*8H%6SF,DS ;LQH%W.N.=P!&.<U0U7PW+-\,+KP]IUFEM-)9F*
M*W:X,@1CS@R-R>2>33?&'AZ\U'4]%U.SBFG%@)HY+:"]>TD99 O*NI'(*#@D
M @F@#2?QCHBV=I=)<S3+=EQ#'!:RRRML.'S&JEAM/!R!@\'FH(/&=E/XPE\/
M+;7>]+:*=9_LTNQBY?@G9A0 H^8G!)(Z@U@WOABZ31+5-.T">"_$EQ-'/'K#
M>?;32'[S2-G>&ZL.1QT;K6K9:9KEEXO@U"XBAO$N=*M[2[N$D">7-&TC,VTC
ME6+\8Z4 .7QSI6IV<-QHU_&T375M"9I[2;RW$KA=J-M +]O13][%:$OBS1XM
M4DTXSSO<1.(Y#%:RR1HY&0A=5*AB"/ESGD>HK MO"VI0_#_PWHYCB%W875E+
M.H<8 CF5WP>_ /UJ[HMEKNAZMJ-FFG07%A>:C)>"]-R%*)(064I@DL#D#'!&
M.10!#8>/(-8T(W]JIL72_2U;[;:S["#<&(;3M7+-CH,["0&Q@UJWGC/0;'4)
M+.XO'5XI%BFE6WD:&%VQA7E"E$)R."1U%<Y%X;UO_A'9=%>SB40:VE[#<"<$
M31&]\]CCJI"\8/4]*9?^&M??2_$/AR"RMI+/6+N:9=0:X \E)B"X9,9++R%Q
MP?EY% '1ZAXX\/:7?7-E=WSI/:LBW(6WE=8-P#*SLJD*I##YB0.O/!Q<E\1:
M;%K TKS)WN_EWB*VDD2,M]T.ZJ53/;<17.ZEX7U"YL/'<,21EM8A"6>YQ\Q%
MLL?S>GS TM[HFK_\)/9W>EV;6<@D@%U?)>_N[B!0-Z20XY;&Y5/4<'<.E '1
MZOX@T[1# E[)*9K@L(8(('FEDV\L0B L0,C)Q@9%4Y?&OA^*PLKTW^Z&^9DM
MO+AD=I'7[R! I;<,$;<9R,8JMK6GZI;^*['Q!IEG'?B.SELYK9IA$P#.CAU)
MX/*8(..H]*S-)\)ZG::CHM]<K )%U&^O[M(WRL)G5]JJ2!NQD G YR: .MTG
M5['6[!;W3YC+"69#N1D964X965@"I!&"" :S[/QGH-_J$5E;WCL\SLD$C6\B
MPSLN=PCE*A'(P?ND]#3= T:YL;;6X;K"?;=1N)XRC9.Q\8/L:YW3/#NOMI_A
MG0KVQMK>UT.>*5[Z.X#?:!"I5-B8R"V03G&.>N: .M3Q'I,EC;WJW>;>YNC9
MQ/Y;?--O,>W&,CYE(R>..N*98^*-(U+5[C2[.XDFNK=G28+!)LC93@JS[=H/
MMG)'(XKD(?#GB.*#3]'^P6OV*QUPW_VS[3S+$;AI<!,9# /SD_P\9SQU7AC2
MKG2H]6%RJ*;K5+BZ3:<Y1VRI/OB@#-;Q-=QZKK-O)<6L,5KJUI90F6)VRLL<
M1*_+SN+2$ G@9&>*U6\5:0FK)ICRSI/)-Y".]K*L328)V"4KL+<'C/:L"_\
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M:V'0*VP8=P>^Z1BO7^ >M '345R_C2ZU*$:%:Z9?M8O?:HMM+,L:N1&8I6.
MP(S\H(/J!U&0>=U*_P#$\NO:IHVES:O,^E6L @E@^R#SI70MYD_F;<@D 80
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M1L(/+^R?8=NWCR.GE_[OM46K^'[75-/FMT_T:X:SELX;J,?/ D@ .W_OE3^
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M$;XXP"H)R0O]T'OC&:9JWB>RTJ^6Q-O>WEWY7GM!9VYE9(\XW-CH"00.YP<
MXKG=5\72ZAXA\,V6BW-ZEAJ4,ETUU:6JR>8H*!5^<'"C<=_&1QTH Z.'PEX?
MM]1.H1:1:)=F4S><L8W!SG+#T)SSCKWJW:Z+IMEJ-UJ%M9Q0W=US/*@P9#ZG
MWX'Y55U?Q)9Z1=PV;0W=U>3(TJV]G 97$:D N0.@R0/<],U4O_&VEV,KQ^3?
MW!A@6XN3;VCO]FC89!DXR#@$[?O8'2@#5?1M->221K*$O)<I=.2OWID "O\
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M02/0\<^AJP90RD%2,@@\$55FU*T@U.UTZ27;=72220IM)W*FW<<]!C>O7UH
MPK;PS<KX=\2:9+-$KZK<7DD;J20BS A<\#D9YJM;Z!KD\GAZXN_L5I/IEO<0
M.8)FE&6C5$=<HN>5)(/3U-=<TL:2)&TBJ\F0BDX+8&3@=^*KV6I6FH27:6LN
M]K2<V\PVD;9 JL1SUX9>1QS0!P6D^"==CU&TN[\V@E@TZXM)I_M\UP]S+($'
MF'>H" E2=HZ9[\5VWAW3Y=)\,Z5IMPR--:6<,$A0DJ61 IQG'&16E10 4444
M %%%% !1110 4444 %%%% !1110 4444 %<1K.G+/\5] G-W>1XTZZDV1S%5
M^22#C'H<\CO@>E=O436\#7*7+0QF>-61)2HW*IP2 >H!P,CV'I0!YKH.NW%Q
MXM\/S6EUJ3:?J\=RV+Z\20S*J[E<1+_J\$=L<'!&:K:/?WUZOAJ^EGEEOG\-
M:@_FDY<OO@P?KTKTBUT'1[*Z:ZM-)L;>X9B[2Q6Z*Y8@@G(&<X)Y]S4\.G6-
ML83!9V\1@C,<12)5\M"02JX' ) X'H* .(TKQ%)>7G@*!-3\Y[S3I)KM%E!,
MA$*$,P_WMWXYK$M[[6K/X:Z1K!UB_N;S5Y[:"XEEN BP1LY'R$C"$C"ESDY.
M>N*]+L]!T?3YC-9:58VTI8N7AMT1BQ&"<@=2.]3_ -G6/]G_ -G_ &.W^Q;=
MGV?RE\O;Z;<8Q[4 8/A&+5[>74H=1D+6P=&M8Y+S[3+&"OS!GP"1D C.3R?:
MN<UB_N+J;QE=W'B"[TR;1>+*"&8(BJ(%D61U_P"6F]V(P<CC YKOM.TG3M(@
M,&F:?:V4+'<8[:%8U)]<*!S3+O0])O[V*]O-+LKBZAQY4\UNCNG?AB,B@#DM
M'?4]<\92M>ZC>VL5IIUA=-8POL0S2>86#=R/EP5Z'OT%:'B^YG.K>'M*%_-8
M6>H7,BW$\$GENVR)F6,/_#N([<G;@=:Z=;>!+B2X2&-9Y%57D"@,X7. 3U(&
M3CTR:CO].L=4M3:ZA9V]W;L03%<1+(A(Z'!!% 'DEOJ-YI^E7]OINHRW4=WX
ML:TEO/M"H[1^0IQYH&%)953=C//J<UKSQZM!'I<.IR[XD\26WV57NA<2QH8R
M2KO@9^;)&><$5Z!_8VE_89;'^S;/[)+CS(/(7RWP !E<8/"@?@/2FVNB:396
MT=O::79001R><D<5NJJK_P!X # ;WZT >?+KT\GBG1[RPNM2-G?:M-9O]JO$
M*2JJRA@L ^X%9!AN#@#/6K6@:OJE[KUAX7FO9VN]'N+A]2F)^::)<"WW'_;$
MJ,?7RS7;1Z#H\5^]_'I-BEX[^8UPMN@D9O[Q;&<\GGWJ'3M"CL-<U?5C+YMQ
MJ+19^0#RTC3:J#UY+'/^U[4 4]=O;FW\5>%K>&9TAN;F=9D4\2 6\C 'Z$ _
MA7'Z'=:K%I_A/6IM;U"YFU'46M+B&:0&$Q$38 7'!!13NZ]>W%>FR6\$LL4L
MD,;R0DM$[*"4)&"5/;()''8U&NG62101)9VZQV[^9"@B4"-N?F48X/)Y'J:
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M--=8F&/G_P!(E^;CCGKQ7,Z,L6C>'+Y3>ZS)+?>(;BRACANPK.XFDQ\[?<R
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MQ?P>7CJ.?EYSFNB\"QWEY%>ZO>ZK>W+M>WEO'!))^ZBC2X=5 7N1MZGG!QT
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MG:VX=!QQ4X\'7]SKU]=S?8+"WNK>X@N!8,^;LR#"O(A 4,HR<C))/7% &_\
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M)P!D^I('XT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *XGXGZ=%<>%FO)))]]M/;F.-965-QGC&XJ.&.,@9SC)KMJQO$'AFQ\2
MP)!J$MX(5Y,<%T\2L00P+!2,X*@C/2@#,\<Z.FI:<9%\,PZ[<K%(D<<TRH(B
M1]X!N,Y[CGCK5WP3/%=^!M%>*[ENT^QQH9Y05=RHVL2.H.0>_P"-.NO"EG=P
MP1O?:NABC,1>+49E:1<YPY#?-U/)Y]ZG@\-Z9:K81VT+P0V$#V\$,<K*@1@
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M[(%QM56)R% &,#MGU-7[?P[IEKXAN==AM]NH7,*P22;C@HN,8'0?=7_OD>E
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MS$YP%!SDCK7(:QX*UBXUG6;FQ\A7O]GV:]34I[9[3;&J F*-=LI!4D$GG@'
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MOE)'-4],\$Z-I-Y9W-L+LM9*R6J2W4CI C#!5%)P!C^0]!0!Q_@'_C[\$_\
M8M7'_HVWK9UJ+5)_B=9QZ5=6UK*=&FWS3PF7:OG1]%#+DYQU/3-=#IOAG2])
M?3WM(71K"T:SM\R$[8F*L0<]3E%YJX=,M6UE-6*'[6ENUL&W''EE@Q&.G51S
M0!QJ>+K^_P##FBW*W]O8ZA>12M)##ILMZ\C(P4E$0Y5,YR3GJ!FF:?\ $"X2
MRTO5-7C@AL+[1I+S]VI!6XA^:11D]&0Y Z_*>M;Q\$:,(;*.$7=N;-)(HWM[
MJ2-S'(VYT+*02"0#[8XQ3KCP3H-UH>G:/-9EK+3I5EMD\QLJ5SP3G)&"00>H
M- '+2>+O$K3QZ<46WU"WTV&[N?*TN:Z#32[B(\(?D4;<$DY)Z8P:ZN\UJ]@^
M']SKC6GV6_CTM[LVTP/[J41%MC#@\'BIM3\,V&IZ@M^TEY;7@B\EIK.Y>%GC
MR2%;:>0"21W&3CK5VYTRVN]'FTJ<.]K-;M;.&D8LR%=IRQ.2<=\YH X^/Q1K
M>DW4;ZT]G=6]SH\^IK':PM&T+0["4R6.X$2=<#D=.<5+8:[XAMKWPY+JL]A<
M6VNDIY-O R-;.8FE7#%CO7"D$D#L?:NE?0=/DNK2X>#>]K;26D89B5\I]FX$
M=#G8O6J.E>#=(TB[M[FW%U(UJACM$N+J25+92,$1JQ(7CCUQQTH IZ_C_A/?
M"V0"/)ON#W^1*YZR\274'@C0#I]W9V%Q+I8N196VE2W1X Z+&W[N//&3^?%>
M@W.EVEWJ5G?S(3<6BR+"P8@ . &X[\ 5C'P+H@@LH8UNX4M+462^3=21EX.O
MEN01N&?QY/K0!S-K>ZQXA\5:+J.FSVEA/?>&8[F5Y83,$WNK;57<N>3U)Z4^
MU\0RZX^A75U96BW5QI6IB614)*/$\<;>62>%8Y..>U='+X%T61+'R_MEM)8V
M:V5O+;7<D3I"O\.5//3G/]*N0^%M(MEL5@M?+2QM9;2W57.%CDV[QUY)V+R>
M>OK0!Y_8W-PGANPALOL]O=IX(BF2\,1:5<!<J"&'&,X]#@]L5O:9KNJ:)9>%
MWUJ]M[C3]0M2DMSY)C:*3RA)'N)9LY59 3W..E=%;>%])M5A6.W)6'3QIBJS
MDC[.,?*?7IUZUC:[X%AOO!D?AFS9WM#<PEFN[AW:*%74L$)R<[5V@<#F@#8\
M-ZA>ZMX6MM2OXTBFNXVG6-5QLC8DQ@\]=A7/OFN)\":GK>F:'X'M[J>RET[4
M[7R$ACA99(=D#2*V\M\Q(0@C:,9&.G/IPC18Q&JA4 VA1P /2LJV\-:9:6^C
M00PN(]'_ ./,%R=G[MH^?7Y6/6@#E++Q7K\FF:)XCFDL6TS5KR* 6*0,)(8Y
M7V(WF;OF894L-H'7&,5"GQ U**XT:UN(;=I5O9K;6652!"JS+ C+SQN:2-N<
M\9KIK3P3HME?0W$4=SY<$S3P6KW+M!#(<Y9(R=H/)QQ@9.,4ZX\%:%=3:U-+
M:,7UE$2\(D8;MHP"O/RGH<CN : .8?QQJMRNF1P 1#5);R>&:*QDNF2UB<(G
M[M#DLVY6W= #TZ5>LO%VJV[Z+-KELEI:7;75M/)) \)$L>6BD"L<JKQHYVGD
M''-;USX3TJXL=.M52:V_LU!'9RVTS120KM"X# Y(( !!R#BDU'PEI6K>'?[#
MU!;BZL]P<F:Y=I"V[=G>3N[D=>AQTH Y%/&NNW9TRUV_9)[NQ;4F>+39;MEC
M>0B%-B'@[<%F)Z\ #-7K;Q!XIU;4M%T^*.UTJXNM.DO+P7-L[M&R2*F%0LI^
M;=W/ /K72:GX:T_4[BWN6-Q:W-O&8HY[.=H7$9QE"5/*\#@],<5-;:'96M];
M7J"9[FWM6M$DEF:1C&S*QR6)).5')YH I>*-6O=/&EV>G&%+S4[T6J33H72(
M;'=FV@C<<(0!D<D5GZOJ6KZ7!964VMVBZA+YK9M](FN))E4C!$2.2H&?F/(R
M1C&:W]9T6RUVS2VO5DQ'(LT4D4C1R12+T964@@C)_,UFR>"]*D%LQEU$3VXD
M47*WTHF=7(+JS[LD$J..V!C% &9X<\77VM77AM9HH8TU+2I[N=54\21O$HVY
M/ ^=N#STJC)XNUR3P]IVI9CMK62YO([V]CLGN!;K%,Z1YC5@0I"_,W(&.V<C
MH7\$:*UCIMK$EU;KIRM';26UU)%(B-]Y=RD$@X'Y"D_X0G2$TFWTNV:^M;.#
MS0L5M>21AED8LZM@\C)/7D=B* ,#5?&.JR:M=66CNKBSLX9Q)#IDUVMU)(I9
M1E#B-" .<DG=[<NO=;\0ZX-4MK$6NG+9:7%/<P7<#2.\DT;,8\AAL"@8S@G/
M;C%=#<>#]*EFAF@^UV,D5NEKNL;IX-T2?=1MIY R<'J,]:34?!FCZG=?:)UN
ME=H%MIA%=R(+B)<[5EPWSXR>O/)SD&@"KHCWT7PITR33 AOTT6%K<2+N4R"$
M%01Z$X%8(^)__$R%R88O[$.D?:?,YW_:A%Y_E?\ ?KMUS7H%A90:;IUK86RE
M;>VB2&)2<D*H  SWX%<__P *]\-?V6-.^P'[*+_^T GF-_KNF<YZ8^7'3'%
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MA:'1DG8_:E^U&U$9G$&ULF/S/EW9V]>V<<T 6#XIT$:7%J;:M:+8RR&))VD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB82'/W@"/E;MU(]J-+\-#1;+3+#3M0N8;&R@DA,6%8S,V,.S$<,#N/'&6Z4
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MM)<6\5CJ"W,Z[%W[)8PHV,5SC!89!&:FB\?3MX1?7WL].:)I(43R-0,B1;V
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M1Q),5+,VUB>64  '\,5T.A^&+K03!:VVLRMI-N6\FS>W0LJG.$,F,E1GCC/
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M %%%% !1110 4444 %%%% !1156^U&QTR%9K^[@M8V<1J\T@0%B< #/4GTH
MM45FZKX@T?0A&=5U2TLO-SL^T3*F['7&3VK0CDCEB66-U>-U#*ZG(8'H0?2@
M!U%9>G>)-$U>ZEM=-U:RNYXAN>."=78#.,X!Z9XS4FJZ[I.A0I-JVI6ME&YV
MHUQ*$W'VSUH T**CM[B&[MX[BWECFAD4.DD;!E93T((ZBH=1U"UTJPEOKZ80
MVT0!=R"<9..@YZF@"U15>&^M;B[N;6&XC>XM2HGC4Y:,L-RY';(YJQ0 444T
M.A=D#*64 E0>1GI0 ZBBB@ HHJO#?6MQ>7-I#<1O<6VWSXU.6CW#*Y';(YH
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M,C7!&U6QD#!/'N?6@#)\;ZE=:9H4)M+C[(US>V]K)=  _9TDD56<9XS@X!/
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MBUMQ>-=B",7+1B)IMHWE 20N>N 23CW- &!XVU&ZT_2;-+6Y-I]LU""TENE
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MYO#FB7&F#39M(L9+%9#*+9K=3&'))+!<8!R3S[FDO/#6A:C>1WE[H]A<7,8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHIHD1I&C#J74 LH/(!Z9'X'\J '4444 %%%% !1110 4444
M%%%-:2-'1&=59SA 3@L<9P/7@&@!U%%% !1110 4444 %%%% !1110 4444
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MOH;F^L)ID6.?[%<&(3*HPNX#N!P",''>B[\)6%UJSZBL]_;32JBW"VUT\:W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#UP0"/QJU10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML!N+5+6WDG::,8R5"*2>H_#Z4 ;]%<G>^/\ 2[:ZT-;>*ZO+75E=X[BVMI9
MJA21PJ$DY&"O!7J1BMW5=8LM%MXIKQY!YL@BBCBB:5Y'()VJJ@DG )X'0$T
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>foraresidentagreement011.jpg
<TEXT>
begin 644 foraresidentagreement011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?* Q_=?Z.TOR^O(QS69:^-=<;P^GB.[TVQBTG[4L3A)F:58O-,;RGC  ZX]
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M "JH'+83(SQP<]: .LHKC_#OBK4]<L]0D6WT_P"W01L5TSSFCN(9!G:DNX<
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MWM@=/E-P8U'D\\ (B@'D\^]%CX*2SO?MTFN:M=7@L7L(YY9(\QQL5(*A4 W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@LQ8>AX )X/&!46F^-+74KNP3^S[ZWM=2W?8+N94$=SM4MP Q9<J"PW 9 H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+')SUXXP>G7K6 ]YK6CKXQUJQU"*.VL];#-:-;AO/RD <,Y.1\I&,8P>N>@
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MT!.V@#T.@G R>E>5^+K_ %R'1/%>B3ZNTSV5E;WD5XD*I(4D9U,;[> <ID$
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M!:Q6T=I&T5QM5"YD<L&4G<<;< #'6O2J "BBB@ HHHH **** "BBB@ HHHH
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MI?VDEH&@U";S[I-[?O'PHSUXX1>F.E5I/$-O97NK_;[RUCM;%8"0JOYB&0'
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MG.Z-T5HQP71F #J/5214*^-=$EMKV6&>=WM(/M#PO:RQNR= RJR@LN>,J"*
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MD4NOFO'Y*L0 &;8N"0,9'O4&@Z%X@;_A#[+4=+ALH?#\>Z2X2Y63SF$!B54
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MVPYXSW(P:N:_X8U?7Y]:N$@CMFO=+LHXDED!'G1322M&VW/'*@D<<GK7?T4
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M#!74A^H)P<\<UN:[X<EOOA\=!TZ.."2.WA2"*20LH\HJP1FZD'9M)]\UT]%
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M@XWJC,,*Q3< 3P#7&IX2UJ>PUS?:2HU]J.GW$4=U>">3RXGB+[VSC.$/&3Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEV4%W"G!?;P#@9/7U77/'S:9J0TV,:4EU%9)=SF[OC'&Q;.(XSL)8G:?F(
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M^,-6U.[T6UTW2;9GU#2HM3E>>Y*)"K$9484ECR .![XH [2BN1LO&<MY'I<
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M^$[76)KV66XF0W>ER:6P3'RQN22PX^]S]*WZ* ,2/PS;1W6ISB>4MJ%E#9R
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MJ*T2TE@\N(^<J]]Q4E6/3(]!C!YK:UG0+77#8)>%FM[2X%P8" 4F8*P4/GJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !7/>+/$L_AJRCN8M*FO4,B+*XD6-(E9U3))R2<L,
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MF6+Y\^- PWCC@%HY%[_=K4;Q5IEC9V#:U=VNFW=U DS6TLPS'D#.3QP"<;B
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M _>&XYP1D8Z57U#7?%VG0>*&_M2QE'AY%N QLL-=*8Q)L8;L* ,C(Y.1TQR
M>F45@>*=:N=*T"*XL5C%U=W-O:PM,"4C:614W, 1D#=G&><51U2ZU71M/@M[
MOQ C7=S<E8'@TLR32J$)*K&K$9!!);& .H[T =;4-O:6]KYOV>"*+SI#+)Y:
M!=[GJQQU)P.:X?1/%VJ7P\.QW'E[[K5+VPNF,)C+K"DVT[2?D8F-21]13KKQ
M%X@FL]3>RC9EM-;>TEDM[;SI8;81AMRQY^=MQ /4X)X.* .\HKSJZ\8:A>7]
MAI^DWTD\;::+U[ZUTTS&4L[(H\LGY!E&W9YS@<5:M=;\3ZUJ%AIB&WT:]32D
MO[M9K<R[I&=D"!2PVKE&)YSR!D4 =K#=V]Q:BZAN(I+<@L)4<%"!U.1Q3X9H
MKF".>"5)89%#I(C!E92,@@CJ".]<9X)W?\*CL]V-WV*7..F<M6/X7O\ 7],T
M7P5;RW]K+:ZM8K;11);8-L5MC)&X.[Y^$PV>,GC% 'IU%<1X=\6:AKM]HMCM
MBCN8[:>365V_ZN2-O)"#TS('8>R>].\:^(;W2Y+A-,U,I<VUD;HVL6FM<$XW
M8,C@X1#MQV/!.3C@ [4D $DX ZFFI(DF=CJV.N#FN3\779O_ (1ZQ>LH0W&B
MR2E1VW1$X_6LB&=_#'AIKG3O">G:)>W<MI:12H(RLC2N$#OY>#A=V<$\YH ]
M%HKSS6?$FO>&H]?L[B\M[^>UTC^TK6Y^SB,J0Q0HZ@D$9 (/'?KBK]Q=^)(=
M3TG06U6U%[?I/=2W:VGRQ)&(QY:*6Y.Z3[Q[#IF@#M*"0 23@#O7G^K>(?$$
M6NOH=M,YGL[".>:XM=-,PFE=G"@KN^1/DYY))/!&.=#Q/=7=[\(-6NKZU-I>
M3:+*\]N?^6;F$EE_ YH [ $$ @Y![U1U#2-+UN!(]2L+2^B0[D%Q$L@4^HR#
MBO.+2]GTS0+KP+;RLE_)<QVNGL#\RVEP"^\?]<T$P_[9CUJ7PW=_V-X$TK3K
M"_:R=[Z_CAA@L6NI9%2XEX50> !C)((Z=,T >D6\%II\,-G;106T2C;%#&H1
M0!SA5']*L5Y[H_B&YUB3P9=7MM;-<W$U]%)(;?#J8E=<IG)0MLY'OBHO#/BW
MQ%K<^DZ@+6XDL=0E;SH/L)2.VA(8JZS9^8@A0<C!R<8Q0!Z/17#67BK4I_#G
MA>^=HO.U+5/LMQA."F9>@['Y%JDWBGQ#:>'-?\13SVLL-I>7%E:6:6YY*W/E
M([MG)QW48R!US0!Z-3&EC0X>1%/H3BN7\+ZEKEQJMU:ZC%<RV8@62*[N++[,
MPDR0T>W)!&,$'Z@YKG[S2DU/XGZZ)/#.E:RB6MD"U^R@P ^;]T&-LYQSTZ"@
M#TNFF-&=7**74$*Q'(SUQ7#:MXIU/3+S6M&3R?[1::U72,IPR3_("1WV,LI/
ML!5-_%OB*ZU2_DTZVN)HK+4C9K:)8%DF1&"R,TV?E;[Q&!@8&<YH ]'HKSF_
M\2>(X8M>U:*\LULM(U-;86AMLM-'^[W;GW<'$G&!U'.:TM"356^(_B42ZJ9+
M.+[.1;&'C#(Q !SQCOQS0!U]S;07MK+;74,<\$JE)(I%#*ZGJ"#P14@ 50J@
M  8 ':EHH **** "BBB@ HHHH **** (K:UM[*W6WM8(X(4SMCC4*HR<G 'N
M34M%% !1110 4444 %%%% &9=^'=$O[Y;Z\T>PN+M<;9YK9'<8Z?,1GBM.BB
M@ HHHH **** "BBB@#,F\.Z)<:D-2FT>PDO@0PN7MD,@(Z'=C.16G110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ,FABN8'@GB26*12KQNH96!Z@@]
M15/3=#TG1A(-+TRSLA)C?]F@6/=CIG &:OT4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %8VJ^%M)UJ\%W>13>=Y
M)@=H;F2+S(LYV.$8;ER3P<]3ZFMFB@#-L=!TW3IX)K6W,<D%FEC&=[';"ARJ
M\GGZ]?>L76O!-I?Z/H6BVL$,>F:=>Q3LDK,S".,-\JYSDDD Y/W2U=910!6U
M'3[;5=-N=/O8_,M;J)H94W%=R,,$9'(X/:LK4O!VBZK=-<7,$ZR/$()O(NI8
M1/&,X60(P#CD]<]<5O44 8EYX3TB^GADGAG\N(1@6R7,B0$(<INB#!#@@=1V
M'I2Q>%=)BU1M0:.>:;]YM6XNI)8X_,^_L1F*KGIP.G'2MJB@#"L/"&DZ8K1V
MPO1"8FA6![^=XXT/!"(7POM@<=L59TGP]I^BRSS6HN'GG"K)-<W,D\C*N=J[
MG8G R<#W-:E% %&'1["!-01+92FH2M+=*Y+"1F4(<@]BJ@8Z50LO".E:?#+#
M ;\PR0&W$<FH3NL<9_A0%SLZ#!&".QK=HH Y\>"]$.GWEG+!/.MXR-/+/=2R
M2L4.4/F,Q8;3R,$8HA\$Z#!;7L M)'6^,373RW,CO,T;;D+,S$D@]\^W2N@H
MH Q[CPQI5SJ=UJ$D4PGNX/L]P$N)%25-I7YD#;20"0#C(J>UT+3K.Y%Q!;[9
M1:1V0;>Q_<H257D]MQYZ\]:T:* .!U/P$ZZG;2:99V,]C;Z='86\%Q>30-;A
M&8Y#H&+Y!'!(QMX/)KJM,TA[?PQ;Z1J=RVHLMJ+>XEESF;Y<-G)SSSU.:U**
M ,>P\,:7IWV PQSLU@'%LTUS)*8PX (RS'(P  #TQQ3+CPEHUQ:-;M;2(#=O
M>K)%.Z2).Y)9U=2&4G<>AQ@XZ5MT4 9,/AS3819?+<2O93M<023W,DKB1D9"
M2S,2?E8C!X':H]0\*:5J.H/?2K=PW,B".9[2\EM_.4= _EL-V,GKS6U10!GM
MHFGO<WMPT!,M[;I;7#;V^>-=V!UX^^W(YYJ&\\-Z5?:1:Z7-;M]FM-GV8QRN
MCPE!A65U(8$#C.?7UK6HH Q8/">C6]FMJML[*+M+UGDG=Y'G0@J[.268@J.I
M(P,=*FN?#NEWD>K)/;%EU9!'>CS&'F*$V <'Y?EXXQ6I10!2U'2;'5M+DTV^
M@$UI(H5HR2.A!!!'(((!!!R"*RSX*T9K:*)A?-)%,9TN3?SF=7*["1+OWX*\
M8SC':NAHH Y]O!>A'28M-2UEBMX;AKJ)HKF19(Y6))=9 VX$[F[]S1%X,T6V
ML&L[2.[M8FN#<EK:]FC<R%0K,7#;CD#G)Y//7FN@HH P)/!FB-#9QQ6\]J;.
M(PP26EU+#(J$Y*ET8,P)Y.2>>>M.O?!^C7YM6GAN ]M"8$DCNY4=HCC*.P8%
MU.!D,36[10!1L='L--T=-)L[<16,:&-8@QP%.<C.<]S6;I/@K0=$NX+FQM95
M:VC,=NLES)(D"D8;RU9B%)QR0,G\37044 <[X=\-_P!CZSX@U258!<:K>"7]
MSG"Q*H5 <C[Q.YCVRQJ?5O"6CZW>/=7L,QDDA^SR^5<R1":/)(1PC , 6/7/
M4UMT4 4;C1[&ZT*319H=VGR6_P!E:+>1F/;MQG.>G?.:6_TFQU32Y-,O;=9K
M.10K1DD<#!&".000""#D$9J[10!@1^#-$2PO[22">X34(Q#=27-U+++(@SA?
M,9BP R< $=35O6/#^G:X+<WB3"6V8M!-;SO#)&2,'#H00".",X-:E% &#/X.
MT:<VS+'=02V\/D)-;7LT,ACSG:SJP9AG)^8GDD]ZT;G2K.\T672+B-I+*6W-
ML\9D;+1E=I&[.[IWSFKM% &:= TMM;MM9-HIU"VMS;0S$G*QDY(ZX_'KR?4U
M3E\':+);6L"P3PBUEEEA>"ZEBD1I6+28=6#88L<C..GH*WJ* .4@\)&RU[1?
M[/BM[;1M*%Q)'&)'>5Y9MVX8(P%&XG.3UQ@ 5H6/A/2M-OA=6:W<.UVD6W6\
MF\A6;.XB+=L&<GC&.<UMT4 <[#X&\/V^H17L=I+YL-P;F%#<RF.&1B2Q1"VU
M<DDD <U?'A_2AI5WIAM%>RNY)9)XG)8.TC%G/)XRQ)XZ=L5IT4 9FE:%::.9
M#;2WLA<!2;J]EGP!T \QCC\*JW_A#2=1U.74I?MT5W,B1R/:ZA/;[U7.W(C=
M0<9/YUNT4 9=SX>TN\UJPUBXM1)?V"LEO,7;*!A@Y&<'@GKG&3CK4$GA/2GU
M234%6[AFED$LR07DL4<KC&&>-6"L>!G(YQSFMNB@#*E\-Z5/9:A9R6I,&H3_
M &BY7S&^>3Y><YR/N+P,#BB7PYILNL2ZJ8YENIH?)F,=Q(B2J 0-R!@I(#'!
M(R,UJT4 5[&R@TZPM[*V5E@MXUBC5G+$*HP,DDD\=S5BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\0^*=.\-1PM>BX
M=I6552"(N0"P7<QZ*N6 R2.O&36W7%?$Z_@@\)R63>:UQ/+ T:1PNY8)/&S?
M=!Q@ GF@#H]>UVS\.:1-J5\9#%'@!(EW/(Q. JCN35FPOHM1TRVU" /Y-S"D
MR!A\VUE##(]<&N*\50:OK175M,M;.^TJ'3YC!'/<20.LSJRM)L\IMQ"<*#C[
MS>HK5\*:F]GX9\.V&I6[07DNGAE2)7D4)&B_>;:-K$$?*>^0,XH GT[QA:W^
MLQ:5+I^I6%Q<1--;?;8!&)U7&[;R2",@D, >>E:1UBV7Q"NB,)!=/:F[0E?D
M9 P4@'/4$KD8[BN,\-ZY9>)_&2ZO=FXAGCCDMM,L9+653'&>7D=BNT.^P8&>
M  .235SXBR7FD1Z9XETZVEN;JP>6$Q1(69DFC*C@?]-!$?PH T[;QQHMWX?U
M?6X9)6L]*EFBN/E&XM'R=HSSG(QZY%= DRLD;-^[:0 A'P&^GUKRA_#=SH^M
MZ;X5AMY9+#58[&2ZF524#6N3+N/^V$B'OFD\4Z<;OQ9X@CU>YMK5+B.)=.N)
M])FNY$3RQDV[HXV.)-QP!G.#R,4 >N$@=32;ASR..OM7,>,[&YF\&M-;[KC4
M--,5] 0N&DDA(<C'JP#+C_:K@8+35+[4EMI;:Z-IXQN$O9MZ$"WCBE9F5O[N
MZ 0K@]\T >EWOB-;$Q"6PN4\W4DT]#)M&XMC$BX)RO/?!X/%6=%UB/68;N2.
M)HQ;7DUH0QSN,;E2?H<5PDEI<^?<'[/+SXSBE'R'[FR/YOI[UTW@F*2&SU@2
MQNA;6KUEW*1D&9L$>QH T]!UN'7M)AOXD,0E:0"-F!8;'9"?S6M+>N_9N&[&
M=N><5XQH5E8"WT"&QTNXB\31ZT99YVM75Q;^<Y<F0C'EF,XQG&3C&:LZ3IDD
MNOH-2O;>TUN/67G9O[(F:ZE03$JHN ^TQ-'A?N[0IP>1F@#U]F"J68@ <DGM
M1N7 .X8/0YZUP_Q&@N9?[#9O*.EQW;->^?:/=1#]VWEF2-64LH;WP"5)Z5A0
M^'[:XMO#EIYBZCIDNO33-'%926T$2&VE^148G]WN]]IW$=.* /2K[5++3H(9
M[J=8XIIHX(VP6#.[!5''J2.>E07NN6VFK?S7T<T%G96XN)+MES&5^;(7!+$C
M;R,=QC->:ZEH-G%H.JPS:0CZ=I_BF&6*$VN]8;8F!I=BX/R?,^0!C&:L>(M(
M@U2V\8QV.F++:/X<M#81+;87*BX*!%(X897  R.* /09M;ABU_3M)$;.U[;S
MSI*#PHC,8(/U\P?E6D'5BP5@2O! /2O.9H89K_0Y/"EJMO"-&U-;;R;<PHDQ
M,&.,#!+ GWP:Q?#6ER&WBETN\M[?68=*GC>VM](FMIGE:/@7$K.0S"0 Y(R3
MDCK0!Z?>:W#::UIFF;"[W[2JKJPPAC3<<U:>[*:C%:?9IV62)I#. /+3:0-I
M.<Y.>..QKRWPU:Z+_P ))X.DT?2I[>XAMIDU&4VCQ8D\GI*Q #2;MW/)]^1G
MIO$T$TGB^!TBD9!H&H)N521N+08'U.#Q[4 =F'5F*A@2.H!Z4.ZQKN=@J^I.
M*\V\.:#!I&H>!;FRT\V\]QILBW\JH0TA,*,/-/4G<.-W3H*O^*X]/'C2QF\2
M6?VG0A82+");<SPI<[QG<H! 8I]TD?W@* .[R,@9Z]*-R@9+#'UKRK2_.T./
MPIJ.H07<&F07.H)%YD+L]O!(2;=74 LOR@ 9Z<"HX].&M:5ID=U87)M;GQ?<
MSR0S1,A,3"<C>O4*<@$'UP>M 'K(92NX$%<9SGC%)YB>7YF]=F,[L\?G7.^*
M],T[_A";C3&D_L^Q58T4P6QD2,*ZE08U'*< ,.!M)Z"N(22"YM="EU;1+>+P
MY!?727"6MDXM9GVCR9S#C(0G?U!&[!ST- 'I&JZS%I<FF(T;2_;[Q;1"I&%+
M(S;CZCY/UK1WKOV;ANQG;GG%>6:?92*-/>RM)XM(;Q6)K"(Q,@C@^SL"P4C*
M(9-Y P!S[BJGA_2Y)-;M?[1O;>TUV'59)IB-(F-W*/,;Y3<;]IB9"!G;M"X'
M:@#U]F5%+,P51U).!6+9^)$O7G6&PN7\G4FT]S'M.TJ,F0Y(PGYGGI6+XZCM
MFU;P[)J]L;C08YIC=HT)EC$ACQ$9$ .5SN'(P"17-:-9".RLA96%S!:#Q@98
M8Y(70K#Y1P=K<A>G7ITXZ4 >L!U+%0P++U /(H#HP)#*<'!P>A]*\A\B>W7Q
M%8^'+=;Z[N+&]E344LG@O()&<'R9'8#>22=IX(V#CO5S4[/PS?\ @V>V\-:7
M)!YEQIR7/DVDD#$"Y3AC@9<#<2>HZD]* /43+&$WF10O3=GBJ\VIV=OJ=MIT
MLP6[NDDDACP?F5-NXYZ#&]>OK7G?BO1K;3?$.EVXM=-M/#L5E*L,=QI;75K'
M.T@+9C1E"L5/#'_: Y-0IH>E:?JW@FXU*!-2@2UN;<7TVG-DONC: %6#,N!O
M"[CQ@\\T >EVE[]JBFD>WFMA%*\?[\ ;@IQO&"?E/49Y]A5D,I4,&!!Z$'K7
MD\EL$\A]7LY9=!7Q)J,E[&T+2(<E_)9T .Y-WL1DJ33#I,=[:-#:6,R>';CQ
M-;-:6_E/&OD^6!*57@K&7W^@Y/8T >MJRNNY6# ]P<U5M-3L[ZZO+:VF#S6<
MHAG7!&QRJOCGK\K*>/6N=\):='I/B+Q196=H+33UN8)((8TV1*6@7>4 X&2.
M<=ZY6XTJ*RN_B#;Z/IB6^OSJTMC)!:[)'B:"+=Y<@&.7#\ _>YZT >JJZ/G:
MRM@X.#G!I6=5^\P'U-><^'X-&?QEI,WA+3VM+.*RF34F6U:!6SL\I9,@;I P
M8]R.<]:T[W0[35?BFL^H6*W,-OI,;1>:FZ-91,^#@\;@.AZC/% '9;UW[-PW
M8SMSSB@.A<H&4L.2N>17D.A:9))KEM_:5[;VFN0ZO)-*1I$QNY1YC?+]H#[3
M$T9 SMVA<#M3K!S=>-]$O+?2[6PNO[4N4NX8-.D6=$,<PS/<$[6#$*P&/3!X
MH ]<#J6*A@67J >10KH^[:RG:<'!Z&O(%@N+>#Q%8>&[=;VZGT^[E34DLG@O
M(G9P?)E=@-['<=IX(V=.]7K:VTB;6+>3PAIKVMK'I5TFHE+1X0V57RD?(&Z3
M=N/<CG/6@#U$.K,5# D<D ]*:TR*DA#!C&,L >17F?A_0X=%E\"WECIC174V
MFR"_=$(>8^0K!9&/).\<;NG08K/\+_O_ !5I%W::=:6/FZ?=+>6]GITL!A8A
M"(YI6.)7!![ YR>XH ]/T'6(M>T*PU2)#$+RVCN!$S L@89 --T#68]?T>'4
M8HFB64N C$$C:[)_[+7EO@VRL%3P-'I.F7%MK=NH;597M7C80^0P82.P^8%C
M'M&3T&,8J19+WPIX3T/Q/;V<KW$/VNPG@VD,ZRRN8<@^DHC'T<T >MW5Q]FL
MI[E8I)S%&SB*( N^!G:N2!DXP,D4L<ZO!'*X,6]5.R3 9<]C[]JY:ZT1M&^$
M]]I$>Z::+29T=E&3+*8V+-[EF)/XU@#PW9ZQK=^=4TP7*1^&[-(A-&2JR?O\
MX!XWCCGJ,\8S0!Z$^IV<>JQ:6\P%Y+"\Z1X/**55CGIU=>.O-6=Z[]FX;L9V
MYYQ7ENGV%B-<\#:IKFF)+-/H:Q&XFM/,;[6#;E-QVDJX^?!.,<^]4_#^F22:
MW:_VC>V]IKL.JR33$:1,;N4>8WRFXW[3$R$#.W:%P.U 'KV],XWKG&<9I0ZM
MT8'DC@UY++X=A3X<^*KY-.8:M<W=\GG;#YQC-TQ"J>H7@-@<9Y[UOZK9:9X1
M\1^&KJWL?LFE0I=Q2M;P,P6218]I;:"26V'D]3[F@#N]R@9W#'UJI>ZI9:='
M;R74ZHEQ,D$1P2&=SA1QZGOTKR5C9FS\.R:S8W/V&;Q%J<LMO+;N6*-]H8;X
MP,E>A(P1@'/%.N-'T^;P]->-HX?08?$T4]I'+9EA%:'RQ*RQE<K&6#G &,<X
MQ0![)U&::LB.I974J.I!XKE/&,33?#YTTB"4VI6W)@M8RKFU#H9%11@C]UN&
MT#..*XW5;2QGM/%4OA33S#I#^'98IEM[5H8Y;GG9M3 W.$W D#NH- 'KP93G
M# X.#@]*,CCD<]*R](T+3-,T;[#:644,$RYG4+S*Q4!F<]68@<D\FO)XGUK2
M#;:J]I>RKX.(TT1"-B;J-VDC+*/XAL^S-D>AH ]AFU%8+SR7@F\H0/.UR #$
MNT@%2<YW<YZ= :H/XGLBV@M;9GM]:?$$R_* ODM,&(//*KTZ\UQMEX8DM[W3
M-+O+07.[PW=+<^9'N1[AYHG?.>,ERQK/T?1M(U'P]X L8M*40QW(&IP_93$#
M.MDX?S1@;B6 !)R#T.>E 'K>]-F_<NS&=V>,5G:?K46H:KJM@D;*VG2QQLY(
MP^^-9 1^# 5YQ<Z<EEIT]G-82#P[;>*B;BU2%FC6U,(8?(!S$)64D 8_ 55?
M2[2ZTSQ+!I>G7,&EW6N:888UA>+,>Z .R#@JO#$$8P.F!0![#YL856\Q<,<
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M7&$<%B6Z_=&<8S52YTR2Y\3:M'J=[;V6I/JPEM)WTB:>Z\H,IB\F97P%P-I
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M.-R44*1D!\\D X&.^)O%/C:3PS?$2?V0UNC1Y@>_VW<BL0"R1[<<9[GG!Z4
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M[V(_VEK8UCQM)H_B*WL)O[(:*:\AM1"E_F['F,%$ABVX !8<9Z<Y[4 =G17
MS^,H-#AU:3RP)GUTV$1O+QA%O,2.7+$'RT"Y^51U''6I]/\ 'YNXH5^S6TLI
MU:+37DMK@R0L'3>)$;:,\<$'H0>: .WHKC]7\:SZ;_;8ATP7,FG7UG:1QB;:
M9C/Y?<C (\S].U5M5\;WND7MMI-XFBVVJ-;&ZG-Q?LD"KO*HJ,4W,QP<\ #!
MZ\4 =S17,S:Z=6^&UUKEJLMJ\VF2SH-WS1-Y9Z$>A'7\:Y[0+Z73/"-QKMO9
M>(;F\@TY)WCU.\E:.?@,YC#,PS@$C '4#O0!Z/17':MX_MM.6_N88%N;&SL(
M+IIA)M#23OMBCY& ".2>P(XK/'Q(>+3]9D>WL+R?3[:.Z5M/NS+%(&?:4+%1
MM8'\P0>* /0:*X?4/$_B""VURQFT^RM=3M]+.H6KQW32)LRRD,2GWUVYZ$'C
MI70>%[K4KWPW87.JK +J6%')@<L&!4'<<JN">X P/6@#8HHHH **** *5MI5
MI::E?:A$A%U>[/.<L3D(NU0/0#G@=R3WJ[110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %8.K>&WOM7BU:QU2YTV_6 VSRPHCB
M2+=N 974C(.2"/4]<UO44 <_IWA"PTN?2);:6?\ XED5Q&F]@QE,S*SNYQRQ
M9<\8ZFL_4_ $6H_VG FLW]KI^I2_:+BSB$>TRX&6#%2P!V@E<X)]B17844 <
M]<>&)AJ]YJ&F:U>:<;XJUU'%'$ZNRJ%#KO4[6V@ ]C@<5H66CQ6.KZGJ*2.T
MFH-&TBMC"[$"#'X"M&B@#'U/0?M^MZ;JT-_/:7-DKQ_NU1A+$Y0LC!@<9*+R
M.1S64O@2!6^R_P!JWIT;[7]L&F83R_,\SS,;MN[9O^;;GK[<5UM% &=JNCPZ
MM)ISRR.AL;M;M-F/F959<'V^8U1OO#4LNLS:KINKW6FW%S$D5R(HXY%E"9VG
M#J<,-Q&1VZ@XK?HH YW4_"SZO=6QO-8NY+*&:&X^RF.+F2(@J=X7<,E02 ?7
M& <5A:3X'N[@7RZKJ%[%8RZS/?'3@8S'*!.7C.[!8*<*Q7/;MSGOZ* .2O/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 50U#0])U9T?4M+LKQD&$:YMTD*CT&X'%7Z* ,F?PMX>NHK>*XT+3)8[<8@
M22TC81#.<*"..>>*U5541410JJ,!0, "EHH IS:3IMQ)<23:?:RO<H(YV>%6
M,J#HK$CYA[&E?2M.E</)86KN(3;AFA4D1'JG3[OMTJW10!FV_A_1;2PFL+;2
M+"&SG_UMO';(L<G^\H&#^-$7AW1(;9[>+1]/2"2,1/&ML@5D!)"D8P1DDX]Z
MTJ* *-]HVEZG#%#J&FV=W%"08DG@614/J 1Q2Q:/ID)MS%IUI&;=G> K H\I
MF^\5XX)SR1UJ[10!1DT329K2XM)=,LGMKF0RSPM I25SU9AC!)P.3S44WAS0
M[C3HM.GT;3Y;&$YCMGM4,:'V4C K3HH AM;6WLK:.VM((K>",82*) BJ/8#@
M5-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M52?FP3G'7!R.E,E\/7VJ2SWKZ1)%9WWB*UO!93*NY8HT57D=02!N*DD=>F:
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MC QRDXD(,>#U!YQC%2:5XPU'4&TBRE>VAOHA=-K+,ORQ"WS&3UX#.48?[.:
M.\) !)( '4FHUNK=YQ D\33&,2B,."VPG ;'IGO7GEEXKU"XOY[*>Y&HV5UH
M]Q>1R2Z6]JA*;!\H<_/&PD]^@YYJ+2]22VO[;4GFM-/5?!]O+O,1\F'YB?N
M@[1_=!]A0!Z3<7$-K;R7%Q-'##&I9Y)&"JH'4DG@"EDECAB>65U2-%+,[' 4
M#DDGL*\HUWQ!J-]X7\::3>S27$<.BBZAFFL&M)/G\Q2I1NH^0$' ZD=JUM:U
M'7+%=2T?5KNTO([[0;RZ0P0&/R'C"@K]X[E(D&"><CWH ]"1TEC62-U=& 96
M4Y!!Z$&G5YG_ ,)+JZ-9:-I?G1"TT>UN&DBT]KHR/(&"J0"-JC9R>ISQC%=_
MH]U=7VBV-U?6IM+N:!'FMVZQ.5!9?P.10!;#JS,JL"R\, >1]:S-1\-:'J]R
M+G4=)L[J<+L\R6(,2O\ =/J/8\5R.J:[?:9?^)FTR"QCNUU73K59'A_UGFK"
MI,A!RV Y /85O>'=0U4Z_K.BZK=0W;V2V\T=Q%#Y6Y90_P I7)Z%#SZ&@#I$
M18T5$4*BC"JHP /04Q;B%[B2W6:-IHU5GC# LH;."1U .#CZ&N3^(1U%=/TD
MZ=J!LV;5K2-F$>[=NE4#/(X]1WZ5C7:Z]!XQ\1RZ?J5K%/;:-9R32RVI?SG7
MSR %W *I(;/4CC% '=:GHFEZTL2ZE86]UY1)C,J E">N#U&?:K%G96NG6D=I
M96T5M;QC"11(%5?H!7 7/C35M1N[&VTY9;4R:1!J,C0V#79+RYVI@$;5&TY/
M4YXQBNWT.[O+_0K&[U"T-I>30(\]N?\ EFY'S#\Z +]%>>^(?$7B.UN?%<]A
M=645IH,,=PL4EN7:?,7F,A;<-HX/(&>1Z<VH]?UC3-4O+76=2T\1-I#:DEQ]
MF94M6#;2I&[+J-P/4$X/K0!W%1O<0Q310R31I+*2(T9@&? R<#O@<UYO)XTU
MFRL_$JF9KE['1_[1M9KG3GM6W9<8*-]Y?E!!X[@U'XKU75/#<_AS5]5>/4;J
M.2ZFV6T)C2,&WQM/))1222W7;DXXH ]0HK@-2\1ZU;7VE:,EV);F:Q:]N+VQ
ML#<!OF"JL: \+S]XD\ =S587GB;4_$7@^6XNCI<T]M=_:+4VQP60J"Q4M_$,
M$ \KGOF@#TBBFR.(XV<@D*"3BO/[#Q-K[:=X=\07-S9R6.M744)L$@(,"39V
M%9-V69>-V1@\XQB@#T*BO.K7Q+XC,-IJT]U9-8RZX^F&T6W(8QFX:$.7W?>!
M XQC ]37HM !17FD/BSQ'#X*BU^YGM99;^YCM+6WAM&;R2TWE[SALN<9.T8Y
MP,]ZOV_B/6(-/U0:E<26J120+9W]SI;J\QD)!C$ .7<$8&/[PX.#D [RBO.K
M;Q1XDN-(U>.WCEN+G3]1B@><6!286[1H[/Y!(RXW8QW'.#T-R#Q#J&M7FDZ5
MH^KVQ,]G-=SZBUF06$<BQA!$2-K;F^;/3:>!G@ Z34O#6B:Q<K<:CI5I=3*N
MS?+$&)7KM)[CV/%::(D4:QQJJ(H"JJC  '0 5Y[!XH\0ZA)I6FPSV4%[+J-[
MI]U<F LC>0&/F(F[@D#H3@'UQBK$/B;46T-X;O4XH-1BU2;3Q+!8/.]SY>3E
M(E)PV,$GD#!_  [B2XAADBCEFC1YF*Q*S %V )(4=S@$\=@:)KB&W\OSIHX_
M,<1IO8#<QZ*,]2?2O+FU?5_$"^%)!+##J46NWEIY\MLRC$<,Z[S%G(;:/NY^
M][59O-4U"\DM=.U.6*>YTOQ1;6_VB*/8)5,8D4E<G# /@X]* /1;.RMM/MA;
MV<$<$(9F"1C RQ+$_4DD_C4]><6'B_Q!J>H1W=I:SRV;:FUH;5=/;8L"RF)I
M#/G&X8+$8QQCKS7H<ZRO;R)#((I60A)"NX*V.#COCTH DHKRS1]?UO1?AOI5
MS)>F^NM1O%M('-LTC0[G?<Q ;,APIP..<"KTWB;Q1;Z5*@B"W#:G:VEI=WMD
MT(E29@IW1YSE22,C&1CI0!Z+17#WEWXI&O\ ]A6VKV2O#I?VR2[>RR7?S'4
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MT5VN%R?W00X;<>@((Z4MOXKT.ZL;V\BU&/R+%=UT75D,2XR"RD @$ X..<4
M6$T+34LK^R^RJ]M?R22W,;DL)&D^_G/8^E1Z3X?L]&=FMIKZ3*"-1<WLLX11
MV4.Q _G2:=XGT35I;B.QU*"9K9=\N&P G/S GJO!^89'O45KXO\ #][:W-S!
MJMN8+5!)+(Q*JJ'HV3C*G'!&0: +NK:/9ZW9"TOD=HUD65&CD:-XW4Y5E92"
M"#W!KE]:\!0/811:3%&[?V@E]=1WMU+FY98RG,OS.A^Z<CKC'0FNFTO6]-UI
M)6T^Z6;R6"R+@JR$C(RK $9'(R.:8WB'2$@\Y[^%8_M?V'<QQ^_W;?+^N>*
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M9%U=)'',^XG<J;MO'08W-T]:HVWBW0;O5!IL&J02719D5 3AV7[RJV,,1@Y
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M]#Q3)O#.MV_CJ]\56]DL[+<Q;+-I4*RQ-!''(\>2 LBE3@G&1N'0BO1J* .
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MPRGD@ C)KT2B@#S6X\):PNC:'?F&X?4HK^;4-1M[2X1)2\RN"$=CM)3<JCD
MA3@U;@\,3L^BSPZ9>Q!=<;4+M=0N(Y)!_H[H)#M8C[VS@$GOZUW]% &-XLTM
M=8\*ZC9-*L+-"7BF8X$4B?,CY]F4'\*XC3=+U?6O"-AXF^QK-JEWJL6M2V>\
M+YD2C9'&K-@9$>UAG R.U>FRQ1SPO#-&LD3J5='&0P/!!!ZBE1$BC6.-51%
M5548  Z "@#SK5/#^MZY#XCU1=,:SGO$LEMK&::/S)/L\ID)<J2JEL[1R<8Y
MQ3-9T;Q!XA7Q9<G1)+3^T-&BL[2&6XB+NZM*2&VL54_..Y&".<Y ]*HH 8D:
MQPK&BA550H4#  ]*\T\/:%X@.F>#M&O=#-@-$F6YN+O[1$Z-MC=0B!3NW,7^
M;( &#R>*].HH \TL]%\116NBZ*VBL(=,UHW<E\;F/9)$9)&!1=V[.'&00,8X
MS4W]C:X)M8L]-TZ]L]+NK2\\VVNKB&2)[B3)0P88LH8LQ(;:O/0&O1:* .,T
M?P_?VVM&YN+51'_PCUK8[BRG]ZK2%TZ_[2\]#7/VGA;7-+3P]=R6FIRF#0H=
M.N(=-NXHY894.>2[!64YQPW\(ZBO4Z* /.-0\/ZCIVGZ8OAK2-3M=3MK,0V]
MPMW"T<>6W&*X#-\Z \Y4,>3@BM**PU>V\;"?3;&]L[.>Y:34FEGB>UN%\L@.
MB[C(LA(3LHP#G-=K10!RFL6NIV/C.UU^STR74X/L#V<D,$D:R1,75PP\QE!!
MQ@\YX'6LK1O"NIVE_P"';JZM8QY-YJ%Y<1JZLMJ9]S(@]<;L9'?/:O0** .<
M\9:;?7]AI\VGVXNIK#4(;PVV\*9E0G*@MP#SD9P,@5FZBNM7>K:)XB7P]/\
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MGLM9.LV19QAU1(\CCIO D3!Y^:NJ\):5/IWA6WANR5O[D/<W;#KY\I+O^1;
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M^O'N;HQ10@OR P5CC<VU0!T7G%6M+\:+J=SI%M]@:&:]>[AG1I 3;RVYVNO
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M;!R1@8(ST%?3?&FH7%OHE]J&B)96&L2I'!(+OS'CWQED+KL &X@ <_Q#//%
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MSKR:M<ZS(\UNDR6;):QJ\/F#'S-CYPHZ C'&3FK.@^'&TC4-1U&XO?M5[?\
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M6,/NC>/;@=  ^>YXJU9Z-'9ZWJFIB5G;4/*WH1PGEJ5&/KFM$.C,RJREE^\
M>1]:Y^T\5M?ZQ<V-IH6IS16MV;2:\!A$2. "3S('( 8=%H S]+\!OIMSHQ;6
M[J>ST:1VLK5HD 5&C=-K,!EB _!XZ=.<UG^&?!6H-IFGIJ^HW*6MMJ$MZNFM
M&F!()G:/YQSMY#[?7OCBM>X\<PH;R6ST75;^PLI'CN+VV2,QJR</M#.'?:00
M=JGH>M37GC.VBN[*WT_3;_5FO+,WT9LA'CR<J-WSNN?O+P,GF@""Y\$_:+;7
MK+^U)5L=7D,S0^4I,4C;=Q#=2#MZ'IDTNH^#9;J\U1K+6KBQM-6Q]NMXXD;>
M=@0LC'E"5 !Z],C!JY+XPTQ/""^)HA<3V;JICCCC_>NS,$"!3CYMQVX]:T]*
MU.VUG2+34[1BUO=PK-&3UPPS@^_K0!FP^%K6VNM0E@D:..\L(; 1 <1)&) I
M'KQ)^E3KH$(\'CPXTK/ +#["9".2OE[,X^E6[:_\^6Z26!K<03^2K2.N)?E!
MRN"<=<8.#QTJQ#/%<1B2"5)8ST9&##\Q0!S&DZ!<WEEH%YJF^WU#3]/ELY8A
MA@S.$5FSZ?N\CV:H[3PU/9ZOX5LT#/IV@V+@7#X!DE*+$@Q_N^83]175-<0+
M*(FFC$C':$+#).,XQ].:([F"662*.:-Y(^'16!*_4=J ,76_#;ZIJ]CJEMJ#
M6=W:Q20AC"LH*2%2<!NC?(,-]<@BJ=AX&MK"WTV%+V9Q8Z?<6"EE&764H2Q]
MQL_6NE2[MI YCN(G"-L8JX.UNF#Z'VIT5Q#.K-#+'(%8JQ1@<$=0<=Z *VE:
M;'I6AV.EJYECM+:.W#,/OA5"Y(]\5Q?A7P)&/ U_I>I+<V[ZC.S@%P9;>-&
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M<IK+2W4,%DR-<6)N0Y1&"@.#'G"@GC(Q72>&8+27QM>ZCH6GR66CMI\<,O\
MHC6R33AR00C*I)5<@MCN!VKN:* /-O'-A>W%YXN:WM+B42^&(XHC'&6WN)9S
MM7'5N1P.>11K/AR:PU74X/#6G_9&N/#-Q$C6\>Q7G#CR\L.K_,V">>37I-%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***S]5US2]#BBDU.^AM5FD$<?F-@NQ.  .IZ]J
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MU9H8X5NHI9HC.D=Q;/&QC! W<C&/F'OS]: -:BBHY[B&UB,MQ-'%&" 7D8*
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M'$JL_P!2!DT >4Z)JCO8>'-1@\1WMYK-QK'V2XM7O2ZF'>X=3%G VH VXC/
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M^MO/\BXMHY8_M!S)M*@C<>Y]30VA:0\'D-I5BT/F&7RS;H5WGJV,=?>KX 4
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M"T&VT/0H]*1C<(-[2O*HS*SL6=F'3DL:N6NGV5C T%G9V]O"Q),<,2HI)Z\
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MUOM1>XB)W&1MTBX!&&"X4>FT5U] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;%I]TUY:KYSGRY6));KS]X\'(H \U;Q/J.CW&MV&CPZ?9WM[XHBTJ.Z6V 5
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MK5S(SC(SUQ0 M%)N49RP^7KSTJMJ%Z;&T>=;::Y92H\F#:7.6 R-Q XSD\]
M: +5%95SXAL(8]7\N3SI]*B,EQ",@CY-X&3P<CTJUIM_'J6GVUW'A?.A279G
M)0,H(!_.@"W135D1G9%=2R_>4'D?6EW+@'<,'@<]: %HJG8:I9:G]H^QSB7[
M/,\$N 1M=3AASU^O2@:I9'5VTKSQ]M6$3F+!^X6*@YZ=0>.M %RBLOP_K</B
M#1K748D,7VA"XB9@64!BO]*TO,3S#'O7>!G;GG'TH =12$A022 !R2>U4]0U
M:QTO3_MUW<+';;T3S "PR[!5Z9ZDB@"[164NN0'Q'/HY7:8K..Z\XL-I#NZ!
M?KE/UK3>1(UW.ZJ,XRQQS0 ZBFM(B??=5^IQ2D@=2!0 M%-61'3<KJRCN#D4
M+)&Z!U=60]&!R#0 ZBJ3ZO8)J=OIS7*_:KF)Y8D&3N5"H8YZ<%U_/VJV9$";
MRZA?7/% #J*R]#UM-9T2#5&A:UBG+>6)6'S)N(5L^C !A[$5J4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7+^.(99K'1Q%&\A76[%V"*3A1,I)/L/
M6NHHH XK5/#]CK?Q+!U338[RT31L*)X]T>\RGL>-V#]1FN,CM;UM,\(/K B7
M3H])>(G4=-DO(DGW*!O0,NUB@P&;T8=Z]HHH P?"FG1VO@^RL'N&OX!&R!YK
M=HM\98X7RWR0H4A0#G@"O-H=+BMO +V&GZ:EK<V^L?\ $X0:<S;K<7$I7>J[
M3,@4J< GY?:O9Z* /(Y=$M[GP_<1VEPMY9WNM:?YEO8Z=+9PQ#S4$A12QZKR
MQ4X&/6N@NO">D7'CRQLI=%MVTF#1YO+M_('D*YF7^'&W/S,?Q)KO** /*/"V
MA+IUOX OXK"2._D>6.^N&1C*R&WDPLC'D@%4P#P, "M+P"EO9:Y<V%C;175J
M+=I3JAL'M[@,9,^3.6 \Q^2<\'Y3D<UZ+10!Y]XBCTI/',\WBK3S=Z6^FQI8
M&2T:XB63>_FJ %.)"#'@XR0,"LW0_#;/J?@676-)66ZAL+O>]S '>(*T;0*[
M$'#*#QDY!W>]>IT4 <7\1].LKNPT>ZO]/CN[>TU.%YRUOYVR$G#\8)V_=S]/
M:L+4_#>FZK>^,[I])29%TF :>6@("?N7(\L$?*P(7H,C@5ZC10!YG<6;7]SJ
M(U.2]@AN?"UI%-<Q0L[JQDEW< $DC.2/0\UO^ )M^FWT2:?9V\,-UMCN;*T:
MVBNQL7]X(VY!_A/497@UUM% 'E6K:1XD\2OXEU*PM;-0\R0V+W+NDR?96+(R
M#;C#2[R.1D$=JQ?$EU!XGU'4)+O3U%O=Z3:;[BYL9KA]-W!W<J$1MC#/(8KR
MH.2*]OK"U#PAI.IWMQ=3"[C>Z4)<K;WDL23@# #JK 'CCZ<4 8&CZ'IE[X[U
M74EL8)88+.Q.FRF/,48VO\T?8' 3D<@8%<WX+TJ0WVC&[O(;77K621[M%T:5
M+B5RKAQ-<;RK(2=P8C!PN,<"O7888[>".&%%CBC4(B*,!0!@ "GT >0>"-*;
M^T-$:]NXK;7+621KR--'E2XF<JX=9K@N5923N#$8)"XQP*2P\(V4FB>%)Y=)
M/VN?694O9"C!WA/G_(YZ^6=J?*?EZ<<U[!10!Y!J6E7-IIU]9VMJ(-&M_$^^
M6 V330K;F!6SY*E=T8E8$@'&>>@-3#0;:YTJQ@AE6_T^Y\1Q2/!;:?):01+Y
M1#A$8GY">20=I+,/45ZS10!Y+KOAZVBT;QC91:.AL+;5+.ZMK=+7<B+M@,S1
MKCT\S.WU8=S7I%K)9Q^'UDTFT4VBP%K>WAC\H,,'"JN!MS].]:5% 'CGAY#-
MKMO<V>GVMHDVAW2W,%CI<MLL4G[LK%(['$K@[N< CGUJ>X\.KIWPW\*M:6$<
M$<CVDVLE[-K@R#R6.9HP0TBK(RY!/'T&*]<HH Y/P'906EAJ#VM['<6T]V9$
MC@L'M(83L4,(T<GY21N)!QDM[UCZ5%I,7B[5%UW39)==?5?,LIVLWD;R,+Y1
M20*0J*,@\@ AL]>?1** /'=+LH&M-#MXM-G3QI%JJ27]R;5UD"B4F9WEQ@QL
MF0.2#E0/:R?#T4>F76KIIK#5E\6%X[GRR95B-]@[3U"%&;('!!)[UZS10!Y/
MK'AZWAL_B)/::/&ES+<1+#)%; .Z&*!G"D#)!?)..^3UJMXRL[&5_'$6K:5<
M7>KW$/\ Q*)%M'D/E?9P%$;@?*!)YA89'7G.:]AHH \@\0::UQXAOX]9DMX+
M:?3K>*QENM(EO"HV$.(F1QY<@?GIN/RGM6C<^&+;4M5\1G5+-M1:'0K2.">Y
MA.6DV3;G53T?(4_WAGWKTZB@#S&PL;)/%OA34]8TQ9+BYT.-!<RV9D;[6&B*
M[FVDJX&<$XP >:HH!!X>T2RU#2;1HI+K46-UJ.G27:0'[0Q51$N#N<$X)(X4
MXSFO7** /,?"%M>H_@3[1!.I@LM0C??&R^6-\84$'E>!P#Z5K^/)83?Z5;76
MFV,MO(LS?;+[3WO8XF&W""-"/G<$X)(^Z0,YKMZ* /)_#VAC4U\"V^LZ>]Q!
M!IU\LD5S$VQ2)(@BNK<=!P&ST'I44%G%:Z9X;BUJQEE\/V>HZE'+!);M+''B
M606Y=,'*!<@$C ROM7KM% '&?#:VCM=)U9;>SGM+5M5G>WBFC:-A&=NWY6Y
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MO[L?+Y74Q_\ @2 V/0UZ=5.+2[2'5[C55C/VRXB2%Y"Q/R(6*J!T RQ/'7-
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MQQD9XZU@&VO)K;PI-KGD"Q_X1^*/=J6ER7L:W/&\,H9=CE=N"W7# =Z]FHH
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MDFS9YX=7)SMW%25SMSC)SZ8V+?P[9Q1ZU%(7FAU>9I;B-^GS1K&5&.V$_4T
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M:25W*YD.S"IP3QDX'3)Q3-?N_$*:QX4\RQLO[1_M"=$CBNF\F1?LTGS,Q3(
MR21@_=XZUMGP99_\(G9Z MU<HMFZ2VUTA7S8Y$;<KCC&0>Q&"*EA\-,;K3;N
M^U:[OKJQN)+A))510Q>(Q[=JJ % ;/'?O0!G1>+KU] NKF>+2K*\L[][&Y:[
MO3';J5YW*^W+9!7"X!YZ\50'Q$EDT"UOEM[&,R7\MC-=R7+&SB*;L/Y@7.UL
M #('+<GUU[GP3;RN9K?4+FWNAJ;ZG%,JHVR1H_+(VL""NTGKR#WI;?PA-9:;
M+:66O7T33W$MQ/*\4,AF,GW@P9,=>1@#KZ<4 9VL^/7T[4(=-C_LE+L6*7DS
M7-Z4B.XD*D;!,MDJWS$  8XYXEM_&.I:OJ6E6ND:5"5O=-CU&1[R<Q^2C-@K
M@*26].W7\;$/@>'3?L3:+JMYITMM9)8LZK')YT2$E=P=2-P);!&/O'M6M;Z'
M'#K<>K/=3S7*6*V1,FWYP&W;S@#YB?3 ]J ,SPWXGN-=U6^MI8K&W6V>1#;>
M>WVJ/:^U6>,J!M8#<"#CD=<\;.N$C0-2()!%K+@C_=-85YX7OTGN-5AU2XOM
M5BM)K;3_ #UCC6'S".69$!;!5>N> >,G-;RZ>SZ$--N;F2=S;>1+<' 9SMVE
MO3)ZT <%:^.CI.CZ'I4#:>+E-$MKN634+HQ*VY,*BX4DL=K$D\#CKFM6/QGJ
MVK75I;Z'I%N[7.E1:EF]N#%Y89F'ED!22<@#TZ^V;R^#1:/93:7J]Y87-O8Q
M6#R(D;B>*/[FY64C<,G!&/O'K6G;:''!K0U5[J>:Y^PI9,TFWYPK%MYP!\Q+
M'.,#V% &!;>-+[6ET>/0M-MY+B^TX:E*MY<&-8HR0 @*J26+$C.,#:3[5@:%
MXS;1?".@6C_9([Z_:\D+W]P4BA5)VSE@"6.64 #W.>*Z:'P)%8VVDKINKWUC
M<:?9_8?M$8C9I8<@X8,I&01D$#CFEA\"V]C8Z7%IVIWMK=:;YP@N_D=V25MS
MHX8$,"<>^5!S0!0A\=ZCJ4&BQZ5I5M)>:D]U&WFW)$,30, 6#!260\D$#)R/
M?&E9>*+NZ\87&B20V%M]G(4QS7#+/,OEAC)$NW#)N.WKV)..E:$?A_-]I5]=
M:A<W5UIZS*LDBHOF>;C.X*H Q@ 8 ]\U#<^&#?:[:ZA>:I=3P6=P;FWM&2,+
M')M*_>"[BN&/&?KG&* ':]K=W8:AINE:;:PW&H:@9#'Y\A2.-(P"[,0"3]Y0
M !R3U%8<OCC4DM(H4T>!]7_MC^R)8/M)$0<Q&02!]N=NW:>F<$]2.>@USP^N
MKSV5Y#>SV-_8LYM[F$*Q <8=2K @J0!VZ@&J=OX,LX([,M=W,UQ#J1U.6XD*
M[IYBC)\V  !M;   P%% &P]Q>6^BM<7$=J+V. NZ><5AW@9(WE<A<]R.G:N.
MMOB',]OK@%O8:C/IUK'=(VEW1FBD5V9=I.W(*[<G /!SCM77ZWI%OKVB7FE7
M;2+!=Q&)VC.& /<>]9%MX2G@N[R_;7[]]1N;:*V^T^7"/*6-V9=JA-N/F.<@
M]3^ !H^'M3DUC25O'FT^8,Q"26$YEC8?4@8/4$>WX5RUUXZUF 7=W%H5M+86
MVJG3#_I9665S((U91MP!N9<Y/<^G/3Z!H,>A17F+F6YN+VX-S<32*J[W*JO"
MJ  ,*.WN<U4?PA9OI]Q9FXGV3ZHNILW&1()5EVCC[N5 ]<4 5(/%.I+%KEO?
MVNF6U_I9B+.]Z5MC'(,AC(4R,?-D8Y('KQ0LOB$\MK--+!9316FIP65U<V=R
M9(1'*J[95.!T9U4@].3FM?5/!EIJEQJ-PUW<0SWDEK,'3:?*>W.4(!!!YZ@Y
M!JI?>$C!X;\3IYMUJ][JT+,ZRF-&>01;%"X"JO1<>F* -G1M9?6+O5@L 2UL
M[LVL4N[)E95&\X[ ,2O_  $URMQJ&N67CKQ0^DV-M=K#96DL@N;DQC@2G:H"
MGYFYY. ,5U7A?1SH/AFPTUW,DT40,\A.3)*WS2-^+%C^-9VJ>#3?ZK?ZA;:W
MJ%@]_ EO<I;^65>-0PXW*<-\Q^8<C- &->_$R%FMETY;!#)IT6HG^T+HP[A*
M"4C7"G+8!R>@XZYX[32-136-%L=2CC>-+N!)U20890R@X/N,UCOX.CMKF"XT
M74KG29([2.R80I'(LD4>=@(=3RN3@^_.:Z&"-HH(XVE>5D4*9'QN<@=3@ 9/
ML * )**** "BBB@ HHHH **** "BBB@ HHHH **** "H9KNVMO\ 7W$473_6
M.%ZG'?W.*FKD-2T.#4_B78W%]IRW5K!I4NQY8M\:R^:F.O&[:6QWQF@#J?ME
ML+L6IN(?M)&X0[QOQZXZXI&OK1)V@:Z@690"8S( P!.!QUY) _&O*K#1)GUJ
M2VU26[@U$:XUVDD>C/(TB^=N1A<@%0A3"G)&!E<53U.WM;73I+:_T:Y_MX>)
M8YGOFLVVF-KQ2CB;&TJ8RJ!02>V.,@ ]D-Q J2.9HPL9VN2PPI]#Z=1^=5HM
M0W7MY!+#Y,=N\:+,\B8E+ '@ Y')QR!GMFO-?$!N[;3?&FBC2]2GO-0OUN;;
MR+1WCDB,<(+;P-HP48$9SZ U:\2Z/=7\WBR%K"XEANM2TK 6-L21JT.\@CJ
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MCE,C-(OEH#L+ KSCG!% 'HUQ>6UHBO<W$,*L=JF1PH)]!FDGO+6U4M<7,,(
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M /0=7U:ST/2;G4[^7RK6VC,DC8R< 9X'<^U4)/%%E'KMK8;X?L]Q92W?VLS
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MG:7 ;;2+*!I996B@1#),,.^% RP[$]Z +=%%% !1110 4444 %%%% !1110
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MV@E<W)61E4L<#:A&XD YR!U&: .VJK/IUI<W]I?2Q;KFTW^0^XC9O&&XS@Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(J0JISCD88'K4>MVFH)XQT'5K2P>\MX(;FVG$<B*T?FF(A_F(RH\LYQSZ T
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M3-'&K%Q(@!^51P%;'\\GFL/2+^]U^^\&W=Q>L+NYT_4Q]IC1,J=\0# 8VY
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MQHC[9%)*ML55."IP<=ZZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#+'N&5)1P#@CH>AQ5'5/&^@Z/?7-G>7,PFM0K7/EVTDBP(PR'=E4A5]SQ^5
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M,A6Z68SJXS\DASN91G"DY.<#GO2'P=X>.IMJ)TFW^UM.+CS,'B4$-O S@-D
MDCKWS26/C#1+][I4N9(3:P?:9/M4#P9AY_>KO W)P?F'%2Z3XGTS6;EK:U:X
M2<1"=8[FVDA+QDX#J'4;ESW'J/6@".X\&^';O4)+Z?2;>2YD<2.Y!Y<8P^,X
MW<#YL9]Z?XIT/_A(_#T^E;T03/$S&1=RD)(KD$=\A2/QHU;Q1IFC72VMRUS+
M<F,S&&UM9)W2,'&]@BG:N>,GK@XK UWQ@TFM>'+#1[N9;?5$>X-W!827*L@
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M=OF*0^.1D$<#DUW]% ' WOAC48;C2QH>F1:9-:PV\(O(-18JD*$%HGC*_O5
MW!<^N?EJY8Z+JT'C8WUM:+INGO),]ZJ7IDCO,C",(BN$?.&8C'0CYLYKLJ*
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M.5XI%?:V,X!VX[XS7-ZUX9UWQ+!KU[<VEM97-WI0TZUMA<>9GYRY9V  ')
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(&7))Q_$.I/;!9_PGNI7.GZ#%'$EO?:A'<O<2Q6,UXL?D.(VV11_,=S$8).
M.N3BNY?2[:36H=696^UPV[VR'=QL=E8\>N46LMO!>E?8[*"!KJV>R>5[>X@G
M*RQ^8Q9QGN"3T((X'I0!9\,:G?:MH45UJ-F]K=;Y(W1H7BWA7*APC_,H8 ,
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MQ3K.N:QH_B^&P%E;6.FV#13Q7,3F69GM_,?#!@$VJX ^5LD'I7>:-_R ]/\
M^O:/_P!!%9&J^"-(UBZO)[A[V,7L0BNXH+EXTN HPI< \D#CW  .17000I;6
M\4$8(2) BY/8# H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH *JR:E9
M137$,EW"DEO")YE9P#'&<X<^@^5N?8U:KA/'6@:GJ&JV,VEVYECOX6TK4B&
MV6SNC%^>N )!Q_?H Z74-?L[72VNH+NSDDDM)+NV66X"),B*&+;N<)RN6P<
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ME&);G<X'DH02&;T&%//L:XWX:QW]_%>:WJVU[L!-+BD!W!X[?*LX/^W*9#^
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MGQ%I.M&2.PU*TN9X5!FCAE#&//KCMG(_"G:;XAT;6+B6#3=4M+N6(9=(90Q
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M4 %%%% !1110!#;V=M:&8V\$<1FD,LNQ0-[GJQ]3P.?:IJ** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "L;7O%&E>&TA.H3.'F8*D<49=CE@NX@=%!8#)P.0.I%;-<
M3\4=3LK3PE+:3SJEQ/+ T4>"2X2>,L1]!S0!T&K:\NDS1Q-INJ7>]=VZSM6E
M4<]"1T-2Z)K5IK^BV^K60E%M.&9/-0JV 2.GX5B>*]8:\\+P6^B3^9<:U(MG
M:SQ@D('SOD]@J!S]0*UXKC3-!73]$CW18MF%M$D;-^[B50>0,9 (X/)[9H K
M:=XML-1U:/3?L]_:7$T336XO+5H1.BD!BN?3<,@X//2I_$7B73/"VGQWNJ2O
M'#)*(5*(6.2"<X'8!6)/8 UQFFWL-]\2]-NM-U>?78WM[A)_/B _LU#AAMVJ
MH4LP52&!8@=>#5OQ';ZEXB\9265GIUG>V6FV#Q3K=W3P*9;D%3M*QODB,$=!
MCS: ._!R,BBN#TJ]O)OA)J-MJ&5U+3;*YL;D@GEXD9=P/&0RA6S[USWAV73%
MU/0;GP]#<SW*:7,^M*GF"23]TI59"W_+0R?=[XSCB@#UVJUY?VNGK"UU,(A-
M,D$9(/S.QPJ_B:\B\/3PS:WYVFP65M%=:#=/<P6"2820&(JLKMP\J[F&<!AD
MYZBK%YX8T6T^''AC4+JP5LSZ?<:A/,&=MK;?,9R><8.#Z#CH* /7JK75_:V+
MVR7,PC:ZF$$((/SN06"_DI/X5YIKT;VFL'0M)#C3O%T$"V[Q9"PB,!9R/3-O
MM(]UK9^(VG:2T7ANZU*UB:RM-319G=,K%"T;@Y]%W;/TH [NBO(]<&C/>>*%
MUI)&U+8O]@A5??Y7D+Y?V;'1O,W9V\YZ\5U/B:+4(? ^FZI<!WU/2&MKZ<)R
M6* "8<=<H9* .SK.TC6(=9BNWACD06UW+:-OQRT;;21CL<5Y9I:ZI=:I;:5<
MBY,'B:[AUMBP.(8E9Y'C)[?+';+C_;-3OHL$.F:GKL=O(-5B\5?N9]S;D0WB
M*P7T4JS9'0YYH ]=HKQ[7A92#Q2M^DQ\7_:W&CX#^<%POV?R".BY^]CC.[=4
M_B71UO!X^U"YBD>_L;6&6SD5F'DRK;AM\8!X;<!R.>,4 >M45Q&B:5!HGQ!$
M%A%)%;W.C"6XRS-YLRR@!V)/+X8Y)Y-<CXD;19-7\=Q7PG?6!)'_ &2JB0L)
MC:Q;/)QP'W[<XYQC/% 'LM%>.^(+>:Y\1:I#XAO["RF:TMUL)[R"1VC/E?.U
MNRN '$FXG'S?=[8KH].T:WN_'.LWFI^;<2V-I9M!,0P"OY;[I%3INX'8D=.]
M '?T5XO:O]D\,:SIND+%>K%%:M<ZOIB.LMQ#YV)5E')\[R]Y)!)(/;@58U)-
M--GXJ;PBN-&_X1R83_90PA-SSLV]M^W=NQS]W- 'L%4M8U*/1M%O]4F1WBL[
M>2X=$QN8(I8@9[\5PC6%OX9\122:?87$L4WARYN+F"*1]]W+&\6W+9R9"'<;
MNO-<O"\4EMXF_LV.Q2UN?"UP\D6FQR"+S1T#%N'D 8@G //(H ]L@F%Q;Q3*
M"%D0. >N",U2M-8AO-9U+3$CD66P$1D9L;6\Q2PQ^5<SXRR/!^CBX$O]F_:K
M4:D$S_Q[_P 6['.W.W=[9[5R\$^D:?%XQGTO3C<Z/++8)&C&1( I.UGSC/E*
M<D[1@@$=#0!ZM?W]KIEFUW>3"&!"JLY!P"S!1T]20*LUXA+8VUYX0\71+;VL
M^G6U]:7-LMG ZVZ#">8T2G/&-^2.#R:U/&5QH<\*V-E8Z<+9=*:6PN9DD<2$
MLX"6RK_RT!&=PY^9>"* /4KV[^Q0++]GN)\R)'L@3>PW,!G'H,Y)[ &K-<-K
M<ES/\.-"E=I'N'GTMI&YW$F>$L3^N:HZ4]G9_$R:.#[+JD]Y<3M)<!'6[L,+
M]R0G@Q97:O3J,9ZT >CT5Y5XE?PZWCKQ#'XDWO&-,M3:H0Y7S#YV=H''F<#;
M_%UQWJQH>BRZIXDT,>(X99[FV\.6TLB3,V!<"0_,PZ%QSUZ$F@#TVBO&XUM9
M+6'"R_\ "??VP"YP_G!?M/S9/_/#R?\ @.,=ZUX+:[_X3 >#2DWV&#4FUH28
M.TVWWUCS_P!?#'CT6@#T2QN_MUJ)_L]Q;Y9E\NX38XVL1G'H<9'J"*KZ1K$.
MLPW4D$<B"VNYK1@^.6C<J2,=B1Q7F$ M/L'AH>(U8Z#]IU3SQ,&,7G_:&\GS
M/^ ^9MSQG'M5..)H_#E@JCR= .OWS7']H0RO'Y9+^3YRY#%<X^\<9V[J /;*
MSM+UB'59M1CACD0V%VUI(7Q\S!%;(QVPX_*O-&MK.UTS14U#4(+[PJ^JSO/Y
M$3K:Q Q'RHR"3F(29/7;D@=JZ/X<1P16'B,:;'*EJVKRM;"8.,IY,6TC=SM]
M/;% '<T5X[H2V3IX8-DLW_"8B]0ZNQ5_."_-]H\XG^#KMSQ]W;76_#[1K6&U
MO=6>!CJ$U_?1F:1B6$?VE\*,]%X!P.Y)[T =)K>L0Z'IPO9XY)$,\,&V/&<R
M2+&#SV!8$^U6+6[^U2W*?9[B+R)?*W2IM$G .Y/5><9]0:\<U*/3)8+H7L4S
M^+!XA0R?+(7$(O%V9QQY/E;<9^7..];.J003V_B,7]_;V<2^(UD07T;/;3XM
M8OW<@!'R'D]<9 Z]" >IUG6FL0WFM:CI:1R++8+$TC'&UO,!(Q]-M>;)=Z1>
M76B3^)]-6QT)]*?[);2AV@2X$I!QP.2@4ID X)QS4FLK,LGB=[)+P63+I/G&
M,2>;]DS^]Q_'GR\Y[XSWH ]6HKR=K;1KB;7X_#][_9WAN73(TN+FV1C;I<F4
MX( P#\O#[<<$9(ZU4N+EKGPS81P66G6>BPZRT=[+;Q2-8W">22LFP%3Y1<J"
M,[=R\DC- 'L=9VFZQ#J=YJEM%'(KZ=<BVD+8PS&-),CVPX'X&O,VMK2VT?31
M=:C;WOA:36G>Z6TB=+:",P'9'@DYB\W!/.W+8[5TGPXBLXY/$_\ 9L<J6#:J
M#;^8K#*?9X<%=W.WT[8QCC% '4:'K$.O:3%J,$<D<<CR(%DQD;'9#T]U-:->
M)Z#%IBP:"FGQSKXH76R9?ED$@MO/<R9SQY7EYZ?+D^N:WM(@NCXP@\'NLOV/
M1;R75 YSAX&&;=,]\/)(,?\ 3$4 >BM?VJZDFG&8"[>%IUBP<E%(4M^;*/QJ
MOHFL0ZYIIO8(Y(T\^:#:^,YCD:,GCL2A(]JY/6['1X?BQHU]J5M"//L9(X)I
M$R&N5EA\L _WL;L?C7/Z=HL%II&DZU#;R)JC>)Y(VGW-N$37DB,GLA4\CIDY
MZ\T >NT5X[#:O=>)[L:AJEC8ZXNM%H7EMI6NS")1Y:QMOP8FCPN -N"<\Y-=
M1XR.G_\ "5Z2/$@!\._99_\ 7 F#[5N3;YG;.S?MW<9SCF@#L;F_M;.>UAN)
MA')=RF&!2#\[A6; _P" JQ_"J^GZQ#J&I:K91QR*^G3I!(S8PQ:-) 1[8<#Z
MBO*Y=.T\Z3X=OM9M2VC0Z[<K!)=HQ,=DR3>4&SR$+;,9[;:L>(=$M9X?B)JX
MMY#?6CQRV$JE@8F2TA96C'8Y')')QB@#UVBO(O%4'VOQ;K46L7]A9*]O"-+G
MO8)':,%/F:W97 #B3<3CYON]L5T6CZ)#>_$'5;O4@]W/96UB;>5]RJ)"C[G"
M] QP/<=.YH [NBO,_%,GAW_A8]S'XGRUB=%A*)(',6_S9NH7C?C[N>>N.:Q+
MV5W\-:'INOV%N;[^QC(ESJBRR.7R0L<:+_RVQM).=W(ZT >SU6L[^UOQ.;68
M2^1,T$N ?E=?O+^%>=:'ID>OZ[X<EUB.6Z$?AFVG(E9MIGW#YF'=AD]>F<U0
ML]!L$T_Q9:Z3;16_B&QU*2]M8U4J^R-UDB'^ZV-O_ C0!Z[6+:^(HKPSM#9W
M4L46H&P$D2;@6& SGT16W*3_ +)K+\"7)UR'4?%1618]6G'V5'X*V\0V)QVR
MV]O^!5S>FB0>"?#<8W>?%XE*7 '4.+J7?G\: /0=*U>+57OXUC:*:QNGM98V
M/(( 93]&5E8?6M&N4\/9;QSXP=/]5YMHA(Z>8( 6_':4K@IVU/3KYK6,7(M_
M!MV]VV 3Y\$LJE![[8&F''<"@#U^:[\F]MK;[/</Y^_]ZB92/:,_.>V>@]:Q
M]&\7V>MRZ2D%O.AU.P>_CWX^5%9%*G!Z_O!T]#7+:%;W2ZGX/O;A95GU&2_O
M[A6S\IE4,JGTVJ57'M4/@.*1+OP5NC==OAJX5LKC!\VWX- 'J%%>5>)/[(;7
M?%*^)4D:]\M/[%!5RVSR1C[/C^/S=^=O.<9XJ1- .M:Q>)XCMWN+F'PU9%U=
MFVBX_?[F !QO!'!ZC/'6@#T ZQ"/$8T7RY//-H;O?QMVAPF/7.36C7E=EIMQ
MXE73;:[DE$][X.C5KAL[EF+(0Q/]X-@_A6QX"O[OQ/J%WXBOHGAD@@CTQ8F&
M-LJ#=<$#_KH0N?\ IG0!WE%>)[M,F&H+:^<WBU?$DHLC^\+JGVOYMAZ"+9OW
M8XZYYK?&CSO;>/-7L()7UZ*YN8M/DRQ:/_1TP(QT!)8].IQZ"@#TVBO)[)=.
M.JV+^ U83C3;G[>4# %O+'E";=P9?,]?F^]VJ&(Z4?AY>?\ ",K./$?]FQ_;
MV1)?/SN3SO,]9?OX_BZ[>* /7J*\DM-/TN;2M<:T\1Z;::?-:11RIIEK(L,3
M^9P[@N>2/E8<$KU(QFFR2:;?>$K8R+HVFV]GJ,OEPO&YTW4<1XR!@8!W<=<,
MIP&H ]4O[^UTNREO+V80V\0!>1@2!DX[>Y%5VUB%?$::+Y<GGO:-=A^-NT.$
MQZYRU<=XIABUOX,>=)I#P;;.&=+-U+-!MQD=,\+GMG%1#0_#VN^,],BAM(;G
M1%T68PQID0L?/7L.#U)&>_/84 >CU6EO[6"_M[&28+<W*N\,9!RX3&X_AN'Y
MUY.MW;R>%?"]AK-I:2JUK/MN]6$DD:E'"K&$7[TA&,9.<*<9)I-.M+!Q\/-2
M\00!F-C-;R3W*$GS!L,2L3SNX;&?>@#V*BN \>R:4GBOPPNMLW]F,EX)@=WE
MGY8\>8%_ASCKQG&:Y9TN!H>EABD?A8ZQ>&/[?#)) +?!\CS%!!\K=NV[CC[F
M>U 'M%%>3PZ+;WD?A?3WODU'2Y]8NGVVJR1PK%]GD81#+$F/</7!!QTJ[-'I
MVD?$:W6U2SU"66:&W6U9'%SIR+$%W1GD&' R1P,D\GI0!Z717C>F+:R0:+Y2
MR_\ "<C54-^V'\X+YI\[S#_SR\O./X<;<<U9?2(H]-OM<6&7^U8?%16&<LQ9
M(S>JK*O/"%6;('!R2: /6ZSM)UB'5S?>3'(GV.[>T??CYF3&2,=N:\PUJ\AG
M\9136]G:VFHV^OVT#';*]Y)$945G+=%B96( Y4@^O%=GX46X2V\4>2N)CJ]T
M8MPX)PN/PS0!N:CK$.FW^EVDL<C/J-PUO&5QA2(WDR?;"$?C6C7C'AV/1GU/
MP+):13G7%G?^UW99-PF^S2[_ #B>-^_.,\XSCBI-$N+;4?&VASV]C:69NYKN
M&_M8DD:<+Y4A"7+G@DE00"/ID4 >M6-_:ZG:"ZLYA- 6= X!QE6*L.?1E(_"
MK->.:6=#T;P-/9C2[1KG^U7M]12<.D=NIGF\MY\#E N,#H<CZUU?PQ)&F:S$
MAC^S1:K(+988W2)8S'&W[M6Y"99B.W/'% '7V%W]OLH[G[/<6^_/[JX38ZX.
M.1VZ59KR70])BU?_ (0FTU."2:V^PZBTL3E@KD2Q8#C^(=\'CCVKH?#TTFG?
M#+42UK<W:V3ZA'%;*["1XXYI0D:MU^Z  1STQ0!W-%>(0R7(3Q"?#8MD6;0A
M)LT:.14\P2?-@G[TH1B,C!Z9&:Z._/A__A!]7/@Q'$?^C?;/L2R F+S!YF/]
MOR_,W8^;IGM0!Z917E^J'PQ_9FG_ -BH!X:.II_:_P!E600E/*?;N[;=_E[\
M>VZL^XM(+K3]4@T<3)X<GUK34M/(+(G,B"<Q'J$Y'*\9W8H ]@K.T+6(=?T.
MTU6WCDCANH_,5),;@/?%<)K.G>'M+\6P6&L6IAT2+3!_9D2*^Q;@RN9-FWGS
M<&/&/F]*Q+:2S'@[PGIFJ:=9[6TZ1UN-321T5@P'EI&OWI3G(Y!&.,YH ]GH
MKRCP]I:^(9_!\.NPRW47_"-N\T<Y;:\@>$#>/XC@G@]^>HJO:-;#2_"2>)R[
MZ!'%>Q/]IW-%YRRA81+ZXC#A=W?WQ0!Z_17D&NQ6,^O)'<SV5MH3:5"-*;5(
M)G0'+[S&2RE91\G7YL;<=Z]/T**6'P_IT4]VUY*EK&KW+(5,Q"CYR#R">N#Z
MT :%%%% !1110 4444 %%%% !1110 4444 %%%% !117,ZYXN&A:A?VT]IN6
M#2VO[=@_,[*VUH\8X.3'SS]_VH Z:BN O?'(O_#<DD5C*-^@W&HW0CN3&]N5
M&T1A@,ABPD&[C&PFK>G:QK\WCXZ:L5J=)72[:X"O<,9%#-("_P#J\LQ*X(+8
MPH.<DB@#M**\U\">(]5M= \*VVH:?']AU$-;0W7VHO-Y@1W!=-N K!&Q\Q/3
M/7 W?%6JZ_8^)/#EII$=F\-Y-*DJ7$QC\PK"[!21&Q &,Y')(QC!S0!TU[:1
M:A87%E/DPW$31/M.#M8$''X&EM+:.RLX+6'/E01K&F3DX48'\J\['B/5=!U'
MQE?II\=UIEGJ:/<22715U0P0 B--I!('S')4'/'.<7?$/Q)AT;5=3M(ETYAI
M:JUQ'<WPAFF)0.5A3:=Q"D=2,DX]Z .]HKGO%6HQV_AJ*\"SM')=6BJ(IVA;
M#SQJ/F'./FY'<9'>LC4_'&I6,FN3Q:+!)INB7*Q74S7961U*1N2B;#D@/D@D
M#@8// !U4VDVMQK5KJLH=KFUBDBA!;Y5#E=QQZ_*!GTSZU>KE_\ A*+J7QE<
MZ##;V,?V<*0+JZ:.:<,F[?$FPAE!.TG/4'T&<+3?&/B&S\':AK&J6%K>/#J;
M6D,<%SAGS=F';S&H 7("G^+'.,T >BT5S]AKFH-K]KHVIV-M!=2V,MX[6]P9
M$7;*J!02JDY# DX'(QSUK+M?&M]JMMI$6EZ7 ^HZC'/.8Y[DI%#%$X0L6"$D
MDE0 !W/I0!VE%<9#K/B>3X@PZ;):6,5DVFI<2PFZ+,A+[68$1_,0<@#(!&#P
M>*K:-XINIM,T?3]'L?M%_>I<SXO[URL44<NTLTFUF8EF4 8[]<"@#O**XD>.
M;Z>/3[>VT:-M4N-0GTZ:W>ZVQPRQ(SEM^WYDPN<XS@],\4V;QY=6VB^?<:?:
MV]W'J;:;<O+<D6L#*I;S&DV9"$;0,J.6 ..M '<52L]*MK&^U"\A#^;?RK--
MELC<J*@QZ<**JWNN)I7A6;7-02/;;VIN)5MI/,5L#.$8@;L]C@=:RX/$>N1:
MI;:;J>CV5O<ZA;2RV7EWC.GF( 3'*?+!4X8?,H8<'\0#JZ*X;X817A\&+J-Q
M;P?;;W=*9?M+R&=LMRY*_*<DCC/&/I6%-KGB.^^'0O\ 48K>2==:@2 VUP0\
MNV_V%#\BA1\H4')R.3B@#U:BN5M/$VIDZW:7VGV-OJ.F)%+_ ,?Q^SO')NVL
M9"@*XVMGY>W'6N=U+Q]JEWX5U^72CI9O],DA#7-I>>? R28.4;9RPY4J1[YH
M ],HK*N]6DT?PS<ZMK$4436D#SSQVTAD7"@G"LRJ3D#N!R:QH/$NNQZA9V.H
MZ-96\^I02R6.R]9U$B*&\N4^6-O!^\H;H?;(!UU%>4)KGB34/!7A#4KR&">^
MGU2 Q^5<;/M *2?ZSY $YZ@!N!W/%=!<>/I-,TO46U6RMK?4;*_BL#&+K]P[
MR*KHYD91M7:^3E<C:>M ';T5P"_$=VTN^EALK._N[2\M;8+87HDAF\]@JE9"
MHP02001P1UYKIKS5+[2O"-[JVH6EN+RSM)KA[>"8O&2BLP <J#R .=O&>] &
MS17)V'BK4WU6RL]2TB"V74K62YLC'=^8<H%)23Y0%.&!R"PZ\U1LOB \M[J-
MG-'I4\UKILNH+_9NH_:% C(!C<[!M;+#G'//I0!UL&E6UOK%YJD8?[3=Q112
MDMQMCW[<#M]]JNUYYJ/B?Q=+I>@7]MINGV:ZC?PJL4EX69HW4D*_[HA<\Y*Y
M(XQGG&I>>-)M/@UN*YTY/[2T][=(+=)B5N3.%$>UBH(!D++T_A)H Z^BJEM<
M7DE]=PSV7DP1;/)G\T,)\KEOE'*X/'/7K7,ZUXUDT37X+*==),,MU#;"(:C_
M *61(P4/Y.WH"W3/0$^U '8T5P]WXXU*V?5+I=%@;2]+U!;.YF:[(D8$H-R)
ML(.-X)!(]JH^./$FJW7A[Q?;Z5IT3V6FVTEO<7371CE$AA#DQKM((0.I.6!/
M..G(!Z-17+^,;^XT_P"'M]/;2%+A[=((Y!U1I"L8;Z@OG\*R?$%[;Z&=9LHH
MKORM/\-><@BO7B&Q2X 4#[K_ "_?'/Y4 =]17)03&S^(EK&A80ZII!=E+$_O
M('4 _4K,03WVBGZYXQ;1+K6+9[#S9K2RBNK-5DYNF=S&$Z?*=^P=_OB@#JJ*
M\^UGQQ%?>&[R:WM9GMQH::E*\-TT,D9D;"1AE&5/ROD]MO3FJ/B.XF2\\7!9
MI $O='"X8_*#)'G'UH ]/HK$\3Z[/H-I926MB+V>[O([1(C+Y8R^<$M@\<?Y
MZ5CGQM=VMIJ,-]I<7]KVE]#8QV\%P6BGDF"F,ARH*C#<Y7C:>M '9T5Y[XC\
M7^(-/T/Q%:-9V=GK5AIXOHI8K@R1-$=PWKNC^\I4_*1@\<UUZ:C<67AZ74M9
MB@ADMX7FG6VD,JA5!/!*J2<#T'- &G17G*ZYK-YXK\*7>J6$-A9SP75PGDW9
ME^7R0=L@VKA@,'C(Z\\<Z5CXTU&9=&U"\TB&#1]9E6*UE2Z+S)O4M&9$V  ,
M!V8XR.M ':51M=)M;35;_4HPYN;[RQ*S-G 1<*H]!R3]6-4?$NM3Z+;0RQ/I
M,2NQ#2ZG??9HU] #M;<3^&,5BP>.;W4[7PZVDZ3#+/K4$\@$UUMC@,14-E@I
M++\QP0,G XY. #MJ*Y'3/&LEY)HZW>GK;"^GNK*9A-N$-S"6&P' W!@DA!XZ
M#CFLK_A+O$.J:OX;ETNSLDT_4FNRJ3W)4S1H3L<XC.W*@.,'G=@^M 'H=%>:
MV/B/5=$E\179T^.XTJ#76CFF>Z(E4.8T_=IM((7<"<D9R<5I7OBA]'O?$#V]
MC/=S1:K9V:Q/=G:[31Q ; PQ&/GZ#@GGO0!W%%<7+XVO=/M-974]+MX[_39+
M9-D-T6A<3L%1C(4!4 D[B5X SS6CX9U_4-9O=7MKVTLHO[.G2#S;2Y:99&*!
MSU1<8#*.YSGVR ='17#7WQ%33H5^T:>?/766TVXC67/E1 Y\_..FQD;'^UUJ
M6\\2F\U.T1;640QZ^=.ADCNFC$K+ [,S #YE#AEVG/*Y[8H Z==*MDUN75P'
M^U2VR6S'=\NQ69AQZY<U=KRB]UOQ)>_#[6[G4HK<O;ZN(8#;7!WG9?*OE\HH
M"@#:&)R1R0*[?1-=U"\UJ_T?5K""TO+6&*X4V]P9D>.0N!R54@@HP/'I0!T%
M174"W5I-;L[HLJ,A:,X901C(/8UR?BCQK)X9OL3+I)ME:,&*34=EW(K$ LD6
MWG&?7G!Z5%K/C75-/NO$'V318+BST())=2R7>QI$,2R$(H0_, 3U(' YYX .
MMTZPM]+TVUT^TC\NVMHEAB7T51@?RIECIEKITEX]LK)]KG-Q*N[(WD $@=L[
M03[DGO7/:AXV&GKKRR669K"&":TC$G-VLPVQXXX)D!3OC@]\5J:_KDNB:;;2
M+:+<7UW/':P0"3:K2OZO@X4 $DX/ Z4 7=/TRVTQ;D6RL#<W#W,K,V2SL>3^
M0 'H !5RO-O%OB?6QX5\4:;):6]GJUE9+,9(+MBC02;EWQML#!@588('KFMS
M4QJ'AKX9ZA)IMK:6E]:64TJ1I<-)'$0&8LK,F6('(!4 G@X'- '6T5YU>ZCX
MB;5_!LOV.TDU&>&Z+1+=L(2/+0AW;8#[X"GG@>M6I_B*MOI%B]Q;V=IJ-S>S
MV+I=7GEV\3PEA(QEVY*_*,?+DE@..30!W=%87A3Q&GB;2Y;I4A5X+A[:0P3>
M;$S+CYD? W*00<X'IVK#L/'6I7,&EZC<Z+#!I.H7HL5D6[+RK(79%8IL V%A
MC[V><XH [FJ.CZ3:Z'ID5A9A_)C+-EVW,S,Q9F)[DDD_C7&P?$ZWN-7ABC73
MVM)M0^P*BWP-WG>8Q(8=O";AZYVG=[59'C;53IFM:K_841T_39KBW4BY)DF>
M.7R]VT(=J8R2<DC!X(Y(!U6F:5;:3#/%:APL]Q+<ON;/SR,6;\,DU=KD3XMO
M'LM+2UM],OM0U29X[8VM\7MBB+N:1I-F1@#& I.<?A7E\<WUO;202:-&VKP:
MI%ILMLEU^[+2('1U<J/E((ZC(Y].0#MJ*Y.W\4Z@;/68[NRT^VU'2IDCE\R^
M*VQ5U5P_FE,@8;D;>H]ZP;KQ8WB'28"K6RRV?B.QM9)+&Z\Z&4&2-LJ^!D$-
M@C'!!% 'I5%8GB+7+C2FT^UL;1+K4-1N/(MXY93&@PC.S,P!( 53T!).*YC0
MM9U2U3Q=>7<-C!<Q:LB.EW?[+>$?9X>?,V_=[@;0>><<T >A45YM=^.=8U+0
M;>ZT:/3?/CUV'3;AX[SS(907C^X_EG*L' )P"O.,D5J^*O&EWX5MA<7<6BJ(
MK<32P2:GLFE/\:PH4^?&."<9Z8% ':45S?CK4)K+P-J5Q:.8YI8U@BD'5&E9
M8PP]QOS^%9NJ:S#X6O\ 5%M[6:1-*\/+<QQ&Z81LJ-( NS! ;Y/O]<<=J .I
MN-*MKK5;+4I _P!HLED6(AN,2 !LCO\ =%7:XW_A-;O3[B\77M+CM(X],DU2
M(P7'G,8HR R,-H <;EZ$CGKQ5+Q+J.O7'@BYGU'3[>P#R6<D)MKMI&&ZXCRC
MY1<$#TR#D_B =_17*:AXR:QTKQ5>BQ#G0I?+">;CSOW4<F<X^7_68[]*S?%_
MB/59K#Q38Z3IL4MOIMDZ75P]T8Y [PE_W:A2#M4JQR1UP* .]HKSU_$_]AP7
M]X;>>XDL?#UI>%6NFV29,@P$QA6^7ENIR/2M&3QE?Z9+J<>M:.D+VNF/JD26
MMSYQ>-20R-E5PX..F1SUXH [&BN5\/>)M3U7Q!<Z9=V>G)'!9Q71GL[UIQ^\
M+!5^X!G",3SZ8'/$6J>*]8AU76;/2]%M[I-)ACGFDFNS%YBLI;:@"-\WRGK@
M>] '7T5R-OXOO=5UZRL='TR*6VGT^VU)[FXN#'LBE9Q@*%)+X7('0\Y(XS7@
M\<7TMM9:P^DPKX?O;Q;6*<7),X#R>6DC1[-NTMC@-D @^U ';45R^G>)M0U.
M:XO8M-MET&&>:!KE[HB8^465I!'LQMW*1C=GO[5D:'\3(]7O["(0V+QZC'(]
MO%:7PFN(MJ%PLL>T!25!Z$X/!]: ._HKA;;Q]<S>$;K7S9V#K&8@(8+QG: N
MP5A<#RP8]F06P#P#QQS=36GNM6\+F;R7>\:YVR:??M);D+&2#]T"3([$?*>F
M: .MHKA]$\<:EJ/]@W5YHL%KIVM.T,#I=F21) C.-R[ -I"-C!STR!G 2Q\<
MZAJ&M:;;PZ=8_9+^[N+="UZWGQ"'=N9XPF!G8<#/&0">: .YHKG-:OI8/%6C
MVMM$TES-:WCQ!KIHH2R"/ =0#NSNZX)7G .:Y$:QK5[\);/Q)JOD?;+)X+Z&
M:&0DR!7 ?>NQ0I*%UP,C!ZT >HT5D>(M;.AZ?%+%;?:;JYN([6V@W[ \CG R
MV#@#DDX/ Z&N2\2^,/$%AH/B*U^R6EGK6G6:7:2Q7!DB:%RPWKNCY8%"-K#'
MO0!Z)17 ZA>>(D\=:,L5C9/J$FDW?F0?;7%NF)H<,7\O<>,#[F<MZ<TZ;XD1
M+I6BR^596EYJ8F)6_O!%#!Y+;),OM.[YL  #GKQB@#O**X2'Q]>ZE;Z,NDZ3
M;W%YJ4ES"0]YB&-H#AF$@4[D/)! R>..>.YC+F-3(JJY W!3D ]\'O0 ZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K!\1>%+3Q'=Z5<7,TL;:?<"8"/
M&)5RK&-O]DE$)_W:WJHS:Q86^KV^E2W"K>7$3S1QGNJE0>>G5UX[_A0!@P>
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M)95B:5!(PRJ%ADCV% '/6/@VTL9=+F6ZN)9[*[GO7EDV[KB65'1V;  'W^
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M$'[G((.<D5T+W$,:HSS1JKD!2S !B>F/6J(UVQDO+^R@E\Z\L4#2P+PWS*2
M"< DX/?COB@"C-X;N;^P2VU369[MDO(+I7\F.,*8G5PH"CH2O.2?;%6?%5I/
MJ'@_6[*UC,EQ<6$\42 @;G:-@!SZDU=AOHFL+>ZN/]%\Y%;RYG4%21G:2"1D
M=.":FDGBA4M+*B #<2S 8'K^M ')6'@<R01-K&JWMZR:>]C#')L4VZ2*!)@J
M!N;  W'L/J:=:>!!"2USK%S<XTN32HU,4:+'$^WD!0/F^0<]_05U<EQ#%&))
M)HT1B &9@ <].:>6"J68@ #))[4 8.H>%TO=!TW38KV:WDTYX9+:Y559@\0P
M"01@Y&<CWK,U+PQ+J'Q!T#4I$D>"PM':YN"5"SR @1*5'=2TC],"NCN=4BBM
MTEMD-[NECC*V[H2H9@-QR0,#.?7CC-7/-CV;_,79G&[/&<X_GQ0!G:9!J:ZG
MJMS?3_Z/+,JV=OD$11JH!;([LV3CL,>]8ESX#2>]N775KJ.TN-1BU)[98XSF
M9&1N7(W;?D'&>/7'%=7Y\1G,/FIYH&XIN&['KB@7$)D$8FC,C9PNX9..#Q[4
M 8%QX/M;C2M8T]KF8)JEY]KD8 91ODX'M^['YU3UCP(NJ/K$<6LWME9ZPO\
MIEM"J$.^P)N#$$KD!<@=<>YK;UC64TB?2XWB+_;[P6@8-CRR8W?<?7_5X_&M
M!)X9$1HY8V5_N%6!#?3UH Q_%&BR:SX/O])MW GD@Q S=!(N&0G_ ($HJI?>
M%T\00WEU>M-:7&IZ.-/GA!5O)#;F.",@L"Y'IQ73!U)8!@2OWAGI]:Y^\\8:
M=#H5SJMFPO([>Z6T=%.TA_.$)ZCH&)Y[XXH 2#2;EO' U*6,K9V6FBTMF+ F
M1W<-(<#I@1QCGU-2:WX4M-<UO2-4FFECETURP1,;9AN5PK^P=$8>XK;CFBF!
M,4B.%)4E6!P1VI(IXIU+0RI(H."48$ ^G% ')P?#S3K?0M>TJ.ZN/+UB1V9S
M@F%#RL:?[*Y;&?4U=U#P?:ZA+JLCW,RG49K69PH'R&!E90/KMYK?DGAB=$DE
M1'<X168 L?;UJK_;%A_;3:1]H7[<L*SF(_W"2!STSD'CK0 S5]'BU?[!YLKQ
M_8[R.[7;CYF3. ?;FLS4/!EIJ$FJ2M=7$4U]<6]TDL> UO+"JA&7((/W0><]
M2*O>'M>@\0:/:WZ*(7N$+^07#,H#%<_I6D)XC,81*GF@;BFX;L>N* .:/@J*
M[M=775M2N;ZZU2T^Q2W!5(S'" V%15&!RS'G.3^5;$&ELVA-IFIW;Z@)(FAF
ME=%0R*P((PN .#BKJSQ/)Y:RHSXSM# G&<9Q]>*'N(8V"O-&K%@H!8 D^GUH
M Y;3O!!M;[3+B\UN]OTTV)X+:&9(U41LFS#;5!9L8Y/I]<KIW@=;)]-AFU>\
MNM-TN3S+&RE5 (R 53<P&YPH) S[9SBNH>>&.1(Y)8T=^$5F +?0=Z1[B"(X
MDFC0],,P';/\J ,C6O#K:KJ=AJ5OJ,UC>622QI(D:2 I)MW<." ?E&#]>H-5
M]*\'6NDMHICNIY/[*BN(XS)C,@F8$EL#J-O:M72M9T_6K""]L+E98)QF,]"?
MP/-7@RL6"L"5.#@]#0!PWB?P;))X)NM(TPSRW=QJ7VN&8,JM;O)<;V?/HH9O
M<CCO6U?>%HIAHIT^\ET^32 4MVC17'EE-A0A@1T Y[8KH** .<G\'VL^DZMI
M[7,P34KW[;(P RC;D; ]OD'YT77@^UNKN]N&N9E:[U&UU!@ ,*T C"J/8^4,
M_4UT=% '#^,O"D]Y:ZE=6*37,U_-9&>&,H&6."3<3'OPI;!/#\<5;\$V.J:?
M]N@G@N(-)'E_8HKN.W28-SYA(@ 4+G;C//7VKK:* .5O_ 6FZEKFJ:G/+,3J
M-B]G)",;%W*JM(/]K:B#/^S4UIX.M;33-$LA=SR'2KLWOFO@M/*1(&+_ %,K
M&NDHH Y5O!*-9ZG8G4[DV-[>B]6'8G[F3SA,V&QD@L._0&MF+1XHO$=UK0E<
MRW%K%;-&<;0(V=@1[GS#^5:-% '(:MX#34[O5775KJWMM4>*6Z@2.,[GC"JN
M&(W!<(N1_+)J_>>%+:\@\21-<2J->C\N8@#]V/)$7R_@,\UT%% '&ZUX6;4O
M&_AJ[6&3[+I\,C7,VX!9-I0PH1U)#C>.PVGUK>U[0XM>L([=YY;:6&9+BWN(
M<;HI4.58 @@]P01R":U** .4E\$1WFG:S#J&IW-U>:M"L$]V412D:YVJB@8
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MUO$8;>!HHMT:XPH+[<MM&,?09S7144 <O;^$KN"[O=1_MZX.JW4<4)NA;1*
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M4 8J>'V:_P!)OKS49[JZTX3 2.B+YGF  Y"@ 8  &/QS6U110 4444 %%%%
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M@GJ """1\PYQ3X_&NF/I=Q>20WD,MO="S>SDA_?^>V-J!02"2&4@@XP<YX-
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MS J&8#.>"&7G@UH/XJMH=8AT^XL-1MQ/.UM!<RP;8I9 &.T'.>0K8) !QP:
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MG#X/GCM/%%M!-$(]4L([2VWDY3; 8LOQZD'C-=/I]NUIIMK;.06AA2,D="0
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M>LE[%]H+2L%AF#"09SPP7ANX'I4FAW5E?^';G4+[6[AO$$\5ZEQ9/?M@,OF
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MS$H0 )QCY?3@D<>M 'EMEJ4E[%X<L]9U:ZM]-NKC5#--]L>$RR1SD11F4,&
M"ER!D9V#TIOB_5[);*Z@TS4KF62PTD7$-[+KLENIR7",@7/GOE<?-P?E&>:]
M1EL+.>V^S2VD$D&[=Y3Q@KG.<XQC.3FDET^RF:)I;.WD:(;8RT2DH.F!QP*
M/,;F33+WQE=RZYKD^G>9X>LY@8;QK;>VZ8ELJ025SD+G'/(..($U;7!8PZOM
M=M;'@MYP2GS&3>I#;?7OCUKU6;3K&X $]G;R@;<;XE;&W.WJ.V3CTR:F\J/S
M?-V+YFW;OQSCTSZ4 <#X*6\.M0S1ZK936,U@6E@36Y;^29]R;9@)$79P6!QQ
M\PXXJKXROK[3=?\ %-YIK%;J+P[:E77J@^T3AFZ'HI)S@]*]#MM/LK-Y'M;2
M"!Y#EVBC"EOK@<U+Y4?FM+Y:>8RA2V.2!G SZ<G\Z /)[JZU/2M!UR\L]8M$
MM381E8K?6Y;^19#(!YH>108P58@L#@$!NQJ*.\_XIOQ)JVEZK<+"9+2.W@&M
M&\DMQYB!R2LCA=Q/KG /KBO1M4\+Z;J.CW&G1Q+9),Z2&2TC1&WHX=21@@\J
M.""#4>F^&([74;G4;Z\EU*\N(D@9YHXU58T8L %50.I)R<F@#GI+T6'Q$5KJ
M]-]'>W8@M5MM2<-:-Y7,<EL#M9<JS;N2"PR. :Y_3[^V'A/P]IDIE65[>[N
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M^MW%E:WBE;FVAG4KM(EC#<9!QSVR!^0HFLK6XMA;3VT,MN !Y3QAEP.G!XH
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M6"! 0H!"CM]/:@#S#P_/J4">#-4&HW]Y>ZS82O=I<7#-'*P@\Q,)]U<,, J
M<$YSG--\#3ZK?W6@:B^JV?F7".=0C?6I9I;@F,DJ+9D"QLCXX4_* 1S7J"VT
M""(+#&HA&(@$ V#&./3CCBF1Z?90W3W45I EP_WY5C =OJ<9- '%^+[*P?X@
M>%;F^NI[=&CNH]RWLD"Y"JRCY6 R<G/]X#!R *Y_4-3=M,UO5#K5W'XHMM6>
MWL[%;UU  F"Q1" ':RNF"25).XG/''J]Q:V]TJK<013*C!U$B!MK#H1GO3#8
MVC7@O&M8#=*,"8QC>!Z;NM '*_%&UAN/!$KSR2QI#=VLA:.=XP!Y\88L5(R
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MW%G!I9T]I(1>W\EI$\^\AL,GWG5=N 3QDD4 >D45YGI^F2:OKNAZ;JVK3:C
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M"V 6,:Y!/)Y[FJ^GNWB"W\,V\M[>FTO=;U02;)GC:2)3.RH3D,%^4#''''%
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M C<?E[\')R#6#X8FO;[5;"YN=8T^VUD:C(+R&749/M,BAG#0FW/R@;<;<<
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MQVJ3@#)'3AMW->K)X>L=5UC3[O3CITK)=3ZE+#;W$HD '[U>798\8SU^9NM
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M+H/,5A) ?E1,@%1GCY<8S4/A6ZAUCQ7ILES>B*\AOKMYVGU%Q)=_,XCC$.<
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M*<'Z9 JG;^/3// [:)=1Z=+J+:9]L:1,><)&C!"YR5+*!GL3T.,T =@%"YP
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M#M9>7\IN C1B;=GKY;%<8]#FNGK.N]8BM-;T[2WC=I;Y)F1QC:OEA2<_7<*
M,#2/!4VBWRBVGTQM/6Y>=%ETT-<H&8OL$V\# )."5R!Q[UI^)=!N=;.ERV>H
M"QN-/N_M<;M!YH8^6Z;2,CCY^>^ <8/(W:CFE\F"278\FQ2VR,99L#. .YH
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MS4<EAH]K\9&NKNSA2XNM-A-K,T7+S+)*'PV/O!-F?;%=[10!Y'X6T.#2]+\
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MU89R1DDG'!KM_A[HUGI7@W2IH+<QW5W8V\MU(Y)>1_+!RQ//&2!Z#CM74T4
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M^;#&7RMHR)=VW./FQMQ3;XO9MJU]*DJVUMXP@N)W"$[8A!""YQ_"">37J5%
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MM;^F:=;:1I5IIMFA2VM8EAB4G)"J,#)[GBN8@\!&">S3^V[HZ=8WYOK6S\I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %5#IEJVL)JIC/VQ+=K8/N./++!B,=.JCFK=
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 5+;3+6TO[V^AC*W%Z4:=MQ.XJNU>.W [59D021LA) 8$$J<'GT/:G44 5=-
MTZUTC3+;3K&(16MM&(HDR3A0,#D\GZFK5%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !52'3+6#5;K4HXR+JZCCBE?<?F5-VT8Z#&]O
MSJW10 4444 %%%% !1110 4444 %5=1TZTU;3Y["^A$UM.NV1"2,CZCD'W'(
MJU10!DZ9X<T_2KM[R'[3-=/'Y1GNKJ2=PF<[078X&><#KWK6HHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<R!\\Q,,C;G@[AG@CKFJ.D^&-:AT_P )VU\;!3H,^"T$KMYT2VSQ*PR@PQ+
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MY)6C*_P\K\ASWYZ&M#PAH%_HD^H-.EM9V<_E_9].M;EYXH"N[<REU7;NR/E
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M<O-G(P#NV@8SPM1^'?!EUIBV\-UI6CB2UMF@COX;B5I')39N\MDPF1UPQ]J
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M7DC1KM+*ZNK*K<@@Y&.0>HK,T?P?JNG1>'S-<V<LVFR7\DS+N"N9V<KM&/\
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MGUQQB@#I-(\1VNKW=Q9"WN[.]MT622VNXMC[&R%<<D$$@C(/!'.*CUSQ1;:
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M2$9COE7Y@N >!R3BH_AQ?W&H>%G:XN3<&&^N8(Y#.9\QK*P7]X0"X P QY(
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M0,5+1N&&1P1D=Q4M>(V'B77[#P9:W>EVR66F_P!IWHU&ZT_3UF:W56^1O*R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_$?@
MK0/%K0G6K.2Y\D80"XDC'7/(5@#SZUT%% '*W?PX\,7L-G'+93!K.(PPRQW<
MR2",DDJ7#;F&2>"3UK>TK2K'1-,@TW3;9+:S@7;'$G11G/XG))R>M7** ,>X
M\+:-=7>IW4]D'EU2W%K>$NV)8P" N,X'!/(P:BMO!V@VD>CQP6 1-&+&Q D?
M]T6&&/7YLY/7-;M% '*S_#KPS/81V)LIX[='E<+%>3)GS2#("0P)!('!XI=2
M^'/A357M&N=*4&U@%M%Y,KQ?N1TC;:PW+['-=310!S-YX \-WVKR:I+92I<S
M%6F\BZEB28KT+JK!6_$5-=^"?#UZ]^UQ8;S?W$5S<GSG&^2/[AX/&,=!@'O7
M044 <K=?#CPM>:C/?3Z<[33W NI%%S*L9F!!\S8&V[N.3CGGU-7+GP7H%W9Z
MO:36.Z#5Y1-?+YKCS7&,'(/R_='3%;U% '-:IX"\.ZQJ)O[JSE6Z:-8I)+>Z
MEA,J#H'V,-V/>FZS\/?#&O7HN[_3BT_E"%VCGDC\V,=%<*PW#ZYKIZ* .;U?
MP%X9UR:QEO\ 2HW-E%Y, 1VC41?\\R%(!7_9/'YU!/\ #?PO<:=::>UC,MI:
MQF&.&.[F12A8L5;#?,,DGG-=710 R**."%(845(HU"HBC 4#@ 4^BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<)O3>NUAV(([$$$?A7 ^+Y;36=<TN::\U#2M.^PRO!JME#(LS2,=IA)VG:N
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M['F"UA>5T5AGY5+8]CQ7C\MI))IOC1-.MK=K6XT% BZ=IDEI#)*#*,*C$[V
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M+AR!@<'/>@#9.OVDMA?W-BLM\UC(\4L$"C>9%QE1N(!Z]<X]ZTC(BXW,JDD
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MVTNX%J[2!<C[.T<N,*BC&>0!AL]>?8%W!!N(+8Y(]: %HHHH **** "BBB@
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M9U'3%6*Q-IJ<C1PI#<E[B$;696E3;@ A><'Y20.:[^@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>foraresidentagreement012.jpg
<TEXT>
begin 644 foraresidentagreement012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8!E*8&T8R0 <YV]JK:5!<ZG\6-5OKF"PFAL[2V-K*P8RPI()<;,C +<[OPH
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MM);O%H79[4(F_;(64 Y7(R,<C'.<U%#J6N:GXK\%7FIV=G;V]V+B>%;>9F9
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MU@FO[6.9I/*6-YE#%\ [0">N"#CW%+=:GI]C+%%=WUM;R2G$:32JA<^P)YH
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M]_:0RGK@$D<@U6M]"N&UB\LM4;5(KB37#>Q26^E^8KKYP>-Q<!2% 4*I!8$
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MD16AF#%SC(!.P<_[/M6[XBTUKSQ7(]Q:7DNG2>'KNVF>V0ELO)%\JD?QE0Q
MZ\5V=(65<;B!DX&3WH Y+P*UZ(;ZWFMW^QP-&EK=RV!LY;A=O(>,@'*\#=@
M]AQ7.Z5X:DL_#_A>:/2&BU"/7&FN7$&)50O,"S'&=I4J.>,8]J]0I P.<$'!
MP<=J /)CI=P^BR:&=#O/^$C;63<_VC]D/EX^T^8)_/QMP(^,9W?PXKJ?#=JF
MG>-/$T,FF2Q275TMS;W(M2(GB,,2D"0#&=ZM\N<]\5V-% 'C^LPV]WJ'Q"L%
MT"ZOM2O9D@M)XK7S%#FUBV@R#_5[6(;+8'H216EJ%DUEJ7B6+6=#N]6FU&UA
MCLIH;-IU<"$(8]P!$?[S<WS$#YLYKT6VL+6TN+NX@A"2W<@EG8$_.P4("?\
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M?>BS)0C;&%?S<?($8,V21[9YJ?6="N)M=\26NJ-J:QZG+&UO-9Z7]IWQB-%
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MD*JIE0XW*^$'.<>U;D:>7&B;F;: -S')/U/K0 ZBBB@ HHHH **** "BBB@
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MU^+;0+:XWP7#I%<2^8P$I"D;N.>>#GITQZ(\4<BA7C1E'(#*"!3L#.<#/3-
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M,]M<O''-*7E!F 4C)XR/K],9VG?8+S5?A]J^NW)$]WHC9N)KEHQ+./LY0?>
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M/GN#COABB@_[)KN4BCC^XBKU^Z,51T31K?0M,6QMGED7S))7EF(+R.[EV9B
M,DECVH XKQ)>6VG>.[>[GN[>_+26MNFG+>O%<VKE^)(XU.)%.X%@0.%/) Q6
M.M@EIINHZ]!/=)?Q>+#&C"X<(J->K&R; =N&5FSQSGV%>MF-#()"BEP,!L<C
M\:78N,;1C.>G>@#R+6]:A?Q=%+9F.UO8=?M[1_,U*4W,B&1%?$'W5B*MQS@Y
MSU-6]0_Y$GQA_P!C%_[7@KU#RH]Y?8N\XRV.>.E.V+@C:,$Y/% '*?$J/S?
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M"K,#\P//&,5+>^'-8O#I5X^M6_\ :NGW$DHF-C^Y970H4\L2 C /!+$Y'.:
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MFD5_,BCVARP4DJPW*<<\'UXJ2]\(75S-XF2/5(X[+7H&22)K8L\4IA$.X/O
M*X4';CKW%6;WPG#J%Y:RW%P6@BTN?39(@F#(LOEY;.>,"/I@]?:@#.T[X@P7
MDT:36!@%S:27=KMN8Y6=44,5<*?D;!!QR.O.16SX9UVY\0Z8FHR:5-86T\:2
MV_G2*S2(PSD@?=_'L1TZ5EZ3X0O-/M&LY[W398!:M;1R0Z8(IR"NT,[[R"<=
M<!<UT&C:?_9&AZ?IOF^;]CMH[?S-NW?L4+G'.,XZ4 8.I>-)+.757M-&N+VQ
MT@[;ZYCE1=A"!V"*>7*J03T]!DUGV]_?:O\ %)H_+NCI=MI\$\#17Q2/]X9?
MWC1@C?NVA<-G&,]ZN:AX-OYI=9@L-:2TTW6F+WD#6OF2*S($<Q/O 7<JCJK8
M/(K7L/#T6G^()]2AEQ%)8V]DD&W[BQ-(0=V><^9C&.WO0!/=:Q':^(=.T@Q,
MSWL,\RR \*(C'D$>_F#\JPI/'<9@LOLVGE[B]O+JTBCEN%B3,#LC9<]SMX7&
M3^!K1U[0;S4=3TW5--U".RO;$2QJ9K?SD>.0+N!4,ISE%(.>W>LC_A"+V/PO
M_8::I97,4DUS)</?Z<)A)YLC."%#J%9=QYZ'T% '5W-_%8Z3-J-Z#!%! 9Y@
M2"8U5=S=.N,'I7/6?C"ZFN[&"[T&XL_[3B>33R\Z-YK*F_8X'W&*@GN.#SQ6
ML-"MV\*#P]<2S3VQLOL4DCM\[ILV$D^I%96F^%=1CU#2[C5]9COH])1ELTBM
M/))8ILWR'>VYMI(X"CDG% %/X:SW^H:-<ZIJ270N+JYERTUX94(660 (F<1A
M0 O &< UH:IXLETC5[>VN]+9+.>ZCM4N/M,>\M(0JL(\YV[B!GKWQ6CX<T;^
MP-$BT[S_ #_+DE?S-FW.^1GQC)Z;L?A7-77P\DN=8FN_[1M1#)JD6I9>Q#7&
MY'1O+\W?]SY, !01GN!@@%BX\>-!/>O_ &)<MIUA?BQNKSS4 5BRJ&5<Y8 N
MN?3/?G%RX\9P6]OJ9:SE^UV.H1V MMPW3/(4\LK[,'!]L'TIESX-^T:+K.G?
M;]O]IZA]M\SRL^7\T;;<9Y_U?7CKTJE>^'9+SXK6>I+',ME!9K/<$K^ZEN%+
MI#SW95DD)]/D]J .DU[6H=!TMKR6*2=C(D,,$6-\LCL%1!G Y)')Z5RGB'QE
MJ=OX=\1V_P#9<EAK5EIK7<:_:$=?+(8>:K#J5*G*D \#KFNG\1:(-?TK[(+E
MK:>.:.XM[A5#&*6-PZM@]1D<CN,UBW'@R\U.VUM]6U:*;4-3TYM.66"U,<5O
M$0W1"[$G+9.6YP!Q0!K^%K>6V\.6B3QW,<K+N=;F[:Y?)[[V)SGKCMG%<GI?
MBW5Y)_"-O8V<][9:E8RS22W<\?G,5*<D@ 94-DX'.?:O088_)MXXLYV*%SZX
M%<E:>"KK3;7PTMCJL:W&BQ20&26U+K/&^W=\H<;3\HP<G'H: -'0_$S:[J-[
M#!8[;2UGEMVF-PA<21MM(:/JH."03U&#@9HU_P 23:1J>G:;::5-J%YJ"3-$
MD<BHJ^7LSN9N@P_7VQWJ"V\+70\7)KUY?6CO#')%&+:R\F217Q@3/O.\*!QP
M.>:TKS1OM?B/2]7\_;]@BGC\K9G?YNSG.>,;/0YS0!AKXI^Q2ZFJPWEW=-K"
MZ?#;RRH%$C0I)A6P-J 9/.3G/7(%9.I^+]2O(=(N(-,NH)HO$)L)+2&Y5C.5
MBE!4G@;=P!Y],]J3Q?X5G6-F3[1<VU[K8O[DP6OG&!1;^6!Y7)D^95.1R"0<
M?+5OP[H5[?6%BEQ$ME::3JOVFR_T+[.]Q%Y3*=T>?D)>1^3R=N2.: #5_'&J
M1Z%+/9:08M1M=6@T^[MY9E(3>\?W6Z,&610#QC=DCBMA_%-P-?M]%72LWK6T
M=S<(UTB^6KLR_)G_ %A7:2<8 XYYQ4.H>#&O+;6TBU$13:CJ$&H1.8=PA>(1
M;01N&X$P@GD?>]LTFM^%-1\0?8X[W4K#RH6BD=TT\B9)$8,6AD\P^7NQCD,0
M,\F@#6\1Z[%X<T=M0EB,H$D<2KO"#<[A 68\*N2,D]!7.:SKFL1:]X6>'3IS
M-<K=A[&&Z4H^%7:S/D*5 ^;.,\],\5U>K6MW>:>\%G/;0RL1DW-OY\;+W5DW
M+D'ZUS^B^"!I$VD2B^5C8274ACC@\N,F<YVQKN/EHO8<T 6+?Q7<7N@KJ%II
M#F=+B2VN()KF.);=XV*MN<G!&5X(!SD=*S(O$SZYJOA"ZM3/;0W-U>0W%OYF
M06BCD4@[3A@&7(/T-277@*21(FAU"W:2+4[K4!'=V?G0-YQ8[6CWC)7=PV?P
MYJ?1_ _]DC1LZ@)3IMW=W1Q;A!)Y^_Y0 <+MW]O3H* +7@"ZN+WP-I=Q=3R3
MSO&Q:21BS-\[=2:HV7CQKN6RE?1+F'3KN^?3TNVE0_O0S*/D!SM)0C/KVQS6
M[X;T;_A'_#]GI7G^?]G4KYNS;NRQ/3)QU]:RX?!ODZ)INF_;\_8M4.H>9Y7W
M\S/+LQGC[^,^V<4 03^._*6>^&D7#Z';W9M)=0$J<,'\MG$?4H'X)Z\$X(J;
MP_K^L:CXK\0:==Z<L=G8W"QQ2B525!B1@"!R<[MV>V<=JJR>!KIX+C21K"#P
M_<7C7;VGV7]]\TGFM&)=^ A?/\.<$C-;%CH=U8>*-3U.*^C-GJ)226V: [UD
M6-8P5DW8VX4<;>O>@!-7\02V6JV^DZ?ISZAJ,T+7!C$JQ)'$I"[F8^I(  !S
MSTQ68/'BW$.EBRT>ZGO+^6X@^RET1H983B17).  0>1G@< YQ6AJ^@7MQKEO
MK6D:C%97T=NUK)]HMC/'+$6#8*AU(((R"#W-<Y=>$]3T[4_#,6DWC_:(9KVY
MNK^6V\Q&EE&YBZ C 9B0 ""..>* -,^/[=-+CEDL7CU%[]].-E),B[)D!9LR
M$[=@4;MW<$<9.*C/Q"C.GPRPZ5-<7KZE_9;6L,R-B;RS("'SM*$ <\8!YZ$4
MC^ "^FPEM1CDU:/4)-2:ZFM \4DKJ493%N^YM( &[(P#FKZ^%IY8]+-S=V:R
MV.H_;B+.R\F-_P!VZ;-N\D??SN)/3I0!%KGC"[\/V*WU]HC);1PK+<M]LBW)
M_>"+G+E>_3/;-,@\3:F/'.KZ;<6*+I-E:PSFX\U<QJWFDN1U(.P#';&>]5/$
MWP]D\07VK3)J-K%'J=ND#F>Q$\L&T$#RG+C:#G)&#SG!!.1KS^&99/$EUJ*7
ML8LKZR2SO;5X"S2*GF;2CAAM_P!8<Y!Z=J *6B>/;?6-2T^V:S\B/4HVDLG^
MT1R,P5=V)$4Y0E>0.>A!P>*W-:U*[TVW22UL!=%B=Q>Y2%(Q[LWKVP#^%9'A
MOPI=Z ]M"]WIT]I:Q>5$R::([AE P-\@<@G'4A1FI_$WAF77;S3+N&YM4DL3
M)B*\M?M$+[P!DIN7YAC@YXR?6@"BGC^.ZM-%>QTYI;G55F:.&:X2(*8F"NN\
MY#-N/ '4 G@5UDTLD=I),EN\LBQEA"I4,QQG:"2!D].3CWKBY/ 5T/!\'AN/
M4K&2U43"5KK31(29'9@Z .H1EW$ \CO@=*Z34=$%_P"%KC0_MD\8EM#:_:0<
MR#*[=V>Y[GUH I:'XH;5-9NM)NK$6EY!"EQA+A)E9&8KU7HP*\@^HZU)JOBF
MVT;4KFUNXG5(=-DU$2Y&'6,X=1[C*G_@54O#G@^71-:DU.:ZL6=[-+0065@+
M:-0K%@V-S$GFI_%GA&/Q2^F,;MK8V<^Z3";O.A;'F1'D8#87GG&.E $>G>-(
M=5BTHVFGW$D]_937;0!E#0^654HV<#<7;8,D#(/I5"\\9E].\06MY:36%U8Z
M7)?;K2ZCE;RP&!VM@A7!7H01R.M2P_#^.*3Q*1J<P768GAAV)M-FCEW<*<\Y
M>1F[=AVJI#\.I?L^J)-J%C&U]I#Z6%LM.$$<:MG#[=Y+'GD9_*@#4D\96EA;
MZN+J&8-I5E%=_,P+7,;H=I7'<LK+]?K5+4?B+;Z=+>>98$PZ<$^WL;F-7B8J
MKLJ(3F3:K G&/09/%6]9\$1:QJFC7AO6B6Q58[F(1Y%W&KI(BMSP Z ]^I'>
MH[GP9.NN7]_I]UIR1:A*LT\=[IPN&1PJJ3&V]<9"C@@C//M0!>MO$TU]XJO=
M&M=)FDAL71;F],JK&N^)9%P.K'YL$#IU[U/K>OMIEY8Z?:6+WVHWN]H8%D$:
MA$ +NS'H!N4="22.*ETW1O[/UG6=0\_?_:4T<OE[,>7LB6/&<\YVY[=:KZ[H
M-UJ&I:?JNFW\=GJ-B)$1IH/.CDCDV[E90RGJJD$$8Q0!RGB7Q3?ZIH-G%86-
MW;SOK,>G7\*78ADC8,"8Q(IZ.",,I'![9KN]TMAHR&&UFN)885"P&8,[$ #!
M=SR?5B>>M8$7@HK8P)+J)DN_[635KF?R<":0$?*%S\JX"J.3@#O6OXDT;_A(
M?#UYI7V@V_VA0OF!=V,$'!7(RIQ@C/()% &"?B!'!IVM3W>FNMQI(A:6&"=)
M@ZRG"E6'?(;(('3WI\_CF6QBU7^T=#N;:XT^UCO6A\U)"]NS%2X*\ KM8E?;
M@G-55^'LCVNMQS:A:1R:K';(19V ABA\EV;Y4WG.=V.3_@.AET&*7Q'=:M-(
M)(KC3UL7MBF05#NQ.<\YWXQCM0!);:Y#>>(+C2[>,R"WM8KB2X5AL!D+;5^I
M"EOH1ZU2U+Q+<PZO/I>E:/+J=S:P)/<[9EB6,/NVJ"WWG.UCCIZD9K/^&FA7
M&B^%5:]$_P!LNG\QA<#$BQJ!'$C>A$:)D>I-7=0\.:E_;MUJNB:O#82WL"07
M23VGG@[-VUT^==K ,1SD'CCB@#,@\:7^I^)]"BTK3_/TG4M.>[WO(J.,/&"2
M#TV;R"O<GCI5/P[XNOK2)DO]/O)[*77;FP%^\ZG:S7+K&H4G<4'RKGC'88%;
M-OX,;2[C0)-(OU@72K5[-UN(/-\^)RC-R&7:Y,><\CD\4X>#<:-%I_V_[FL_
MVKO\KK_I/G^7C/\ P'/XX[4 5;GXAV=OJ$Z?9=UC;7HL9KG[0@<2%@A(BSN9
M0Q )Z\' (%:6D^)9]7UN_LH-(F6TL;A[::]>50ID4 X5>IX(Y[9'7G%&W\&3
MV.L7-Q9W6G?8[F\:\DCN=.$LR,S;G"2[Q@$Y(RIQFMK1=&_L=M3/G^;]MOI+
MO[FW9N"C;U.<;>OO0!3UKQ+/INN6>CV6D3:A=W4$DZA)5C5%1E!+%NGW_P \
M#OFJ</B:'3]'UW49/MMR+34WMA'(Z$ERR(J(< !-SC&>F3DUL2Z-YOBJUUOS
M\>192VGD[/O;WC;=G/&/+QC'?VKE_$_AFY@\(:Q:6OFWAU#54O)%BA#-'&98
MV<;"3YF I^7^(<8H K>(_%VIRZ'K$9TVXL+O3+ZPC?[/=!VD\R:(E5(QU5L<
MXSD@U;UKQOJ=KX>\2-%H[6FKZ3:K<>5+,DB>6X8K)D<'!1LK[=35+1/#UWJ.
MF:CHXC-II0N+2Z@NI=.^S2RRI*)) T9()&(T 8@=3UQ71ZKX0CU:?Q"\EXR)
MK&FQV!58^8MOF_/G//\ K>G'W??@ AG\6WMM<Z;I\FC?\3.\ADF^SM>1H-J,
M!A6/#.=P.T=NI%:?BN]&F^$=6OFDN(Q;VDDI>V95E7"D_*6! /U!K'UKPGK&
MOZ%'I=_JVF2*T9CFD.EDLIR<219E_=N!W.[D9XZ5MZ[HO]M>%K_1/M#1?:[5
M[;SF7>5W+MW$9&?S% &+J7C2?3[O4;6UT2ZOQIEK'=7,JS(@$;*6XSU;"G@=
M<=1QGJ;2YBO;."ZA),4T:R(2,94C(_G6(_A??<:_+]LQ_:UG':X\O_5;$==W
M7YL[\XXZ5KZ99_V=I5G8^9YGV:!(=^,;MJ@9QVZ4 6J*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBN*UC2;;6?B98P7Z22VL6E23"+>RH9!,@!8 \XR
M2,_7M0!VM9^D:O!K$5V\$<B"VNY;1]X'+1L5)&#TR.*\ML(I+KQ))]NU;3['
M7TUIF E63[6T0F^6-/FP8FBP.!MP<GD$U8GNK2VTV>VU&TM7M[KQ'?@SZA(R
M6T.&<@OC[V>B@\9[\4 >I7-]:V<UK#<3+')=2^3 I_C?:6P/^ JQ_"DM[P7%
MU=0""XC-NZJ7DC*I)E0V4/\ $!G!/J"*\=BMM.G\,>%;W7$1K&TUV[@>:8.$
MBM_](" [OF"9$8&[IP*U];DE6Y\29:X&E?VU8"],1;BT\B+?TY"]-V.V: /5
M**\=U$6K:7XI'AB5QH#16(C>U=O*%SY_[SR2./N;,[>,^^:[#0M-M]#^(.IZ
M?IT;PV,FF6]PT6]F4R^9*I?DGYB N3WP,T =5%?6LU]<64<RM<VZH\L8ZH'S
MM)^NUORJQ7FLUG8V/Q(\2200Q1ZW<Z;%-I>[AI9=DX<KG@_PYJAX<;2GU/PF
MWA^25]7Y_MO+.7V>2V_[1GHWF[,;N<].* /6:*\^^(-U8/JEIIU]:66'M)9(
MKF_>386R!Y<2)]Z4]1W Z9S69H.G)XDN_"L6MK-=1-X8665))&"R2;HQEP#\
MQY)Y[\]10!ZI17D,6J7WAOPEX<\4XN+HQVT^FSQL2S."S?9R?4B1%3/_ $TK
MLWT8:7\,WTF[U22T=;(I<7ZY+)(P^>3CG&YB>W'<4 =76?K&KP:+:P7$\<CK
M-=0VJB,#(:6144G)Z L,UYG;ZG;0:+8W$5O9VVGZ;X@A-S>Z<S&TF0Q$&5<]
M%!90W4 CJ>:BUJ^M]6L?$UVCW4FGOX@TTJ\*R!C&!;AFCQ\W8D%>O4=J /8:
M*\D$6DW,?BB+1=52P\-O%9XNLNUL+D.QD7J/E91&KX(^]R<YJM=7PN])T'-K
MIVGZ EY=17+,9'T^5U \M\C;^[8[\9^7<._!H ]DHKR-HK*VM/#D6LZK!>^%
MWNKQGE0N+96.##&S$G*+^\"Y.,A?05'IM];V>CV.H)/<)I-IXLF+S3E_W4'E
MR(I<MR%RR#YO49H ]@HKQ_4M1GU#3M?N[*9_[,E\20?:9)$D"?9?L\620,-Y
M9;;DC@J2>AIYL89-#6*RU:UN=.NM>LE$6E-(D5N"RK(J-N) /4[3@$GIF@#U
M6^OK73+*2\O)EAMX\;Y&Z#)P/U(J/5M1BT?1K[4YT=X;.WDN'5,;BJ*6(&>_
M%>6^(M$M8-%\<Z7!:-_9]HUI=6]N-S+$Q0&1E';@$G'O78:[_9K_  HUH:*8
MGL#I5UY!@.Y2/+?H>_.: .JMYEN+:*=00LB!P#UP1FI*\DTW^S!JEL/#+S$C
M1;D:QEI"0^U/+\W=TEW;^OS8SVIESI:Z7\/O"T\.([:]>VEUF>Z:1U<&!B#-
M@YV;RH/( X!XH ]>HKR8RV&G^&5CDN=*U/2KS5]L3B21+"Q'DY(8Y.Y"P.%S
MMW..F*I6$\?]A:5'J\I'AI-<NX[DCS%@6/:QA#9^81;B,9X^[GB@#U:35X(_
M$-OHQCD,\]K)=*X VA49%(/.<Y<=NQK0KS8:/H&M^+M!@MH6N-%72;QHD+R;
M'_?Q#!R<LN22 >. 1P!6QX0>_P#^%9J(&DDO8H[J*W,IW-E))%C!)Z\*HYH
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M %BBEF))   '4DD #WKA[^:SLOB='*)+34[JZN(8?LK%EN[#]WC>G8Q8^9N
M,D\GI6GXOEU"_P#$>AZ1IMG#=M;N=3N8YYS"A6/Y8P6"-_RT;<!C_EG0!UEC
M>V^HV%O?6L@DM[B)98G'\2L,@_D:L5XM<7EUI/AN+PYJ-H@.GZZL;6:RN\4M
MK(DDT<9=4W,H^[PG6,9&,U8L]*L+G1M$M(98S%=^)7:[M[.20"%3#,1 Q(5L
M!=H.0.#TQB@#V&BO(_$]G;P>*+S3K^ZT[3].CL((M)-_Y@6,88,82K "0''^
MU@+CBH=<BDDUN:UU_5]/1/[+MEL+S4%D0,^UO,DAPP"R;\$_Q?=[4 >Q45YA
M?Z)'JNNZC%JLDM\;?PS:LLFYT5YMT_[T*#PW&1W&:ATZRN=/?PQ?:9YYU35-
M"N9+J221G-Q-Y43H7W$\AV./0''2@#U6BO(/!L44DMC<0:O8+?I82C4+6%9?
MM4SF/G[1N8X=7YR1Z@<&K/AO1[>SC\ 7,<<WG:G8O'J#O([&=3:[]KY/0,!@
M=N@H ].L;ZUU*U%U9S+- 69 Z],JQ5A^!!'X52\0^(]-\+Z8-1U65HK7S%C+
MJA;!/L.W6N.^'MUX?\.^&KE"8[:[COWMKQ%5BZNUS(L*L "1D$8/H<UM^.X%
MN+71(9(Q)&^LVH=",@J6.<^U &ZVK68U6UT[S-UQ=027$6T95D0H"<]/^6BU
M>KR:P@U;2/&H\/Q1RR2:7HU]_9EPPR)(7:$PJ2?XE*E#[*#WI/#C:6^H>$FT
M"25]:SG6\LYDV>2WF?:,]&\W9C=SGIQ0!ZU5:TO!=FX @N(O)F:(^=&4WX ^
M9<]5YX/L:Y/Q%I-MK?Q"T2SOTDELQIMW(\0=E1V$D &X \XSG![@'M7+:U=O
M!:723QM<6\GBR19+>1G"31B ML;8K-MR <!2,@9XR: /3M2U>#3+K3+>6.1F
MU"Z^S1E ,*WEN^3STPAZ>HJQ>7UKI\22W<RQ))*D*EN[NP51^)(%>366CZ;=
M:7X=M8WADBN/$DTES#:22 09@G80DD*V NU3D#(/3!HU;2;&+P_K-M<6^=,T
MKQ/;&-7W%;>W8V[28]$^=SZ#)H ]AHK*TS4](:2#2M.GC;99QW,4<8)7R"2J
M,&Z8.T]\\5YUXGFT ^+/%D6O32B1;* V";Y /-,;_P"K X\W.W'\7IWH ]:H
MKR=GL?[1B3XAN5 T6T^RBX9@AFVM]HVXZR[MO3YL8Q56X.O:=HNA&Y-W]MU_
M2ET>4OG?',7'E._HPC>4DGNM 'L5%>.6S:]=:/K4-H;HWWAG29M,@89W2S%V
M&]?5O*BB(/K)21PV@\/>)KG1]7TUXO\ A'KE9+/3ED!,FW*R2;F.)!\PYPQW
M<]* /9**Q-$TB#1O#WEZ;$1/+'YS-(Y9I9B@^9B3R20,UYUX?:PD/A-M,DF;
MQ6;A#K0+/YP78WG^>#T7=]W/?;MH ]@HKBOASI-M%I,FK.DC:A<75W&\LKLQ
MV"YD 4 G 7Y0<#W/>LU-*EFO?'>K6D<TFM6T\L>FDNQ$;FSCQL7IDEN?7 ]*
M /1Z*\=T*&V:RN;G3M7T_P U=%N!=VEHLOG2L4&&GW,<2*V>2 WS&KNG>%].
M?5O",,D-P\.H:/++J"//(1<NH@*F7GYL%VP#_("@#U6BO&7>Y'A[PK%J$\"Z
M-'-?PSOJ6]H-R2LD"RD$<! V-QQD#OBK;16-M;^&HM<U2&]\,-+>L9E+BV#[
MAY$;$DDJH\P+DXX'M0!Z7I.KP:Q%=R0)(@MKN6T?S .6C8J2,'ID<5H5X]IL
MD>A>&4\3VHNOL>E:[=M(L@<N]G*Y1B0WS$C*/SS\M=UX9ANM/\$F\OHII;ZZ
M274+B%"=Y>3+^6OH0"$&/04 =/17C7AV&SU[7A968L[:TU30KA;F*PDD?RY"
MT6WS';@RKN;GAAWZBK=EK-[J>DZIKNJ6-S<'1=-&F2VP=X_-N=P^T-D<A?EC
MY&>-U 'J-_>"PL9;HP7$XC&?*MXS)(W/91UJ"RU>"^U;4].CCD673VC61F V
ML70.,<^A[UY$)@ND>-HM-DM/L?V"SEB&F%_(\PO(&*$]3A5!*\<>H-=!K5W%
M8:AXQDNK-;BWEO;")_-D:.) T:#?(R\[%ZGL>AXH [W6-7@T6WMYIXY'6>ZA
MM5$8&0TKA 3D] 3S1K>KP:%I,NHW$<CQ1LBE8P-QW.$'4CNPKR$M$WA;6(-^
M[2XO$=BT?]GB4(L1\EG,/\6,[B-O?)'6K=X+%],\5CPZ=^@$Z=Y?E$M%]H\X
M>9Y>?]GR]V._OF@#V.J][?6NG0">[F6*)I$B#-_>=@JC\6('XUY-XAC>Z\4^
M((=3U6PTV]\Z,:7/=K)YL<?EH5:WPP!^??D $DY!XQ76_$ZQM;KPA'+?0K+'
M:WUI+(Q!PB>>@D;CMLW9]LT =I17EU^_A<^(9DU^2,:$-,@.BY=O)8?/YACQ
MUD^YC'S8QBMB,^(T^"Y(^T_V\-*;9NSYV[:<9[[\8]]WO0!V=Y<BSLI[DQ33
M"&-G\N%-[O@9PJCJ3V%10ZE:S7GV-9,78@2X:!@0RHQ(!(^JD?A7D\$-H-!\
M1W.CZOIKQ_\ "/W2RV>G+(&,FW*R2;F.)!\PYPQW<]*V[*RTBV^*-K<WL44=
MW=:/;-:O)D&296</M]6"[<CTH [C0M7@U_1+35;:.2.&Z3>BR ;@/?!(K0KR
M+PMI$&EZ1X U.UCFCOKJ[:"ZD,C$O$T,S;&!.-H*+@=!CBHO#$4ESK5@][JV
MGVOB&/4)&NXF63[9*NYP8V!;!C*XV\;0 I% 'L5%<5\.M)MHM+FU9TD;4+B[
MNXWED=F(07+@* 3@+\H.![GO7*>('L';Q8-3DF'BL7#C15#.)MNQ?(\@#MN^
M]CONW4 >DMKZMXF.AP6-S/)%"DUS.A01P*^\)NRP8D[&^Z#CBM>N%T#1K9/B
M9KE]/:1B]6QLG,H!XD<3"0CZX%5==UB#1?%'BB.^GDB:^TB 6*!68S.OGAEC
M ZL"RY YY!Z4 >B45Y#<SVMD/#&H7$EMJ-V-,L8ETFX9UG!)'[VW(ZO\WS#'
M1!DBNQ\<7:Z=-X;U">4PV5MJRM=3<[8T:&5 6/9=S*,GCD4 =;17DDTZZW;Z
MFT4MR;2Z\76J*Z%XRT1B@!*G@A3S@CL<BGZM:_V/!XITVR6X@T:*_P!/>>*!
MF_=V[[/M!3'(!4$G';=0!Z1#J\$^OWFCJD@GM;>*X=R!M*R%P .<Y_=G/'<5
MH5XS,+:,^-9/!AE^SG3++RWMM[+M\V7S?)/ILW?<[YQS2W$-NGA3Q1<:+K&G
M20-IR*;720X5) _$ARQPY!(/0G STH ]EZ5CR^)=/6VT>YA9KFWU:X6"VEB'
M!+(SACG'&$/YBI+3P]IECH\NE06P^R3!O-1W9C(6&&+$G))[FO*]%TW2+SP-
MX+T^!,2#5H8]2CB=D=91!*&5\'*GC!''!]Z /7[^\%A8RW1@N)Q&,^5;QF21
MO95'4U9KRO4+<Z9X/^(&FV0DBM;6Z46L2DXC#0PNP3T&YF.!ZFKMU-9V7Q06
M19+35+J[N8X_()9;O3QY6"RCH8>-QZ<L>3TH [?6]:LO#VD3ZIJ#LEM#MW;%
M+,22%  '))) Q5JSNX+^R@O+:0203QK+&XZ,K#(/Y&N0\6R:AJ'BG1-)TVR@
MO/LF[4[F.XG,*$+\D0+!&YWL6QC_ )9UQL][=:5X3M_#NHVJA]-UQ+>2T$KO
M%-:LCRQ(65-S+C"\)U09 &: /9Z*\?M=+L9_#FF6MO+'Y=YXE!NH+*21?(1E
MD/DDD*V I Y X/'&*?XEL;:V\3WFFWUSING:;'80QZ4;[S D?W]YA*L ) VW
M_:QMQQ0!Z[17CNMQ22:U):^(-7T](_[+MEL;S4%D0.^UO,DAPP"R[L$_Q8V]
MJU+W1(]6UV^AU666^^S^&+9EDW.BO-NG_>[0?O<9'<9H ].HKRK3+*XT]O"U
M]IIG.J:IH=Q)=2RR,YN)O*B="^X]0Y./0''2JO@R**6?3[B'5[!-02QD&H6L
M2R_:IG,?/VC<QPROSDCU X- 'K]5[&^M=2M1<V<RS0EF0.O3*L58?@01^%>8
M>&M'M[.'X?W4:3>?J=DT6H.\CL9U-J7VOD] P&!VZ"MOX6VVE66BWMI9QQ1:
MC#=SI>Q#.],3R^6&!Z?+T]J .SL[P7@G(@N(?*F:+]]&4W[?XESU4]CWJS7D
MU^L$FEWSW^I6=NL/B&\D2WU,L+:Z R/+<CIC=E>O(Z&O1?#5T+WPQIERME)8
MK+;1L+:0DM$-HPI)Y./>@#4HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME16P&=#E=WJ <''J!5^N/_X36ZOI=*AT713>2:EI@U*/SKD0K&AV\,=K'/S
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M>976HZQI1\21VFJ7=];Z#/:7N96#R/$5+3P,P'.$!8=QD5U/A+49];.JZO\
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M]Q).]M"TTD7DO(4!9H\D[2>ZY)XZ<FJNF:#H^B^;_9>EV=EYO,GV:!8]WIG
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M8TD8VD./FW@C(P#DUHZ!I5M>3^$1:VL]Q;:5-?1W37,"J8;COE02J_,3C!(
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M.%VY.3P<'C-=;X?TPZ+X;TS2BX<V=I%;EQT8HH7/Z4 :-%%% !1110 4444
M%%%% !1110 4444 %%%% !4<MQ#"\22S1QO,VR)78 NV"<#U. 3@=@:DKD[\
MO=_$W3[;<%%II-Q<PY&0)7D2/=COA=P_X$: .HFGBMT#S2I&I8("[  L3@#G
MN20!]:DKR#=KDOPV\ZZU*&]F;7XDM_-A9=CKJ.WYFW$E20, 8V@8YK>OO%VM
M>'[;Q'!?-:W]WIXM#;2Q6[1JWVAR@#(&8G:P)X.2..M 'H-0SW=M;9\^XBBP
MC2'S'"_*N-S<]AD9/;(KF_"VKZQ>ZE>6FH13RVT<4<D-Y)ITEGN8E@T95R<X
MPI!'9L=JLZKX1M=7U5[^XN[G+"W4Q KLV12&39@CHYQN]=H]* .AJO9V=KIU
MLEI:1)#"I8K&G &22?U)/XUR.JZ=#;_%/PY>AYGFN8[P-YDK,JJL:855Z*.I
MX')/-<IXNL+O3+;Q'J5UH-S<:L+U;G3=9C:,B&/*"- Q<.N#E2@'.>^: /8,
MC(&1D]J,@$#(R>E>0>--/NM.MO%.IWFA7-SJ0F%SI>L1-&1;(JIL4$N'3# @
MJH^;=WS3O&FG7-G;>+-3U'0KFZO2HN=+U:)H\6:I$NU06<,A5U8D*/FW=\T
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MC;KC<45QOW ?0$9.:Z+QCH]YKOAFXL+&2-9V>-]DK%8Y@KAC&Y'(5@"IQV-
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M'%,V+Y=1+23N[-.%"[RS$D\ <=*A\+>,M,\1V%BJ7]HVIRV<=Q-;Q-]TE06
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M#U/M0!#I/AVRT>YGN87NI[J=%C>>ZN'F?8N2J@L3@ LQ^I.:M6>EVEC>7UW
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M-I):KO4><8E7<!D\'Y<<X[5V+--JFARYM9;26XA=1#<%=R$@@;MI(_(FK]%
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MW2,3*@0H 3G(^4D9'-5[SPEH]]-#,\-Q%-%"+=9+6[E@9HAT1C&P+ >ASU-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116+X@\4Z;X:CA:^,
M[-*RJJ01%R 6"[CCA5RP&21UQUH VJ*QM7\1P:5?06*V=Y?7LT;3+;V<89A&
MI +G<0 ,L!UR<\9JYI.JVNMZ5;:E9.S6UPF]"RE3Z$$'H0<C\* +M%8>E^*+
M?6;L)8V-_)9L65+\Q 0.5SG!)W$9! .W![&G>(O%.F>%UL6U1Y(TO+@6Z.J9
M"L03EO10 <GM0!M45175;9M<DT<;_M26RW1X^78S,HY]<J:N;UPQW#"]?:@!
MU%8DGBBP^S:'=6I:YMM9N%AMY5&T -&\@8@X.,)TZ\UI7=Y]ECA=+:>Y$LJ1
M8@4-M#'&\Y(^4=2?TH LT4FX9 R,GH*"P!P2,^F: %HJM>W9LH%E%M/<%I$C
MV0*"PW,!N.2.!G)]@:L;@"!D9/2@!:*K:A?VNE:=<ZA>RB*UMHVEED()VJHR
M3@<GCTJI/K<$&O6&E%&+7MO-<+*"-JK&8P0?KY@_*@#4HJM/=F&\M;<6T\HN
M"P,L:@I%A<Y<YXST& >:L @YP0<=?:@!:*QO$GBC3?"MI;W.IM((YYA"OEIN
M(."2Q'90 23V K8+ #)( ]30 M%(6 &21BC<-VW(SUQ0 M%)N&[;D9ZXHR,@
M9&3VH 6BD!!&00?I0&##(((]0: %HJ"ZO+>RLKB\N) EO;QM)*^,[549)P.>
M@I\$\=S;QSPMOBE4.C>H(R#0!)156SO/M=L9GMY[7$CILN %8[6*YX)X.,CV
M(J2ZG-K9SW AEF,4;.(H@"[X&=J@D9)Z#F@":BHXI1)!'*RM'O4'9)@,N>Q]
MZA;4;1-5CTQI@+R2%KA(L'F-656.>G5U'KS0!:HI-PW;<C/7%&X9QD9]* %H
MK-UW68=!TI[^:-I522*,HA&?WDBQ@\^A;/X5HE@" 2,GH* %HK-U_68?#^A7
MNJS1M*EK$96C0@,P'IFK=Y>06%C/>W4GEV]O&TLKX)VJHR3@<]!0!/14<5Q%
M/;I<1N#$ZAU;H"",@U)0 44FX;MN1GKBC(SC(SZ4 +12%@,9(&>!FLW3]9BU
M#4M5LEC9'TZX6W9F(PY:)),C\'Q^% &G12%@" 2 3T'K7.7WC"VL9]2B>UE8
MV%W:6KD$?,;@H%(]AO&?I0!TE%%(&5AD$$>H- "T4@(.<$''!H# D@$$CK[4
M +12;EY^8<=>>E5KW4K/3UMVNIA&+B9((C@G<[?=''KZ]* +5%(6 (R0,]/>
MH[JYALK2:ZN'V001M)(^"=J@9)X]A0!+144%S#<VD5U#(&@E02(_0%2,@\^U
M2]: "BDR,XR,]<49!.,C- "T4@92NX$$>H-5;[4K/3;9+F[G$<+RQPJ^"<N[
M!%''JS ?C0!;HI"P&,D#/ YI: "BD#!LX(..#B@D*,D@ >M "T4A8*,D@#U)
MH) &20![T +156VU*TO+J\MK>8/-9R"*X7!&QBBN!SU^5E/'K5D$$D @D=:
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MR?([&-6 ))4E<G R1D=<5!!X+LXXH3+>74]TNHKJ4US(5WSS*NT;L* %"X
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M<%(CN8[<D^P'4]<<U9F^(;PZ3IYFM[2VU*ZO+BSD$\Y$$30,RR-N"Y8':,#
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MEJ$<MR9;AED*_9H-PC4*1D#GDC.<5U9\+O#JMW>:=K5]81WDHGN;>%8F1Y
MI8%T)4D* <'MG@\T7GA&RO;#Q#://<*FN/OG*D90^6D?R\>B \YY)H S/%?C
M:7PS>,2VD/!'Y9:V>\(NI%8@$JFW QDXR><'I7-^+9K]8/':V31_/?6$4GF2
M,N(WCB4@8'?(!]B:ZS5O EOJMSJ;_P!JW]M;ZF8VN[>'R]KLBA5.XJ6 PJY
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M,Y))Y"@*.N.!T% '":#XLUZ#P5#J&IPVMY>W=\;.R5)2OF2-.Z?O#MPJKCJ
M20OK71:+KFH3:[>Z'J]K;0WMO!'=)):R,\<L3EES\P!!#(01]#59/ ULND3Z
M6=3OC;&Z^UV>/+#64GF&3,;;<GYF/WMW''K6CH_A\:9>W6H7%_<ZAJ-TB1R7
M-P$4B-,[4544!0"S'IR3S0!RMQJ.N6'C3Q;-I5E:W4=O;6LT@N;AH\A8W.Q
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M[B:V>.>.XAGAV[HY(V#*0&!!Y'0BH(_#<*W&HW$MW<33ZA916<\C;1D1AQO
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MO;2]4M:W4,ZC&3%(& _*O*_$EA)I;:[;VFF[+6?7-/DMK=8,Q3,(T9\1C'F
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MT8\\#WJ*?4TCEL?)C$\%TS SI*@6-0A;=R<L#C'RYZYZ5YMH/@ZU2Q^'@GT
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MU.ZTMIX7LY[?SX[,S;)C)"8RQ53MX#X8X YY% &UH?B.VUE)0WEV\Z7=Q;+
MTH+.(96C+ <'!VY]JTVO+5+I;5KF$7+#<L)<;R/4#K7F4?AKRM'-]'H[KJA\
M6&X\X6Y\WROMQ&[.,[/+)YZ8)/>H#HDLNO:G:ZI)>07<VL_:H)H='>9F02*T
M3+< $* H"G)&T CZ@'K$LT4(!ED2,$X!=@,G&?Y G\*A34;&00%+VW87&1#B
M53YF.NWGG\*YWQMI8U9_#D$EF;NW76(WG3RRZA!%+RP_NY('/'..]<E?>$XX
MM(\836NA[;P:Q%)8M';'>$'D/F+ X&XR'Y>,[J /47O;1+M+5[J%;EQE83(
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MA458M0DO3/>6XM&M_(+J-JA6Y*X&<]R6Z=*Y6336?2KG26T6[/BM]9-PM_\
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M^'=&N;.R'AVZM9U-@]MY\K8\I%1E4LR@/R <;L9YH ] L]9MKW3?M44D32K
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MCIZ^QO\ AMC;>+/%>F)_J$N(;Q%_NF:/YQ^+(S?5C0!U5%%% !1110 4444
M%4=4TBQUJV2WOX/-1)!*A5V1D<=&5E(93R>01U-7J* *&EZ+8:-'*EC"4,S[
MY9))&DDD;&,L[DLW  Y-7Z** "BBB@ JHVFVCZK'J;0@WD4+0)(6/RHQ!8 9
MQR5'.,\5;HH **** *HTZT&J-J8A'VQX1;M+D\QABP&.G5B?QJU110 4444
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M< C(R"#D,00000>E:E% '-Q^"[ 6SI/=7ES<2WT%]-=RNOFRR1,K(#A0H4;
M, #C/<YJ]XHL9]3\):S86JA[BZL9H8E) !9D( R>G)K6HH Y72O!%I;"*74;
MN]U&1+(V:17DJND$;@;U7 !.< ;F). !FIM*\&VNF7EE<2:CJ-\-/1DL8KN1
M66V!7:=NU06.WY<L6.":Z2B@#CKGX:Z%<Z?K%F9+Q$U6Z%U(\<H#1,&+XC./
ME7+.<<_?;UK4O_"UO=7=K>6=[>:7=VT'V9);,I\T.0=C*ZLI (R.,CUK=HH
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MS8>#-.>6X^S7&@WOF1I*T>XAX "=I!!&3SU&30!Z5_;%BT-C/%*9X;YPEO+
MAD1LJ6!RH("X!Y/%7J\D\*2VMKX0\!)IEZY>74(8[U%NF?#_ &:7<C L=O('
MR\#CI45KJ"2:?I]^FK7#>,I-86&>S^V.6Q]HVR1-!NP(UBR?N\ !L]Z /8**
M\GNHIDTW6M?&H:A]NL_$8AM_]+?RXXS<QH4V9VE2'8'(/Z"M6VO8;+XD>7->
MQZF]]=R1P-;Z@_F6>V(YBDMP=NP;3\WJ1D9P: /0Z*XWQU?V<,^E6%TBDW1E
M97N-3DL;==B@G>Z9)//"X]3QBN$'B%SH'A/^U;B>YM98+\.IU%K<2,DRI&3,
M2I8JN>#SSNZB@#VVBO+=,TD7E[X0TBYUFYO+4Z-<S7$EGJ$A2ZD#P<F0-N8!
MF)&".G89%5!<:C?>(=2:75["QU.#6?*@-UJTL4B0B1=B+;[=C*Z?]]%\]1P
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M71%\F3?CEB/FPG [Y]JWX-42\T*+5K*&6YCGMUN(8DVAY R[E W$ $Y'4@4
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M*,6JZ2B,\3S)(@5P2K[@?F'!!'7(H [F:"&YC\N>*.5,YVNH89^AIX 4
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M'##VQ4.J^.QI]UJT<&BWEY!I,:3WEQ$\858F0/N7<06(7)P/3Z9G\=ZE+9^
M[W4+&:5' A>-X20Y!D3ICGD''XT =$;2V9HV:")FB&(V9 2OT/:IB 001D'M
M7)GQS!9'45UK3+K3)+.S^W!)&20RPYV_+L)&[=@%?4CDYK)\0>-)I_"_B*V6
MWFTS4X-)EO(&2X20[0",AD)VLIQD>XP30!WT=O#"%$4,:! 0H50, ]0*1[:"
M1%1X(V16W!2@(!]?K7/Z9XJFNK^33[K1;VUNA9?;;=)'C9KB,$*>C85LE>"?
MXASUK+U?Q=<RZ)XEL9+*?3-3M='GO(66=). K $,A.UE8#CZ8)H [5[>"2,1
MO#&R [@I4$ ^N*KZ?IEMIBW MU.ZXG>XF=CEG=CR2?88 ]  .U<3:7^JZA\0
M]/LI8[[[%;:5#<AHKP(CNQ.9'4'+CY=NTY[G'.:Z35?$<MIJXTG3M+GU*^%O
M]IE2.1(UCC+%5)9B.20<#V.<4 ;9BC)),:$DACE1R1T/Z"G!%#EPH#-@$XY.
M*\YU3Q'=>(M7\)QZ9!J*Z9?K/-+Y%T+>0O'\I1B&!^0Y)&<'ISBM[Q1XAU71
M]<T&ST_3/MD=]/(DO[Q%+;8G8*I8C!^7.3Q@$=30!TDUM!<;?.ACDV'*[U!P
M?49I_EIN9MBY88)QU'I^IKSX>,;S1=8\62W5A?7FFV-_&9)UD79:Q&"'(56.
M3@EF( [YZFM?6O'5OI-[J$"6,MU'ID:R7TB2QIY8*[L*K$%V"_,0.Q'4\4 =
M0UO"WE[H8SY9S'E1\A]O2D^S0"X-QY,?G$8\S:-V/KUK/UC7[72-(CU I)<B
M=XXK>*$#?,\A 15R0.2>I( &37,:_P".M0T_P_KQCT>2UUK3;070@FD1T,;;
M@) P/S %6!'!R* .Y\J/RS'Y:;"<E=HQUST^M!BC(<&-2'^_D?>XQSZUQ&H:
M_K4'B_0T32;QI+C3KMGTY+A-H99(=KNV[;P"<'D_-CO5W_A/+673-*GM;*:2
M[U(RB*UDD2(QF([9=[$X 5N.,Y)&* )M0\$P7\^J%=5U"VM=5Q]NM8?*V3?(
M(S\S(77*J =K#VQ72Q1I#$D4:[410J@=@.E<@?'\4UOIOV'2+R[O+Z:>W6U1
MT!CEA.'#,3MP,$[@<8^H%=?$S/$C.AC8J"4)!*GTR* '4444 %%%% !1110
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MCP^UW&T^EB!H9Y+</&SQ#'S1D\J1D$9[]:</"-Q/I\,$\NEV\D>H6UY_Q+[
MPH1$X?:1O)).#SVSTKK:* .+OO 0NK:;%W ;D:N^J0&>V\R(%EVF-T)^9<$\
M@@YP>U2R^$+V2PLWAN=+L]3LKW[9;O::>8X/N%"CIORV59N=P/(]*ZBXO;:U
MFMHIYDCDN9/*A5CR[[2V![X5C^%3T 8/AS0;O2+G5KN^U!+VYU*X6X=D@\I4
M(C5-H&3Q\O&3GUR>:Q;SP-J5P;VTAUJ&+2KK4DU(PFTW2[Q(DC)OWXVEES]W
M//7'7N*H:IJ]OI+6(G21OMETEI'L .'8$@G)Z?*: .(/A?7-8OO&%D+\6.E:
ME?A)5DLRSR1&WA5FB?< -WS(20P&..0:UKWPCJ2W>K?V/JT%G9ZNJBYCEM3*
M\;",1EHF#@ E%7[P/(S[5V%07E[;:?;&XNYDAA#*A=S@99@JC\20/QH P[+P
MG%I][=R6UQMMY=+M]-BB*Y,:Q>9AB<\\2#CCI[TLGA=W^'R>%Q?O&ZZ>EG]J
M1,'Y4"[MN>AQR,]#C-::ZO;MX@DT4))]I2U6[+8&S8SLH&<YSE3VJ_0!Y_\
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M[B1)DB 0Q^2@(#*><@ Y)8&O8" 2"0,CI00"02!D=#0!P7AJST>Q^)GBJ/\
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M8Z%<PZIJ"Z>TXUC3[AY)'!DP1*F3MFVEB,'/!P!C%>R1QI#$D4:A(T4*J@8
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M)HU,8S)!@@,PDW9QD\ 'C%:=_<V^G_$"TDN+RTU:\GEM;<V@G:.ZLV*C,D:
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M$,?DH" RGD$ ')+ U[!M'' XZ>U& 2"0,CH: *MKJ5G>W5Y;6\XDFLY!%<*
M1L8J& YZ\$'BK=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ-=;Y8!<^5'93/)'%_?=%0M&.OW@.A]*LZGK,=OX4O=;L6BN8XK*2[A8'*2
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MKA?6(;,R =]N<=ZO2>+='73;/4(YKBYM[Q"\!M;26=F4=25125QGG(&#QUH
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MWED"JH..%0Y.001P5ZG%9WB+QK/IFG7 @N8FN&UA-.CD@L9I1;J2F[<H'S.
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M.R%_(D$9?!;RRY7:'P"=A(;VH Z*BL0^+M%&J_V=]J?SO/\ LWF>1)Y/G?\
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M##5-02\\UM2RA!R,9;+D/E\%<8%=+J>@MJ7BZVN[B&.73?[+NK.=6/WC(\1
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MK*LK$X88"@!NG?M7>44 >=7V@^)YM#T[= \OB*""1(M5AOQ$T#,Y*K*-H$J
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MQ&/3#K7.Z/X?U_PU_8=[!I\-_+#H<.F75N+D1M&\9W!E8C!4DD'OP#S7H=%
M'G]IX8UK1K?PW<PV\%Y<V5U=SW4$<VQ5^T%V.PL.0I;';(Y]JGD\+ZFRW("1
M_O/$T6IK\X_U"F/)^ORGBNYHH \_U[P=J>I7>MW,(7,FI6=];(+AH3,(8U5E
MWKRA.&P?4"F3>%;V6P:^L](DM]2BO[6\\J]U1[EKH0D_*78L$X9L<GG&<5Z'
M10!R_ARPU=?$FN:OJEG#:+?QVRPQ)-YC*(PX.X@ 9^8'CCGJ<5G:GX:U2_O/
M&%@(HTLM>MQY5X)1^Z<0"+:R=3RN<CL:[FB@#CK+3]<U3Q#HM_JFFP:=%I,,
MHQ'<"4SR.H3Y< 80 $\\YQQQ6;\0M+FO->T6&QE5)=8#Z5>)GYFM>)78?[JH
MX_[:UZ'33&C.KE%+KG:Q'(SUQ0!QMUIFN:3KVM7.DZ9;7UOJL,*ION!%]G=$
M*88$'*8P?EYZ\54LO#6M^&;K3&TRW@U%8]$BTN1I)_*V/&Q(<\$E#N/ Y&!7
M?T4 <[X:T>[TOP!I^CW(07<%@L#A6R-X7'6LW2O#6H6@\#^=''G1[!X+K#@[
M7,*)\OKR#7:44 <!J&@^((H/%&D65C;7-KKTLDB7LEP%^S^;$L;ATQEMNTD8
MSG@<5;?PM>I)XF2(*\=[H\%C;,S#+.B3*=WI]]:[2B@#E;+0;V#7?#EVR((K
M#2);2<AN1(Q@P!ZC]VU375AJ4/CZVU:WM4N+.6Q^QS-YH1H2)-^[!^\,$].>
M*Z2B@#A?#_A;4].N/##W"1@:=#?I/AP<&6163'KP#1;>%M2BT'1K1HXA+::]
M)?R@.,"(S2N"/?:Z\5W5% 'G.G>#;JSOVL[S3+B^M?[3:]CN1K$J0@&8RJ6@
MW8WJ3T"X)&<\FNC\6:?J%T^BWNFVR74NG:@+EX&E$9=#%)&<,>,CS >?2NCH
MH X"^T/Q##%XGTVRT^UN+?7W>1;J2Y"BW,D*QN'7&6"[<C;G/3BNWL;46.GV
MUHKEQ!$L08]3M &?TJQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<1K%A//\6-#D35;RW7^S;IO+B$6TA9(,K\R$X;(SSG@8(YSV]4;_ $73=4GM
M9[ZSBGFM'\R!W'S1MQT/X#CV% '!6^JZS>R:58V^IM9_;-?U.UEEB@C+>5$9
MRH *XS\@^8@^IS4,6I^(K2QDU&;Q!/<#3]?33!"T$06>$W"QDR$+DOA^J[1\
MHXZY]#CT;389(9([*%7AGDN(V"\K))NWL/=MS9^IH;1M-:"2!K*$Q27 NG7;
MPTH8.'/ON /X4 <$NL>+-5U74[C3(=0;[%JK6D<*M:K:&*-E#"3<WF[F7+9'
M3*XXZZ]N)_\ A,_&5M9WBV;265I.+AD#K#,RRIO*G@X6-#@^E;MQX7T.[U/^
MTI]+MGO"RL92G+,OW2PZ$C P3TQ4=OX;MO-UQ[\I>#5Y/WR.F%$00(L>,\@
M$Y[EC0!L1!A"@=_,8*,N!C<?7%/IL<:11K'&H5$ 55'0 =!3J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M):K\_P#@&'IFC75NWAE;FTYMTN/-R-PA##**3[9 _"D_LNX33IE2S97.O+,
MJ8)B$ZG=_NXYK=_X1K2/^?,?]_&_QH_X1K2/^?,?]_&_QI>W3=[_ (>;??S&
MJ#2M;\?)+MY&9IL?V34[ZVN]+GEN)[]IX[D0;DV'&QMYX&T<8Z\<"LO0M-EM
M_P"SH=0.H)<V,CR,?LJK%NPVYC-MY5LD]<G(S73_ /"-:1_SYC_OXW^-(?#6
MCD$&S!![>8W^-/V\+-:Z^7_!#V,M/+S_ . <GX6RKZ(]]%)%_H[Q69^S!1(S
MKO.YPY+<*2,A<]>O%6X-&DM?!>AHNFL6@E@FO;98_GD49)R/XB&(;'M6ZOA+
M0D*;=/0>7]SYV^3MQSQ^%2_\(UI'_/F/^_C?XU4\3%RNK_=Z^?F3&A)*SM_5
MO+R.<O;&YO8M;O;+3YXH)?LC1P-'Y;S-%)O=@AP0=N ,\G%)J[S7=OXHOC9W
M,%N^CK'&T\90N5\TG@\C[PX.#^8KI/\ A&M(_P"?,?\ ?QO\::_A?1I8VC>R
M5D88(+M@C\Z2Q$%_7IY^0W0F_P"O7R\S(TY-^M6=Y::3<6<%G821S!H0AD)*
M%47^]C:QR..>O-273D:]!JEUI5W/:SZ>(TC%OYCPN6+,K*,[205&>GR\FM0>
M&M( P+,?]_&_QI?^$:TC_GS'_?QO\:EU87OKV_K4KV4[6T_KY'/W5N89M<CG
MT6XN#?Q(+39 '4+Y041DCA-K GD@<YIZ:',9=0%Y:BXE&BP6RRLF[?(!)O"D
M]\[?TK=_X1K2/^?,?]_&_P :/^$:TC_GS'_?QO\ &G]8C:R;_JWGY"]A*]W_
M %OY>9E:;I;V>H>')(K,PB/3I8[EE3&&(B(#>^0QY[YKJJS8=!TRWF2:*UVR
M(<J=['!_.M*L*LU-I_UO<VIPY58****R- HHHH **** "BBB@ HHHH ****
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M, JL"I SGYN*MCQW:SP:<++3KRXO+Z2>-;,F..2-X3B56+,%W \8!.>HXYH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTYEB5C]UXP'R&7GGO_LXKI]+LWT[2;.RDN9+E[>!(FGD^]*54#<?<XS5NB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** *FIZ79:SI\MAJ%NL]M)C<A)'(.001R""
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M=U:)#<O;W-NUM)'->S2KY3#!1=[G8,?W<5MQQI#$D48PB*%4>@%.HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ JGJ.F6NJQ0Q7:%EAN([E,,1AXV#*>/<#BKE% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '/^,]8O-"\.27UDJAA-$DDS
MQ-(MO&S@/*47!8*I)Q56'Q-#I&@6]_J6JQ:Q#=7(AM;C3K;/F;A\J[59LG(8
M9'MQ6YJIU06@;25LWN0X)2[9E1U[C<H)4].<'Z5Q]GX'U!)/M<AL+:6;6H=3
MEM+4MY,2HFPA"5&7;J3A02: +_\ PL;25$QELM5B^RS"&]\RT(%F6("F0YQ@
MY!^4MP<]*AU_QC-H*:Y/$DNH-9W=K +=+<*(!(J$Y;=\V=V0<#!('O3M4\(7
MU]IWB^WCGMU?6IDD@+%L(%AB0[N/6,],\$4:QX0O[^+Q1Y$]LLFJ3VL]MO+8
M4PK'P^!P"8^V>#^% $=WXQN;/Q@EN]CJ<MM+I*W*V,-J&E5_-8,S>GR@<%O3
M&372IJ\%[X;_ +9T^02P2VIN(&(.&&W<,CK^%4;+2=1/BH:Y>BUC+Z:MJ\,,
MC/MD$C/P2HRN".>#[4F@:!<Z5X#M-!GEB:YALOL[.A)0MM(R,C./PH YKP=X
MTU#5]4T6VDU?2]5&H:>;JZCLX]DE@X5"%<AV!!+%<$ Y'UKJ[?Q7IMSI^CWL
M?G>3JT_D6V4YW;7;YN>!B-OTKG-%\(:U'+X974QI5O'H,059;-G>6X(A,6"6
M5=JG.XCG) INF^$/$-J/#]A/-IO]FZ)?-.DB,YEG3;(JY!7"D"3D9.>N1C!
M+5KXAO+C5?#L<6H&:WN[[4()R;=8]PB\P!<9.-I7&01G&>^*BN?'2ZAJOAR'
M28[Z*UOM2,9N);;$5U"(I2=C'/&Y4(Z$CD9&:FT_P;>6TNCF:>W9+.^U"XE"
M,V62X:4J%XZ@.,_CC-5=-\)^([>/PSI]U/IG]GZ!<!TDC9S+<(L4D:$@J A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **IZIJEIH
M]BU[>R&.!72,L%+<NX1>!_M,*N4 %%%% !15"VU>WNM9O]+C603V21/*6 VD
M2;MN#G_8.>/2K] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!R/Q,D2'P+=2RNJ1QW-HSLQP% N8B2?:LKQ)
MXBT/6;S0S_;-O-X;-S+'J$T%UB(2"/,22NIX4G)P3@D+FO0Z0JI4J0"#U!%
M'DBC[78PVEG>7;:#+XHCAL98[AP7MS#\ZH^<F/?O (/T/2GZEG2;?Q#I<4]S
M!H=MKEDMQMF?]Q:R1Q-* V=RH6/.#P&:O6,  #' Z48!SQUZT >---9VH\:R
M>&;NX;3PNFAI[:5Y-D!D<3&)^3@)OY4X'..E3ZI<6$-IXK_X1.^,NCIX=F>=
M[>Y:6*.YYV%6R<.4W9P>RDUZ\ %&   ..* JJNU5 'H!0!P^CZ?'HOC^SM;2
M6Y\J\T:2>Y$L[R>;*DL0#G<3\V';GWKN:** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL3Q3K,^@:7#J$4<;P)
M=P1W6_/R0NX1F&#U&X'Z UG)XNE;XDOX:-N@LA:DK<<[C<@*YCZXQY;JWYT
M=917"7?C'6_^$ O/$EAIUG+L^U3Q&61E1;>,ML9@,EF8*#@8'/45MW>O7-IK
MGAZV>*+['JJRQO)@[DF""1 #G&"%D_$"@#H**X33_B"T\/BR>[MHXH='$DUJ
M1G_2(%,B!NO.7B<<>U;.KZUJ.C^ )]9GAMQJ4%D)I(R#Y8EVC<.N=H.>] '1
M45QK^)-2M/!VN:V^H:'J;65L\T!TX-Y>Y5)(<[VSVZ$=ZKR>+=;TR:^M-3AT
MZ>X31IM5MY;5751Y>!LD1B3R6&"#S@T =U1532[I[[2;*[D55>>!)6"] 64$
MX_.K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_BJ2V,(N&$/E27SQNGE_=.<DY()SWP *DO==+>++*YT^XN8LZ\-/E$^K.3(
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M=U-<2?;XI=9D=I1APT0M2@6-E(&-IR IR3DUT'C>_M_[2MM-9[A)OLDMSO\
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M"23@^I)%<)I&GW5Q_P (3YVO:VXUK36EU#-_)^](BC=<<_N\$D93:2.I.22
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MD)WY"@DX4G)!Q6YH_B(:EJ-SIEUIUUIVH6\:3&WN"C;HV) =61F!&5(/.0:
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M .G^P6?VW[;]D@^UXV^?Y8WX]-V,T6UA9V32-:VD$#2G=(8HPI<^IP.:P/\
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MS84,>2>H/KQ5K7/#\FH?$W198A*+1;?[1J'[L^7(8'S;@MTW!Y&..N%KNZ*
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MKS.(@V[&-VW)QGJ*=::!(_Q:OM042KIUO ESL9"$-Y(IC+*>^(D ..[5W5%
M'&_$G3;K4?#UL-,,R:JE[$MI+$A8QER8W)QT7RW<D^U6+CPM=V%_IM]X=GM8
M)+*Q_LXP7<;-&\(*E<%2"&!7WSDUU5% '$IX*U"P@TNZL-1MWU6TNKFZFDN(
M3Y4[7&3)\JME<$C')^[S6UX6T2YT+3[F&[NTNY[B\FNGE2/RP3(VX@+DXZ^M
M;E% '$GP7J)TJ^TX:C;(BZF=3TZ80L6CE,YFQ(-V&7)V\8XK5T?1-0CUZYUS
M6+FVEO9;9+2..UC98XHU8L?O$DDLWMC %=#10!CZ;HSV'B#6]2:97747A94
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFCI#F<I?(Y-TQ\QQR/+&.X^^>*PETO3;?X*QZW#:P0:S;!YK2\BC"S>?YS!
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MPL' 615) D5CG&/GKJ/%_P#R3&T_ZZ:=_P"E$- '<5$+JW:W^T+/$83_ ,M
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M>2*\MW1" S+*I"YZ9.>,UY-XCMH=/L?'>DZ7%&NF1#3Y5MAQ#%.\OSJ .%!
MC) '&>G-;WBBPELOAYJGVC1]*TV5[BV^73GW*X$\>"Q,:<\GL: /07ECC*!W
M52YVJ&.-QQG ]3P:1;B%K?[0LT9AV[O,##;CUSTQ7,>,?^0MX0_[#0_])YZY
M23=;Z?J/P\0E7GU5;> *>18SYG<CV"+,GX"@#TN35-/BD$<E];(Y (5IE!(/
M3C-2-?6B7(MFNH%G/2(R ,?PZUY]::9)<_$?Q((M#T:]MXY;-7DO'VO"OD+_
M *M?+8'CW'-<_P",;=I=6\<L^CV<]MNM$FU&0YEL%,* RHFW+;?O<,.E 'L%
MQ?V=HP6YNX(689 DD"DC\:234;&$QB6\MT\P!DW2J-P/<<\BN!UBQN+KXDP1
M6VF:7JQ30TS_ &E*57'G'Y@1&^2?H*O3:1IU_P#$[[+?:;9SPQZ!&%ADA5T3
M]\PPH(Z8XZ4 =SU&14*W5NPB*SQ$2DB/#CY\=<>M<K\/<166M65NY;3K/5I[
M>QRVX+$ I**?[JN74>F,=JX.WT>37/#O@.TMYS;WBQ7LUK./^6<R$,C?3(&1
MW!- 'M0D0R-&'4NH!90>0#TR/P/Y4CS11R1QO(BO(2$5F +$<G [UP?@;6AK
M_B[7+YHC!<?8+**Y@/6&9'N%=#]&!^HP>]<_XXU1+OQ-J%_#%?2W/AM8?L'D
M6<TL;3[A+."Z*57,81.2,9- 'K5Q=6]G$9;F>*",'&^5PH_,TDEW;0VWVF2X
MB2# /FLX"X/?/2N'A_L[Q1\1]U]'#>6<>BP76FQ3*'1A*[[Y0IXW8$8SV!]Z
M2XTC2G^(NE:)+96PTFVTV>ZM+(H/)-P9@'8)T)4-P.VXXH [G[7;?9?M7VB+
M[/MW>;O&S'KGIBB&\M;FW^T07,,L'/[Q'#+QUY'%</K&D:4GC/PSHGV*VCTB
M7[9=&T5 (9;E1'MRG0D!G;&.O/:J&NV=KI?B/Q+:Z7#';VT_A>:>[A@4*GF@
ME8V*C@,5WCW"^U 'H]O>6UV&-M<PS!>IC<-C\J;;W]G=.4M[N"9EY(CD#$?E
M7F7@RU*>+=),^EVFCR+H6Z(6C!AJ*L8\L[!5P4P#M()_>9S5"#2]/LO@OH.M
MV=I;V^N0QVS6ES#&%E>9I%79D<L&!((.<@T >PO-%&\:22(KR'"*S %CUP/6
M@S1"983(@E8%@A8;B/7%>3>/-12^\27\\,=])<^'(8GL/L]G-,C76Y9I S(I
M5?W:QI\Q'WVJSXACEU_Q?INNZ"V^]M=$&HV S@3#S!F,^SHS+]2#VH ]162-
MRX5U)0X< _=.,X/IP14$6HV,T,DT5Y;R11<2.LJD)]3GBO(Y=8M];TG6KJWF
M9=*U7Q)817;YVE8'AMPZL?X>?D;ZD5U'C_0='TSX?Z]-I^F65K,UEY1,$2Q[
MD#+P<#D9_*@#MK>]M+S=]FNH9]N-WE2!L?7%.^U6X@:?SXO)7.Z3>-HP<')Z
M<&LKP]I\UE'.;C1=(TR1R,#37+AP/[Q,:=,GUZUP&JV@GN]8\ EF2/5=8CN$
MVG!%M*IGEQ[;X95_X$* /5FEC1D5Y$5G.$!."QQGCUX!-5WU73HMOF7]JF]0
MR[IE&X'H1STKS[PM>S>(]2T<W)W2Z#I,B77M=LY@.??$$O\ WW6:VEZ?<?!K
MPK=3V%K+<9TN/S7A5GVF>(%<D9Q@D8]S0!ZQ#>6MQM\FYADW@E=C@[@.#C'I
MD4]98W+A9%8QG#@'.TXS@^G!!K@]9M[G3/B#H$/AW3=.W#3;W]Q)(;>( R09
M(V(W.<=OQJWX%:\EU/Q<=1@@BN3JJ^9'!(9$'^C0]&*J3QCL* .G76-,=@JZ
MC:,Q. !.I)/YU8^TP>2\WG1^4F=S[AM7'!R>V,&N(L= T9/BGJ<::18*D6E6
MDD:BV0!'\V?Y@,<'@<^PKD[F;7Q\*/%,<%AIKZ9YNI[IWO'68+Y\NXB,1D9'
M./FY]J /9?.B\QH_,3>JABNX9 .<''IP?RJ.VO+6]0O:W,,Z*=I:)PP!].*X
M'4=';7_%'B324N3;-=^'K2(2@9VDR3]1W'8CN,UK>$;I;?5K_1;S0K#2]6@@
MBEE>P \FYB)94=3@$8*L-K#(]30!U$U[:VTL<4]S#%)(<1H\@4O] >M2K+&[
MNBNK.A =0<E<C//IQ7!>%M'TGQ _B6[UJPM;Z];5KFVE-S&',<2-MC09^ZNS
M:PQ_>S6GX9"KXT\9!?NBYM0/I]ECH ZGSHO/$'F)YQ7>(]PW;>F<>E*LL;2/
M&KJ73&Y0>5STR.U>.7>OVH\7MXPVWNZWU06(D%G,8/L !B<^;MV8\UFD^]_"
M!UKN=!('Q"\7*3\Q6R8#V\MAG\P?RH Z26^LX;8W$MU!' #M,K2 *#G&,].O
M%$NH64$<<DUW!&D@RC/( &'L2>:\RTG0;S5O"NC:GI\-E>R6&H:C*+&]_P!3
M<J]Q*,@X.U@/NM@CD^M,N+B#Q!J?@N72?#^GF/R-23^SKXB.*%D>)7'RHXX8
M'&!@^U 'JL4L<\2RPR))&W*LAR#]"*(YHI2XCD1RC;7VL#M;T/H:JVUDHT=+
M.2WBM T.QX;-RJ1DCY@C *1R3@@ ]^*X'2K?3-)\)_$&V9WL=-BOKE&>W&6C
M4VT0)7U;G/N: /1+:^M+PR"UNH)S&<.(I VT^AQTHNKVTLE5KNYA@5CM4RR!
M03Z#-><>#;6[T[QA8)K6EVNEW<FD-#:)9(HCN%5D+F3!X=?DPO(&YL,<\3^,
MK>\O/&BKHVG6>K7T6DNL]K?J/)BC=SL=23]]F5AMQ@A>67C(!Z."",CD4R.:
M*5G6.1',;;7"L#M/H?0URWA[5=-T?X766I133RV%CIV[=.-LA$:X((['*D8&
M?;-<GX!O4TKQ3;6\BWJ3:]9F>\-S930#[>K-(^TR*H;*NPXSQ$* /4Q=6[0-
M.)XC"N=T@<;1CKD^U,FO[.WE6*:[@CD895'D )^@->%;W\-_#740S'^R_$%A
M=;23Q#>)OX]A(B_]])[UZ&FD:;J_Q*UB/4M/M;Q%T>R 6XA60#+SYQD<4 =Q
M))'#&TDKJB*,LS'  ]S5:/5=.FD$<5_:NYZ*LRDG\,US'@&..Z\,7UC(!=:9
M#J%U;6GG?O%>W60A1DYW*.5'L!69H.C:7#<^.)8M-LXY+>^=876!08Q]DBX4
MXX')Z>IH ]!^T0^4DOG1^7)@(^X8;/3![Y[4K31)+'$\B+))G8A8 MCDX'>O
M(H9M?;P)X&2ZL--CTX7>D[)HKQWE(WQ[<H8P 3QGYCCWI/&6L13^)]0UB**^
MEN/#;PK8^19321LP.^Z!D52JY0A#DC&WF@#U:;5-/MY6BFOK6.1>J/,H(_ F
MK,<L<T:R1.KQL,JRG((]C7">+M.T;4=1\(WZV%E.+W5XRTQ@4F:,VTQ&XXY'
M"]?05W,$$-K D%O%'#"@PD<:A54>@ Z4 24444 %%%% !1110 4444 %%%%
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MP]I>A><=/MC&\Y!EE>1Y9'QTR[DL0.<#/&:TZ* ,'4?!GA_5=0DOKS35>XE
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M:*=HHR^7F=D/F8R#M*]^*Z?7]!?5/$?A>_6WBD33;J665GQE5,+ 8]?GV'\
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M.;N/85$>% +#)5LN!C;Q7=T4 <%X%T*\T!+:UNO"MG!.GFK+JD<D1=@69AG
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M$9!O&W&U@K="2.,^P!W5%<GX U'7-4T2:XUEK5\7=Q'&\3DL=D\B$$;0 !M
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M46[!G+E2J'@E2!UYIVAW;:7J+^&QIUI:K::<EYMM78QAGDD!49 ./DSGU)H
MZJBO+I]9EUQ[7563R&O/!MW<F)6)",S0G@^V>M=[X:)/A72"22390Y)_W!0!
MJ4444 %%%% !1110 4444 %%%% !1110 4444 %87B?PVWB:R6R?5KRRMLJT
MD=ND1\PJRLI)=&(P5'3'OFMVN?UGQ-_9WB#3-%M8(+B[O0\C"6Y$(CC4J">A
M)8EQA<#.#R* ([GPK/+>V^HPZ]?P:G%;&UDNECA)GCW;@&0IM!!Z%0/QJSI7
MAJ+18M/@L[Z\%O:+-NB9U(N'D;<7DXY;=N(Q@?,>*U%O;5[IK5+F%KE!EH1(
M"X'J1UH6\M7F,*7,+2A2Q0."P ."<>@/'UH P-/\)2V.OW6K2Z_?W;7:+'<P
MS10!)50,$!VQ@C&\]",]\TS2O ]OIESIY?4[Z[L],+'3[.<ILM\J5'(4,VU2
M57<3@'\:Z&._LYK9[F*[@>!,[I5D!5<=<G.!4D$\-S"LUO+'+$WW7C8,I^A%
M %+5M'@UC[#Y\DB?8[N.[39CEDS@'(Z<TNKZ1#K$=HD\DB"UNXKM-F.6C;<
M<]JLK>VCW36J74+7"#+0B0%P/4CK0M]:-.L"W4!F8$K&)!N.#@X'7@@C\* ,
M?5/#!O=7;5;'5KW2[R2 6T[VPC82Q@DKD.K ,"S88<\GK534_A_H^I>'=-T,
MM<06M@P,;1/\[*5975B0<AU9@WKFM#Q#XCMM!L))R8YYXWA4VPE"OB258]V.
M3@;\].U;$DB11M)(ZHBC+,QP /4F@#(NO#R3ZK<:G;WMS:7<MFEHKPA#Y:H[
M." RD9RQ'.1BJ-KX)M8)HKF:^N;B[74AJ4DS!%\V41&( JJ@!=I[#.1DFK7B
M#Q19Z)X?.JQM#=AY(XH%6=565W<(!NY &6R3S@ U4MO%DUSXDMM$2TLS/]E2
MYNW6^!6,.6 6/Y,R'Y"?X>,&@".'P);0R10?VG?/I$%U]LBTQO+\I9-^\#=M
MWE0_S!2V,X[#%6Y?"%E+I5]IYGN!%>:@-0=@1D/YJRX''3* >N*VX+RUN7D2
MWN897B.V18W#%#Z''2J.H^(])TO3+O4+F^A^SVG$QC<.5/I@=_:@"I<>&#>Z
MY:ZA>:K=SPVEP;FWM&2,)'(5*_>"AR &/!/YU9UW08M;CM6^TSVEW9S>?;74
M&W?$^TJ>&!!!5B"".0:TX9HKB)989$DC;HZ,"#^(I] ',CP5:/IUW;W-]=W-
MS>7<%W<W<FP22/$Z,@P%"A1Y8& .F>YS71S1)/!)#(,I(I5AZ@C!I]% '-:;
MX.BT^#189-3O+I=&E+6GFB,$)Y)B"':HR K$YZY[]JD/A"R,K2>?<9;5AJW4
M?ZP*%V]/NX'U]ZZ&B@# M/#)BU^/5[S5+N^FMXY(K99DC41*Y!89106^Z ,D
M_GS5F]\/6.I:Y;:G>K]H-M \,4$JJT:ERI9\$?>^4#Z9K6HH \^\4^!LO]HT
MFUGDAN+^&YN[2U>*,J$B>/=$'PFYLH&#'! ..:N:%X<U"YM84U=KJ"VL-12[
MTV"8PF9$6/;MD,0V8W,Y '(&.:[6B@# OO#+S:S-JFGZO>:9<W$217/D)&ZR
MA,[21(K88;B,CMUS27?A=Y-4.I6&LWVGW<L"6]Q)$L3B=4SM+!T(##<W(QUZ
M5T%% &,?#ENU_>WCW-P\UWI\=A(6*_=0N=W ^\?,.>W XJ*+PI8Q_P!BAI)9
M%TJS>RC5L8D1D1#NXZX0=,=36]10!S^C>&9M%2&VCUR_GTZWC\J"SE6(A$QA
M07";V"C@9/US19^$K.RM/#MO'/.RZ$,6Y8C,G[IHOFX]&)XQS7044 8^A: -
M!-Y'#?7$UI/.\\=O*$VP,[L[A2%#$%F/WB<5%J7A6QU3Q-I>NS23+<:>'"QH
M1LE!Z;QCG:<D=.36[10!R5E\/M+L/#=[HD,]UY%W<K</(S*7784*(#C[JB-5
M ]*NZSX1L];EU62>>=#J6G+ITOED?*@9VW#(^]^\/7C@5T%% '/3^%=VMW&I
MV6KW]@;OR_MD,'EE9R@PIRRDJ=H"DJ1D ?6B7PA93:3?Z<T]P(KV_%_(P(RK
M^8LF!QTR@'TKH:* *.L:5:ZYI%SIEX&-O<)M8HVUE[@@]B" 1[BLN3PS=W>E
M7>GZAXCU*ZBN4$3$I#&P3/S %$'+#*D^AXP:Z*B@#A-=\#;; VNB-/#!<:M:
M7;P0NB+:A'7S)(L]#@!L<\C@<FM'_A![>:SU%+[4KV\N]0D@:>[D"*^V%@T:
M*%4*%!![<[C7544 8FK>'O[0U.WU2TU&YT[4((F@\Z!4;?&Q!*LKJ01D @]1
M4&K^%I]8TP:=<:_J'V:2 P72^7 3<*>I.8_E;DC*X^F1FNBHH YZY\*+>:E9
MSW&J7;V5G/'<06)6/8DB+A<-MWX[XW=?;BL7Q+X'^U>"[7P[IXGE']H"4W!D
M57@225FE;/&?D>1<#GYA[UW=% #(HDAB2*-0D:*%50. !T%<M9^!+:TDM(?[
M3OI=*LKC[3:Z<_E^7$X)9?F"[V52<@%N..N!7644 9^CZ1#HT%S#!)(ZSW4U
MTQ?'#2.7(&.P)XJAJ_A@ZEK,.KVNK7NG7T-NULKVX1E*,P8AE=2#T'TQ6_10
M!P?B3P)%=>$]'\.Z?%,\,-\AEN&F =(FW^>['C<75W4@=3)TP*[M55%"J %
MP .@%+10!SVE^$++29=(>&>X<Z7!/!%O(^82LK,6P.H*#&*(?"%E!IVF62SW
M!CT^_:_C)(RSLTC8/'3,A_(5T-% ' Z#X%N3;XU>_O4MUU6>_&F[XVB9OM#O
M$V0"V,;&V[L9ZCJ*W5\(62SQRB>XS'JSZL!D?ZQD9"O3[N&/O[UT-% '+6_@
MB&W@NK!=7U Z/.LZC3LQA$$H;< P7?@;F(!;@_04[3/!D5C>+=7.JWM^Z6#:
M<BS"-56$E3@!%7GY>OO]*Z>B@#FM-\'QV$&B0RZG>78T:4O:&41@A/):$(=J
MC("L3GKGJ>U067@2VLWLX?[3OI=*L;C[3::<_E^7$X)*_,%WLJDY4%N..N!7
M644 <]_PB%E_9AL//N/+.J?VINR,^9]H\_;T^[NX]<=ZOZ_HL'B#1Y=.N)98
MD=D=9(L;D='#J1D$'#*.""#6E10!RI\#P30ZD+S5+ZZFU&2VDGF<1J<P.&4*
M%4 #@#&/UYJ_JWA[^T-3M]4M-1N=.U"&)H/.@5&#QL02K*ZD'D @]1^-;=%
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MM^PLTT_3K6RC9FCMXDB5FZD* !G\JL44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7):IH\=S\2M%OFT])%CT^ZW7#0!@D@> QY;'!^\1WZX[UUM%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,U33Y='2.2>UN8E$K+(<(5 ;')(')&,UU&A:M-K.G_:IM-N=/;=M$5PR,6&
M0RLC,"ISUSV- &G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^^V?O#(  XQG.:[#Q-8>([U8AH5]IL491X[BWU"U,J2 XP<@@C'/'0YKH**
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M[E*LH.",@$=.XYIZ77B^;Q''HQUNQ3[5IWV_SUL<F A@IC4%L%267ELG@^O
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M4$@$J3BL?6O'MA_PB^K7VAW(FNK2U:>(R6\BQR $#<I8 .N2.5)'(H U=/\
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M(!!!&0>U8>E^,-$UG4%L;&XG>X:+SU5[2:,-'V<,R@%3V.<'M6=JWB*]@O\
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M.,(TH78K'(X)!YJ/2_%]EJOB75-#CAN$GL) F]H) K_*"3DJ N"<#)YZC(H
MV[2VCLK2*VB:5DC7:#+*TCGZLQ))]R:R;;PAHMI&(H;:41+=K>1Q-<R,D<H8
ML"BEL*,L3M&!STK-O/$UW;:GXA@,MG##I[62PO.CE?WQPP;;R2>@]"1GBKU[
MXX\.:??365WJ:Q36\JQ3YB<K"S!2N]@NU =PP6(!Y&>#0!8O?"^D:A]M-Q:L
M7O)(I9G65T;?'CRV4@@J1@8*XJ%/!NA+IM_8&UD>"_=9+HR7$CO(ZXPQ<L6W
M#:#D'.15:X\::7<:)JMWI>H0"6PB$CF[AE5$4YVN5VAF0X."N0<<5+:>,+&Y
M\77WATQ3I/:I&WFF&38Q8.2,[<* $ZDX.>.E &Y:6T=E:16T32LD:[0996D<
M_5F))/N36#X?\+1Z7<^(+FYBMGDUB]>:18P2OE8VJIR.21N)[9<U:TWQ9HFK
M78MK.\+R,C21EX7C29%ZM&S*%D R.5)'-8X\>6&H^)]"TW2+I)XKV283,\#K
MO1(F8-&S !EW*!N7(H UM*\(:-HMTES9P3>;%&8H?/N99A AQE8P[$(.!PN.
ME0V'@;P_IM_;7MK92+-:2.]MNN9'6#<K*PC4L552&/R@ =/08D\-:S-?:-=2
M:@0;K3[F>UN6C0_,8V(#!1S\R[6P/6N?E^)%O=>%X-9M%:U1=2AMKG[5"X5(
MFG,;,&8*"=H)XSMZ'F@#L-4TFVU>!(KE[E/+?>CVUS) X."/O(P.,$\=*AL/
M#NE:7-;2V5H(7MK9K6(AV.V-F#$<GDE@#D\^_-0VWBW0[O3KV_2^"6]D<7)G
MB>)HC@$;E<!N01CCG/&:L:5KVG:T9ULII#) 0)8IH'AD3(RI*. P!P<'&#@T
M 49/!>A/!:1+;30BT61(F@NI8F".VYT+*P+*3S@DBI[?PKHMI%:QP681+6UD
MLX5$C?)#(5+KU[[5YZC'%&AZS)JMUK<4D2(-.U VB%2?G411OD^^7(_"N:M_
MB.L>F^'+_48(X8=4TZ:\E$>6970Q!40?Q%C)@#J3B@#MK6QMK+3H-/@B"VL$
M2PQQDE@$4;0.>O [UD:9X,T/1[RWNK.WF$MM&T5N9;J600HV,H@9B%7@<"IH
M-1U*/PM+J>I6<5O>)!).;57W!  2J,W=L8R1QG.*P_#OBW5;_4M(M-2MK KJ
ME@;V)K*5BT  0XD5AP#O !!Z@B@#H]'T*PT&"2#3HY8H7<OY33NZIDYP@8D(
M,D\+@51OO!6A:C>SW5S:S,UQ(DLT:W4J122+@*YC#!2P"KSC/ JL/&^E:C:1
MSZ-J,$B&YMXFEF@F$;"5PNU6"X+\X_V3][%5=.\>Z>NI:I8ZM=I#+;ZFUI$5
MA<HJ?*$\QP"JDDD#<1F@#>D\.:5---*]KEYKR*^D/F-S-&%"-U[!%XZ<=*MZ
MCIUIJVG7&GWT(FM;A#'+&21N4^XY'U%9][XLT33]1:QN;PI,C(DA$+M'$SXV
MB20*50G(P&(ZBH[WQGH&GZA=6%Q?,+JU4O<1I!)(8E">9EMJD ;>0>_0<\4
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M75_MW^AO+Y"D1/YAER1Y?E[=^_(/RXSQTK)TCQU979URZN;E?[/M+^.TM3'
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M;V;2]L$\6H172P0(5^1A'&FW)8?,=V=N,\5H7=C/+K_CC2HU!N-6TN.:U!.
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M<GWC(N2!@8. <BNBTVQU&P\;:W.UF'L-1,,J7*RK\A2((5*]<Y&<CCFNEHH
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MMX=UO_A'+;19K!%-CK<5VLWGJ5GA^UF9F ZC"D<'DGI7H*(L:*B*%11@*HP
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M&*"U\E@]JJ?Q;XV()9Y#@$<$5V,36L4IM(3"DBKYAA0@$!B?FVCL3GGUS4]
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MSZ?-ZUV5I&T5G!&_WTC56^H%344 %%%% !1110 4444 %%%% !1110 4444
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M48;N[D811:=%$\TH5<M@R@HH'!)/L*VK?3[2UN[JZ@@1)[ME:>0=9"JA1GZ
M8J#5-$TW6DB34;1)_);?&22&0XP<$$$9'!]: .#T[7_$&L:?X7MO[3DL[B]O
M;ZUNI_(B:0K"9 #C!0/^['(RN<\$5)%KNMS166B-JKQW$NNW&FOJ8BC\TQ1H
M\@XV[ Y "YVXZG%=M:>'](L$M$M-/@A2S>22W6-<")I,[RH[9W-^=,NO#6C7
MMG-:7&GPR0S7'VIU.1^]_O@]0WN* ,#P%%-#J?BV*XO3>RIJP5K@HJE\6\/4
M+QD#@X Y!X'2N4O+*ZA\%_$N675KNY19[J/R95B"EO)B._Y4!SCC&<8[9YKU
M#2]%TW1(I8M,LHK6.5P\BQ# 9MH7)]\*.:KS>%]$N+B_GETZ%I-0B,5V><3*
M0 0PSCHH&>O H Y2_P!:UOPK>:JEQJ+ZL(]"FU-%EA1!'+&P&U=@!V'<."21
MCJ:N>%;GQ1)JMNU\FI3:;/:&26:^%HH6;*E?*$#$[""W#9Q@<]:ZR33K.6\^
MUR6T;W'DM;[V&<QD@E?H2!5/2_#.C:).9M.L([>0H8P5)(5<@[5!.%&0.!@<
M"@#*@_Y*S?\ _8#M_P#T?-6%JFMZW)I?BK7[?6FLQH=S+%!8"&,Q2")5)$A9
M2Y+YXVLN 177ZKX4T/6[U;S4=.BGN5C$0D)(.P$D#@CC)/YTEQX1\/W>HB_G
MTJWDN04)<@X8K]TL.C$8&"0<8% '(ZQJOB&:7Q==VFLRV,6BVD=U;VRV\;;G
M\CS"LA922N01@8/)YZ"I-3U'5=>N-=BAU=M+MM.TN&<1)%&ZS-+&[,9"X)V
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M;[-JUKIF[S<;C,L9W].,>;T[XZC-:^JZYIVB_9/[0N5A^U3B"+<>K'^0XZT
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M":BLJ^\2Z/I]M;W,]_!Y,]PEM&Z.&!=B !D>YY/:M-'61%=&#(PRK*<@CU%
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "N-^)=T!X6DL([:^N+FXEA
M>-+:SEFX2:-FR44A> 3R1G'&:[*B@#A_$$VG2WUGK=O<^(K*^EM6BC-AILCM
M-'NSY;+)"P5MW(W!3R><5;\'Q3>&O#>C:+?6UVUW)#-/(R1F18FW&0H[CC=\
M^!ZD'%=82 ,D@#WI: //_#6JKK_B[^U]3LM4M;ORWMM/M)]-N$2VB^\S/(R!
M/,?:.^  %!)SF]\2=%_MGP_:K'#<23I?0*#;YWB*1Q%,..=IC=\^W/:NRHH
MX37K>SL?&MG=ZMI4MWHJ:8;>V$5DURD$V_+#8BL5+)M ./X2,UCZ3;7GAU?"
M5_?Z??)9V_\ :,?E16[S26L<SAH$9$!8850O3@X%>IT4 <KX"CN8_#=P]Q9W
M%K++J-[,(+A-C@/<2,N1]"/:N*T7[6_B+1=1?2AI_DVUV+R&#2GLX[7*9$;3
M-P_*_>'&1GC(KU_/..],EBCFB>*5%>-U*LK#(8'@@B@#QOP1;PEM$EO[06EX
M-'EM[$#37C:[9D5V9I#D,X521CKN8]\5>E\,R6/PS\*"TTPVY1[2?5D2R,TK
M 1MDR1?>DVR,"5Y(QTXQ7?Z;X2T72;J*YM+602P(4@\VYEE$*D8(C#L0@QQ\
MH''%;5 'DM[HDS>''N-.EN[BSDUN&[O(O['>)1&L85BEL0"Z[@C$ <E2>:Z[
MP/8P6T>IW-O<3R1W=P)"KZ<]DBL$524C8#K@9/0D&NLHH \HGT=X]&\:Z78:
M/-'J,MZTR"*T9//M"T19$D "G<H<;0<YSQ6YH$%I=>.DU'0M*FL-,CTQH+EG
ML7M5ED,B&-0C*I8J _.,#=C-=W10!Q-Q9VUG\53?2Z4TANM-C2WN$M"Z^>DD
MA;+A2$.TKRQ''?BN<\,Q7ESXLT"\_LD6)2VN4NX+?2)+6.V+*"(FD;B3E>HX
MR,]Q7K.>:* /'/">BZY8>&I[2>RN3JM_H.S3+UHV4VI$6#;-_P \B'PP/&[/
M/*UM>!M,MUU>PN8VNH+BTL&@DM_[%>S4 [/E>0C#D%>,$_Q'O7I-% 'E_P 1
MTN;V?6;%=(0L^E[;6=-)>ZENG(D^02KQ%L.#SSELBF^(M-U*YM_%!6RNI7GT
M"PC3$3$R2!YBRCCEAD9'49%>I49YQWH Y;X@Z>^J>%19K;27"R7UF)(XU))3
M[3&6/'. N23V KG?$^C+8^++.06J6^B+IS00K#I!O(HI3(6<>6@.PL"OS8YP
M1]?2Z* /)]4L9+32M.T9;![FV&CE(;VYT62YGE8D@08_Y8X&#\WZ8-));SV5
MMX<ODL;F[UH:396TMA>:7)-'* 03B7&(9%+,22>PR.AKUG.:,B@#R76M/5[7
MQ;IUUHEW<^(;^[=]-NELW<%2JB!EG VQB/'.6&-I]>;FL^&1?#X@7%UI7VJ\
M>P1;.9H"S.XMO^67'7>!]WG('I7IU&><=Z /(?'*:A?66J69T<_:3I47V>9-
M(DN9[N3821YPXCV-V/.3D=0*MZY:V2>)O$LVK^';R_-YIT$-G*E@\X9]C[D4
M@':Q)7DX''7BO4Z* /*-0T+Q$^FWUJD5P^HGPE:6KRKG]Y,KOYB!NA8C/?\
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M"I51"RS ;8Q&1SEAC!/?GUJB@#D_&]G=W/A6WC\B6]CBNK:2_@A3<T\"R*9
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M)%MWN&3.UT";6VH,@ #'?U)K0TK2+?1X[I+=I&%S=2W3^80</(VY@, <9Z4
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MW=E200"1N4J<'K43^!+)[YIO[1U%;<Z@NIBS61!$+@.'+?<W$$CH6(Y.,<8
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M])6-IW621O-,2/G!"C=MR,'N>.!7;Z;81:5I5GIT#.T-I D$9<Y8JJA1G'?
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M7>!N/R&-"O4_. _H-GO0!4O/$^OL=:ETVRT]X-$ 6Z$SN&N)1$LKK'CA0 P
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M6==TA-/75(-.D>\U&&T#VK. $<-DX;H01ZG.>U5M5\7W]D^OQV]BDG]FW5M
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MH\5_]@DU:Q2\W!?L[7""3)Z#;G.34D>K:;--)#%J%H\L:&1T692RJ#M+$9X
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M<_(^.".=P [C-5=$T"YO+36-!M(O+T_4=+DAFOYM(ELWBE(VH@$C9=0&<X&
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M;F2T@E\IA'++&,L%;&#T;!Z$J0,XHN/%NBVMO?3S71$=G<BTD*Q,Q:8@'RT
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M0N<$DXSG-8/A)IY19W>F:SIS:J-.F-S:1W,DES<2^7QYR.?E99,<D#&2!P:
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M(P>5#XVYYSUXKHM2UI-,U72;.6$F/49G@$^[ CD"%U!'^T%;\1[T :8  P
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M;>_6J&G>+YH]-T2WL=/O-2NM2-WY1N;I0R^5)@[WVCY>>,#(  P: .Y(!!!
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MB-Z$. ,@\<X[UR&B>-M4_P"$7DU'5],#3O?O96D<$RDW$AG>-4Z +MV@%CU
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MC3[).-UPHO"ACQP!PH7DX;.3BNML?$][<KJUO-HQAU/33&6MA=(4=9!E6$A
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MQY;(_ (.X=<<@YQ74V$UU/8Q2WMJMK<L#OA642!#G^\ ,_E0!9HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *P-7\,+JVI7-X;LQ&?2IM-VB/.!(0=^<]
ML=/UK?I&95QN8#)P,GO0!B1^'%CU'0KO[42=*LY;4+L_UN\1C=G/&/+Z<]:S
M(O!$MEI&@06&J^3J&BJR073V^])%<8=7CW#@\=&!! YKKF95&68 >YI<\XH
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M\^OS:QIM];6\US"D-PEU9"Y1MA;:R_,I5@&(ZD'CCBMZSO#=K,6MI[?RYGB
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M4-YK6IZ:(RCV#1*SL1AS(FX8I8=8CF\27FC")A);6L-R9,\,)&D4#\/+/YT
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MU=]:<WQB.I"U.#"'5# Q8!@3\ZL3@KQQ75,RKC<P&3@9/4T%E4@$@9.!D]:
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MEV@=/-"RKN900"1P>?;/2O6** /*=3MF U-K^UFDT?\ X2P27Z>4S*]O]F0
MLH'S)YFS/4<>QJK%96WV;7SHVGSP:?)K^E26R>0Z H'@W,BD9"9#$<8QTXKV
M"B@#R75= ADTSQAJYT]GU6#6E>SN"A,D87R"#&>PR6SMZ]\XJAKD6G:CXNUM
M-8M;3[''J]NSZE<V<LYACC2(F(.L9C5&.00SC&]L@YKVFN>N/!6C75S<2RI=
M>5<R^?<6JW<@@E?CYFC#;3G R.AQR#0!!X\GC@T*W6;3[>\@ENXXY#=0M+#
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M*P.G3+'!.<5:\>0Z>_B7PQ+K%F]SID1NC<#R6EC7*(%,BJ#E<XZC'KTKO**
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MN[NPDNVD<EAY4(4C:XP#NSGD<<5EM)HS:]H;>++5[F%O#$!<3V[S()=QR74
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M3:,\< =A6!IEO:067A8^*+%I=$2QNE$<]LTL271F&TNF#R4W[21ZXY->PT4
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MCZ5V%FMTEI&M[-#-<@?O)(8C&C'V4LQ'YFIZ* "BBB@ HHHH **** "BBB@
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ME@5EG;(>0 <@B-43)ZY-;&J^'K;5]2M;R>65?(M[BWV(<;EF"ACGJ"-G'UH
MYVP\?/-JMUI\Z:3-+'837J_V=J/VC9Y94&.3Y!M/S#!]CZ5K6OBAKB3PPAM
MO]MVK7!/F?ZG$:OCI\WWL=NE5=+\#)87%I)=:K<WL=I82:=#"\<:*L+[,_=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#)>3(=-L$M6@:)-S/YJY &/O%F*@8]:9J'C"$Z5J.1?:1?68@=TN+9'D5))
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M)!R",$$@Y%:T^MVUEH#ZSJ$<UE;QQ>9(DZ?O$_V2%)RV>,#.2:YV'PA/]EL
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M21@D%>')<<<C@\U-8^"98/&%_J,US&^E2>=+:6RY#Q33A!,Q/3G82/\ KHU
M%_3?&>GZG>6<,=M>Q07^[[#=S1!8KK:"QV')(RH+#<!D#(S5G6/$MMI%];V(
MM+V^O)XVF$%G$'98U(#.V2 !D@>I/0&N=\*>!Y= N-/BGTS1)$L%*1ZA'O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>foraresidentagreement013.jpg
<TEXT>
begin 644 foraresidentagreement013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YWQ'J6JV^JZ+INE36D$FH2RJ\MS TP4)&7X5
M77KC'6NBK!\0:-J&HW^E7^F7=K;W.GR2.!<P-*CAT*$85E/?UH H0>*Y]*N]
M1T[Q%Y+W=J('ADL8F_TI9F94"QDL0^Y&&,D=#D#.+G_"9:;Y)S#>"\%P+7[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "L/Q-X:'B>S6SEU6^L[;(9X[418D*LK*271CP5'0CWS6Y10!AW>
M@7MU;00#Q-JT(2,QRO$( TP)ZD^5\I[97;^?-30>'K2UCT^WMI)H;"RMWMQ9
M*P,,J, /W@()8C''/<YSFM:B@#!B\':'!X@MM9M]/MX+BW@>%$BA14^9E.[
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MPM+ED,=N=I4$$*&8A20-Q. ?QKJ** ,_1-(@T+28M.MGD>&(N5:0@M\S%CT
M[L:T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI" -MY P#WK1\5Z=HP\/0"TU^^NH8M5T]YF.K22^2K3H-Q;=D9&2,G (!&*
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MJ1APJM@>O#KS7G33:E!!HVEZKK0BTV[U::-[BTU)Y'2(0EXX'N,*V2X(SU(
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MWC-O"4D?S'4H,,V0=Q'<Y .?:IJ* *CZ7I\MV;N2QM7N2 #,T*ER 01SC/!
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MW6.YE2)Y/[[1AMA;CJ16A<Z=:WEU9W,\(>:SD,L#9(V,5*$\=?E9ASZU:HH
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M74.GS8#*#M?&YL;@<9XJ#2_"ND:-<+-8031;052,W4K11@]0D;,47\ *V:*
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MD<_C7744 <EJO@33Y/"^JZ5I42PS:B$$LUS*\Q?:1@,SEF( ! '09J_;>#-
MM;6_MX[ F._@-M<>9/([-%@CRPS,2JX)P%( SQ6]10!ES^'-(N5O5GL8Y%OH
M([>X#DD21INV#&>,;FY'//L*I_\ "$Z!]D6W-K.0LPG64WDQF5PI4$2[]XX)
M& V,$UT%% '/MX(\./IT5@VFK]FBN&NHU\UP5F((+AMV=WS'G/!YZ\U8MO"N
MBVEE%:0V6(HKH7@W2NS-.#D2,Q)9FZ?>)Z5L44 8H\*:.NJMJ*6\L=P\PG=8
M[F5(GD'\;1A@A;@<D5;U?1;#7;1+;4(6DC2194*2-&R..C*RD,#R>0>]7Z*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M *>K:7;:UI-UIEZ':UNHS'*J.4)4]1D<U+96<&GV-O96L8CM[>-8HD'1548
M_(5/10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH?'&D3WL,*I>"WGN#:PWS6["WDER1M5_<@@'H2, FK3>*=,73YKXM+Y,-_\
MV>QV<^=YHAZ>FXCGTKF;/PAKL>EZ9X<N&T_^Q]/O([A;M)7,\L<<GF(ACVX4
MY"@MN/ /'-)=>$O$3I=Z9 VF?V;+K2ZH)WE?S2OGK,T>P+@$$'#;CG@8&<@
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M*71]1)BFC>T31+;3(BQ.\M$9,L1C&"'7OZT 77\7::9K.*TCN[YKNV2[3[+
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MY9+9()  P0 !1J6JRK:^)]0C\1WHUC3M8,5C9+>$+@NFV/ROXPV6'(/MC!H
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M+S9$G^5?-0%N S-M&,X]L5VUF-07X:7RZG=PW=PMK=*)HI_.!0;P@+X&Y@N
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M/,P%8;"0#GN>*H6?]GV/CGQ9JDU]?QE+&"Z6(73[F4Q2EL1DX; !P",*>F*
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MCR^<XW?Q9JIXEN8[_1M?N[_7+J/48=:%I%8?:ML?E+,FQ?)Z'*?/NQGOG H
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M86=BNVTM(+==H7$,808&<#CL,G\S36TVQ>_6^>RMFO%&U;@Q*9 /0-C-6J*
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MHD5T;3RMRX+C*YSUS_%C/:M?Q5JMS:W5K9V.IO;74D;R"&#3FNY7 (&[@X5
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MJ(7,!NFM1-&;A4$ABW#>%)(#8ZX)!&?8UR7Q"&I1>#H#:ZD8+A+VR269(O\
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M(G^+]Y)%^#TFI>)_$RZIJFGV"RR7.DPPKMAT\S)=SM$)#N;(V*<@#'(Y.>U
M'I%%><:IXN\13ZMJMOI5K<1R:;%%LMDL3.)IGB$A21P1L'S!>.>I]JU&U[58
M?%T,&I2/IFGSF%+-6M/,CN&9,LC2@_))NR #@' ZYH [.BN:US4M2D\2Z=X?
MTRYBLWN+::[FNI(O,(2-D4*BD@9)D!).< =.:YY/$_B.\_LW2X+FSBOWUBZT
MRXNS 61EBC=_,5,\-@#C.-V>U 'HU%<[XEU2_P!%T6PCMY89-0O+J"Q6XEC^
M17<X,A0'V)"YZX&:Y#Q=J>OVNB>*M%GU5))K33([Z&]A@\M]CEU:-@#@'*9#
M#L>E 'IAN8%N4MC-&+AT+K$6&YE! ) ZD D<^XJ6O/M0L];;QYH5M#J\*WO]
MDWGFWC6@.5\V _*F[ /W1R3QFJP\;:S=:=X>MD#)>WXNS<SVEH9B/L\GEG9'
MGC<2#SG S0!Z517GRZ[XKNVT#3LPZ=>7TMW'--/:')CBP4D6,MP67!P3@$^V
M*W?%FIZGI6FZ8-/FMQ>75_!:&2:,LGSG!;:"/KC/XT =)17G&H>+M<T(:SID
M\L5]>V]S90VUTEL1Q<DCYHU/++M; !&<K2W/B;Q18Z'J<GE,9(KFRCLKJ^LS
M!YOG3*CJR _PYZC'##N* /1J*X;6=3U_0+BQ34=4"::L1:XU2/3MZ>:7X610
MQ\M-I'S>O4BH-2\1:_)9>)M;L+RT@M-"FEC6SD@W?:!$@=R[Y!7=D@8''!.<
MT >@45YYJGB+Q'--XDN--O+6UM='LXKR.*6V\QI283(48[A@<$9'//MS=NO$
M>IQZ_8274QT[1KF*V:"46GG1RR2'YHY) ?W9Y4*2 ,GJ>E ';45SWBG4Y;%;
M.WM]2:TN+EV")#8M=32A1D[5'0#J201TZ9KF$\6Z_=>%='U5RUM;,UTFHWMO
M8F9HC%(41C%G*J=K%L9VXQQUH ](HKB[OQ!J$'B2R%Q?+;:+<);_ &6ZCL_-
MANG<_,K.#^Z)RH7/'/4]*SI/%&O_ -A2>*TNK4:?'J!MQIIM_F:$7'D$F3.?
M,ZMTQT&.] 'HM-21)4#QNKJ>C*<BN5T:_P!;UW5;^[COK:WT^SU&6S%F;;<T
MBQG:S%]P(8G)&!@#'!K$TW79AX2T6.TNX].N;DW++;6&EF=G"2D95%X11GYB
M1R6'()Y /1Z*\OM=5UWQ#J'@>_74ELFO+>Y\Z)(,HSH &."W?L#]VK(\7>(K
MW5+V;3[6XE@M=4:R%HEB622-) DC&;/#?>8<8& "#UH ]#GN(+6$S7$T<,0(
M!>1@J@DX')]20/QJ2O*O%&H:WK?AO6;X7EM%IMMJR60LC!EBL=RB%_,SD,6&
M<8QCCKS7<^+M3O-%\-W&JV84FS9)IE9<[H5<&4#T.S<0?:@#<IJR(Y8*ZL4.
M& .<'K@_G7FUSX_U,WVOVMLL'[QXX=#?;GS7\T6\A/\ >"R$'Z57UZYU"6'6
MEL+F&PDA\36,#2P6X#3!OLW+D$9.7YSU QTH ].6Y@>YDMUFC:>-59X@P+*&
MS@D=0#@X]<&I:\UNH]?@\8>(I+#5;:*>UT:TDFEDM=_G.OGD#;N 53@YZGIB
MN[T34&U;0-.U%D"-=VL4Y0=%+J&Q^M %^BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K$U?PEI.MZE!J%XEV+N"(Q1RV][- 50G)'[MUZG'Y#TK;K#U;Q
M FCW\PN)+?[-#8/=L@+F<E65> !C;SC.<Y(XQ0 EWX/TB]BM$E%X)+1&CBN$
MOIEFV-]Y3*'WL#@<$GI5F+P[I=N;#R+8PK80O!;+%(RJB. && <$_*.3DU6T
M?Q;I.L:/I^HI<+ M\R11QS94F5DW^6,@;CC/3@XK=H Y[1O!6B^'Y8'TT7\2
MP9\N%M2N'B&<Y_=LY4]2>1UYZUK:AIEIJD,45Y%YB13QW"#<5Q)&P93P>Q X
MZ5;HH J?V;:?VL-4\K_3!!]G\S<?]7NW8QTZ]^M9<G@W1&LK&UC@GMQ8*RVL
MEO=212QJWW@'5@Q![@G' ]*WZ* ,RYTE?^$<N=*M&8![:2&-IY6D.6!&69B6
M/)ZG)K)\.^!M*T2TLR\!FNX;,6Q,D\DL: J!((T<X0,1S@"NIHH Y[3_  3H
M6FSQS6\%P7B@>VB,UW+*(XFQE%#,0J\#@=*MS^&]*N?#T&A26["PMTB2%$E=
M6C\O&PJX.X$;1SG/%:U% &.WA?1Y8[J.:U,ZW=K%:7'G2O(9(X]VP$L2<C<Q
MW=23G.:9#X4TZ&SN+43:FZ3A SR:E<.Z[3E=K%\K@^A&>^:VZ* *&DZ/9:+:
MO;V2.%DD,LCRRM(\CG&69F))/ ZGL*KGPSI!\/)H1M,Z=& $B\QLI@[@0V=P
M(/((.16O10!R6M^"8+_0/[+MY9I4DO;:><WUW+,7CCE5F4%BQ&5!  P,G\:O
M0^#-#AL;VT-O-,EZR-<O/<R2R2;""@+LQ; QP,X_,UOT4 9FKZ!I^MM;R7:3
M+/;%C!/;SO#+'N&& ="#@@#(Z' JI=^$-)O;.*TG-^T$:-&5&H3CS48Y99#O
MRX))^]GKCI6]10!AWGA'2+V[^U&.YMIC$L+FSNY;?S$7[JL(V7<!DXSTJVVA
M:<[ZB[6Y+:C"L%T=[?O$52H'7CACR,=:T:* ,AO#.EF]T^\6*:.>PB$$#17$
MB?NQ@A& 8;UR <-FEU7PWIFLW4-U=QSB>)&B$D%Q)"S1L061BC#<I('!]*UJ
M* ,K3_#FE:7)926=KY365HUG;_.QV0EE8KR>>47D\\56F\&Z)-96=H+>:)+.
M222WD@N9(I(S(27PZL&PV3D9Q^0K>HH H:/HNGZ#8_8M,MQ;V_F-)L#%OF8Y
M)Y)[UFW'@?P[=6^KP3:<&CU>59;T"1QYCJ<@Y!^7!YXQR3ZUT-% &+J'A72-
M2FMYIX)4>"$VZFWN)(=T1Q^[;8PW+P.#D5-I_AW2]+DLY+.V,;6=F+& ^8QV
MP@@[>3SRHY//'6M2B@#*?PYI,FF7^FO:!K2_EDEN(R[?.[G+'.<CGGC&.V*I
MIX)T)8+^)X+B?^T(5@NGGNY9'E122H+,Q/&X]*Z&B@"E+I%C/J+W\L >X>V-
MHS%C@Q$Y*XZ=?QINC:-9Z#IR6%CYXMT^XLT[RE!@ *"Y)"@   <"K]% '/CP
M5H2Z?/8"VF^RS3"X$?VJ7$,@8L&B^;]T=Q)^3'6K^D:%8:(DPLXY-\[[YIII
MGEEE;& 6=R6. ,#GCM6C10!@3>"]"GU&2]DM92TDPN)(!<R""248P[1!MA;@
M')'49ZU:N/#>E75MJUO-;%HM6.;U?,8>8=BIZ_+\JJ.,=*U:* ,2_P#"FE:C
MJ#WTBW<-Q(BQRO:WDMOYRCH'\MANQD]>:N:KH]EK-@+.]C9HE=9$*2,CHZG*
MLK*0001U!J_10!A6_@_1+:)XTMI6WW<5\[27$CL\\>W:Y9F))^5?8XYJ>\\-
M:1J']H?:K,2_V@L:W.7;Y_+^X1@_*1U!&#GFM:B@#$M?">CVMK?V_D2W OX_
M)NI+JXDFDE3!&TN[%L $X /&34MCX;TW3Y+&6))WEL8Y(H))[F25E20J6&68
MY^XN,],<8K6HH PYO".BS645K]GDC6&XDNH9(;B2.2.61F9V5U8,,EVR,XP<
M8Q5B#P]IUN]@X2>22Q>22"2>YDE<,ZE6)9F);()ZYQVK4HH IZKI5GK6FS:?
M?Q&2VEQN4.5.00P((((((!!'<5%:Z%86=U]JC25KC[*MH999WD9HU+, 2Q.3
MEF.3SSUK1HH YU_ ^@/#9PBVFCCM+46<8ANI8]T _P"6;E6&]?9L]_4U8_X1
M32%.DF.&:)M)B$%HT5S(A6,;?D8AOG7Y%R&R#CFMJB@"I/IMI<:E::A+%NNK
M19%A?<1M#XW<=#G:.M9\_A+1KBT%N;:1 MU)>))%/)')'-(S,[JZL&7)9N <
M8.,8K;HH RH/#NG0&Q;9/+)8RO-!)/<R2N'92C$LS$MPQ&#D#M5>/P?HL2W"
M+;S>5/=I>-$;F0QK,LGF!D4MA?G^8@  ]\UNT4 9=UX=TF^?46NK-9?[1BCA
MN@S-B14SMXSP1N/(P?R%5T\):4-/N;*7[;<P7.P2"ZOIICA#N4 LQ*X/IC/?
M-;E% $=Q;QW5M+;S+NBE0HZYQE2,$<5EGPOI7VG3+A(9HI=-B$%NT5Q(F(QM
MPC88;U^53ALCBMBB@"I-IMI<:E:ZC+%NNK5)$A?<1M#[=W'0YVKU]*SI_"&B
MW%FEL;:2-8[F2[CDAN)(Y(Y9&9G975@PR6;@''.,8K<HH Q[?PMH]K:VMO%:
MG9;77VQ&:5V<SX(,C,3ESAC]XG]!5W4M-M-6LFL[V+S8&='*[BO*,'7D<\,H
M-6Z* ,>?POI=QJ5WJ#)<)<7<0BN#%=2QK( , E58#<!P&ZCUJ;2="L=%$YM%
MF:6X8/--<3O-)(0,#+N2< < 9P*TJ* , >"]"&I?;A:R[OM'VKR/M,GD>=G/
MF>5NV;L\YQUYZ\U:N/#>E75KJUM-;%HM6;=>KYC#S#L5.N?E^55'&.E:M% &
M==:#IE]<W%Q=6BS/<6GV*7>25>').TC..I//6J$7@K0X].GL6AN9X9_+W?:+
MR:5UV'*;&9BR;2<C:1BN@HH Q8_"VF):BWD^UW*BXBN0UU>2S-YD;!D.YF)
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M,<GRC!.[@CT/%&D>,M8OVT5KK1K6WAUNT>:RV79=E=8Q(!(-H ##.""<8YH
M[>BN4TCQE_;,F@16]GB74;>6>[0OS:"/",#QR?-(3MT)[58U/7=3/B!]%T2Q
MM;BY@M5NKB2[G:)%5F944;58ECL;V '?- '1T5Y=J&J7GC#6/!TD6GVQL+I+
MF62UN;IUQ-&0K@[5(.PYVGN2>G%5]&U^X\/6>LZYJMK8?;KS6I=/BF:]<+N$
MK#:[,GRQHJ<$ D@= 30!ZS17 Q_$2>33IF@L;2]O(M1M[$?9;O,$WG8VLLA7
MC&<$$<$=ZM/XUOK&WU2WU#2X#JUG=6]K%#;W!:*=KC:(_G905&2<Y'&TD9H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUF9%O;5Y@\;*T3/(5C_Y9^6P'3&,8.<TS2;G58]/\.:Y)K>H3S7FL/9S02R
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M#(TE_(EXDNH#RO+#NIB6#;\K+@8YW$KR3FBPN=533]*UU];U"6:;Q ]DT#R
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MHECQN3+'D9!&?J*R'U*31E\2:5<ZCJMQ!!?6D%FRSK]HW3JA\OS6Z*6)Y)R
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MUEI=L+;3[.WM+<'(BMXEC4'Z 8KGD\7RS>-8M&@TNYFLI;%+I+M N,,V-W+
M[,<=,Y[8I_ASQ1;7RV-G+<7$]S=0SSQW$L"Q+(L<Q1EP"0"N5^HY]: -<:#H
MZZH=372K$:@>3="W3S?^^\9_6IQI]D(4A%G;B))?.1!$NU9-Q;>!CAMQ)SUR
M<US\?CNQNH+9]/T[4K^2X@:Y6&WB3>L(8J)#N8##$': 22.U;UAJ=IJ>E6^I
MVLP>SGB$R2'@;",Y.>E &7KGA'2]:CD?[+;6][)+!(]XENIE812I(%+=2#L
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M6]VZ<2+R[,0$$ $0DRS9[@]@3GK@$$QVWCC3I,M=VE]IT36DE[#)=Q*JS0H
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M:#GD@,N?K0 +HFDIJAU-=,LEU!NMT+=1*>WW\9_6K<5O! TK0PQQM,_F2%%
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M[6?(;<1CEL@'/7(KD?&/C=-/TC7X-,M[^:ZL;)V>\MH5>*VE:,M'N).2>5/
M( ()P*ZR"Z6/2([RZE"HL EED;@ ;<DF@"/3=(M],FOIXB[SWUP;B>60@LQP
M%4<=E4*H'H/7)J8Z?9%F8V=N2TPN"?*7F4  /T^]@ 9Z\"L&R\;VE[/;1?V9
MJD O8GEL7GA55NPJ[L)\V0Q7D!PN17#1^+-?G\-6EZ1KWG:MJPMV:..VVPQB
M5QL@R>&*@+EL\J3QU(!ZO)I]E,MRLMG;R+= "X#1*1* ,#=Q\W''-9>F^%=.
MTO5=0NK6""*VO+:&V-G' JQ(L9D/ ''/FG(QV]ZIR>,[+3@\,MOJ5Q;V)C@O
M=0,:%()"%XD(()/S*6V*0,]J2_\ 'VFZ?>:A#)8ZD\6G3+#>W,< ,4&Y58,2
M6R1AQG:"1@D@#!(!LVV@:-9V[V]KI-A!#)&T3QQ6R*K(W52 .0>XJW':V\,S
M3101)*Z*C.J ,57.T$^@R<#MDUD7/BFWAUJ73+?3]0O9+<QBZEM8@R6Y?E0V
M6!)P0<*&P"":@E\:Z?%>O$;6]:SCNQ92:@L:_9TG+!=A.[=]XA20NT'C- %[
M2="CTO4M7U#S?-N=3N!-(Y0+M545$3W  Z^I-6=1T?2]76-=3TZTO5C.Y!<P
M+(%/J-P.*;K&KVNAZ:]]>%S&&5%2-=SR.S!511W8D@"N6U[QV]OX8\02VNG7
M]IK&GV1G%M<QQ[D5@VR7ABK("IS@D\$8H [(6EL)891;Q>9"A2)]@RBG&0I[
M X' ]!Z47=I;7]L]M>6\5Q;R##Q3('5A[@\&L_PWYXT"V>ZDOWE92S'4/+$H
MY[^7\N.X]B*SK+QSIU]<V06SU"*SOY#%9W\L2B"X;!("G=N&0#@LH![4 ;-K
MHNE65M';VFF6<$$4GFQQQ0*JH_3< !@-[]:EDT^RE\[S+.W?SV5Y=T2GS&7&
MTMQR1M&">F!Z5EZ%XIMO$-S<1V=C?K# \D;74T06(NC[&53G)/&<XQCOD$57
MU3Q+!HNKZJ]W<SM;6&EI>R6Z0*0%+R L&SDD[,;3@# YYH U[[1-)U2:*;4-
M,LKN6'_5/<0+(R?0D<59%O +DW(AC$Y01F7:-VT'.W/7&23BL?2?%-MJVJ2:
M=]BO[.X$ N8UNX0GG1$XWK@DCG&0V",CBI-8\1P:3>6]BEG>7]]<(\J6UFBL
MXC7 9R690 "P')Y)XS0!<CT;2X=2?4HM-LTOY!A[I8%$K#W;&3^=1VWA_1;*
MYFN;72+""XF!$LL5LBM(#U#$#)S[UEWGC.UMIC#!I>JWLL5LES<QV\ W6R,"
M5\P,R_-@'Y1EN.E-N/'6G)-;PV-GJ&IR7-DM_$+*$-NA8D;LLP Z=#@\C&3Q
M0!OI8VD9MREK OV9-D&V,#REP!A?[HP ,#T%13Z-I=U8M97&FV<MH[F1H)(%
M9"Q))8J1C)))SZFL:7QSIVW2_L5K?Z@^J6C7=K':P@ED7;G.X@*?G'4@<$9S
M@%R^-=/FT[3;JSMKV\FU'?\ 9[2&-1,=G$FX,P5=IX.3UP.<T ;%OI6G6D=O
M';:?:PI;$F!8X541$@@E0!\N02./6B?2=.N;6>UGT^UEM[A]\T3PJR2-QRP(
MP3P.3Z5C-XVT]K*RFMK6^NKF\EEABL8H@)P\1(D#!F"KM(P23CIC.159?&5T
M_B^PTA-"U 075FUPSO&JO&PD1<L"_P!U=QSP3TQD4 ;&N:#!K/A^31U86T#>
M6%\M!A CJP '3'RXJ:WT+2+2UN+6WTJQAM[G/GPQVZ*DN>NX 8;\:PK/Q?!#
MI5JS&]U2\N[NYAMX8;=$ED\J1U;C<%"J !N+#/'<XJ5_'FEII]O=?9=0:2:]
M;3_LBP9FCN K-L9<XZ+U!(Y!SCD &]?Z98:I:_9=0LK:[M\@^5<1+(N1T.""
M*9+H^F3::--ETZTDL  !:M IB '0;,8_2H-#UVWUZVN)(8+BVEMIVM[BWN5"
MR12  X."0>&4@@D8-9VI>.='TFRU*ZO3/&FG7B6<ZE!NW.%(8#/*[7#9] ?2
M@#4G\/Z+=6$5A<:1836</^JMY+9&C3_=4C _"G7.A:1>V,5C=:58SV<6/+MY
M;=&C3'3"D8%9&L^)K>":XM(;B>":TN[*&:5(%D4F>0 (,D=01D]@P(R>*Q-0
M\:ZE<:/XW2+3KJRETB&<6UV53:K+ KC=\Q^;+9'&,8SSD4 =C/H.CW5G!:7&
ME6,UM;D&&&2W1DC/^RI&!^%3QZ?91&(QV=NAA9WB*Q*-C/G<1QP3DYQUR:QM
M"\5P:M>1Z>]G?VMTUJ+J,W<(03QY"EUP21@D9#!3R.*M:OXBATJ_MK!;*\OK
MRXC>5(+54+"-"H9CO91@%EX!R<\"@"^NG620V\26<"1VQW0*L8 B.",J,?*<
M$CCU-<IIGP]CL9]+$VH"XMM,E,MLHM$25FVLO[R4<OPQS@#)ZYJU;:Y=Q>(O
M$R21W5W!9BT^SVL$8+@NG( X[\G)P/:I8?&U@Y5+BTOK2<7\>GRPSHNZ&61=
MR%BK$;6RH!!/+"@#8T_1M+TGS?[-TVSLO-.9/LT"Q[SZG:!FFW^B:3JISJ.F
M65X< 9N(%DX!)'4'H2<?4UG77C'3K:6[A6&ZGF@O$L5CA0$SSL@DV)D@'"G)
M)( P>>*K3>/--MK 7$UGJ"S_ &X:>]F(0TZ3E-ZJ0&(.1C!!(^8<]< &EK&@
M0ZP^E+*X2WL+M+L0J@P[("$'L 2#_P ! K7KG1XST]+/5I[NWN[-]*@2XN8+
MA%$@1D+# #$$\%>OW@16_#)YL,<FQTWJ&V.,,N1T/O0 ^BBB@ HHHH ****
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M-+:!0"!$5A:/GVR1T[5U59^L:U::':1W%WYK>;*L,4<,9D>21NBJHZG@_D:
M,:'P_J=EXBL-0M9K5H5TV/3[I9"P9=C%@Z8!!ZD8..U8_A[P-JFG:[I.H7TM
MA))8),DURC2//>%UQO<MT/\ L\CDX/:NBE\8Z5!=7,$@O%^R1++<R"TD*P[E
M#*K$#AL$';UYK?H Y+PU9ZOH*:'X=$<4EG9Z>QO;K8V"^0(UC/&3PY(QP-O3
M(S/XKT&_UFXTZ6U:VF@MFD\ZRNY'2*;< %8[ <E<' (P=QZ<&MK3M4M=5BGD
MM69E@N)+9\KC#QL58?F#3["_MM3LTN[1R\#DA6*%<X)!X(!Z@T <3IO@K6-"
MM-#FTZXT^2_TU;N&1)0Z0R13R^9\N,E2I5>.>XSWJUIG@[4;7^R7NKRVEFM=
M9NM2G:-&4.)EF&%!S@YE'!/0=37:T4 <=<^#[N?1M8LEN80]]K":@C'.%19(
MGVGCKB,_F*'\(7;7,\HN8<2>((]6 YXC6-$*]/O90^U=C10!QVI^$+N^NM9E
M2YA47VH6%T@;/RK;F,L#QU/EG'U%2?\ "-:@_C:'6@NGV<4<CF66T:02WD90
MJJ2KC:<9!W$D_*,8KK:* .'L/"&K0:+I>E7%Q9&+3-3CNH9(R^Z2)79L,".&
M^8#C(XZTOB[PAJ7B#4KB2*2RFM9['[,D5ZTF+5\MF5$7AB0P'."-HY[5V]%
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M4S_>\D$1L6W;!\O\63D^QT4 87BS1[W6M*AM[&>-&CN4EDBE=D2X1<YC9EY
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MK-E^'EQ]BTABFFWUSI\MX3!>!O)ECGE,G4 E67Y><'N/>O0Z* .+/A34+/\
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M2H">W[SY?<.U=[110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&!]W.XX/K6K<>)=4;4+;2M.TJUN=2:S%[<![TI!$A8JH601DN6(;'RC@9.*
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M4@ *?PY S9_'&LZE9^&KS1;.SQ>ZG-9W,;WF4=HUE^57$;90F/<' !X QR<
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M9Z/;7IF,G,A<.-N,<?ZOKD]?:@#J**XN^\<W%MX8TS7([/38X;RP2\*7NIB
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MEJP)WGY< $CD'IT/6@#*N_"]YJFD26FI:U)+<":*XMKB&V2+[/)&P96"\YY
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M7H+NVN@3;W$4P'7RW#8_*H8+_P V[NX9('@6WD6-9'=<2[E!^7!R.3CD YH
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MU#7]+TO3I;^ZO(A;1.L;LAW88D # [Y-7#>6JB(FYA E.(\N/G/MZT <Y?\
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MS-2-Z<W5S(RP^5+U+'+-G)X^@X%3_P#"=7C:=IJO#I]G?W-[<V4TMU,1;1/
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MR]C=(K'$5NN&,_\ WP\9Q_M5-=>(GO\ 5[$?9%,":^]A;2"9UR4MY"[D*<,
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M\RYN(=D:[PN3D=STJJ/ ]M*FH_;M4U&_FO;%].$UPZ;X8&SE4VJ!G."68$G
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MD6YEW<ZA,REB,8"(HRW4Y.>..#FK&C>'X])NKN]EO;J_O[L(LUU<[ Q5,[5
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M !:2(X("'@O@#'0<5I^.;*XN?#OVJR@DGO=.N8;ZWBC7+.8W!90.Y9-ZX]Z
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M]L>,\#&<C.,=L$]"\-Q9^/W?2K2ZF^VW8>]6[TYO+AQ#M\Z*XP!T51LRV<G
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M=1744>DFTAMG8(1$I/+@%3@\CC(ZXH [W4?%V@Z9 DT^J6I5IH8?W<RL092
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M110 4444 %%%% %:_L+74[-[2]A$T#E69"2 2K!AT]P#5FBB@ HHHH ****
M"BBB@ HHHH **** "JT5A:PW]Q?1PA;JY1$EDR<NJ;MH_#<WYU9HH **** "
MJLNG6DVHV]_+"K75LCI#(2?D#XW8'3G:.?:K5% $4-M!;F4PPI&97,DA50-[
M8 W'U. !GVJ6BB@ HHHH *JW&G6EW=VEU/"LDUH[/ Q)^1F4J2!TS@D?C5JB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Q-7\,6VJZC%J*WE]8WL<1@,]E*$9XB<[&R"",\@]1S@UMT4
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MZ9K:T^S-A9K;M=7%TP))FN'#.Q)SS@ ?@ *LT4 <-X/\ KI6EZ*VJ7-Y+<V
M,B6C7&^WAF((+J,9SACC)(&3@"M[_A%-+;PW/H+K*]E-))*V7PX=Y3+D,,8(
M<Y'I@5MT4 <W'X*TUHK]=0GO-4DOK;[)+->RAG$/)V+M"A1DYR!G.#G@4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE/%FL^(=$EM9+"'3
M)+6YNX+1//,@</*X3)QQ@$UU=8'BO2[K5;73([1%9K?5+2YDRP&(XY59C^0Z
M4 9,WC&?0_$D6G>(9;:-6TXW)%G!+*6?S2/E !8@(,GCCFMD^(K5[^P:*_LC
MI]S82WH<[MS(NSYU;[H4!^<\\C'>F_V7<_\ "?'5MB_9/[+^S!]PSO\ -W8Q
MUQBN:T;PGJEC:: EU8PSK9:'=V=Q TP"O)(T15,\\$(PSSB@#LM)UNQUN%Y;
M%YF1<<RV\D.01D$;U&0?49%8<WC&2+Q['H?V5#IQ(MGO-QRMV8S*(\=,>6 ?
MJP%.\':?JVF_;X[J*YM], C%A9W5RMQ+#@'>-X)^0_+M!8D8/3.*YV3P%KL_
MAB:Z.KW2:Y)='519 PFW%T'WJN[9OP %3._''IQ0!UVI>,]!TF]>TN[N43(Z
M1.(K6655=\;4+(I 8Y&%)SR.*FC\5:++K$VDQWNZ]@+"9!$^(L+N.]L;5XY&
M2,X.,X->87>H&'7=<O;S,FFQ:S#--IL=_%'(\R+"%Q$8R[D,H/$@#[0<8Z]U
M#X9NYM+\9V4I6!M9N9C!*#G"/;QQACCT(;B@#4TWQ9HFJS-%:7I+"(S@RPO$
M'B'5T+J Z\CYER.1ZTEAXNT/4GD6VO&)2$W'[R"2/?$.KH64;UY'*Y'(]:Y*
MS\'7=_IDUE?:9>VEX-+GLH[R?5FN8T:1 A\M-Q(4X!Y"XP.*GT?PU>>4/MFC
MWL-[;Z?+;1W%QJS7$>YE"D1J6.%.!R0N,#B@#9C^(GA:7:(]4+ET\R(+;RDS
MC('[H;?WA&>0F2.^*O/XMT1=*L]26],MO>$K;>3"\DDI&<A8U4N2,'(QQ@YQ
M6/IOAR_MKCP2\D,8&DZ;);W.&!V.T42@#UY1N16(W@W5[>+2+K[/-,]E=ZD9
M+:TOC;R-'<3ET97! R %RI(^\>XH [";QGX?@LK.[?45,5Z76WV1.S2,IPRA
M0"VX'C;C.<C'%4=2^(&C6-EI-["9KNVU&Z-NKQ02$QXSN+*%)# C&T@'KZ&J
MFG>&9K;4_#UW!I[VD5M->3W4<UWY\BO*N Q8D[B3R<$XS56;PWK-OIXE@LTG
MG@\2R:HMN)E4R0LS]"> </G!QTH [#4-:L-+L(KR[E=(IF5(@L+N[LPR%5%!
M8MC/ &>#Z5S]_P"-[6P\2:=#-*RZ;>:=-<*/LLC3-(LD8"A -_W6<D;<\9[5
MH>)[&34]&ME.DSW<JRK*$M[L036[A3AT?(&03CJ,@GKT.9H.BZ]'KFC:CK3)
M--!I5Q;3R[U+!WFC9 < 9.Q<$@8R#ZT ;,WBS1HM.L[\74D]M>(7@:VMY)RZ
MC&3M120!D9R..]9]YXI+ZMI2Z9-!/I]]IEW>+*!G<8_*V$'T^<Y%8=OH/B;3
MM&T:QCBG>UB-V;JWL[Q8)"[REHF,G]P*6R%.>1P<8IVB^$=7L;7P]'/%&&L=
M*OK6?$H;$DKQE #W!"GF@#3O/%%[:_"JT\3$P+=R65K<2%E_=@R;-W&>!\Q[
MUKV/BW0M02\>"_"K9QB:?SXWAV1G)#_.!E.#\PR..M8E[X<U.;X26GA^**(Z
ME%8VL)C=QLWQ^7N!;T^4UGZQX8UWQ;)K%S=6<6E22Z3_ &?;QM<"3S'\SS"S
M,O1,@*.^"3@=* .PTGQ'I>MS20V,\AEC19&CF@DA8H>C!74$J<'YAD53;Q58
MV U*;5=0M(K>VOA:*R*^48QJP5\C[WS9R.,$=\U3\,Z1+#JSZC=Z1?VET+;R
M!->:J;O(+!BJC<<#(!R<'VJC/X7U.2\NY!"A23Q-;ZBN7',"1Q*3]<H>.O%
M&AJ?Q!T:Q\.7.L6YGNDM[A+:2$02)(CL1PRE=R\'.2 #QZBK]UXOT6SAMY9K
MB<?:(VE2-;29I-@."[1A2RJ/5@!6!KGA?5+V/Q@;:*,MJ#VDEJ&D \PQ*F0?
M3)7'-1ZMHFK7?B2'7_[,OF6>P6UEM+35/L\L#+([ EE8*ZD/SSP1WH Z.Z\8
M:#:36<,FH*TE[$LULL,;RF5&Z,NP'(]^PY/%1CQOX=.H"Q&H@S?:3:']S)L2
M8,5\MGV[58D8 )&>,9R*HZ)X:DTOQ%IUS#9+;6-MHHLUC\[S#$_F!MFX\D8'
M7VKEK"QUG7-)U?1+?3HA93^(IY7U S@>6B7>]LIC<7^3 QQR,D8H [U/%FAR
M:K<::M\#=6V[[0OEOMAVC<=[XVKQSR><''2JK>.=#;3[VZMYYI3:VQN?*-M*
MC21] R!ERZDX&Y00,U0;PI>7>@>,]-<I;R:S<SM;RYS\KPHBEL>ZGCTJKI7A
MNYG\YKS2;VUO!ITMHEQ=:LUT@+A00B[CA25!R0#\HXH VK+QMI%UX?LM7E>>
M%;O:J0&VE:1I"H8JB!=SX'=01P35B7Q?H4.EV^HM?;K>XD,,(CA=Y'D&<H(U
M4ON&TY&,C!S7(R^'=<N=)\+3S:;<1W&BQ-:S6EOJ(BDE4Q(OF)(I ZI]TD9!
M-65\.W^FRZ+J^F:-(9;6YNI+FQFOQ)*_G* 9/,8D%LJ"1GH3S0!O>$?$+>)+
M/4[I9(I((=0EM[=T4C,:A<9SSGDYZ5#;>-M*@TC2Y]2U"%KJ^MC/$MG!,XF
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MDMFE2:9LJJ&,D/R>P*GGIQ7,1^.[?4?$@LM+N(VM5TJXO)#<6\L;*RM&$;#
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M%"+O5E'WR3P3TZ4 ;NIZM8:-:"ZU&ZCMH2X0,Y^\QZ #J3["K:.LD:R(P9&
M*D=P:\IN9M5UY_#*W.LW$<]KXBN;'[3;Q1 3>7'.%FPR, V%*D#Y>6XZ8Z3X
MAVMQ<)X=$&HW-G_Q.($)A6,Y))PWS*>1CCMSR#Q0!UL5[;37D]G',C7%NJ-+
M&#R@;.W/UP?RJ>O,K^WU:+Q+XPN;#7)[22QTRUE++!$[3R+'*1OW*1MX.0H&
M<\$8Q3[KQ'XAUG5%M-.748?+TFVO!_9RVI+2S!CE_/890;<87GKDCB@#T>6:
M.WA>::1(XD4L[NP"J!U))Z"JUEJ^FZDSK8:C:73(,L()E<J/?!XKFO%DE]-\
M']7EU.!8+]]&D:YB4@A)/*.X @D8!SWJK?S:QH'P^UG4_LNE6-Y!8^9;26(+
M<A<Y8,H'IZ]Z .[J"\O+?3[*>\NYEAMH$,DLC=$4#))K@]1UG7/#-WJ\4VK_
M -H%=!FU*(W,*(L4Z-C"[ /D.X<$D\=>:R-3FUN[\)>+9KG4-8N-+70G"C4;
M..W)N"K^9M C5BH 7!Z?,>6[ 'JD5Y;3SRP17$3S1*K21JX+(&SM)'49P<9Z
MXI)KVVM[JWM99D2>Y+"%">7VC)Q]!S7$7-YKLNH^);712INH+;3VA")&LFUB
M_F;688+;0=N_(!_&LZ:XFUS5/"<=EK&H1W"7=[#-<75O$+F%EB.Y"H79N X!
MVD=#S0!Z9-#%<1-%-&DD;##(Z@@_4&D@MX;:(16\,<4:]$C4*!^ K!\&W][>
MZ9>PZA<FZGL=0N+/[0R*K2JCX5F"@#.",X '%8NAZKJ]QX6D\7W&JRS!H+F<
M:4(HQ$NS?M12%W[AMY)8YYX'8 [RBN T[4=:LKOPG<W.N/J4>NY6>V:&)4CS
M TH>+:H8*"N#N+9!]:33/$VIW'A_P/<2W@:YU.],5V=B@RJ(IB1C'&&5>F.E
M 'H%%>2:PVMZO\+_ !-JU[K]QL O8H[:*")4"1S.HR=A8G"X)!'&._)Z'Q%-
MK>@I9SS:MJCZ+;P2/>7]M#;O,K[@0TJ%,&(+D?(N>.?6@#NJ*:DB2#*.K< \
M'UZ4Z@ HHHH **** "F211RA1)&KA6##<,X(Z'ZT^B@ HHHH *8D4<6[RT5-
MS;FVC&3ZGWI]% !1110 4444 -"*'9PH#-C) Y..E.HHH **** "BBB@ J V
M5HUT+IK6$W &!,8QO'X]:GHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!ABC:592BF100KD<@'&0#^ _*GT44 %%%% !1110 4444 %%%% !1
M110 UD5P ZA@"",C.".AIU%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5E:CX:T?5[R.[O["*XF154%\X(!R PSA@"20#GK6K10!GRZ)ID]O?V\MG
M&T5^^^Z0CB5MJKD_@JC\*JWWA'0-2OI+V\TN":XEV^8S _.5&%)&<$@< ]16
MU10!GRZ)IDTLTDEG&SSSQ7,C$?>ECV[&/N-BX^E.U31].UNV2WU.SBNH4?S%
M25<@-@C/UPQ_.KU% &1%X6T.'1YM)33+?[#,V^6)EW;VX.YB>2W YSG@>E6-
M+T;3]&BDCL+<0K(VYSN+,QZ<EB2:OT4 95IX:T:QU)]0MM/B2Z?=F3DXW'+;
M03A<GKC&:AT[PAX>TF[2[L-)MX)XRVR1 <H"""%]!R>!QS6W10!@6O@[0]*E
M^UZ3I5G;7L4;+;R%"5C)7&<9[\ D8)'>H--\&V<?AR'3-82&_D6YENVD"% L
MLDC.2G.5QO('.<5TU% &--X4T*XTR'3I=-B:UAD\V-<G*.<Y8-G<#R><YYIQ
M\+Z(?[/QIL"G3CFT* KY7()QCU(!(/4C-:]% %#5=%T[7+9+?4K5+B*.02(&
MR"K $9!'(."1^)JK>>$M O\ 4?M]UI5O+<_*6=AP^W[NX=&QVR#BMFB@""]L
MK;4;*:RO($GMIT*21.,AE/4&JUEHFFZ?)!):VJQR00M!&^22L98,5R3W(!K0
MHH Q[CPKH=S86]E+IT1@MF9X N5,1.22K Y&<G.#6A96-KIUE'9VD*Q6\8(6
M->@R<G\R2?QJQ10!AVW@[P_:&;[/ID40EC>)E4L%"M]X*,X4'_9Q5O\ L'2M
MZO\ V?;Y%K]BQLX,'_/,CH5]C6C10!B6?A#0+" PVVEPHAEBE(Y)W1MNCY)S
MA3R!T%%WX/\ #U_J$E_=:3;2W4I5GD9?O,, -CIN  &>N.*VZ* ,J/PUH\>K
M_P!JK81"]W%Q*<G#$8+ 9P&(R"0,G)HF\-:-<:3!I4VG026$#K)% RY56!R"
M/Q)K5HH R]4\.Z3K4L4VH6232Q JD@)5PIZC<I!P?3I5?Q!H<VH^%+C0M,DM
M[*.>W-H2\1=8X64H0J@CD \=JW** ,6\\)Z'J+VTE_IT-U+;Q"%'D&24'16_
MO#/.#D9J[:Z1I]E+#+;6L<;P6RVD;+_#"O1![#%7:* ,:Z\)Z%>PB*?3HV02
MRS8#,IW2'=(<@Y^8\D=#1>>$O#^H26TEUI-K(;:(0Q#9@",=$P."H[ Y K9H
MH SX-#TRV\GR;*%?)M19(,9 @&/DY[<"J=KX.\/65I=6EOI-NL%W'Y4T9!8,
MG/R<]%Y/ X%;E% &;:Z!I5GY?D648\N!K92V6_=,VYE.<Y!(SS4.F>%="T:5
MY=/TR"!WC\HL 20G]Q<_=7V&!6Q10!1AT;3H(]/2*TC5=.7;: ?\L1LV8'_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158414961184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COMPASS Pathways plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">33 Broadwick Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">W1F 0DQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">676-6461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, par value of &#163;0.008 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMPS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,621,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001816590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158415268928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 117,103<span></span>
</td>
<td class="nump">$ 143,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income tax</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">50,381<span></span>
</td>
<td class="nump">47,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">167,826<span></span>
</td>
<td class="nump">191,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investment</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">2,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">2,598<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">173,310<span></span>
</td>
<td class="nump">197,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,875<span></span>
</td>
<td class="nump">4,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">6,267<span></span>
</td>
<td class="nump">9,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,254<span></span>
</td>
<td class="nump">15,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,666<span></span>
</td>
<td class="nump">16,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">463,973<span></span>
</td>
<td class="nump">458,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss)</a></td>
<td class="num">(17,445)<span></span>
</td>
<td class="num">(16,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(285,354)<span></span>
</td>
<td class="num">(261,146)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">161,644<span></span>
</td>
<td class="nump">181,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">173,310<span></span>
</td>
<td class="nump">197,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary and deferred shares</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember', window );">Deferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary and deferred shares</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158414823920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share)</a></td>
<td class="nump">&#163; 0.008<span></span>
</td>
<td class="nump">&#163; 0.008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">42,779,485<span></span>
</td>
<td class="nump">42,631,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">42,779,485<span></span>
</td>
<td class="nump">42,631,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">42,779,485<span></span>
</td>
<td class="nump">42,631,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember', window );">Deferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share)</a></td>
<td class="nump">&#163; 21,921.504<span></span>
</td>
<td class="nump">&#163; 21,921.504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_DeferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158413360016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 19,035<span></span>
</td>
<td class="nump">$ 15,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,753<span></span>
</td>
<td class="nump">10,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">31,788<span></span>
</td>
<td class="nump">25,420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS:</a></td>
<td class="num">(31,788)<span></span>
</td>
<td class="num">(25,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>OTHER INCOME, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit', window );">Benefit from R&amp;D tax credit</a></td>
<td class="nump">4,316<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">7,710<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(24,078)<span></span>
</td>
<td class="num">(21,031)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,208)<span></span>
</td>
<td class="num">(21,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(578)<span></span>
</td>
<td class="num">(7,193)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (24,786)<span></span>
</td>
<td class="num">$ (28,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding - basic (in shares)</a></td>
<td class="nump">42,725,863<span></span>
</td>
<td class="nump">42,036,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding - diluted (in shares)</a></td>
<td class="nump">42,725,863<span></span>
</td>
<td class="nump">42,036,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409998832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders&#8217; Equity<br> $ in Thousands</strong></div></th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>ACCUMULATED DEFICIT </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>COMMON STOCK </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Deferred shares </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Deferred shares </div>
<div>COMMON STOCK </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,019,874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 284,412<span></span>
</td>
<td class="nump">$ 444,750<span></span>
</td>
<td class="nump">$ 8,840<span></span>
</td>
<td class="num">$ (169,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">376,158<span></span>
</td>
<td class="nump">376,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,659<span></span>
</td>
<td class="nump">68,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized loss on foreign currency translation</a></td>
<td class="num">(7,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,464,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">259,574<span></span>
</td>
<td class="nump">448,271<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
<td class="num">(190,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 21,921.504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,631,794<span></span>
</td>
<td class="nump">42,631,794,000<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 181,280<span></span>
</td>
<td class="nump">458,825<span></span>
</td>
<td class="num">(16,867)<span></span>
</td>
<td class="num">(261,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares) | shares</a></td>
<td class="nump">3,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,790<span></span>
</td>
<td class="nump">3,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares under ATM offering, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares under ATM facility, net of issuance costs</a></td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares tendered for withholding taxes</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,579<span></span>
</td>
<td class="nump">30,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">4,071<span></span>
</td>
<td class="nump">4,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized loss on foreign currency translation</a></td>
<td class="num">(578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,779,485<span></span>
</td>
<td class="nump">42,779,485,000<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 161,644<span></span>
</td>
<td class="nump">$ 463,973<span></span>
</td>
<td class="num">$ (17,445)<span></span>
</td>
<td class="num">$ (285,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 21,921.504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158412745568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,208)<span></span>
</td>
<td class="num">$ (21,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Non-cash gain on foreign currency remeasurement</a></td>
<td class="num">(2,107)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash share-based compensation</a></td>
<td class="nump">4,071<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expenses</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,484)<span></span>
</td>
<td class="num">(1,386)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred and prepaid tax assets</a></td>
<td class="nump">129<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(478)<span></span>
</td>
<td class="num">(538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(973)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(3,216)<span></span>
</td>
<td class="num">(2,650)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(27,723)<span></span>
</td>
<td class="num">(23,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net of issuance costs</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of tax withholding on stock award</a></td>
<td class="num">(109)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">666<span></span>
</td>
<td class="num">(6,543)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(26,007)<span></span>
</td>
<td class="num">(29,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">143,381<span></span>
</td>
<td class="nump">273,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">117,374<span></span>
</td>
<td class="nump">243,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption', window );">Right&#160;of&#160;use&#160;assets&#160;obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ProceedsFromStockOptionsExercisedNotReceived', window );">Proceeds from exercise of options received and recorded in other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_DeferredOfferingCostsIncludedInAccruedExpenses', window );">Deferred issuance costs included in accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">117,103<span></span>
</td>
<td class="nump">243,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 117,374<span></span>
</td>
<td class="nump">$ 243,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_DeferredOfferingCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included In Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_DeferredOfferingCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ProceedsFromStockOptionsExercisedNotReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised, Not Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ProceedsFromStockOptionsExercisedNotReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use&#160;Assets&#160;Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adoption</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416943856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business</a></td>
<td class="text">Nature of Business <div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMPASS Pathways plc, or the Company, is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has funded its operations primarily with proceeds from the sale of its convertible preferred shares, the issuance of convertible notes, and through the sale of American Depository Shares, or ADSs, in connection with the Company&#8217;s initial public offering, or the IPO, in September 2020, and its May 2021 follow-on offering. On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Sales of the Company&#8217;s ADSs, if any, will be made at market prices. Through March 31, 2023 we sold 157,836 ADSs, resulting in $1.6&#160;million in net proceeds. During the second quarter of 2023, through May 10, 2023, we sold 2,824,202 ADSs, resulting in $26.9&#160;million in net proceeds.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred recurring losses since its inception, including net losses of $24.2 million and $21.2 million for the three months ended March 31, 2023 and 2022, respectively. In addition, as of March&#160;31, 2023, the Company had an accumulated deficit of $285.4 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes the cash and cash equivalents on hand as of March&#160;31, 2023 of $117.1 million, together with the net proceeds from the sale of the Company&#8217;s ADSs, through May 10, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months, including progressing our Phase 3 clinical program, our Phase 2 studies in anorexia nervosa and PTSD and costs associated with operating as a public company. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.  We will need substantial additional funding to complete the development and commercialization of our Phase 3 clinical program, and our Phase 2 studies in anorexia nervosa and PTSD.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Further, changing circumstances, some of which may be beyond our control, such as heightened or fluctuating inflation and interest rates, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. There can be no assurance that additional funding will be available on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial conditions.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Market volatility, instability in the banking system, geopolitical tensions resulting from the ongoing war between Ukraine and Russia, heightened or fluctuating inflation and interest rates and the related impact on U.S., U.K. and global economies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the risk of credit-rating downgrades and economic slowdown or recession in the United States due to debt ceiling and budget deficit concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%"> or efforts to combat inflation or other economic or other factors could adversely impact our operations, financial results and ability to raise additional funding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158517988432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual condensed consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2023, the results of its operations and comprehensive loss for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 28, 2023. The condensed consolidated balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash as of March&#160;31, 2023 and December&#160;31, 2022 represents a collateral deposit for employee credit cards. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:69.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment; however, the Company operates in two geographic regions: the United Kingdom, or UK, and the United States. The Company&#8217;s fixed assets are primarily located in the UK. The Company&#8217;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract Costs, Prepayments and Accruals</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepayments and accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as an expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimates the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 8 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $1.0&#160;million, on the Company&#8217;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#8217;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 10 for right-of-use assets and liabilities recorded during the periods ended March 31, 2023 and 2022 respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#8217;s leases are classified as operating leases.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has historically not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency is the currency of the primary economic environment in which an entity&#8217;s operations are conducted. On January 1, 2023, COMPASS Pathways plc and its wholly owned subsidiary COMPASS Pathfinder Holdings Limited changed their functional currency to the U.S. dollar. COMPASS Pathways plc and COMPASS Pathfinder Holdings Limited have no operating activities and their primary functions are to serve as a financing vehicle to fund the operations of the Company&#8217;s operating entities, to serve as the listing company needed to access U.S. capital markets, and to hold investments.  Therefore, its financing source is the primary indicator of its cash flows and its functional currency. The change in functional currency from the British Pound Sterling is due to a change in the source of the Company&#8217;s financing and cash flows going forward, which will now primarily be U.S. Dollars (&#8220;USD&#8221;).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of COMPASS Pathfinder Holdings Limited&#8217;s wholly owned non-U.S. subsidiary, COMPASS Pathfinder Limited, is British Pound Sterling and the functional currency of its U.S. subsidiary, COMPASS Pathways Inc. is USD. The functional currency of these subsidiaries is the same as the local currency.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The translated balances of monetary and non-monetary assets and liabilities recorded in the reporting entity&#8217;s condensed consolidated financial statements as of the end of the prior reporting period become the new accounting basis for those assets and liabilities in the period of the change. To the extent that the distinct and separable operation has monetary assets and liabilities denominated in the old functional currency, such balances will create transaction gains and losses subsequent to the change in functional currency. The balance recorded in the cumulative translation adjustment account for prior periods is not reversed upon the change in functional currency.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company translates the assets and liabilities of COMPASS Pathfinder Limited into USD at the exchange rate in effect on the balance sheet date. Income and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive (loss)/income.</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &#160;</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of March 31, 2023 and December 31, 2022, the Company has not identified any uncertain tax positions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit from Research and Development Tax Credit </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, in effect through March 31, 2023, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.3% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.7%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#8364;7.5 million which may impact the Company's ability to claim R&amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim. As announced in His Majesty&#8217;s Treasury Autumn Statement 2022, the rates for the SME R&amp;D tax relief regime have been reduced such that for qualifying expenditure from April 1, 2023 the effective credit decreased from 33.3% to 18.6%. For subcontracted expenditure, as there is a restriction to 65% of costs, the effective credit decreased from 21.7% to 12.1%.  New rules were announced in the UK Parliament Finance Act  2023 for an enhanced rate of relief, which would be 27.0% for qualifying expenditure and 17.5% for qualifying subcontracted expenditure. The legislation is not yet final, and therefore the Company is unable to determine whether it would meet the criteria for the enhanced rate of relief until the legislation and more detailed guidance has been published.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. For the three months ended March 31, 2023 and 2022, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div>The Company enters into foreign currency contracts to reduce the risk that its cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying condensed consolidated statements of operations and comprehensive loss as other income, net. The Company did not enter into any contracts during the three-months ended March 31, 2023 and 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158419188384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416172560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text">Accrued Expenses and Other Liabilities<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416172560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary Shares</a></td>
<td class="text">Ordinary Shares<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Sales of the Company&#8217;s ADSs, if any, will be made at market prices. Through March 31, 2023 we sold 157,836 ADSs, resulting in $1.6&#160;million in net proceeds. During the second quarter of 2023, through May 10, 2023, we sold 2,824,202 ADSs, resulting in $26.9&#160;million in net proceeds.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued in total 3,790 ordinary shares to settle share options exercised by employees and non-employees compared to 376,158 in the three months ended March 31, 2022. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, a total of 31,856 restricted share units vested, of which 21,579 were issued and 10,277 were settled.  During the three months ended March 31, 2023, a total of 30,481 ordinary shares were issued in settlement of restricted share units, of which 8,902 were vested and not issued at December 31, 2022 and 21,579 vested and were issued during the three months ended March 31, 2023.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, a total of 68,534 ordinary shares were issued in settlement of restricted share units, of which 57,875 were vested and not issued at December 31, 2021 and 10,659 vested and were issued during the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158498786864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#8217;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company was authorized to issue a total of 1,600,329 ordinary shares underlying outstanding options granted under the 2017 Plan prior to the IPO.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2017 Plan, typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTAyOQ_92763bc4-2b40-44c3-9547-92efbadbe1ef">three</span> or four-year service period with 33.3% and 25% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire 10 years from the date of grant.  Restricted share units granted under the 2017 Plan typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted on June 30, 2020 were subject to 25% vesting upon the earlier occurrence of (i) the one year anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for three years for the remaining 75% of the allocation until vested in full.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted share units granted on June 30, 2020 are subject to 25% vesting upon the earlier of (i) the one year anniversary of the date of grant, or (ii) the first day following the six-month anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is 20% higher than the listing price for at least five consecutive trading days. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Share Purchase Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of 340,053 ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) 510,080 ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in capitalization.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 1, 2021, the Company launched the SIP and the ESPP, through which employees can purchase shares at a discounted price. At the end of six months, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a 15% discount.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Share Option Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s board of directors adopted, and the Company&#8217;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development committee to make equity-based and cash-based incentive awards to the Company&#8217;s officers, employees, directors and other key persons (including consultants).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2020 Plan generally expire 10 years from the date of grant and typically vest over a 4 year service period with 25% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially reserved 2,074,325 of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to 4% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by the compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is 5,460,391 shares as of March 31, 2023, of which 253,084 shares remained available for future grant.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted in 2022 under the 2020 Plan to employees generally expire 10 years from the date of grant. There are three potential vesting conditions for the 2022 grants including: (i) 25% per year over four year service period, (ii) four year service period with 25% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years; and (iii) monthly vesting over four year service period.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, the Company granted options to purchase 2,076,950 and 1,111,569 ordinary shares to employees and non-employees, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Inducement Option Award</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company granted to its new chief executive officer a non-qualified share option to purchase up to 600,000 ordinary shares as an inducement grant. The non-qualified share option has a 10 year term and vests one-fourth on August 1, 2023 and the remaining three-fourths in equal monthly installments over the following 36 months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#8217;s 2020 Plan and the Company&#8217;s standard form of non-qualified share option agreement. <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Restricted Share Units</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s unvested restricted share units during the three months ended March 31, 2023 are as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, there was $4.4 million and $2.6 million of unrecognized compensation cost related to unvested restricted share units, respectively, which is expected to be recognized over a weighted-average period of 3.2 years and 3.0 years, respectively. The exercise price of restricted share units is at a nominal value less than $0.01 per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Share Options</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share options activity for the three months ended March 31, 2023:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was less than $0.1 million and $4.9 million, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s ordinary shares for those share options that had exercise prices lower than the fair value of the Company&#8217;s ordinary shares.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of share options granted was $8.27 and $11.38 per share during the three months ended March 31, 2023, and 2022, respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and 2022, there was $42.3 million and $35.2 million of unrecognized compensation cost related to unvested share options, which is expected to be recognized over a weighted-average period of 3.1 years and 3.4 years, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Option Valuation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the three months ended March 31, 2023, and 2022 were as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying ordinary shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.98</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416959888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,208)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,171)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,725,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,036,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.57)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, and options granted, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share attributable to ordinary shareholders is the same. The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,559,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,442,071</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756,183</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158498786864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use of assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right of use assets</a></td>
<td class="text">Right of use of assets<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York, NY</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a twelve month membership agreement with WeWork for rentable office space.  The membership is cancellable with 90 days&#8217; notice.  This agreement is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#8217;s condensed consolidated balance sheets. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Soho, London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a two-year operating lease with Fora Space Limited commencing on September 1, 2021. The noncancellable term is 24 months and there is no option to extend the lease. The recurring residency fee per month is &#163;136,200, and the Company paid a refundable deposit of &#163;136,200 at the execution of the agreement. Additionally, at the start of each calendar year, the monthly residency fee is subject to an automatic inflation linked increase of the previous year&#8217;s amount.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denmark Hill, London, UK</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into an agreement for a lease with South London and Maudsley NHS Foundation Trust for land and buildings at 5 Windsor Walk, Maudsley Hospital, Denmark Hill, London, UK. The lease commenced on June 21, 2022 and has a contractual term of five years. The rent is &#163;180,000 per year, with no deposit payable, and payment dates occurring once per quarter.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s costs included in its condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through March 31, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the future minimum lease payments due under operating leases as of March 31, 2023, (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:85.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.203%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416258592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of March 31, 2023 or 2022.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#8217;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416234368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Company entered into a two-year operating lease with Fora Space Limited commencing on September 1, 2023. The noncancellable term is 24 months and there is no option to extend the lease. The recurring residency fee per month is &#163;130,000, and the Company paid a refundable deposit of &#163;156,000 at the execution of the agreement. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, through May 10, 2023, under our Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell its ADSs, each representing one ordinary share, we sold 2,824,202 ADSs, resulting in $26.9&#160;million in net proceeds.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158414978096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual condensed consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2023, the results of its operations and comprehensive loss for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023 and 2022.</span></div>The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 28, 2023. The condensed consolidated balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashRestricted cash as of March&#160;31, 2023 and December&#160;31, 2022 represents a collateral deposit for employee credit cards.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment</a></td>
<td class="text">InvestmentThe investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:69.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></div>Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the three months ended March 31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment; however, the Company operates in two geographic regions: the United Kingdom, or UK, and the United States. The Company&#8217;s fixed assets are primarily located in the UK. The Company&#8217;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Research Contract Costs, Prepayments and Accruals</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Contract Costs, Prepayments and Accruals</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepayments and accrual estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as an expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimates the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 8 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $1.0&#160;million, on the Company&#8217;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#8217;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 10 for right-of-use assets and liabilities recorded during the periods ended March 31, 2023 and 2022 respectively.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#8217;s leases are classified as operating leases.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has historically not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency is the currency of the primary economic environment in which an entity&#8217;s operations are conducted. On January 1, 2023, COMPASS Pathways plc and its wholly owned subsidiary COMPASS Pathfinder Holdings Limited changed their functional currency to the U.S. dollar. COMPASS Pathways plc and COMPASS Pathfinder Holdings Limited have no operating activities and their primary functions are to serve as a financing vehicle to fund the operations of the Company&#8217;s operating entities, to serve as the listing company needed to access U.S. capital markets, and to hold investments.  Therefore, its financing source is the primary indicator of its cash flows and its functional currency. The change in functional currency from the British Pound Sterling is due to a change in the source of the Company&#8217;s financing and cash flows going forward, which will now primarily be U.S. Dollars (&#8220;USD&#8221;).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of COMPASS Pathfinder Holdings Limited&#8217;s wholly owned non-U.S. subsidiary, COMPASS Pathfinder Limited, is British Pound Sterling and the functional currency of its U.S. subsidiary, COMPASS Pathways Inc. is USD. The functional currency of these subsidiaries is the same as the local currency.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The translated balances of monetary and non-monetary assets and liabilities recorded in the reporting entity&#8217;s condensed consolidated financial statements as of the end of the prior reporting period become the new accounting basis for those assets and liabilities in the period of the change. To the extent that the distinct and separable operation has monetary assets and liabilities denominated in the old functional currency, such balances will create transaction gains and losses subsequent to the change in functional currency. The balance recorded in the cumulative translation adjustment account for prior periods is not reversed upon the change in functional currency.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company translates the assets and liabilities of COMPASS Pathfinder Limited into USD at the exchange rate in effect on the balance sheet date. Income and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive (loss)/income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &#160;</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of March 31, 2023 and December 31, 2022, the Company has not identified any uncertain tax positions.</span></div>The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock', window );">Benefit from Research and Development Tax Credit</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit from Research and Development Tax Credit </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, in effect through March 31, 2023, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.3% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.7%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#8364;7.5 million which may impact the Company's ability to claim R&amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim. As announced in His Majesty&#8217;s Treasury Autumn Statement 2022, the rates for the SME R&amp;D tax relief regime have been reduced such that for qualifying expenditure from April 1, 2023 the effective credit decreased from 33.3% to 18.6%. For subcontracted expenditure, as there is a restriction to 65% of costs, the effective credit decreased from 21.7% to 12.1%.  New rules were announced in the UK Parliament Finance Act  2023 for an enhanced rate of relief, which would be 27.0% for qualifying expenditure and 17.5% for qualifying subcontracted expenditure. The legislation is not yet final, and therefore the Company is unable to determine whether it would meet the criteria for the enhanced rate of relief until the legislation and more detailed guidance has been published.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. For the three months ended March 31, 2023 and 2022, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares </span></div>outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">DerivativesThe Company enters into foreign currency contracts to reduce the risk that its cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying condensed consolidated statements of operations and comprehensive loss as other income, net.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Benefit From Research And Development Tax Credit, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416204912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:69.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409995888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416206912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158415266176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Share Units Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s unvested restricted share units during the three months ended March 31, 2023 are as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and Outstanding as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share options activity for the three months ended March 31, 2023:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the three months ended March 31, 2023, and 2022 were as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying ordinary shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.98</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416904672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,208)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,171)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,725,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,036,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.57)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,034,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,559,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,442,071</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756,183</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158416173088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use of assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Costs Included in Operating Expenses Related To Right of Use Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s costs included in its condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through March 31, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Due Under Operating Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the future minimum lease payments due under operating leases as of March 31, 2023, (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:85.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.203%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409971424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">31 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfOrdinarySharesConversionRatio', window );">Ordinary share conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,208<span></span>
</td>
<td class="nump">$ 21,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,354<span></span>
</td>
<td class="nump">$ 261,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,103<span></span>
</td>
<td class="nump">$ 243,684<span></span>
</td>
<td class="nump">117,103<span></span>
</td>
<td class="nump">$ 143,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_SaleOfStockMaximumAmountAllowableForSale', window );">Maximum amount of stock that may be sold</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember', window );">At-The-Market Offering | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_NumberOfOrdinarySharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_NumberOfOrdinarySharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_SaleOfStockMaximumAmountAllowableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Allowable For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_SaleOfStockMaximumAmountAllowableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158412747152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409911680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> &#163; in Thousands, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>region</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>region</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>GBP (&#163;) </div>
<div>region</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfGeographicRegions', window );">Number of geographic regions | region</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains</a></td>
<td class="nump">$ 2,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim', window );">Maximum qualifying research and development expenditures with connected parties (in percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember', window );">United Kingdom Research and Development Tax Credit Regime, Small or Medium-Sized Enterprises (SME)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent', window );">Cash rebate percent (in percent)</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable', window );">Total aid claimable (in euros) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims', window );">Cap on payable claims (in GBP) | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember', window );">United Kingdom Research and Development Tax Credit Regime</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent', window );">Cash rebate percent (in percent)</a></td>
<td class="nump">21.70%<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount', window );">Annual offset amount (in euros) | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent', window );">Percentage of taxable profits (in percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_NumberOfGeographicRegions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Geographic Regions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_NumberOfGeographicRegions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expenditures Tax Credit, Connected Parties Maximum Percentage of Total Claim</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Cap on Payable Credit Claims</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Cash Rebate Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Total Aid Claimable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409027392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditCurrent', window );">UK R&amp;D tax credit</a></td>
<td class="nump">$ 18,672<span></span>
</td>
<td class="nump">$ 13,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance premium</a></td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">2,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_PrepaidExpenseResearchAndDevelopmentCurrent', window );">Prepaid research and development</a></td>
<td class="nump">26,775<span></span>
</td>
<td class="nump">28,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT recoverable</a></td>
<td class="nump">1,689<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,490<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 50,381<span></span>
</td>
<td class="nump">$ 47,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_PrepaidExpenseResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_PrepaidExpenseResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158413276928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expense</a></td>
<td class="nump">$ 1,815<span></span>
</td>
<td class="nump">$ 1,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional expenses</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefit costs</a></td>
<td class="nump">2,976<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll tax payable</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">672<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total accrued expenses and other liabilities</a></td>
<td class="nump">$ 6,267<span></span>
</td>
<td class="nump">$ 9,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158412832608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">31 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Oct. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares)</a></td>
<td class="nump">2,824,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember', window );">American Depositary Shares | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_SaleOfStockAmountAuthorized', window );">Amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,790<span></span>
</td>
<td class="nump">376,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued related to vesting of restricted share units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,579<span></span>
</td>
<td class="nump">10,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod', window );">Settled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share units issued in settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested not issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,902<span></span>
</td>
<td class="nump">57,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares | 2022 And 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share units issued in settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_SaleOfStockAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_SaleOfStockAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Restricted Stock Award, Settled In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_VestingPeriodAxis=cmps_A2022And2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_VestingPeriodAxis=cmps_A2022And2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158414890576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2017 Equity Incentive Plan (Details) - 2017 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>day </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares) | shares</a></td>
<td class="nump">1,600,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Options Granted Before June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche two | Grant Date June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche one | Grant Date June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice', window );">Percentage amount closing price is higher than listing price</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days | day</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cmps_OptionsGrantedBeforeJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cmps_OptionsGrantedBeforeJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cmps_GrantDateJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cmps_GrantDateJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409885312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2020 Employee Share Purchase Plan (Details) - Employee stock - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum', window );">Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance', window );">Maximum increase in shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod', window );">Stock plan, offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Saving period (in percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158415084832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2020 Share Option Plan (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,460,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember', window );">Ordinary shares | 2020 Share Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,074,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease', window );">Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076,950<span></span>
</td>
<td class="nump">1,111,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158408882208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - 2022 Inducement Grant Option Award (Details) - 2022 Inducement Grant Option Award - Ordinary shares<br></strong></div></th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158415194896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Share Units (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,076,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested and Outstanding, ending balance (in shares)</a></td>
<td class="nump">4,434,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 8.27<span></span>
</td>
<td class="nump">$ 11.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, ending balance (in dollars per share)</a></td>
<td class="nump">$ 14.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested and Outstanding, beginning balance (in shares)</a></td>
<td class="nump">271,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">175,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(31,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited (in shares)</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested and Outstanding, ending balance (in shares)</a></td>
<td class="nump">407,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 12.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">10.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">12.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">12.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, ending balance (in dollars per share)</a></td>
<td class="nump">$ 11.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition (in years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice', window );">Exercise price (in pound sterling per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409920368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Share Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">7,034,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,034,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,600,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (in shares)</a></td>
<td class="nump">4,434,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,434,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="nump">$ 13.55<span></span>
</td>
<td class="nump">13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">10.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (in dollars per share)</a></td>
<td class="nump">$ 14.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding balance (in years)</a></td>
<td class="text">8 years 7 months 17 days<span></span>
</td>
<td class="text">8 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm', window );">Unvested (in years)</a></td>
<td class="text">9 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 17,648<span></span>
</td>
<td class="nump">$ 13,013<span></span>
</td>
<td class="nump">$ 17,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">15,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, aggregate intrinsic value</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised during the period (less than in 2023)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.27<span></span>
</td>
<td class="nump">$ 11.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost of options</a></td>
<td class="nump">$ 42,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,300<span></span>
</td>
<td class="nump">$ 35,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,790)<span></span>
</td>
<td class="num">(376,158)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,092,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,092,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158417259664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Valuation Assumptions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percent)</a></td>
<td class="nump">87.12%<span></span>
</td>
<td class="nump">80.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percent)</a></td>
<td class="nump">3.47%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="nump">$ 15.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 4,071<span></span>
</td>
<td class="nump">$ 3,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158412571056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 4,071<span></span>
</td>
<td class="nump">$ 3,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="nump">$ 1,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158415000736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,208)<span></span>
</td>
<td class="num">$ (21,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ordinary shareholders - basic</a></td>
<td class="num">(24,208)<span></span>
</td>
<td class="num">(21,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to ordinary shareholders - diluted</a></td>
<td class="num">$ (24,208)<span></span>
</td>
<td class="num">$ (21,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding - basic (in shares)</a></td>
<td class="nump">42,725,863<span></span>
</td>
<td class="nump">42,036,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding - diluted (in shares)</a></td>
<td class="nump">42,725,863<span></span>
</td>
<td class="nump">42,036,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158415146576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,442,071<span></span>
</td>
<td class="nump">4,756,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember', window );">Unvested restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">407,529<span></span>
</td>
<td class="nump">197,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,034,542<span></span>
</td>
<td class="nump">4,559,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409898352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use of assets - Narrative (Details) - GBP (&#163;)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_WeWorkMember', window );">WeWork</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_LeaseCancellationNotificationPeriod', window );">Lease cancellation notification period (in days)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_SohoLondonUKMember', window );">Soho, London, UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeasesNoncancelableTerm', window );">Operating leases, noncancelable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeaseMonthlyPayment', window );">Operating lease, monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 136,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_RefundableLeaseDepositPayments', window );">Refundable lease deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_DenmarkHillLondonUKMember', window );">Denmark Hill, London, UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeaseAnnualPayment', window );">Operating lease, annual payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_LeaseCancellationNotificationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Cancellation Notification Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_LeaseCancellationNotificationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OperatingLeaseAnnualPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OperatingLeaseAnnualPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OperatingLeaseMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OperatingLeaseMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OperatingLeasesNoncancelableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Noncancelable Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OperatingLeasesNoncancelableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_RefundableLeaseDepositPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable Lease Deposit, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_RefundableLeaseDepositPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_WeWorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_WeWorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_SohoLondonUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_SohoLondonUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_DenmarkHillLondonUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_DenmarkHillLondonUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158409879552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">660<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_CashFlowLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (in percent)</a></td>
<td class="nump">6.01%<span></span>
</td>
<td class="nump">4.67%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158408857120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">December 31, 2023</a></td>
<td class="nump">$ 1,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">December 31, 2024</a></td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">December 31, 2025</a></td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">December 31, 2026</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140158413191648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">31 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 10, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeasesNoncancelableTerm', window );">Operating leases, noncancelable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OperatingLeaseMonthlyPayment', window );">Operating lease, monthly payment | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_RefundableLeaseDepositPayments', window );">Refundable lease deposit | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="nump">2,824,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction | $</a></td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OperatingLeaseMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OperatingLeaseMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OperatingLeasesNoncancelableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Noncancelable Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OperatingLeasesNoncancelableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_RefundableLeaseDepositPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable Lease Deposit, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_RefundableLeaseDepositPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>cmps-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmps="http://compasspathways.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmps-20230331.xsd" xlink:type="simple"/>
    <context id="i37033c72113244f3aee8649c4898c51e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib00da7419466450d8612fe7a2961b23e_I20230509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="i152e65e381d441028d0e315d17e7e808_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifca3cadf83964b62a844d82c3b5e7165_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4ba3b4df2464eec920f3e4371cc1421_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i996a9a2f8d294a9f95e96689ead7e84e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied43d7e0b5ea423c95391b44528d3a53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54af68e04565485696634eacfdfb44f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i141ce2dc3cbb40bd99c09099ae6fabbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36576268599e4fd8bf18172064ed862d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i898f890161564fe59100013d33b6fbf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i791c0755a9154956b424d9d20a0f7f01_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a89f22f54c64b9e9b9aab3c0f6d7efb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if70809ae9cce49cfac3b711f0475be91_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i930583009ce145dd84d88be7a117f69a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if9c6df05b14e473ba0b9e00b725c4e39_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic03566c748b444fe94d62e9e28a827ae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i67ebb5874ffc463eae558a0bca081f38_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i15382a1c78b24f7781f909cac2666727_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7765db2674724718901c035cce089b95_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia98b20644358427a878a9249c15fc81e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7cd164da18c74147b770195a655c5b6a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3ecb856e1088469e91d8161b926b64b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e11cf9e5ac74fb2ac41daf1d28be1e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48b92bc0ebd64ca2ac7a3bd9ea558598_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iccea7b15b4b34b7881a38a9aeb5a255d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0a788380d1dd41a192369ee1283627cb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib62e231bc5e04aadaa0e552da9eaa69b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie933ef689fe34ea1857fb293be2148bc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:DeferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iee88fb1648c24d69a547b9473b48ce0b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib62efe8423eb495089400103d98fb87b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idffcb1da5bec4469ab5d69a783ed74e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifb330f455e5841ea8450b766d642b939_I20211008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="i8cc171482c7f4d51822f9ae8848dea3e_D20211008-20211008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iea51b6a765944cd995e3725b1074692b_D20230401-20230510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-05-10</endDate>
        </period>
    </context>
    <context id="ia12a666d1e1c4e28811b0491bb87e477_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i74d151acb50c43c5a8922ab30b91f0da_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia7dc74026a9740bf91b61706f4057936_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i269e60958eaf430baf2c5267c8716c7f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i89200d84b6204258aa19770fb2ce7ef4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifcb5e67ff9464397aed19cb5b9642c90_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i49ac0527569949da8f64c6fe440b8ed9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cmps:UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i72e49c2f29fa4138890d882ae5cb4ab9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cmps:UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i48ff1631256746aeb10f884e312e3153_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie9e6809fbe984861af6f54d5e62599f3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia690ad07e30d41c9b898dec4e27afca1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cmps:VestingPeriodAxis">cmps:A2022And2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2d4eb30a399e4393b48bbd2412557894_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b3c9a2da33a404d81407048dc2c35ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8cae53ddb92e46c3b992b638b4a42023_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idaa046deac9b4142b090bb9346a58d27_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1143bd0e2ad345caa5c640706694c0b4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i40dc657ea5ac431794e05ae7a1ce76d8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i35930be1fdbb4fa798087223a146bcb9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:OptionsGrantedBeforeJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6f0a16794335461d959dba6be9403f37_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i407fd6f5b5ed4bcaafd6554faeeaf095_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1adb7d0ef4fb497d9b87d9bed2778ce5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i00a9c14553ea40949dd06a45c06c9b03_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie31fdecdb0224ff48a4b130a9225404d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i31e66ff9fe5f4627ae22fcc1d62c3001_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i395fbda845a44eac841de73744035c26_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2d15bad6c8da46cf885b153b00184437_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie0831ccc811b4e5d84580b833bf10c0e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9aa096c9847d432ebe62c81328b458a2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3183dfe431c04796b01b1c6fdb1a0756_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i338fadaff380485fbfe31f0080cdd810_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iea26013103954eadb8a7947d75c821d7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i837240d0e61b4f5780239e38d5361ef5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i696b4083af51453a8c2cfb18cfdb4482_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i15ccc93511924535a1cde0fc5143bb33_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="ia22f0d118f1942caa4258c79bae792fb_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ie8ab588a8f374a63b091c9535ea47d6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia7cedba3e82645e49ca80bcc90a72a68_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia91e30a56bc9415dbd1e86b1d6ec64dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab7fb606ccca48e58144d35f683e689d_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56c06e81a4384be9a4547b9d54649e6c_D20230331-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6c1c0a2584554db98438e2f27622af72_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i478445e4a46e43758c8383eb32aaf0ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5872a113b2294faaad1b68db7ae836e2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4b25b7dbd74c4562b936a90dfd191b50_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice52714f9f134f59b22998dd73137b2a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id60ff16effaf4307b5d9f1c7ce5bc358_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1623488c9f64721a60c4349e61ce8bf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie2b773ca49914d34bba229e76da492dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i73ea83c879704be889d92560678ef374_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i122471b5c0c34e05bdaaf376bf6de99c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibbeae02a508346edb94df36fd8e95a81_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:WeWorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="iba372f6eca8f430eb43a67755847815d_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:WeWorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i7678bc3cc61d4f73b03996330cea7a9f_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="id87803bd77d841e3917a974e88083e5a_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i33bec60d253644c1918ad73a71213b08_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:SohoLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8636ff5e270740d08068434308a1c41a_I20220621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:DenmarkHillLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="iccc7b27ad5a34f7986912f9169f8eac5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:DenmarkHillLondonUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd439c7411164a75bab3f2705e3ffb57_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="i4c4ad1b7be0048e289dcf0230cc72a31_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="region">
        <measure>cmps:region</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="day">
        <measure>cmps:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl8yLTItMS0xLTE0MDE2Mg_69a68532-c599-4880-b1fd-8865be75f7dd">0001816590</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl8zLTItMS0xLTE0MDE2Mg_ed037f94-f695-41d2-bf0e-39ea043e770a">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl80LTItMS0xLTE0MDE2Mg_b91d4dba-c051-4db1-b84b-9a27d02e49bd">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl81LTItMS0xLTE0MDE2Mg_07ac0ace-e7e2-416b-8fef-cc5278b78af5">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80L2ZyYWc6Mzk0ZDVkODhiY2FhNGUxMWExZmJhN2VhOThlZDJhYjgvdGFibGU6MjAyMGI5ODk4MmMwNDBkY2E1MjZmMzY2YTVkYTRkN2IvdGFibGVyYW5nZToyMDIwYjk4OTgyYzA0MGRjYTUyNmYzNjZhNWRhNGQ3Yl82LTItMS0xLTE0MDE2Mg_5b8f7f34-db2a-48f3-8c53-a84ac9b89c69">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="idaa046deac9b4142b090bb9346a58d27_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTAyOQ_92763bc4-2b40-44c3-9547-92efbadbe1ef">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjM4_6c3bfbad-12a4-4622-b030-f0c788460c21">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjMx_caded53f-d0be-4e8d-8dca-fbcadc8f23e6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjg_e3ae8d84-d2de-4a97-a1d6-d4f90b2e4468">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjM5_5e5c018f-ef4a-46d8-b7ec-8d5181c30477">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjQw_e2f2db37-0237-46b9-9c79-ac666023e205">001-39522</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjI4_761aac2a-3467-4f98-82bf-b63d6b4e7956">COMPASS Pathways plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6OTA0ZmE3MTViOWY5NDNhM2E5ZTk0YmJlNmM3YzYzMTEvdGFibGVyYW5nZTo5MDRmYTcxNWI5Zjk0M2EzYTllOTRiYmU2YzdjNjMxMV8wLTAtMS0xLTE0MDE2Mg_ff4a8f21-6e8c-4597-b0bf-0cd5ea2ef22d">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjUw_9efe6725-1187-4d61-a612-62805562f91f">33 Broadwick Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjM0_4b04472c-a6db-4732-aaa7-9ba1cee6e340">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjQ2_2b958642-43a4-4d43-b4ad-14a1c60a81fe">W1F 0DQ</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjQy_ae1ca032-1c5b-4543-a1aa-dedf49be2a92">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjI5_c6a4ff9e-00bb-4da3-8b72-d358be925787">716</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8zODQ4MjkwNjk5NTI2_ae5206dc-5187-4816-9cf6-9de892b0fbf0">676-6461</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NDhhMzk2ZWZkODEwNGFmOGE2YmIyMDM2ODYzMzFlOGYvdGFibGVyYW5nZTo0OGEzOTZlZmQ4MTA0YWY4YTZiYjIwMzY4NjMzMWU4Zl8xLTAtMS0xLTE0MDE2Mg_5ef50bd6-cd57-4bbd-b1f9-b28def7ab30d">American Depositary Shares, each representing one ordinary share, par value of &#xa3;0.008 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NDhhMzk2ZWZkODEwNGFmOGE2YmIyMDM2ODYzMzFlOGYvdGFibGVyYW5nZTo0OGEzOTZlZmQ4MTA0YWY4YTZiYjIwMzY4NjMzMWU4Zl8xLTItMS0xLTE0MDE2Mg_7df6d9b3-26ef-471d-9d1c-1355355a19e6">CMPS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NDhhMzk2ZWZkODEwNGFmOGE2YmIyMDM2ODYzMzFlOGYvdGFibGVyYW5nZTo0OGEzOTZlZmQ4MTA0YWY4YTZiYjIwMzY4NjMzMWU4Zl8xLTQtMS0xLTE0MDE2Mg_6c6c404c-ca71-4b8f-b9e9-c07795c2f493">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjM2_43e5b795-df58-460f-9dc1-30732b72936d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjQz_7a9a0c1e-71b8-476f-8f6f-cc9bdbc31454">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NTdiNTk3ZTUzYzhiNDI2MDg4N2E0M2E1MGVmNTkwNDUvdGFibGVyYW5nZTo1N2I1OTdlNTNjOGI0MjYwODg3YTQzYTUwZWY1OTA0NV8xLTAtMS0xLTE0OTMzNg_b1dfa2d4-e2ab-43fb-a5b7-8928e6a2b433">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NTdiNTk3ZTUzYzhiNDI2MDg4N2E0M2E1MGVmNTkwNDUvdGFibGVyYW5nZTo1N2I1OTdlNTNjOGI0MjYwODg3YTQzYTUwZWY1OTA0NV8xLTMtMS0xLTE0MDE2Mg_eb661e9c-12bf-49e4-99d6-71e13415702f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGFibGU6NTdiNTk3ZTUzYzhiNDI2MDg4N2E0M2E1MGVmNTkwNDUvdGFibGVyYW5nZTo1N2I1OTdlNTNjOGI0MjYwODg3YTQzYTUwZWY1OTA0NV8yLTMtMS0xLTE0MDE2Mg_6a0f3b74-ef2a-457f-8d7e-d244a29bd40e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMjMw_aea3f5b0-562e-4da0-96da-4e4e7391daa5">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib00da7419466450d8612fe7a2961b23e_I20230509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8xL2ZyYWc6YTk2ZDJjNDU0NDNjNGQ3YWI0YTRjZWIyYWUwM2Y3MTEvdGV4dHJlZ2lvbjphOTZkMmM0NTQ0M2M0ZDdhYjRhNGNlYjJhZTAzZjcxMV8yMTY3_baa58697-5b74-46d7-ab01-64b2c2ec9d5f"
      unitRef="shares">45621678</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNC0xLTEtMS0xNDAxNjI_445529c6-08dd-4561-9205-319857d20692"
      unitRef="usd">117103000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNC0zLTEtMS0xNDAxNjI_008743f6-fb8b-43bb-91c0-d75818c8e830"
      unitRef="usd">143206000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNS0xLTEtMS0xNDAxNjI_ab246577-61b6-4838-b2af-ae6a69883b0f"
      unitRef="usd">271000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNS0zLTEtMS0xNDAxNjI_5ed5293b-f46f-40d4-8d4e-5bda1d8fc1a5"
      unitRef="usd">175000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidTaxes
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNi0xLTEtMS0xNDAxNjI_f8def8a1-ce56-4028-8851-ec9cc19b82fd"
      unitRef="usd">71000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNi0zLTEtMS0xNDAxNjI_019c1579-28b9-4ca4-9127-e44b55785718"
      unitRef="usd">575000</us-gaap:PrepaidTaxes>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNy0xLTEtMS0xNDAxNjI_5968e97c-824f-4b48-9727-c76ac301b962"
      unitRef="usd">50381000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfNy0zLTEtMS0xNDAxNjI_40e4c1ba-9866-4805-8556-2ad455df0d47"
      unitRef="usd">47695000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfOC0xLTEtMS0xNDAxNjI_4d0afed1-ca05-4f4e-996b-24571a4b5871"
      unitRef="usd">167826000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfOC0zLTEtMS0xNDAxNjI_33e94828-9b3c-44a9-aa51-dd5e74fa0752"
      unitRef="usd">191651000</us-gaap:AssetsCurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTAtMS0xLTEtMTQwMTYy_3300d9d2-9961-42b2-91e4-c41d99ff83c1"
      unitRef="usd">469000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTAtMy0xLTEtMTQwMTYy_582c46ec-3735-4750-a552-b00703149907"
      unitRef="usd">469000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTEtMS0xLTEtMTQwMTYy_0dd0d231-d33b-4bc2-81fc-d8a1494e85c7"
      unitRef="usd">612000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTEtMy0xLTEtMTQwMTYy_26693bfb-8f87-4742-9c87-64415849c469"
      unitRef="usd">617000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTItMS0xLTEtMTQwMTYy_723ae5df-6bdb-43fd-a29e-6fd5437c3dd3"
      unitRef="usd">1593000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTItMy0xLTEtMTQwMTYy_8b9f5e42-14fd-4146-bfe2-da6e2078e879"
      unitRef="usd">2006000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTMtMS0xLTEtMTQwMTYy_235ebb51-1c07-4449-8ac9-d07f278650ba"
      unitRef="usd">2598000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTMtMy0xLTEtMTQwMTYy_e7868d7e-caa3-4600-b17a-81dd81820578"
      unitRef="usd">2224000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTQtMS0xLTEtMTQwMTYy_08c3d2b6-027f-47b9-b940-621356f8a163"
      unitRef="usd">212000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTQtMy0xLTEtMTQwMTYy_1062c5ad-52d4-4e61-9da4-758dbe2313f6"
      unitRef="usd">327000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTUtMS0xLTEtMTQwMTYy_40fe7166-0e86-4432-a7e4-eae31191b06d"
      unitRef="usd">173310000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTUtMy0xLTEtMTQwMTYy_d6eb80fa-584c-47c4-b669-986dec8d90fd"
      unitRef="usd">197294000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTgtMS0xLTEtMTQwMTYy_4516780c-3414-4a44-96fa-da4a905306e9"
      unitRef="usd">3875000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTgtMy0xLTEtMTQwMTYy_bd677761-1360-4ca9-b3f1-839d5e430e44"
      unitRef="usd">4761000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTktMS0xLTEtMTQwMTYy_4f8952f9-8613-4ae2-963d-a09ee2599e1f"
      unitRef="usd">6267000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMTktMy0xLTEtMTQwMTYy_c057f62b-a25e-4bf3-8697-7cf1d5195ac4"
      unitRef="usd">9325000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjAtMS0xLTEtMTQwMTYy_f60af427-5ce8-465e-8c00-3891b5ede858"
      unitRef="usd">1112000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjAtMy0xLTEtMTQwMTYy_a8e841e1-cde0-42a1-8ea2-9278a1638c91"
      unitRef="usd">1510000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjEtMS0xLTEtMTQwMTYy_4e8640f8-facf-4d9d-bb4f-718a0d2017ae"
      unitRef="usd">11254000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjEtMy0xLTEtMTQwMTYy_569ca36c-61ef-4dd4-9447-1ecbc3e84b16"
      unitRef="usd">15596000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjMtMS0xLTEtMTQwMTYy_b3182dca-fad9-4df0-8efc-362eaa260f25"
      unitRef="usd">412000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjMtMy0xLTEtMTQwMTYy_a2fa5c9b-7042-4a43-a3a2-99feb200677e"
      unitRef="usd">418000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjQtMS0xLTEtMTQwMTYy_0dbe0e14-c8a4-40f5-8aca-9ce301f3fb4c"
      unitRef="usd">11666000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjQtMy0xLTEtMTQwMTYy_79e6383d-233a-43f4-8b59-29199a71e4ad"
      unitRef="usd">16014000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjYtMS0xLTEtMTQwMTYy_fc304270-5273-4eb8-86a8-532df4c912df"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjYtMy0xLTEtMTQwMTYy_774e33dd-848f-47e7-92da-e87afddfe584"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMjI_1ad7058a-e391-4ecd-9b0e-6d82c5708183"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMjI_95f530b0-04b4-4c77-9c29-6e97836a6bf1"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMzY_34f2783c-721e-408d-ad82-f43fa45212c3"
      unitRef="shares">42779485</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMzY_765a2d62-d31a-4205-b9f7-f2155dbfdeb4"
      unitRef="shares">42779485</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfMzY_c02c65a0-af91-4b10-98b0-d7607d57dc85"
      unitRef="shares">42779485</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfNDM_33459943-9046-4258-97f4-b0b72967edb6"
      unitRef="shares">42631794</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfNDM_b37e8693-bcc1-40a1-a389-e3d6de049f8e"
      unitRef="shares">42631794</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMC0xLTEtMTQwMTYyL3RleHRyZWdpb246ZjYxNmUxOTJmYTlkNDcyNzlhZDQzNGM2YWI3N2U5NmRfNDM_f17858b9-c56b-451f-813e-edae3b7fca60"
      unitRef="shares">42631794</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMS0xLTEtMTQwMTYy_d478c260-8817-423d-a38c-4abb66db7b02"
      unitRef="usd">442000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjgtMy0xLTEtMTQwMTYy_d81e7ffc-3f8e-48e2-bdb9-486ade6c5c30"
      unitRef="usd">440000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMjI_8bd09ef8-207d-4908-9052-a361f9d85713"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMjI_fd12dd69-fd6b-4186-ad74-8b96c3024266"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_004cd51f-5225-48f2-99b6-c6a96c7d5b07"
      unitRef="shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_3f3b95bb-e273-4da7-9282-20a8acb8fb81"
      unitRef="shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_690ba02a-b06d-4a23-bab5-57aad2a0d8bb"
      unitRef="shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_c8bb65d8-40db-4d4b-9ced-dbcdb23a5935"
      unitRef="shares">1</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_df09192a-d6ae-4a7f-9309-f79d98239f4f"
      unitRef="shares">1</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMC0xLTEtMTQwMTYyL3RleHRyZWdpb246NjEyNjkzY2U1NmU1NDIyMDk0MGIxZDNlYzk2Njk4ZjlfMzY_ff5da8ef-8b50-4b19-bf94-01d5161acd93"
      unitRef="shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMS0xLTEtMTQwMTYy_df19d582-cd9d-4b1d-9bca-4da71b7028ee"
      unitRef="usd">28000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMjktMy0xLTEtMTQwMTYy_b42cd473-6438-44c4-90ce-3198cbe03788"
      unitRef="usd">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzAtMS0xLTEtMTQwMTYy_216549e3-274c-49ff-9ee7-1f51d9652b48"
      unitRef="usd">463973000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzAtMy0xLTEtMTQwMTYy_dcad0306-757f-4432-9cde-d9467d998975"
      unitRef="usd">458825000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzEtMS0xLTEtMTQwMTYy_bc3edaab-4342-464f-98b9-3142cac8bda7"
      unitRef="usd">-17445000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzEtMy0xLTEtMTQwMTYy_1b979236-b9f8-4875-b9db-a9d23e98732c"
      unitRef="usd">-16867000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzItMS0xLTEtMTQwMTYy_85c1d3c9-ea25-44fe-a36f-079763ada458"
      unitRef="usd">-285354000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzItMy0xLTEtMTQwMTYy_b97a05bd-8bf3-4536-9d26-75ae3913164b"
      unitRef="usd">-261146000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzMtMS0xLTEtMTQwMTYy_33d269eb-bca4-4237-9d29-bc0ccf03fe85"
      unitRef="usd">161644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzMtMy0xLTEtMTQwMTYy_61facf68-63e1-4123-8ebc-c3f599648f87"
      unitRef="usd">181280000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzQtMS0xLTEtMTQwMTYy_0dd8582a-4db3-4b14-b4d4-a647390237ce"
      unitRef="usd">173310000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yNS9mcmFnOjgzNmIxYTc4YWVlMDQ1MWE5YWFiZjQyNDlmZGMyZDk3L3RhYmxlOjI5NjNjZjcxM2I5MDQ4NTRiODQ5OTUwZWEzNTM2YWYzL3RhYmxlcmFuZ2U6Mjk2M2NmNzEzYjkwNDg1NGI4NDk5NTBlYTM1MzZhZjNfMzQtMy0xLTEtMTQwMTYy_ed3bca0c-6354-4012-a7fa-5909dfd61725"
      unitRef="usd">197294000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMy0xLTEtMS0xNDAxNjI_c6ad9e98-0460-4535-83e3-4d559323de1b"
      unitRef="usd">19035000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMy0zLTEtMS0xNDAxNjI_5839b829-3f24-4bb9-94c5-5834210344de"
      unitRef="usd">15362000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNC0xLTEtMS0xNDAxNjI_010819a8-3063-4bf8-a233-41645c6b0d3a"
      unitRef="usd">12753000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNC0zLTEtMS0xNDAxNjI_4db96392-5894-44a0-b023-ec60dd8b38f6"
      unitRef="usd">10058000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNS0xLTEtMS0xNDAxNjI_8c7aef83-b6ef-4664-92b0-2328c716529f"
      unitRef="usd">31788000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNS0zLTEtMS0xNDAxNjI_f46731bc-c972-4994-8629-5fe4b9ae8183"
      unitRef="usd">25420000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNi0xLTEtMS0xNDAxNjI_0e434ee9-b0db-44a3-a190-5628a60d18c7"
      unitRef="usd">-31788000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfNi0zLTEtMS0xNDAxNjI_f3d3f1e4-117f-4c82-8832-ea92c310498c"
      unitRef="usd">-25420000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfOC0xLTEtMS0xNDAxNjI_63e5bb39-b4d9-4d16-b0ca-59841bc61357"
      unitRef="usd">709000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfOC0zLTEtMS0xNDAxNjI_a07b89d1-52c5-4af5-8104-359cd632d541"
      unitRef="usd">134000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfOS0xLTEtMS0xNDAxNjI_8a49caf1-795f-4e4c-ab57-33b47e2fd5e0"
      unitRef="usd">2685000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfOS0zLTEtMS0xNDAxNjI_3cae0c2b-a212-4438-a4f1-6e0bf27ff7cf"
      unitRef="usd">1333000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTAtMS0xLTEtMTQwMTYy_ea40cad1-b858-475d-a6a8-2e0c721fa292"
      unitRef="usd">-4316000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTAtMy0xLTEtMTQwMTYy_f52fb8c6-1cb1-4fa0-aa1e-6e2b3aa9b7fe"
      unitRef="usd">-2922000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTEtMS0xLTEtMTQwMTYy_c6719d71-7cc5-4dbe-8bc3-ab4693e1d8a5"
      unitRef="usd">7710000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTEtMy0xLTEtMTQwMTYy_a096731f-da2c-48cd-85f9-cda77f2842da"
      unitRef="usd">4389000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTItMS0xLTEtMTQwMTYy_b4572873-561e-41f0-b867-0afcd0e47e02"
      unitRef="usd">-24078000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTItMy0xLTEtMTQwMTYy_a962fbd0-2dd5-442f-8d33-a7db3011babf"
      unitRef="usd">-21031000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTMtMS0xLTEtMTQwMTYy_9f8fcd99-7d42-4de0-9ff1-7334bc57e969"
      unitRef="usd">130000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTMtMy0xLTEtMTQwMTYy_dc36a0e9-f84b-4393-a75f-df76d6516dc4"
      unitRef="usd">140000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTQtMS0xLTEtMTQwMTYy_98cacd09-89e1-417a-adee-7fb358725d0d"
      unitRef="usd">-24208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTQtMy0xLTEtMTQwMTYy_ddaf53b1-b992-44cb-bfc8-b42d3b802004"
      unitRef="usd">-21171000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTYtMS0xLTEtMTQwMTYy_1c59ced8-1fb8-4faf-a1ca-b8e092850684"
      unitRef="usd">-578000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTYtMy0xLTEtMTQwMTYy_ea34f858-0d3d-4e4a-a8be-c1b8bdbb3869"
      unitRef="usd">-7193000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTctMS0xLTEtMTQwMTYy_92b0cddf-27f9-4cf8-9da4-44cd5a5baf42"
      unitRef="usd">-24786000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTctMy0xLTEtMTQwMTYy_9bf16778-14da-4d55-a85a-27f4861dcd86"
      unitRef="usd">-28364000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTgtMS0xLTEtMTQwMTYy_65ed4d81-e9a8-4f0c-9400-030f4e4232ba"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTgtMS0xLTEtMTQwMTYy_851f2bf9-fffc-4e95-8137-218db3411fe0"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTgtMy0xLTEtMTQwMTYy_e708671b-3f96-4736-9ec4-db1e696d8f83"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTgtMy0xLTEtMTQwMTYy_ece6acf3-9b79-4a35-a26d-6f603f3d465e"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTktMS0xLTEtMTQwMTYy_0e4b51d0-430b-44ab-82dd-fbf6796d6e76"
      unitRef="shares">42725863</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTktMS0xLTEtMTQwMTYy_2f2f64a2-a831-492c-bf73-c0e69ff3683d"
      unitRef="shares">42725863</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTktMy0xLTEtMTQwMTYy_0ea6bd18-6817-41d3-8ba4-ea56cd9312ca"
      unitRef="shares">42036563</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8yOC9mcmFnOjI5NzU4ZWVjZTZmNjQxM2JiZTI5NGQ0MTA0ZTRhN2RlL3RhYmxlOjJjZjMxNjI5MWI5ODQ3ZDE5Y2EyNDVkYmFkNzZjMzBjL3RhYmxlcmFuZ2U6MmNmMzE2MjkxYjk4NDdkMTljYTI0NWRiYWQ3NmMzMGNfMTktMy0xLTEtMTQwMTYy_ce984243-3117-41b5-9ab7-786e44f48463"
      unitRef="shares">42036563</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iba4de34994aa4f5089e7fdc27e2ce29e_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjUtMS0xLTEtMTQwMTYyL3RleHRyZWdpb246MDgyMGQwOWI2NWJkNDEzOGE4MzYxZGRjOTA5OTU5YThfMjE_1ad7058a-e391-4ecd-9b0e-6d82c5708183"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i62e2d9d6e3c441adb9a1ec3449ef9716_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjUtMS0xLTEtMTQwMTYyL3RleHRyZWdpb246MDgyMGQwOWI2NWJkNDEzOGE4MzYxZGRjOTA5OTU5YThfMjE_95f530b0-04b4-4c77-9c29-6e97836a6bf1"
      unitRef="gbpPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic4ba3b4df2464eec920f3e4371cc1421_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjYtNS0xLTEtMTQwMTYyL3RleHRyZWdpb246YzA0OTk0NTNjZWRlNDkyZmE0Y2UyNGViMmNlMTc0MWNfNQ_8bd09ef8-207d-4908-9052-a361f9d85713"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i29fb4e8b380a46d69fb6c105ae7c01d8_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjYtNS0xLTEtMTQwMTYyL3RleHRyZWdpb246YzA0OTk0NTNjZWRlNDkyZmE0Y2UyNGViMmNlMTc0MWNfNQ_fd12dd69-fd6b-4186-ad74-8b96c3024266"
      unitRef="gbpPerShare">21921.504</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i996a9a2f8d294a9f95e96689ead7e84e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMS0xLTEtMTQwMTYy_b457a6b1-e2a0-4a40-a62d-6116fd7790a2"
      unitRef="shares">42019874000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i996a9a2f8d294a9f95e96689ead7e84e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMy0xLTEtMTQwMTYy_73845165-8442-4835-a94c-09a1c25e9e29"
      unitRef="usd">435000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ied43d7e0b5ea423c95391b44528d3a53_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtNS0xLTEtMTQwMTYy_1d8afc90-0d9c-4cee-aec4-d600c37cb481"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ied43d7e0b5ea423c95391b44528d3a53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtNy0xLTEtMTQwMTYy_a038545a-e96f-4597-84b1-ab12511b60b8"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54af68e04565485696634eacfdfb44f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtOS0xLTEtMTQwMTYy_61faf2fe-e281-4015-9a5c-832994c16de8"
      unitRef="usd">444750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i141ce2dc3cbb40bd99c09099ae6fabbf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMTEtMS0xLTE0MDE2Mg_690e923d-0b9e-405b-a54f-9ab8fa064ab6"
      unitRef="usd">8840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36576268599e4fd8bf18172064ed862d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMTMtMS0xLTE0MDE2Mg_5ed18c81-d53b-4724-84f5-aef0284b3f79"
      unitRef="usd">-169641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i898f890161564fe59100013d33b6fbf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjgtMTUtMS0xLTE0MDE2Mg_c581b0ee-2bb8-4089-ba56-3f8ae130e072"
      unitRef="usd">284412000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjktMS0xLTEtMTQwMTYy_7ec75267-e69c-458f-93a8-3a3ba97c6e35"
      unitRef="shares">376158000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjktMy0xLTEtMTQwMTYy_8da949fc-0f1b-4116-b553-45ed81e8b3c5"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i791c0755a9154956b424d9d20a0f7f01_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjktOS0xLTEtMTQwMTYy_45ee7713-4fee-4b9f-a289-fcdea8247300"
      unitRef="usd">393000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMjktMTUtMS0xLTE0MDE2Mg_aca62236-34b7-47e9-be79-d02ecaa195ab"
      unitRef="usd">397000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzAtMS0xLTEtMTQwMTYy_d92dc5a2-4962-4c3f-ae1c-1405a4d77677"
      unitRef="shares">68534000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ifa2305935fd54d678e30543b7ad745c8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzAtMy0xLTEtMTQwMTYy_06497bb7-cb74-478e-9ef7-9a5af9f10f0d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzAtMTUtMS0xLTE0MDE2Mg_ba3f1272-c202-4c47-bcbe-bc27fac9bfbc"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i791c0755a9154956b424d9d20a0f7f01_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzEtOS0xLTEtMTQwMTYy_1f82b9e2-5d42-4161-aa0e-f7677ff51738"
      unitRef="usd">3128000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzEtMTUtMS0xLTE0MDE2Mg_80b7b20a-339e-4f94-b6bb-aef3efcaa504"
      unitRef="usd">3128000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i4a89f22f54c64b9e9b9aab3c0f6d7efb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzItMTEtMS0xLTE0MDE2Mg_b5004e8f-001b-4c59-95d9-5baadc9f8d2b"
      unitRef="usd">-7193000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzItMTUtMS0xLTE0MDE2Mg_3e864b6d-1707-4e15-8bb9-3e1294fa5bce"
      unitRef="usd">-7193000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="if70809ae9cce49cfac3b711f0475be91_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzMtMTMtMS0xLTE0MDE2Mg_4f24c92b-abe6-42e1-b86f-24a4bf45953e"
      unitRef="usd">-21171000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzMtMTUtMS0xLTE0MDE2Mg_343ea59a-ae21-4345-a9be-0798706b9af1"
      unitRef="usd">-21171000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i930583009ce145dd84d88be7a117f69a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMS0xLTEtMTQwMTYy_3d6090b0-a368-4bb7-b5d1-dbf935a79124"
      unitRef="shares">42464566000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i930583009ce145dd84d88be7a117f69a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMy0xLTEtMTQwMTYy_525637fb-b782-42eb-be81-52d18121cba8"
      unitRef="usd">440000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if9c6df05b14e473ba0b9e00b725c4e39_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtNS0xLTEtMTQwMTYy_dbfc3a31-5770-4e61-9dd8-599bedf5833b"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if9c6df05b14e473ba0b9e00b725c4e39_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtNy0xLTEtMTQwMTYy_09e07689-e285-41db-9a16-ae7408b33aee"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic03566c748b444fe94d62e9e28a827ae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtOS0xLTEtMTQwMTYy_b7b5659e-f5a7-46bb-9feb-7b063f1c0b3f"
      unitRef="usd">448271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67ebb5874ffc463eae558a0bca081f38_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMTEtMS0xLTE0MDE2Mg_e352eeb5-9b6d-472d-a1e6-3b6948595440"
      unitRef="usd">1647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15382a1c78b24f7781f909cac2666727_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMTMtMS0xLTE0MDE2Mg_c75d7f00-e047-4e56-acd9-63a681d004b2"
      unitRef="usd">-190812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7765db2674724718901c035cce089b95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMzQtMTUtMS0xLTE0MDE2Mg_740adf9c-3e75-4f19-a3aa-c88f3e5483eb"
      unitRef="usd">259574000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia98b20644358427a878a9249c15fc81e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMS0xLTEtMTQwMTYy_0fbe0853-eabd-4159-b960-7086fd1c5e14"
      unitRef="shares">42631794000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia98b20644358427a878a9249c15fc81e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMy0xLTEtMTQwMTYy_30223534-7194-46d0-a3a5-ca204e8dcd66"
      unitRef="usd">440000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7cd164da18c74147b770195a655c5b6a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtNS0xLTEtMTQwMTYy_c6fa0e6f-1c42-4068-994d-1beace5413dd"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7cd164da18c74147b770195a655c5b6a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtNy0xLTEtMTQwMTYy_8cabfacd-9f0a-463b-bef1-e9f1415084c3"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3ecb856e1088469e91d8161b926b64b0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtOS0xLTEtMTQwMTYy_17f16676-342f-451b-9c79-9cc2cc43d02d"
      unitRef="usd">458825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e11cf9e5ac74fb2ac41daf1d28be1e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMTEtMS0xLTE0MDE2Mg_5f2390a7-5fe4-4b6e-ab8d-c7083d1cd2c5"
      unitRef="usd">-16867000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48b92bc0ebd64ca2ac7a3bd9ea558598_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMTMtMS0xLTE0MDE2Mg_be829fea-a1c2-4ac3-ab68-d8fbeb964d90"
      unitRef="usd">-261146000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDEtMTUtMS0xLTE0MDE2Mg_17f8b6f9-0f48-4be1-8fba-a1f019ed024d"
      unitRef="usd">181280000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDMtMS0xLTEtMTQwMTYy_91317d9e-9369-4f7b-b7d3-d665f9e00ba4"
      unitRef="shares">3790000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDQtMS0xLTEtMTQwMTYy_fabebbc7-509b-4fe9-adbd-6125778752c2"
      unitRef="shares">113420000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDQtMy0xLTEtMTQwMTYy_bfbab56d-4f53-4829-bd66-3b7ab3404bea"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDQtOS0xLTEtMTQwMTYy_de4b52bc-0b6a-4f1e-b58f-5925e7a3a905"
      unitRef="usd">1187000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDQtMTUtMS0xLTE0MDE2Mg_74925d67-79b7-44a2-8b58-fefdcdad65d9"
      unitRef="usd">1188000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTQtMS0xLTEtMTQ1Nzg4_fe4cbd5d-d0bf-4e92-8a07-98f2dede52ab"
      unitRef="shares">30481000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i41bab5f8eda042df864a4ee9852e39ea_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTQtMy0xLTEtMTQ1Nzg4_8f7caba2-061f-494c-948e-3d0495371f72"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTQtOS0xLTEtMTQ1Nzg4_27bdb761-3a11-4d54-8d9d-4b9320cbb35f"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTQtMTUtMS0xLTE0NTc4OA_92da273b-ff6c-4bc5-a695-22dbbd567c7e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTUtOS0xLTEtMTQ1Nzg4_c3a0d432-643e-470d-9fc9-696af296db68"
      unitRef="usd">109000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfMTUtMTUtMS0xLTE0NTc4OA_d97a7017-ee6f-4a85-8a64-b51c1a3234f3"
      unitRef="usd">109000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i51bdbe609bb74180b1d01c5c9d5f1631_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDUtOS0xLTEtMTQwMTYy_f2c5e55f-a4ae-4b62-9687-63fadf38ee6b"
      unitRef="usd">4071000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDUtMTUtMS0xLTE0MDE2Mg_b43b840f-f436-4434-bb9b-88bc886475df"
      unitRef="usd">4071000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="iccea7b15b4b34b7881a38a9aeb5a255d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDYtMTEtMS0xLTE0MDE2Mg_d1f84900-9576-4a05-af1c-fce82abe2c09"
      unitRef="usd">-578000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDYtMTUtMS0xLTE0MDE2Mg_132a2cb3-74e6-499b-968f-07bbfb3d9107"
      unitRef="usd">-578000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0a788380d1dd41a192369ee1283627cb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDctMTMtMS0xLTE0MDE2Mg_8af6a80e-cdc2-4054-9890-29e589d65430"
      unitRef="usd">-24208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDctMTUtMS0xLTE0MDE2Mg_b4da8da7-542d-4fd2-9f95-88b575f9d8e0"
      unitRef="usd">-24208000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib62e231bc5e04aadaa0e552da9eaa69b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMS0xLTEtMTQwMTYy_47233eff-55ed-4bd4-88f1-8c4dc24dce5c"
      unitRef="shares">42779485000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib62e231bc5e04aadaa0e552da9eaa69b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMy0xLTEtMTQwMTYy_aa4502cd-ad0a-4960-82aa-8dcf2c797723"
      unitRef="usd">442000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie933ef689fe34ea1857fb293be2148bc_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtNS0xLTEtMTQwMTYy_6f48ab0a-16b6-4926-b630-6ac63f7bcbbe"
      unitRef="shares">1000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie933ef689fe34ea1857fb293be2148bc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtNy0xLTEtMTQwMTYy_62e8c1b5-b4a8-44f1-aa67-ec21855dd8ae"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee88fb1648c24d69a547b9473b48ce0b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtOS0xLTEtMTQwMTYy_56f65fa1-0da6-4626-b357-f20c118db992"
      unitRef="usd">463973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib62efe8423eb495089400103d98fb87b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMTEtMS0xLTE0MDE2Mg_79c2177e-a4e4-43a2-a86d-3a1f9f9542dc"
      unitRef="usd">-17445000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idffcb1da5bec4469ab5d69a783ed74e6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMTMtMS0xLTE0MDE2Mg_84b04efc-bae2-4e67-b142-7f26cad20e55"
      unitRef="usd">-285354000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zMS9mcmFnOmM2YTc5ZTFiYzQ3YTQzMGFiYjk5Nzg0ZGMzODE2YTBiL3RhYmxlOmYwNjQzNmQ2NDI2ZDQwYjViMjBjMGI2OTA4OTIxODI3L3RhYmxlcmFuZ2U6ZjA2NDM2ZDY0MjZkNDBiNWIyMGMwYjY5MDg5MjE4MjdfNDgtMTUtMS0xLTE0MDE2Mg_9d63e1af-2e4f-4719-bf29-7a57dbbfab4a"
      unitRef="usd">161644000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMy0xLTEtMS0xNDAxNjI_c1cccf5b-630d-4c56-8111-87d127086545"
      unitRef="usd">-24208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMy0zLTEtMS0xNDAxNjI_bd2925c8-dfbd-4ada-bec8-663ac49f374f"
      unitRef="usd">-21171000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNS0xLTEtMS0xNDAxNjI_cd00abc8-9400-49f3-a739-d0d09a2995e5"
      unitRef="usd">48000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNS0zLTEtMS0xNDAxNjI_9ecb1f5e-4d04-4cbb-a663-67dd59df66e9"
      unitRef="usd">54000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNi0xLTEtMS0xNDAxNjI_3024929f-deec-4bf6-9532-b429b5c4bb7f"
      unitRef="usd">2107000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNi0zLTEtMS0xNDAxNjI_c106ce2d-e620-4ab0-8de5-5ff802dcdee0"
      unitRef="usd">219000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNy0xLTEtMS0xNDAxNjI_5086d244-2a7d-4207-9e61-03ff54a665d0"
      unitRef="usd">4071000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfNy0zLTEtMS0xNDAxNjI_475f7cae-a790-4efa-85e1-2fce56e2ab1d"
      unitRef="usd">3128000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfOC0xLTEtMS0xNDAxNjI_1d1bbb09-632f-4132-8fab-a82f684be5d9"
      unitRef="usd">539000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfOC0zLTEtMS0xNDAxNjI_ce9e9474-8354-4c2e-9b65-20c49959966b"
      unitRef="usd">550000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTAtMS0xLTEtMTQwMTYy_f17c0735-5921-47da-9007-3f4f47245341"
      unitRef="usd">1484000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTAtMy0xLTEtMTQwMTYy_90fd87c6-1525-4ab2-ac07-d5b942d274df"
      unitRef="usd">1386000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTEtMS0xLTEtMTQwMTYy_c326366f-17ba-4d8e-a17f-ce35d4ae2894"
      unitRef="usd">-129000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTEtMy0xLTEtMTQwMTYy_5b77c736-9587-4ae1-acf4-eb7c02cd3768"
      unitRef="usd">135000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTItMS0xLTEtMTQwMTYy_59f2bbc4-9ced-4bb0-a3fe-809f77767f7c"
      unitRef="usd">44000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTItMy0xLTEtMTQwMTYy_84df1be7-e9e0-4da9-a0e7-87ba66ee5b1b"
      unitRef="usd">311000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTMtMS0xLTEtMTQwMTYy_885c2d99-065d-4924-83fc-e5c981bacc8f"
      unitRef="usd">-478000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTMtMy0xLTEtMTQwMTYy_a0fc14be-9c91-46ef-841d-609a6f567b6f"
      unitRef="usd">-538000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTQtMS0xLTEtMTQwMTYy_9788f655-b85e-46a0-a97c-1c9babf20d6c"
      unitRef="usd">-973000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTQtMy0xLTEtMTQwMTYy_dc4b8f35-a66b-4df0-8a7a-c648bf040e3b"
      unitRef="usd">-445000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTUtMS0xLTEtMTQwMTYy_8de25093-3a88-4313-82f1-ebd6618288d1"
      unitRef="usd">-3216000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTUtMy0xLTEtMTQwMTYy_7677723a-1daa-4492-91eb-8186bf3e1177"
      unitRef="usd">-2650000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTYtMS0xLTEtMTQwMTYy_4048359f-04ec-4ec8-82c0-65476ed8ea98"
      unitRef="usd">-27723000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTYtMy0xLTEtMTQwMTYy_5a39599d-0678-4956-8557-9a4631286d93"
      unitRef="usd">-23123000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTgtMS0xLTEtMTQwMTYy_22d0b06c-d114-4186-ab8b-509f23615738"
      unitRef="usd">29000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTgtMy0xLTEtMTQwMTYy_4eb7c98a-ab47-4669-9f6f-b2e18c540876"
      unitRef="usd">82000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTktMS0xLTEtMTQwMTYy_8d6b1e83-892d-43ce-9bdc-329a4279a30a"
      unitRef="usd">-29000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMTktMy0xLTEtMTQwMTYy_2589a9d6-ea67-40b7-8e57-b7798cd09896"
      unitRef="usd">-82000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjEtMS0xLTEtMTQ1NzA3_cd914c61-524d-44c4-a870-cb9cbe219b7f"
      unitRef="usd">1188000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjEtMy0xLTEtMTQ1NzA3_3f695ae3-3f8c-43b3-a707-ff131ed20879"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjItMS0xLTEtMTQ1NzE5_1ccf4a9a-ec80-4795-ae9a-ac7611c8b653"
      unitRef="usd">109000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjItMy0xLTEtMTQ1NzE5_563894d3-d8e6-45d2-874e-5ac4c147e896"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjItMS0xLTEtMTQwMTYy_d45440dc-89df-42b6-a59a-eb1578ac301b"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjItMy0xLTEtMTQwMTYy_3d0e9570-ea36-4556-b726-89cfa78add00"
      unitRef="usd">189000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjMtMS0xLTEtMTQwMTYy_69bea6ad-9003-4d0b-bcac-89be7768f5fa"
      unitRef="usd">1079000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjMtMy0xLTEtMTQwMTYy_49fcd1d3-9c95-49f4-a45f-82246d5d4955"
      unitRef="usd">189000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjQtMS0xLTEtMTQwMTYy_1c785c21-1303-4444-8e34-3c3bf850b233"
      unitRef="usd">666000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjQtMy0xLTEtMTQwMTYy_858d8e8f-21f9-4367-838d-46d576dd037f"
      unitRef="usd">-6543000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjUtMS0xLTEtMTQwMTYy_3ecb7b79-66bc-474f-8c98-6e6123be1466"
      unitRef="usd">-26007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjUtMy0xLTEtMTQwMTYy_c682ab8b-b164-4da0-bd64-8db0a176435f"
      unitRef="usd">-29559000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjYtMS0xLTEtMTQwMTYy_89107a64-6f0e-4e37-81f4-32fc5ff5c8e9"
      unitRef="usd">143381000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i898f890161564fe59100013d33b6fbf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjYtMy0xLTEtMTQwMTYy_6ee24670-94ee-4d47-8b04-1ad90a70de4b"
      unitRef="usd">273347000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjctMS0xLTEtMTQwMTYy_b11967a0-d546-433f-955c-68bfe7705157"
      unitRef="usd">117374000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7765db2674724718901c035cce089b95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMjctMy0xLTEtMTQwMTYy_89731e85-b2cd-48d8-a122-e64fe2981d50"
      unitRef="usd">243788000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzEtMS0xLTEtMTQ1NzQw_b056cdbe-883a-4f29-a5ba-dc6fdd660507"
      unitRef="usd">92000</cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption>
    <cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzEtMy0xLTEtMTQ1NzQw_85604d53-6d9f-4799-b799-a55fef27c76d"
      unitRef="usd">0</cmps:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption>
    <cmps:ProceedsFromStockOptionsExercisedNotReceived
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzEtMS0xLTEtMTQwMTYy_e9164ac7-454d-423a-a13e-0bf674ddf90d"
      unitRef="usd">0</cmps:ProceedsFromStockOptionsExercisedNotReceived>
    <cmps:ProceedsFromStockOptionsExercisedNotReceived
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzEtMy0xLTEtMTQwMTYy_d0408c9a-26a1-444a-b380-aff46a019955"
      unitRef="usd">208000</cmps:ProceedsFromStockOptionsExercisedNotReceived>
    <cmps:DeferredOfferingCostsIncludedInAccruedExpenses
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzItMS0xLTEtMTQwMTYy_6991aa42-e2be-4247-a6d6-9037e3a8f79f"
      unitRef="usd">0</cmps:DeferredOfferingCostsIncludedInAccruedExpenses>
    <cmps:DeferredOfferingCostsIncludedInAccruedExpenses
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOjgzMWRhOThjYzJiYTRhYzE5ODA1ZTQ5NzEzODVmODMzL3RhYmxlcmFuZ2U6ODMxZGE5OGNjMmJhNGFjMTk4MDVlNDk3MTM4NWY4MzNfMzItMy0xLTEtMTQwMTYy_e17ac83b-0bf2-4deb-af33-e5d302734ae8"
      unitRef="usd">835000</cmps:DeferredOfferingCostsIncludedInAccruedExpenses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfMi0xLTEtMS0xNDAxNjI_cfd3b41e-240b-4e85-81d8-689c9ffe6203"
      unitRef="usd">117103000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7765db2674724718901c035cce089b95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfMi0zLTEtMS0xNDAxNjI_73a2554f-cba2-4c3d-8ca2-bdc9e0342518"
      unitRef="usd">243684000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfMy0xLTEtMS0xNDAxNjI_1d6be6b4-c0b2-46c0-8db6-f5d2ffe56c2d"
      unitRef="usd">271000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i7765db2674724718901c035cce089b95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfMy0zLTEtMS0xNDAxNjI_a8ebbcdb-7aa2-4a87-b453-c5daf46bb408"
      unitRef="usd">104000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfNC0xLTEtMS0xNDAxNjI_ce8d47af-7331-44c2-86fa-ed290f0e82a9"
      unitRef="usd">117374000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7765db2674724718901c035cce089b95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF8zNC9mcmFnOjJhOWMwZmVkYzllMDRhYTFiNDFlOGE1YTQ4MzZjMjEyL3RhYmxlOmQ1NDc4YjcyNGUxYzQ2MDg5ODEyNDg1NzNmMDdiNTE4L3RhYmxlcmFuZ2U6ZDU0NzhiNzI0ZTFjNDYwODk4MTI0ODU3M2YwN2I1MThfNC0zLTEtMS0xNDAxNjI_4adbedb5-2ecb-454c-a2dc-865337741c50"
      unitRef="usd">243788000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfNDk1Mw_16b5bdd1-447c-4b79-a133-3589ef02ea8b">Nature of Business &lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COMPASS Pathways plc, or the Company, is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has funded its operations primarily with proceeds from the sale of its convertible preferred shares, the issuance of convertible notes, and through the sale of American Depository Shares, or ADSs, in connection with the Company&#x2019;s initial public offering, or the IPO, in September 2020, and its May 2021 follow-on offering. On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Sales of the Company&#x2019;s ADSs, if any, will be made at market prices. Through March 31, 2023 we sold 157,836 ADSs, resulting in $1.6&#160;million in net proceeds. During the second quarter of 2023, through May 10, 2023, we sold 2,824,202 ADSs, resulting in $26.9&#160;million in net proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has incurred recurring losses since its inception, including net losses of $24.2 million and $21.2 million for the three months ended March 31, 2023 and 2022, respectively. In addition, as of March&#160;31, 2023, the Company had an accumulated deficit of $285.4 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes the cash and cash equivalents on hand as of March&#160;31, 2023 of $117.1 million, together with the net proceeds from the sale of the Company&#x2019;s ADSs, through May 10, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months, including progressing our Phase 3 clinical program, our Phase 2 studies in anorexia nervosa and PTSD and costs associated with operating as a public company. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.  We will need substantial additional funding to complete the development and commercialization of our Phase 3 clinical program, and our Phase 2 studies in anorexia nervosa and PTSD.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%"&gt;Further, changing circumstances, some of which may be beyond our control, such as heightened or fluctuating inflation and interest rates, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. There can be no assurance that additional funding will be available on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#x2019;s business, results of operations, and financial conditions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%"&gt;Market volatility, instability in the banking system, geopolitical tensions resulting from the ongoing war between Ukraine and Russia, heightened or fluctuating inflation and interest rates and the related impact on U.S., U.K. and global economies, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the risk of credit-rating downgrades and economic slowdown or recession in the United States due to debt ceiling and budget deficit concerns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%"&gt; or efforts to combat inflation or other economic or other factors could adversely impact our operations, financial results and ability to raise additional funding.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <cmps:SaleOfStockMaximumAmountAllowableForSale
      contextRef="ifb330f455e5841ea8450b766d642b939_I20211008"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTgwMg_2b977aa3-bdca-44e3-ba53-94d81059e9c7"
      unitRef="usd">150000000</cmps:SaleOfStockMaximumAmountAllowableForSale>
    <cmps:NumberOfOrdinarySharesConversionRatio
      contextRef="i8cc171482c7f4d51822f9ae8848dea3e_D20211008-20211008"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTgzNg_353960c9-119b-423c-aed2-9b0f5e6e7541"
      unitRef="number">1</cmps:NumberOfOrdinarySharesConversionRatio>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTA5OTUxMTY0MTcwNw_9e2e3494-e45d-4bf6-b714-be9cc6c62d07"
      unitRef="shares">157836</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTA5OTUxMTY0MTcwOQ_4e830ec4-c2c9-4521-888f-e31d8564948b"
      unitRef="usd">1600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTA5OTUxMTY1MjE2Nw_ed3d2f39-2943-4a86-8023-33756b0ab149"
      unitRef="shares">2824202</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMTA5OTUxMTY1MjE3OA_7a83fdfa-3dca-4542-98a8-971adacde829"
      unitRef="usd">26900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:NetIncomeLoss
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfNTQ5NzU1ODE5MDgz_c4f04603-9fa6-4759-b2a0-96dce0988214"
      unitRef="usd">-24200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfNTQ5NzU1ODE5MDg2_79aa8249-dcc4-4f3a-8347-b9c5fd2043b5"
      unitRef="usd">-21200000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia12a666d1e1c4e28811b0491bb87e477_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMjI4MA_ab9bd1f1-bdf0-43ae-b2ad-245bb09c8078"
      unitRef="usd">-285400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80MC9mcmFnOjM3YWUzNmU4ZWJlNTRmMDBhNjc2NDVkZjY5ODU4Y2EyL3RleHRyZWdpb246MzdhZTM2ZThlYmU1NGYwMGE2NzY0NWRmNjk4NThjYTJfMjkwMg_31e2843d-719d-4bdd-b006-254e23859a89"
      unitRef="usd">117100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODg_fb8578ca-4b65-410f-873f-c969f1eeeb04">Summary of Significant Accounting Policies&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual condensed consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of March 31, 2023, the results of its operations and comprehensive loss for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K that was filed with the SEC, on February 28, 2023. The condensed consolidated balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash as of March&#160;31, 2023 and December&#160;31, 2022 represents a collateral deposit for employee credit cards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision maker, the Company&#x2019;s Chief Executive Officer, view the Company&#x2019;s operations and manage its business as a single operating segment; however, the Company operates in two geographic regions: the United Kingdom, or UK, and the United States. The Company&#x2019;s fixed assets are primarily located in the UK. The Company&#x2019;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Contract Costs, Prepayments and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepayments and accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as an expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimates the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 8 for the Company&#x2019;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of ordinary shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $1.0&#160;million, on the Company&#x2019;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#x2019;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 10 for right-of-use assets and liabilities recorded during the periods ended March 31, 2023 and 2022 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#x2019;s leases are classified as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has historically not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency is the currency of the primary economic environment in which an entity&#x2019;s operations are conducted. On January 1, 2023, COMPASS Pathways plc and its wholly owned subsidiary COMPASS Pathfinder Holdings Limited changed their functional currency to the U.S. dollar. COMPASS Pathways plc and COMPASS Pathfinder Holdings Limited have no operating activities and their primary functions are to serve as a financing vehicle to fund the operations of the Company&#x2019;s operating entities, to serve as the listing company needed to access U.S. capital markets, and to hold investments.  Therefore, its financing source is the primary indicator of its cash flows and its functional currency. The change in functional currency from the British Pound Sterling is due to a change in the source of the Company&#x2019;s financing and cash flows going forward, which will now primarily be U.S. Dollars (&#x201c;USD&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of COMPASS Pathfinder Holdings Limited&#x2019;s wholly owned non-U.S. subsidiary, COMPASS Pathfinder Limited, is British Pound Sterling and the functional currency of its U.S. subsidiary, COMPASS Pathways Inc. is USD. The functional currency of these subsidiaries is the same as the local currency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The translated balances of monetary and non-monetary assets and liabilities recorded in the reporting entity&#x2019;s condensed consolidated financial statements as of the end of the prior reporting period become the new accounting basis for those assets and liabilities in the period of the change. To the extent that the distinct and separable operation has monetary assets and liabilities denominated in the old functional currency, such balances will create transaction gains and losses subsequent to the change in functional currency. The balance recorded in the cumulative translation adjustment account for prior periods is not reversed upon the change in functional currency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company translates the assets and liabilities of COMPASS Pathfinder Limited into USD at the exchange rate in effect on the balance sheet date. Income and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive (loss)/income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of March 31, 2023 and December 31, 2022, the Company has not identified any uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Benefit from Research and Development Tax Credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, in effect through March 31, 2023, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.3% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.7%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#x20ac;7.5 million which may impact the Company's ability to claim R&amp;amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on credit claims under the SME Program in excess of &#xa3;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim. As announced in His Majesty&#x2019;s Treasury Autumn Statement 2022, the rates for the SME R&amp;amp;D tax relief regime have been reduced such that for qualifying expenditure from April 1, 2023 the effective credit decreased from 33.3% to 18.6%. For subcontracted expenditure, as there is a restriction to 65% of costs, the effective credit decreased from 21.7% to 12.1%.  New rules were announced in the UK Parliament Finance Act  2023 for an enhanced rate of relief, which would be 27.0% for qualifying expenditure and 17.5% for qualifying subcontracted expenditure. The legislation is not yet final, and therefore the Company is unable to determine whether it would meet the criteria for the enhanced rate of relief until the legislation and more detailed guidance has been published.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#xa3;5.0 million plus an incremental 50% of UK taxable profits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. For the three months ended March 31, 2023 and 2022, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;The Company enters into foreign currency contracts to reduce the risk that its cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying condensed consolidated statements of operations and comprehensive loss as other income, net. The Company did not enter into any contracts during the three-months ended March 31, 2023 and 2022.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODQ_942beee5-cb37-483b-9748-3bda372e1f0a">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual condensed consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of March 31, 2023, the results of its operations and comprehensive loss for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023, any other interim periods, or any future years or periods. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K that was filed with the SEC, on February 28, 2023. The condensed consolidated balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg2MDA_439a2655-8a56-4bc9-a45f-606a8bc5e07b">Principles of ConsolidationThe accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTQ_88aadfd3-a2a9-4dca-8203-f43ca77dbf7b">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg2MDE_4cc387b1-6048-421b-9b3c-456ab2811c3d">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company does not currently have any material cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTA_c3a8309c-77ee-4006-9927-903f85ebd51e">Restricted CashRestricted cash as of March&#160;31, 2023 and December&#160;31, 2022 represents a collateral deposit for employee credit cards.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1Nzg_e6235708-6ab8-4dd9-9da6-316557e45ba9">InvestmentThe investment does not have readily determinable fair value and it is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value up to the original cost, in circumstances where the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTU_931ff20b-0990-494d-82e3-0628cc7a3c0c">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1Nzk_c69e2ba9-30a3-4c1d-8029-f0abbe940452">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Expenditures for repairs and maintenance are charged to expense as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODI_4503d4b5-b599-4670-b498-ebf7f5e6e841">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i74d151acb50c43c5a8922ab30b91f0da_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RhYmxlOjBjYTYyY2Y3N2U4ZDRjYjBhZDlmNzI3M2Y5OGU2ODhkL3RhYmxlcmFuZ2U6MGNhNjJjZjc3ZThkNGNiMGFkOWY3MjczZjk4ZTY4OGRfMS0xLTEtMS0xNDAxNjI_ff23c831-e6d7-440b-a689-f14044597892">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia7dc74026a9740bf91b61706f4057936_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RhYmxlOjBjYTYyY2Y3N2U4ZDRjYjBhZDlmNzI3M2Y5OGU2ODhkL3RhYmxlcmFuZ2U6MGNhNjJjZjc3ZThkNGNiMGFkOWY3MjczZjk4ZTY4OGRfMi0xLTEtMS0xNDAxNjIvdGV4dHJlZ2lvbjpmODUwNzRjNmYxZGI0YTlmODQxNDViZTk2M2VmYWNkNF80_83645493-2506-4620-a7de-ccf6bac95d95">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i269e60958eaf430baf2c5267c8716c7f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RhYmxlOjBjYTYyY2Y3N2U4ZDRjYjBhZDlmNzI3M2Y5OGU2ODhkL3RhYmxlcmFuZ2U6MGNhNjJjZjc3ZThkNGNiMGFkOWY3MjczZjk4ZTY4OGRfMi0xLTEtMS0xNDAxNjIvdGV4dHJlZ2lvbjpmODUwNzRjNmYxZGI0YTlmODQxNDViZTk2M2VmYWNkNF83_5166cbaf-932d-4696-b5f6-4ff1e264e84a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i89200d84b6204258aa19770fb2ce7ef4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RhYmxlOjBjYTYyY2Y3N2U4ZDRjYjBhZDlmNzI3M2Y5OGU2ODhkL3RhYmxlcmFuZ2U6MGNhNjJjZjc3ZThkNGNiMGFkOWY3MjczZjk4ZTY4OGRfMy0xLTEtMS0xNDAxNjI_8be8d311-58cf-45be-a33e-fda48ac6e610">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTY_4565096f-9a4f-4d61-8309-98e02460e581">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses or had triggering events related to its underlying assets for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODU_1af7653e-e397-4a2e-96c7-1b4409d243a3">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision maker, the Company&#x2019;s Chief Executive Officer, view the Company&#x2019;s operations and manage its business as a single operating segment; however, the Company operates in two geographic regions: the United Kingdom, or UK, and the United States. The Company&#x2019;s fixed assets are primarily located in the UK. The Company&#x2019;s singular concentration is focused on accelerating patient access to evidence-based innovation in mental health.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <cmps:NumberOfGeographicRegions
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfNzEzOQ_db083394-c4ae-4ee8-8bb4-f2b095cc761d"
      unitRef="region">2</cmps:NumberOfGeographicRegions>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODY_55155859-b94e-440a-bb66-713747a43fda">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, and external costs of outside vendors engaged to conduct clinical development activities, clinical trials and the cost to manufacture clinical trial materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTE_3385929d-f38b-4bf8-a581-4b84bf54b0a3">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Contract Costs, Prepayments and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development-related contracts with research institutions and other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records prepayments and accruals for estimated ongoing research costs and receives updated estimates of costs and amounts owed on a monthly basis from its third-party service providers. When evaluating the adequacy of the prepayments and accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted cost estimates from third-party service providers. Estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepayments and accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODA_7429581d-9caf-45a8-98b7-2f19b2596baa">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all share-based payment awards granted to employees and non-employees as share-based compensation expense at fair value. The Company grants equity awards under its share-based compensation programs, which may include share options and restricted ordinary shares. The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized as an expense over the requisite service period, which is the vesting period, on a straight-line basis. Share-based compensation expense is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes share-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company launched the Share Incentive Plan, or the SIP, and Employee Share Purchase Plan, or the ESPP, through which employees can purchase shares at a discounted price. The Company estimates the fair value of stock options and shares to be issued under the SIP and ESPP using the Black-Scholes option-pricing model on the date of grant. The fair value of shares to be issued under these plans are recognized and amortized on a straight-line basis over the purchase period, which is generally six months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no performance conditions attached to the share options granted by the Company to date. The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 8 for the Company&#x2019;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company lacks sufficient company-specific historical and implied volatility information for its ordinary shares. Therefore, it estimates its expected share volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of ordinary shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The fair value of ordinary shares is determined by reference to the closing price of ADSs on the Nasdaq Global Select Market on the day prior to or day of the grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMzI5ODUzNDkxMTk4NA_e858f3f6-7c3d-4abd-8a43-4bc3617cc920"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTc_ea930483-7fc4-4f72-bc7a-963a0dc4dfc7">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2021, the Company adopted ASU No. 2016-02, Leases (Topic 842), as amended, using the modified retrospective method and utilizing the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases, or ASC 840. The Company has elected to apply the package of three expedients to all of its leases requiring (1) no reassessment of whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, or (3) the capitalization of initial direct costs for any existing leases. Adoption of this standard resulted in the recording of operating lease right-of-use assets and current operating lease liabilities of $1.0&#160;million, on the Company&#x2019;s balance sheet on the effective date. The adoption of the standard did not have a material effect on the Company&#x2019;s statements of operations and comprehensive loss, statements of cash flows or accumulated deficit. Refer to Note 10 for right-of-use assets and liabilities recorded during the periods ended March 31, 2023 and 2022 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and to allocate all the contract consideration to the lease component only. All the Company&#x2019;s leases are classified as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts has historically not been readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As the Company does not have a rating agency-based credit rating, quotes were obtained from lenders to establish an estimated secured rate to borrow based on Company and market-based factors as of the respective lease measurement dates. The Company has elected not to recognize leases with an original term of one year or less on the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;balance sheets. The Company typically only includes the non-cancelable lease term in its assessment of a lease arrangement unless there is an option to extend the lease that is reasonably certain of exercise. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are recognized on a straight-line basis over the lease term, and they are categorized within research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The operating lease cash flows are categorized under net cash used in operating activities in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifcb5e67ff9464397aed19cb5b9642c90_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMTQ4MDA_8b447e3b-06aa-40ed-ac08-018e8e799b86"
      unitRef="usd">1000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifcb5e67ff9464397aed19cb5b9642c90_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMTQ4MDA_d73cee71-fcd6-41e3-b47f-e588707c3c63"
      unitRef="usd">1000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTM_1ca62cf1-8ec9-4ad5-bb89-a63a6a1ceea5">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency is the currency of the primary economic environment in which an entity&#x2019;s operations are conducted. On January 1, 2023, COMPASS Pathways plc and its wholly owned subsidiary COMPASS Pathfinder Holdings Limited changed their functional currency to the U.S. dollar. COMPASS Pathways plc and COMPASS Pathfinder Holdings Limited have no operating activities and their primary functions are to serve as a financing vehicle to fund the operations of the Company&#x2019;s operating entities, to serve as the listing company needed to access U.S. capital markets, and to hold investments.  Therefore, its financing source is the primary indicator of its cash flows and its functional currency. The change in functional currency from the British Pound Sterling is due to a change in the source of the Company&#x2019;s financing and cash flows going forward, which will now primarily be U.S. Dollars (&#x201c;USD&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of COMPASS Pathfinder Holdings Limited&#x2019;s wholly owned non-U.S. subsidiary, COMPASS Pathfinder Limited, is British Pound Sterling and the functional currency of its U.S. subsidiary, COMPASS Pathways Inc. is USD. The functional currency of these subsidiaries is the same as the local currency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The translated balances of monetary and non-monetary assets and liabilities recorded in the reporting entity&#x2019;s condensed consolidated financial statements as of the end of the prior reporting period become the new accounting basis for those assets and liabilities in the period of the change. To the extent that the distinct and separable operation has monetary assets and liabilities denominated in the old functional currency, such balances will create transaction gains and losses subsequent to the change in functional currency. The balance recorded in the cumulative translation adjustment account for prior periods is not reversed upon the change in functional currency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company translates the assets and liabilities of COMPASS Pathfinder Limited into USD at the exchange rate in effect on the balance sheet date. Income and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive (loss)/income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTg_249bb462-9f81-45ea-b23c-61e5538452a3">&lt;div style="margin-bottom:4pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that deferred tax assets will be recovered in the future to the extent management believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the condensed consolidated financial statements. The amount of benefit that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. As of March 31, 2023 and December 31, 2022, the Company has not identified any uncertain tax positions.&lt;/span&gt;&lt;/div&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022 no accrued interest or penalties are included on the related tax liability line in the condensed consolidated balance sheets.</us-gaap:IncomeTaxPolicyTextBlock>
    <cmps:BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1OTk_b962916d-8e1c-4b4b-b59e-cab8e66fd731">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Benefit from Research and Development Tax Credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a company that carries out extensive research and development activities, the Company benefits from the UK research and development tax credit regime under the scheme for small or medium-sized enterprises, or SME. Under the SME regime, in effect through March 31, 2023, the Company is able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.3% of such qualifying research and development expenditure. The Company meets the conditions of the SME regime. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.7%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate taxation in the UK. Due to the nature of the business, the Company has generated losses since inception. The benefit from research and development, or R&amp;amp;D, tax credits is recognized in the condensed consolidated statements of operations and comprehensive loss as a component of other income, net, and represents the sum of the research and development tax credits recoverable in the UK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The UK research and development tax credit is fully refundable to the Company and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the UK research and development tax credit as a benefit which is included in net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any UK research and development tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not be able to continue to claim research and development tax credits under the SME regime in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#x20ac;7.5 million which may impact the Company's ability to claim R&amp;amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on credit claims under the SME Program in excess of &#xa3;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim. As announced in His Majesty&#x2019;s Treasury Autumn Statement 2022, the rates for the SME R&amp;amp;D tax relief regime have been reduced such that for qualifying expenditure from April 1, 2023 the effective credit decreased from 33.3% to 18.6%. For subcontracted expenditure, as there is a restriction to 65% of costs, the effective credit decreased from 21.7% to 12.1%.  New rules were announced in the UK Parliament Finance Act  2023 for an enhanced rate of relief, which would be 27.0% for qualifying expenditure and 17.5% for qualifying subcontracted expenditure. The legislation is not yet final, and therefore the Company is unable to determine whether it would meet the criteria for the enhanced rate of relief until the legislation and more detailed guidance has been published.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#xa3;5.0 million plus an incremental 50% of UK taxable profits.&lt;/span&gt;&lt;/div&gt;</cmps:BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock>
    <cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent
      contextRef="i49ac0527569949da8f64c6fe440b8ed9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjM3NzI_59957d39-b239-4b2a-846f-26bd1fb28b35"
      unitRef="number">0.333</cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent>
    <cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent
      contextRef="i72e49c2f29fa4138890d882ae5cb4ab9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjQxOTM_833d44e3-09c0-4d27-b99d-b91684295aae"
      unitRef="number">0.217</cmps:ResearchAndDevelopmentTaxCreditCashRebatePercent>
    <cmps:ResearchAndDevelopmentTaxCreditTotalAidClaimable
      contextRef="i49ac0527569949da8f64c6fe440b8ed9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfNTQ5NzU1ODUzMzcx_5ce6c9b5-2463-4ab4-ad2c-ffa5a95d1641"
      unitRef="eur">7500000</cmps:ResearchAndDevelopmentTaxCreditTotalAidClaimable>
    <cmps:ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims
      contextRef="i49ac0527569949da8f64c6fe440b8ed9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfNTQ5NzU1ODUzMzc3_68a00842-0a2d-4052-b5bf-b64bf05991cf"
      unitRef="gbp">20000</cmps:ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims>
    <cmps:ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfNTQ5NzU1ODUzMzg2_d57c4cba-6a31-4d0e-b5fd-a1fb6726284a"
      unitRef="number">0.15</cmps:ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim>
    <cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount
      contextRef="i72e49c2f29fa4138890d882ae5cb4ab9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjY4MDc_b1025bde-f887-4344-8460-90faf40ce087"
      unitRef="gbp">5000000.0</cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount>
    <cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent
      contextRef="i72e49c2f29fa4138890d882ae5cb4ab9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjY4Mzg_7201e4be-f51c-42a2-aa9c-b613ad6dc042"
      unitRef="number">0.50</cmps:ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODc_ee0c00a8-014f-4a25-87c5-e8c23a6e6c65">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. For the three months ended March 31, 2023 and 2022, the only component of accumulated other comprehensive loss is foreign currency translation adjustment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjg1ODM_9b0ada44-a53a-4008-b584-dcf9b45a9f98">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reported losses since inception and has computed basic net loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares &lt;/span&gt;&lt;/div&gt;outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary shares, including unvested restricted shares and outstanding options. Because the Company has reported net losses since inception, these potential ordinary shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF80Ni9mcmFnOjExM2I2ZjIzZTFjYTQ2MWFhMjA4YTZkZDJiMDBmMTQ0L3RleHRyZWdpb246MTEzYjZmMjNlMWNhNDYxYWEyMDhhNmRkMmIwMGYxNDRfMjE5OTAyMzI4NDIwNw_7aca314a-b107-4c3d-96bb-fc93cbfdc624">DerivativesThe Company enters into foreign currency contracts to reduce the risk that its cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  The Company does not enter into foreign currency contracts for speculative purposes.  The Company recognizes derivative instruments, which do not qualify for hedge accounting, as either assets or liabilities on the balance sheet at fair value.  The Company records changes in the fair value (gains or losses) of the derivatives in the accompanying condensed consolidated statements of operations and comprehensive loss as other income, net.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RleHRyZWdpb246OGJkN2IxODczMzQ1NDcyZDg0NDFlNGM0NjBhMzJlMDdfMTM1_16153cad-fa92-4f6f-a76e-5013293893b7">Prepaid Expenses and Other Current Assets&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UK R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RleHRyZWdpb246OGJkN2IxODczMzQ1NDcyZDg0NDFlNGM0NjBhMzJlMDdfMTM2_019b909a-3455-4f30-afef-fef8def87829">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UK R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <cmps:ResearchAndDevelopmentTaxCreditCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfMi0xLTEtMS0xNDAxNjI_ae5da7a3-859a-4127-b3de-746ef456a5e9"
      unitRef="usd">18672000</cmps:ResearchAndDevelopmentTaxCreditCurrent>
    <cmps:ResearchAndDevelopmentTaxCreditCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfMi0zLTEtMS0xNDAxNjI_f5170a09-e501-4ac0-a4b9-734b96115228"
      unitRef="usd">13972000</cmps:ResearchAndDevelopmentTaxCreditCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfMy0xLTEtMS0xNDAxNjI_ad352f5a-b2bc-48f5-8d6c-b403d0a36244"
      unitRef="usd">1755000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfMy0zLTEtMS0xNDAxNjI_15838a03-3e05-4216-8575-3378f20506b7"
      unitRef="usd">2818000</us-gaap:PrepaidInsurance>
    <cmps:PrepaidExpenseResearchAndDevelopmentCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfNC0xLTEtMS0xNDAxNjI_f77e933c-02b5-4885-aef0-ea037b3c34e7"
      unitRef="usd">26775000</cmps:PrepaidExpenseResearchAndDevelopmentCurrent>
    <cmps:PrepaidExpenseResearchAndDevelopmentCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfNC0zLTEtMS0xNDAxNjI_19ac2802-2640-4949-9e67-a290b3e8674c"
      unitRef="usd">28211000</cmps:PrepaidExpenseResearchAndDevelopmentCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfNS0xLTEtMS0xNDAxNjI_c4274133-a8dd-461e-b4ee-5ed374451060"
      unitRef="usd">1689000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfNS0zLTEtMS0xNDAxNjI_f85890dc-a7b1-418b-8743-a94156d83f21"
      unitRef="usd">1652000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfOC0xLTEtMS0xNDAxNjI_226c9369-416b-4935-b9e2-7d08aaec8009"
      unitRef="usd">1490000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfOC0zLTEtMS0xNDAxNjI_d599b5e4-4bba-4d83-8870-77c576c18876"
      unitRef="usd">1042000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfOS0xLTEtMS0xNDAxNjI_45b5ba0b-e009-446a-bf79-a9b2122f3388"
      unitRef="usd">50381000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF81NS9mcmFnOjhiZDdiMTg3MzM0NTQ3MmQ4NDQxZTRjNDYwYTMyZTA3L3RhYmxlOmE3NTVkNmRkMDdhZDQ5NzQ4ODJlYjYzZDdhNDllOGJjL3RhYmxlcmFuZ2U6YTc1NWQ2ZGQwN2FkNDk3NDg4MmViNjNkN2E0OWU4YmNfOS0zLTEtMS0xNDAxNjI_9563ec23-6874-461d-bd70-d90c7b9fa813"
      unitRef="usd">47695000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RleHRyZWdpb246MDljOGMwOWM2NDc3NDM4MGI4MTAzMWViNjhhMmY2MDdfMTI5_9af47793-f6c9-468f-9bdd-70fac00170c1">Accrued Expenses and Other Liabilities&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RleHRyZWdpb246MDljOGMwOWM2NDc3NDM4MGI4MTAzMWViNjhhMmY2MDdfMTMw_5e0c0678-fda7-484f-9939-8258c7853fc6">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cmps:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfMi0xLTEtMS0xNDAxNjI_8e1f9422-c0cc-4927-9f19-69c6352d3535"
      unitRef="usd">1815000</cmps:AccruedResearchAndDevelopmentExpenseCurrent>
    <cmps:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfMi0zLTEtMS0xNDAxNjI_59fdbc21-7f6f-4585-8a71-dd04928a4390"
      unitRef="usd">1684000</cmps:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfMy0xLTEtMS0xNDAxNjI_77213987-b168-47fe-8d9f-4c934a8893fa"
      unitRef="usd">803000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfMy0zLTEtMS0xNDAxNjI_a19e66e8-b55d-4041-8571-295f7f1e7bc8"
      unitRef="usd">1284000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNC0xLTEtMS0xNDAxNjI_f98a3bd3-8143-4989-aab4-c8bdb9a6743c"
      unitRef="usd">2976000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNC0zLTEtMS0xNDAxNjI_5d7a19c5-9600-437a-a8d3-59df8657e65c"
      unitRef="usd">5534000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNS0xLTEtMS0xNDAxNjI_7d49247a-47e4-4c39-b051-55c61b720306"
      unitRef="usd">1000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNS0zLTEtMS0xNDAxNjI_f7d41235-2bef-43ea-a686-e4924b66001d"
      unitRef="usd">167000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNi0xLTEtMS0xNDAxNjI_39e1ed0b-ab67-40d7-b9ce-03274011e3c2"
      unitRef="usd">672000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNi0zLTEtMS0xNDAxNjI_510ebec3-c818-4658-a2f7-e4e2a70034d6"
      unitRef="usd">656000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNy0xLTEtMS0xNDAxNjI_2889ef43-488e-455e-a27b-1e4eb5a0f0db"
      unitRef="usd">6267000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF82MS9mcmFnOjA5YzhjMDljNjQ3NzQzODBiODEwMzFlYjY4YTJmNjA3L3RhYmxlOjgyMjkxNDE0YzNiMzRiMDdhNTY0NmNjMTQzZGMzMTI0L3RhYmxlcmFuZ2U6ODIyOTE0MTRjM2IzNGIwN2E1NjQ2Y2MxNDNkYzMxMjRfNy0zLTEtMS0xNDAxNjI_7ba8cc54-287a-4303-bf79-7ef78483d2e1"
      unitRef="usd">9325000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfMTY5NA_d5c948d2-554e-41a6-ba1c-620840ff7cf6">Ordinary Shares&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Sales of the Company&#x2019;s ADSs, if any, will be made at market prices. Through March 31, 2023 we sold 157,836 ADSs, resulting in $1.6&#160;million in net proceeds. During the second quarter of 2023, through May 10, 2023, we sold 2,824,202 ADSs, resulting in $26.9&#160;million in net proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company issued in total 3,790 ordinary shares to settle share options exercised by employees and non-employees compared to 376,158 in the three months ended March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, a total of 31,856 restricted share units vested, of which 21,579 were issued and 10,277 were settled.  During the three months ended March 31, 2023, a total of 30,481 ordinary shares were issued in settlement of restricted share units, of which 8,902 were vested and not issued at December 31, 2022 and 21,579 vested and were issued during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, a total of 68,534 ordinary shares were issued in settlement of restricted share units, of which 57,875 were vested and not issued at December 31, 2021 and 10,659 vested and were issued during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cmps:SaleOfStockAmountAuthorized
      contextRef="ifb330f455e5841ea8450b766d642b939_I20211008"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfMzg0ODI5MDcwNDEyOA_ee1230f2-487c-4ce2-8a8b-29fc1a1e627e"
      unitRef="usd">150000000</cmps:SaleOfStockAmountAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4MzA4_9e2e3494-e45d-4bf6-b714-be9cc6c62d07"
      unitRef="shares">157836</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4MzMw_4e830ec4-c2c9-4521-888f-e31d8564948b"
      unitRef="usd">1600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfMTA5OTUxMTYzNDY1NQ_df01f27a-f5ab-49d0-990b-82106dc07286"
      unitRef="shares">2824202</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfMTA5OTUxMTYzNDY2Ng_8788fd19-78b4-4576-8fb1-376d596c5870"
      unitRef="usd">26900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE1Njg1_c2ed17f3-2507-45c1-8720-64ef31b80328"
      unitRef="shares">3790</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie9e6809fbe984861af6f54d5e62599f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE1Njg5_dd9480d4-79c5-47ee-8ce9-451eda5a85b7"
      unitRef="shares">376158</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod
      contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NTAw_29803105-b244-44ff-a95e-aa6f809a5c30"
      unitRef="shares">31856</cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NTg4_1d13ea70-0a90-490e-9ec2-9a15b979651d"
      unitRef="shares">21579</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod
      contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NjIw_4a150552-8ffe-4330-be33-1895584e9c94"
      unitRef="shares">10277</cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ia690ad07e30d41c9b898dec4e27afca1_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODIwNzM2_93c8222e-92aa-49ad-b2eb-e9beac7ec4c1"
      unitRef="shares">30481</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i2d4eb30a399e4393b48bbd2412557894_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NDM4_260e4e44-ee77-43af-ad2b-5b6394792fff"
      unitRef="shares">8902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i48ff1631256746aeb10f884e312e3153_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODIwNzMx_e27ff0e8-283a-41f6-9921-94489dc982b4"
      unitRef="shares">21579</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie9e6809fbe984861af6f54d5e62599f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE2MTM2_91383a5b-6819-44bf-8d4b-5504a1173ef8"
      unitRef="shares">68534</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7b3c9a2da33a404d81407048dc2c35ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE4NzYw_db2cfdbe-7554-4b1a-a68d-80b4968a3666"
      unitRef="shares">57875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie9e6809fbe984861af6f54d5e62599f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83MC9mcmFnOmZlZjg2MGMzNWRmNzQzOGNiZWU3MDRlODNhZTJlYmI0L3RleHRyZWdpb246ZmVmODYwYzM1ZGY3NDM4Y2JlZTcwNGU4M2FlMmViYjRfNTQ5NzU1ODE2MTQy_f31b8973-3a46-4303-bd06-fc4f711bf00d"
      unitRef="shares">10659</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODMwNQ_978c865f-a9ad-4163-92e9-219db1ef18e2">Share-Based Compensation&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#x2019;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, the Company was authorized to issue a total of 1,600,329 ordinary shares underlying outstanding options granted under the 2017 Plan prior to the IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the 2017 Plan, typically vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTAyOQ_92763bc4-2b40-44c3-9547-92efbadbe1ef"&gt;three&lt;/span&gt; or four-year service period with 33.3% and 25% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire 10 years from the date of grant.  Restricted share units granted under the 2017 Plan typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options granted on June 30, 2020 were subject to 25% vesting upon the earlier occurrence of (i) the one year anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for three years for the remaining 75% of the allocation until vested in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The restricted share units granted on June 30, 2020 are subject to 25% vesting upon the earlier of (i) the one year anniversary of the date of grant, or (ii) the first day following the six-month anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is 20% higher than the listing price for at least five consecutive trading days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Share Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#x2019;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of 340,053 ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) 510,080 ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in capitalization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On October 1, 2021, the Company launched the SIP and the ESPP, through which employees can purchase shares at a discounted price. At the end of six months, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a 15% discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Share Option Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#x2019;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development committee to make equity-based and cash-based incentive awards to the Company&#x2019;s officers, employees, directors and other key persons (including consultants).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the 2020 Plan generally expire 10 years from the date of grant and typically vest over a 4 year service period with 25% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially reserved 2,074,325 of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to 4% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by the compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is 5,460,391 shares as of March 31, 2023, of which 253,084 shares remained available for future grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options granted in 2022 under the 2020 Plan to employees generally expire 10 years from the date of grant. There are three potential vesting conditions for the 2022 grants including: (i) 25% per year over four year service period, (ii) four year service period with 25% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years; and (iii) monthly vesting over four year service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023 and 2022, the Company granted options to purchase 2,076,950 and 1,111,569 ordinary shares to employees and non-employees, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Inducement Option Award&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022, the Company granted to its new chief executive officer a non-qualified share option to purchase up to 600,000 ordinary shares as an inducement grant. The non-qualified share option has a 10 year term and vests one-fourth on August 1, 2023 and the remaining three-fourths in equal monthly installments over the following 36 months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#x2019;s 2020 Plan and the Company&#x2019;s standard form of non-qualified share option agreement. &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the changes in the Company&#x2019;s unvested restricted share units during the three months ended March 31, 2023 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and Outstanding as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023 and December 31, 2022, there was $4.4 million and $2.6 million of unrecognized compensation cost related to unvested restricted share units, respectively, which is expected to be recognized over a weighted-average period of 3.2 years and 3.0 years, respectively. The exercise price of restricted share units is at a nominal value less than $0.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Share Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s share options activity for the three months ended March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,034,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,434,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was less than $0.1 million and $4.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#x2019;s ordinary shares for those share options that had exercise prices lower than the fair value of the Company&#x2019;s ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value of share options granted was $8.27 and $11.38 per share during the three months ended March 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023 and 2022, there was $42.3 million and $35.2 million of unrecognized compensation cost related to unvested share options, which is expected to be recognized over a weighted-average period of 3.1 years and 3.4 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Option Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the three months ended March 31, 2023, and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of underlying ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8cae53ddb92e46c3b992b638b4a42023_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjAz_7b2b42e1-5025-435c-9b72-cc856198b133"
      unitRef="shares">1600329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1143bd0e2ad345caa5c640706694c0b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5MQ_a5f8413f-c60b-4014-beda-895c25ecd259">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i40dc657ea5ac431794e05ae7a1ce76d8_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjM1_18518358-ce22-4351-bb95-c9a6fdfed435"
      unitRef="number">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i35930be1fdbb4fa798087223a146bcb9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTA3MA_5e6778f8-fe71-455b-bf07-37ede7de656b"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6f0a16794335461d959dba6be9403f37_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODMwMQ_36dabdd6-f309-4b6d-88bc-0cfb68fc7f20">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i407fd6f5b5ed4bcaafd6554faeeaf095_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODMwMg_4f8ef2dc-3a12-4d2a-b371-94a82730b5df">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i407fd6f5b5ed4bcaafd6554faeeaf095_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTQwNA_91dd2f45-ee30-4db9-bf39-f1271399061d"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i35930be1fdbb4fa798087223a146bcb9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTU1OA_3a557ffa-4557-4632-af83-130265947434"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i35930be1fdbb4fa798087223a146bcb9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTYwOA_6d24cfba-3da1-4d68-b55a-2c8f5c71d229">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1adb7d0ef4fb497d9b87d9bed2778ce5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODMwMw_399dd3c0-53f1-4cce-8cd5-3accdcf48ffb">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1adb7d0ef4fb497d9b87d9bed2778ce5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTc5OA_adcfb4a0-160b-40b9-9e34-64f7d0abe807"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTkwOA_9d9db1f7-5790-4022-94f6-a5bab5ca5036"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTk0Nw_d44fa919-b3a2-4911-b17f-6fd74913683f">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice
      contextRef="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMjE1Ng_776716db-3587-4dab-b79c-6f8a630d55d7"
      unitRef="number">0.20</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays
      contextRef="i72c09a2b4cae4c439c34d4056f91949d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMjIwMg_ebf3eb45-d171-458b-a11b-8040443cfb8c"
      unitRef="day">5</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i00a9c14553ea40949dd06a45c06c9b03_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMjYxOA_09e586f9-5eca-4a2d-8e3e-b9cc59c6ab3e"
      unitRef="shares">340053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum
      contextRef="i00a9c14553ea40949dd06a45c06c9b03_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMjkwNw_cd94ac78-393d-47c1-ab47-b22b003cb207"
      unitRef="number">0.01</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance
      contextRef="ie31fdecdb0224ff48a4b130a9225404d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMzAwMg_80a9c143-a8d5-4ccb-8a47-dc5901e0ee01"
      unitRef="shares">510080</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod
      contextRef="i31e66ff9fe5f4627ae22fcc1d62c3001_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMzQwNQ_bc134ac3-6079-4978-abf8-ff217b664566">P6M</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i31e66ff9fe5f4627ae22fcc1d62c3001_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMzUzOA_f194a98c-420e-4abf-abd6-6c4e99673058"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i395fbda845a44eac841de73744035c26_D20200901-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDEzOA_c0c68cac-cfbe-4af3-ad77-2974f7aaaca7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i395fbda845a44eac841de73744035c26_D20200901-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDE5MA_ce876f6b-8914-4c19-9df6-0cbcebe7a4f9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i395fbda845a44eac841de73744035c26_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDIxOA_6d1b2ad1-4cf6-4f28-8506-8aa3ef9a46ef"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2d15bad6c8da46cf885b153b00184437_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjUy_c1259cb2-eeb9-4c7b-9582-f7d69d39dcca"
      unitRef="shares">2074325</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease
      contextRef="i2d15bad6c8da46cf885b153b00184437_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDY0MA_1c1b3163-30cc-4dde-bffd-c69a6d1fd126"
      unitRef="number">0.04</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease>
    <us-gaap:SharesIssued
      contextRef="ie0831ccc811b4e5d84580b833bf10c0e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjYz_57eef420-510a-4d9a-90c1-857c1d01a8a9"
      unitRef="shares">5460391</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9aa096c9847d432ebe62c81328b458a2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMjg5_cc145a91-7d7b-4d2c-96a9-9b31edb2c3d2"
      unitRef="shares">253084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3183dfe431c04796b01b1c6fdb1a0756_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTIyMA_9ea9b07f-bdaf-4883-82df-a1afc08e3d3a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i338fadaff380485fbfe31f0080cdd810_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTMyNw_6520e1e3-584f-46ca-b668-245496b47ac0"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i338fadaff380485fbfe31f0080cdd810_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5NA_880522ee-cae4-4d9c-9cba-441551b7229d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iea26013103954eadb8a7947d75c821d7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5Mw_626ae6c9-a0e9-4c0f-815e-2f83bd954166">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iea26013103954eadb8a7947d75c821d7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQwMQ_6092ef4e-27b2-441f-85fd-edfb95d81326"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i837240d0e61b4f5780239e38d5361ef5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5OQ_462ccb29-6f8b-43b3-b551-757e18a4e7a6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie31fdecdb0224ff48a4b130a9225404d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMzI2_a2a4a06e-9737-4e48-9ad7-fc01327825ce"
      unitRef="shares">2076950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i696b4083af51453a8c2cfb18cfdb4482_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMzMw_e418aa98-268a-4bdb-91e6-b6f61849bc3b"
      unitRef="shares">1111569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i15ccc93511924535a1cde0fc5143bb33_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTkwMw_6a7c1db6-dc15-41ce-8120-f1759b9a58af"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia22f0d118f1942caa4258c79bae792fb_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5NQ_fc970074-685f-4c1f-9101-9e65de3c8bff">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia22f0d118f1942caa4258c79bae792fb_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNjEyOA_b6c81507-dc07-4741-830e-fd3003751d05">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5Nw_a30f9d33-994c-4e19-8d02-4e59a952c8f1">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the changes in the Company&#x2019;s unvested restricted share units during the three months ended March 31, 2023 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and Outstanding as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="ie8ab588a8f374a63b091c9535ea47d6d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMS0xLTEtMS0xNDAxNjI_4de73338-8ac6-4868-8d2d-04d4433cbc9c"
      unitRef="shares">271135</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie8ab588a8f374a63b091c9535ea47d6d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMS0zLTEtMS0xNDAxNjI_02c51038-3fcb-4884-b1ea-c6a074718a71"
      unitRef="usdPerShare">12.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMi0xLTEtMS0xNDAxNjI_634cf52a-506f-4f0f-9b70-3824b8271bad"
      unitRef="shares">175750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMi0zLTEtMS0xNDAxNjI_79383388-50fe-43d0-a5cb-ff7b4cd9bb5a"
      unitRef="usdPerShare">10.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod
      contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMy0xLTEtMS0xNDAxNjI_0543440d-e085-48da-9799-76ea978659b1"
      unitRef="shares">31856</cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfMy0zLTEtMS0xNDAxNjI_e6636bdd-a726-45c2-a94b-061c2bb44fd5"
      unitRef="usdPerShare">12.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfNC0xLTEtMS0xNDAxNjI_b92c65d0-714c-4773-8da3-0356cfb60720"
      unitRef="shares">7500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfNC0zLTEtMS0xNDAxNjI_e16628dd-b9a5-47b2-ae33-04c6d4126768"
      unitRef="usdPerShare">12.42</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i9aa096c9847d432ebe62c81328b458a2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfNS0xLTEtMS0xNDAxNjI_7ae178ae-c4ec-426b-8263-7eecbe37ebca"
      unitRef="shares">407529</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9aa096c9847d432ebe62c81328b458a2_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjczNWNhYTZjYjMzNjRhODFiNTY1OGIxNTM5MTQ1NzNiL3RhYmxlcmFuZ2U6NzM1Y2FhNmNiMzM2NGE4MWI1NjU4YjE1MzkxNDU3M2JfNS0zLTEtMS0xNDAxNjI_52cf0bdf-b9d3-477c-8086-0344896201b1"
      unitRef="usdPerShare">11.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9aa096c9847d432ebe62c81328b458a2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTU4OA_b74c940f-c16f-4839-8049-23558e35ab78"
      unitRef="usd">4400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie8ab588a8f374a63b091c9535ea47d6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTYwNg_b4c12d20-11c3-488c-b78f-a7902acf3b0f"
      unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfMTA5OTUxMTYzNjc0NQ_a6089194-3e9d-4f17-a432-5729719011ba">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia7cedba3e82645e49ca80bcc90a72a68_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTYxOA_64095855-52aa-4d7b-b7eb-768da83bfbf7">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice
      contextRef="i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyMzY0_791c90fe-230c-4a8d-adb4-6abab96cca6f"
      unitRef="usdPerShare">0.01</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5Mg_331695e9-8660-452e-84cf-a20ef7114096">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s share options activity for the three months ended March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.197%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,034,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,434,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia91e30a56bc9415dbd1e86b1d6ec64dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMS0xLTEtMS0xNDAxNjI_5320dea9-cc41-4418-89ee-b832fa595487"
      unitRef="shares">5092732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMS0zLTEtMS0xNDAxNjI_52546804-c9cc-44e4-b481-135475fa10a3"
      unitRef="usdPerShare">13.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iab7fb606ccca48e58144d35f683e689d_D20221231-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMS01LTEtMS0xNDAxNjI_1f14e88e-3e56-4d89-a7f3-8ee2cf47ceb5">P8Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ifca3cadf83964b62a844d82c3b5e7165_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMS03LTEtMS0xNDAxNjI_7bdc3e93-488e-4d48-bc33-85e5f5724f10"
      unitRef="usd">13013000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMi0xLTEtMS0xNDAxNjI_69fb53a1-0114-45b7-8c1a-f003965b34f1"
      unitRef="shares">2076950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMi0zLTEtMS0xNDAxNjI_5a800471-caeb-434a-8d54-6b108a630b3f"
      unitRef="usdPerShare">10.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMy0xLTEtMS0xNDAxNjI_c682e69f-5388-457d-8893-09835c91c746"
      unitRef="shares">3790</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfMy0zLTEtMS0xNDAxNjI_5f9ff093-c590-4ccd-a396-1e2b11f0d736"
      unitRef="usdPerShare">0.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNC0xLTEtMS0xNDAxNjI_4c1b5ea2-c321-4aec-9c63-411657953837"
      unitRef="shares">131350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNC0zLTEtMS0xNDAxNjI_ebdd5f96-de15-4d65-835f-a4d0da2545c2"
      unitRef="usdPerShare">24.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNS0xLTEtMS0xNDAxNjI_88ae7c0c-a95a-4ce1-b481-7bec494a561d"
      unitRef="shares">7034542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNS0zLTEtMS0xNDAxNjI_6b9ff598-9dc7-4ff4-a4a4-1bcbab33dbcb"
      unitRef="usdPerShare">13.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i56c06e81a4384be9a4547b9d54649e6c_D20230331-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNS01LTEtMS0xNDAxNjI_530169d9-bb14-41a2-8331-9c2e7c97f41d">P8Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNS03LTEtMS0xNDAxNjI_7fa6e653-9037-4f24-a907-be4e5fa7256f"
      unitRef="usd">17648000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNi0xLTEtMS0xNDAxNjI_9f71f802-5ab0-4261-a765-d4e22157f557"
      unitRef="shares">2600262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNi0zLTEtMS0xNDAxNjI_a3d328ab-d41d-4d10-becf-1e0efe43973e"
      unitRef="usdPerShare">10.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i56c06e81a4384be9a4547b9d54649e6c_D20230331-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNi01LTEtMS0xNDAxNjI_4004a5b5-0e3b-42a0-85d7-8039c6ad62ea">P7Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNi03LTEtMS0xNDAxNjI_87fd11bc-ace4-426d-a899-4f85b9e8c82f"
      unitRef="usd">15048000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNy0xLTEtMS0xNDAxNjI_4c063b34-31d8-4199-bba5-8b9be4d77e46"
      unitRef="shares">4434280</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNy0zLTEtMS0xNDAxNjI_169012be-b00c-45f4-96a6-f711141c17cf"
      unitRef="usdPerShare">14.65</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm
      contextRef="i56c06e81a4384be9a4547b9d54649e6c_D20230331-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNy01LTEtMS0xNDAxNjI_d330dbdc-954c-4509-90f7-1e5944cb5554">P9Y3M7D</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOmVkZThlZjMxYjVkNzQyYTM4ZjNmZWM5YTI4ZDQ3MzYzL3RhYmxlcmFuZ2U6ZWRlOGVmMzFiNWQ3NDJhMzhmM2ZlYzlhMjhkNDczNjNfNy03LTEtMS0xNDAxNjI_bf3dfdb5-564d-44ff-b406-6839d09a19db"
      unitRef="usd">2600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNTQ5NzU1ODIyOTEx_bc71033b-edb3-4148-8fed-811ca241ce27"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTYzMg_78d14cb0-6c9c-40e6-8da2-c052acf8d9d3"
      unitRef="usd">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTY3MA_b6312347-804c-4ed7-a217-57cf2926d846"
      unitRef="usdPerShare">8.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTY3NA_ef58503c-256d-4048-8863-ce85b0ea663e"
      unitRef="usdPerShare">11.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTc0MA_20aeb0d4-1f97-46b7-93fa-bda242a61eda"
      unitRef="usd">42300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i7765db2674724718901c035cce089b95_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTc0Ng_52e87388-8976-4b1b-a278-c8547dcfc520"
      unitRef="usd">35200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6c1c0a2584554db98438e2f27622af72_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTc1Mg_5486e295-8441-4b49-96b8-1e22a95d5d06">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i478445e4a46e43758c8383eb32aaf0ba_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfNDM5ODA0NjUxOTc1Ng_c8119729-47f2-49d8-8928-48ba1a8d5fba">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI5MA_dd44ef2d-55b0-492a-9e3e-6c4810c91d7f">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the three months ended March 31, 2023, and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of underlying ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfMi0xLTEtMS0xNDAxNjI_d52b294e-13aa-448f-abac-13caada39b3e">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfMi0zLTEtMS0xNDAxNjI_5762af2e-1e7d-48cf-945f-9279de82c1bd">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfMy0xLTEtMS0xNDAxNjI_bfefc78e-540b-48bd-827c-0910840b7f43"
      unitRef="number">0.8712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfMy0zLTEtMS0xNDAxNjI_396752d8-ea49-497f-b76b-7c42b111c2d3"
      unitRef="number">0.8020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNC0xLTEtMS0xNDAxNjI_5695bbbf-a632-4908-aa9b-f0442d3a599d"
      unitRef="number">0.0347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNC0zLTEtMS0xNDAxNjI_237dc58e-9165-4c2c-a2e6-feaa75b64b45"
      unitRef="number">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNS0xLTEtMS0xNDAxNjI_5d3a6446-ca64-487b-97a6-84e3d5fea52d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNS0zLTEtMS0xNDAxNjI_a256fda2-c383-4e50-a273-382fee7c515f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNi0xLTEtMS0xNDAxNjI_a2b820bc-7c49-431c-b2a4-776e7b4ae270"
      unitRef="usdPerShare">10.85</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjRlN2ZhNzg0NTBjYTRiZmI5ZjUyZDMyNDQ1NmY0YWJiL3RhYmxlcmFuZ2U6NGU3ZmE3ODQ1MGNhNGJmYjlmNTJkMzI0NDU2ZjRhYmJfNi0zLTEtMS0xNDAxNjI_84351bdc-1152-4b91-8eb6-ed42f0293d6a"
      unitRef="usdPerShare">15.98</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RleHRyZWdpb246MDIxOThmMTQ2MzE4NGRmM2E5NGYyNDkzMGQ3NmFiZjVfODI4OQ_8ac9bf4c-f5f9-4ee5-9247-d371576773b5">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5872a113b2294faaad1b68db7ae836e2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfMi0xLTEtMS0xNDAxNjI_cd26c2d4-f87b-4aa3-8514-3ec3a8cd76a7"
      unitRef="usd">2244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b25b7dbd74c4562b936a90dfd191b50_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfMi0zLTEtMS0xNDAxNjI_2df645ed-c736-437f-bfdf-a5ece830e159"
      unitRef="usd">1792000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice52714f9f134f59b22998dd73137b2a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfMy0xLTEtMS0xNDAxNjI_50b9e90d-228a-4a54-94c6-99649afd2e18"
      unitRef="usd">1827000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id60ff16effaf4307b5d9f1c7ce5bc358_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfMy0zLTEtMS0xNDAxNjI_daee672f-4849-4afe-a3e8-9165e8e9f069"
      unitRef="usd">1336000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfNC0xLTEtMS0xNDAxNjI_83a2a2c7-7427-4af6-ab16-68c2225311da"
      unitRef="usd">4071000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF83My9mcmFnOjAyMTk4ZjE0NjMxODRkZjNhOTRmMjQ5MzBkNzZhYmY1L3RhYmxlOjYzNTk3MjBjZWMwNjQzNWY5MGUzOGU4YjcxZjVlMGE2L3RhYmxlcmFuZ2U6NjM1OTcyMGNlYzA2NDM1ZjkwZTM4ZThiNzFmNWUwYTZfNC0zLTEtMS0xNDAxNjI_9ff76162-d389-420f-97ad-3d50b950db9b"
      unitRef="usd">3128000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RleHRyZWdpb246ZDNhNjIzYjI0NjA5NGY3ODkyYjdlOTNiMDk4YTBjMjVfOTc4_d63717d0-5f52-4c08-9a47-fc45e29c87a3">Net Loss Per Share&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of ordinary shares used in net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,725,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,036,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, and options granted, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share attributable to ordinary shareholders is the same. The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,034,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,559,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,442,071&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,756,183&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RleHRyZWdpb246ZDNhNjIzYjI0NjA5NGY3ODkyYjdlOTNiMDk4YTBjMjVfOTc5_f6e53e48-97af-4061-8112-21e1fc77f610">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of ordinary shares used in net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,725,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,036,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfMy0xLTEtMS0xNDAxNjI_5871db2d-7472-4335-a66b-ee9cca113e3e"
      unitRef="usd">-24208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfMy0zLTEtMS0xNDAxNjI_30bc1723-b610-4796-81b3-b8d1ee3da9a5"
      unitRef="usd">-21171000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNC0xLTEtMS0xNDAxNjI_455ff1bf-fd85-4a59-a84f-189aed91c4d0"
      unitRef="usd">-24208000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNC0xLTEtMS0xNDAxNjI_7acacb66-08c7-4964-998a-57858e2c0aa8"
      unitRef="usd">-24208000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNC0zLTEtMS0xNDAxNjI_2d321a80-27ae-4e28-aa0e-0c4adee084eb"
      unitRef="usd">-21171000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNC0zLTEtMS0xNDAxNjI_78feaafa-02e0-4e62-a0da-865badbda30f"
      unitRef="usd">-21171000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNy0xLTEtMS0xNDAxNjI_a1836849-b40d-405e-8b7d-05311dbbf130"
      unitRef="shares">42725863</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNy0xLTEtMS0xNDAxNjI_ae02944a-db84-45aa-a148-88eacc7c752d"
      unitRef="shares">42725863</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNy0zLTEtMS0xNDAxNjI_600bd655-63ef-4098-ae7e-977646c100dd"
      unitRef="shares">42036563</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfNy0zLTEtMS0xNDAxNjI_c2ca3b39-4939-4d9f-a63c-384bae0dec7c"
      unitRef="shares">42036563</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfOC0xLTEtMS0xNDAxNjI_714253ed-6b79-4c65-8756-6348aefd7e4b"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfOC0xLTEtMS0xNDAxNjI_889447ea-3d99-4a49-835c-64843c232c0f"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfOC0zLTEtMS0xNDAxNjI_724ac107-4fb8-497c-843f-14f56ceab36f"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjRjY2FjMTRhMWU0OTQ2ZGQ4MGI4ZDE0NTk3ZWYxMzk1L3RhYmxlcmFuZ2U6NGNjYWMxNGExZTQ5NDZkZDgwYjhkMTQ1OTdlZjEzOTVfOC0zLTEtMS0xNDAxNjI_850947f5-9440-4004-953c-8a7ed17972de"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RleHRyZWdpb246ZDNhNjIzYjI0NjA5NGY3ODkyYjdlOTNiMDk4YTBjMjVfOTgw_2bf88db9-5cf0-41a0-92f7-a98bcb9088b8">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,034,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,559,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,442,071&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,756,183&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic1623488c9f64721a60c4349e61ce8bf_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfMi0xLTEtMS0xNDAxNjI_3033e67a-3031-43bb-acf7-b940ddc9c107"
      unitRef="shares">407529</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie2b773ca49914d34bba229e76da492dd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfMi0zLTEtMS0xNDAxNjI_e0915a29-803c-477e-8a75-7ae4f971795c"
      unitRef="shares">197071</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i73ea83c879704be889d92560678ef374_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfNC0xLTEtMS0xNDAxNjI_5919c6df-f225-4cd3-a958-b175f224949c"
      unitRef="shares">7034542</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i122471b5c0c34e05bdaaf376bf6de99c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfNC0zLTEtMS0xNDAxNjI_a367f7d7-e2e5-44ae-9f82-7e1e012edd94"
      unitRef="shares">4559112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfNS0xLTEtMS0xNDAxNjI_866297de-58d0-4b5f-91d9-46568a6b081a"
      unitRef="shares">7442071</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84Mi9mcmFnOmQzYTYyM2IyNDYwOTRmNzg5MmI3ZTkzYjA5OGEwYzI1L3RhYmxlOjBiZmQ1ODgxZmZlZDQ1NzdhYWNlNWE1NWVlMmY3ODQxL3RhYmxlcmFuZ2U6MGJmZDU4ODFmZmVkNDU3N2FhY2U1YTU1ZWUyZjc4NDFfNS0zLTEtMS0xNDAxNjI_5dabe619-15d6-41ba-9013-d89e8950eab4"
      unitRef="shares">4756183</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwNA_412b888c-bc4e-4af9-8d6d-2ab6f65f27f2">Right of use of assets&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New York, NY&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company entered into a twelve month membership agreement with WeWork for rentable office space.  The membership is cancellable with 90 days&#x2019; notice.  This agreement is accounted for as a short-term lease as the Company is not reasonably certain to extend the lease beyond twelve months and is therefore not recognized on the Company&#x2019;s condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Soho, London, UK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a two-year operating lease with Fora Space Limited commencing on September 1, 2021. The noncancellable term is 24 months and there is no option to extend the lease. The recurring residency fee per month is &#xa3;136,200, and the Company paid a refundable deposit of &#xa3;136,200 at the execution of the agreement. Additionally, at the start of each calendar year, the monthly residency fee is subject to an automatic inflation linked increase of the previous year&#x2019;s amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Denmark Hill, London, UK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company entered into an agreement for a lease with South London and Maudsley NHS Foundation Trust for land and buildings at 5 Windsor Walk, Maudsley Hospital, Denmark Hill, London, UK. The lease commenced on June 21, 2022 and has a contractual term of five years. The rent is &#xa3;180,000 per year, with no deposit payable, and payment dates occurring once per quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s costs included in its condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through March 31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the future minimum lease payments due under operating leases as of March 31, 2023, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ibbeae02a508346edb94df36fd8e95a81_I20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwNg_a672912b-2fcf-4638-8241-45c14a228333">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cmps:LeaseCancellationNotificationPeriod
      contextRef="iba372f6eca8f430eb43a67755847815d_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfNjIx_616ab972-8ff7-4415-b7d1-cd552d4f4c91">P90D</cmps:LeaseCancellationNotificationPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i7678bc3cc61d4f73b03996330cea7a9f_I20210731"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwMQ_be01a497-8717-4279-a81a-7046444c73c1">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cmps:OperatingLeasesNoncancelableTerm
      contextRef="id87803bd77d841e3917a974e88083e5a_D20210701-20210731"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMTU4MA_b0b47e9c-aad3-4e21-9c65-eecbdd917aa4">P24M</cmps:OperatingLeasesNoncancelableTerm>
    <cmps:OperatingLeaseMonthlyPayment
      contextRef="i33bec60d253644c1918ad73a71213b08_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMTY3NQ_4f35ac9e-607c-457b-8282-7fab3461e1d2"
      unitRef="gbp">136200</cmps:OperatingLeaseMonthlyPayment>
    <cmps:RefundableLeaseDepositPayments
      contextRef="i33bec60d253644c1918ad73a71213b08_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMTcyNA_543fd966-4c3e-4432-bf2e-9065b6f06742"
      unitRef="gbp">136200</cmps:RefundableLeaseDepositPayments>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8636ff5e270740d08068434308a1c41a_I20220621"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMjczNg_2a4235c0-6a72-4b27-b3e9-77db39a1412f">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cmps:OperatingLeaseAnnualPayment
      contextRef="iccc7b27ad5a34f7986912f9169f8eac5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMjc1Mg_29179127-b2e4-425c-b405-f70cc488bf28"
      unitRef="gbp">180000</cmps:OperatingLeaseAnnualPayment>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwMg_17288933-18fe-421d-be29-3b86dfb73988">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s costs included in its condensed consolidated statements of operations and comprehensive loss related to right of use lease assets we have entered into through March 31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMy0xLTEtMS0xNDAxNjI_08881d8d-0e12-4ba1-ba62-73ea390bbdc2"
      unitRef="usd">573000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMy0zLTEtMS0xNDAxNjI_b5d43cc3-8053-432c-96fd-edf2983a675c"
      unitRef="usd">560000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfNS0xLTEtMS0xNDAxNjI_2d627c8a-3004-461d-b83d-d774609a52c2"
      unitRef="usd">87000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfNS0zLTEtMS0xNDAxNjI_ef8949e1-bfe7-4172-9873-c3b12d5fcbe5"
      unitRef="usd">86000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfNi0xLTEtMS0xNDAxNjI_9006e23b-cc3f-4492-a3d4-9405a8d3cecb"
      unitRef="usd">660000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfNi0zLTEtMS0xNDAxNjI_5dab5a34-7269-4329-bfaf-210df87c8ed1"
      unitRef="usd">646000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfOC0xLTEtMS0xNDAxNjI_fcf3cd62-3881-4b57-b664-beed9723f5f2"
      unitRef="usd">562000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfOC0zLTEtMS0xNDAxNjI_1c753526-621e-4ef3-88df-0e91e06e97b4"
      unitRef="usd">578000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfOS0xLTEtMS0xNDAxNjI_e1b66890-99a5-4484-b105-db20b89253d4"
      unitRef="usd">102000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7c9bd58e0ceb4377a9d3107d1d58c27a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfOS0zLTEtMS0xNDAxNjI_aca67f03-cea7-486f-afeb-30b37f4c7985"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMTAtMS0xLTEtMTQwMTYy_c0cc5573-3632-489b-a717-d27b3837fbec">P1Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7765db2674724718901c035cce089b95_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMTAtMy0xLTEtMTQwMTYy_fff85470-c8fb-4816-bce1-d104d6362c6a">P0Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMTEtMS0xLTEtMTQwMTYy_8898dc8f-3ccd-4579-bfeb-4126b8f870ce"
      unitRef="number">0.0601</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7765db2674724718901c035cce089b95_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjAwMDQ3OTEyZTQwNzQ4YjFhMWY1ZjViNzJlYzNiMzlhL3RhYmxlcmFuZ2U6MDAwNDc5MTJlNDA3NDhiMWExZjVmNWI3MmVjM2IzOWFfMTEtMy0xLTEtMTQwMTYy_44a6196f-c2f1-4e6c-a942-c0c6ec93de17"
      unitRef="number">0.0467</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RleHRyZWdpb246Mzk4NWYyNjQxNmQwNDBlNGIxMDExZGU4ZDQ1M2UzMWVfMzIwMw_7ad1a4cc-7f5a-4831-8891-efa377a007e5">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the future minimum lease payments due under operating leases as of March 31, 2023, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfMC0xLTEtMS0xNDAxNjI_91fc719e-43fb-425e-b5d6-bb968783c04f"
      unitRef="usd">1058000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfMS0xLTEtMS0xNDAxNjI_5b9b1c4b-9e95-445a-a13f-5a254404e92b"
      unitRef="usd">271000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfMi0xLTEtMS0xNDAxNjI_e1bbda0a-1aab-4710-8968-554c747ce719"
      unitRef="usd">223000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfMy0xLTEtMS0xNDAxNjI_a2325d24-c015-4f6f-8460-99ee43515421"
      unitRef="usd">55000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfNS0xLTEtMS0xNDAxNjI_92d2b147-628a-418d-8a3b-096d9e593982"
      unitRef="usd">1607000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfNi0xLTEtMS0xNDAxNjI_5ccbc978-2535-4ead-a388-a9887875bfe6"
      unitRef="usd">83000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i152e65e381d441028d0e315d17e7e808_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84NS9mcmFnOjM5ODVmMjY0MTZkMDQwZTRiMTAxMWRlOGQ0NTNlMzFlL3RhYmxlOjUxYTFkM2QyMzk2ZDRiMDc4NWMzMzY4NTM1YTE0Y2M4L3RhYmxlcmFuZ2U6NTFhMWQzZDIzOTZkNGIwNzg1YzMzNjg1MzVhMTRjYzhfNy0xLTEtMS0xNDAxNjI_0bd42205-1c60-410d-99da-6f482d2ebedf"
      unitRef="usd">1524000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF84OC9mcmFnOjliMzI0MGU5NTE0OTQ1ZjA4NDk0YzA3MDljNmIzM2EzL3RleHRyZWdpb246OWIzMjQwZTk1MTQ5NDVmMDg0OTRjMDcwOWM2YjMzYTNfMTMzOQ_a708bb78-4a08-442c-963f-7fe374bb3e4f">Commitments and Contingencies&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of March 31, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#x2019;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i37033c72113244f3aee8649c4898c51e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYyNzgwMg_62342abb-3c51-488f-bbe0-1fc789695e54">Subsequent Events&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, the Company entered into a two-year operating lease with Fora Space Limited commencing on September 1, 2023. The noncancellable term is 24 months and there is no option to extend the lease. The recurring residency fee per month is &#xa3;130,000, and the Company paid a refundable deposit of &#xa3;156,000 at the execution of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2023, through May 10, 2023, under our Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may issue and sell its ADSs, each representing one ordinary share, we sold 2,824,202 ADSs, resulting in $26.9&#160;million in net proceeds.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idd439c7411164a75bab3f2705e3ffb57_I20230430"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjExMw_c971eb13-a772-41b6-91a8-4065a43eaabd">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cmps:OperatingLeasesNoncancelableTerm
      contextRef="i4c4ad1b7be0048e289dcf0230cc72a31_D20230401-20230430"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjA3NQ_ca637523-d9c8-4ccf-806b-0f0be678cad4">P24M</cmps:OperatingLeasesNoncancelableTerm>
    <cmps:OperatingLeaseMonthlyPayment
      contextRef="i4c4ad1b7be0048e289dcf0230cc72a31_D20230401-20230430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjA5NA_f2c64303-290e-4363-9d29-a33380665fd6"
      unitRef="gbp">130000</cmps:OperatingLeaseMonthlyPayment>
    <cmps:RefundableLeaseDepositPayments
      contextRef="i4c4ad1b7be0048e289dcf0230cc72a31_D20230401-20230430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjEwNA_fb1f5b80-c636-4bfe-b3b2-1c0abd71f672"
      unitRef="gbp">156000</cmps:RefundableLeaseDepositPayments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjkwOQ_2f64d186-54c8-4104-a045-094310bbc13a"
      unitRef="shares">2824202</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iea51b6a765944cd995e3725b1074692b_D20230401-20230510"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMjkwNWE3Yzk2NTQ5MTZiZGQ0NDEzNTBjNzY1MTIwL3NlYzoxMzI5MDVhN2M5NjU0OTE2YmRkNDQxMzUwYzc2NTEyMF85NC9mcmFnOjEwYTg1ODUwMmU4NzQwNzVhYTczZGEwYjk5MzIyZDJkL3RleHRyZWdpb246MTBhODU4NTAyZTg3NDA3NWFhNzNkYTBiOTkzMjJkMmRfMTA5OTUxMTYzMjkyMA_bc3d572d-2144-42ca-bb02-41b69894be96"
      unitRef="usd">26900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%L25WQNT\VJGS;SP\@W(E'CF&T&QZ59>+3<YQ_G67J=ZO-@AO>?F?9F24"Q
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M#Z@4&+*D*#_!4V7KX@D(MP5GZ7ZP4)#&6?5-GO<WHC4 V@,#T'X .G0 W@_
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M;Y8H7W["L\M3E.0H9DL.KYU9/*%EN_>)[$Z*=%.];.)'6A3INCI<L7#!LM*
M?[],T^+MI'Q_Q?ZM+I?_!U!+ P04    "  M.*M6ONCK,5<'  #]'P  &
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M?Z-WA\IU53HYD7'ZE-6>6,;4:EKGE/$[D;(]-W4+-W6=\?M(E=(P)EF]32-
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MTM80=U:8[KLTX?P3C5@T&TDS_Q1358-\](!M26;TSA:I/D80)]L1D]L_38^
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MB,'S+HPB0"X7D%16W'W7$$AB#R/+]N*KY75Q L"U;<$>61^U-YP76?6E?"Q
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M,6;+S:&D-)J911^>)3Y7_#V]4&@F-K#X0-8NDF 5TLX&,[#NA=!7+%MM;1&
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M+ <YP=C,%R'B5UC'UT_EX&?@Z0=S9X>]AH/^(CTFVO%3$<]+LB&5@YWF_6-
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MO"W3CNA*U+PMN4$\EC2FEZY'K[H1;0SY&RDI&+X1-YQM"$>?^- 74L*(=D.
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MNF;#/ZZMH7W% _0];AWWOV""\(=F7OTO4$L#!!0    ( "TXJU92H61@XP(
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MR6;A9#0.D^G!2RW:N\6IUVW\6X4ZK0M4>Z'WJ_USZ*I]!3R)MV\ILFO#B8W
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M/'IS50B?'QEY$%V;+O:5BW@FI+\UWF7D>0/6UPX1]P-V,+ST%E\!4$L#!!0
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MY] D^'4ME:GCRG$$_/2<Y>.[;U[.9R]>N6236^L,6US:(FAJO@ZJ.J&70=S
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M5X@6L:2,.0$&]80F3K-_<N3*_E3B1E5 TJ#RG0^D!G>E!XH!T4FJ<O>G1GJ
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M@VDR%5;GZ2D1(4FJ&/;%.+B#5O<W[9=I7*=\1UMA\WIPV3'F2),K1]F $"O
M)%3#=!!%1OTDK?%;END17HTJ-6'[UP5@R I.LZN[^(3@=0GQ**.*$GO>IR*>
M5/CL\A[="+P&Z0I9MA4WF(&DQ1S6>RC9NP^0R4 -.!PBY3U$T2>>9(C8C HW
M8[6( &N8XYVME]HP'-3WCU2&LSGXOVGV*V1_>6.QW82SUEG7 Y0*=KCFM)N9
M )DCANM(CTNPEI0\T)?O+UF +KRH\>.7D).1#^@\?7%U>8DSU;9=K85T43'!
MYV=;_QX+.RJBRA)( Q*.?DX736-H70F0#-C5_$M'L61<P3&<0P? VBO;X=W
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M6)PLT/8Q)!'C!0[^I0,\UA)X#S7%CG9YW#J=-GM*9]C>\VD3* SWM]GT)-N
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M85GRY$;K$SA>&$.[C2_0_R](_P%02P,$%     @ +3BK5CWW7_+F @  3 8
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M"9OMWCB O#56U5MC8E!SV;W9RS8/IQBD6X/4\^X<>99WS++Y5*L-:+>;T-S
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M& UXI2AA,!%(5D6!Q>L8*%\,O=!;+3R0?*[,@C\:E#B'*:C'<B+TS&]94E(
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MZ<;+#N>ZU05A O3[C'.UFI@-VN9Y] =02P,$%     @ +3BK5D5N)$_8!@
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M70<J;U[?=75#LK*Z+A9,JLNG>LS4YP%P':#&4\;DKJ%OH/:#(_H+4$L#!!0
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M\H_%4TC; S(K7ERDK/Y)GIJVMN@QWC!>9&VP6,Z2O/D=?6U/Q$Z X/0'&&V
M<6S J T8[0>,7P@8MP'C_0#KA0"S#3"/[<%J ZQC>[#; /O8'IPVP*FO;G,Y
MZFOI1CR:3LKBB915:T&K/M1"U-'B$B9YY>X=+\761,3QZ8=RGN1"6G*WBDK*
MR&N7\BA)V1ORCGRZ<\GK5V_(*Y+DY"9)4R$;FPRYZ+8*'L9M%]=-%\8+7>CD
MILCYBA$OG]-Y3_Q,'3\Z%.\=Z-\X! @.[(#J"(;BA&_/NO%\UJ\-)?$F^D9T
M[2TQ-&/4=T(.19=G9*2_&.X>'V[TG4YUN$MC9;A_?+C>=RW^W;&'ZO /,3\C
MFM/7NW0A1]L_GU'-&[W FZ418Z18D#M>Q _DCU_%=O*>TXS]V?>'TL#&_;#J
M-G7!UE%,+P?B/L1H^4@'TY]_TBWMESY)D# 7"?.0,!\)"Y"P$ 23Q!MOQ1NK
MZ%/O*RWCA-'*/58-W:185Y,!,8*+P;I>P][T*:C$GJI@ S-K6#5+>IR.['-M
M,GS<50O9HX>$^4A8@(2%()BDEKE5RU2J=<7?_;:B[\1(^R#FSA\6"UHF^;+/
M)27G5)>0,!<)\Y P'PD+D+ 0!).<L[;.6<C[J(44#PESD3 /"?.1L  )"T$P
M23Q[*YZM'.SNHK2YAU;>O6UOG"1A;$/GU6,/+Z.<1<US]H$[J[*C4Z5$PEPD
MS$/"?"0LL'^8C>BF[8PL>3X2@OJ4='.VNCE*W69BAI;,:1GQ)O<3T^11B%9(
MHO7)I<2>*A<2YB)A'A+F(V%! ]-'NW:=[:L%ZE%2ZWRKUKEZ)-O<,_IE0W-.
MZ&/U\SLY?B:G1)^J%Q+F(F$>$N8C80$2%H)@DH:ZUF44->1<KJ6!W(/27"C-
M@])\*"V TD(4339P)Z>M_U^3NK:GW4F%X1AC0S/DH7^FWJ63Q4/2/"C-A]("
M*"U$T63QC$X\X[^9WK5<:7IA6&?G^Y(INS]9,B3-@])\*"V TD(439:L*SGH
MRL3R]"H3T[@XRHE+UP5+^$[U[CMYGR<\B5)RN[E/DU@YYU-W<_*-%UJ.@-(\
M*,V'T@(H+4319#6[HH0^AD[]H,4(*,V%TCPHS8?2 B@M1-%D [O:A7Z@>)$5
M&_'L&VWXJBB3OWK+_==JQLG>02L74)H'I?E06@"EA2W-DK)_72E2UJDK2^C*
MY'/W]9CF$:%7)F@Q DISH30/2O.AM !*"U$TV;JN)J';T-LHM/( I;E0F@>E
M^5!: *6%*)IL8%>FT-5UBG_\]1(U]V07G6.^8-+;RM)-1V[G0??-A]("*"U$
MT61[NDJ$KBY%?*:,T_E!5:!%AY8F2: [IK7O"K2> *7Y4%H I84HFOQUV:ZF
M8"@SQM,[*85;TC2J!.,%>12J)?FR&J=$ UXF<;6A&;(V><(/#ECJCD^UL*5)
MZ6+=M/?R>&Y/,UVSS+UF'G3??"@M@-)"%$W6JRL8& <*!I3S]/"(I::<[,J/
MI05=,VQ[WQ5H*0!*\Z&T $H+4319J:X48*A+ 1_[1Z.N",5JY[*J4G](.V3V
M>@:EN2UM5V++,4?C_9$,6AR T@(H+4319.VZXH"A+@ZT4Z^\X,^J'9(+6@6
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MOY=KBRXZ@;WV%1>OJ5S\WBQO9<*ZR6==UB])@#/2&HD744="Q-!%# ],^!K
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M_OY#2:)ODJ;BGZ;;6Y3?;2X_SU678D5">N6H9"0HWU!G_/-/7M_]M8DMI%@
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MLE.1[&A)EL/U PMZ?,M:F*$D0X)Y3IMDDYBD]2T#&55H=BN:72W-'W8B%7)
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M,L:+(VC%C4BV^1FK^T2(),HO-XRN&,\*R-\?DD2\W&0&JH. \_\ 4$L#!!0
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M%WU\RWC6(683R3:ZR5HRB2V;'H;850-7 ?A\Q9@\3-0&19_N_0-02P,$%
M  @ +3BK5K,#'1]+ P  HPH  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&ULK99M;],P$,>_RBE,:)/&\M0G1EMIW4 @ 9I6!B\0+]S&;2P<N]A..[X]
M9R?-LN*6(NU-&]OW/]_/#^<;;J3ZJ7-*#3P47.A1D!NSN@Q#/<]I0?2%7%&!
M(PNI"F*PJ9:A7BE*,B<J>)A$42\L"!/!>.CZ;M5X*$O#F:"W"G19%$3]GE N
M-Z,@#K8==VR9&]L1CH<KLJ13:NY7MPI;8>,E8P45FDD!BBY&P55\>1U'5N L
MOC*ZT:UOL"@S*7_:QH=L%$0V(LKIW%@7!/_6])IR;CUA'+]JIT$SIQ6VO[?>
MWSEXA)D13:\E_\8RDX^"00 979"2FSNY>4]KH*[U-Y=<NU_8U+91 /-2&UG4
M8HR@8*+Z)P_U0K0$Z,<O2&I!LBOH[!&DM2!UH%5D#NN&&#(>*KD!9:W1F_UP
M:^/42,.$W<:I43C*4&?&G_&D?)1:PRU5,,V)HO *IGA8LI)3D MX2Y1@8MDR
M.(<)T6P.1&1PPWAI: :G-]00QO49JN^G-W!Z<@8G$(*V @U,P+U@1I]C)WY_
MR66I4:Z'H4$&&TDXK^.=5/$F>^)-X9,4)M?P5F0T>ZH/D;U9@&2[ )/DH,-/
M1%U &I]#$B6I)Y[KX^7)@7#29C]2YR_=X^_OY8;O5S-M%)[W'[[EJMQU_.YL
M$KC4*S*GHP!ON:9J38/QRQ=Q+WKC8WTF9T_(.PUYYY!W=Q(YGD0?9*7L.:5-
M3.OQJZ231(-AN&Z'[S.+XW[<F#T)K-L$UCTJ,"#&*#8K#9GAU3 2I,J8P-Q7
MG?)<\HPJC1=@9J^'#Z.:I_LO#)_9?HQ>@]%[7HRLNML^D-YQ^^$SVP_2;T#Z
M!T&^N=2,28>LJ<*G9@=  [Y6VF!ZP7NTW0TXQ;13#9_Y@/I_+7DGZ2?=02_=
M0?(91FFOVS)\ C5HH ;/"95M\^YAK,&Q6#[#0UBO&ZS7QQVZ%:8S73\OCSN2
M2<Z):HUZ*:HI!NUC%%UT^SL(?BM_^''T^#Q&_P_07OWC$.I9_L6PQVP'(FP]
M]P552U<%:9C+4ICJX6MZFTKKRM47._T36X&Y,N+1356^X;.V9$(#IPMT&5WT
M\6BHJB*J&D:N7%$QDP9+%/>98Q5)E37 \8649MNP$S1UZ?@/4$L#!!0    (
M "TXJU;9=GN((@,  'H,   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM
M;,U776^;,!3]*Q:3IE7:RG=(N@2I23>M4CM%C;H]3'MPX298!9O9)NG^_6Q#
M:$AIM$IYR$NPS;V'<XY]R66\8?Q19  2/14Y%1,KD[*\L&V19%!@<<Y*H.K.
MDO$"2S7E*UN4''!JDHK<]AQG8!>84"L>F[4YC\>LDCFA,.=(5$6!^=\IY&PS
ML5QKNW!'5IG4"W8\+O$*%B#ORSE7,[M%24D!5!!&$8?EQ+IT+V:NHQ-,Q \"
M&[$S1EK* V./>G*=3BQ',X(<$JDAL+JL809YKI$4CS\-J-4^4R?NCK?H7XUX
M)>8!"YBQ_"=)93:QAA9*88FK7-ZQS3=H!(4:+V&Y,+]HT\0Z%DHJ(5G1)"L&
M!:'U%3\U1NPD*)S^!*])\/83@E<2_";!-T)K9D;6%98X'G.V05Q'*S0],-Z8
M;*6&4+V-"\G57:+R9/Q=G90;)@2: T>+#'- G]!"'9:TR@&Q);JDDJ0DK[3;
M: %)Q8DD(-"7IR2O4DC1DK,"S5A15A*;G5%)7S"GA*YV43]<@<0D%V<*7^@5
M,;:E$J!IV$E#=EJ3]5XAZZ-;1F6F'D[5D[OYMA+>JO>VZJ?>0<!;S,^1[WY$
MGN/Y/7QF_Y_N':#CMYOA&SS_%;QC>?WK1@&C:PF%^-WG<LTBZ&>A7QP7HL0)
M3"SU9A# UV#%[]^Y ^=SGT5' NL8%K2&!8?0NX:)9\.@8UC2-0RVAI7*,%$?
M3D*;0WG6YU=-(C0D]'MQ'4=!X#F1.[;7NU:\C NB<. ._3:NHS)L588'5=[3
M-0BIU"A^DI-$#VO>%26RMXX. KYUAX\$UM$^:+4/3J(D!L<T[$A@'<.BUK#H
M%$HB>GG4G2CT1GL5\3+,'46[A=/1.&PU#@]JK+>4E9I^[_$_F/[6W3P26$?I
MJ%4Z.HGC/SJF84<"ZQCF.L\-C7,*!="PZ/PI.'X0!MY>"?0$!F$X<EUOKPCL
MG2ZN +XRS:U03"LJZY:F76T;Z$O3-NZM3W5C;;K#9YBZ*U<-RXI0@7)8*DCG
M/%*L>-WHUA/)2M,K/C"I.D\SS-3' 7 =H.XO&9/;B7Y ^[D1_P-02P,$%
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M[RK&JR+K]J^>:+&S'=1::.S'[##'EAFD,<#O&R'T<6(V:)OPY#]02P,$%
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ML_)DLFP(6NBSNF<J!,WUY1*P?"BJ@_Q_3JG8-=0 ]?GP^!]02P,$%     @
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ML9S$3?ZR5>HXE)WK4R/JS=N]S9O)C[\!4$L#!!0    ( "TXJU;N2=W_G@$
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M02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M
M(:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)
M"EF3_R3KN]:KO_ZIT:YQK<KFZ,^Z/T?S3U!+ 0(4 Q0    ( "TXJU8'04UB
M@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @ +3BK5E=>6]7M    *P(  !$              ( !KP   &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ +3BK5IE<G",0!@  G"<  !,
M             ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  M.*M6YDLSS<H%   &'@  &               @($,"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ +3BK5@@FX$#]!0  \!P  !@
M             ("!# X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( "TXJU:H='QKZ (  /4*   8              " @3\4  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  M.*M6=CN%C/0$  "^
M$@  &               @(%=%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ +3BK5L5 ;B67"   X44  !@              ("!AQP
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "TXJU:^Z.LQ
M5P<  /T?   8              " @50E  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    "  M.*M669(-BV$*   X&0  &
M@('A+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ +3BK
M5D;3)01[(   =&8  !@              ("!>#<  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( "TXJU92H61@XP(  &T&   8
M      " @2E8  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "TXJU;J\HGU"08  /X-   9              "
M@=1S  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ +3BK
M5AM\3AD_!   ]0D  !D              ("!%'H  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    "  M.*M6+\!B_E #   9!P  &0
M        @(&*?@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( "TXJU8]DXA3BB   .-K   9              " @1&"  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ +3BK5HLA8)#. @  %P8
M !D              ("!TJ(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    "  M.*M6/?=?\N8"  !,!@  &0              @('7I0
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "TXJU8!ZNZ.
MR0(  #8&   9              " @?2H  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ +3BK5H@4X19C!0   @X  !D
M ("!]*L  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  M
M.*M62D[DJ=$#  !%"0  &0              @(&.L0  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "TXJU8BQ4<& P0  (L)   9
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M970R-RYX;6Q02P$"% ,4    "  M.*M6<< N8.L"  !\"   &0
M    @($ES0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M "TXJU:L/1!=L@8  $]!   9              " @4?0  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ +3BK5I8AL\:P!   .!H  !D
M             ("!,-<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    "  M.*M6"[P+3C<#  #A"0  &0              @($7W   >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "TXJU89]I:DM@4
M %DK   9              " @87?  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ +3BK5L+)J81L @  V@4  !D              ("!
M<N4  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  M.*M6
MBF55-SP%  #X'@  &0              @($5Z   >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( "TXJU8E<]T0<@<  !0X   9
M      " @8CM  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ +3BK5K-$BWM8 P  K0D  !D              ("!,?4  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  M.*M6,%28/Q0#  "S"P
M&0              @(' ^   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( "TXJU:S QT?2P,  *,*   9              " @0O\  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ +3BK5MEV>X@B
M P  >@P  !D              ("!C?\  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    "  M.*M6'"-%UCT$  !U&@  &0
M@('F @$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "TX
MJU9O&K[BF ,  ) +   9              " @5H' 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ +3BK5B6!LMV< @  +0<  !D
M         ("!*0L! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M    "  M.*M6=O*+ 2@$   K%@  &0              @('\#0$ >&PO=V]R
M:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "TXJU8($L'9< ,  .P5
M   -              "  5L2 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     S #, W T  '(> 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>104</ContextCount>
  <ElementCount>243</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/AccruedExpensesandOtherLiabilities</Role>
      <ShortName>Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/OrdinaryShares</Role>
      <ShortName>Ordinary Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Right of use of assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/Rightofuseofassets</Role>
      <ShortName>Right of use of assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://compasspathways.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/AccruedExpensesandOtherLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/ShareBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/NetLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Right of use of assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RightofuseofassetsTables</Role>
      <ShortName>Right of use of assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/Rightofuseofassets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/NatureofBusiness</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Accrued Expenses and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Ordinary Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/OrdinarySharesDetails</Role>
      <ShortName>Ordinary Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/OrdinaryShares</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails</Role>
      <ShortName>Share-Based Compensation - 2017 Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails</Role>
      <ShortName>Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails</Role>
      <ShortName>Share-Based Compensation - 2020 Share Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails</Role>
      <ShortName>Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Share-Based Compensation - Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Share-based Compensation - Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails</Role>
      <ShortName>Share-based Compensation - Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Share-Based Compensation - Schedule of Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Right of use of assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RightofuseofassetsNarrativeDetails</Role>
      <ShortName>Right of use of assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails</Role>
      <ShortName>Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails</Role>
      <ShortName>Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cmps-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/SubsequentEvents</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 10-Q should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. cmps-20230331.htm </Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  cmps-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="cmps-20230331.htm">cmps-20230331.htm</File>
    <File>cmps-20230331.xsd</File>
    <File>cmps-20230331_cal.xml</File>
    <File>cmps-20230331_def.xml</File>
    <File>cmps-20230331_lab.xml</File>
    <File>cmps-20230331_pre.xml</File>
    <File>cmps-q1x23xex311ceo302cert.htm</File>
    <File>cmps-q1x23xex312cfo302cert.htm</File>
    <File>cmps-q1x23xex321ceoxcfosec.htm</File>
    <File>foraresidentagreement.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="436">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cmps-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 436,
    "http://xbrl.sec.gov/dei/2022": 28
   },
   "contextCount": 104,
   "dts": {
    "calculationLink": {
     "local": [
      "cmps-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmps-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cmps-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cmps-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmps-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cmps-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 371,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 34,
   "keyStandard": 209,
   "memberCustom": 20,
   "memberStandard": 19,
   "nsprefix": "cmps",
   "nsuri": "http://compasspathways.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://compasspathways.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Accrued Expenses and Other Liabilities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://compasspathways.com/role/AccruedExpensesandOtherLiabilities",
     "shortName": "Accrued Expenses and Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Ordinary Shares",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://compasspathways.com/role/OrdinaryShares",
     "shortName": "Ordinary Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://compasspathways.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://compasspathways.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Right of use of assets",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://compasspathways.com/role/Rightofuseofassets",
     "shortName": "Right of use of assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://compasspathways.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://compasspathways.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i152e65e381d441028d0e315d17e7e808_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i152e65e381d441028d0e315d17e7e808_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Accrued Expenses and Other Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://compasspathways.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://compasspathways.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Right of use of assets (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://compasspathways.com/role/RightofuseofassetsTables",
     "shortName": "Right of use of assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i8cc171482c7f4d51822f9ae8848dea3e_D20211008-20211008",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cmps:NumberOfOrdinarySharesConversionRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Nature of Business (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://compasspathways.com/role/NatureofBusinessDetails",
     "shortName": "Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i8cc171482c7f4d51822f9ae8848dea3e_D20211008-20211008",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cmps:NumberOfOrdinarySharesConversionRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i74d151acb50c43c5a8922ab30b91f0da_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i74d151acb50c43c5a8922ab30b91f0da_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cmps:NumberOfGeographicRegions",
      "reportCount": 1,
      "unitRef": "region",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseLiabilityCurrent",
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "ifcb5e67ff9464397aed19cb5b9642c90_I20210101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i152e65e381d441028d0e315d17e7e808_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmps:ResearchAndDevelopmentTaxCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i152e65e381d441028d0e315d17e7e808_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmps:ResearchAndDevelopmentTaxCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i152e65e381d441028d0e315d17e7e808_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmps:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Accrued Expenses and Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i152e65e381d441028d0e315d17e7e808_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmps:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Ordinary Shares (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://compasspathways.com/role/OrdinarySharesDetails",
     "shortName": "Ordinary Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "ifb330f455e5841ea8450b766d642b939_I20211008",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cmps:SaleOfStockAmountAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "iba4de34994aa4f5089e7fdc27e2ce29e_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "iba4de34994aa4f5089e7fdc27e2ce29e_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i8cae53ddb92e46c3b992b638b4a42023_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
     "shortName": "Share-Based Compensation - 2017 Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i8cae53ddb92e46c3b992b638b4a42023_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i00a9c14553ea40949dd06a45c06c9b03_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
     "shortName": "Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i00a9c14553ea40949dd06a45c06c9b03_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
     "shortName": "Share-Based Compensation - 2020 Share Option Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i395fbda845a44eac841de73744035c26_D20200901-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i15ccc93511924535a1cde0fc5143bb33_I20220801",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
     "shortName": "Share-Based Compensation - 2022 Inducement Grant Option Award (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i15ccc93511924535a1cde0fc5143bb33_I20220801",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Share-Based Compensation - Restricted Share Units (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
     "shortName": "Share-Based Compensation - Restricted Share Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i5ca144c161424a039afa7f48a9ea7b7b_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "cmps:StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Share-based Compensation - Share Options (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails",
     "shortName": "Share-based Compensation - Share Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Share-Based Compensation - Schedule of Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails",
     "shortName": "Share-Based Compensation - Schedule of Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i5872a113b2294faaad1b68db7ae836e2_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails",
     "shortName": "Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "ibbeae02a508346edb94df36fd8e95a81_I20220831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Right of use of assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails",
     "shortName": "Right of use of assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "ibbeae02a508346edb94df36fd8e95a81_I20220831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails",
     "shortName": "Right of use of assets - Summary of costs included in operating expenses related to right of use assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i152e65e381d441028d0e315d17e7e808_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails",
     "shortName": "Right of use of assets - Summary of future minimum lease payments due to operating leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i152e65e381d441028d0e315d17e7e808_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "ic20396ba94624e2da3d0b197c0bb72e8_D20200901-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://compasspathways.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "idd439c7411164a75bab3f2705e3ffb57_I20230430",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i996a9a2f8d294a9f95e96689ead7e84e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Shareholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i996a9a2f8d294a9f95e96689ead7e84e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Nature of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://compasspathways.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmps-20230331.htm",
      "contextRef": "i37033c72113244f3aee8649c4898c51e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 40,
   "tag": {
    "cmps_A2017EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Equity Incentive Plan",
        "label": "2017 Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017EquityIncentivePlanMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_A2020ShareOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Share Option Plan",
        "label": "2020 Share Option Plan [Member]",
        "terseLabel": "2020 Share Option Plan"
       }
      }
     },
     "localname": "A2020ShareOptionPlanMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_A2022And2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 And 2023",
        "label": "2022 And 2023 [Member]",
        "terseLabel": "2022 And 2023"
       }
      }
     },
     "localname": "A2022And2023Member",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_A2022InducementGrantOptionAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Inducement Grant Option Award",
        "label": "2022 Inducement Grant Option Award [Member]",
        "terseLabel": "2022 Inducement Grant Option Award"
       }
      }
     },
     "localname": "A2022InducementGrantOptionAwardMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Expense, Current",
        "label": "Accrued Research And Development Expense, Current",
        "terseLabel": "Accrued research and development expense"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Shares",
        "label": "American Depositary Shares [Member]",
        "terseLabel": "American Depositary Shares"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Offering",
        "label": "At-The-Market Offering [Member]",
        "terseLabel": "At-The-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benefit From Research And Development Tax Credit, Policy",
        "label": "Benefit From Research And Development Tax Credit, Policy [Policy Text Block]",
        "terseLabel": "Benefit from Research and Development Tax Credit"
       }
      }
     },
     "localname": "BenefitFromResearchAndDevelopmentTaxCreditPolicyPolicyTextBlock",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmps_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmps_DeferredOfferingCostsIncludedInAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Included In Accrued Expenses",
        "label": "Deferred Offering Costs Included In Accrued Expenses",
        "terseLabel": "Deferred issuance costs included in accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccruedExpenses",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_DeferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares",
        "label": "Deferred Shares [Member]",
        "terseLabel": "Deferred shares"
       }
      }
     },
     "localname": "DeferredSharesMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_DenmarkHillLondonUKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denmark Hill, London, UK",
        "label": "Denmark Hill, London, UK [Member]",
        "terseLabel": "Denmark Hill, London, UK"
       }
      }
     },
     "localname": "DenmarkHillLondonUKMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_GrantDateJune302020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Date June 30, 2020",
        "label": "Grant Date June 30, 2020 [Member]",
        "terseLabel": "Grant Date June 30, 2020"
       }
      }
     },
     "localname": "GrantDateJune302020Member",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_LeaseCancellationNotificationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Cancellation Notification Period",
        "label": "Lease Cancellation Notification Period",
        "terseLabel": "Lease cancellation notification period (in days)"
       }
      }
     },
     "localname": "LeaseCancellationNotificationPeriod",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmps_NumberOfGeographicRegions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Geographic Regions",
        "label": "Number Of Geographic Regions",
        "terseLabel": "Number of geographic regions"
       }
      }
     },
     "localname": "NumberOfGeographicRegions",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmps_NumberOfOrdinarySharesConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Ordinary Shares Conversion Ratio",
        "label": "Number Of Ordinary Shares Conversion Ratio",
        "terseLabel": "Ordinary share conversion ratio"
       }
      }
     },
     "localname": "NumberOfOrdinarySharesConversionRatio",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cmps_OperatingLeaseAnnualPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Annual Payment",
        "label": "Operating Lease, Annual Payment",
        "terseLabel": "Operating lease, annual payment"
       }
      }
     },
     "localname": "OperatingLeaseAnnualPayment",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_OperatingLeaseMonthlyPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Payment",
        "label": "Operating Lease, Monthly Payment",
        "terseLabel": "Operating lease, monthly payment"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyPayment",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_OperatingLeasesNoncancelableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Noncancelable Term",
        "label": "Operating Leases, Noncancelable Term",
        "terseLabel": "Operating leases, noncancelable term"
       }
      }
     },
     "localname": "OperatingLeasesNoncancelableTerm",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmps_OptionsGrantedBeforeJune302020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Granted Before June 30, 2020",
        "label": "Options Granted Before June 30, 2020 [Member]",
        "terseLabel": "Options Granted Before June 30, 2020"
       }
      }
     },
     "localname": "OptionsGrantedBeforeJune302020Member",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_OrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares",
        "label": "Ordinary Shares [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_PrepaidExpenseResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expense, Research And Development, Current",
        "label": "Prepaid Expense, Research And Development, Current",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "PrepaidExpenseResearchAndDevelopmentCurrent",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ProceedsFromStockOptionsExercisedNotReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised, Not Received",
        "label": "Proceeds From Stock Options Exercised, Not Received",
        "terseLabel": "Proceeds from exercise of options received and recorded in other current assets"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedNotReceived",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_RefundableLeaseDepositPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refundable Lease Deposit, Payments",
        "label": "Refundable Lease Deposit, Payments",
        "terseLabel": "Refundable lease deposit"
       }
      }
     },
     "localname": "RefundableLeaseDepositPayments",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount",
        "label": "Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Amount",
        "terseLabel": "Annual offset amount (in euros)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetAmount",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent",
        "label": "Research And Development Arrangement with Federal Government, Tax Credit Annual Offset, Percent",
        "terseLabel": "Percentage of taxable profits (in percent)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentTaxCreditAnnualOffsetPercent",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expenditures Tax Credit, Connected Parties Maximum Percentage of Total Claim",
        "label": "Research And Development Expenditures Tax Credit, Connected Parties Maximum Percentage of Total Claim",
        "terseLabel": "Maximum qualifying research and development expenditures with connected parties (in percent)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Cap on Payable Credit Claims",
        "label": "Research And Development Tax Credit, Cap on Payable Credit Claims",
        "terseLabel": "Cap on payable claims (in GBP)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCapOnPayableCreditClaims",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditCashRebatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Cash Rebate Percent",
        "label": "Research And Development Tax Credit, Cash Rebate Percent",
        "terseLabel": "Cash rebate percent (in percent)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCashRebatePercent",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Current",
        "label": "Research And Development Tax Credit, Current",
        "terseLabel": "UK R&amp;D tax credit"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCurrent",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Income Tax Expense (Benefit)",
        "label": "Research And Development Tax Credit, Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit from R&amp;D tax credit"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ResearchAndDevelopmentTaxCreditTotalAidClaimable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit, Total Aid Claimable",
        "label": "Research And Development Tax Credit, Total Aid Claimable",
        "terseLabel": "Total aid claimable (in euros)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditTotalAidClaimable",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use\u00a0Assets\u00a0Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adoption",
        "label": "Right-Of-Use\u00a0Assets\u00a0Obtained In Exchange For New Operating Lease Liabilities, Including Initial Adoption",
        "terseLabel": "Right\u00a0of\u00a0use\u00a0assets\u00a0obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_SaleOfStockAmountAuthorized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Amount Authorized",
        "label": "Sale Of Stock, Amount Authorized",
        "terseLabel": "Amount authorized"
       }
      }
     },
     "localname": "SaleOfStockAmountAuthorized",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_SaleOfStockMaximumAmountAllowableForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Amount Allowable For Sale",
        "label": "Sale Of Stock, Maximum Amount Allowable For Sale",
        "terseLabel": "Maximum amount of stock that may be sold"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountAllowableForSale",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercise Price",
        "terseLabel": "Exercise price (in pound sterling per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance",
        "terseLabel": "Maximum increase in shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase",
        "terseLabel": "Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Nonvested, Weighted Average Remaining Contractual Term",
        "terseLabel": "Unvested (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price",
        "terseLabel": "Percentage amount closing price is higher than listing price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "terseLabel": "Stock plan, offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Vesting Condition One",
        "label": "Share-Based Payment Arrangement, Vesting Condition One [Member]",
        "terseLabel": "Vesting condition one"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingConditionOneMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Vesting Condition Three",
        "label": "Share-Based Payment Arrangement, Vesting Condition Three [Member]",
        "terseLabel": "Vesting condition three"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingConditionThreeMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Vesting Condition Two",
        "label": "Share-Based Payment Arrangement, Vesting Condition Two [Member]",
        "terseLabel": "Vesting condition two"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingConditionTwoMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_ShareOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Options",
        "label": "Share Options [Member]",
        "terseLabel": "Share options"
       }
      }
     },
     "localname": "ShareOptionsMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_SohoLondonUKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Soho, London, UK",
        "label": "Soho, London, UK [Member]",
        "terseLabel": "Soho, London, UK"
       }
      }
     },
     "localname": "SohoLondonUKMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Restricted Stock Award, Settled In Period",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Settled In Period",
        "terseLabel": "Settled (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardSettledInPeriod",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmps_StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Vested In Period",
        "negatedTerseLabel": "Vested (in shares)",
        "verboseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVestedInPeriod",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Kingdom Research And Development Tax Credit Regime",
        "label": "United Kingdom Research And Development Tax Credit Regime [Member]",
        "terseLabel": "United Kingdom Research and Development Tax Credit Regime"
       }
      }
     },
     "localname": "UnitedKingdomResearchAndDevelopmentTaxCreditRegimeMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Kingdom Research And Development Tax Credit Regime, Small Or Medium-Sized Enterprises (SME)",
        "label": "United Kingdom Research And Development Tax Credit Regime, Small Or Medium-Sized Enterprises (SME) [Member]",
        "terseLabel": "United Kingdom Research and Development Tax Credit Regime, Small or Medium-Sized Enterprises (SME)"
       }
      }
     },
     "localname": "UnitedKingdomResearchAndDevelopmentTaxCreditRegimeSmallOrMediumSizedEnterprisesSMEMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_UnvestedRestrictedShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Share Units",
        "label": "Unvested Restricted Share Units [Member]",
        "terseLabel": "Unvested restricted share units"
       }
      }
     },
     "localname": "UnvestedRestrictedShareUnitsMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_VestingPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period",
        "label": "Vesting Period [Axis]",
        "terseLabel": "Vesting Period [Axis]"
       }
      }
     },
     "localname": "VestingPeriodAxis",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmps_VestingPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period [Domain]",
        "label": "Vesting Period [Domain]",
        "terseLabel": "Vesting Period [Domain]"
       }
      }
     },
     "localname": "VestingPeriodDomain",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmps_WeWorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WeWork",
        "label": "WeWork [Member]",
        "terseLabel": "WeWork"
       }
      }
     },
     "localname": "WeWorkMember",
     "nsuri": "http://compasspathways.com/20230331",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r228",
      "r231",
      "r417",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r247",
      "r382",
      "r395",
      "r411",
      "r412",
      "r426",
      "r427",
      "r433",
      "r462",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r247",
      "r382",
      "r395",
      "r411",
      "r412",
      "r426",
      "r427",
      "r433",
      "r462",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r246",
      "r247",
      "r277",
      "r278",
      "r279",
      "r381",
      "r382",
      "r395",
      "r411",
      "r412",
      "r426",
      "r427",
      "r433",
      "r458",
      "r462",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r246",
      "r247",
      "r277",
      "r278",
      "r279",
      "r381",
      "r382",
      "r395",
      "r411",
      "r412",
      "r426",
      "r427",
      "r433",
      "r458",
      "r462",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r228",
      "r231",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other liabilities",
        "totalLabel": "Total accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r432"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Payroll Taxes, Current",
        "terseLabel": "Payroll tax payable"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r118",
      "r391",
      "r403",
      "r407"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r80",
      "r377",
      "r398",
      "r399",
      "r444",
      "r445",
      "r446",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE (LOSS)/ INCOME"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r432"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r451",
      "r452",
      "r453",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "ADDITIONAL PAID-IN CAPITAL"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r145",
      "r146",
      "r147",
      "r148",
      "r157",
      "r200",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r286",
      "r287",
      "r288",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r384",
      "r385",
      "r386",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares tendered for withholding taxes"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r74",
      "r75",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r96",
      "r114",
      "r136",
      "r187",
      "r195",
      "r197",
      "r204",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r309",
      "r311",
      "r326",
      "r432",
      "r460",
      "r461",
      "r498"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r110",
      "r120",
      "r136",
      "r204",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r309",
      "r311",
      "r326",
      "r432",
      "r460",
      "r461",
      "r498"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r112",
      "r414"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r35",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r29",
      "r34",
      "r39"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r29",
      "r87"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r136",
      "r161",
      "r162",
      "r169",
      "r171",
      "r178",
      "r179",
      "r204",
      "r219",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r229",
      "r230",
      "r233",
      "r237",
      "r244",
      "r326",
      "r413",
      "r440",
      "r449",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r12",
      "r92",
      "r100"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r52",
      "r213",
      "r214",
      "r408",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r451",
      "r452",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "COMMON STOCK"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in GBP per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r432"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary and deferred shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r122",
      "r124",
      "r129",
      "r387",
      "r392"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r95",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Conversion of Stock [Line Items]",
        "terseLabel": "Conversion of Stock [Line Items]"
       }
      }
     },
     "localname": "ConversionOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockTable": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table may be used to disclose all the information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction. It may include a description sufficient information to understand the nature and purpose of the conversion, as well as the financial instruments converted from and to (for example, preferred, common, treasury, etc.) the amounts converted, the new shares issued, and the value of the new shares issued, if applicable. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock [Table]",
        "terseLabel": "Conversion of Stock [Table]"
       }
      }
     },
     "localname": "ConversionOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r32",
      "r185"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r251",
      "r282",
      "r283",
      "r285",
      "r290",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r130",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r158",
      "r161",
      "r169",
      "r170",
      "r171",
      "r175",
      "r323",
      "r324",
      "r388",
      "r393",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r130",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r161",
      "r169",
      "r170",
      "r171",
      "r175",
      "r323",
      "r324",
      "r388",
      "r393",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefit costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost of options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r56",
      "r106",
      "r126",
      "r127",
      "r128",
      "r141",
      "r142",
      "r143",
      "r146",
      "r154",
      "r156",
      "r177",
      "r208",
      "r245",
      "r286",
      "r287",
      "r288",
      "r302",
      "r303",
      "r322",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r377",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r335",
      "r337",
      "r339",
      "r340"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange gains"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r33",
      "r492",
      "r493"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Non-cash gain on foreign currency remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Research Contract Costs, Prepayments and Accruals"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r22",
      "r88",
      "r93",
      "r102",
      "r187",
      "r194",
      "r196",
      "r198",
      "r389",
      "r423"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r137",
      "r155",
      "r156",
      "r186",
      "r295",
      "r304",
      "r305",
      "r394"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r291",
      "r292",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred and prepaid tax assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r447",
      "r495"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r203",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r369",
      "r431"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Costs Included in Operating Expenses Related To Right of Use Assets"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Due Under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "December 31, 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsNarrativeDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/Rightofuseofassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r136",
      "r204",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r310",
      "r311",
      "r312",
      "r326",
      "r422",
      "r460",
      "r498",
      "r499"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r91",
      "r98",
      "r432",
      "r450",
      "r456",
      "r491"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r111",
      "r136",
      "r204",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r310",
      "r311",
      "r312",
      "r326",
      "r432",
      "r460",
      "r498",
      "r499"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r29",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r33",
      "r94",
      "r101",
      "r109",
      "r121",
      "r123",
      "r128",
      "r136",
      "r145",
      "r149",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r167",
      "r187",
      "r194",
      "r196",
      "r198",
      "r204",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r324",
      "r326",
      "r423",
      "r460"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r158",
      "r159",
      "r168",
      "r171",
      "r187",
      "r194",
      "r196",
      "r198",
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to ordinary shareholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to ordinary shareholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r41",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r157",
      "r175",
      "r200",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r286",
      "r287",
      "r288",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r384",
      "r385",
      "r386",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r187",
      "r194",
      "r196",
      "r198",
      "r423"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS:"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r363",
      "r431"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryoffutureminimumleasepaymentsduetooperatingleasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r360",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used in operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r368",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r367",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r119",
      "r432"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r16",
      "r18",
      "r336",
      "r338",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Unrealized loss on foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign exchange translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "OTHER INCOME, NET:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r432"
     ],
     "calculation": {
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r442",
      "r457"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments of tax withholding on stock award"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r415",
      "r424",
      "r457"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance premium"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r416",
      "r425",
      "r457"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid income tax"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r73"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r50",
      "r99",
      "r390",
      "r432"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r76",
      "r103",
      "r506"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r39",
      "r112"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r63",
      "r97",
      "r402",
      "r407",
      "r432"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r106",
      "r141",
      "r142",
      "r143",
      "r146",
      "r154",
      "r156",
      "r208",
      "r286",
      "r287",
      "r288",
      "r302",
      "r303",
      "r322",
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "ACCUMULATED DEFICIT"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r366",
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/AccruedExpensesandOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Share Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r248",
      "r250",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r65",
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r115",
      "r116",
      "r117",
      "r178",
      "r229",
      "r230",
      "r231",
      "r233",
      "r237",
      "r242",
      "r244",
      "r426",
      "r440",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Saving period (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "verboseLabel": "Vested not issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails",
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised during the period (less than in 2023)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r255",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting percentage (in percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Unvested, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Unvested and Outstanding, ending balance (in shares)",
        "periodStartLabel": "Unvested and Outstanding, beginning balance (in shares)",
        "terseLabel": "Unvested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, beginning balance (in dollars per share)",
        "terseLabel": "Unvested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding balance (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r364",
      "r431"
     ],
     "calculation": {
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/RightofuseofassetsSummaryofcostsincludedinoperatingexpensesrelatedtorightofuseassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r136",
      "r161",
      "r162",
      "r169",
      "r171",
      "r178",
      "r179",
      "r204",
      "r219",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r229",
      "r230",
      "r233",
      "r237",
      "r244",
      "r326",
      "r413",
      "r440",
      "r449",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r56",
      "r106",
      "r126",
      "r127",
      "r128",
      "r141",
      "r142",
      "r143",
      "r146",
      "r154",
      "r156",
      "r177",
      "r208",
      "r245",
      "r286",
      "r287",
      "r288",
      "r302",
      "r303",
      "r322",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r377",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r177",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r56",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ordinary shares under ATM offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r56",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Restricted share units issued in settlement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r1",
      "r2",
      "r56",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)",
        "verboseLabel": "Shares issued related to vesting of restricted share units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r56",
      "r63",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of share options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SharebasedCompensationShareOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r56",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares under ATM facility, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r56",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r56",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r47",
      "r432",
      "r450",
      "r456",
      "r491"
     ],
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r135",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r245",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/OrdinaryShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r349",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r349",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r349",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r349",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/OrdinarySharesDetails",
      "http://compasspathways.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r145",
      "r146",
      "r147",
      "r148",
      "r157",
      "r200",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r286",
      "r287",
      "r288",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r384",
      "r385",
      "r386",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r180",
      "r181",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT recoverable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r160",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average ordinary shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r158",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average ordinary shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r437": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r438": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r439": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001628280-23-017390-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-017390-xbrl.zip
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M ,_3 G_AM1#B_?\.S8I7VNVG/?B9%X)<70;'NVG/2OAW!'D=C2U>FOK0BGI
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M9C)0,?(%IIJ&GN (E#I"(B2^I-IC:\00OW( :'D,(9'G!X$,:20H!3^(@2=
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M:>+-R=_3,PM6GTVFK.@<Y7_&BJ+(PU)*4U5*M:] D",D(L\3,482Z=6'-*M
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M9W&Y8T6X=B0[3MOII[2GTM[)?YY5CD#KA4MJ.1F%$?*$"D-E]GKU& [-!E<
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MEKB7]IK#+CQ).J7!/M*QB1.$X*4 ML)@DRF-/:YU%% F:<0BZ6.]R*5Q>MS
M*:63[;U4#KLENMDHL;7WSTCLI5>?R-'5J=<8JHO]J[./[.+P8O^V<7%YW?RZ
M[YW>7I)FZXO?:)TE9Q^_H.;>_FVS]?=%\_84-UH'UY^\9N?T-KUIW![XC;U_
MVDW2\)L7)^BPM4].NT>7S;TO<.[D^O16PG/V1XT/T<TG<C8Z_2J#T]8E.=O[
M]T5S[P2>V[QH?OSBG7X]0*>MHXNSKP=PS<EU@\#(6OM7ZN,_5/WKWYTSTKD2
M%_WV8>OLLM%M(!@;:I &.MM3[=.+HW;S(XSGXM_ML];N[=F%O&G\$XT:%PWZ
MS6S*$PNN7$PX=6D SJ9 'G)C@#)11 ,DC7N.D?O%XJ$)%7;N2&HMC\N5Q_LQ
MWG*0XE,PXFZ6\,YCM3Z] PV)F<[G%^(O0_ )=-89'>E^F@TVG!A4"!_ "VX&
MVW%RHY4[R(:_H)S??)/@QRC?BUV%A':ICI0;*<G=6, 9&<7$TX&![Q',^Q_S
MHNXXSLM@G,6<\^5D]ZBU?_3IU#G:_WQXU'(^GQP=G^PV6T[KT %XU@(,YF#/
M.3QRL/^;^MTY_."T_K7O3"&W,6K;?=\RIS'SZ"LBS^]^=V4 G4%;._^MV-HI
M/%<''%JMG!<0J&(#R_W"?YX5)P5'W"Z\LVUN<Q4?N2/-,U?W?CGQ.O^F88(C
M%5%7$072Q5GH<JP"5]&8(4$TI4&TL=,PJ<8%HO'PIF,F_HY1?5#9KPIC'A[]
MI#E9ZFA> AUF,#[;H>5^RQ+S3OX+FA;_FZ]]B7 4NSJF'""DBEP1:@GVQ<<1
MEAZB86A,"POI0M/2.MIM'A]8)?YKZO?!F+LJ!1]G:=?Y5O[/&:3COY^& Z>_
M\8G(<'$4(7J5*,+BV7N?=KM);D+6SH<$W [@**&S[><TB_LV5FW>5KSLEY/V
M+]??3 6F$E[HPOR$(.V"N4R&S.4R" (XI@GRS8H$=CWF$U)[C4_S&JT OYD0
MSK/+XI$^MP4?O8%9!_[EY/& ?@L#S+DDW/5H /(8L\B-B(A=$7@J$%2'S ?'
M[OUAX_/N\;'SF0_:UWR4._V._*YHKE(D>;$-^&W_ALN!Y0HGC9ULS T.SYV\
MKZ59 E5.TG.20>[(MO6C?J]CS*\>8WY$V.J%5P?)%O+\'YEW^OAY?Z;'EN2\
MCW85>4C_QA!H 32<FYUB8I8MTM]=0'X9BV%J"C/PX6PE@"TMM-E$V>A]JF9#
M'/ %<ENK<Y[UL_1*%E>M:7CC0R(^G@2'K5UTUMV'8_\DAU]/?;BOW2#[_EGK
M$IUV_]UI=ALPYM/;R3W_P'/\WEDKA?$==4];\J;Y]< _N[@$X[1_>]KJ= Y;
M1\EI]X2<WJJ+YD7#&*;K3ZW=0>,8W7QJ[:/&WCYIG'^+P3>,8H+=0$?2I3X+
M78' 3"&I?,V)C@E1&SO[O?,.[RG'_/]7WM'YO3:JE(EU9_=F.G!V^R91QBBN
MF:];3ZF^QTY;07/ WTW!X<V<BV&6Y"J1UN=-8^N")M.":2_-SGDON;6_?U]?
MPM\S(P=;1UO'6T[9.22S4W!09FT59<Y.,]WZ_2Y+O![H7Q$-OJM4IO.\_.<3
M# "OI4[^&>!_<OV-Z5@'(?%=C", _BK +@\P<0,2(=\/3%IOO+'C><[?6<K5
M=2(OG>-!IO7@T;C_%V.H]_#G8=9*K]?3Q/]4%!=]HP)1&A()3*2$2T./N)SS
MT&6"8ZEUH#V*-G:*G.H[0=R7(M'G-!_PSEG2+\#:+T:E+^0;$<R'V2,N]4RZ
MAJ*>*ZC)WJ! I0#Q",=Z8^<K_N"@O>]G;/RJ@EY ^;M@O\3XYK8UQ?D_Q5ZC
M;UQCR1&(/I8^* $?V(MCSEVE54R9T(0SLK%CNB-HY?P'P)9*NZO+9?<@KY(+
M3,"HGP'J3/J\X^@;+6WQ-QP& *;S3><VZ0,/*OW[TW-47WL=]W$SX?S_L?/;
M,PJ=,:B[F>:_I+(^\+_)@-,X9MI%2( T*>ZYD0B)JSP_$IH1/XS"C9T0!_,B
M]/MS&E331:GSN9WV?LE%K-O#O2_4?L_%I=]L'1#0>3Y!@9*N;W%TA .7R1C^
MHW3$B$"QB 'X!&'@!C3 =Z'/B@OY;Y,EDO_]/Q'!X1^Y,] =W3<<X/0L"VPZ
MH 8[0^,].QP$=LEJKPZB+W&);\E,Q![%1)..*.4:B\X  /2'63XTBRV#U($K
M;,P"D]_$[\:TFL2&73G8_IG,U1=> D!;)/BA)0"/;$51\$-+  ^?"Z/E+RQX
M:(N1M1IL],NM@K220<>N:.YSV79LV_KU#8 N_L2RLN.-?54KX]:*'H^Z(NV\
MM:][FS1KEMD#VLB:OI%MLSN? [;LNIW D8G!>\KRS)2M1Z;4=Y&U7S ['1W?
ML53=1*F.WE@Q<&G+?9_132DAQP@38;7A6KHIQ;)K<Z_=;L"8SKZ>71[N[5\W
M/W[H'GXT[SH8-?8:Y'#O]+9Q^Z%S^/%T?MD5P76WX-YTSKK@MK1VT>G74WH*
MWW5Z<7#=N#VES8O&;>/K"3WKP!CO+KOZ.O:14($KE0_.C1#*%3AFKB"1TG'(
MA8?4QLZN)1]PSY[NIWDRX-G(*39#V2RD(M-]^&$6IT"W&;\A+;=,<7)SV:;3
MYYESQ3M#*TA&37A_& P>F836XIJ'PT3+U"5C>7E9@4!/TI"U?OA)_5!:VL+0
MULKA$<KA8%XYA"H.%!.>2P(=NS3$RF4*2Q=[O@__QS$S-6'O&Y^/:^']M807
M/?-R3&7<]TNT523OWLF]@K-KO!;STO+]95Z^ QE(BJAT)0\Q&/\H=@73S)4H
M#)DO24R99^!OKOA_G8^=5/".<ZP[6@Z<!L\NOY<I\$ 4C* 'PF +@UWK=.FC
M4UN]^PNR7SB =]!3)JM(.V+DR+:6EX[ID@8>CK;Y6"98-Y4\_1O^W6GSW(F3
MCE8.[W0, $RS@8G^_7>8F-C?('6$+B^ 9X[#?Y[)W"JJM,H@X%3LL!)W$Q@T
MITV5EJ/@+*!*<RF 3*FM_XR)8VM+<^<W>!XH!B<? @[-VZG)X*[*I 9M/I@?
M^S6?':498G%S^0V_;]KTPM](\8T"U N<%Q>&[>%Z>RG<9$91/L=4 .9V$':0
M/!\X##F*C_*MY\]\>#_,,GA_47=H ,^ #X;Y6BK$G\I0(=^HIWT!BLM5L1^Y
M-$ QP!6)70^%'A$A85X OLSIW:11Q]8>!G\XS=09ER$N+%U]?+.%=15MP_+
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M9QRY_ VH:<.213>HAX-^OV\YIS#T<CI-X/GY$9(9[9O4AC^UZ'?]C6ONQ;Y
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MW#2>,EOC( XX=^ " N*&XV/ E2=EL\#2#9U@N7P,B!8]S"*\S,1Z+)W[<,=
M@\OX7],%)TZT*GD!<)M]/"]!I'Z(;XP+:NUU-;IB(#6[O"2[&(QNX:XY(<I-
M@)UNJG1G*M1AXYN)+*./E<LQOKRZL#;,JTGD2HS-1I=E6.J.7A=ZE)9DE,,L
M*SP@@.7&<J?@-!HL9ATPWDLS?9-P>%IVE>:\"(GUTWS@ I\,31!*&I8QC '^
MIMU6RKIOGUO'>S7=7X'NFY5?:ZC I76A@#3GUJ4::-GNP9C/D\(RZ%Z[@-[F
M63.Q@!I^KS2U.T#CC)\7E!M3M;#=RD1VIH,;TNPSJ'B)!KBZLC0W^J&?CV1;
M@_JW.ZEV^^FP!PZR,=5V 8&;H+KAA&&OJP>.>1BP0%OSSJ!MG>F:YB](\](Q
MCH=F60"$DHM.DA>AK"Z@-;LZ]]XN_A<UPS=2=SK:D'H!VN.R;==3S.'SM(B<
M#6PDQ7@05>2Q>)PU'8V"^/\JB'\T'4@[Z/7 OS,*HN:'Y^:'B;>5W)9!VZ[M
M/VDW$K6LT!N:!>\B7"IYOR!Z%:"OEJ]K2CUWL 0 E;31$IF6NKI8($FZ8ICE
M)0[_@16<B?M=T_"Y:6BV/JZ49KD$5L4ZKI+J1$G$6<$#>]E.52%S?=.@P61[
MW$^P7RX!T'N-!,!9.GOVVNI85@S.*XC_TG,2X ?[$+;L*I;9Z\2DHDQOZO!@
M=F(M_S\I_\96EFN%YV9'&9M[9;L]<\!B_0&OT-4XK#4<S"B%IZW-.R:"E\AA
MAV>EHSV^S"U2;,K(FUGI@LO+_+K:#KP@"I\ [S2;X&YI-M 6:;6973H=1RO4
M.!QN)_TB.TO8>Z:7&X=V)_@_[M_WO:;DLZZ0C#.N' $R%2<_DETS=K.*WWIH
M8F,6JX&S-<F%K:7U16G,,Q/4<&*ME>#RTHFSM%NH]/GTF/'R9;XYO90YDR;"
MS89B-C%QSELN6V-W3->NH<BM92@2N(N\F=H]?B' ;E>F8YLS5>:^7Q<FFO=&
MXV!W.DXY[R0 @_,TLXIY1HM;8]PSP123"EEEL=X3=XEMXNC !%S  RBRG?K:
M+,=97)D73J#1-*7^J%GA!6UVD:*O9]>QC 2;[3N27FP(8UWU;I)/UCSMD2J9
M^MHD"%TE::<H23"\]B"]2[\/'J0'9EEE*D9;I#IGJD![#WF%-2O\/"LLUN2Y
M4];BG/22\8Z2H/>MSV5/=/AUE=)Z/LZ-,&'5WGFG4"?*^6KZ,Y99XC9@?@'.
M?V[2^\W5-5V?DZXSQ"RE[:+0^'D)N8V<%G4'9FU##Q)CVZ?6K]400'J-QY[=
M*.LX+HJ7>C-Y?0.=&4 M"^3D& ,Y54"5V0*%.@/S92TE'X#;"J"U4'P6VDS2
M?DP-5#K2Y4K"I1Z9W.P\[?7T R&(E:3(*B=)3R3&B,IY)Q63?&1>Y.EHD)FT
M:]=LR_T,"Y*<Z[2?FL4>$XDJ*BRG2SZ2G@&O!:U+\R=XKZ@:&N4#W=UTBM'I
MGBX,7-P9&G@S*.XV38GS@0V*%>\#Z-0I%Z'LU6FF38F KLI$Q[?;XLA)<*LS
MLB__;#VSXX&-<EI=?;)UO.7L&12>%1G?F>GZ#M,@3=7<P"T+0E5ZW3O/N"J'
M,9Z.O)->FW-%294LJ@D66GI'#2V<5UH,'*EMMJI]EABJ<VV<-I-H/C 3+$%-
ME>^)X0N+G#=P),3TY]LEGDZGB@Y>69PX/=&S;R\K^,J#_X&7J[0[32I>E+29
M"H>B*JR;FCQY"S+BH@E^,4%P.+5U$1R@K1Y<:]USCHQ;RXL6T9<FD<_FZE;5
M@!5?I+T9//Q=-3LN=5])B5YE'3LKT?VA,.D691:%! ZW9<! +0T\7-1I]I/R
M1U5G:Q?C#_\YV',Q&U^[.?9K2V>VFU2!JHI7BTONNKUCD2G&5;"#>5*9(6Q$
MN6"L<34I+ZJ2*_L]]J,FI=J/P;PU%_TH%UVWM:6#"6< !66'@Y1;NVR5A9P$
MH"H]+-.LGTZ5=KW_\-[^RX&#X-XK/;ZR"'(6R4( E8$1BB2^#P?OIWVB@PJS
M'165[,[[5.FB<4 4S#8.L)GA)=M9VU#P75',E1?-"6I>>4Z-4\XXX+DBPITE
M<EP L+MW7%IP(':AEO+IO07,WLF#O-Q;N83B>5F@DQ>I#3K?>BPP-]_QR'XI
M+TV_KZ8QPM!J3-,9P59OS^J_3@*0QU2)FV+HJ@F",?4337E?_;6MX;Q3,/_=
M:5NU.3J%B9FJ>L],+8 M]7^H>T#NE(T.JKC)3-^/S;*.$TP*!WS7,W7NL_T
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M#Q5V/@:^6W@)0^JD8,:LIVPUHK&GU_I^WIV4G)FU]=(4#WOC31,*MWR\QK@
M!)9(PXRJ0'[7>KQ\.GG0# A\:F'KH[[?A#B*R1^5.S"8V^SZ=64G[+#NF.\G
M9:'68K8$@W!/[?(/@54;E#9C-$L:)6V+G,$\*8)$Q4)QT2_!_,X35>7#YG<
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MSS 1(+DQR!IC^3G8M3GG%ICM1-IIUX XXXP72R^E<R_;(&J;#_+GG;.5BU&
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MQB'?C7S \(0KZOLJ1HJ&&SLTW S8FD<!B+_B4*"5FDK])UO]G\B6>ILJ:5E
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MKM>:5A3RU7+\8G(\FI-C'\A% RU=+_3 Y0M]Y'+?)ZY *$0>IHRA<-7D^%<
M>9^G]QLQI4>VC?:FT]./P15O6^TL+_>DF.//'=X;[/;4?C7-35UKEJ=IEOV[
M" $IA12H?E=YGG"ID,2-<"Q=%7%0*U1'O@3-$F!2KS*MB^ M+[>D%KSE"=Z\
M22=!P#P1"S>*HQ!,.@5H+N&O )2E'U$&]IX9P0O7=B%II2WW8=$!LW?N=.R&
M479:W#1VA_#CYY>3WK:&65IV246$3X8&1V8PA_%)KFUPN0XJ+T__'-PU_"'Q
MN/95[ 9"F3*V6+F<,.T&L?*I%TI/*6]C!V_Z[ W6V=:BO/24E%J47TR4YZ%$
M)%CL:P 0F((44TP#5\2:N(H'FJ PTE$(4()LHK=8C[K2*&-/QSJSN]_RFSHU
M=;G@H9K; UL'U.(WQ9)TLU8WRU0WC;O(@7B^%L+'+I8(/!=*F1MQR5R%PIB$
M4> CP8VZ\5GTEH(&CU)(;T]<EP40:G%](7&=1P<:1#)2H78EYYY+ X1<@4/N
M@OY5$8X(\L/(B"LA]&?1P0.U)74,8D$,PE:NU,&&%RQE*95.VI-5YEJM7IZ@
M7KXL6$"(I*>("%Q$PMBEH6"N8!2Y <&>'Y@ZU\ #]?+4!80ZBK!.,KK4PI9:
M1G]61N<A $8!D3Y7KD\4=:DV7?44IV[H1TIHH(H7!QL['GGB6L,ZA ?6J9IE
M,1+XW@??FZK[J&3VE9N*QS<,?/+WOQEUN]RBG=K_6I[R/;D+D"B*C0T$@*2C
MP*74(RX/-74U!YIAA@4*E.D;Y&UZ&"W) WNT3+QRF*76;;5N>]8"I5JW+56W
MS0-+%6@1H9B[?D0E.'^2NB((F*F/ACF.%$.FE1%FX29ARXHN/;MN6VHW-;1
M)<ULF,KN;K_TJEMC?#K8_?O@TT'K8/_8V6WN.<?_VCW:_]?AI[W]H^/_X^Q_
M.3EHG2YIXPRO;_8T'9I]K.;IMT*;9SQVE+_">F95T#;%)+]85=MZ-$K:E=)N
MD.?T^<@49-1;8?PB?>:7YAF6#/2YX)^ZSGOI:.I\@:?HXR",D'0]BJE+.:4N
M"P!<*4XY0[Z' LTV=KS-:*4ZT-5;7]0JZ44<NEHE/;]*FG?PA K", RPB[T
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MPUZ]Z77C+;;K;KW#M\ -OAMOZ3WOK8';V7C9&EB\_4[MW"5B@@ 7QN?"E6"
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M&*.(>3[7)22R/A@DF96:!(RYHP"R!C<UH7<_V550KJ#<$CSU/"F(2HK@J%1
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M1X&D?AJ'(E_"_M[.XDI%/^]R'8NB9E-'%W^%6066;@Y+I],\C 3IHG0<>>P
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M;ZPT]LX'D<<0XK?8Z1WG^[:KDYS?P.MJ'U3?AF_E9V$2-XX';3"I4P?WRP5
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M:+G8YCL"_EPH?^K RON@+;YAUAI#56G@IER%T[.9P>9T9UCA-)S&H<0,T'&
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M2V0.ZJ7B(%YL3@FF+A,I7 */3!P<CY\B C:A"3P/2 O$$T,K4,-S2Q6:ZNF
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MX)EK$6 $M)JJ^BTXK\8CM,I:8,!8;$C@>@<J.I_0^34VHTF;KF6#JR\8(2S
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M&J8S5] \\]PNI>F*VSTM;G<QR^W*C!:)2B1Q64()5R8ABFM)"@;_S2E(M50
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M<BJC.E=@J$K.C94R<ZQ(,TV3@N<RU5'AY16Q931I$ENRXD;WKR=O9#N[7\Y
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M6Z167_WJZ:'2PEBE1":I=1QXMM"2Y]05J:.E\TW/EY^==/KL\(<\.OZ)OW9
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M3]F8;#5Z.M%%/9VZ:MPSA]%6^KSUH<X=#H9DI1D&MV<#@!H+JBH#M.)\(^!
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M-7//.15E0>*9B6]8NL-# [OYF3KW7$>/F; LT_$2Q_&PHLPUC)[E[EK_U"Y
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M9OO"2BS/M2R>>-9<'?21J%,J$N_R0GV$S^U:WO2ZJ-8$R]YAOBNLP-%]$$U
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MZ,SW0CWPN*O[3-BQ \P53&7LZ.Q;IO6JLX<[7]R&JG0=5]IBKC3;D $;<!'
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MW<1P/78#E6!]%=4N_@!&4M51X0>U-KRG[<=QBE]AD6:O^D$YX@41#E5GX0G
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M=G W=C!CHIF1Y]B.Y>JN90J=B<36?3].=$,$IC!<$7@([NAX_@XYIK=&^YH
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M[R6 X@ ULVP.%4T2+/5*+&4/620&5" D!^/GA5"]:T<7?$3?\A2(2;OD12J
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M6U^BZ5'2DJY@CH8<,H2K'(RA2T+$(FJKHN>*AE OTBES3GH%== 1Z/<#RF/
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M(@#A>:NV00Y##;=#Y95"S#:Y=;!2N)O$UN730!9PAC1R:Z#M3BJB>@7E6\*
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M^-,']EBM:.P\*<*X=$2W4 NDMTL=&S5-[$GG9K\*T%._P[RH6!,P+G')";I
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M:I^Y7\.$6/_-S0M84KH VNNQDD0[AT&;XF9N!&D<;2W:N.L,&V\A)"R\] -
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MA@^3,BNYI4R'.9'O.[Q'88:E/"+-6"")DKKUZL/S@H,%=51;UKSI/\JFIT*
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M\VAJ%%0N)X2%H&IZK%>E95.>7G@:GQ[Z")>-BF*?1.L12:ANBYB%D^(P(#)
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M^^N'<PG[W[*$?:]HES'-DE.^"\6SS1CF.\((;(,=ZSX2[V:Q026.OLAA5OA
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M"MVE#(;\HR'JCDM$WOKTA[94,.I="0"H^:3>]G@H> C7502\'ZTSG1HP3^$
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M=2U]GFB>]:_(\@1;0=;A^-?MPYP<G,=#")BM%0<NS+4^2\,D<&$1EG"IJPZ
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M@%GT:A@D.4*)@BQ.%5"<UKEID'!M&@?7*!#.VVGS63+NG,>@4=8#P&<2!'W
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M(+!K8CI#L7)66)8+C*3QH8Z N\AIAETX*%7WRVO<AU-5?2$0&-7Y^DJ<8^I
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M*7OH7>FC'(7%"ND;&[*\%NTM-PJK(;%S/"[,U&.&3;=)"%8R<,NN,G)].<L
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M,CYA-H8'6YK!"?V*BE;:!)B6%IYDBN_M1!\]VSY.V<D?SCZ<"5A&[(P*$J
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MO=$.PK?HCQ,@I*8\M1FL0%$CF1'1Z])>3?C,]/2"$*2<.'-Q>651;G;G\23
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M;3^G[%(,T2C]<&IANNLIJNI_].U>FUN3J-]IV.\6-2D,1AS0#X]%E0&J1=-
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MX]D5R[OEZW#>D <=!M_["PR]F"ZVY<C* C\J=R7.OB<(!/G^:$NK<%(X?1%
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M'Q\,QK#?$2J!K>KKK$XW49' V -FU!TC[9#*68.X@EJL#V$"=#NR375";N9
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MZ3HUPU%I)ZS#))[I19[0:J!BFCGL:WG&6!"FU2:?FU/)3%R/-9)@!:,J+LR
MC6[BMY0B3>9<X*?*U'M3KQR1#9;SO38!<8X3RM9'\9G:Y?U&2&WAV$*:5 GL
M0$1D)#%*ECKS>,=WA+Q-*=OJ.E^\S ++/Y5CF(E!%94#[3)HS8832VQ8<>,
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MC;\0G* H*-;CJM$V(R^V1!SR$A2MYXJ#.+ 1Y-*!S4*12I33AUW=9]O870[
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M,.QMLZQK)K#DJ=](R)"876#U>:24D@79ZVP65\ITD]-?WKF''ZA5SHSF![:
MZ"V2Z:,25FV[*<=Q'&LX+<I5%J!SAY,RQ.X4*"4+=9 7&O&RP/7RH @6 %H
MX8I0,5-R6DES0O2%-C+=!)R?P05+NJ#."ZQ4B6J$77'7I8PIGC$"[$F9;!"
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M.<%M6BNW6EQ]?:>O[U>HH@85[W1'E,AA?T=5Z>_&86AJ?.7[=WU-5+HE*GN
M1/ETJ;YO)^_37-I/V/:X7@]AD4I3[FEU&;A95O.?O#+ 5ZWNMD/T/44/>=AW
MRW>R4934P#='I>]03)?;7N#\FVY.':4"ZAU/S]S3A@E<"7:#?BR^50:V2!RR
MW7H?6B6-4A@C\UE0BH@[:D35'-O.NJ[B?P 9)BK/UKYMCU=0"C5K <7#7!"
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M3G[$FE]8O\D!J>8Y[?=:8_.;^XJ.]QCBKI3WF<Q!?1LCTUK#5!3I=F,?S[^
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M/ F?C].WI?MV!\K%).#H2CQ'%V+=RM_E4$AZO=\"EBJ-)B?%9++7;C-UX)J
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MC_F.F2\_M#"HS,+5*- ],J+R?";?D.\QTQ 330R )QP3^S@"MJ+H=P[2O4K
M+VF5&3 @$3Z)Z1ZYMU^3^PX9->^@[CVVEQA(1 ,IQP;@$&:4)FZ#&14*LJ^R
M9$LDG>(KM<EVIN']WMJ";0@"'U2Z*RP$P;708;2[VC1Z1V]<VNTL^3Y09X)L
MN44D,.!O\#YC@W/&3-XU:KN)2;S:[[V7I\(MU_:_P,%+$(O[:+M&'42!3@D5
MG8RU8.'/<L2,ONHO*8?!2TO''@/<(X@\[>@O[63Q(&+>R0AS3$QM0"AFZ#OL
M+CKVTHE^K9EMAJ_:2>RFSDQ-DLITURTRAXRB%B-R6=5L"-GNQG!Y4NDL[JK=
M@C27' (5^S88TXKGU%HH\3,5F2$$]_R&92_0[ .WK.9^A'I4XD@P-2F-L[!/
MNONZ@LGF,(I21YF_CF'L-.J]FMU6$15SPR%<=&EH![<[5*G[>TWZSIAE<1*:
M\^'+-]3D-J]06CJ<V ,0!/FDGWPRH+H)E:Z.UFS+'FQD^#X/$C3@:[UUAW:Z
M ]KIU0[MM$,[W:)C'XK,794/,IJH/X!I9^\IX62K#.$ ZB#T)B!^E,6U0LE4
M90=MPE4E,P0%1ZV@7$>,6'01!Q>S!.$#'[Z@;$OOV@RLBMA:*/N&M52?)R:
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MJI?"'DYU\L1^U+$@X>R\:\E^(2VL0LN%E(V<>+OAUMH<9+*O>B"J]F+U5V^
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M1L.9V8S06T%QUSX?C4I0:OZV%*9#\8S)F*HG<^>N2(R.N:H(TVJG&'14LCO
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MEZ1#P9PAEHFJ"HN%]G.70OC$/O,YO)"@Q0>*QHYK0#,]1W]3OQ'[T@O:9?N
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M<V(>_,7<1=S9Q-Q,_)6>[3NZ':CXIWHZ_4ZML"8J[_[R[O]02P,$%     @
M+3BK5N8O6=UC%0  @<<  !4   !C;7!S+3(P,C,P,S,Q7V-A;"YX;6S=75MS
M6S>2?L^OT'I?%S'NEU22*<>.IUSEB5V.LS/[Q&H #8L;7K3G4+8UOWX;U,6Z
M6A2)0QVG*I%%FN;YT/VA;V@ /_[M\WQV\!&[?KI<_/1$?,^?'. B+?-T\>&G
M)W^\?\G\D[_]_-UW/_X'8__ZY=WK@Q?+=#S'Q>K@>8>PPGSP:;HZ//AGQO[/
M@](MYP?_7'9_3C\"8S^O_]'SY=%)-_UPN#J07*KK?]O]4 ",U<:PP'-F6O+
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M,1DP#ATDB0&$,]XK/L)J#$-:C4]!UMMS]+9X;1_Q_CPYRS<H+#9[&S*!MDF
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M'U.]#X8[D1Q4(7:2U<U#8W=&#R]^7@$7YDK.TW,JMUDQ,CJ*K&J$J$MS780
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M5SL4_G!V)8=MY$5L(WD31$(-A@]!0.L(@I5L!'E5'7:/56Z []&KS>!"&:*
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M\K,*U.$"/CN+[F%UV('O0S@ *P%Z2DXE5"!DS6!,2Q"/1K>1/I[_DU'Z[@[
M?A5BC9C._O1A$W8/KP>74X&4,CXYXA.1\1@B!5%* =Z&[$+5&FWW6>!W 3E
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M:.=T=.BE6Z_/5:\=:AW0CUGK#B.YWO4P&Z/_E>;SDROKIF3GDT@&R O)EF!
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M#G.X=Q+7S?S /KP>X+2_ YFU1)*W1' !"QC& E$5"ZX(Z4M$4K5WB>"^I/_
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M]XM_"RX/T:^#08W+N'6/_V+V7@Q#TCFA#!8(6Z*L%PFP2@LV.R,"VTY6]:Y
M60GF25D(N[-[@%DK5[UF/.4OK_@XEW=[:R <REAX$-WAK(8.XKPG@M%1%D,<
M' \CU35G]"1!!]M*J'2&* L[R;6@X/]D[#XI[%#:LH9)<1!EV40$O>\Y7LU_
M>T\_X?2?-']3*TW'9^\^#R@))4?AP!O'1 <T3'048$U%KYTLM[J3K8B!KWS%
M 0R'SL*8=.?DIJ->EC]N?[2Q(/_^+_\/4$L#!!0    ( "TXJU8XO@$$"ZL
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M&<3.\O_YA33%+OI1C=]:6W^2'3[Z+\T+%5A#!#1&X&;U2:YA G<*;  %:J1
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M0L88ARA*$&0R9E#FL1*\=K5A+E9P;TG&9NJVBH!.$[ ANQN5]1\<.VX;!/+
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M1AB%*#>[B301D!>D4$S$JLBX"^LZ]C\VFNW$![1UI=;8ES.Z>.X*6VQ6K(!
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M"$X@PBJ'.,HI3.OEA<F<2B<[^$ _8UM%UF*"6DY@! 6_&5$=SYH/ 6MGY'J
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MGWZ1'^4#+6?=+^_EXB&>9!'/3>$^*#-&(2H(ATQ$QJ>1D"Q-HE@59Z08."W
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M2H2F>L@Z9J? BC*5P%C%*41Y(2!-1 )Y4J1IGA(<Q>*\DN4'>AZ;_?WZJUG
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M: ;Z!!QX;'P#.P1-[G%@W_2SK@#KLIQO^6(W6<Y;_:^:= V5*9'>8' %.A1
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M9911B+!@D$B4P82BN. B)Z1(G*X'#_4T-FO&!'S5>]95=27'*\"#D%I>_?D
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MWJOU.2/<;QT_>W;&4.'/&3S+VG_NX_K&:,U76KN+TI(_M#!(+A')>0IBJC!
M*". 9#P#)@X+IPARE3BE0781&YL2_:3G@D]?9MH:T>MQCW/7**L.A.U48RC<
M>G=2[;!Y$]4V7*^VG TRP<*B.D@-' %U7NCC8">+=_Q4R+9,XZ/:K9+S)&>F
M^5P98GI4)&>G4B#/&:4P34!>Y)D)^F2 "I*#(BZ*6%),9>)T@W,A/V-31&U5
ML]RTT*639*>H!H2^;Q.NN^EE3R4@ ^$72.-=RLV@2C$0=(=Z,]2PGD=E_DV*
MU]D!;4-46X#'A<>VW^>J[OVIGWY4IXN8E:S_M:RT\4S93&[7.A:I-NU89G*V
MM-E'40(8A G(> [3#.FS-W.*PK^*%*-3XZ_?OYN2^-J8W&U.O%<'T:LW]'6^
M$<LS_=AG_KJ[R$V9)V5*7AHI])YBY.C'4+[J3(1R&%Q%AF&]#-><IB/7Q%69
M<=LQ5\OUY/?I?/K]]7M=4$B*/":(9$#RG ,DF0 LSCB04B20Y(070MCL8D<C
MCVUGJ9FSVS6.<>K6Y!=)W[-VK?D*6$&I5=HN#:9?VM%>^F];S74\WB#:I%6,
M9H6W/^!GIS[,^=+<%+V3U9\/\R;15/]F\5T^TQ]R-9$PYQ#Q0N-CLCL3;5PR
MF24@*0A6,:<%R?!D+K\:P_K9WKRT(F[UV9+JLSUBH;]/>),Y;0J$O2SE"YV*
M:$U_1'2UDJX7-7:S8&>YA0-U&%W0\!O]UG#\%U-988-OQ754LAW.JG)"*9 5
M9$=S4*O%"89#*\/M93_]M+U(N:.K;Z:/O?[#U)9\H[/27EG?T>7RYW3^M;QW
MF112I%*(!.14"8"@H@#G&0%Q&BLJBT+%=LVL/>F/S<+8N:SDFG$WK>2*?2ZX
M5 E6@..B3(Y5@"B9@#B+]48ALHP5R>1-+MEB!.CO\O%_"/YV^T./F/:\4^R
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M =_>@7_61<=,4</E8JY_Y++R-R[OOAEN-F7)RB>F<SY]F<GGLGB>D#F+5<Y
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M$+$0"!2Y*46<T!@0TR9,&X@<Q:F4,G,J1=Q"9W1FW$[=KM(?&SW,^>Q55+>
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M'_2\T]1CBNGL=3U]DY\E?UV6OON=Y$>$B<0B+I-+4X"$MB-H83K9)A111+C
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M@?26!P.#:C5_@ YUW@4CN9]Z[J;KG[=+2>\60DZPB%,9*P:@@C% A,> "D4
MIR1+4Y1*6E@%Q!T./#KM9;(Y#'.1X<[^3+,'UOF#C"\$?7LZ[*1W.K&<$M7K
MF+(WT&!GDU/L[QY(3O[>,YV \^6K%'IU*[DRC7/H[+V43;7\25%@FC$F@1 P
M!TB)!#!8Y"!3".M_%S%*N%.)ETYR8UN8-;?1RPZ[D:SR15W#_[MQMC,=PJ'7
M_S&E!&Z7T\BPNNE^$3 \WPJ44!'XW<2&#;*W$OPHCM[N+3]M\C<YUU;!['8N
M;L7WZ7RZ*KVB;[+.L9[06"D2LQS$"90 )4B?7%!,@21<Y(H@*:E3Q:@S],:F
M3VIVRQH"=(]A-V5R#F8[;1(0O)[5R2YN^[PVY1?"J1-+5 +IDW/4!E4HEJ(?
M:A3;UR[IK+4Y8^MO)<^D::<+$WTF8(("FA$!4)S$$E*5T=CI$G5_^+$IC*J'
MED\++:_>62-T.%2,]=@KJ]<F6=?LCF77%BM0/ZQ-E:</T[E\T#^N)CDAC*:4
MFMZ8>J]7B0149CG("Y;!A":IA$Y>RF,28UNM._W:#8]1R:1OH;8MD'8K^#)X
M>E[%CLCX%V0[$CYT%;8M@>N47CL2L+7>VO&3;DN;?W]950E+=?)1?8^6IJJ0
M/,\ S"34ZSI. >$,@SPN!.&D@)A957-N&7]TB]IP&%47/I9G_C;DNA=R #SZ
M7L4E%#5WYQO86F$BZKOUJM!!C]CL$1H(H\L5W!G!*^UF'C(J*X5I&I=JJ^VU
M0736&9X;A77N,6]_IKD@7WVB/TW:BSZ4E$5;:J_'AVT/RL;SE@HNLB+F(#>:
M#*DB!A0*J:V6F&*("D%9[NCA=&)@;/JN<=TU;L[RT+THRTOM=/!T=GZZ38J,
MH<H4H2!.F2F%D)F;GX0 E><2*X454<*E_5FODS)  [-G0R.B8Y@::T]U;X#W
M[[LN68]JWDN4J_IJS=K8X;\?A[87=N%<W&[DAW9Z>X%SP@WN-XYGE,]BOF@N
MS*LDJ,97:Z)YTY2G0&\VF59UA3DFDQQDL2(\2Y($4>FBZEHIC5.G5>IK6F?W
MS:5COZ5V7.WT5!"T>E9(NSS6>9#1;S6; 7LJG84B5.1,*YUA V3.B7L4!W/V
MA0O*2['S-4%82TV031'"CZ_&?JXSQ5<3+AF"A8F>$809PQ8")J$ C&.&*4,9
MS-/)2]GY[_.:+M>67KA^N'59;H<\][?ROM2\5B; ZWIE0F[+G#\FOT[GIG]6
MQ*A^A5>EILKR4BN?^E(]S']6\#Q1D(*\H!0@C I 4@A!S$DND90<)TD]__=S
M\8O-?L/Q->9>EG^.=^(1@804%(*T[ ^/(-(6!2:@B E/E.),?PK.=>2N.^E#
M''PW$SZZ";6\ +C^- WA?PQ4"6ZG.'8E[Z9B3P"OW4!3$K+06P]<#E_8K3^H
M3Q9RZY'<A;>P>KSU@O_3%$;5FK.J8^T8$6 UUIB4P^:*T2SD'8[_I:F7WTMU
M>Q>40M]%=M*\SO6D#0RM-Y96+WNNC%>VFHHI7?[\3,MJ6H90V?NLH!PFB'$@
M.)$ L4Q;2TA;2XD^):4XEA!S[&0MM5$:F[UCV-NL%;^F<JV@6JJ8$%#UK59<
M4')7'^<0"*4R6ND,JR;.B7ND&LZ^X!'3\%<YEVJZ?J_9.]T1ZIG^J$HXG"YL
ME"9"Y8(JK3$2K3&@C $I" <T9RD22D@HK$(00S S-J52BQ.9N8]:>Z:9JOV5
M4 [! Y=.FT7TQ8"3T;/::N;A_=X\W+;.@U<]F?!SY! -,N!<#10ZXCMG@:),
M @':&9)R*8WAXE<"H;$7[!)J3#\3N+S?_+24+W0JZIN+YDX_@QS'B!0 I3D%
M*(<0X (R %.8YY@0QH23Q["=U-CVJYK)4R$5O.(XHF6<M)MEW(&UG6D<!L&>
M-YDJ***!<-,(-7A Q'DP IG)'80&M9//"WQH*%N\$;0\R?OIG,[YZ3(8E',J
M**2 *XP!0J:^*C%M;5">%U!!DC.G/C;N+(Q-RQR6)WG_\/'VXUT?Y4FZYL4R
M(J)7M/L.E>@N3[(1XDKE22Q [+<\21<#8RA/8@&097D2FY$\[:@F".2#Z4+W
M9+JP/"I-M,RGFF!!%,L) W%..$ 9YJ9F"0-ID>0I)3!CRJGC<B>UL>FY;?F?
M6=FA;VG8!0L%7O5?O.RH3JPM3:E0"/9M36W *QF]B9X:]#2S4<EM0)/*!I10
M5E4GK6$-*QNQCVPKJY>\TQ5>O[^6[0Q+$^Y$M?RF,F2*"D:@ IR:5DJ,98#)
M%(%,"*QB(8C 3JV4K"F/3<G<WMU]^?W+A]OG^W?1X_._WS]%=X^_?WJZ__?[
MCY\?_GX?_?;A\?/GO_QK]/!1__N]<S2\Y738Z9Y>0.Y9#]T^WCU$M^OU<LI>
MUV4 _'H1?:+E6?ALSI=/L+L;0N&BW"WI#AW>[@;'B;AVQP'\%-<[J:0^7XJ[
MQ6J]NJ,OTS6=3?_;U)4ISZ";>/IRTW\W7?'98O6ZE%M7+ROBG,(X!SD7IE$0
M9H#%(@9,<,7S!.493%STV:4,C4W-';A55CMI*/7)OK()'"VJB^?-3O$-.1L]
MZ\-&E*B4Y2;:D>:F<7[=["8)514KMD+57=SZ*=$?"NA :O5B=@;5MJ' .U3"
MP<;UT\WW=&E"TU>?9-40^_"6+4[2/,YS!'""*4 I*P!%3 $LJ0D,+U"<.YU1
MS] ;FV8U3B+3D*WL"%TR[*9"S\%KIR$#@M:S FPXC3XU> W3?<02H4":ZQRU
M0163I>B'>L?VM0L2E8XZ4$Y2*2 DL  9$P*@A$J 8Y$"#O,TS_4OF;!J2-)-
M9G1*9#'7)_'5MRI3H&["RW<8#M%D_J*>\"/2("<#\K>QTF4T?@EF\&I^W=#T
MVBE]#(W-6^/JNI_VTP\/W[5QLRP#>9?:J'E9K.CL47U8S+]^T&=/45D[AYLE
M9BAC'!+3(5R:*GY:>Z@D!XE(I&"0LS1UZA?KP\38=,M6!A-Y:G@')?->!SZO
M6;'3.WUCW;-6VH5Y&34"G(1\&(/G$CP#J3(O%@95=)> =*@&+QHKI!%UG#AT
MU,6[3ASZFWYPO7J8?RK38/^0YC9"<_HFE_2K+'_YCJ[E>RW6W^GL54XR#%/*
M10P(CLVU@3;,L,@9H$*?42%/*)5.P1@#\S\VU5QR6.>(BL5L1I?5,;*T GW2
M10?\%"XQ)D<QP0-:J9>FEU8H1/HKJ7"XB1HDHAJ*ZI'(@!$9-*(2CKXMW][G
ML5>3NC_N1V"K]SXU=H> _MGP2-FY_:YI<#I_)_4>/5V;?* R7[:^C)6I\3,(
M G):*("H$N80D0&9$GV^4%S@S&J3LZ UM@VIX3;:LGLNC=T9WNZ-(S!H?=]N
MM^+E4]#T#' .Z2SA !PH6\7CPW/+1[%#I#/=Y,P0PV63V,FRERQB^8I_8^EG
MK:'UP*9GM2:Q-*&+12I32D#&& 0H2?2A <7ZJ$!A0A"5,456KI@N(F-3GYO6
MR5M&HXI3]];21X!VZ\U0,/5]_>V.D%=SZ38(+NHN?33HX.VEV\0ZU5^Z]5GW
M1?Y!8S[[]&TQEU6!D4DLI)0J)B I8 I09OJF%%D"&"4QXAF55%FWC3\<?&R+
MNN0O*AFLB_O8+^8CX,XOXDO@Z'GQ.B#AM&C;1/9:K$>##;9(V\3879RMS_CY
M_^ISU.IY<<O_ZW6ZE)^6IJKD^N<G/7'KV[DP94_*9%!S-8)8GG.04KTI([-X
M6<82@'F:ZE6L%S2/)W/YU<3Z/=M[\.PYL/J02?4A'_'18V2<'N@;-2%Q"V5:
M,Y;,EP%8LN'<S1'G,"=V/K3 $ ^C*QJF3;AOS7;4\'T3E9Q786[W9U%V=E:Y
M Q;(S^1 >% 7D3L@A]X=CQ$\;S3X-RE>R^HL)QU*9<V6VF54)V/]+ ,BM]>-
M29**1,D<")$F  D3"YPA E26H830C":.%2LO9FEL)DTCT:9*81UQ<C*:HI+L
MIDER;"\0T==\6MXT##I+ UX>6$U*KU'!X: -Y<^_G*%A7?3! #SRNH<;^<+\
MU2H;Q$3"ZM-A89H-8*"DB0BF20RPX@SD<2YE3 5)8N[2A. $#2>-.D#[ 9,E
M5F7C/WZZ?[I]?GC\Z)J#?PI).]5W(3X]Z[)M)FK3;< P&+#50(?XH7-.=RA<
M)]/T6,36_-(3C_HM\=/5A>K@ROIN L54RB2'($YC"%!60(!ID8."9YF0*H4Y
M<<HGM: Y-J-JKSZ=V#+MI@5LP+;3"H$A[%E+M%;WJQGN(5G4 :! >L2&XJ!Z
MQ0&"0SWC\NJE1\'#3 1MYDRY(3R=O1HWT?YY(:,DQB37RH<5!4 )SP 6C .<
M**P@*003L=_YSXF/L>FGW4/?J22<4IAJ^57B^![TW&;+]737VQST?:1SA7^@
M(YT7GL'/<6Y<7.GPY@55^XG-;[@KMX6J__Y^L51RJO]^/E!4H91CB"#(8(8!
M2E,"&,2FWD@!!4P@$VXM4:\GRM@T^H;S< '$U_E$+/> 7V+B!_0,!NM:L^G"
MO8'D2A'&5YW=L37 <1?DU^R1XSUAO;71\>?(T\.R7P7LD:WI=&[J#M[_X-\,
M\YJ3_;IA34O9GY,<%PIGA0!Q)O3VFE$.6&(\+S%)<TX(0['3;=<%O(QM?RQ%
M,?;VMF!@M*CE,<D4LI8H4HME-)=_1MO&J%7%0>\^V)=,J*5W9YAIZMOK<U24
M,'K<F:#[W0DZJ&BX:9L=H&)]0%!#>8HNX&18#]+ED!UYE@(,Z5GJIFP2]5GR
MUV6YZ/^8KK\M7M=/DHKI[.<[J976]^G<G,LVFO_VNVG\/9$Q1B+7"C@7,@5(
M(06(T/]!.(,PRY(4NL4<>',R-AW\4&ZI[GYP_ZFPTY^# -RS]JP[T6V%B/ZL
MI(AJ,:)=.7:L]INHDB5@=9U+X0Q5=\>;CV$K\EP*UU&MGHL'],BC.]-VI+J
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M))EI6F'>C3T2D ZBU"I+$:&F/4&01@+C)G"4F+5H?<&X)XGCND'M83>DACH
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M8FZ);J*D9TD4#U[F&E*R=16R(M\ :_L":YA^J&*O :@>I7'<@_!IX-9641T
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M^GQ6HX&U58R9!\UR@1)K8J[)%B*& CH:HQURKK!U!=F#!'720J:AGW&TV#O
MT T>SEO"92X#KY5PJN:#92UJ>PL.7!5$F;6WMG5@<R<AG7@<QROZYHWTT5+O
M #I7FIEL[:>+T4A!M*<@:%=)KR%*1EP$[A4OP6O5NF'U+2+&A4P#Q=[?,N8
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M2)\.G[<&WSVAJCNVFK_AJLXCNAC2?L@K[HV/:/:(^Q!IK9RPL)A-9Q\O%KF
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MM!=)FI@EY.S,9NZH,]( D[9@]:M\;/W"/'(+\P.7O[(3693))W)#F:D)HL9
M),\3HB.O(JGBM6W]7GHLS<^[&?H^&+WM!CZAMCNVNX\W'#_<ZN[\V4_7/7U
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M_XJ+V;6]_V(V.PNG)Z4L<;7IS3Z)J90L:MU[$/5^F;[RJ#*P)*QU(=F0S1&
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M?+:II,=\<HTYHS%K@Q)$, %(B B.HP/C.?,VJ:B:3[7:B\!Q;WL'15YC[?0
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M6H\I>)"@D0O_>D-A.^5U@,1SN:Q]$JV1D.$SA%+[2ANO-VG#IBA,1A>;7.O
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M/$+4.H-*GJ*-:+2US2LS.KI9SN&1K0MWG !NK^]9[EG5.&:#1FE!969 ><G
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MC@?M-"_ YN %38.E-C9?CVV J;,:?\>_KS?_V-W$4\ 0!>F"248>I9P'[[4
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M/1X*=7#[Z1>L[\+EQQ\NUO^\N6K<*B+EDK!.=/?1D2)<+A Q)S!>">ZU5NK
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MQA9X;=C?AR?O<F%K.[>PGZB&Y82%BV?D-I%3P8(Q*[KU56Y5 PDF)!)T ,Q
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MV'VH;JO^=]@2(?+#0_>BKK+\OIQ_4N*>"-E>_,_0NBV*'"-W0,-YM:QP'B'
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M2*^\(W)EFYC.$9IN"GH=BM!2N-<N]TQ=;V"&T+:HAHFO[W:I/R(O'H4M!?U
MWQ-+ @UT3?(*"&KGCAK#-LBB^!7T8]$UH[7'4Z_>O3_W>E6T_T82?0*CF66!
MJLM@ - 8>?K*V7/ZC0[T2I9:::XAHL,8#_@\T%JW_JC-_5&;\+A #<4Z[U88
M;TJE_#SZ^K["?KVGWIHP<MO1'KWF[K::TX>"1UI79&?,],G1I7 K8I!&K7B
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MU%I\-T]PEP-U,Y;+&9P><)] I1+LL;GW%^7GEAG83H22H!.M\?BLWA1MLXM
M1=N*'>*=[?Q$08HC1(4JDZ,C'82()ZKDJQ,OFJ\%]8>_C*X$UI74PF4AH5Z'
MP[42: *?.C']:XN-ZFZ-NF>8JT!M<UYQ8\='@MN;%P*O4$$K5@B1UL?R56FR
MQ7^I=IEL*(>H-6:[2,/^JM>%%Q-[#+\6\:\2L^@I\=Y,P^.D\X6@=4",N)V;
M7;(=-'@0?>]V;G<121!%+7ZAC#L6^TW\<.I))^9:Z7EU.[_LDO&"H-\ZT[A9
M,K+)</]VX-KS2M.NUYZ3Y<*7MI3X@@?\B68"FZ50?QI9H5D?CL,VC1SFWOL[
MRUUSQSWDNYMX<@$0;,3D$?2AB)<Q&B<&3!O%OZ&%4J0B__3G=/,<_VYNGN.A
MF^?XCW3S]-=_!)/0PZ8D=KLXE$G7F#P2EI_"TF76H)W^='Z=]D,J3L=Y&3#J
ML\_.'.(/>&U_XL?/^?%K>EQB>*='>T 7'HR@"\_DAZDXI H.5=.IU>'$Z&0=
MUT05H?M"_IW8LR07O#<3\3[^M3-SR(?Z<O3+#@H1'46O9_4/W3"[L(@/E*.Z
MX7@)'5G&K7J.F$"O#*MF=F7DX/4V-DNP."JK:BX;8TU3D3*OF!D$+Y_+ AU\
M:8&\/] 6*'(&)AY"OTH/+\G$!4P@%,+BLP>LT$SZ !"0CZJ"I']AZ*2[+;JE
MN^D**-W $TA?$J>75=>UV/Y'%N.01P: A6'@^N&&NK".<MY$F@4)@%*@$>NE
MA(3#H#+6!S@25":@6.WPJ+?ZK 12WV36U-J,S8O9[+*#&H ^.$"/D%GFM815
MULP[!'9'WEP4,,C61>]='<9Q;QAZB@4VVTQB[8_GI[I;$[::QZZAPMZ:=>LE
MBTS=\QK!]-)<8SJ I[T!_%7'_E=LV5^]+O;7D2T)0R"^CBW-@$G!.0D T^(S
MR;5ET=L<5NM%3S,%R\2OX"#,%('ZD'N(L@[YI#=DTYEUY&(IP1- I[;+E@QN
M83='!"_P2(?(&.S6B>$RJW*CSF?]HRK\JF9_7L*.PG$;L6 *Y)BIXH9F3Z$0
M5[-E>>-QJ7"Q8H6HD[QR3;4JH%K=Q'.+W\"C,#X8W<#TP^2#TP;$MA@MTH+$
MZG*RBHAS$]\.R9CTRSN)L"& YCZH*2317'.)1:HGIR$0.UDCHFMJY6:Y-3BI
M<( PRB9&Q$5VP3T.?%W,-+(GL<-L&/@[XW'1R/IZF^G ^/7 :S\&P>0?XR '
MS?EPS[VCL;V+QD;?3=U'"#S:/EZ\%$\%VSZ[HR^Q\V?\.+U@J.]$)*B/'(KA
M(0_I4U%LAN-BU9>TT#+?3@27X#MCL ,/G-$Q=!:>2UN'%F4% 9""]8^.88!P
M./!IN:U:W8DEO0N8-G\DAMI*Q &-'(4!&="(I$293=2?LE!U6EP]Y7I19P9F
M8!LJC<.D(S<X)L^ 5AKZP<]5?ZV/:.E^QB[/@\D,&CU[Y!?&!]**QQ28PE(Y
M'-,\%A\>$29R\)'K%P(H\VR-$P443 -W$=PG'HNET;6=E@0E],E27(X10L*0
M #PH:?^Y#/^ Y\8DAL:7YB\A'J2R)^0U:D*%9C?^*E@J3C.C*$42]K"8GD^S
MSV@I*V3F5&P9^3A60M1CAW?/G;.+@ADU->Y[U"Y77</+V'0S52"H2U:K-F2N
MU#;IH;&R@Z^_""G=W1-:J0L&]2 .C^<6#/DA<9^5;%J*YQ$ C&SN/2PCK09[
MCZ&!T8HU$2_D@8/GDV') %GA49@5UO\#L7LZ>TQ*\,EB-ARD=1O924M\R>9U
MI2N_\8A[!O\PWXSS:5@S$[(A =#5<OA[Z;^8F&:3'>U#46DDYP4L0-J",]#R
M@(^='\C8HZ8>^S@CR3#83>A$,K-W)VJ=&#4#@23Y+VR$\@*PG!ID[= R7;%^
MZ$SWY!7ZNBXVRTRI(*'^2;P!!F[@U&H >4BC8U<-\UV+!D@F!VN+3=/A *=P
M[:2SWEF+%YI.4O&$+/<>8HH!(V'!#WH+CJT&,?!I/!*))L2$&##] \\OM"3V
M%G'0/B5?H5@?#P,*K9$/BT2_3JEXDORF2KIWLPL[8G@1+Y1NDBCW8 I0"U.4
M\I[,X)CH7-1G.#OAOV#Q@+@D?"NL3<Y5^9L5[7U1K#TOM:@\O:H@V(==6=S9
M4\ 6'=1TP=8(BGE386L:\\F)J18K)9Y2\7-8;\Y=H]'[4#W2)J&3T[B83@V%
MR*GD"<EKN)Z=]?<D@IH*(.@OM;_*ZD]%*Z&&;!F@1-9'#P& &9\X4:/D[)F!
M^2X*Q;.2Q&0I[I*@C; R @<A<J\VO#G(W6"=>U74B*-NV??/JV]J&0(W62U)
MZ^ E&X3B:QAD"N-D3BB(1^$%WNL&4*7CHQ/S!!/[MZP@B8T9D*+$-$',$HJ$
MIY*LVJY6@,&?T??T]'?S/3T=^IZ>_B&^)R(@,0J(6('0]QH;L5!@.>UDP6=L
M"-F8FT1O>-<L S!S=M>S9*Q:YM%B9RX$AI*9(2?-1(!%IOUGCM5)Y#+D1)$.
MB! )3@LIL2PO() 1V M1VQU5:4';U=+._8*&0L>MK%4EWF4)<.(R3M@[<9L5
M<JDA](!1?%67G(,F+(%QNDFJ6;-KHSQ-.*HB.J%BS8K(.1+4J<1C/GG<'!&;
MN%H"$=.'_5ILII,0DC;;*-^8[J=*5T_-$\%G',B&-L<J+RS;)P$3$;?_6##@
MA\Q<D(K(!%5G-1X8Q65Z/>\R-@K)&$H--&R28G TEGG<_5Y_R.@2"C=G=4W(
MG!3<-QNPC ,N9QWCPGT3BE:' A'$.&2R:2/FS31%AED-B&%9-<*=LQ7Q@]R6
M<HH#,JHA-QT=!G7PJ+6WC<3PB.$7KQ&= 3:(11\T)AH+ 5*DO)=@4Q>_T'NB
M448^Q<2^&;>B2]&HQ#_&*2D</Y+)<T+K.';72(Y6754;7BK.>])6. >#"']O
MU#*S4)O@H6T,NFI%%))(,UGC[+@H 6PZ53>D]SE\P7\@.PX]H5QW07G2> A@
M 1U/ <-I2F^)30^PX1@I"*^O?HG3B=%I2CJ8%]GK=XBC9%#]<W65CT 3]]P5
M&8< I2_:^/&)@>FHOQ7IRI(34Y2:M5#5 A?($?ZOMOA9;.U8R57EXSX#VH.S
M5)=9N5)HPPI):I%LYP'8/-1+PI,_5, ^KS1X3U@!<;S![U2T'*<HO$[-3S\:
M, .#TH3_HL@;+SR,Z\L0X'OLRC:+E5WE>,+P%:LO.05-D;,J31;+JP*V@*;^
M<UM<7.-X;XKPPR@.>TS1]/[:^#B/G.-)I.<AH:'O^_((\-& R0.';@_C/7#7
M< ESQ:='G&O!LPISX#?DI^Y1^\B)UU>L&5_,*X&P"Y!$5*)Q<YS'?,ACCH=G
MYO*P+,.P2^KQQ?G+#XK20EI(*<C9M97E$JR-I1MQYC?_)2$$2W.;F#=;@^H!
MOI&&USFK0ARS>R;5(H5>'+.Q4C-FUT_8/H7-XYE G<X )PZ""A('V\_P&A;H
M9 /0L$7XTCL<^Z5)1E-2-S0O[M%@<7=ZY2-28HE!WB&#%H3%4)#=T0VPG(S\
MSE,J,EXP*3@"F%@Y$6BCE@JG7N*T,P_O%)3 )<IX45G#L(<:?Y;C:0AQ937,
MY&@>>>8/G3:'53A&HSX\4"YDR"K$1JB,;?0ZY-L^T%F<P9/T&A4T81$H7Y9Q
M38"17N\+B4%QUY.>/0@^(5F>U,#HD&%7%5D]<N[<,?7N5R9K_=(<DU'L'8?H
MH6N".:Z@%D1S.@;4< X=LI_L"<@->K'I5J&>W[@HY6G7B$^LZ0G.B\*FGBA]
M>%$.AW^NW?!,E2XG\LGW+&$@4MSG@ G&RH!O85$%6:_N0&O9OG:S"J=HP=[L
MD#"J*R?Y5/F-9ZXG[AP/K*2 8>^DI+5"H "<\3LD0M@,:#CA;0'!0I.!O!=C
MMOB\03;:,A2L,<:C<A5M',1^*H@F>3=(2![?,QZ?3J[1@$Q<V&-T;_R!YB<7
MM?)?!!%J.2*Y5R.Q)*1P:"X@$(A%"R<6=W\J6AP:MKA0)/G8)3XLRC+$<JL0
MI?<C/2J$R+,(NV+MQ Z#88-[*  HFN3GEJG!]"Z-^8:0G+4S,BJ)" OZGX;@
M%0\S+-F']N#K$Z^G;[3_B)?IXN@!LK5.UAE?DO$H'M,@V;P>GGT6Y40.VHI]
M1K.80+!4'P;%<;ZT;D_W0G%)^B 1E%1OL9]59UEQP*>%S=EM@,HJ;];"!E,#
MH0G&OK<9OZ212\3'PU2"IT<<GRV78A _>];<2O9EB!3'@Y4F[IC+S3AY%0,&
M;VK<#A\!T7S(HM6T264\S>Z>>TL6OGK&2V&7:Z5I"&OU5E;BT5-^;?VF*D94
MS*%+]0I:ZP.XLF-/(1X550#9Q77Q1%L951OP,'L08W6A:V+%,]XJ9?V9KS5"
ML]G0>UI8QO0]1 79!I_V"I'&@CF8J&!4.WU.M3OQ6K( A7I;8W:V(DS0&T]D
M!M^OY8Y'*?=[?TH_W\GOYN<[&?KY3OX0/]]34M0_CKDR8B)E\XZ9I!?(MK$C
M9,1))HA5>;<)>+X&2%+?OG (+<BAH S&P"*(,>-J+;\6%A#!A9,&AX;8GH63
M9L4<_BSGJP],I%5QSC/)>N5&@$&JK3_D^\GK[-YQ98^1=6)<RI/B<]FP<V[)
M$8H FF*.HE_Z3+JLAJG26S0_=#3CQZ[G#^J*R!<>/Z0L9_IS/@&* GA/C_I1
M50M,5GC-N1H2:E/W;*,VIX3%?&RKJE'^A9[,\;?F9O& YN;&9TA]S=SOB+E?
MK&V(D#1MIFL&"Q?S-G7>A>4B%56;4L<E;=5TOY^"OW#JZS"[A,=R'"-66F9G
MHGZN*_-@,29)UFOF;8L1.(J-KNUJ47UFV3+&$$?"5 *S/%!W.#+2,;PM#_<I
M6WP]XS\(('\BK%+4$-/&7GEQ"?)YYA6Q!N/3;KNL&C%4[X<$]U,$H[RI,0AN
MD0X)214/U:QVR"6MO@!UI97*84FG%A?F?IZ!2]$98): !J63'I<RHLUB4YTX
M SX59B]<I!6\2H#FJ0. 1; ]WB.="3C0AB2&WZBR'=01E=X7(KTO(+V?2^L'
M+I;UHASYOM1\[21@:[6&2HWMA]9:3GW4JAW:\*%3\KUE(P?R5)UXD;(YY$=+
M6I-\&^V'Y*R@Q2,Y]$G5J'ZQ&1]9&:]CR2Z6**)G&].%H*"4RM+:+5&48*SJ
M%'N?,JO+Y'$UEAGCUL5]G(2,U")H<I*IM'"W1"OT 0)*,B6=.U&<4<SVW(GJ
MPA(Z39.TAY"7U!"* _4<B5Z1;N0=)V?<N(+1'O*OQZE,/JI_5Y6Y,9.\ZF9:
MAC6JBA$2#]3OSTC/>PO-^#WPFZ"^/!.P(RG3+)5.&('$K(W9QB3.WYN$/$+F
MX@PBN^-Z38UR'(UC]%/0T\'ZKX/Y)NO^"!!K#V,["'8I+RXPB%S"8+G]#2BE
MD<(YFM..1P.J+5I&)%DNEP#%FA/ZN?1_8!#,%<C;Y\K[-%9#D]@12ESC&D5(
M@QX1C"!R[['6SS&/Q ?II?2.FHL2/& ;$X<<27;0P-0RBL($JKQ+/D H,&;E
MD@K/('B:AS;-C%&$/OY!(H]M0@YP"O1B6,#)3VTM<*[*B^"DC:B44Z0<Z ".
MI"8/OZ(@5?8KX- B_,N"X0&EIY?GK$L64VP*8ZICU))O'#Y,1"EAD['[KUH6
M6BV*<1N")&Y03Y.VMC#5<;8=J1>,ZD^^O['J!2>,]P9(E^&R(6(0B3@]V2N?
MV@1T%;SRN?DP1&'@06G*0C+1D=)<,O'(3//5'3U>]821X+VA@6%PSJ:,(V3\
M6O2/2\@Q:UHR@J02+J%EB]."IT$NI,MV6]#9DGH%KLD6!1)K16LV)XGE,(_,
M3&L0Q8/N01;4CS^V67'U-[:2^ZP^IJ_1=7AHDT\&*[G>/KC)K*$/]IAU>BL8
MZ#3'#4ZA>D2">Q2P*U!D@W@YYR??H$@L8X%1Q_&>S#<ICRFE6_542N/4<Q8Q
MR5 -"JS6Y_E)1KU'3\6"X.NJ3J^UT*5X9CQFMJSFG_@UE)IT9#VUH?IL*/!5
M5YWX@ LK@:$B0*.E@T*ZRGZT>7ZV\*'V402)K#[#*D*6X,0CHF&HU;PM2ZM@
M..\VLXK!!UPUSULH8M#*K%'8LK%9GWH,OUC-264"A>/H3SU0@#9 MD_( O#<
M,1$''$)@LY<X&LJB3=@M4S9D7'6MHLFU+]*KNK*1>0+BO)4_ ;'HZIE\8$^K
M3ZG!@?VEDQT((^5J4TFJD$I=V3R&ZY=1(E60V2PU?\GFFKF]AL]C5DF1/)C3
M6+SFSYF/^.QW\Q4]&_J*GOTAOB(FL:F1&)1XG,4-[[:H2]NT8'K-?E0NX=-)
M 3Z!2,QHC]8W;$X)+51*"I*C:_11&H1J8FEXTN0=C4?SA^%2ER=%&5*!K@%M
M2W\9SZOQ4'[<V(7JU>6G8ET(@-@' O0WKJ,!K"8R:U'!S^>F6=;#V#R#_F8'
MU.N(<A8XV,+U/%O]1@-;OO;W/".VR'QYO&")Q_"F!RR7,V+N!!&44-6:\K-X
M>1NQ&B5,%D(X+*,7B2^A;%2!0OAR&X)!ZESC"($(E%54#$.4<3(VBJSVLK+)
M6''V!7JL2A9-E@4NWV@@AJ$8Y^*2&<V(#WECB;6/5E8:$106Q+@\7OW#,?98
M287$+4=@XAB0UKRX*PW4 Q9J7 U8D:K*32\4[FE($M;B4\W.6%X -*J-1<,Z
MLF$):2NJ.A656[Z.2<(6)G-,M@]1,9B[V.5QKKRWT/MU375D46U_G)6AB>$M
MC%]IJ#(!6\9^L"PFR%SOW^E0\TT9 2FJWXFYGV.L.*U^*T<UXD@K%*409CG7
M?,XX_?CD*+'3^[6?V+=C;@8&-)#4PX%FW8,D_"?']4&;1O"#U1C&R2>5"JA1
MDJ^436KT>]!JU*@<)]44#E('H1XC/CY^3\219\OR-) 2G>L%%^%F_3;4_>DI
M?Y&NP_ R\.4BI9N)G4E+"KWS99& G>6""GYC3L((Q%,E.9*RL@5CSVELM43.
M TWWUJ&10CCU71'\HGU[&<CP-5N9UES%)5-_6^-]M7A0LF,LIR4:3GQ:['SH
M>ME'TV6+&$F]]9:Y7[IG7[3R1A7^T7E6C*N/%+^>]99:(?)'B%4"R,Q#.A5Z
M9JHLQKPYB10<V$9VC2.C-N2*RKB05L2"?(P&MU!*E:((N_88>,U#O(+C4>6%
MAD<?P*'Z'"DN5^C1A8DPT8 P)^G,_>6;J'W,G@Z:T6Z*9V7W;7 WQ&*4743[
MYBO:UQBWI.:J!HQ7B**?Y+3$),;FZM,T0,7?/;S!L(M(L0]#]Y*KYI)\[&B+
MH +99ZDH-G*8I/\\1GU%QM)M=5_PM0E,-UW->SU8SSZ4R_0O@\@$; 4/;Q+C
M?!2LPZN+*DAJW\YX'@'B*983!FNNH6T<@I.-UN1@=5ZIQX4V<%.TG6)5-1_(
M:00D$<QA\;Y6&_O.#TW&PU_+*+DV]9"0'P.],A*NIT(QVVF\BZ%;%Y\WXC*R
MV$7CO:#8;P'=\@D&^*6&$KLPIQTJ>C92YZ!N  -(\C?76YT@C=G'X%CNAF+P
M\?#W@+)15,8]!Z 0X5D)!DVQAK#',?LPM*A@0Y3:[3>.X>?F9#''6)2U&)*6
M$P=(;%O<>R>-1]3Y-04ZQ8A)*B;F>L-S9A6T%?4L<*ITYU7V'GN,8^9[\O'#
MG^/N:%#WR)*02X!J@4;G? XD=XIKI??II-?MQ'(5)T'X6Y94#VRYY]PS^O]W
M(9XW'AOCO/-G7%'E25ZP73SA5(UZ5C:W^#,GZJZYH!7IKR3*)SX/UN@_XJGP
M9;,+E+W;N=TI9ZY;S5=+['=Q#T0:ULNX,A("/2&79G!N!FXR+VJ#*V8;2=WG
MF.S!/S$U+@.R^Y^9&D<S^R<G;7$K<=(6PI,(-%3KM75V&1=@^SI"P86H3+F8
M6+BBVI1KYACWA53(N_,)_M2VQFSKT"@N<*GS>PA)MJT7[3TG":F+@FW>"LTW
M8LJI#K.I6IG(<AN^AP7+-I"8\Y/4)F/O8\?7 :4U#R20BM$=N"%:4DQ6]@>J
MM)4("C F4B2R@9U=KG#U ]N6ZJ@+,2KU9]+_QN1&7\N%>ER9F23<&FX'MC(1
MTM7:!!,?/4WND_$)J):CPC(>7GKOB59M\Y&L(G$%ZXK59=&RK1\P!ZD+UK/M
MOB*AD<MU=2<%!4-:TY=R>[2/&.)GY8%;SSUBGD%L]/2Q,FHQ-+&OF+.0:N+H
M2A23'5$*'ND&1;'V]])[VQ->^&=T<)[^;@[.TZ&#\_0/<7#2)DS=Q['DNB]0
M_N112N[%W>T ,KG&U=3C+3^3T8"%%,NF$#D0!Q!2,RQUX)F(N^&LKQ:9:-!>
M\-I]47SRC@3Q[H2B%(9;?;C&>XE"<//,KK2[R\JEJF;2\\P'), #>0:'>HU)
M+]X_>H/D(]/@L?W*J9BC925E3FD8!\CXTF"0GL<^OF4L0X8)0NN$VVABB0MU
MX;YX3"G@1(UX/9/E9&&L]=0??*CT6JC7 B(W*VB9VU%TRT/H G?#&.9:UN,0
M2+S1HOS8L<DC@^EOF5Z1$TCA02(-$5,?Q[FMJISKC*C8*02%J4UDI .O<!5?
MG>5EAS*N+90[/56B[@XKJQA\KNA+!RY\Y=A5(+;+@7K"4QI*6\1R31-('GTF
MHK@>2[?8B?(Y?&'%O>/=D&\:JFH.+G 4B6BR1I^/?/2&,H= UV9LIMYR&S3*
MXD_4-20EJX$Y!^GD6:T93%$G,\FLU@)PM$:'CZZ1+;MF$S-6@%YZAQ+21H'T
M^'2TD=Z[T "CPB-Z)X/<^FCPRYJMKW/-4?8[HBTQ1>1#X%#8BJDO,937F+"_
M8"=D=HF)><8VE=49*^^*B+6 L#D"[,$\*<5E,<7][XOSZ\M_?[ST9C^7,Z*K
MG'=7&O&U4C2\0-___.['?V<*!1SJW8_N_.7?W[[[^/KRXKM+=_W]^37]S]4'
M1__W]MVU.W>OKO[7Y<63Z\OW;]SY=^\O+]]<OKW><U>OY#'_E;V !Z_>4M<7
M[NHMC>KERW?O+\[?OKQT'Z^NOY>77KX^__'#)29Q_O:"WG+O+]]>?CQ_G;9&
M_UR^YV:NWTWZO7WX_OSU:_>2I/75VQ\ON:M7/](W-$WJ"LU>OGIU^?):)GKH
M7H04N"&]*W-@1 /B% ]BGMA14)@.*O2 DO_%/3SAX6 7;:O.7\=Z;<6WFC""
M+\K;%UCT+T1<<69:DME8Q_C+W8#(',Q!YLE8Z1X',[;0J,-L? E &4#A#N92
MPMIMM:@PA^=Z&85 7W&9R2A&-\*G^E/34D5=6\$Y(P7U/>B6SL_T^+\]R*#4
M0 84&,^PXS09QT/#4![(<CZ7LP=_ZJ^9]L!NP$TL@9>.9V@G?(1WZ-@2A>.<
MF_8AZ;.C]H[:'O_H."_7D-(&3$SK@RO(]-PC#LU@V'4)\EFX=CF/7?@^&P_P
M9HS6V\J/IN2/5OK0A#V'J#V<H5[6 Z8-6?<K+IBUVDS/=30'8VAKGT'\2!4^
MP_D?>;]8^U"":+C-1_-,N7$$-W@(AW$)C!5?4B\6-V*-J*2/ '0"'307QQ<M
MT20L$DA1,75>WFF$PM;D*$Y+\9D=JDOC@6,W7K7#*/-T+#P".NI['^6%QM8!
ME*8=Q)L"L%F^38I[>.^H=U]J!K(E3]A-4HOX-3DP3]V[=2*XAQ!H0Y,*X0CE
M(D,Q@K^JQ#;?7-S>F$++E#]Y,&5'(SS!#[--<SBEYM0]%^D+4,A>EOPC6MUS
MG<)!7-6MGZ0G05\FF)%<".M,GGK \=&_BC *_/@T1QO+X4-CD8HEHWQHW'=C
MF2\PM-C_+;58#%@C5^YP1 (53H048U_]K7*Q,A1 J=;J0A)P5R_GOI\;,ZA=
MG<TRE!NTL@KV*U\7S:*;2.91M2#S'J*P8$</+9CF_& *QC_D@ACOXS1+*"I(
M9_%P+PW %I4U"#)*(9-<.<#PG &$S4,ZCH?TN&LJG(13MY,3Y]Z4&D'>W7/:
MW%-U  =?77!3)Q[,'BF,K G?T*J.QS^?VXH,X-_);24MI6ZKZ?X?X[?"%I[\
M.H+HW>;E3Q/HD)2P8!)%WDQAWR>.<]"(,OB"[) 4@KU'!"N6BGSMA<8#]68V
M;\'AC!6?-Z6_K,X/PI_7D'"9Y ;%P2TI9608KQ&DMEB9O6!\G$1"<WHFL3RM
MC\1PI8?K(R5EGB)&TR]QK(&!6P"!%2=# U])5R4NLU\CVXO3'=4L +<1V!;S
M*7U+M!;FC9IV:H"%).M44G,M(W*80RE3/77RWT7, >07J(:0S>.;\EC28R0^
M$^!$PF90:<WR"<(.Z^V0<=YD(G4,IHX;YJ,;=AH4>KK/&K,HAL6 !5":12\Q
M7$+T.7\D_*5'F)^_]6B@#_.=!<&KPW>LWZ.&AE[<4N^Y5U](U1JL153;U2&3
M=M6M+%!:<+9^L1'8G*8.;!"4'<,6['D;,7O EAG7B*8/#2RJ!BBZLH<+0?O/
M6M/!#O=%^8YL1ZO"$E..9!6I?.X\WD)0YGWCTQJ(6]AS'_7^B4?FN$B4;2'"
MAR9HH^E/#Y4K*B&OAZ*MJ2(23S,WJUM6SVXMCZ4BYQS*63O 7]>/T$6@!#U=
M"T:<D([E/0T^KTP5U*"9 G67<5DITSSZ5UI9J)<A#1,E,7ZM'8W#PR'.D+GR
MIES'=UI->N[ZGHV,8#R7;DM2O&23K#Y.M*?FW(H1OCV>'F:]]_A:ZKKI,5LV
MX8H7X;-&,;WBCH&Y\QUXOKA8#'>U[-0H/=4<Y MB8R4"P!/WJ=C:32^B1TDQ
M;].W3J&"NP$L33PA2:&=1^;%-<0\@JJRS/-&P@5R*S'4@,)O*Z %1-^TF\52
M*@!U+&EX>^_7<>Z?'^@1!GHU@+A!3'5<R&RX:VGP8T02\-B&UAC4<AM*K)%K
MKB&CN=C^RPNN%0D#GT&<PO !2EUL'^J3C1"MYV0T%0]:AL,511,\%DM5ZYX)
ME>M<R(GF%3H>VTK>0)ZG>)^\L-9"U5+71L]$?)PYVW$LA&-VB6&1*B^N'Y+7
M69#7OO@2#PD^J_EM535%-"(%L2N W)=8B,>F^S-B-N$\TEF\$' \_;TW?;C6
M_JA]B8;';A"T%WRYT:A(@D0"0IY1U'":51NC525;A"\S4B1P;*QI@;AAQ8W:
MRFI4H;PZ1Z[\+3K;- ,##T+GQFG:M6(BW*#<("M'6<6/W'M:K1/2BVO5QLJ@
MX69DCV;F2Y22*XLD?T'O?_5Y<HP?KOF26)_:T'1ZT1S;E[R3N* K@;@%I36J
MV\")GI7DRXC:/#&E>6+5Z">"'RH4#J;*^D3X\ 04#,1O$T88@0BC5%'40?%I
MJIRDX;7Z@3].5X<9UF=,-N25VHT?'%,:W$R$J1\ZN4+!TUH8#OV(N%]2<RP4
M<Y[QQ<IV)4IT(9%@^D#>GC8F2#>F!P3W1UOX).*\DRB!,ZP*T0( ?HQ@O$,]
M:_/X2(]Z]06?[A^$H]F=%^%R7:F/#QR6E(=I^U?%30)3-NF&/;BY 4=OE5VY
M0;V?7CB@\26ZHF)P)"66I*+L3 ]V+?W(7^G!DCA 1V6K>3.T\&E2:4#]0^&%
M8?$3VD7)34>>%1=L'33_FU8ELD#'\LAL\P#AK./D&+<N;H@NL3"[$]+TFW@7
M\288+A1$_A!J\>0=P&9UL<8=XCZ53DDA<OKZ?K% >A]Z<K>,*.!:CC>=N>3J
M\:E&9_80PP=SN\&XK5IUB(.FZ$]?68GMXV7&AS3DDL2NHDG2.;*19@67FMPQ
M%0H>["Q'D^WM;C)N#SDGG6J=9XS<%?^J\E"ACD/WMFJQ(\%E&L>/Q>/QJ/EJ
M%6L"?5C'NA V_IA)2FU"JQ,>H&8DJLYD7,0GA---F$%.5.XLF(][[VB,V/<9
MD>S@.V3LH): B]+]/(_OI=<6S&87I;ACB+D!EFYM!P+%0#:X/*9;LU-FXE/8
ML%EDYY0;UB51R-+X=9M-$MRU5$RL#4T*N:082QOXH1_N1#(X9*HAZH4O,!&-
M:^"=H\%BBD"1?3["/NM]9GW/M^RCW PG"$C6\UDHJ(<U0LSS#OT)G9+3W\TI
M.1UQ2D[_&*<D;9Q<>99) IHG?,T1#[PF\$D[*M%74>PMWM58FMZ$I*Y9)$J?
M.Z.P(UB*BSKK<BE%0']TC)X:,&6AN.-QA3XJ71JEW;#OQZ23C%7O&F;%-C:7
MN)Y;XZTF37>6.^W BB1NGY16KV+M1B*EM1U5DZ[6O+ *U=0,E;\5"UXF]E2
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M^/?[ZS>OO_U_4$L! A0#%     @ +3BK5I<PK4TY- , ?#\8 !$
M     ( !     &-M<',M,C R,S S,S$N:'1M4$L! A0#%     @ +3BK5D\*
M0YRO#@  HY4  !$              ( !:#0# &-M<',M,C R,S S,S$N>'-D
M4$L! A0#%     @ +3BK5N8O6=UC%0  @<<  !4              ( !1D,#
M &-M<',M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( "TXJU85KB$4*4<
M "]& P 5              "  =Q8 P!C;7!S+3(P,C,P,S,Q7V1E9BYX;6Q0
M2P$"% ,4    "  M.*M6.+X!! NK  #39 < %0              @ $XH ,
M8VUP<RTR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ +3BK5A7ZSS@A<
MK#H% !4              ( !=DL$ &-M<',M,C R,S S,S%?<')E+GAM;%!+
M 0(4 Q0    ( "TXJU8D0K"HD0@  ,XI   >              "  <J[! !C
M;7!S+7$Q>#(S>&5X,S$Q8V5O,S R8V5R="YH=&U02P$"% ,4    "  M.*M6
M**O488,(  #L*   '@              @ &7Q 0 8VUP<RUQ,7@R,WAE>#,Q
M,F-F;S,P,F-E<G0N:'1M4$L! A0#%     @ +3BK5@G%E&23!0  2R$  !X
M             ( !5LT$ &-M<',M<3%X,C-X97@S,C%C96]X8V9O<V5C+FAT
M;5!+ 0(4 Q0    ( "TXJU;D4\]--T,  ,W:   9              "  273
M! !F;W)A<F5S:61E;G1A9W)E96UE;G0N:'1M4$L%!@     *  H M0(  ),6
$!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
